<SEC-DOCUMENT>0000875045-24-000032.txt : 20241030
<SEC-HEADER>0000875045-24-000032.hdr.sgml : 20241030
<ACCEPTANCE-DATETIME>20241030163122
ACCESSION NUMBER:		0000875045-24-000032
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		132
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241030
DATE AS OF CHANGE:		20241030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		241410819

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20240930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8df3ebeb-6aab-4ece-9956-fcebea1610fa,g:6874ad4b-e1dd-42ba-8d50-e940c01ea5b0,d:5e7e277eefb645c9b9cc7c9e24d79fea-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:biib="http://www.biogenidec.com/20240930" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20240930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">145,719,340</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20240930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>biib:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">biib:MeasurementInputProbabilityRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentFutureDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentCommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabIgANMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAMRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabPMNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabIgANMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAMRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabPMNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ClinicalInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ClinicalInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:CompletedTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:CompletedTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityTerminatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:OmnibusEquityPlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:OmnibusEquityPlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MosunetuzumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:LenderDisputeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2024</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-19311</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><img src="biib-20240930_g1.jpg" alt="biogenlogoa11.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:47.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">MA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">679-2000</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:35.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of October&#160;29, 2024, was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">145,719,340</ix:nonFraction> shares.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Quarterly Period Ended September 30, 2024</span><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.866%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;I&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_16">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_19">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_22">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Nine Months Ended September 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_22">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_25">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Nine Months Ended September 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_25">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_28">Condensed Consolidated Balance Sheets&#160;&#8212; As of September 30, 2024 and December&#160;31, 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_28">10</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_31">Condensed Consolidated Statements of Cash Flow&#160;&#8212; For the Nine Months Ended September 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_31">11</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_34">Condensed Consolidated Statements of Equity &#8212; For the Three and Nine Months Ended September 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_34">12</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_37">14</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_118">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_118">52</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_247">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_247">80</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_253">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_253">82</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;II&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_256">OTHER INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_259">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_259">83</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_262">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_262">83</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_265">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_265">98</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_268">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_268">98</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_271">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_271">99</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_277">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_277">100</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the PSLRA) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the PSLRA. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; "contemplate," "continue," &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; "predict," "project", "should," "target," &#8220;will,&#8221; &#8220;would&#8221; or the negative of these words or other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our marketed products or competing products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our plans and investments in our portfolio as well as implementation of our corporate strategy;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the execution of our strategic and growth initiatives, including the ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of global health outbreaks or adverse weather events on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our use of information systems and data and the potential impacts of any breakdowns, invasions, corruptions, destructions and/or breaches of such systems or those of our business partners;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy manufacturing facility in RTP, North Carolina to be operational;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. Because some of these risks and uncertainties cannot be predicted or quantified and some are beyond our control, you should not rely on our forward-looking statements as predictions of future events and you should not place undue reliance on these statements. Moreover, we operate in a very competitive and rapidly changing environment, new risks and uncertainties may emerge from time to time and it is not possible for us to predict all risks nor identify all uncertainties. Forward-looking statements speak only as of the date of this report and are based on information and estimates available to us at this time. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. You should read this report with the understanding that our actual future results, performance, events and circumstances might be materially different from what we expect.</span></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM&#174;, AVONEX&#174;, BYOOVIZ&#174;, PLEGRIDY&#174;, QALSODY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SKYCLARYS&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and VUMERITY&#174; are registered trademarks of Biogen. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BENEPALI&#8482;, FLIXABI&#8482;, FUMADERM&#8482;, IMRALDI&#8482;, OPUVIZ&#8482; and TOFIDENCE&#8482; are trademarks of Biogen.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACTEMRA&#174;, COLUMVI&#174;, ENBREL&#174;, EYLEA&#174;, FAMPYRA&#8482;, GAZYVA&#174;, LEQEMBI&#174;, HUMIRA&#174;, LUCENTIS&#174;, LUNSUMIO&#174;, OCREVUS&#174;, REMICADE&#174;, ZURZUVAE&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEFINED TERMS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Form 10-K</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Report on Form 10-K for the year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020 Share Repurchase Program</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Board of Directors authorized program to repurchase up to $5.0 billion of our common stock</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 Omnibus Equity Plan</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2024 Omnibus Equity Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2017 Omnibus Equity Plan</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2017 Omnibus Equity Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 ESPP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2024 Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2015 ESPP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2015 Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan</span></div></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.5&#160;billion term loan credit agreement</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AbbVie Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acorda</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acorda Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Artificial Intelligence</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alkermes</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alkermes plc</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ALS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amyotrophic Lateral Sclerosis</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMR</span></div></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibody-Mediated Rejection</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AOCI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASO</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antisense Oligonucleotide</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASU</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounting Standards Update</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ATV</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibody Transport Vehicle</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biologics License Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blackstone</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blackstone Life Sciences</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CCPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">California Consumer Privacy Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CHMP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Committee for Medicinal Products for Human Use</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CISA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cybersecurity and Infrastructure Security Agency</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CJEU</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Court of Justice of the European Union</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CLE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cutaneous Lupus Erythematosus</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CLL</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chronic Lymphocytic Leukemia</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CLO</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Legal Officer</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODM</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Operating Decision Maker</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convergence</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convergence Pharmaceuticals Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CRL</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complete Response Letter</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CROs</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract Research Organizations</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DEA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Drug Enforcement Agency</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali Therapeutics Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Directors Plan</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2015 Non-Employee Directors Equity Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">District Court</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. District Court for the District of Massachusetts</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DOJ</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Department of Justice</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Commission</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eisai Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EPO</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Patent Office</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERM</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enterprise Risk Management</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">E.U.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Friedreich's Ataxia</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FCPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Corrupt Practices Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FDIC</span></td><td colspan="3" style="border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal Deposit Insurance Corporation</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEFINED TERMS (continued)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fit for Growth</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost saving program initiated in 2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FSS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal Supply Schedule</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genentech</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genentech, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Intangible Low Tax Income</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GloBE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Anti-Base Erosion</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GMP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Good Manufacturing Practices</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HI-Bio</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Human Immunology Biosciences, Inc.</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Humana</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Humana Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IgAN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Immunoglobulin A Nephropathy</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ionis</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ionis Pharmaceuticals Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IRA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inflation Reduction Act of 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IT</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Information Technology</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intravenous</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LHI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large Hemispheric Infarction</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LRRK2</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leucine-Rich Repeat Kinase 2</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MAA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketing Authorization Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MDD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Major Depressive Disorder</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mylan Ireland</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mylan Ireland Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NCD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">National Coverage Decision</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune SubOne AG</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NMPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">National Medicinal Products Administration</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OECD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Organization for Economic Co-operation and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODD</span></div></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Orphan Drug Designation</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OIE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (Income) Expense, Net</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PDUFA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prescription Drug User Fee Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PMN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Primary Membranous Nephropathy</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Polpharma</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Polpharma Biologics S.A.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPACA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient Protection and Affordable Care Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postpartum Depression</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Primary Progressive MS</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PRV</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relapsing MS</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RRMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relapsing-Remitting MS</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RTP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research Triangle Park</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung Bioepis</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung Bioepis Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung BioLogics</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung BioLogics Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, General and Administrative</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SLE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Systemic Lupus Erythematosus</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SMA</span></td><td colspan="3" style="border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEFINED TERMS (continued)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SMN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Survival Motor Neuron</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SOD1</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Superoxide Dismutase 1</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SWISSMEDIC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss Agency for Therapeutic Products</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TBA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Technical Boards of Appeal</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transition Toll Tax</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.K.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. GAAP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounting Principles Generally Accepted in the U.S.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VA</span></td><td colspan="3" style="border-bottom:1pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veterans Administration</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I FINANCIAL INFORMATION</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_19"></div><div style="text-align:center"><span><br/></span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_22"></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-31">1,769.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-32">1,805.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-33">5,380.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-34">5,414.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-35">446.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-36">420.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-37">1,284.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-38">1,253.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-39">250.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-40">304.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-41">555.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-42">781.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-43">2,465.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-44">2,530.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-45">7,221.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-46">7,449.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-47">638.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-48">659.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-49">1,726.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-50">1,915.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-51">542.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-52">736.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-53">1,509.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-54">1,891.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-55">588.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-56">788.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-57">1,723.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-58">1,941.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-59">130.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-60">60.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-61">295.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-62">164.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-63">69.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-64">50.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-65">197.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-66">164.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-67">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="f-68">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-69">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="f-70">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-71">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-72">76.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-73">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-74">120.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="6" id="f-77">88.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-78">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-79">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-80">300.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-81">193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-82">248.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-83">2,014.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-84">2,671.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-85">5,606.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-86">6,444.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-87">451.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-88">141.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-89">1,614.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-90">1,005.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-91">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-92">72.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-93">249.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-94">92.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-95">388.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-96">68.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-97">1,365.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-98">912.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-100">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-102">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-103">388.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-104">68.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-105">1,365.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-106">911.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings (loss) per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-107">2.67</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-108">0.47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-109">9.38</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-110">6.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings (loss) per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-111">2.66</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-112">0.47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-113">9.35</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-114">6.26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings (loss) per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-115">145.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-116">144.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-117">145.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-118">144.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings (loss) per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-119">146.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-120">144.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-121">146.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-122">145.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-123">388.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-124">68.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-125">1,365.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-126">911.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="f-127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-128">14.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="f-129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-130">15.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-131">41.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-132">29.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-133">6.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-134">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-135">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-136">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-137">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-138">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-139">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-140">30.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-141">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-142">11.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-143">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-144">13.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-145">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-146">5.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-147">388.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-148">54.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-149">1,373.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-150">917.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-152">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-154">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-155">388.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-156">54.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-157">1,373.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-158">918.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-159">1,699.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-160">1,049.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-161">2.0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-162">2.4</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-163">1,536.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-164">1,664.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-165">451.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-166">435.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-167">2,469.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-168">2,527.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-169">674.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-170">1,182.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-171">6,830.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-172">6,859.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-173">3,210.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-174">3,309.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-175">380.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-176">420.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-177">9,805.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-178">8,363.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-179">6,485.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-180">6,219.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-181">968.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-182">928.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-183">631.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-184">745.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-185">28,313.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-186">26,844.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion notes payable and term loan</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-187">1,748.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="f-188">150.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="f-189">499.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="f-190">257.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-191">422.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-192">403.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-193">2,755.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-194">2,623.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-195">5,425.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-196">3,434.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and term loan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-197">4,545.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-198">6,788.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-199">882.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-200">641.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-201">357.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-202">400.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-203">744.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-204">781.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-205">11,954.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-206">12,045.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments, contingencies and guarantees</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-18" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-207"/></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-19" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-208"/></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-209">0.001</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-211">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-212">0.0005</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-213">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-214">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-215">488.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-216">302.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-217">145.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-218">153.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-219">18,993.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-220">17,627.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-221">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-222">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-223">16,358.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-224">14,799.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-225">28,313.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-226">26,844.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-227">1,365.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-228">912.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-229">489.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-230">354.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-231">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="f-232">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Excess and obsolescence charges related to inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-233">68.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-234">62.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Amortization of acquired inventory step-up</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationOfInventoryStepUp" scale="6" id="f-235">185.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:AmortizationOfInventoryStepUp" format="ixt:fixed-zero" scale="6" id="f-236">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-237">216.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-238">209.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-239">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="f-240">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-241">99.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-242">377.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(Gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="f-243">22.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="f-244">275.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="f-245">88.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="f-246">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-247">95.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-248">98.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effects of business acquired:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-249">127.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-250">76.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-251">15.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-252">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-253">207.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-254">34.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-255">84.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-256">293.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="f-257">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="f-258">114.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-259">65.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-260">71.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-261">2,114.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-262">1,534.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-263">114.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-264">211.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="6" id="f-265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-266">7,380.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="f-267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-268">5,140.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquisition of Reata, net of cash acquired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-269">6,335.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquisition of HI-Bio, net of cash acquired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-270">1,074.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sale of equity interest in Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="f-271">406.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="f-272">788.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sale of priority review voucher</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-273">88.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-274">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquisitions of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-275">179.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-276">34.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sales of strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" id="f-277">96.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" id="f-278">106.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-279">4.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-280">1.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-281">780.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-282">3,448.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-283">34.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-284">48.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Repayment of borrowings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-285">650.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-286">159.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from borrowings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="f-288">997.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net (distribution) contribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" format="ixt:fixed-zero" scale="6" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="f-290">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-291">6.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-292">1.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-293">691.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-294">795.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="f-295">642.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-296">1,118.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-297">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-298">12.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-299">1,049.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-300">3,419.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-301">1,699.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-302">2,287.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2024</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-305">169.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-306">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-307">407.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-308">146.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-309">18,604.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-310">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-311">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-312">15,889.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-313">388.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-314">388.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-315">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-316">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:fixed-zero" scale="6" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-318">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-319">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-321">1.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-322">1.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-323">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-324">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2024</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-329">169.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-330">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-331">488.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-332">145.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-333">18,993.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-334">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-335">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-336">16,358.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-339">168.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-340">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-341">302.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-342">153.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-343">17,627.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-344">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-345">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-346">14,799.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-347">1,365.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-348">1,365.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-349">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-350">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-351">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-352">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-353">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-354">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-355">66.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-356">66.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-357">224.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-358">224.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-359">3.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-360">3.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2024</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-363">169.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-364">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-365">488.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-366">145.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-367">18,993.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-368">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-369">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-370">16,358.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.350%"><tr><td style="width:1.0%"/><td style="width:20.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.634%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="69" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-373">168.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-374">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-375">170.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-376">172.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-377">17,446.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-62" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-378">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-379">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-380">14,466.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-381">6.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-382">14,460.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-383">68.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-384">68.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-385">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-386">68.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-387">13.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-388">13.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-389">13.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-390">2.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-391">2.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-392">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-393">9.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-394">9.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-395">9.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-397">2.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-398">2.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-399">2.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-400">64.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-401">64.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-402">64.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-403">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-404">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-405">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-408">168.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-409">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-410">242.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-411">159.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-412">17,377.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-413">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-414">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-415">14,483.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-416">4.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-417">14,479.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="69" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-80" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-420">167.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-421">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-422">73.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-423">164.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-424">16,466.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-85" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-425">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-426">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-427">13,397.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-428">9.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-429">13,388.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-430">911.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-431">911.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-432">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-433">912.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-434">5.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-435">5.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-436">5.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-437">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-438">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-439">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-440">38.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-441">38.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-442">38.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-443">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-444">86.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-445">86.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-446">86.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-447">217.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-448">217.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-449">217.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-450">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-451">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-452">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2023</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-453">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-455">168.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-456">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-457">242.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-458">159.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-459">17,377.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-460">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-461">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-462">14,483.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-463">4.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-464">14,479.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_40"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 1:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Summary of Significant Accounting Policies</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-465" continuedAt="f-465-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div><ix:nonNumeric contextRef="c-1" name="biib:BusinessOverviewPolicyTextBlock" id="f-466" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2024, we completed the acquisition of HI-Bio. As a result of this transaction we acquired HI-Bio's lead asset, felzartamab, an anti-CD38 antibody currently being evaluated for three leading indications, AMR, PMN and IgAN. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets, as well as TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-467" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2023 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-468">one</ix:nonFraction> operating segment, focused on advancing our pipeline in neurology, specialized immunology and rare diseases.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-465-1" continuedAt="f-465-2"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-469" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="f-470">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. In November 2023 we terminated the Neurimmune Agreement, which resulted in the deconsolidation of our variable interest entity, Neurimmune. For additional information on the deconsolidation of Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-471" continuedAt="f-471-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div></ix:nonNumeric><div style="margin-top:6pt"><ix:continuation id="f-471-1"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2023 Form&#160;10-K.</span></ix:continuation><span style="color:#3051f2;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-472" continuedAt="f-472-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024 the SEC issued a final rule under SEC Release No. 33-11275, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new rule will require large accelerated filers to disclose material climate-related risks that are reasonably likely to have a material impact on their business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and/or material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the new rules will require disclosure within the notes to the financial statements of the effects of severe weather events and other natural conditions and information on any climate-related targets or goals, subject to certain materiality thresholds. The final rule, if adopted, includes a phased-in compliance period which will begin phasing in with our annual report for the year ending December 31, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that this new rule will have on our company's disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-472-1"><ix:continuation id="f-465-2"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023 the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. All disclosure requirements under this standard are also required for public entities with a single reportable segment. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. While this accounting standard will increase disclosures, we do not expect the adoption of this standard to have a material impact on our consolidated financial position or results of operations.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2023 the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This standard establishes incremental disaggregation of income tax disclosures pertaining to the effective tax rate reconciliation and income taxes paid. This standard is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a prospective basis with the option to apply it retrospectively. While this accounting standard will increase disclosures, we do not expect the adoption of this standard to have a material impact on our consolidated financial position or results of operations.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_43"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-473" continuedAt="f-473-1" escape="true"><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 2:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acquisitions</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Human Immunology Biosciences</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody, is currently being evaluated for three leading indications, Antibody-Mediated Rejection (AMR), Primary Membranous Nephropathy (PMN) and Immunoglobulin A Nephropathy (IgAN). Felzartamab has received Breakthrough Therapy Designation and ODD from the FDA for development in the treatment of PMN and AMR and has received ODD in the treatment of antibody-mediated rejection in kidney transplant recipients. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we paid shareholders of HI-Bio approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-474">1.15</ix:nonFraction>&#160;billion at closing and may pay up to an additional </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="f-475">650.0</ix:nonFraction>&#160;million in potential future development and regulatory milestone payments.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-476">1.15</ix:nonFraction>&#160;billion paid includes approximately $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="biib:PaymentsToAcquireBusinessGrossNonVestedEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-477">74.5</ix:nonFraction>&#160;million related to HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, of which $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-478">56.4</ix:nonFraction>&#160;million was recognized as share-based compensation payments to settle non-vested equity awards attributable to the post-acquisition service period and therefore not reflected as a component of total purchase price paid. Of the total $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-479">56.4</ix:nonFraction>&#160;million, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-480">42.5</ix:nonFraction>&#160;million as a charge to research and development expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-481">13.9</ix:nonFraction>&#160;million as a charge to selling, general and </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing we also paid an additional </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-482">43.7</ix:nonFraction>&#160;million related to working capital adjustments as of the transaction close date, which was included as a component of total purchase price paid.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded this acquisition through available cash on hand and accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the lead program felzartamab, the HI-Bio pipeline acquired includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial, and the potential for continued development in a range of complement-mediated diseases.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-473-1" continuedAt="f-473-2"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Consideration</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-483" continuedAt="f-483-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of HI-Bio is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of July&#160;2, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to HI-Bio shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-484">1,137.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="f-485">485.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-486">1,622.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> Represents total consideration paid to shareholders of HI-Bio of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-487">1.15</ix:nonFraction>&#160;billion, plus an additional $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-488">43.7</ix:nonFraction>&#160;million related to working capital adjustments as of the transaction close date, less $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-489">56.4</ix:nonFraction>&#160;million of cash paid for HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, which were recognized as compensation attributable to the post-acquisition service period and therefore not reflected as a component of total consideration. </span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Contingent Consideration:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We may make certain contingent payments to the former shareholders of HI-Bio upon the achievement of certain development and regulatory milestones. As of the acquisition date, the maximum aggregate amount payable for these potential milestones was $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="f-490">650.0</ix:nonFraction>&#160;million. The acquisition-date fair value of these milestones was approximately $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-491">485.1</ix:nonFraction>&#160;million and was estimated utilizing a probability-adjusted discounted cash flow calculation using an appropriate discount rate dependent on the nature and timing of the milestone payments, which ranged from </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-492">6.2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-100" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-493">7.0</ix:nonFraction>%, and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">probabilities of technological and regulatory success ranging from <ix:nonFraction unitRef="number" contextRef="c-101" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-494">67.0</ix:nonFraction>% to near certain probability.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Of the total contingent consideration, approximately $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-495">279.3</ix:nonFraction>&#160;million related to milestones classified as short-term and reflected as a component of accrued expense and other with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-496">205.8</ix:nonFraction>&#160;million reflected as a component of other long-term liabilities within our condensed consolidated balance sheets. The short-term liability relates to the fourth patient dosed in a phase 3 clinical trial of felzartamab in a first and s</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">econd indication, which would trigger milestone payments of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-497"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-498">150.0</ix:nonFraction></ix:nonFraction>&#160;million each.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent changes in the fair value of the contingent consideration obligation will be recognized as (gain) loss on fair value remeasurement of contingent consideration within our condensed consolidated statements of income. This fair value measurement was based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements. For additional information related to the fair value of this obligation, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Contractual Commitments: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired HI-Bio's pre-existing in-license commitments under third-party agreements, which include tiered royalties on potential future sales of felzartamab and izastobart/HIB210, ranging from high-single digit to mid-teen percentages, as well as potential future development, regulatory and commercial milestone payments related to felzartamab and izastobart/HIB210 of up to $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-499">130.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-500">230.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-501">640.0</ix:nonFraction>&#160;million, respectively. Because the achievement of these milestones was not considered probable as of the transaction close date, such contingencies have not been recorded in our financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-473-2" continuedAt="f-473-3"><div style="margin-bottom:3pt;margin-top:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Preliminary Purchase Price Allocation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-502" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation of the separately identifiable assets acquired and liabilities assumed as of July&#160;2, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:19.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July&#160;2, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="f-503">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (IgAN)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-504">920.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (AMR)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-505">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (PMN)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-506">265.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-507">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expense and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="6" id="f-508">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" scale="6" id="f-509">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="f-510">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" scale="6" id="f-511">35.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="f-512">304.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" scale="6" id="f-513">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-514">1,365.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-515">256.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-516">1,622.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intang</span><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ible assets:</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets comprised of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-517">1.6</ix:nonFraction>&#160;billion of IPR&amp;D related to HI-Bio's lead asset felzartamab. This includes $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-518">920.0</ix:nonFraction>&#160;million of IPR&amp;D related to felzartamab indication for IgAN, $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-519">450.0</ix:nonFraction>&#160;million of IPR&amp;D related to felzartamab indication for AMR and $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-520">265.0</ix:nonFraction>&#160;million of IPR&amp;D related to felzartamab indication for PMN. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing cash flow analyses and a discount rate of <ix:nonFraction unitRef="number" contextRef="c-114" decimals="3" name="biib:IntangibleAssetMeasurementInput" scale="-2" id="f-521">14.5</ix:nonFraction>%. These fair value measurements were based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acq</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uired that could not be individually identified and separately recognized. We recognized goodwill of approximately $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-522">256.5</ix:nonFraction>&#160;million, which is not deductible for tax purposes. The goodwill recognized from our acquisition of HI-Bio is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-related expenses:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acquisition-related expense, primarily comprised</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of advisory and legal fees, and other transaction costs, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-523"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-524">2.8</ix:nonFraction></ix:nonFraction>&#160;million and were recorded within selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Assumptions in the Allocations of Purchase Price</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he results of operations of HI-Bio, along with the estimated fair values of the assets acquired and liabilities assumed in the HI-Bio acquisition, have been included in our condensed consolidated financial statements since the closing of the HI-Bio acquisition on July&#160;2, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management's analysis related to certain matters, such as finalizing our assessment of intangible assets, goodwill and income taxes, among other items. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. The final determination may result in asset and liability fair values that are different than the preliminary estimates. There were no purchase price allocation adjustments during the third quarter of 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-473-3" continuedAt="f-473-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the acquisition date, our results of operations include the results of operations of HI-Bio. HI-Bio operations had an immaterial impact on our results of operations for the three and nine months ended September 30, 2024. Due to the immateriality of HI-Bio's historic revenue and expenses, additional pro forma information combining the results of operations of Biogen and HI-Bio have not been included.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a  biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction we acquired SKYCLARYS (omaveloxolone), the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs. The acquisition of Reata is expected to complement our global portfolio of neuromuscular and rare disease therapies. The addition of SKYCLARYS is anticipated to provide potential operating synergies with SPINRAZA and QALSODY.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we paid Reata shareholders $<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="1" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-525">172.50</ix:nonFraction> in cash for each issued and outstanding Reata share, which totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-526">6.6</ix:nonFraction>&#160;billion. In addition, we agreed to pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-527">983.9</ix:nonFraction>&#160;million in cash for Reata's outstanding equity awards, inclusive of employer taxes, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" format="ixt:num-dot-decimal" scale="6" id="f-528">590.5</ix:nonFraction>&#160;million was attributable to pre-acquisition services and is therefore reflected as a component of total purchase price paid. Of the $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-529">983.9</ix:nonFraction>&#160;million paid to Reata's equity award holders, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-530">393.4</ix:nonFraction>&#160;million as compensation attributable to the post-acquisition service period, of which $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-531">196.4</ix:nonFraction>&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-532">197.0</ix:nonFraction>&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded this acquisition through available cash, cash equivalents and marketable securities, supplemented by the issuance of a $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="f-533">1.0</ix:nonFraction> billion term loan under our 2023 Term Loan. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Consideration</span></div><ix:continuation id="f-483-1" continuedAt="f-483-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of Reata is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to Reata shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-534">6,602.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of Reata equity compensation pre-acquisition services and related taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" scale="6" id="f-535">590.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-536">7,193.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents cash consideration transferred of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="1" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-537">172.50</ix:nonFraction> per outstanding Reata common stock based on <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="-5" name="biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-538">38.3</ix:nonFraction>&#160;million Reata shares outstanding at closing.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-473-4" continuedAt="f-473-5"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We finalized purchase accounting for this acquisition in the third quarter of 2024. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, and reflects measurement period adjustments made to the amounts initially recorded as of the acquisition date on <ix:continuation id="f-483-2" continuedAt="f-483-3">September&#160;26, 2023. The measurement period adjustments summarized below resulted from updates to our valuation assumptions related to the estimated amounts and timing of future cash flows associated with certain intangible assets, updates of our assumptions related to the quantities, selling location and remaining manufacturing and selling costs of acquired inventory, and other assets and liabilities. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.</ix:continuation></span></div><ix:continuation id="f-483-3"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:19.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as adjusted)</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="f-539">267.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="f-540">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="f-541">1,259.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="f-542">54.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology for SKYCLARYS (U.S.)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-543">4,200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development (omaveloxolone)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-544">2,300.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-545">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-546">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" scale="6" id="f-547">121.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" scale="6" id="f-548">110.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="f-549">159.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payable to Blackstone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="f-550">300.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="f-551">909.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" scale="6" id="f-552">151.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" sign="-" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" scale="6" id="f-553">2.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-554">6,724.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-555">469.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-556">7,193.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes measurement period adjustments recorded in the first quarter of 2024 that increased accrued expense and other by $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" format="ixt:num-dot-decimal" scale="6" id="f-557">4.9</ix:nonFraction>&#160;million, deferred tax liability by $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" sign="-" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" format="ixt:num-dot-decimal" scale="6" id="f-558">4.1</ix:nonFraction>&#160;million and goodwill by $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" sign="-" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-559">9.0</ix:nonFraction>&#160;million, as well as </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">measurement period adjustments recorded in the third quarter of 2024 that increased other current assets by $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-560">1.0</ix:nonFraction>&#160;million and accrued expense and other by $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" format="ixt:num-dot-decimal" scale="6" id="f-561">3.9</ix:nonFraction>&#160;million, and decreased deferred tax liability by $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" sign="-" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" format="ixt:num-dot-decimal" scale="6" id="f-562">7.2</ix:nonFraction>&#160;million and goodwill by $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" sign="-" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-563">4.3</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total inventory acquired was</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="9" id="f-564">1.3</ix:nonFraction>&#160;billion, which reflects a step-up in the fair value of finished goods and work-in-process inventory for SKYCLARYS. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold, which is expected to be sold over a period of approximately <ix:nonNumeric contextRef="c-117" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" format="ixt-sec:duryear" id="f-565">4</ix:nonNumeric> years from the acquisition date. For the three and nine months ended September 30, 2024, amortization from the fair value step-up adjustment was approximately $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-566">50.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-567">185.1</ix:nonFraction>&#160;million, respectively. The three and nine months ended September 30, 2024, include approximately $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-568">2.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-569">48.5</ix:nonFraction>&#160;million, respectively, of inventory used for clinical purposes, which is reflected within research and development expense within our condensed consolidated statements of income.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-473-5"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intang</span><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ible assets:</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets are comprised of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-570">4.2</ix:nonFraction>&#160;billion related to SKYCLARYS commercialization rights in the U.S., $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-571">2.3</ix:nonFraction>&#160;billion of IPR&amp;D related to the omaveloxolone program outside the U.S., which had not yet received regulatory approval in the E.U. as of the acquisition date, $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-572">100.0</ix:nonFraction>&#160;million related to a rare pediatric disease priority voucher which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party and $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-573">40.0</ix:nonFraction>&#160;million related to other clinical programs. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="c-117" decimals="3" name="biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="f-574">14.3</ix:nonFraction>% and the estimated fair value of the priority review voucher was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our valuation of the SKYCLARYS commercialization rights reflects the assumption that, using an economic consumption model, the related $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-575">4.2</ix:nonFraction>&#160;billion intangible asset will be amortized over its expected economic life. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon SKYCLARYS </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receiving E.U. regulatory approval in February 2024, we began selling the product in certain countries in Europe, and began amortizing the $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-576">2.3</ix:nonFraction>&#160;billion I</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PR&amp;D asset related to the program outside the U.S. over its expected economic life using an economic consumption model. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We assumed responsibility for a single-tenant, build-to-suit building of approximately <ix:nonFraction unitRef="sqft" contextRef="c-117" decimals="0" name="biib:OperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-577">327,400</ix:nonFraction> square feet of office and laboratory space located in Plano, Texas, with an initial lease term of <ix:nonNumeric contextRef="c-117" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-578">16</ix:nonNumeric> years. We recorded a lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-579">151.8</ix:nonFraction>&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately <ix:nonNumeric contextRef="c-117" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-580">15</ix:nonNumeric> years, with a corresponding right-of-use asset of approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="6" id="f-581">121.2</ix:nonFraction>&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. We recognized goodwill of approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-582">469.2</ix:nonFraction>&#160;million, which is not deductible for tax purposes. The goodwill recognized from our acquisition of Reata is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-related expenses:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acquisition-related expense, primarily comprised of regulatory, advisory and legal fees, and other transaction costs, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" format="ixt:num-dot-decimal" scale="6" id="f-583">26.3</ix:nonFraction>&#160;million and were recorded within selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023.</span></div></ix:continuation><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_46"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 3:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispositions</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-584" continuedAt="f-584-1" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="c-137" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-585">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="f-586">2.3</ix:nonFraction>&#160;billion. Under the terms of this transaction, we received approximately $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="f-587">1.0</ix:nonFraction>&#160;billion in cash at closing, with approximately $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-8" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="f-588">1.3</ix:nonFraction>&#160;billion in cash to be deferred over two payments. The first deferred payment of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="f-589">812.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2023 and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the second deferred payment of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="f-590">437.5</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2024, we recognized</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> a gain</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-591">7.5</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to reflect the change in fair value associated with the passage of time related to the second deferred payment </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">due to us, which was received in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2023, we recognized a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-592">13.7</ix:nonFraction>&#160;million to reflect the change in fair value associated with changes in interest rates and the passage of time related to the first deferred payment due to us, which was received in April 2023. Additionally, for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2023, we recognized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-593">7.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-594">16.9</ix:nonFraction>&#160;million, respectively, to reflect the changes in fair value associated with changes in interest rates and the passage of time related to the second deferred payment due to us, which was received in April 2024. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-584-1"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-595">103.0</ix:nonFraction>&#160;million upon the closing of the PRV purchase, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-596">14.4</ix:nonFraction>&#160;million was paid to Ionis. Our net portion of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-597">88.6</ix:nonFraction>&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024.</span></div></ix:continuation><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_49"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 4:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restructuring</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-598" continuedAt="f-598-1" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Fit for Growth Restructuring Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-8" name="biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" format="ixt:num-dot-decimal" scale="9" id="f-599">1.0</ix:nonFraction>&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately <ix:nonFraction unitRef="employee" contextRef="c-150" decimals="INF" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" format="ixt:num-dot-decimal" scale="0" id="f-600">1,000</ix:nonFraction> employees and we expect to incur restructuring charges ranging from approximately $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-601">260.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-602">280.0</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-603" continuedAt="f-603-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-605">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-606">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-608">5.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-609">5.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-611">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-612">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-614">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-615">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-616">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-618">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-619">37.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-620">17.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-621">55.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-622">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-623">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-624">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-625">37.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-626">23.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-627">61.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-629">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-630">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-632">17.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-633">17.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-635">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-636">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-637">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-638">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-639">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-640">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-642">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-643">62.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-644">33.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-645">96.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-646">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-647">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-648">43.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-649">62.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-650">51.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-651">114.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Integration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimate we will incur total integration charges ranging from approximately $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-652">35.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-653">40.0</ix:nonFraction>&#160;million, related to severance and employment costs, which are expected to be paid by the end of 2024. These amounts were substantially incurred during 2023.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-598-1"><ix:continuation id="f-603-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-655">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-656">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-657">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-658">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-659">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-661">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-662">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-663">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-664">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-666">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-668">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-669">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-670">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-671">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-672">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-673">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-674">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-675">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-676">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-677">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-679">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-680">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-681">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-682">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-683">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-685">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-686">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-687">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-688">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-689">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-690">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-692">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-693">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-694">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-695">21.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-696">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-697">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-698">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-699">21.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-700">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-701">21.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately <ix:nonFraction unitRef="sqft" contextRef="c-117" decimals="0" name="biib:OperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-702">327,400</ix:nonFraction> square feet of office and laboratory space located in Plano, Texas, with an initial lease term of <ix:nonNumeric contextRef="c-117" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-703">16</ix:nonNumeric> years. We do not intend to occupy this building and are evaluating opportunities to sublease the property. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HI-Bio Integration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, following the close of our HI-Bio acquisition in July 2024, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-704"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-705">1.5</ix:nonFraction></ix:nonFraction>&#160;million of severance and employment costs, which are reflected in restructuring charges within our condensed consolidated statements of income for the three and nine months ended September 30, 2024.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restructuring Reserve</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-706" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to workforce reductions are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of January 1</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-707">75.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-708">35.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-709">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-710">7.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-711">42.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-712">15.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" sign="-" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-713">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" sign="-" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-714">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-715">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-716">28.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-717">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-718">17.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-719">11.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-720">13.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" format="ixt:fixed-zero" scale="6" id="f-721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-722">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-723">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-724">32.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-725">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-726">58.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-727">4.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-728">31.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-729">2.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" sign="-" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-730">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-731">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-732">59.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_52"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 5:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Revenue</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-733" continuedAt="f-733-1" escape="true"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-734" continuedAt="f-734-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-735">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-736">192.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-737">232.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-738">58.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-739">181.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-740">239.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-741">134.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-742">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-743">158.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-744">148.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-745">16.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-746">165.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-747">175.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-748">215.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-749">390.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-750">206.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-751">198.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-752">405.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-753">115.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-754">60.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-755">176.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-756">148.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-757">63.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-758">212.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-759">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-760">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-761">61.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-762">31.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-763">34.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-764">65.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-765">143.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-766">94.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-767">237.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-768">180.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-769">97.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-770">277.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-771">227.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-772">178.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-773">406.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-774">244.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-775">211.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-776">456.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-777">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-778">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-779">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-780">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-781">20.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-782">20.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-783">546.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-784">507.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-785">1,053.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-786">631.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-787">527.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-788">1,159.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-789">153.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-790">228.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-791">381.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-792">150.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-793">297.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-794">448.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-795">81.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-796">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-797">102.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-798">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-799">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-800">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-801">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-802">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-803">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-804">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-805">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-806">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-807">240.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-808">254.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-809">494.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-810">152.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-811">297.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-812">449.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-813">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-814">118.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-815">118.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-816">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-817">112.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-818">112.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-820">54.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-821">54.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-822">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-823">54.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-824">54.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-826">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-827">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-828">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-829">20.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-830">20.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-831">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-832">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-833">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-834">6.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-835">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-836">6.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-837">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-839">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-840">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-841">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-842">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-843">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-844">192.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-845">196.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-846">6.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-847">188.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-848">194.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-849">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-851">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-852">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-853">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-854">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-855">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-856">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-857">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-858">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-859">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-860">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-861">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-862">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-863">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-864">0.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-865">1.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-866">2.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-867">813.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-868">956.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-869">1,769.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-870">790.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-871">1,014.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-872">1,805.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-733-1" continuedAt="f-733-2"><ix:continuation id="f-734-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-873">127.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-874">611.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-875">739.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-876">199.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-877">568.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-878">768.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-879">385.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-880">66.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-881">451.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-882">372.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-883">47.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-884">419.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-885">512.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-886">677.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-887">1,190.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-888">571.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-889">616.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-890">1,188.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-891">344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-892">193.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-893">537.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-894">397.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-895">207.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-896">604.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-897">84.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-898">109.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-899">194.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-900">95.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-901">125.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-902">220.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-903">428.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-904">303.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-905">732.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-906">492.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-907">333.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-908">825.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-909">690.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-910">609.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-911">1,299.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-912">750.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-913">662.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-914">1,412.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-915">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-916">57.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-917">57.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-918">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-919">67.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-920">67.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-921">1,631.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-922">1,648.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-923">3,279.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-924">1,814.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-925">1,678.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-926">3,493.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-927">458.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-928">692.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-929">1,151.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-930">453.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-931">875.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-932">1,328.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-933">230.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-934">49.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-935">280.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-936">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-937">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-938">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-939">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-940">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-941">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-942">2.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-943">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-944">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-945">703.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-946">749.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-947">1,452.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-948">455.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-949">875.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-950">1,331.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-951">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-952">354.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-953">354.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-954">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-955">331.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-956">331.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-958">162.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-959">162.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-960">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-961">167.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-962">167.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-963">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-964">47.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-965">47.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-967">60.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-968">60.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-969">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-970">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-971">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-972">21.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-973">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-974">22.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-975">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-977">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-978">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-979">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-980">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-981">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-982">572.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-983">591.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-984">21.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-985">560.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-986">581.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-987">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-989">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-990">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-991">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-992">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-993">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-994">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-995">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-996">1.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-997">5.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-998">7.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-999">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1000">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1001">56.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1002">1.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1003">5.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-467" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1004">7.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1005">2,405.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1006">2,975.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1007">5,380.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1008">2,293.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1009">3,121.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1010">5,414.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="c-17" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-1011"><ix:nonFraction unitRef="wholesaler" contextRef="c-1" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-1012"><ix:nonFraction unitRef="wholesaler" contextRef="c-15" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-1013"><ix:nonFraction unitRef="wholesaler" contextRef="c-16" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-1014">two</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="c-472" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-1015">25.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-473" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-1016">14.8</ix:nonFraction>% of gross product revenue for the three months ended September 30, 2024, and <ix:nonFraction unitRef="number" contextRef="c-474" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-1017">25.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-475" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-1018">12.9</ix:nonFraction>% of gross product revenue for the nine months ended September 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="c-17" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-1019"><ix:nonFraction unitRef="wholesaler" contextRef="c-1" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-1020"><ix:nonFraction unitRef="wholesaler" contextRef="c-15" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-1021"><ix:nonFraction unitRef="wholesaler" contextRef="c-16" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-1022">two</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="c-476" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-1023">26.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-477" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-1024">10.5</ix:nonFraction>% of gross product revenue for the three months ended September 30, 2023, and <ix:nonFraction unitRef="number" contextRef="c-478" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-1025">27.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-479" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-1026">9.1</ix:nonFraction>% of gross product revenue for the nine months ended September 30, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-733-2" continuedAt="f-733-3"><ix:nonNumeric contextRef="c-1" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="f-1027" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1028">173.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1029">857.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1030">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-1031">1,062.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="f-1032">605.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-1033">2,004.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="f-1034">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-1035">2,625.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-1036">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-1037">33.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-1038">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-1039">12.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="f-1040">439.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-1041">1,391.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="f-1042">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-1043">1,831.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-1044">160.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-1045">514.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-1046">17.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-1047">692.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1048">185.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1049">923.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1050">42.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-1051">1,151.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="f-1052" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1053">150.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1054">135.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-1055">1,000.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1056">926.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-1057">1,151.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-1058">1,062.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="c-1" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="f-1059" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1060">346.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1061">319.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1062">985.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-496" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1063">928.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-497" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-1064">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-1065">98.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-1066">285.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-1067">315.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-497" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-1068">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-1069">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-1070">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-1071">10.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1072">446.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1073">420.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1074">1,284.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1075">1,253.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Manufacturing, Royalty and Other Revenue</span></div><ix:nonNumeric contextRef="c-1" name="biib:OtherrevenuesTableTextBlock" id="f-1076" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized in the table below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1077">221.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1078">252.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1079">474.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1080">742.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1081">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1082">51.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1083">81.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1084">38.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1085">250.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1086">304.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1087">555.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1088">781.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers. During the first quarter of 2023 we began recognizing contract manufacturing revenue for LEQEMBI, upon accelerated approval of LEQEMBI in the U.S. Prior to accelerated approval, our share of contract manufacturing amounts related to LEQEMBI were recognized in research and development expense within our condensed consolidated statements of income.</span></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our <ix:nonFraction unitRef="number" contextRef="c-509" decimals="2" name="biib:ShareOfNonControlingInterestRecognized" scale="-2" id="f-1089">50.0</ix:nonFraction>% share of LEQEMBI product revenue, net and cost of sales, including royalties, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-733-3"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we are not the principal, as well as royalties we receive from net sales on products related to patents that we have out-licensed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_55"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 6:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Inventory</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-1091" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-1090" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-1092">368.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-1093">426.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-1094">1,803.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-1095">1,926.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-1096">391.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-1097">255.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1098">2,563.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1099">2,609.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-1100">2,469.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-1101">2,527.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryNoncurrent" scale="6" id="f-1102">94.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryNoncurrent" scale="6" id="f-1103">81.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1104">2,563.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1105">2,609.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term inventory is included in investments and other assets within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recorded approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="9" id="f-1106">1.3</ix:nonFraction>&#160;billion of acquired inventory, which includes measurement period adjustments, related to SKYCLARYS as a result of our acquisition of Reata in September 2023. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold, which is expected to be sold over a period of approximately <ix:nonNumeric contextRef="c-117" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" format="ixt-sec:duryear" id="f-1107">4</ix:nonNumeric> years from the acquisition date. For the three and nine months ended September 30, 2024, amortization from the fair value step-up adjustment was approximately $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-1108">50.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-1109">185.1</ix:nonFraction>&#160;million, respectively. The three and nine months ended September 30, 2024, include approximately $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-1110">2.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-1111">48.5</ix:nonFraction>&#160;million, respectively, of inventory used for clinical purposes, which is reflected within research and development expense within our condensed consolidated statements of income. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_58"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 7:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Intangible Assets and Goodwill</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-1112" continuedAt="f-1112-1" escape="true"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="f-1113" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired and in-licensed rights and patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-510" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1114">2</ix:nonNumeric>-<ix:nonNumeric contextRef="c-511" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1115">21</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1116">10,552.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1117">2,697.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1118">7,855.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1119">8,180.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1120">2,440.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1121">5,739.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-514" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1122">13</ix:nonNumeric>-<ix:nonNumeric contextRef="c-515" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1123">31</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1124">3,548.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1125">3,445.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1126">103.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1127">3,548.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1128">3,429.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1129">119.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1130">14,101.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1131">6,142.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1132">7,958.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1133">11,728.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1134">5,869.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1135">5,859.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1136">1,682.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1137">1,682.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1138">2,340.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1139">2,340.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1140">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1141">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1142">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1143">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1144">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1145">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1146">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1147">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1148">15,948.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1149">6,142.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1150">9,805.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1151">14,232.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1152">5,869.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1153">8,363.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1112-1" continuedAt="f-1112-2"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets, totaled </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1154">130.3</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1155">295.5</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1156">60.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1157">164.0</ix:nonFraction> million, respectivel</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, a</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mortization of acquired intangible assets, excluding impairment charges, totaled $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1158">110.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1159">275.3</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1160">60.9</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1161">164.0</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, in the prior year comparative periods. The increases were primarily due to amortization for the Reata acquisition acquired intangible assets associated with SKYCLARYS. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets reflects impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1162"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1163">20.2</ix:nonFraction></ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, related to intangible assets associated with Samsung Bioepis commercializ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ation rights terminated during the third quarter of 2024. For the three and nine months ended September 30, 2023, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt-sec:numwordsen" scale="0" id="f-1164"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt-sec:numwordsen" scale="0" id="f-1165">no</ix:nonFraction></ix:nonFraction> impair</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ment charges.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our 2019 Development and Commercialization Agreement with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between <ix:nonNumeric contextRef="c-527" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1166">2</ix:nonNumeric> to <ix:nonNumeric contextRef="c-528" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1167">31</ix:nonNumeric> years, with a remaining weighted average useful life of <ix:nonNumeric contextRef="c-512" name="biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" format="ixt-sec:duryear" id="f-1168">13</ix:nonNumeric> years for acquired and in-licensed rights and patents and <ix:nonNumeric contextRef="c-516" name="biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" format="ixt-sec:duryear" id="f-1169">10</ix:nonNumeric> years for developed technology and other. In connection with our acquisition of Reata in September 2023 we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1170">4.2</ix:nonFraction>&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset, with an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1171">2.3</ix:nonFraction>&#160;billion, from IPR&amp;D to completed technology.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value associated with our IPR&amp;D assets as of December 31, 2023, related to the IPR&amp;D programs we acquired in connection with our acquisition of Reata in September 2023, with an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1172">2.3</ix:nonFraction>&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset from IPR&amp;D to completed technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value associated with our IPR&amp;D assets as of September 30, 2024, primarily relates to the IPR&amp;D programs we acquired in connection with our acquisition of HI-Bio in July 2024, with an estimated fair value of approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1173">1.6</ix:nonFraction>&#160;billion.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease PRV that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-1174">100.0</ix:nonFraction>&#160;million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisitions of Reata and HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1112-2"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-1175" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="f-1176">125.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-1177">510.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-1178">550.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-1179">585.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-1180">615.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-1181">655.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-1182" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1183">6,219.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from HI-Bio acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1184">256.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from Reata acquisition</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1185">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="f-1186">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1187">6,485.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to Reata measurement period adjustments recognized during the nine months ended September 30, 2024.</span></div></ix:nonNumeric><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisitions of Reata and HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-1188">no</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_61"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 8:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fair Value Measurements</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-1190" continuedAt="f-1190-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-1189" continuedAt="f-1189-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-1191">802.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1192">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-1193">802.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1195">304.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1196">304.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1199">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1201">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1203">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1205">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-1207">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-1208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-1209">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-1210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1211">1,156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1212">304.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1213">851.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="f-1215">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="f-1216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="f-1217">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="f-1218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1219">287.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1222">287.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="f-1223">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="f-1225">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="f-1227">221.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="f-1230">221.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1231">542.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1233">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1234">508.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div><span><br/></span></div><ix:continuation id="f-1189-1" continuedAt="f-1189-2"><ix:continuation id="f-1190-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-1235">610.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1236">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-1237">610.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1238">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1239">416.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1240">416.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1241">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1242">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="f-1243">430.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1244">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1245">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="f-1246">430.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1247">11.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1248">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1249">11.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1250">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1251">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1252">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1253">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1254">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1255">1,506.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1256">416.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1257">660.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1258">430.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1259">31.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1260">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1261">31.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1262">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1263">31.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1264">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1265">31.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1266">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our <ix:nonFraction unitRef="number" contextRef="c-542" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1267">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-1268"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-1269">no</ix:nonFraction></ix:nonFraction> material impairments of our assets measured and carried at fair value as of September 30, 2024 and December 31, 2023. In addition, there have been no changes to our valuation techniques as of September 30, 2024 and December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-1270" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-1271">508.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-544" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1272">5.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-545" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1273">5.8</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-546" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1274">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2030</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1189-2" continuedAt="f-1189-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rates were calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of our contingent consideration obligations, which ranged from <ix:nonFraction unitRef="number" contextRef="c-101" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1275">67.0</ix:nonFraction>% to near certain probability as of September 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 as of September 30, 2024 and December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-1276" continuedAt="f-1276-1" escape="true">The following table provides a roll forward of the fair value of our contingent consideration obligation, which was classified as a Level 3 measurement:</ix:nonNumeric></span></div><ix:continuation id="f-1276-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.176%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three and Nine Months Ended September 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="6" id="f-1277"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="6" id="f-1278">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration resulting from HI-Bio acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="f-1279"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="f-1280">485.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-1281"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-1282">23.8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-1283">508.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, approximately $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1284">287.1</ix:nonFraction> million of the fair value of the total contingent consideration obligation was classified as short-term and reflected as a component of accrued expense and other within our condensed consolidated balance sheets with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="f-1285">221.8</ix:nonFraction> million reflected as a component of other long-term liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the three and nine months ended September 30, 2024, the changes in the fair value of our contingent consideration obligations were primarily due to changes in interest rates used to revalue our contingent consideration liabilities, the passage of time and updates to the expected timing of achieving certain milestones which will trigger contingent consideration payments.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1189-3"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="f-1286" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan 364-day tranche</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-547" decimals="-5" name="biib:NotesPayableCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-547" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-1288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-5" name="biib:NotesPayableCurrentFairValueDisclosure" scale="6" id="f-1289">150.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="f-1290">150.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-5" name="biib:NotesPayableCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1291">1,739.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1292">1,748.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-5" name="biib:NotesPayableCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1293">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-1294">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-5" name="biib:NotesPayableCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1295">1,739.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1296">1,748.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-5" name="biib:NotesPayableCurrentFairValueDisclosure" scale="6" id="f-1297">150.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="f-1298">150.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan three-year tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-5" name="us-gaap:NotesPayable" format="ixt:fixed-zero" scale="6" id="f-1300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1301">500.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1302">500.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-5" name="us-gaap:NotesPayable" format="ixt:fixed-zero" scale="6" id="f-1304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1305">1,721.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1306">1,746.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1307">1,339.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1308">1,494.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-557" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1309">1,279.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1310">1,493.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1311">1,079.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1312">1,101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-560" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1313">1,089.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1314">1,100.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1315">1,034.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1316">1,474.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1317">1,049.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1318">1,474.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1319">490.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1320">475.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1321">498.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1322">472.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1323">3,943.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1324">4,545.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1325">6,137.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1326">6,788.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1327">5,683.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1328">6,293.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1329">6,287.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1330">6,938.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we drew $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="f-1331">1.0</ix:nonFraction> billion from our 2023 Term Loan, comprised of a $<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1332">500.0</ix:nonFraction> million floating rate 364-day tranche and a $<ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1333">500.0</ix:nonFraction> million floating rate three-year tranche. As of September 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The fair values of our Senior Notes as of September 30, 2024, compared to December 31, 2023, remained flat reflecting a mix of higher and lower U.S. treasury yields and credit spreads across the maturity spectrum. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div></ix:continuation><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_67"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 9:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Financial Instruments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-1334" continuedAt="f-1334-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-1335" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1336">802.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1337">610.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1338">802.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1339">610.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our money market funds approximates fair value due to their short-term maturities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-1340" continuedAt="f-1340-1" escape="true">The following tables summarize our marketable equity securities, classified as available-for-sale:</ix:nonNumeric></span></div><ix:continuation id="f-1340-1" continuedAt="f-1340-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1341">58.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1343">8.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1344">50.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1345">676.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1347">421.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1348">254.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1349">734.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1351">429.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1352">304.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div><span><br/></span></div><ix:continuation id="f-1334-1"><ix:continuation id="f-1340-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1353">31.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1354">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1355">21.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1356">10.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1357">948.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1358">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1359">542.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1360">406.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1361">979.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1362">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1363">563.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1364">416.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="f-1365" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.747%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.394%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1366">5,698.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1367">7,380.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-1368">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-1369">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-1370">16.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-1371">18.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of December 31, 2023, we have sold all of our marketable debt securities. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three and nine months ended September 30, 2023, primarily relate to sales of U.S. treasuries and corporate bonds.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-5" name="biib:StrategicInvestmentPortfolio" scale="6" id="f-1372">353.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-5" name="biib:StrategicInvestmentPortfolio" scale="6" id="f-1373">460.7</ix:nonFraction> million, respectively, which are included in other current assets and investments and other assets within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio as of September 30, 2024, was primarily due to the decrease in the fair value of our investment in Sage common stock, partially offset by an increase in the fair value of our investment in Denali common stock. Additionally, we sold a portion of our Denali and Sangamo common stock during 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our strategic investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div></ix:continuation><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_73"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 10:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Derivative Instruments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-1374" continuedAt="f-1374-1" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of September 30, 2024 and December 31, 2023, had durations of <ix:nonNumeric contextRef="c-580" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1375">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-581" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1376">15</ix:nonNumeric> months and <ix:nonNumeric contextRef="c-582" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1377">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-583" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1378">12</ix:nonNumeric> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1374-1" continuedAt="f-1374-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="f-1379" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-584" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1380">1,569.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-585" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1381">1,169.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-586" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1382">32.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-587" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="f-1383">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-588" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1384">72.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-589" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="f-1385">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1386">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="f-1387">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1388">1,686.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1389">1,169.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock" id="f-1390" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="f-1391">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:UnrealizedGainOnDerivatives" format="ixt:fixed-zero" scale="6" id="f-1392">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="f-1393">43.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="f-1394">34.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="f-1395">41.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="f-1396">34.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized losses of approximately $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" format="ixt:num-dot-decimal" scale="6" id="f-1397">41.5</ix:nonFraction>&#160;million to be settled over the next 15 months, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="f-1398">38.5</ix:nonFraction>&#160;million of these net unrealized losses are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2024 and December 31, 2023, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-1399" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1400">7.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1401">1.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1402">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1403">2.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1404">1.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1405">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1406">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1407">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1408">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1409">18.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1410">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1411">1.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1412">8.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1413">2.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1414">1.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1415">2.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1416">1,339.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1417">1,301.5</ix:nonFraction> million as of September 30, 2024 and December 31, 2023, respectively. Net gains of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1418">23.4</ix:nonFraction> million and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1374-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net losses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1419">6.6</ix:nonFraction> million related to these contracts were recorded as a component of other (income) expense, net for the three and nine months ended September 30, 2024, respectively, compared to net losses of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1420">22.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1421">28.0</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-1422" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1423">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1424">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1425">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="f-1426">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1427">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1428">26.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1429">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="f-1430">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1431">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1432">11.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1433">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1434">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_76"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 11:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-1435" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1436">2,604.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1437">2,402.5</ix:nonFraction> million as of September 30, 2024 and December 31, 2023, respectively. For the three and nine months ended September 30, 2024, depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1438">72.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1439">213.9</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1440">64.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1441">190.7</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we built a large-scale biologics manufacturing facility in Solothurn, Switzerland. This facility includes <ix:nonFraction unitRef="sqft" contextRef="c-624" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="f-1442">393,000</ix:nonFraction> square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="c-625" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="f-1443">290,000</ix:nonFraction> square feet of warehouse, utilities and support space and <ix:nonFraction unitRef="sqft" contextRef="c-626" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="f-1444">51,000</ix:nonFraction> square feet of administrative space. As of December 31, 2023, we had approximately $<ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-5" name="us-gaap:ConstructionInProgressGross" scale="6" id="f-1445">728.8</ix:nonFraction> million capitalized as construction in progress related to this facility. In the second quarter of 2021 a portion of this facility (the first manufacturing suite) received a GMP multi-product license from SWISSMEDIC and was placed into service. The second manufacturing suite, which was also licensed to operate by SWISSMEDIC, became operational in the first quarter of 2024, resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="f-1446">717.3</ix:nonFraction>&#160;million of fixed assets being placed into service. Solothurn has been approved for the manufacture of LEQEMBI.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_79"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 12:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Leases</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1447" escape="true"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6100 Legacy Drive Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we assumed responsibility for a single-tenant, build-to-suit building of approximately <ix:nonFraction unitRef="sqft" contextRef="c-117" decimals="0" name="biib:OperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-1448">327,400</ix:nonFraction> square feet of office and laboratory space located in Plano, Texas, with an initial lease term of <ix:nonNumeric contextRef="c-117" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1449">16</ix:nonNumeric> years. We recorded a lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1450">151.8</ix:nonFraction>&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately <ix:nonNumeric contextRef="c-117" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1451">15</ix:nonNumeric> years, with a corresponding right-of-use asset of approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1452">121.2</ix:nonFraction>&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_85"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 13:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indebtedness</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Term Loan <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1453" continuedAt="f-1453-1" escape="true">Credit Agreement</ix:nonNumeric></span></div><ix:continuation id="f-1453-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $<ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1454">1.5</ix:nonFraction>&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="f-1455">1.0</ix:nonFraction> billion from the 2023 Term Loan, comprised of a $<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1456">500.0</ix:nonFraction>&#160;million floating rate 364-day tranche and a $<ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1457">500.0</ix:nonFraction>&#160;million floating rate three-year tranche. The remaining unused commitment of $<ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1458">500.0</ix:nonFraction>&#160;million was terminated. As of December 31, 2023, we repaid $<ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" format="ixt:num-dot-decimal" scale="6" id="f-1459">350.0</ix:nonFraction>&#160;million of the 364--day tranche. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1460">150.0</ix:nonFraction>&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the first quarter of 2024 we repaid $<ix:nonFraction unitRef="usd" contextRef="c-633" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1461">250.0</ix:nonFraction>&#160;million of the three-year tranche, with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-634" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1462">250.0</ix:nonFraction>&#160;million portion of the three-year tranche being subsequently repaid in full during the second quarter of 2024. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_88"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 14:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1463" continuedAt="f-1463-1" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-635" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1464">5.0</ix:nonFraction> billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and nine months ended September 30, 2024 and 2023. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-636" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="f-1465">2.1</ix:nonFraction> billion remained available under our 2020 Share Repurchase Program as of September 30, 2024.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1463-1" continuedAt="f-1463-2"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1466" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-637" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1467">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-638" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1468">2.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-639" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1469">153.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1470">146.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-640" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1471">49.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-641" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1472">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1473">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1474">7.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-640" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1475">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-641" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1478">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-640" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1479">41.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-641" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1480">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1481">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1482">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-643" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1483">31.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1484">2.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1485">112.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1486">145.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1487">25.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-647" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1488">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1489">126.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1490">153.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1491">11.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1492">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1493">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1494">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1495">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1498">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1499">6.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1500">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1501">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1502">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-643" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1503">31.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1504">2.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1505">112.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1506">145.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1507">14.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1508">13.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1509">0.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1510">144.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1511">172.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1512">2.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1513">29.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1514">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1515">30.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1516">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1517">12.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1518">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1519">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1520">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1521">12.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1522">14.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1523">29.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1524">0.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1525">30.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1526">13.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1527">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1528">16.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1529">0.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1530">175.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1531">159.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1532">15.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1533">15.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1534">1.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1535">163.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1536">164.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1537">2.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1538">18.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1539">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1540">11.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1541">10.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1542">13.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1543">17.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1544">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1545">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1546">4.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1547">15.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1548">1.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1549">0.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1550">11.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1551">5.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1552">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1553">16.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1554">0.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1555">175.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1556">159.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="f-1557" escape="true"><ix:continuation id="f-1463-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.372%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-672" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1559">15.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1561">17.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-672" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-1562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1563">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-1564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1565">3.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-1566">7.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-1567">1.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1568">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1569">18.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-1570">1.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="f-1571">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-1572">8.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="f-1573">2.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1574">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1575">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1576">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1577">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1578">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-1579">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1580">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1581">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-680" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1582">8.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1583">12.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-682" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1584">5.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-683" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1585">4.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_91"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 15:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per Share</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1586" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1587" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1588">388.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1589">68.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1590">1,365.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1591">911.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1592">145.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1593">144.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1594">145.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1595">144.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-684" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1596">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-685" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-1597">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-686" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1598">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-687" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1599">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-688" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1600">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-689" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-1601">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-690" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1602">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-691" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1603">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1604">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="f-1605">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1606">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1607">0.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1608">146.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1609">144.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1610">146.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1611">145.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income (loss) per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_94"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 16:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share-Based Payments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1612" continuedAt="f-1612-1" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1613" continuedAt="f-1613-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-692" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1614">69.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-693" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1615">217.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-694" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1616">124.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1617">276.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1618">61.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1619">234.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1620">150.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1621">333.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1622">131.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1623">452.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1624">275.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1625">609.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1626">2.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1627">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1628">8.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1629">8.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1630">128.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1631">449.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1632">267.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1633">601.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1634">24.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1635">98.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1636">50.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1637">126.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1638">104.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1639">350.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-702" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1640">216.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1641">474.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1612-1" continuedAt="f-1612-2"><ix:continuation id="f-1613-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we recognized Reata equity-based compensation expense, inclusive of employer taxes, of approximately $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1642">393.4</ix:nonFraction>&#160;million attributable to the post-acquisition service period, of which $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1643">196.4</ix:nonFraction>&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1644">197.0</ix:nonFraction>&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we recognized HI-Bio equity-based compensation expense, inclusive of employer taxes, of approximately $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1645">56.4</ix:nonFraction>&#160;million attributable to the post-acquisition service period, of which $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1646">42.5</ix:nonFraction>&#160;million was recognized as a charge to research and development expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1647">13.9</ix:nonFraction>&#160;million as a charge to selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-1648" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-704" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1649">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1650">53.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1651">174.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1652">175.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1653">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1654">7.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1655">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1656">27.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1657">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-713" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1658">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1659">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-715" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1660">8.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-716" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1661">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1662">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1663">2.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1664">4.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1665">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1666">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1667">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1668">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1669">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1670">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1671">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1672">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1674">387.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1676">387.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HI-Bio equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1677">56.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1678">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1679">56.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1680">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1681">131.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1682">452.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1683">275.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1684">609.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1685">2.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1686">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1687">8.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1688">8.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1689">128.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1690">449.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1691">267.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1692">601.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the Reata and HI-Bio equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to Reata and HI-Bio employees and required no future services to vest. For additional information on our acquisition of Reata and HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1612-2"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Omnibus Equity Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024 our shareholders approved the 2024 Omnibus Equity Plan for share-based awards to our prospective and current employees, non-employee directors, officers or consultants. Awards granted from the 2024 Omnibus Equity Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2024 Omnibus Equity Plan consist of <ix:nonFraction unitRef="shares" contextRef="c-730" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="f-1693">3.7</ix:nonFraction> million shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) on the date that our shareholders approved the 2024 Omnibus Equity Plan, plus shares that were subject to awards under the 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) that remain unissued upon the cancellation, surrender, exchange, termination or forfeiture of such awards. The 2024 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a <ix:nonFraction unitRef="number" contextRef="c-731" decimals="1" name="biib:RatioOfNumberOfSharesReservedUnderPlan" scale="0" id="f-1694">1.5</ix:nonFraction>-to-1 ratio.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not made any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan since our shareholders approved the 2024 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan in the future, except that unused shares under the 2017 Omnibus Equity Plan have been carried over for use under the 2024 Omnibus Equity Plan. Awards outstanding under the 2017 Omnibus Equity Plan and the Directors Plan as of the date our shareholders approved the 2024 Omnibus Equity Plan will remain outstanding and subject to the terms and conditions of the 2017 Omnibus Equity Plan and the Directors Plan, as applicable, and the relevant award agreements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024 our shareholders approved the 2024 ESPP. The 2024 ESPP, which became effective on July 1, 2024, replaced the 2015 ESPP, which expired on June 30, 2024. The maximum number of shares of our common stock that may be purchased under the 2024 ESPP is <ix:nonFraction unitRef="shares" contextRef="c-732" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="f-1695">2.5</ix:nonFraction> million.</span></div></ix:continuation><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_97"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 17:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Income Taxes</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1696" continuedAt="f-1696-1" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Tax Rate</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1697" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1698">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1699">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1700">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1701">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1702">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1703">1.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1704">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1705">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings, including valuation allowances</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1706">11.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1707">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1708">7.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1709">6.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1710">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1711">24.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1712">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1713">7.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased inventory valuation step-up and intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1714">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1715">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1716">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1717">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1718">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1719">14.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1720">1.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1721">1.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1722">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1723">7.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1724">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1725">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1726">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1727">51.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1728">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1729">9.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, our effective tax rate includes a decrease in our valuation allowance related to changes in projected future foreign taxable income, partially offset by the impact of certain foreign uncertain tax positions.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1696-1"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for the three months ended September 30, 2023, reflects a tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1730">72.9</ix:nonFraction>&#160;million recognized as a result of a pretax loss from operations of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1731">141.2</ix:nonFraction>&#160;million recorded during the third quarter of 2023, which was driven, in part, by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses. For all other periods presented, the effective tax rates reflect tax expense on pretax income from operations in the respective periods.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nine months ended September 30, 2023, was also impacted by the resolution of an uncertain tax matter related to tax credits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2019 or state, local or non-U.S. income tax examinations for years before 2013.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="f-1732">55.0</ix:nonFraction>&#160;million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:continuation><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_100"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 18:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Other Consolidated Financial Statement Detail</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="f-1733" continuedAt="f-1733-1" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="f-1734" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1735">11.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1736">95.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1737">49.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1738">252.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1739">59.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1740">63.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1741">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1742">175.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1743">39.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1744">317.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1745">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1746">289.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1747">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1748">11.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1749">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1750">30.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1751">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1752">3.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1753">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1754">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1755">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1756">300.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1757">193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1758">248.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GainLossOnInvestmentsTextBlock" id="f-1759" continuedAt="f-1759-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1760">39.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1761">302.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1762">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1763">273.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1764">10.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1765">4.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1766">5.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1767">5.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1768">28.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1769">297.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1770">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1771">268.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1733-1" continuedAt="f-1733-2"><ix:continuation id="f-1759-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2024, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1772">53.3</ix:nonFraction>&#160;million, partially offset by a decrease in the fair value of Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1773">22.7</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1774">295.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-736" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1775">90.2</ix:nonFraction>&#160;million, partially offset by an increase in the fair value of Denali and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1776">70.1</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1777">265.0</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-1778" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-1779">1,000.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1780">926.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-1781">288.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-1782">335.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="f-1783">280.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="f-1784">214.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-1785">178.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-1786">191.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1787">287.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1788">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata related accrued expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:SettlementLiabilitiesCurrent" scale="6" id="f-1789">82.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:SettlementLiabilitiesCurrent" scale="6" id="f-1790">117.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="f-1791">637.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="f-1792">838.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1793">2,755.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1794">2,623.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1733-2">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-1795">744.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-1796">781.1</ix:nonFraction> million as of September 30, 2024 and December 31, 2023, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="f-1797">162.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="f-1798">403.2</ix:nonFraction> million, respectively</ix:continuation>.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_103"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-1799" continuedAt="f-1799-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 19:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborative and Other Relationships</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1799-1" continuedAt="f-1799-2"><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">U.S.:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">Canada:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from <ix:nonFraction unitRef="number" contextRef="c-739" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1800">13.5</ix:nonFraction>% and increasing up to <ix:nonFraction unitRef="number" contextRef="c-740" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1801">24.0</ix:nonFraction>% if annual net sales exceed $<ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-5" name="biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" format="ixt:num-dot-decimal" scale="6" id="f-1802">900.0</ix:nonFraction>&#160;million. There will be a <ix:nonFraction unitRef="number" contextRef="c-741" decimals="INF" name="biib:Reductioninroyaltyrate" scale="-2" id="f-1803">50.0</ix:nonFraction>% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we receive a gross <ix:nonFraction unitRef="number" contextRef="c-742" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1804">3.0</ix:nonFraction>% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting <ix:nonNumeric contextRef="c-741" name="biib:PeriodOfCollaborationAgreement" format="ixt-sec:duryear" id="f-1805">11</ix:nonNumeric> years from the first commercial sale of OCREVUS on a country-by-country basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUNSUMIO (mosunetuzumab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. Under our collaboration with Genentech, we were responsible for <ix:nonFraction unitRef="number" contextRef="c-743" decimals="INF" name="biib:PercentageOfFutureDevelopmentCosts" scale="-2" id="f-1806">30.0</ix:nonFraction>% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S. In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COLUMVI (glofitamab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 we entered into an agreement with Genentech related to the commercialization and sharing of economics for COLUMVI, a bispecific antibody for the treatment of B-cell non-Hodgkin's lymphoma, which was subsequently granted accelerated approval by the FDA in June 2023. Under the terms of this agreement, we will have no payment obligations. Genentech will have sole decision-making rights on the commercialization of COLUMVI within the U.S. and we will receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 Roche announced that COLUMVI, in combination with chemotherapy GemOx (glofitamab-gxbm), demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma</span><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1799-2" continuedAt="f-1799-3"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Formulas</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN and LUNSUMIO Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a <ix:nonFraction unitRef="number" contextRef="c-744" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" scale="-2" id="f-1807">30.0</ix:nonFraction>% share on the first $<ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1808"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1809">50.0</ix:nonFraction></ix:nonFraction>&#160;million of combined co-promotion operating profits earned each calendar year. <ix:nonNumeric contextRef="c-1" name="biib:CoPromotionProfitSharingFormulaTableTextBlock" id="f-1810" continuedAt="f-1810-1" escape="true">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $<ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1811"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1812">50.0</ix:nonFraction></ix:nonFraction>&#160;million varies upon the following events, as summarized in the table below:</ix:nonNumeric></span></div><ix:continuation id="f-1810-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-744" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="f-1813">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-744" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1814">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-744" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" scale="-2" id="f-1815">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $<ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-5" name="biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1816">500.0</ix:nonFraction>&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $<ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-5" name="biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1817">150.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $<ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-5" name="biib:SalesTriggerGrossSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="f-1818">350.0</ix:nonFraction>&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was <ix:nonFraction unitRef="number" contextRef="c-745" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1819">35.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax profit-sharing formula for GAZYVA provides for a <ix:nonFraction unitRef="number" contextRef="c-745" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1820">35.0</ix:nonFraction>% share on the first $<ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1821"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1822">50.0</ix:nonFraction></ix:nonFraction>&#160;million of operating profits earned each calendar year. <ix:nonNumeric contextRef="c-1" name="biib:PretaxProfitSharingFormulaTableTextBlock" id="f-1823" continuedAt="f-1823-1" escape="true">Our share of annual co-promotion profits in excess of $<ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1824"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1825">50.0</ix:nonFraction></ix:nonFraction>&#160;million varies upon the following events, as summarized in the table below:</ix:nonNumeric></span></div><ix:continuation id="f-1823-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-745" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="f-1826">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-745" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1827">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second GAZYVA Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $<ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-5" name="biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1828">500.0</ix:nonFraction>&#160;million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the Second GAZYVA Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for GAZYVA was <ix:nonFraction unitRef="number" contextRef="c-745" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1829">35.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023 we accrued a $<ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-5" name="biib:AccruedPaymentToTerminationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-1830">31.0</ix:nonFraction>&#160;million payable to Eisai related to the termination of an agreement whereby Eisai co-promoted or distributed our MS products in certain Asia-Pacific markets and settings. As of December 31, 2023, we paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-5" name="biib:PaymentsMadeToTerminationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-1831">16.0</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-5" name="biib:AccruedPaymentToTerminationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-1832">31.0</ix:nonFraction>&#160;million payable. The remaining portion was subsequently paid in January 2024. This termination fee is included in selling, general and administrative expense in our condensed consolidated statements of income for the nine months ended September 30, 2023.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LEQEMBI (lecanemab) Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease (the LEQEMBI Collaboration).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We and Eisai co-promote LEQEMBI and share profits and losses equally. We currently manufacture LEQEMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1799-3" continuedAt="f-1799-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 the FDA granted traditional approval of LEQEMBI. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Outside of the U.S., LEQEMBI is now approved in Japan (September 2023), China (January 2024), South Korea (May 2024), Hong Kong (July 2024), Israel (July 2024), United Arab Emirates (August 2024) and Great Britain (August 2024).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of LEQEMBI in the U.S., we began recognizing our <ix:nonFraction unitRef="number" contextRef="c-509" decimals="2" name="biib:ShareOfNonControlingInterestRecognized" scale="-2" id="f-1833">50.0</ix:nonFraction>% share of LEQEMBI product revenue, net and cost of sales, including royalties, within other revenue in our condensed consolidated statements of income, as we are not the principal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of LEQEMBI sales and marketing expense and development expense are recorded within selling, general and administrative expense and research and development expense, respectively, within our condensed consolidated statements of income.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="f-1834" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1835">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1836">88.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1837">255.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1838">282.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1839">38.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1840">44.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1841">127.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1842">141.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1843">164.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1844">163.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-755" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1845">476.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-756" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1846">191.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1847">82.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1848">81.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-755" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1849">238.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-756" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1850">95.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s discussed above were approximately $<ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-5" name="biib:AccountsReceivableFromCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1851">93.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-5" name="biib:AccountsReceivableFromCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1852">1.4</ix:nonFraction>&#160;million as of September 30, 2024 and December 31, 2023, respectively. Amounts payable to Eisai related to the agreements discussed above were approximately $<ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-5" name="biib:AccountsPayableToCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1853">146.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-5" name="biib:AccountsPayableToCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1854">118.4</ix:nonFraction>&#160;million as of September 30, 2024 and December 31, 2023, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" id="f-1855" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-758" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1856">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-759" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1857">13.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-760" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1858">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-761" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1859">46.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-758" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1860">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-759" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1861">6.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-760" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1862">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-761" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1863">23.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the treatment of PPD and potential treatment of MDD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1799-4" continuedAt="f-1799-5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">epilepsy. In July 2024 we and Sage announced that the Phase 2 KINETIC 2 dose-range study of BIIB124 did not meet its endpoints. Based on these results, we discontinued our further development of BIIB124.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. ZURZUVAE for PPD became commercially available in the U.S. during the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024 we and Sage agreed to not pursue further development of zuranolone for the potential treatment of MDD. This decision was based on the significant new investment and time we expect would be needed to conduct the additional studies required to support approval of this indication.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. During the fourth quarter of 2023 we accrued a milestone payment due to Sage of $<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="f-1864">75.0</ix:nonFraction>&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S., which was recorded within intangible assets, net in our condensed consolidated balance sheets, and subsequently paid in January 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, we recognized net profit-sharing expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1865">9.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1866">20.5</ix:nonFraction> million, respectively, to reflect Sage's <ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="biib:ShareOfNetProfitFromSageTherapeuticsPercent" scale="-2" id="f-1867">50.0</ix:nonFraction>% share of net collaboration results in the U.S. for ZURZUVAE for PPD, compared to net loss reimbursement of approximately $<ix:nonFraction unitRef="usd" contextRef="c-765" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1868"><ix:nonFraction unitRef="usd" contextRef="c-766" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1869">5.9</ix:nonFraction></ix:nonFraction> million in both prior year comparative periods. These amounts are recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" id="f-1870" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Sage collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-767" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1871">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-768" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1872">72.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-769" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1873">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-770" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1874">158.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-767" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1875">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-768" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1876">36.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-769" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1877">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-770" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1878">79.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Sage collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-771" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1879">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-772" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1880">54.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-773" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1881">82.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-774" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1882">152.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-771" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1883">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-772" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1884">27.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-773" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1885">41.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-774" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1886">76.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease (LRRK2 Collaboration) and also entered into a separate agreement to obtain an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its ATV-enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. In July 2024 we terminated our license with Denali for the ATV-enabled anti-amyloid beta program. This termination also results in the termination of the exclusive option agreement, as discussed above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LRRK2 Collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" id="f-1887" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1888">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-776" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1889">12.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-777" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1890">44.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-778" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1891">51.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1892">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-776" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1893">7.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-777" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1894">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-778" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1895">30.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1799-5" continuedAt="f-1799-6"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, we recorded approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-779" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-1896">26.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-780" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-1897">42.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-781" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="6" id="f-1898">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-782" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-1899">2.8</ix:nonFraction> million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the prior year comparative periods.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="c-783" decimals="INF" name="biib:ContingentCommercializedRightsNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-1900">two</ix:nonFraction> potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately <ix:nonFraction unitRef="number" contextRef="c-783" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1901">45.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024 we notified Samsung Bioepis of our decision to terminate our 2019 Development and Commercialization Agreement (the DCA Agreement) solely within the U.S. and Canada. As a result of this termination we recognized impairment charges of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1902"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1903">20.2</ix:nonFraction></ix:nonFraction> million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which were recorded within amortization and impairment of acquired intangible assets within our condensed consolidated statements of income for the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2024. Biogen will transfer commercialization rights for BYOOVIZ and OPUVIZ in the U.S. and Canada back to Samsung Bioepis over a period of up to 18 months. During this transition period, we will continue to commercialize BYOOVIZ. The termination does not impact the other markets in the DCA Agreement.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Samsung Bioepis up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-784" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="f-1904">165.0</ix:nonFraction> million in additional development, regulatory and sales-based milestones associated with the remaining major markets covered by the agreement.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="c-784" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1905">50.0</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2024, we recognized net profit-sharing expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-785" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1906">60.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-786" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1907">176.8</ix:nonFraction>&#160;million, respectively, to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="c-784" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1908">50.0</ix:nonFraction>% sharing of the net collaboration profits, compared to a net profit-sharing expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-787" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1909">56.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-788" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1910">170.4</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024 we exercised our option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="c-784" name="biib:CollaborativeArrangementTermExtension" format="ixt-sec:durwordsen" id="f-1911">five years</ix:nonNumeric>. In connection with this exercise, we paid Samsung Bioepis an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="c-784" decimals="-5" name="biib:ContractOptionExerciseFee" scale="6" id="f-1912">60.0</ix:nonFraction> million in July 2024 which was recognized in intangible assets, net within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufa</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cturing, royalty and other revenue in our condensed consolidated statements of income.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1799-6" continuedAt="f-1799-7"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were approximately $<ix:nonFraction unitRef="usd" contextRef="c-789" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-1913">20.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-790" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-1914">9.9</ix:nonFraction>&#160;million as of September 30, 2024 and December 31, 2023, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were approximately $<ix:nonFraction unitRef="usd" contextRef="c-789" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1915">82.6</ix:nonFraction>&#160;million and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-790" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1916">73.7</ix:nonFraction>&#160;million as of September 30, 2024 and December 31, 2023, respectively.</span></div></ix:continuation><div style="margin-top:6pt"><ix:continuation id="f-1799-7" continuedAt="f-1799-8"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1799-8"> to our consolidated financial statements included in our 2023 Form 10-K.</ix:continuation> </span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_109"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 20:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investments in Variable Interest Entities</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="f-1917" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2007 we consolidated the results of Neurimmune as we determined we were the primary beneficiary because we had the power through the collaboration to direct the activities that most significantly impacted the entity's economic performance and we were required to fund <ix:nonFraction unitRef="number" contextRef="c-791" decimals="INF" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="f-1918">100.0</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. The collaboration and license agreement with Neurimmune was for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023 we notified Neurimmune of our decision to terminate the Neurimmune Agreement. Subsequent to the termination, we reconsidered our relationship with Neurimmune and determined that we were no longer the primary beneficiary of the variable interest entity. As a result, we recorded a net gain on the deconsolidation of Neurimmune of approximately $<ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-5" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="f-1919">3.0</ix:nonFraction>&#160;million, which was recorded in other (income) expense, net within our consolidated statements of income for the year ended December 31, 2023, included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="f-1920">23.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="f-1921">16.4</ix:nonFraction> million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div></ix:nonNumeric><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_112"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 21:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Litigation</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-1922" continuedAt="f-1922-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims, investigations and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. If an estimate of the </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1922-1" continuedAt="f-1922-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation asserted against Biogen</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are defendants in three securities actions pending in the District Court, one filed by Nadia Shash and Amjad Khan in November 2020 and related to ADUHELM, one filed by the Oklahoma Firefighters Pension and Retirement System in February 2022 and related to ADUHELM and one filed by Thomas Allen Gray in June 2024 and related to statements about our compliance controls, 2023 earnings guidance and other matters. All allege violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation asserted against Reata</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in March 2024 the United States District Court for the Eastern District of Texas granted final approval of the previously disclosed settlement of litigation filed by putative stockholders of Reata (later acquired by Biogen) alleging violations of the federal securities laws by Reata, certain of its former officers and directors, and certain underwriters under 15 U.S.C. &#167;78j(b) and &#167;78t(a), 17 C.F.R. &#167;240.10b-5, and 15U.S.C. &#167;&#167;77k, 77l(a)(2) and 77o, and dismissed the action with prejudice.  </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Actions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and members of the Board of Directors are named as defendants in five derivative actions pending in the District Court, one filed by The Booth Family Trust in February 2022, one filed by Elaine Wang in July 2022, one filed by Jonathan Blaufarb (Blaufarb I) in July 2024, one filed by Lawrence Hollin in October 2024 and one filed by Jonathan Blaufarb (Blaufarb II) in October 2024. The Booth, Wang and Blaufarb II actions relate to ADUHELM and other matters, and the Blaufarb and Hollin actions relate to statements about our compliance controls, 2023 earnings guidance and other matters. The actions allege breach of fiduciary duty, waste of corporate assets and other common law claims, and violations of the Securities Exchange Act of 1934, 15 U.S.C. &#167;78a et seq. The actions seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#8217; fees and costs payable to the plaintiffs. The Booth and Wang actions are stayed.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Technical Boards of Appeal of the European Patent Office upheld the validity of Fresenius Kabi Deutschland GmbH's (Fresenius Kabi's) European Patent 3 145 488 (the EP '488 Patent), which expires in May 2035. In June 2022 Fresenius Kabi filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes the French counterpart of the EP &#8216;488 Patent. In March 2024 the D&#252;sseldorf Regional Court dismissed Fresenius Kabi's claim of infringement of the German counterpart of the EP '488 Patent and Fresenius Kabi has appealed to the Higher Regional Court of D&#252;sseldorf.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Former Convergence Shareholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, asserted claims of $<ix:nonFraction unitRef="usd" contextRef="c-792" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="f-1923">200.0</ix:nonFraction> million for alleged breaches of the contract pursuant to which we acquired Convergence. In June 2023 Shareholder Representative Services LLC and 24 former shareholders filed a suit against us in the High Court of Justice of England and Wales asserting one of the 2019 claims and seeking payment of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-1924">49.9</ix:nonFraction>&#160;million, interest and costs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1922-2"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the District Court dismissed the previously disclosed action filed against us by Humana in September 2020. Humana had alleged damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients and had alleged violations of the federal RICO Act and state laws. In December 2023 Humana appealed to the United States Court of Appeals for the First Circuit and the appeal is pending.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023 Genentech, Inc. filed suit against us in the U.S. District Court for the Northern District of California and claims that it is owed royalties of approximately $<ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-1925">92.7</ix:nonFraction>&#160;million on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen, together with interest and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lender Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2024, BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP filed suit against us and Reata Pharmaceuticals, Inc. in the Supreme Court of the State of New York alleging breach of a loan agreement with Reata and seeking payment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-794" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-1926">23.2</ix:nonFraction>&#160;million, plus interest, costs and attorneys' fees.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Antitrust Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August and September 2024, four suits were filed against us in the U.S. District Court for the Northern District of Illinois, by Local No. 1 Health Fund; the Mayor and City Council of Baltimore; New York State Teamsters Council Health and Hospital Fund; and Teamsters Local 237 Welfare Fund and Teamsters Local 237 Retirees' Benefit Fund. Plaintiffs allege violations of federal antitrust laws including 15 U.S.C. &#167;&#167; 1, 2 and 13(c) and various state laws, based on contracts with pharmacy benefit managers related to TECFIDERA and VUMERITY. Plaintiffs seek declarations of the actions as class actions, monetary, declaratory and equitable relief, and attorneys' fees and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received subpoenas from the SEC seeking information relating to ADUHELM and its launch, and our equity plans. We have also received subpoenas from the DOJ and SEC seeking information relating to our business operations in several foreign countries. The Italian Competition Authority is investigating Biogen and other companies in relation to our biosimilar product BYOOVIZ.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TYSABRI Biosimilar Patent Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#167;262, seeking a declaratory judgment of patent infringement.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annulment Proceedings in the General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 Mylan Ireland filed an action in the General Court of the European Union (General Court) to annul the EMA's decision not to validate its applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. In October 2024 the General Court dismissed the action.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;8 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he results of operations of Reata and HI-Bio, along with the estimated fair values of the assets acquired and liabilities assumed in the acquisitions, have been included in our condensed consolidated financial statements since the closing of the Reata and HI-Bio acquisitions on September&#160;26, 2023 and July&#160;2, 2024, respectively.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_121"></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">EXECUTIVE SUMMARY</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INTRODUCTION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2024, we completed the acquisition of HI-Bio. As a result of this transaction we acquired HI-Bio's lead asset, felzartamab, an anti-CD38 antibody currently being evaluated for three leading indications, AMR, PMN and IgAN. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets, as well as TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we expanded our large molecule production capacity and built a large-scale biologics manufacturing facility in Solothurn, Switzerland. In the second quarter of 2021 a portion of this facility (the first manufacturing suite) received a GMP multi-product license from SWISSMEDIC and was placed into service. The second manufacturing suite, which was also licensed to operate by SWISSMEDIC, became operational in the first quarter of 2024. Solothurn has been approved for the manufacture of LEQEMBI. We believe that the Solothurn facility will support our anticipated near to mid-term needs for the manufacturing of biologic assets. The plant represents a significant increase in our overall manufacturing capacity and is not yet being fully utilized, resulting in our recording of excess capacity charges. If we are unable to fully utilize our manufacturing facilities, we will incur </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional excess capacity charges which would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BUSINESS ENVIRONMENT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed, for example the IRA has certain provisions related to drug pricing. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and/or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics on employees, the global economy and the delivery of healthcare treatments, geopolitical events, supply chain disruptions, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion on our business environment, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our 2023 Form 10-K. For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in North America, Brazil and certain European countries and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and we expect that TECFIDERA revenue will continue to decline in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a favorable decision of the CJEU affirming TECFIDERA's right to regulatory data and marketing protection, the EC determined that TECFIDERA is entitled to an additional year of market protection, which extends through February 2, 2025. Our entitlement to this additional year of market protection is being challenged. As of September 30, 2024, some of the TECFIDERA generics have not yet fully exited some European markets. We are closely monitoring this situation and seeking to enforce our legal right to market protection. In addition, are continuing to defend and seek to enforce our EP 2 653 873 patent related to TECFIDERA, which expires in 2028.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BUSINESS UPDATE REGARDING MACROECONOMIC CONDITIONS AND OTHER DISRUPTIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant portions of our business are conducted in Europe, Asia and other international geographies. Factors such as global health outbreaks, adverse weather events, geopolitical events, inflation, labor or raw material shortages and other supply chain disruptions could result in product shortages or other difficulties and delays or increased costs in manufacturing our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT ECONOMIC CONDITIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions remain vulnerable as markets continue to be impacted in part by elevated inflation, higher interest rates, extreme weather events, global supply chain uncertainties and risks associated with geopolitical conflicts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ADVERSE WEATHER EVENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse weather conditions, including hurricane, earthquake and natural disaster damage, may affect our ability to do business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have operations in RTP, North Carolina, which were not impacted by recent hurricanes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GLOBAL SUPPLY CHAIN DISRUPTIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global supply chain disruptions, such as strikes, work stoppages, port congestion, port closures and other logistical problems, may affect our ability to do business. For example, recent major port strikes on the East and Gulf Coasts of the U.S. resulted in delayed cargo movement for several days, with the potential for future port strikes as further contract negotiations are expected in January 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our primary shipping method for resources and finished goods is through air freight, the recent port strikes did not impact our business, however, we will continue to assess any future port disruptions and if necessary, secure alternative transportation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GEOPOLITICAL TENSIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global disputes and interruptions in international relationships, including tariffs, trade protection measures, import or export licensing requirements and the imposition of trade sanctions or similar restrictions by the U.S. or other governments, affect our ability to do business. For example, tensions between China and Taiwan and tensions between the U.S. and China have led to a series of tariffs and sanctions being imposed by the U.S. on imports from China mainland, as well as other business restrictions, with additional restrictive measures being proposed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and the pharmaceutical industry, utilize China-based partners for certain raw materials, ingredients and components for our pharmaceutical products and their delivery devices. Engaging alternative suppliers may involve seeking additional regulatory approvals and be costly in terms of time and resources needed. For example, certain early processes related to our acquired SKYCLARYS product rely on a single supplier based in China. We are continuing to evaluate SKYCLARYS' supply chain and prioritizing actions to mitigate risks associated with its manufacturing and our ability to supply patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing geopolitical tensions related to Russia's invasion of Ukraine and the military conflict in the Middle East have resulted in global business disruptions and economic volatility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, sanctions and other restrictions have been levied on the government and businesses in Russia. Although we do not have affiliates or employees, in either Russia or Ukraine, we do provide various therapies to patients in Russia through a distributor. In addition, new government sanctions on the export of certain manufacturing materials to Russia may delay or limit our ability to get new products approved. The impact of the conflict on our operations and financial performance remains uncertain and will depend on future developments, including the severity and duration of the conflict between Russia and Ukraine, its impact on regional and global economic conditions and whether the conflict spreads or has effects on countries outside Ukraine and Russia.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor the ongoing conflict between Russia and Ukraine as well as the military conflict in the Middle East and assess any potential impacts on our business, supply chain, partners or customers, as well as any factors that could have an adverse effect on our results of operations. Revenue generated from sales in Russia and Ukraine represent less than 2.0% of total revenue for the three and nine months ended September 30, 2024 and 2023. Additionally, revenue generated from sales in the broader Middle East region represents less than 2.0% of total revenue for the three and nine months ended September 30, 2024 and 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CLIMATE-RELATED DISCLOSURES</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024 the SEC adopted final rules designed to enhance disclosures related to the impacts of climate-related matters. The final rules require disclosures of material climate-related risks, activities to mitigate or adapt to such risks, information about our board of directors' oversight of climate-related risks and management&#8217;s role in managing material climate-related risks and information on any climate-related targets or goals that are material to our business, results of operations or financial condition. In addition, the E.U. and California have enacted similar legislation and regulations. The E.U.'s Corporate Sustainability Reporting Directive will require expansive disclosures on various ESG matters for companies whose business and assets exceed certain thresholds within E.U. countries. California's new environmental disclosure laws will impose additional climate-related reporting requirements on large companies conducting business in the state of California.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that these new rules and laws will have on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL HIGHLIGHTS</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, reflects the following:</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_127"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL REVENUE</span></td></tr></table></div><div><img src="biib-20240930_g2.jpg" alt="6" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$64.5 million or 2.5%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DILUTED EARNINGS (LOSS) PER SHARE</span></td></tr></table></div><div><img src="biib-20240930_g3.jpg" alt="22" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3.13 or 666.0%</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_130"></div></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRODUCT REVENUE, NET</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20240930_g4.jpg" alt="6" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$35.8 million or 2.0%</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">MS revenue decreased $105.1 million, or 9.1%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Rare disease revenue increased $44.9 million, or 10.0%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">The decrease in MS product revenue was primarily due to a decrease in Interferon demand due to competition as patients transition to higher efficacy therapies and a decrease in global TYSABRI revenue driven by increased competition, unfavorable channel dynamics in the U.S. and a decrease in pricing in certain international markets.</span></div><div style="margin-top:1.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">The increase in rare disease product revenue was primarily due to global SKYCLARYS revenue of $102.3 million in the third quarter of 2024, partially offset by a decrease in rest of world SPINRAZA revenue driven by the loss of an annual tender in Russia which resulted in an unfavorable impact of approximately $45.0&#160;million. The decrease was also impacted by the timing of SPINRAZA shipments and the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:1.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">U.S. product revenue for ZURZUVAE was $22.0&#160;million during the third quarter of 2024.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_133"></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL COST AND EXPENSE</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20240930_g5.jpg" alt="6" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$656.7 million or 24.6%</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Cost of sales decreased $20.9 million, or 3.2%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">R&amp;D expense decreased $193.6 million, or 26.3%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">SG&amp;A expense decreased $199.8 million, or 25.3%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Amortization and impairment of acquired intangible assets increased $69.4 million, or 114.0%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.34pt">The decrease in cost of sales was primarily due to favorable product mix from decreased contract manufacturing revenue and lower idle capacity charges.</span></div><div style="margin-top:1.5pt;padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">The decrease in R&amp;D expense was primarily driven by approximately $197.0&#160;million of equity-based compensation expense recognized in 2023 related to the Reata acquisition, cost-reduction measures realized in 2024 in connection with our portfolio prioritization initiatives and our Fit for Growth program, as well as higher spend on clinical trials and close out costs incurred during 2023, partially offset by approximately $42.5&#160;million of equity-based compensation expense recognized in 2024 related to the HI-Bio acquisition.</span></div><div style="margin-top:1.5pt;padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.34pt">The decrease in SG&amp;A expense was primarily due to cost-reduction measures realized in 2024 in connection with our Fit for Growth program and approximately $196.4&#160;million of equity-based compensation expense recognized in 2023 related to the acquisition of Reata. </span></div><div style="margin-top:1.5pt;padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.34pt">The increase in amortization and impairment of acquired intangible assets was primarily due to </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amortization for the Reata acquisition acquired intangible assets associated with SKYCLARYS, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as well as impairment charges of $20.2 million related to commercialization rights terminated during the third quarter of 2024.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_136"></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">Cash and cash equivalents totaled approximately $1.7 billion as of September 30, 2024, compared to approximately $1.0 billion as of December 31, 2023.</span></div><div style="margin-top:1.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">We generated approximately $2.1 billion of net cash flow from operations for the nine months ended September 30, 2024.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">In July 2024 we completed the acquisition of HI-Bio for $1.15&#160;billion, which was funded through available cash on hand.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ACQUISITIONS AND DIVESTITURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HUMAN IMMUNOLOGY BIOSCIENCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody, is currently being evaluated for three leading indications, Antibody-Mediated Rejection (AMR), Primary Membranous Nephropathy (PMN) and Immunoglobulin A Nephropathy (IgAN). Felzartamab has received Breakthrough Therapy Designation and ODD from the FDA for development in the treatment of PMN and AMR and has received ODD in the treatment of antibody-mediated rejection in kidney transplant recipients. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we paid shareholders of HI-Bio approximately $1.15&#160;billion, at closing and may pay up to an additional </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$650.0&#160;million in potential future development and regulatory milestone payments.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded this acquisition through available cash on hand and accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the lead program felzartamab, the HI-Bio pipeline acquired includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial, and the potential for continued development in a range of complement-mediated diseases. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SALE OF PRIORITY REVIEW VOUCHER</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $103.0&#160;million upon the closing of the PRV purchase, of which approximately $14.4&#160;million was paid to Ionis. Our net portion of approximately $88.6&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the nine months ended September 30, 2024. For additional information on the sale of our PRV, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DEVELOPMENTS IN KEY COLLABORATIVE RELATIONSHIPS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LEQEMBI (lecanemab)</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In July 2024 Eisai presented new clinical data from the CLARITY AD study open-label extension of LEQEMBI, demonstrating that three years of continuous LEQEMBI treatment reduced clinical decline, resulting in a clinically meaningful benefit for early Alzheimer's disease patients.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2024 the FDA accepted for review the supplemental BLA for LEQEMBI monthly IV maintenance dosing for the treatment of early Alzheimer's disease, with a PDUFA action date set for January 25, 2025.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In May 2024 Eisai initiated the rolling submission of a BLA to the FDA for LEQEMBI subcutaneous autoinjector for weekly maintenance dosing after being granted Fast Track designation by the FDA in May 2024.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of World</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In October 2024 the Therapeutic Goods Administration of Australia issued a public statement about the initial decision not to register lecanemab. Eisai will request a reconsideration of this decision.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In August 2024 LEQEMBI was approved by the Medicines and Healthcare products Regulatory Agency in Great Britain and by the Ministry of Health and Prevention in the United Arab Emirates.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In July 2024 the CHMP of the EMA adopted a negative opinion on the MAA for LEQEMBI. Eisai will seek re-examination of the CHMP opinion.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In July 2024 LEQEMBI was approved in Hong Kong and Israel.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2024 we and Eisai announced the launch of LEQEMBI in China, which had been approved by the NMPA in China in January 2024.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In May 2024 the Ministry of Food and Drug Safety approved LEQEMBI in South Korea.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER KEY DEVELOPMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FELZARTAMAB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024 the FDA granted felzartamab Breakthrough Therapy Designation for the treatment of late AMR without T-cell mediated rejection in kidney transplant patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024 we and UCB announced positive topline data from the Phase 3 PHOENYCS GO study of dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in people living with moderate-to-severe SLE. The Phase 3 study met the primary endpoint demonstrating clinical improvement in moderate-to-severe SLE with clinical improvements observed among key secondary endpoints. Based on these results, UCB and Biogen will be initiating a second Phase 3 study in 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SPINRAZA (nusinersen)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024 we announced positive topline data from the Phase 2/3 DEVOTE study of nusinersen, which evaluated the safety and efficacy of a higher dose regimen of nusinersen in treatment-naive symptomatic infants with SMA. Based on this data we will plan to submit for regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DISCONTINUED PROGRAMS AND STUDIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SAGE COLLABORATION</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024 we and Sage agreed to not pursue further development of zuranolone for the potential treatment of MDD. This decision was based on the significant new investment and time we expect would be needed to conduct the additional studies required to support approval of this indication.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For additional information on our collaboration with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SAMSUNG BIOEPIS 2019 DEVELOPMENT AND COMMERCIALIZATION AGREEMENT </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024 we notified Samsung Bioepis of our decision to terminate our 2019 Development and Commercialization Agreement (the DCA Agreement) solely within the U.S. and Canada. Biogen will transfer commercialization rights for BYOOVIZ and OPUVIZ in the U.S. and Canada back to Samsung Bioepis over a period of up to 18 months. During this transition period, we will continue to commercialize BYOOVIZ. The termination does not impact the other markets in the DCA Agreement. For additional information on our 2019 Development and Commercialization Agreement with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ACORDA COLLABORATION</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024 we notified Acorda of our decision to terminate our collaboration and license agreement, effective January 1, 2025. As a result of this termination, Acorda will regain global commercialization rights to FAMPYRA. On April 1, 2024, Acorda filed for bankruptcy protection and announced its intention to sell substantially all its assets to a third party. On July 10, 2024, Merz Therapeutics announced that it had completed the acquisition of FAMPYRA, and related assets from Acorda. We are now working with Merz Therapeutics on the transition of global commercialization rights of FAMPYRA.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BIIB105</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024 we and Ionis announced that the Phase 1/2 ALSpire study of BIIB105, an investigational ASO for the potential treatment of ALS, did not meet its endpoints. Based on these results, we discontinued our further development of BIIB105.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BIIB121</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024 we announced that we have elected not to exercise our option to license and lead development of BIIB121, an ASO for the potential treatment of Angelman syndrome.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BIIB124</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024 we and Sage announced that the Phase 2 KINETIC 2 dose-range study of BIIB124 did not meet its endpoints. Based on these results, we discontinued our further development of BIIB124.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:13pt"><span style="color:#00587f;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following revenue discussion should be read in conjunction with </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Revenue</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">956.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,805.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,465.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,530.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,975.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,380.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,414.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(225.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,221.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,449.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(228.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_148"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PRODUCT REVENUE</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">507.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">527.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,159.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(105.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">956.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,805.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,631.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,648.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,814.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,678.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,493.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(213.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">455.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,331.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,975.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,380.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,414.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM, ADUHELM and ZURZUVAE, which became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MULTIPLE SCLEROSIS</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20240930_g6.jpg" alt="6" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global TYSABRI revenue decreased $50.2 million, from $456.3 million in 2023 to $406.1 million in 2024, or 11.0%, primarily due to increased competition, unfavorable channel dynamics in the U.S. and a decrease in pricing in certain international markets.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global TECFIDERA revenue decreased $6.7 million, from $239.5 million in 2023 to $232.8 million in 2024, or 2.8%, driven by a decrease in demand as a result of multiple TECFIDERA generic entrants in North America, Brazil and certain E.U. countries.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global Interferon revenue decreased $40.2 million, from $277.7 million in 2023 to $237.5 million in 2024, or 14.5%, driven by a decrease in demand as patients transition to higher efficacy therapies.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global VUMERITY revenue decreased $7.4 million, from $165.5 million in 2023 to $158.1 million in 2024, or 4.5%, primarily due to unfavorable channel dynamics in the U.S., partially offset by an increase in demand in rest of world VUMERITY.</span></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.5pt solid #679acb;padding:0 1pt"/></tr></table></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_154"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20240930_g7.jpg" alt="4" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global TYSABRI revenue decreased $112.6 million, from $1,412.2 million in 2023 to $1,299.6 million in 2024, or 8.0%, primarily due to a decrease in U.S. TYSABRI revenue driven by increased competition, unfavorable channel dynamics and higher discounts and allowances, as well as a decrease in pricing in rest of world TYSABRI.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global TECFIDERA revenue decreased $28.9 million, from $768.2 million in 2023 to $739.3 million in 2024, or 3.8%, driven by a decrease in demand as a result of multiple TECFIDERA generic entrants in North America, Brazil and certain E.U. countries.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global Interferon revenue decreased $93.7 million, from $825.7 million in 2023 to $732.0 million in 2024, or 11.3%, driven by a decrease in demand as patients transition to higher efficacy therapies.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.3pt">Global VUMERITY revenue increased $31.5 million, from $419.9 million in 2023 to $451.4 million in 2024, or 7.5%, primarily due to an increase in global demand and favorable channel dynamics.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_157"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MS revenue includes sales from TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024 we expect total MS revenue will continue to decline as a result of increasing competition for many of our MS products in both the U.S. and rest of world markets. Additionally, a biosimilar entrant of TYSABRI was approved in the U.S. and the E.U. in 2023. We believe that future sales of TYSABRI may be adversely affected by the entrance of this biosimilar.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RARE DISEASE</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><img src="biib-20240930_g8.jpg" alt="6" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.6pt">U.S. SPINRAZA revenue increased $2.6 million, from $150.5 million in 2023 to $153.1 million in 2024, or 1.7%, primarily due to favorable net pricing, offset in part by unfavorable channel dynamics and a decrease in demand.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Rest of world SPINRAZA revenue decreased $69.4 million, from $297.7 million in 2023 to $228.3 million in 2024, or 23.3%, driven by the loss of an annual tender in Russia which resulted in an unfavorable impact of approximately $45.0&#160;million. The decrease was also impacted by the timing of shipments and the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Global SKYCLARYS revenue was $102.3 million in 2024, including $81.8 million of U.S. SKYCLARYS revenue, which we began recognizing during the fourth quarter of 2023, subsequent to our acquisition of Reata, and $20.5 million of rest of world SKYCLARYS revenue, which was approved in the E.U. and became commercially available during the first quarter of 2024. </span></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_163"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20240930_g9.jpg" alt="4" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.6pt">U.S. SPINRAZA revenue increased $5.9 million, from $453.0 million in 2023 to $458.9 million in 2024, or 1.3%, primarily due to favorable net pricing, offset by a decrease in demand.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Rest of world SPINRAZA revenue decreased $182.7 million, from $875.6 million in 2023 to $692.9 million in 2024, or 20.9%, driven by the loss of an annual tender in Russia which resulted in an unfavorable impact of approximately $45.0&#160;million. The decrease was also impacted by the timing of shipments and the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Global SKYCLARYS revenue was $280.3 million in 2024, including $230.4 million of U.S. SKYCLARYS revenue, which we began recognizing during the fourth quarter of 2023, subsequent to our acquisition of Reata, and $49.9 million of rest of world SKYCLARYS revenue, which was approved in the E.U. and became commercially available during the first quarter of 2024. </span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_166"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare disease revenue includes sales from SPINRAZA, QALSODY, which became commercially available in the U.S. during the second quarter of 2023, and SKYCLARYS, which was obtained as part of our acquisition of Reata in September 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition of Reata. In February 2024 the EC approved SKYCLARYS in the E.U. for the treatment of FA in adults and adolescents aged 16 years and older, which became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024 we expect growth in rare disease revenue as we continue to launch SKYCLARYS in the U.S. and E.U. We expect global SPINRAZA revenue to decrease by high-single digits.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BIOSIMILARS</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20240930_g10.jpg" alt="6" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:307px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12pt">For the three and nine months ended September 30, 2024, compared to the same periods of 2023, the increases in biosimilar revenue were primarily due to increases in sales volumes related to BENEPALI, offset by decreases in pricing due to competitive pressures.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_175"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilars revenue includes sales from BENEPALI, IMRALDI, FLIXABI, BYOOVIZ and TOFIDENCE. In 2023 BYOOVIZ became commercially available in certain international markets. During the third quarter of 2023 the FDA approved TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, which became commercially available in the U.S. during the second quarter of 2024. TOFIDENCE was also approved in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work with our third-party contract manufacturers for IMRALDI and BENEPALI to address supply constraints. If not resolved these supply constraints could have an adverse impact on 2024 sales. In addition, one of our contract manufacturers for IMRALDI and BENEPALI entered into a proposed acquisition by a third party, which is expected to close at the end of 2024. We are currently evaluating the impact this will have on our biosimilars business and working to implement mitigation activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating our strategic options, we have made the decision to retain our biosimilars business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REVENUE FROM ANTI-CD20 THERAPEUTIC PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN, including RITUXAN HYCELA, GAZYVA and LUNSUMIO collaboration operating profits in the U.S., royalty revenue on sales of OCREVUS and other revenue from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">928.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ROYALTY REVENUE ON SALES OF OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, the increases in royalty revenue on sales of OCREVUS were primarily due to sales growth of OCREVUS in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BIOGEN'S SHARE OF PRE-TAX PROFITS IN THE U.S. FOR RITUXAN, GAZYVA AND LUNSUMIO</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, the decreases in our share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO were primarily due to decreases in sales of RITUXAN in the U.S. resulting from competition from multiple biosimilar products, partially offset by increases in sales of GAZYVA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER REVENUE FROM ANTI-CD20 THERAPEUTIC PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits from RITUXAN in Canada, royalty revenue on sales of LUNSUMIO outside the U.S. and royalty revenue on net sales of COLUMVI in the U.S., which became commercially available during the second quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_181"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTRACT MANUFACTURING, ROYALTY AND OTHER REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">742.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTRACT MANUFACTURING REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, the decreases in contract manufacturing revenue were primarily driven by higher volumes in 2023 due to the timing of batch production, which includes batches related to LEQEMBI that we began recognizing in the first quarter of 2023 upon the accelerated approval of LEQEMBI in the U.S.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, as part of the 2020 sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we provided FUJIFILM with certain minimum batch production commitment guarantees, including batches related to our contract manufacturing arrangements. As of December 31, 2023, these batch commitments have been satisfied and we expect that our contract manufacturing revenue will be lower in 2024, compared to 2023, as we are no longer supplying contract manufacturing customers using Hiller&#248;d in this manner.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ROYALTY AND OTHER REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, as we are not the principal, as well as royalties we receive from net sales on products related to patents that we have out-licensed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_184"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESERVES FOR DISCOUNTS AND ALLOWANCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,971.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,959.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">856.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">845.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,612.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,547.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, reserves for discounts and allowances as a percentage of gross product revenue were 32.6% and 32.4%, respectively, compared to 31.7% in both prior year comparative periods. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTRACTUAL ADJUSTMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates in the U.S., pharmacy rebates, co-payment (copay) assistance, VA, 340B discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2024, compared to the same period in 2023, the decrease in contractual adjustments was primarily due to lower Medicaid rebates, partially offset by higher government rebates in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2024, compared to the same period in 2023, the increase in contractual adjustments was primarily due to higher government rebates in the U.S. and higher other rebates in biosimilars, partially offset by lower government rebates in rest of world and lower Medicaid rebates in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DISCOUNTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts, wholesaler incentives and volume related discounts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2024, compared to the same period in 2023, the increase in discounts was primarily driven by higher purchase discounts in rest of world and the U.S. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2024, compared to the same period in 2023, the increase in discounts was primarily driven by higher purchase and volume discounts for biosimilars.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RETURNS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for estimated product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, the decreases in returns were primarily driven by lower returns in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Revenue,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">COST AND EXPENSE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expense is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.412%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">736.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(193.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">788.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(199.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(91.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(285.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,014.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,671.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(656.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,915.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(188.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,509.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,891.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(381.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,941.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,606.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,444.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(837.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COST OF SALES, EXCLUDING AMORTIZATION AND IMPAIRMENT OF ACQUIRED INTANGIBLE ASSETS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,204.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,915.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRODUCT COST OF SALES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, the decreases in product cost of sales were primarily due to favorable product mix from decreased contract manufacturing revenue and lower idle capacity charges, offset in part by $48.4&#160;million and $136.6&#160;million, respectively, in SKYCLARYS amortization costs. Contract manufacturing revenue includes LEQEMBI inventory produced for Eisai, beginning in the first quarter of 2023 upon the accelerated approval of LEQEMBI in the U.S. Cost of sales as a percentage of revenue was adversely affected by LEQEMBI batches due to minimal margins.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Reata in September 2023 we recorded a fair value step-up adjustment related to the acquired inventory of SKYCLARYS of approximately $1.3&#160;billion. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold, which is expected to be sold over a period of approximately 4 years from the acquisition date. For the three and nine months ended September 30, 2024, amortization from the fair value step-up adjustment, associated with SKYCLARYS, as a result of inventory sold was approximately $48.4&#160;million and $136.6&#160;million, respectively. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROYALTY COST OF SALES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s in royalty cost of sales were primarily due to lower royalties associated with sales of SPINRAZA and TYSABRI.</span></div><div style="margin-top:5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Write Downs and Other Charges</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, we recorded approximately $35.0&#160;million and $113.3&#160;million, respectively, of aggregate gross idle capacity charges. We had no significant gross idle capacity charges for the three and nine months ended September 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESEARCH AND DEVELOPMENT</span></div><div><img src="biib-20240930_g11.jpg" alt="29" style="height:766px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div><span><br/></span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Research and development expense, as a percentage of total revenue, was 22.0% and 29.1% for the three months ended September 30, 2024 and 2023, respectively. For the three months ended September 30, 2024, compared to the same period in 2023, the decrease in research and development was primarily driven by approximately $197.0&#160;million of equity-based compensation expense recognized in 2023 related to the Reata acquisition,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">cost-reduction measures realized in 2024 in connection with our portfolio prioritization initiatives and our Fit for Growth program, as well as higher spend on clinical trials and close out costs incurred during 2023. The decrease was partially offset by approximately $42.5&#160;million of equity-based compensation expense recognized in 2024 related to the HI-Bio acquisition.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">EARLY STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Q3 2024 vs. Q3 2023</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in early stage programs was driven by a decrease in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">advancement of BIIB059 for the treatment of CLE into late stage; and</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">discontinuation of BIIB121 for the treatment of Angelman syndrome.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">development of BIIB080 for the treatment of Alzheimer's disease.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">LATE STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Q3 2024 vs. Q3 2023</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The increase in late stage programs was driven by an increase in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">advancement of BIIB059 for the treatment of CLE into late stage; and</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">increased spend in BIIB059 for the treatment of SLE.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The increase was partially offset by a decrease in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">advancement of TOFIDENCE from late stage to marketed upon the approval of TOFIDENCE in the U.S.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">MARKETED PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Q3 2024 vs. Q3 2023</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in marketed programs was driven by a decrease in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">discontinuation of ADUHELM for the treatment of Alzheimer's disease; and</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">decreased spend on ZURZUVAE for MDD.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">increased spend in SKYCLARYS as a result of our acquisition of Reata in September 2023; and</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">advancement of TOFIDENCE from late stage to marketed upon the approval of TOFIDENCE in the U.S.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.581%"><div><img src="biib-20240930_g12.jpg" alt="4" style="height:864px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div><span><br/></span></div></div><div style="display:inline-block;max-width:6.837%;min-width:5.837%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.582%"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Research and development expense, as a percentage of total revenue, was 20.9% and 25.4% for the nine months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024, compared to the same period in 2023, the decrease in research and development was primarily driven by approximately $197.0&#160;million of equity-based compensation expense recognized in 2023 related to the Reata acquisition, cost-reduction measures realized in 2024 in connection with our portfolio prioritization initiatives and our Fit for Growth program, as well as higher spend on clinical trials and close out costs incurred during 2023, partially offset by approximately $48.5&#160;million of step-up amortization related to SKYCLARYS inventory and approximately $42.5&#160;million of equity-based compensation expense recognized in 2024 related to the HI-Bio acquisition.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">EARLY STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2024 vs. YTD 2023</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in early stage programs was driven by a decrease in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of BIIB059 for the treatment of CLE into late stage;</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of BIIB121 for the treatment of Angelman syndrome; and</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of BIIB131 for the treatment of acute ischemic stroke.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">development of BIIB080 for the treatment of Alzheimer's disease; and</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">development of cemdomespib for the treatment of diabetic neuropathic pain.</span></div><div style="margin-top:1.5pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">LATE STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2024 vs. YTD 2023</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in late stage programs was driven by a decrease in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of ZURZUVAE from late stage to marketed upon the approval of ZURZUVAE for PPD in the U.S.;</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of QALSODY from late stage to marketed upon the accelerated approval of QALSODY in the U.S.;</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of TOFIDENCE from late stage to marketed upon the approval of TOFIDENCE in the U.S.; and</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of BIIB093 for LHI.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of BIIB059 for the treatment of CLE into late stage.</span></div><div style="margin-top:1.5pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">MARKETED PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2024 vs. YTD 2023</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in marketed programs was driven by a decrease in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of ADUHELM for the treatment of Alzheimer's disease; and </span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">decreased spend on ZURZUVAE for MDD.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">increased spend in SKYCLARYS as a result of our acquisition of Reata in September 2023;</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of QALSODY from late stage to marketed upon the accelerated approval of QALSODY in the U.S.; and</span></div><div style="text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of TOFIDENCE from late stage to marketed upon the approval of TOFIDENCE in the U.S.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense is reported above based on the following classifications. The development stage reported is based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Research and discovery:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents costs incurred to support our discovery research and translational science efforts. </span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Early stage programs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are programs in Phase 1 or Phase 2 development.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Late stage programs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are programs in Phase 3 development or in registration stage.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Marketed products:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Other research and development costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding any milestone and upfront payments, we expect our core research and development expense to decrease in 2024, while continuing to invest in our pipeline, such as our acquisition of HI-Bio in July 2024. This is primarily due to the continued realization of our cost savings initiatives. We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_205"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SELLING, GENERAL AND ADMINISTRATIVE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, selling, general and administrative expense decreased by approximately 25.3% and 11.2%, respectively, primarily due to cost-reduction measures realized in 2024 in connection with our Fit for Growth program and approximately $196.4&#160;million of equity-based compensation expense recognized in 2023 related to the acquisition of Reata. The decrease was partially offset by an increase in operational spending on sales and marketing activities in support of LEQEMBI and SKYCLARYS as we continue to expand our U.S. and international product launches.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, selling, general and administrative expense included the recognition of approximately $13.9&#160;million in equity-based compensation expense related to our acquisition of HI-Bio that was associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. Additionally, the three and nine months ended September 30, 2024, include transaction and integration-related expense incurred of approximately $2.4&#160;million and $3.2&#160;million, respectively, related to the acquisition of HI-Bio.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, selling, general and administrative expense included the recognition of approximately $196.4&#160;million in equity-based compensation expense related to our acquisition of Reata that was associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. Additionally, the three and nine months ended September 30, 2023, includes transaction and integration-related expense incurred of approximately $29.6&#160;million related to the acquisition of Reata.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, selling, general and administrative expense also included a $31.0&#160;million obligation to Eisai related to the termination of the co-promotion agreement for our MS products in Japan during the first quarter of 2023 and accelerated depreciation recognized during the second quarter of 2023 of approximately $11.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GENERAL AND ADMINISTRATIVE EXPENSE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, general and administrative expense decreased by approximately $178.1&#160;million, or 48.9%, and $183.3&#160;million, or 26.2%, respectively, compared to the same periods in 2023, due to the recognition of approximately $196.4&#160;million in equity-based compensation expense in 2023 related to our acquisition of Reata.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisitions of Reata and HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AMORTIZATION AND IMPAIRMENT OF ACQUIRED INTANGIBLE ASSETS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to TYSABRI, AVONEX, SPINRAZA, VUMERITY and SKYCLARYS, which was obtained as part of our acquisition of Reata in September 2023. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, the increases in amortization and impairment of acquired intangible assets were primarily due to </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortization for the Reata acquisition acquired intangible assets associated with SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets reflects impairment charges of $20.2 million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to intangible assets associated with Samsung Bioepis commercializ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ation rights terminated during the third quarter of 2024.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we h</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ad no i</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mpairment charges.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the amortization and impairment of our acquired intangible assets, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Intangible Assets and Goodwill</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our 2019 Development and Commercialization Agreement with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_211"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COLLABORATION PROFIT SHARING/(LOSS REIMBURSEMENT)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit sharing/(loss reimbursement) includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars 2013 commercial agreement with Samsung Bioepis and, beginning in the third quarter of 2023, collaboration profit sharing/(loss reimbursement) related to Sage's 50.0% share of income and expense in the U.S. related to ZURZUVAE for PPD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, we recognized net profit-sharing expense of approximately $60.3 million and $176.8 million, respectively, to reflect Samsung Bioepis' 50.0% share of the net collaboration profits, compared to net profit-sharing expense of approximately $56.4 million and $170.4 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three and nine months ended September 30, 2024, we recognized net profit-sharing expense of approximately $9.0 million and $20.5 million, respectively, to reflect Sage's 50.0% share of net collaboration results in the U.S. for ZURZUVAE for PPD, compared to net loss reimbursement of approximately $5.9 million in both prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration and license arrangements with Samsung Bioepis and Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_1963"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(GAIN) LOSS ON FAIR VALUE REMEASUREMENT OF CONTINGENT CONSIDERATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable for certain of our business combinations include future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. In connection with our acquisition of HI-Bio in July 2024 we recorded contingent consideration obligations related to potential milestone payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the changes in the fair value of our contingent consideration obligations were primarily due to changes in interest rates used to revalue our contingent consideration liabilities, the passage of time and updates to the expected timing of achieving certain milestones which will trigger contingent consideration payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESTRUCTURING CHARGES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 FIT FOR GROWTH RESTRUCTURING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately 1,000 employees and we expect to incur restructuring charges ranging from approximately $260.0&#160;million to $280.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">REATA INTEGRATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimate we will incur total integration charges ranging from approximately $35.0&#160;million to $40.0&#160;million, related to severance and employment costs, which are expected to be paid by the end of 2024. These amounts were substantially incurred during 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HI-BIO INTEGRATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, following the close of our HI-Bio acquisition in July 2024, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we incurred approximately $1.5&#160;million of severance and employment costs, which are reflected in restructuring charges within our condensed consolidated statements of income for the three and nine months ended September 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our cost saving initiatives, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Restructuring,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_217"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER (INCOME) EXPENSE, NET</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, the changes in other (income) expense, net primarily reflect lower interest income driven by lower cash balances in 2024, compared to the same periods in 2023, as well as higher net losses on our holdings in equity securities in 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NET (GAINS) LOSSES IN EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2024, net unrealized and realized gains on our holdings in equity securities were approximately $28.2 million and $10.9 million, respectively, compared to net unrealized and realized losses of approximately $297.6 million and $4.4 million, respectively, in the prior year comparative period. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized gains recognized during the three months ended September 30, 2024, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $53.3&#160;million, partially offset by a decrease in the fair value of Sage common stock of approximately $22.7&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $295.6&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2024, net unrealized losses and realized gains on our holdings in equity securities were approximately $27.3 million and $5.4 million, respectively, compared to net unrealized and realized losses of approximately $268.3 million and $5.3 million, respectively, in the prior year comparative period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized losses recognized during the nine months ended September 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage common stock of approximately $90.2&#160;million, partially offset by an increase in the fair value of Denali and Sangamo common stock of approximately $70.1&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $265.0&#160;million.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_220"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INCOME TAX PROVISION</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) before income tax (benefit) expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,614.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, our effective tax rate includes a decrease in our valuation allowance related to changes in projected future foreign taxable income, partially offset by the impact of certain foreign uncertain tax positions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for the three months ended September 30, 2023, reflects a tax benefit of $72.9&#160;million recognized as a result of a pretax loss from operations of $141.2&#160;million recorded during the third quarter of 2023, which was driven, in part, by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses. For all other periods presented, the effective tax rates reflect tax expense on pretax income from operations in the respective periods.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nine months ended September 30, 2023, was also impacted by the resolution of an uncertain tax matter related to tax credits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:112%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:112%">PILLAR TWO</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OECD has issued model rules, which generally provide for a jurisdictional minimum effective tax rate of 15.0%. Various countries have or are in the process of enacting legislation intended to implement the principles effective January 1, 2024. Our income tax provision for the three and nine months ended September 30, 2024, reflects currently enacted legislation and guidance related to the OECD model rules.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our income taxes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#00587f;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,699.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">649.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,699.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">649.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,598.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,065.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable and term loan</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,545.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,788.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,242.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,293.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,938.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(644.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,830.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,859.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,425.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,434.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,990.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,405.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,425.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,019.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_229"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically financed and expect to continue to fund our operating and capital expenditures primarily through cash flow earned through our operations, as well as our existing cash resources. We believe that generic and biosimilar competition for many of our key products, the continued overall decline of our MS business and our investments in the launch of key new products and the development of our pipeline will have a significant adverse impact on our future cash flow from operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio. Under the terms of this acquisition, we paid shareholders of HI-Bio approximately $1.15&#160;billion, as well as an additional $43.7&#160;million related to working capital adjustments as of the transaction close date. These amounts were funded through available cash on hand. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:115%">LIQUIDITY</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:115%">WORKING CAPITAL</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. Our working capital was $1.4 billion and $3.4 billion as of September 30, 2024 and December 31, 2023, respectively. The change in working capital reflects a decrease in total current assets of approximately $28.8 million and an increase in total current liabilities of approximately $2.0 billion. The changes in total current assets and total current liabilities were primarily driven by the following:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT ASSETS</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$649.3 million increase in cash and cash equivalents;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$127.9 million decrease in accounts receivable, net related to our ongoing operations; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$508.0 million decrease in other current assets primarily due to the receipt of $437.5&#160;million from Samsung BioLogics related to the sale of our 49.9% equity interest in Samsung Bioepis.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT LIABILITIES</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$131.5 million increase in accrued expense and other primarily due to $287.1 million of short-term contingent consideration recognized from our acquisition of HI-Bio, offset in part by the timing of our annual incentive compensation payment and other benefits-related payments; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$1.6 billion increase in current portion of debt primarily due to the reclassification of our $1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15, 2025, from long-term to short--term and the repayment of our 2023 Term Loan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to our condensed consolidated financial statements included in this report. For additional information on the sale of our equity interest in Samsung Bioepis and the sale of our PRV, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to our condensed consolidated financial statements included in this report. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to our condensed consolidated financial statements included in this report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, we had cash, cash equivalents and marketable securities totaling approximately $1.7 billion compared to approximately $1.0 billion as of December 31, 2023. The increase in the balance was primarily due to cash generated by our operations, the receipt of $437.5&#160;million in April 2024 from Samsung BioLogics related to the sale of our 49.9% equity interest in Samsung Bioepis and the net cash receipt of $88.6&#160;million from the sale of one of our two PRV's. The increase was offset in part by $1.15&#160;billion of cash and cash equivalents used to fund our acquisition of HI-Bio in July 2024 and $650.0&#160;million of cash used for the repayment of our 2023 Term Loan.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. We have experienced no significant limitations in our liquidity resulting from uncertainties in the banking sector.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our significant common stock investments in our strategic investment portfolio:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.003%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CASH FLOW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,114.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,534.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(780.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,448.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(691.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">795.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">OPERATING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">non-cash operating items such as depreciation and amortization, impairment charges, unrealized (gain) loss on strategic investments and share-based compensation;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">(gains) losses on the disposal of assets, deferred income taxes, changes in the fair value of contingent payments associated with our acquisitions of businesses and acquired IPR&amp;D.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2024, compared to the same period in 2023, the increase in net cash flow provided by operating activities was primarily due to higher net income, lower employee-benefit payments made during the first quarter of 2024, as compared to the same period in 2023, lower estimated federal tax payments made during the third quarter of 2024, as compared to the same period in 2023, and changes in non-cash adjustments to net income. The increase was partially offset by the timing of working capital, which includes higher inventory levels, primarily associated with our contract manufacturing for LEQEMBI.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">INVESTING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2024, compared to the same period in 2023, the change in net cash flow in investing activities was primarily due to cash payments made associated with our acquisition of HI-Bio in 2024 and with our acquisition of Reata in 2023. Additionally, cash outlay in 2023 was partially offset by net proceeds received from the sale of our marketable securities. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FINANCING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2024, compared to the same period in 2023, the change in net cash flow in financing activities was primarily due to the repayment of our 2023 Term Loan for $650.0&#160;million during 2024 compared to the issuance of term loans totaling $1.0 billion under our 2023 Term Loan which were used to partially fund our acquisition of Reata in 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis and the sale of our PRV, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_235"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">CAPITAL RESOURCES</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DEBT AND CREDIT FACILITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LONG-TERM DEBT AND TERM LOAN CREDIT AGREEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term obligations primarily consist of long-term debt related to our Senior Notes with final maturity dates ranging between 2025 and 2051. As of September 30, 2024, our outstanding balance related to long-term debt was $4.5 billion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $1.0 billion from the 2023 Term Loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of December 31, 2023, we repaid </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$350.0&#160;million of the 364--day tranche. The remaining $150.0&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the first quarter of 2024 we repaid $250.0&#160;million of the three-year tranche, with the remaining $250.0&#160;million portion of the three-year tranche being subsequently repaid in full during the second quarter of 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 REVOLVING CREDIT FACILITY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024 we entered into a $1.5&#160;billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility entered into in January 2020, as discussed below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2020 REVOLVING CREDIT FACILITY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we were permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility included a financial covenant that required us not to exceed a maximum consolidated leverage ratio. This credit facility was terminated in August 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, we had no outstanding borrowings and were in compliance with all covenants under both facilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair and carrying values of our outstanding borrowings as of September 30, 2024 and December 31, 2023, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Senior Notes and credit facility please read, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SHARE REPURCHASE PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and nine months ended September 30, 2024 and 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2024.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_238"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS AND OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments and contingent payments, as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our collaboration and licensing arrangements include royalty payment obligations. For additional information on our royalty payments please read, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 22, Commitments and Contingencies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our contractual obligations since December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTINGENT CONSIDERATION RELATED TO BUSINESS COMBINATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we may make additional payments based upon the achievement of certain milestone events. We recognized the contingent consideration obligations associated with this acquisition at its fair value on the acquisition date and we revalue this obligation each reporting period. We may pay up to an additional $650.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in potential future development and regulatory milestone payments.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The acquisition-date fair value of these milestones was approximately $485.1&#160;million. We anticipate that we may trigger the first milestone payment of approximately $150.0&#160;million within the next six months.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTINGENT DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of September 30, 2024, we could trigger potential future milestone payments to third parties of up to approximately $5.4 billion, including approximately $0.9 billion in development milestones, approximately $0.6 billion in regulatory milestones and approximately $3.9 billion in commercial milestones, as part of our various collaborations, including licensing and development programs and HI-Bio's pre-existing commitments, as discussed below. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of September 30, 2024, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to approximately $15.0&#160;million in milestones in 2024 under our current agreements, excluding opt-in payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired HI-Bio's pre-existing in-license commitments under third-party agreements, which include tiered royalties on potential future sales of felzartamab and izastobart/HIB210, ranging from high-single digit to mid-teen percentages, as well as potential future development, regulatory and commercial milestone payments related to felzartamab and izastobart/HIB210 of up to $130.0&#160;million, $230.0&#160;million and $640.0&#160;million, respectively. This amount includes potential milestone payments due upon the first patient dosed in a phase 3 clinical trial of felzartamab in a first and second indication of $35.0&#160;million and $30.0&#160;million, respectively. We anticipate that we may trigger the first milestone payment of $35.0&#160;million within the next six months.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER FUNDING COMMITMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $31.4 million in our condensed consolidated balance sheets for expenditures incurred by CROs as of September 30, 2024. We have approximately $576.6 million in cancellable future commitments based on existing CRO contracts as of September 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TAX RELATED OBLIGATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of September 30, 2024, we have approximately $186.3 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, we have accrued income tax liabilities of approximately $234.0&#160;million and $419.5&#160;million, respectively, under the Transition Toll Tax. The amount accrued as of September 30, 2024, is expected to be paid within one year. The Transition Toll Tax is being paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_241"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_244"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTINGENT CONSIDERATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue the remaining obligations and record increases or decreases in their fair value as an adjustment to contingent consideration expense in our condensed consolidated statements of income. Changes in the fair value of our contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and achievement and timing of any cumulative sales-based and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development milestones or changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions described above, could have a material impact on the amount of contingent consideration expense we record in any given period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for Contingent Consideration, as discussed above, there have been no material changes to our critical accounting estimates since our 2023 Form&#160;10-K. For a discussion of our other critical accounting estimates, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2023 Form&#160;10-K. </span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_247"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flow and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and equity price exposure as well as changes in economic conditions in the markets in which we operate as a result of the conflict between Russia and Ukraine and the military conflict in the Middle East. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, foreign currency options, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FOREIGN CURRENCY EXCHANGE RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar and Swiss franc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expense will increase when reported in U.S. dollars.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of September 30, 2024, and is not expected to have a material impact on our results of operations or financial position in the future. In December 2023 the Argentinian Peso experienced a substantial devaluation following a presidential election. The devaluation resulted in a $16.0&#160;million charge recorded during the fourth quarter of 2023 in other (income) expense, net within our consolidated statements of income for the year ended December 31, 2023, included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REVENUE AND OPERATING EXPENSE HEDGING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts and foreign currency options to manage foreign currency risk, with the majority of our forward contracts and options used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 15 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BALANCE SHEET RISK MANAGEMENT HEDGING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of September 30, 2024 and December 31, 2023, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $291.4 million and $249.4 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CREDIT RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate in certain countries where weakness in economic conditions, including the effects of the conflict between Russia and Ukraine and the military conflict in the Middle East, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of September 30, 2024 and December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EQUITY PRICE RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. We may sell such equity securities based on our business considerations, which may include limiting our price risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. The potential change in fair value for equity price sensitive instruments has been assessed on a hypothetical 10.0% adverse movement. As of September 30, 2024 and December 31, 2023, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $30.5&#160;million and $41.7&#160;million, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of September 30, 2024. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2024, we completed our acquisition of HI-Bio. The HI-Bio acquisition was accounted for as a business combination using the acquisition method of accounting. The results of operations of the acquired HI-Bio business have been included in our results of operations since July&#160;2, 2024, and we are currently in the process of evaluating and integrating HI-Bio's historical internal controls over financial reporting with ours.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the evaluation and integration of internal controls resulting from the HI-Bio acquisition, as discussed above, there were no changes in our internal control over financial reporting during the quarter ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_256"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II OTHER INFORMATION</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_259"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings as of September 30, 2024, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_262"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenue from our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenue is concentrated on sales of our products in increasingly competitive markets. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenue and results of operations or could cause a decline in our stock price: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction, greater acceptance or more favorable reimbursement of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those relating to inflation and those resulting from governmental or regulatory requirements, including those relating to any future potential drug price negotiation under the IRA; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third-parties;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, geopolitical events, regulatory or legislative developments; or</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEQEMBI is in the early stages of commercial launch in the U.S. and certain international markets and SKYCLARYS is in the early stages of commercial launch in the U.S. and certain European markets. In addition to risks associated with new product launches and the other factors described in these Risk Factors, Biogen&#8217;s and Eisai&#8217;s ability to successfully commercialize LEQEMBI and our ability to successfully commercialize SKYCLARYS may be adversely affected due to:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">Eisai&#8217;s ability to obtain and maintain adequate reimbursement for LEQEMBI;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">the effectiveness of Eisai's and Biogen&#8217;s commercial strategy for marketing LEQEMBI;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">requirements such as participation in a registry and the use of imaging or other diagnostics for LEQEMBI;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">our ability to obtain approval in other markets;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">the approval of other new products for the same or similar indications;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">Eisai&#8217;s and Biogen&#8217;s ability to maintain a positive reputation among patients, healthcare providers and others in the Alzheimer&#8217;s disease community, which may be impacted by pricing and reimbursement decisions relating to LEQEMBI, which are made by Eisai and/or third parties;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">Biogen's ability to obtain and maintain adequate reimbursement for SKYCLARYS; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">the effectiveness of Biogen's commercial strategy for marketing SKYCLARYS.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success will depend upon the successful development of new products from our research and development activities or our licenses or acquisitions from third parties, as well as additional indications for our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product development is very expensive and involves a high degree of uncertainty and risk and may not be successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the treatment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of diseases. The development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience with the development of such therapies. For example, we are currently seeking approval of LEQEMBI in Europe and Eisai will be seeking reexamination of the CHMP opinion, and the approval of a subcutaneous formulation of LEQEMBI in the U.S. and any delays or challenges may impact our ability to realize the anticipated benefits from LEQEMBI.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. Furthermore, the approval of a product candidate by one regulatory agency does not mean that other regulatory agencies will also approve such product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early-stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce or delay the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or we prioritize other opportunities in our pipeline. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of new products or products with additional indications may not meet investor expectations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has reduced, and may in the future, significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. For instance, demand and price for TECFIDERA declined significantly as a result of multiple TECFIDERA generic entrants entering the U.S. market in 2020. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete, maintain and grow our business may also be adversely affected due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of other products, including products that may be more efficacious, safer, less expensive or more convenient alternatives to our products, including our own products and products of our collaborators;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat patients; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to identify, attract and maintain new and current patients to our therapies;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the reluctance of physicians to prescribe, and patients to use, our products without additional data on the efficacy and safety of such products;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our products, generic or biosimilars of our products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes, pricing and reimbursement decisions or adverse experiences or events that may occur with patients treated with our products or generic or biosimilars of our products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain and maintain appropriate pricing and adequate reimbursement for our products compared to our competitors in key markets; or</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our products.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies, companies, the entry into strategic alliances and collaborations or our Fit for Growth program, as well as our ability to execute on strategic decisions and initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement to make any such acquisition if suitable candidates are identified.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons, including failure to obtain regulatory or other approvals as well as a result of disputes or litigation. Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions or strategic decisions, such as the decision to retain the biosimilars business, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations. For example, we recently acquired Reata and HI-Bio and are in the process of integrating Reata and HI-Bio into our Company. The ultimate success of our acquisitions of Reata and HI-Bio and our ability to realize the anticipated benefits from the acquisitions, including future performance of the SKYCLARYS product and further development of the felzartamab product and anticipated synergies, depends on, among other things, how effective we are in integrating the Biogen, Reata and HI-Bio operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face risks associated with our Fit for Growth program that may impair our ability to achieve anticipated savings and operational efficiencies or that may otherwise harm our business. These risks include delays in implementation of cost optimization actions, loss of workforce capabilities, higher than anticipated separation expenses, litigation and the failure to meet financial and operational targets. In addition, the calculation of the anticipated cost savings and other benefits resulting from our Fit for Growth program are subject to many estimates and assumptions. These estimates and assumptions are subject to significant business, economic, competitive and other uncertainties and contingencies, many of which are beyond our control. if these estimates and assumptions are incorrect or if we experience delays or unforeseen events, our business and financial results could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product, diagnosis of the condition it treats and the cost to administer it may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to receive reimbursement for our products or our ability to receive comparable reimbursement to that of competing products; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price). Drug prices are under significant scrutiny in the markets in which our products are prescribed; for example the IRA has certain provisions related to drug pricing. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth and result in reductions in revenue. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenue. Additionally, in certain jurisdictions governmental health agencies may adjust, retroactively and/or prospectively, reimbursement rates for our products. Reimbursement for our products by governments, including the timing of any reimbursements, may also be affected by budgetary or political constraints, particularly in challenging economic environments. Government agencies often do not set their own budgets and therefore, have limited control over the amount of money they can spend. In addition, these agencies experience political pressure that may dictate the manner in which they spend money. There can be no assurance that the economic, budgeting or political issues will not worsen and adversely impact sales or reimbursements of our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors could cause our revenue to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways may significantly reduce the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators and other third-parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative and other third-party relationships for revenue and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third-parties. Reliance on third-parties subjects us to a number of risks, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators or third-parties devote to our programs, products or product candidates, which may affect our ability to achieve development goals or milestones;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones, payment of development or commercial costs, ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators or third-parties fail to perform; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators or third-parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">third-party relationships require the parties to cooperate, and failure to do so effectively could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators or third-parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue or reputation as well as involve us in possible legal proceedings; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators or third-parties could subject us to civil or criminal investigations and monetary and injunctive penalties, require management attention, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenue from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs (including those contained in the IRA) and increasing pressure from social sources could significantly influence the manner in which our products are prescribed, purchased and reimbursed. For example, provisions of the PPACA have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is substantial public attention on the costs of prescription drugs and we expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. In addition, there have been (including elements of the IRA), and are expected to continue to be, legislative proposals to address prescription drug pricing. Some of these proposals could have significant effects on our business, including an executive order issued in September 2020 to test a &#8220;most favored nation&#8221; model for Part B and Part D drugs that tie reimbursement rates to international drug pricing metrics. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are requesting manufacturers to pay supplemental </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expense may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenue and may continue to adversely affect our revenue and results of operations in the future.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and commercialization of biosimilar products require specialized expertise and are very costly and subject to complex regulation. Our success in commercializing biosimilars is subject to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third-Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent, in part, on the efforts of collaboration partners and other third-parties over whom we have limited or no control in the development and manufacturing of biosimilars products. For example, a recently announced potential acquisition of a contract development and manufacturing organization by a third party may impact its operational, strategic or financial risk. If these third-parties fail to perform successfully, or reduce their third party manufacturing production, our biosimilar product development or commercialization of biosimilar products could be delayed, revenue from biosimilar products could decline and/or we may not realize the anticipated benefits of these arrangements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties we may be unable to meet demand. We are dependent on a third-party for the manufacture of our biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive intellectual property clearances and infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies that may receive greater acceptance or more favorable reimbursement. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success in this business area.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to obtain, defend or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of exclusivity and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenue may be reduced in a short period of time. In addition, manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third-parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third-parties to be pertinent to the manufacture, use or sale of our products.&#160;Legal proceedings may also be necessary to determine the rights, obligations and payments claimed during and after the expiration of intellectual property license agreements we have entered with third parties. Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing and marketing our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain could reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies, disagree with our trial design or endpoints or not approve adequate reimbursement. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements, requiring confirmatory trials and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expense, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third-parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third-parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be affected, including adversely affecting our expenses associated with such trials. We may need to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales to decline or our stock price to experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or safety warnings that may be required to be included in the label of our products may significantly reduce expected revenue for those products and require significant expense and management time.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our information systems could subject us to liability or interrupt the operation of our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information systems and data to operate our business. Changes in how we operate have caused us to modify our business practices in ways that heighten this dependence, including changing the requirement that most of our office-based employees in the U.S. and our other key markets work from the office, with many of our employees now working in hybrid or full-remote positions. As a result, we are increasingly dependent upon our information systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our information systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). Breakdowns, invasions, corruptions, destructions and/or breaches, which impact may include, but not limited to, comprising the capacity, reliability or security of our information systems or those of our business partners, including our cloud technologies, and/or unauthorized access to our data and information could subject us to significant liability, negatively impact our business operations, and/or require replacement of technology and/or sizeable ransom payments. Our information systems, including our cloud technologies, continue to increase in multitude and complexity, increasing our vulnerability when breakdowns, malicious intrusions and random attacks occur.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, patients, customers or other business partners, may be exposed to unauthorized persons or to the public.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity threats and incidents are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect, particularly when they impact vendors, customers or suppliers, and other companies in our supply chain. Cybersecurity threats and incidents are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and may include or target employees or contractors acting with careless or malicious intent. Recent developments in the threat landscape include use of AI and machine learning, as well as an increased number of cyber extortion attacks, with higher financial ransom demand amounts and increasing sophistication and variety of ransomware techniques and methodology. Geopolitical instability, including that related to Russia's invasion of Ukraine or the conflict in the Middle East, may increase the risk of cybersecurity threats. Cybersecurity threats or incidents may include deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our information systems and data. Cybersecurity threats and incidents also include manufacturing, hardware or software supply chain attacks, which could cause a delay in the manufacturing of products or products produced for contract manufacturing or lead to a data privacy or security breach. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies heightens these and other operational risks, and any failure by cloud or other technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent cybersecurity threats or incidents in our systems and any such incidents could materially adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in material financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Regulations continue to change as regulators worldwide consider new rules. For example, the SEC has adopted additional disclosure rules regarding cyber security risk management, strategy, governance and incident reporting by public companies. These new regulations or other regulations being considered in Europe and around the world may impact the manner in which we operate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. New U.S. data privacy and security laws, such as the CCPA, and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Risks of Reliance on Third-Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third-parties are independent entities subject to their own unique operational, strategic and financial risks that are outside of our control. For example, a recently announced potential acquisition of a contract development and manufacturing organization by a third party may impact its operational, strategic or financial risk. These third-parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor or raw material shortages, geopolitical instability, public health epidemics, natural disasters, power failures, cyber-attacks and many other factors.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with current GMP (cGMP).</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are required to maintain compliance with cGMP and other stringent requirements, as applicable, and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third-parties to receive regulatory approval or pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, factors such as geopolitical events, global health outbreaks, weather events, labor or raw material shortages and other supply chain disruptions could result in difficulties and delays in manufacturing our products, which could have an adverse impact on our results in operations or result in product shortages. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management, personnel and other organizational changes may disrupt our operations, and we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management, other personnel and our overall retention rate may disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and other personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract or retain them. We may face difficulty in attracting and retaining talent for a number of reasons, including management changes, integration related to the Reata and HI-Bio acquisitions, the underperformance or discontinuation of one or more marketed, pre-clinical or clinical programs, recruitment by competitors or changes in the overall labor market. In addition, changes in our organizational structure or in our flexible working arrangements could impact employees' productivity and morale as well as our ability to attract, retain and motivate employees. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions, and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions with physicians and other health care providers that prescribe or purchase our products are also subject to laws and government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies are facing heightened scrutiny of their relationships with health care providers and have been the target of lawsuits and investigations alleging violations of laws and government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including testing, insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these or other patient assistance programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we submitted to the government. In addition, legal proceedings and investigations are inherently unpredictable, and large judgments or settlements sometimes occur. While we believe that we have appropriate compliance controls, policies and procedures in place to comply with the laws or regulations of the jurisdictions in which we operate, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate such laws or regulations. Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenue. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents or distributors and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory approvals of products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing, reimbursement or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increased cost of goods due to factors such as inflation and supply chain disruptions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">additional complexity in manufacturing or conducting clinical research internationally, including materials manufactured in China or working with CROs in China;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">delays in clinical trials relating to geopolitical instability related to Russia's invasion of Ukraine and the military conflict in the Middle East;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenue, net income and value of certain of our investments; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or embargoes and other trade restrictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. FCPA prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. In addition, while we believe that we have appropriate compliance controls, policies and procedures in place to comply with the FCPA, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and we might be held responsible. If our employees, agents, distributors, collaborators or third-party providers are found to have engaged in such practices, we could suffer severe penalties and may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We built a large-scale biologics manufacturing facility and are building a gene therapy manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we have expanded our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Solothurn facility was approved by the FDA for LEQEMBI, there can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of other products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we are building a new gene therapy manufacturing facility in RTP, North Carolina with no assurance that this investment will be fully utilized. If we are unable to fully utilize this gene therapy manufacturing facility, charges from excess capacity may occur and would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity may continue to occur and would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third-parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms and artificial intelligence based software presents new risks and challenges.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and create uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on social media. We may also encounter criticism on social media regarding our company, management, product candidates or products. The immediacy of social media precludes us from having real-time control over postings made regarding us via social media, whether matters of fact or opinion. Our reputation could be damaged by negative publicity or if adverse information concerning us is posted on social media platforms or similar mediums, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business. Additionally, the use of AI based software is increasingly being used in the biopharmaceutical industry. Use of AI based software may lead to the release of confidential proprietary information which may impact our ability to realize the benefit of our intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenue, expense and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expense that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the costs associated with decisions to terminate research and development programs;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, charges for excess capacity, charges for excess or obsolete inventory and charges for inventory write-downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expense and increased bad debt reserves;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expense, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms which could significantly increase our financing costs. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a disadvantage compared to our competitors that have less debt.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio could adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, negative company-specific news, biotechnology market sentiment, instability in the global financial markets that reduces the liquidity of securities in our portfolio, declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. Additionally, the recently enacted IRA includes an excise tax on share repurchases, which will increase the cost of share repurchases. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third-party from attempting to acquire us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively and the effects of the integration of Reata and HI-Bio. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the OECD&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates. Many countries have or are in the process of enacting legislation intended to implement the OECD GloBE Model Rules effective on January 1, 2024. The impact on the Company will depend on the timing of implementation, the exact nature of each country's GloBE legislation, guidance and regulations thereon and their application by tax authorities either prospectively or retrospectively.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental and operational risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds which make us subject to changing and evolving rules and interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business. Additionally, regulators have passed new environmental disclosure rules. For example, the SEC, the E.U. and California have implemented new climate disclosure rules that will generally require additional disclosure. Additionally, other regulators are considering environmental disclosure rules. These new rules collectively will impose additional disclosure requirements elating to climate-related risks and emissions disclosures. We expect to be subject to these new laws, which impose extensive reporting obligations about greenhouse gas emissions and climate-related financial risks. These recently enacted and proposed regulations may require us to incur compliance and disclosure costs and will likely require substantial management attention.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the third quarter of 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2024 - July 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 1, 2024 - August 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 1, 2024 - September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There were no share repurchases during the third quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and nine months ended September 30, 2024 and 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2024.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_268"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TRADING ARRANGEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no trading arrangements for the purchase or sale of our securities <ix:nonNumeric contextRef="c-15" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1927"><ix:nonNumeric contextRef="c-15" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1928">entered</ix:nonNumeric></ix:nonNumeric> into or <ix:nonNumeric contextRef="c-15" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1929"><ix:nonNumeric contextRef="c-15" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1930">terminated</ix:nonNumeric></ix:nonNumeric> by our Directors or Officers during the third quarter of 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_271"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_274"></div><div style="-sec-extract:summary;margin-top:14pt;text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">EXHIBIT&#160;INDEX&#160;</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.024%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement, dated as of August 12, 2024, among Biogen Inc., Bank of America, N.A., as administrative agent, swing line lender and the L/C issuer, and the other lenders party thereto. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 14, 2024.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2024930xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2024930xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2024930xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September 30, 2024, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104++</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline XBRL.</span></div></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i5e7e277eefb645c9b9cc7c9e24d79fea_277"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5e7e277eefb645c9b9cc7c9e24d79fea_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;padding-left:297pt;text-indent:-13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.590%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October&#160;30, 2024 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2024930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4d079f6f85e943c18257522d5b84f0c9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher A. Viehbacher, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October&#160;30, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2024930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i404e441f77fd469cae0b33a2a9c19660_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael R. McDonnell, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October&#160;30, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2024930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibd8fe41cf3f24c30aae8584337aeab79_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October&#160;30, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October&#160;30, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>biib-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8df3ebeb-6aab-4ece-9956-fcebea1610fa,g:6874ad4b-e1dd-42ba-8d50-e940c01ea5b0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20240930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20240930">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>9952151 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>9952153 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952154 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>9952156 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>9952158 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Dispositions" roleURI="http://www.biogenidec.com/role/Dispositions">
        <link:definition>9952159 - Disclosure - Dispositions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiatives" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives">
        <link:definition>9952160 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>9952161 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>9952162 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>9952163 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>9952164 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>9952165 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>9952166 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment">
        <link:definition>9952167 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.biogenidec.com/role/Leases">
        <link:definition>9952168 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>9952169 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>9952170 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>9952171 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>9952172 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>9952173 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>9952174 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>9952175 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>9952176 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>9952177 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.biogenidec.com/role/AcquisitionsTables">
        <link:definition>9954472 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables">
        <link:definition>9954473 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>9954474 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>9954475 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>9954476 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>9954477 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>9954478 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>9954479 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>9954480 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>9954481 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>9954482 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>9954483 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>9954484 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>9954485 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails">
        <link:definition>9954487 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPurchasePriceConsiderationDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails">
        <link:definition>9954488 - Disclosure - Acquisitions - Purchase Price Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPreliminatyPurchasePriceAllocationDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails">
        <link:definition>9954489 - Disclosure - Acquisitions - Preliminaty Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DispositionsDetailsTextual" roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual">
        <link:definition>9954490 - Disclosure - Dispositions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails">
        <link:definition>9954491 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails">
        <link:definition>9954492 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails">
        <link:definition>9954493 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails">
        <link:definition>9954494 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyproductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails">
        <link:definition>9954495 - Disclosure - Revenues - Revenues by product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1">
        <link:definition>9954496 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2">
        <link:definition>9954497 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>9954498 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>9954499 - Disclosure - Revenues - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails">
        <link:definition>9954500 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryComponentsofInventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails">
        <link:definition>9954501 - Disclosure - Inventory - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails">
        <link:definition>9954502 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails">
        <link:definition>9954503 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1">
        <link:definition>9954503 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>9954504 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails">
        <link:definition>9954505 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillChangesinGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails">
        <link:definition>9954506 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails">
        <link:definition>9954507 - Disclosure - Fair Value Measurements - Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954508 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails">
        <link:definition>9954509 - Disclosure - Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDebtInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails">
        <link:definition>9954510 - Disclosure - Fair Value Measurements - Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>9954511 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>9954512 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>9954513 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>9954514 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>9954515 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>9954516 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>9954517 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetailsTextual" roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual">
        <link:definition>9954518 - Disclosure - Leases (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>9954519 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>9954520 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>9954521 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>9954522 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>9954523 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails">
        <link:definition>9954524 - Disclosure - Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails">
        <link:definition>9954525 - Disclosure - Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPaymentsNarrativeDetails" roleURI="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails">
        <link:definition>9954526 - Disclosure - Share-based Payments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxRateDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails">
        <link:definition>9954527 - Disclosure - Income Taxes - Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954528 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>9954529 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>9954530 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsOCREVUSDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails">
        <link:definition>9954531 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsProfitSharingDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails">
        <link:definition>9954532 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEisaiDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails">
        <link:definition>9954533 - Disclosure - Collaborative and Other Relationships - Eisai (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails">
        <link:definition>9954534 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails">
        <link:definition>9954535 - Disclosure - Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails">
        <link:definition>9954536 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails">
        <link:definition>9954537 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails">
        <link:definition>9954538 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails">
        <link:definition>9954539 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails">
        <link:definition>9954540 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sangamo Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsOtherArrangementsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails">
        <link:definition>9954541 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSamsungBioepisDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails">
        <link:definition>9954542 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>9954543 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>9954544 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AmortizationOfInventoryStepUp" abstract="false" name="AmortizationOfInventoryStepUp" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NoncontrollingInterestCapitalContribution" abstract="false" name="NoncontrollingInterestCapitalContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DivestituresAbstract" abstract="true" name="DivestituresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" abstract="false" name="DerivativeInstrumentsUnrealizedGainLossTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_CoPromotionProfitSharingFormulaTableTextBlock" abstract="false" name="CoPromotionProfitSharingFormulaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_PretaxProfitSharingFormulaTableTextBlock" abstract="false" name="PretaxProfitSharingFormulaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_HumanImmunologyBiosciencesMember" abstract="true" name="HumanImmunologyBiosciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReataPharmaceuticalsIncMember" abstract="true" name="ReataPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SKYCLARYSMember" abstract="true" name="SKYCLARYSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PriorityReviewVoucherMember" abstract="true" name="PriorityReviewVoucherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherClinicalProgramsMember" abstract="true" name="OtherClinicalProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityMember" abstract="true" name="TheCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ClinicalInventoryMember" abstract="true" name="ClinicalInventoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FelzartamabAndIzastobartHIB210Member" abstract="true" name="FelzartamabAndIzastobartHIB210Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Phase3ClinicalTrialFelzartamabOneMember" abstract="true" name="Phase3ClinicalTrialFelzartamabOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Phase3ClinicalTrialFelzartamabTwoMember" abstract="true" name="Phase3ClinicalTrialFelzartamabTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MilestonePaymentFutureDevelopmentMember" abstract="true" name="MilestonePaymentFutureDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MilestonePaymentRegulatoryMember" abstract="true" name="MilestonePaymentRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MilestonePaymentCommercialMember" abstract="true" name="MilestonePaymentCommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MeasurementInputProbabilityRateMember" abstract="true" name="MeasurementInputProbabilityRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" abstract="true" name="HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" abstract="false" name="PaymentsToAcquireBusinessGrossNonVestedEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" abstract="false" name="BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IntangibleAssetMeasurementInput" abstract="false" name="IntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" abstract="false" name="PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" abstract="false" name="BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" abstract="false" name="FairValueIndefiniteLivedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_OperatingLeaseArea" abstract="false" name="OperatingLeaseArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" abstract="false" name="BusinessAcquisitionNumberOfCommonStockSharesAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_FelzartamabIgANMember" abstract="true" name="FelzartamabIgANMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FelzartamabAMRMember" abstract="true" name="FelzartamabAMRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FelzartamabPMNMember" abstract="true" name="FelzartamabPMNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PaymentDueAtFirstAnniversaryMember" abstract="true" name="PaymentDueAtFirstAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PaymentDueAtSecondAnniversaryMember" abstract="true" name="PaymentDueAtSecondAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_IonisPharmaceuticalsInc.Member" abstract="true" name="IonisPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PayablesToDivestitureOfInterestInJointVenture" abstract="false" name="PayablesToDivestitureOfInterestInJointVenture" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2023CostSavingInitiativesMember" abstract="true" name="A2023CostSavingInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReataIntegrationMember" abstract="true" name="ReataIntegrationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" abstract="false" name="RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2023And2022CostSavingInitiativesMember" abstract="true" name="A2023And2022CostSavingInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_VUMERITYMember" abstract="true" name="VUMERITYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AVONEXMember" abstract="true" name="AVONEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PLEGRIDYMember" abstract="true" name="PLEGRIDYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_RareDiseaseProductRevenueMember" abstract="true" name="RareDiseaseProductRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_QALSODYMember" abstract="true" name="QALSODYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BYOOVIZMember" abstract="true" name="BYOOVIZMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TOFIDENCEMember" abstract="true" name="TOFIDENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ZURZUVAEMember" abstract="true" name="ZURZUVAEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FUMADERMAndADUHELMMember" abstract="true" name="FUMADERMAndADUHELMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RoyaltyAttributedToOCREVUSMember" abstract="true" name="RoyaltyAttributedToOCREVUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ContractManufacturingAndOtherRevenueMember" abstract="true" name="ContractManufacturingAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_LEQEMBICollaborationMember" abstract="true" name="LEQEMBICollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_ShareOfNonControlingInterestRecognized" abstract="false" name="ShareOfNonControlingInterestRecognized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_InventoryNetCurrentAndNoncurrent" abstract="false" name="InventoryNetCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AcquiredAndInLicensedRightsAndPatentsMember" abstract="true" name="AcquiredAndInLicensedRightsAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CompletedTechnologyMember" abstract="true" name="CompletedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" abstract="false" name="FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_OtherAssetsCurrentFairValueDisclosure" abstract="false" name="OtherAssetsCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SeniorNotes3.250DueFebruary152051Member" abstract="true" name="SeniorNotes3.250DueFebruary152051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TermLoan2023ThreeYearTrancheMember" abstract="true" name="TermLoan2023ThreeYearTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" abstract="true" name="NonCurrentPortionOfNotesPayableAndTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityFloatingRate364DayTrancheMember" abstract="true" name="TheCreditFacilityFloatingRate364DayTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" abstract="true" name="TheCreditFacilityFloatingRateThreeYearTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NotesPayableCurrentFairValueDisclosure" abstract="false" name="NotesPayableCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesCurrentMember" abstract="true" name="EquitySecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_UnrealizedGainOnDerivatives" abstract="false" name="UnrealizedGainOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UnrealizedLossOnDerivatives" abstract="false" name="UnrealizedLossOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" abstract="false" name="ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SolothurnSwitzerlandMember" abstract="true" name="SolothurnSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="biib_TheCreditFacilityTerminatedMember" abstract="true" name="TheCreditFacilityTerminatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A2023TermLoanMember" abstract="true" name="A2023TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FloatingRate364DayTrancheMember" abstract="true" name="FloatingRate364DayTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A2020ShareRepurchaseProgramMember" abstract="true" name="A2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_OmnibusEquityPlan2024Member" abstract="true" name="OmnibusEquityPlan2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RatioOfNumberOfSharesReservedUnderPlan" abstract="false" name="RatioOfNumberOfSharesReservedUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_IonisSangamoDenaliAndSageMember" abstract="true" name="IonisSangamoDenaliAndSageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SangamoMember" abstract="true" name="SangamoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_OCREVUSMember" abstract="true" name="OCREVUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_MosunetuzumabMember" abstract="true" name="MosunetuzumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" abstract="false" name="FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" abstract="false" name="Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Reductioninroyaltyrate" abstract="false" name="Reductioninroyaltyrate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_PeriodOfCollaborationAgreement" abstract="false" name="PeriodOfCollaborationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PercentageOfFutureDevelopmentCosts" abstract="false" name="PercentageOfFutureDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_RituxanMember" abstract="true" name="RituxanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_GAZYVAMember" abstract="true" name="GAZYVAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" abstract="false" name="PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" abstract="false" name="CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" abstract="false" name="ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" abstract="false" name="ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SalesTriggerGrossSalesThreshold" abstract="false" name="SalesTriggerGrossSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AccruedPaymentToTerminationAgreement" abstract="false" name="AccruedPaymentToTerminationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentsMadeToTerminationAgreement" abstract="false" name="PaymentsMadeToTerminationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AccountsReceivableFromCollaborator" abstract="false" name="AccountsReceivableFromCollaborator" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AccountsPayableToCollaborator" abstract="false" name="AccountsPayableToCollaborator" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UCBPharmaS.A.Member" abstract="true" name="UCBPharmaS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ShareOfNetProfitFromSageTherapeuticsPercent" abstract="false" name="ShareOfNetProfitFromSageTherapeuticsPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_OtherresearchanddiscoveryMember" abstract="true" name="OtherresearchanddiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ContingentCommercializedRightsNumberOfProducts" abstract="false" name="ContingentCommercializedRightsNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_EquityMethodInvestmentsExpectedProfitShare" abstract="false" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CollaborativeArrangementTermExtension" abstract="false" name="CollaborativeArrangementTermExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GenentechMember" abstract="true" name="GenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_LenderDisputeMember" abstract="true" name="LenderDisputeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>biib-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8df3ebeb-6aab-4ece-9956-fcebea1610fa,g:6874ad4b-e1dd-42ba-8d50-e940c01ea5b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fce8190b-62e8-4222-880a-70d763ad8ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_825cd8fa-cdc5-472b-a1b1-a0309df6215d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fce8190b-62e8-4222-880a-70d763ad8ea1" xlink:to="loc_us-gaap_Revenues_825cd8fa-cdc5-472b-a1b1-a0309df6215d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9d72e455-1985-42ef-ada8-5f37d1897472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fce8190b-62e8-4222-880a-70d763ad8ea1" xlink:to="loc_us-gaap_CostsAndExpenses_9d72e455-1985-42ef-ada8-5f37d1897472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_14795ea6-1d5e-4a0a-a64d-f15daaf391bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_13af03b4-83e8-4ce2-be17-2665085f75b0" xlink:href="biib-20240930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_14795ea6-1d5e-4a0a-a64d-f15daaf391bb" xlink:to="loc_biib_Collaborationprofitlosssharing_13af03b4-83e8-4ce2-be17-2665085f75b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_dce748e1-1b48-469b-9b9e-7731493b38f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_14795ea6-1d5e-4a0a-a64d-f15daaf391bb" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_dce748e1-1b48-469b-9b9e-7731493b38f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b32e739b-651f-4ded-9d69-114089448c69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_14795ea6-1d5e-4a0a-a64d-f15daaf391bb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b32e739b-651f-4ded-9d69-114089448c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2684dc36-3c2e-4276-a151-99db092acb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_14795ea6-1d5e-4a0a-a64d-f15daaf391bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2684dc36-3c2e-4276-a151-99db092acb0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6afff4d4-3b5b-40d2-99da-a3295257d3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_14795ea6-1d5e-4a0a-a64d-f15daaf391bb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6afff4d4-3b5b-40d2-99da-a3295257d3f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_a99a6c29-a4db-490a-9e1c-09874b6f1554" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_14795ea6-1d5e-4a0a-a64d-f15daaf391bb" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_a99a6c29-a4db-490a-9e1c-09874b6f1554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_338ff064-2f81-42ab-a797-82e6f2495cb0" xlink:href="biib-20240930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_14795ea6-1d5e-4a0a-a64d-f15daaf391bb" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_338ff064-2f81-42ab-a797-82e6f2495cb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9be22262-c661-4ce5-b055-440774501c22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_14795ea6-1d5e-4a0a-a64d-f15daaf391bb" xlink:to="loc_us-gaap_RestructuringCharges_9be22262-c661-4ce5-b055-440774501c22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3733ff0f-d26d-4d1d-8a24-97ee9c360d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_14795ea6-1d5e-4a0a-a64d-f15daaf391bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3733ff0f-d26d-4d1d-8a24-97ee9c360d27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce6828a4-b836-4975-ae32-228e79e925db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6c070c9f-df97-4284-98a5-8df9ef386612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ce6828a4-b836-4975-ae32-228e79e925db" xlink:to="loc_us-gaap_ProfitLoss_6c070c9f-df97-4284-98a5-8df9ef386612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8aa9418a-5f37-4ece-b68c-bd5d9bca1777" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ce6828a4-b836-4975-ae32-228e79e925db" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8aa9418a-5f37-4ece-b68c-bd5d9bca1777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_77e2a563-d6d6-4ca8-9a56-6bf68ce18f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12b520b4-c784-4485-9e45-b00974628e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_77e2a563-d6d6-4ca8-9a56-6bf68ce18f25" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12b520b4-c784-4485-9e45-b00974628e33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f79bfb96-bd9f-4ba7-9612-baa86d3fd663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_77e2a563-d6d6-4ca8-9a56-6bf68ce18f25" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f79bfb96-bd9f-4ba7-9612-baa86d3fd663" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_58cb8873-9243-46c3-aaf7-c7d6afcb0771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b4f8f1ad-0310-41f6-afb5-0599e001e742" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_58cb8873-9243-46c3-aaf7-c7d6afcb0771" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b4f8f1ad-0310-41f6-afb5-0599e001e742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_69f1a3ed-65f9-4dc8-a7c2-b08345493fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_58cb8873-9243-46c3-aaf7-c7d6afcb0771" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_69f1a3ed-65f9-4dc8-a7c2-b08345493fe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5cab416d-30e4-46e2-91ad-eba90c3950b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d4126e86-f682-4660-bb7a-b3309b2c5ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5cab416d-30e4-46e2-91ad-eba90c3950b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d4126e86-f682-4660-bb7a-b3309b2c5ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b169ad24-5c32-4062-b4aa-d627e5bd3b81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5cab416d-30e4-46e2-91ad-eba90c3950b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b169ad24-5c32-4062-b4aa-d627e5bd3b81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_4ff3c800-5218-44d4-b360-0552b977e627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5cab416d-30e4-46e2-91ad-eba90c3950b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_4ff3c800-5218-44d4-b360-0552b977e627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_15f9a330-a7b3-4827-b944-65c10ceebcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5cab416d-30e4-46e2-91ad-eba90c3950b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_15f9a330-a7b3-4827-b944-65c10ceebcb4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6161fb5b-7a27-4ad7-8258-20dd7aea7403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_01068167-80f5-4aae-912e-80eb94279d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6161fb5b-7a27-4ad7-8258-20dd7aea7403" xlink:to="loc_us-gaap_NetIncomeLoss_01068167-80f5-4aae-912e-80eb94279d7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_37c1b13e-9536-4e0c-bcf6-c7287666be56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6161fb5b-7a27-4ad7-8258-20dd7aea7403" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_37c1b13e-9536-4e0c-bcf6-c7287666be56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4af5246-9ae4-41cd-8ed3-53c11379b39c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73e459e2-64ad-4b42-9af0-6ed663d8c78d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4af5246-9ae4-41cd-8ed3-53c11379b39c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73e459e2-64ad-4b42-9af0-6ed663d8c78d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0d157b78-7cb4-456e-9788-1a1ac8c61a81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4af5246-9ae4-41cd-8ed3-53c11379b39c" xlink:to="loc_us-gaap_Liabilities_0d157b78-7cb4-456e-9788-1a1ac8c61a81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0d2f943e-5791-4f06-8807-0a099eebc977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4af5246-9ae4-41cd-8ed3-53c11379b39c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0d2f943e-5791-4f06-8807-0a099eebc977" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_58587a38-82ac-47c6-8a7c-ca7516540903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1d2b5007-f6ca-480b-9d46-26ac54fc09ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58587a38-82ac-47c6-8a7c-ca7516540903" xlink:to="loc_us-gaap_AssetsCurrent_1d2b5007-f6ca-480b-9d46-26ac54fc09ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fb78dc33-cebc-44a4-9a86-afd82c812ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58587a38-82ac-47c6-8a7c-ca7516540903" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fb78dc33-cebc-44a4-9a86-afd82c812ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a47e630-6462-480d-8439-94c0e2d3f385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58587a38-82ac-47c6-8a7c-ca7516540903" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a47e630-6462-480d-8439-94c0e2d3f385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_24f1350c-a428-4f74-9438-7c9516c61177" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58587a38-82ac-47c6-8a7c-ca7516540903" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_24f1350c-a428-4f74-9438-7c9516c61177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cce1c711-2525-45e0-b2a9-029b682737de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58587a38-82ac-47c6-8a7c-ca7516540903" xlink:to="loc_us-gaap_Goodwill_cce1c711-2525-45e0-b2a9-029b682737de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6aa0b62d-a75a-4475-85b7-8ffd78f26bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58587a38-82ac-47c6-8a7c-ca7516540903" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6aa0b62d-a75a-4475-85b7-8ffd78f26bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_33af709b-590c-4c37-bc34-c6fb4d2e789d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58587a38-82ac-47c6-8a7c-ca7516540903" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_33af709b-590c-4c37-bc34-c6fb4d2e789d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e852adb0-3b13-43f1-b9db-280a4fea5fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d88beb79-ea87-4497-b847-95de05ddd933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e852adb0-3b13-43f1-b9db-280a4fea5fe2" xlink:to="loc_us-gaap_LiabilitiesCurrent_d88beb79-ea87-4497-b847-95de05ddd933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_85e3388d-80dd-4df7-bc1e-15b40fdb3085" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e852adb0-3b13-43f1-b9db-280a4fea5fe2" xlink:to="loc_us-gaap_LongTermDebt_85e3388d-80dd-4df7-bc1e-15b40fdb3085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_47386daa-554d-4bff-be0f-6a483f1d634d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e852adb0-3b13-43f1-b9db-280a4fea5fe2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_47386daa-554d-4bff-be0f-6a483f1d634d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a6997462-028d-4500-826e-8b9b7b55fa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e852adb0-3b13-43f1-b9db-280a4fea5fe2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a6997462-028d-4500-826e-8b9b7b55fa0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_038908eb-3afa-44d1-ae11-631492760827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e852adb0-3b13-43f1-b9db-280a4fea5fe2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_038908eb-3afa-44d1-ae11-631492760827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2fa53e22-2bfa-4841-98e0-3faf5d8fb370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a5c50819-cdfe-4182-979a-8c0579f729f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2fa53e22-2bfa-4841-98e0-3faf5d8fb370" xlink:to="loc_us-gaap_TreasuryStockValue_a5c50819-cdfe-4182-979a-8c0579f729f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_69f07048-38cc-4cc4-b53e-835253045972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2fa53e22-2bfa-4841-98e0-3faf5d8fb370" xlink:to="loc_us-gaap_AdditionalPaidInCapital_69f07048-38cc-4cc4-b53e-835253045972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20f231f4-f22c-48b2-b9f0-2cfe67d3700e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2fa53e22-2bfa-4841-98e0-3faf5d8fb370" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20f231f4-f22c-48b2-b9f0-2cfe67d3700e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_68d131af-638f-4052-a653-46c4bca3badf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2fa53e22-2bfa-4841-98e0-3faf5d8fb370" xlink:to="loc_us-gaap_PreferredStockValue_68d131af-638f-4052-a653-46c4bca3badf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_07460c86-8755-406d-ad77-a00e235e22b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2fa53e22-2bfa-4841-98e0-3faf5d8fb370" xlink:to="loc_us-gaap_CommonStockValue_07460c86-8755-406d-ad77-a00e235e22b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_510414af-d0cb-4578-94da-2fcad3053345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2fa53e22-2bfa-4841-98e0-3faf5d8fb370" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_510414af-d0cb-4578-94da-2fcad3053345" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0bece8b0-9631-45a6-9b41-908c3f4c273e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_c75d9634-5885-4378-88e0-86dc08693a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0bece8b0-9631-45a6-9b41-908c3f4c273e" xlink:to="loc_us-gaap_NotesPayableCurrent_c75d9634-5885-4378-88e0-86dc08693a4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3110864c-fe4d-4562-aed5-3420ae825da6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0bece8b0-9631-45a6-9b41-908c3f4c273e" xlink:to="loc_us-gaap_AccountsPayableCurrent_3110864c-fe4d-4562-aed5-3420ae825da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_6f83cd87-e55f-42d5-a901-a83289ee43fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0bece8b0-9631-45a6-9b41-908c3f4c273e" xlink:to="loc_us-gaap_TaxesPayableCurrent_6f83cd87-e55f-42d5-a901-a83289ee43fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9e3d7ee3-3258-4763-8260-0b96838b2464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0bece8b0-9631-45a6-9b41-908c3f4c273e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9e3d7ee3-3258-4763-8260-0b96838b2464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_39cf9fdb-af12-448e-8b30-da60cc06a2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2943999d-68f9-4179-9650-dae305a95749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39cf9fdb-af12-448e-8b30-da60cc06a2f8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2943999d-68f9-4179-9650-dae305a95749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dca1ac61-5250-4420-ae72-ac26d9833ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39cf9fdb-af12-448e-8b30-da60cc06a2f8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dca1ac61-5250-4420-ae72-ac26d9833ed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_537a3be4-edbf-461a-aa45-abee54a81a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39cf9fdb-af12-448e-8b30-da60cc06a2f8" xlink:to="loc_us-gaap_InventoryNet_537a3be4-edbf-461a-aa45-abee54a81a0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5fdf954d-6ca9-4ff7-b282-b3790f690c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39cf9fdb-af12-448e-8b30-da60cc06a2f8" xlink:to="loc_us-gaap_OtherAssetsCurrent_5fdf954d-6ca9-4ff7-b282-b3790f690c3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5057f2f3-fd02-491f-b8bb-b65a4768e8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_294abd61-6f42-4c2f-89fc-b3e45695f25f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5057f2f3-fd02-491f-b8bb-b65a4768e8a7" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_294abd61-6f42-4c2f-89fc-b3e45695f25f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_25e082fa-9df1-4915-8972-c5b99d57b79b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5057f2f3-fd02-491f-b8bb-b65a4768e8a7" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_25e082fa-9df1-4915-8972-c5b99d57b79b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_99dcc798-dbee-42ba-be53-0926733e21a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5057f2f3-fd02-491f-b8bb-b65a4768e8a7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_99dcc798-dbee-42ba-be53-0926733e21a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_04ce8644-1a81-45f9-bdd2-572d76c671af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5057f2f3-fd02-491f-b8bb-b65a4768e8a7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_04ce8644-1a81-45f9-bdd2-572d76c671af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_9bd77347-d2d6-41e0-b7a4-61864c7e4429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5057f2f3-fd02-491f-b8bb-b65a4768e8a7" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_9bd77347-d2d6-41e0-b7a4-61864c7e4429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba2aff-fde1-435e-9988-009169b31077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4ae840e9-b59a-4087-b3fe-956e65aa0514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba2aff-fde1-435e-9988-009169b31077" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4ae840e9-b59a-4087-b3fe-956e65aa0514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_5810b92d-cd2a-435a-87a2-886f031992cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba2aff-fde1-435e-9988-009169b31077" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_5810b92d-cd2a-435a-87a2-886f031992cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_808408b8-fe7f-43c0-9bc0-3e352bb02854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba2aff-fde1-435e-9988-009169b31077" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_808408b8-fe7f-43c0-9bc0-3e352bb02854" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ac4620b2-fcce-43bd-a09b-4536180f2601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba2aff-fde1-435e-9988-009169b31077" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ac4620b2-fcce-43bd-a09b-4536180f2601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3b573b72-f8b1-42dd-bc37-dc5b18574925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba2aff-fde1-435e-9988-009169b31077" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3b573b72-f8b1-42dd-bc37-dc5b18574925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_dd7d1072-6230-49aa-8998-fe624a78d244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba2aff-fde1-435e-9988-009169b31077" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_dd7d1072-6230-49aa-8998-fe624a78d244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2dea81df-7c26-4e41-9594-02369584a55b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba2aff-fde1-435e-9988-009169b31077" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2dea81df-7c26-4e41-9594-02369584a55b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f9bba88c-bd87-4857-9731-ff7c1e04a449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba2aff-fde1-435e-9988-009169b31077" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f9bba88c-bd87-4857-9731-ff7c1e04a449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5fa6362-02a0-42ef-861d-5eee01b17e49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba2aff-fde1-435e-9988-009169b31077" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5fa6362-02a0-42ef-861d-5eee01b17e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d2dfb483-0263-4063-abb2-92b14d206bff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d2dfb483-0263-4063-abb2-92b14d206bff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6484141e-0551-4b72-8443-e63be6df9271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6484141e-0551-4b72-8443-e63be6df9271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp_d9defe1f-c0e8-496e-8484-001525ba7564" xlink:href="biib-20240930.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_biib_AmortizationOfInventoryStepUp_d9defe1f-c0e8-496e-8484-001525ba7564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c486234b-c8b6-48d9-867d-e4cc41f24e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c486234b-c8b6-48d9-867d-e4cc41f24e4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8a822bf7-ec70-4cf8-aa9e-23adc652f27d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8a822bf7-ec70-4cf8-aa9e-23adc652f27d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_44c1d629-df05-44c5-b68f-728be6617a71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_InventoryWriteDown_44c1d629-df05-44c5-b68f-728be6617a71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8567973b-3d2a-41f2-9bc4-add980750885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_ProfitLoss_8567973b-3d2a-41f2-9bc4-add980750885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ad5ba67e-2405-497f-ba2b-4c7d6f3f061c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ad5ba67e-2405-497f-ba2b-4c7d6f3f061c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4f193895-081f-4994-9881-6a2584eb10f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4f193895-081f-4994-9881-6a2584eb10f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1e324839-92f8-459e-903f-9c775171a6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1e324839-92f8-459e-903f-9c775171a6ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_99dd222d-d527-413c-b46e-c13e5ea77b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_99dd222d-d527-413c-b46e-c13e5ea77b2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_daaefc0d-0098-45bf-943a-29e9f7c490a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_daaefc0d-0098-45bf-943a-29e9f7c490a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_63a8c2dc-0ee6-4359-b117-1ebbee48c069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_63a8c2dc-0ee6-4359-b117-1ebbee48c069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7dd1b5e2-af7f-4b1d-ace4-ce6975f4319d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7dd1b5e2-af7f-4b1d-ace4-ce6975f4319d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ffd5ac9d-fe71-4e84-adfb-e51737fb0707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ffd5ac9d-fe71-4e84-adfb-e51737fb0707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_65cc7037-d3e3-492a-9093-1aef3481bb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1af27330-f48b-4f77-9cb5-6e69030f8f46" xlink:to="loc_us-gaap_ShareBasedCompensation_65cc7037-d3e3-492a-9093-1aef3481bb0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1d948d24-5bb4-4b1f-8ba7-5c7954ccc5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16d54361-7c17-4355-ba35-7418e942ba13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1d948d24-5bb4-4b1f-8ba7-5c7954ccc5a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16d54361-7c17-4355-ba35-7418e942ba13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d3ec5714-c3f2-4281-8b7f-13e99c9e82c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1d948d24-5bb4-4b1f-8ba7-5c7954ccc5a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d3ec5714-c3f2-4281-8b7f-13e99c9e82c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_370d4ad1-e339-4cfb-9a5f-6cbcd5eb84e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1d948d24-5bb4-4b1f-8ba7-5c7954ccc5a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_370d4ad1-e339-4cfb-9a5f-6cbcd5eb84e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d030c312-d067-4711-a00f-00db14f52eab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_119cc5e4-187e-4a16-98e3-f4fb2905b15f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d030c312-d067-4711-a00f-00db14f52eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_119cc5e4-187e-4a16-98e3-f4fb2905b15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4ef4bfa6-5525-438a-8dc7-66db12b71022" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d030c312-d067-4711-a00f-00db14f52eab" xlink:to="loc_us-gaap_Goodwill_4ef4bfa6-5525-438a-8dc7-66db12b71022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a1f57540-6c05-470f-a3a9-1eec888d4b74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a1f57540-6c05-470f-a3a9-1eec888d4b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_53c1543e-e638-44d3-87f4-641e7ee7e37f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_53c1543e-e638-44d3-87f4-641e7ee7e37f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6f4aceb8-5826-4122-b4f7-87e54486bf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6f4aceb8-5826-4122-b4f7-87e54486bf8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_0fb04098-45ef-48a7-83d2-3f262ece7663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_0fb04098-45ef-48a7-83d2-3f262ece7663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8cf59160-7983-4ce6-a55b-0e1131badca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8cf59160-7983-4ce6-a55b-0e1131badca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_55a4f0d5-04f2-402a-aa4c-fe2f078ba560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_55a4f0d5-04f2-402a-aa4c-fe2f078ba560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_326a6af7-a047-4cf7-b2a3-b0de370b25c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_326a6af7-a047-4cf7-b2a3-b0de370b25c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_04345f8b-c020-4ec0-bee2-0336660f7e2e" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_04345f8b-c020-4ec0-bee2-0336660f7e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_16ed9f7e-ce2a-4022-ab95-ae1a956440a5" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_16ed9f7e-ce2a-4022-ab95-ae1a956440a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_f503885e-d096-4cee-bbb5-9400969aa049" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_f503885e-d096-4cee-bbb5-9400969aa049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_24001bd1-5c12-492a-929d-c39d418f2b03" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_24001bd1-5c12-492a-929d-c39d418f2b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_8b1b16ec-efd5-45b8-8d7e-89e07d13995c" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_8b1b16ec-efd5-45b8-8d7e-89e07d13995c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_45fd0d0a-256d-4136-acdd-8d96d0be6637" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_45fd0d0a-256d-4136-acdd-8d96d0be6637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2e1c5fbe-2f3f-4b5f-8022-0ce8fc709635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2e1c5fbe-2f3f-4b5f-8022-0ce8fc709635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_7c5b7282-7b7b-4280-b233-ff13b5e01e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_68665052-632a-4e95-9965-fb1e79f9a6c9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_7c5b7282-7b7b-4280-b233-ff13b5e01e2e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_94d3b302-cf6a-4107-9d8c-260b8f4b971f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_6fb13c23-604b-4ba4-8f47-c359d013a27e" xlink:href="biib-20240930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_94d3b302-cf6a-4107-9d8c-260b8f4b971f" xlink:to="loc_biib_ShareOfCoPromotionProfits_6fb13c23-604b-4ba4-8f47-c359d013a27e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_c718d4f9-545c-4615-b359-431fa6c3afcd" xlink:href="biib-20240930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cb67e5e9-6b3e-43b1-801a-8fe9a76fafde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_c718d4f9-545c-4615-b359-431fa6c3afcd" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_cb67e5e9-6b3e-43b1-801a-8fe9a76fafde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4a507619-3b67-4502-934a-dd15fe4725be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_c718d4f9-545c-4615-b359-431fa6c3afcd" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4a507619-3b67-4502-934a-dd15fe4725be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_36c0c088-3242-46d7-bd5e-4a66414bf9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_c718d4f9-545c-4615-b359-431fa6c3afcd" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_36c0c088-3242-46d7-bd5e-4a66414bf9ed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a26a09ab-38df-42ac-883d-e268cf2b9125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_30f88685-726c-4d2c-95a4-76278498a9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a26a09ab-38df-42ac-883d-e268cf2b9125" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_30f88685-726c-4d2c-95a4-76278498a9a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c370faab-edbe-4a50-8da7-f8df7a174c53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a26a09ab-38df-42ac-883d-e268cf2b9125" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c370faab-edbe-4a50-8da7-f8df7a174c53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6880ec43-e988-4c31-bab2-a1c6eea01dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_22926375-c424-424f-997e-ce910feb64fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6880ec43-e988-4c31-bab2-a1c6eea01dc2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_22926375-c424-424f-997e-ce910feb64fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e614afec-ddfc-4355-b8f6-94caaf4abaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6880ec43-e988-4c31-bab2-a1c6eea01dc2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e614afec-ddfc-4355-b8f6-94caaf4abaf9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c01069dd-5fb4-486f-bb74-ece3817339a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6b51759c-2af0-4cf5-8e53-3f17459e2cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c01069dd-5fb4-486f-bb74-ece3817339a8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6b51759c-2af0-4cf5-8e53-3f17459e2cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ce7a132-fba3-4eec-b2e3-7fa2a06a33fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c01069dd-5fb4-486f-bb74-ece3817339a8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ce7a132-fba3-4eec-b2e3-7fa2a06a33fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20240930.xsd#FinancialInstrumentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_4ba736fc-d901-4860-b41b-2e29957a0789" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_157744c9-e89e-47ed-b23b-3509af10b55c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_4ba736fc-d901-4860-b41b-2e29957a0789" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_157744c9-e89e-47ed-b23b-3509af10b55c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_bc984843-af18-407c-83bc-72948aea0c9d" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_4ba736fc-d901-4860-b41b-2e29957a0789" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_bc984843-af18-407c-83bc-72948aea0c9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_9e434c30-f779-41bc-9133-917c69ab97c2" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_4ba736fc-d901-4860-b41b-2e29957a0789" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_9e434c30-f779-41bc-9133-917c69ab97c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddcf1bdf-3e09-45e6-b299-bf1e6c82b6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e16aa7f-25ca-458e-98c6-80843503464b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddcf1bdf-3e09-45e6-b299-bf1e6c82b6d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e16aa7f-25ca-458e-98c6-80843503464b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_554e73e6-0797-41b1-91ae-f3986da56cda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddcf1bdf-3e09-45e6-b299-bf1e6c82b6d1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_554e73e6-0797-41b1-91ae-f3986da56cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_811e7f08-7fb0-42ad-83e3-cc925c1f5c40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_95749a77-da7e-4c3c-952b-4c7dd44339ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_811e7f08-7fb0-42ad-83e3-cc925c1f5c40" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_95749a77-da7e-4c3c-952b-4c7dd44339ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2f837ef1-75c7-4d33-bb00-bc5bb99fc319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a3ad3148-0758-4310-a2d0-1329efb9bdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2f837ef1-75c7-4d33-bb00-bc5bb99fc319" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a3ad3148-0758-4310-a2d0-1329efb9bdd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_990d01fe-dc16-45ec-8804-448cda8649b5" xlink:href="biib-20240930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2f837ef1-75c7-4d33-bb00-bc5bb99fc319" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_990d01fe-dc16-45ec-8804-448cda8649b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IncomeTaxesTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a0f5c010-8e86-41af-a5ec-f6d4dbe90836" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3284395d-e187-46ea-a70f-8be398f47aec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a0f5c010-8e86-41af-a5ec-f6d4dbe90836" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3284395d-e187-46ea-a70f-8be398f47aec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_18658e17-ccb4-493e-ae65-608cd3f5eca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a0f5c010-8e86-41af-a5ec-f6d4dbe90836" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_18658e17-ccb4-493e-ae65-608cd3f5eca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3383b89c-faf9-48a2-b3d4-3b5d452cf426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a0f5c010-8e86-41af-a5ec-f6d4dbe90836" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3383b89c-faf9-48a2-b3d4-3b5d452cf426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_6404706c-f0d5-4efe-b5dd-0dd7e645aa65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a0f5c010-8e86-41af-a5ec-f6d4dbe90836" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_6404706c-f0d5-4efe-b5dd-0dd7e645aa65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_c2e0881d-18be-4475-8adc-6fd380e9096d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a0f5c010-8e86-41af-a5ec-f6d4dbe90836" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_c2e0881d-18be-4475-8adc-6fd380e9096d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_888cfaef-52f4-47d8-8efd-7d7d9900813f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a0f5c010-8e86-41af-a5ec-f6d4dbe90836" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_888cfaef-52f4-47d8-8efd-7d7d9900813f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_60e002a0-dc8e-43fb-8c35-33d550c4aab4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a0f5c010-8e86-41af-a5ec-f6d4dbe90836" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_60e002a0-dc8e-43fb-8c35-33d550c4aab4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_01f903c2-bdb8-4df7-b475-3bb0c33f3d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f94c6860-4067-4078-8358-1213fb040ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_01f903c2-bdb8-4df7-b475-3bb0c33f3d31" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f94c6860-4067-4078-8358-1213fb040ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9107de40-51d1-4e6d-b063-9b55814a1f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_01f903c2-bdb8-4df7-b475-3bb0c33f3d31" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9107de40-51d1-4e6d-b063-9b55814a1f7a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>biib-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8df3ebeb-6aab-4ece-9956-fcebea1610fa,g:6874ad4b-e1dd-42ba-8d50-e940c01ea5b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0dd2ecdd-2d08-4d5e-ac94-8c5596502fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_StatementTable_0dd2ecdd-2d08-4d5e-ac94-8c5596502fdb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5508415c-90c5-430d-be13-605d83cd4018" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0dd2ecdd-2d08-4d5e-ac94-8c5596502fdb" xlink:to="loc_srt_ProductOrServiceAxis_5508415c-90c5-430d-be13-605d83cd4018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5508415c-90c5-430d-be13-605d83cd4018_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5508415c-90c5-430d-be13-605d83cd4018" xlink:to="loc_srt_ProductsAndServicesDomain_5508415c-90c5-430d-be13-605d83cd4018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3595786a-23f7-4487-b8a0-a216c4193e83" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5508415c-90c5-430d-be13-605d83cd4018" xlink:to="loc_srt_ProductsAndServicesDomain_3595786a-23f7-4487-b8a0-a216c4193e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7b4ae19d-09b4-46bb-abc5-7065a48149f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3595786a-23f7-4487-b8a0-a216c4193e83" xlink:to="loc_us-gaap_ProductMember_7b4ae19d-09b4-46bb-abc5-7065a48149f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_874b8e0f-1a21-43f1-8320-8501fd128145" xlink:href="biib-20240930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3595786a-23f7-4487-b8a0-a216c4193e83" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_874b8e0f-1a21-43f1-8320-8501fd128145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_214653ea-bb34-4044-998f-e12c19136a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3595786a-23f7-4487-b8a0-a216c4193e83" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_214653ea-bb34-4044-998f-e12c19136a2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_398c8672-9ef2-484d-b2bb-35c38baf30c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_Revenues_398c8672-9ef2-484d-b2bb-35c38baf30c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f75d69d2-69ee-4591-9e41-c93018d81326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f75d69d2-69ee-4591-9e41-c93018d81326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_804700af-0b82-4248-93bc-7cf407f763e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_804700af-0b82-4248-93bc-7cf407f763e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6bb66989-72e8-4096-952a-ddb2f53a5d14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6bb66989-72e8-4096-952a-ddb2f53a5d14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_265a8584-41de-4eb4-87f5-064319014e78" xlink:href="biib-20240930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_265a8584-41de-4eb4-87f5-064319014e78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_5fdf467c-09af-4c16-9288-d4efe2182a27" xlink:href="biib-20240930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_biib_Collaborationprofitlosssharing_5fdf467c-09af-4c16-9288-d4efe2182a27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_765083d0-26f3-4af7-a5b7-f47d93590bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_765083d0-26f3-4af7-a5b7-f47d93590bb0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a02cc5da-ad9d-49fd-b39b-c3ada024f961" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_RestructuringCharges_a02cc5da-ad9d-49fd-b39b-c3ada024f961" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_c1932294-3ab5-47e1-9f7e-7210b9113279" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_c1932294-3ab5-47e1-9f7e-7210b9113279" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_48d7c47b-7de3-476d-b2a2-904cf44eae14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_48d7c47b-7de3-476d-b2a2-904cf44eae14" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ed30d7e9-ae4f-4e6d-9345-7b5fab48b648" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_CostsAndExpenses_ed30d7e9-ae4f-4e6d-9345-7b5fab48b648" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_319b85ba-fdf0-4b91-a662-21cd134e2b15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_319b85ba-fdf0-4b91-a662-21cd134e2b15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dfc3eafd-9f22-46a6-bfed-fd3379d7ba4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dfc3eafd-9f22-46a6-bfed-fd3379d7ba4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3b6f9b9a-fdfa-4ba8-9ece-139b20af3010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_ProfitLoss_3b6f9b9a-fdfa-4ba8-9ece-139b20af3010" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_00c1768a-e7c7-4e11-a98b-ff99aaf4fc01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_00c1768a-e7c7-4e11-a98b-ff99aaf4fc01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a7de20e-7286-4bd3-8b0d-d564399989b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_NetIncomeLoss_6a7de20e-7286-4bd3-8b0d-d564399989b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c4e8c934-8755-4d6a-94cf-3244b0fdce69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_EarningsPerShareAbstract_c4e8c934-8755-4d6a-94cf-3244b0fdce69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6e9f033a-deea-4c5a-a257-74d094a0cee7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c4e8c934-8755-4d6a-94cf-3244b0fdce69" xlink:to="loc_us-gaap_EarningsPerShareBasic_6e9f033a-deea-4c5a-a257-74d094a0cee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3db42930-eead-44f1-af3d-609a7430a449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c4e8c934-8755-4d6a-94cf-3244b0fdce69" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3db42930-eead-44f1-af3d-609a7430a449" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0bb4f7a4-3fc9-401b-9d5b-85b5978538b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0bb4f7a4-3fc9-401b-9d5b-85b5978538b3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e582cb48-5da8-4acd-acd6-ba4224cd3965" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0bb4f7a4-3fc9-401b-9d5b-85b5978538b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e582cb48-5da8-4acd-acd6-ba4224cd3965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0dc6f9c1-454c-40fe-932c-f751c9c93f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0bb4f7a4-3fc9-401b-9d5b-85b5978538b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0dc6f9c1-454c-40fe-932c-f751c9c93f73" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_642700e2-a87a-4581-a957-775c5797b39e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_53d639aa-eec2-4413-b232-f07c3acd5f67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_642700e2-a87a-4581-a957-775c5797b39e" xlink:to="loc_us-gaap_StatementTable_53d639aa-eec2-4413-b232-f07c3acd5f67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0779d1c8-35fb-42d8-b226-ad46f4a6ae63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_53d639aa-eec2-4413-b232-f07c3acd5f67" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0779d1c8-35fb-42d8-b226-ad46f4a6ae63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0779d1c8-35fb-42d8-b226-ad46f4a6ae63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0779d1c8-35fb-42d8-b226-ad46f4a6ae63" xlink:to="loc_us-gaap_RelatedPartyDomain_0779d1c8-35fb-42d8-b226-ad46f4a6ae63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_dbef291b-752b-4153-b29b-4b17e3b33c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0779d1c8-35fb-42d8-b226-ad46f4a6ae63" xlink:to="loc_us-gaap_RelatedPartyDomain_dbef291b-752b-4153-b29b-4b17e3b33c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_226b5dce-e89d-469c-9ec4-4abbf9abe8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_dbef291b-752b-4153-b29b-4b17e3b33c2c" xlink:to="loc_us-gaap_NonrelatedPartyMember_226b5dce-e89d-469c-9ec4-4abbf9abe8d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_4836dbf2-8fa3-439e-861d-faf5a1b7ca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_dbef291b-752b-4153-b29b-4b17e3b33c2c" xlink:to="loc_us-gaap_RelatedPartyMember_4836dbf2-8fa3-439e-861d-faf5a1b7ca2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_642700e2-a87a-4581-a957-775c5797b39e" xlink:to="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c27ddfab-71cf-4f37-a8a5-23fa1a70651d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c27ddfab-71cf-4f37-a8a5-23fa1a70651d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_60a66e0e-e43a-4ce3-a203-37ceef45c44d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_60a66e0e-e43a-4ce3-a203-37ceef45c44d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_63046584-5a69-4f55-a007-b339128f637a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:to="loc_us-gaap_InventoryNet_63046584-5a69-4f55-a007-b339128f637a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2c18febe-62c7-42a6-9514-2c607d8bed9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:to="loc_us-gaap_OtherAssetsCurrent_2c18febe-62c7-42a6-9514-2c607d8bed9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7e8d5515-6d17-4f52-896b-b96457011ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:to="loc_us-gaap_AssetsCurrent_7e8d5515-6d17-4f52-896b-b96457011ac0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d70d7cee-cfe8-495d-9268-b57b6d4d42ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d70d7cee-cfe8-495d-9268-b57b6d4d42ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_852635a7-09fb-4445-bd6f-82fb6ad894b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_852635a7-09fb-4445-bd6f-82fb6ad894b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0284cf9c-92e6-46b6-b4df-503dcb8b06af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0284cf9c-92e6-46b6-b4df-503dcb8b06af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2d686af5-de9d-4de2-ad43-05a38a39c7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_Goodwill_2d686af5-de9d-4de2-ad43-05a38a39c7bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_5e5249d8-86cd-4d86-8b0f-7649f8763d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_5e5249d8-86cd-4d86-8b0f-7649f8763d83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9c570295-ce58-4458-bb6d-9d4c815aca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9c570295-ce58-4458-bb6d-9d4c815aca5c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_51f4d9e1-12e7-422e-87e8-d97ec49a5877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_Assets_51f4d9e1-12e7-422e-87e8-d97ec49a5877" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_642700e2-a87a-4581-a957-775c5797b39e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_f76067ed-9d07-4c80-94da-2d8688f00c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:to="loc_us-gaap_NotesPayableCurrent_f76067ed-9d07-4c80-94da-2d8688f00c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_28983f08-23aa-4109-af5d-bed751a7f5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:to="loc_us-gaap_TaxesPayableCurrent_28983f08-23aa-4109-af5d-bed751a7f5b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_67f6fb88-7144-45e5-a2ee-c8a251fbb30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:to="loc_us-gaap_AccountsPayableCurrent_67f6fb88-7144-45e5-a2ee-c8a251fbb30c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3b03a616-b6ee-4f03-81cb-7eea8b91d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3b03a616-b6ee-4f03-81cb-7eea8b91d59e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ee26829a-11cb-4279-a4d7-ed1c3a8cd184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:to="loc_us-gaap_LiabilitiesCurrent_ee26829a-11cb-4279-a4d7-ed1c3a8cd184" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f43a1fe7-5b0b-4e1e-a294-6858af9cdd85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_LongTermDebt_f43a1fe7-5b0b-4e1e-a294-6858af9cdd85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_413e8490-72c7-45bc-b48b-e32b1b1607e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_413e8490-72c7-45bc-b48b-e32b1b1607e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5699997e-0c7c-4397-9e71-f4f24681442a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5699997e-0c7c-4397-9e71-f4f24681442a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1c403529-94f2-4f58-b950-9c702091336e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1c403529-94f2-4f58-b950-9c702091336e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0864db26-0834-44fd-81be-00ffae4148e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_Liabilities_0864db26-0834-44fd-81be-00ffae4148e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_85dca307-1d5f-417e-9ade-b8e74ddd7dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_85dca307-1d5f-417e-9ade-b8e74ddd7dd0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_36c7d7ca-c485-4c08-ba0a-b54105229f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_36c7d7ca-c485-4c08-ba0a-b54105229f43" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_36c7d7ca-c485-4c08-ba0a-b54105229f43" xlink:to="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_45a7a24d-290e-4901-b1d0-055201a8ad36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_PreferredStockValue_45a7a24d-290e-4901-b1d0-055201a8ad36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b8cd6182-2dc1-4241-b1d6-d11267d95d21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_CommonStockValue_b8cd6182-2dc1-4241-b1d6-d11267d95d21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6cc29e32-eb6b-4aa1-a8b4-30fa6aef8837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6cc29e32-eb6b-4aa1-a8b4-30fa6aef8837" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5460b31a-3924-41c5-88f2-876502695c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5460b31a-3924-41c5-88f2-876502695c49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_845229f2-142d-45f6-8932-7267f4d017b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_845229f2-142d-45f6-8932-7267f4d017b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6c56a80d-dddf-45b7-afd3-cc1780108101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_TreasuryStockValue_6c56a80d-dddf-45b7-afd3-cc1780108101" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70b95f8c-9b74-4f17-a80d-6c3f5972de02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_36c7d7ca-c485-4c08-ba0a-b54105229f43" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70b95f8c-9b74-4f17-a80d-6c3f5972de02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7cf004d5-802a-4bad-b50c-ddefdafb175a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7cf004d5-802a-4bad-b50c-ddefdafb175a" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_af16e64d-fff8-4fdb-9f3d-76d9315a1994" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_StatementTable_af16e64d-fff8-4fdb-9f3d-76d9315a1994" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8c60a17e-9bb2-4494-8761-12b812d4d804" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_af16e64d-fff8-4fdb-9f3d-76d9315a1994" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8c60a17e-9bb2-4494-8761-12b812d4d804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8c60a17e-9bb2-4494-8761-12b812d4d804_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8c60a17e-9bb2-4494-8761-12b812d4d804" xlink:to="loc_us-gaap_RelatedPartyDomain_8c60a17e-9bb2-4494-8761-12b812d4d804_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ceb0e20b-5fe8-44ee-8da9-c612d21570e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8c60a17e-9bb2-4494-8761-12b812d4d804" xlink:to="loc_us-gaap_RelatedPartyDomain_ceb0e20b-5fe8-44ee-8da9-c612d21570e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_9c666344-5732-44bd-bc96-d1c89ad64012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ceb0e20b-5fe8-44ee-8da9-c612d21570e5" xlink:to="loc_us-gaap_NonrelatedPartyMember_9c666344-5732-44bd-bc96-d1c89ad64012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_59db43df-5043-4a5f-bfab-c821a6ffede0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ceb0e20b-5fe8-44ee-8da9-c612d21570e5" xlink:to="loc_us-gaap_RelatedPartyMember_59db43df-5043-4a5f-bfab-c821a6ffede0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e6ba60c4-15b3-4ff7-9b60-6050ea6c16d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e6ba60c4-15b3-4ff7-9b60-6050ea6c16d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b63da02-8769-45c9-b7d2-00988f494a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e6ba60c4-15b3-4ff7-9b60-6050ea6c16d1" xlink:to="loc_us-gaap_ProfitLoss_4b63da02-8769-45c9-b7d2-00988f494a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e6ba60c4-15b3-4ff7-9b60-6050ea6c16d1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8323a370-2d41-4175-ab6e-ae29e9a1ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8323a370-2d41-4175-ab6e-ae29e9a1ce34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9f08fb77-807e-478a-ac34-b59745c23ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9f08fb77-807e-478a-ac34-b59745c23ffb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_34bf7159-b182-43f1-b04b-6a5bfe9b182e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_InventoryWriteDown_34bf7159-b182-43f1-b04b-6a5bfe9b182e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp_f7126ae4-475e-4a39-a11c-222ccf0aa939" xlink:href="biib-20240930.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_biib_AmortizationOfInventoryStepUp_f7126ae4-475e-4a39-a11c-222ccf0aa939" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3b2f06bf-fed4-402b-a69d-5d9e4877ef5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_ShareBasedCompensation_3b2f06bf-fed4-402b-a69d-5d9e4877ef5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7f8111f9-7d51-4f88-9cfc-023dec50871f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7f8111f9-7d51-4f88-9cfc-023dec50871f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b54fb92f-8316-4f24-9aab-7974e86bb020" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b54fb92f-8316-4f24-9aab-7974e86bb020" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_11d9a8ae-3ded-43fd-a769-8c832a9be9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_11d9a8ae-3ded-43fd-a769-8c832a9be9fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8c2aee54-d008-4c95-9124-6b1fe25e50b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8c2aee54-d008-4c95-9124-6b1fe25e50b9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8a5c3f9f-7c40-4cbd-bef8-e794c12b728b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8a5c3f9f-7c40-4cbd-bef8-e794c12b728b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7e95d8ac-982e-45d2-b14f-6bf1370753c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7e95d8ac-982e-45d2-b14f-6bf1370753c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a4fe5613-e117-4edc-9fc0-0f6328cfbe26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a4fe5613-e117-4edc-9fc0-0f6328cfbe26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_15140265-d060-4a1e-900a-590c5dc18187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_15140265-d060-4a1e-900a-590c5dc18187" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2eef80f5-dc5b-4cfe-ab91-31387facdb08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2eef80f5-dc5b-4cfe-ab91-31387facdb08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a16c8e27-0aea-4f16-a4b6-3d59537ebf92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a16c8e27-0aea-4f16-a4b6-3d59537ebf92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6750d36e-688f-4b89-947b-46758e76ca53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6750d36e-688f-4b89-947b-46758e76ca53" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_863d5fb3-347c-42de-a5b3-8eb0cb5b997a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_863d5fb3-347c-42de-a5b3-8eb0cb5b997a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2830e251-7139-4779-9929-5af593970b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2830e251-7139-4779-9929-5af593970b7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_23b40537-d25c-4795-bd17-95dd719b3d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_23b40537-d25c-4795-bd17-95dd719b3d03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0cc0cc0e-acf8-45fc-a6bb-6cff4b3b388e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0cc0cc0e-acf8-45fc-a6bb-6cff4b3b388e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_9905144c-dff4-4885-a6ef-cdff799f4b56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_9905144c-dff4-4885-a6ef-cdff799f4b56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5285491f-4623-4aa7-9740-fdb855a494a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5285491f-4623-4aa7-9740-fdb855a494a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0ffe4be6-cff6-4933-9560-1128e0e347f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0ffe4be6-cff6-4933-9560-1128e0e347f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_4dd27a1a-bf44-4831-9bd8-3ee48b2058e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_4dd27a1a-bf44-4831-9bd8-3ee48b2058e7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a125ec00-0c94-4e83-93b3-9a825e45797c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a125ec00-0c94-4e83-93b3-9a825e45797c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e40c5c3b-b821-45ea-bba0-6deb42657aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e40c5c3b-b821-45ea-bba0-6deb42657aa2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0b601219-50f6-42f1-8be5-4fee89d780e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0b601219-50f6-42f1-8be5-4fee89d780e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_16532fa1-1d7f-4545-9f12-8df491d54529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_16532fa1-1d7f-4545-9f12-8df491d54529" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2479e865-f037-40cb-878c-fe375ea5153e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2479e865-f037-40cb-878c-fe375ea5153e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_4a2a37e1-4fe8-4a11-bae3-512e62619b60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_4a2a37e1-4fe8-4a11-bae3-512e62619b60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9368d9a8-a704-44ce-8282-200af004cc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9368d9a8-a704-44ce-8282-200af004cc23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eb13e01a-a132-4c6d-a120-2a678f6edb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eb13e01a-a132-4c6d-a120-2a678f6edb6b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_bf805d02-899d-4e7e-a3fa-64698211a6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_bf805d02-899d-4e7e-a3fa-64698211a6c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e65500d-d635-4871-bfc7-89247c047b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e65500d-d635-4871-bfc7-89247c047b0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a3abb60-8cee-42c1-93a2-4cad22e97c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a3abb60-8cee-42c1-93a2-4cad22e97c5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48115caa-8926-41b9-925e-114e512a0a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d4b28215-1638-48f6-9280-067b16cbb63f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StatementTable_d4b28215-1638-48f6-9280-067b16cbb63f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b9c1edbf-14d6-4003-b769-0c11212be378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d4b28215-1638-48f6-9280-067b16cbb63f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b9c1edbf-14d6-4003-b769-0c11212be378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b9c1edbf-14d6-4003-b769-0c11212be378_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b9c1edbf-14d6-4003-b769-0c11212be378" xlink:to="loc_us-gaap_EquityComponentDomain_b9c1edbf-14d6-4003-b769-0c11212be378_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b9c1edbf-14d6-4003-b769-0c11212be378" xlink:to="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d931fbd5-d90a-44ef-b883-c02d200b0986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_PreferredStockMember_d931fbd5-d90a-44ef-b883-c02d200b0986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b88a8e98-1007-4875-b370-7dc30287e738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_CommonStockMember_b88a8e98-1007-4875-b370-7dc30287e738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_11334386-4b7e-4f55-914e-879153fffc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_11334386-4b7e-4f55-914e-879153fffc0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cabe6be1-28a8-4d4c-9f71-1d96e4bd8825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cabe6be1-28a8-4d4c-9f71-1d96e4bd8825" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b09b235a-5c97-4cf1-83d8-23cfebad6342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_RetainedEarningsMember_b09b235a-5c97-4cf1-83d8-23cfebad6342" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_d41c77f1-76bf-49ad-a509-73bda7ca546c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_TreasuryStockCommonMember_d41c77f1-76bf-49ad-a509-73bda7ca546c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_6a5233f6-f550-4b38-8298-8f9c6c00646a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_ParentMember_6a5233f6-f550-4b38-8298-8f9c6c00646a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_dffa807e-f3fc-40ea-a46d-aac5e8d282a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_dffa807e-f3fc-40ea-a46d-aac5e8d282a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e05b1792-4b7a-428d-9e19-408f4aa9464b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e05b1792-4b7a-428d-9e19-408f4aa9464b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7c7b546-d8e6-4c56-9841-357eec3901d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7c7b546-d8e6-4c56-9841-357eec3901d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_2d649933-b86e-4636-954c-a645e4c2b06a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_TreasuryStockCommonShares_2d649933-b86e-4636-954c-a645e4c2b06a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2902c44f-e24b-437e-81ca-ac81d3cae5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_ProfitLoss_2902c44f-e24b-437e-81ca-ac81d3cae5ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d71cf091-9341-4c4d-8f38-dfb583210c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d71cf091-9341-4c4d-8f38-dfb583210c5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_8f184d2a-0544-49b6-a19e-b3a25f8e8547" xlink:href="biib-20240930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_8f184d2a-0544-49b6-a19e-b3a25f8e8547" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_6c9cd51c-a2c2-4cda-9850-4806b47a5c96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_6c9cd51c-a2c2-4cda-9850-4806b47a5c96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_d8804d95-c13e-4feb-a2b8-18ac2a886d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_d8804d95-c13e-4feb-a2b8-18ac2a886d2f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2a4fe4a9-821a-4585-9912-e12c9518ddfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2a4fe4a9-821a-4585-9912-e12c9518ddfc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b26af76e-d8cb-4692-8cfe-b95bf85f7498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b26af76e-d8cb-4692-8cfe-b95bf85f7498" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_08a7a56b-6e07-4bbc-b763-46eaba8ccd77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_08a7a56b-6e07-4bbc-b763-46eaba8ccd77" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_68455651-163e-40a9-a0e9-f723a3cb9249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockholdersEquityOther_68455651-163e-40a9-a0e9-f723a3cb9249" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f72476b-6eb0-4ae2-b4b9-2970d4f8c827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_00b4850d-241c-421b-a074-e218ca48ed18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5b6be3bf-48b3-4230-992a-5564b4b20f78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_653badff-ae1c-47a0-8276-131d62f2b13f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_653badff-ae1c-47a0-8276-131d62f2b13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_653badff-ae1c-47a0-8276-131d62f2b13f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_653badff-ae1c-47a0-8276-131d62f2b13f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_653badff-ae1c-47a0-8276-131d62f2b13f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c1e6f76-c529-4d7f-a997-509fadeb72ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_653badff-ae1c-47a0-8276-131d62f2b13f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c1e6f76-c529-4d7f-a997-509fadeb72ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_ee66fc1e-0756-4c85-b8cf-fed87ffe21de" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c1e6f76-c529-4d7f-a997-509fadeb72ef" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_ee66fc1e-0756-4c85-b8cf-fed87ffe21de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_a9f606d3-bcd7-4c03-a021-a81f66fd8f93" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c1e6f76-c529-4d7f-a997-509fadeb72ef" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_a9f606d3-bcd7-4c03-a021-a81f66fd8f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40fe4ee2-44a4-4d76-858d-a83cf781c74a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40fe4ee2-44a4-4d76-858d-a83cf781c74a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40fe4ee2-44a4-4d76-858d-a83cf781c74a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40fe4ee2-44a4-4d76-858d-a83cf781c74a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40fe4ee2-44a4-4d76-858d-a83cf781c74a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40fe4ee2-44a4-4d76-858d-a83cf781c74a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_f82fe95f-8a37-4e4d-9e55-e1ba4d465e22" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:to="loc_biib_SKYCLARYSMember_f82fe95f-8a37-4e4d-9e55-e1ba4d465e22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5ad52ae7-13f8-48e1-8269-10fbf2696c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5ad52ae7-13f8-48e1-8269-10fbf2696c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_07ce7983-fdee-4bce-b686-385d28965618" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:to="loc_biib_PriorityReviewVoucherMember_07ce7983-fdee-4bce-b686-385d28965618" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_05b7083f-3331-44cf-81a5-d043ad9c9a3e" xlink:href="biib-20240930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:to="loc_biib_OtherClinicalProgramsMember_05b7083f-3331-44cf-81a5-d043ad9c9a3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a59d5fd6-095d-46ff-a222-e2ed4cfe109d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a59d5fd6-095d-46ff-a222-e2ed4cfe109d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a59d5fd6-095d-46ff-a222-e2ed4cfe109d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a59d5fd6-095d-46ff-a222-e2ed4cfe109d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a59d5fd6-095d-46ff-a222-e2ed4cfe109d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9b60206-7146-45e7-a303-882222bb495c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a59d5fd6-095d-46ff-a222-e2ed4cfe109d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9b60206-7146-45e7-a303-882222bb495c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_39a98c24-9a3a-45d4-b828-1b7e9a734278" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9b60206-7146-45e7-a303-882222bb495c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_39a98c24-9a3a-45d4-b828-1b7e9a734278" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e018a66d-1994-480c-8fe8-e46eec85e0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9b60206-7146-45e7-a303-882222bb495c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e018a66d-1994-480c-8fe8-e46eec85e0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2d2711c7-e749-4ff5-902f-67d40cc5e80c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_srt_StatementScenarioAxis_2d2711c7-e749-4ff5-902f-67d40cc5e80c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2d2711c7-e749-4ff5-902f-67d40cc5e80c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2d2711c7-e749-4ff5-902f-67d40cc5e80c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2d2711c7-e749-4ff5-902f-67d40cc5e80c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d9962010-284f-421d-b0c8-6b6241e8309a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2d2711c7-e749-4ff5-902f-67d40cc5e80c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d9962010-284f-421d-b0c8-6b6241e8309a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_695cb410-e698-41c7-a312-aff12a0a3d1a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_d9962010-284f-421d-b0c8-6b6241e8309a" xlink:to="loc_srt_ScenarioForecastMember_695cb410-e698-41c7-a312-aff12a0a3d1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_59b09223-a073-421c-8146-879bd9b6966b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_CreditFacilityAxis_59b09223-a073-421c-8146-879bd9b6966b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_59b09223-a073-421c-8146-879bd9b6966b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_59b09223-a073-421c-8146-879bd9b6966b" xlink:to="loc_us-gaap_CreditFacilityDomain_59b09223-a073-421c-8146-879bd9b6966b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5b074665-a7c1-43fa-af3c-97b5b06abef2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_59b09223-a073-421c-8146-879bd9b6966b" xlink:to="loc_us-gaap_CreditFacilityDomain_5b074665-a7c1-43fa-af3c-97b5b06abef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ac2493da-74d4-4dbe-9feb-b4c760cd414d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5b074665-a7c1-43fa-af3c-97b5b06abef2" xlink:to="loc_us-gaap_SecuredDebtMember_ac2493da-74d4-4dbe-9feb-b4c760cd414d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f4b5dc2d-f228-47a5-861c-e6684d1ac193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_DebtInstrumentAxis_f4b5dc2d-f228-47a5-861c-e6684d1ac193" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f4b5dc2d-f228-47a5-861c-e6684d1ac193_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f4b5dc2d-f228-47a5-861c-e6684d1ac193" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f4b5dc2d-f228-47a5-861c-e6684d1ac193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_93729c74-c8cb-4b16-b6b8-a63f3cddc655" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f4b5dc2d-f228-47a5-861c-e6684d1ac193" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_93729c74-c8cb-4b16-b6b8-a63f3cddc655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_a8fe533a-bcea-477c-b9ed-7223060c7233" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93729c74-c8cb-4b16-b6b8-a63f3cddc655" xlink:to="loc_biib_TheCreditFacilityMember_a8fe533a-bcea-477c-b9ed-7223060c7233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a42024b5-fa03-4318-aa01-752787a77d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a42024b5-fa03-4318-aa01-752787a77d8d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a42024b5-fa03-4318-aa01-752787a77d8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a42024b5-fa03-4318-aa01-752787a77d8d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a42024b5-fa03-4318-aa01-752787a77d8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_928130cf-b959-477a-bd6d-925b7baeaed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a42024b5-fa03-4318-aa01-752787a77d8d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_928130cf-b959-477a-bd6d-925b7baeaed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1dbc5f6a-055b-4bc0-9f13-6f4b57007874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_928130cf-b959-477a-bd6d-925b7baeaed2" xlink:to="loc_us-gaap_LineOfCreditMember_1dbc5f6a-055b-4bc0-9f13-6f4b57007874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8007f6ff-0c8c-4fe3-9ada-c432cebbb6d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_srt_ProductOrServiceAxis_8007f6ff-0c8c-4fe3-9ada-c432cebbb6d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8007f6ff-0c8c-4fe3-9ada-c432cebbb6d9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8007f6ff-0c8c-4fe3-9ada-c432cebbb6d9" xlink:to="loc_srt_ProductsAndServicesDomain_8007f6ff-0c8c-4fe3-9ada-c432cebbb6d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_df1253ff-1e14-4fee-8ecc-ba65ae78e83b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8007f6ff-0c8c-4fe3-9ada-c432cebbb6d9" xlink:to="loc_srt_ProductsAndServicesDomain_df1253ff-1e14-4fee-8ecc-ba65ae78e83b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember_f0fa5026-9366-4f3f-8318-95656ed8219f" xlink:href="biib-20240930.xsd#biib_ClinicalInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_df1253ff-1e14-4fee-8ecc-ba65ae78e83b" xlink:to="loc_biib_ClinicalInventoryMember_f0fa5026-9366-4f3f-8318-95656ed8219f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAndIzastobartHIB210Member_7417586f-d631-4ea8-a8fd-f0ff3fa066c1" xlink:href="biib-20240930.xsd#biib_FelzartamabAndIzastobartHIB210Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_df1253ff-1e14-4fee-8ecc-ba65ae78e83b" xlink:to="loc_biib_FelzartamabAndIzastobartHIB210Member_7417586f-d631-4ea8-a8fd-f0ff3fa066c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_50d8e092-f3a0-4ae5-8b2a-1b5f6ddf1993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_50d8e092-f3a0-4ae5-8b2a-1b5f6ddf1993" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_50d8e092-f3a0-4ae5-8b2a-1b5f6ddf1993_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_50d8e092-f3a0-4ae5-8b2a-1b5f6ddf1993" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_50d8e092-f3a0-4ae5-8b2a-1b5f6ddf1993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_1935c030-910c-42c3-81cf-c5c8dd00786a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_50d8e092-f3a0-4ae5-8b2a-1b5f6ddf1993" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_1935c030-910c-42c3-81cf-c5c8dd00786a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember_69c9db1f-bcfa-4503-92d0-4debffcf2c24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_1935c030-910c-42c3-81cf-c5c8dd00786a" xlink:to="loc_us-gaap_FairValueAdjustmentToInventoryMember_69c9db1f-bcfa-4503-92d0-4debffcf2c24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8120cd8a-57d8-4e1c-ae84-a37d6d4dbcf5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_srt_RangeAxis_8120cd8a-57d8-4e1c-ae84-a37d6d4dbcf5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8120cd8a-57d8-4e1c-ae84-a37d6d4dbcf5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8120cd8a-57d8-4e1c-ae84-a37d6d4dbcf5" xlink:to="loc_srt_RangeMember_8120cd8a-57d8-4e1c-ae84-a37d6d4dbcf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c3c76d54-20b1-4660-a235-84674c5fb442" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8120cd8a-57d8-4e1c-ae84-a37d6d4dbcf5" xlink:to="loc_srt_RangeMember_c3c76d54-20b1-4660-a235-84674c5fb442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_499c78ab-b40c-45d3-876a-4cb395da1b6c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c3c76d54-20b1-4660-a235-84674c5fb442" xlink:to="loc_srt_MinimumMember_499c78ab-b40c-45d3-876a-4cb395da1b6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5cd7fbc7-bb3f-4af3-b84f-bb54e9928233" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c3c76d54-20b1-4660-a235-84674c5fb442" xlink:to="loc_srt_MaximumMember_5cd7fbc7-bb3f-4af3-b84f-bb54e9928233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_8205d069-1703-4f0d-aace-80093e3157aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_8205d069-1703-4f0d-aace-80093e3157aa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8205d069-1703-4f0d-aace-80093e3157aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_8205d069-1703-4f0d-aace-80093e3157aa" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8205d069-1703-4f0d-aace-80093e3157aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_8205d069-1703-4f0d-aace-80093e3157aa" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_f2b0c886-ff9d-446a-9a6b-035bcf83d106" xlink:href="biib-20240930.xsd#biib_Phase3ClinicalTrialFelzartamabOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_f2b0c886-ff9d-446a-9a6b-035bcf83d106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_6ce38508-d1b5-4530-ae6f-4f1f06e85b0d" xlink:href="biib-20240930.xsd#biib_Phase3ClinicalTrialFelzartamabTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_6ce38508-d1b5-4530-ae6f-4f1f06e85b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentFutureDevelopmentMember_63394fd7-e984-40de-83bb-dc06f9e2e43e" xlink:href="biib-20240930.xsd#biib_MilestonePaymentFutureDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:to="loc_biib_MilestonePaymentFutureDevelopmentMember_63394fd7-e984-40de-83bb-dc06f9e2e43e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentRegulatoryMember_2c3fa8f2-8e94-4ea6-908b-d984cc68a081" xlink:href="biib-20240930.xsd#biib_MilestonePaymentRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:to="loc_biib_MilestonePaymentRegulatoryMember_2c3fa8f2-8e94-4ea6-908b-d984cc68a081" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentCommercialMember_e4cb620b-3fbb-44b5-9939-611f740e93a1" xlink:href="biib-20240930.xsd#biib_MilestonePaymentCommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:to="loc_biib_MilestonePaymentCommercialMember_e4cb620b-3fbb-44b5-9939-611f740e93a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_5753bb63-b217-4aee-9b52-c1c3160a1554" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_srt_RestatementAxis_5753bb63-b217-4aee-9b52-c1c3160a1554" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5753bb63-b217-4aee-9b52-c1c3160a1554_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_5753bb63-b217-4aee-9b52-c1c3160a1554" xlink:to="loc_srt_RestatementDomain_5753bb63-b217-4aee-9b52-c1c3160a1554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_13e44009-1367-4c8f-bb89-ae94b69d84ea" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_5753bb63-b217-4aee-9b52-c1c3160a1554" xlink:to="loc_srt_RestatementDomain_13e44009-1367-4c8f-bb89-ae94b69d84ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_d1a25da3-2848-495c-a1e4-83d11904a4dc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_13e44009-1367-4c8f-bb89-ae94b69d84ea" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_d1a25da3-2848-495c-a1e4-83d11904a4dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ad9c5fb7-7497-41a7-b4d8-c40bae3e3f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ad9c5fb7-7497-41a7-b4d8-c40bae3e3f3f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ad9c5fb7-7497-41a7-b4d8-c40bae3e3f3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ad9c5fb7-7497-41a7-b4d8-c40bae3e3f3f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ad9c5fb7-7497-41a7-b4d8-c40bae3e3f3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_37d30d04-1f9c-4dd2-8cfc-b10facfa4ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ad9c5fb7-7497-41a7-b4d8-c40bae3e3f3f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_37d30d04-1f9c-4dd2-8cfc-b10facfa4ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8ea78600-dd50-4d87-b3c0-a2464c377620" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_37d30d04-1f9c-4dd2-8cfc-b10facfa4ff1" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8ea78600-dd50-4d87-b3c0-a2464c377620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MeasurementInputProbabilityRateMember_509a97c6-11e7-4d3a-af27-e76b958ab76e" xlink:href="biib-20240930.xsd#biib_MeasurementInputProbabilityRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_37d30d04-1f9c-4dd2-8cfc-b10facfa4ff1" xlink:to="loc_biib_MeasurementInputProbabilityRateMember_509a97c6-11e7-4d3a-af27-e76b958ab76e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_5fb96214-d930-490e-ad0e-b8e312e486b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_5fb96214-d930-490e-ad0e-b8e312e486b3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_5fb96214-d930-490e-ad0e-b8e312e486b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_5fb96214-d930-490e-ad0e-b8e312e486b3" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_5fb96214-d930-490e-ad0e-b8e312e486b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_97a7d5d6-f934-4c38-a6cf-069d9494e56d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_5fb96214-d930-490e-ad0e-b8e312e486b3" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_97a7d5d6-f934-4c38-a6cf-069d9494e56d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_67837e05-95f4-4217-be83-563de5f1a1c6" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_97a7d5d6-f934-4c38-a6cf-069d9494e56d" xlink:to="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_67837e05-95f4-4217-be83-563de5f1a1c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2ad7ed5a-32b9-444e-86a5-0a3ff5986c15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2ad7ed5a-32b9-444e-86a5-0a3ff5986c15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_43b1b495-86c3-49e5-9309-4ec63b4b81b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_43b1b495-86c3-49e5-9309-4ec63b4b81b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_b04aea23-c9d1-4018-8260-a1db3bffc26f" xlink:href="biib-20240930.xsd#biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_b04aea23-c9d1-4018-8260-a1db3bffc26f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_76c41cdb-296a-4808-93c7-176346ff99db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_76c41cdb-296a-4808-93c7-176346ff99db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_4747d97d-9fb0-406f-9cc1-4d655ba611c1" xlink:href="biib-20240930.xsd#biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_4747d97d-9fb0-406f-9cc1-4d655ba611c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a21fe70c-01b8-4c87-9412-61969f89700e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a21fe70c-01b8-4c87-9412-61969f89700e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a6821d42-5bc6-4a2a-b48c-03646ee5666b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a6821d42-5bc6-4a2a-b48c-03646ee5666b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2ae522f4-43fb-4493-874d-d7f8935a6be1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2ae522f4-43fb-4493-874d-d7f8935a6be1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8ff8f9a7-4c0c-4def-a18b-fc358ccd2d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8ff8f9a7-4c0c-4def-a18b-fc358ccd2d42" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5a484336-6c77-4d86-b3f7-acad32431baa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5a484336-6c77-4d86-b3f7-acad32431baa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetMeasurementInput_b64e08c5-8bae-49bf-a6f8-9d6aafe5b1d5" xlink:href="biib-20240930.xsd#biib_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_IntangibleAssetMeasurementInput_b64e08c5-8bae-49bf-a6f8-9d6aafe5b1d5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9dab4032-d21d-409e-b7b2-45eac26c8123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_Goodwill_9dab4032-d21d-409e-b7b2-45eac26c8123" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_72e07313-7fac-447d-8d09-8a608e381339" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_72e07313-7fac-447d-8d09-8a608e381339" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_349928a9-823c-408e-8d31-07cc3fffdf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_349928a9-823c-408e-8d31-07cc3fffdf8f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_e3491143-be89-41f5-9366-4b63881972c9" xlink:href="biib-20240930.xsd#biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_e3491143-be89-41f5-9366-4b63881972c9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_757e8ce3-992c-4df0-9f21-2f5039f806a6" xlink:href="biib-20240930.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_757e8ce3-992c-4df0-9f21-2f5039f806a6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_53a684f3-28a4-4fe7-b571-149c5f9faf03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_OperatingExpenses_53a684f3-28a4-4fe7-b571-149c5f9faf03" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_27064e92-e566-4380-b858-c3393bb19a99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_27064e92-e566-4380-b858-c3393bb19a99" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_07328301-1178-4b5a-aa84-e40954fd0287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_07328301-1178-4b5a-aa84-e40954fd0287" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8a671065-1308-4f5e-9218-55af5aad8ece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8a671065-1308-4f5e-9218-55af5aad8ece" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e6c8cec9-d5a9-4aac-9f5b-ac74adb5705e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e6c8cec9-d5a9-4aac-9f5b-ac74adb5705e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2480e305-b0b4-43a3-9a4a-8a3d77a97486" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2480e305-b0b4-43a3-9a4a-8a3d77a97486" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_03cfc9c3-38b7-4986-8a12-52b2c95015a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_ProfitLoss_03cfc9c3-38b7-4986-8a12-52b2c95015a1" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a9e6dfd6-8785-40f1-8266-fdea95a4be71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a9e6dfd6-8785-40f1-8266-fdea95a4be71" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_ae52c197-21ee-4e57-8691-1c39de306625" xlink:href="biib-20240930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_ae52c197-21ee-4e57-8691-1c39de306625" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_67f9650d-90d4-4c68-bb2d-bdc88068a1ac" xlink:href="biib-20240930.xsd#biib_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_OperatingLeaseArea_67f9650d-90d4-4c68-bb2d-bdc88068a1ac" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_071ff27b-3305-44e3-bde2-d0f5a01bc17f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_071ff27b-3305-44e3-bde2-d0f5a01bc17f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_b0cd3bbc-aa02-4307-ba72-c2ebe2f25dc3" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_b0cd3bbc-aa02-4307-ba72-c2ebe2f25dc3" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c2ccb453-925a-433b-97ec-a26590740cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c2ccb453-925a-433b-97ec-a26590740cae" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_7a5fdc1e-f614-48a3-ac24-595d568f88de" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_7a5fdc1e-f614-48a3-ac24-595d568f88de" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_ee530a80-1112-4bee-9bc4-e5a98b5b76d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_ee530a80-1112-4bee-9bc4-e5a98b5b76d4" xlink:type="arc" order="30"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#AcquisitionsPurchasePriceConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3c6630f-8041-4869-917d-dc6fd11bcc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3c6630f-8041-4869-917d-dc6fd11bcc5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_db0ea3f9-679b-4b0d-9bd2-a2ee1348273e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3c6630f-8041-4869-917d-dc6fd11bcc5b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_db0ea3f9-679b-4b0d-9bd2-a2ee1348273e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db0ea3f9-679b-4b0d-9bd2-a2ee1348273e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_db0ea3f9-679b-4b0d-9bd2-a2ee1348273e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_db0ea3f9-679b-4b0d-9bd2-a2ee1348273e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5953cb1f-0ca3-43aa-b580-ee0868d951aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_db0ea3f9-679b-4b0d-9bd2-a2ee1348273e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5953cb1f-0ca3-43aa-b580-ee0868d951aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_3d4e28df-dce5-4bab-b631-0aa35b0678e0" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5953cb1f-0ca3-43aa-b580-ee0868d951aa" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_3d4e28df-dce5-4bab-b631-0aa35b0678e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_9693cf20-e4cf-47d6-b207-a04915993ec2" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5953cb1f-0ca3-43aa-b580-ee0868d951aa" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_9693cf20-e4cf-47d6-b207-a04915993ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_ec2d84fe-0cb2-4028-ab3c-cc55585a9011" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3c6630f-8041-4869-917d-dc6fd11bcc5b" xlink:to="loc_srt_RestatementAxis_ec2d84fe-0cb2-4028-ab3c-cc55585a9011" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_ec2d84fe-0cb2-4028-ab3c-cc55585a9011_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_ec2d84fe-0cb2-4028-ab3c-cc55585a9011" xlink:to="loc_srt_RestatementDomain_ec2d84fe-0cb2-4028-ab3c-cc55585a9011_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_4a042205-90da-4883-aafd-70844dee3033" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_ec2d84fe-0cb2-4028-ab3c-cc55585a9011" xlink:to="loc_srt_RestatementDomain_4a042205-90da-4883-aafd-70844dee3033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_6e861d74-9b4d-4560-a6d2-aca01505f7a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_4a042205-90da-4883-aafd-70844dee3033" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_6e861d74-9b4d-4560-a6d2-aca01505f7a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1efa52fd-8907-4900-872f-aba8c2fbf9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1efa52fd-8907-4900-872f-aba8c2fbf9f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1ab480a3-675e-4ba0-acba-dc3ad7cad259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1ab480a3-675e-4ba0-acba-dc3ad7cad259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_acdd748e-f2a1-490c-bd3f-629aa7454f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_acdd748e-f2a1-490c-bd3f-629aa7454f72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_f68858d6-e54c-4ec7-8b0d-a8a70964f827" xlink:href="biib-20240930.xsd#biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_f68858d6-e54c-4ec7-8b0d-a8a70964f827" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_acf151c5-deb5-4035-9b3b-99bd761285c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_acf151c5-deb5-4035-9b3b-99bd761285c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_696a54f1-16b0-4177-a002-bd238a292520" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_696a54f1-16b0-4177-a002-bd238a292520" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_9e49f202-5ac2-484a-8837-0651fb228e48" xlink:href="biib-20240930.xsd#biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_9e49f202-5ac2-484a-8837-0651fb228e48" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4b483958-a796-4857-92e5-8b9a30e96b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4b483958-a796-4857-92e5-8b9a30e96b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b483958-a796-4857-92e5-8b9a30e96b1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4b483958-a796-4857-92e5-8b9a30e96b1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b483958-a796-4857-92e5-8b9a30e96b1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4621ccf1-0d93-45ca-82b9-ccaa653cf3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4b483958-a796-4857-92e5-8b9a30e96b1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4621ccf1-0d93-45ca-82b9-ccaa653cf3ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_af34bb49-8a1a-450c-b19e-86f86bdf1370" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4621ccf1-0d93-45ca-82b9-ccaa653cf3ba" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_af34bb49-8a1a-450c-b19e-86f86bdf1370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_0fbd77dc-1c0a-4062-bf59-1ecda9a9b60a" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4621ccf1-0d93-45ca-82b9-ccaa653cf3ba" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_0fbd77dc-1c0a-4062-bf59-1ecda9a9b60a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57ac9cc9-a622-433c-a036-fadbcccef037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57ac9cc9-a622-433c-a036-fadbcccef037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_57ac9cc9-a622-433c-a036-fadbcccef037_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57ac9cc9-a622-433c-a036-fadbcccef037" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_57ac9cc9-a622-433c-a036-fadbcccef037_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57ac9cc9-a622-433c-a036-fadbcccef037" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_dafae641-9259-4e09-91c8-fb899fa037a4" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:to="loc_biib_SKYCLARYSMember_dafae641-9259-4e09-91c8-fb899fa037a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4772ce8b-cbbc-4f21-80e0-a8dc08797f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4772ce8b-cbbc-4f21-80e0-a8dc08797f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_fb54e98c-aa0f-45e7-8638-7f464248eb43" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:to="loc_biib_PriorityReviewVoucherMember_fb54e98c-aa0f-45e7-8638-7f464248eb43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_edf6d41e-a04a-4bc8-93bd-2525d84a6f54" xlink:href="biib-20240930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:to="loc_biib_OtherClinicalProgramsMember_edf6d41e-a04a-4bc8-93bd-2525d84a6f54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a718a41b-ac05-42d6-b4e5-2649771798f6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:to="loc_srt_ProductOrServiceAxis_a718a41b-ac05-42d6-b4e5-2649771798f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a718a41b-ac05-42d6-b4e5-2649771798f6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a718a41b-ac05-42d6-b4e5-2649771798f6" xlink:to="loc_srt_ProductsAndServicesDomain_a718a41b-ac05-42d6-b4e5-2649771798f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_788f2989-fddc-4269-a67b-e0360dbf219d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a718a41b-ac05-42d6-b4e5-2649771798f6" xlink:to="loc_srt_ProductsAndServicesDomain_788f2989-fddc-4269-a67b-e0360dbf219d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabIgANMember_74b6b267-c5f2-404b-8070-768dd83a10f2" xlink:href="biib-20240930.xsd#biib_FelzartamabIgANMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_788f2989-fddc-4269-a67b-e0360dbf219d" xlink:to="loc_biib_FelzartamabIgANMember_74b6b267-c5f2-404b-8070-768dd83a10f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAMRMember_662e4b21-62fe-418d-b2eb-ac5adbbd48ff" xlink:href="biib-20240930.xsd#biib_FelzartamabAMRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_788f2989-fddc-4269-a67b-e0360dbf219d" xlink:to="loc_biib_FelzartamabAMRMember_662e4b21-62fe-418d-b2eb-ac5adbbd48ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabPMNMember_12d6f902-8ac4-4858-bd48-d31aa6e180c7" xlink:href="biib-20240930.xsd#biib_FelzartamabPMNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_788f2989-fddc-4269-a67b-e0360dbf219d" xlink:to="loc_biib_FelzartamabPMNMember_12d6f902-8ac4-4858-bd48-d31aa6e180c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_249c49ab-7929-47b0-85bd-7328cf420f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_249c49ab-7929-47b0-85bd-7328cf420f25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_008eab9c-8740-40b5-a160-1a27e20c69f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_008eab9c-8740-40b5-a160-1a27e20c69f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_499bf98f-5c30-49b0-ab9c-3d6757e0f642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_499bf98f-5c30-49b0-ab9c-3d6757e0f642" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_02b1655f-1515-4e89-acf4-5afb22b9b5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_02b1655f-1515-4e89-acf4-5afb22b9b5d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e3a3fbf5-ff96-46bd-a3a8-54dc1a475107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e3a3fbf5-ff96-46bd-a3a8-54dc1a475107" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_89c14905-08b5-470d-a210-b5c3f5c73f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_89c14905-08b5-470d-a210-b5c3f5c73f8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_58438e96-6aa7-463b-a8d1-79e2f01f1d9f" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_58438e96-6aa7-463b-a8d1-79e2f01f1d9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_422ef87d-9827-4aee-b95e-cd81eaa4923c" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_422ef87d-9827-4aee-b95e-cd81eaa4923c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6927db7f-6e46-40ef-be63-125443538cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6927db7f-6e46-40ef-be63-125443538cc5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_6bcebe6b-6428-4108-a6ab-9795e82c500c" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_6bcebe6b-6428-4108-a6ab-9795e82c500c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_c76359ea-8d10-4eda-85fa-5e4393e40944" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_c76359ea-8d10-4eda-85fa-5e4393e40944" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_7770f9cb-7e81-44ca-8938-b17c68cd2c61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_7770f9cb-7e81-44ca-8938-b17c68cd2c61" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b2dc8865-b0ea-4b5b-9c0a-a08aae5e2a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b2dc8865-b0ea-4b5b-9c0a-a08aae5e2a1b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_cb94d63c-e257-4060-b123-e8d173cb34a3" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_cb94d63c-e257-4060-b123-e8d173cb34a3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_148a47eb-c776-4b38-8f1d-fb60861efac7" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_148a47eb-c776-4b38-8f1d-fb60861efac7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a1d4a4f1-5627-442b-8fdd-2b1110133544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a1d4a4f1-5627-442b-8fdd-2b1110133544" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f1f7a07e-2774-4261-913f-9445b2d90c47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_Goodwill_f1f7a07e-2774-4261-913f-9445b2d90c47" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_82c88ffb-7e16-451c-a060-89645017d394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_82c88ffb-7e16-451c-a060-89645017d394" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_b1afef7c-01da-4d7a-94dc-074df2934c30" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_b1afef7c-01da-4d7a-94dc-074df2934c30" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_ce849c1b-1b5f-495b-93ae-745351885388" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_ce849c1b-1b5f-495b-93ae-745351885388" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_348cbac6-8df2-48fd-b1a7-e0fb7e9a09fd" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_348cbac6-8df2-48fd-b1a7-e0fb7e9a09fd" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets_b83d2876-83ac-4bf4-b704-4546a568c31d" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets_b83d2876-83ac-4bf4-b704-4546a568c31d" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20240930.xsd#DispositionsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c75f2128-9957-445a-878f-673320e6efd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c75f2128-9957-445a-878f-673320e6efd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c75f2128-9957-445a-878f-673320e6efd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c75f2128-9957-445a-878f-673320e6efd7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c75f2128-9957-445a-878f-673320e6efd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea1f4c7a-042f-4315-a649-9b6e9036f1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c75f2128-9957-445a-878f-673320e6efd7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea1f4c7a-042f-4315-a649-9b6e9036f1d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_66e8f0a7-f77c-4b8e-81bd-395cab8f1a7b" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea1f4c7a-042f-4315-a649-9b6e9036f1d8" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_66e8f0a7-f77c-4b8e-81bd-395cab8f1a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_52d5b5a9-a007-4656-9acb-a00ced0479e2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_52d5b5a9-a007-4656-9acb-a00ced0479e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_52d5b5a9-a007-4656-9acb-a00ced0479e2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_52d5b5a9-a007-4656-9acb-a00ced0479e2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_52d5b5a9-a007-4656-9acb-a00ced0479e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b7a207fe-3d07-40f6-beb1-eb6c66513784" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_52d5b5a9-a007-4656-9acb-a00ced0479e2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b7a207fe-3d07-40f6-beb1-eb6c66513784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_75f23deb-b1f8-484c-8b44-ceee0f11f92c" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b7a207fe-3d07-40f6-beb1-eb6c66513784" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_75f23deb-b1f8-484c-8b44-ceee0f11f92c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_e8ec87cd-a86f-4794-a6ce-e0b405d01477" xlink:href="biib-20240930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_e8ec87cd-a86f-4794-a6ce-e0b405d01477" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_e8ec87cd-a86f-4794-a6ce-e0b405d01477_default" xlink:href="biib-20240930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_e8ec87cd-a86f-4794-a6ce-e0b405d01477" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_e8ec87cd-a86f-4794-a6ce-e0b405d01477_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_7187198a-608e-4bc3-9813-f20c56186fe5" xlink:href="biib-20240930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_e8ec87cd-a86f-4794-a6ce-e0b405d01477" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_7187198a-608e-4bc3-9813-f20c56186fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_4cc36551-ea64-469c-915e-295721b14292" xlink:href="biib-20240930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_7187198a-608e-4bc3-9813-f20c56186fe5" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_4cc36551-ea64-469c-915e-295721b14292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_db837151-0cee-4312-b37a-a4eafcbd090a" xlink:href="biib-20240930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_7187198a-608e-4bc3-9813-f20c56186fe5" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_db837151-0cee-4312-b37a-a4eafcbd090a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5dfd7c8e-d858-48af-87b2-3811271a72f3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:to="loc_srt_CounterpartyNameAxis_5dfd7c8e-d858-48af-87b2-3811271a72f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dfd7c8e-d858-48af-87b2-3811271a72f3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5dfd7c8e-d858-48af-87b2-3811271a72f3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dfd7c8e-d858-48af-87b2-3811271a72f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8cc7f8f0-dc2b-493a-9861-234064c3918f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5dfd7c8e-d858-48af-87b2-3811271a72f3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8cc7f8f0-dc2b-493a-9861-234064c3918f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_6915ef67-29ff-4eb0-88a2-13895f477bf8" xlink:href="biib-20240930.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8cc7f8f0-dc2b-493a-9861-234064c3918f" xlink:to="loc_biib_IonisPharmaceuticalsInc.Member_6915ef67-29ff-4eb0-88a2-13895f477bf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_90faaae2-a5c9-4ee5-ad97-91a7e4b2e04b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_90faaae2-a5c9-4ee5-ad97-91a7e4b2e04b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_552f2bb8-833e-486a-b86b-70f80d59a201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_552f2bb8-833e-486a-b86b-70f80d59a201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_8cd95431-2d0f-4d04-9acd-1c1c5b3514c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_8cd95431-2d0f-4d04-9acd-1c1c5b3514c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_a1ca62b0-74fe-4a82-b49b-fc1797af391c" xlink:href="biib-20240930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_a1ca62b0-74fe-4a82-b49b-fc1797af391c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6f0c0d5c-9d7e-4490-ab4c-235a85bc02af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6f0c0d5c-9d7e-4490-ab4c-235a85bc02af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_10ef3af8-4e9f-4081-a2d5-a4c9c32ede7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_10ef3af8-4e9f-4081-a2d5-a4c9c32ede7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0ba8d07c-a117-4589-baee-9bf8d95a2cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_AccountsPayableCurrent_0ba8d07c-a117-4589-baee-9bf8d95a2cc8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_b020d0ec-5fde-483d-994c-067dec08faaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_b020d0ec-5fde-483d-994c-067dec08faaf" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8619b0d1-0de0-4c61-9152-e4beafe8c143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_27f9d5c9-aad3-421e-aa49-e7b6c9bb5b69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8619b0d1-0de0-4c61-9152-e4beafe8c143" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_27f9d5c9-aad3-421e-aa49-e7b6c9bb5b69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3dddb19c-239a-4491-8a66-c48128ab000f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_27f9d5c9-aad3-421e-aa49-e7b6c9bb5b69" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3dddb19c-239a-4491-8a66-c48128ab000f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3dddb19c-239a-4491-8a66-c48128ab000f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3dddb19c-239a-4491-8a66-c48128ab000f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3dddb19c-239a-4491-8a66-c48128ab000f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2fe0ef8a-a727-4231-835d-eaf2d61d8707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3dddb19c-239a-4491-8a66-c48128ab000f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2fe0ef8a-a727-4231-835d-eaf2d61d8707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_59aa4958-586d-4d3b-b5b6-d3893e080ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2fe0ef8a-a727-4231-835d-eaf2d61d8707" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_59aa4958-586d-4d3b-b5b6-d3893e080ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f32fb529-9e52-46a5-a12f-900dcc554b78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2fe0ef8a-a727-4231-835d-eaf2d61d8707" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f32fb529-9e52-46a5-a12f-900dcc554b78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_28b9375a-00ae-474e-af2c-e8bdd12cc925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2fe0ef8a-a727-4231-835d-eaf2d61d8707" xlink:to="loc_us-gaap_RestructuringChargesMember_28b9375a-00ae-474e-af2c-e8bdd12cc925" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_cbf56f45-981e-4bc7-b33f-dd9ed5ea58e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_27f9d5c9-aad3-421e-aa49-e7b6c9bb5b69" xlink:to="loc_us-gaap_RestructuringPlanAxis_cbf56f45-981e-4bc7-b33f-dd9ed5ea58e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_cbf56f45-981e-4bc7-b33f-dd9ed5ea58e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_cbf56f45-981e-4bc7-b33f-dd9ed5ea58e1" xlink:to="loc_us-gaap_RestructuringPlanDomain_cbf56f45-981e-4bc7-b33f-dd9ed5ea58e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_8ed144a7-199a-4597-8f99-4e985f27b4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_cbf56f45-981e-4bc7-b33f-dd9ed5ea58e1" xlink:to="loc_us-gaap_RestructuringPlanDomain_8ed144a7-199a-4597-8f99-4e985f27b4c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_f51e7916-9a78-497f-ad16-ec1230f4e79c" xlink:href="biib-20240930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_8ed144a7-199a-4597-8f99-4e985f27b4c5" xlink:to="loc_biib_A2023CostSavingInitiativesMember_f51e7916-9a78-497f-ad16-ec1230f4e79c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_d9142d7f-edcb-42ee-99ed-ee9dbfdd6e9f" xlink:href="biib-20240930.xsd#biib_ReataIntegrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_8ed144a7-199a-4597-8f99-4e985f27b4c5" xlink:to="loc_biib_ReataIntegrationMember_d9142d7f-edcb-42ee-99ed-ee9dbfdd6e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_1e73ad1d-79a2-4ff5-95ee-e68cd4f76d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8619b0d1-0de0-4c61-9152-e4beafe8c143" xlink:to="loc_us-gaap_SeveranceCosts1_1e73ad1d-79a2-4ff5-95ee-e68cd4f76d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_31087073-be4d-4e7d-8b9a-7c3082aa0057" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8619b0d1-0de0-4c61-9152-e4beafe8c143" xlink:to="loc_us-gaap_OtherRestructuringCosts_31087073-be4d-4e7d-8b9a-7c3082aa0057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f73ff384-383d-4dda-92f8-950b73d78b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8619b0d1-0de0-4c61-9152-e4beafe8c143" xlink:to="loc_us-gaap_RestructuringCharges_f73ff384-383d-4dda-92f8-950b73d78b5e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_b3c22550-6e57-4cbf-9cf0-70e49c0bd558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:to="loc_us-gaap_RestructuringPlanAxis_b3c22550-6e57-4cbf-9cf0-70e49c0bd558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b3c22550-6e57-4cbf-9cf0-70e49c0bd558_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_b3c22550-6e57-4cbf-9cf0-70e49c0bd558" xlink:to="loc_us-gaap_RestructuringPlanDomain_b3c22550-6e57-4cbf-9cf0-70e49c0bd558_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_9996bb2e-e71e-4a40-9e95-88fb8326f102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_b3c22550-6e57-4cbf-9cf0-70e49c0bd558" xlink:to="loc_us-gaap_RestructuringPlanDomain_9996bb2e-e71e-4a40-9e95-88fb8326f102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_52e812f1-0b36-48b2-9b4b-46cfb32b54f4" xlink:href="biib-20240930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_9996bb2e-e71e-4a40-9e95-88fb8326f102" xlink:to="loc_biib_A2023CostSavingInitiativesMember_52e812f1-0b36-48b2-9b4b-46cfb32b54f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_acb3d043-266f-45de-a5d4-2f37483dfecd" xlink:href="biib-20240930.xsd#biib_ReataIntegrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_9996bb2e-e71e-4a40-9e95-88fb8326f102" xlink:to="loc_biib_ReataIntegrationMember_acb3d043-266f-45de-a5d4-2f37483dfecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_83372d57-d039-4a73-976f-22bba980cd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_83372d57-d039-4a73-976f-22bba980cd4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83372d57-d039-4a73-976f-22bba980cd4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_83372d57-d039-4a73-976f-22bba980cd4d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83372d57-d039-4a73-976f-22bba980cd4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7283bbb6-c6aa-4b20-b19e-8ae6da4ce69b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_83372d57-d039-4a73-976f-22bba980cd4d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7283bbb6-c6aa-4b20-b19e-8ae6da4ce69b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_982494e0-2236-4f87-b4ea-782ba7e21996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7283bbb6-c6aa-4b20-b19e-8ae6da4ce69b" xlink:to="loc_us-gaap_RestructuringChargesMember_982494e0-2236-4f87-b4ea-782ba7e21996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5c907b99-f6f1-4f5c-8b6c-2416e721b89e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:to="loc_srt_RangeAxis_5c907b99-f6f1-4f5c-8b6c-2416e721b89e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5c907b99-f6f1-4f5c-8b6c-2416e721b89e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5c907b99-f6f1-4f5c-8b6c-2416e721b89e" xlink:to="loc_srt_RangeMember_5c907b99-f6f1-4f5c-8b6c-2416e721b89e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_24980e12-ffa7-4e72-8b2f-2e49aec02906" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5c907b99-f6f1-4f5c-8b6c-2416e721b89e" xlink:to="loc_srt_RangeMember_24980e12-ffa7-4e72-8b2f-2e49aec02906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca52baf3-768f-4009-9897-324954b11322" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_24980e12-ffa7-4e72-8b2f-2e49aec02906" xlink:to="loc_srt_MinimumMember_ca52baf3-768f-4009-9897-324954b11322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d7029cb-e858-4a0a-a454-e5c29db288ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_24980e12-ffa7-4e72-8b2f-2e49aec02906" xlink:to="loc_srt_MaximumMember_9d7029cb-e858-4a0a-a454-e5c29db288ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_061c9fa6-f7e0-4265-b91d-4091b110b46a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_061c9fa6-f7e0-4265-b91d-4091b110b46a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_061c9fa6-f7e0-4265-b91d-4091b110b46a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_061c9fa6-f7e0-4265-b91d-4091b110b46a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_061c9fa6-f7e0-4265-b91d-4091b110b46a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07c819b9-517e-4933-a313-d0906d6c395f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_061c9fa6-f7e0-4265-b91d-4091b110b46a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07c819b9-517e-4933-a313-d0906d6c395f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_ec91048b-0fc5-4cd1-9caf-f23e123d1cf3" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07c819b9-517e-4933-a313-d0906d6c395f" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_ec91048b-0fc5-4cd1-9caf-f23e123d1cf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_a8175bd5-335d-44aa-840a-afb5e8bd2c3f" xlink:href="biib-20240930.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_a8175bd5-335d-44aa-840a-afb5e8bd2c3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_68946724-a5ec-46b9-beaf-d458ce9ba288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_68946724-a5ec-46b9-beaf-d458ce9ba288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c6374417-c7be-474b-bde8-f738a7f2c12c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_SeveranceCosts1_c6374417-c7be-474b-bde8-f738a7f2c12c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_48f67ff0-2c8c-48d8-a591-5acbe010c729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_48f67ff0-2c8c-48d8-a591-5acbe010c729" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_7ca162d9-3402-4b12-8514-04b1b714904c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_7ca162d9-3402-4b12-8514-04b1b714904c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_7c90e1d5-d029-4ce0-863b-4b759e8a67e3" xlink:href="biib-20240930.xsd#biib_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_biib_OperatingLeaseArea_7c90e1d5-d029-4ce0-863b-4b759e8a67e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f8d4a7cc-996a-4bc4-9a0a-b37e26bbe16f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f8d4a7cc-996a-4bc4-9a0a-b37e26bbe16f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_57de8256-6338-43a2-bf94-3b4acefae49c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_57de8256-6338-43a2-bf94-3b4acefae49c" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6b3a0e55-c1fa-4aae-b19e-929c25a64bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_39d85336-9964-4879-b432-7318c82482b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6b3a0e55-c1fa-4aae-b19e-929c25a64bea" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_39d85336-9964-4879-b432-7318c82482b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a0bfa550-e7d6-4de9-8ba0-b1b37c6db882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_39d85336-9964-4879-b432-7318c82482b5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a0bfa550-e7d6-4de9-8ba0-b1b37c6db882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a0bfa550-e7d6-4de9-8ba0-b1b37c6db882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a0bfa550-e7d6-4de9-8ba0-b1b37c6db882" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a0bfa550-e7d6-4de9-8ba0-b1b37c6db882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_bc31a7d2-9e8f-46f1-a3a6-157628e2dc19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a0bfa550-e7d6-4de9-8ba0-b1b37c6db882" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_bc31a7d2-9e8f-46f1-a3a6-157628e2dc19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_8492d451-1a85-4d05-9091-3ddf48448b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bc31a7d2-9e8f-46f1-a3a6-157628e2dc19" xlink:to="loc_us-gaap_EmployeeSeveranceMember_8492d451-1a85-4d05-9091-3ddf48448b9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2ccc34bb-1cbe-4623-a691-e82d65403de5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_39d85336-9964-4879-b432-7318c82482b5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2ccc34bb-1cbe-4623-a691-e82d65403de5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2ccc34bb-1cbe-4623-a691-e82d65403de5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2ccc34bb-1cbe-4623-a691-e82d65403de5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2ccc34bb-1cbe-4623-a691-e82d65403de5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4c08b44d-998f-4bc0-b6d1-8d5786ae64b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2ccc34bb-1cbe-4623-a691-e82d65403de5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4c08b44d-998f-4bc0-b6d1-8d5786ae64b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_3fa89703-9066-4965-9d1f-d064045556ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4c08b44d-998f-4bc0-b6d1-8d5786ae64b8" xlink:to="loc_us-gaap_RestructuringChargesMember_3fa89703-9066-4965-9d1f-d064045556ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d0885910-a545-43df-aceb-2e1cc81fc5af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6b3a0e55-c1fa-4aae-b19e-929c25a64bea" xlink:to="loc_us-gaap_RestructuringCharges_d0885910-a545-43df-aceb-2e1cc81fc5af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82ba1cd3-31ca-4b86-a87b-d4b2e7d58799" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82ba1cd3-31ca-4b86-a87b-d4b2e7d58799" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_46b5fb1e-2b02-4b2c-a579-b3abe3244eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82ba1cd3-31ca-4b86-a87b-d4b2e7d58799" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_46b5fb1e-2b02-4b2c-a579-b3abe3244eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_46b5fb1e-2b02-4b2c-a579-b3abe3244eaf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_46b5fb1e-2b02-4b2c-a579-b3abe3244eaf" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_46b5fb1e-2b02-4b2c-a579-b3abe3244eaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_863d6ddd-991e-4234-b118-d0c350e6693e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_46b5fb1e-2b02-4b2c-a579-b3abe3244eaf" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_863d6ddd-991e-4234-b118-d0c350e6693e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_9909add0-410b-4dfd-a577-99f4866ecf93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_863d6ddd-991e-4234-b118-d0c350e6693e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_9909add0-410b-4dfd-a577-99f4866ecf93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_cc5b735e-9c49-4280-a0d5-d50899d2b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82ba1cd3-31ca-4b86-a87b-d4b2e7d58799" xlink:to="loc_us-gaap_RestructuringPlanAxis_cc5b735e-9c49-4280-a0d5-d50899d2b1df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_cc5b735e-9c49-4280-a0d5-d50899d2b1df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_cc5b735e-9c49-4280-a0d5-d50899d2b1df" xlink:to="loc_us-gaap_RestructuringPlanDomain_cc5b735e-9c49-4280-a0d5-d50899d2b1df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_c264a97f-ef28-4e96-ab04-9ba7720b1c87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_cc5b735e-9c49-4280-a0d5-d50899d2b1df" xlink:to="loc_us-gaap_RestructuringPlanDomain_c264a97f-ef28-4e96-ab04-9ba7720b1c87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_7c260366-9013-41e0-9545-61c1d5308dd0" xlink:href="biib-20240930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_c264a97f-ef28-4e96-ab04-9ba7720b1c87" xlink:to="loc_biib_A2023CostSavingInitiativesMember_7c260366-9013-41e0-9545-61c1d5308dd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember_ece7a150-d3dd-4b49-8075-d7606c8c685d" xlink:href="biib-20240930.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_c264a97f-ef28-4e96-ab04-9ba7720b1c87" xlink:to="loc_biib_A2023And2022CostSavingInitiativesMember_ece7a150-d3dd-4b49-8075-d7606c8c685d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f3685404-62ee-4029-988a-ef0b7e0b7d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:to="loc_us-gaap_RestructuringReserve_f3685404-62ee-4029-988a-ef0b7e0b7d6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_7ccbd5c3-188b-47a7-978e-981d2d1a0dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:to="loc_us-gaap_RestructuringCharges_7ccbd5c3-188b-47a7-978e-981d2d1a0dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_e0d817da-6e60-407b-ab01-8b1d07912d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:to="loc_us-gaap_PaymentsForRestructuring_e0d817da-6e60-407b-ab01-8b1d07912d4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment_021bd398-019d-47f8-ad9b-c5a45fa92c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:to="loc_us-gaap_RestructuringReserveTranslationAdjustment_021bd398-019d-47f8-ad9b-c5a45fa92c6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_a112e81d-c669-4659-aa95-566fcc2d7c45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_322dcad7-2dfb-4c7c-aed7-d5ce17cb271f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0fdc6767-b550-4321-ac4d-fe1e9bf3235f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_322dcad7-2dfb-4c7c-aed7-d5ce17cb271f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0fdc6767-b550-4321-ac4d-fe1e9bf3235f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eaa21d59-4fe9-41db-ba79-113f89f7307d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0fdc6767-b550-4321-ac4d-fe1e9bf3235f" xlink:to="loc_srt_ProductOrServiceAxis_eaa21d59-4fe9-41db-ba79-113f89f7307d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eaa21d59-4fe9-41db-ba79-113f89f7307d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_eaa21d59-4fe9-41db-ba79-113f89f7307d" xlink:to="loc_srt_ProductsAndServicesDomain_eaa21d59-4fe9-41db-ba79-113f89f7307d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55fd981e-4a2e-4b43-b0f9-078f90b9ce40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_eaa21d59-4fe9-41db-ba79-113f89f7307d" xlink:to="loc_srt_ProductsAndServicesDomain_55fd981e-4a2e-4b43-b0f9-078f90b9ce40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_55fd981e-4a2e-4b43-b0f9-078f90b9ce40" xlink:to="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_e4c372ce-835d-4ae3-8a83-7357b30affbd" xlink:href="biib-20240930.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_MSProductRevenuesMember_e4c372ce-835d-4ae3-8a83-7357b30affbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_2cbeda7b-3182-4d70-b5fe-be72b77e6a9d" xlink:href="biib-20240930.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_e4c372ce-835d-4ae3-8a83-7357b30affbd" xlink:to="loc_biib_FumarateMember_2cbeda7b-3182-4d70-b5fe-be72b77e6a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_c3da04a5-5a63-4858-acf6-32a05e6483f4" xlink:href="biib-20240930.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_2cbeda7b-3182-4d70-b5fe-be72b77e6a9d" xlink:to="loc_biib_TECFIDERAMember_c3da04a5-5a63-4858-acf6-32a05e6483f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_04da5445-e069-49e2-8d86-a474607ccb6c" xlink:href="biib-20240930.xsd#biib_VUMERITYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_2cbeda7b-3182-4d70-b5fe-be72b77e6a9d" xlink:to="loc_biib_VUMERITYMember_04da5445-e069-49e2-8d86-a474607ccb6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_8bca5d45-62f5-4c16-b193-0e475b9fad64" xlink:href="biib-20240930.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_e4c372ce-835d-4ae3-8a83-7357b30affbd" xlink:to="loc_biib_InterferonMember_8bca5d45-62f5-4c16-b193-0e475b9fad64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_01de4ab0-1c52-4e32-bb78-8c045bfb0164" xlink:href="biib-20240930.xsd#biib_AVONEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_8bca5d45-62f5-4c16-b193-0e475b9fad64" xlink:to="loc_biib_AVONEXMember_01de4ab0-1c52-4e32-bb78-8c045bfb0164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_94177a62-b525-4b0c-bbdf-01fa278d8673" xlink:href="biib-20240930.xsd#biib_PLEGRIDYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_8bca5d45-62f5-4c16-b193-0e475b9fad64" xlink:to="loc_biib_PLEGRIDYMember_94177a62-b525-4b0c-bbdf-01fa278d8673" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_8dc8e44a-e4f8-4134-9760-9d5cc308d052" xlink:href="biib-20240930.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_TysabriProductMember_8dc8e44a-e4f8-4134-9760-9d5cc308d052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_1ff3e89c-761f-4be7-b727-c4ffd9de6d4d" xlink:href="biib-20240930.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_FAMPYRAMember_1ff3e89c-761f-4be7-b727-c4ffd9de6d4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RareDiseaseProductRevenueMember_479ffd0a-7cef-442e-a718-d84a68124257" xlink:href="biib-20240930.xsd#biib_RareDiseaseProductRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_RareDiseaseProductRevenueMember_479ffd0a-7cef-442e-a718-d84a68124257" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_QALSODYMember_6b0dbfe3-d047-43cb-94ee-3f0acd1d8162" xlink:href="biib-20240930.xsd#biib_QALSODYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RareDiseaseProductRevenueMember_479ffd0a-7cef-442e-a718-d84a68124257" xlink:to="loc_biib_QALSODYMember_6b0dbfe3-d047-43cb-94ee-3f0acd1d8162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_65e50159-aa96-416b-8ec7-8eafbed354b2" xlink:href="biib-20240930.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RareDiseaseProductRevenueMember_479ffd0a-7cef-442e-a718-d84a68124257" xlink:to="loc_biib_SPINRAZAMember_65e50159-aa96-416b-8ec7-8eafbed354b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_53cae746-8bdc-4628-a6fd-9969abffc39f" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RareDiseaseProductRevenueMember_479ffd0a-7cef-442e-a718-d84a68124257" xlink:to="loc_biib_SKYCLARYSMember_53cae746-8bdc-4628-a6fd-9969abffc39f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:href="biib-20240930.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_182f8ff5-e603-4fa0-b235-1d430841ba1c" xlink:href="biib-20240930.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:to="loc_biib_BENEPALIMember_182f8ff5-e603-4fa0-b235-1d430841ba1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_b48644b9-6243-47bd-b173-ea9fba930f4d" xlink:href="biib-20240930.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:to="loc_biib_IMRALDIMember_b48644b9-6243-47bd-b173-ea9fba930f4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_5e92c3bb-39cf-47b2-bd1e-59c434624ee5" xlink:href="biib-20240930.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:to="loc_biib_FLIXABIMember_5e92c3bb-39cf-47b2-bd1e-59c434624ee5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_5243cad4-aa37-4a3b-99ff-c69356832c78" xlink:href="biib-20240930.xsd#biib_BYOOVIZMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:to="loc_biib_BYOOVIZMember_5243cad4-aa37-4a3b-99ff-c69356832c78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TOFIDENCEMember_cd987cc1-c726-4fd4-b486-e7854504debd" xlink:href="biib-20240930.xsd#biib_TOFIDENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:to="loc_biib_TOFIDENCEMember_cd987cc1-c726-4fd4-b486-e7854504debd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherProductsMember_2dc51197-d748-47e6-bd81-5e71252b1183" xlink:href="biib-20240930.xsd#biib_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_OtherProductsMember_2dc51197-d748-47e6-bd81-5e71252b1183" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZURZUVAEMember_004f7dcb-31c5-45a9-876c-a0a6a420ca82" xlink:href="biib-20240930.xsd#biib_ZURZUVAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_OtherProductsMember_2dc51197-d748-47e6-bd81-5e71252b1183" xlink:to="loc_biib_ZURZUVAEMember_004f7dcb-31c5-45a9-876c-a0a6a420ca82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember_04cb4918-6eea-4052-82a0-f89e759168ae" xlink:href="biib-20240930.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_OtherProductsMember_2dc51197-d748-47e6-bd81-5e71252b1183" xlink:to="loc_biib_FUMADERMAndADUHELMMember_04cb4918-6eea-4052-82a0-f89e759168ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9d49f492-8cee-462a-ac10-36baada4a445" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0fdc6767-b550-4321-ac4d-fe1e9bf3235f" xlink:to="loc_srt_StatementGeographicalAxis_9d49f492-8cee-462a-ac10-36baada4a445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9d49f492-8cee-462a-ac10-36baada4a445_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9d49f492-8cee-462a-ac10-36baada4a445" xlink:to="loc_srt_SegmentGeographicalDomain_9d49f492-8cee-462a-ac10-36baada4a445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd93f575-0f20-4fc8-b18d-d8435afb9768" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9d49f492-8cee-462a-ac10-36baada4a445" xlink:to="loc_srt_SegmentGeographicalDomain_cd93f575-0f20-4fc8-b18d-d8435afb9768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_864863ab-9e29-40e3-9068-d8851f9bade3" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cd93f575-0f20-4fc8-b18d-d8435afb9768" xlink:to="loc_country_US_864863ab-9e29-40e3-9068-d8851f9bade3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_96146907-1e04-40ad-ba07-d94065f6170b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cd93f575-0f20-4fc8-b18d-d8435afb9768" xlink:to="loc_us-gaap_NonUsMember_96146907-1e04-40ad-ba07-d94065f6170b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a00a420c-0491-4a76-b17f-2397ece9fd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_322dcad7-2dfb-4c7c-aed7-d5ce17cb271f" xlink:to="loc_us-gaap_Revenues_a00a420c-0491-4a76-b17f-2397ece9fd8b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_30adfde5-22e6-471b-b208-b8069b17b1f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_30adfde5-22e6-471b-b208-b8069b17b1f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c48b1f9c-e24b-4fab-acf1-64ae90ca42a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_30adfde5-22e6-471b-b208-b8069b17b1f9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c48b1f9c-e24b-4fab-acf1-64ae90ca42a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c48b1f9c-e24b-4fab-acf1-64ae90ca42a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c48b1f9c-e24b-4fab-acf1-64ae90ca42a8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c48b1f9c-e24b-4fab-acf1-64ae90ca42a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_46953d0a-eefa-4c78-bc52-0b573555859f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c48b1f9c-e24b-4fab-acf1-64ae90ca42a8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_46953d0a-eefa-4c78-bc52-0b573555859f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_4844c5c8-5a6b-46c3-bdd9-740f4451d2f3" xlink:href="biib-20240930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_46953d0a-eefa-4c78-bc52-0b573555859f" xlink:to="loc_biib_ReserveforCashDiscountsMember_4844c5c8-5a6b-46c3-bdd9-740f4451d2f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_731c1415-8e98-49dd-a36f-dcd14c27dc1a" xlink:href="biib-20240930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_46953d0a-eefa-4c78-bc52-0b573555859f" xlink:to="loc_biib_ContractualAdjustmentsMember_731c1415-8e98-49dd-a36f-dcd14c27dc1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_e64bf29c-019e-4e5f-8d3a-f0032a11d8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_46953d0a-eefa-4c78-bc52-0b573555859f" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_e64bf29c-019e-4e5f-8d3a-f0032a11d8ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_04e381ff-3971-4afd-9e5a-bd67e6b425e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_04e381ff-3971-4afd-9e5a-bd67e6b425e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_c007dce1-6a01-4981-8c10-9d5056fe10c8" xlink:href="biib-20240930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_c007dce1-6a01-4981-8c10-9d5056fe10c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_5cc3b1d1-f117-4a09-916b-ef3d38eed3e2" xlink:href="biib-20240930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_5cc3b1d1-f117-4a09-916b-ef3d38eed3e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_6baf64b7-fa70-4302-9b44-14d6a3ce1c8a" xlink:href="biib-20240930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_6baf64b7-fa70-4302-9b44-14d6a3ce1c8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_0be21d79-fdf6-4978-a4bd-d988a0f47515" xlink:href="biib-20240930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_0be21d79-fdf6-4978-a4bd-d988a0f47515" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_aa293204-a300-43e8-afb7-60dc9074905e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8ec67a24-0e2c-4121-9b11-a706772a0406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_46a12c46-9552-4ffa-8165-f7768bdf6685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8ec67a24-0e2c-4121-9b11-a706772a0406" xlink:to="loc_us-gaap_StatementTable_46a12c46-9552-4ffa-8165-f7768bdf6685" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c1f4562d-4a86-4641-b66f-9b9f1c9b3338" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_46a12c46-9552-4ffa-8165-f7768bdf6685" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c1f4562d-4a86-4641-b66f-9b9f1c9b3338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c1f4562d-4a86-4641-b66f-9b9f1c9b3338_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c1f4562d-4a86-4641-b66f-9b9f1c9b3338" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c1f4562d-4a86-4641-b66f-9b9f1c9b3338_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2015c003-a293-42e8-894d-f329bf48bf43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c1f4562d-4a86-4641-b66f-9b9f1c9b3338" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2015c003-a293-42e8-894d-f329bf48bf43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e7aef5da-3155-42e0-9ecf-a58169e2d300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2015c003-a293-42e8-894d-f329bf48bf43" xlink:to="loc_us-gaap_AccountsReceivableMember_e7aef5da-3155-42e0-9ecf-a58169e2d300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5684b7f0-2023-4c9c-a9b6-cad90f31fc22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2015c003-a293-42e8-894d-f329bf48bf43" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_5684b7f0-2023-4c9c-a9b6-cad90f31fc22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_41d17363-7d42-4b7d-94ec-8df5163a04ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ec67a24-0e2c-4121-9b11-a706772a0406" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_41d17363-7d42-4b7d-94ec-8df5163a04ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_22eea5cb-9d18-40fe-b907-081126a2b9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d1e2adc3-78ce-481c-bdb8-041706a4f664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22eea5cb-9d18-40fe-b907-081126a2b9bf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d1e2adc3-78ce-481c-bdb8-041706a4f664" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_887115a2-3804-413d-9b11-c0e9ea157d52" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1e2adc3-78ce-481c-bdb8-041706a4f664" xlink:to="loc_srt_ProductOrServiceAxis_887115a2-3804-413d-9b11-c0e9ea157d52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_887115a2-3804-413d-9b11-c0e9ea157d52_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_887115a2-3804-413d-9b11-c0e9ea157d52" xlink:to="loc_srt_ProductsAndServicesDomain_887115a2-3804-413d-9b11-c0e9ea157d52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_148c30d9-3ced-4d92-9d2f-e3b4ac9d4fa3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_887115a2-3804-413d-9b11-c0e9ea157d52" xlink:to="loc_srt_ProductsAndServicesDomain_148c30d9-3ced-4d92-9d2f-e3b4ac9d4fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ac5c3e09-6eff-4f5d-b801-105c59cb90ab" xlink:href="biib-20240930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_148c30d9-3ced-4d92-9d2f-e3b4ac9d4fa3" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ac5c3e09-6eff-4f5d-b801-105c59cb90ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember_b795b320-2c8a-42d7-87a1-fc5ebec1a183" xlink:href="biib-20240930.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_148c30d9-3ced-4d92-9d2f-e3b4ac9d4fa3" xlink:to="loc_biib_RoyaltyAttributedToOCREVUSMember_b795b320-2c8a-42d7-87a1-fc5ebec1a183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d3a5b7fd-7640-48ee-b8af-b80a2c984b26" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1e2adc3-78ce-481c-bdb8-041706a4f664" xlink:to="loc_srt_MajorCustomersAxis_d3a5b7fd-7640-48ee-b8af-b80a2c984b26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d3a5b7fd-7640-48ee-b8af-b80a2c984b26_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d3a5b7fd-7640-48ee-b8af-b80a2c984b26" xlink:to="loc_srt_NameOfMajorCustomerDomain_d3a5b7fd-7640-48ee-b8af-b80a2c984b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_83713b63-b94b-4ddf-8112-da58a894ff21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d3a5b7fd-7640-48ee-b8af-b80a2c984b26" xlink:to="loc_srt_NameOfMajorCustomerDomain_83713b63-b94b-4ddf-8112-da58a894ff21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_cefd7780-a1af-4710-addd-8a2de816c93b" xlink:href="biib-20240930.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_83713b63-b94b-4ddf-8112-da58a894ff21" xlink:to="loc_biib_RocheGroupGenentechMember_cefd7780-a1af-4710-addd-8a2de816c93b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_efa5f08d-09c3-4f8f-8c89-7291d7b17d50" xlink:href="biib-20240930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22eea5cb-9d18-40fe-b907-081126a2b9bf" xlink:to="loc_biib_ShareOfCoPromotionProfits_efa5f08d-09c3-4f8f-8c89-7291d7b17d50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0568ab67-cf0d-4882-a2c7-204ae59f93eb" xlink:href="biib-20240930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22eea5cb-9d18-40fe-b907-081126a2b9bf" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0568ab67-cf0d-4882-a2c7-204ae59f93eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f0342f87-f139-46e5-ad33-d0c77328b6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22eea5cb-9d18-40fe-b907-081126a2b9bf" xlink:to="loc_us-gaap_Revenues_f0342f87-f139-46e5-ad33-d0c77328b6a2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesOtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_54848eaa-a612-478f-a2ef-b20ad793dc08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_17f3716d-c393-4d97-8091-be23e0e3201c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_54848eaa-a612-478f-a2ef-b20ad793dc08" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_17f3716d-c393-4d97-8091-be23e0e3201c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d5452800-8d22-4ccd-b6c0-296315da9d06" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_17f3716d-c393-4d97-8091-be23e0e3201c" xlink:to="loc_srt_ProductOrServiceAxis_d5452800-8d22-4ccd-b6c0-296315da9d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d5452800-8d22-4ccd-b6c0-296315da9d06_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d5452800-8d22-4ccd-b6c0-296315da9d06" xlink:to="loc_srt_ProductsAndServicesDomain_d5452800-8d22-4ccd-b6c0-296315da9d06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ecf1b570-4a56-49fe-8909-cb9389d833e9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d5452800-8d22-4ccd-b6c0-296315da9d06" xlink:to="loc_srt_ProductsAndServicesDomain_ecf1b570-4a56-49fe-8909-cb9389d833e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember_2484fc42-7cae-4fd2-bf26-8896b04a5454" xlink:href="biib-20240930.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ecf1b570-4a56-49fe-8909-cb9389d833e9" xlink:to="loc_biib_ContractManufacturingAndOtherRevenueMember_2484fc42-7cae-4fd2-bf26-8896b04a5454" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_2511e60b-9a30-47cc-8cc8-ecbe37c504c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ecf1b570-4a56-49fe-8909-cb9389d833e9" xlink:to="loc_us-gaap_RoyaltyMember_2511e60b-9a30-47cc-8cc8-ecbe37c504c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_3165d4aa-a761-4cf8-a628-95f2f7d76f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ecf1b570-4a56-49fe-8909-cb9389d833e9" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_3165d4aa-a761-4cf8-a628-95f2f7d76f28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e9b650de-8993-4a73-8a17-75c987438d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_54848eaa-a612-478f-a2ef-b20ad793dc08" xlink:to="loc_us-gaap_Revenues_e9b650de-8993-4a73-8a17-75c987438d39" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_006f0340-bf75-40ae-b325-a28170979a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_006f0340-bf75-40ae-b325-a28170979a2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1ded1440-17a0-4fe6-89a2-270e739c717b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_006f0340-bf75-40ae-b325-a28170979a2a" xlink:to="loc_srt_ProductOrServiceAxis_1ded1440-17a0-4fe6-89a2-270e739c717b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1ded1440-17a0-4fe6-89a2-270e739c717b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1ded1440-17a0-4fe6-89a2-270e739c717b" xlink:to="loc_srt_ProductsAndServicesDomain_1ded1440-17a0-4fe6-89a2-270e739c717b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a2aaca9-e621-47e8-843e-c63c9bb1484b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1ded1440-17a0-4fe6-89a2-270e739c717b" xlink:to="loc_srt_ProductsAndServicesDomain_7a2aaca9-e621-47e8-843e-c63c9bb1484b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_15042b6f-c75d-4f96-b36a-e70d90425522" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a2aaca9-e621-47e8-843e-c63c9bb1484b" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_15042b6f-c75d-4f96-b36a-e70d90425522" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_7dd37ea9-fe8b-4d59-8846-cb04d8d535fd" xlink:href="biib-20240930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a2aaca9-e621-47e8-843e-c63c9bb1484b" xlink:to="loc_biib_LEQEMBICollaborationMember_7dd37ea9-fe8b-4d59-8846-cb04d8d535fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6a40b240-1b44-4803-86f6-997ba5e548ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_006f0340-bf75-40ae-b325-a28170979a2a" xlink:to="loc_srt_MajorCustomersAxis_6a40b240-1b44-4803-86f6-997ba5e548ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6a40b240-1b44-4803-86f6-997ba5e548ca_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6a40b240-1b44-4803-86f6-997ba5e548ca" xlink:to="loc_srt_NameOfMajorCustomerDomain_6a40b240-1b44-4803-86f6-997ba5e548ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ae21a458-e726-45a3-922e-48e7b81a5d7a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6a40b240-1b44-4803-86f6-997ba5e548ca" xlink:to="loc_srt_NameOfMajorCustomerDomain_ae21a458-e726-45a3-922e-48e7b81a5d7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_87857fed-6304-4767-bd53-6e037a64af66" xlink:href="biib-20240930.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae21a458-e726-45a3-922e-48e7b81a5d7a" xlink:to="loc_biib_DistributorOneMember_87857fed-6304-4767-bd53-6e037a64af66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_796d737c-f9fc-40f6-91b8-d78b841f6e95" xlink:href="biib-20240930.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae21a458-e726-45a3-922e-48e7b81a5d7a" xlink:to="loc_biib_DistributorTwoMember_796d737c-f9fc-40f6-91b8-d78b841f6e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_35da383a-2892-478d-bba1-c03985941297" xlink:href="biib-20240930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_35da383a-2892-478d-bba1-c03985941297" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_f5f00814-860f-4fb8-8db6-f1c9925448db" xlink:href="biib-20240930.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:to="loc_biib_NumberOfWholesalers_f5f00814-860f-4fb8-8db6-f1c9925448db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_506eb1c2-7af6-40a9-8d0e-cd9046260bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:to="loc_us-gaap_Revenues_506eb1c2-7af6-40a9-8d0e-cd9046260bd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_01ed55e0-4c2a-40bf-88f8-76e84efd70b8" xlink:href="biib-20240930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_01ed55e0-4c2a-40bf-88f8-76e84efd70b8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#InventoryNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:to="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f114a819-a86b-4173-b4fd-bba600bb5718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f114a819-a86b-4173-b4fd-bba600bb5718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f114a819-a86b-4173-b4fd-bba600bb5718_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f114a819-a86b-4173-b4fd-bba600bb5718" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f114a819-a86b-4173-b4fd-bba600bb5718_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a703f12-dff1-4871-b408-cf9c9873110f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f114a819-a86b-4173-b4fd-bba600bb5718" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a703f12-dff1-4871-b408-cf9c9873110f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_6dc73cb3-24d4-43e2-bcc1-b3fc376da1e1" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a703f12-dff1-4871-b408-cf9c9873110f" xlink:to="loc_biib_EisaiMember_6dc73cb3-24d4-43e2-bcc1-b3fc376da1e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6191ed54-0364-403c-bbc6-0ba5a7c13e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6191ed54-0364-403c-bbc6-0ba5a7c13e2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6191ed54-0364-403c-bbc6-0ba5a7c13e2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6191ed54-0364-403c-bbc6-0ba5a7c13e2a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6191ed54-0364-403c-bbc6-0ba5a7c13e2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23e87063-8cf0-457f-b785-9255fb81b966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6191ed54-0364-403c-bbc6-0ba5a7c13e2a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23e87063-8cf0-457f-b785-9255fb81b966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_781af977-af06-4feb-bd78-ef0fa8b85f4e" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23e87063-8cf0-457f-b785-9255fb81b966" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_781af977-af06-4feb-bd78-ef0fa8b85f4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_6422b807-eb24-4375-8d22-5152326cd6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_6422b807-eb24-4375-8d22-5152326cd6b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_6422b807-eb24-4375-8d22-5152326cd6b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_6422b807-eb24-4375-8d22-5152326cd6b1" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_6422b807-eb24-4375-8d22-5152326cd6b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_58b5c941-e859-4df1-b465-3612dc411478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_6422b807-eb24-4375-8d22-5152326cd6b1" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_58b5c941-e859-4df1-b465-3612dc411478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember_0cf48866-3d4a-4161-bd61-bceec318b848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_58b5c941-e859-4df1-b465-3612dc411478" xlink:to="loc_us-gaap_FairValueAdjustmentToInventoryMember_0cf48866-3d4a-4161-bd61-bceec318b848" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_082e4f34-3650-43a6-b607-b9ced48fe7ff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:to="loc_srt_ProductOrServiceAxis_082e4f34-3650-43a6-b607-b9ced48fe7ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_082e4f34-3650-43a6-b607-b9ced48fe7ff_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_082e4f34-3650-43a6-b607-b9ced48fe7ff" xlink:to="loc_srt_ProductsAndServicesDomain_082e4f34-3650-43a6-b607-b9ced48fe7ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c42e4eaa-ca18-4a8b-acbc-ac721abf6ca1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_082e4f34-3650-43a6-b607-b9ced48fe7ff" xlink:to="loc_srt_ProductsAndServicesDomain_c42e4eaa-ca18-4a8b-acbc-ac721abf6ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember_312106de-2bee-462e-91e6-9c7785bbbb87" xlink:href="biib-20240930.xsd#biib_ClinicalInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c42e4eaa-ca18-4a8b-acbc-ac721abf6ca1" xlink:to="loc_biib_ClinicalInventoryMember_312106de-2bee-462e-91e6-9c7785bbbb87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_782f796b-7606-4f49-a92f-9f0ec0420ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_782f796b-7606-4f49-a92f-9f0ec0420ac7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_8ff9bc05-a1cf-466f-bae2-e35e12547d46" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_8ff9bc05-a1cf-466f-bae2-e35e12547d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_056d533f-2dae-44af-bb54-a0777a2cda55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:to="loc_us-gaap_ProfitLoss_056d533f-2dae-44af-bb54-a0777a2cda55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7c898f23-6385-4df3-8585-9c51e3fe0e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7c898f23-6385-4df3-8585-9c51e3fe0e8b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_da9c1abf-44b7-4c8c-9339-4202187a6de2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ad5836c8-4ecf-4f72-ab23-dad7d89f0063" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_da9c1abf-44b7-4c8c-9339-4202187a6de2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ad5836c8-4ecf-4f72-ab23-dad7d89f0063" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cb1bec97-96c2-4ef1-98ff-79efff221a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ad5836c8-4ecf-4f72-ab23-dad7d89f0063" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cb1bec97-96c2-4ef1-98ff-79efff221a4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cb1bec97-96c2-4ef1-98ff-79efff221a4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cb1bec97-96c2-4ef1-98ff-79efff221a4a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cb1bec97-96c2-4ef1-98ff-79efff221a4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_526439a6-5c8a-4b15-8b02-83fa1c23fe61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cb1bec97-96c2-4ef1-98ff-79efff221a4a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_526439a6-5c8a-4b15-8b02-83fa1c23fe61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_ac147a6a-c9ac-4617-9469-b66f6989d7d6" xlink:href="biib-20240930.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_526439a6-5c8a-4b15-8b02-83fa1c23fe61" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_ac147a6a-c9ac-4617-9469-b66f6989d7d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_42af09c1-1579-439e-ac27-fd17269b27cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_526439a6-5c8a-4b15-8b02-83fa1c23fe61" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_42af09c1-1579-439e-ac27-fd17269b27cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_234a5acb-3cc0-454c-b0dd-1abd6c902301" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ad5836c8-4ecf-4f72-ab23-dad7d89f0063" xlink:to="loc_srt_RangeAxis_234a5acb-3cc0-454c-b0dd-1abd6c902301" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_234a5acb-3cc0-454c-b0dd-1abd6c902301_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_234a5acb-3cc0-454c-b0dd-1abd6c902301" xlink:to="loc_srt_RangeMember_234a5acb-3cc0-454c-b0dd-1abd6c902301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d19a3449-151c-42c6-8932-f3270c558cb4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_234a5acb-3cc0-454c-b0dd-1abd6c902301" xlink:to="loc_srt_RangeMember_d19a3449-151c-42c6-8932-f3270c558cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9e408f52-5821-49ac-844c-21d5b0f94025" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d19a3449-151c-42c6-8932-f3270c558cb4" xlink:to="loc_srt_MinimumMember_9e408f52-5821-49ac-844c-21d5b0f94025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40350c86-0840-4d46-ad17-013406710a12" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d19a3449-151c-42c6-8932-f3270c558cb4" xlink:to="loc_srt_MaximumMember_40350c86-0840-4d46-ad17-013406710a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6075bbcd-aaa2-4632-b00d-4979a83bb62b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_da9c1abf-44b7-4c8c-9339-4202187a6de2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6075bbcd-aaa2-4632-b00d-4979a83bb62b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_38e02b35-1111-4bb9-8fd4-797d6e6e6639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_da9c1abf-44b7-4c8c-9339-4202187a6de2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_38e02b35-1111-4bb9-8fd4-797d6e6e6639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_819de58c-a6fc-443d-a04e-23d5307c41c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_38e02b35-1111-4bb9-8fd4-797d6e6e6639" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_819de58c-a6fc-443d-a04e-23d5307c41c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c8554113-b3a9-4224-9a9c-9f0a13a012d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_38e02b35-1111-4bb9-8fd4-797d6e6e6639" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c8554113-b3a9-4224-9a9c-9f0a13a012d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67ca1e3a-4143-4197-a207-336837acecb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_38e02b35-1111-4bb9-8fd4-797d6e6e6639" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67ca1e3a-4143-4197-a207-336837acecb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e4566752-aad6-4ce6-b2f3-3f6d457e9376" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_381ab30a-539e-42f2-bdd0-55d8eb2f9eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e4566752-aad6-4ce6-b2f3-3f6d457e9376" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_381ab30a-539e-42f2-bdd0-55d8eb2f9eaf" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3f158f68-3b05-4130-8b3a-d6fb1e7f704a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_381ab30a-539e-42f2-bdd0-55d8eb2f9eaf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3f158f68-3b05-4130-8b3a-d6fb1e7f704a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3f158f68-3b05-4130-8b3a-d6fb1e7f704a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3f158f68-3b05-4130-8b3a-d6fb1e7f704a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3f158f68-3b05-4130-8b3a-d6fb1e7f704a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a065ed1-c543-4f63-8265-4ee65e2ff4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3f158f68-3b05-4130-8b3a-d6fb1e7f704a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a065ed1-c543-4f63-8265-4ee65e2ff4d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5ea9fade-10f6-4447-ad7c-f1cd485c4607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a065ed1-c543-4f63-8265-4ee65e2ff4d1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5ea9fade-10f6-4447-ad7c-f1cd485c4607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_e2db0905-ca91-4bc8-9f26-90cd3416b491" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a065ed1-c543-4f63-8265-4ee65e2ff4d1" xlink:to="loc_biib_PriorityReviewVoucherMember_e2db0905-ca91-4bc8-9f26-90cd3416b491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_242ae254-20d1-4c49-9b2c-3f0f1e9a6e84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a065ed1-c543-4f63-8265-4ee65e2ff4d1" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_242ae254-20d1-4c49-9b2c-3f0f1e9a6e84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f61c2bf4-9a8b-42d0-afd3-9bae7e507aea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e4566752-aad6-4ce6-b2f3-3f6d457e9376" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f61c2bf4-9a8b-42d0-afd3-9bae7e507aea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2c6f9941-2776-4e30-9fa4-e3f00431c295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2c6f9941-2776-4e30-9fa4-e3f00431c295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c6f9941-2776-4e30-9fa4-e3f00431c295_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2c6f9941-2776-4e30-9fa4-e3f00431c295" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2c6f9941-2776-4e30-9fa4-e3f00431c295_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e343d771-4876-488e-b487-035ac53874b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2c6f9941-2776-4e30-9fa4-e3f00431c295" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e343d771-4876-488e-b487-035ac53874b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_717bbf70-bd7d-4b19-918e-a755a540eae4" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e343d771-4876-488e-b487-035ac53874b7" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_717bbf70-bd7d-4b19-918e-a755a540eae4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_45ecf6b5-8643-497d-b0cf-223ba9f33a1f" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e343d771-4876-488e-b487-035ac53874b7" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_45ecf6b5-8643-497d-b0cf-223ba9f33a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_702adf10-f8b4-4985-9bbb-925a46e2cb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_702adf10-f8b4-4985-9bbb-925a46e2cb5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_702adf10-f8b4-4985-9bbb-925a46e2cb5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_702adf10-f8b4-4985-9bbb-925a46e2cb5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_702adf10-f8b4-4985-9bbb-925a46e2cb5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_702adf10-f8b4-4985-9bbb-925a46e2cb5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_bbebcfb5-d960-4fb1-b163-ea21c4d0c19d" xlink:href="biib-20240930.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_bbebcfb5-d960-4fb1-b163-ea21c4d0c19d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_b31c7e99-4f95-48f3-8a08-28ecc63df022" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_b31c7e99-4f95-48f3-8a08-28ecc63df022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_7e716b18-5c48-4f43-a983-a57630402021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_7e716b18-5c48-4f43-a983-a57630402021" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_d857104f-026f-456d-8f25-19ef3518b9b0" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_biib_SKYCLARYSMember_d857104f-026f-456d-8f25-19ef3518b9b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_e3bf5852-c5ed-4bd0-9c39-50fc5eb91475" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_biib_PriorityReviewVoucherMember_e3bf5852-c5ed-4bd0-9c39-50fc5eb91475" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CompletedTechnologyMember_d6774eac-2724-419f-9aeb-5ad00753c85c" xlink:href="biib-20240930.xsd#biib_CompletedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_biib_CompletedTechnologyMember_d6774eac-2724-419f-9aeb-5ad00753c85c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ce36ecf-0bfa-4716-8c7d-3fd9a1d470a9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:to="loc_srt_RangeAxis_3ce36ecf-0bfa-4716-8c7d-3fd9a1d470a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ce36ecf-0bfa-4716-8c7d-3fd9a1d470a9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3ce36ecf-0bfa-4716-8c7d-3fd9a1d470a9" xlink:to="loc_srt_RangeMember_3ce36ecf-0bfa-4716-8c7d-3fd9a1d470a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2581a603-8cde-46ef-88c1-ab9da83661d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3ce36ecf-0bfa-4716-8c7d-3fd9a1d470a9" xlink:to="loc_srt_RangeMember_2581a603-8cde-46ef-88c1-ab9da83661d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_110b69b0-c354-470f-a2b5-945be4093648" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2581a603-8cde-46ef-88c1-ab9da83661d5" xlink:to="loc_srt_MinimumMember_110b69b0-c354-470f-a2b5-945be4093648" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_613b92e3-ed7f-4e93-b146-ea38c389f1d3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2581a603-8cde-46ef-88c1-ab9da83661d5" xlink:to="loc_srt_MaximumMember_613b92e3-ed7f-4e93-b146-ea38c389f1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6a08d823-2f65-41ab-93fd-b2087c543e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6a08d823-2f65-41ab-93fd-b2087c543e88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a08d823-2f65-41ab-93fd-b2087c543e88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6a08d823-2f65-41ab-93fd-b2087c543e88" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a08d823-2f65-41ab-93fd-b2087c543e88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd893bc4-1b94-446c-bcb5-b78dde339c21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6a08d823-2f65-41ab-93fd-b2087c543e88" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd893bc4-1b94-446c-bcb5-b78dde339c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6d2a3d2a-83b9-4e03-bc78-a468b32b087d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd893bc4-1b94-446c-bcb5-b78dde339c21" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6d2a3d2a-83b9-4e03-bc78-a468b32b087d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_b65bcc26-c2fc-4edb-b717-4f897589dadb" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd893bc4-1b94-446c-bcb5-b78dde339c21" xlink:to="loc_biib_PriorityReviewVoucherMember_b65bcc26-c2fc-4edb-b717-4f897589dadb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_a6a4fd11-9826-4a9e-ab2a-8c45ecb46465" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd893bc4-1b94-446c-bcb5-b78dde339c21" xlink:to="loc_biib_SKYCLARYSMember_a6a4fd11-9826-4a9e-ab2a-8c45ecb46465" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_40ac9429-fca6-4def-bbab-48881c49e0df" xlink:href="biib-20240930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_40ac9429-fca6-4def-bbab-48881c49e0df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96285787-07af-4409-a8c4-5ba39356d5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96285787-07af-4409-a8c4-5ba39356d5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9f8369c2-b5d7-430f-99c9-ff5681068c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9f8369c2-b5d7-430f-99c9-ff5681068c5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_b78f7c36-6cae-47e0-97f9-4c91285cf8a4" xlink:href="biib-20240930.xsd#biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_b78f7c36-6cae-47e0-97f9-4c91285cf8a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b07ad7bb-5a3e-4cb1-a1dd-b38448cd8ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b07ad7bb-5a3e-4cb1-a1dd-b38448cd8ca9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_59232073-cdef-474a-abed-32bf1a1fb774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_59232073-cdef-474a-abed-32bf1a1fb774" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwillChangesinGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_a38c351f-fe07-44a2-b68d-a7c8f7cc34a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_059f8557-ddf7-47c9-bb4b-22edcff2f986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_a38c351f-fe07-44a2-b68d-a7c8f7cc34a4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_059f8557-ddf7-47c9-bb4b-22edcff2f986" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1350b490-1698-4ea3-a7a8-241126aee213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_059f8557-ddf7-47c9-bb4b-22edcff2f986" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1350b490-1698-4ea3-a7a8-241126aee213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1350b490-1698-4ea3-a7a8-241126aee213_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1350b490-1698-4ea3-a7a8-241126aee213" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1350b490-1698-4ea3-a7a8-241126aee213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5066998-01d7-4eea-968a-e305d757a68f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1350b490-1698-4ea3-a7a8-241126aee213" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5066998-01d7-4eea-968a-e305d757a68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_c8438fc4-57d8-432d-8d76-0d99054d179a" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5066998-01d7-4eea-968a-e305d757a68f" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_c8438fc4-57d8-432d-8d76-0d99054d179a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_b64e54a8-03f5-44df-a2d2-a25323d70fdc" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5066998-01d7-4eea-968a-e305d757a68f" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_b64e54a8-03f5-44df-a2d2-a25323d70fdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a38c351f-fe07-44a2-b68d-a7c8f7cc34a4" xlink:to="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2651c760-33f8-4902-9af4-3f81f6aff80e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:to="loc_us-gaap_Goodwill_2651c760-33f8-4902-9af4-3f81f6aff80e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_85f27829-7ed9-4257-a513-fbaa3571a372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_85f27829-7ed9-4257-a513-fbaa3571a372" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_0e821cf6-fe54-4a34-a3d9-f972b8eefe50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_0e821cf6-fe54-4a34-a3d9-f972b8eefe50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2853d280-de9e-4013-ad7b-855ca5e3efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f7524f9-011d-4b08-903c-003a9f1154d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a38c351f-fe07-44a2-b68d-a7c8f7cc34a4" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f7524f9-011d-4b08-903c-003a9f1154d2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d950fd73-22b0-421d-9401-846517468025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d950fd73-22b0-421d-9401-846517468025" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98ce8bb8-60da-47c9-9b1b-44369a876810" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98ce8bb8-60da-47c9-9b1b-44369a876810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98ce8bb8-60da-47c9-9b1b-44369a876810_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98ce8bb8-60da-47c9-9b1b-44369a876810" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98ce8bb8-60da-47c9-9b1b-44369a876810_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6011df99-ea1a-4483-a910-fb40299be895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98ce8bb8-60da-47c9-9b1b-44369a876810" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6011df99-ea1a-4483-a910-fb40299be895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2c248dca-6300-4b67-a86f-c40645ae7641" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6011df99-ea1a-4483-a910-fb40299be895" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2c248dca-6300-4b67-a86f-c40645ae7641" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_05f9af78-17dc-42dd-97c2-5f88abfe2cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6011df99-ea1a-4483-a910-fb40299be895" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_05f9af78-17dc-42dd-97c2-5f88abfe2cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9b783bc9-6281-4526-bacc-df4463055730" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6011df99-ea1a-4483-a910-fb40299be895" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9b783bc9-6281-4526-bacc-df4463055730" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b1b3378-3290-477b-87e2-da18857ff00d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b1b3378-3290-477b-87e2-da18857ff00d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b1b3378-3290-477b-87e2-da18857ff00d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b1b3378-3290-477b-87e2-da18857ff00d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b1b3378-3290-477b-87e2-da18857ff00d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_89f3822d-b308-4587-85ec-d9ca1753073c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b1b3378-3290-477b-87e2-da18857ff00d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_89f3822d-b308-4587-85ec-d9ca1753073c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6db26e6c-a784-43aa-b4e4-9e66b165e520" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_89f3822d-b308-4587-85ec-d9ca1753073c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6db26e6c-a784-43aa-b4e4-9e66b165e520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22c65e9c-8a60-4433-88fa-b35a2510071a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22c65e9c-8a60-4433-88fa-b35a2510071a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_22c65e9c-8a60-4433-88fa-b35a2510071a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22c65e9c-8a60-4433-88fa-b35a2510071a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_22c65e9c-8a60-4433-88fa-b35a2510071a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_170a629a-8569-4ed8-9767-a84c7e024ca5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22c65e9c-8a60-4433-88fa-b35a2510071a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_170a629a-8569-4ed8-9767-a84c7e024ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5fbe9c2f-3ea7-49b0-83ea-8eaf96978632" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_170a629a-8569-4ed8-9767-a84c7e024ca5" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5fbe9c2f-3ea7-49b0-83ea-8eaf96978632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d950fd73-22b0-421d-9401-846517468025" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_072e5855-a030-4527-b7cc-b0914334541a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_072e5855-a030-4527-b7cc-b0914334541a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_f3260367-4ed9-4f2a-8064-bd0f078d72f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_f3260367-4ed9-4f2a-8064-bd0f078d72f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_d8eca924-ab3b-4670-96fe-93b5085925f2" xlink:href="biib-20240930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_d8eca924-ab3b-4670-96fe-93b5085925f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_bb0b94f4-70b5-46bf-85cd-2981661e7226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_bb0b94f4-70b5-46bf-85cd-2981661e7226" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_de64eacd-2439-4546-aa18-bcc0854dfdf8" xlink:href="biib-20240930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_de64eacd-2439-4546-aa18-bcc0854dfdf8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_9bb80eb7-ba3b-43b0-a400-f571572e7cef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_us-gaap_DerivativeAssets_9bb80eb7-ba3b-43b0-a400-f571572e7cef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2f4c490e-6436-4798-ba88-14bb2dd544f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2f4c490e-6436-4798-ba88-14bb2dd544f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_74118cfb-40c5-4138-bc77-85205fa359d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_74118cfb-40c5-4138-bc77-85205fa359d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_9f9e093a-d911-4219-8738-479dae0571d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_74118cfb-40c5-4138-bc77-85205fa359d5" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_9f9e093a-d911-4219-8738-479dae0571d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_dc6adc85-6368-4cec-8873-ccd0e071604e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_74118cfb-40c5-4138-bc77-85205fa359d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_dc6adc85-6368-4cec-8873-ccd0e071604e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_6b7594c6-f217-4f34-89ea-70ad5bff97c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_6b7594c6-f217-4f34-89ea-70ad5bff97c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_889d0e13-81e9-4765-aa2f-ae0263e0bb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_6b7594c6-f217-4f34-89ea-70ad5bff97c2" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_889d0e13-81e9-4765-aa2f-ae0263e0bb1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_56e49888-013b-47b2-b9f5-d52f637dd3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_6b7594c6-f217-4f34-89ea-70ad5bff97c2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_56e49888-013b-47b2-b9f5-d52f637dd3cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_50e96e08-608e-41c5-ae68-baf6b6ee29b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_50e96e08-608e-41c5-ae68-baf6b6ee29b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f237bd20-0b50-4e3e-b93c-730b6fe79c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f237bd20-0b50-4e3e-b93c-730b6fe79c8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3c06a64c-2445-448c-a478-6f08e30f880d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3c06a64c-2445-448c-a478-6f08e30f880d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d2c2ae6f-85bd-4706-92d0-67292dda6fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:to="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_806482ad-09ed-45f8-87ee-2b09408d4678" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_806482ad-09ed-45f8-87ee-2b09408d4678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_806482ad-09ed-45f8-87ee-2b09408d4678_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_806482ad-09ed-45f8-87ee-2b09408d4678" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_806482ad-09ed-45f8-87ee-2b09408d4678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_53d98d75-1f48-4ce6-9d2d-39a05ec1eb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_806482ad-09ed-45f8-87ee-2b09408d4678" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_53d98d75-1f48-4ce6-9d2d-39a05ec1eb0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_dfc12ffd-2830-41dc-84ff-0c9cc793f4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_53d98d75-1f48-4ce6-9d2d-39a05ec1eb0c" xlink:to="loc_us-gaap_LineOfCreditMember_dfc12ffd-2830-41dc-84ff-0c9cc793f4e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87ddf0df-203a-4040-9352-cb85cb7f4654" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87ddf0df-203a-4040-9352-cb85cb7f4654" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_87ddf0df-203a-4040-9352-cb85cb7f4654_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87ddf0df-203a-4040-9352-cb85cb7f4654" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_87ddf0df-203a-4040-9352-cb85cb7f4654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b0c78dd-4829-475c-8aec-5067d69679cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87ddf0df-203a-4040-9352-cb85cb7f4654" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b0c78dd-4829-475c-8aec-5067d69679cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_6b02d31f-8d32-48ff-8b21-f95ee41ec38e" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b0c78dd-4829-475c-8aec-5067d69679cc" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_6b02d31f-8d32-48ff-8b21-f95ee41ec38e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ed00040f-e923-4dc6-b3c4-9eb570dfa8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ed00040f-e923-4dc6-b3c4-9eb570dfa8f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ed00040f-e923-4dc6-b3c4-9eb570dfa8f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ed00040f-e923-4dc6-b3c4-9eb570dfa8f4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ed00040f-e923-4dc6-b3c4-9eb570dfa8f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5f0c7e37-ccfd-4661-8be5-58e626610656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ed00040f-e923-4dc6-b3c4-9eb570dfa8f4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5f0c7e37-ccfd-4661-8be5-58e626610656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MeasurementInputProbabilityRateMember_aa42dfad-eea6-41f4-b2df-823e23e63789" xlink:href="biib-20240930.xsd#biib_MeasurementInputProbabilityRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5f0c7e37-ccfd-4661-8be5-58e626610656" xlink:to="loc_biib_MeasurementInputProbabilityRateMember_aa42dfad-eea6-41f4-b2df-823e23e63789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1b5ab0e8-4f97-4db5-8ed0-41181b5c4db4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:to="loc_us-gaap_AssetImpairmentCharges_1b5ab0e8-4f97-4db5-8ed0-41181b5c4db4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_97adb49e-9358-4b13-9947-f20a3c5c7928" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_97adb49e-9358-4b13-9947-f20a3c5c7928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_59a3ec38-b22c-47bf-adc7-dedd8eee6241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_59a3ec38-b22c-47bf-adc7-dedd8eee6241" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b7187423-c151-4eb8-ad05-200f82b6fb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b7187423-c151-4eb8-ad05-200f82b6fb1f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8f7e218e-e7c9-4464-ab35-4c605879b2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8f7e218e-e7c9-4464-ab35-4c605879b2c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ecc43317-9434-42aa-9bde-f04cd4791bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ecc43317-9434-42aa-9bde-f04cd4791bc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ecc43317-9434-42aa-9bde-f04cd4791bc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ecc43317-9434-42aa-9bde-f04cd4791bc1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ecc43317-9434-42aa-9bde-f04cd4791bc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11d5813d-66b4-47b0-bad1-76f82bf94874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ecc43317-9434-42aa-9bde-f04cd4791bc1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11d5813d-66b4-47b0-bad1-76f82bf94874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0a8b25aa-1327-4526-8cd1-3450be4075e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11d5813d-66b4-47b0-bad1-76f82bf94874" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0a8b25aa-1327-4526-8cd1-3450be4075e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e34fa60c-740a-4e20-80d3-574c55f8802a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:to="loc_srt_RangeAxis_e34fa60c-740a-4e20-80d3-574c55f8802a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e34fa60c-740a-4e20-80d3-574c55f8802a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e34fa60c-740a-4e20-80d3-574c55f8802a" xlink:to="loc_srt_RangeMember_e34fa60c-740a-4e20-80d3-574c55f8802a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6002bfd-9edf-4789-98ed-7309e0b225cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e34fa60c-740a-4e20-80d3-574c55f8802a" xlink:to="loc_srt_RangeMember_a6002bfd-9edf-4789-98ed-7309e0b225cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c05a7111-0a82-49b7-a613-70eb10a021b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6002bfd-9edf-4789-98ed-7309e0b225cd" xlink:to="loc_srt_MinimumMember_c05a7111-0a82-49b7-a613-70eb10a021b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_da3b8ba0-d43b-4e92-99a8-bb29d45bb16f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6002bfd-9edf-4789-98ed-7309e0b225cd" xlink:to="loc_srt_MaximumMember_da3b8ba0-d43b-4e92-99a8-bb29d45bb16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_201b96bf-abaf-4aaa-be9d-d989898b9c33" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6002bfd-9edf-4789-98ed-7309e0b225cd" xlink:to="loc_srt_WeightedAverageMember_201b96bf-abaf-4aaa-be9d-d989898b9c33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_251e91bc-2125-4283-9666-961c459e254e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_251e91bc-2125-4283-9666-961c459e254e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_251e91bc-2125-4283-9666-961c459e254e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_251e91bc-2125-4283-9666-961c459e254e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_251e91bc-2125-4283-9666-961c459e254e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cdca5f0e-c7df-49c6-bbd6-beb3d9fbcc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_251e91bc-2125-4283-9666-961c459e254e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cdca5f0e-c7df-49c6-bbd6-beb3d9fbcc9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_3da0b5ca-437e-43dd-9943-a6fc1f7fe5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cdca5f0e-c7df-49c6-bbd6-beb3d9fbcc9e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_3da0b5ca-437e-43dd-9943-a6fc1f7fe5fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6a01483a-4119-4256-95b5-d3ad756b9143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8f7e218e-e7c9-4464-ab35-4c605879b2c7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6a01483a-4119-4256-95b5-d3ad756b9143" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c57b78dd-2586-41da-ad87-742d4ca10f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8f7e218e-e7c9-4464-ab35-4c605879b2c7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c57b78dd-2586-41da-ad87-742d4ca10f4f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasurementsDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b6bc34c3-d54a-49ef-81ec-7001fe90f51d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:to="loc_us-gaap_DebtInstrumentAxis_b6bc34c3-d54a-49ef-81ec-7001fe90f51d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b6bc34c3-d54a-49ef-81ec-7001fe90f51d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b6bc34c3-d54a-49ef-81ec-7001fe90f51d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b6bc34c3-d54a-49ef-81ec-7001fe90f51d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b6bc34c3-d54a-49ef-81ec-7001fe90f51d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_2c8f3279-7999-410a-be8b-2e5d0b1159c0" xlink:href="biib-20240930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_2c8f3279-7999-410a-be8b-2e5d0b1159c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_1fe4a11a-ecad-4220-ae78-90b97f248017" xlink:href="biib-20240930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_1fe4a11a-ecad-4220-ae78-90b97f248017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_c432c311-69be-4789-9603-3d2cb0180247" xlink:href="biib-20240930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_c432c311-69be-4789-9603-3d2cb0180247" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotes3.250DueFebruary152051Member_b0a24c76-f21e-4e24-87ed-e3aa7bdc0dfb" xlink:href="biib-20240930.xsd#biib_SeniorNotes3.250DueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_SeniorNotes3.250DueFebruary152051Member_b0a24c76-f21e-4e24-87ed-e3aa7bdc0dfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_c4629c4d-d0cb-4134-a479-f02ca3c5a2a9" xlink:href="biib-20240930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_c4629c4d-d0cb-4134-a479-f02ca3c5a2a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember_2124efa7-8937-453b-84df-03b6aa79a064" xlink:href="biib-20240930.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_TermLoan2023ThreeYearTrancheMember_2124efa7-8937-453b-84df-03b6aa79a064" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_dac17ab4-0e13-4ad1-a381-f1a1b331472f" xlink:href="biib-20240930.xsd#biib_NonCurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_dac17ab4-0e13-4ad1-a381-f1a1b331472f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_168e5ab2-b74f-4afd-975b-1e814edd87dd" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_TheCreditFacilityMember_168e5ab2-b74f-4afd-975b-1e814edd87dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_67730992-584f-4a8d-b0fa-e4fcc10d545c" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_67730992-584f-4a8d-b0fa-e4fcc10d545c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_5a5a6164-fb0d-4a31-8612-44c6f8dc2f1b" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_5a5a6164-fb0d-4a31-8612-44c6f8dc2f1b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_60903319-82a5-4d50-ac97-7091e8d6c6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_60903319-82a5-4d50-ac97-7091e8d6c6b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_60903319-82a5-4d50-ac97-7091e8d6c6b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_60903319-82a5-4d50-ac97-7091e8d6c6b4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_60903319-82a5-4d50-ac97-7091e8d6c6b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e910e0f5-ecdc-430b-943b-2a792a02a71f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_60903319-82a5-4d50-ac97-7091e8d6c6b4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e910e0f5-ecdc-430b-943b-2a792a02a71f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8dc35604-1db8-4217-8425-4506494625ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e910e0f5-ecdc-430b-943b-2a792a02a71f" xlink:to="loc_us-gaap_SeniorNotesMember_8dc35604-1db8-4217-8425-4506494625ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5b12b871-32af-428c-bdc2-3d935fd030e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e910e0f5-ecdc-430b-943b-2a792a02a71f" xlink:to="loc_us-gaap_LineOfCreditMember_5b12b871-32af-428c-bdc2-3d935fd030e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a199b41d-4d6f-40f8-a3e4-ac8a2339b681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a199b41d-4d6f-40f8-a3e4-ac8a2339b681" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a199b41d-4d6f-40f8-a3e4-ac8a2339b681_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a199b41d-4d6f-40f8-a3e4-ac8a2339b681" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a199b41d-4d6f-40f8-a3e4-ac8a2339b681_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c0b2670-8aec-455b-a49d-2ba14bb529dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a199b41d-4d6f-40f8-a3e4-ac8a2339b681" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c0b2670-8aec-455b-a49d-2ba14bb529dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_faf57320-14bf-426f-bfe7-e763e984d852" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c0b2670-8aec-455b-a49d-2ba14bb529dd" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_faf57320-14bf-426f-bfe7-e763e984d852" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b8215d27-ecda-4b7e-93c1-000b0ed2d7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:to="loc_us-gaap_CreditFacilityAxis_b8215d27-ecda-4b7e-93c1-000b0ed2d7f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b8215d27-ecda-4b7e-93c1-000b0ed2d7f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b8215d27-ecda-4b7e-93c1-000b0ed2d7f4" xlink:to="loc_us-gaap_CreditFacilityDomain_b8215d27-ecda-4b7e-93c1-000b0ed2d7f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5581036b-fd1e-4af4-b4c1-6b92de3a0860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b8215d27-ecda-4b7e-93c1-000b0ed2d7f4" xlink:to="loc_us-gaap_CreditFacilityDomain_5581036b-fd1e-4af4-b4c1-6b92de3a0860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_48b6139f-110c-4e0a-a5b5-7debdf2341c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5581036b-fd1e-4af4-b4c1-6b92de3a0860" xlink:to="loc_us-gaap_SecuredDebtMember_48b6139f-110c-4e0a-a5b5-7debdf2341c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NotesPayableCurrentFairValueDisclosure_9af3fcf2-8fcd-4a6b-b598-351d0f2a90d8" xlink:href="biib-20240930.xsd#biib_NotesPayableCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_biib_NotesPayableCurrentFairValueDisclosure_9af3fcf2-8fcd-4a6b-b598-351d0f2a90d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_13a1ef07-804d-49bb-b809-e5985e19116f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_13a1ef07-804d-49bb-b809-e5985e19116f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_93570ce1-2096-4b85-86f1-de31a6b84679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_NotesPayableCurrent_93570ce1-2096-4b85-86f1-de31a6b84679" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_4bb3ad74-d4c6-4473-a084-c057b2c32603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_NotesPayable_4bb3ad74-d4c6-4473-a084-c057b2c32603" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_36e213ec-6c94-4ab8-9cc1-8790947c8744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_36e213ec-6c94-4ab8-9cc1-8790947c8744" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_25b17adf-c27e-4e4b-979c-eab8dac538f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_25b17adf-c27e-4e4b-979c-eab8dac538f4" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_3f37cb72-4a74-4aa9-8b8a-86f38c16b9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5fd5b2b1-7f4a-46c7-90a6-b01adb33ada9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3f37cb72-4a74-4aa9-8b8a-86f38c16b9ab" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5fd5b2b1-7f4a-46c7-90a6-b01adb33ada9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f24b9199-721c-4df3-b7cd-8a100e9f9cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5fd5b2b1-7f4a-46c7-90a6-b01adb33ada9" xlink:to="loc_us-gaap_InvestmentTypeAxis_f24b9199-721c-4df3-b7cd-8a100e9f9cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f24b9199-721c-4df3-b7cd-8a100e9f9cd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_f24b9199-721c-4df3-b7cd-8a100e9f9cd8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f24b9199-721c-4df3-b7cd-8a100e9f9cd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5937deab-f8ac-4fc1-92ca-8c95c4d42d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_f24b9199-721c-4df3-b7cd-8a100e9f9cd8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5937deab-f8ac-4fc1-92ca-8c95c4d42d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_642b2eb0-e5ad-4574-a9c2-c850d1de681e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5937deab-f8ac-4fc1-92ca-8c95c4d42d9a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_642b2eb0-e5ad-4574-a9c2-c850d1de681e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6331ccfe-0d57-4892-8da3-98a0bad7d01c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3f37cb72-4a74-4aa9-8b8a-86f38c16b9ab" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6331ccfe-0d57-4892-8da3-98a0bad7d01c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_28be35ef-7a1b-4a40-a799-5f1da1d2149f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6331ccfe-0d57-4892-8da3-98a0bad7d01c" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_28be35ef-7a1b-4a40-a799-5f1da1d2149f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20240930.xsd#FinancialInstrumentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72ceadcd-69c8-4446-80ca-6a55c2a16861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_83c6f76b-38b6-4a16-ae63-de1c4bef4dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72ceadcd-69c8-4446-80ca-6a55c2a16861" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_83c6f76b-38b6-4a16-ae63-de1c4bef4dcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_23e3d079-9f18-4af5-9346-2e4c7801b1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_83c6f76b-38b6-4a16-ae63-de1c4bef4dcf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_23e3d079-9f18-4af5-9346-2e4c7801b1c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23e3d079-9f18-4af5-9346-2e4c7801b1c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_23e3d079-9f18-4af5-9346-2e4c7801b1c9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23e3d079-9f18-4af5-9346-2e4c7801b1c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_281796ef-6e03-47d4-b3b5-d84935817c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_23e3d079-9f18-4af5-9346-2e4c7801b1c9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_281796ef-6e03-47d4-b3b5-d84935817c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_59588d55-5d4a-41cf-a064-00d1e107f46d" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_281796ef-6e03-47d4-b3b5-d84935817c84" xlink:to="loc_biib_EquitySecuritiesCurrentMember_59588d55-5d4a-41cf-a064-00d1e107f46d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_050e1e25-6b1f-4550-bffc-7e9d40527063" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_281796ef-6e03-47d4-b3b5-d84935817c84" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_050e1e25-6b1f-4550-bffc-7e9d40527063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72ceadcd-69c8-4446-80ca-6a55c2a16861" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_3f698b22-981f-43da-ac9a-cec345576d82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_3f698b22-981f-43da-ac9a-cec345576d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_e361e978-1a03-43e9-b101-edda5360ff74" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_e361e978-1a03-43e9-b101-edda5360ff74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_188c5193-c9ce-41cd-b4c4-569c00836612" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_188c5193-c9ce-41cd-b4c4-569c00836612" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_207aebde-cfbe-450e-864b-7884ec5cb540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_207aebde-cfbe-450e-864b-7884ec5cb540" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20240930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a0eb0652-663f-466b-b5cb-44269dbe22d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_48d60428-80bf-4952-aa01-3c230b481317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0eb0652-663f-466b-b5cb-44269dbe22d1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_48d60428-80bf-4952-aa01-3c230b481317" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5cc17853-c708-44b2-ab65-f93a3ab3229e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_48d60428-80bf-4952-aa01-3c230b481317" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5cc17853-c708-44b2-ab65-f93a3ab3229e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5cc17853-c708-44b2-ab65-f93a3ab3229e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5cc17853-c708-44b2-ab65-f93a3ab3229e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5cc17853-c708-44b2-ab65-f93a3ab3229e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c986e6cf-f538-4bd9-9eee-49d188ebc75e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5cc17853-c708-44b2-ab65-f93a3ab3229e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c986e6cf-f538-4bd9-9eee-49d188ebc75e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_55541a28-e864-4372-b61d-6beb122b0250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c986e6cf-f538-4bd9-9eee-49d188ebc75e" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_55541a28-e864-4372-b61d-6beb122b0250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4ab18215-f9d8-4eea-9272-71e73eafabc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_48d60428-80bf-4952-aa01-3c230b481317" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4ab18215-f9d8-4eea-9272-71e73eafabc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ab18215-f9d8-4eea-9272-71e73eafabc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4ab18215-f9d8-4eea-9272-71e73eafabc1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4ab18215-f9d8-4eea-9272-71e73eafabc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da17164e-3fe4-4dc6-a2b5-36154eae2e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4ab18215-f9d8-4eea-9272-71e73eafabc1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da17164e-3fe4-4dc6-a2b5-36154eae2e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_748b031d-28fa-4170-aa8c-bbf020ae7cf3" xlink:href="biib-20240930.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da17164e-3fe4-4dc6-a2b5-36154eae2e0f" xlink:to="loc_biib_StrategicInvestmentsMember_748b031d-28fa-4170-aa8c-bbf020ae7cf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_24ba8632-e063-4a6f-a838-dac0aa6d1435" xlink:href="biib-20240930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0eb0652-663f-466b-b5cb-44269dbe22d1" xlink:to="loc_biib_StrategicInvestmentPortfolio_24ba8632-e063-4a6f-a838-dac0aa6d1435" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#DerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f043f9c-9f3e-4d80-b0c7-3dbb6d24a877" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f043f9c-9f3e-4d80-b0c7-3dbb6d24a877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8f043f9c-9f3e-4d80-b0c7-3dbb6d24a877_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f043f9c-9f3e-4d80-b0c7-3dbb6d24a877" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8f043f9c-9f3e-4d80-b0c7-3dbb6d24a877_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b7ff7106-559f-4c87-a368-c5560ead2f18" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f043f9c-9f3e-4d80-b0c7-3dbb6d24a877" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b7ff7106-559f-4c87-a368-c5560ead2f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_3f6449cf-0c54-4c2b-9adf-bc5d6aeeed6b" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b7ff7106-559f-4c87-a368-c5560ead2f18" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_3f6449cf-0c54-4c2b-9adf-bc5d6aeeed6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_8e697be5-5b9a-42ee-890c-21a0ba06a5d6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_srt_CurrencyAxis_8e697be5-5b9a-42ee-890c-21a0ba06a5d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_8e697be5-5b9a-42ee-890c-21a0ba06a5d6_default" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_8e697be5-5b9a-42ee-890c-21a0ba06a5d6" xlink:to="loc_currency_AllCurrenciesDomain_8e697be5-5b9a-42ee-890c-21a0ba06a5d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_8e697be5-5b9a-42ee-890c-21a0ba06a5d6" xlink:to="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_d95352df-5904-4644-90d0-e30c421e94b1" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:to="loc_currency_EUR_d95352df-5904-4644-90d0-e30c421e94b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_d9609489-e87d-4f87-87bb-c1d1534eb9b0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:to="loc_currency_CHF_d9609489-e87d-4f87-87bb-c1d1534eb9b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_12192145-7f59-4a47-8da3-76b9788d4cd8" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:to="loc_currency_JPY_12192145-7f59-4a47-8da3-76b9788d4cd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_8e9e93ae-0889-4d69-bb03-1c676cdebaac" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:to="loc_currency_CAD_8e9e93ae-0889-4d69-bb03-1c676cdebaac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_90947daa-1904-4a3b-b84b-08cb5cc7a9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_90947daa-1904-4a3b-b84b-08cb5cc7a9cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_90947daa-1904-4a3b-b84b-08cb5cc7a9cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90947daa-1904-4a3b-b84b-08cb5cc7a9cb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_90947daa-1904-4a3b-b84b-08cb5cc7a9cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2d623a5-7fd4-4551-8e1c-0c8b08c6c52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90947daa-1904-4a3b-b84b-08cb5cc7a9cb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2d623a5-7fd4-4551-8e1c-0c8b08c6c52c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_ce100d13-40b2-4d37-b129-f25323f8a8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a2d623a5-7fd4-4551-8e1c-0c8b08c6c52c" xlink:to="loc_us-gaap_SalesMember_ce100d13-40b2-4d37-b129-f25323f8a8a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_adab985a-9dcc-49fe-9f32-8adf4fa5c653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a2d623a5-7fd4-4551-8e1c-0c8b08c6c52c" xlink:to="loc_us-gaap_OperatingExpenseMember_adab985a-9dcc-49fe-9f32-8adf4fa5c653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_49e9bc4b-d809-48f8-817c-9f7b3fd43bef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_49e9bc4b-d809-48f8-817c-9f7b3fd43bef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_49e9bc4b-d809-48f8-817c-9f7b3fd43bef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_49e9bc4b-d809-48f8-817c-9f7b3fd43bef" xlink:to="loc_us-gaap_HedgingRelationshipDomain_49e9bc4b-d809-48f8-817c-9f7b3fd43bef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_990cd513-dcc2-4534-b7d0-b08d511ec339" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_49e9bc4b-d809-48f8-817c-9f7b3fd43bef" xlink:to="loc_us-gaap_HedgingRelationshipDomain_990cd513-dcc2-4534-b7d0-b08d511ec339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_1f77c73d-583b-4010-a874-697f4cef0cf4" xlink:href="biib-20240930.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_990cd513-dcc2-4534-b7d0-b08d511ec339" xlink:to="loc_biib_CashflowsrevenueMember_1f77c73d-583b-4010-a874-697f4cef0cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_7992d1c0-5b65-4c27-a4ce-7b29057cd5b0" xlink:href="biib-20240930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_990cd513-dcc2-4534-b7d0-b08d511ec339" xlink:to="loc_biib_CashflowsoperatingexpensesMember_7992d1c0-5b65-4c27-a4ce-7b29057cd5b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9080ac78-a4e7-4992-9c02-1f9c959a8c44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_990cd513-dcc2-4534-b7d0-b08d511ec339" xlink:to="loc_us-gaap_CashFlowHedgingMember_9080ac78-a4e7-4992-9c02-1f9c959a8c44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9c029934-de74-414e-826d-7b5921ade8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9c029934-de74-414e-826d-7b5921ade8c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9c029934-de74-414e-826d-7b5921ade8c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9c029934-de74-414e-826d-7b5921ade8c7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9c029934-de74-414e-826d-7b5921ade8c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e22637a6-f259-4482-a619-06bcb0e77b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9c029934-de74-414e-826d-7b5921ade8c7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e22637a6-f259-4482-a619-06bcb0e77b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b9df3c8a-2d03-4df9-80fa-4f30eda87ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e22637a6-f259-4482-a619-06bcb0e77b9a" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b9df3c8a-2d03-4df9-80fa-4f30eda87ead" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1adb612d-4800-42d0-bedc-96c8dcfed345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1adb612d-4800-42d0-bedc-96c8dcfed345" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1adb612d-4800-42d0-bedc-96c8dcfed345_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1adb612d-4800-42d0-bedc-96c8dcfed345" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1adb612d-4800-42d0-bedc-96c8dcfed345_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1adb612d-4800-42d0-bedc-96c8dcfed345" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_b538a411-735a-4f89-ac60-dbb1268cc909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_b538a411-735a-4f89-ac60-dbb1268cc909" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_876567bc-98dd-4522-934d-aa7a4a501e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_876567bc-98dd-4522-934d-aa7a4a501e6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_bef152fb-fc3e-4120-b80c-2288ab8af3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_bef152fb-fc3e-4120-b80c-2288ab8af3dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2d1eda93-1294-4506-9a41-c728fe1b1715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2d1eda93-1294-4506-9a41-c728fe1b1715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2a1260eb-8134-40a2-8fa9-48a97c3430be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_HedgingDesignationAxis_2a1260eb-8134-40a2-8fa9-48a97c3430be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2a1260eb-8134-40a2-8fa9-48a97c3430be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_2a1260eb-8134-40a2-8fa9-48a97c3430be" xlink:to="loc_us-gaap_HedgingDesignationDomain_2a1260eb-8134-40a2-8fa9-48a97c3430be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_93ed6a60-d202-4b7a-9d49-8f9a8df22cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_2a1260eb-8134-40a2-8fa9-48a97c3430be" xlink:to="loc_us-gaap_HedgingDesignationDomain_93ed6a60-d202-4b7a-9d49-8f9a8df22cdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e2d4800-998b-46e0-9014-a1a16a17517d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_93ed6a60-d202-4b7a-9d49-8f9a8df22cdf" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e2d4800-998b-46e0-9014-a1a16a17517d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_94a7bdbf-9b10-44b7-9b2b-53359554de8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_93ed6a60-d202-4b7a-9d49-8f9a8df22cdf" xlink:to="loc_us-gaap_NondesignatedMember_94a7bdbf-9b10-44b7-9b2b-53359554de8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_75dd9d39-6ac3-4397-975b-505f6c2f742a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_srt_RangeAxis_75dd9d39-6ac3-4397-975b-505f6c2f742a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75dd9d39-6ac3-4397-975b-505f6c2f742a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_75dd9d39-6ac3-4397-975b-505f6c2f742a" xlink:to="loc_srt_RangeMember_75dd9d39-6ac3-4397-975b-505f6c2f742a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ed9257e-f04a-49c7-9b68-0eea424ed51b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_75dd9d39-6ac3-4397-975b-505f6c2f742a" xlink:to="loc_srt_RangeMember_1ed9257e-f04a-49c7-9b68-0eea424ed51b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e3010949-29e8-441e-9218-e0eba202679b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1ed9257e-f04a-49c7-9b68-0eea424ed51b" xlink:to="loc_srt_MinimumMember_e3010949-29e8-441e-9218-e0eba202679b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8fd894a-2239-42c0-a1cd-df4db8500baf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1ed9257e-f04a-49c7-9b68-0eea424ed51b" xlink:to="loc_srt_MaximumMember_e8fd894a-2239-42c0-a1cd-df4db8500baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c7d38672-80c0-418b-a421-5c85e0fe6882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c7d38672-80c0-418b-a421-5c85e0fe6882" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c7d38672-80c0-418b-a421-5c85e0fe6882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c7d38672-80c0-418b-a421-5c85e0fe6882" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c7d38672-80c0-418b-a421-5c85e0fe6882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4b980e6-b6f9-4dd0-aac5-3b8e4dd97e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c7d38672-80c0-418b-a421-5c85e0fe6882" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4b980e6-b6f9-4dd0-aac5-3b8e4dd97e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_ed315412-ca3a-4533-b3dc-f655a832f805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_ed315412-ca3a-4533-b3dc-f655a832f805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_fe5ff583-f8fe-4bf3-94b3-5f363efbe1bf" xlink:href="biib-20240930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_biib_UnrealizedGainOnDerivatives_fe5ff583-f8fe-4bf3-94b3-5f363efbe1bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_49f7d515-b373-4be4-9c94-63bc023affd4" xlink:href="biib-20240930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_biib_UnrealizedLossOnDerivatives_49f7d515-b373-4be4-9c94-63bc023affd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_13c7852b-9e4e-4379-b5f3-b595ac0e091c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_13c7852b-9e4e-4379-b5f3-b595ac0e091c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_01620cdc-8e56-4314-a188-3dac970a046d" xlink:href="biib-20240930.xsd#biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_01620cdc-8e56-4314-a188-3dac970a046d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_38cd4412-75ec-4c48-b7b8-17d7c4a8a336" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_38cd4412-75ec-4c48-b7b8-17d7c4a8a336" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_c8723253-2753-4c50-ae60-5968096c1301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_c8723253-2753-4c50-ae60-5968096c1301" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e398c4f7-3be1-4ea8-b98d-d3c2a1741757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e398c4f7-3be1-4ea8-b98d-d3c2a1741757" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1b1c71b1-7b37-4ac6-a2d5-da1e2395bb77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1b1c71b1-7b37-4ac6-a2d5-da1e2395bb77" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6545c5cc-6d77-4b5d-b75e-0b7f7a6306f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6545c5cc-6d77-4b5d-b75e-0b7f7a6306f0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_26580609-9c83-43ab-8962-da9f444449e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_26580609-9c83-43ab-8962-da9f444449e8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_08a5cf16-0e2c-48af-817b-25268d71f580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_08a5cf16-0e2c-48af-817b-25268d71f580" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_26625780-cd93-48a5-96b4-2aba188e3a04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_26625780-cd93-48a5-96b4-2aba188e3a04" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e687d49b-66e5-4ef2-b5f5-0942514ae49f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e687d49b-66e5-4ef2-b5f5-0942514ae49f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_f2df6204-b6dd-4af6-bc83-ce2bf7dea07e" xlink:href="biib-20240930.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e687d49b-66e5-4ef2-b5f5-0942514ae49f" xlink:to="loc_biib_FacilityLocationAxis_f2df6204-b6dd-4af6-bc83-ce2bf7dea07e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_f2df6204-b6dd-4af6-bc83-ce2bf7dea07e_default" xlink:href="biib-20240930.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_f2df6204-b6dd-4af6-bc83-ce2bf7dea07e" xlink:to="loc_biib_FacilityLocationDomain_f2df6204-b6dd-4af6-bc83-ce2bf7dea07e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_f2204ad0-d76e-4195-a212-c3ab10faae51" xlink:href="biib-20240930.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_f2df6204-b6dd-4af6-bc83-ce2bf7dea07e" xlink:to="loc_biib_FacilityLocationDomain_f2204ad0-d76e-4195-a212-c3ab10faae51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_466e5d3b-a871-45a2-af91-f053303def97" xlink:href="biib-20240930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_f2204ad0-d76e-4195-a212-c3ab10faae51" xlink:to="loc_biib_SolothurnSwitzerlandMember_466e5d3b-a871-45a2-af91-f053303def97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_5c1c02b0-29ca-4abe-af36-dad504a94330" xlink:href="biib-20240930.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e687d49b-66e5-4ef2-b5f5-0942514ae49f" xlink:to="loc_biib_FacilityTypeAxis_5c1c02b0-29ca-4abe-af36-dad504a94330" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_5c1c02b0-29ca-4abe-af36-dad504a94330_default" xlink:href="biib-20240930.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_5c1c02b0-29ca-4abe-af36-dad504a94330" xlink:to="loc_biib_FacilityTypeDomain_5c1c02b0-29ca-4abe-af36-dad504a94330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_4d162853-0d34-4245-aab6-cb3a3c68cd77" xlink:href="biib-20240930.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_5c1c02b0-29ca-4abe-af36-dad504a94330" xlink:to="loc_biib_FacilityTypeDomain_4d162853-0d34-4245-aab6-cb3a3c68cd77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_02f0b0ac-8821-4e82-a89b-5b06bff5fd0c" xlink:href="biib-20240930.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_4d162853-0d34-4245-aab6-cb3a3c68cd77" xlink:to="loc_biib_BiologicsManufacturingMember_02f0b0ac-8821-4e82-a89b-5b06bff5fd0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_295aea24-1bb6-4866-87a1-417ea7b034bc" xlink:href="biib-20240930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_4d162853-0d34-4245-aab6-cb3a3c68cd77" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_295aea24-1bb6-4866-87a1-417ea7b034bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_6bfa2e94-ba46-4962-bc54-bb906ae57fb0" xlink:href="biib-20240930.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_4d162853-0d34-4245-aab6-cb3a3c68cd77" xlink:to="loc_biib_AdministrativeSpaceMember_6bfa2e94-ba46-4962-bc54-bb906ae57fb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_df1ea40e-b404-420b-ad6e-321d254d01cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_df1ea40e-b404-420b-ad6e-321d254d01cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_53594c37-147f-48b2-be2b-ded1837369d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_Depreciation_53594c37-147f-48b2-be2b-ded1837369d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_34e8d32a-9761-4420-aca6-e2a6fa97687f" xlink:href="biib-20240930.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_biib_NumberOfSquareFeet_34e8d32a-9761-4420-aca6-e2a6fa97687f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_4555a6e5-b676-4319-9d5e-eabe77cdd926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_ConstructionInProgressGross_4555a6e5-b676-4319-9d5e-eabe77cdd926" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1284506c-5e88-4173-b2ea-88a08e7a2d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1284506c-5e88-4173-b2ea-88a08e7a2d9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_269281a2-14b5-43c0-9fa4-1910d9a9f463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_269281a2-14b5-43c0-9fa4-1910d9a9f463" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="simple" xlink:href="biib-20240930.xsd#LeasesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_d6aab5d6-384d-4727-b81a-b62ce5576322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_d6aab5d6-384d-4727-b81a-b62ce5576322" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_edea172f-ceb4-4efe-8cdc-520e067b659e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_d6aab5d6-384d-4727-b81a-b62ce5576322" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_edea172f-ceb4-4efe-8cdc-520e067b659e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edea172f-ceb4-4efe-8cdc-520e067b659e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_edea172f-ceb4-4efe-8cdc-520e067b659e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edea172f-ceb4-4efe-8cdc-520e067b659e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26c4a2f6-b9ef-48a6-add0-92e605844caa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_edea172f-ceb4-4efe-8cdc-520e067b659e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26c4a2f6-b9ef-48a6-add0-92e605844caa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_9b9fddcc-bf4b-495d-8913-0c24fd111d1b" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26c4a2f6-b9ef-48a6-add0-92e605844caa" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_9b9fddcc-bf4b-495d-8913-0c24fd111d1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_da3d7e1b-2bf0-4e7a-8678-9f74ddeb5c1b" xlink:href="biib-20240930.xsd#biib_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_biib_OperatingLeaseArea_da3d7e1b-2bf0-4e7a-8678-9f74ddeb5c1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_849f7c14-3293-4414-abfb-2138c7c89dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_849f7c14-3293-4414-abfb-2138c7c89dfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_5a26cf46-6ebe-4585-8e1a-71b0ab67f38d" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_5a26cf46-6ebe-4585-8e1a-71b0ab67f38d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_e48ace50-a003-4435-834a-5e224d1d3f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_e48ace50-a003-4435-834a-5e224d1d3f1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_c6936e4a-0f83-4549-8804-4b946fd5c451" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_c6936e4a-0f83-4549-8804-4b946fd5c451" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_259e580a-07c7-4386-bc7f-9c8e6beaa429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_259e580a-07c7-4386-bc7f-9c8e6beaa429" xlink:to="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d60a7174-ae9e-4235-a57c-fce31766f92d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:to="loc_us-gaap_DebtInstrumentAxis_d60a7174-ae9e-4235-a57c-fce31766f92d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d60a7174-ae9e-4235-a57c-fce31766f92d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d60a7174-ae9e-4235-a57c-fce31766f92d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d60a7174-ae9e-4235-a57c-fce31766f92d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d60a7174-ae9e-4235-a57c-fce31766f92d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_8fa1a88c-44c0-4b59-807e-1c0c75f63bf4" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_8fa1a88c-44c0-4b59-807e-1c0c75f63bf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_e4d0f1fd-b4bf-4443-934b-e2cdeba41385" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_e4d0f1fd-b4bf-4443-934b-e2cdeba41385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember_7431eb50-9e97-44d3-8fe5-ccf0b0c79f4d" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:to="loc_biib_TheCreditFacilityTerminatedMember_7431eb50-9e97-44d3-8fe5-ccf0b0c79f4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_a8c8e545-b86c-4a7f-8110-1c526f377f2e" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:to="loc_biib_TheCreditFacilityMember_a8c8e545-b86c-4a7f-8110-1c526f377f2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023TermLoanMember_c9f23208-d0fb-4869-9655-c5c937c19c9f" xlink:href="biib-20240930.xsd#biib_A2023TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:to="loc_biib_A2023TermLoanMember_c9f23208-d0fb-4869-9655-c5c937c19c9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_af975c7e-56b6-46a2-ad03-cf30da88c171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_af975c7e-56b6-46a2-ad03-cf30da88c171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_af975c7e-56b6-46a2-ad03-cf30da88c171_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af975c7e-56b6-46a2-ad03-cf30da88c171" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_af975c7e-56b6-46a2-ad03-cf30da88c171_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_21882f48-bf0e-4763-a433-8245727bee09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af975c7e-56b6-46a2-ad03-cf30da88c171" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_21882f48-bf0e-4763-a433-8245727bee09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c78e8360-fdec-4863-a286-5854133599ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_21882f48-bf0e-4763-a433-8245727bee09" xlink:to="loc_us-gaap_LineOfCreditMember_c78e8360-fdec-4863-a286-5854133599ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_33a00097-7c9b-4748-bb5b-8de2be41eb29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:to="loc_us-gaap_CreditFacilityAxis_33a00097-7c9b-4748-bb5b-8de2be41eb29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_33a00097-7c9b-4748-bb5b-8de2be41eb29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_33a00097-7c9b-4748-bb5b-8de2be41eb29" xlink:to="loc_us-gaap_CreditFacilityDomain_33a00097-7c9b-4748-bb5b-8de2be41eb29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7486ac94-51d5-4425-88db-2284c4a6a786" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_33a00097-7c9b-4748-bb5b-8de2be41eb29" xlink:to="loc_us-gaap_CreditFacilityDomain_7486ac94-51d5-4425-88db-2284c4a6a786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_8423e924-e6ee-441e-857c-5f9e9b846371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7486ac94-51d5-4425-88db-2284c4a6a786" xlink:to="loc_us-gaap_SecuredDebtMember_8423e924-e6ee-441e-857c-5f9e9b846371" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FloatingRate364DayTrancheMember_ed6cb898-00bf-4291-960a-1533e8b235e4" xlink:href="biib-20240930.xsd#biib_FloatingRate364DayTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7486ac94-51d5-4425-88db-2284c4a6a786" xlink:to="loc_biib_FloatingRate364DayTrancheMember_ed6cb898-00bf-4291-960a-1533e8b235e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember_a904d549-b1f4-49ab-ab1c-051333fc9ea4" xlink:href="biib-20240930.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7486ac94-51d5-4425-88db-2284c4a6a786" xlink:to="loc_biib_TermLoan2023ThreeYearTrancheMember_a904d549-b1f4-49ab-ab1c-051333fc9ea4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7e682432-8095-47a7-8a58-ebd320b44a70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7e682432-8095-47a7-8a58-ebd320b44a70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7e682432-8095-47a7-8a58-ebd320b44a70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7e682432-8095-47a7-8a58-ebd320b44a70" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7e682432-8095-47a7-8a58-ebd320b44a70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4d6ff9-fcea-40fb-8e3b-bfd3fd8ec85b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7e682432-8095-47a7-8a58-ebd320b44a70" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4d6ff9-fcea-40fb-8e3b-bfd3fd8ec85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_12c47362-e83d-4b7a-87f7-7f71a4a177d0" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4d6ff9-fcea-40fb-8e3b-bfd3fd8ec85b" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_12c47362-e83d-4b7a-87f7-7f71a4a177d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ea77737c-8b5b-4942-aeb6-e7e1964c8d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_259e580a-07c7-4386-bc7f-9c8e6beaa429" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ea77737c-8b5b-4942-aeb6-e7e1964c8d7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f8cc4c52-4868-4e59-80f7-106b4d69cf29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_259e580a-07c7-4386-bc7f-9c8e6beaa429" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f8cc4c52-4868-4e59-80f7-106b4d69cf29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_2e505876-e0a3-4f3c-a378-760331fb9bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_259e580a-07c7-4386-bc7f-9c8e6beaa429" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_2e505876-e0a3-4f3c-a378-760331fb9bad" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#ShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_532bd639-860e-4660-9fd9-7aceb4a1b755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_860fa8bb-ee13-4a1f-a64b-0e19da12a490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_532bd639-860e-4660-9fd9-7aceb4a1b755" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_860fa8bb-ee13-4a1f-a64b-0e19da12a490" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_94f7e26a-8921-44be-9e3f-7f4f48a04519" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_860fa8bb-ee13-4a1f-a64b-0e19da12a490" xlink:to="loc_srt_ShareRepurchaseProgramAxis_94f7e26a-8921-44be-9e3f-7f4f48a04519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_94f7e26a-8921-44be-9e3f-7f4f48a04519_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_94f7e26a-8921-44be-9e3f-7f4f48a04519" xlink:to="loc_srt_ShareRepurchaseProgramDomain_94f7e26a-8921-44be-9e3f-7f4f48a04519_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_d7ac667a-7560-4e52-aa7a-bd71ec0468b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_94f7e26a-8921-44be-9e3f-7f4f48a04519" xlink:to="loc_srt_ShareRepurchaseProgramDomain_d7ac667a-7560-4e52-aa7a-bd71ec0468b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_97f7f77a-0b59-4c74-8bdb-58b470067283" xlink:href="biib-20240930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_d7ac667a-7560-4e52-aa7a-bd71ec0468b9" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_97f7f77a-0b59-4c74-8bdb-58b470067283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_9a419b38-cf16-4ece-bfac-29bcf69ef935" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_532bd639-860e-4660-9fd9-7aceb4a1b755" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_9a419b38-cf16-4ece-bfac-29bcf69ef935" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c5518f56-3375-460f-ae5c-6b11959c4ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_532bd639-860e-4660-9fd9-7aceb4a1b755" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c5518f56-3375-460f-ae5c-6b11959c4ecd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bf48cf14-bff9-4db9-900f-746edfc3de6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bf48cf14-bff9-4db9-900f-746edfc3de6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_daf87fbe-d3a4-44d7-b9b0-c39c82486006" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bf48cf14-bff9-4db9-900f-746edfc3de6c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_daf87fbe-d3a4-44d7-b9b0-c39c82486006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_daf87fbe-d3a4-44d7-b9b0-c39c82486006_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_daf87fbe-d3a4-44d7-b9b0-c39c82486006" xlink:to="loc_us-gaap_EquityComponentDomain_daf87fbe-d3a4-44d7-b9b0-c39c82486006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_daf87fbe-d3a4-44d7-b9b0-c39c82486006" xlink:to="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fd3a4d26-901c-4a5c-a63f-d9aff251e251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fd3a4d26-901c-4a5c-a63f-d9aff251e251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_79634b18-8d71-49d5-81c9-8ecf318bbdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_79634b18-8d71-49d5-81c9-8ecf318bbdcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_75601411-9b28-4c8c-a000-a2665417d2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_75601411-9b28-4c8c-a000-a2665417d2ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_0e3b43d9-e63d-4560-9051-8fb50be0e8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_0e3b43d9-e63d-4560-9051-8fb50be0e8ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3ecce5ab-d7e9-443c-a391-73408183e3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3ecce5ab-d7e9-443c-a391-73408183e3dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c727309e-2605-43f0-a9fc-39be4b798a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_59ab42c7-d3fb-4c98-9351-dc7a8cf6e0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_59ab42c7-d3fb-4c98-9351-dc7a8cf6e0fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ecede2d8-33b9-452b-972f-204eeba4e6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ecede2d8-33b9-452b-972f-204eeba4e6dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_168cd276-a28d-4098-8193-378b6f3b550e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_168cd276-a28d-4098-8193-378b6f3b550e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eb9be9d2-5eb1-4ce5-b687-7deef55c3f84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b0503b53-f817-4529-b9e9-a9403f462b00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b0503b53-f817-4529-b9e9-a9403f462b00" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ca496eef-8bed-4844-b664-fed3ab1f96fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ca496eef-8bed-4844-b664-fed3ab1f96fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ca496eef-8bed-4844-b664-fed3ab1f96fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ca496eef-8bed-4844-b664-fed3ab1f96fd" xlink:to="loc_us-gaap_EquityComponentDomain_ca496eef-8bed-4844-b664-fed3ab1f96fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2cc7dc48-893d-497b-817b-376e047c6aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ca496eef-8bed-4844-b664-fed3ab1f96fd" xlink:to="loc_us-gaap_EquityComponentDomain_2cc7dc48-893d-497b-817b-376e047c6aeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_40c9673b-ef56-4186-9e36-0089dce7cda9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2cc7dc48-893d-497b-817b-376e047c6aeb" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_40c9673b-ef56-4186-9e36-0089dce7cda9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_4a4a3701-d689-4a3b-b107-55844053708b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2cc7dc48-893d-497b-817b-376e047c6aeb" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_4a4a3701-d689-4a3b-b107-55844053708b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_761c6682-2319-485d-9e9b-0709fadcfc39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_761c6682-2319-485d-9e9b-0709fadcfc39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_761c6682-2319-485d-9e9b-0709fadcfc39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_761c6682-2319-485d-9e9b-0709fadcfc39" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_761c6682-2319-485d-9e9b-0709fadcfc39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_947c8f31-1a78-4d9a-b052-a36f39108396" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_761c6682-2319-485d-9e9b-0709fadcfc39" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_947c8f31-1a78-4d9a-b052-a36f39108396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_bdd5f2f8-dfd2-45fd-a002-53b1e46f3606" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_947c8f31-1a78-4d9a-b052-a36f39108396" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_bdd5f2f8-dfd2-45fd-a002-53b1e46f3606" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baac84fd-27fa-40a3-9b78-492cc268e34c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baac84fd-27fa-40a3-9b78-492cc268e34c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_baac84fd-27fa-40a3-9b78-492cc268e34c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baac84fd-27fa-40a3-9b78-492cc268e34c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_baac84fd-27fa-40a3-9b78-492cc268e34c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_efdb8b62-dd96-490c-99c4-d6eac0cdd79a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baac84fd-27fa-40a3-9b78-492cc268e34c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_efdb8b62-dd96-490c-99c4-d6eac0cdd79a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_a5109c5b-d520-4179-9f40-c61b3490dde4" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_efdb8b62-dd96-490c-99c4-d6eac0cdd79a" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_a5109c5b-d520-4179-9f40-c61b3490dde4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_4c89e396-125e-4cda-87b8-877bc2f90f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_4c89e396-125e-4cda-87b8-877bc2f90f72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ee49c4fb-4ef5-4976-8cc4-e52a98dd0a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ee49c4fb-4ef5-4976-8cc4-e52a98dd0a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_89d1af01-5500-46a5-9bfd-5f420cd92b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_Revenues_89d1af01-5500-46a5-9bfd-5f420cd92b90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_838efd59-1291-4d6f-a50e-9440761afd80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_OperatingExpenses_838efd59-1291-4d6f-a50e-9440761afd80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_558b3ac0-8c6c-448f-a21b-cfd68f3afd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_NetIncomeLoss_558b3ac0-8c6c-448f-a21b-cfd68f3afd4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d9caf90e-0d6a-47ee-9f0f-eeabbba0e770" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d9caf90e-0d6a-47ee-9f0f-eeabbba0e770" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48e8b64d-be93-404b-a66c-4d58b3c2cbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ceefe822-4ee9-4972-9b65-2156bbb20f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48e8b64d-be93-404b-a66c-4d58b3c2cbe4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ceefe822-4ee9-4972-9b65-2156bbb20f11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2c537fbd-0a03-4420-afc0-2c5c8ed2849f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ceefe822-4ee9-4972-9b65-2156bbb20f11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2c537fbd-0a03-4420-afc0-2c5c8ed2849f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c537fbd-0a03-4420-afc0-2c5c8ed2849f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2c537fbd-0a03-4420-afc0-2c5c8ed2849f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c537fbd-0a03-4420-afc0-2c5c8ed2849f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257c2df4-f7d5-444c-bcc0-c2291f105d57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2c537fbd-0a03-4420-afc0-2c5c8ed2849f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257c2df4-f7d5-444c-bcc0-c2291f105d57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_05125c4b-9ccd-4e97-8e68-f98dcce4765e" xlink:href="biib-20240930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257c2df4-f7d5-444c-bcc0-c2291f105d57" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_05125c4b-9ccd-4e97-8e68-f98dcce4765e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_0fec75f2-0a8b-44bd-94d8-b1ec518d674b" xlink:href="biib-20240930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257c2df4-f7d5-444c-bcc0-c2291f105d57" xlink:to="loc_biib_MarketStockUnitsMember_0fec75f2-0a8b-44bd-94d8-b1ec518d674b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_a1c2d090-0440-40c3-9371-f7b6d20201bf" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257c2df4-f7d5-444c-bcc0-c2291f105d57" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_a1c2d090-0440-40c3-9371-f7b6d20201bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_91203487-3c81-468a-b818-5c8e9e59ab7b" xlink:href="biib-20240930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48e8b64d-be93-404b-a66c-4d58b3c2cbe4" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_91203487-3c81-468a-b818-5c8e9e59ab7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_9b97fb45-3547-4341-9f4a-ed442a5ce82d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_91203487-3c81-468a-b818-5c8e9e59ab7b" xlink:to="loc_us-gaap_NetIncomeLossAbstract_9b97fb45-3547-4341-9f4a-ed442a5ce82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cda32820-8836-4cc0-bebb-077607959366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_9b97fb45-3547-4341-9f4a-ed442a5ce82d" xlink:to="loc_us-gaap_NetIncomeLoss_cda32820-8836-4cc0-bebb-077607959366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54153f10-c5c7-40e6-8dc9-02c7afe87307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_91203487-3c81-468a-b818-5c8e9e59ab7b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54153f10-c5c7-40e6-8dc9-02c7afe87307" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1e5d545a-24df-4b22-b538-01d6328d5ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54153f10-c5c7-40e6-8dc9-02c7afe87307" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1e5d545a-24df-4b22-b538-01d6328d5ba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_840dadb7-a66a-4f1b-a5bb-1dfa11d6ef85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54153f10-c5c7-40e6-8dc9-02c7afe87307" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_840dadb7-a66a-4f1b-a5bb-1dfa11d6ef85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_78bb9827-c587-437a-a0dd-5e2864db0c36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_840dadb7-a66a-4f1b-a5bb-1dfa11d6ef85" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_78bb9827-c587-437a-a0dd-5e2864db0c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bb50f0d6-4c58-4b8d-ac2a-8f4bef449165" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_840dadb7-a66a-4f1b-a5bb-1dfa11d6ef85" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bb50f0d6-4c58-4b8d-ac2a-8f4bef449165" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b43d59e6-f024-491e-920d-07f2d2cad388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54153f10-c5c7-40e6-8dc9-02c7afe87307" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b43d59e6-f024-491e-920d-07f2d2cad388" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7cb74d85-7b52-492d-9a6e-844ea5af5a82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7cb74d85-7b52-492d-9a6e-844ea5af5a82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_69f01c90-719a-4b7f-b148-1a9738f9124b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7cb74d85-7b52-492d-9a6e-844ea5af5a82" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_69f01c90-719a-4b7f-b148-1a9738f9124b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_69f01c90-719a-4b7f-b148-1a9738f9124b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69f01c90-719a-4b7f-b148-1a9738f9124b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_69f01c90-719a-4b7f-b148-1a9738f9124b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4372358-4eb5-4d7c-808e-562ea0b84568" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69f01c90-719a-4b7f-b148-1a9738f9124b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4372358-4eb5-4d7c-808e-562ea0b84568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6a89266b-6366-4c93-86f2-7432661ea58e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4372358-4eb5-4d7c-808e-562ea0b84568" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6a89266b-6366-4c93-86f2-7432661ea58e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4cc11988-e2af-4447-ad0f-69f6cc24e442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4372358-4eb5-4d7c-808e-562ea0b84568" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4cc11988-e2af-4447-ad0f-69f6cc24e442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_0966a41f-30d7-4064-86a7-d34b72f6aca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4372358-4eb5-4d7c-808e-562ea0b84568" xlink:to="loc_us-gaap_ParentMember_0966a41f-30d7-4064-86a7-d34b72f6aca5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c945a948-c408-4bb1-a396-ce8e21b6a758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7cb74d85-7b52-492d-9a6e-844ea5af5a82" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c945a948-c408-4bb1-a396-ce8e21b6a758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c945a948-c408-4bb1-a396-ce8e21b6a758_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c945a948-c408-4bb1-a396-ce8e21b6a758" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c945a948-c408-4bb1-a396-ce8e21b6a758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a6181-33a5-4048-81ab-79fea2e6d587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c945a948-c408-4bb1-a396-ce8e21b6a758" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a6181-33a5-4048-81ab-79fea2e6d587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_c31e1ede-2a2e-4fb9-9d8c-421dc552a7dd" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a6181-33a5-4048-81ab-79fea2e6d587" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_c31e1ede-2a2e-4fb9-9d8c-421dc552a7dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc180324-32b3-44e1-8417-d385952848dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc180324-32b3-44e1-8417-d385952848dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_97d4d563-b320-4b74-bd79-cdb49554dacf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_97d4d563-b320-4b74-bd79-cdb49554dacf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_68275a6e-8b15-4c72-9466-6ede0046312e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_68275a6e-8b15-4c72-9466-6ede0046312e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_deaf1857-48ef-4771-a95c-18994d7ba036" xlink:href="biib-20240930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_deaf1857-48ef-4771-a95c-18994d7ba036" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_e6bc7c5f-1724-4c05-9e60-5a5192bc4663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_e6bc7c5f-1724-4c05-9e60-5a5192bc4663" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f59b9047-b59c-45e4-a197-fc0aa64f12e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:to="loc_us-gaap_OperatingExpenses_f59b9047-b59c-45e4-a197-fc0aa64f12e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_95a475f7-abf5-4c4e-829c-3759edb127d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_95a475f7-abf5-4c4e-829c-3759edb127d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a5e97897-86ed-42d9-bb76-373e2dc67f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a5e97897-86ed-42d9-bb76-373e2dc67f56" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7746b6e4-13fb-4aeb-9954-1cf3f81bbc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a26ecd7e-b605-49b5-8be1-f3b06e24e42c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7746b6e4-13fb-4aeb-9954-1cf3f81bbc5d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a26ecd7e-b605-49b5-8be1-f3b06e24e42c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a82ae731-ba85-453e-bcfd-e92c13d72295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a26ecd7e-b605-49b5-8be1-f3b06e24e42c" xlink:to="loc_us-gaap_AwardTypeAxis_a82ae731-ba85-453e-bcfd-e92c13d72295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a82ae731-ba85-453e-bcfd-e92c13d72295_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a82ae731-ba85-453e-bcfd-e92c13d72295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a82ae731-ba85-453e-bcfd-e92c13d72295_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a82ae731-ba85-453e-bcfd-e92c13d72295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_a8582d95-6ddc-4dbb-ae8e-5778ad73a450" xlink:href="biib-20240930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_biib_MarketStockUnitsMember_a8582d95-6ddc-4dbb-ae8e-5778ad73a450" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_5ac3fbc0-5ef2-444b-9516-40c1104e77ee" xlink:href="biib-20240930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_5ac3fbc0-5ef2-444b-9516-40c1104e77ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_2947f7b5-a164-4f35-89e5-f195a8473c1e" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_2947f7b5-a164-4f35-89e5-f195a8473c1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_372f61c0-2358-4de9-b0c9-cee9e2bf39ac" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_372f61c0-2358-4de9-b0c9-cee9e2bf39ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_a7cc7048-dfd3-463c-abff-9265688033cc" xlink:href="biib-20240930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_a7cc7048-dfd3-463c-abff-9265688033cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_09bb5fae-4ad6-4b87-a8ea-906e78964bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_09bb5fae-4ad6-4b87-a8ea-906e78964bb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2e9bd782-9193-44ee-9787-05424bf8921a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a26ecd7e-b605-49b5-8be1-f3b06e24e42c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2e9bd782-9193-44ee-9787-05424bf8921a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e9bd782-9193-44ee-9787-05424bf8921a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2e9bd782-9193-44ee-9787-05424bf8921a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e9bd782-9193-44ee-9787-05424bf8921a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01befdd6-3780-45b4-a243-9c848e0f514f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2e9bd782-9193-44ee-9787-05424bf8921a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01befdd6-3780-45b4-a243-9c848e0f514f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_79bf308e-cf23-42c4-ba7e-a46807c8d8a1" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01befdd6-3780-45b4-a243-9c848e0f514f" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_79bf308e-cf23-42c4-ba7e-a46807c8d8a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_bf1a55da-6376-45b0-a8bd-3122b04ae5fc" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01befdd6-3780-45b4-a243-9c848e0f514f" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_bf1a55da-6376-45b0-a8bd-3122b04ae5fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:href="biib-20240930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7746b6e4-13fb-4aeb-9954-1cf3f81bbc5d" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6a703551-036c-4869-be90-d54bd9dec514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6a703551-036c-4869-be90-d54bd9dec514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_487ae6ec-6c87-49ea-b9a6-14da58fb1ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_487ae6ec-6c87-49ea-b9a6-14da58fb1ef8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_34514279-ec0f-442d-acd3-18b4b79abf8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_34514279-ec0f-442d-acd3-18b4b79abf8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_38090191-ba71-4bb9-bbea-fd23ea7efb75" xlink:href="biib-20240930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_38090191-ba71-4bb9-bbea-fd23ea7efb75" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#SharebasedPaymentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_37552b23-f4e8-499c-bd01-c98556e387b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:to="loc_us-gaap_PlanNameAxis_37552b23-f4e8-499c-bd01-c98556e387b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_37552b23-f4e8-499c-bd01-c98556e387b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_37552b23-f4e8-499c-bd01-c98556e387b8" xlink:to="loc_us-gaap_PlanNameDomain_37552b23-f4e8-499c-bd01-c98556e387b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fdebc74e-1f73-48ae-8aee-5d25407dfb38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_37552b23-f4e8-499c-bd01-c98556e387b8" xlink:to="loc_us-gaap_PlanNameDomain_fdebc74e-1f73-48ae-8aee-5d25407dfb38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OmnibusEquityPlan2024Member_d81b58eb-e0b4-44c7-b83b-6639333ad3b9" xlink:href="biib-20240930.xsd#biib_OmnibusEquityPlan2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fdebc74e-1f73-48ae-8aee-5d25407dfb38" xlink:to="loc_biib_OmnibusEquityPlan2024Member_d81b58eb-e0b4-44c7-b83b-6639333ad3b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e6fffe1f-d774-42f2-8b8a-f85adadf9d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e6fffe1f-d774-42f2-8b8a-f85adadf9d56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6fffe1f-d774-42f2-8b8a-f85adadf9d56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6fffe1f-d774-42f2-8b8a-f85adadf9d56" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6fffe1f-d774-42f2-8b8a-f85adadf9d56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9226d5fd-af18-404b-88ab-b5fd25506c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6fffe1f-d774-42f2-8b8a-f85adadf9d56" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9226d5fd-af18-404b-88ab-b5fd25506c60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_2c0bbebd-ba58-45dc-954d-a29da282d341" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9226d5fd-af18-404b-88ab-b5fd25506c60" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_2c0bbebd-ba58-45dc-954d-a29da282d341" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_12bbec28-f1b6-4270-87eb-0b3fccfbc9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_12bbec28-f1b6-4270-87eb-0b3fccfbc9ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_12bbec28-f1b6-4270-87eb-0b3fccfbc9ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_12bbec28-f1b6-4270-87eb-0b3fccfbc9ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_12bbec28-f1b6-4270-87eb-0b3fccfbc9ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b6231066-455a-43c5-9770-02ff05a9438d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_12bbec28-f1b6-4270-87eb-0b3fccfbc9ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b6231066-455a-43c5-9770-02ff05a9438d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f487de07-f974-4f66-8d70-654bf51eb3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6231066-455a-43c5-9770-02ff05a9438d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f487de07-f974-4f66-8d70-654bf51eb3f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_84a64725-e1be-4005-a602-373d17166d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6231066-455a-43c5-9770-02ff05a9438d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_84a64725-e1be-4005-a602-373d17166d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9dc81b83-b418-4b5f-a92b-f72a7d19b90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9dc81b83-b418-4b5f-a92b-f72a7d19b90c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_a4732ba6-7bc9-481c-ae73-4217efabb8e2" xlink:href="biib-20240930.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_a4732ba6-7bc9-481c-ae73-4217efabb8e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_57778f19-e37a-434f-8c01-076e6599541f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_57778f19-e37a-434f-8c01-076e6599541f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ec1d5ab3-b8ea-48c5-b301-73c3327a0aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:to="loc_us-gaap_OperatingExpenses_ec1d5ab3-b8ea-48c5-b301-73c3327a0aa7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_1b6d8202-2539-447a-9d1f-eb7f04a9e190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_4ac48237-0a5d-48d3-a042-48764666328c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1b6d8202-2539-447a-9d1f-eb7f04a9e190" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_4ac48237-0a5d-48d3-a042-48764666328c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5bc524fb-ba89-4224-ba82-4c1e7255c5df" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4ac48237-0a5d-48d3-a042-48764666328c" xlink:to="loc_srt_StatementScenarioAxis_5bc524fb-ba89-4224-ba82-4c1e7255c5df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5bc524fb-ba89-4224-ba82-4c1e7255c5df_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_5bc524fb-ba89-4224-ba82-4c1e7255c5df" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5bc524fb-ba89-4224-ba82-4c1e7255c5df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9927eab0-7eb4-4617-938e-ba14c8b74106" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_5bc524fb-ba89-4224-ba82-4c1e7255c5df" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9927eab0-7eb4-4617-938e-ba14c8b74106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0247cd3c-d661-4dfe-b439-0345a7a1d558" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9927eab0-7eb4-4617-938e-ba14c8b74106" xlink:to="loc_srt_ScenarioForecastMember_0247cd3c-d661-4dfe-b439-0345a7a1d558" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7526090e-dd78-4184-aee7-7bc1dee34a8d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4ac48237-0a5d-48d3-a042-48764666328c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7526090e-dd78-4184-aee7-7bc1dee34a8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7526090e-dd78-4184-aee7-7bc1dee34a8d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7526090e-dd78-4184-aee7-7bc1dee34a8d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7526090e-dd78-4184-aee7-7bc1dee34a8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0a00cb56-2612-46d5-baef-59f7050c63d3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7526090e-dd78-4184-aee7-7bc1dee34a8d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0a00cb56-2612-46d5-baef-59f7050c63d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_c4c1de4f-19e1-4309-9a22-8190cfdef801" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0a00cb56-2612-46d5-baef-59f7050c63d3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_c4c1de4f-19e1-4309-9a22-8190cfdef801" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70f6fa1f-88b7-4a92-b77e-c52a65ae9021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1b6d8202-2539-447a-9d1f-eb7f04a9e190" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70f6fa1f-88b7-4a92-b77e-c52a65ae9021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6cf2ddc3-d4cb-4698-bba5-abb95d2c6648" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1b6d8202-2539-447a-9d1f-eb7f04a9e190" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6cf2ddc3-d4cb-4698-bba5-abb95d2c6648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_b01a4b07-0536-498e-a2d3-856e02ca7ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1b6d8202-2539-447a-9d1f-eb7f04a9e190" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_b01a4b07-0536-498e-a2d3-856e02ca7ea3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c60f75cf-7ef4-45f4-9201-c4c273bffd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c60f75cf-7ef4-45f4-9201-c4c273bffd1e" xlink:to="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2e94aa07-6ea5-41c7-b84f-8f4db96f7ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2e94aa07-6ea5-41c7-b84f-8f4db96f7ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2e94aa07-6ea5-41c7-b84f-8f4db96f7ad2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2e94aa07-6ea5-41c7-b84f-8f4db96f7ad2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2e94aa07-6ea5-41c7-b84f-8f4db96f7ad2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_20d268a6-da3f-4587-b181-84760de8a276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2e94aa07-6ea5-41c7-b84f-8f4db96f7ad2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_20d268a6-da3f-4587-b181-84760de8a276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_624d608b-a5b5-4a10-b760-1631c5209472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_20d268a6-da3f-4587-b181-84760de8a276" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_624d608b-a5b5-4a10-b760-1631c5209472" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ab55ed18-31d9-4b45-9ae3-aaebb1c5aa78" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:to="loc_dei_LegalEntityAxis_ab55ed18-31d9-4b45-9ae3-aaebb1c5aa78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ab55ed18-31d9-4b45-9ae3-aaebb1c5aa78_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ab55ed18-31d9-4b45-9ae3-aaebb1c5aa78" xlink:to="loc_dei_EntityDomain_ab55ed18-31d9-4b45-9ae3-aaebb1c5aa78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_25116645-ec80-471c-bf58-3c86abac3531" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ab55ed18-31d9-4b45-9ae3-aaebb1c5aa78" xlink:to="loc_dei_EntityDomain_25116645-ec80-471c-bf58-3c86abac3531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_94971278-bad2-4574-a79c-82f5acbdfff0" xlink:href="biib-20240930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_25116645-ec80-471c-bf58-3c86abac3531" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_94971278-bad2-4574-a79c-82f5acbdfff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ce1e73b6-ddf9-4ecb-b8ce-de2776e06192" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ce1e73b6-ddf9-4ecb-b8ce-de2776e06192" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ce1e73b6-ddf9-4ecb-b8ce-de2776e06192_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ce1e73b6-ddf9-4ecb-b8ce-de2776e06192" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ce1e73b6-ddf9-4ecb-b8ce-de2776e06192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_50ea43fa-dd8d-447c-92cd-4518d603e40d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ce1e73b6-ddf9-4ecb-b8ce-de2776e06192" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_50ea43fa-dd8d-447c-92cd-4518d603e40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7233ee2c-04c9-467e-b3f5-c752bfa6762e" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_50ea43fa-dd8d-447c-92cd-4518d603e40d" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_7233ee2c-04c9-467e-b3f5-c752bfa6762e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c60f75cf-7ef4-45f4-9201-c4c273bffd1e" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_597b2dd0-6f6e-43b3-be81-f643d3a269f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_597b2dd0-6f6e-43b3-be81-f643d3a269f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ba358823-aa09-4d70-8c50-ff59927735a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_InterestExpense_ba358823-aa09-4d70-8c50-ff59927735a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_545d4f78-d362-4995-99af-abed9c8c2b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_545d4f78-d362-4995-99af-abed9c8c2b47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_33ffdf10-4cb7-4e1d-b5a8-4cd958307f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_33ffdf10-4cb7-4e1d-b5a8-4cd958307f43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a7dd181e-01ee-4edc-bf2c-6f6260f5218c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a7dd181e-01ee-4edc-bf2c-6f6260f5218c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8a10e582-5f42-48ad-ad77-bd5b159eea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8a10e582-5f42-48ad-ad77-bd5b159eea0a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4be73ea7-1c1e-4bbb-8abe-3a0e0f6afc62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c60f75cf-7ef4-45f4-9201-c4c273bffd1e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4be73ea7-1c1e-4bbb-8abe-3a0e0f6afc62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3f3382ba-74cb-48e7-b709-8630cb810f82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4be73ea7-1c1e-4bbb-8abe-3a0e0f6afc62" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3f3382ba-74cb-48e7-b709-8630cb810f82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d6a996c5-949a-4531-9626-5f5d9ac3ac27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4be73ea7-1c1e-4bbb-8abe-3a0e0f6afc62" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d6a996c5-949a-4531-9626-5f5d9ac3ac27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cf1581c3-2535-45f4-85ce-d04291f792a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4be73ea7-1c1e-4bbb-8abe-3a0e0f6afc62" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cf1581c3-2535-45f4-85ce-d04291f792a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c60f75cf-7ef4-45f4-9201-c4c273bffd1e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e1b00cae-263b-4867-8190-cb4cbfb685bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e1b00cae-263b-4867-8190-cb4cbfb685bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_11c77794-1d18-45e6-b54d-b3e232a0573d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_11c77794-1d18-45e6-b54d-b3e232a0573d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_de30f796-b0fc-46a4-870f-ef21bd61a245" xlink:href="biib-20240930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_biib_Collaborationexpensesaccrual_de30f796-b0fc-46a4-870f-ef21bd61a245" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_9952ff23-b3a9-435b-ae79-9cd4e56daa45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_9952ff23-b3a9-435b-ae79-9cd4e56daa45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_07a2bc93-db4d-44b5-a426-b6258fbd2611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_07a2bc93-db4d-44b5-a426-b6258fbd2611" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_11fde7a5-661d-4f5d-bfe6-aa87fa705b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_11fde7a5-661d-4f5d-bfe6-aa87fa705b0f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c9f1ae15-1f9d-49dd-9e5b-7df9746bca64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c9f1ae15-1f9d-49dd-9e5b-7df9746bca64" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20240930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_45a21ced-0a15-4505-9328-dcdd7ec61259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_StatementTable_45a21ced-0a15-4505-9328-dcdd7ec61259" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_703e5eda-fff8-417b-bcf9-aef2fe1e3412" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_45a21ced-0a15-4505-9328-dcdd7ec61259" xlink:to="loc_dei_LegalEntityAxis_703e5eda-fff8-417b-bcf9-aef2fe1e3412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_703e5eda-fff8-417b-bcf9-aef2fe1e3412_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_703e5eda-fff8-417b-bcf9-aef2fe1e3412" xlink:to="loc_dei_EntityDomain_703e5eda-fff8-417b-bcf9-aef2fe1e3412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_83aadeb0-0ccc-4332-882a-100ff754db03" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_703e5eda-fff8-417b-bcf9-aef2fe1e3412" xlink:to="loc_dei_EntityDomain_83aadeb0-0ccc-4332-882a-100ff754db03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_130f2220-0906-4ec0-8c88-0f987420bbed" xlink:href="biib-20240930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_83aadeb0-0ccc-4332-882a-100ff754db03" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_130f2220-0906-4ec0-8c88-0f987420bbed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoMember_52b50ca4-6d8e-4a84-9b2b-d809cae35d72" xlink:href="biib-20240930.xsd#biib_SangamoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_83aadeb0-0ccc-4332-882a-100ff754db03" xlink:to="loc_biib_SangamoMember_52b50ca4-6d8e-4a84-9b2b-d809cae35d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_1bb970a6-ea83-455a-83e5-02389a5e9e67" xlink:href="biib-20240930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_83aadeb0-0ccc-4332-882a-100ff754db03" xlink:to="loc_biib_SageTherapeuticsIncMember_1bb970a6-ea83-455a-83e5-02389a5e9e67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1d9fb6b8-5372-4977-9a3c-3238eabd00d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_45a21ced-0a15-4505-9328-dcdd7ec61259" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1d9fb6b8-5372-4977-9a3c-3238eabd00d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d9fb6b8-5372-4977-9a3c-3238eabd00d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d9fb6b8-5372-4977-9a3c-3238eabd00d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d9fb6b8-5372-4977-9a3c-3238eabd00d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_13f2ea89-ab4d-4aeb-b7d6-2c3a1d6f65da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d9fb6b8-5372-4977-9a3c-3238eabd00d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_13f2ea89-ab4d-4aeb-b7d6-2c3a1d6f65da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_d942c060-8b5b-4134-be7b-10d55385fdfb" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_13f2ea89-ab4d-4aeb-b7d6-2c3a1d6f65da" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_d942c060-8b5b-4134-be7b-10d55385fdfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c768f239-77c2-4a2d-accc-557fa8aa69c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c768f239-77c2-4a2d-accc-557fa8aa69c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_33babdc3-bbee-4dd8-bf96-2bc0d7240547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_33babdc3-bbee-4dd8-bf96-2bc0d7240547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ea327ef2-3b40-433a-a345-d292324a3541" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ea327ef2-3b40-433a-a345-d292324a3541" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_509070d9-9116-4e9e-b6ef-cb12ace24546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_509070d9-9116-4e9e-b6ef-cb12ace24546" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c488f632-6622-4051-9242-4605b772c45b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c488f632-6622-4051-9242-4605b772c45b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_95d37814-ab6c-482f-b21f-d5841dc9f0d4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:to="loc_srt_ProductOrServiceAxis_95d37814-ab6c-482f-b21f-d5841dc9f0d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_95d37814-ab6c-482f-b21f-d5841dc9f0d4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_95d37814-ab6c-482f-b21f-d5841dc9f0d4" xlink:to="loc_srt_ProductsAndServicesDomain_95d37814-ab6c-482f-b21f-d5841dc9f0d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14bb8289-ed1c-4a57-81b8-83f8ff896589" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_95d37814-ab6c-482f-b21f-d5841dc9f0d4" xlink:to="loc_srt_ProductsAndServicesDomain_14bb8289-ed1c-4a57-81b8-83f8ff896589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember_66463e1d-80cc-4663-a57d-a85d00595455" xlink:href="biib-20240930.xsd#biib_OCREVUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14bb8289-ed1c-4a57-81b8-83f8ff896589" xlink:to="loc_biib_OCREVUSMember_66463e1d-80cc-4663-a57d-a85d00595455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MosunetuzumabMember_3e439cd6-6bcf-4de0-9cb1-df2b54bbad6e" xlink:href="biib-20240930.xsd#biib_MosunetuzumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14bb8289-ed1c-4a57-81b8-83f8ff896589" xlink:to="loc_biib_MosunetuzumabMember_3e439cd6-6bcf-4de0-9cb1-df2b54bbad6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_abdcc053-1bdc-45d7-bf66-35bfa780a78a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:to="loc_srt_RangeAxis_abdcc053-1bdc-45d7-bf66-35bfa780a78a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_abdcc053-1bdc-45d7-bf66-35bfa780a78a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_abdcc053-1bdc-45d7-bf66-35bfa780a78a" xlink:to="loc_srt_RangeMember_abdcc053-1bdc-45d7-bf66-35bfa780a78a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c1b61487-9881-4436-b393-05550e253e60" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_abdcc053-1bdc-45d7-bf66-35bfa780a78a" xlink:to="loc_srt_RangeMember_c1b61487-9881-4436-b393-05550e253e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_47369332-a39e-4dcc-b74e-105803108093" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c1b61487-9881-4436-b393-05550e253e60" xlink:to="loc_srt_MinimumMember_47369332-a39e-4dcc-b74e-105803108093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_80f75f3f-05fa-40ef-ad79-d02fff4512e8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c1b61487-9881-4436-b393-05550e253e60" xlink:to="loc_srt_MaximumMember_80f75f3f-05fa-40ef-ad79-d02fff4512e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_98c3bae7-12d9-4071-8a11-6c1803e931cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:to="loc_srt_StatementGeographicalAxis_98c3bae7-12d9-4071-8a11-6c1803e931cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_98c3bae7-12d9-4071-8a11-6c1803e931cd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_98c3bae7-12d9-4071-8a11-6c1803e931cd" xlink:to="loc_srt_SegmentGeographicalDomain_98c3bae7-12d9-4071-8a11-6c1803e931cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e496dabf-5bc5-4e8c-a6fa-2371cc85f319" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_98c3bae7-12d9-4071-8a11-6c1803e931cd" xlink:to="loc_srt_SegmentGeographicalDomain_e496dabf-5bc5-4e8c-a6fa-2371cc85f319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_cef95cba-e74d-4f01-ba0d-613205738d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e496dabf-5bc5-4e8c-a6fa-2371cc85f319" xlink:to="loc_us-gaap_ForeignCountryMember_cef95cba-e74d-4f01-ba0d-613205738d9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_bd5813c7-e662-43da-906c-7bb98a2e2787" xlink:href="biib-20240930.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_bd5813c7-e662-43da-906c-7bb98a2e2787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_1b451363-e605-463a-a341-93c3073e9e2b" xlink:href="biib-20240930.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_1b451363-e605-463a-a341-93c3073e9e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate_30f41c54-3fee-4aee-a430-ea1d1cb318e9" xlink:href="biib-20240930.xsd#biib_Reductioninroyaltyrate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_biib_Reductioninroyaltyrate_30f41c54-3fee-4aee-a430-ea1d1cb318e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement_ef675d39-7329-4fe1-a2b0-9489cc1a7a6d" xlink:href="biib-20240930.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_biib_PeriodOfCollaborationAgreement_ef675d39-7329-4fe1-a2b0-9489cc1a7a6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts_3c4d29a0-c9af-41ec-a02c-309d8fcaa925" xlink:href="biib-20240930.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_biib_PercentageOfFutureDevelopmentCosts_3c4d29a0-c9af-41ec-a02c-309d8fcaa925" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a1b5d7f-fbb6-496e-8fac-badadafe36fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a1b5d7f-fbb6-496e-8fac-badadafe36fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c8ea6a1-5dad-4aa3-a61b-9dd60abcc924" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a1b5d7f-fbb6-496e-8fac-badadafe36fe" xlink:to="loc_srt_ProductOrServiceAxis_3c8ea6a1-5dad-4aa3-a61b-9dd60abcc924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c8ea6a1-5dad-4aa3-a61b-9dd60abcc924_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3c8ea6a1-5dad-4aa3-a61b-9dd60abcc924" xlink:to="loc_srt_ProductsAndServicesDomain_3c8ea6a1-5dad-4aa3-a61b-9dd60abcc924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc888306-4efd-4970-aadf-292204a52069" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3c8ea6a1-5dad-4aa3-a61b-9dd60abcc924" xlink:to="loc_srt_ProductsAndServicesDomain_dc888306-4efd-4970-aadf-292204a52069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_d077be93-2c7d-456c-b4cd-adb63796b0ad" xlink:href="biib-20240930.xsd#biib_RituxanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc888306-4efd-4970-aadf-292204a52069" xlink:to="loc_biib_RituxanMember_d077be93-2c7d-456c-b4cd-adb63796b0ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_4ad02cac-805e-423a-a791-f8037d099fad" xlink:href="biib-20240930.xsd#biib_GAZYVAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc888306-4efd-4970-aadf-292204a52069" xlink:to="loc_biib_GAZYVAMember_4ad02cac-805e-423a-a791-f8037d099fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_ad1ceaa4-08c8-487a-9cb8-1a5a82ca0323" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_ad1ceaa4-08c8-487a-9cb8-1a5a82ca0323" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_a5e66bd0-b884-4d86-89bc-bdd8f3d1d55a" xlink:href="biib-20240930.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_a5e66bd0-b884-4d86-89bc-bdd8f3d1d55a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2ba0655a-a8e6-4eb2-bc87-ef599d8710c1" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2ba0655a-a8e6-4eb2-bc87-ef599d8710c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_6410835c-f254-460c-aec7-8f14fe9b8f9f" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_6410835c-f254-460c-aec7-8f14fe9b8f9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_f9c6a702-d3fe-4416-9d2a-9194954030c0" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_f9c6a702-d3fe-4416-9d2a-9194954030c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_a92f9454-9feb-49a4-b476-c111f668f035" xlink:href="biib-20240930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_a92f9454-9feb-49a4-b476-c111f668f035" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_00c35282-2cb5-4550-9716-0ac0bb7e0d82" xlink:href="biib-20240930.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_00c35282-2cb5-4550-9716-0ac0bb7e0d82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_f5f8399c-9fe8-451b-9a4e-f007172315f5" xlink:href="biib-20240930.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_f5f8399c-9fe8-451b-9a4e-f007172315f5" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_313cfe11-cfcf-49d5-bc36-fb6ba9ce8f88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdb5e434-d296-4649-b53e-c1623541cb31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_313cfe11-cfcf-49d5-bc36-fb6ba9ce8f88" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdb5e434-d296-4649-b53e-c1623541cb31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_34bb8c23-ff90-4187-b92b-23171766020d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdb5e434-d296-4649-b53e-c1623541cb31" xlink:to="loc_srt_ProductOrServiceAxis_34bb8c23-ff90-4187-b92b-23171766020d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34bb8c23-ff90-4187-b92b-23171766020d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_34bb8c23-ff90-4187-b92b-23171766020d" xlink:to="loc_srt_ProductsAndServicesDomain_34bb8c23-ff90-4187-b92b-23171766020d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7db501d7-a666-4103-a758-eb95d1a1839f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_34bb8c23-ff90-4187-b92b-23171766020d" xlink:to="loc_srt_ProductsAndServicesDomain_7db501d7-a666-4103-a758-eb95d1a1839f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_e349bf12-20dd-4e62-a132-ed83f56fedbe" xlink:href="biib-20240930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7db501d7-a666-4103-a758-eb95d1a1839f" xlink:to="loc_biib_LEQEMBICollaborationMember_e349bf12-20dd-4e62-a132-ed83f56fedbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_186a6c2e-fb02-41dc-9c2e-178b496a4080" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdb5e434-d296-4649-b53e-c1623541cb31" xlink:to="loc_us-gaap_TypeOfArrangementAxis_186a6c2e-fb02-41dc-9c2e-178b496a4080" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_186a6c2e-fb02-41dc-9c2e-178b496a4080_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_186a6c2e-fb02-41dc-9c2e-178b496a4080" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_186a6c2e-fb02-41dc-9c2e-178b496a4080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1da5d241-ef57-4917-8a74-ebe4891f684b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_186a6c2e-fb02-41dc-9c2e-178b496a4080" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1da5d241-ef57-4917-8a74-ebe4891f684b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_ea9bb7ba-2805-4ab0-ac22-0ec5d4862edd" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1da5d241-ef57-4917-8a74-ebe4891f684b" xlink:to="loc_biib_EisaiMember_ea9bb7ba-2805-4ab0-ac22-0ec5d4862edd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedPaymentToTerminationAgreement_3536249b-9ed4-4d1a-bb42-c1c0aca6d055" xlink:href="biib-20240930.xsd#biib_AccruedPaymentToTerminationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_313cfe11-cfcf-49d5-bc36-fb6ba9ce8f88" xlink:to="loc_biib_AccruedPaymentToTerminationAgreement_3536249b-9ed4-4d1a-bb42-c1c0aca6d055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsMadeToTerminationAgreement_83d2e8dc-e599-4615-b564-613ee43da3fd" xlink:href="biib-20240930.xsd#biib_PaymentsMadeToTerminationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_313cfe11-cfcf-49d5-bc36-fb6ba9ce8f88" xlink:to="loc_biib_PaymentsMadeToTerminationAgreement_83d2e8dc-e599-4615-b564-613ee43da3fd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfd3c49d-2732-4640-bf0f-512721c8858b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfd3c49d-2732-4640-bf0f-512721c8858b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9d5bc930-519b-4b0f-99aa-cfdd52350656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9d5bc930-519b-4b0f-99aa-cfdd52350656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d5bc930-519b-4b0f-99aa-cfdd52350656_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d5bc930-519b-4b0f-99aa-cfdd52350656" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d5bc930-519b-4b0f-99aa-cfdd52350656_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1443e7d2-e8e4-440a-ae67-15b91e4d944f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d5bc930-519b-4b0f-99aa-cfdd52350656" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1443e7d2-e8e4-440a-ae67-15b91e4d944f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_732746e9-fa43-49cb-9c5f-e9220c6c48f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1443e7d2-e8e4-440a-ae67-15b91e4d944f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_732746e9-fa43-49cb-9c5f-e9220c6c48f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_23a74a9d-5fd3-4da1-9cab-d2dd2c126209" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:to="loc_srt_ProductOrServiceAxis_23a74a9d-5fd3-4da1-9cab-d2dd2c126209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23a74a9d-5fd3-4da1-9cab-d2dd2c126209_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_23a74a9d-5fd3-4da1-9cab-d2dd2c126209" xlink:to="loc_srt_ProductsAndServicesDomain_23a74a9d-5fd3-4da1-9cab-d2dd2c126209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f4853954-fad8-4f1b-8b3d-60f05f6585fa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_23a74a9d-5fd3-4da1-9cab-d2dd2c126209" xlink:to="loc_srt_ProductsAndServicesDomain_f4853954-fad8-4f1b-8b3d-60f05f6585fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_01dfe271-5d7c-4708-85f9-081ae9b4c100" xlink:href="biib-20240930.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f4853954-fad8-4f1b-8b3d-60f05f6585fa" xlink:to="loc_biib_E2609andBAN2401Member_01dfe271-5d7c-4708-85f9-081ae9b4c100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8c80cb6c-d3f7-422f-87b3-5dd7ff25d0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8c80cb6c-d3f7-422f-87b3-5dd7ff25d0ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8c80cb6c-d3f7-422f-87b3-5dd7ff25d0ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c80cb6c-d3f7-422f-87b3-5dd7ff25d0ef" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8c80cb6c-d3f7-422f-87b3-5dd7ff25d0ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71c05594-3708-4427-8b65-70439322791e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c80cb6c-d3f7-422f-87b3-5dd7ff25d0ef" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71c05594-3708-4427-8b65-70439322791e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_a018a3d7-b577-4cd8-879f-ee3f17ce455f" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71c05594-3708-4427-8b65-70439322791e" xlink:to="loc_biib_EisaiMember_a018a3d7-b577-4cd8-879f-ee3f17ce455f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_9118b597-fe02-491c-b5c0-0cad473d6fa0" xlink:href="biib-20240930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfd3c49d-2732-4640-bf0f-512721c8858b" xlink:to="loc_biib_ExpenseIncurredByCollaboration_9118b597-fe02-491c-b5c0-0cad473d6fa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_62232c2c-bdd3-42c3-a996-082a0d57dbb2" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfd3c49d-2732-4640-bf0f-512721c8858b" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_62232c2c-bdd3-42c3-a996-082a0d57dbb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_7731e38c-09f5-44ea-86ac-b5d17fcc2d5c" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfd3c49d-2732-4640-bf0f-512721c8858b" xlink:to="loc_biib_Expenseincurredbythecollaboration_7731e38c-09f5-44ea-86ac-b5d17fcc2d5c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7652b882-ae0e-45a8-84f5-763ed9340516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7652b882-ae0e-45a8-84f5-763ed9340516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7652b882-ae0e-45a8-84f5-763ed9340516_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7652b882-ae0e-45a8-84f5-763ed9340516" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7652b882-ae0e-45a8-84f5-763ed9340516_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22fdafc5-7d31-42ce-a4f6-bf25faa11c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7652b882-ae0e-45a8-84f5-763ed9340516" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22fdafc5-7d31-42ce-a4f6-bf25faa11c8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_09935faf-42d3-4e71-85ea-536b495f9114" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22fdafc5-7d31-42ce-a4f6-bf25faa11c8a" xlink:to="loc_biib_EisaiMember_09935faf-42d3-4e71-85ea-536b495f9114" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a16a887-0c88-4d7a-968f-a3f46d086c00" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:to="loc_srt_RangeAxis_0a16a887-0c88-4d7a-968f-a3f46d086c00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0a16a887-0c88-4d7a-968f-a3f46d086c00_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0a16a887-0c88-4d7a-968f-a3f46d086c00" xlink:to="loc_srt_RangeMember_0a16a887-0c88-4d7a-968f-a3f46d086c00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce140285-0dbc-491e-bfa2-4abcedc25491" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0a16a887-0c88-4d7a-968f-a3f46d086c00" xlink:to="loc_srt_RangeMember_ce140285-0dbc-491e-bfa2-4abcedc25491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d00e084f-b766-477c-bd1c-998f0c594e49" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ce140285-0dbc-491e-bfa2-4abcedc25491" xlink:to="loc_srt_MaximumMember_d00e084f-b766-477c-bd1c-998f0c594e49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c15fc727-1b44-4caa-9519-98e4d111f2c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:to="loc_srt_StatementScenarioAxis_c15fc727-1b44-4caa-9519-98e4d111f2c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c15fc727-1b44-4caa-9519-98e4d111f2c5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c15fc727-1b44-4caa-9519-98e4d111f2c5" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c15fc727-1b44-4caa-9519-98e4d111f2c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a6f9a0fc-9a05-4f40-9d2d-57c7a0ff3e1f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c15fc727-1b44-4caa-9519-98e4d111f2c5" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a6f9a0fc-9a05-4f40-9d2d-57c7a0ff3e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0c7eb01f-da13-4042-a8d1-6a690129a513" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a6f9a0fc-9a05-4f40-9d2d-57c7a0ff3e1f" xlink:to="loc_srt_ScenarioForecastMember_0c7eb01f-da13-4042-a8d1-6a690129a513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2e1f4352-d911-42bc-bd12-561a2ec91c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2e1f4352-d911-42bc-bd12-561a2ec91c9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_5fead81e-9279-40ec-b971-bcfda3562c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:to="loc_us-gaap_InventoryWriteDown_5fead81e-9279-40ec-b971-bcfda3562c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator_87719ff4-b020-4b70-b18e-93fc0056c9bb" xlink:href="biib-20240930.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:to="loc_biib_AccountsReceivableFromCollaborator_87719ff4-b020-4b70-b18e-93fc0056c9bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator_1ff41404-cceb-4e28-a2a3-561659917eae" xlink:href="biib-20240930.xsd#biib_AccountsPayableToCollaborator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:to="loc_biib_AccountsPayableToCollaborator_1ff41404-cceb-4e28-a2a3-561659917eae" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_74b31167-1d84-4280-9305-ec06d2b4817c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_74b31167-1d84-4280-9305-ec06d2b4817c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74b31167-1d84-4280-9305-ec06d2b4817c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_74b31167-1d84-4280-9305-ec06d2b4817c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74b31167-1d84-4280-9305-ec06d2b4817c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d06316b1-b29e-425f-819a-76d8901e1fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_74b31167-1d84-4280-9305-ec06d2b4817c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d06316b1-b29e-425f-819a-76d8901e1fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_296fbe06-5fd0-45aa-a5c3-73888a578c73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d06316b1-b29e-425f-819a-76d8901e1fd6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_296fbe06-5fd0-45aa-a5c3-73888a578c73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b6dc2fff-0917-452e-a479-bb60fbc0d946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d06316b1-b29e-425f-819a-76d8901e1fd6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b6dc2fff-0917-452e-a479-bb60fbc0d946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_395171f4-22bc-4924-b72b-3f94a1805202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:to="loc_us-gaap_TypeOfArrangementAxis_395171f4-22bc-4924-b72b-3f94a1805202" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_395171f4-22bc-4924-b72b-3f94a1805202_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_395171f4-22bc-4924-b72b-3f94a1805202" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_395171f4-22bc-4924-b72b-3f94a1805202_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30f3d17f-78db-4475-ad9d-ea97345818ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_395171f4-22bc-4924-b72b-3f94a1805202" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30f3d17f-78db-4475-ad9d-ea97345818ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_cec475f3-dbbd-49a6-8a55-ceaf3e299d15" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30f3d17f-78db-4475-ad9d-ea97345818ce" xlink:to="loc_biib_EisaiMember_cec475f3-dbbd-49a6-8a55-ceaf3e299d15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7aa90edc-d0f9-43dc-8991-5b4561303646" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:to="loc_srt_ProductOrServiceAxis_7aa90edc-d0f9-43dc-8991-5b4561303646" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7aa90edc-d0f9-43dc-8991-5b4561303646_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7aa90edc-d0f9-43dc-8991-5b4561303646" xlink:to="loc_srt_ProductsAndServicesDomain_7aa90edc-d0f9-43dc-8991-5b4561303646_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b4499db7-7798-45d1-9ea1-598c6277efd3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7aa90edc-d0f9-43dc-8991-5b4561303646" xlink:to="loc_srt_ProductsAndServicesDomain_b4499db7-7798-45d1-9ea1-598c6277efd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_9b6770f5-fd35-49a7-add6-7ba5cbb77b60" xlink:href="biib-20240930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b4499db7-7798-45d1-9ea1-598c6277efd3" xlink:to="loc_biib_LEQEMBICollaborationMember_9b6770f5-fd35-49a7-add6-7ba5cbb77b60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_a8c85f2d-6e4d-42a5-9526-9240b138adce" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:to="loc_biib_Expenseincurredbythecollaboration_a8c85f2d-6e4d-42a5-9526-9240b138adce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_0c22f578-5f8f-4bed-bb76-b6c381dcb5b1" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_0c22f578-5f8f-4bed-bb76-b6c381dcb5b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_27943897-08f8-486d-a5c3-d2c44c935f29" xlink:href="biib-20240930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_27943897-08f8-486d-a5c3-d2c44c935f29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_02833cc6-b87d-4464-9490-46900f6e2d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_02833cc6-b87d-4464-9490-46900f6e2d3e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68e92d2d-f8ec-43b9-bcd1-5873cee42e71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87260a8a-7d9d-4142-a0fc-9e67ba63f3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68e92d2d-f8ec-43b9-bcd1-5873cee42e71" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87260a8a-7d9d-4142-a0fc-9e67ba63f3d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_de48a7a9-1c05-4b27-9fca-ff14a0b1c032" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87260a8a-7d9d-4142-a0fc-9e67ba63f3d7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_de48a7a9-1c05-4b27-9fca-ff14a0b1c032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_de48a7a9-1c05-4b27-9fca-ff14a0b1c032_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_de48a7a9-1c05-4b27-9fca-ff14a0b1c032" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_de48a7a9-1c05-4b27-9fca-ff14a0b1c032_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca7af74c-da3f-4621-bff7-2a41c6b2592c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_de48a7a9-1c05-4b27-9fca-ff14a0b1c032" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca7af74c-da3f-4621-bff7-2a41c6b2592c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6f2e05db-b92e-4de1-84d9-69ee79f5a290" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca7af74c-da3f-4621-bff7-2a41c6b2592c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6f2e05db-b92e-4de1-84d9-69ee79f5a290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b3e8132b-0d53-4167-b4b0-25c31caca959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87260a8a-7d9d-4142-a0fc-9e67ba63f3d7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b3e8132b-0d53-4167-b4b0-25c31caca959" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3e8132b-0d53-4167-b4b0-25c31caca959_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b3e8132b-0d53-4167-b4b0-25c31caca959" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3e8132b-0d53-4167-b4b0-25c31caca959_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fba7a9d4-038f-45fc-8cc1-2fcdc5e8960f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b3e8132b-0d53-4167-b4b0-25c31caca959" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fba7a9d4-038f-45fc-8cc1-2fcdc5e8960f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_0fc69c22-e506-427d-8150-26640ff0b479" xlink:href="biib-20240930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fba7a9d4-038f-45fc-8cc1-2fcdc5e8960f" xlink:to="loc_biib_UCBPharmaS.A.Member_0fc69c22-e506-427d-8150-26640ff0b479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_b69be361-b738-4b81-b1a8-d72314943647" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68e92d2d-f8ec-43b9-bcd1-5873cee42e71" xlink:to="loc_biib_Expenseincurredbythecollaboration_b69be361-b738-4b81-b1a8-d72314943647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9b37eb9b-a288-45e0-bdd3-fa325532c935" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68e92d2d-f8ec-43b9-bcd1-5873cee42e71" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9b37eb9b-a288-45e0-bdd3-fa325532c935" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_42e6be3b-d308-431f-9727-8af030570e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_42e6be3b-d308-431f-9727-8af030570e75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42e6be3b-d308-431f-9727-8af030570e75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42e6be3b-d308-431f-9727-8af030570e75" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42e6be3b-d308-431f-9727-8af030570e75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aaadb17b-b70e-402a-9bfc-24ed5da7b2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42e6be3b-d308-431f-9727-8af030570e75" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aaadb17b-b70e-402a-9bfc-24ed5da7b2ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8c4ffcac-4ef6-46b6-bc79-c5b194527aed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aaadb17b-b70e-402a-9bfc-24ed5da7b2ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8c4ffcac-4ef6-46b6-bc79-c5b194527aed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f2c6c016-a267-4957-a97b-7ae4fc0ba017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aaadb17b-b70e-402a-9bfc-24ed5da7b2ac" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f2c6c016-a267-4957-a97b-7ae4fc0ba017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_215fc743-865a-473b-99dd-13bee8e741c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:to="loc_us-gaap_TypeOfArrangementAxis_215fc743-865a-473b-99dd-13bee8e741c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_215fc743-865a-473b-99dd-13bee8e741c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_215fc743-865a-473b-99dd-13bee8e741c0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_215fc743-865a-473b-99dd-13bee8e741c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6abeddb9-bc1a-4174-b796-a3ab34c1682d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_215fc743-865a-473b-99dd-13bee8e741c0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6abeddb9-bc1a-4174-b796-a3ab34c1682d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_3c748fa3-acaf-4e69-9056-5fbcd13b590a" xlink:href="biib-20240930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6abeddb9-bc1a-4174-b796-a3ab34c1682d" xlink:to="loc_biib_SageTherapeuticsIncMember_3c748fa3-acaf-4e69-9056-5fbcd13b590a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4ff35025-a340-451b-87d5-a451b8e04548" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:to="loc_srt_StatementScenarioAxis_4ff35025-a340-451b-87d5-a451b8e04548" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4ff35025-a340-451b-87d5-a451b8e04548_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_4ff35025-a340-451b-87d5-a451b8e04548" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4ff35025-a340-451b-87d5-a451b8e04548_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bff6e5ae-1340-4353-886a-6b78ded6e2ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_4ff35025-a340-451b-87d5-a451b8e04548" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bff6e5ae-1340-4353-886a-6b78ded6e2ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_8554235a-9ff4-4bb7-947a-7b5b44dc80c4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bff6e5ae-1340-4353-886a-6b78ded6e2ed" xlink:to="loc_srt_ScenarioForecastMember_8554235a-9ff4-4bb7-947a-7b5b44dc80c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_cb2b28f3-7e87-4e30-8861-5183a034929c" xlink:href="biib-20240930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_cb2b28f3-7e87-4e30-8861-5183a034929c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_1c966a2c-de77-4a5f-85bf-d2ecc4a47660" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_biib_Expenseincurredbythecollaboration_1c966a2c-de77-4a5f-85bf-d2ecc4a47660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_e6c43eb9-9b6a-4e5e-aee0-b59d71135bef" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_e6c43eb9-9b6a-4e5e-aee0-b59d71135bef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_bf1e3230-c660-4ab9-b9ab-219e1efa5915" xlink:href="biib-20240930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_bf1e3230-c660-4ab9-b9ab-219e1efa5915" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_f755141a-bf63-469c-b725-494505621cc9" xlink:href="biib-20240930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_biib_Collaborationprofitlosssharing_f755141a-bf63-469c-b725-494505621cc9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca9f6f93-f37c-4bcd-9e44-d97369f42ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_631be611-d88d-44c6-a27e-0971e10b8c27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca9f6f93-f37c-4bcd-9e44-d97369f42ba4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_631be611-d88d-44c6-a27e-0971e10b8c27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_345adcc3-5490-4c4d-95e4-d313059ffa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_631be611-d88d-44c6-a27e-0971e10b8c27" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_345adcc3-5490-4c4d-95e4-d313059ffa3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_345adcc3-5490-4c4d-95e4-d313059ffa3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_345adcc3-5490-4c4d-95e4-d313059ffa3c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_345adcc3-5490-4c4d-95e4-d313059ffa3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6cc4b0d8-b317-47ee-85d1-b18e2232c831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_345adcc3-5490-4c4d-95e4-d313059ffa3c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6cc4b0d8-b317-47ee-85d1-b18e2232c831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9bd19715-50cd-4d7d-afa6-729b2cfd39c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6cc4b0d8-b317-47ee-85d1-b18e2232c831" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9bd19715-50cd-4d7d-afa6-729b2cfd39c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7360829b-6521-4898-89f5-843318e82014" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_631be611-d88d-44c6-a27e-0971e10b8c27" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7360829b-6521-4898-89f5-843318e82014" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7360829b-6521-4898-89f5-843318e82014_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7360829b-6521-4898-89f5-843318e82014" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7360829b-6521-4898-89f5-843318e82014_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b73c7c30-84c2-4dba-bfd9-c97f13ee771a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7360829b-6521-4898-89f5-843318e82014" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b73c7c30-84c2-4dba-bfd9-c97f13ee771a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_b26e68d3-5b25-4ae2-b10c-d050e91b97c3" xlink:href="biib-20240930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b73c7c30-84c2-4dba-bfd9-c97f13ee771a" xlink:to="loc_biib_DenaliTherapeuticsIncMember_b26e68d3-5b25-4ae2-b10c-d050e91b97c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_efa647c7-9bd4-400e-bea9-0492bc4fbdcd" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca9f6f93-f37c-4bcd-9e44-d97369f42ba4" xlink:to="loc_biib_Expenseincurredbythecollaboration_efa647c7-9bd4-400e-bea9-0492bc4fbdcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_6ddc4042-980c-4349-8b8b-780d10b92f0e" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca9f6f93-f37c-4bcd-9e44-d97369f42ba4" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_6ddc4042-980c-4349-8b8b-780d10b92f0e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52070a09-3214-4037-86ad-0b9b779ff51a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3ef34e1-6c2f-4f5f-bf73-f1f8054e2949" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52070a09-3214-4037-86ad-0b9b779ff51a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3ef34e1-6c2f-4f5f-bf73-f1f8054e2949" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cd29393d-87f1-4e2c-9b8a-6851cd5eb308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3ef34e1-6c2f-4f5f-bf73-f1f8054e2949" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cd29393d-87f1-4e2c-9b8a-6851cd5eb308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cd29393d-87f1-4e2c-9b8a-6851cd5eb308_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cd29393d-87f1-4e2c-9b8a-6851cd5eb308" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cd29393d-87f1-4e2c-9b8a-6851cd5eb308_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cb8028a0-8b96-409e-8d46-71a575eeebef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cd29393d-87f1-4e2c-9b8a-6851cd5eb308" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cb8028a0-8b96-409e-8d46-71a575eeebef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bddb7602-0221-4ed3-af84-34deb998c498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cb8028a0-8b96-409e-8d46-71a575eeebef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bddb7602-0221-4ed3-af84-34deb998c498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_6b57c189-9152-4f3b-a560-f467101fe32c" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52070a09-3214-4037-86ad-0b9b779ff51a" xlink:to="loc_biib_Expenseincurredbythecollaboration_6b57c189-9152-4f3b-a560-f467101fe32c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_c4cfa772-1ac1-4647-8c8c-d85aacd83fbd" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52070a09-3214-4037-86ad-0b9b779ff51a" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_c4cfa772-1ac1-4647-8c8c-d85aacd83fbd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8f57f9d-cf92-423f-b1f8-29712a66d549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ffcb950d-5f90-47b7-a93c-4c1327dd2426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8f57f9d-cf92-423f-b1f8-29712a66d549" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ffcb950d-5f90-47b7-a93c-4c1327dd2426" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a9428c94-f74b-460b-be40-e4408ce347f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ffcb950d-5f90-47b7-a93c-4c1327dd2426" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a9428c94-f74b-460b-be40-e4408ce347f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9428c94-f74b-460b-be40-e4408ce347f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a9428c94-f74b-460b-be40-e4408ce347f2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9428c94-f74b-460b-be40-e4408ce347f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2950aa33-18d8-4844-a1cd-2cd5701704d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a9428c94-f74b-460b-be40-e4408ce347f2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2950aa33-18d8-4844-a1cd-2cd5701704d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_3cf809a5-84c8-4adc-9ad9-656006b97e73" xlink:href="biib-20240930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2950aa33-18d8-4844-a1cd-2cd5701704d9" xlink:to="loc_biib_OtherresearchanddiscoveryMember_3cf809a5-84c8-4adc-9ad9-656006b97e73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_59aa134d-a110-47c5-8d57-488e1fac26b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8f57f9d-cf92-423f-b1f8-29712a66d549" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_59aa134d-a110-47c5-8d57-488e1fac26b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f2fdbdc2-526b-4b0d-878a-5d7158713ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f2fdbdc2-526b-4b0d-878a-5d7158713ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2fdbdc2-526b-4b0d-878a-5d7158713ed7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f2fdbdc2-526b-4b0d-878a-5d7158713ed7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2fdbdc2-526b-4b0d-878a-5d7158713ed7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4407175b-d0b8-4598-996c-5d44d51ee95b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f2fdbdc2-526b-4b0d-878a-5d7158713ed7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4407175b-d0b8-4598-996c-5d44d51ee95b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_74187885-f8df-44c4-8888-5d72168bf150" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4407175b-d0b8-4598-996c-5d44d51ee95b" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_74187885-f8df-44c4-8888-5d72168bf150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36f03b92-611c-4a1f-b74d-c7529b3181b8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36f03b92-611c-4a1f-b74d-c7529b3181b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_36f03b92-611c-4a1f-b74d-c7529b3181b8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36f03b92-611c-4a1f-b74d-c7529b3181b8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_36f03b92-611c-4a1f-b74d-c7529b3181b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bd1091fe-aaab-44a6-a671-0ce00b9e843f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36f03b92-611c-4a1f-b74d-c7529b3181b8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bd1091fe-aaab-44a6-a671-0ce00b9e843f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_bd960818-ff9d-4923-ac4f-21c59f98904b" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bd1091fe-aaab-44a6-a671-0ce00b9e843f" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_bd960818-ff9d-4923-ac4f-21c59f98904b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24a35ba2-9762-4354-ab06-c53687f14ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24a35ba2-9762-4354-ab06-c53687f14ecb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_24a35ba2-9762-4354-ab06-c53687f14ecb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24a35ba2-9762-4354-ab06-c53687f14ecb" xlink:to="loc_us-gaap_RelatedPartyDomain_24a35ba2-9762-4354-ab06-c53687f14ecb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9c753752-5351-4edd-95be-325d4811dd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24a35ba2-9762-4354-ab06-c53687f14ecb" xlink:to="loc_us-gaap_RelatedPartyDomain_9c753752-5351-4edd-95be-325d4811dd2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_1266aca8-dac7-476a-861a-0468592800c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9c753752-5351-4edd-95be-325d4811dd2d" xlink:to="loc_us-gaap_RelatedPartyMember_1266aca8-dac7-476a-861a-0468592800c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_7c8779b5-0e13-4611-8690-1dca4ea5db54" xlink:href="biib-20240930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_7c8779b5-0e13-4611-8690-1dca4ea5db54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ec2970fd-1ea3-4732-bd33-80a1f8379c7d" xlink:href="biib-20240930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ec2970fd-1ea3-4732-bd33-80a1f8379c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_396fa4d9-8079-45ce-85f2-2bac7856629f" xlink:href="biib-20240930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_396fa4d9-8079-45ce-85f2-2bac7856629f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementTermExtension_f5db47c3-3bdb-4d9b-b771-475e7a896624" xlink:href="biib-20240930.xsd#biib_CollaborativeArrangementTermExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_CollaborativeArrangementTermExtension_f5db47c3-3bdb-4d9b-b771-475e7a896624" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_61f3a6f7-66fb-473b-b14e-11d2d697ae34" xlink:href="biib-20240930.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_ContractOptionExerciseFee_61f3a6f7-66fb-473b-b14e-11d2d697ae34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_20be60f0-791c-4f67-aaa4-23dea338627a" xlink:href="biib-20240930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_Collaborationprofitlosssharing_20be60f0-791c-4f67-aaa4-23dea338627a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_247a38cc-5169-4250-8694-bb833ab0d622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_us-gaap_AccountsReceivableNet_247a38cc-5169-4250-8694-bb833ab0d622" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_0e9e68ee-2d79-4c23-aa2c-667f2ac9ff1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_0e9e68ee-2d79-4c23-aa2c-667f2ac9ff1b" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_103b02ee-235a-4235-9c49-75b5d83b90b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c3254fbb-f8fc-4bb4-8e89-18211974b73c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_103b02ee-235a-4235-9c49-75b5d83b90b4" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c3254fbb-f8fc-4bb4-8e89-18211974b73c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_c67e0e69-1f8e-4245-a76c-c3fdb973bcd7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c3254fbb-f8fc-4bb4-8e89-18211974b73c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_c67e0e69-1f8e-4245-a76c-c3fdb973bcd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c67e0e69-1f8e-4245-a76c-c3fdb973bcd7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c67e0e69-1f8e-4245-a76c-c3fdb973bcd7" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c67e0e69-1f8e-4245-a76c-c3fdb973bcd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f871197c-f0a5-4d9d-a852-bf87c1cf3a83" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c67e0e69-1f8e-4245-a76c-c3fdb973bcd7" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f871197c-f0a5-4d9d-a852-bf87c1cf3a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_adb26868-a288-41a7-ac63-dc7c2b7905cb" xlink:href="biib-20240930.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f871197c-f0a5-4d9d-a852-bf87c1cf3a83" xlink:to="loc_biib_NeurimmuneMember_adb26868-a288-41a7-ac63-dc7c2b7905cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_ea33b8f2-1dea-4bf2-be79-2f815c962e77" xlink:href="biib-20240930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_103b02ee-235a-4235-9c49-75b5d83b90b4" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_ea33b8f2-1dea-4bf2-be79-2f815c962e77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_a08ba517-2d0a-4879-a965-3c19db7f9a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_103b02ee-235a-4235-9c49-75b5d83b90b4" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_a08ba517-2d0a-4879-a965-3c19db7f9a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_00c9e110-93f9-4971-81d5-df6d4bdb0022" xlink:href="biib-20240930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_103b02ee-235a-4235-9c49-75b5d83b90b4" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_00c9e110-93f9-4971-81d5-df6d4bdb0022" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#LitigationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_12a4f1d6-9f91-4228-bfcf-3780ec1a7cda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e897ce4a-db63-4b92-97fa-ed21d3e34765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_12a4f1d6-9f91-4228-bfcf-3780ec1a7cda" xlink:to="loc_us-gaap_LossContingenciesTable_e897ce4a-db63-4b92-97fa-ed21d3e34765" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_fa48452b-d1e4-44cb-b2b3-2aacaf6d8196" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e897ce4a-db63-4b92-97fa-ed21d3e34765" xlink:to="loc_srt_LitigationCaseAxis_fa48452b-d1e4-44cb-b2b3-2aacaf6d8196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_fa48452b-d1e4-44cb-b2b3-2aacaf6d8196_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_fa48452b-d1e4-44cb-b2b3-2aacaf6d8196" xlink:to="loc_srt_LitigationCaseTypeDomain_fa48452b-d1e4-44cb-b2b3-2aacaf6d8196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5295c932-dbe1-491d-9713-f682b5a1edf0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_fa48452b-d1e4-44cb-b2b3-2aacaf6d8196" xlink:to="loc_srt_LitigationCaseTypeDomain_5295c932-dbe1-491d-9713-f682b5a1edf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember_dd1c5c8f-a0db-40bc-acf2-835e77399678" xlink:href="biib-20240930.xsd#biib_GenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5295c932-dbe1-491d-9713-f682b5a1edf0" xlink:to="loc_biib_GenentechMember_dd1c5c8f-a0db-40bc-acf2-835e77399678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember_a311f433-7581-46d5-8b16-c4a7708ad70d" xlink:href="biib-20240930.xsd#biib_LenderDisputeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5295c932-dbe1-491d-9713-f682b5a1edf0" xlink:to="loc_biib_LenderDisputeMember_a311f433-7581-46d5-8b16-c4a7708ad70d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1decc729-9f71-4346-a436-6115da0b093b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_12a4f1d6-9f91-4228-bfcf-3780ec1a7cda" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1decc729-9f71-4346-a436-6115da0b093b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_99d9897a-7b21-4c36-9a64-b8e18f99beed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_12a4f1d6-9f91-4228-bfcf-3780ec1a7cda" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_99d9897a-7b21-4c36-9a64-b8e18f99beed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_590e84b2-0e9f-432e-899c-4f5ba0a9ac26" xlink:href="biib-20240930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_590e84b2-0e9f-432e-899c-4f5ba0a9ac26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_e2fe4bd1-1657-4028-a7a3-d4ced15d8115" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_e2fe4bd1-1657-4028-a7a3-d4ced15d8115" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_db3c1e10-7630-4468-8b9c-205bf8f634fe" xlink:href="biib-20240930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_db3c1e10-7630-4468-8b9c-205bf8f634fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_ffa4070e-fa0f-4962-823b-d9045448b0f2" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_ffa4070e-fa0f-4962-823b-d9045448b0f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_9497ec5b-ab46-4b67-91c3-18685241405f" xlink:href="biib-20240930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_MarketStockUnitsMember_9497ec5b-ab46-4b67-91c3-18685241405f" xlink:type="arc" order="7"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>biib-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8df3ebeb-6aab-4ece-9956-fcebea1610fa,g:6874ad4b-e1dd-42ba-8d50-e940c01ea5b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_7f25edc8-63de-4a85-bb6b-4aecc612e9b0_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20240930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6965bb4f-709c-41bb-bc23-7102b8c053be_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_853d70f5-3250-4fde-bd34-5d09c0d5a052_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_019055ab-3d82-452c-80ef-6125e8c4a6c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_cdb8f625-7022-4fa5-9fc3-1c91ba783dd3_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_3965735c-8a86-4377-a6ee-b3714ba57614_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_3d718c54-8a8f-4394-90dc-86327cb43d90_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_594ada1d-a112-48e7-9b1c-40173cd341da_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_12472966-d72d-4035-8529-86ba07a3b09e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_ee904d3b-37cd-4e3f-8188-81978dad7c25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_78605c10-8b3e-42e1-b15c-8ba6ebdb4dc4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_b3fee6e5-6a39-481d-a1ae-b361464fcb14_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4f132c01-1468-42ef-ad3f-b58b5090861a_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: Net (gains) losses realized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_90997f5a-3191-4648-b8c9-743e4f0f0d4e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_14202bab-e26d-49c4-9e53-bc616568f1bc_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5a9ed4fb-5e7c-4ae0-a2be-a54a5c5c009f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_c9d72aa6-149c-4395-9f96-3cb1778e7380_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ea71a856-23dc-472f-acdc-00cd4caa6da6_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7d0cdc56-fcaf-4599-8721-31d67f896025_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_850af309-7ebe-4697-a44d-60d943ca26f5_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20240930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_4c85ca8b-7871-460b-8a13-8c33a083ff5a_terseLabel_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty percentage to be received</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_label_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Percentage To Be Received On Sale Of Product</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_documentation_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:href="biib-20240930.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:to="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_9b6707ac-24a7-4bdf-b591-3f37d2759e77_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20240930.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_65b55341-c465-4fd2-8875-0123ba9611e6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_072606c1-4717-4ec2-8115-cc52066231cb_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (gains) losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_56f0f7fa-d4de-452f-8eb4-a6047b4f61cf_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_befc0509-a429-4989-be80-7df762e5c862_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0bfadd08-4d83-4743-af42-2d45e1c84fe5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_fe87e14b-9066-4544-bee7-7cb9c3b53585_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_ee525c9e-b852-4fbd-a71f-a13fcf668b77_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023TermLoanMember_9f62d5a4-4347-426e-b5b0-92a30339144b_terseLabel_en-US" xlink:label="lab_biib_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Term Loan</link:label>
    <link:label id="lab_biib_A2023TermLoanMember_label_en-US" xlink:label="lab_biib_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Term Loan [Member]</link:label>
    <link:label id="lab_biib_A2023TermLoanMember_documentation_en-US" xlink:label="lab_biib_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023TermLoanMember" xlink:href="biib-20240930.xsd#biib_A2023TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023TermLoanMember" xlink:to="lab_biib_A2023TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_d8b60c94-e3d0-4c5c-b7e6-60b367cc6466_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of priority review voucher, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_24914e86-b3c6-4d8b-a125-1425f7d4b413_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_79a46e6d-01e0-4cad-9d68-be33dc771fff_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements and non-collaborative arrangement transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_793e1dcd-61fb-4501-bad7-419e04ad0225_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_9676b7c9-fed5-4ef8-86bb-5d652f4e6836_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_58b67134-3750-4d9c-818f-000555c64bc6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_8691214a-4880-4ea9-9ff8-65b6812123b0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_69d8374d-4504-4083-b8eb-6911a4d5a743_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_904977c5-1587-440d-bd8a-dbd373cbce4c_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_44c4e1b7-b391-4a57-b93b-6ac5f7683997_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_387d2b6f-706b-47e2-86e3-cc1c9562b5c7_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6e7202cf-c20f-496f-929e-183451af59a8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_a75a4444-eb87-4c27-8259-f64c14f4d251_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ca00bc37-4de0-448b-ae1e-39e0f4cddc8f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5f7b05e0-2bce-4646-9939-c1f548ba47ab_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6219fa5f-08b9-4b0f-b39d-c8d20c17a5bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flow provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_369c56e1-8328-4b09-be33-20d4b5f77470_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_09e19856-0e61-4907-abfb-e95c4704d0f5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e999ee1a-0952-4adc-a4a9-6c46eb4d14ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TOFIDENCEMember_8fd8e068-c9f0-47a9-bacb-e463c609ebf5_terseLabel_en-US" xlink:label="lab_biib_TOFIDENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TOFIDENCE</link:label>
    <link:label id="lab_biib_TOFIDENCEMember_label_en-US" xlink:label="lab_biib_TOFIDENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TOFIDENCE [Member]</link:label>
    <link:label id="lab_biib_TOFIDENCEMember_documentation_en-US" xlink:label="lab_biib_TOFIDENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TOFIDENCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TOFIDENCEMember" xlink:href="biib-20240930.xsd#biib_TOFIDENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TOFIDENCEMember" xlink:to="lab_biib_TOFIDENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_4e4bf4fc-4956-4bde-a578-61cd6c31580c_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_0c7de042-5a69-42e6-b8df-efb7275f1ff3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_fdf3e7f2-81d3-4427-8d19-2a9106e7ba88_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20240930.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_9017989b-382a-4518-a7c3-3bb0233a915c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d5152571-0d26-4034-9a0a-393111f1a283_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_00f94e59-8be0-4af5-8788-d347d3e1ca84_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20240930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_9ef2c8e6-cf64-4ce9-917b-4109965108be_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_511168af-11aa-4380-b330-94bb896e99be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bd3b934e-9413-491f-aec5-9a5ad146cc1f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_b893824d-323e-4912-9b3b-fe87676f6e08_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20240930.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e1b4818d-67ea-4dca-9381-afe515fe98c0_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6ffc7ebd-9143-490a-a6f9-067bffb0dcf6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_60363afc-13df-4658-ae68-5317b4734e71_terseLabel_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_label_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_documentation_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:href="biib-20240930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:to="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_81d0480d-8119-4ea2-bc62-02bcd1c7cc98_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8eb2b693-6c82-4250-bd08-0b83889a2650_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentCommercialMember_41bf36ac-7b8a-40c7-9132-1d4e5d04c199_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentCommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Commercial</link:label>
    <link:label id="lab_biib_MilestonePaymentCommercialMember_label_en-US" xlink:label="lab_biib_MilestonePaymentCommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Commercial [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentCommercialMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentCommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Commercial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentCommercialMember" xlink:href="biib-20240930.xsd#biib_MilestonePaymentCommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentCommercialMember" xlink:to="lab_biib_MilestonePaymentCommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_68f16279-796e-49e5-acdb-4ce3de5b86a0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c53e33c7-09ac-4e87-a258-bd424e28e3df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_158f731d-1739-4434-8baf-dde2d4b38f2a_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20240930.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_91443ca3-d794-4a76-bdce-32a28c492da7_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20240930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_4e6ff37d-af0b-4bbc-ad00-b3df67b56b43_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_153ebd5a-e3db-4585-a343-6acb22bcfaf3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_3efe387b-bce0-4926-a3ee-56e726ded4d3_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20240930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4775cfec-9447-4328-bea5-3969603966dd_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_0fcd9b99-5df1-4437-a484-dbee413e9e12_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_bf54d066-408c-4f2f-bfff-224747d224f6_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_b209f974-6c1c-4442-a352-d7a58d0a9764_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_cd2f14a4-5a89-48f6-8335-1b787f7f8a33_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b4ae84c4-8784-4772-b1f2-4e94640162c8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_964ea78d-3621-408b-889d-a142fce25787_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_9c389f72-39d0-42bd-8fe8-2e4c6c16e64b_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember" xlink:href="biib-20240930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember" xlink:to="lab_biib_OtherresearchanddiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_af13d697-c792-4746-a181-c6149cf32116_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_67ded936-d3d6-4ebd-a2cd-3e7e6ecf653b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_ccf56fb2-1efa-4eff-8406-eaf61e7da3c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_23e1563d-1811-44d9-8a09-39d53009a1dc_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_1ab3ebe9-860f-4ef3-9338-c7a40307d851_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_97384810-e6e2-4fde-8cd5-ac90a8761d21_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_65ab2f33-41d0-4108-b940-c5d1ac798ad9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9b11e07d-22b9-4e3c-98e5-932fe0a1ad7c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_3243ef8f-0b3f-44b1-a9e9-337c3d29b504_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20240930.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_71c987f4-b31b-4a63-a450-abac2bf279db_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_159a2d1c-eb88-4d7d-9506-44a02d42c6db_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_3cfcb26c-c58d-4559-ba57-220ca547099e_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20240930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BYOOVIZMember_66f90981-9025-4cf2-8b31-538170651985_terseLabel_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BYOOVIZ</link:label>
    <link:label id="lab_biib_BYOOVIZMember_label_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BYOOVIZ [Member]</link:label>
    <link:label id="lab_biib_BYOOVIZMember_documentation_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BYOOVIZ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember" xlink:href="biib-20240930.xsd#biib_BYOOVIZMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BYOOVIZMember" xlink:to="lab_biib_BYOOVIZMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_412bb9cd-0e6e-4e61-b1a1-598ee5793485_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1ed3d1ef-01c0-432c-96f4-eddee658b844_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_63dad6f0-aa2b-4088-b058-c00986045331_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_fe02f95b-1d68-4f8a-9815-63db772b7ef8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_45f61537-c054-442f-8d30-7b4c7f19ae39_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_1775c905-1fb3-45d3-8ded-a5796a54c081_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20240930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b4b44278-9d72-46e7-9e82-948b89b23d43_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07c91f1e-6522-4119-9558-2b35c806721c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_8137d8e2-6426-424d-9b1b-24e6e75016ee_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_3d6c56c7-ea53-440c-aed1-c286579abf61_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_e0067781-2aa1-4fc0-af99-4dc6d4ded560_verboseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_a709dc7c-f347-4b65-9b37-451fbeadfaf5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_c9183ca3-a88f-4dcd-9001-4d0d4b294759_terseLabel_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_label_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis, Sangamo, Denali and Sage [Member]</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_documentation_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember" xlink:href="biib-20240930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisSangamoDenaliAndSageMember" xlink:to="lab_biib_IonisSangamoDenaliAndSageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a2ca88a2-40cc-4699-8a8d-c07962f00ab5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_bbfd9111-5658-47a4-9dc0-f771750db6ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_db055a34-d606-4740-9d61-3f9223028048_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_141a2ea4-3ce1-486c-9946-00ae932edc98_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PriorityReviewVoucherMember_e0b76152-601f-463a-9628-73a62fe2c1e3_terseLabel_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Priority review voucher</link:label>
    <link:label id="lab_biib_PriorityReviewVoucherMember_label_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Priority Review Voucher [Member]</link:label>
    <link:label id="lab_biib_PriorityReviewVoucherMember_documentation_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Priority Review Voucher</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PriorityReviewVoucherMember" xlink:to="lab_biib_PriorityReviewVoucherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b26bbbe1-2533-4a0b-9bce-bbde5d1c35c9_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_157cf609-b82f-4a50-b2bc-1a0bd1a90e5e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (distribution) contribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_419d4dc4-4170-4369-8d00-8fc1d0450137_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a176ae9-d693-4a67-97b7-808a025d9bf1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c17b93cb-b8a2-441c-8588-ac317d0941da_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_25a4f666-71cf-4bba-a341-a9cf5495ebaa_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_4d021097-b60e-419b-93d5-880fd2b22081_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FelzartamabPMNMember_b20bc387-0d5d-4731-95ca-eb0dbe3fc5d9_terseLabel_en-US" xlink:label="lab_biib_FelzartamabPMNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Felzartamab (PMN)</link:label>
    <link:label id="lab_biib_FelzartamabPMNMember_label_en-US" xlink:label="lab_biib_FelzartamabPMNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Felzartamab (PMN) [Member]</link:label>
    <link:label id="lab_biib_FelzartamabPMNMember_documentation_en-US" xlink:label="lab_biib_FelzartamabPMNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Felzartamab (PMN)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabPMNMember" xlink:href="biib-20240930.xsd#biib_FelzartamabPMNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FelzartamabPMNMember" xlink:to="lab_biib_FelzartamabPMNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_cdfd57ee-2327-4e51-9797-5d915ce9bedf_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20240930.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_3d9f14a4-4282-4e65-8d20-f8c76aa4d2f2_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_58b5f865-ed54-45f7-87b5-b6d24a5ecab6_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_159fe2a5-2933-4bf1-9b73-b3ca174c3e73_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_7c2147a2-6fa3-4c3c-939e-343ec110d74e_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_36042e0c-de1e-462b-a38b-e9a8a0b6a74c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_0283b2b0-0700-44b7-b4a1-4efca1843e5c_terseLabel_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_label_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio Of Number Of Shares Reserved Under Plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_documentation_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio Of Number Of Shares Reserved Under Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:href="biib-20240930.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:to="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_f42d0f2e-6df8-46b7-9580-78c2ba479f34_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_4144e3c5-a745-4ecc-a1b2-298ef0c553c5_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_cee53378-cae4-49c7-b32f-6a0357132033_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_9b3fb17d-c965-4962-8068-6fefef75db66_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_b1ef35b0-3d55-4e98-8473-377b6455781d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7a538eda-b440-490f-b6e6-5e1b7278474e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ce105420-bc24-4596-8b81-f38dcfdc32ec_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_e14b4109-c263-4dff-9c20-eac273fb3f19_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bf4c14a7-d88e-4fce-bab6-beced99bf58b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_acc9fa28-1185-4ee8-87c0-b9b5c4f4d7cb_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_df38a9ef-6ec3-4b1e-8f10-cc065b88f4d4_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_5f5caa2e-c4e3-4d1b-8309-842d0e7d8f85_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_0dd579e0-d7fa-4135-8261-c4960a871a5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fc76b021-4769-41b3-8b80-d1d0e53afa37_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_beba0091-602f-4be0-ba4c-2704f89af488_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_810bf8c4-66ab-45bc-8e27-06817c7b9fde_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_280d3ef0-96f0-4fa8-98bb-e2b6e4f54efd_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20240930.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0442e464-adfd-4ad2-9c73-537738e247f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c4886703-fe73-4c00-ae32-a4081a6f8fa6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_9c17d7b2-cfb8-4aa2-8923-73173305f977_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_370f8d5a-f38d-4958-92a9-085f4efcda03_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20240930.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_7babd1be-a7d8-4c6d-a3e8-f1ebda1680ba_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityMember_9201efb2-6b23-4736-816d-1622b5438522_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Credit Facility</link:label>
    <link:label id="lab_biib_TheCreditFacilityMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityMember" xlink:to="lab_biib_TheCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_22bc8b0f-3f4a-424e-aae8-d6fa5e2b4ab6_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2278deee-72e5-4752-9940-4a074f37040f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_c50300b5-37d7-40e7-93b3-4b102fb586e0_terseLabel_en-US" xlink:label="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Current Portion Of Notes Payable And Term Loan</link:label>
    <link:label id="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_label_en-US" xlink:label="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Portion Of Notes Payable And Term Loan [Member]</link:label>
    <link:label id="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_documentation_en-US" xlink:label="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Portion Of Notes Payable And Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:href="biib-20240930.xsd#biib_NonCurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:to="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_956dda08-54e3-44d6-9e4d-77a19ef7a04b_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e9697d54-0724-4170-a5cb-803d807cb922_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_cae8cb6d-375e-47cc-8994-3e9eb143882f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_43af633b-d1ba-4ed4-96e6-02b19acaeed4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_8db3ddd0-b34b-47cb-a800-001b75913a82_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20240930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_3a937fa8-983f-4a31-bcba-664da17e7342_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_3f0ea5c2-f01b-417a-a9ad-6f9dc05454d5_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_55e1fc86-0bc8-48ed-9de6-6819068e5734_totalLabel_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_label_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:href="biib-20240930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:to="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c59ca3aa-326a-4827-a971-3f22bc023ed7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2e6f6f77-fc47-4661-be5d-b9c90715e76c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1d865563-36e0-471c-ade6-6b41ac9e50a2_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1ec8655b-4d4b-407f-b48b-01959bfdd234_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8a671c30-6aae-4130-8f6a-7574bf11ba02_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_9da5e478-33d6-4738-b0d8-d6805fe04c89_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_a8671017-8920-45ec-a8db-469d84c018b7_terseLabel_en-US" xlink:label="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock shares acquired</link:label>
    <link:label id="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_label_en-US" xlink:label="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Number of Common Stock Shares Acquired</link:label>
    <link:label id="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_documentation_en-US" xlink:label="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Number of Common Stock Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:href="biib-20240930.xsd#biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:to="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_b61d4f78-eefa-4b2e-89c7-2cef123045a8_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20240930.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_d85602e9-c6d3-4576-90c8-64d1f8c83cfb_terseLabel_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables to divestiture of interest in joint venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_documentation_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:href="biib-20240930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:to="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_79b5b0b6-ab54-46b5-8ad7-b89c9c94282b_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales to be achieved in any twelve consecutive months under option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:href="biib-20240930.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:to="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_084e69b6-94ec-4540-8bac-d53b3d18d931_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c1182c62-c56e-4e5a-b5f5-157001597481_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f8111b56-6873-4a02-9b8c-40540bdb035e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_6d75bf68-6fb0-471e-9afb-63099b8d116e_terseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:href="biib-20240930.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:to="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9e44cd91-bdda-49fb-8598-c28a52eaf161_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_f23c3fd8-0263-4c65-81f3-4e5314f2cd9a_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_e581de4f-62fe-45d8-8f5f-fcfe2af290bb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_23d94a5d-e8b7-413b-b1c9-0b9c6b8260fa_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Due At First Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:href="biib-20240930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:to="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0bd22380-1e8b-43f8-a9e7-eaf362d536f2_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_c5bd6258-88d7-47d1-a9a3-bf2dbf249469_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20240930.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_cfbd5ee6-a3d0-4559-9c01-d6dfe62a3516_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c6e85379-9ba2-4057-98ed-64960da6ec30_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9d2a26ec-1b4a-4c2b-94ae-607462e5a0e3_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_8b032e37-500d-4770-8de2-9541339096a1_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to the UCB collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to the UCB Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to the UCB Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:href="biib-20240930.xsd#biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CompletedTechnologyMember_44e30938-10f3-4f95-a148-e9358efe7d3a_terseLabel_en-US" xlink:label="lab_biib_CompletedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Completed Technology</link:label>
    <link:label id="lab_biib_CompletedTechnologyMember_label_en-US" xlink:label="lab_biib_CompletedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Completed Technology [Member]</link:label>
    <link:label id="lab_biib_CompletedTechnologyMember_documentation_en-US" xlink:label="lab_biib_CompletedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Completed Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CompletedTechnologyMember" xlink:href="biib-20240930.xsd#biib_CompletedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CompletedTechnologyMember" xlink:to="lab_biib_CompletedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_c0934505-5498-4477-b30d-8f3cf9e1acb1_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_76646825-3bee-4f0a-af6c-127a9d6dc437_terseLabel_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding equity awards</link:label>
    <link:label id="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_label_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross, Outstanding Equity Awards</link:label>
    <link:label id="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_documentation_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross, Outstanding Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:href="biib-20240930.xsd#biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:to="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5d4f1457-bbc8-42bb-ae56-3b8369de632a_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange (gains) losses, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_48009f1f-7106-476e-857e-e6046fcc6f71_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_6f68fe21-3db0-46ae-ab4e-f35167b248a3_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20240930.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b812cdc4-93fa-418c-85c4-f3ea6e668f10_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_fd282a40-ef87-4257-bb71-ea1d3b5504c4_terseLabel_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM And ADUHELM</link:label>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_label_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM And ADUHELM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM And ADUHELM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember" xlink:href="biib-20240930.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMAndADUHELMMember" xlink:to="lab_biib_FUMADERMAndADUHELMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_fa5f642d-9c47-4799-92dc-44f9ae593060_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_517dea29-ceb4-42f8-9e0f-9aef2fadbc3e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_fc844f26-fe38-4bd1-a126-717eaabfae69_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7ccad650-ed32-479f-98a2-bae52db14228_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of priority review voucher</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_df1207cb-3c30-4d63-8d5a-736dfffde553_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_1a33dff6-1a25-41ce-9e92-b8e615f31eca_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20240930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1b239e62-f3a0-46be-945f-dbb1d058ec05_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f1829374-e176-4b3e-a490-62c12b2205d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d3b8618e-e492-476b-ad3d-8351f475a389_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_8fb7945a-2d3e-4af4-b827-0a6e6d01127e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_b503a8dd-04c9-4d96-998a-969905af3a69_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_8337332e-2da4-43f7-9bb8-a630df87c738_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_a27756a7-c423-4109-bb59-9475bd9f55a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3c8905e5-55b8-43d1-9486-d413461fff3c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_231f850c-87ed-4643-ac75-64aa07f891ac_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_46a9e0f3-1faf-4db4-8b88-10950b81678d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess and obsolescence charges related to inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_87211564-3dcb-43ef-8488-90745d68620c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flow provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_cbcbe1e6-599e-451e-ae99-1920601cd6e9_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReataIntegrationMember_0c292e78-0858-4807-8f75-ea90a2ae5153_terseLabel_en-US" xlink:label="lab_biib_ReataIntegrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reata Integration</link:label>
    <link:label id="lab_biib_ReataIntegrationMember_label_en-US" xlink:label="lab_biib_ReataIntegrationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reata Integration [Member]</link:label>
    <link:label id="lab_biib_ReataIntegrationMember_documentation_en-US" xlink:label="lab_biib_ReataIntegrationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reata Integration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember" xlink:href="biib-20240930.xsd#biib_ReataIntegrationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReataIntegrationMember" xlink:to="lab_biib_ReataIntegrationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_4bade6e6-b55a-4575-b0b9-3ba2f403520e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3734b536-3d58-4a52-b231-cec2f7986c6d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_19911155-d88e-4c1a-939f-2264ab621076_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from divestiture of interest in joint venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_64197dfd-27b2-42fc-8f21-ba862f0b3270_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_dcd7af57-d886-4d63-999b-b66e06c80152_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c478179c-d54a-473f-ba62-de663a6da207_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_220c3fca-9513-4620-b7b9-1d55a9f5b71a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_1e0777ba-8b33-4939-bf36-757e0242847a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a5aac70e-e3f5-4df7-84c7-8c0d858a6938_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_32f33cfb-4e09-4c5c-8982-abc6573ee47e_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20240930.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_f5280e49-f06b-44fe-9007-08e2e87ed95c_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_89662dd0-0441-4bf1-b73f-a1c62a76bd03_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis" xlink:to="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_2e6c5d1e-1c14-49de-bb6d-4ee7bc6b25ab_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20240930.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_0d053384-fe47-4dc5-a778-aee2a297b9a3_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20240930.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FelzartamabAMRMember_71c0cdb1-6bde-4db7-b10b-10b786a7fbcf_terseLabel_en-US" xlink:label="lab_biib_FelzartamabAMRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Felzartamab (AMR)</link:label>
    <link:label id="lab_biib_FelzartamabAMRMember_label_en-US" xlink:label="lab_biib_FelzartamabAMRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Felzartamab (AMR) [Member]</link:label>
    <link:label id="lab_biib_FelzartamabAMRMember_documentation_en-US" xlink:label="lab_biib_FelzartamabAMRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Felzartamab (AMR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAMRMember" xlink:href="biib-20240930.xsd#biib_FelzartamabAMRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FelzartamabAMRMember" xlink:to="lab_biib_FelzartamabAMRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_30426064-f00e-4471-a11a-467d9ed6a6bb_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_93eef8dc-b4c6-4f0c-abd4-058491a4fff2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ef540bfe-c02d-45e0-8958-257adcc6b2b7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c50d2e51-90b4-44d6-a329-4d712e0586ef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ad964449-f9d2-4850-9780-070960f96db4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_b2e2f7a9-3e1a-4725-8bb9-b2795ca8fd15_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20240930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e2a7f601-159c-4887-8ab9-bf116feed274_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0886e9ef-ddab-4e98-aa02-df082566ccb5_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_4dbffeb8-3b76-4779-913b-4cbaa703755f_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20240930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentFutureDevelopmentMember_4b8e26fe-a2fe-4a50-9cb5-dd3f8684c5c2_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentFutureDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Future Development</link:label>
    <link:label id="lab_biib_MilestonePaymentFutureDevelopmentMember_label_en-US" xlink:label="lab_biib_MilestonePaymentFutureDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Future Development [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentFutureDevelopmentMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentFutureDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Future Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentFutureDevelopmentMember" xlink:href="biib-20240930.xsd#biib_MilestonePaymentFutureDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentFutureDevelopmentMember" xlink:to="lab_biib_MilestonePaymentFutureDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_1e703aab-59f5-4631-b179-e1dc708ce0d9_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20240930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_e59df1d4-fe66-473d-97eb-ee1b0d006d89_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_a377ed51-7e13-41c1-8cb1-356edd52c894_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20240930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ecd4a806-cbdd-4213-adef-4de413b8a656_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_ef92683e-4678-4f47-9525-3da670c77446_terseLabel_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_label_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_documentation_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:href="biib-20240930.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:to="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_fac91538-5b9a-45b6-babb-cae7cd8e33e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccountsPayableToCollaborator_edda70ed-dc39-4a19-8303-331040e9feb7_terseLabel_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts payable</link:label>
    <link:label id="lab_biib_AccountsPayableToCollaborator_label_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, To Collaborator</link:label>
    <link:label id="lab_biib_AccountsPayableToCollaborator_documentation_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, To Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator" xlink:href="biib-20240930.xsd#biib_AccountsPayableToCollaborator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccountsPayableToCollaborator" xlink:to="lab_biib_AccountsPayableToCollaborator" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_63cfd8c3-37d1-4301-9eab-8387e846a7e9_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_abf52941-5576-4f71-8e4f-f3940b05f87b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1f8d948f-c64c-4ee6-b09a-52adde51d42b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaS.A.Member_ed21b318-901d-4268-88a2-59932fa35430_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A.</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member" xlink:href="biib-20240930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member" xlink:to="lab_biib_UCBPharmaS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ae885a45-4585-4126-bc60-b6e7acb895da_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a073380f-318d-4d3e-b91e-cf7940d4e39a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_1e0b3d00-8cdd-4217-afc7-aece0a02dadf_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_424d02c9-cbb7-4f6e-962a-d941546e688a_terseLabel_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets, receivable</link:label>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_label_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current, Fair Value Disclosure,</link:label>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Assets, Current, Fair Value Disclosure,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure" xlink:href="biib-20240930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherAssetsCurrentFairValueDisclosure" xlink:to="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_d6909a65-791f-43a7-8818-f158ece285cf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_847ec305-54fb-49dd-84da-b75c74012035_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_5513ec08-3d45-45fe-a18c-8bb0b4a8605b_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_fac17afb-99b2-45b1-8efc-f15ca867271d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_3e192182-3a70-4f0b-b9df-2619c2d8e405_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_0b2b9e36-d5e9-4b50-9e2f-53057c7b974f_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_12e4aa65-8b41-49bf-b000-b685f6902a7a_terseLabel_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives</link:label>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_label_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives [Member]</link:label>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_documentation_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember" xlink:href="biib-20240930.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023And2022CostSavingInitiativesMember" xlink:to="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_b68c8f53-939a-449f-bb3d-b4a1c079e04c_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FloatingRate364DayTrancheMember_f1ac7301-05cd-4d91-af02-570d077d8a3c_terseLabel_en-US" xlink:label="lab_biib_FloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Floating Rate 364-Day Tranche</link:label>
    <link:label id="lab_biib_FloatingRate364DayTrancheMember_label_en-US" xlink:label="lab_biib_FloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Floating Rate 364-Day Tranche [Member]</link:label>
    <link:label id="lab_biib_FloatingRate364DayTrancheMember_documentation_en-US" xlink:label="lab_biib_FloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Floating Rate 364-Day Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FloatingRate364DayTrancheMember" xlink:href="biib-20240930.xsd#biib_FloatingRate364DayTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FloatingRate364DayTrancheMember" xlink:to="lab_biib_FloatingRate364DayTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2233b71e-b90d-45a0-9153-aa0f1620c475_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_a16eb174-f420-4821-9d0a-b31507022bd1_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_7bbf0b64-3794-426b-9942-0f2cadb154d0_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a22d0ac8-7058-48dd-8351-e0863fe6a777_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ae51ff3f-65ba-4602-b19b-493582b178d0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_bad9809d-6324-4ea3-8404-23086065915c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_1412eab1-6d15-4b5b-9e6f-b4e734e701cb_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember" xlink:href="biib-20240930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember" xlink:to="lab_biib_SolothurnSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_603216a2-b180-462b-86af-22620f6291ad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_ca6422c5-0e26-4205-b817-9ed7eeb6804e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_aa202ed5-4a1e-41da-ac0f-cce4b9e562e4_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20240930.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59bf6015-a3a3-43a8-8cf4-544f5dbb198c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MeasurementInputProbabilityRateMember_eb8e44d8-771d-4ba2-9461-25ccbd7d12ba_terseLabel_en-US" xlink:label="lab_biib_MeasurementInputProbabilityRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Rate</link:label>
    <link:label id="lab_biib_MeasurementInputProbabilityRateMember_label_en-US" xlink:label="lab_biib_MeasurementInputProbabilityRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Rate [Member]</link:label>
    <link:label id="lab_biib_MeasurementInputProbabilityRateMember_documentation_en-US" xlink:label="lab_biib_MeasurementInputProbabilityRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MeasurementInputProbabilityRateMember" xlink:href="biib-20240930.xsd#biib_MeasurementInputProbabilityRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MeasurementInputProbabilityRateMember" xlink:to="lab_biib_MeasurementInputProbabilityRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_bf9d4fe8-625e-4c51-a4e3-df5157d9be53_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, goodwill</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_label_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_documentation_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:to="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NotesPayableCurrentFairValueDisclosure_9cce023d-6b98-4376-924a-9c23b2746794_terseLabel_en-US" xlink:label="lab_biib_NotesPayableCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, current, fair value disclosure</link:label>
    <link:label id="lab_biib_NotesPayableCurrentFairValueDisclosure_label_en-US" xlink:label="lab_biib_NotesPayableCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current, Fair Value Disclosure</link:label>
    <link:label id="lab_biib_NotesPayableCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_NotesPayableCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Payable, Current, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NotesPayableCurrentFairValueDisclosure" xlink:href="biib-20240930.xsd#biib_NotesPayableCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableCurrentFairValueDisclosure" xlink:to="lab_biib_NotesPayableCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_86f58bb3-0136-4587-aa4d-58584cbdd8d2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net of effects of business acquired:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5d8b5661-290a-4842-b87a-918696b0dbdd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_372dcaf0-f202-457a-8e34-68d99c79abd6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_d1a9ee15-906e-4fdd-947f-eb7386f772f8_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ed1ff6c7-5e1b-4be4-8156-24d7e9707f87_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_442364a7-bfbf-4022-aa41-8758b934db44_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a20f6277-a9d7-4112-8ec2-096faaa69e4e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_9f733f5a-d74f-4a3f-ab03-465c98992ce7_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit sharing/(loss reimbursement)</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20240930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GAZYVAMember_448600cf-6694-467b-ae49-427309ffa307_terseLabel_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GAZYVA</link:label>
    <link:label id="lab_biib_GAZYVAMember_label_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:label id="lab_biib_GAZYVAMember_documentation_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember" xlink:href="biib-20240930.xsd#biib_GAZYVAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GAZYVAMember" xlink:to="lab_biib_GAZYVAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_485aa1bd-a016-4a36-b5a9-a02837e9c597_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets(1)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7442a0c-148f-4c25-8957-7816670c400e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2d158985-5092-4339-babb-4931fc50015f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_fa581e10-3dac-498e-b469-7c92ef1b4937_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_7bb3683c-d6ea-4e50-8249-9929146d4cf0_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherProductsMember_e2672f2f-01d8-4a5d-92cd-fd7ba5b606a6_terseLabel_en-US" xlink:label="lab_biib_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_biib_OtherProductsMember_label_en-US" xlink:label="lab_biib_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_biib_OtherProductsMember_documentation_en-US" xlink:label="lab_biib_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherProductsMember" xlink:href="biib-20240930.xsd#biib_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherProductsMember" xlink:to="lab_biib_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_189bc9ad-925b-44cd-9d07-7e4126e04f26_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_fcaa268d-75e7-4cc0-add4-674ef38baf38_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil tax assessment, including interest and penalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_7fb831f5-2455-4fa4-8568-e34bd6544192_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Due At Second Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:href="biib-20240930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:to="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_0db34fb0-095b-454f-bab2-588a7dbd96df_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b26d933b-74cc-48d1-9ee0-0cfa6e555d72_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_b1302c00-8cd6-40ac-bfe3-2e3262620038_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_ea500ceb-57b7-4cca-b579-661cb64f3d6f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_93dba7fb-49c6-45d8-b5fa-2c772a8accd5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated Depreciation and Other Costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringCosts" xlink:to="lab_us-gaap_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b3ac266d-1504-4e28-b90a-b5688372eab3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8a85f3ca-e310-4248-8718-46a1693f4456_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_7cc19f13-6e46-40cf-a303-b7637fbcc9d7_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20240930.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_2bbc9fc4-3945-42ec-b393-a400c2e3c86f_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_83c169c4-c4cf-412b-aacb-721ebe70ce01_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20240930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_81729189-bce1-4db7-8bf4-40cad70a7531_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_be2fefb3-fb21-4847-8223-9af23c16dbbf_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_bcf4cd33-08aa-42c7-b217-d25c8eb09c66_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_3976e9bd-b132-433c-a37c-8b805e866984_terseLabel_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember" xlink:href="biib-20240930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2020ShareRepurchaseProgramMember" xlink:to="lab_biib_A2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4fcccadd-b7b1-4dc3-8b15-c4f3400e8350_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e9056cd5-6fc0-41c9-ae93-4c9cdafd1d5d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ce0ddd12-7d63-4da0-9b95-0a5545d8bcaa_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_c40481ea-82dd-43e2-a967-b9c0d4303dfb_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_56e90407-48af-4711-8c04-6cc380f903f9_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_34419178-e416-4d27-aa20-722775473a2d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedges, Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsMadeToTerminationAgreement_92150253-6da3-47c6-9240-c9899f7cc8c2_terseLabel_en-US" xlink:label="lab_biib_PaymentsMadeToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments Made To Termination Agreement</link:label>
    <link:label id="lab_biib_PaymentsMadeToTerminationAgreement_label_en-US" xlink:label="lab_biib_PaymentsMadeToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Made To Termination Agreement</link:label>
    <link:label id="lab_biib_PaymentsMadeToTerminationAgreement_documentation_en-US" xlink:label="lab_biib_PaymentsMadeToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Made To Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsMadeToTerminationAgreement" xlink:href="biib-20240930.xsd#biib_PaymentsMadeToTerminationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsMadeToTerminationAgreement" xlink:to="lab_biib_PaymentsMadeToTerminationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_650138f9-13c4-46fd-b17f-f2cfde2f937d_terseLabel_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pretax profit sharing formula</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_label_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_documentation_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:href="biib-20240930.xsd#biib_PretaxProfitSharingFormulaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:to="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_da3413aa-d888-4761-bf8a-f4922d6f6b5b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_b8fc12fa-9b36-44e2-a088-a8ca6110e771_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RituxanMember_372a58b0-fd2a-4504-82a8-273cf3f43fff_terseLabel_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RITUXAN</link:label>
    <link:label id="lab_biib_RituxanMember_label_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RITUXAN [Member]</link:label>
    <link:label id="lab_biib_RituxanMember_documentation_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember" xlink:href="biib-20240930.xsd#biib_RituxanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RituxanMember" xlink:to="lab_biib_RituxanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_6d79a3df-fe5d-4bf9-ab1f-03ec6689c7a7_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20240930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_1b04e7d6-8748-4f9a-a44d-dded0d60d2fa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_81883936-3902-486c-b6b6-3d5685b2e4ca_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c7389049-af17-40b0-8a93-22d1c4e4c8f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_d62ceb06-191b-473c-969d-31bdb4a7fcb8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Recognized Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d7bca65d-a77e-4cd4-aecb-85e3e1bba1aa_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_8e9a108d-92c0-40c1-b6ea-c58aba3097d9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_34817147-4c8e-42a3-aef3-0b2a5021e693_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_a5a0f8d4-34ec-4431-ba12-979542b09b9d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7bd498ca-ca17-4b35-9140-8aefacc5d469_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_e6e4cc57-1231-4a33-8fb8-cd96123cc5b2_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5ceef968-d5b2-4fb7-a203-7200bbd26848_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b479b196-cc95-45a2-a6a3-bac6d68bffbb_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (gains) losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_53b1158b-2166-432c-89aa-baba2840554a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember_0f30e89e-841b-43dd-b840-fe038241ebf2_terseLabel_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab Two</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember_label_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab Two [Member]</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember_documentation_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:href="biib-20240930.xsd#biib_Phase3ClinicalTrialFelzartamabTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:to="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cd147ee4-e5c3-48e0-b1cb-a461ade902fb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_fd9b4cd4-73cc-4f73-9ca8-96ec48c58c04_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_048924d1-ecef-45d4-a089-70fbc5fe858e_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20240930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0aff9648-d985-494f-94d6-e091c4a01c28_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of priority review voucher, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_f956f948-68c8-4576-af21-70a2c35c831a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_ee2607c7-559c-4f40-a7a7-678045fbdf12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ab49137b-8a26-4240-ba39-7a2ef5597b95_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_496d98ff-34ff-42c8-bf46-88aacaac0119_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_06262339-31f4-4702-8516-f1e41fe4fa24_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_81dc6fbc-60ef-4b43-8f72-34e4175ff193_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_21ec07d0-fe9c-43d9-bd59-e04d631e6e10_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20240930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b10a53c6-ecf0-42c2-a02a-a5924b6c2fe9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember_3c634531-59b9-44ce-848e-951a2d34eeaf_terseLabel_en-US" xlink:label="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember_label_en-US" xlink:label="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired And In Licensed Rights And Patents [Member]</link:label>
    <link:label id="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember_documentation_en-US" xlink:label="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired And In Licensed Rights And Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:href="biib-20240930.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:to="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_28eae8e0-d046-428e-a333-00c1d06a11e1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Integration related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_09c75f40-6c19-473f-b604-89c7fb739482_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Operating [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_6f4165e0-80ea-4397-bddd-745d83521c7a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_800a9e68-ac78-400f-b54b-703558e0c297_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a362df5d-8917-4376-8c60-0be1ff59eb6b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_0052ff6a-a4ce-4183-a36f-d7810b772b23_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_ada4aae2-b658-43b9-b7d1-0c417a761f1b_terseLabel_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-vested equity awards</link:label>
    <link:label id="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_label_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Gross, Non-Vested Equity Awards</link:label>
    <link:label id="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_documentation_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Gross, Non-Vested Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:href="biib-20240930.xsd#biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:to="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettlementLiabilitiesCurrent_dc7a8d67-2421-44bb-b7a8-1fd42ccaa89a_terseLabel_en-US" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reata related accrued expense</link:label>
    <link:label id="lab_us-gaap_SettlementLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:to="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_9066e252-89b7-4d7c-9b8c-e79813e1c6aa_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_70b253ed-8f7a-4f70-91b7-bff37441a5a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_a95b5778-cec3-46a3-9e66-6c311c4bc65c_terseLabel_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_label_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_documentation_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement" xlink:href="biib-20240930.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodOfCollaborationAgreement" xlink:to="lab_biib_PeriodOfCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_bdec117d-2a66-4afa-9088-59c2796f641d_terseLabel_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_label_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_documentation_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold" xlink:href="biib-20240930.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SalesTriggerGrossSalesThreshold" xlink:to="lab_biib_SalesTriggerGrossSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_2f23400d-68a5-4ebd-b0ac-a770e118f4d7_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20240930.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_37e8a2f4-f7c6-4698-b4de-959aae1d7ead_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2719b558-6388-4640-bc71-dc6f2fa0d805_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1f2b11be-ca5d-4d62-bc6c-b9434a935e8a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_1f687025-6c45-4e21-9790-8f399d12a558_terseLabel_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences Pre-Existing In License Commitments</link:label>
    <link:label id="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_label_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences Pre-Existing In License Commitments [Member]</link:label>
    <link:label id="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_documentation_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences Pre-Existing In License Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:to="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a9b8a596-29d8-497d-9d89-1d92e78f82d6_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_2f6c21b6-4363-4b83-a569-0c79f8659036_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1d0791c7-8999-435a-9eaf-e9a8bd4e886c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_812247e8-cc13-42d2-81dd-adda3815d688_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_24c152a1-9c45-48f7-b707-7091436d90cf_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments, contingencies and guarantees</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_41c30cb9-ad40-476c-8c1c-1934a264350a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c7626296-440f-463c-af5d-0dada08749ea_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b3aa178-0b0c-4bcc-abc4-c5d4cadc32d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_612f2942-430c-4de2-bdab-4793df123f5a_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20240930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_94980361-22b8-4c5d-8f37-8db9fe388eb5_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_97735eb0-824e-414a-9ae3-f812b10a2afa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0ad219b6-9bb1-44b3-90f6-3b115c4269fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_727a1403-e487-4194-be28-061ffe12a230_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e6a51475-ee3f-4b72-9027-902be0af7882_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_196fcc8e-5ff3-4147-9ccc-5309b68b8248_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_4562c681-caa5-416d-87be-87ce3951e23c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_03e43435-eaa3-417d-8446-63bec55c3baf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_741806c2-a4a2-46ef-b665-2139fa26b11f_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20240930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_41d9f33e-c90f-44b0-b5f5-2e935a3a0cb0_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20240930.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OmnibusEquityPlan2024Member_c13d0c08-ab96-499e-aedc-7614ad9b7841_terseLabel_en-US" xlink:label="lab_biib_OmnibusEquityPlan2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omnibus Equity Plan 2024</link:label>
    <link:label id="lab_biib_OmnibusEquityPlan2024Member_label_en-US" xlink:label="lab_biib_OmnibusEquityPlan2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omnibus Equity Plan 2024 [Member]</link:label>
    <link:label id="lab_biib_OmnibusEquityPlan2024Member_documentation_en-US" xlink:label="lab_biib_OmnibusEquityPlan2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omnibus Equity Plan 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OmnibusEquityPlan2024Member" xlink:href="biib-20240930.xsd#biib_OmnibusEquityPlan2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OmnibusEquityPlan2024Member" xlink:to="lab_biib_OmnibusEquityPlan2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_abe1f6dd-d20b-4323-94d1-c877a3f3b281_terseLabel_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract manufacturing revenue</link:label>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_label_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract manufacturing and other revenue [Member]</link:label>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_documentation_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember" xlink:href="biib-20240930.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractManufacturingAndOtherRevenueMember" xlink:to="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2249915b-3235-4511-86a5-16d7d0932eaf_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_176fe471-83df-498d-b6cf-5b148a4a4cce_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_f5e0bbb9-e71b-4b98-a1b0-5038cacbb87b_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_7250eba1-b0d8-4cd0-aff6-ac1549005054_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_471a5042-86f8-43fa-910d-683a5836f570_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_deab99cb-5afb-4e6f-921f-544c4c46393b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAdjustment_616b6514-2538-447e-a785-3df3084a533c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency and other adjustments</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAdjustment_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveTranslationAdjustment" xlink:to="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44f0ca30-b696-45b9-ba48-28a6ba865514_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_1085f5a5-986d-4bc8-9675-f5f6e4546c2d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9e602e87-0ef5-4ca3-b7f0-629dbcab7ba3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_7bc951ad-3f84-4291-a956-9bfd57977d6a_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:to="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_29f32d83-1b17-45f9-9896-9ae340ecae62_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_0cd0ac95-2aa0-4047-b7cf-801301213962_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_674e0a5f-00df-4ee9-8905-94906fdaf757_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_d05692fa-df15-4845-af20-eccf88206e2b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_f9ecf5ca-2ab1-43f2-b180-f6a64ba69cac_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation, gain (loss), amount</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_deb3b648-50b8-4de3-8bf0-335ef4cd0eaa_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_label_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_documentation_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:href="biib-20240930.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:to="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_596af579-a06b-471d-991b-10153bc6b576_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_fd759b77-85e8-461e-a2d5-274c94d867e6_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20240930.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_46bf47ef-b415-4093-854c-225fb68d760b_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_3e778e30-be02-4fdf-9e22-8c9b337ba48f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_43ded495-100b-4bcd-8262-9e5c4b890798_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_cafd35c1-d3d3-4295-9988-5bcfc9929915_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities:</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:to="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b16a0a93-996d-427b-9bbf-d6d9a19b3f7c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_ac0473bf-e3bf-40b8-a065-a208b7b26963_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9abbc10a-9851-4278-b66b-eecdd61e7477_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7f62ad2a-cef6-4e06-9da9-8abfed444f7f_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ca33e8e9-9387-4505-9b80-5bd3243cc77e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_28bf8317-ab02-4f93-8df1-2ac4ff2b0c70_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0b448f0a-d4bb-4fcc-962a-273d0941759d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b0a8dab0-b4b3-481a-b568-cba34a5af46f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_26655e63-8d89-4c91-8c23-dc5348286124_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_5fa7a9e7-ff63-44c8-aa2e-5760e99e1acf_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_9f470581-af09-45a7-85f9-cc3e2f6f6419_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:href="biib-20240930.xsd#biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_c8e63c5f-7fbc-4ba1-98fe-d0dcb904c237_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb5c3f19-cf3d-43cf-ae7d-ad0fe19d6849_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_248b3a32-cca6-4e80-9b7f-050546cb57ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_caa54de9-9491-4d3e-80b1-0de633d79658_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_60ba6817-09aa-4ea4-a36f-80a9a17cb6bc_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_fcb4aa0b-1ff7-422f-ba00-9eed368eb862_terseLabel_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reata Pharmaceuticals, Inc</link:label>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_label_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reata Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reata Pharmaceuticals, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReataPharmaceuticalsIncMember" xlink:to="lab_biib_ReataPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_d4f0a372-c001-4294-b124-60d4ab711b90_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_324549c3-6cde-4b4b-abf7-cd3d6d1ee96b_verboseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_3b26896e-7b37-44fe-b5f6-72517db9321c_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_e9a9f917-5347-4f47-9677-7bf69d4c9432_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill resulting from acquisition</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_842ccbb1-fc0d-44bd-805a-572dcca753b1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_334510e5-3bd2-4b6e-b013-e8aa51f9a4db_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_cae656b7-4615-4d69-827b-69209de6cea4_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Credit Facility, Terminated</link:label>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility, Terminated [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Credit Facility, Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityTerminatedMember" xlink:to="lab_biib_TheCreditFacilityTerminatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_b525f593-983c-45bc-8084-2834d7eaa1c9_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion notes payable and term loan</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0617ccdd-123e-4e21-ba2d-65821da3af72_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_8d0a5909-f61e-424e-a894-df69ac8cfa3d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZURZUVAEMember_f193f9a8-3cc4-42e2-9818-89d2c4bb51ab_terseLabel_en-US" xlink:label="lab_biib_ZURZUVAEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZURZUVAE</link:label>
    <link:label id="lab_biib_ZURZUVAEMember_label_en-US" xlink:label="lab_biib_ZURZUVAEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZURZUVAE [Member]</link:label>
    <link:label id="lab_biib_ZURZUVAEMember_documentation_en-US" xlink:label="lab_biib_ZURZUVAEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZURZUVAE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZURZUVAEMember" xlink:href="biib-20240930.xsd#biib_ZURZUVAEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZURZUVAEMember" xlink:to="lab_biib_ZURZUVAEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9e7c4e10-b419-4c0a-b8ea-ecf87301ce45_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_200542a3-7233-4848-be8c-686533c3a483_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20240930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d735f43d-ac4a-4f6a-8301-4b1578a45f1d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_3bef634e-b19f-4422-88d9-b0df084f6693_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_27c124df-d7e0-4470-824b-0bc0d050f563_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_a39e4950-70fd-4478-88ab-2193ec08c2d1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_de722724-3aa6-40e1-a604-daf75689c896_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued expense and other(1)</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_36f8bb71-fb6e-4c57-97a1-b14e4e01dce5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_3d07316f-9ad0-4d42-9829-91ec1fc4ac4f_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20240930.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_26848471-3568-4bc9-9e11-f67a5a604057_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_122f55e1-b59c-4825-a50c-e03cdc6658df_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20240930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_abace87d-be0c-423d-86a8-ddeee6261364_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8ce70657-622c-4963-9c69-ae651e86d41e_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_20f7c508-338b-4f1c-8d90-b9692dfcbc76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c73da169-fadd-485d-958b-1c597479ec15_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_6cf236cd-62e0-467f-aaa7-b549cade211a_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_0b38f4af-cd7e-4436-8b59-a8b86aa0e076_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_45cfa913-23c6-453d-91b7-3c21f9a273e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4b3e655e-9851-43d5-9469-3cf49e503850_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b972566e-49fa-448f-934e-687569caa876_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7e177d69-5cb0-4f0b-a731-2f0d64d7ad91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_fa3bbde7-800f-4086-9090-a65bdbd6b073_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_500ba0fc-7b43-4351-9d5f-f0c84e0a5e0d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_91910585-fa0d-45f1-98a8-bc12a52aa2f4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract manufacturing, royalty and other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_eb508292-66f4-4228-91f2-b568bf6654b9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_c010a5cb-97ec-4e0f-aa77-bf2c8c1e3af0_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_e5ef3246-d92a-4824-b62f-59e1f50fa48e_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain" xlink:to="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7ab7d962-35a3-4ca1-8a42-4337ba033b80_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5468809f-f744-4e7d-bf07-e2858eff3a6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8d3e5d14-2387-48b4-9f86-679869cc1d82_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_259b10c8-80e5-40f7-854b-1c31dba59d47_terseLabel_en-US" xlink:label="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average remaining useful life</link:label>
    <link:label id="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_label_en-US" xlink:label="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life</link:label>
    <link:label id="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_documentation_en-US" xlink:label="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:href="biib-20240930.xsd#biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:to="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_72876eea-0648-456e-b03e-f67cd972065c_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f027ad28-330c-464b-8480-48f98627c6f3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5879a833-86be-49d4-9901-cb587b5169c0_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_39e8c04b-83ea-4017-832b-a9f23ad28c13_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_475d8864-b73f-4c09-b6b1-fa8929c4d7cd_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20240930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_48a5586a-7c36-4742-9a33-95750eec14ec_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c415db4d-8f57-4b06-887d-69a4c7d0668e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_72e147fc-48ad-4619-831e-d2726f193ebc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_a9edde44-30a9-4be9-b261-13120d274d92_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2cf3d0d4-8e61-402c-a514-6d59a54ff31b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_686c7f5c-1ffb-4d5d-8397-d8e77f4cd62b_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expense</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_cdf3ae69-3f4b-4b00-b162-a7e1565e371a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_9ab9324e-1466-4a14-9493-2dff27284f14_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SKYCLARYSMember_2b0cb2ff-69ff-4bb8-8bcf-4462dd6749b6_terseLabel_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Completed technology for SKYCLARYS (U.S.)</link:label>
    <link:label id="lab_biib_SKYCLARYSMember_label_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SKYCLARYS [Member]</link:label>
    <link:label id="lab_biib_SKYCLARYSMember_documentation_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SKYCLARYS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SKYCLARYSMember" xlink:to="lab_biib_SKYCLARYSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_104e4f0d-e35c-427b-a5dc-a7116c4ba7dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9bbb0955-4c28-4369-98de-7dd9b3977938_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_946a179b-e598-4040-bdc7-76998fa8ffd2_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_61630808-ea39-40ca-a283-aa57de1a7eb1_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductioninroyaltyrate_902378f2-b82d-4949-8ed9-e54808d9f6b4_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_label_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate" xlink:href="biib-20240930.xsd#biib_Reductioninroyaltyrate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyrate" xlink:to="lab_biib_Reductioninroyaltyrate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_911376f7-35d4-4dd4-b605-635b9b07b558_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_bc89d8c2-e0a8-47e0-b6e3-43eb6d818c8a_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20240930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_e0e0281e-213d-4193-af38-32a36486a241_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c01e6415-81d1-4ff1-934a-5ef9ea5bb667_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5611c3a4-c400-4b6d-a8c7-17cab059b13b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_6a3c9641-a5ea-4d87-bff8-a71d5ad80736_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_372c4de9-4bde-488f-a274-8182cc65a651_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bfb0b90a-b1cc-4724-bbe9-44278005c54f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b163e495-9f1e-4c80-a19f-baabc96cddcd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LenderDisputeMember_0017abc2-60e0-41ba-b647-ee8435a1f225_terseLabel_en-US" xlink:label="lab_biib_LenderDisputeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Dispute</link:label>
    <link:label id="lab_biib_LenderDisputeMember_label_en-US" xlink:label="lab_biib_LenderDisputeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Dispute [Member]</link:label>
    <link:label id="lab_biib_LenderDisputeMember_documentation_en-US" xlink:label="lab_biib_LenderDisputeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lender Dispute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember" xlink:href="biib-20240930.xsd#biib_LenderDisputeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LenderDisputeMember" xlink:to="lab_biib_LenderDisputeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_e9ea3b0a-3814-41b6-9112-01bc20f9d911_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_f40c1ec6-548e-433c-a901-0a5334546698_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_label_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_documentation_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:to="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b471d333-fd39-4a9c-bbd9-7ca77519e4d1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e44748a-4dfa-4660-8c68-38b6d992cc7f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddbc6cb6-dd6e-4fea-b401-174d4de64202_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_0b8a2efa-2073-467a-8554-34bf0c8a4747_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_296b1ac9-9057-473a-b8f1-efb9ef57d078_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FelzartamabIgANMember_0bd4144a-f9f9-4ee2-bc08-26526062ccf3_terseLabel_en-US" xlink:label="lab_biib_FelzartamabIgANMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Felzartamab (IgAN)</link:label>
    <link:label id="lab_biib_FelzartamabIgANMember_label_en-US" xlink:label="lab_biib_FelzartamabIgANMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Felzartamab (IgAN) [Member]</link:label>
    <link:label id="lab_biib_FelzartamabIgANMember_documentation_en-US" xlink:label="lab_biib_FelzartamabIgANMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Felzartamab (IgAN)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabIgANMember" xlink:href="biib-20240930.xsd#biib_FelzartamabIgANMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FelzartamabIgANMember" xlink:to="lab_biib_FelzartamabIgANMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_92ed156d-d815-4f77-9833-667eef8e476d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_9a421aa7-d546-4651-89bb-420bbb104b20_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_cf163338-55ff-4298-a03a-4502891438a6_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5063c569-6feb-40cd-9d37-53f7b712624c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_fa00491b-f543-40dc-b988-22297cf1117e_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20240930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_b90b141e-6ecc-40f0-9662-a50f659bd82d_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_05f56bf4-4749-4b79-bd27-515ae92c17ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_d6cfd3cd-72f4-46f8-b5ce-f9a3674ef798_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20240930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_fee66182-2443-4135-8b08-8197049fade4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2c83b71a-0bcb-4471-8206-6f31a9630f77_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentRegulatoryMember_d5a42b4f-12e3-4135-bcb3-2e2b0ced3929_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Regulatory</link:label>
    <link:label id="lab_biib_MilestonePaymentRegulatoryMember_label_en-US" xlink:label="lab_biib_MilestonePaymentRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Regulatory [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentRegulatoryMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentRegulatoryMember" xlink:href="biib-20240930.xsd#biib_MilestonePaymentRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentRegulatoryMember" xlink:to="lab_biib_MilestonePaymentRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_2fa681ed-f05c-4809-980b-5a1797b3f889_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20240930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_c9c74114-ec8c-457d-89fa-47a2b59cbe69_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20240930.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_76442196-159f-46d4-824b-130e9937afb7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_efd0f8db-5961-4c60-a2e7-59bdf2ead7bc_terseLabel_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets discount rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Indefinite Lived Intangible Assets Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Indefinite Lived Intangible Assets Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:href="biib-20240930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:to="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_631dbd2b-ba2a-405d-a62f-7eabd132e120_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense asset acquired</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_95fa1dfd-68f2-464c-a635-bbdc5bbc292c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_42ddcc7e-59ba-4c0a-bf72-0697a8a70fbf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gains) losses on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_30a07fed-2899-44f7-8aa5-cce2e7e9556b_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected profit share percentage</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:href="biib-20240930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_ce4832b8-7f0f-4ea3-84d2-e9e1a17e141d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of intangible assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0da30f5-bdd3-4ebe-9119-9c040767606a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccruedPaymentToTerminationAgreement_bf897719-a788-41ae-9cc4-c47edc4c138f_terseLabel_en-US" xlink:label="lab_biib_AccruedPaymentToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable Due To Termination Agreement</link:label>
    <link:label id="lab_biib_AccruedPaymentToTerminationAgreement_label_en-US" xlink:label="lab_biib_AccruedPaymentToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Payment To Termination Agreement</link:label>
    <link:label id="lab_biib_AccruedPaymentToTerminationAgreement_documentation_en-US" xlink:label="lab_biib_AccruedPaymentToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Payment To Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedPaymentToTerminationAgreement" xlink:href="biib-20240930.xsd#biib_AccruedPaymentToTerminationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedPaymentToTerminationAgreement" xlink:to="lab_biib_AccruedPaymentToTerminationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0b48f860-f553-4957-831a-b65feca25923_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_ecbd6f20-624c-433e-911e-b9f7161c897e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bc4b18e7-d3f4-4878-b364-aa544ff172a8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_334ea927-0b75-4e70-90dc-ceb9658095f1_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20240930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DivestituresAbstract_e07d4806-4ce2-4024-909b-eb0dbf5eaf55_terseLabel_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_label_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract" xlink:href="biib-20240930.xsd#biib_DivestituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract" xlink:to="lab_biib_DivestituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b729a3f0-b888-4ae1-9fd1-6de9015a85f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_ebf3bc8b-bd8f-4ed7-8bc6-d8055567dd23_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8cd7ad2c-c958-4d73-999d-dbb35d5ad397_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentToInventoryMember_3c43a5a0-9aad-425a-ba15-3dbd0d68d403_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentToInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment to Inventory</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentToInventoryMember_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentToInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment to Inventory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentToInventoryMember" xlink:to="lab_us-gaap_FairValueAdjustmentToInventoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_8c3e0841-f353-4b84-a358-a6047bac697b_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_9614414c-74b2-433d-a191-ef67ff57b02f_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital adjustment</link:label>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_label_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Working Capital Adjustment</link:label>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:href="biib-20240930.xsd#biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:to="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ebafeb35-2626-4048-b516-934afc92bfb3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e2db6381-53ee-46b7-a8fa-acffaf9f0580_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_dce340db-9a40-4231-829a-6ed2ad5c56ca_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_51bec581-6f33-4dfc-8767-11472ee4d3a6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_498a9ae4-7ccb-4da3-83b3-52a46ac3518a_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20240930.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_99753592-95bd-44da-be1b-25c733fe87af_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_6aba9a24-2df6-4fe0-bb89-a4ed84a441aa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_1155b638-6b0b-4823-8123-b6bab2d5a12f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_537c5144-a689-4003-878f-fe69bca336e6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_dc9af5d8-cb82-48f4-82b8-89036e09c8fa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_7f4b995c-5b65-4a6a-abe3-e75392a53c3f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b68494c7-d6ad-4fab-a297-592c70da1cec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabOneMember_4e9dc49b-b2d4-4774-8ef0-bd10fda86aba_terseLabel_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab One</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabOneMember_label_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab One [Member]</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabOneMember_documentation_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:href="biib-20240930.xsd#biib_Phase3ClinicalTrialFelzartamabOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:to="lab_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_4c5c4d6d-2eb1-4de6-a804-054138f77f16_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:href="biib-20240930.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:to="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3a135ab5-9e59-49a8-af1b-d97fdf8c0b49_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_644a6e3a-1f92-4473-aefe-601c9abb2044_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_84608413-9730-4e49-994f-e74eb3ac9d9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9c6fe938-5ee5-4a57-a4b0-6755a7b4a162_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_00fd84aa-2f1d-4abd-86da-916d1145551e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $2.0 and $2.4, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3eee15aa-65ab-410d-aa2b-619153a5ef6c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_88a1d00d-4904-415d-ab65-37a6dffe16cd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ea4f6661-da07-4b88-b2f7-e43753b0371c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingLeaseArea_29bf936a-eebd-4839-9e30-17189196f11a_terseLabel_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease area</link:label>
    <link:label id="lab_biib_OperatingLeaseArea_label_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Area</link:label>
    <link:label id="lab_biib_OperatingLeaseArea_documentation_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea" xlink:href="biib-20240930.xsd#biib_OperatingLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingLeaseArea" xlink:to="lab_biib_OperatingLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_c690b442-0ba2-4c8f-ba6a-46024a318130_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20240930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_b69795f5-c18f-4f14-b651-98dc28750cb3_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_HumanImmunologyBiosciencesMember_1c9bdb6c-06bd-4d29-9845-54805633a818_terseLabel_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences</link:label>
    <link:label id="lab_biib_HumanImmunologyBiosciencesMember_label_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences [Member]</link:label>
    <link:label id="lab_biib_HumanImmunologyBiosciencesMember_documentation_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HumanImmunologyBiosciencesMember" xlink:to="lab_biib_HumanImmunologyBiosciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_843c986b-78ec-4522-af77-6003f6756f21_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_3ba60b4c-8877-42e9-9be5-6051a680bd26_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility Floating Rate 364-Day Tranche</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate 364-Day Tranche [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility Floating Rate 364-Day Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:to="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_f7a5b6ad-00a7-4854-92a2-0e9b3851f3d2_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20240930.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_0e17a9f6-88a7-4eba-a853-bb7c8bac77de_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_ed1bb05d-c8c1-4c91-a6d0-9bb10efa0f95_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1e53cdec-fd98-473c-8387-e42efc61dd05_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_fb94dd8e-735c-42c9-8487-1bd8bf2d7c78_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_00ff1397-e160-4e89-b10b-83c1b2dde464_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20240930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_13e583b4-47d1-4c27-bd79-f1b8f9cb42ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_20e470e9-e6b5-4a10-adf6-0f126863d406_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2eab15c7-1577-40ae-937a-52e5f26295d4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_574cffb8-8c9c-4aeb-ab83-fefb06b06356_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_8b17d8ec-5c2b-45de-88c0-b6f11f19df1a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_a98ec1b5-ec21-46bc-9878-bf6aa25fdc02_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_88dc0f9c-5335-4126-b8b0-29173f006c99_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_b10e0df1-e170-4b6d-ae36-85bb1168e04e_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20240930.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aa978fb-e6da-4f95-965a-a6b2faa12a46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ba59c972-b03e-46f6-a927-2247dc915d1e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_5b8f4916-6bde-4764-9911-70e77745d421_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_47cbad99-c4f3-4af9-bf3b-d5030332b8ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_49be4bc9-d3b9-4a39-b9d1-2b64e1112a3a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_95cf7f09-8721-4c57-a34c-f33c67e6ec51_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4457c6dc-a695-4d38-8881-40a6d7932c51_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b510d206-71a2-4921-ae48-731d923f54d0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_3e210f8e-84ab-43cf-8cb7-9c017f966fd1_terseLabel_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs</link:label>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_label_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Future Development Costs</link:label>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_documentation_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Future Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts" xlink:href="biib-20240930.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfFutureDevelopmentCosts" xlink:to="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OCREVUSMember_bf67d7e1-3736-4aed-b789-4d4768b5990a_terseLabel_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:label id="lab_biib_OCREVUSMember_label_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCREVUS [Member]</link:label>
    <link:label id="lab_biib_OCREVUSMember_documentation_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember" xlink:href="biib-20240930.xsd#biib_OCREVUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OCREVUSMember" xlink:to="lab_biib_OCREVUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_087b4815-f61f-483d-8b52-0b932ec2e4bd_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_259e7977-b469-4cda-8048-f0c9b66fb77a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_4d5da68e-4a0f-4c6a-bf1f-eee54675a979_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ad11f255-7b87-4dc0-a4f0-8900cf596528_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_745d8959-c410-4558-a7a6-aa629fdd3fab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a443d460-4db7-4a7d-b92e-e7787f131ab1_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a99b119a-a290-47fd-88e1-020964e5c0e0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7608bfdd-d76f-4f54-873a-402dda4cd10a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_e9fa92bf-91c1-4223-858f-17897a0ec84c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_1cd1ba59-f343-479e-ac61-c906af6fb3c1_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_5b6494c4-c062-470d-bbb1-858bb826721f_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20240930.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ab759c18-b553-408f-a066-f904327ac856_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_d1760e4f-14a9-45be-acde-ebff98e60bee_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_90b2bb12-0d38-4ba8-b40c-3df9e5a127cb_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_7a647986-a654-4dfe-8037-74103963d1c2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_e4a9fe60-4401-4931-9d6b-7fcc4aca09dc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring, Business Transformation and Other Cost Saving Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_89964e74-c402-47dd-a5f0-c39a95cbec65_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1c7d5160-320c-4925-aed3-ef726e69c75a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_e26730b6-1dea-4c3f-90f6-74409dbf9576_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_6583d58a-bf60-44d5-a727-cb6e6d4e2d5c_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8044610d-79d0-453c-b1ec-a6acb353bdce_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_d19b7fc6-0019-4d31-b8cb-4db6cb56cd7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration resulting from HI-Bio acquisition</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_44f9093d-9c57-4d5a-a40c-0b41f37fd6da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoMember_950e3e0e-0646-4862-b3f5-79fe10f45476_terseLabel_en-US" xlink:label="lab_biib_SangamoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sangamo</link:label>
    <link:label id="lab_biib_SangamoMember_label_en-US" xlink:label="lab_biib_SangamoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sangamo [Member]</link:label>
    <link:label id="lab_biib_SangamoMember_documentation_en-US" xlink:label="lab_biib_SangamoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sangamo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoMember" xlink:href="biib-20240930.xsd#biib_SangamoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoMember" xlink:to="lab_biib_SangamoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_85cb955c-9146-4ce9-b496-ddc959e6c214_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives" xlink:href="biib-20240930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainOnDerivatives" xlink:to="lab_biib_UnrealizedGainOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_69bb835d-9ae2-4582-aa07-ae4187ba178b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_94e6d8a9-809a-45a8-be7a-d5999ad98766_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_850b6ff3-7c66-4a8d-910f-0591525e1a36_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_24d65307-da44-40a6-a67b-e4bad3fbda72_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory amortization period</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GenentechMember_d7294863-0212-40c7-8dd8-706a6510ed40_terseLabel_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_GenentechMember_label_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech [Member]</link:label>
    <link:label id="lab_biib_GenentechMember_documentation_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember" xlink:href="biib-20240930.xsd#biib_GenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GenentechMember" xlink:to="lab_biib_GenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b8f91268-ac90-442e-bdb1-06fcc6a13a88_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_48a49fd5-7d0b-484d-b5e3-6d6f18e20ab2_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b66667ee-481c-4513-8130-190e601b563a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b1d9dd20-9c97-4b02-a809-4637b559ecfa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac07152a-5c1e-400f-82da-a8aed9ea3e30_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_ada0d090-2f40-4a17-8816-44dc82f8110d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_f6499859-11ac-46e6-b1d9-90deb68edac6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition cost expensed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ClinicalInventoryMember_574115f7-aa14-4c63-ab53-4dcfc69c279b_terseLabel_en-US" xlink:label="lab_biib_ClinicalInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Inventory</link:label>
    <link:label id="lab_biib_ClinicalInventoryMember_label_en-US" xlink:label="lab_biib_ClinicalInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Inventory [Member]</link:label>
    <link:label id="lab_biib_ClinicalInventoryMember_documentation_en-US" xlink:label="lab_biib_ClinicalInventoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember" xlink:href="biib-20240930.xsd#biib_ClinicalInventoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ClinicalInventoryMember" xlink:to="lab_biib_ClinicalInventoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_0519c8ae-2a10-4bd6-a72a-dba67aaad6f0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_341550e8-f351-422a-8d26-cbc8de7d92ea_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_1accdff6-085a-45e2-8ee0-fdf679dfef45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6c94214-f72e-44f4-a6c9-3e8a5a0329e8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_32113c13-ff84-4e93-8ad7-92cc6886a74f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_80e02f8a-c512-487a-8c2e-e9bb183f9a42_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20240930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets_67de95e6-5a82-4a67-a913-032c925347bc_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets_label_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets_documentation_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets" xlink:to="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8da537d1-f5ec-4d00-91fa-4a1d68c5cd77_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_fa88e47e-39ed-49db-a621-d9b87627163a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f199b033-271e-4323-b237-d621ec7a3fc2_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_363ce58e-16f1-4e09-8708-fe0dd3e84edb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_80149d07-a0ff-4afa-8013-f6f23167932f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_aa2a29c5-dafa-42ce-9938-c8703dc29cd0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b1e75d73-f73f-456b-8ffe-e15f48cd8397_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_5c585181-576f-4108-9592-185d77df0cfe_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9c286680-f670-44e9-84cb-08ffdb51126b_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_5f5133a7-683e-4c22-bfba-3e0a9120c1c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5df1ed7b-eb02-4dd3-9423-09895c5ebbf3_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_54ffcb80-21e4-4b36-a955-26b22920e7be_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_02009b5a-0aca-40d1-ae5a-cef4cb22b69c_terseLabel_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from noncontrolling interest</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_label_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_documentation_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution" xlink:href="biib-20240930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NoncontrollingInterestCapitalContribution" xlink:to="lab_biib_NoncontrollingInterestCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_af05f705-b842-4136-835f-21ede638b7e3_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20240930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_3204e72a-029e-4319-aa45-a5cc4423a950_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6e257168-1f2e-4364-adca-6c15f6e45d5a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_eb56b6fc-cfdc-4bcf-a7c8-9f904597bc9d_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_e5aa3345-0d20-4cd9-affd-fcc67cdf0091_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_fa88b637-c925-49a3-be57-b6567c4b0a98_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborativeArrangementTermExtension_b0c88ed3-22ae-44ae-90f5-a8e76622539d_terseLabel_en-US" xlink:label="lab_biib_CollaborativeArrangementTermExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborativeArrangementTermExtension_label_en-US" xlink:label="lab_biib_CollaborativeArrangementTermExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term Extension</link:label>
    <link:label id="lab_biib_CollaborativeArrangementTermExtension_documentation_en-US" xlink:label="lab_biib_CollaborativeArrangementTermExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementTermExtension" xlink:href="biib-20240930.xsd#biib_CollaborativeArrangementTermExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeArrangementTermExtension" xlink:to="lab_biib_CollaborativeArrangementTermExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_da0fb41e-8c4f-4358-8761-b08606fd4a81_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_6fd6d0fe-b4d9-4fdd-ad16-46acfab2d9f6_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.25% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20240930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_853d42a8-da81-4eff-b66c-8215a527657c_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_802a749f-9436-405d-98d4-0bdbb6f05862_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_9943b8a5-f0ed-4650-827e-26c6155a6ee5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ff7357f1-3e8c-4a27-93e5-353defb03957_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_16a89e48-bf2a-4da7-be07-3e80da94cdfd_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_cec3a427-6440-43c9-b242-3aacdc237394_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_aeb708c9-f0a8-4528-b87a-e87ced256e36_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Inc. shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_188b6ad1-b24c-44a6-9587-59907ef1d9ff_terseLabel_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Attributed To OCREVUS</link:label>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_label_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Attributed To OCREVUS [Member]</link:label>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_documentation_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Attributed To OCREVUS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember" xlink:href="biib-20240930.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyAttributedToOCREVUSMember" xlink:to="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_4bb342da-d9a6-4d27-a7fd-148d655bad11_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20240930.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_e9d10b25-3969-4179-b5c7-4da994bedbac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent payable to Blackstone</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2fb51315-51ca-4ac8-9470-9b1ca1411af7_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_78a0eee8-26ed-4d6e-a0a8-69f1ce40596c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_cc326fc2-4d53-47f7-8f58-325683edfb23_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_392b2359-1a11-4db7-bc4b-628172b79f71_negatedTerseLabel_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives" xlink:href="biib-20240930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedLossOnDerivatives" xlink:to="lab_biib_UnrealizedLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0d2e0b27-fe6a-4a66-a84f-f94bcf6388a5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_538ebb10-8a4d-482a-9506-7ad8fe8e12ce_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b7387eee-66c4-4e62-94d2-fda0d3702ddd_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_2fb01081-6bac-406d-a756-6eee538231bc_terseLabel_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of net profit from sage therapeutics, Percent</link:label>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_label_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Net Profit From Sage Therapeutics, Percent</link:label>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_documentation_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Of Net Profit From Sage Therapeutics, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:href="biib-20240930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:to="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherClinicalProgramsMember_da07576a-81ec-4301-ad79-14404bedb72f_terseLabel_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other clinical programs</link:label>
    <link:label id="lab_biib_OtherClinicalProgramsMember_label_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Clinical Programs [Member]</link:label>
    <link:label id="lab_biib_OtherClinicalProgramsMember_documentation_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Clinical Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember" xlink:href="biib-20240930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherClinicalProgramsMember" xlink:to="lab_biib_OtherClinicalProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_1440406c-f942-4a33-a06d-150b2b19eb33_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TermLoan2023ThreeYearTrancheMember_66e1aeba-aca3-410a-a551-39b860e5dfb9_terseLabel_en-US" xlink:label="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Term Loan Three-Year Tranche</link:label>
    <link:label id="lab_biib_TermLoan2023ThreeYearTrancheMember_label_en-US" xlink:label="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan 2023 Three-Year Tranche [Member]</link:label>
    <link:label id="lab_biib_TermLoan2023ThreeYearTrancheMember_documentation_en-US" xlink:label="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan 2023 Three-Year Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember" xlink:href="biib-20240930.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermLoan2023ThreeYearTrancheMember" xlink:to="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9e0bdbf6-1e31-4e6c-b3c6-2d066ea1e728_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2828e64c-cf06-4c97-98fa-ea4d549d9635_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20240930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_QALSODYMember_35e37c24-8a92-4262-ab4b-88b23f04e095_terseLabel_en-US" xlink:label="lab_biib_QALSODYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">QALSODY</link:label>
    <link:label id="lab_biib_QALSODYMember_label_en-US" xlink:label="lab_biib_QALSODYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">QALSODY [Member]</link:label>
    <link:label id="lab_biib_QALSODYMember_documentation_en-US" xlink:label="lab_biib_QALSODYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">QALSODY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_QALSODYMember" xlink:href="biib-20240930.xsd#biib_QALSODYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_QALSODYMember" xlink:to="lab_biib_QALSODYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_42c0f619-2d74-437d-abf1-a6282bc9d344_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0a14e47f-527e-4c57-9a09-ccdbce33ae57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f7d191e3-e0a8-4233-bacd-fd6d70b0b554_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_2a0d7cb8-f5c9-47b9-99a3-b2bb16100777_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20240930.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_38023462-e8a6-4c7c-a4ad-ea409fdc8f25_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_629f24c9-c702-4d77-b780-219ccb461171_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20240930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_1e84e38a-3d7d-4b9c-9ccd-8fb486ad90c3_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20240930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_da40a300-44b9-4346-b0d2-de265cb52c0f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_73320912-3b0a-4c42-bd67-402178fbc1e6_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_eedfe404-7298-4fa3-af01-93f0cbcee5a6_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, accrued expense and other</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_label_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expense And Other</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_documentation_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expense And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:to="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_749e5349-483e-426f-9633-4d11ac8e8c17_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_261448f4-378a-4b74-a9df-494404b6a43c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_36b2e74f-f061-4ceb-af8d-ef129c9ad92e_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_053c067c-dac4-465b-b135-4a0fa1f8eb25_terseLabel_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected operating expense reduction</link:label>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_label_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring And Related Activities, Expected Operating Expense Reduction</link:label>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_documentation_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring And Related Activities, Expected Operating Expense Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:href="biib-20240930.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:to="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_3604f0e8-8aee-4556-8bbe-1d2da5689c7c_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20240930.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c930f012-e0b1-4f22-a255-0d5565c39e7c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a1d01343-b125-4d2b-add7-b3ec48bc76cd_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c1e4772d-5c9b-48a9-b82d-8708e81fb4de_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_5671ed56-7632-4db3-b114-f4468aae0439_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_085eac87-a5c8-4d0c-9cec-6366c5f9221b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_e9e853f4-a907-4732-b992-1efaa31ed9fe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LEQEMBICollaborationMember_ae03a61a-14aa-4281-bc42-967c454ea266_terseLabel_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEQEMBI Collaboration</link:label>
    <link:label id="lab_biib_LEQEMBICollaborationMember_label_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LEQEMBI Collaboration [Member]</link:label>
    <link:label id="lab_biib_LEQEMBICollaborationMember_documentation_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LEQEMBI Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember" xlink:href="biib-20240930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LEQEMBICollaborationMember" xlink:to="lab_biib_LEQEMBICollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AVONEXMember_7d57271b-99a8-4552-ac49-4d3de1474e76_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_label_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_documentation_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember" xlink:href="biib-20240930.xsd#biib_AVONEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember" xlink:to="lab_biib_AVONEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VUMERITYMember_1990e893-96a0-4baf-a920-a07a710033bd_terseLabel_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VUMERITY</link:label>
    <link:label id="lab_biib_VUMERITYMember_label_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VUMERITY [Member]</link:label>
    <link:label id="lab_biib_VUMERITYMember_documentation_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VUMERITY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember" xlink:href="biib-20240930.xsd#biib_VUMERITYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VUMERITYMember" xlink:to="lab_biib_VUMERITYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e260e130-3882-4b5b-b978-de4753286f60_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d8802d32-45f1-4543-9a25-d92b80c33526_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_53d933ab-f38f-4fe8-80cc-d892e077b948_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PLEGRIDYMember_ab6ed78e-dfbe-4664-848f-12c7be0a75c0_terseLabel_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PLEGRIDY</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_label_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_documentation_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PLEGRIDY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember" xlink:href="biib-20240930.xsd#biib_PLEGRIDYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLEGRIDYMember" xlink:to="lab_biib_PLEGRIDYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9628a0da-1c7f-4cdc-b42a-fae6ac07aa20_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_fbd30c0c-76f5-4809-89b4-7e8d357ba48b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_c2481445-11fb-4aff-b0b9-3c27ad922138_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, GILTI, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_2dc4387c-592d-4975-9888-0ba0f4df1b1f_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20240930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_13794cb6-e82e-4461-b27f-851965728635_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f2c4e110-8823-4a18-9d10-74e1026f715e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f8b45223-cb6d-487c-b367-d8500c09b6d3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5bd51ef5-5aec-4248-818f-7694ed8c166a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_59557aab-68bc-41a6-ae5e-1884609ebf92_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_e2a3c9d1-4846-4174-9ca7-c4fefdd68d8d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_370d7f94-3952-4fa1-b4f5-6cfa1e1777a4_terseLabel_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Cost Saving Initiatives</link:label>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_label_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Cost Saving Initiatives [Member]</link:label>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_documentation_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Cost Saving Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember" xlink:href="biib-20240930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023CostSavingInitiativesMember" xlink:to="lab_biib_A2023CostSavingInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f77875ed-2255-4995-a036-078a1aef8d52_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_424731d3-7c96-4a96-8f71-e6c14b8886e2_terseLabel_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts receivable</link:label>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_label_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, From Collaborator</link:label>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_documentation_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, From Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator" xlink:href="biib-20240930.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccountsReceivableFromCollaborator" xlink:to="lab_biib_AccountsReceivableFromCollaborator" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_75170091-dfd8-4004-858b-fcab0ca44184_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_3ef1fd0a-1005-4030-98e6-46782638887e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_964bb0aa-1510-4a2a-85b1-741c7e9946ba_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_6e23b490-8271-427c-bfc8-b9909d0c55a6_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20240930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_6acb7115-499b-473d-bfc4-c51b804547ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_f5d80760-480a-4df9-bd19-00e43bb26890_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d76fc956-2d94-4b22-9aea-24de4b92f673_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_734e4727-7caa-49a9-bc89-affaa6ef5f4a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_105c826e-e4e3-4e55-b2a8-b0cf1449fe6d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_64005f38-678b-4fe8-812e-e38f1f5f9747_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_eee11804-1c7c-498b-a634-78a33caef6c5_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_1bcde2dd-5cc2-4c5b-9413-7e05da066aed_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_f6d748fc-910f-443e-9460-347e7ccc3a1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expense and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_44f491f9-f0c3-4610-bd2f-d80d8eb6d44d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c58f8bc8-cfaa-4985-a303-7263ba854497_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_24e2de85-5b98-4f17-b7ee-d56d2d738607_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20240930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_63e442fb-4cc0-4f62-801f-b9fd5e9e5696_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_57a336db-f796-41fe-a2f9-ac1e1cec339a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_dd4a335e-dd1f-4e8a-bba1-1fdc6b0e08a8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_f7749443-d42f-4c47-9cc5-aa1a0f294eae_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member" xlink:href="biib-20240930.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsInc.Member" xlink:to="lab_biib_IonisPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_2d89f025-7cba-4d8b-84de-97b936acbc78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21ee80c9-1815-41b5-9d6a-4f9d84c885b2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_60fceb6f-85ad-496c-b86c-13c5d5526348_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flow provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_4b1d9455-03bf-4c33-abc2-c19567a1f971_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of equity interest in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_5c16143b-9d75-43d2-9526-825ced012f40_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesCurrentMember" xlink:to="lab_biib_EquitySecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_590d7a09-4c41-4c5b-ab5f-0e070ddca91c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_254f7d39-1bb6-4625-80e8-65c2cce58f90_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_0f115bf1-0ab0-44d8-bb37-4973f8f09650_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_dcfcb081-0f42-4299-8b06-4ac9616cc0c3_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20240930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e2624734-004d-42dd-a3ee-16251f51d4ac_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_790f7a2a-f2fd-4ba3-a643-c8c98de39e0f_terseLabel_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of non-controling interest recognized</link:label>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_label_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Non-Controling Interest Recognized</link:label>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_documentation_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Of Non-Controling Interest Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized" xlink:href="biib-20240930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfNonControlingInterestRecognized" xlink:to="lab_biib_ShareOfNonControlingInterestRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b3cb9cba-1ade-4421-8a94-412ad4b09743_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_50d4eede-d8f8-497c-94d4-b68a5f54f2cb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3cb4e881-205f-4333-8327-c92d24fbaf0e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9028a7c5-db1b-4e16-b423-dbfd09da04f5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_aab43337-dce5-4b3f-a688-57de8224befe_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_0739eeb5-67a8-4617-8c3c-5ee7a89a7edd_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity compensation pre-acquisition services</link:label>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_label_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</link:label>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_documentation_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:href="biib-20240930.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:to="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_51f23b11-d0b9-496b-87bb-81d37ba50f84_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_0078b813-4dd0-45cc-b855-76f5a17fa7c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_164aee13-6cd3-49e5-b1c4-d0e7468354b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d75578e3-08be-42d8-b960-fb473f54b62c_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4d1c97c0-30eb-45e1-8bdf-1bb60e816000_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e7f5a2d6-fe90-4252-a3b0-1e76f36ccffb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_890db5d2-7eba-4da1-ac10-c5426ce840b0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetMeasurementInput_6831ceb0-9fc8-4f68-b7cc-e8ff72ddbb85_terseLabel_en-US" xlink:label="lab_biib_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_biib_IntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_biib_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_biib_IntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_biib_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetMeasurementInput" xlink:href="biib-20240930.xsd#biib_IntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetMeasurementInput" xlink:to="lab_biib_IntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9a689bf2-ae03-4e40-993d-0737f3e18a7f_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_8e2db76c-f946-4eea-9f5a-8157b0bd8809_terseLabel_en-US" xlink:label="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</link:label>
    <link:label id="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_label_en-US" xlink:label="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</link:label>
    <link:label id="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_documentation_en-US" xlink:label="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:href="biib-20240930.xsd#biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:to="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_4ae5c3e7-94f0-4e9f-bafd-52cad9fa61bf_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_b0cb16b3-45c3-4179-8af0-97c28c665e58_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_8974d3bf-2bcf-493e-9675-b05bf769ba82_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_d24ab38e-6686-43ce-bec8-8f8d6413e362_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6c4465c0-6e36-4dcb-8fe1-9534df6f0b4e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_dcb4d948-7eb4-472d-b971-4c7d021ca071_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b2f6d752-800b-4832-88e0-77e73b305897_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotes3.250DueFebruary152051Member_c1fdc2d5-2fd2-4e69-850e-0506bf9e753d_terseLabel_en-US" xlink:label="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:label id="lab_biib_SeniorNotes3.250DueFebruary152051Member_label_en-US" xlink:label="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 3.250%, Due February 15, 2051 [Member]</link:label>
    <link:label id="lab_biib_SeniorNotes3.250DueFebruary152051Member_documentation_en-US" xlink:label="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 3.250%, Due February 15, 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotes3.250DueFebruary152051Member" xlink:href="biib-20240930.xsd#biib_SeniorNotes3.250DueFebruary152051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotes3.250DueFebruary152051Member" xlink:to="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_bd124d77-4759-468f-b827-89384d8b26a8_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20240930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_91deae30-cfe5-4f6e-84a2-69e296f47eb3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f465e72e-e19b-4f90-ad4f-0e9337df8823_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_581033eb-763d-4c44-87ea-6df8ffd01c95_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_9191453d-f10b-40a6-a5f7-ac72f7d44aa1_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_ae65a5a0-be79-4f56-a4be-9b54e7951426_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_388958d7-d36e-4ed4-8922-8a4920257d85_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_63efe640-be23-431a-a54c-97681f98ffae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of outcomes, value, high</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_886845ca-6517-4240-acd7-e6f61759b634_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20240930.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_3b9e876c-b889-4c5d-ad11-39a7da4fefa7_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_3dccf164-8a1d-4ab5-a0f1-ad38e3450396_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_6238ad41-3c95-4ecb-bf96-147b1cd67dac_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6b4ca952-74ec-4d0e-9b8e-caa7e02cb4ef_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_8bfccf82-9f4b-4f05-a5f0-3093edd42449_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sage Therapeutics</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20240930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5fcbb19f-e1aa-4ee9-96dd-16ae5673e9dd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a7eacc40-8494-4089-b074-3e9e945f48f7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_897d477a-fcd7-477f-a926-b0841ea7e488_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_851f7c24-470c-440d-9f65-8b9826e073ab_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dispositions</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_90d4aa61-d753-4960-8978-d699a42c94ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6edb55b2-784d-4030-a6ad-743d7a881ca9_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_606831a1-c647-47eb-be3a-6b2ad8f88770_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_13a915ee-7a91-4cf3-998f-35d82fea2a49_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_acc89168-fdd0-48b1-a766-687686329c1f_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:href="biib-20240930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:to="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_4e0ed578-bd1b-464f-a39d-f0de134f998a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0e5a0f83-d8bd-4dcf-bec8-d1b3e056754f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationOfInventoryStepUp_23d49389-456a-409c-bf87-36a6aabb540e_terseLabel_en-US" xlink:label="lab_biib_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired inventory step-up</link:label>
    <link:label id="lab_biib_AmortizationOfInventoryStepUp_label_en-US" xlink:label="lab_biib_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Inventory Step-Up</link:label>
    <link:label id="lab_biib_AmortizationOfInventoryStepUp_documentation_en-US" xlink:label="lab_biib_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Inventory Step-Up</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp" xlink:href="biib-20240930.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationOfInventoryStepUp" xlink:to="lab_biib_AmortizationOfInventoryStepUp" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_7806d7b7-e19c-4e07-b38c-c5be3dceba8b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_97c1f088-e505-49b3-9797-bcd166ad3e09_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0c83fd64-73f9-4d06-af93-5c992fddd2c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_4a1a2c5c-7715-4da1-a790-84ba606ddcb7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_10824b75-84f8-4c94-8a6a-c34a4a1ee159_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e6f90e6f-015b-4175-8dc9-38db1600b28a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_960dd03d-2dba-4de4-83a8-9846c89b4c47_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d17ff917-b426-4c10-9d08-12b7a5d2dc53_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_2e4f4684-e5d8-48bc-91af-ae96ecea697c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a9125a1f-9fdc-49f4-8f61-f8bda45e495e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_e1a16247-569e-4337-8c51-696e6938c87a_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20240930.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4e4aa415-f1d5-4671-98b8-ff57dc0dd953_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_a206e387-a49c-4688-abdf-b9063125b807_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_4346a8ee-d35d-481a-8eef-89f2d34758b2_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt, Maturing in More than Three Months</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt, Maturing in More than Three Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_a2523b30-fdfa-4a8e-a763-1383496dd49a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5dca3542-9301-4899-b51c-5559eeb92156_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1c49ac7c-6773-4467-a9bb-eb20183acdd4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MosunetuzumabMember_fc884360-4a17-489f-8b40-07b546bba245_terseLabel_en-US" xlink:label="lab_biib_MosunetuzumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mosunetuzumab</link:label>
    <link:label id="lab_biib_MosunetuzumabMember_label_en-US" xlink:label="lab_biib_MosunetuzumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mosunetuzumab [Member]</link:label>
    <link:label id="lab_biib_MosunetuzumabMember_documentation_en-US" xlink:label="lab_biib_MosunetuzumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mosunetuzumab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MosunetuzumabMember" xlink:href="biib-20240930.xsd#biib_MosunetuzumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MosunetuzumabMember" xlink:to="lab_biib_MosunetuzumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_79964cd2-e378-434d-bee0-d15a11b2e659_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ce53be49-301a-4db6-8edf-792b603d1a6a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_c6f38839-43cb-498e-b81e-38c50ad02cf8_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20240930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_620f1e31-5107-4a46-be40-8603e1c0cc93_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_722ebc0e-f9c9-4e1e-9be0-56698e8b585e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_89944b1c-4d43-4c26-8eb5-7ca93025b43f_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_27406aeb-9bf6-41e7-b2d9-6ced030ee1d7_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:href="biib-20240930.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d333bee0-4d24-4b2b-8b3d-bd66bdc7ade7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RareDiseaseProductRevenueMember_fff3964d-3d48-4ce6-8320-0a26c67c38a3_terseLabel_en-US" xlink:label="lab_biib_RareDiseaseProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rare Disease Product Revenue</link:label>
    <link:label id="lab_biib_RareDiseaseProductRevenueMember_label_en-US" xlink:label="lab_biib_RareDiseaseProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rare Disease Product Revenue [Member]</link:label>
    <link:label id="lab_biib_RareDiseaseProductRevenueMember_documentation_en-US" xlink:label="lab_biib_RareDiseaseProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rare Disease Product Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RareDiseaseProductRevenueMember" xlink:href="biib-20240930.xsd#biib_RareDiseaseProductRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RareDiseaseProductRevenueMember" xlink:to="lab_biib_RareDiseaseProductRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_6b42bc88-b4bd-4048-9bc8-7b7c8b8d2f88_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5e402173-bbdf-4e4b-b14b-222e17dfceae_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FelzartamabAndIzastobartHIB210Member_4ebfb725-d123-41aa-8992-282b1d00c46d_terseLabel_en-US" xlink:label="lab_biib_FelzartamabAndIzastobartHIB210Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Felzartamab And Izastobart/HIB210</link:label>
    <link:label id="lab_biib_FelzartamabAndIzastobartHIB210Member_label_en-US" xlink:label="lab_biib_FelzartamabAndIzastobartHIB210Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Felzartamab And Izastobart/HIB210 [Member]</link:label>
    <link:label id="lab_biib_FelzartamabAndIzastobartHIB210Member_documentation_en-US" xlink:label="lab_biib_FelzartamabAndIzastobartHIB210Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Felzartamab And Izastobart/HIB210</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAndIzastobartHIB210Member" xlink:href="biib-20240930.xsd#biib_FelzartamabAndIzastobartHIB210Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FelzartamabAndIzastobartHIB210Member" xlink:to="lab_biib_FelzartamabAndIzastobartHIB210Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_efa00ef2-2b74-46e0-8bd6-e9bd5da91b0c_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve, beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_ae52b415-e953-4461-bbb9-8979ad4cea6f_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve, ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_cca88e7b-f5bf-4faf-8a84-91bad4edc0f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dd3de2f1-b20b-4880-9486-7455ff5350ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_9867a1ce-01a0-4c88-85c2-ea38da843ac3_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20240930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>biib-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8df3ebeb-6aab-4ece-9956-fcebea1610fa,g:6874ad4b-e1dd-42ba-8d50-e940c01ea5b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20240930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f9d7633e-9a1c-4475-a35e-668f2420fd8f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_DocumentType_f9d7633e-9a1c-4475-a35e-668f2420fd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1fe96769-deb0-413c-b8f8-61c4f1dc40e8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_DocumentQuarterlyReport_1fe96769-deb0-413c-b8f8-61c4f1dc40e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_296c5d26-7a9a-49e8-8ad7-d1b8e39ea1cb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_DocumentPeriodEndDate_296c5d26-7a9a-49e8-8ad7-d1b8e39ea1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_88d8a7cf-1247-408c-8c92-07b1821cbf11" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_DocumentTransitionReport_88d8a7cf-1247-408c-8c92-07b1821cbf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7bc5e5ce-f931-4631-8aed-e69bba676e72" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityFileNumber_7bc5e5ce-f931-4631-8aed-e69bba676e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_80931b99-e81f-4879-972e-6bacb327ae16" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityRegistrantName_80931b99-e81f-4879-972e-6bacb327ae16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fb83e3c1-3e90-4483-9139-607c54a8e055" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityCentralIndexKey_fb83e3c1-3e90-4483-9139-607c54a8e055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bfaf647f-cc57-4275-b5ad-fe3216f781c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_CurrentFiscalYearEndDate_bfaf647f-cc57-4275-b5ad-fe3216f781c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c4614ca7-af4c-4655-bd5c-6b68364eb469" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_DocumentFiscalYearFocus_c4614ca7-af4c-4655-bd5c-6b68364eb469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_06693a4f-d72d-4f40-ad26-5dce3b46a526" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_06693a4f-d72d-4f40-ad26-5dce3b46a526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2ddc3d41-5414-4970-b864-800e4b25bbca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_AmendmentFlag_2ddc3d41-5414-4970-b864-800e4b25bbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5502de1a-7658-4e3a-950d-f049b654e1f1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5502de1a-7658-4e3a-950d-f049b654e1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_bb4156a1-aff7-452e-ab31-fbbb6ca865e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityTaxIdentificationNumber_bb4156a1-aff7-452e-ab31-fbbb6ca865e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d67b6c7a-b6a9-4c62-b7f3-f50736611cef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityAddressAddressLine1_d67b6c7a-b6a9-4c62-b7f3-f50736611cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_50a1a250-c015-4b53-a755-bacbb88b73f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityAddressCityOrTown_50a1a250-c015-4b53-a755-bacbb88b73f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5cdb0aba-bc44-4ea9-8dfa-e896dfceaf63" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityAddressStateOrProvince_5cdb0aba-bc44-4ea9-8dfa-e896dfceaf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2ba696f3-45c2-405c-a8d5-4bb4e60e1ca4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityAddressPostalZipCode_2ba696f3-45c2-405c-a8d5-4bb4e60e1ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e277aeed-eb98-4446-b6ce-d3309209efc5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_CityAreaCode_e277aeed-eb98-4446-b6ce-d3309209efc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e1d6f4b2-0932-41e0-aa47-27d8453a6585" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_LocalPhoneNumber_e1d6f4b2-0932-41e0-aa47-27d8453a6585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7a6a16f4-760f-401e-8254-9d45284b2d44" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_Security12bTitle_7a6a16f4-760f-401e-8254-9d45284b2d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1c0394de-aa0e-4992-b6ae-e44e016c94a1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_TradingSymbol_1c0394de-aa0e-4992-b6ae-e44e016c94a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9b870a84-423f-4c0d-951c-e44c79794c49" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_SecurityExchangeName_9b870a84-423f-4c0d-951c-e44c79794c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c1ec968d-2aa1-48f8-abb3-e3bd86f61899" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityCurrentReportingStatus_c1ec968d-2aa1-48f8-abb3-e3bd86f61899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_36f63ba9-99e6-4224-a2ec-2611a638e3f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityInteractiveDataCurrent_36f63ba9-99e6-4224-a2ec-2611a638e3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_319713df-d146-418f-bcf3-ecf352a001d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityFilerCategory_319713df-d146-418f-bcf3-ecf352a001d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_69c5e1a7-4ee9-4cf9-9f32-c6a45fa38b57" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntitySmallBusiness_69c5e1a7-4ee9-4cf9-9f32-c6a45fa38b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_14bd90d8-7fad-470e-8631-e202d2a8f66e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityEmergingGrowthCompany_14bd90d8-7fad-470e-8631-e202d2a8f66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6844fea2-6402-4f25-b150-2f492dfd447a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityShellCompany_6844fea2-6402-4f25-b150-2f492dfd447a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fdfb46bb-50a8-4525-bcba-a1881e8d2b2b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9de5b0db-6455-40db-9aa1-10ffaacfa0d0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fdfb46bb-50a8-4525-bcba-a1881e8d2b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_35131df2-8134-45ac-bb2a-ebf1f24a5fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0dd2ecdd-2d08-4d5e-ac94-8c5596502fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_35131df2-8134-45ac-bb2a-ebf1f24a5fd9" xlink:to="loc_us-gaap_StatementTable_0dd2ecdd-2d08-4d5e-ac94-8c5596502fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5508415c-90c5-430d-be13-605d83cd4018" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0dd2ecdd-2d08-4d5e-ac94-8c5596502fdb" xlink:to="loc_srt_ProductOrServiceAxis_5508415c-90c5-430d-be13-605d83cd4018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3595786a-23f7-4487-b8a0-a216c4193e83" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5508415c-90c5-430d-be13-605d83cd4018" xlink:to="loc_srt_ProductsAndServicesDomain_3595786a-23f7-4487-b8a0-a216c4193e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7b4ae19d-09b4-46bb-abc5-7065a48149f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3595786a-23f7-4487-b8a0-a216c4193e83" xlink:to="loc_us-gaap_ProductMember_7b4ae19d-09b4-46bb-abc5-7065a48149f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_874b8e0f-1a21-43f1-8320-8501fd128145" xlink:href="biib-20240930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3595786a-23f7-4487-b8a0-a216c4193e83" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_874b8e0f-1a21-43f1-8320-8501fd128145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_214653ea-bb34-4044-998f-e12c19136a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3595786a-23f7-4487-b8a0-a216c4193e83" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_214653ea-bb34-4044-998f-e12c19136a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0dd2ecdd-2d08-4d5e-ac94-8c5596502fdb" xlink:to="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_398c8672-9ef2-484d-b2bb-35c38baf30c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_Revenues_398c8672-9ef2-484d-b2bb-35c38baf30c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f75d69d2-69ee-4591-9e41-c93018d81326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f75d69d2-69ee-4591-9e41-c93018d81326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_804700af-0b82-4248-93bc-7cf407f763e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_804700af-0b82-4248-93bc-7cf407f763e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6bb66989-72e8-4096-952a-ddb2f53a5d14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6bb66989-72e8-4096-952a-ddb2f53a5d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_265a8584-41de-4eb4-87f5-064319014e78" xlink:href="biib-20240930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_265a8584-41de-4eb4-87f5-064319014e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_5fdf467c-09af-4c16-9288-d4efe2182a27" xlink:href="biib-20240930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_biib_Collaborationprofitlosssharing_5fdf467c-09af-4c16-9288-d4efe2182a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_765083d0-26f3-4af7-a5b7-f47d93590bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_765083d0-26f3-4af7-a5b7-f47d93590bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a02cc5da-ad9d-49fd-b39b-c3ada024f961" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_RestructuringCharges_a02cc5da-ad9d-49fd-b39b-c3ada024f961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_c1932294-3ab5-47e1-9f7e-7210b9113279" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_c1932294-3ab5-47e1-9f7e-7210b9113279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_48d7c47b-7de3-476d-b2a2-904cf44eae14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_48d7c47b-7de3-476d-b2a2-904cf44eae14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ed30d7e9-ae4f-4e6d-9345-7b5fab48b648" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_256c589d-a8bb-4ebd-a499-fae4cde5492d" xlink:to="loc_us-gaap_CostsAndExpenses_ed30d7e9-ae4f-4e6d-9345-7b5fab48b648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_319b85ba-fdf0-4b91-a662-21cd134e2b15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_319b85ba-fdf0-4b91-a662-21cd134e2b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dfc3eafd-9f22-46a6-bfed-fd3379d7ba4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dfc3eafd-9f22-46a6-bfed-fd3379d7ba4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3b6f9b9a-fdfa-4ba8-9ece-139b20af3010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_ProfitLoss_3b6f9b9a-fdfa-4ba8-9ece-139b20af3010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_00c1768a-e7c7-4e11-a98b-ff99aaf4fc01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_00c1768a-e7c7-4e11-a98b-ff99aaf4fc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a7de20e-7286-4bd3-8b0d-d564399989b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_NetIncomeLoss_6a7de20e-7286-4bd3-8b0d-d564399989b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c4e8c934-8755-4d6a-94cf-3244b0fdce69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_EarningsPerShareAbstract_c4e8c934-8755-4d6a-94cf-3244b0fdce69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6e9f033a-deea-4c5a-a257-74d094a0cee7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c4e8c934-8755-4d6a-94cf-3244b0fdce69" xlink:to="loc_us-gaap_EarningsPerShareBasic_6e9f033a-deea-4c5a-a257-74d094a0cee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3db42930-eead-44f1-af3d-609a7430a449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c4e8c934-8755-4d6a-94cf-3244b0fdce69" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3db42930-eead-44f1-af3d-609a7430a449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0bb4f7a4-3fc9-401b-9d5b-85b5978538b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0278a228-351b-4941-b237-5e7ae5b03b7f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0bb4f7a4-3fc9-401b-9d5b-85b5978538b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e582cb48-5da8-4acd-acd6-ba4224cd3965" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0bb4f7a4-3fc9-401b-9d5b-85b5978538b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e582cb48-5da8-4acd-acd6-ba4224cd3965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0dc6f9c1-454c-40fe-932c-f751c9c93f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0bb4f7a4-3fc9-401b-9d5b-85b5978538b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0dc6f9c1-454c-40fe-932c-f751c9c93f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_76c1d890-1b59-4391-aba0-b3a86f84ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83c028dd-ae92-4a50-b697-0a81307f08a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_76c1d890-1b59-4391-aba0-b3a86f84ce09" xlink:to="loc_us-gaap_NetIncomeLoss_83c028dd-ae92-4a50-b697-0a81307f08a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_efa22fa5-a8d2-4e0b-8401-1526d39cd97c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_76c1d890-1b59-4391-aba0-b3a86f84ce09" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_efa22fa5-a8d2-4e0b-8401-1526d39cd97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_615c1082-a5bd-4fb1-af12-38ad20a9e519" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_efa22fa5-a8d2-4e0b-8401-1526d39cd97c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_615c1082-a5bd-4fb1-af12-38ad20a9e519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_aff7c2dc-5b1b-46e3-bd5a-d4c6c4acb954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_efa22fa5-a8d2-4e0b-8401-1526d39cd97c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_aff7c2dc-5b1b-46e3-bd5a-d4c6c4acb954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a66c8dac-5527-45b5-8950-851d2ebecb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_efa22fa5-a8d2-4e0b-8401-1526d39cd97c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a66c8dac-5527-45b5-8950-851d2ebecb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a062079a-9b33-449f-bedd-fd97ada7ad68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_efa22fa5-a8d2-4e0b-8401-1526d39cd97c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a062079a-9b33-449f-bedd-fd97ada7ad68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fb1e93da-42f7-4da8-adec-e6c09d9c8969" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_efa22fa5-a8d2-4e0b-8401-1526d39cd97c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fb1e93da-42f7-4da8-adec-e6c09d9c8969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1851846b-5495-474a-9c55-a1a95201ee9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_efa22fa5-a8d2-4e0b-8401-1526d39cd97c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1851846b-5495-474a-9c55-a1a95201ee9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_5a445fda-90b9-44b6-aa82-93133a2ab740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_efa22fa5-a8d2-4e0b-8401-1526d39cd97c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_5a445fda-90b9-44b6-aa82-93133a2ab740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_95d75fdc-27d6-49ac-8874-937dd3d36268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_efa22fa5-a8d2-4e0b-8401-1526d39cd97c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_95d75fdc-27d6-49ac-8874-937dd3d36268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1b3d2135-4d13-4467-8688-f92b271d0cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_53d639aa-eec2-4413-b232-f07c3acd5f67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1b3d2135-4d13-4467-8688-f92b271d0cd5" xlink:to="loc_us-gaap_StatementTable_53d639aa-eec2-4413-b232-f07c3acd5f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0779d1c8-35fb-42d8-b226-ad46f4a6ae63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_53d639aa-eec2-4413-b232-f07c3acd5f67" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0779d1c8-35fb-42d8-b226-ad46f4a6ae63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_dbef291b-752b-4153-b29b-4b17e3b33c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0779d1c8-35fb-42d8-b226-ad46f4a6ae63" xlink:to="loc_us-gaap_RelatedPartyDomain_dbef291b-752b-4153-b29b-4b17e3b33c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_226b5dce-e89d-469c-9ec4-4abbf9abe8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_dbef291b-752b-4153-b29b-4b17e3b33c2c" xlink:to="loc_us-gaap_NonrelatedPartyMember_226b5dce-e89d-469c-9ec4-4abbf9abe8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_4836dbf2-8fa3-439e-861d-faf5a1b7ca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_dbef291b-752b-4153-b29b-4b17e3b33c2c" xlink:to="loc_us-gaap_RelatedPartyMember_4836dbf2-8fa3-439e-861d-faf5a1b7ca2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_642700e2-a87a-4581-a957-775c5797b39e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_53d639aa-eec2-4413-b232-f07c3acd5f67" xlink:to="loc_us-gaap_StatementLineItems_642700e2-a87a-4581-a957-775c5797b39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_642700e2-a87a-4581-a957-775c5797b39e" xlink:to="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c27ddfab-71cf-4f37-a8a5-23fa1a70651d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c27ddfab-71cf-4f37-a8a5-23fa1a70651d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_60a66e0e-e43a-4ce3-a203-37ceef45c44d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_60a66e0e-e43a-4ce3-a203-37ceef45c44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_63046584-5a69-4f55-a007-b339128f637a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:to="loc_us-gaap_InventoryNet_63046584-5a69-4f55-a007-b339128f637a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2c18febe-62c7-42a6-9514-2c607d8bed9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:to="loc_us-gaap_OtherAssetsCurrent_2c18febe-62c7-42a6-9514-2c607d8bed9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7e8d5515-6d17-4f52-896b-b96457011ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_360af8ec-ed6b-42b1-b04f-3a30c3a2fc59" xlink:to="loc_us-gaap_AssetsCurrent_7e8d5515-6d17-4f52-896b-b96457011ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d70d7cee-cfe8-495d-9268-b57b6d4d42ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d70d7cee-cfe8-495d-9268-b57b6d4d42ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_852635a7-09fb-4445-bd6f-82fb6ad894b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_852635a7-09fb-4445-bd6f-82fb6ad894b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0284cf9c-92e6-46b6-b4df-503dcb8b06af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0284cf9c-92e6-46b6-b4df-503dcb8b06af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2d686af5-de9d-4de2-ad43-05a38a39c7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_Goodwill_2d686af5-de9d-4de2-ad43-05a38a39c7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_5e5249d8-86cd-4d86-8b0f-7649f8763d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_5e5249d8-86cd-4d86-8b0f-7649f8763d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9c570295-ce58-4458-bb6d-9d4c815aca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9c570295-ce58-4458-bb6d-9d4c815aca5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_51f4d9e1-12e7-422e-87e8-d97ec49a5877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_720f4774-ff33-44d8-af69-3961a7eae48e" xlink:to="loc_us-gaap_Assets_51f4d9e1-12e7-422e-87e8-d97ec49a5877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_642700e2-a87a-4581-a957-775c5797b39e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_f76067ed-9d07-4c80-94da-2d8688f00c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:to="loc_us-gaap_NotesPayableCurrent_f76067ed-9d07-4c80-94da-2d8688f00c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_28983f08-23aa-4109-af5d-bed751a7f5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:to="loc_us-gaap_TaxesPayableCurrent_28983f08-23aa-4109-af5d-bed751a7f5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_67f6fb88-7144-45e5-a2ee-c8a251fbb30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:to="loc_us-gaap_AccountsPayableCurrent_67f6fb88-7144-45e5-a2ee-c8a251fbb30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3b03a616-b6ee-4f03-81cb-7eea8b91d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3b03a616-b6ee-4f03-81cb-7eea8b91d59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ee26829a-11cb-4279-a4d7-ed1c3a8cd184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c9b228b5-1b06-4823-9457-1d2a3f49db9d" xlink:to="loc_us-gaap_LiabilitiesCurrent_ee26829a-11cb-4279-a4d7-ed1c3a8cd184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f43a1fe7-5b0b-4e1e-a294-6858af9cdd85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_LongTermDebt_f43a1fe7-5b0b-4e1e-a294-6858af9cdd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_413e8490-72c7-45bc-b48b-e32b1b1607e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_413e8490-72c7-45bc-b48b-e32b1b1607e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5699997e-0c7c-4397-9e71-f4f24681442a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5699997e-0c7c-4397-9e71-f4f24681442a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1c403529-94f2-4f58-b950-9c702091336e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1c403529-94f2-4f58-b950-9c702091336e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0864db26-0834-44fd-81be-00ffae4148e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_Liabilities_0864db26-0834-44fd-81be-00ffae4148e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_85dca307-1d5f-417e-9ade-b8e74ddd7dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_85dca307-1d5f-417e-9ade-b8e74ddd7dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_36c7d7ca-c485-4c08-ba0a-b54105229f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_36c7d7ca-c485-4c08-ba0a-b54105229f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_36c7d7ca-c485-4c08-ba0a-b54105229f43" xlink:to="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_45a7a24d-290e-4901-b1d0-055201a8ad36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_PreferredStockValue_45a7a24d-290e-4901-b1d0-055201a8ad36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b8cd6182-2dc1-4241-b1d6-d11267d95d21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_CommonStockValue_b8cd6182-2dc1-4241-b1d6-d11267d95d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6cc29e32-eb6b-4aa1-a8b4-30fa6aef8837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6cc29e32-eb6b-4aa1-a8b4-30fa6aef8837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5460b31a-3924-41c5-88f2-876502695c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5460b31a-3924-41c5-88f2-876502695c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_845229f2-142d-45f6-8932-7267f4d017b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_845229f2-142d-45f6-8932-7267f4d017b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6c56a80d-dddf-45b7-afd3-cc1780108101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cb53309e-eb09-4ef5-b85b-5a475ad13d56" xlink:to="loc_us-gaap_TreasuryStockValue_6c56a80d-dddf-45b7-afd3-cc1780108101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70b95f8c-9b74-4f17-a80d-6c3f5972de02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_36c7d7ca-c485-4c08-ba0a-b54105229f43" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70b95f8c-9b74-4f17-a80d-6c3f5972de02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7cf004d5-802a-4bad-b50c-ddefdafb175a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b91432c3-9189-437e-bf99-45e6da54ecbd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7cf004d5-802a-4bad-b50c-ddefdafb175a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="biib-20240930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9f6afe6a-a457-4b2e-875c-f603af511c62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4508edd0-3d1f-4c93-bab5-82192ca38e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9f6afe6a-a457-4b2e-875c-f603af511c62" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4508edd0-3d1f-4c93-bab5-82192ca38e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2fa3d0f2-08e5-40be-98e6-8bc436023ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9f6afe6a-a457-4b2e-875c-f603af511c62" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2fa3d0f2-08e5-40be-98e6-8bc436023ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_95578352-0210-4dfa-ae29-f79a426f1974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9f6afe6a-a457-4b2e-875c-f603af511c62" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_95578352-0210-4dfa-ae29-f79a426f1974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9b27c351-6b0c-4360-ad7c-11a5ecebdb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_af16e64d-fff8-4fdb-9f3d-76d9315a1994" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9b27c351-6b0c-4360-ad7c-11a5ecebdb9a" xlink:to="loc_us-gaap_StatementTable_af16e64d-fff8-4fdb-9f3d-76d9315a1994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8c60a17e-9bb2-4494-8761-12b812d4d804" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_af16e64d-fff8-4fdb-9f3d-76d9315a1994" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8c60a17e-9bb2-4494-8761-12b812d4d804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ceb0e20b-5fe8-44ee-8da9-c612d21570e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8c60a17e-9bb2-4494-8761-12b812d4d804" xlink:to="loc_us-gaap_RelatedPartyDomain_ceb0e20b-5fe8-44ee-8da9-c612d21570e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_9c666344-5732-44bd-bc96-d1c89ad64012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ceb0e20b-5fe8-44ee-8da9-c612d21570e5" xlink:to="loc_us-gaap_NonrelatedPartyMember_9c666344-5732-44bd-bc96-d1c89ad64012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_59db43df-5043-4a5f-bfab-c821a6ffede0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ceb0e20b-5fe8-44ee-8da9-c612d21570e5" xlink:to="loc_us-gaap_RelatedPartyMember_59db43df-5043-4a5f-bfab-c821a6ffede0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_af16e64d-fff8-4fdb-9f3d-76d9315a1994" xlink:to="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e6ba60c4-15b3-4ff7-9b60-6050ea6c16d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e6ba60c4-15b3-4ff7-9b60-6050ea6c16d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b63da02-8769-45c9-b7d2-00988f494a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e6ba60c4-15b3-4ff7-9b60-6050ea6c16d1" xlink:to="loc_us-gaap_ProfitLoss_4b63da02-8769-45c9-b7d2-00988f494a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e6ba60c4-15b3-4ff7-9b60-6050ea6c16d1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8323a370-2d41-4175-ab6e-ae29e9a1ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8323a370-2d41-4175-ab6e-ae29e9a1ce34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9f08fb77-807e-478a-ac34-b59745c23ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9f08fb77-807e-478a-ac34-b59745c23ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_34bf7159-b182-43f1-b04b-6a5bfe9b182e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_InventoryWriteDown_34bf7159-b182-43f1-b04b-6a5bfe9b182e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp_f7126ae4-475e-4a39-a11c-222ccf0aa939" xlink:href="biib-20240930.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_biib_AmortizationOfInventoryStepUp_f7126ae4-475e-4a39-a11c-222ccf0aa939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3b2f06bf-fed4-402b-a69d-5d9e4877ef5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_ShareBasedCompensation_3b2f06bf-fed4-402b-a69d-5d9e4877ef5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7f8111f9-7d51-4f88-9cfc-023dec50871f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7f8111f9-7d51-4f88-9cfc-023dec50871f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b54fb92f-8316-4f24-9aab-7974e86bb020" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b54fb92f-8316-4f24-9aab-7974e86bb020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_11d9a8ae-3ded-43fd-a769-8c832a9be9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_11d9a8ae-3ded-43fd-a769-8c832a9be9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8c2aee54-d008-4c95-9124-6b1fe25e50b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8c2aee54-d008-4c95-9124-6b1fe25e50b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8a5c3f9f-7c40-4cbd-bef8-e794c12b728b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8a5c3f9f-7c40-4cbd-bef8-e794c12b728b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7e95d8ac-982e-45d2-b14f-6bf1370753c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7e95d8ac-982e-45d2-b14f-6bf1370753c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a4fe5613-e117-4edc-9fc0-0f6328cfbe26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a4fe5613-e117-4edc-9fc0-0f6328cfbe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_15140265-d060-4a1e-900a-590c5dc18187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_15140265-d060-4a1e-900a-590c5dc18187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2eef80f5-dc5b-4cfe-ab91-31387facdb08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2eef80f5-dc5b-4cfe-ab91-31387facdb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a16c8e27-0aea-4f16-a4b6-3d59537ebf92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9520d9a6-bdde-4ac0-9da9-d5a9e169f479" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a16c8e27-0aea-4f16-a4b6-3d59537ebf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6750d36e-688f-4b89-947b-46758e76ca53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d29c9d78-79a3-4c4b-881f-3398f757faae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6750d36e-688f-4b89-947b-46758e76ca53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_863d5fb3-347c-42de-a5b3-8eb0cb5b997a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_863d5fb3-347c-42de-a5b3-8eb0cb5b997a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2830e251-7139-4779-9929-5af593970b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2830e251-7139-4779-9929-5af593970b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_23b40537-d25c-4795-bd17-95dd719b3d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_23b40537-d25c-4795-bd17-95dd719b3d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0cc0cc0e-acf8-45fc-a6bb-6cff4b3b388e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0cc0cc0e-acf8-45fc-a6bb-6cff4b3b388e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_9905144c-dff4-4885-a6ef-cdff799f4b56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_9905144c-dff4-4885-a6ef-cdff799f4b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5285491f-4623-4aa7-9740-fdb855a494a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5285491f-4623-4aa7-9740-fdb855a494a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0ffe4be6-cff6-4933-9560-1128e0e347f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0ffe4be6-cff6-4933-9560-1128e0e347f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_4dd27a1a-bf44-4831-9bd8-3ee48b2058e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_4dd27a1a-bf44-4831-9bd8-3ee48b2058e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a125ec00-0c94-4e83-93b3-9a825e45797c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a125ec00-0c94-4e83-93b3-9a825e45797c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e40c5c3b-b821-45ea-bba0-6deb42657aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c9c7f40f-102b-4d84-8634-5f2b9cc84745" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e40c5c3b-b821-45ea-bba0-6deb42657aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0b601219-50f6-42f1-8be5-4fee89d780e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0b601219-50f6-42f1-8be5-4fee89d780e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_16532fa1-1d7f-4545-9f12-8df491d54529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_16532fa1-1d7f-4545-9f12-8df491d54529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2479e865-f037-40cb-878c-fe375ea5153e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2479e865-f037-40cb-878c-fe375ea5153e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_4a2a37e1-4fe8-4a11-bae3-512e62619b60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_4a2a37e1-4fe8-4a11-bae3-512e62619b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9368d9a8-a704-44ce-8282-200af004cc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9368d9a8-a704-44ce-8282-200af004cc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eb13e01a-a132-4c6d-a120-2a678f6edb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2f7b819-1e94-4a48-b898-58c14aa4d631" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eb13e01a-a132-4c6d-a120-2a678f6edb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_bf805d02-899d-4e7e-a3fa-64698211a6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_bf805d02-899d-4e7e-a3fa-64698211a6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e65500d-d635-4871-bfc7-89247c047b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e65500d-d635-4871-bfc7-89247c047b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a3abb60-8cee-42c1-93a2-4cad22e97c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a3abb60-8cee-42c1-93a2-4cad22e97c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48115caa-8926-41b9-925e-114e512a0a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fc250896-547c-4ec2-aa37-eeb327e79382" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48115caa-8926-41b9-925e-114e512a0a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20240930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f703a248-424c-4480-aed3-acbf6c7c17e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d4b28215-1638-48f6-9280-067b16cbb63f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f703a248-424c-4480-aed3-acbf6c7c17e0" xlink:to="loc_us-gaap_StatementTable_d4b28215-1638-48f6-9280-067b16cbb63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b9c1edbf-14d6-4003-b769-0c11212be378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d4b28215-1638-48f6-9280-067b16cbb63f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b9c1edbf-14d6-4003-b769-0c11212be378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b9c1edbf-14d6-4003-b769-0c11212be378" xlink:to="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d931fbd5-d90a-44ef-b883-c02d200b0986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_PreferredStockMember_d931fbd5-d90a-44ef-b883-c02d200b0986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b88a8e98-1007-4875-b370-7dc30287e738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_CommonStockMember_b88a8e98-1007-4875-b370-7dc30287e738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_11334386-4b7e-4f55-914e-879153fffc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_11334386-4b7e-4f55-914e-879153fffc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cabe6be1-28a8-4d4c-9f71-1d96e4bd8825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cabe6be1-28a8-4d4c-9f71-1d96e4bd8825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b09b235a-5c97-4cf1-83d8-23cfebad6342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_RetainedEarningsMember_b09b235a-5c97-4cf1-83d8-23cfebad6342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_d41c77f1-76bf-49ad-a509-73bda7ca546c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_TreasuryStockCommonMember_d41c77f1-76bf-49ad-a509-73bda7ca546c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_6a5233f6-f550-4b38-8298-8f9c6c00646a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_ParentMember_6a5233f6-f550-4b38-8298-8f9c6c00646a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_dffa807e-f3fc-40ea-a46d-aac5e8d282a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d1dec490-2ab0-4565-8997-a95970bbf39e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_dffa807e-f3fc-40ea-a46d-aac5e8d282a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d4b28215-1638-48f6-9280-067b16cbb63f" xlink:to="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e05b1792-4b7a-428d-9e19-408f4aa9464b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e05b1792-4b7a-428d-9e19-408f4aa9464b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7c7b546-d8e6-4c56-9841-357eec3901d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7c7b546-d8e6-4c56-9841-357eec3901d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_2d649933-b86e-4636-954c-a645e4c2b06a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_TreasuryStockCommonShares_2d649933-b86e-4636-954c-a645e4c2b06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2902c44f-e24b-437e-81ca-ac81d3cae5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_ProfitLoss_2902c44f-e24b-437e-81ca-ac81d3cae5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d71cf091-9341-4c4d-8f38-dfb583210c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d71cf091-9341-4c4d-8f38-dfb583210c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_8f184d2a-0544-49b6-a19e-b3a25f8e8547" xlink:href="biib-20240930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_8f184d2a-0544-49b6-a19e-b3a25f8e8547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_6c9cd51c-a2c2-4cda-9850-4806b47a5c96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_6c9cd51c-a2c2-4cda-9850-4806b47a5c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_d8804d95-c13e-4feb-a2b8-18ac2a886d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_d8804d95-c13e-4feb-a2b8-18ac2a886d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2a4fe4a9-821a-4585-9912-e12c9518ddfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2a4fe4a9-821a-4585-9912-e12c9518ddfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b26af76e-d8cb-4692-8cfe-b95bf85f7498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b26af76e-d8cb-4692-8cfe-b95bf85f7498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_08a7a56b-6e07-4bbc-b763-46eaba8ccd77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_08a7a56b-6e07-4bbc-b763-46eaba8ccd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_68455651-163e-40a9-a0e9-f723a3cb9249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockholdersEquityOther_68455651-163e-40a9-a0e9-f723a3cb9249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f72476b-6eb0-4ae2-b4b9-2970d4f8c827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f72476b-6eb0-4ae2-b4b9-2970d4f8c827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_00b4850d-241c-421b-a074-e218ca48ed18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_00b4850d-241c-421b-a074-e218ca48ed18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5b6be3bf-48b3-4230-992a-5564b4b20f78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99a39120-a04a-43ce-9293-53f97845bf53" xlink:to="loc_us-gaap_TreasuryStockCommonShares_5b6be3bf-48b3-4230-992a-5564b4b20f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20240930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eb6ae399-ed73-4110-bcba-b5545412bcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_58131b07-67a9-425a-98c8-287d2c2d7cef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb6ae399-ed73-4110-bcba-b5545412bcf2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_58131b07-67a9-425a-98c8-287d2c2d7cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20240930.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8fd8ba33-00bb-4497-8080-46624202775a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7bf22692-1157-4803-b910-1bba03eb11f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8fd8ba33-00bb-4497-8080-46624202775a" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7bf22692-1157-4803-b910-1bba03eb11f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Dispositions" xlink:type="simple" xlink:href="biib-20240930.xsd#Dispositions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Dispositions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_ac253722-b440-47df-8cf4-71a3a6a281c6" xlink:href="biib-20240930.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_55b6995e-85e2-445b-9780-fca0824bb512" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_ac253722-b440-47df-8cf4-71a3a6a281c6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_55b6995e-85e2-445b-9780-fca0824bb512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="simple" xlink:href="biib-20240930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiatives"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4af8c8ce-7063-4438-be89-a0daa1597a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_e08bb0c4-6d45-4bb2-aceb-2f383aba0cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4af8c8ce-7063-4438-be89-a0daa1597a7b" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_e08bb0c4-6d45-4bb2-aceb-2f383aba0cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20240930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_27907f63-ca76-4d8d-9f38-0bfa452b3d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4858b633-09a0-47b3-ac4e-032b3d420860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_27907f63-ca76-4d8d-9f38-0bfa452b3d98" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4858b633-09a0-47b3-ac4e-032b3d420860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20240930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_00091b64-93db-499d-8b97-5b300bd03292" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_08bfe7f3-5c7c-414a-8c56-89490763318e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_00091b64-93db-499d-8b97-5b300bd03292" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_08bfe7f3-5c7c-414a-8c56-89490763318e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b777f79-0a55-4922-932e-2d2504303d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3b44f99f-0975-4fa1-9046-d9faaf14a9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b777f79-0a55-4922-932e-2d2504303d3b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3b44f99f-0975-4fa1-9046-d9faaf14a9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e15a17c8-19ef-4561-9dd5-8b7d380b7298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_68df290f-c839-4d4d-a0d7-3450d3f5e8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e15a17c8-19ef-4561-9dd5-8b7d380b7298" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_68df290f-c839-4d4d-a0d7-3450d3f5e8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20240930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_12b98b9c-d9f3-4722-9011-80f424050566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_81b7c656-edcd-4a89-a14d-d4ca1bb81a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_12b98b9c-d9f3-4722-9011-80f424050566" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_81b7c656-edcd-4a89-a14d-d4ca1bb81a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20240930.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c45ef040-c370-47bd-9f17-d27c4dd3b8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3d0df683-93ff-473f-8b35-28454a7ee197" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c45ef040-c370-47bd-9f17-d27c4dd3b8ee" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3d0df683-93ff-473f-8b35-28454a7ee197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20240930.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8c1785aa-f7a0-4693-b9f8-cbec1fc5f6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_857cb479-6f24-4ffe-afe0-306b50aaf575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8c1785aa-f7a0-4693-b9f8-cbec1fc5f6f8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_857cb479-6f24-4ffe-afe0-306b50aaf575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:type="simple" xlink:href="biib-20240930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7c492bf5-fa65-471d-bbee-eb5fa3988839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_4702a2e5-2489-4c48-9312-0fae8e2392e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7c492bf5-fa65-471d-bbee-eb5fa3988839" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_4702a2e5-2489-4c48-9312-0fae8e2392e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20240930.xsd#Indebtedness"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_877e7080-cad6-40c3-919c-bd8d77b2220f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2de48225-c358-4647-9298-cb65f1995b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_877e7080-cad6-40c3-919c-bd8d77b2220f" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2de48225-c358-4647-9298-cb65f1995b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20240930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_68bde75b-0a42-482c-a704-f2881650dbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dc5ad208-b6b9-42c8-bf36-d3e16d410c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68bde75b-0a42-482c-a704-f2881650dbf9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dc5ad208-b6b9-42c8-bf36-d3e16d410c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20240930.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_db79c8b4-e22f-4ff3-a287-1002a258530c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_634c4673-0d7a-4768-922a-fb8dd4261b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_db79c8b4-e22f-4ff3-a287-1002a258530c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_634c4673-0d7a-4768-922a-fb8dd4261b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20240930.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38ad07ff-13fa-47d0-9b39-64277b329544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_81d5ca8b-63d9-42e3-83ef-10e848a37b94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38ad07ff-13fa-47d0-9b39-64277b329544" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_81d5ca8b-63d9-42e3-83ef-10e848a37b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20240930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5ec2854b-f784-4b43-906f-a9c60a1164a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4a7c538c-25f0-479c-9b67-82a84cbd1150" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5ec2854b-f784-4b43-906f-a9c60a1164a4" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4a7c538c-25f0-479c-9b67-82a84cbd1150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20240930.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9255667d-7912-4625-943e-03fb64104cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_f3308c5a-038d-414e-9aa6-d58c0431732b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9255667d-7912-4625-943e-03fb64104cc1" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_f3308c5a-038d-414e-9aa6-d58c0431732b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6384a1b-7ff8-4a6c-96e5-e49a895cd1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dea6cd75-8405-478f-8a60-9228d6d51c04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6384a1b-7ff8-4a6c-96e5-e49a895cd1eb" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dea6cd75-8405-478f-8a60-9228d6d51c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20240930.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_04e99623-cf84-4a8d-a091-76611cdaea93" xlink:href="biib-20240930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_281482ab-e42f-45f6-b1a7-c36ec56f41fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_04e99623-cf84-4a8d-a091-76611cdaea93" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_281482ab-e42f-45f6-b1a7-c36ec56f41fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20240930.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_d1261736-5dfc-4de2-ad76-5f790c9c5ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_7685d4bb-9c86-491b-8cae-a83762a696b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_d1261736-5dfc-4de2-ad76-5f790c9c5ba3" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_7685d4bb-9c86-491b-8cae-a83762a696b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20240930.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eb019717-fec2-45a8-803f-f234f23f2d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_44ef2c16-4a20-42c0-a6bf-94874f97dbb8" xlink:href="biib-20240930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb019717-fec2-45a8-803f-f234f23f2d4e" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_44ef2c16-4a20-42c0-a6bf-94874f97dbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_663a9e03-b578-4f29-91da-37bacc0dae01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb019717-fec2-45a8-803f-f234f23f2d4e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_663a9e03-b578-4f29-91da-37bacc0dae01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0ed0da51-bf8b-4203-b8cf-92620ba51e76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb019717-fec2-45a8-803f-f234f23f2d4e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0ed0da51-bf8b-4203-b8cf-92620ba51e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a80d9730-a77d-4bae-857a-8b4a316d4f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb019717-fec2-45a8-803f-f234f23f2d4e" xlink:to="loc_us-gaap_UseOfEstimates_a80d9730-a77d-4bae-857a-8b4a316d4f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25a3866e-de40-4c9f-b6f5-ed038b80e372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb019717-fec2-45a8-803f-f234f23f2d4e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25a3866e-de40-4c9f-b6f5-ed038b80e372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="biib-20240930.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5cefc9a5-e3f3-4419-8572-169e961f6920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0fc3d7e8-e48a-44a1-b4fb-144da74c0186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5cefc9a5-e3f3-4419-8572-169e961f6920" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0fc3d7e8-e48a-44a1-b4fb-144da74c0186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_78571d38-682b-4f85-922d-702b31d8ed07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5cefc9a5-e3f3-4419-8572-169e961f6920" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_78571d38-682b-4f85-922d-702b31d8ed07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="simple" xlink:href="biib-20240930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0e207779-ef48-4d36-8158-49ac7ec101a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_82a31572-aa35-44d5-8e41-59b20dc1fc90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0e207779-ef48-4d36-8158-49ac7ec101a0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_82a31572-aa35-44d5-8e41-59b20dc1fc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_2042895f-7699-4b89-9230-dcd3f05a181b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0e207779-ef48-4d36-8158-49ac7ec101a0" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_2042895f-7699-4b89-9230-dcd3f05a181b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_29b77b0b-d2a2-4dab-912b-c93c34b787fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d3e72a26-23d1-4b2e-9c20-eb12561f305a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_29b77b0b-d2a2-4dab-912b-c93c34b787fb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d3e72a26-23d1-4b2e-9c20-eb12561f305a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_ac63a328-5077-4c2e-ba92-accbdcaf17ec" xlink:href="biib-20240930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_29b77b0b-d2a2-4dab-912b-c93c34b787fb" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_ac63a328-5077-4c2e-ba92-accbdcaf17ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_c80bbd72-88bb-4786-abcd-d36d97721b76" xlink:href="biib-20240930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_29b77b0b-d2a2-4dab-912b-c93c34b787fb" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_c80bbd72-88bb-4786-abcd-d36d97721b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_188f67c0-a4fe-468a-8234-84a2c6d2f74d" xlink:href="biib-20240930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_29b77b0b-d2a2-4dab-912b-c93c34b787fb" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_188f67c0-a4fe-468a-8234-84a2c6d2f74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_d663c598-df0e-4392-8b1c-835901e067d2" xlink:href="biib-20240930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_29b77b0b-d2a2-4dab-912b-c93c34b787fb" xlink:to="loc_biib_OtherrevenuesTableTextBlock_d663c598-df0e-4392-8b1c-835901e067d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20240930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5eeee415-e70d-4b2b-a477-f084467fea2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_259bf7b7-ebc6-4611-81f6-8eb3a0d3ab06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5eeee415-e70d-4b2b-a477-f084467fea2a" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_259bf7b7-ebc6-4611-81f6-8eb3a0d3ab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_473b914e-146c-4c20-903a-8e0dfc580d74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_af67b75d-6da8-4e21-be71-86a19d76f008" xlink:href="biib-20240930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_473b914e-146c-4c20-903a-8e0dfc580d74" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_af67b75d-6da8-4e21-be71-86a19d76f008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0316bf38-fd61-4c0b-8d28-2175ed74e746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_473b914e-146c-4c20-903a-8e0dfc580d74" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0316bf38-fd61-4c0b-8d28-2175ed74e746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_bdf4efc6-22a1-4035-b870-8bb3eb0cc5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_473b914e-146c-4c20-903a-8e0dfc580d74" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_bdf4efc6-22a1-4035-b870-8bb3eb0cc5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2594e697-27fc-4748-ae1c-5e9412986e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e8352d5a-8c0e-49e9-a6c0-10442c6b99bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2594e697-27fc-4748-ae1c-5e9412986e1a" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e8352d5a-8c0e-49e9-a6c0-10442c6b99bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_eb3a43b1-135a-466d-98cc-3397f6c40ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2594e697-27fc-4748-ae1c-5e9412986e1a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_eb3a43b1-135a-466d-98cc-3397f6c40ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_60e02298-639d-4449-88ed-16a67db46dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2594e697-27fc-4748-ae1c-5e9412986e1a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_60e02298-639d-4449-88ed-16a67db46dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_4d6469bc-6706-40ff-a405-2fbfb6591cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2594e697-27fc-4748-ae1c-5e9412986e1a" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_4d6469bc-6706-40ff-a405-2fbfb6591cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20240930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da2d5f96-1f50-451c-8d1c-ba7081ead947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_fe230a8b-4f8e-4dc5-9445-3ca0ac05d3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da2d5f96-1f50-451c-8d1c-ba7081ead947" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_fe230a8b-4f8e-4dc5-9445-3ca0ac05d3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_4cf29da7-2e68-4989-8778-6fc2ee81ed33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da2d5f96-1f50-451c-8d1c-ba7081ead947" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_4cf29da7-2e68-4989-8778-6fc2ee81ed33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_a9f2d52a-549e-4982-89da-6ddcb8b7daff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da2d5f96-1f50-451c-8d1c-ba7081ead947" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_a9f2d52a-549e-4982-89da-6ddcb8b7daff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20240930.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_801af441-0930-4883-a478-7215442381fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_85a9af7f-ce1a-489a-a846-882707b96a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_801af441-0930-4883-a478-7215442381fb" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_85a9af7f-ce1a-489a-a846-882707b96a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_a85c2a78-1ce1-4900-82d8-7d0b7dfae125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_801af441-0930-4883-a478-7215442381fb" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_a85c2a78-1ce1-4900-82d8-7d0b7dfae125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_14d14d7d-2cfa-48a2-b050-7c81893fddac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_801af441-0930-4883-a478-7215442381fb" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_14d14d7d-2cfa-48a2-b050-7c81893fddac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_916665fb-f7c9-4e77-b16a-2ed98a4ae666" xlink:href="biib-20240930.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_801af441-0930-4883-a478-7215442381fb" xlink:to="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_916665fb-f7c9-4e77-b16a-2ed98a4ae666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20240930.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0e484f2d-8a32-4945-b4da-81bb55e89459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74629538-a056-4bf0-9414-770a1b2467c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0e484f2d-8a32-4945-b4da-81bb55e89459" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_74629538-a056-4bf0-9414-770a1b2467c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_cf6f4f97-add3-4c31-b523-a50dd87299f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0e484f2d-8a32-4945-b4da-81bb55e89459" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_cf6f4f97-add3-4c31-b523-a50dd87299f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20240930.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b488015e-e0d3-434d-9743-779ee3e4cfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_318a5c4f-63c3-4069-8d30-98056cd1bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b488015e-e0d3-434d-9743-779ee3e4cfb0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_318a5c4f-63c3-4069-8d30-98056cd1bf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20240930.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8ff34052-1fa6-41ed-975f-b8efd082203b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_46b5324f-b39a-4a20-a522-b4afad052940" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8ff34052-1fa6-41ed-975f-b8efd082203b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_46b5324f-b39a-4a20-a522-b4afad052940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3f65b350-353a-4e0d-917c-14726dea5793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8ff34052-1fa6-41ed-975f-b8efd082203b" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3f65b350-353a-4e0d-917c-14726dea5793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20240930.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3a2232c9-0263-4a25-92c2-57ac1edd8173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3856614d-26ae-4fb7-8bd7-77833233e4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a2232c9-0263-4a25-92c2-57ac1edd8173" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3856614d-26ae-4fb7-8bd7-77833233e4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20240930.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1656fb7-4e2e-4b17-ae13-be983c3f197d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5ea4342b-1e1c-42ee-bf6e-6718165b7e89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1656fb7-4e2e-4b17-ae13-be983c3f197d" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5ea4342b-1e1c-42ee-bf6e-6718165b7e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_a3e3b06b-00dc-44bf-9717-ad5d1109a89e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1656fb7-4e2e-4b17-ae13-be983c3f197d" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_a3e3b06b-00dc-44bf-9717-ad5d1109a89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ba010bb2-57fa-488a-9797-b109def1de96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1656fb7-4e2e-4b17-ae13-be983c3f197d" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ba010bb2-57fa-488a-9797-b109def1de96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2ac9f94-3b60-4a12-8aa5-d1fd9898556a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_ec186146-913e-4b5c-809a-4245410e5c24" xlink:href="biib-20240930.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2ac9f94-3b60-4a12-8aa5-d1fd9898556a" xlink:to="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_ec186146-913e-4b5c-809a-4245410e5c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_76a33d39-8b8a-454f-aef5-e77d909b21ce" xlink:href="biib-20240930.xsd#biib_PretaxProfitSharingFormulaTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2ac9f94-3b60-4a12-8aa5-d1fd9898556a" xlink:to="loc_biib_PretaxProfitSharingFormulaTableTextBlock_76a33d39-8b8a-454f-aef5-e77d909b21ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_139ead56-b27a-49e9-a43a-52557c2e41d4" xlink:href="biib-20240930.xsd#biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2ac9f94-3b60-4a12-8aa5-d1fd9898556a" xlink:to="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_139ead56-b27a-49e9-a43a-52557c2e41d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_45e97dc3-03fb-48b8-ab6c-453e54cc10f0" xlink:href="biib-20240930.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2ac9f94-3b60-4a12-8aa5-d1fd9898556a" xlink:to="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_45e97dc3-03fb-48b8-ab6c-453e54cc10f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_dac59a9b-8d8d-4bfc-be97-5c6e124ba81d" xlink:href="biib-20240930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2ac9f94-3b60-4a12-8aa5-d1fd9898556a" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_dac59a9b-8d8d-4bfc-be97-5c6e124ba81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_0db16c49-d91f-4155-9bbd-a34c914044b1" xlink:href="biib-20240930.xsd#biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2ac9f94-3b60-4a12-8aa5-d1fd9898556a" xlink:to="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_0db16c49-d91f-4155-9bbd-a34c914044b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_652eab8b-c404-42b6-bfb3-5b8b75f84254" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_4f5d2751-4674-4237-927e-447802beb10f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_652eab8b-c404-42b6-bfb3-5b8b75f84254" xlink:to="loc_us-gaap_NumberOfReportableSegments_4f5d2751-4674-4237-927e-447802beb10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_873e0500-e9c0-48d6-8ea6-3f74aa73e01e" xlink:href="biib-20240930.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_652eab8b-c404-42b6-bfb3-5b8b75f84254" xlink:to="loc_biib_InterestInSubsidiary_873e0500-e9c0-48d6-8ea6-3f74aa73e01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4dc4955a-8292-4c4c-b971-c166c5601bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4dc4955a-8292-4c4c-b971-c166c5601bf1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_653badff-ae1c-47a0-8276-131d62f2b13f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_653badff-ae1c-47a0-8276-131d62f2b13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c1e6f76-c529-4d7f-a997-509fadeb72ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_653badff-ae1c-47a0-8276-131d62f2b13f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c1e6f76-c529-4d7f-a997-509fadeb72ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_ee66fc1e-0756-4c85-b8cf-fed87ffe21de" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c1e6f76-c529-4d7f-a997-509fadeb72ef" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_ee66fc1e-0756-4c85-b8cf-fed87ffe21de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_a9f606d3-bcd7-4c03-a021-a81f66fd8f93" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0c1e6f76-c529-4d7f-a997-509fadeb72ef" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_a9f606d3-bcd7-4c03-a021-a81f66fd8f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40fe4ee2-44a4-4d76-858d-a83cf781c74a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40fe4ee2-44a4-4d76-858d-a83cf781c74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_40fe4ee2-44a4-4d76-858d-a83cf781c74a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_f82fe95f-8a37-4e4d-9e55-e1ba4d465e22" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:to="loc_biib_SKYCLARYSMember_f82fe95f-8a37-4e4d-9e55-e1ba4d465e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5ad52ae7-13f8-48e1-8269-10fbf2696c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5ad52ae7-13f8-48e1-8269-10fbf2696c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_07ce7983-fdee-4bce-b686-385d28965618" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:to="loc_biib_PriorityReviewVoucherMember_07ce7983-fdee-4bce-b686-385d28965618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_05b7083f-3331-44cf-81a5-d043ad9c9a3e" xlink:href="biib-20240930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d0625cac-cbf6-44e0-9480-6f7763b81c2e" xlink:to="loc_biib_OtherClinicalProgramsMember_05b7083f-3331-44cf-81a5-d043ad9c9a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a59d5fd6-095d-46ff-a222-e2ed4cfe109d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a59d5fd6-095d-46ff-a222-e2ed4cfe109d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9b60206-7146-45e7-a303-882222bb495c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a59d5fd6-095d-46ff-a222-e2ed4cfe109d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9b60206-7146-45e7-a303-882222bb495c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_39a98c24-9a3a-45d4-b828-1b7e9a734278" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9b60206-7146-45e7-a303-882222bb495c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_39a98c24-9a3a-45d4-b828-1b7e9a734278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e018a66d-1994-480c-8fe8-e46eec85e0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9b60206-7146-45e7-a303-882222bb495c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e018a66d-1994-480c-8fe8-e46eec85e0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2d2711c7-e749-4ff5-902f-67d40cc5e80c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_srt_StatementScenarioAxis_2d2711c7-e749-4ff5-902f-67d40cc5e80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d9962010-284f-421d-b0c8-6b6241e8309a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2d2711c7-e749-4ff5-902f-67d40cc5e80c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d9962010-284f-421d-b0c8-6b6241e8309a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_695cb410-e698-41c7-a312-aff12a0a3d1a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_d9962010-284f-421d-b0c8-6b6241e8309a" xlink:to="loc_srt_ScenarioForecastMember_695cb410-e698-41c7-a312-aff12a0a3d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_59b09223-a073-421c-8146-879bd9b6966b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_CreditFacilityAxis_59b09223-a073-421c-8146-879bd9b6966b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5b074665-a7c1-43fa-af3c-97b5b06abef2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_59b09223-a073-421c-8146-879bd9b6966b" xlink:to="loc_us-gaap_CreditFacilityDomain_5b074665-a7c1-43fa-af3c-97b5b06abef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ac2493da-74d4-4dbe-9feb-b4c760cd414d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5b074665-a7c1-43fa-af3c-97b5b06abef2" xlink:to="loc_us-gaap_SecuredDebtMember_ac2493da-74d4-4dbe-9feb-b4c760cd414d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f4b5dc2d-f228-47a5-861c-e6684d1ac193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_DebtInstrumentAxis_f4b5dc2d-f228-47a5-861c-e6684d1ac193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_93729c74-c8cb-4b16-b6b8-a63f3cddc655" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f4b5dc2d-f228-47a5-861c-e6684d1ac193" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_93729c74-c8cb-4b16-b6b8-a63f3cddc655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_a8fe533a-bcea-477c-b9ed-7223060c7233" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_93729c74-c8cb-4b16-b6b8-a63f3cddc655" xlink:to="loc_biib_TheCreditFacilityMember_a8fe533a-bcea-477c-b9ed-7223060c7233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a42024b5-fa03-4318-aa01-752787a77d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a42024b5-fa03-4318-aa01-752787a77d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_928130cf-b959-477a-bd6d-925b7baeaed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a42024b5-fa03-4318-aa01-752787a77d8d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_928130cf-b959-477a-bd6d-925b7baeaed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1dbc5f6a-055b-4bc0-9f13-6f4b57007874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_928130cf-b959-477a-bd6d-925b7baeaed2" xlink:to="loc_us-gaap_LineOfCreditMember_1dbc5f6a-055b-4bc0-9f13-6f4b57007874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8007f6ff-0c8c-4fe3-9ada-c432cebbb6d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_srt_ProductOrServiceAxis_8007f6ff-0c8c-4fe3-9ada-c432cebbb6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_df1253ff-1e14-4fee-8ecc-ba65ae78e83b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8007f6ff-0c8c-4fe3-9ada-c432cebbb6d9" xlink:to="loc_srt_ProductsAndServicesDomain_df1253ff-1e14-4fee-8ecc-ba65ae78e83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember_f0fa5026-9366-4f3f-8318-95656ed8219f" xlink:href="biib-20240930.xsd#biib_ClinicalInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_df1253ff-1e14-4fee-8ecc-ba65ae78e83b" xlink:to="loc_biib_ClinicalInventoryMember_f0fa5026-9366-4f3f-8318-95656ed8219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAndIzastobartHIB210Member_7417586f-d631-4ea8-a8fd-f0ff3fa066c1" xlink:href="biib-20240930.xsd#biib_FelzartamabAndIzastobartHIB210Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_df1253ff-1e14-4fee-8ecc-ba65ae78e83b" xlink:to="loc_biib_FelzartamabAndIzastobartHIB210Member_7417586f-d631-4ea8-a8fd-f0ff3fa066c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_50d8e092-f3a0-4ae5-8b2a-1b5f6ddf1993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_50d8e092-f3a0-4ae5-8b2a-1b5f6ddf1993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_1935c030-910c-42c3-81cf-c5c8dd00786a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_50d8e092-f3a0-4ae5-8b2a-1b5f6ddf1993" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_1935c030-910c-42c3-81cf-c5c8dd00786a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember_69c9db1f-bcfa-4503-92d0-4debffcf2c24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_1935c030-910c-42c3-81cf-c5c8dd00786a" xlink:to="loc_us-gaap_FairValueAdjustmentToInventoryMember_69c9db1f-bcfa-4503-92d0-4debffcf2c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8120cd8a-57d8-4e1c-ae84-a37d6d4dbcf5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_srt_RangeAxis_8120cd8a-57d8-4e1c-ae84-a37d6d4dbcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c3c76d54-20b1-4660-a235-84674c5fb442" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8120cd8a-57d8-4e1c-ae84-a37d6d4dbcf5" xlink:to="loc_srt_RangeMember_c3c76d54-20b1-4660-a235-84674c5fb442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_499c78ab-b40c-45d3-876a-4cb395da1b6c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c3c76d54-20b1-4660-a235-84674c5fb442" xlink:to="loc_srt_MinimumMember_499c78ab-b40c-45d3-876a-4cb395da1b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5cd7fbc7-bb3f-4af3-b84f-bb54e9928233" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c3c76d54-20b1-4660-a235-84674c5fb442" xlink:to="loc_srt_MaximumMember_5cd7fbc7-bb3f-4af3-b84f-bb54e9928233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_8205d069-1703-4f0d-aace-80093e3157aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_8205d069-1703-4f0d-aace-80093e3157aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_8205d069-1703-4f0d-aace-80093e3157aa" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_f2b0c886-ff9d-446a-9a6b-035bcf83d106" xlink:href="biib-20240930.xsd#biib_Phase3ClinicalTrialFelzartamabOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_f2b0c886-ff9d-446a-9a6b-035bcf83d106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_6ce38508-d1b5-4530-ae6f-4f1f06e85b0d" xlink:href="biib-20240930.xsd#biib_Phase3ClinicalTrialFelzartamabTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_6ce38508-d1b5-4530-ae6f-4f1f06e85b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentFutureDevelopmentMember_63394fd7-e984-40de-83bb-dc06f9e2e43e" xlink:href="biib-20240930.xsd#biib_MilestonePaymentFutureDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:to="loc_biib_MilestonePaymentFutureDevelopmentMember_63394fd7-e984-40de-83bb-dc06f9e2e43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentRegulatoryMember_2c3fa8f2-8e94-4ea6-908b-d984cc68a081" xlink:href="biib-20240930.xsd#biib_MilestonePaymentRegulatoryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:to="loc_biib_MilestonePaymentRegulatoryMember_2c3fa8f2-8e94-4ea6-908b-d984cc68a081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentCommercialMember_e4cb620b-3fbb-44b5-9939-611f740e93a1" xlink:href="biib-20240930.xsd#biib_MilestonePaymentCommercialMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b4dd95f5-a517-4f15-ab97-32b3f65eef95" xlink:to="loc_biib_MilestonePaymentCommercialMember_e4cb620b-3fbb-44b5-9939-611f740e93a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_5753bb63-b217-4aee-9b52-c1c3160a1554" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_srt_RestatementAxis_5753bb63-b217-4aee-9b52-c1c3160a1554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_13e44009-1367-4c8f-bb89-ae94b69d84ea" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_5753bb63-b217-4aee-9b52-c1c3160a1554" xlink:to="loc_srt_RestatementDomain_13e44009-1367-4c8f-bb89-ae94b69d84ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_d1a25da3-2848-495c-a1e4-83d11904a4dc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_13e44009-1367-4c8f-bb89-ae94b69d84ea" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_d1a25da3-2848-495c-a1e4-83d11904a4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ad9c5fb7-7497-41a7-b4d8-c40bae3e3f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ad9c5fb7-7497-41a7-b4d8-c40bae3e3f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_37d30d04-1f9c-4dd2-8cfc-b10facfa4ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ad9c5fb7-7497-41a7-b4d8-c40bae3e3f3f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_37d30d04-1f9c-4dd2-8cfc-b10facfa4ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8ea78600-dd50-4d87-b3c0-a2464c377620" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_37d30d04-1f9c-4dd2-8cfc-b10facfa4ff1" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8ea78600-dd50-4d87-b3c0-a2464c377620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MeasurementInputProbabilityRateMember_509a97c6-11e7-4d3a-af27-e76b958ab76e" xlink:href="biib-20240930.xsd#biib_MeasurementInputProbabilityRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_37d30d04-1f9c-4dd2-8cfc-b10facfa4ff1" xlink:to="loc_biib_MeasurementInputProbabilityRateMember_509a97c6-11e7-4d3a-af27-e76b958ab76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_5fb96214-d930-490e-ad0e-b8e312e486b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_5fb96214-d930-490e-ad0e-b8e312e486b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_97a7d5d6-f934-4c38-a6cf-069d9494e56d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_5fb96214-d930-490e-ad0e-b8e312e486b3" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_97a7d5d6-f934-4c38-a6cf-069d9494e56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_67837e05-95f4-4217-be83-563de5f1a1c6" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_97a7d5d6-f934-4c38-a6cf-069d9494e56d" xlink:to="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_67837e05-95f4-4217-be83-563de5f1a1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed695692-b09c-4485-8572-c5b53a5bf4eb" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2ad7ed5a-32b9-444e-86a5-0a3ff5986c15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2ad7ed5a-32b9-444e-86a5-0a3ff5986c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_43b1b495-86c3-49e5-9309-4ec63b4b81b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_43b1b495-86c3-49e5-9309-4ec63b4b81b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_b04aea23-c9d1-4018-8260-a1db3bffc26f" xlink:href="biib-20240930.xsd#biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_b04aea23-c9d1-4018-8260-a1db3bffc26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_76c41cdb-296a-4808-93c7-176346ff99db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_76c41cdb-296a-4808-93c7-176346ff99db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_4747d97d-9fb0-406f-9cc1-4d655ba611c1" xlink:href="biib-20240930.xsd#biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_4747d97d-9fb0-406f-9cc1-4d655ba611c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a21fe70c-01b8-4c87-9412-61969f89700e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a21fe70c-01b8-4c87-9412-61969f89700e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a6821d42-5bc6-4a2a-b48c-03646ee5666b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a6821d42-5bc6-4a2a-b48c-03646ee5666b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2ae522f4-43fb-4493-874d-d7f8935a6be1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2ae522f4-43fb-4493-874d-d7f8935a6be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8ff8f9a7-4c0c-4def-a18b-fc358ccd2d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8ff8f9a7-4c0c-4def-a18b-fc358ccd2d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5a484336-6c77-4d86-b3f7-acad32431baa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5a484336-6c77-4d86-b3f7-acad32431baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetMeasurementInput_b64e08c5-8bae-49bf-a6f8-9d6aafe5b1d5" xlink:href="biib-20240930.xsd#biib_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_IntangibleAssetMeasurementInput_b64e08c5-8bae-49bf-a6f8-9d6aafe5b1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9dab4032-d21d-409e-b7b2-45eac26c8123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_Goodwill_9dab4032-d21d-409e-b7b2-45eac26c8123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_72e07313-7fac-447d-8d09-8a608e381339" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_72e07313-7fac-447d-8d09-8a608e381339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_349928a9-823c-408e-8d31-07cc3fffdf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_349928a9-823c-408e-8d31-07cc3fffdf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_e3491143-be89-41f5-9366-4b63881972c9" xlink:href="biib-20240930.xsd#biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_e3491143-be89-41f5-9366-4b63881972c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_757e8ce3-992c-4df0-9f21-2f5039f806a6" xlink:href="biib-20240930.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_757e8ce3-992c-4df0-9f21-2f5039f806a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_53a684f3-28a4-4fe7-b571-149c5f9faf03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_OperatingExpenses_53a684f3-28a4-4fe7-b571-149c5f9faf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_27064e92-e566-4380-b858-c3393bb19a99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_27064e92-e566-4380-b858-c3393bb19a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_07328301-1178-4b5a-aa84-e40954fd0287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_07328301-1178-4b5a-aa84-e40954fd0287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8a671065-1308-4f5e-9218-55af5aad8ece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8a671065-1308-4f5e-9218-55af5aad8ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e6c8cec9-d5a9-4aac-9f5b-ac74adb5705e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e6c8cec9-d5a9-4aac-9f5b-ac74adb5705e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2480e305-b0b4-43a3-9a4a-8a3d77a97486" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_2480e305-b0b4-43a3-9a4a-8a3d77a97486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_03cfc9c3-38b7-4986-8a12-52b2c95015a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_ProfitLoss_03cfc9c3-38b7-4986-8a12-52b2c95015a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a9e6dfd6-8785-40f1-8266-fdea95a4be71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a9e6dfd6-8785-40f1-8266-fdea95a4be71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_ae52c197-21ee-4e57-8691-1c39de306625" xlink:href="biib-20240930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_ae52c197-21ee-4e57-8691-1c39de306625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_67f9650d-90d4-4c68-bb2d-bdc88068a1ac" xlink:href="biib-20240930.xsd#biib_OperatingLeaseArea"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_OperatingLeaseArea_67f9650d-90d4-4c68-bb2d-bdc88068a1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_071ff27b-3305-44e3-bde2-d0f5a01bc17f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_071ff27b-3305-44e3-bde2-d0f5a01bc17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_b0cd3bbc-aa02-4307-ba72-c2ebe2f25dc3" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_b0cd3bbc-aa02-4307-ba72-c2ebe2f25dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c2ccb453-925a-433b-97ec-a26590740cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c2ccb453-925a-433b-97ec-a26590740cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_7a5fdc1e-f614-48a3-ac24-595d568f88de" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_7a5fdc1e-f614-48a3-ac24-595d568f88de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_ee530a80-1112-4bee-9bc4-e5a98b5b76d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d8076f87-81bd-410a-b068-558d51643dca" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_ee530a80-1112-4bee-9bc4-e5a98b5b76d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#AcquisitionsPurchasePriceConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a3989a09-8ffa-42b4-8f93-48e4ba501ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3c6630f-8041-4869-917d-dc6fd11bcc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a3989a09-8ffa-42b4-8f93-48e4ba501ec4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3c6630f-8041-4869-917d-dc6fd11bcc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_db0ea3f9-679b-4b0d-9bd2-a2ee1348273e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3c6630f-8041-4869-917d-dc6fd11bcc5b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_db0ea3f9-679b-4b0d-9bd2-a2ee1348273e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5953cb1f-0ca3-43aa-b580-ee0868d951aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_db0ea3f9-679b-4b0d-9bd2-a2ee1348273e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5953cb1f-0ca3-43aa-b580-ee0868d951aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_3d4e28df-dce5-4bab-b631-0aa35b0678e0" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5953cb1f-0ca3-43aa-b580-ee0868d951aa" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_3d4e28df-dce5-4bab-b631-0aa35b0678e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_9693cf20-e4cf-47d6-b207-a04915993ec2" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5953cb1f-0ca3-43aa-b580-ee0868d951aa" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_9693cf20-e4cf-47d6-b207-a04915993ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_ec2d84fe-0cb2-4028-ab3c-cc55585a9011" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3c6630f-8041-4869-917d-dc6fd11bcc5b" xlink:to="loc_srt_RestatementAxis_ec2d84fe-0cb2-4028-ab3c-cc55585a9011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_4a042205-90da-4883-aafd-70844dee3033" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_ec2d84fe-0cb2-4028-ab3c-cc55585a9011" xlink:to="loc_srt_RestatementDomain_4a042205-90da-4883-aafd-70844dee3033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_6e861d74-9b4d-4560-a6d2-aca01505f7a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_4a042205-90da-4883-aafd-70844dee3033" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_6e861d74-9b4d-4560-a6d2-aca01505f7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a3c6630f-8041-4869-917d-dc6fd11bcc5b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1efa52fd-8907-4900-872f-aba8c2fbf9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1efa52fd-8907-4900-872f-aba8c2fbf9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1ab480a3-675e-4ba0-acba-dc3ad7cad259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_1ab480a3-675e-4ba0-acba-dc3ad7cad259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_acdd748e-f2a1-490c-bd3f-629aa7454f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_acdd748e-f2a1-490c-bd3f-629aa7454f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_f68858d6-e54c-4ec7-8b0d-a8a70964f827" xlink:href="biib-20240930.xsd#biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_f68858d6-e54c-4ec7-8b0d-a8a70964f827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_acf151c5-deb5-4035-9b3b-99bd761285c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_acf151c5-deb5-4035-9b3b-99bd761285c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_696a54f1-16b0-4177-a002-bd238a292520" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_696a54f1-16b0-4177-a002-bd238a292520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_9e49f202-5ac2-484a-8837-0651fb228e48" xlink:href="biib-20240930.xsd#biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b990b05f-2289-4b3a-b5a4-8643211d375e" xlink:to="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_9e49f202-5ac2-484a-8837-0651fb228e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3c0b1ac2-2bd5-47fd-a2a3-10a3196ca381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3c0b1ac2-2bd5-47fd-a2a3-10a3196ca381" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4b483958-a796-4857-92e5-8b9a30e96b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4b483958-a796-4857-92e5-8b9a30e96b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4621ccf1-0d93-45ca-82b9-ccaa653cf3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4b483958-a796-4857-92e5-8b9a30e96b1f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4621ccf1-0d93-45ca-82b9-ccaa653cf3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_af34bb49-8a1a-450c-b19e-86f86bdf1370" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4621ccf1-0d93-45ca-82b9-ccaa653cf3ba" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_af34bb49-8a1a-450c-b19e-86f86bdf1370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_0fbd77dc-1c0a-4062-bf59-1ecda9a9b60a" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4621ccf1-0d93-45ca-82b9-ccaa653cf3ba" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_0fbd77dc-1c0a-4062-bf59-1ecda9a9b60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57ac9cc9-a622-433c-a036-fadbcccef037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57ac9cc9-a622-433c-a036-fadbcccef037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_57ac9cc9-a622-433c-a036-fadbcccef037" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_dafae641-9259-4e09-91c8-fb899fa037a4" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:to="loc_biib_SKYCLARYSMember_dafae641-9259-4e09-91c8-fb899fa037a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4772ce8b-cbbc-4f21-80e0-a8dc08797f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4772ce8b-cbbc-4f21-80e0-a8dc08797f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_fb54e98c-aa0f-45e7-8638-7f464248eb43" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:to="loc_biib_PriorityReviewVoucherMember_fb54e98c-aa0f-45e7-8638-7f464248eb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_edf6d41e-a04a-4bc8-93bd-2525d84a6f54" xlink:href="biib-20240930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_075dd4a4-d5ed-4dfd-a742-5ac6e1e25faf" xlink:to="loc_biib_OtherClinicalProgramsMember_edf6d41e-a04a-4bc8-93bd-2525d84a6f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a718a41b-ac05-42d6-b4e5-2649771798f6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:to="loc_srt_ProductOrServiceAxis_a718a41b-ac05-42d6-b4e5-2649771798f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_788f2989-fddc-4269-a67b-e0360dbf219d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a718a41b-ac05-42d6-b4e5-2649771798f6" xlink:to="loc_srt_ProductsAndServicesDomain_788f2989-fddc-4269-a67b-e0360dbf219d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabIgANMember_74b6b267-c5f2-404b-8070-768dd83a10f2" xlink:href="biib-20240930.xsd#biib_FelzartamabIgANMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_788f2989-fddc-4269-a67b-e0360dbf219d" xlink:to="loc_biib_FelzartamabIgANMember_74b6b267-c5f2-404b-8070-768dd83a10f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAMRMember_662e4b21-62fe-418d-b2eb-ac5adbbd48ff" xlink:href="biib-20240930.xsd#biib_FelzartamabAMRMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_788f2989-fddc-4269-a67b-e0360dbf219d" xlink:to="loc_biib_FelzartamabAMRMember_662e4b21-62fe-418d-b2eb-ac5adbbd48ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabPMNMember_12d6f902-8ac4-4858-bd48-d31aa6e180c7" xlink:href="biib-20240930.xsd#biib_FelzartamabPMNMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_788f2989-fddc-4269-a67b-e0360dbf219d" xlink:to="loc_biib_FelzartamabPMNMember_12d6f902-8ac4-4858-bd48-d31aa6e180c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95d37ab8-e7ea-4c50-aaa4-cb6a0d8ca974" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_249c49ab-7929-47b0-85bd-7328cf420f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_249c49ab-7929-47b0-85bd-7328cf420f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_008eab9c-8740-40b5-a160-1a27e20c69f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_008eab9c-8740-40b5-a160-1a27e20c69f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_499bf98f-5c30-49b0-ab9c-3d6757e0f642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_499bf98f-5c30-49b0-ab9c-3d6757e0f642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_02b1655f-1515-4e89-acf4-5afb22b9b5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_02b1655f-1515-4e89-acf4-5afb22b9b5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e3a3fbf5-ff96-46bd-a3a8-54dc1a475107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e3a3fbf5-ff96-46bd-a3a8-54dc1a475107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_89c14905-08b5-470d-a210-b5c3f5c73f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_89c14905-08b5-470d-a210-b5c3f5c73f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_58438e96-6aa7-463b-a8d1-79e2f01f1d9f" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_58438e96-6aa7-463b-a8d1-79e2f01f1d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_422ef87d-9827-4aee-b95e-cd81eaa4923c" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_422ef87d-9827-4aee-b95e-cd81eaa4923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6927db7f-6e46-40ef-be63-125443538cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6927db7f-6e46-40ef-be63-125443538cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_6bcebe6b-6428-4108-a6ab-9795e82c500c" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_6bcebe6b-6428-4108-a6ab-9795e82c500c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_c76359ea-8d10-4eda-85fa-5e4393e40944" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_c76359ea-8d10-4eda-85fa-5e4393e40944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_7770f9cb-7e81-44ca-8938-b17c68cd2c61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_7770f9cb-7e81-44ca-8938-b17c68cd2c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b2dc8865-b0ea-4b5b-9c0a-a08aae5e2a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b2dc8865-b0ea-4b5b-9c0a-a08aae5e2a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_cb94d63c-e257-4060-b123-e8d173cb34a3" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_cb94d63c-e257-4060-b123-e8d173cb34a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_148a47eb-c776-4b38-8f1d-fb60861efac7" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_148a47eb-c776-4b38-8f1d-fb60861efac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a1d4a4f1-5627-442b-8fdd-2b1110133544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a1d4a4f1-5627-442b-8fdd-2b1110133544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f1f7a07e-2774-4261-913f-9445b2d90c47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_Goodwill_f1f7a07e-2774-4261-913f-9445b2d90c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_82c88ffb-7e16-451c-a060-89645017d394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_82c88ffb-7e16-451c-a060-89645017d394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_b1afef7c-01da-4d7a-94dc-074df2934c30" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther_b1afef7c-01da-4d7a-94dc-074df2934c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_ce849c1b-1b5f-495b-93ae-745351885388" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_ce849c1b-1b5f-495b-93ae-745351885388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_348cbac6-8df2-48fd-b1a7-e0fb7e9a09fd" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_348cbac6-8df2-48fd-b1a7-e0fb7e9a09fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets_b83d2876-83ac-4bf4-b704-4546a568c31d" xlink:href="biib-20240930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9077c1d7-c170-41dc-98bd-5686fbbcaa6c" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets_b83d2876-83ac-4bf4-b704-4546a568c31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20240930.xsd#DispositionsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_aa713d5d-0653-4a06-86b6-32dd3722c2d4" xlink:href="biib-20240930.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_aa713d5d-0653-4a06-86b6-32dd3722c2d4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c75f2128-9957-445a-878f-673320e6efd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c75f2128-9957-445a-878f-673320e6efd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea1f4c7a-042f-4315-a649-9b6e9036f1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c75f2128-9957-445a-878f-673320e6efd7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea1f4c7a-042f-4315-a649-9b6e9036f1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_66e8f0a7-f77c-4b8e-81bd-395cab8f1a7b" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea1f4c7a-042f-4315-a649-9b6e9036f1d8" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_66e8f0a7-f77c-4b8e-81bd-395cab8f1a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_52d5b5a9-a007-4656-9acb-a00ced0479e2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_52d5b5a9-a007-4656-9acb-a00ced0479e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b7a207fe-3d07-40f6-beb1-eb6c66513784" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_52d5b5a9-a007-4656-9acb-a00ced0479e2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b7a207fe-3d07-40f6-beb1-eb6c66513784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_75f23deb-b1f8-484c-8b44-ceee0f11f92c" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b7a207fe-3d07-40f6-beb1-eb6c66513784" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_75f23deb-b1f8-484c-8b44-ceee0f11f92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_e8ec87cd-a86f-4794-a6ce-e0b405d01477" xlink:href="biib-20240930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_e8ec87cd-a86f-4794-a6ce-e0b405d01477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_7187198a-608e-4bc3-9813-f20c56186fe5" xlink:href="biib-20240930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_e8ec87cd-a86f-4794-a6ce-e0b405d01477" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_7187198a-608e-4bc3-9813-f20c56186fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_4cc36551-ea64-469c-915e-295721b14292" xlink:href="biib-20240930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_7187198a-608e-4bc3-9813-f20c56186fe5" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_4cc36551-ea64-469c-915e-295721b14292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_db837151-0cee-4312-b37a-a4eafcbd090a" xlink:href="biib-20240930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_7187198a-608e-4bc3-9813-f20c56186fe5" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_db837151-0cee-4312-b37a-a4eafcbd090a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5dfd7c8e-d858-48af-87b2-3811271a72f3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:to="loc_srt_CounterpartyNameAxis_5dfd7c8e-d858-48af-87b2-3811271a72f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8cc7f8f0-dc2b-493a-9861-234064c3918f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5dfd7c8e-d858-48af-87b2-3811271a72f3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8cc7f8f0-dc2b-493a-9861-234064c3918f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_6915ef67-29ff-4eb0-88a2-13895f477bf8" xlink:href="biib-20240930.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8cc7f8f0-dc2b-493a-9861-234064c3918f" xlink:to="loc_biib_IonisPharmaceuticalsInc.Member_6915ef67-29ff-4eb0-88a2-13895f477bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2c86e509-3c6d-4538-bf91-c38f0151957d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_90faaae2-a5c9-4ee5-ad97-91a7e4b2e04b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_90faaae2-a5c9-4ee5-ad97-91a7e4b2e04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_552f2bb8-833e-486a-b86b-70f80d59a201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_552f2bb8-833e-486a-b86b-70f80d59a201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_8cd95431-2d0f-4d04-9acd-1c1c5b3514c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_8cd95431-2d0f-4d04-9acd-1c1c5b3514c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_a1ca62b0-74fe-4a82-b49b-fc1797af391c" xlink:href="biib-20240930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_a1ca62b0-74fe-4a82-b49b-fc1797af391c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6f0c0d5c-9d7e-4490-ab4c-235a85bc02af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6f0c0d5c-9d7e-4490-ab4c-235a85bc02af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_10ef3af8-4e9f-4081-a2d5-a4c9c32ede7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_10ef3af8-4e9f-4081-a2d5-a4c9c32ede7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0ba8d07c-a117-4589-baee-9bf8d95a2cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_AccountsPayableCurrent_0ba8d07c-a117-4589-baee-9bf8d95a2cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_b020d0ec-5fde-483d-994c-067dec08faaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_64060da0-f457-4cda-9f8e-f19af98416d4" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_b020d0ec-5fde-483d-994c-067dec08faaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_311f49dd-8f68-4f35-9ce3-fa3f8a6e3a92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_27f9d5c9-aad3-421e-aa49-e7b6c9bb5b69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_311f49dd-8f68-4f35-9ce3-fa3f8a6e3a92" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_27f9d5c9-aad3-421e-aa49-e7b6c9bb5b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3dddb19c-239a-4491-8a66-c48128ab000f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_27f9d5c9-aad3-421e-aa49-e7b6c9bb5b69" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3dddb19c-239a-4491-8a66-c48128ab000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2fe0ef8a-a727-4231-835d-eaf2d61d8707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3dddb19c-239a-4491-8a66-c48128ab000f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2fe0ef8a-a727-4231-835d-eaf2d61d8707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_59aa4958-586d-4d3b-b5b6-d3893e080ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2fe0ef8a-a727-4231-835d-eaf2d61d8707" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_59aa4958-586d-4d3b-b5b6-d3893e080ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f32fb529-9e52-46a5-a12f-900dcc554b78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2fe0ef8a-a727-4231-835d-eaf2d61d8707" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f32fb529-9e52-46a5-a12f-900dcc554b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_28b9375a-00ae-474e-af2c-e8bdd12cc925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2fe0ef8a-a727-4231-835d-eaf2d61d8707" xlink:to="loc_us-gaap_RestructuringChargesMember_28b9375a-00ae-474e-af2c-e8bdd12cc925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_cbf56f45-981e-4bc7-b33f-dd9ed5ea58e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_27f9d5c9-aad3-421e-aa49-e7b6c9bb5b69" xlink:to="loc_us-gaap_RestructuringPlanAxis_cbf56f45-981e-4bc7-b33f-dd9ed5ea58e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_8ed144a7-199a-4597-8f99-4e985f27b4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_cbf56f45-981e-4bc7-b33f-dd9ed5ea58e1" xlink:to="loc_us-gaap_RestructuringPlanDomain_8ed144a7-199a-4597-8f99-4e985f27b4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_f51e7916-9a78-497f-ad16-ec1230f4e79c" xlink:href="biib-20240930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_8ed144a7-199a-4597-8f99-4e985f27b4c5" xlink:to="loc_biib_A2023CostSavingInitiativesMember_f51e7916-9a78-497f-ad16-ec1230f4e79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_d9142d7f-edcb-42ee-99ed-ee9dbfdd6e9f" xlink:href="biib-20240930.xsd#biib_ReataIntegrationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_8ed144a7-199a-4597-8f99-4e985f27b4c5" xlink:to="loc_biib_ReataIntegrationMember_d9142d7f-edcb-42ee-99ed-ee9dbfdd6e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8619b0d1-0de0-4c61-9152-e4beafe8c143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_27f9d5c9-aad3-421e-aa49-e7b6c9bb5b69" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8619b0d1-0de0-4c61-9152-e4beafe8c143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_1e73ad1d-79a2-4ff5-95ee-e68cd4f76d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8619b0d1-0de0-4c61-9152-e4beafe8c143" xlink:to="loc_us-gaap_SeveranceCosts1_1e73ad1d-79a2-4ff5-95ee-e68cd4f76d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_31087073-be4d-4e7d-8b9a-7c3082aa0057" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8619b0d1-0de0-4c61-9152-e4beafe8c143" xlink:to="loc_us-gaap_OtherRestructuringCosts_31087073-be4d-4e7d-8b9a-7c3082aa0057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f73ff384-383d-4dda-92f8-950b73d78b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8619b0d1-0de0-4c61-9152-e4beafe8c143" xlink:to="loc_us-gaap_RestructuringCharges_f73ff384-383d-4dda-92f8-950b73d78b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5e9ddde4-f2b3-454d-8ae8-0de799ee2a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_311f49dd-8f68-4f35-9ce3-fa3f8a6e3a92" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5e9ddde4-f2b3-454d-8ae8-0de799ee2a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a20293f4-1b09-4e52-97b8-34c11be57fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a20293f4-1b09-4e52-97b8-34c11be57fa1" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_b3c22550-6e57-4cbf-9cf0-70e49c0bd558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:to="loc_us-gaap_RestructuringPlanAxis_b3c22550-6e57-4cbf-9cf0-70e49c0bd558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_9996bb2e-e71e-4a40-9e95-88fb8326f102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_b3c22550-6e57-4cbf-9cf0-70e49c0bd558" xlink:to="loc_us-gaap_RestructuringPlanDomain_9996bb2e-e71e-4a40-9e95-88fb8326f102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_52e812f1-0b36-48b2-9b4b-46cfb32b54f4" xlink:href="biib-20240930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_9996bb2e-e71e-4a40-9e95-88fb8326f102" xlink:to="loc_biib_A2023CostSavingInitiativesMember_52e812f1-0b36-48b2-9b4b-46cfb32b54f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_acb3d043-266f-45de-a5d4-2f37483dfecd" xlink:href="biib-20240930.xsd#biib_ReataIntegrationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_9996bb2e-e71e-4a40-9e95-88fb8326f102" xlink:to="loc_biib_ReataIntegrationMember_acb3d043-266f-45de-a5d4-2f37483dfecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_83372d57-d039-4a73-976f-22bba980cd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_83372d57-d039-4a73-976f-22bba980cd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7283bbb6-c6aa-4b20-b19e-8ae6da4ce69b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_83372d57-d039-4a73-976f-22bba980cd4d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7283bbb6-c6aa-4b20-b19e-8ae6da4ce69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_982494e0-2236-4f87-b4ea-782ba7e21996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7283bbb6-c6aa-4b20-b19e-8ae6da4ce69b" xlink:to="loc_us-gaap_RestructuringChargesMember_982494e0-2236-4f87-b4ea-782ba7e21996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5c907b99-f6f1-4f5c-8b6c-2416e721b89e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:to="loc_srt_RangeAxis_5c907b99-f6f1-4f5c-8b6c-2416e721b89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_24980e12-ffa7-4e72-8b2f-2e49aec02906" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5c907b99-f6f1-4f5c-8b6c-2416e721b89e" xlink:to="loc_srt_RangeMember_24980e12-ffa7-4e72-8b2f-2e49aec02906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca52baf3-768f-4009-9897-324954b11322" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_24980e12-ffa7-4e72-8b2f-2e49aec02906" xlink:to="loc_srt_MinimumMember_ca52baf3-768f-4009-9897-324954b11322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d7029cb-e858-4a0a-a454-e5c29db288ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_24980e12-ffa7-4e72-8b2f-2e49aec02906" xlink:to="loc_srt_MaximumMember_9d7029cb-e858-4a0a-a454-e5c29db288ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_061c9fa6-f7e0-4265-b91d-4091b110b46a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_061c9fa6-f7e0-4265-b91d-4091b110b46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07c819b9-517e-4933-a313-d0906d6c395f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_061c9fa6-f7e0-4265-b91d-4091b110b46a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07c819b9-517e-4933-a313-d0906d6c395f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_ec91048b-0fc5-4cd1-9caf-f23e123d1cf3" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07c819b9-517e-4933-a313-d0906d6c395f" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_ec91048b-0fc5-4cd1-9caf-f23e123d1cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c540254c-2190-462d-bbde-a4711db82c99" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_a8175bd5-335d-44aa-840a-afb5e8bd2c3f" xlink:href="biib-20240930.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_a8175bd5-335d-44aa-840a-afb5e8bd2c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_68946724-a5ec-46b9-beaf-d458ce9ba288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_68946724-a5ec-46b9-beaf-d458ce9ba288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c6374417-c7be-474b-bde8-f738a7f2c12c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_SeveranceCosts1_c6374417-c7be-474b-bde8-f738a7f2c12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_48f67ff0-2c8c-48d8-a591-5acbe010c729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_48f67ff0-2c8c-48d8-a591-5acbe010c729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_7ca162d9-3402-4b12-8514-04b1b714904c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_7ca162d9-3402-4b12-8514-04b1b714904c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_7c90e1d5-d029-4ce0-863b-4b759e8a67e3" xlink:href="biib-20240930.xsd#biib_OperatingLeaseArea"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_biib_OperatingLeaseArea_7c90e1d5-d029-4ce0-863b-4b759e8a67e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f8d4a7cc-996a-4bc4-9a0a-b37e26bbe16f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f8d4a7cc-996a-4bc4-9a0a-b37e26bbe16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_57de8256-6338-43a2-bf94-3b4acefae49c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f73412ba-fc31-4e75-a4f7-accd30d9aa98" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_57de8256-6338-43a2-bf94-3b4acefae49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_42bf242d-93a7-4b3d-9d9c-c1a1286b6487" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_39d85336-9964-4879-b432-7318c82482b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_42bf242d-93a7-4b3d-9d9c-c1a1286b6487" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_39d85336-9964-4879-b432-7318c82482b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a0bfa550-e7d6-4de9-8ba0-b1b37c6db882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_39d85336-9964-4879-b432-7318c82482b5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a0bfa550-e7d6-4de9-8ba0-b1b37c6db882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_bc31a7d2-9e8f-46f1-a3a6-157628e2dc19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a0bfa550-e7d6-4de9-8ba0-b1b37c6db882" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_bc31a7d2-9e8f-46f1-a3a6-157628e2dc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_8492d451-1a85-4d05-9091-3ddf48448b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bc31a7d2-9e8f-46f1-a3a6-157628e2dc19" xlink:to="loc_us-gaap_EmployeeSeveranceMember_8492d451-1a85-4d05-9091-3ddf48448b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2ccc34bb-1cbe-4623-a691-e82d65403de5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_39d85336-9964-4879-b432-7318c82482b5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2ccc34bb-1cbe-4623-a691-e82d65403de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4c08b44d-998f-4bc0-b6d1-8d5786ae64b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2ccc34bb-1cbe-4623-a691-e82d65403de5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4c08b44d-998f-4bc0-b6d1-8d5786ae64b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_3fa89703-9066-4965-9d1f-d064045556ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4c08b44d-998f-4bc0-b6d1-8d5786ae64b8" xlink:to="loc_us-gaap_RestructuringChargesMember_3fa89703-9066-4965-9d1f-d064045556ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6b3a0e55-c1fa-4aae-b19e-929c25a64bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_39d85336-9964-4879-b432-7318c82482b5" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6b3a0e55-c1fa-4aae-b19e-929c25a64bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d0885910-a545-43df-aceb-2e1cc81fc5af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6b3a0e55-c1fa-4aae-b19e-929c25a64bea" xlink:to="loc_us-gaap_RestructuringCharges_d0885910-a545-43df-aceb-2e1cc81fc5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5a027d65-68a6-4e95-86f1-25ad03145831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82ba1cd3-31ca-4b86-a87b-d4b2e7d58799" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5a027d65-68a6-4e95-86f1-25ad03145831" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82ba1cd3-31ca-4b86-a87b-d4b2e7d58799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_46b5fb1e-2b02-4b2c-a579-b3abe3244eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82ba1cd3-31ca-4b86-a87b-d4b2e7d58799" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_46b5fb1e-2b02-4b2c-a579-b3abe3244eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_863d6ddd-991e-4234-b118-d0c350e6693e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_46b5fb1e-2b02-4b2c-a579-b3abe3244eaf" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_863d6ddd-991e-4234-b118-d0c350e6693e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_9909add0-410b-4dfd-a577-99f4866ecf93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_863d6ddd-991e-4234-b118-d0c350e6693e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_9909add0-410b-4dfd-a577-99f4866ecf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_cc5b735e-9c49-4280-a0d5-d50899d2b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82ba1cd3-31ca-4b86-a87b-d4b2e7d58799" xlink:to="loc_us-gaap_RestructuringPlanAxis_cc5b735e-9c49-4280-a0d5-d50899d2b1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_c264a97f-ef28-4e96-ab04-9ba7720b1c87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_cc5b735e-9c49-4280-a0d5-d50899d2b1df" xlink:to="loc_us-gaap_RestructuringPlanDomain_c264a97f-ef28-4e96-ab04-9ba7720b1c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_7c260366-9013-41e0-9545-61c1d5308dd0" xlink:href="biib-20240930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_c264a97f-ef28-4e96-ab04-9ba7720b1c87" xlink:to="loc_biib_A2023CostSavingInitiativesMember_7c260366-9013-41e0-9545-61c1d5308dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember_ece7a150-d3dd-4b49-8075-d7606c8c685d" xlink:href="biib-20240930.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_c264a97f-ef28-4e96-ab04-9ba7720b1c87" xlink:to="loc_biib_A2023And2022CostSavingInitiativesMember_ece7a150-d3dd-4b49-8075-d7606c8c685d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82ba1cd3-31ca-4b86-a87b-d4b2e7d58799" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f3685404-62ee-4029-988a-ef0b7e0b7d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:to="loc_us-gaap_RestructuringReserve_f3685404-62ee-4029-988a-ef0b7e0b7d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_7ccbd5c3-188b-47a7-978e-981d2d1a0dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:to="loc_us-gaap_RestructuringCharges_7ccbd5c3-188b-47a7-978e-981d2d1a0dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_e0d817da-6e60-407b-ab01-8b1d07912d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:to="loc_us-gaap_PaymentsForRestructuring_e0d817da-6e60-407b-ab01-8b1d07912d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment_021bd398-019d-47f8-ad9b-c5a45fa92c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:to="loc_us-gaap_RestructuringReserveTranslationAdjustment_021bd398-019d-47f8-ad9b-c5a45fa92c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_a112e81d-c669-4659-aa95-566fcc2d7c45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_daf02283-6aee-4b88-a1f1-e1792d84e3a4" xlink:to="loc_us-gaap_RestructuringReserve_a112e81d-c669-4659-aa95-566fcc2d7c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_25b13274-b01e-41c2-a3f1-715259222604" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0fdc6767-b550-4321-ac4d-fe1e9bf3235f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_25b13274-b01e-41c2-a3f1-715259222604" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0fdc6767-b550-4321-ac4d-fe1e9bf3235f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eaa21d59-4fe9-41db-ba79-113f89f7307d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0fdc6767-b550-4321-ac4d-fe1e9bf3235f" xlink:to="loc_srt_ProductOrServiceAxis_eaa21d59-4fe9-41db-ba79-113f89f7307d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_55fd981e-4a2e-4b43-b0f9-078f90b9ce40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_eaa21d59-4fe9-41db-ba79-113f89f7307d" xlink:to="loc_srt_ProductsAndServicesDomain_55fd981e-4a2e-4b43-b0f9-078f90b9ce40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_55fd981e-4a2e-4b43-b0f9-078f90b9ce40" xlink:to="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_e4c372ce-835d-4ae3-8a83-7357b30affbd" xlink:href="biib-20240930.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_MSProductRevenuesMember_e4c372ce-835d-4ae3-8a83-7357b30affbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_2cbeda7b-3182-4d70-b5fe-be72b77e6a9d" xlink:href="biib-20240930.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_e4c372ce-835d-4ae3-8a83-7357b30affbd" xlink:to="loc_biib_FumarateMember_2cbeda7b-3182-4d70-b5fe-be72b77e6a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_c3da04a5-5a63-4858-acf6-32a05e6483f4" xlink:href="biib-20240930.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_2cbeda7b-3182-4d70-b5fe-be72b77e6a9d" xlink:to="loc_biib_TECFIDERAMember_c3da04a5-5a63-4858-acf6-32a05e6483f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_04da5445-e069-49e2-8d86-a474607ccb6c" xlink:href="biib-20240930.xsd#biib_VUMERITYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_2cbeda7b-3182-4d70-b5fe-be72b77e6a9d" xlink:to="loc_biib_VUMERITYMember_04da5445-e069-49e2-8d86-a474607ccb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_8bca5d45-62f5-4c16-b193-0e475b9fad64" xlink:href="biib-20240930.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_e4c372ce-835d-4ae3-8a83-7357b30affbd" xlink:to="loc_biib_InterferonMember_8bca5d45-62f5-4c16-b193-0e475b9fad64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_01de4ab0-1c52-4e32-bb78-8c045bfb0164" xlink:href="biib-20240930.xsd#biib_AVONEXMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_8bca5d45-62f5-4c16-b193-0e475b9fad64" xlink:to="loc_biib_AVONEXMember_01de4ab0-1c52-4e32-bb78-8c045bfb0164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_94177a62-b525-4b0c-bbdf-01fa278d8673" xlink:href="biib-20240930.xsd#biib_PLEGRIDYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_8bca5d45-62f5-4c16-b193-0e475b9fad64" xlink:to="loc_biib_PLEGRIDYMember_94177a62-b525-4b0c-bbdf-01fa278d8673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_8dc8e44a-e4f8-4134-9760-9d5cc308d052" xlink:href="biib-20240930.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_TysabriProductMember_8dc8e44a-e4f8-4134-9760-9d5cc308d052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_1ff3e89c-761f-4be7-b727-c4ffd9de6d4d" xlink:href="biib-20240930.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_FAMPYRAMember_1ff3e89c-761f-4be7-b727-c4ffd9de6d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RareDiseaseProductRevenueMember_479ffd0a-7cef-442e-a718-d84a68124257" xlink:href="biib-20240930.xsd#biib_RareDiseaseProductRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_RareDiseaseProductRevenueMember_479ffd0a-7cef-442e-a718-d84a68124257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_QALSODYMember_6b0dbfe3-d047-43cb-94ee-3f0acd1d8162" xlink:href="biib-20240930.xsd#biib_QALSODYMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RareDiseaseProductRevenueMember_479ffd0a-7cef-442e-a718-d84a68124257" xlink:to="loc_biib_QALSODYMember_6b0dbfe3-d047-43cb-94ee-3f0acd1d8162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_65e50159-aa96-416b-8ec7-8eafbed354b2" xlink:href="biib-20240930.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RareDiseaseProductRevenueMember_479ffd0a-7cef-442e-a718-d84a68124257" xlink:to="loc_biib_SPINRAZAMember_65e50159-aa96-416b-8ec7-8eafbed354b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_53cae746-8bdc-4628-a6fd-9969abffc39f" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RareDiseaseProductRevenueMember_479ffd0a-7cef-442e-a718-d84a68124257" xlink:to="loc_biib_SKYCLARYSMember_53cae746-8bdc-4628-a6fd-9969abffc39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:href="biib-20240930.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_182f8ff5-e603-4fa0-b235-1d430841ba1c" xlink:href="biib-20240930.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:to="loc_biib_BENEPALIMember_182f8ff5-e603-4fa0-b235-1d430841ba1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_b48644b9-6243-47bd-b173-ea9fba930f4d" xlink:href="biib-20240930.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:to="loc_biib_IMRALDIMember_b48644b9-6243-47bd-b173-ea9fba930f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_5e92c3bb-39cf-47b2-bd1e-59c434624ee5" xlink:href="biib-20240930.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:to="loc_biib_FLIXABIMember_5e92c3bb-39cf-47b2-bd1e-59c434624ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_5243cad4-aa37-4a3b-99ff-c69356832c78" xlink:href="biib-20240930.xsd#biib_BYOOVIZMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:to="loc_biib_BYOOVIZMember_5243cad4-aa37-4a3b-99ff-c69356832c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TOFIDENCEMember_cd987cc1-c726-4fd4-b486-e7854504debd" xlink:href="biib-20240930.xsd#biib_TOFIDENCEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_72ab1d36-17bd-4644-867f-fe469555c08a" xlink:to="loc_biib_TOFIDENCEMember_cd987cc1-c726-4fd4-b486-e7854504debd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherProductsMember_2dc51197-d748-47e6-bd81-5e71252b1183" xlink:href="biib-20240930.xsd#biib_OtherProductsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ffaf160d-11a3-4fb1-9d84-79c9de56e60e" xlink:to="loc_biib_OtherProductsMember_2dc51197-d748-47e6-bd81-5e71252b1183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZURZUVAEMember_004f7dcb-31c5-45a9-876c-a0a6a420ca82" xlink:href="biib-20240930.xsd#biib_ZURZUVAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherProductsMember_2dc51197-d748-47e6-bd81-5e71252b1183" xlink:to="loc_biib_ZURZUVAEMember_004f7dcb-31c5-45a9-876c-a0a6a420ca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember_04cb4918-6eea-4052-82a0-f89e759168ae" xlink:href="biib-20240930.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherProductsMember_2dc51197-d748-47e6-bd81-5e71252b1183" xlink:to="loc_biib_FUMADERMAndADUHELMMember_04cb4918-6eea-4052-82a0-f89e759168ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9d49f492-8cee-462a-ac10-36baada4a445" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0fdc6767-b550-4321-ac4d-fe1e9bf3235f" xlink:to="loc_srt_StatementGeographicalAxis_9d49f492-8cee-462a-ac10-36baada4a445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd93f575-0f20-4fc8-b18d-d8435afb9768" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9d49f492-8cee-462a-ac10-36baada4a445" xlink:to="loc_srt_SegmentGeographicalDomain_cd93f575-0f20-4fc8-b18d-d8435afb9768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_864863ab-9e29-40e3-9068-d8851f9bade3" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cd93f575-0f20-4fc8-b18d-d8435afb9768" xlink:to="loc_country_US_864863ab-9e29-40e3-9068-d8851f9bade3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_96146907-1e04-40ad-ba07-d94065f6170b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cd93f575-0f20-4fc8-b18d-d8435afb9768" xlink:to="loc_us-gaap_NonUsMember_96146907-1e04-40ad-ba07-d94065f6170b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_322dcad7-2dfb-4c7c-aed7-d5ce17cb271f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0fdc6767-b550-4321-ac4d-fe1e9bf3235f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_322dcad7-2dfb-4c7c-aed7-d5ce17cb271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a00a420c-0491-4a76-b17f-2397ece9fd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_322dcad7-2dfb-4c7c-aed7-d5ce17cb271f" xlink:to="loc_us-gaap_Revenues_a00a420c-0491-4a76-b17f-2397ece9fd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_8f08614c-c117-461c-b4a9-53548c835c69" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_30adfde5-22e6-471b-b208-b8069b17b1f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_8f08614c-c117-461c-b4a9-53548c835c69" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_30adfde5-22e6-471b-b208-b8069b17b1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c48b1f9c-e24b-4fab-acf1-64ae90ca42a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_30adfde5-22e6-471b-b208-b8069b17b1f9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c48b1f9c-e24b-4fab-acf1-64ae90ca42a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_46953d0a-eefa-4c78-bc52-0b573555859f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c48b1f9c-e24b-4fab-acf1-64ae90ca42a8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_46953d0a-eefa-4c78-bc52-0b573555859f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_4844c5c8-5a6b-46c3-bdd9-740f4451d2f3" xlink:href="biib-20240930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_46953d0a-eefa-4c78-bc52-0b573555859f" xlink:to="loc_biib_ReserveforCashDiscountsMember_4844c5c8-5a6b-46c3-bdd9-740f4451d2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_731c1415-8e98-49dd-a36f-dcd14c27dc1a" xlink:href="biib-20240930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_46953d0a-eefa-4c78-bc52-0b573555859f" xlink:to="loc_biib_ContractualAdjustmentsMember_731c1415-8e98-49dd-a36f-dcd14c27dc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_e64bf29c-019e-4e5f-8d3a-f0032a11d8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_46953d0a-eefa-4c78-bc52-0b573555859f" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_e64bf29c-019e-4e5f-8d3a-f0032a11d8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_30adfde5-22e6-471b-b208-b8069b17b1f9" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_04e381ff-3971-4afd-9e5a-bd67e6b425e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_04e381ff-3971-4afd-9e5a-bd67e6b425e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_c007dce1-6a01-4981-8c10-9d5056fe10c8" xlink:href="biib-20240930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_c007dce1-6a01-4981-8c10-9d5056fe10c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_5cc3b1d1-f117-4a09-916b-ef3d38eed3e2" xlink:href="biib-20240930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_5cc3b1d1-f117-4a09-916b-ef3d38eed3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_6baf64b7-fa70-4302-9b44-14d6a3ce1c8a" xlink:href="biib-20240930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_6baf64b7-fa70-4302-9b44-14d6a3ce1c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_0be21d79-fdf6-4978-a4bd-d988a0f47515" xlink:href="biib-20240930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_0be21d79-fdf6-4978-a4bd-d988a0f47515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_aa293204-a300-43e8-afb7-60dc9074905e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_841eff3a-a9cc-430a-9e46-6bbc711c1be4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_aa293204-a300-43e8-afb7-60dc9074905e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_b55dc8ab-16e9-4ec7-b870-843c372acdce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_46a12c46-9552-4ffa-8165-f7768bdf6685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_b55dc8ab-16e9-4ec7-b870-843c372acdce" xlink:to="loc_us-gaap_StatementTable_46a12c46-9552-4ffa-8165-f7768bdf6685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c1f4562d-4a86-4641-b66f-9b9f1c9b3338" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_46a12c46-9552-4ffa-8165-f7768bdf6685" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c1f4562d-4a86-4641-b66f-9b9f1c9b3338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2015c003-a293-42e8-894d-f329bf48bf43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c1f4562d-4a86-4641-b66f-9b9f1c9b3338" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2015c003-a293-42e8-894d-f329bf48bf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e7aef5da-3155-42e0-9ecf-a58169e2d300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2015c003-a293-42e8-894d-f329bf48bf43" xlink:to="loc_us-gaap_AccountsReceivableMember_e7aef5da-3155-42e0-9ecf-a58169e2d300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5684b7f0-2023-4c9c-a9b6-cad90f31fc22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2015c003-a293-42e8-894d-f329bf48bf43" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_5684b7f0-2023-4c9c-a9b6-cad90f31fc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8ec67a24-0e2c-4121-9b11-a706772a0406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_46a12c46-9552-4ffa-8165-f7768bdf6685" xlink:to="loc_us-gaap_StatementLineItems_8ec67a24-0e2c-4121-9b11-a706772a0406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_41d17363-7d42-4b7d-94ec-8df5163a04ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ec67a24-0e2c-4121-9b11-a706772a0406" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_41d17363-7d42-4b7d-94ec-8df5163a04ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_dcdbe581-0da1-4664-b71f-f0d87770afd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d1e2adc3-78ce-481c-bdb8-041706a4f664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_dcdbe581-0da1-4664-b71f-f0d87770afd0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d1e2adc3-78ce-481c-bdb8-041706a4f664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_887115a2-3804-413d-9b11-c0e9ea157d52" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1e2adc3-78ce-481c-bdb8-041706a4f664" xlink:to="loc_srt_ProductOrServiceAxis_887115a2-3804-413d-9b11-c0e9ea157d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_148c30d9-3ced-4d92-9d2f-e3b4ac9d4fa3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_887115a2-3804-413d-9b11-c0e9ea157d52" xlink:to="loc_srt_ProductsAndServicesDomain_148c30d9-3ced-4d92-9d2f-e3b4ac9d4fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ac5c3e09-6eff-4f5d-b801-105c59cb90ab" xlink:href="biib-20240930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_148c30d9-3ced-4d92-9d2f-e3b4ac9d4fa3" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_ac5c3e09-6eff-4f5d-b801-105c59cb90ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember_b795b320-2c8a-42d7-87a1-fc5ebec1a183" xlink:href="biib-20240930.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_148c30d9-3ced-4d92-9d2f-e3b4ac9d4fa3" xlink:to="loc_biib_RoyaltyAttributedToOCREVUSMember_b795b320-2c8a-42d7-87a1-fc5ebec1a183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d3a5b7fd-7640-48ee-b8af-b80a2c984b26" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1e2adc3-78ce-481c-bdb8-041706a4f664" xlink:to="loc_srt_MajorCustomersAxis_d3a5b7fd-7640-48ee-b8af-b80a2c984b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_83713b63-b94b-4ddf-8112-da58a894ff21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d3a5b7fd-7640-48ee-b8af-b80a2c984b26" xlink:to="loc_srt_NameOfMajorCustomerDomain_83713b63-b94b-4ddf-8112-da58a894ff21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_cefd7780-a1af-4710-addd-8a2de816c93b" xlink:href="biib-20240930.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_83713b63-b94b-4ddf-8112-da58a894ff21" xlink:to="loc_biib_RocheGroupGenentechMember_cefd7780-a1af-4710-addd-8a2de816c93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_22eea5cb-9d18-40fe-b907-081126a2b9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d1e2adc3-78ce-481c-bdb8-041706a4f664" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_22eea5cb-9d18-40fe-b907-081126a2b9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_efa5f08d-09c3-4f8f-8c89-7291d7b17d50" xlink:href="biib-20240930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22eea5cb-9d18-40fe-b907-081126a2b9bf" xlink:to="loc_biib_ShareOfCoPromotionProfits_efa5f08d-09c3-4f8f-8c89-7291d7b17d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0568ab67-cf0d-4882-a2c7-204ae59f93eb" xlink:href="biib-20240930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22eea5cb-9d18-40fe-b907-081126a2b9bf" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_0568ab67-cf0d-4882-a2c7-204ae59f93eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f0342f87-f139-46e5-ad33-d0c77328b6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22eea5cb-9d18-40fe-b907-081126a2b9bf" xlink:to="loc_us-gaap_Revenues_f0342f87-f139-46e5-ad33-d0c77328b6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesOtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_89cb7a73-d794-45e8-806e-e07c16a4e876" xlink:href="biib-20240930.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_17f3716d-c393-4d97-8091-be23e0e3201c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_89cb7a73-d794-45e8-806e-e07c16a4e876" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_17f3716d-c393-4d97-8091-be23e0e3201c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d5452800-8d22-4ccd-b6c0-296315da9d06" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_17f3716d-c393-4d97-8091-be23e0e3201c" xlink:to="loc_srt_ProductOrServiceAxis_d5452800-8d22-4ccd-b6c0-296315da9d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ecf1b570-4a56-49fe-8909-cb9389d833e9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d5452800-8d22-4ccd-b6c0-296315da9d06" xlink:to="loc_srt_ProductsAndServicesDomain_ecf1b570-4a56-49fe-8909-cb9389d833e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember_2484fc42-7cae-4fd2-bf26-8896b04a5454" xlink:href="biib-20240930.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ecf1b570-4a56-49fe-8909-cb9389d833e9" xlink:to="loc_biib_ContractManufacturingAndOtherRevenueMember_2484fc42-7cae-4fd2-bf26-8896b04a5454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_2511e60b-9a30-47cc-8cc8-ecbe37c504c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ecf1b570-4a56-49fe-8909-cb9389d833e9" xlink:to="loc_us-gaap_RoyaltyMember_2511e60b-9a30-47cc-8cc8-ecbe37c504c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_3165d4aa-a761-4cf8-a628-95f2f7d76f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ecf1b570-4a56-49fe-8909-cb9389d833e9" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_3165d4aa-a761-4cf8-a628-95f2f7d76f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_54848eaa-a612-478f-a2ef-b20ad793dc08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_17f3716d-c393-4d97-8091-be23e0e3201c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_54848eaa-a612-478f-a2ef-b20ad793dc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e9b650de-8993-4a73-8a17-75c987438d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_54848eaa-a612-478f-a2ef-b20ad793dc08" xlink:to="loc_us-gaap_Revenues_e9b650de-8993-4a73-8a17-75c987438d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5f5eff9b-be16-4ef8-94f6-cede3d9fd01e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_006f0340-bf75-40ae-b325-a28170979a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5f5eff9b-be16-4ef8-94f6-cede3d9fd01e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_006f0340-bf75-40ae-b325-a28170979a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1ded1440-17a0-4fe6-89a2-270e739c717b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_006f0340-bf75-40ae-b325-a28170979a2a" xlink:to="loc_srt_ProductOrServiceAxis_1ded1440-17a0-4fe6-89a2-270e739c717b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a2aaca9-e621-47e8-843e-c63c9bb1484b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1ded1440-17a0-4fe6-89a2-270e739c717b" xlink:to="loc_srt_ProductsAndServicesDomain_7a2aaca9-e621-47e8-843e-c63c9bb1484b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_15042b6f-c75d-4f96-b36a-e70d90425522" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a2aaca9-e621-47e8-843e-c63c9bb1484b" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_15042b6f-c75d-4f96-b36a-e70d90425522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_7dd37ea9-fe8b-4d59-8846-cb04d8d535fd" xlink:href="biib-20240930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a2aaca9-e621-47e8-843e-c63c9bb1484b" xlink:to="loc_biib_LEQEMBICollaborationMember_7dd37ea9-fe8b-4d59-8846-cb04d8d535fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6a40b240-1b44-4803-86f6-997ba5e548ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_006f0340-bf75-40ae-b325-a28170979a2a" xlink:to="loc_srt_MajorCustomersAxis_6a40b240-1b44-4803-86f6-997ba5e548ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ae21a458-e726-45a3-922e-48e7b81a5d7a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6a40b240-1b44-4803-86f6-997ba5e548ca" xlink:to="loc_srt_NameOfMajorCustomerDomain_ae21a458-e726-45a3-922e-48e7b81a5d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_87857fed-6304-4767-bd53-6e037a64af66" xlink:href="biib-20240930.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae21a458-e726-45a3-922e-48e7b81a5d7a" xlink:to="loc_biib_DistributorOneMember_87857fed-6304-4767-bd53-6e037a64af66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_796d737c-f9fc-40f6-91b8-d78b841f6e95" xlink:href="biib-20240930.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ae21a458-e726-45a3-922e-48e7b81a5d7a" xlink:to="loc_biib_DistributorTwoMember_796d737c-f9fc-40f6-91b8-d78b841f6e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_006f0340-bf75-40ae-b325-a28170979a2a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_35da383a-2892-478d-bba1-c03985941297" xlink:href="biib-20240930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_35da383a-2892-478d-bba1-c03985941297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_f5f00814-860f-4fb8-8db6-f1c9925448db" xlink:href="biib-20240930.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:to="loc_biib_NumberOfWholesalers_f5f00814-860f-4fb8-8db6-f1c9925448db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_506eb1c2-7af6-40a9-8d0e-cd9046260bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:to="loc_us-gaap_Revenues_506eb1c2-7af6-40a9-8d0e-cd9046260bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_01ed55e0-4c2a-40bf-88f8-76e84efd70b8" xlink:href="biib-20240930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b448f3c5-6d93-4d9e-a353-876fc5a0974b" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_01ed55e0-4c2a-40bf-88f8-76e84efd70b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3cb3a3f3-c41d-4ea6-8829-6e3df650d10f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_749d0b2e-1f26-4113-9919-53b7fc7407a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3cb3a3f3-c41d-4ea6-8829-6e3df650d10f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_749d0b2e-1f26-4113-9919-53b7fc7407a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3dd2d33b-b1df-43aa-9494-cc5034127794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3cb3a3f3-c41d-4ea6-8829-6e3df650d10f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3dd2d33b-b1df-43aa-9494-cc5034127794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_01809de2-706a-4930-9ff5-8689feb37f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3cb3a3f3-c41d-4ea6-8829-6e3df650d10f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_01809de2-706a-4930-9ff5-8689feb37f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_899f69f8-719c-46d7-a344-16912ca223bf" xlink:href="biib-20240930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3cb3a3f3-c41d-4ea6-8829-6e3df650d10f" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_899f69f8-719c-46d7-a344-16912ca223bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7c6082ed-022b-4e08-a4ca-22b081d332f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3cb3a3f3-c41d-4ea6-8829-6e3df650d10f" xlink:to="loc_us-gaap_InventoryNet_7c6082ed-022b-4e08-a4ca-22b081d332f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_57befd5f-2e97-4e99-ab6a-52eb626fb51b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3cb3a3f3-c41d-4ea6-8829-6e3df650d10f" xlink:to="loc_us-gaap_InventoryNoncurrent_57befd5f-2e97-4e99-ab6a-52eb626fb51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_714d5926-38c5-4567-8bb3-d20b62047a27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_714d5926-38c5-4567-8bb3-d20b62047a27" xlink:to="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f114a819-a86b-4173-b4fd-bba600bb5718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f114a819-a86b-4173-b4fd-bba600bb5718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a703f12-dff1-4871-b408-cf9c9873110f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f114a819-a86b-4173-b4fd-bba600bb5718" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a703f12-dff1-4871-b408-cf9c9873110f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_6dc73cb3-24d4-43e2-bcc1-b3fc376da1e1" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a703f12-dff1-4871-b408-cf9c9873110f" xlink:to="loc_biib_EisaiMember_6dc73cb3-24d4-43e2-bcc1-b3fc376da1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6191ed54-0364-403c-bbc6-0ba5a7c13e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6191ed54-0364-403c-bbc6-0ba5a7c13e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23e87063-8cf0-457f-b785-9255fb81b966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6191ed54-0364-403c-bbc6-0ba5a7c13e2a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23e87063-8cf0-457f-b785-9255fb81b966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_781af977-af06-4feb-bd78-ef0fa8b85f4e" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_23e87063-8cf0-457f-b785-9255fb81b966" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_781af977-af06-4feb-bd78-ef0fa8b85f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_6422b807-eb24-4375-8d22-5152326cd6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_6422b807-eb24-4375-8d22-5152326cd6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_58b5c941-e859-4df1-b465-3612dc411478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_6422b807-eb24-4375-8d22-5152326cd6b1" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_58b5c941-e859-4df1-b465-3612dc411478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember_0cf48866-3d4a-4161-bd61-bceec318b848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_58b5c941-e859-4df1-b465-3612dc411478" xlink:to="loc_us-gaap_FairValueAdjustmentToInventoryMember_0cf48866-3d4a-4161-bd61-bceec318b848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_082e4f34-3650-43a6-b607-b9ced48fe7ff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:to="loc_srt_ProductOrServiceAxis_082e4f34-3650-43a6-b607-b9ced48fe7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c42e4eaa-ca18-4a8b-acbc-ac721abf6ca1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_082e4f34-3650-43a6-b607-b9ced48fe7ff" xlink:to="loc_srt_ProductsAndServicesDomain_c42e4eaa-ca18-4a8b-acbc-ac721abf6ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember_312106de-2bee-462e-91e6-9c7785bbbb87" xlink:href="biib-20240930.xsd#biib_ClinicalInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c42e4eaa-ca18-4a8b-acbc-ac721abf6ca1" xlink:to="loc_biib_ClinicalInventoryMember_312106de-2bee-462e-91e6-9c7785bbbb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_c74488e4-e538-4af1-a2c8-813b468fc083" xlink:to="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_782f796b-7606-4f49-a92f-9f0ec0420ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_782f796b-7606-4f49-a92f-9f0ec0420ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_8ff9bc05-a1cf-466f-bae2-e35e12547d46" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_8ff9bc05-a1cf-466f-bae2-e35e12547d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_056d533f-2dae-44af-bb54-a0777a2cda55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:to="loc_us-gaap_ProfitLoss_056d533f-2dae-44af-bb54-a0777a2cda55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7c898f23-6385-4df3-8585-9c51e3fe0e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_f6ced7ee-a5f7-47be-bc1d-2ada35a6197e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7c898f23-6385-4df3-8585-9c51e3fe0e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_294cfdc9-3d30-4a4d-abe7-826e7493e949" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ad5836c8-4ecf-4f72-ab23-dad7d89f0063" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_294cfdc9-3d30-4a4d-abe7-826e7493e949" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ad5836c8-4ecf-4f72-ab23-dad7d89f0063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cb1bec97-96c2-4ef1-98ff-79efff221a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ad5836c8-4ecf-4f72-ab23-dad7d89f0063" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cb1bec97-96c2-4ef1-98ff-79efff221a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_526439a6-5c8a-4b15-8b02-83fa1c23fe61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cb1bec97-96c2-4ef1-98ff-79efff221a4a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_526439a6-5c8a-4b15-8b02-83fa1c23fe61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_ac147a6a-c9ac-4617-9469-b66f6989d7d6" xlink:href="biib-20240930.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_526439a6-5c8a-4b15-8b02-83fa1c23fe61" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_ac147a6a-c9ac-4617-9469-b66f6989d7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_42af09c1-1579-439e-ac27-fd17269b27cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_526439a6-5c8a-4b15-8b02-83fa1c23fe61" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_42af09c1-1579-439e-ac27-fd17269b27cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_234a5acb-3cc0-454c-b0dd-1abd6c902301" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ad5836c8-4ecf-4f72-ab23-dad7d89f0063" xlink:to="loc_srt_RangeAxis_234a5acb-3cc0-454c-b0dd-1abd6c902301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d19a3449-151c-42c6-8932-f3270c558cb4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_234a5acb-3cc0-454c-b0dd-1abd6c902301" xlink:to="loc_srt_RangeMember_d19a3449-151c-42c6-8932-f3270c558cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9e408f52-5821-49ac-844c-21d5b0f94025" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d19a3449-151c-42c6-8932-f3270c558cb4" xlink:to="loc_srt_MinimumMember_9e408f52-5821-49ac-844c-21d5b0f94025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40350c86-0840-4d46-ad17-013406710a12" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d19a3449-151c-42c6-8932-f3270c558cb4" xlink:to="loc_srt_MaximumMember_40350c86-0840-4d46-ad17-013406710a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_da9c1abf-44b7-4c8c-9339-4202187a6de2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ad5836c8-4ecf-4f72-ab23-dad7d89f0063" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_da9c1abf-44b7-4c8c-9339-4202187a6de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6075bbcd-aaa2-4632-b00d-4979a83bb62b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_da9c1abf-44b7-4c8c-9339-4202187a6de2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6075bbcd-aaa2-4632-b00d-4979a83bb62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_38e02b35-1111-4bb9-8fd4-797d6e6e6639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_da9c1abf-44b7-4c8c-9339-4202187a6de2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_38e02b35-1111-4bb9-8fd4-797d6e6e6639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_819de58c-a6fc-443d-a04e-23d5307c41c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_38e02b35-1111-4bb9-8fd4-797d6e6e6639" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_819de58c-a6fc-443d-a04e-23d5307c41c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c8554113-b3a9-4224-9a9c-9f0a13a012d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_38e02b35-1111-4bb9-8fd4-797d6e6e6639" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c8554113-b3a9-4224-9a9c-9f0a13a012d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67ca1e3a-4143-4197-a207-336837acecb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_38e02b35-1111-4bb9-8fd4-797d6e6e6639" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67ca1e3a-4143-4197-a207-336837acecb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_381ab30a-539e-42f2-bdd0-55d8eb2f9eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_294cfdc9-3d30-4a4d-abe7-826e7493e949" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_381ab30a-539e-42f2-bdd0-55d8eb2f9eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3f158f68-3b05-4130-8b3a-d6fb1e7f704a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_381ab30a-539e-42f2-bdd0-55d8eb2f9eaf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3f158f68-3b05-4130-8b3a-d6fb1e7f704a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a065ed1-c543-4f63-8265-4ee65e2ff4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3f158f68-3b05-4130-8b3a-d6fb1e7f704a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a065ed1-c543-4f63-8265-4ee65e2ff4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5ea9fade-10f6-4447-ad7c-f1cd485c4607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a065ed1-c543-4f63-8265-4ee65e2ff4d1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5ea9fade-10f6-4447-ad7c-f1cd485c4607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_e2db0905-ca91-4bc8-9f26-90cd3416b491" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a065ed1-c543-4f63-8265-4ee65e2ff4d1" xlink:to="loc_biib_PriorityReviewVoucherMember_e2db0905-ca91-4bc8-9f26-90cd3416b491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_242ae254-20d1-4c49-9b2c-3f0f1e9a6e84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a065ed1-c543-4f63-8265-4ee65e2ff4d1" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_242ae254-20d1-4c49-9b2c-3f0f1e9a6e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e4566752-aad6-4ce6-b2f3-3f6d457e9376" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_381ab30a-539e-42f2-bdd0-55d8eb2f9eaf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e4566752-aad6-4ce6-b2f3-3f6d457e9376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f61c2bf4-9a8b-42d0-afd3-9bae7e507aea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_e4566752-aad6-4ce6-b2f3-3f6d457e9376" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f61c2bf4-9a8b-42d0-afd3-9bae7e507aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_da113058-9be9-4f9a-9605-5802810afddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_294cfdc9-3d30-4a4d-abe7-826e7493e949" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_da113058-9be9-4f9a-9605-5802810afddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_445dfeac-cee4-4d66-8ccc-42ca86863cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_da113058-9be9-4f9a-9605-5802810afddb" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_445dfeac-cee4-4d66-8ccc-42ca86863cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_16a80654-236a-4422-955a-650be29cc0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_da113058-9be9-4f9a-9605-5802810afddb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_16a80654-236a-4422-955a-650be29cc0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a305dada-6226-4e1e-83dc-cc049ac66d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_da113058-9be9-4f9a-9605-5802810afddb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a305dada-6226-4e1e-83dc-cc049ac66d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2e82b8ba-e4e6-4463-9f15-9da53839d282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2e82b8ba-e4e6-4463-9f15-9da53839d282" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2c6f9941-2776-4e30-9fa4-e3f00431c295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2c6f9941-2776-4e30-9fa4-e3f00431c295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e343d771-4876-488e-b487-035ac53874b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2c6f9941-2776-4e30-9fa4-e3f00431c295" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e343d771-4876-488e-b487-035ac53874b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_717bbf70-bd7d-4b19-918e-a755a540eae4" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e343d771-4876-488e-b487-035ac53874b7" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_717bbf70-bd7d-4b19-918e-a755a540eae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_45ecf6b5-8643-497d-b0cf-223ba9f33a1f" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e343d771-4876-488e-b487-035ac53874b7" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_45ecf6b5-8643-497d-b0cf-223ba9f33a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_702adf10-f8b4-4985-9bbb-925a46e2cb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_702adf10-f8b4-4985-9bbb-925a46e2cb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_702adf10-f8b4-4985-9bbb-925a46e2cb5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_bbebcfb5-d960-4fb1-b163-ea21c4d0c19d" xlink:href="biib-20240930.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_bbebcfb5-d960-4fb1-b163-ea21c4d0c19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_b31c7e99-4f95-48f3-8a08-28ecc63df022" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_b31c7e99-4f95-48f3-8a08-28ecc63df022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_7e716b18-5c48-4f43-a983-a57630402021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_7e716b18-5c48-4f43-a983-a57630402021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_d857104f-026f-456d-8f25-19ef3518b9b0" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_biib_SKYCLARYSMember_d857104f-026f-456d-8f25-19ef3518b9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_e3bf5852-c5ed-4bd0-9c39-50fc5eb91475" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_biib_PriorityReviewVoucherMember_e3bf5852-c5ed-4bd0-9c39-50fc5eb91475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CompletedTechnologyMember_d6774eac-2724-419f-9aeb-5ad00753c85c" xlink:href="biib-20240930.xsd#biib_CompletedTechnologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2597007b-9246-473e-9615-2f0fc288c88b" xlink:to="loc_biib_CompletedTechnologyMember_d6774eac-2724-419f-9aeb-5ad00753c85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ce36ecf-0bfa-4716-8c7d-3fd9a1d470a9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:to="loc_srt_RangeAxis_3ce36ecf-0bfa-4716-8c7d-3fd9a1d470a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2581a603-8cde-46ef-88c1-ab9da83661d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3ce36ecf-0bfa-4716-8c7d-3fd9a1d470a9" xlink:to="loc_srt_RangeMember_2581a603-8cde-46ef-88c1-ab9da83661d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_110b69b0-c354-470f-a2b5-945be4093648" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2581a603-8cde-46ef-88c1-ab9da83661d5" xlink:to="loc_srt_MinimumMember_110b69b0-c354-470f-a2b5-945be4093648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_613b92e3-ed7f-4e93-b146-ea38c389f1d3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2581a603-8cde-46ef-88c1-ab9da83661d5" xlink:to="loc_srt_MaximumMember_613b92e3-ed7f-4e93-b146-ea38c389f1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6a08d823-2f65-41ab-93fd-b2087c543e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6a08d823-2f65-41ab-93fd-b2087c543e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd893bc4-1b94-446c-bcb5-b78dde339c21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6a08d823-2f65-41ab-93fd-b2087c543e88" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd893bc4-1b94-446c-bcb5-b78dde339c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6d2a3d2a-83b9-4e03-bc78-a468b32b087d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd893bc4-1b94-446c-bcb5-b78dde339c21" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6d2a3d2a-83b9-4e03-bc78-a468b32b087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_b65bcc26-c2fc-4edb-b717-4f897589dadb" xlink:href="biib-20240930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd893bc4-1b94-446c-bcb5-b78dde339c21" xlink:to="loc_biib_PriorityReviewVoucherMember_b65bcc26-c2fc-4edb-b717-4f897589dadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_a6a4fd11-9826-4a9e-ab2a-8c45ecb46465" xlink:href="biib-20240930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bd893bc4-1b94-446c-bcb5-b78dde339c21" xlink:to="loc_biib_SKYCLARYSMember_a6a4fd11-9826-4a9e-ab2a-8c45ecb46465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_abe889ea-91be-46c0-91c7-bdc25f1f628a" xlink:to="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_40ac9429-fca6-4def-bbab-48881c49e0df" xlink:href="biib-20240930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_40ac9429-fca6-4def-bbab-48881c49e0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96285787-07af-4409-a8c4-5ba39356d5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96285787-07af-4409-a8c4-5ba39356d5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9f8369c2-b5d7-430f-99c9-ff5681068c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9f8369c2-b5d7-430f-99c9-ff5681068c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_b78f7c36-6cae-47e0-97f9-4c91285cf8a4" xlink:href="biib-20240930.xsd#biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_b78f7c36-6cae-47e0-97f9-4c91285cf8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b07ad7bb-5a3e-4cb1-a1dd-b38448cd8ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b07ad7bb-5a3e-4cb1-a1dd-b38448cd8ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_59232073-cdef-474a-abed-32bf1a1fb774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7fe36bc3-5803-41f8-ad79-236b49ecb0cf" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_59232073-cdef-474a-abed-32bf1a1fb774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4843c241-9252-4093-87d3-edd4a460dbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_98fa7ebd-d63c-42f8-83b7-bdc21bd407e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4843c241-9252-4093-87d3-edd4a460dbc2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_98fa7ebd-d63c-42f8-83b7-bdc21bd407e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f27cef9e-3153-4864-bf01-5ccc3c1e3973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4843c241-9252-4093-87d3-edd4a460dbc2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f27cef9e-3153-4864-bf01-5ccc3c1e3973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d240378d-7279-4ab2-b722-4ac8b3a3fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4843c241-9252-4093-87d3-edd4a460dbc2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d240378d-7279-4ab2-b722-4ac8b3a3fa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_09e364fc-9032-4c0d-bbc6-af303a41034d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4843c241-9252-4093-87d3-edd4a460dbc2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_09e364fc-9032-4c0d-bbc6-af303a41034d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5db31258-f11f-48d7-a006-ebeeeb225449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4843c241-9252-4093-87d3-edd4a460dbc2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5db31258-f11f-48d7-a006-ebeeeb225449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ca1b8199-aa46-4dc6-8e62-a8b409d2cf60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4843c241-9252-4093-87d3-edd4a460dbc2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ca1b8199-aa46-4dc6-8e62-a8b409d2cf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IntangibleAssetsandGoodwillChangesinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bafb05a3-5d57-46d0-ba93-1c1110c9217a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_059f8557-ddf7-47c9-bb4b-22edcff2f986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bafb05a3-5d57-46d0-ba93-1c1110c9217a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_059f8557-ddf7-47c9-bb4b-22edcff2f986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1350b490-1698-4ea3-a7a8-241126aee213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_059f8557-ddf7-47c9-bb4b-22edcff2f986" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1350b490-1698-4ea3-a7a8-241126aee213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5066998-01d7-4eea-968a-e305d757a68f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1350b490-1698-4ea3-a7a8-241126aee213" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5066998-01d7-4eea-968a-e305d757a68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_c8438fc4-57d8-432d-8d76-0d99054d179a" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5066998-01d7-4eea-968a-e305d757a68f" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_c8438fc4-57d8-432d-8d76-0d99054d179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_b64e54a8-03f5-44df-a2d2-a25323d70fdc" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a5066998-01d7-4eea-968a-e305d757a68f" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_b64e54a8-03f5-44df-a2d2-a25323d70fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_a38c351f-fe07-44a2-b68d-a7c8f7cc34a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_059f8557-ddf7-47c9-bb4b-22edcff2f986" xlink:to="loc_us-gaap_GoodwillLineItems_a38c351f-fe07-44a2-b68d-a7c8f7cc34a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a38c351f-fe07-44a2-b68d-a7c8f7cc34a4" xlink:to="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2651c760-33f8-4902-9af4-3f81f6aff80e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:to="loc_us-gaap_Goodwill_2651c760-33f8-4902-9af4-3f81f6aff80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_85f27829-7ed9-4257-a513-fbaa3571a372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_85f27829-7ed9-4257-a513-fbaa3571a372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_0e821cf6-fe54-4a34-a3d9-f972b8eefe50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_0e821cf6-fe54-4a34-a3d9-f972b8eefe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2853d280-de9e-4013-ad7b-855ca5e3efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2b569ef7-c54f-412f-b19c-0d46acb64026" xlink:to="loc_us-gaap_Goodwill_2853d280-de9e-4013-ad7b-855ca5e3efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f7524f9-011d-4b08-903c-003a9f1154d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a38c351f-fe07-44a2-b68d-a7c8f7cc34a4" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f7524f9-011d-4b08-903c-003a9f1154d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4e3aaf42-9ab2-4741-a2db-02e916e1cb39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4e3aaf42-9ab2-4741-a2db-02e916e1cb39" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98ce8bb8-60da-47c9-9b1b-44369a876810" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98ce8bb8-60da-47c9-9b1b-44369a876810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6011df99-ea1a-4483-a910-fb40299be895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_98ce8bb8-60da-47c9-9b1b-44369a876810" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6011df99-ea1a-4483-a910-fb40299be895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2c248dca-6300-4b67-a86f-c40645ae7641" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6011df99-ea1a-4483-a910-fb40299be895" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2c248dca-6300-4b67-a86f-c40645ae7641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_05f9af78-17dc-42dd-97c2-5f88abfe2cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6011df99-ea1a-4483-a910-fb40299be895" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_05f9af78-17dc-42dd-97c2-5f88abfe2cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9b783bc9-6281-4526-bacc-df4463055730" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6011df99-ea1a-4483-a910-fb40299be895" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9b783bc9-6281-4526-bacc-df4463055730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b1b3378-3290-477b-87e2-da18857ff00d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b1b3378-3290-477b-87e2-da18857ff00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_89f3822d-b308-4587-85ec-d9ca1753073c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b1b3378-3290-477b-87e2-da18857ff00d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_89f3822d-b308-4587-85ec-d9ca1753073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6db26e6c-a784-43aa-b4e4-9e66b165e520" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_89f3822d-b308-4587-85ec-d9ca1753073c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6db26e6c-a784-43aa-b4e4-9e66b165e520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22c65e9c-8a60-4433-88fa-b35a2510071a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22c65e9c-8a60-4433-88fa-b35a2510071a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_170a629a-8569-4ed8-9767-a84c7e024ca5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_22c65e9c-8a60-4433-88fa-b35a2510071a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_170a629a-8569-4ed8-9767-a84c7e024ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5fbe9c2f-3ea7-49b0-83ea-8eaf96978632" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_170a629a-8569-4ed8-9767-a84c7e024ca5" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5fbe9c2f-3ea7-49b0-83ea-8eaf96978632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d950fd73-22b0-421d-9401-846517468025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c17564a5-035d-41a0-a732-753ef81f035d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d950fd73-22b0-421d-9401-846517468025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d950fd73-22b0-421d-9401-846517468025" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_072e5855-a030-4527-b7cc-b0914334541a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_072e5855-a030-4527-b7cc-b0914334541a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_f3260367-4ed9-4f2a-8064-bd0f078d72f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_f3260367-4ed9-4f2a-8064-bd0f078d72f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_d8eca924-ab3b-4670-96fe-93b5085925f2" xlink:href="biib-20240930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_d8eca924-ab3b-4670-96fe-93b5085925f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_bb0b94f4-70b5-46bf-85cd-2981661e7226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_bb0b94f4-70b5-46bf-85cd-2981661e7226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_de64eacd-2439-4546-aa18-bcc0854dfdf8" xlink:href="biib-20240930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_de64eacd-2439-4546-aa18-bcc0854dfdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_9bb80eb7-ba3b-43b0-a400-f571572e7cef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_us-gaap_DerivativeAssets_9bb80eb7-ba3b-43b0-a400-f571572e7cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2f4c490e-6436-4798-ba88-14bb2dd544f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f89c971e-d92e-42d4-a455-ed0c6aa55b51" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2f4c490e-6436-4798-ba88-14bb2dd544f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_74118cfb-40c5-4138-bc77-85205fa359d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_74118cfb-40c5-4138-bc77-85205fa359d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_9f9e093a-d911-4219-8738-479dae0571d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_74118cfb-40c5-4138-bc77-85205fa359d5" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_9f9e093a-d911-4219-8738-479dae0571d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_dc6adc85-6368-4cec-8873-ccd0e071604e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_74118cfb-40c5-4138-bc77-85205fa359d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_dc6adc85-6368-4cec-8873-ccd0e071604e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_6b7594c6-f217-4f34-89ea-70ad5bff97c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_6b7594c6-f217-4f34-89ea-70ad5bff97c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_889d0e13-81e9-4765-aa2f-ae0263e0bb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_6b7594c6-f217-4f34-89ea-70ad5bff97c2" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_889d0e13-81e9-4765-aa2f-ae0263e0bb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_56e49888-013b-47b2-b9f5-d52f637dd3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_6b7594c6-f217-4f34-89ea-70ad5bff97c2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_56e49888-013b-47b2-b9f5-d52f637dd3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_50e96e08-608e-41c5-ae68-baf6b6ee29b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_50e96e08-608e-41c5-ae68-baf6b6ee29b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f237bd20-0b50-4e3e-b93c-730b6fe79c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa8e7f09-c393-41b8-bdf8-f1bc354efad4" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f237bd20-0b50-4e3e-b93c-730b6fe79c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3c06a64c-2445-448c-a478-6f08e30f880d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3c06a64c-2445-448c-a478-6f08e30f880d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d2c2ae6f-85bd-4706-92d0-67292dda6fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_41d6a6da-af28-4b20-9c5e-19f36d393a63" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d2c2ae6f-85bd-4706-92d0-67292dda6fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_493c9c18-1a5c-4304-8842-1371278a7784" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_493c9c18-1a5c-4304-8842-1371278a7784" xlink:to="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_806482ad-09ed-45f8-87ee-2b09408d4678" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_806482ad-09ed-45f8-87ee-2b09408d4678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_53d98d75-1f48-4ce6-9d2d-39a05ec1eb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_806482ad-09ed-45f8-87ee-2b09408d4678" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_53d98d75-1f48-4ce6-9d2d-39a05ec1eb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_dfc12ffd-2830-41dc-84ff-0c9cc793f4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_53d98d75-1f48-4ce6-9d2d-39a05ec1eb0c" xlink:to="loc_us-gaap_LineOfCreditMember_dfc12ffd-2830-41dc-84ff-0c9cc793f4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87ddf0df-203a-4040-9352-cb85cb7f4654" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87ddf0df-203a-4040-9352-cb85cb7f4654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b0c78dd-4829-475c-8aec-5067d69679cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87ddf0df-203a-4040-9352-cb85cb7f4654" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b0c78dd-4829-475c-8aec-5067d69679cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_6b02d31f-8d32-48ff-8b21-f95ee41ec38e" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b0c78dd-4829-475c-8aec-5067d69679cc" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_6b02d31f-8d32-48ff-8b21-f95ee41ec38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ed00040f-e923-4dc6-b3c4-9eb570dfa8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ed00040f-e923-4dc6-b3c4-9eb570dfa8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5f0c7e37-ccfd-4661-8be5-58e626610656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ed00040f-e923-4dc6-b3c4-9eb570dfa8f4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5f0c7e37-ccfd-4661-8be5-58e626610656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MeasurementInputProbabilityRateMember_aa42dfad-eea6-41f4-b2df-823e23e63789" xlink:href="biib-20240930.xsd#biib_MeasurementInputProbabilityRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5f0c7e37-ccfd-4661-8be5-58e626610656" xlink:to="loc_biib_MeasurementInputProbabilityRateMember_aa42dfad-eea6-41f4-b2df-823e23e63789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a68714e3-2775-4dfe-8565-9f073af42e2b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1b5ab0e8-4f97-4db5-8ed0-41181b5c4db4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:to="loc_us-gaap_AssetImpairmentCharges_1b5ab0e8-4f97-4db5-8ed0-41181b5c4db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_97adb49e-9358-4b13-9947-f20a3c5c7928" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_97adb49e-9358-4b13-9947-f20a3c5c7928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_59a3ec38-b22c-47bf-adc7-dedd8eee6241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_59a3ec38-b22c-47bf-adc7-dedd8eee6241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b7187423-c151-4eb8-ad05-200f82b6fb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3152b178-caed-40b6-829c-d0942be36af4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b7187423-c151-4eb8-ad05-200f82b6fb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cb0a3f08-5ae3-4806-9c15-62e4bcb25f49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cb0a3f08-5ae3-4806-9c15-62e4bcb25f49" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ecc43317-9434-42aa-9bde-f04cd4791bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ecc43317-9434-42aa-9bde-f04cd4791bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11d5813d-66b4-47b0-bad1-76f82bf94874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ecc43317-9434-42aa-9bde-f04cd4791bc1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11d5813d-66b4-47b0-bad1-76f82bf94874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0a8b25aa-1327-4526-8cd1-3450be4075e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11d5813d-66b4-47b0-bad1-76f82bf94874" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0a8b25aa-1327-4526-8cd1-3450be4075e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e34fa60c-740a-4e20-80d3-574c55f8802a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:to="loc_srt_RangeAxis_e34fa60c-740a-4e20-80d3-574c55f8802a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6002bfd-9edf-4789-98ed-7309e0b225cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e34fa60c-740a-4e20-80d3-574c55f8802a" xlink:to="loc_srt_RangeMember_a6002bfd-9edf-4789-98ed-7309e0b225cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c05a7111-0a82-49b7-a613-70eb10a021b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6002bfd-9edf-4789-98ed-7309e0b225cd" xlink:to="loc_srt_MinimumMember_c05a7111-0a82-49b7-a613-70eb10a021b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_da3b8ba0-d43b-4e92-99a8-bb29d45bb16f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6002bfd-9edf-4789-98ed-7309e0b225cd" xlink:to="loc_srt_MaximumMember_da3b8ba0-d43b-4e92-99a8-bb29d45bb16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_201b96bf-abaf-4aaa-be9d-d989898b9c33" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6002bfd-9edf-4789-98ed-7309e0b225cd" xlink:to="loc_srt_WeightedAverageMember_201b96bf-abaf-4aaa-be9d-d989898b9c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_251e91bc-2125-4283-9666-961c459e254e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_251e91bc-2125-4283-9666-961c459e254e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cdca5f0e-c7df-49c6-bbd6-beb3d9fbcc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_251e91bc-2125-4283-9666-961c459e254e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cdca5f0e-c7df-49c6-bbd6-beb3d9fbcc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_3da0b5ca-437e-43dd-9943-a6fc1f7fe5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cdca5f0e-c7df-49c6-bbd6-beb3d9fbcc9e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_3da0b5ca-437e-43dd-9943-a6fc1f7fe5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8f7e218e-e7c9-4464-ab35-4c605879b2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_786e8ef9-1ced-4d36-b700-ea1631b09e0f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8f7e218e-e7c9-4464-ab35-4c605879b2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6a01483a-4119-4256-95b5-d3ad756b9143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8f7e218e-e7c9-4464-ab35-4c605879b2c7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6a01483a-4119-4256-95b5-d3ad756b9143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c57b78dd-2586-41da-ad87-742d4ca10f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8f7e218e-e7c9-4464-ab35-4c605879b2c7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c57b78dd-2586-41da-ad87-742d4ca10f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasurementsDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1e3b4d1f-d281-478c-b0c7-a744b48fd8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1e3b4d1f-d281-478c-b0c7-a744b48fd8a1" xlink:to="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b6bc34c3-d54a-49ef-81ec-7001fe90f51d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:to="loc_us-gaap_DebtInstrumentAxis_b6bc34c3-d54a-49ef-81ec-7001fe90f51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b6bc34c3-d54a-49ef-81ec-7001fe90f51d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_2c8f3279-7999-410a-be8b-2e5d0b1159c0" xlink:href="biib-20240930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_2c8f3279-7999-410a-be8b-2e5d0b1159c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_1fe4a11a-ecad-4220-ae78-90b97f248017" xlink:href="biib-20240930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_1fe4a11a-ecad-4220-ae78-90b97f248017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_c432c311-69be-4789-9603-3d2cb0180247" xlink:href="biib-20240930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_c432c311-69be-4789-9603-3d2cb0180247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotes3.250DueFebruary152051Member_b0a24c76-f21e-4e24-87ed-e3aa7bdc0dfb" xlink:href="biib-20240930.xsd#biib_SeniorNotes3.250DueFebruary152051Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_SeniorNotes3.250DueFebruary152051Member_b0a24c76-f21e-4e24-87ed-e3aa7bdc0dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_c4629c4d-d0cb-4134-a479-f02ca3c5a2a9" xlink:href="biib-20240930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_c4629c4d-d0cb-4134-a479-f02ca3c5a2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember_2124efa7-8937-453b-84df-03b6aa79a064" xlink:href="biib-20240930.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_TermLoan2023ThreeYearTrancheMember_2124efa7-8937-453b-84df-03b6aa79a064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_dac17ab4-0e13-4ad1-a381-f1a1b331472f" xlink:href="biib-20240930.xsd#biib_NonCurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_dac17ab4-0e13-4ad1-a381-f1a1b331472f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_168e5ab2-b74f-4afd-975b-1e814edd87dd" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_TheCreditFacilityMember_168e5ab2-b74f-4afd-975b-1e814edd87dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_67730992-584f-4a8d-b0fa-e4fcc10d545c" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_67730992-584f-4a8d-b0fa-e4fcc10d545c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_5a5a6164-fb0d-4a31-8612-44c6f8dc2f1b" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bcfbb14c-51d2-4ed0-9d85-10993b73243e" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_5a5a6164-fb0d-4a31-8612-44c6f8dc2f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_60903319-82a5-4d50-ac97-7091e8d6c6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_60903319-82a5-4d50-ac97-7091e8d6c6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e910e0f5-ecdc-430b-943b-2a792a02a71f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_60903319-82a5-4d50-ac97-7091e8d6c6b4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e910e0f5-ecdc-430b-943b-2a792a02a71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8dc35604-1db8-4217-8425-4506494625ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e910e0f5-ecdc-430b-943b-2a792a02a71f" xlink:to="loc_us-gaap_SeniorNotesMember_8dc35604-1db8-4217-8425-4506494625ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5b12b871-32af-428c-bdc2-3d935fd030e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e910e0f5-ecdc-430b-943b-2a792a02a71f" xlink:to="loc_us-gaap_LineOfCreditMember_5b12b871-32af-428c-bdc2-3d935fd030e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a199b41d-4d6f-40f8-a3e4-ac8a2339b681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a199b41d-4d6f-40f8-a3e4-ac8a2339b681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c0b2670-8aec-455b-a49d-2ba14bb529dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a199b41d-4d6f-40f8-a3e4-ac8a2339b681" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c0b2670-8aec-455b-a49d-2ba14bb529dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_faf57320-14bf-426f-bfe7-e763e984d852" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c0b2670-8aec-455b-a49d-2ba14bb529dd" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_faf57320-14bf-426f-bfe7-e763e984d852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b8215d27-ecda-4b7e-93c1-000b0ed2d7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:to="loc_us-gaap_CreditFacilityAxis_b8215d27-ecda-4b7e-93c1-000b0ed2d7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5581036b-fd1e-4af4-b4c1-6b92de3a0860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b8215d27-ecda-4b7e-93c1-000b0ed2d7f4" xlink:to="loc_us-gaap_CreditFacilityDomain_5581036b-fd1e-4af4-b4c1-6b92de3a0860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_48b6139f-110c-4e0a-a5b5-7debdf2341c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5581036b-fd1e-4af4-b4c1-6b92de3a0860" xlink:to="loc_us-gaap_SecuredDebtMember_48b6139f-110c-4e0a-a5b5-7debdf2341c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_107e7b79-c6d2-4cbe-b501-f5061a005522" xlink:to="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NotesPayableCurrentFairValueDisclosure_9af3fcf2-8fcd-4a6b-b598-351d0f2a90d8" xlink:href="biib-20240930.xsd#biib_NotesPayableCurrentFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_biib_NotesPayableCurrentFairValueDisclosure_9af3fcf2-8fcd-4a6b-b598-351d0f2a90d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_13a1ef07-804d-49bb-b809-e5985e19116f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_13a1ef07-804d-49bb-b809-e5985e19116f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_93570ce1-2096-4b85-86f1-de31a6b84679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_NotesPayableCurrent_93570ce1-2096-4b85-86f1-de31a6b84679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_4bb3ad74-d4c6-4473-a084-c057b2c32603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_NotesPayable_4bb3ad74-d4c6-4473-a084-c057b2c32603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_36e213ec-6c94-4ab8-9cc1-8790947c8744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_36e213ec-6c94-4ab8-9cc1-8790947c8744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_25b17adf-c27e-4e4b-979c-eab8dac538f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_88c0f4f3-eb5f-4060-926f-54d9edcff898" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_25b17adf-c27e-4e4b-979c-eab8dac538f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20240930.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e852ff13-37fd-4b4d-bcfa-c13bb6744dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bbd52583-2d98-45dd-81d1-a36e2a7efaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e852ff13-37fd-4b4d-bcfa-c13bb6744dd7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bbd52583-2d98-45dd-81d1-a36e2a7efaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a136f9b9-0c82-4428-b436-f88c40855c96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bbd52583-2d98-45dd-81d1-a36e2a7efaa3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a136f9b9-0c82-4428-b436-f88c40855c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c0b88d19-3257-4a22-a584-b2a6b816f824" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bbd52583-2d98-45dd-81d1-a36e2a7efaa3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c0b88d19-3257-4a22-a584-b2a6b816f824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a0498b1e-e482-4d61-9bb4-d1ac057b3c03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bbd52583-2d98-45dd-81d1-a36e2a7efaa3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a0498b1e-e482-4d61-9bb4-d1ac057b3c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_92217b86-6e70-48e8-836e-71b74cad970d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bbd52583-2d98-45dd-81d1-a36e2a7efaa3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_92217b86-6e70-48e8-836e-71b74cad970d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5593f025-6ac9-4a6f-bdad-c144ac1dc894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5fd5b2b1-7f4a-46c7-90a6-b01adb33ada9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5593f025-6ac9-4a6f-bdad-c144ac1dc894" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5fd5b2b1-7f4a-46c7-90a6-b01adb33ada9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f24b9199-721c-4df3-b7cd-8a100e9f9cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5fd5b2b1-7f4a-46c7-90a6-b01adb33ada9" xlink:to="loc_us-gaap_InvestmentTypeAxis_f24b9199-721c-4df3-b7cd-8a100e9f9cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5937deab-f8ac-4fc1-92ca-8c95c4d42d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_f24b9199-721c-4df3-b7cd-8a100e9f9cd8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5937deab-f8ac-4fc1-92ca-8c95c4d42d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_642b2eb0-e5ad-4574-a9c2-c850d1de681e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5937deab-f8ac-4fc1-92ca-8c95c4d42d9a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_642b2eb0-e5ad-4574-a9c2-c850d1de681e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_3f37cb72-4a74-4aa9-8b8a-86f38c16b9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5fd5b2b1-7f4a-46c7-90a6-b01adb33ada9" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_3f37cb72-4a74-4aa9-8b8a-86f38c16b9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6331ccfe-0d57-4892-8da3-98a0bad7d01c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3f37cb72-4a74-4aa9-8b8a-86f38c16b9ab" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6331ccfe-0d57-4892-8da3-98a0bad7d01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_28be35ef-7a1b-4a40-a799-5f1da1d2149f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6331ccfe-0d57-4892-8da3-98a0bad7d01c" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_28be35ef-7a1b-4a40-a799-5f1da1d2149f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20240930.xsd#FinancialInstrumentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_052a3236-a193-456d-b6c9-785d2624a864" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_83c6f76b-38b6-4a16-ae63-de1c4bef4dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_052a3236-a193-456d-b6c9-785d2624a864" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_83c6f76b-38b6-4a16-ae63-de1c4bef4dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_23e3d079-9f18-4af5-9346-2e4c7801b1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_83c6f76b-38b6-4a16-ae63-de1c4bef4dcf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_23e3d079-9f18-4af5-9346-2e4c7801b1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_281796ef-6e03-47d4-b3b5-d84935817c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_23e3d079-9f18-4af5-9346-2e4c7801b1c9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_281796ef-6e03-47d4-b3b5-d84935817c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_59588d55-5d4a-41cf-a064-00d1e107f46d" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_281796ef-6e03-47d4-b3b5-d84935817c84" xlink:to="loc_biib_EquitySecuritiesCurrentMember_59588d55-5d4a-41cf-a064-00d1e107f46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_050e1e25-6b1f-4550-bffc-7e9d40527063" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_281796ef-6e03-47d4-b3b5-d84935817c84" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_050e1e25-6b1f-4550-bffc-7e9d40527063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72ceadcd-69c8-4446-80ca-6a55c2a16861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_83c6f76b-38b6-4a16-ae63-de1c4bef4dcf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72ceadcd-69c8-4446-80ca-6a55c2a16861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72ceadcd-69c8-4446-80ca-6a55c2a16861" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_3f698b22-981f-43da-ac9a-cec345576d82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_3f698b22-981f-43da-ac9a-cec345576d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_e361e978-1a03-43e9-b101-edda5360ff74" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_e361e978-1a03-43e9-b101-edda5360ff74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_188c5193-c9ce-41cd-b4c4-569c00836612" xlink:href="biib-20240930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_188c5193-c9ce-41cd-b4c4-569c00836612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_207aebde-cfbe-450e-864b-7884ec5cb540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_42803d56-6ed2-441c-8b81-cfa4c9061e75" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_207aebde-cfbe-450e-864b-7884ec5cb540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20240930.xsd#FinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f57d2f5f-f165-44ce-83ee-29b9be8da509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8abf12c5-80ec-4fed-9043-e62c81c9e4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f57d2f5f-f165-44ce-83ee-29b9be8da509" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8abf12c5-80ec-4fed-9043-e62c81c9e4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_9cb3cdc2-1f47-42c1-b08f-183c2258e604" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f57d2f5f-f165-44ce-83ee-29b9be8da509" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_9cb3cdc2-1f47-42c1-b08f-183c2258e604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_d07aa4f5-0124-45db-9a9d-63bf011a8583" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f57d2f5f-f165-44ce-83ee-29b9be8da509" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_d07aa4f5-0124-45db-9a9d-63bf011a8583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20240930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9ee67072-0671-4ba4-8270-c839aa01bdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_48d60428-80bf-4952-aa01-3c230b481317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9ee67072-0671-4ba4-8270-c839aa01bdd9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_48d60428-80bf-4952-aa01-3c230b481317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5cc17853-c708-44b2-ab65-f93a3ab3229e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_48d60428-80bf-4952-aa01-3c230b481317" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5cc17853-c708-44b2-ab65-f93a3ab3229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c986e6cf-f538-4bd9-9eee-49d188ebc75e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5cc17853-c708-44b2-ab65-f93a3ab3229e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c986e6cf-f538-4bd9-9eee-49d188ebc75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_55541a28-e864-4372-b61d-6beb122b0250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c986e6cf-f538-4bd9-9eee-49d188ebc75e" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_55541a28-e864-4372-b61d-6beb122b0250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4ab18215-f9d8-4eea-9272-71e73eafabc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_48d60428-80bf-4952-aa01-3c230b481317" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4ab18215-f9d8-4eea-9272-71e73eafabc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da17164e-3fe4-4dc6-a2b5-36154eae2e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4ab18215-f9d8-4eea-9272-71e73eafabc1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da17164e-3fe4-4dc6-a2b5-36154eae2e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_748b031d-28fa-4170-aa8c-bbf020ae7cf3" xlink:href="biib-20240930.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da17164e-3fe4-4dc6-a2b5-36154eae2e0f" xlink:to="loc_biib_StrategicInvestmentsMember_748b031d-28fa-4170-aa8c-bbf020ae7cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a0eb0652-663f-466b-b5cb-44269dbe22d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_48d60428-80bf-4952-aa01-3c230b481317" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a0eb0652-663f-466b-b5cb-44269dbe22d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_24ba8632-e063-4a6f-a838-dac0aa6d1435" xlink:href="biib-20240930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0eb0652-663f-466b-b5cb-44269dbe22d1" xlink:to="loc_biib_StrategicInvestmentPortfolio_24ba8632-e063-4a6f-a838-dac0aa6d1435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#DerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1bea847e-831f-4889-92e8-06dc40ebeb49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1bea847e-831f-4889-92e8-06dc40ebeb49" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f043f9c-9f3e-4d80-b0c7-3dbb6d24a877" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f043f9c-9f3e-4d80-b0c7-3dbb6d24a877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b7ff7106-559f-4c87-a368-c5560ead2f18" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8f043f9c-9f3e-4d80-b0c7-3dbb6d24a877" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b7ff7106-559f-4c87-a368-c5560ead2f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_3f6449cf-0c54-4c2b-9adf-bc5d6aeeed6b" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b7ff7106-559f-4c87-a368-c5560ead2f18" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_3f6449cf-0c54-4c2b-9adf-bc5d6aeeed6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_8e697be5-5b9a-42ee-890c-21a0ba06a5d6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_srt_CurrencyAxis_8e697be5-5b9a-42ee-890c-21a0ba06a5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_8e697be5-5b9a-42ee-890c-21a0ba06a5d6" xlink:to="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_d95352df-5904-4644-90d0-e30c421e94b1" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:to="loc_currency_EUR_d95352df-5904-4644-90d0-e30c421e94b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_d9609489-e87d-4f87-87bb-c1d1534eb9b0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CHF"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:to="loc_currency_CHF_d9609489-e87d-4f87-87bb-c1d1534eb9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_12192145-7f59-4a47-8da3-76b9788d4cd8" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_JPY"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:to="loc_currency_JPY_12192145-7f59-4a47-8da3-76b9788d4cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_8e9e93ae-0889-4d69-bb03-1c676cdebaac" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_ea738216-63dc-4d11-949e-c151839bd117" xlink:to="loc_currency_CAD_8e9e93ae-0889-4d69-bb03-1c676cdebaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_90947daa-1904-4a3b-b84b-08cb5cc7a9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_90947daa-1904-4a3b-b84b-08cb5cc7a9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2d623a5-7fd4-4551-8e1c-0c8b08c6c52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90947daa-1904-4a3b-b84b-08cb5cc7a9cb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2d623a5-7fd4-4551-8e1c-0c8b08c6c52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_ce100d13-40b2-4d37-b129-f25323f8a8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a2d623a5-7fd4-4551-8e1c-0c8b08c6c52c" xlink:to="loc_us-gaap_SalesMember_ce100d13-40b2-4d37-b129-f25323f8a8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_adab985a-9dcc-49fe-9f32-8adf4fa5c653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a2d623a5-7fd4-4551-8e1c-0c8b08c6c52c" xlink:to="loc_us-gaap_OperatingExpenseMember_adab985a-9dcc-49fe-9f32-8adf4fa5c653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_49e9bc4b-d809-48f8-817c-9f7b3fd43bef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_49e9bc4b-d809-48f8-817c-9f7b3fd43bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_990cd513-dcc2-4534-b7d0-b08d511ec339" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_49e9bc4b-d809-48f8-817c-9f7b3fd43bef" xlink:to="loc_us-gaap_HedgingRelationshipDomain_990cd513-dcc2-4534-b7d0-b08d511ec339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_1f77c73d-583b-4010-a874-697f4cef0cf4" xlink:href="biib-20240930.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_990cd513-dcc2-4534-b7d0-b08d511ec339" xlink:to="loc_biib_CashflowsrevenueMember_1f77c73d-583b-4010-a874-697f4cef0cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_7992d1c0-5b65-4c27-a4ce-7b29057cd5b0" xlink:href="biib-20240930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_990cd513-dcc2-4534-b7d0-b08d511ec339" xlink:to="loc_biib_CashflowsoperatingexpensesMember_7992d1c0-5b65-4c27-a4ce-7b29057cd5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9080ac78-a4e7-4992-9c02-1f9c959a8c44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_990cd513-dcc2-4534-b7d0-b08d511ec339" xlink:to="loc_us-gaap_CashFlowHedgingMember_9080ac78-a4e7-4992-9c02-1f9c959a8c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9c029934-de74-414e-826d-7b5921ade8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9c029934-de74-414e-826d-7b5921ade8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e22637a6-f259-4482-a619-06bcb0e77b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9c029934-de74-414e-826d-7b5921ade8c7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e22637a6-f259-4482-a619-06bcb0e77b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b9df3c8a-2d03-4df9-80fa-4f30eda87ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e22637a6-f259-4482-a619-06bcb0e77b9a" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b9df3c8a-2d03-4df9-80fa-4f30eda87ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1adb612d-4800-42d0-bedc-96c8dcfed345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1adb612d-4800-42d0-bedc-96c8dcfed345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1adb612d-4800-42d0-bedc-96c8dcfed345" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_b538a411-735a-4f89-ac60-dbb1268cc909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_b538a411-735a-4f89-ac60-dbb1268cc909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_876567bc-98dd-4522-934d-aa7a4a501e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_876567bc-98dd-4522-934d-aa7a4a501e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_bef152fb-fc3e-4120-b80c-2288ab8af3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_bef152fb-fc3e-4120-b80c-2288ab8af3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2d1eda93-1294-4506-9a41-c728fe1b1715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c16483e3-a386-482a-a992-9079fcc2c414" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2d1eda93-1294-4506-9a41-c728fe1b1715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2a1260eb-8134-40a2-8fa9-48a97c3430be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_HedgingDesignationAxis_2a1260eb-8134-40a2-8fa9-48a97c3430be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_93ed6a60-d202-4b7a-9d49-8f9a8df22cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_2a1260eb-8134-40a2-8fa9-48a97c3430be" xlink:to="loc_us-gaap_HedgingDesignationDomain_93ed6a60-d202-4b7a-9d49-8f9a8df22cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e2d4800-998b-46e0-9014-a1a16a17517d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_93ed6a60-d202-4b7a-9d49-8f9a8df22cdf" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e2d4800-998b-46e0-9014-a1a16a17517d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_94a7bdbf-9b10-44b7-9b2b-53359554de8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_93ed6a60-d202-4b7a-9d49-8f9a8df22cdf" xlink:to="loc_us-gaap_NondesignatedMember_94a7bdbf-9b10-44b7-9b2b-53359554de8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_75dd9d39-6ac3-4397-975b-505f6c2f742a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_srt_RangeAxis_75dd9d39-6ac3-4397-975b-505f6c2f742a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ed9257e-f04a-49c7-9b68-0eea424ed51b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_75dd9d39-6ac3-4397-975b-505f6c2f742a" xlink:to="loc_srt_RangeMember_1ed9257e-f04a-49c7-9b68-0eea424ed51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e3010949-29e8-441e-9218-e0eba202679b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1ed9257e-f04a-49c7-9b68-0eea424ed51b" xlink:to="loc_srt_MinimumMember_e3010949-29e8-441e-9218-e0eba202679b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8fd894a-2239-42c0-a1cd-df4db8500baf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1ed9257e-f04a-49c7-9b68-0eea424ed51b" xlink:to="loc_srt_MaximumMember_e8fd894a-2239-42c0-a1cd-df4db8500baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c7d38672-80c0-418b-a421-5c85e0fe6882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c7d38672-80c0-418b-a421-5c85e0fe6882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4b980e6-b6f9-4dd0-aac5-3b8e4dd97e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c7d38672-80c0-418b-a421-5c85e0fe6882" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4b980e6-b6f9-4dd0-aac5-3b8e4dd97e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_75ed07ce-b543-43b4-8140-afc08b0a48cb" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_ed315412-ca3a-4533-b3dc-f655a832f805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_ed315412-ca3a-4533-b3dc-f655a832f805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_fe5ff583-f8fe-4bf3-94b3-5f363efbe1bf" xlink:href="biib-20240930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_biib_UnrealizedGainOnDerivatives_fe5ff583-f8fe-4bf3-94b3-5f363efbe1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_49f7d515-b373-4be4-9c94-63bc023affd4" xlink:href="biib-20240930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_biib_UnrealizedLossOnDerivatives_49f7d515-b373-4be4-9c94-63bc023affd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_13c7852b-9e4e-4379-b5f3-b595ac0e091c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_13c7852b-9e4e-4379-b5f3-b595ac0e091c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_01620cdc-8e56-4314-a188-3dac970a046d" xlink:href="biib-20240930.xsd#biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_01620cdc-8e56-4314-a188-3dac970a046d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_38cd4412-75ec-4c48-b7b8-17d7c4a8a336" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_38cd4412-75ec-4c48-b7b8-17d7c4a8a336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_c8723253-2753-4c50-ae60-5968096c1301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_c8723253-2753-4c50-ae60-5968096c1301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e398c4f7-3be1-4ea8-b98d-d3c2a1741757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e398c4f7-3be1-4ea8-b98d-d3c2a1741757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1b1c71b1-7b37-4ac6-a2d5-da1e2395bb77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1b1c71b1-7b37-4ac6-a2d5-da1e2395bb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6545c5cc-6d77-4b5d-b75e-0b7f7a6306f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6545c5cc-6d77-4b5d-b75e-0b7f7a6306f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_26580609-9c83-43ab-8962-da9f444449e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_26580609-9c83-43ab-8962-da9f444449e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_08a5cf16-0e2c-48af-817b-25268d71f580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_08a5cf16-0e2c-48af-817b-25268d71f580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_26625780-cd93-48a5-96b4-2aba188e3a04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_47533e17-ad5f-40fe-ae34-70e003f90f2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_26625780-cd93-48a5-96b4-2aba188e3a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_42a98380-dfd8-45ef-a37c-c7d45463b63a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e687d49b-66e5-4ef2-b5f5-0942514ae49f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_42a98380-dfd8-45ef-a37c-c7d45463b63a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e687d49b-66e5-4ef2-b5f5-0942514ae49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_f2df6204-b6dd-4af6-bc83-ce2bf7dea07e" xlink:href="biib-20240930.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e687d49b-66e5-4ef2-b5f5-0942514ae49f" xlink:to="loc_biib_FacilityLocationAxis_f2df6204-b6dd-4af6-bc83-ce2bf7dea07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_f2204ad0-d76e-4195-a212-c3ab10faae51" xlink:href="biib-20240930.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_f2df6204-b6dd-4af6-bc83-ce2bf7dea07e" xlink:to="loc_biib_FacilityLocationDomain_f2204ad0-d76e-4195-a212-c3ab10faae51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_466e5d3b-a871-45a2-af91-f053303def97" xlink:href="biib-20240930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_f2204ad0-d76e-4195-a212-c3ab10faae51" xlink:to="loc_biib_SolothurnSwitzerlandMember_466e5d3b-a871-45a2-af91-f053303def97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_5c1c02b0-29ca-4abe-af36-dad504a94330" xlink:href="biib-20240930.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e687d49b-66e5-4ef2-b5f5-0942514ae49f" xlink:to="loc_biib_FacilityTypeAxis_5c1c02b0-29ca-4abe-af36-dad504a94330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_4d162853-0d34-4245-aab6-cb3a3c68cd77" xlink:href="biib-20240930.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_5c1c02b0-29ca-4abe-af36-dad504a94330" xlink:to="loc_biib_FacilityTypeDomain_4d162853-0d34-4245-aab6-cb3a3c68cd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_02f0b0ac-8821-4e82-a89b-5b06bff5fd0c" xlink:href="biib-20240930.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_4d162853-0d34-4245-aab6-cb3a3c68cd77" xlink:to="loc_biib_BiologicsManufacturingMember_02f0b0ac-8821-4e82-a89b-5b06bff5fd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_295aea24-1bb6-4866-87a1-417ea7b034bc" xlink:href="biib-20240930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_4d162853-0d34-4245-aab6-cb3a3c68cd77" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_295aea24-1bb6-4866-87a1-417ea7b034bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_6bfa2e94-ba46-4962-bc54-bb906ae57fb0" xlink:href="biib-20240930.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_4d162853-0d34-4245-aab6-cb3a3c68cd77" xlink:to="loc_biib_AdministrativeSpaceMember_6bfa2e94-ba46-4962-bc54-bb906ae57fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e687d49b-66e5-4ef2-b5f5-0942514ae49f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_df1ea40e-b404-420b-ad6e-321d254d01cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_df1ea40e-b404-420b-ad6e-321d254d01cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_53594c37-147f-48b2-be2b-ded1837369d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_Depreciation_53594c37-147f-48b2-be2b-ded1837369d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_34e8d32a-9761-4420-aca6-e2a6fa97687f" xlink:href="biib-20240930.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_biib_NumberOfSquareFeet_34e8d32a-9761-4420-aca6-e2a6fa97687f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_4555a6e5-b676-4319-9d5e-eabe77cdd926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_ConstructionInProgressGross_4555a6e5-b676-4319-9d5e-eabe77cdd926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1284506c-5e88-4173-b2ea-88a08e7a2d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1284506c-5e88-4173-b2ea-88a08e7a2d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_269281a2-14b5-43c0-9fa4-1910d9a9f463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ae9ecfe1-20d2-46e1-8fa3-8c4e03d33ba3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_269281a2-14b5-43c0-9fa4-1910d9a9f463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="simple" xlink:href="biib-20240930.xsd#LeasesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_30f5b400-ebdc-459d-a43f-a827521390d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_d6aab5d6-384d-4727-b81a-b62ce5576322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_30f5b400-ebdc-459d-a43f-a827521390d8" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_d6aab5d6-384d-4727-b81a-b62ce5576322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_edea172f-ceb4-4efe-8cdc-520e067b659e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_d6aab5d6-384d-4727-b81a-b62ce5576322" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_edea172f-ceb4-4efe-8cdc-520e067b659e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26c4a2f6-b9ef-48a6-add0-92e605844caa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_edea172f-ceb4-4efe-8cdc-520e067b659e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26c4a2f6-b9ef-48a6-add0-92e605844caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_9b9fddcc-bf4b-495d-8913-0c24fd111d1b" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26c4a2f6-b9ef-48a6-add0-92e605844caa" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_9b9fddcc-bf4b-495d-8913-0c24fd111d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_d6aab5d6-384d-4727-b81a-b62ce5576322" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_da3d7e1b-2bf0-4e7a-8678-9f74ddeb5c1b" xlink:href="biib-20240930.xsd#biib_OperatingLeaseArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_biib_OperatingLeaseArea_da3d7e1b-2bf0-4e7a-8678-9f74ddeb5c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_849f7c14-3293-4414-abfb-2138c7c89dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_849f7c14-3293-4414-abfb-2138c7c89dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_5a26cf46-6ebe-4585-8e1a-71b0ab67f38d" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_5a26cf46-6ebe-4585-8e1a-71b0ab67f38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_e48ace50-a003-4435-834a-5e224d1d3f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_e48ace50-a003-4435-834a-5e224d1d3f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_c6936e4a-0f83-4549-8804-4b946fd5c451" xlink:href="biib-20240930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_12f2895c-bf89-4795-b06c-4216be9f8356" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_c6936e4a-0f83-4549-8804-4b946fd5c451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bf8692b5-085d-4ca0-a25b-051a6f5e7f93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bf8692b5-085d-4ca0-a25b-051a6f5e7f93" xlink:to="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d60a7174-ae9e-4235-a57c-fce31766f92d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:to="loc_us-gaap_DebtInstrumentAxis_d60a7174-ae9e-4235-a57c-fce31766f92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d60a7174-ae9e-4235-a57c-fce31766f92d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_8fa1a88c-44c0-4b59-807e-1c0c75f63bf4" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_8fa1a88c-44c0-4b59-807e-1c0c75f63bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_e4d0f1fd-b4bf-4443-934b-e2cdeba41385" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_e4d0f1fd-b4bf-4443-934b-e2cdeba41385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember_7431eb50-9e97-44d3-8fe5-ccf0b0c79f4d" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:to="loc_biib_TheCreditFacilityTerminatedMember_7431eb50-9e97-44d3-8fe5-ccf0b0c79f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_a8c8e545-b86c-4a7f-8110-1c526f377f2e" xlink:href="biib-20240930.xsd#biib_TheCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:to="loc_biib_TheCreditFacilityMember_a8c8e545-b86c-4a7f-8110-1c526f377f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023TermLoanMember_c9f23208-d0fb-4869-9655-c5c937c19c9f" xlink:href="biib-20240930.xsd#biib_A2023TermLoanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a675b67d-5777-4469-abff-4207fcc78d60" xlink:to="loc_biib_A2023TermLoanMember_c9f23208-d0fb-4869-9655-c5c937c19c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_af975c7e-56b6-46a2-ad03-cf30da88c171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_af975c7e-56b6-46a2-ad03-cf30da88c171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_21882f48-bf0e-4763-a433-8245727bee09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af975c7e-56b6-46a2-ad03-cf30da88c171" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_21882f48-bf0e-4763-a433-8245727bee09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c78e8360-fdec-4863-a286-5854133599ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_21882f48-bf0e-4763-a433-8245727bee09" xlink:to="loc_us-gaap_LineOfCreditMember_c78e8360-fdec-4863-a286-5854133599ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_33a00097-7c9b-4748-bb5b-8de2be41eb29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:to="loc_us-gaap_CreditFacilityAxis_33a00097-7c9b-4748-bb5b-8de2be41eb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7486ac94-51d5-4425-88db-2284c4a6a786" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_33a00097-7c9b-4748-bb5b-8de2be41eb29" xlink:to="loc_us-gaap_CreditFacilityDomain_7486ac94-51d5-4425-88db-2284c4a6a786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_8423e924-e6ee-441e-857c-5f9e9b846371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7486ac94-51d5-4425-88db-2284c4a6a786" xlink:to="loc_us-gaap_SecuredDebtMember_8423e924-e6ee-441e-857c-5f9e9b846371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FloatingRate364DayTrancheMember_ed6cb898-00bf-4291-960a-1533e8b235e4" xlink:href="biib-20240930.xsd#biib_FloatingRate364DayTrancheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7486ac94-51d5-4425-88db-2284c4a6a786" xlink:to="loc_biib_FloatingRate364DayTrancheMember_ed6cb898-00bf-4291-960a-1533e8b235e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember_a904d549-b1f4-49ab-ab1c-051333fc9ea4" xlink:href="biib-20240930.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7486ac94-51d5-4425-88db-2284c4a6a786" xlink:to="loc_biib_TermLoan2023ThreeYearTrancheMember_a904d549-b1f4-49ab-ab1c-051333fc9ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7e682432-8095-47a7-8a58-ebd320b44a70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7e682432-8095-47a7-8a58-ebd320b44a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4d6ff9-fcea-40fb-8e3b-bfd3fd8ec85b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7e682432-8095-47a7-8a58-ebd320b44a70" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4d6ff9-fcea-40fb-8e3b-bfd3fd8ec85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_12c47362-e83d-4b7a-87f7-7f71a4a177d0" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4d6ff9-fcea-40fb-8e3b-bfd3fd8ec85b" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_12c47362-e83d-4b7a-87f7-7f71a4a177d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_259e580a-07c7-4386-bc7f-9c8e6beaa429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_878e2c30-ec4a-4a94-a629-0c6e63f3cfe2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_259e580a-07c7-4386-bc7f-9c8e6beaa429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ea77737c-8b5b-4942-aeb6-e7e1964c8d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_259e580a-07c7-4386-bc7f-9c8e6beaa429" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ea77737c-8b5b-4942-aeb6-e7e1964c8d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f8cc4c52-4868-4e59-80f7-106b4d69cf29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_259e580a-07c7-4386-bc7f-9c8e6beaa429" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f8cc4c52-4868-4e59-80f7-106b4d69cf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_2e505876-e0a3-4f3c-a378-760331fb9bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_259e580a-07c7-4386-bc7f-9c8e6beaa429" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_2e505876-e0a3-4f3c-a378-760331fb9bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#ShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_137d97cc-54e0-43db-b762-60090a0371fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_860fa8bb-ee13-4a1f-a64b-0e19da12a490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_137d97cc-54e0-43db-b762-60090a0371fa" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_860fa8bb-ee13-4a1f-a64b-0e19da12a490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_94f7e26a-8921-44be-9e3f-7f4f48a04519" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_860fa8bb-ee13-4a1f-a64b-0e19da12a490" xlink:to="loc_srt_ShareRepurchaseProgramAxis_94f7e26a-8921-44be-9e3f-7f4f48a04519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_d7ac667a-7560-4e52-aa7a-bd71ec0468b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_94f7e26a-8921-44be-9e3f-7f4f48a04519" xlink:to="loc_srt_ShareRepurchaseProgramDomain_d7ac667a-7560-4e52-aa7a-bd71ec0468b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_97f7f77a-0b59-4c74-8bdb-58b470067283" xlink:href="biib-20240930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_d7ac667a-7560-4e52-aa7a-bd71ec0468b9" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_97f7f77a-0b59-4c74-8bdb-58b470067283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_532bd639-860e-4660-9fd9-7aceb4a1b755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_860fa8bb-ee13-4a1f-a64b-0e19da12a490" xlink:to="loc_us-gaap_ClassOfStockLineItems_532bd639-860e-4660-9fd9-7aceb4a1b755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_9a419b38-cf16-4ece-bfac-29bcf69ef935" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_532bd639-860e-4660-9fd9-7aceb4a1b755" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_9a419b38-cf16-4ece-bfac-29bcf69ef935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c5518f56-3375-460f-ae5c-6b11959c4ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_532bd639-860e-4660-9fd9-7aceb4a1b755" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c5518f56-3375-460f-ae5c-6b11959c4ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_69212f06-0835-4025-9c16-263869e54aad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bf48cf14-bff9-4db9-900f-746edfc3de6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69212f06-0835-4025-9c16-263869e54aad" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bf48cf14-bff9-4db9-900f-746edfc3de6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_daf87fbe-d3a4-44d7-b9b0-c39c82486006" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bf48cf14-bff9-4db9-900f-746edfc3de6c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_daf87fbe-d3a4-44d7-b9b0-c39c82486006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_daf87fbe-d3a4-44d7-b9b0-c39c82486006" xlink:to="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fd3a4d26-901c-4a5c-a63f-d9aff251e251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fd3a4d26-901c-4a5c-a63f-d9aff251e251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_79634b18-8d71-49d5-81c9-8ecf318bbdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_79634b18-8d71-49d5-81c9-8ecf318bbdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_75601411-9b28-4c8c-a000-a2665417d2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_75601411-9b28-4c8c-a000-a2665417d2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_0e3b43d9-e63d-4560-9051-8fb50be0e8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62c64670-4862-40a0-a50c-fb9fbd183f4e" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_0e3b43d9-e63d-4560-9051-8fb50be0e8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bf48cf14-bff9-4db9-900f-746edfc3de6c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3ecce5ab-d7e9-443c-a391-73408183e3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3ecce5ab-d7e9-443c-a391-73408183e3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c727309e-2605-43f0-a9fc-39be4b798a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c727309e-2605-43f0-a9fc-39be4b798a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_59ab42c7-d3fb-4c98-9351-dc7a8cf6e0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_59ab42c7-d3fb-4c98-9351-dc7a8cf6e0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ecede2d8-33b9-452b-972f-204eeba4e6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ecede2d8-33b9-452b-972f-204eeba4e6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_168cd276-a28d-4098-8193-378b6f3b550e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_168cd276-a28d-4098-8193-378b6f3b550e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eb9be9d2-5eb1-4ce5-b687-7deef55c3f84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eb9be9d2-5eb1-4ce5-b687-7deef55c3f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b0503b53-f817-4529-b9e9-a9403f462b00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cbd978cf-7a17-4a85-a302-cb0709e3b5e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b0503b53-f817-4529-b9e9-a9403f462b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_54a93f93-42aa-4aa2-8af9-6deccbad04b4" xlink:href="biib-20240930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_54a93f93-42aa-4aa2-8af9-6deccbad04b4" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ca496eef-8bed-4844-b664-fed3ab1f96fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ca496eef-8bed-4844-b664-fed3ab1f96fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2cc7dc48-893d-497b-817b-376e047c6aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ca496eef-8bed-4844-b664-fed3ab1f96fd" xlink:to="loc_us-gaap_EquityComponentDomain_2cc7dc48-893d-497b-817b-376e047c6aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_40c9673b-ef56-4186-9e36-0089dce7cda9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2cc7dc48-893d-497b-817b-376e047c6aeb" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_40c9673b-ef56-4186-9e36-0089dce7cda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_4a4a3701-d689-4a3b-b107-55844053708b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2cc7dc48-893d-497b-817b-376e047c6aeb" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_4a4a3701-d689-4a3b-b107-55844053708b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_761c6682-2319-485d-9e9b-0709fadcfc39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_761c6682-2319-485d-9e9b-0709fadcfc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_947c8f31-1a78-4d9a-b052-a36f39108396" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_761c6682-2319-485d-9e9b-0709fadcfc39" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_947c8f31-1a78-4d9a-b052-a36f39108396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_bdd5f2f8-dfd2-45fd-a002-53b1e46f3606" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_947c8f31-1a78-4d9a-b052-a36f39108396" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_bdd5f2f8-dfd2-45fd-a002-53b1e46f3606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baac84fd-27fa-40a3-9b78-492cc268e34c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baac84fd-27fa-40a3-9b78-492cc268e34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_efdb8b62-dd96-490c-99c4-d6eac0cdd79a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baac84fd-27fa-40a3-9b78-492cc268e34c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_efdb8b62-dd96-490c-99c4-d6eac0cdd79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_a5109c5b-d520-4179-9f40-c61b3490dde4" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_efdb8b62-dd96-490c-99c4-d6eac0cdd79a" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_a5109c5b-d520-4179-9f40-c61b3490dde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_72eac573-04cf-44e8-a1fe-b40f9979f0d4" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_4c89e396-125e-4cda-87b8-877bc2f90f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_4c89e396-125e-4cda-87b8-877bc2f90f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ee49c4fb-4ef5-4976-8cc4-e52a98dd0a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ee49c4fb-4ef5-4976-8cc4-e52a98dd0a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_89d1af01-5500-46a5-9bfd-5f420cd92b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_Revenues_89d1af01-5500-46a5-9bfd-5f420cd92b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_838efd59-1291-4d6f-a50e-9440761afd80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_OperatingExpenses_838efd59-1291-4d6f-a50e-9440761afd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_558b3ac0-8c6c-448f-a21b-cfd68f3afd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_NetIncomeLoss_558b3ac0-8c6c-448f-a21b-cfd68f3afd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d9caf90e-0d6a-47ee-9f0f-eeabbba0e770" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_1ef7bf2e-7450-4777-837d-54d1f82bddbe" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d9caf90e-0d6a-47ee-9f0f-eeabbba0e770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2ee3bcf9-7285-433b-93c6-2187814f2607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ceefe822-4ee9-4972-9b65-2156bbb20f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ee3bcf9-7285-433b-93c6-2187814f2607" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ceefe822-4ee9-4972-9b65-2156bbb20f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2c537fbd-0a03-4420-afc0-2c5c8ed2849f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ceefe822-4ee9-4972-9b65-2156bbb20f11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2c537fbd-0a03-4420-afc0-2c5c8ed2849f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257c2df4-f7d5-444c-bcc0-c2291f105d57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2c537fbd-0a03-4420-afc0-2c5c8ed2849f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257c2df4-f7d5-444c-bcc0-c2291f105d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_05125c4b-9ccd-4e97-8e68-f98dcce4765e" xlink:href="biib-20240930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257c2df4-f7d5-444c-bcc0-c2291f105d57" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_05125c4b-9ccd-4e97-8e68-f98dcce4765e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_0fec75f2-0a8b-44bd-94d8-b1ec518d674b" xlink:href="biib-20240930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257c2df4-f7d5-444c-bcc0-c2291f105d57" xlink:to="loc_biib_MarketStockUnitsMember_0fec75f2-0a8b-44bd-94d8-b1ec518d674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_a1c2d090-0440-40c3-9371-f7b6d20201bf" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_257c2df4-f7d5-444c-bcc0-c2291f105d57" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_a1c2d090-0440-40c3-9371-f7b6d20201bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48e8b64d-be93-404b-a66c-4d58b3c2cbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ceefe822-4ee9-4972-9b65-2156bbb20f11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48e8b64d-be93-404b-a66c-4d58b3c2cbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_91203487-3c81-468a-b818-5c8e9e59ab7b" xlink:href="biib-20240930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_48e8b64d-be93-404b-a66c-4d58b3c2cbe4" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_91203487-3c81-468a-b818-5c8e9e59ab7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_9b97fb45-3547-4341-9f4a-ed442a5ce82d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_91203487-3c81-468a-b818-5c8e9e59ab7b" xlink:to="loc_us-gaap_NetIncomeLossAbstract_9b97fb45-3547-4341-9f4a-ed442a5ce82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cda32820-8836-4cc0-bebb-077607959366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_9b97fb45-3547-4341-9f4a-ed442a5ce82d" xlink:to="loc_us-gaap_NetIncomeLoss_cda32820-8836-4cc0-bebb-077607959366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54153f10-c5c7-40e6-8dc9-02c7afe87307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_91203487-3c81-468a-b818-5c8e9e59ab7b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54153f10-c5c7-40e6-8dc9-02c7afe87307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1e5d545a-24df-4b22-b538-01d6328d5ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54153f10-c5c7-40e6-8dc9-02c7afe87307" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1e5d545a-24df-4b22-b538-01d6328d5ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_840dadb7-a66a-4f1b-a5bb-1dfa11d6ef85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54153f10-c5c7-40e6-8dc9-02c7afe87307" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_840dadb7-a66a-4f1b-a5bb-1dfa11d6ef85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_78bb9827-c587-437a-a0dd-5e2864db0c36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_840dadb7-a66a-4f1b-a5bb-1dfa11d6ef85" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_78bb9827-c587-437a-a0dd-5e2864db0c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bb50f0d6-4c58-4b8d-ac2a-8f4bef449165" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_840dadb7-a66a-4f1b-a5bb-1dfa11d6ef85" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bb50f0d6-4c58-4b8d-ac2a-8f4bef449165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b43d59e6-f024-491e-920d-07f2d2cad388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_54153f10-c5c7-40e6-8dc9-02c7afe87307" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b43d59e6-f024-491e-920d-07f2d2cad388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_574eb743-a786-4bdf-9dbf-49954369f450" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7cb74d85-7b52-492d-9a6e-844ea5af5a82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_574eb743-a786-4bdf-9dbf-49954369f450" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7cb74d85-7b52-492d-9a6e-844ea5af5a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_69f01c90-719a-4b7f-b148-1a9738f9124b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7cb74d85-7b52-492d-9a6e-844ea5af5a82" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_69f01c90-719a-4b7f-b148-1a9738f9124b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4372358-4eb5-4d7c-808e-562ea0b84568" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69f01c90-719a-4b7f-b148-1a9738f9124b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4372358-4eb5-4d7c-808e-562ea0b84568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6a89266b-6366-4c93-86f2-7432661ea58e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4372358-4eb5-4d7c-808e-562ea0b84568" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6a89266b-6366-4c93-86f2-7432661ea58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4cc11988-e2af-4447-ad0f-69f6cc24e442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4372358-4eb5-4d7c-808e-562ea0b84568" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4cc11988-e2af-4447-ad0f-69f6cc24e442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_0966a41f-30d7-4064-86a7-d34b72f6aca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4372358-4eb5-4d7c-808e-562ea0b84568" xlink:to="loc_us-gaap_ParentMember_0966a41f-30d7-4064-86a7-d34b72f6aca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c945a948-c408-4bb1-a396-ce8e21b6a758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7cb74d85-7b52-492d-9a6e-844ea5af5a82" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c945a948-c408-4bb1-a396-ce8e21b6a758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a6181-33a5-4048-81ab-79fea2e6d587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c945a948-c408-4bb1-a396-ce8e21b6a758" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a6181-33a5-4048-81ab-79fea2e6d587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_c31e1ede-2a2e-4fb9-9d8c-421dc552a7dd" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_697a6181-33a5-4048-81ab-79fea2e6d587" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_c31e1ede-2a2e-4fb9-9d8c-421dc552a7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7cb74d85-7b52-492d-9a6e-844ea5af5a82" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc180324-32b3-44e1-8417-d385952848dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc180324-32b3-44e1-8417-d385952848dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_97d4d563-b320-4b74-bd79-cdb49554dacf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_97d4d563-b320-4b74-bd79-cdb49554dacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_68275a6e-8b15-4c72-9466-6ede0046312e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_68275a6e-8b15-4c72-9466-6ede0046312e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_deaf1857-48ef-4771-a95c-18994d7ba036" xlink:href="biib-20240930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_deaf1857-48ef-4771-a95c-18994d7ba036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_e6bc7c5f-1724-4c05-9e60-5a5192bc4663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_20328d82-6706-4900-b399-0303b9b91ceb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_e6bc7c5f-1724-4c05-9e60-5a5192bc4663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f59b9047-b59c-45e4-a197-fc0aa64f12e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:to="loc_us-gaap_OperatingExpenses_f59b9047-b59c-45e4-a197-fc0aa64f12e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_95a475f7-abf5-4c4e-829c-3759edb127d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_95a475f7-abf5-4c4e-829c-3759edb127d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a5e97897-86ed-42d9-bb76-373e2dc67f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5aa94ad5-65ba-48ef-9aa8-39e558e61a5f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a5e97897-86ed-42d9-bb76-373e2dc67f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4691dafb-4497-4ba3-b270-1a79dcf042c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a26ecd7e-b605-49b5-8be1-f3b06e24e42c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4691dafb-4497-4ba3-b270-1a79dcf042c6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a26ecd7e-b605-49b5-8be1-f3b06e24e42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a82ae731-ba85-453e-bcfd-e92c13d72295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a26ecd7e-b605-49b5-8be1-f3b06e24e42c" xlink:to="loc_us-gaap_AwardTypeAxis_a82ae731-ba85-453e-bcfd-e92c13d72295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a82ae731-ba85-453e-bcfd-e92c13d72295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_a8582d95-6ddc-4dbb-ae8e-5778ad73a450" xlink:href="biib-20240930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_biib_MarketStockUnitsMember_a8582d95-6ddc-4dbb-ae8e-5778ad73a450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_5ac3fbc0-5ef2-444b-9516-40c1104e77ee" xlink:href="biib-20240930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_5ac3fbc0-5ef2-444b-9516-40c1104e77ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_2947f7b5-a164-4f35-89e5-f195a8473c1e" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_2947f7b5-a164-4f35-89e5-f195a8473c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_372f61c0-2358-4de9-b0c9-cee9e2bf39ac" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_372f61c0-2358-4de9-b0c9-cee9e2bf39ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_a7cc7048-dfd3-463c-abff-9265688033cc" xlink:href="biib-20240930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_a7cc7048-dfd3-463c-abff-9265688033cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_09bb5fae-4ad6-4b87-a8ea-906e78964bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b393c6d8-5b59-4449-8f0b-a78298822c1f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_09bb5fae-4ad6-4b87-a8ea-906e78964bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2e9bd782-9193-44ee-9787-05424bf8921a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a26ecd7e-b605-49b5-8be1-f3b06e24e42c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2e9bd782-9193-44ee-9787-05424bf8921a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01befdd6-3780-45b4-a243-9c848e0f514f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2e9bd782-9193-44ee-9787-05424bf8921a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01befdd6-3780-45b4-a243-9c848e0f514f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_79bf308e-cf23-42c4-ba7e-a46807c8d8a1" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01befdd6-3780-45b4-a243-9c848e0f514f" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_79bf308e-cf23-42c4-ba7e-a46807c8d8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_bf1a55da-6376-45b0-a8bd-3122b04ae5fc" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01befdd6-3780-45b4-a243-9c848e0f514f" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_bf1a55da-6376-45b0-a8bd-3122b04ae5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7746b6e4-13fb-4aeb-9954-1cf3f81bbc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a26ecd7e-b605-49b5-8be1-f3b06e24e42c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7746b6e4-13fb-4aeb-9954-1cf3f81bbc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:href="biib-20240930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7746b6e4-13fb-4aeb-9954-1cf3f81bbc5d" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6a703551-036c-4869-be90-d54bd9dec514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6a703551-036c-4869-be90-d54bd9dec514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_487ae6ec-6c87-49ea-b9a6-14da58fb1ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_487ae6ec-6c87-49ea-b9a6-14da58fb1ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_34514279-ec0f-442d-acd3-18b4b79abf8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_34514279-ec0f-442d-acd3-18b4b79abf8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_38090191-ba71-4bb9-bbea-fd23ea7efb75" xlink:href="biib-20240930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8fb68ed8-3842-4b3c-8013-96ae0e516e97" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_38090191-ba71-4bb9-bbea-fd23ea7efb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#SharebasedPaymentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3df18ae1-23fe-4b75-8633-75fc4fb89714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3df18ae1-23fe-4b75-8633-75fc4fb89714" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_37552b23-f4e8-499c-bd01-c98556e387b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:to="loc_us-gaap_PlanNameAxis_37552b23-f4e8-499c-bd01-c98556e387b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fdebc74e-1f73-48ae-8aee-5d25407dfb38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_37552b23-f4e8-499c-bd01-c98556e387b8" xlink:to="loc_us-gaap_PlanNameDomain_fdebc74e-1f73-48ae-8aee-5d25407dfb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OmnibusEquityPlan2024Member_d81b58eb-e0b4-44c7-b83b-6639333ad3b9" xlink:href="biib-20240930.xsd#biib_OmnibusEquityPlan2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fdebc74e-1f73-48ae-8aee-5d25407dfb38" xlink:to="loc_biib_OmnibusEquityPlan2024Member_d81b58eb-e0b4-44c7-b83b-6639333ad3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e6fffe1f-d774-42f2-8b8a-f85adadf9d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e6fffe1f-d774-42f2-8b8a-f85adadf9d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9226d5fd-af18-404b-88ab-b5fd25506c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e6fffe1f-d774-42f2-8b8a-f85adadf9d56" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9226d5fd-af18-404b-88ab-b5fd25506c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_2c0bbebd-ba58-45dc-954d-a29da282d341" xlink:href="biib-20240930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9226d5fd-af18-404b-88ab-b5fd25506c60" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_2c0bbebd-ba58-45dc-954d-a29da282d341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_12bbec28-f1b6-4270-87eb-0b3fccfbc9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_12bbec28-f1b6-4270-87eb-0b3fccfbc9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b6231066-455a-43c5-9770-02ff05a9438d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_12bbec28-f1b6-4270-87eb-0b3fccfbc9ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b6231066-455a-43c5-9770-02ff05a9438d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f487de07-f974-4f66-8d70-654bf51eb3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6231066-455a-43c5-9770-02ff05a9438d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f487de07-f974-4f66-8d70-654bf51eb3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_84a64725-e1be-4005-a602-373d17166d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6231066-455a-43c5-9770-02ff05a9438d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_84a64725-e1be-4005-a602-373d17166d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_930982fa-ca0c-407f-a46c-d33873394220" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9dc81b83-b418-4b5f-a92b-f72a7d19b90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9dc81b83-b418-4b5f-a92b-f72a7d19b90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_a4732ba6-7bc9-481c-ae73-4217efabb8e2" xlink:href="biib-20240930.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_a4732ba6-7bc9-481c-ae73-4217efabb8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_57778f19-e37a-434f-8c01-076e6599541f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_57778f19-e37a-434f-8c01-076e6599541f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ec1d5ab3-b8ea-48c5-b301-73c3327a0aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5e83526-e65a-4074-b5c0-ba6ad7750224" xlink:to="loc_us-gaap_OperatingExpenses_ec1d5ab3-b8ea-48c5-b301-73c3327a0aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IncomeTaxesTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a8e8a8f2-98df-4d5e-a95e-2a841c4915f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_40dec234-e267-4a70-bba0-1dcd34bb9747" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a8e8a8f2-98df-4d5e-a95e-2a841c4915f9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_40dec234-e267-4a70-bba0-1dcd34bb9747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5c07978b-638f-4abc-90ab-1e064ba479d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_40dec234-e267-4a70-bba0-1dcd34bb9747" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5c07978b-638f-4abc-90ab-1e064ba479d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4cf52abf-db62-40d9-881b-f0f713a63bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_40dec234-e267-4a70-bba0-1dcd34bb9747" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4cf52abf-db62-40d9-881b-f0f713a63bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_23d8a2e4-fd20-4cee-a42d-f00d9625c5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_40dec234-e267-4a70-bba0-1dcd34bb9747" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_23d8a2e4-fd20-4cee-a42d-f00d9625c5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5d418126-3dd4-4737-a66b-adfa901d0400" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_40dec234-e267-4a70-bba0-1dcd34bb9747" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5d418126-3dd4-4737-a66b-adfa901d0400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_4825e3b6-3e54-44d8-9b36-a79d0ebe3c85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_40dec234-e267-4a70-bba0-1dcd34bb9747" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_4825e3b6-3e54-44d8-9b36-a79d0ebe3c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_a654ac72-fb5f-49ec-89f1-ec2937510d74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_40dec234-e267-4a70-bba0-1dcd34bb9747" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_a654ac72-fb5f-49ec-89f1-ec2937510d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_170ca1f0-8dcb-40be-90ba-d1f6cbc51e37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_40dec234-e267-4a70-bba0-1dcd34bb9747" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_170ca1f0-8dcb-40be-90ba-d1f6cbc51e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_95d80740-b799-4c20-ba56-260c0336d759" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_40dec234-e267-4a70-bba0-1dcd34bb9747" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_95d80740-b799-4c20-ba56-260c0336d759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ebb1e4b8-c38e-41c4-a3b3-c19dc0760302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_4ac48237-0a5d-48d3-a042-48764666328c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebb1e4b8-c38e-41c4-a3b3-c19dc0760302" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_4ac48237-0a5d-48d3-a042-48764666328c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5bc524fb-ba89-4224-ba82-4c1e7255c5df" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4ac48237-0a5d-48d3-a042-48764666328c" xlink:to="loc_srt_StatementScenarioAxis_5bc524fb-ba89-4224-ba82-4c1e7255c5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9927eab0-7eb4-4617-938e-ba14c8b74106" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_5bc524fb-ba89-4224-ba82-4c1e7255c5df" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9927eab0-7eb4-4617-938e-ba14c8b74106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0247cd3c-d661-4dfe-b439-0345a7a1d558" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9927eab0-7eb4-4617-938e-ba14c8b74106" xlink:to="loc_srt_ScenarioForecastMember_0247cd3c-d661-4dfe-b439-0345a7a1d558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7526090e-dd78-4184-aee7-7bc1dee34a8d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4ac48237-0a5d-48d3-a042-48764666328c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7526090e-dd78-4184-aee7-7bc1dee34a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0a00cb56-2612-46d5-baef-59f7050c63d3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7526090e-dd78-4184-aee7-7bc1dee34a8d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0a00cb56-2612-46d5-baef-59f7050c63d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_c4c1de4f-19e1-4309-9a22-8190cfdef801" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0a00cb56-2612-46d5-baef-59f7050c63d3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_c4c1de4f-19e1-4309-9a22-8190cfdef801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_1b6d8202-2539-447a-9d1f-eb7f04a9e190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_4ac48237-0a5d-48d3-a042-48764666328c" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_1b6d8202-2539-447a-9d1f-eb7f04a9e190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70f6fa1f-88b7-4a92-b77e-c52a65ae9021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1b6d8202-2539-447a-9d1f-eb7f04a9e190" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70f6fa1f-88b7-4a92-b77e-c52a65ae9021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6cf2ddc3-d4cb-4698-bba5-abb95d2c6648" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1b6d8202-2539-447a-9d1f-eb7f04a9e190" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6cf2ddc3-d4cb-4698-bba5-abb95d2c6648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_b01a4b07-0536-498e-a2d3-856e02ca7ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_1b6d8202-2539-447a-9d1f-eb7f04a9e190" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_b01a4b07-0536-498e-a2d3-856e02ca7ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d325745d-97e8-4d63-956d-1f05af726e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d325745d-97e8-4d63-956d-1f05af726e2b" xlink:to="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2e94aa07-6ea5-41c7-b84f-8f4db96f7ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2e94aa07-6ea5-41c7-b84f-8f4db96f7ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_20d268a6-da3f-4587-b181-84760de8a276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2e94aa07-6ea5-41c7-b84f-8f4db96f7ad2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_20d268a6-da3f-4587-b181-84760de8a276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_624d608b-a5b5-4a10-b760-1631c5209472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_20d268a6-da3f-4587-b181-84760de8a276" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_624d608b-a5b5-4a10-b760-1631c5209472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ab55ed18-31d9-4b45-9ae3-aaebb1c5aa78" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:to="loc_dei_LegalEntityAxis_ab55ed18-31d9-4b45-9ae3-aaebb1c5aa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_25116645-ec80-471c-bf58-3c86abac3531" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ab55ed18-31d9-4b45-9ae3-aaebb1c5aa78" xlink:to="loc_dei_EntityDomain_25116645-ec80-471c-bf58-3c86abac3531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_94971278-bad2-4574-a79c-82f5acbdfff0" xlink:href="biib-20240930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_25116645-ec80-471c-bf58-3c86abac3531" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_94971278-bad2-4574-a79c-82f5acbdfff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ce1e73b6-ddf9-4ecb-b8ce-de2776e06192" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ce1e73b6-ddf9-4ecb-b8ce-de2776e06192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_50ea43fa-dd8d-447c-92cd-4518d603e40d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ce1e73b6-ddf9-4ecb-b8ce-de2776e06192" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_50ea43fa-dd8d-447c-92cd-4518d603e40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7233ee2c-04c9-467e-b3f5-c752bfa6762e" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_50ea43fa-dd8d-447c-92cd-4518d603e40d" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_7233ee2c-04c9-467e-b3f5-c752bfa6762e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c60f75cf-7ef4-45f4-9201-c4c273bffd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a38610d2-8c8a-4c4f-8be0-ec5aefc35e72" xlink:to="loc_us-gaap_StatementLineItems_c60f75cf-7ef4-45f4-9201-c4c273bffd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c60f75cf-7ef4-45f4-9201-c4c273bffd1e" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_597b2dd0-6f6e-43b3-be81-f643d3a269f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_597b2dd0-6f6e-43b3-be81-f643d3a269f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ba358823-aa09-4d70-8c50-ff59927735a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_InterestExpense_ba358823-aa09-4d70-8c50-ff59927735a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_545d4f78-d362-4995-99af-abed9c8c2b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_545d4f78-d362-4995-99af-abed9c8c2b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_33ffdf10-4cb7-4e1d-b5a8-4cd958307f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_33ffdf10-4cb7-4e1d-b5a8-4cd958307f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a7dd181e-01ee-4edc-bf2c-6f6260f5218c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a7dd181e-01ee-4edc-bf2c-6f6260f5218c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8a10e582-5f42-48ad-ad77-bd5b159eea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_d740c91d-80cf-4b5f-8856-28446f1d35c8" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8a10e582-5f42-48ad-ad77-bd5b159eea0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4be73ea7-1c1e-4bbb-8abe-3a0e0f6afc62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c60f75cf-7ef4-45f4-9201-c4c273bffd1e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4be73ea7-1c1e-4bbb-8abe-3a0e0f6afc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3f3382ba-74cb-48e7-b709-8630cb810f82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4be73ea7-1c1e-4bbb-8abe-3a0e0f6afc62" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3f3382ba-74cb-48e7-b709-8630cb810f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d6a996c5-949a-4531-9626-5f5d9ac3ac27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4be73ea7-1c1e-4bbb-8abe-3a0e0f6afc62" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d6a996c5-949a-4531-9626-5f5d9ac3ac27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cf1581c3-2535-45f4-85ce-d04291f792a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4be73ea7-1c1e-4bbb-8abe-3a0e0f6afc62" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cf1581c3-2535-45f4-85ce-d04291f792a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c60f75cf-7ef4-45f4-9201-c4c273bffd1e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e1b00cae-263b-4867-8190-cb4cbfb685bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e1b00cae-263b-4867-8190-cb4cbfb685bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_11c77794-1d18-45e6-b54d-b3e232a0573d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_11c77794-1d18-45e6-b54d-b3e232a0573d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_de30f796-b0fc-46a4-870f-ef21bd61a245" xlink:href="biib-20240930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_biib_Collaborationexpensesaccrual_de30f796-b0fc-46a4-870f-ef21bd61a245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_9952ff23-b3a9-435b-ae79-9cd4e56daa45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_9952ff23-b3a9-435b-ae79-9cd4e56daa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_07a2bc93-db4d-44b5-a426-b6258fbd2611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_07a2bc93-db4d-44b5-a426-b6258fbd2611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_11fde7a5-661d-4f5d-bfe6-aa87fa705b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_11fde7a5-661d-4f5d-bfe6-aa87fa705b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c9f1ae15-1f9d-49dd-9e5b-7df9746bca64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6a45e29f-3813-433a-a098-e87e2c413798" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c9f1ae15-1f9d-49dd-9e5b-7df9746bca64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20240930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_842387d0-7dc4-42f0-a2be-3975e3176e13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_45a21ced-0a15-4505-9328-dcdd7ec61259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_842387d0-7dc4-42f0-a2be-3975e3176e13" xlink:to="loc_us-gaap_StatementTable_45a21ced-0a15-4505-9328-dcdd7ec61259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_703e5eda-fff8-417b-bcf9-aef2fe1e3412" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_45a21ced-0a15-4505-9328-dcdd7ec61259" xlink:to="loc_dei_LegalEntityAxis_703e5eda-fff8-417b-bcf9-aef2fe1e3412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_83aadeb0-0ccc-4332-882a-100ff754db03" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_703e5eda-fff8-417b-bcf9-aef2fe1e3412" xlink:to="loc_dei_EntityDomain_83aadeb0-0ccc-4332-882a-100ff754db03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_130f2220-0906-4ec0-8c88-0f987420bbed" xlink:href="biib-20240930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_83aadeb0-0ccc-4332-882a-100ff754db03" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_130f2220-0906-4ec0-8c88-0f987420bbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoMember_52b50ca4-6d8e-4a84-9b2b-d809cae35d72" xlink:href="biib-20240930.xsd#biib_SangamoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_83aadeb0-0ccc-4332-882a-100ff754db03" xlink:to="loc_biib_SangamoMember_52b50ca4-6d8e-4a84-9b2b-d809cae35d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_1bb970a6-ea83-455a-83e5-02389a5e9e67" xlink:href="biib-20240930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_83aadeb0-0ccc-4332-882a-100ff754db03" xlink:to="loc_biib_SageTherapeuticsIncMember_1bb970a6-ea83-455a-83e5-02389a5e9e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1d9fb6b8-5372-4977-9a3c-3238eabd00d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_45a21ced-0a15-4505-9328-dcdd7ec61259" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1d9fb6b8-5372-4977-9a3c-3238eabd00d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_13f2ea89-ab4d-4aeb-b7d6-2c3a1d6f65da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d9fb6b8-5372-4977-9a3c-3238eabd00d1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_13f2ea89-ab4d-4aeb-b7d6-2c3a1d6f65da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_d942c060-8b5b-4134-be7b-10d55385fdfb" xlink:href="biib-20240930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_13f2ea89-ab4d-4aeb-b7d6-2c3a1d6f65da" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_d942c060-8b5b-4134-be7b-10d55385fdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_45a21ced-0a15-4505-9328-dcdd7ec61259" xlink:to="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c768f239-77c2-4a2d-accc-557fa8aa69c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c768f239-77c2-4a2d-accc-557fa8aa69c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_33babdc3-bbee-4dd8-bf96-2bc0d7240547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_33babdc3-bbee-4dd8-bf96-2bc0d7240547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ea327ef2-3b40-433a-a345-d292324a3541" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ea327ef2-3b40-433a-a345-d292324a3541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_509070d9-9116-4e9e-b6ef-cb12ace24546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_509070d9-9116-4e9e-b6ef-cb12ace24546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c488f632-6622-4051-9242-4605b772c45b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3eea61e1-6fd1-4475-bf99-556a2ac880b1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c488f632-6622-4051-9242-4605b772c45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3968690-6c24-490e-9c34-f7c95cefd497" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3968690-6c24-490e-9c34-f7c95cefd497" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_95d37814-ab6c-482f-b21f-d5841dc9f0d4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:to="loc_srt_ProductOrServiceAxis_95d37814-ab6c-482f-b21f-d5841dc9f0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14bb8289-ed1c-4a57-81b8-83f8ff896589" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_95d37814-ab6c-482f-b21f-d5841dc9f0d4" xlink:to="loc_srt_ProductsAndServicesDomain_14bb8289-ed1c-4a57-81b8-83f8ff896589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember_66463e1d-80cc-4663-a57d-a85d00595455" xlink:href="biib-20240930.xsd#biib_OCREVUSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14bb8289-ed1c-4a57-81b8-83f8ff896589" xlink:to="loc_biib_OCREVUSMember_66463e1d-80cc-4663-a57d-a85d00595455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MosunetuzumabMember_3e439cd6-6bcf-4de0-9cb1-df2b54bbad6e" xlink:href="biib-20240930.xsd#biib_MosunetuzumabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14bb8289-ed1c-4a57-81b8-83f8ff896589" xlink:to="loc_biib_MosunetuzumabMember_3e439cd6-6bcf-4de0-9cb1-df2b54bbad6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_abdcc053-1bdc-45d7-bf66-35bfa780a78a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:to="loc_srt_RangeAxis_abdcc053-1bdc-45d7-bf66-35bfa780a78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c1b61487-9881-4436-b393-05550e253e60" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_abdcc053-1bdc-45d7-bf66-35bfa780a78a" xlink:to="loc_srt_RangeMember_c1b61487-9881-4436-b393-05550e253e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_47369332-a39e-4dcc-b74e-105803108093" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c1b61487-9881-4436-b393-05550e253e60" xlink:to="loc_srt_MinimumMember_47369332-a39e-4dcc-b74e-105803108093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_80f75f3f-05fa-40ef-ad79-d02fff4512e8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c1b61487-9881-4436-b393-05550e253e60" xlink:to="loc_srt_MaximumMember_80f75f3f-05fa-40ef-ad79-d02fff4512e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_98c3bae7-12d9-4071-8a11-6c1803e931cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:to="loc_srt_StatementGeographicalAxis_98c3bae7-12d9-4071-8a11-6c1803e931cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e496dabf-5bc5-4e8c-a6fa-2371cc85f319" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_98c3bae7-12d9-4071-8a11-6c1803e931cd" xlink:to="loc_srt_SegmentGeographicalDomain_e496dabf-5bc5-4e8c-a6fa-2371cc85f319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_cef95cba-e74d-4f01-ba0d-613205738d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e496dabf-5bc5-4e8c-a6fa-2371cc85f319" xlink:to="loc_us-gaap_ForeignCountryMember_cef95cba-e74d-4f01-ba0d-613205738d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cffd7683-e858-4fc6-81ab-b7a7c1186852" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_bd5813c7-e662-43da-906c-7bb98a2e2787" xlink:href="biib-20240930.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_bd5813c7-e662-43da-906c-7bb98a2e2787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_1b451363-e605-463a-a341-93c3073e9e2b" xlink:href="biib-20240930.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_1b451363-e605-463a-a341-93c3073e9e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate_30f41c54-3fee-4aee-a430-ea1d1cb318e9" xlink:href="biib-20240930.xsd#biib_Reductioninroyaltyrate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_biib_Reductioninroyaltyrate_30f41c54-3fee-4aee-a430-ea1d1cb318e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement_ef675d39-7329-4fe1-a2b0-9489cc1a7a6d" xlink:href="biib-20240930.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_biib_PeriodOfCollaborationAgreement_ef675d39-7329-4fe1-a2b0-9489cc1a7a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts_3c4d29a0-c9af-41ec-a02c-309d8fcaa925" xlink:href="biib-20240930.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_261bd63d-6b26-473a-9b17-0fa604505910" xlink:to="loc_biib_PercentageOfFutureDevelopmentCosts_3c4d29a0-c9af-41ec-a02c-309d8fcaa925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d722673-bc9d-4a02-967c-65b14b4d4268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a1b5d7f-fbb6-496e-8fac-badadafe36fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d722673-bc9d-4a02-967c-65b14b4d4268" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a1b5d7f-fbb6-496e-8fac-badadafe36fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c8ea6a1-5dad-4aa3-a61b-9dd60abcc924" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a1b5d7f-fbb6-496e-8fac-badadafe36fe" xlink:to="loc_srt_ProductOrServiceAxis_3c8ea6a1-5dad-4aa3-a61b-9dd60abcc924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc888306-4efd-4970-aadf-292204a52069" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3c8ea6a1-5dad-4aa3-a61b-9dd60abcc924" xlink:to="loc_srt_ProductsAndServicesDomain_dc888306-4efd-4970-aadf-292204a52069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_d077be93-2c7d-456c-b4cd-adb63796b0ad" xlink:href="biib-20240930.xsd#biib_RituxanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc888306-4efd-4970-aadf-292204a52069" xlink:to="loc_biib_RituxanMember_d077be93-2c7d-456c-b4cd-adb63796b0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_4ad02cac-805e-423a-a791-f8037d099fad" xlink:href="biib-20240930.xsd#biib_GAZYVAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc888306-4efd-4970-aadf-292204a52069" xlink:to="loc_biib_GAZYVAMember_4ad02cac-805e-423a-a791-f8037d099fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a1b5d7f-fbb6-496e-8fac-badadafe36fe" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_ad1ceaa4-08c8-487a-9cb8-1a5a82ca0323" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_ad1ceaa4-08c8-487a-9cb8-1a5a82ca0323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_a5e66bd0-b884-4d86-89bc-bdd8f3d1d55a" xlink:href="biib-20240930.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_a5e66bd0-b884-4d86-89bc-bdd8f3d1d55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2ba0655a-a8e6-4eb2-bc87-ef599d8710c1" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2ba0655a-a8e6-4eb2-bc87-ef599d8710c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_6410835c-f254-460c-aec7-8f14fe9b8f9f" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_6410835c-f254-460c-aec7-8f14fe9b8f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_f9c6a702-d3fe-4416-9d2a-9194954030c0" xlink:href="biib-20240930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_f9c6a702-d3fe-4416-9d2a-9194954030c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_a92f9454-9feb-49a4-b476-c111f668f035" xlink:href="biib-20240930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_a92f9454-9feb-49a4-b476-c111f668f035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_00c35282-2cb5-4550-9716-0ac0bb7e0d82" xlink:href="biib-20240930.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_00c35282-2cb5-4550-9716-0ac0bb7e0d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_f5f8399c-9fe8-451b-9a4e-f007172315f5" xlink:href="biib-20240930.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0dffc3c1-456a-4940-991a-c36122a1a4e0" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_f5f8399c-9fe8-451b-9a4e-f007172315f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5e64e22-62eb-4fbd-867d-aa9ac7be4709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdb5e434-d296-4649-b53e-c1623541cb31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a5e64e22-62eb-4fbd-867d-aa9ac7be4709" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdb5e434-d296-4649-b53e-c1623541cb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_34bb8c23-ff90-4187-b92b-23171766020d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdb5e434-d296-4649-b53e-c1623541cb31" xlink:to="loc_srt_ProductOrServiceAxis_34bb8c23-ff90-4187-b92b-23171766020d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7db501d7-a666-4103-a758-eb95d1a1839f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_34bb8c23-ff90-4187-b92b-23171766020d" xlink:to="loc_srt_ProductsAndServicesDomain_7db501d7-a666-4103-a758-eb95d1a1839f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_e349bf12-20dd-4e62-a132-ed83f56fedbe" xlink:href="biib-20240930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7db501d7-a666-4103-a758-eb95d1a1839f" xlink:to="loc_biib_LEQEMBICollaborationMember_e349bf12-20dd-4e62-a132-ed83f56fedbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_186a6c2e-fb02-41dc-9c2e-178b496a4080" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdb5e434-d296-4649-b53e-c1623541cb31" xlink:to="loc_us-gaap_TypeOfArrangementAxis_186a6c2e-fb02-41dc-9c2e-178b496a4080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1da5d241-ef57-4917-8a74-ebe4891f684b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_186a6c2e-fb02-41dc-9c2e-178b496a4080" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1da5d241-ef57-4917-8a74-ebe4891f684b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_ea9bb7ba-2805-4ab0-ac22-0ec5d4862edd" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1da5d241-ef57-4917-8a74-ebe4891f684b" xlink:to="loc_biib_EisaiMember_ea9bb7ba-2805-4ab0-ac22-0ec5d4862edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_313cfe11-cfcf-49d5-bc36-fb6ba9ce8f88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bdb5e434-d296-4649-b53e-c1623541cb31" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_313cfe11-cfcf-49d5-bc36-fb6ba9ce8f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedPaymentToTerminationAgreement_3536249b-9ed4-4d1a-bb42-c1c0aca6d055" xlink:href="biib-20240930.xsd#biib_AccruedPaymentToTerminationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_313cfe11-cfcf-49d5-bc36-fb6ba9ce8f88" xlink:to="loc_biib_AccruedPaymentToTerminationAgreement_3536249b-9ed4-4d1a-bb42-c1c0aca6d055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsMadeToTerminationAgreement_83d2e8dc-e599-4615-b564-613ee43da3fd" xlink:href="biib-20240930.xsd#biib_PaymentsMadeToTerminationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_313cfe11-cfcf-49d5-bc36-fb6ba9ce8f88" xlink:to="loc_biib_PaymentsMadeToTerminationAgreement_83d2e8dc-e599-4615-b564-613ee43da3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8579677-aefe-48ff-8bcd-0468921d6063" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8579677-aefe-48ff-8bcd-0468921d6063" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9d5bc930-519b-4b0f-99aa-cfdd52350656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9d5bc930-519b-4b0f-99aa-cfdd52350656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1443e7d2-e8e4-440a-ae67-15b91e4d944f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d5bc930-519b-4b0f-99aa-cfdd52350656" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1443e7d2-e8e4-440a-ae67-15b91e4d944f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_732746e9-fa43-49cb-9c5f-e9220c6c48f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1443e7d2-e8e4-440a-ae67-15b91e4d944f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_732746e9-fa43-49cb-9c5f-e9220c6c48f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_23a74a9d-5fd3-4da1-9cab-d2dd2c126209" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:to="loc_srt_ProductOrServiceAxis_23a74a9d-5fd3-4da1-9cab-d2dd2c126209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f4853954-fad8-4f1b-8b3d-60f05f6585fa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_23a74a9d-5fd3-4da1-9cab-d2dd2c126209" xlink:to="loc_srt_ProductsAndServicesDomain_f4853954-fad8-4f1b-8b3d-60f05f6585fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_01dfe271-5d7c-4708-85f9-081ae9b4c100" xlink:href="biib-20240930.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f4853954-fad8-4f1b-8b3d-60f05f6585fa" xlink:to="loc_biib_E2609andBAN2401Member_01dfe271-5d7c-4708-85f9-081ae9b4c100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8c80cb6c-d3f7-422f-87b3-5dd7ff25d0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8c80cb6c-d3f7-422f-87b3-5dd7ff25d0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71c05594-3708-4427-8b65-70439322791e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c80cb6c-d3f7-422f-87b3-5dd7ff25d0ef" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71c05594-3708-4427-8b65-70439322791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_a018a3d7-b577-4cd8-879f-ee3f17ce455f" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_71c05594-3708-4427-8b65-70439322791e" xlink:to="loc_biib_EisaiMember_a018a3d7-b577-4cd8-879f-ee3f17ce455f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfd3c49d-2732-4640-bf0f-512721c8858b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55f06b06-ca70-4842-8b4a-8eb835042863" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfd3c49d-2732-4640-bf0f-512721c8858b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_9118b597-fe02-491c-b5c0-0cad473d6fa0" xlink:href="biib-20240930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfd3c49d-2732-4640-bf0f-512721c8858b" xlink:to="loc_biib_ExpenseIncurredByCollaboration_9118b597-fe02-491c-b5c0-0cad473d6fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_62232c2c-bdd3-42c3-a996-082a0d57dbb2" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfd3c49d-2732-4640-bf0f-512721c8858b" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_62232c2c-bdd3-42c3-a996-082a0d57dbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_7731e38c-09f5-44ea-86ac-b5d17fcc2d5c" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bfd3c49d-2732-4640-bf0f-512721c8858b" xlink:to="loc_biib_Expenseincurredbythecollaboration_7731e38c-09f5-44ea-86ac-b5d17fcc2d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cffc2144-0818-47ea-a4bd-1f029fd3ac64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cffc2144-0818-47ea-a4bd-1f029fd3ac64" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7652b882-ae0e-45a8-84f5-763ed9340516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7652b882-ae0e-45a8-84f5-763ed9340516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22fdafc5-7d31-42ce-a4f6-bf25faa11c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7652b882-ae0e-45a8-84f5-763ed9340516" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22fdafc5-7d31-42ce-a4f6-bf25faa11c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_09935faf-42d3-4e71-85ea-536b495f9114" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22fdafc5-7d31-42ce-a4f6-bf25faa11c8a" xlink:to="loc_biib_EisaiMember_09935faf-42d3-4e71-85ea-536b495f9114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a16a887-0c88-4d7a-968f-a3f46d086c00" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:to="loc_srt_RangeAxis_0a16a887-0c88-4d7a-968f-a3f46d086c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce140285-0dbc-491e-bfa2-4abcedc25491" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0a16a887-0c88-4d7a-968f-a3f46d086c00" xlink:to="loc_srt_RangeMember_ce140285-0dbc-491e-bfa2-4abcedc25491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d00e084f-b766-477c-bd1c-998f0c594e49" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ce140285-0dbc-491e-bfa2-4abcedc25491" xlink:to="loc_srt_MaximumMember_d00e084f-b766-477c-bd1c-998f0c594e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c15fc727-1b44-4caa-9519-98e4d111f2c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:to="loc_srt_StatementScenarioAxis_c15fc727-1b44-4caa-9519-98e4d111f2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a6f9a0fc-9a05-4f40-9d2d-57c7a0ff3e1f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c15fc727-1b44-4caa-9519-98e4d111f2c5" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a6f9a0fc-9a05-4f40-9d2d-57c7a0ff3e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0c7eb01f-da13-4042-a8d1-6a690129a513" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a6f9a0fc-9a05-4f40-9d2d-57c7a0ff3e1f" xlink:to="loc_srt_ScenarioForecastMember_0c7eb01f-da13-4042-a8d1-6a690129a513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_48fc443d-4814-4178-884c-2d98a4aadcc4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2e1f4352-d911-42bc-bd12-561a2ec91c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2e1f4352-d911-42bc-bd12-561a2ec91c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_5fead81e-9279-40ec-b971-bcfda3562c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:to="loc_us-gaap_InventoryWriteDown_5fead81e-9279-40ec-b971-bcfda3562c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator_87719ff4-b020-4b70-b18e-93fc0056c9bb" xlink:href="biib-20240930.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:to="loc_biib_AccountsReceivableFromCollaborator_87719ff4-b020-4b70-b18e-93fc0056c9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator_1ff41404-cceb-4e28-a2a3-561659917eae" xlink:href="biib-20240930.xsd#biib_AccountsPayableToCollaborator"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0a84c166-eea3-41e6-a3a3-21b75e73ffbc" xlink:to="loc_biib_AccountsPayableToCollaborator_1ff41404-cceb-4e28-a2a3-561659917eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a968b2a9-baa8-48a4-b0df-bc5cb8496cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a968b2a9-baa8-48a4-b0df-bc5cb8496cc9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_74b31167-1d84-4280-9305-ec06d2b4817c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_74b31167-1d84-4280-9305-ec06d2b4817c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d06316b1-b29e-425f-819a-76d8901e1fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_74b31167-1d84-4280-9305-ec06d2b4817c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d06316b1-b29e-425f-819a-76d8901e1fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_296fbe06-5fd0-45aa-a5c3-73888a578c73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d06316b1-b29e-425f-819a-76d8901e1fd6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_296fbe06-5fd0-45aa-a5c3-73888a578c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b6dc2fff-0917-452e-a479-bb60fbc0d946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d06316b1-b29e-425f-819a-76d8901e1fd6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b6dc2fff-0917-452e-a479-bb60fbc0d946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_395171f4-22bc-4924-b72b-3f94a1805202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:to="loc_us-gaap_TypeOfArrangementAxis_395171f4-22bc-4924-b72b-3f94a1805202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30f3d17f-78db-4475-ad9d-ea97345818ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_395171f4-22bc-4924-b72b-3f94a1805202" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30f3d17f-78db-4475-ad9d-ea97345818ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_cec475f3-dbbd-49a6-8a55-ceaf3e299d15" xlink:href="biib-20240930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30f3d17f-78db-4475-ad9d-ea97345818ce" xlink:to="loc_biib_EisaiMember_cec475f3-dbbd-49a6-8a55-ceaf3e299d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7aa90edc-d0f9-43dc-8991-5b4561303646" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:to="loc_srt_ProductOrServiceAxis_7aa90edc-d0f9-43dc-8991-5b4561303646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b4499db7-7798-45d1-9ea1-598c6277efd3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7aa90edc-d0f9-43dc-8991-5b4561303646" xlink:to="loc_srt_ProductsAndServicesDomain_b4499db7-7798-45d1-9ea1-598c6277efd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_9b6770f5-fd35-49a7-add6-7ba5cbb77b60" xlink:href="biib-20240930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b4499db7-7798-45d1-9ea1-598c6277efd3" xlink:to="loc_biib_LEQEMBICollaborationMember_9b6770f5-fd35-49a7-add6-7ba5cbb77b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f1e8d8c3-4d57-4799-8ddf-f239815d0693" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_a8c85f2d-6e4d-42a5-9526-9240b138adce" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:to="loc_biib_Expenseincurredbythecollaboration_a8c85f2d-6e4d-42a5-9526-9240b138adce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_0c22f578-5f8f-4bed-bb76-b6c381dcb5b1" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_0c22f578-5f8f-4bed-bb76-b6c381dcb5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_27943897-08f8-486d-a5c3-d2c44c935f29" xlink:href="biib-20240930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_27943897-08f8-486d-a5c3-d2c44c935f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_02833cc6-b87d-4464-9490-46900f6e2d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_837b5453-4a45-44ed-ae53-ae816cfac429" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_02833cc6-b87d-4464-9490-46900f6e2d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dcce2773-dab5-4a59-8f6c-f6554c2ba07a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87260a8a-7d9d-4142-a0fc-9e67ba63f3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dcce2773-dab5-4a59-8f6c-f6554c2ba07a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87260a8a-7d9d-4142-a0fc-9e67ba63f3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_de48a7a9-1c05-4b27-9fca-ff14a0b1c032" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87260a8a-7d9d-4142-a0fc-9e67ba63f3d7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_de48a7a9-1c05-4b27-9fca-ff14a0b1c032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca7af74c-da3f-4621-bff7-2a41c6b2592c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_de48a7a9-1c05-4b27-9fca-ff14a0b1c032" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca7af74c-da3f-4621-bff7-2a41c6b2592c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6f2e05db-b92e-4de1-84d9-69ee79f5a290" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca7af74c-da3f-4621-bff7-2a41c6b2592c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6f2e05db-b92e-4de1-84d9-69ee79f5a290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b3e8132b-0d53-4167-b4b0-25c31caca959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87260a8a-7d9d-4142-a0fc-9e67ba63f3d7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b3e8132b-0d53-4167-b4b0-25c31caca959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fba7a9d4-038f-45fc-8cc1-2fcdc5e8960f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b3e8132b-0d53-4167-b4b0-25c31caca959" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fba7a9d4-038f-45fc-8cc1-2fcdc5e8960f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_0fc69c22-e506-427d-8150-26640ff0b479" xlink:href="biib-20240930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fba7a9d4-038f-45fc-8cc1-2fcdc5e8960f" xlink:to="loc_biib_UCBPharmaS.A.Member_0fc69c22-e506-427d-8150-26640ff0b479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68e92d2d-f8ec-43b9-bcd1-5873cee42e71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87260a8a-7d9d-4142-a0fc-9e67ba63f3d7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68e92d2d-f8ec-43b9-bcd1-5873cee42e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_b69be361-b738-4b81-b1a8-d72314943647" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68e92d2d-f8ec-43b9-bcd1-5873cee42e71" xlink:to="loc_biib_Expenseincurredbythecollaboration_b69be361-b738-4b81-b1a8-d72314943647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9b37eb9b-a288-45e0-bdd3-fa325532c935" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_68e92d2d-f8ec-43b9-bcd1-5873cee42e71" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9b37eb9b-a288-45e0-bdd3-fa325532c935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c9233d8a-fc0a-4b94-b0d2-cb7b0cceea26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c9233d8a-fc0a-4b94-b0d2-cb7b0cceea26" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_42e6be3b-d308-431f-9727-8af030570e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_42e6be3b-d308-431f-9727-8af030570e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aaadb17b-b70e-402a-9bfc-24ed5da7b2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42e6be3b-d308-431f-9727-8af030570e75" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aaadb17b-b70e-402a-9bfc-24ed5da7b2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8c4ffcac-4ef6-46b6-bc79-c5b194527aed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aaadb17b-b70e-402a-9bfc-24ed5da7b2ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8c4ffcac-4ef6-46b6-bc79-c5b194527aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f2c6c016-a267-4957-a97b-7ae4fc0ba017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aaadb17b-b70e-402a-9bfc-24ed5da7b2ac" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f2c6c016-a267-4957-a97b-7ae4fc0ba017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_215fc743-865a-473b-99dd-13bee8e741c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:to="loc_us-gaap_TypeOfArrangementAxis_215fc743-865a-473b-99dd-13bee8e741c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6abeddb9-bc1a-4174-b796-a3ab34c1682d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_215fc743-865a-473b-99dd-13bee8e741c0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6abeddb9-bc1a-4174-b796-a3ab34c1682d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_3c748fa3-acaf-4e69-9056-5fbcd13b590a" xlink:href="biib-20240930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6abeddb9-bc1a-4174-b796-a3ab34c1682d" xlink:to="loc_biib_SageTherapeuticsIncMember_3c748fa3-acaf-4e69-9056-5fbcd13b590a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4ff35025-a340-451b-87d5-a451b8e04548" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:to="loc_srt_StatementScenarioAxis_4ff35025-a340-451b-87d5-a451b8e04548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bff6e5ae-1340-4353-886a-6b78ded6e2ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_4ff35025-a340-451b-87d5-a451b8e04548" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bff6e5ae-1340-4353-886a-6b78ded6e2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_8554235a-9ff4-4bb7-947a-7b5b44dc80c4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bff6e5ae-1340-4353-886a-6b78ded6e2ed" xlink:to="loc_srt_ScenarioForecastMember_8554235a-9ff4-4bb7-947a-7b5b44dc80c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c832fa16-0c07-4e79-b4ad-6f74d51d8e77" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_cb2b28f3-7e87-4e30-8861-5183a034929c" xlink:href="biib-20240930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_cb2b28f3-7e87-4e30-8861-5183a034929c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_1c966a2c-de77-4a5f-85bf-d2ecc4a47660" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_biib_Expenseincurredbythecollaboration_1c966a2c-de77-4a5f-85bf-d2ecc4a47660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_e6c43eb9-9b6a-4e5e-aee0-b59d71135bef" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_e6c43eb9-9b6a-4e5e-aee0-b59d71135bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_bf1e3230-c660-4ab9-b9ab-219e1efa5915" xlink:href="biib-20240930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_bf1e3230-c660-4ab9-b9ab-219e1efa5915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_f755141a-bf63-469c-b725-494505621cc9" xlink:href="biib-20240930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32128057-beaf-4f44-9128-5a2eaa34bd83" xlink:to="loc_biib_Collaborationprofitlosssharing_f755141a-bf63-469c-b725-494505621cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d015eb28-ac10-413f-bd60-58b54e5d4d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_631be611-d88d-44c6-a27e-0971e10b8c27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d015eb28-ac10-413f-bd60-58b54e5d4d7c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_631be611-d88d-44c6-a27e-0971e10b8c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_345adcc3-5490-4c4d-95e4-d313059ffa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_631be611-d88d-44c6-a27e-0971e10b8c27" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_345adcc3-5490-4c4d-95e4-d313059ffa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6cc4b0d8-b317-47ee-85d1-b18e2232c831" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_345adcc3-5490-4c4d-95e4-d313059ffa3c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6cc4b0d8-b317-47ee-85d1-b18e2232c831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9bd19715-50cd-4d7d-afa6-729b2cfd39c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6cc4b0d8-b317-47ee-85d1-b18e2232c831" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9bd19715-50cd-4d7d-afa6-729b2cfd39c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7360829b-6521-4898-89f5-843318e82014" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_631be611-d88d-44c6-a27e-0971e10b8c27" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7360829b-6521-4898-89f5-843318e82014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b73c7c30-84c2-4dba-bfd9-c97f13ee771a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7360829b-6521-4898-89f5-843318e82014" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b73c7c30-84c2-4dba-bfd9-c97f13ee771a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_b26e68d3-5b25-4ae2-b10c-d050e91b97c3" xlink:href="biib-20240930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b73c7c30-84c2-4dba-bfd9-c97f13ee771a" xlink:to="loc_biib_DenaliTherapeuticsIncMember_b26e68d3-5b25-4ae2-b10c-d050e91b97c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca9f6f93-f37c-4bcd-9e44-d97369f42ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_631be611-d88d-44c6-a27e-0971e10b8c27" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca9f6f93-f37c-4bcd-9e44-d97369f42ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_efa647c7-9bd4-400e-bea9-0492bc4fbdcd" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca9f6f93-f37c-4bcd-9e44-d97369f42ba4" xlink:to="loc_biib_Expenseincurredbythecollaboration_efa647c7-9bd4-400e-bea9-0492bc4fbdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_6ddc4042-980c-4349-8b8b-780d10b92f0e" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca9f6f93-f37c-4bcd-9e44-d97369f42ba4" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_6ddc4042-980c-4349-8b8b-780d10b92f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6042db97-ec00-499a-a7ff-2ce58b376b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3ef34e1-6c2f-4f5f-bf73-f1f8054e2949" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6042db97-ec00-499a-a7ff-2ce58b376b5f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3ef34e1-6c2f-4f5f-bf73-f1f8054e2949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cd29393d-87f1-4e2c-9b8a-6851cd5eb308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3ef34e1-6c2f-4f5f-bf73-f1f8054e2949" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cd29393d-87f1-4e2c-9b8a-6851cd5eb308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cb8028a0-8b96-409e-8d46-71a575eeebef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cd29393d-87f1-4e2c-9b8a-6851cd5eb308" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cb8028a0-8b96-409e-8d46-71a575eeebef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bddb7602-0221-4ed3-af84-34deb998c498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cb8028a0-8b96-409e-8d46-71a575eeebef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bddb7602-0221-4ed3-af84-34deb998c498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52070a09-3214-4037-86ad-0b9b779ff51a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c3ef34e1-6c2f-4f5f-bf73-f1f8054e2949" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52070a09-3214-4037-86ad-0b9b779ff51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_6b57c189-9152-4f3b-a560-f467101fe32c" xlink:href="biib-20240930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52070a09-3214-4037-86ad-0b9b779ff51a" xlink:to="loc_biib_Expenseincurredbythecollaboration_6b57c189-9152-4f3b-a560-f467101fe32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_c4cfa772-1ac1-4647-8c8c-d85aacd83fbd" xlink:href="biib-20240930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_52070a09-3214-4037-86ad-0b9b779ff51a" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_c4cfa772-1ac1-4647-8c8c-d85aacd83fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed6c7314-6f25-4000-ac4c-340f845377ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ffcb950d-5f90-47b7-a93c-4c1327dd2426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed6c7314-6f25-4000-ac4c-340f845377ba" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ffcb950d-5f90-47b7-a93c-4c1327dd2426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a9428c94-f74b-460b-be40-e4408ce347f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ffcb950d-5f90-47b7-a93c-4c1327dd2426" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a9428c94-f74b-460b-be40-e4408ce347f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2950aa33-18d8-4844-a1cd-2cd5701704d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a9428c94-f74b-460b-be40-e4408ce347f2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2950aa33-18d8-4844-a1cd-2cd5701704d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_3cf809a5-84c8-4adc-9ad9-656006b97e73" xlink:href="biib-20240930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2950aa33-18d8-4844-a1cd-2cd5701704d9" xlink:to="loc_biib_OtherresearchanddiscoveryMember_3cf809a5-84c8-4adc-9ad9-656006b97e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8f57f9d-cf92-423f-b1f8-29712a66d549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ffcb950d-5f90-47b7-a93c-4c1327dd2426" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8f57f9d-cf92-423f-b1f8-29712a66d549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_59aa134d-a110-47c5-8d57-488e1fac26b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8f57f9d-cf92-423f-b1f8-29712a66d549" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_59aa134d-a110-47c5-8d57-488e1fac26b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_875973c8-a3a1-494d-b80e-cabfc5015e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_875973c8-a3a1-494d-b80e-cabfc5015e4a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f2fdbdc2-526b-4b0d-878a-5d7158713ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f2fdbdc2-526b-4b0d-878a-5d7158713ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4407175b-d0b8-4598-996c-5d44d51ee95b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f2fdbdc2-526b-4b0d-878a-5d7158713ed7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4407175b-d0b8-4598-996c-5d44d51ee95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_74187885-f8df-44c4-8888-5d72168bf150" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4407175b-d0b8-4598-996c-5d44d51ee95b" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_74187885-f8df-44c4-8888-5d72168bf150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36f03b92-611c-4a1f-b74d-c7529b3181b8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36f03b92-611c-4a1f-b74d-c7529b3181b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bd1091fe-aaab-44a6-a671-0ce00b9e843f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_36f03b92-611c-4a1f-b74d-c7529b3181b8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bd1091fe-aaab-44a6-a671-0ce00b9e843f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_bd960818-ff9d-4923-ac4f-21c59f98904b" xlink:href="biib-20240930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bd1091fe-aaab-44a6-a671-0ce00b9e843f" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_bd960818-ff9d-4923-ac4f-21c59f98904b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24a35ba2-9762-4354-ab06-c53687f14ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24a35ba2-9762-4354-ab06-c53687f14ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9c753752-5351-4edd-95be-325d4811dd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24a35ba2-9762-4354-ab06-c53687f14ecb" xlink:to="loc_us-gaap_RelatedPartyDomain_9c753752-5351-4edd-95be-325d4811dd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_1266aca8-dac7-476a-861a-0468592800c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9c753752-5351-4edd-95be-325d4811dd2d" xlink:to="loc_us-gaap_RelatedPartyMember_1266aca8-dac7-476a-861a-0468592800c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0cba30d-2a03-4fa4-9d86-e580642c36a4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_7c8779b5-0e13-4611-8690-1dca4ea5db54" xlink:href="biib-20240930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_7c8779b5-0e13-4611-8690-1dca4ea5db54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ec2970fd-1ea3-4732-bd33-80a1f8379c7d" xlink:href="biib-20240930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ec2970fd-1ea3-4732-bd33-80a1f8379c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_396fa4d9-8079-45ce-85f2-2bac7856629f" xlink:href="biib-20240930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_396fa4d9-8079-45ce-85f2-2bac7856629f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementTermExtension_f5db47c3-3bdb-4d9b-b771-475e7a896624" xlink:href="biib-20240930.xsd#biib_CollaborativeArrangementTermExtension"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_CollaborativeArrangementTermExtension_f5db47c3-3bdb-4d9b-b771-475e7a896624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_61f3a6f7-66fb-473b-b14e-11d2d697ae34" xlink:href="biib-20240930.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_ContractOptionExerciseFee_61f3a6f7-66fb-473b-b14e-11d2d697ae34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_20be60f0-791c-4f67-aaa4-23dea338627a" xlink:href="biib-20240930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_biib_Collaborationprofitlosssharing_20be60f0-791c-4f67-aaa4-23dea338627a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_247a38cc-5169-4250-8694-bb833ab0d622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_us-gaap_AccountsReceivableNet_247a38cc-5169-4250-8694-bb833ab0d622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_0e9e68ee-2d79-4c23-aa2c-667f2ac9ff1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a569718f-11e0-4b4a-8a79-980c6fe38c42" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_0e9e68ee-2d79-4c23-aa2c-667f2ac9ff1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_9c60fecb-ce51-465d-a47a-37ac5cf62e60" xlink:href="biib-20240930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c3254fbb-f8fc-4bb4-8e89-18211974b73c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_9c60fecb-ce51-465d-a47a-37ac5cf62e60" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c3254fbb-f8fc-4bb4-8e89-18211974b73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_c67e0e69-1f8e-4245-a76c-c3fdb973bcd7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c3254fbb-f8fc-4bb4-8e89-18211974b73c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_c67e0e69-1f8e-4245-a76c-c3fdb973bcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f871197c-f0a5-4d9d-a852-bf87c1cf3a83" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c67e0e69-1f8e-4245-a76c-c3fdb973bcd7" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f871197c-f0a5-4d9d-a852-bf87c1cf3a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_adb26868-a288-41a7-ac63-dc7c2b7905cb" xlink:href="biib-20240930.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f871197c-f0a5-4d9d-a852-bf87c1cf3a83" xlink:to="loc_biib_NeurimmuneMember_adb26868-a288-41a7-ac63-dc7c2b7905cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_103b02ee-235a-4235-9c49-75b5d83b90b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c3254fbb-f8fc-4bb4-8e89-18211974b73c" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_103b02ee-235a-4235-9c49-75b5d83b90b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_ea33b8f2-1dea-4bf2-be79-2f815c962e77" xlink:href="biib-20240930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_103b02ee-235a-4235-9c49-75b5d83b90b4" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_ea33b8f2-1dea-4bf2-be79-2f815c962e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_a08ba517-2d0a-4879-a965-3c19db7f9a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_103b02ee-235a-4235-9c49-75b5d83b90b4" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_a08ba517-2d0a-4879-a965-3c19db7f9a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_00c9e110-93f9-4971-81d5-df6d4bdb0022" xlink:href="biib-20240930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_103b02ee-235a-4235-9c49-75b5d83b90b4" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_00c9e110-93f9-4971-81d5-df6d4bdb0022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20240930.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_0f4e045f-fd4d-4af9-824e-74f7a774ab40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e897ce4a-db63-4b92-97fa-ed21d3e34765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_0f4e045f-fd4d-4af9-824e-74f7a774ab40" xlink:to="loc_us-gaap_LossContingenciesTable_e897ce4a-db63-4b92-97fa-ed21d3e34765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_fa48452b-d1e4-44cb-b2b3-2aacaf6d8196" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e897ce4a-db63-4b92-97fa-ed21d3e34765" xlink:to="loc_srt_LitigationCaseAxis_fa48452b-d1e4-44cb-b2b3-2aacaf6d8196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5295c932-dbe1-491d-9713-f682b5a1edf0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_fa48452b-d1e4-44cb-b2b3-2aacaf6d8196" xlink:to="loc_srt_LitigationCaseTypeDomain_5295c932-dbe1-491d-9713-f682b5a1edf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember_dd1c5c8f-a0db-40bc-acf2-835e77399678" xlink:href="biib-20240930.xsd#biib_GenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5295c932-dbe1-491d-9713-f682b5a1edf0" xlink:to="loc_biib_GenentechMember_dd1c5c8f-a0db-40bc-acf2-835e77399678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember_a311f433-7581-46d5-8b16-c4a7708ad70d" xlink:href="biib-20240930.xsd#biib_LenderDisputeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5295c932-dbe1-491d-9713-f682b5a1edf0" xlink:to="loc_biib_LenderDisputeMember_a311f433-7581-46d5-8b16-c4a7708ad70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_12a4f1d6-9f91-4228-bfcf-3780ec1a7cda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e897ce4a-db63-4b92-97fa-ed21d3e34765" xlink:to="loc_us-gaap_LossContingenciesLineItems_12a4f1d6-9f91-4228-bfcf-3780ec1a7cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1decc729-9f71-4346-a436-6115da0b093b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_12a4f1d6-9f91-4228-bfcf-3780ec1a7cda" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1decc729-9f71-4346-a436-6115da0b093b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_99d9897a-7b21-4c36-9a64-b8e18f99beed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_12a4f1d6-9f91-4228-bfcf-3780ec1a7cda" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_99d9897a-7b21-4c36-9a64-b8e18f99beed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20240930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20240930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20240930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20240930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biib_MarketStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>biib-20240930_g1.jpg
<TEXT>
begin 644 biib-20240930_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
M@M9_RCV\5?\ 7[I__I7%7X@U^WW_  6L_P"4>WBK_K]T_P#]*XJ_$&OW[PO_
M .13/_KY+_TF)^%^)/\ R-8_X%^<@HHHK]&/S\_>3_@D]_RCU^&G_7E<?^E<
M]?1%?.__  2>_P"4>OPT_P"O*X_]*YZ^B*_E#/?^1EB/^OD__2F?U!D?_(NP
M_P#@A_Z2@HHHKRCU HHHH *_/;_@X8UR"#X#^ =-9O\ 2KO7Y;F,>J16[*WZ
MS)^=?H37XJ_\%J/VH[7]H#]J9="T>Y6ZT+X?POIB2(VY)KQF!NG4^@*QQ^YA
M)R017VWA_@:F(SFG4BO=IWDW\FE][:_$^-X[QL*&43A+>=HI?--_<D_P/CVB
MBBOZ./Y]"OWP_P""7?A*3P7^P'\,;.2/RFFTHWX7&,K<S27"GKW$H/X]NE?A
MK\%_A7J7QP^+/AWPCI*EM0\17\5C$<9$>]@&<_[*KEB>P4U_1IX0\+6?@7PG
MI>B:;'Y.GZ/:16-K'_<BB0(@_!5%?DOBICHJA0PG5MR^25E]]W]Q^I^&.#DZ
MU;%O9)1^;=W]UE]YI5\[_P#!6'_E'K\2_P#KRM__ $K@KZ(KYW_X*P_\H]?B
M7_UY6_\ Z5P5^5Y#_P C/#_]?(?^E(_3<[_Y%V(_P3_])9^#=%%%?U<?R^%?
MO)_P2>_Y1Z_#3_KRN/\ TKGK\&Z_>3_@D]_RCU^&G_7E<?\ I7/7YEXI_P#(
MMI?]?%_Z3(_1O#/_ )&-3_ __2HGT11117X0?MP51\1>(]/\(:#=ZIJM]:Z;
MINGQ-/<W5S*(H;>-1DLS,0%4#N:9XK\5:;X&\,W^LZQ>V^FZ5I<#W-W=3OLC
MMXD!+.Q[  &OQ-_X*2_\%+-;_;-\7S:-HLUYI'PYTV4BTL-Q1]493Q<7('4\
M JAR$'JV2?IN&>&<1G%?DA[L(_%+MY+NWV^\^=XCXDH930YY^].7PQ[^;[)=
MSZ'_ &V_^"Z\[75WX=^"\*1PIF*3Q/?6^YG/K:P., ?[<H.<GY!@,?SK^(?Q
M-\1_%GQ)-K'BC7-5\0:I-]^ZU"Z>XDQZ L3A1V P .F*PZ*_H/)^'L#EE/DP
ML+/K)ZR?J_T6GD?@N;9]C<RJ<^*G==(K2*]%^N_F%%%%>V>.%%%% %K1-<OO
M#.K6^H:;>76GWUJXD@N;:5HIH6'1E92"I]P:^Y/V-/\ @N%XS^%%W9Z+\3EF
M\;>&\B/^T1@:M9KD<EN%N !GA\.<_?XQ7PC17EYIDN#S&E[+%P4NSZKT>Z/2
MRW.,7@*GM<+-Q?5='ZK9G](GPA^,GAGX]> [/Q-X1UBSUS1;X?N[BW;[K#&4
M=3\R.,\JP##N*ZBOY^_V)/VW_%7[$OQ.CUC19'OM$O&5-7T:20K;ZC%Z]]DJ
M\[9 ,@\'*EE/[G_L_P#Q[\-_M,?"K3/&'A2]^V:3J:?=8 36L@^_#*N3MD0\
M$9QT()!!/\_<5\)5LGJ<\?>I2VEV\I>?Y_>E^[<+\54<VI\LO=JQWCW\UY?E
M]S?:T445\@?6!3)95@B:21E1$!9F8X"@=233Z_+?_@L[_P %'[R]U_4/@YX'
MU!K>PLP8/%-_ V'NI>]DC#HBCB3!^9B4. KA_:R'(Z^:XM86AIU;Z)=_\EU9
MX^>9U0RS"O$UM>B75OM_F^B.J_;O_P""X=OX/O[WPK\&Q::E?0DQ7'B:X02V
ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?EW_P '%.G3)XA^%%WM_P!'
MDM]3B#?[2M:DC\F'UY]#7ZB5\;_\%O/V?[CXP?L?-KVG0-/J7@&]&K,JKEFM
M"ICN,>R@I(3_ '837U/!6,AALZH5*FS;7_@2<5^+1\SQAA9XC)Z].&Z2?_@+
M3?X)GXMT445_39_.)[9^P'^V/?\ [%'Q^L_$T<4U[H=[']AUNQCQNN;5B"2F
M>/,1@&7D9P5) 8U^[?PE^+OASXZ> M/\3^%-6M=9T74X]\-Q V<'NC#JCJ>&
M1@&4\$"OYN*],_9D_; \?_LB^*VU3P3KDMBMP1]KL)AYUC?@=!+$>"1R XPX
M!.&&37P/&'!<<VMB<.U&LE;7:2[/LUT?R?2WW'"?&$LK_P!GKIRI-WTWB^Z[
MI]5\^]_Z(**_//X$?\' ?@_Q!:0VWQ$\*ZMX=OL!7O-)Q>V;GNQ1BLD8]AYA
M]Z^EO G_  4Q^ WQ#@1K'XG^&;7=_#JDS:8RGOG[0L?^%?B^.X7S7"2M6H2]
M4KK[U='[!@^),LQ2O1K1]&[/[G9GNU%<GH_QY\#^(51M/\:>$[Y9'"(;?5[>
M7>QQ@#:YR>1Q[UL?\)MHO_07TO\ \"D_QKQ94:D7:46OD>Q&M3DKQDOO-2BN
M/UW]H7P#X7B>34_''@_3DCW!FNM9MX57;UR6<=._I7DGQ._X*N_ 3X6V\WG^
M/M/UJXCX6WT6-]0:4^@>,&/\2X%=6'RO&5WRT:4I/RBW^ARXC,L)05ZU6,?6
M27ZGT77XJ_\ !;;]H#3?C5^V"=+T>X6ZL/ ^GKH\DJ-NCDN_,>2?:?\ 9++&
M?]J)NO%=[^V/_P %T_$'Q3T6\\/_  OTR\\':;= QRZQ=2*=4D0Y&(U0E("1
M_$&=AV93S7P [M*[,S%F8Y))R2:_8.!.#<3@:SQ^.7+*S48]5?=OY:)>;N?D
M_&W%V'QM'ZC@GS1O>4NCMLE\]6_)6"BBNJ^"7P9U_P#:#^*>C>#_  S9F\UC
M6YQ#"O\ !$.KR.>=J(H+,>P4]>E?J56I"G!U*CLDKMO9);L_-*=.52:A!7;T
M275L_2#_ (-ZO@]-IW@[Q[X\N(66/5+F#1K%SQN6$-+,1Z@M)",^J-[U^D5<
M/^SE\"])_9H^"/AWP/HN38Z!:B$RD8:YE)+RS-Z,\C.Y X&[ X %=Q7\L\19
MI_:.8U<6MI/3T2LOP5_4_IGA_+?[/R^EA7O%:^KU?XL****\4]@**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-20240930_g10.jpg
<TEXT>
begin 644 biib-20240930_g10.jpg
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M6:- "!P%)) !KN/VB/ OC37OV]OV<_&^B>%-1N]&T"'QB-<U2VLW>WT\SZ;
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MR\"_&CP/\.-2U;Q!\2-5&C^%/!!NXX9Y=4626.>&68@K%#"T$V^?! 5 =N6
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M-#\%QRZ'::?(]U&UO?Z8\ZF)1N!C6.1F&/E",3C!H [_ .(O[3?Q0NOCI?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+[5-3T&/&F2720+Y*;VDW,GDY\T;"=WW1CD ^./ ^F7OPW_88_9[\<>-K1]
M\/0_M+VOB"(:H/(CTC1KJ[U$VTDQ;"PQD3Q/DX4"9<XS7=?'?5/#Z_\ !131
MOC#JO[5MWX!\(>+_ (3#2?"'C_0KG2Y=/N;R#4));C3VN;VWN($9@4E&-I8I
MMW$C;7VYK&BZ-XATN;0]?TFVOK*YCV7%G>0++%*O]UD8$,/8BL^;X<_#VX\*
M)X$N/ FC/H<8 CT9]+B-H@R6XA*[!R2>G4T ?$7BC1OA/K'P+_:J^*'PX_:
M\8_$F^F^&,ND>(/%>JP:<-)O)8+"Y>*.TEL;>&.XDA60K(P#!?,49-=Q^U%I
M&ER?LO?LS:1)I\+6J_%GX>1+;F,; FY%VXZ8VDC'H<5]7VWA7PO9^'?^$0M/
M#=A%I/D-!_9<=FBV_E'.4\L#;M.3D8QS4EUX?T&^MK:RO=$M)H;*:.6SBEME
M98)(_P#5N@(PK+_"1@CM0!X!\70%_P""F7P9=0 6^'WBM6(ZD![ @'\:\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW7<@FMKF..:+< 2I= & .,X-=A0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6=J7AG3]5NC=W$]RK%0,17!4<>PK1HH Q_P#A!](_Y^;W_P "
MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
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M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
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M_P D'UW!_P#/R/WK_,['_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJX[_AKO\
M9X_Z*%_Y2;O_ .-4?\-=_L\?]%"_\I-W_P#&J/\ 6SA7_H/H_P#@V'_R0?7<
M'_S\C]Z_S.Q_X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:N._X:[_9X_P"BA?\
ME)N__C53Z7^U3\!=9U.WT?3?'?F7-W.D-O'_ &7=#>[,%49,0 R2.3Q51XJX
M7G)1CCJ+;_Z>P_\ DAK&X-NRJ1^]?YG5?\(/I'_/S>_^!;4?\(/I'_/S>_\
M@6U;%%>\=)C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;5\6?M'?!GXI_"WX
M_P"C_$?X$ZAX9\<:7XK^,T%W/X;U#6)+34+?68?#]Y;/:&]02QB$P0LP61 T
M;D+RK$C[KKY^^.G_  3Z^'?Q8^)6E?$WPKXK\1>$+T^*4U;Q4GAKQ%=V4>JL
MME<6WFB.)PD5WB5%^T( YC#J2=P( .%M/AWJO[2GP?\ @Y\0?V3M)T?P';^'
MO&&H37^C>(8V>/1I8K;4M-N4BM[8HMQ)%<2S,H#QJ^W<6 )%:LGC+QQ^S_\
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M-!%&L:DX50!D\TM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC4?\/.?VX?\ HMW_ );6F?\ R-5?5Y^0OK5/LS];J*_)'_AYS^W#_P!%N_\
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M -*KBOCNOL3_ (+0?\E^\+_]B>O_ *57%?'=>A2_AH\RO_%84445H9!1110
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^;?_!:#_DOWA?\
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MY\,W.F?VYIBZCI:70"O/:L[(LFW.5!*-C< 2,'&""=/]GK_DOW@;_L<-,_\
M2J.D_A''22/VXHHHKS#U@HHHH **** /R]_X*^_\G91?]BG9_P#HR>OEFOJ;
M_@K[_P G91?]BG9_^C)Z^6:]&G_#1Y=7^*PHHHJS,**** "BBB@ KT[]B[_D
M[+X>?]C99_\ HP5YC7IW[%W_ "=E\//^QLL__1@I2^%E0^-'[-4445YAZP44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%9VI:SJ%C=&"W\/7-RNT'S8
MF&/IS0!HT5C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7
MO_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[
M_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7
MO_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[
M_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7
MO_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2T ?GG_P6@_Y+]X7_ .Q/7_TJN*\V_8E\>Z'I
M'B#2OAUXX\*:Q)I6M_$70;O3M:T=PGD:G;3,(89MZ[98F$Y+)D,N RY-=_\
M\%B[^YU#X[^&9;K3);4KX14!)2,D?:I^>*\)_9[_ &C/%GP&\2VD]M!;:GH1
MUFSO]3T*_LXIXY7@D#++%YBGR9U&X+*F&&>XXKN@KT4CSJC2KMG0_'/P_<?#
M:]\)_$GP?\1O^$Q\*/J]^WA^TUW3F5+&YM[E)+FUEM)&=-I:6-B5)60-R!R*
MO?M%>-O%7Q$_9B^%?C#QKK<VH:E>:]XH:>YF(R</8!54  (J@!550%4
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M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
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MX:/,K_Q6%%%%:&04444 %%%% !78?L]?\E^\#?\ 8X:9_P"E4=<?78?L]?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN+VKS"NV_9J_Y.,\ ?\ 8[:5_P"ED514R_"*FVH].[_S-*6:X]U8ISZKHO\
M(_>JBBBOAS]'"BBB@ HHHH _+W_@K[_R=E%_V*=G_P"C)Z^6:^IO^"OO_)V4
M7_8IV?\ Z,GKY9KT:?\ #1Y=7^*PHHHJS,**** "BBB@ KT[]B[_ ).R^'G_
M &-EG_Z,%>8UZ=^Q=_R=E\//^QLL_P#T8*4OA94/C1^S5%%%>8>L%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>^JOIOI?\CQ.BK6B:)K'B76;3P[X=TJXOK^_N4M[*RM(3)+/*[!41%7)9B2
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M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
MSXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#S
MXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:
M@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_
MT&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% 'Y<?\ !<#5-/U7]H?PI-IU
MTDR+X+569#T/VNXXKXVT.UFOM:L[*WU&&SDFNHT2[N)O+C@)8 .S_P *KU+=
M@,U]G?\ !<J"&#]HKPFL$*H#X*0D(H'_ "]W%?$]?<Y9_N%/T/S;-],TJ>OZ
M(_0-/A[X[^+W@+3_ (?_ +7O[/\  T\WC761KGQ"TBVDL!I\,>G63#7GFBQ;
M7*O@YD==LHB4#Y\Y^>?A_;? >W_9H;P=I_[2V@^&_$WBJ^9O&AU30-7EDCL8
M),VUC$]M:2(8V=1<2$-\S"%?^69SY-=?%OXA7OPSM?A#<^)KE] L]2EOH+$R
MMM$LB1(0>>5 B4A>@)8CEC7-TZ6$E%-.5E>]EMU[W^[R%6QT)R3C"[M9M[ZV
MZJW9ZONSZ!_X*9>'O#VD?M9>(]2TCQY8ZK<WT\37VGVMI<QR:<5M8 JR-+$J
M.7'S#RV< #G!XK&_;-@'P^UGPI^SCIQ\NT\#>%+/[=$O275;V&.\O)SZL3+'
M%[+ @[5Y)XB\2^(_%^M3^(_%NOWNJ:C=$&YO]1NGGFE( 4%G<EFP !R>@ I?
M$?B;Q)XQUJ?Q)XN\07VJZC<E3<W^I7;SS2[5"C<[DLV%  R>  .U:TJ$H1@F
M[\J_'1?E<PK8B-25225N=W^5V[?-V?R+USX.^(O@\Z+K]SX;U?33JT0N_#]X
M;:2(W:!L"6!L N W\2]Z]:^,7ASQ$?V+?@S%_8-[OAUCQ6TR_97R@,UB06&.
M,X/7TKR:+XI?$V"ZT6^@^(NNI/X<CV>'IDU>8/I:YSMMCNS ,\X3'-='=?M9
M?M47UK)8WW[2_P 0)H9HRDT,OC.^974C!4@RX((X(-.<*TI1:MH[_@U^HJ=2
MA"$XN^JMT[I_H>?UVG[-\L<'[0_@*:5PJ)XTTMF8]@+N+)KBZ[7]FQ5;]HKP
M"K $'QKI0(/?_2XJUJ_PI>C,:/\ &CZH_=G_ (3'PQ_T&H/^^J/^$Q\,?]!J
M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A7YT?K!3_X3'PQ_T&H/^^J/^$Q\
M,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_
MX3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% 'Y+_ /!9K4;+
M4_VP(;FPN5EC_P"$0LEW(>,^9/7R;7UM_P %I(8H/VQ84AB5!_PA]B<*N!_K
M)Z^2:^\R_P#W*GZ(_,\U_P"1E5]6%%%%=AYX4444 %%%% !7JO[#EQ#:_M@?
M#>YN) D:>+[)G8] /,%>55ZO^PNB2?MB_#5'4,#XPL@01D']X*RQ'\"?H_R-
M\+_O5/\ Q+\S]M_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1
M_9VG_P#/C#_WZ%?GA^JE/_A,?#'_ $&H/^^JT4=9$$B-E6&01W%1?V=I_P#S
MXP_]^A4P  P!@#H!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MELQ\Y. +N(G^*HGQ/PU.#C'&T6W_ -/(?_)&M%KVT?5'[K4445\N?K 4444
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M5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV7_HT5.(_@3]'^1IA?\ >J?^)?F?N11117YX?JH4444 %%%% !1110 4444
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M?_2J.O.PG^]T_P#$OS.6A_'CZK\S]EZ***_IP_6PHHHH **** /R8_X+4_\
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MC&ZTK]E3QE\-+C5-?.K:M<>-)(Y+C6KNY+EY%D6>5BL814"$A45D"C&:]QH
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M9H)FO].MKIV<R0Q;;9]N]O+:=ESUKZ<H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _'#_@XY_P"3J_!'_9/4_P#2ZZK\\J_0W_@XY_Y.K\$?]D]3_P!+
MKJOSRK^O> ?^2/P?^'_VYG\;>(?_ "6F-_Q?^VH****^O/C HHHH **** "O
M0?V2?^3J_AE_V4+1?_2Z&O/J]!_9)_Y.K^&7_90M%_\ 2Z&N3,/]PJ_X9?DS
MLR[_ )&%'_''\T?TMT445_#Q_> 4444 %%%% 'XC?\'!7_)^EO\ ]B'IW_HZ
MYKX<K[C_ .#@K_D_2W_[$/3O_1US7PY7]B<%?\DG@O\ KW$_B[CG_DK\=_U\
MD%%%%?4'R@4444 %%%% !7M?_!-__D_3X1_]CYI__HX5XI7M?_!-_P#Y/T^$
M?_8^:?\ ^CA7F9U_R)L3_P!>Y_\ I+/4R/\ Y'>%_P"OD/\ TI']&-%%%?Q,
M?W0%%%% !1110 4444 %%%% !1110!S?Q+\3?$7PS;:/+\./ABOBB2]\0VEI
MJ\3ZY%8_V=I\C$3WP,BMYQB !\E<,^< C%?-'[2/P]^(?QH^(5[<^.O^"2/A
M'QW%IE]+;:/XHU/XC:;!<WMHDC"*0AK?S$5E ?RF8[=Q'K7KO[:WB#X2>&O@
M_#J/QH_:,\2?"_2#K4*)XD\+:J;.Y>8QR[;<N(I<HP#,1MY*#D8Y^4/^%N_\
M$^?^DR7QH_\ "[D_^5] 'UM^R?+\1+#PE=>#O%W[(VC_  BTO2?*70M(T/Q)
M9W\%RK[S*0EK%&L.TA<Y!+F0GL<^KU\^_L'>+/@#XJLO$[_ K]L+QE\6D@EM
M!J<OB[76O3IA(F\L19MXM@DPY;[V?+7ICGZ"H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH _'#_@XY_Y.K\$?]D]3_P!+KJOSRK]#?^#CG_DZOP1_V3U/
M_2ZZK\\J_KW@'_DC\'_A_P#;F?QMXA_\EIC?\7_MJ"BBBOKSXP**** "BBB@
M KT']DG_ ).K^&7_ &4+1?\ TNAKSZO0?V2?^3J_AE_V4+1?_2Z&N3,/]PJ_
MX9?DSLR[_D84?\<?S1_2W1117\/']X!1110 4444 ?B-_P '!7_)^EO_ -B'
MIW_HZYKX<K[C_P"#@K_D_2W_ .Q#T[_T=<U\.5_8G!7_ "2>"_Z]Q/XNXY_Y
M*_'?]?)!1117U!\H%%%% !1110 5[7_P3?\ ^3]/A'_V/FG_ /HX5XI7M?\
MP3?_ .3]/A'_ -CYI_\ Z.%>9G7_ ")L3_U[G_Z2SU,C_P"1WA?^OD/_ $I'
M]&-%%%?Q,?W0%%%% !1110 4444 %%%% !1110!S?Q+O/BQ9VVC'X2Z-HE[+
M)XAM(]>76[J2)8=++'[3+#Y8.Z=5QL5L*3G)KRWQAXB_X*30>+=4@\"?"WX-
MW&AIJ,RZ-<:IXMU.*YEM0Y\IID2T94D*;2RJ2 20"1S7NU? &J^!_P!@C4_B
MOXZT_P#X*-_%X'XB1^,+Z:"VUWXBW^GVL&CR3,VG+9I;7,42Q_93$&0YD60/
MNX*D@'U]\!M3_:BU*#4S^TOX1\$:5(CP_P!CCP9K-U>"52'\WS?M$,6P@^7M
MVYSELXP,^@UX/^Q!X5_82\,6?B1?V(_%&EZG#-+:_P#"2'3?&-WJ_EL!+Y&X
MW-Q+Y609<;=N[!SG Q[Q0 5G:EX9T_5;HW=Q/<JQ4#$5P5''L*T:* ,?_A!]
M(_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GY
MO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_G
MYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\
M"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P
M+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:M
MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:
MC_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q
M_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?
M2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0
M?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y
M^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH _&;_@XDTF
MVT?]J7P5!:R2L&\ (Q,LA8Y^W70ZFOS\K]#?^#CG_DZOP1_V3U/_ $NNJ_/*
MOZ]X!_Y(_!_X?_;F?QMXA_\ ):8W_%_[:@HHHKZ\^,"BBB@ HHHH *[_ /90
MB6X_:E^&L#D@/X_T925.#@WT(ZUP%>@_LD_\G5_#+_LH6B_^ET-<F8?[A5_P
MR_)G9EW_ ",*/^./YH_I#_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBBOX>/
M[P,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/
M^$'TC_GYO?\ P+:MBB@#\/O^"^^F6^D_MUV]K;/(R_\ ""Z>V99"QSYUSW-?
M$E?<?_!P5_R?I;_]B'IW_HZYKX<K^Q."O^23P7_7N)_%W'/_ "5^._Z^2"BB
MBOJ#Y0**** "BBB@ KVC_@G3;1WG[=?PGM968+)XYT]6*-@X\T=#VKQ>O:_^
M";__ "?I\(_^Q\T__P!'"O,SK_D38G_KW/\ ])9ZF1_\CO"_]?(?^E(_H9_X
M0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV**_B8_N@Q_^$'TC_GYO?\ P+:M>-!%
M&L:DX50!D\TM% !1110 4444 %%%% !1110 5\2?#+QYX+_9V\=_$/P3XM_8
M-^*?BVXO/B#K&IQ^.M+^%37O]KI<7<D@#RR89Q'GRXW0M&\21N"I8H/MNB@#
MR_\ 9K^+'A+XI6^L2>%OV=O&7P_%D\ G3Q=X+&CF^WB3!B&3YH3:=W]W>O\
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M/ASX*,9+;[+#X?\ $.GWXU<8EW,YLX8MGE< ;\Y\TXQ@Y]IH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _'#_@XY_P"3J_!'_9/4_P#2ZZK\\J_0W_@X
MY_Y.K\$?]D]3_P!+KJOSRK^O> ?^2/P?^'_VYG\;>(?_ "6F-_Q?^VH****^
MO/C HHHH **** "O0?V2?^3J_AE_V4+1?_2Z&O/J]!_9)_Y.K^&7_90M%_\
M2Z&N3,/]PJ_X9?DSLR[_ )&%'_''\T?TMT445_#Q_> 4444 %%%% 'XC?\'!
M7_)^EO\ ]B'IW_HZYKX<K[C_ .#@K_D_2W_[$/3O_1US7PY7]B<%?\DG@O\
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M_D_3X1_]CYI__HX5XI7M?_!-_P#Y/T^$?_8^:?\ ^CA7F9U_R)L3_P!>Y_\
MI+/4R/\ Y'>%_P"OD/\ TI']&-%%%?Q,?W0%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XX?\''/_)U?
M@C_LGJ?^EUU7YY5^AO\ P<<_\G5^"/\ LGJ?^EUU7YY5_7O /_)'X/\ P_\
MMS/XV\0_^2TQO^+_ -M04445]>?&!1110 4444 %>@_LD_\ )U?PR_[*%HO_
M *70UY]7H/[)/_)U?PR_[*%HO_I=#7)F'^X5?\,OR9V9=_R,*/\ CC^:/Z6Z
M***_AX_O **** "BBB@#\1O^#@K_ )/TM_\ L0]._P#1US7PY7W'_P '!7_)
M^EO_ -B'IW_HZYKX<K^Q."O^23P7_7N)_%W'/_)7X[_KY(****^H/E HHHH
M**** "O:_P#@F_\ \GZ?"/\ ['S3_P#T<*\4KVO_ ()O_P#)^GPC_P"Q\T__
M -'"O,SK_D38G_KW/_TEGJ9'_P CO"_]?(?^E(_HQHHHK^)C^Z HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN:^'*^X_^#@K_D_2W_[$/3O_ $=<U\.5_8G!7_))X+_KW$_B[CG_ )*_'?\
M7R04445]0?*!1110 4444 %>U_\ !-__ )/T^$?_ &/FG_\ HX5XI7M?_!-_
M_D_3X1_]CYI__HX5YF=?\B;$_P#7N?\ Z2SU,C_Y'>%_Z^0_]*1_1C1117\3
M']T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RO_ ,%+
M?VC/'WPO\/2?"KP;X^TSP2NO_#OQ+J@\6:FC&6>XLK:/RM,L6$L8CNY?.9Q(
M2S*L1*(S8Q]45\U?\%*]<\=Z=\"?%VEWGP#@\:>"+WX?:Q]LOK-()KW0=36V
MD-O>/!.RJUNH)8R1;I8V3<%(H [SX,:]\?/!_P 'M3U_XNSZ=XX_L_2H[WPS
M>>$;-H=0UJ#[*)##);R2&(7'F9C5UEV29#$1\YY7]D_XU_M%_$3]H_XL> ?C
MUIFEZ/%X?TGPU>Z'X8TR1)_[)2]2_:2.6Y"@W$Q$$6\C]VK A,CYFYC]A[P=
MJ?P+\/>/OBE9_!SQ+X.^'>H6.EW/AGP$MJU[?&XAMY!?7L%C:O,81<,\(6!/
MG;R"Y1=P%97P;_: MM'_ &S?BM\3-4^!?Q?M]%\9Z5X5L]!O9OA!KBB26T2^
M2??FU_=*IN(_F? ().< T =?H/B+]I+]J3XD?$,_#C]H+_A7.@> _%\OAG3=
M/T_PO9:A<ZA=000RS75VUVKXB9IPJ1Q>6Q1=Q?+"N7M_V\/B!XK_ &?O#^GZ
M%J?AG3_B-K7Q"U+P3J.N2J7TC39--^T27^L*CN-\*VEN9UC9P TJ*S%5)+OC
MSH_PAT?X\^*=9\:? OXW:-J>HQ6ZG5/A1)J\ECXX@6!0B7']F$)#.AWPGSS$
MVQ0?-*'Y>'?]B'Q3X1^ /P\^(^N?!,7M]X<^+%[XU\3?#'0Q'*8=-OO,C.GV
MZ9"7#VT'V3,6=LOD2(-VX;@#V']E3XG>,/&_Q/N+'PC^V]X/^,WA6+3I#KJB
M"RM=6T>[#)Y#PK81K'-;2 R ^8 054K(^2M=_P#M;?&[7_@5\)4UKP1IMG>>
M)]>UVP\/^$[;4F9;9M1O9UAC>8J0?*C!>5\$$K$1D9R/,])OYOVC_P!LGX??
M&'X8?"7Q3X?TCP-HNKP^*/$_BCPK<Z*VI1W4"QV^F11721S7"I,//9BGEQF(
M ,6?%0?M5>&O$/[;7[--U-HOP0\56=[X(^)-O>IX2\460T^?Q);V$X6X2 LV
M##<VTLZQ.2 YP#@$D "_L^?%/QWXE^,VG^'O!?\ P4$\#?%ZUB$R^-?#DEGI
M]G<V480A;K3C8(6D59@J,DQD7:Y_>A@,_4%?*OBK6H/VH/B_\(8O@S\"?&'A
MQ_ 'BM=6UKQ-XE\%W.AQZ1IJ6D\,NEQ&X1#.TYDCC,<.^,*NXG"J:^JJ "BB
MB@ HHHH **** "N$_:'_ &D/A+^S!\.[SXC_ !9\4VUC!!:SR6-@9T%UJ<L4
M32&WMHV8>;(0O Z#JQ R1W=?*_\ P4H^%?B?7_"NN?%_X9^.O#T6N^&OA%XH
ML=7\-^((VE^TZ+>6Z&XN+?RVWP3HULJK)M9'W%&P* /?_A#\:/AA\>/!\?CK
MX4>,[#6M/9_*FDLKA7:VF !:&50<QR+D91L$9!Z$&G>$OC/\+O'GC[Q+\,/!
MOC2SU+7?!WV4>)K"U+,=/:Y$AA1VQMWD0R94$LNWY@,C/CG[,7BRS^,>F^._
M@W\0?A#_ ,*]\=1:!I:>+-0\,:PCR:G97=G)%9WT%]$D<H<)#,JAU#PE!@G@
MUF?LA?#7P+\(OVUOCG\/?AOX:M])T?3O"_@E;6SM@< F+569V9B6=V8EF=B6
M9F+,2230!Z?\5OVR?V;_ (*^*Y/ WQ!^(C0ZO;VJ7-]8:9HM[J,EC"^2LMS]
MDAE^S(0"0TNP$<].:[_PKXJ\->.?#=CXP\&Z]::II6IVR7&GZC83K+#<1,,J
MZ.I(8$=Q7SKX'E^,'[+'Q>^)UE<?LW^)_'-GX^\9OXB\/>)O"DMBY?S;:"'[
M!>?:;B)K?R6APDAW1F-^,$$'Q/X4?M3:E^S1^R/JO@SQ!XR\.>%=?\6_&OQ-
MH7@[4)[L#2- @^V-)>7222!5>WM'>X\L8'FR")0N'. #[4\!?M ?![XH?$'Q
M5\+/ 'CBWU37?!,T,/BBQMX9,6,DOF;$,A4([9BD4A&;:R,K8(Q6WXY\=>#?
MAGX2O_'GQ!\366C:-I<!FU#4M0N!%# F0,LQ]20 .I) &20*^-_V%_BK^R7X
M8_;4\=_##X,?&3P_J-AJ/@KPO8>&'AUF.>;6;FW74Y;QPX.9Y\R&65NI:0L>
MM?8_C/PGX'\9Z;!I'C_P_IFIVD>H6]S;6^JVZ2QK=12"2%U#@CS%=0RD<@CB
M@#B_A7^U_P#L\?&;Q=_P@/@3QY,VMM9M=V^E:OH5]ID]U;J<-- E[#$;B,9&
M6CW =<UZ77R+XZU3XW6O[9?P;\7?M=^$/#>BZ-:ZQJ.G>!+SP'JDVH1R:W>V
M4L8AOY;F*WECC:".;8L43*T@!=P% KZZH **** "BBB@ HHHH _'#_@XY_Y.
MK\$?]D]3_P!+KJOSRK]#?^#CG_DZOP1_V3U/_2ZZK\\J_KW@'_DC\'_A_P#;
MF?QMXA_\EIC?\7_MJ"BBBOKSXP**** "BBB@ KT']DG_ ).K^&7_ &4+1?\
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MEWO_ ("7O_QJC_AH3]F'_HI=[_X"7O\ \:H_ULX5_P"@^C_X-A_\D'UW!_\
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M;6F?_(U>"T4<D.R#VE3NSWK_ (><_MP_]%N_\MK3/_D:C_AYS^W#_P!%N_\
M+:TS_P"1J\%HHY(=D'M*G=GO7_#SG]N'_HMW_EM:9_\ (U7?#G_!2[]MJ_\
M$-A8W?QJWQ37L4<J?\(YIHW*7 (R+;(X-?/%:/A#_D;=+_[",'_HQ:.2'9 J
ME2^[/W7HHHKS3U0HHHH **** /QP_P"#CG_DZOP1_P!D]3_TNNJ_/*OT-_X.
M.?\ DZOP1_V3U/\ TNNJ_/*OZ]X!_P"2/P?^'_VYG\;>(?\ R6F-_P 7_MJ"
MBBBOKSXP**** "BBB@ KT']DG_DZOX9?]E"T7_TNAKSZO0?V2?\ DZOX9?\
M90M%_P#2Z&N3,/\ <*O^&7Y,[,N_Y&%'_''\T?TMT445_#Q_> 4444 %%%%
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MB7.W:=NW;]]LYXP[/FV%=*.YRM%%%40?NWX;_P"1=L/^O*+_ - %7:I>&_\
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MJ,_VMUCTM;Z5PMB8P0K2K%&'D+ E6FV<&-LMM(2BV>!5H^$/^1MTO_L(P?\
MHQ:SJT?"'_(VZ7_V$8/_ $8M,2W/W7HHHKRSV HHHH **** /QP_X..?^3J_
M!'_9/4_]+KJOSUM;JYLKF.]LKAX9H7#Q2Q.59&!R&!'((/.:_0K_ (..?^3J
M_!'_ &3U/_2ZZK\\J_KS@'7@[!_X?U9_&WB%IQIC?\2_])0KN\CEW8LS')).
M232445]@?&!1110 4444 %>@_LD_\G5_#+_LH6B_^ET->?5Z#^R3_P G5_#+
M_LH6B_\ I=#7)F'^X5?\,OR9V9=_R,*/^./YH_I;HHHK^'C^\ HHHH ****
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M<*2J[GPH)P!DUD_#?XGZ_P#"^;6I] L[.8Z]X<O-%O!>1NP2WN4"2,FUEPX
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MZK\\J_KW@'_DC\'_ (?_ &YG\;>(?_):8W_%_P"VH****^O/C HHHH ****
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MEB6.%&=5+L^2V0%.*WCA\ME&ZC_Z5^'<YI8K-XRY7+I?[.GJ^F_4XK_A,_\
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M3]G*_O7OJ[/3H?E7$V:Y;ALZJ4ZM>$9+ET<HI_"NC9[C\(?V@O'7PV\!:CX
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MG_!>+_D<_AQ_V"]1_P#1D%?!FAVLU]K5G96^HPV<DUU&B7=Q-Y<<!+ !V?\
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M (.5/^10^$?_ &$M9_\ 1=G7Y/U_5WAC_P D5AO6?_IR1_(OBI_R7&)]*?\
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MBBB@ HHHH *]K_X)O_\ )^GPC_['S3__ $<*\4KVO_@F_P#\GZ?"/_L?-/\
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M 5W_ .R@)6_:E^&JP.%D/C_1MC,,@'[=#@FN KT']DG_ ).K^&7_ &4+1?\
MTNAKDS#_ '"K_AE^3.S+O^1A1_QQ_-'](?V+QO\ ]!NR_P# 8_XT?8O&_P#T
M&[+_ ,!C_C6Q17\/']X&/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &
M/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% 'X??\%]XM3B_;KMUU:YCE
ME_X073_FB3:,>=<\8KXDK[C_ .#@K_D_2W_[$/3O_1US7PY7]B<%?\DG@O\
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M_!RI_P BA\(_^PEK/_HNSK\GZ_J[PQ_Y(K#>L_\ TY(_D7Q4_P"2XQ/I3_\
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M !1110 5[7_P3?\ ^3]/A'_V/FG_ /HX5XI7M?\ P3?_ .3]/A'_ -CYI_\
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M3U/_ $NNJ_/*OZ]X!_Y(_!_X?_;F?QMXA_\ ):8W_%_[:@HHHKZ\^,"BBB@
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M1^^$_P#V!]6_]&VU?G+\,OB5XR^#_C[2/B9\/]9DL-7T34(;RQN(R<>9&ZN
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M0 4444 %%%% !1110 4444 %%%% !116=J6LZA8W1@M_#US<KM!\V)ACZ<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$Q_"CP]H-O;:9X4.J7=A96E_)-MDO;A[>56N)&+I'&.B@\+DYKY]_9I_:F^
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M%_[.F@_$[X3>./% ^/)UO2K3PYKO_"5WUU>>+-7EN(EN()H)93'/%(AE9DV
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MZMHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(+S3=.U%X9-0T^"=K:836[31!C%( 0'7(^5L$C(YY-3T44 %%%% !1110 44
M44 %%%% !1110 4444 %%%% $%YING:B\,FH:?!.UM,)K=IH@QBD (#KD?*V
M"1D<\FIZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KXN_P""C'_!7K_A@+XVZ7\'/^&>O^$M_M+P
MK!K/]H_\)9]@\OS+FY@\KR_LDV<?9]V[<,[\8XR?M&OQ>_X.+_\ D]KPM_V2
MNQ_].6IU]QX>Y/EV><1QPN-ASTW&3M=K5;:Q:?XGPGB-G.99#PU+%X&IR5%*
M*O:+T;UTDFOP/4_^(EW_ *LJ_P#,C_\ WNKJO@7_ ,'"7_"Z?C;X.^#G_#(O
M]F_\);XJT_1O[1_X3[SOLOVJYC@\WR_L"[]N_=MW+G&,C.:_(>O4_P!A?_D]
MKX._]E4\/?\ IRMZ_;L?X<<&4<#5J0PMG&,FO?J;I-K[9^$Y=XF<;U\PHTYX
MN\92BG^[I;-I/[!_231117\LG]8D5[>VVG64VH7LHCA@B:2:0C.U5&2>/85X
M';_\%3OV![JV2_C_ &A;06TF-MW)HNH)" 3C)D:W"@9[D@5[7X]_Y$76O^P3
M<_\ HIJ^&?V-_C9^U%H'_!-SPGX<\!?L)W_C#3T\'306FHS>+=-%M?1,TH9V
MM2YG=.3F()O< J!DB@#Z_P#BK^T]\!?@G\/=)^*WQ)^)5C8^'-=NX+;1M7@C
MDNHKV6:)Y8A&;=7+AXXW8,!@@=>1GFOAW^WW^R5\6/&EA\// 'Q8^WZQJDIC
ML;/^PK^+S6"EB-\D"HORJ3R1TKY,\;P:#X"_8!_9'B^"NM2_$&'2_C=X<;3'
MB9;-]2NE&HM);#[00(")M\($A&S9AL8-?:/P>^*7QO\ '6N76G?%#]F#4_ U
MG#:>9;ZC>^*=.OUGDW*/*"6LKLIP2VXC'RXZD4 :/PI_:&^"_P ;]8\2>'OA
M5\0+/6;[PAJK:;XDM($=9+"Y5G4HZNJD_-&X##*DHV"<&IK_ ..GPHTQ_&B7
M_C&&,_#RT6Z\9@P2'^S(6M?M8=L+\^8/G^3<<<=>*^&?A3IM_P#LY6VJ?M]^
M#K*5[+1_B[XMT/XM6%K&6-YX>DUVX*WNT?>ELYF$N0,F)I02%%>@^,]1L-8C
M_;EU;2KV*YM;KP+9S6UQ!('26-O"&Y75AP00001U!H ]4A_X*B?L*7,*7%O\
M=5DCD4-'(GAS4BK*1D$$6W(KH/B9^WE^R;\'?%H\"?$;XN1:?J[:?!??81I%
M[,XMY@3'(?*A8 , >"<^HKS_ /8E^,O[14_P&^$WA.Y_8[U>#03X,T.U/BL^
M,]*:(6HLX5%WY F\[:4P_E[=^#C&>*XW6?CE:_!#_@J-\2M0NOA9XX\4B_\
MAKH$8A\$>&)=3D@VRW!W2K&?D4YP">I!H ^HO@U\>_@Y^T+X8D\8?!;XB:;X
MBT^"X-O<RV$I+6\P&3'+&P#Q/@@[7 ."#BF>$_V@/@WXZ^*GB+X(^$O'UG?>
M*O"<<3^(=&B5_,LUD *$DJ%;AESM)VD@'!XKP3]G1O$>D?&_XV_MU>._A?K'
MPZ\$ZMX=L/)TGQ%;);:A?C3H)GN-2N;=6/DG:=B!CN902<=_G_X$>._AW\)?
MC%\!?VI$^)OAJ[\4?%K5=6TOXJZ?INNV\]S')KDQO]/22-'+1K;S+% VX87
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MPK\"_P#!4WX3_##PW\+-&C_9_N;/PUH-GI5I<75[KGFRQ6\"0J[[8@-Q" G
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MO >H>$_&VN2Z[=^%?'TM[;?V-J<P'VB2TFM(Y-\,K .8650I'RL,G/OGP_\
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M$WP[KVA?$3X36 GET+6(+H/XAT:/RIG81,=AFMF:8DX+,AX..-/X _$_XV^
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M!U%%%% !1110 4444 %%%% !1110!\D?\%F?^37]!_['VU_](KZOS.K],?\
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M47B+ E"=5GRN1P<=,B@#>;_@J'^P:DS13?M"V,2QW#027$^DWR0(ZL4(:5H
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M%^$/^"B7['/CSQ5IO@GPI\8/M>J:O?16>GVO_"/ZA'YLTCA$3<]N%7+$#+$
M=R*\2_;Q^!'A+]ES]A2'P!\)+74KS3(_B]I&IZ5HEW>1[;9KC5XY_L5N=J+%
M '8A V=NXY8\FOHSX3_%OX^^-?%?]B_$C]DW5?!FG?9GD_MF\\7:9>IY@(VQ
M^7;2L^6R><8&.: /3**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-20240930_g11.jpg
<TEXT>
begin 644 biib-20240930_g11.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!GP?^(7@;Q;H]Y%\6O\ A<MA)?>(+0W,2ZA:ZM.D"2ZJM[ TJLLSMF21&7!
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M)+JWP?OO'R^*AJ2^1'#;:G;6)MO*V<EC<B3S-^ $(VG.1^4FH_"7X4_MC_\
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M?'$'BJ?2)GL7U6VB\-&:XMB8FWQ0W(B:&1%<$Q32)NYS7(WGA+P1_P $S/\
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M(M+^(_@.WN/&&E7#1WWC&.;7K#S3J<P;.I>8Y^U@S;RLD2NFT B@#];J***
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M-I>I?%'3?ASK-SX1M+P2>68GUF*U:TP'(4R!S$">7 R1[Q^T#^US^SK^R_\
M!B/]H#XS_$^RT[PK=2VT.E7]FDEZ^K3W/_'M!90VRR2WDLN<QQPJ[,,D# )
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^&OV[5,^-KS5+.[:75=,"\V$<]G)'/;+(W$CPO'*4RJR)DY /$OVIO%FB_\
M!2[_ (*"_!7X"_LNPIK.C?LW?%N'QS\7?BK8*&L-'N[2VGBA\-6]R/EN;NX>
M<&YAC)$,<2[SN!0;?_!'1O\ A./VB_VV_C1XPB#^+KC]JG4O"]Q<S#]\-$TC
M3;"+2XLGD1B.:8J.GSD]S6Y^R3^S;_P5/_9FT_P;\&]%U+]D;P]\*_#]Y;PW
M_ASP'\-?$=G=#3Q(#<"VDFU:1!<NN\^=,LFZ1M[[R3G7^)/[$7[5?P?_ &J/
M&?[67_!.[XM^ ]&N?BG;6?\ PLSP'\3]!O+O2+S4;2'R(-7M)+&>*6VN?)"Q
M2IAHY@JL=K@-0!XI\ ?V<_A7\<_^"A__  4+_80\?^'KBZ^%/BYO NOZYH.E
MZG/9)%JFIZ5(]^PDMW1T>Y:T@FDP?GP0VY6*GJ/^"RGC?P;\;_@-?_\ !&O]
MF/PCIOBCXJ_%#1[/3+?PQ86RM8^!="6:%GUO4R@VV-O!'&# IQ)++Y2Q(W;O
M? W_  3^_:9^!_[*WQ<C^#'[3VD_\-)?&76O[<\3_&'6/#.;*"_;R8$CMK+=
M(8[:ULHS!;1NTFUL.^[<RUY-^R+^P-_P5[_8H\#WGA'X-_$K]DV;4-:O3?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KV
MWT6R-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZ
MP\0P0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK
M0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U
M\+O^29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\
M+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX2_X**_%3XO:#\*OV9/BUH7PJ^'\7AZ2^\5_%230K76M:NM1\W9%IME87/\
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M505 !^I=%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XT ;%%9=G:>+4ND>^U:U>(-^\1+<@D>QK4H ****
M"BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T
M-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\ L!6G_HE*W: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@/VC/V9OA#
M^U5X)L/A_P#&?PX-1TW3?$VE:]:(" R7>GWL-[!R0?D,L"!UZ.A93PQKOZ*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M//\ Q^:;_P!<I?YK7I%>;_'G_C\TW_KE+_-: //Z*** "BBB@ HHHH ****
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M^"G_ ".+?]>3_P UKD*Z_P""G_(XM_UY/_-: /6:*** "BBB@ HHHH ****
M"BBB@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\ V 7_ /0UH [K
MX7?\DS\._P#8"M/_ $2E;M87PN_Y)GX=_P"P%:?^B4K=H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KS?X\_\?FF_]<I?YK7I%>;_ !Y_X_--_P"N4O\ -: /
M/Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\+O^29^'?^P%:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-:
M.Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O-_CS_Q^:;_ -<I?YK7I%>;_'G_ (_--_ZY2_S6@#S^
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KK_ (*?\CBW_7D_\UKD*Z_X*?\ (XM_UY/_ #6@#UFBBB@ HHHH
M **** "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'
M\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O-_CS_ ,?FF_\ 7*7^:UZ17F_QY_X_
M--_ZY2_S6@#S^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KK_@I_R.+?]>3_ ,UKD*Z_X*?\CBW_ %Y/_-:
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M;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\
M8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *\W^//_'YIO\ URE_FM>D5YO\>?\ C\TW_KE+_-: //Z*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO\
M@I_R.+?]>3_S6N0KK_@I_P CBW_7D_\ -: /6:*** "BBB@ HHHH **** "B
MBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH
M[KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$[XWZKH'P=\&6_@OP)\,H+U[FW62[UN>^O)'CO+2UMXU\RS0O<3IN,B*@8Y
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MQ\$V#6NB^'-'MM+TBU>=Y6AM;>)8HD+N2SD(BC<Q).,DDU\H_LM?"WXJZ_\
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M_P!%+_\ *->__&:/^&U?V9O^BE_^4:]_^,T >IT5Y9_PVK^S-_T4O_RC7O\
M\9H_X;5_9F_Z*7_Y1KW_ .,T >IT5Y9_PVK^S-_T4O\ \HU[_P#&:/\ AM7]
MF;_HI?\ Y1KW_P",T >IT5Y9_P -J_LS?]%+_P#*->__ !FC_AM7]F;_ **7
M_P"4:]_^,T >IT5Y9_PVK^S-_P!%+_\ *->__&:/^&U?V9O^BE_^4:]_^,T
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MHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-:
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M+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %?FE\5O^2H^)?\
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M)XC_ .1AO_\ K]E_]#->Q_\ "#Z1_P _-[_X%M7C.N1+!K=Y A)"74B@L<G
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MH **** "BBB@ KK_ (*?\CBW_7D_\UKD*Z_X*?\ (XM_UY/_ #6@#UFBBB@
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M]$I6[0 5X)XC_P"1AO\ _K]E_P#0S7O=>">(_P#D8;__ *_9?_0S0!2HHHH
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M .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ KP3Q'_P C#?\
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M-H/E@L!G S7Z(Z;!=VNG6]MJ%\;J>.%%GN3&$\YP &?:.%R<G X&: )J***
M"BBB@ HHHH **** "O8OA#_R(MM_UUE_]#->.U[%\(?^1%MO^NLO_H9H Z:B
MBB@ HHHH *\W^//_ !^:;_URE_FM>D5YO\>?^/S3?^N4O\UH \_HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%<;_ ,- ?"/_ *&W_P D+C_XW1_PT!\(_P#H;?\ R0N/_C='^MG"W_0?1_\
M!L/_ )(/K.&_G7WH[*BN-_X: ^$?_0V_^2%Q_P#&Z/\ AH#X1_\ 0V_^2%Q_
M\;H_ULX6_P"@^C_X-A_\D'UG#?SK[T=E17&_\- ?"/\ Z&W_ ,D+C_XW1_PT
M!\(_^AM_\D+C_P"-T?ZV<+?]!]'_ ,&P_P#D@^LX;^=?>CLJ*XW_ (: ^$?_
M $-O_DA<?_&Z/^&@/A'_ -#;_P"2%Q_\;H_ULX6_Z#Z/_@V'_P D'UG#?SK[
MT=E17&_\- ?"/_H;?_)"X_\ C='_  T!\(_^AM_\D+C_ .-T?ZV<+?\ 0?1_
M\&P_^2#ZSAOYU]Z.RHKC?^&@/A'_ -#;_P"2%Q_\;H_X: ^$?_0V_P#DA<?_
M !NC_6SA;_H/H_\ @V'_ ,D'UG#?SK[T=E17&_\ #0'PC_Z&W_R0N/\ XW1_
MPT!\(_\ H;?_ "0N/_C='^MG"W_0?1_\&P_^2#ZSAOYU]Z.RHKC?^&@/A'_T
M-O\ Y(7'_P ;H_X: ^$?_0V_^2%Q_P#&Z/\ 6SA;_H/H_P#@V'_R0?6<-_.O
MO1V5%<;_ ,- ?"/_ *&W_P D+C_XW1_PT!\(_P#H;?\ R0N/_C='^MG"W_0?
M1_\ !L/_ )(/K.&_G7WH[*BN-_X: ^$?_0V_^2%Q_P#&Z/\ AH#X1_\ 0V_^
M2%Q_\;H_ULX6_P"@^C_X-A_\D'UG#?SK[T=E17&_\- ?"/\ Z&W_ ,D+C_XW
M1_PT!\(_^AM_\D+C_P"-T?ZV<+?]!]'_ ,&P_P#D@^LX;^=?>CLJ*XW_ (:
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MGB/_ )&&_P#^OV7_ -#- %*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *]B^$/_(BVW_767_T,UX[7L7PA_Y$6V_ZZR_^AF@#IJ*** "B
MBB@ KY-_X*5_\ASPE_UZ7G_H45?65?)O_!2O_D.>$O\ KTO/_0HJ_//%3_DA
M\3ZT_P#TY$X<R_W.7R_,^8:***_D8^9"BBB@ HHHH **** "BBFRR"&)I2K,
M%4G"C)./0=S0 ZBOS\^'_P ?/VW/VGOC!\/_ (V_"/XJ^"]*3Q+\/O%.J>'?
M 5QI-S<64<-KJ&FPBSU"9;I"UVYD4&947[.0ZJC!V(^W+KXCV_@CX0-\5/C5
M':^&$TW01J/B>-[T3PZ:R1;YT$J@>:$(8!@,M@8&3BO;S3(L1E<J=.4XRG*Z
M<8WYHR4G'ELTKZIJ\;J^E]K[5*,J=DWJ=/17RE^Q]^TO^TI\6OVM_%G@[XQP
MPZ5X>O/ -AXH\*^$VTZ..YT>VN;N:&%+B4#>\[0Q)+(I.$>5D ^2JVI?&_XW
M?M#>.?&>N>"_VJ]"^#'PZ\'^*I_"VCZM=:-87=WXBU2VP+N4O?GRH[=)28D6
M,%Y-CMN7@5M/AO&4L5*C4G!*,8R<KR<5S6LO=C)N6MK136C=^57&Z$E*S:_X
M<^MJ*\]_9GN_C_/\.&M/VCIM O=<L]3G@LM?\-MMMM;L 0;>^\K)%N\BGYH@
MS %<@X8 <5^U?\9?B_I_Q6^'O[+?P"UK3M"\2?$'^TKN[\6ZIIXO$T73;&.-
MYGBMRRK-.[2QH@8[!\Q8="//I9;5KX]X6$XNW,W*_N\L4Y.5[7LHIO;FZ6OH
M0J;<^5,]WHKYGTGXD_M#_LO?M'^!?@W\??C9:?$7PU\3Y+VQT37;GP[;:7J.
MD:G;P^>L4BVH6&>"5 R@A%=7V@D@\_3%1CL!/ N#YE.,US1E&]FKN+^)1:LT
MTTTGIV:;4X.%NMPHHHKA("BBB@ HHHH **** "O=/^">W_)>9O\ L7[C_P!&
M15X77NG_  3V_P"2\S?]B_<?^C(J^KX&_P"2OP/_ %\B=&$_WJ'J?;E%%%?V
MB?6!1110 4444 %%%% !7RW^V5\'/VS/CE\<].\+_LC?\%:[7X'SV/A2.YU7
MX?P?"K0O$EY>JUS,HU,F_;SXHFP(0%'E[H3SN)%?4E>9?M)_L>?LY_M;:18Z
M;\=?AQ#J=WI$CRZ!X@L;R>PU?1I6&&DLK^U>.YM&.!DQ2+NP V0,4 ?+O_#O
MG_@M;_TL(ZA_XBSX4_QKZB^ 7_"5_!CP%X0^!'[2_P"U9IWQ%^)EU;7CMXAO
M=(L=#O/$2QRO*TL6FVS;%6&%XXV,0(P@9L%S7@TW_!('4?--KI__  5:_;%M
M-*W?+H\?Q?MI%5.1L%U-I[WF.?O&<MP/FXKV/]EW]@O]F/\ 9"N]1\1_"3P1
M=7'BC6XEC\0^//%>M76M>(-74'(6XU&]DEN'3=\PB#B,'E4% 'L=>4?MS_\
M)H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*W
M:POA=_R3/P[_ -@*T_\ 1*5NT %>">(_^1AO_P#K]E_]#->]UX)XC_Y&&_\
M^OV7_P!#- %*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KV+X0_\B+;?]=9?_0S7CM>Q?"'_ )$6V_ZZR_\
MH9H Z:BBB@ HHHH *^3?^"E?_(<\)?\ 7I>?^A15]95\F_\ !2O_ )#GA+_K
MTO/_ $**OSSQ4_Y(?$^M/_TY$X<R_P!SE\OS/F&BBBOY&/F0HHHH **** "B
MBB@ J#5+NXL-,N;^TTV:\E@@>2*SMV423L%)$:ERJAF(P-Q R>2!S4]%-.S
M_*_XN^+_ /@GAXZ_:(T?XN^'O&VI_!37[GP%XBN_&$7A[4)M'U[3/$:7.FB"
MVFM8S^\N&+77[M4(N-I;YMH9?H+Q9X3_ &\/V@O@-\"Y/&'PDT3Q!;V^G6FN
M_%'PSK?B8Z++K&HPJKV<$X%K,%B$@6XFAV8:150A0I!^H]7^"GP\UWXOZ/\
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M?_).U?6/_I2/FRBBBOT\_$ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 5X)XC_P"1AO\
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MYHW:;NXZO1M);I*2T6C7J%%%%=1PA1110 4444 %%%% !7MG[!/_ "7";_L
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M 8U])T5?U*EO=\U[WOKM;TM;I:W7<S_M*O\ #9<MK<MM-[^M[];WZ7MH?/\
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M?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\ HE*W: "OS/\
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MJK*IB;56Y<RYUS6E9*Z^26FL7976@.O4D[RU]3PWPG^SS\:/V??A=\)/@?\
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MJ<)3:32M?E3M?S/!SW$4,/"#JS4;M[M+\SG**F^P7?\ SR_\>%'V"[_YY?\
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MY)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 5^<OQ2_Y*;XC_ .P]>?\
MHYZ_1JOSE^*7_)3?$?\ V'KS_P!'/7V/!_\ 'J^B_-GYUXA_[M0]9?DC!HHH
MK[L_+ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K[A_8H_P"3>=)_Z^KK_P!'O7P]7W#^Q1_R;SI/_7U=?^CWKYGB
MS_D61_Q+\F?;< _\CJ7^!_G$]7HHHK\Y/V(**** "O-?C[_Q^:9_URE_FM>E
M5YK\??\ C\TS_KE+_-:\/B/_ )%%3Y?^E(#SVBBBOS, HHHH **** "BBB@
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M8?!'_D<V_P"O)_YK7I9/_P C2C_B0'KE%%%?JP!1110 4444 %%%% !1110
M4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+
MO^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %?G+\4O^2F^(_P#L/7G_
M *.>OT:K\Y?BE_R4WQ'_ -AZ\_\ 1SU]CP?_ !ZOHOS9^=>(?^[4/67Y(P:*
M**^[/RP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1/O"BO@__A]G_P!6S?\ EY__ ''1_P /L_\ JV;_ ,O/_P"XZ/\ B#_B+_T
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M\XGJ]%%%?G)^Q!1110 5^6W_  <3_P#(Y_"S_L%ZM_Z,M:_4FORV_P"#B?\
MY'/X6?\ 8+U;_P!&6M?:>'W_ "5E#TG_ .D2/C^//^27K^L/_2XGYN4445_2
M!_/84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5]J_\$%O^3X+O_L1;_\ ]'VM?%5?:O\ P06_Y/@N_P#L1;__ -'V
MM?.\6_\ )-8O_ SW^%O^2BPO^-'[+T445_+I_2H4444 %%%% !1110 4444
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M%%?=GY8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?</[%'_)O.D_]?5U_P"CWKX>K[A_8H_Y-YTG_KZNO_1[U\SQ
M9_R+(_XE^3/MN ?^1U+_  /\XGJ]%%%?G)^Q!1110 5^6W_!Q/\ \CG\+/\
ML%ZM_P"C+6OU)K\MO^#B?_D<_A9_V"]6_P#1EK7VGA]_R5E#TG_Z1(^/X\_Y
M)>OZP_\ 2XGYN4445_2!_/84444 %%%% !1110 4444 %%%% !1110 4444
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M^%W_ "3/P[_V K3_ -$I6[0 5X!XD_Y&*_\ ^OV7_P!#->_UX!XD_P"1BO\
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M]A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#TB1\?QY_R2]?UA_Z7$_-RBBBOZ0/Y["BBB@ HHHH **** "BBB@ HHHH
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MYN4445_2!_/84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF]W>_/+^7:W7<^@X:XT_UAQ\L-[#DM%ROS<VS2M;E7?N?5U%%%>"?=!1110
M5^6W_!Q/_P CG\+/^P7JW_HRUK]2:_+;_@XG_P"1S^%G_8+U;_T9:U]IX??\
ME90])_\ I$CX_CS_ ))>OZP_]+B?FY1117]('\]A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7VK_ ,$%O^3X+O\
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MK_\ I;+7ZSX4_P"^8K_#'\V?EOB?_NF&_P 4OR1PM%%%?M9^.A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7[??\
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MM?.\6_\ )-8O_ SW^%O^2BPO^-'[+T445_+I_2H4444 %%%% !1110 4444
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MC^//^27K^L/_ $N)^;E%%%?T@?SV%%%% !1110 4444 %%%% !1110 4444
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M_FG9JZNE<TQ67SPL.?GC)7<6XWTDNCNE\FKIV=GH<_1117H' %%%% !1110
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M]OO^"*?_ "CV\*?]A35?_2Z:OSGQ0_Y)V'_7R/\ Z3,_0?#;_D?S_P"O<O\
MTJ)]74445^ G[F%%%% !7Y;?\'$__(Y_"S_L%ZM_Z,M:_4FORV_X.)_^1S^%
MG_8+U;_T9:U]IX??\E90])_^D2/C^//^27K^L/\ TN)^;E%%%?T@?SV%%%%
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M_P 4OR1PM%%%?M9^.A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHK]K/QT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5^WW_!%/\ Y1[>%/\ L*:K_P"ETU?B#7[??\$4_P#E'MX4_P"PIJO_
M *735^<^*'_).P_Z^1_])F?H/AM_R/Y_]>Y?^E1/JZBBBOP$_<PHHHH *_+;
M_@XG_P"1S^%G_8+U;_T9:U^I-?EM_P '$_\ R.?PL_[!>K?^C+6OM/#[_DK*
M'I/_ -(D?'\>?\DO7]8?^EQ/S<HHHK^D#^>PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[5_X(+?\GP7?_8BW_\
MZ/M:^*J^U?\ @@M_R?!=_P#8BW__ */M:^=XM_Y)K%_X&>_PM_R46%_QH_9>
MBBBOY=/Z5"BBB@ HHHH **** "BBB@ HHHH *\X_:[\*>(_'/[-/C'PCX1TB
M6_U*_P!':*SLX "\K[E.T9[\5Z/10!XGX-_;0_9:\+>$-*\,^(/C5H]K?Z=I
ML%K>VTC/NBFCC5'0X7&0P(_"M+_AN[]D/_HO&B?]]2?_ !%=Y+\*_AA/*T\_
MPXT%W=BSN^CP$L3U).WDTW_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\
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M?^ S_P#DSYK_ (AID7_/RK]\?_D#^?/_ (9?^,?_ $"]$_\ "PTO_P"2:/\
MAE_XQ_\ 0+T3_P +#2__ ))K^@S_ (5-\*_^B:>'_P#P30?_ !%'_"IOA7_T
M33P__P"":#_XBC_B*7$'_/JE_P" S_\ DP_XAID7_/RK]\?_ ) _GS_X9?\
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MR_\ &/\ Z!>B?^%AI?\ \DT?\,O_ !C_ .@7HG_A8:7_ /)-?T&?\*F^%?\
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M*_\ HFGA_P#\$T'_ ,11_P 12X@_Y]4O_ 9__)A_Q#3(O^?E7[X__('\^?\
MPR_\8_\ H%Z)_P"%AI?_ ,DU]0?\$D=(/[,7[5%Q\2/CCKFB:'HK^$[RS6]_
MX2"SN<SO+ RILMY7?D(W.,<=>E?K9_PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\
MHFGA_P#\$T'_ ,17%F/B)G69X&IA:M.FHS5G92OKVO-K\#LP' .3Y=C:>*I5
M*CE!W5W&WSM%?F<+_P -W?LA_P#1>-$_[ZD_^(H_X;N_9#_Z+QHG_?4G_P 1
M7=?\*F^%?_1-/#__ ()H/_B*/^%3?"O_ *)IX?\ _!-!_P#$5\$?<'*^$_VP
MOV9O'/B.S\(^$OC%I-]J6H3"*SLX2^^5ST497&:]*K%T_P"&WP[TF]CU'2_
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M%*SGS8T60 +(M?6] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!QG[1VF>,M;_9Z\>:-\.C+_PD%WX,U2'0O(.'^V/:2K!M
M]_,*X]Z^:O\ @WUU/P;J?_!&KX!'P0T/V:V\&&UO8X<?N[^*ZG2\5@.CBY6;
M<#SG.:^R*_/#]O/_ ()+^/\ P9X,\6?%W_@F5\3_ (L>#]8\1^+K77/'/P;^
M'_Q+CT/2/%<,ES'_ &L;/[1&RZ9J,]OOVS120QF15+*3@T -_P""/GC[P%X.
M^,'[8_C_ %'QQH^A^!?%'[8FHZ7X0NM3U.*VM]3UUX+6"Z2V:1@LTD]UM1 F
M3(ZD+N(K@?\ @L)\,?VS_@;\/;?]L/\ :Z_:1T#XT?L^?#7XBZ=XF\3_  5T
MCP;'X5NI+4:E%'8LUZL]T=3-I)-%)]F?[-'<-$"W(5*^F_V??V,/V:_C_P#\
M$Y++]C_XD_L%ZU\)O 5O(UOI_P //$>K0-JEC)#,)H]36[L;F9DNFG+3"?SC
M,7RSGYR#GC_@C%\)_%^JZ)#^TG^U]^T!\9O"_A[4[?4-.^'_ ,4/'UO=Z))<
MV[^9;R745K9V\M_Y;A6 NI9E)4;@W.0#Z_LKN#4+.&_MB3'/$LD992IVL,C(
M/(X/0UAZ?\)OAGI>N>)_$ECX&TU+[QJT+>++@VJL=6\JV6UC$X.1(%@18P#Q
MM&*Z&L/XG^!HOB?\-?$/PTG\4:SH:>(M#N],?6O#E]]EU'3Q<0O$;BUFPWDS
MQ[]\<F#M=5.#C% 'Q]^V3^U/XC^,2Z__ ,$N/^"9/AK3]8\>2Z,?#_C7Q=:6
MX7PS\)M,FB,#/=21X1[Y82PM].BR^Y0T@2-,-YE_P4!U_P '?L+?LL_ _P#X
M))^ +SQ_HO@3Q#H4.@_$#XF^'/!&KZQ<Z5X4L852\C3^R[6=TU#4CFW1E3;$
MLT\IV[8\]]\$_P#@@W\.?V;O <7PP^ O_!1+]J7PCH$-S+<KI6A?$'2[>)IY
M6W23,%TOYY';EG;+-W)K[)^$?P]F^%'PUT;X<W'Q \1^*WT>R6W;Q%XNOTNM
M3OR"?WMQ*D<:O(<\D(HX'% 'Y>_L@?MP_L5VW_!<?Q!HOP=B\4Z9X7U;]GWP
M?X(\$::OP@\1V*6UQ#JETD5N\,VGH]E;*CQ*+B=8[< $>9\K8_66O+M _9(^
M&7AS]L'Q%^VU8:EK+>+O$_@:P\*:A:2W49L$L;2YFN(F2,1AQ*7G<,Q<J0
MHZGU&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;:WA7=-//($1%]2QX ^M $U%,MKFVO+=+NSN$EBE0/%+&X974C(((X(/K3Z
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MOB_XX?$WXL?$)O#K:#IWB[XJ>(;>\GTK3'E6:6VM(;.VMK: 221QL[B+S&V
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MX[ZYXVT.^\16G[1B:?'\1]"UFY1[)X[/3(]-C2V$:))#F&-6+%V82?.C)@
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M^IW1,DUR+;[.9@&GQ.;;SS:M(!NA9?DK@/VM/^"79\=?'3]B+X(>!])\8O\
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M@\?>,_%OPK_:7^-WPKT?XCZI-J?C_P #?#+QQ%8:-K=]. +FZ:*6UEEM)IP
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M ,'='_9@T[XE>$_ OB?Q9#I>F^(+K4K\P1:Y>0W$+1ZAY5NL<:0RQE8WN7?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M45I;1/+*L42M+*RJI>1T103EF=5&20* -:BBB@ HHHH **** "BBB@ HHHH
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M (_^+/&NOZ1?0?%CXWWOC/08]+EE9[6RFT^PM5BN/,C0+,'M9"0A=<,OS$Y
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M$/"]A=+)X#^#TM]J*^*KV:+RUFO[O4[:%[>"#F2."!"Q<@O,RKM(!\.^/?\
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M3X@_;EFU_2&\,:O\"=,\$6^EK++]O2^MM8O;YYF7R_+\DQW**"'+;@V5 P2
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M.?AO]FCX_?&?X'Z?IW@WQ%X<U-M>\,RZM)>>-7TS4K67=?)/;!-.#012SF.
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MZ-I/BDZKI&I*WB<,E_8W/E0.\;*[1GS88I4>*12I4*[K^S3_ ,%'?AQ\ /\
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M **** "O-M=_9#_9W\2ZY>>(];^'OGWNH7<ES=S?VM=KYDLC%G;"R@#+$G
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M963R?+\TN-@0M\M>!?ME_P#*:K]B;_L4_BM_Z;]%KY2\#>$?%FC_ +<.L?\
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M/_;U_=ZF6B6T,;K% XA?,<9S(-H! /KN3_@HG^Q9%^R9#^W*_P ?M)'PMN5
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M?]A*#_T8M?%X;_>8>J_,#WJBBBOV( HHHH \2_X*#_MH:9^P+^S5=?M&ZOX
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MF?M"?L^^$/%>L_%WX<>(KSXE7NLZ%#,WB&6V\)6,UL;K<O[WR9&+1AL[3TH
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M/V.OVM/A5^W%^SEX6_:?^#*ZC%X?\6Z>;S3K3688XKV&,2R18FCCDD5"3&Q
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M#)VJ3EL#KCI4E[?66FVDFH:C>16\$*%YIYY B(HZDD\ >YK\I?\ @GC^PO\
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MXD_:M_X9C\>?!G5_#OC:?]I._*:K_;%V\<$#Z&-0C:_BVVKW7F/.AAR4^5F
MK[,^/G_!/_X&?M%_LT^%?V8_&VH^)+*Q\"W.D7O@CQ1H.L?9-:T'4M,C$=GJ
M-M<*A5+E%W#<4*$2."F#BO<** /E;PU_P26^#]I\=? 7[4'Q/_:"^+7Q%^(G
MPXUF6]\.>+/''B.RFECADL[BT>Q\BVLX+:*W9;EW?R(HI99$B:21_*0#TKX-
M_L4_"7X'>"_BGX%\'ZKKLMG\7O'6O>+/%#W]Y$\D-]JRJMREN5B4)$ @V*P=
MASEFKU^B@#YY\3_\$T/V?_%G_!/71_\ @FEJ6N^*5^'^B:/HFFVE_#J, U1H
M=+O+:[MBTQ@,98R6D0<B( J6 "D@BM\?/^":'PV^,?QVN_VF_AS\?/BI\'_'
MFKZ7;:;XH\0?"?Q+;V?_  D-M;;A;+?6UY:W5M.\(=U24Q"55;;OV@ ?1]%
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M'MO"GA'3KF"WO=:N[::9(I)I!'$I6!'<[G8#A>_.*ZOP)XX\)?$WP1HWQ)\
MZ];ZKH7B'2K?4M%U.U;,5Y:3QK+#,A/571U8>QKY%_X+L:#HWBK]CCPIX8\1
MZ9#>Z=J7Q_\ AY:W]G<(&CGAD\2V*/&P/564D$=P:\!_9;_:U\9_\$^_^";O
M[07['5S<3:E\2_V8?&$_@7X965TP>YUFWUJ93X.D*G[PD^VPP[1G"6C=<$T
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M;XJ?%/2OAYX_T/Q;X0TC3Y-+U'55D2TU73'TZWA:"%+B-4>VE,X\N3AMPW@
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MJ5I^TM\4-4UD:GH4;&^M='FLK6.QBEEDB0K<6MS'<7$84ND;R!U;+-C[,HH
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ML*OC>J.1E0VU<@'G STJU0!\D_$[_@FAJ?QJ_P""3_@;]@+Q9\1H-#\8>!_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20240930_g12.jpg
<TEXT>
begin 644 biib-20240930_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"CQK^QE_P3,\%? [QCX'\=:1)??$.W^,%B]WXCTEIUCU'3M5=($EU4W<+/\
MZYG?S0CH010!^J5[JVEZ9)!#J.I6]N]U,(K99YE0S2'D(H)^9N.@YKR/]B_]
MKW3OVQ?#GC[Q%IO@:?05\"?%SQ'X%EBGOQ<&\DTF\-LUV"$78LA&X)R5Z;CU
MKY$_9E_9G_9\_P""DW[;W[5WQ._;@^%FE?$#4?AY\4D^'_@/P_XJA^TV_A?1
M+;3;6=9[*)CBVFNIYY9FN$Q(2@VNH&*Z_P#X-]_#&G>"/V:_C)X,T?Q!?:M:
M:1^U3\0+*UU74[]KJYO(XM3\M9I9W)::1PH9I&)+$DDDF@#[PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\+_ &J?^"C7
M[+7['_C/1_A7\3O$6O:MXV\06#W^B^ O OA'4/$&MW5FC%'NOLEA#+)' &#+
MYL@1"58 DJ0 #W2J7B/0K/Q1X>O_  UJ+R+;ZC92VL[1, X21"C%200#@G'!
MKS3]D[]MS]FW]MCPWJWB#]GWQY+J$_AW4!8>*- U;2;G3-6T.[*[A!>6-W''
M/;L0#M+H%?:Q4L 37K% 'G'[(G[+WP[_ &*_V;/"'[+'PEU#5KKPYX*TO[!I
M-QKES'-=O%O9\RO''&K-ESR$48QQ7DWQK_X)6_"_XG_'/Q'^T/\ ##]HWXP_
M![Q'XWLK>V\?M\)/%MOI]OXF\B/RH9KJ*XM;@)<)%^[6X@\F8+_'GFOJ"LWQ
MEXQ\*_#SPAJOQ \=>(;/2-#T+39]0UG5M0G6*WLK2&-I)IY7;A$1%9F8\ *3
M0!X;<_\ !,?]E6W^!GPE_9R\':#J?AOPI\&/B%I'C/PA8Z+?C?+J>GSRSHUU
M).DCW EFFDDF8D22,Y.\$DU]"50\*^*/#OCCPQIOC7P?K5OJ6DZQ80WNEZC9
MRAX;JVE0212HPX961E8$=015^@#P+X[_ /!/KP/\9_VF-$_:Z\,?'+XC_#CQ
MUI7AM/#NH:G\/]6LH8]=T=+LW:6-[#>VERCQK,TC*\8CE'FN ^",=C^S3^RE
M\-OV5C\0#\-]1U>X_P"%D?$S5?'6O_VO=1R^5J6H>5YZ0[(TV0#R5VJVYADY
M=NWIE% 'RPO_  1__9/3]BGP'^P]#JGC.WTCX7ZB-3^'GC:P\0BU\2^']1$\
MTRWMM>P1(J2@W$J_ZLHRG#(V,UTG[-/_  3F^&7[/7Q@N_VB_%7QC^)'Q7^(
ML^AG1+/QM\5O$$%]=Z7IAD$KV=G%:V]M;6T;R*K.4A#N5&YCTKTOP)^T;\(/
MB3\:_'G[/7@[Q.]UXM^&::4WC/36L)HUL1J5N]Q9XE=!'+OBC=OW;-MQAL$@
M5W% '#?M,_L_^"?VK?V>_&?[-7Q)O-1M_#_CKPY=:+K$^D3I%=1V]Q&8W:)W
M1U5P&."58 ]C4/Q@_9G^$GQY_9LUK]E#XJZ$VK>#M?\ "[:#J5K.X\U[8Q"-
M75\?+*N%=9 ,JZJPP0*[^B@#YM\'_P#!+3]G/P1\#O@-^S_I'B#Q:^B?L[>+
MK7Q'X%FGU*W:YN;NW@NX46\86X66,K>RY$:QDD)\PP0?1O@G^RE\-O@+\6OB
ME\9?!>HZO-JOQ=\2VNN>)XM0NHW@AN;>QALD6W58U*(8H$)#,Y+$G(!P.]\4
M^*?#7@?PSJ'C3QGX@LM)T?2;*6\U35-2N5@M[.WB0O)-+(Y"HBJI9F)  !)K
MY4\._P#!<;_@GGX@U[18)O'/C#2/#?B;4X].\,?$?Q'\,=;TWPMJUU(VV..#
M5KFT2V(8Y"R,ZQMC(8@C(!T<_P#P2>_9.U+]E76_V0?$-OXCU#PWK'CW4/&E
MKJDFM>1JNC:Y=:A)J O;&ZMTC:VDAGD8Q, 2%^5BX+!I/@%_P3(^&GP=^-FE
M?M&?$C]H#XK_ !C\:^&M+N-/\&ZY\7/$]O?GPY!<($N390VEK;0QRS(JI)<-
M&\S(-IDVD@^@?M4_MF_L_?L:>&M)\0?''Q5>0W/B+4O[.\+>'="T6ZU75]=O
M-I;[/96-G')/<.%&6V(508+%00:I?LI?MT_LZ?ME?\)!IGP=\0ZM!X@\(745
MOXO\&>+/#=YHNN:')*I>(75A?1131K(H)23:4?:P5B58  ]$^)O@#1?BO\-_
M$/PM\2S7$>G>)=#N]*U"2S<+,L%Q"\+E&8, P5S@D$ XX/2O"/C7_P $IOV3
M/VAOV3/A7^QA\7-(U?5O!WP@O/#MQX6::\B^URG1X%MH%N'\K;(LL >*8*B;
MUE?;L.TK])UP_P"T7^TE\#?V2OA)J?QT_:+^(]AX5\*Z0$%YJE_O;+NP6.*.
M.-6DFE=B%2*-6=R<*I- &'XX_9!^%_Q _:V\"?MG:WJ6M)XL^'GAS5M%T.UM
MKN-;&2WU'RO/::,QEV<>2FTJZ@9.0W;Q+Q[_ ,$7/V?_ !;XE\;-X1_:#^-'
M@7P7\2]7GU/XA?"KP+XXCL?#NNW5S_Q^.\;6SW-M]I&1.MK/ ) 2",&NP_9Y
M_P""KO['7[1_Q=LO@%H.M^+/"OC75[*6]\.>&OB3X U3PW<Z[:QKN>:Q&H6\
M2W0506*QDN%!8J%!(V/VF/\ @I!^S)^RS\1K/X,>,+GQ9XE\;W>DG5CX+^''
M@74O$FJ6NFABAOKB#3X)6MH-P(#R[=Q5MN[:V #6U3]A?X"77Q5^"GQ5T+3+
MS0G^ .EZKIWP]T'1)(H=.AM+^PCL)(98C&S,L<$2",(Z;2,G<.*UX_V4OAM%
M^V1-^W$NHZO_ ,)A/\,XO KVANH_L']FIJ,FH!Q'Y>_S_.D8%O,V[,#9GFI?
M@K^UU^S9^T+\ U_:@^$OQ?TC4? BVES<7GB&>4VD6GK;[OM*W:W 1[1X=K>8
MDRHT>T[@*\*\(_\ !<K_ ()U>+_$NC::GQ&\4Z5H'B74TT[PO\0_$?PXUG3?
M"^LW;MM2*WU:YM4M6W,"%=G5&Q\K'(R 16W_  1?^ UC\$_B1^RY8?M _%R+
MX4?$?3]3M6^&7]OZ>^E>&_M]\M]/+IA>P-Q"WG"3:LLTT:B>7"98$>V_M$?L
M@_"[]IKPEX$\&?$'4M:@M/A[\0-!\8:&VE7<<;R7^D3B>U28O&X:$LH#JH5F
M'1EZUZH2%!9C@#J37CG[)7[??[*'[<USXR@_9;^*:>*D\!:Z-(\27,&F7,$$
M=R0S+Y,DT:+<QLJEEEB+QLI#*Q!!(!POQ9_X);?#KQM\</$7[0GP<_:7^,7P
M9\1>-# _CA?A1XJM;6S\0SPQ"&.YN;6^M+J%;@1*J>="L;D*,L3S7JG[*'[*
M'P@_8R^#\'P6^"]CJ(T\:E=ZGJ>IZWJ<E[J.KZE=2M-=7]Y<RDO/<2R,69S[
M !5 4>DT4 ?-W[:W_!,OX:?MM?%GP'\<M:^/OQ7^'?BOX=:?J=EX=USX5^*(
M-+N!#?B$7"R/);3,<B! -I7@MG.>,WX3_P#!+NQ^&TWB*'Q5^WK^TC\0]-\3
M>$M0\/W^A?$;XC0:E8QPW<?EO<1Q"S3;<(N0CDD+N;*G-?4=% '@/C[_ ()Q
M? ?XC?\ !.J#_@F-KVM^)D^'MOX&TWPI'?VNH0+JIL;%8%A<S&$Q>:1;IN;R
MMIRV%&1B+]I[_@G-\,OVD/C+H_[2&@?&+XB_"SXC:1H,F@MXX^%FNV]E>ZCI
M#R^=_9]VMU;7,%Q LN9$W1;T<DJRYKTOXE_M&_"#X0_$WP#\'_'_ (G>R\0?
M$[5KO3?!=DMA-*+ZYMK22\F0O&A2';!$[9D*@XP"20*[=F5%+NP  R23TH ^
M9?@U_P $D/V.O@WX%^+OPR70]=\4Z!\<EMC\1].\9ZVU^=2FCLQ;2W)F*K-Y
M\[;KB65I&?SY&=#'A57"^&7_  1V^#'@SQ;X-UGXE?M+_&WXIZ'\.=4AU+P!
MX'^)WCB&_P!'T.]@!%K<K%#:PRW4MN#B%KN2<Q\%>1FJ^L_\%U_^";^BZQ>-
M)\3O$UUX4TW5FTO4OBCIOPYUFY\(VEX)/+,3ZS%:M:8#D*9 YB!/+@9(]X_:
M!_:Y_9U_9?\ @Q'^T!\9_B?9:=X5NI;:'2K^S22]?5I[G_CV@LH;99);R67.
M8XX5=F&2!@$@ \N^-G_!+KX6?%7X^:Y^TC\/OC_\6OA-XE\8:;:V/Q ?X4>+
M(=-A\5Q6RF.W:\2:VF*S1Q$Q+<0&&=4.!)P".Z_8L_8A^!O[ OPPU;X.?L]6
MNIVOA[5?%^H^(5L-2O!/]CFO'5G@A;:K>2FU50.7? ^9W/-9?[+_ /P44_9H
M_:R\=ZM\(? E_P")_#_CG1--34M2\!_$/P7J/AW6DL'?8EZEIJ$,3S6Y;"^;
M'N52RABI90>9^/G_  5P_8O_ &?/BQJ_P0UK7O%_BGQ/X9@CG\9:;\./AYJW
MB/\ X1J&1=Z2:A)I]O*EKE?FV,WF;>=N""0#Z9HKRWPY^VS^R;XL_9=/[:N@
M_'WPW-\*UTJ349?&[7PCLHH$8H^\N T<BN#&8F D$G[LKO\ EKRGX7?\%E?V
M&?BE\2_#7PN7Q#XU\+W7CF[6U\ :KX_^&.M:!IGBF9AE(["\O[6*&9W&-B%E
M:0D!0Q(% 'U11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7PI^U7^S/_P4&^ O[?VK_P#!1?\ 8!\!> _B<GC'X>V'ACQW\-/&NO/I
M%\/L,\LMO/IE_L:*,.)2KQR@+N4-\Y8>7]UU\F?'?]B[]L+P?^U#KO[7_P#P
M3W_:0\,^'M6\;:=8VGQ"^'?Q2T&ZU3P[K$MG&8K:_@:UGBN+"Y6$^6WEDQR@
M(SKN4E@#QKX8_P#!47X/>&O%O[0?Q6^/?_!/_7?@G^TI\._@?/XN\7>%]>N+
M>[?Q5X>TQ)V@DM-2M?W5["EPQ@\S:-IE4 L$8)\XZ/\ ML_M13_LBZ5^V3X*
M_:6_:I\5?M"WVCV?B8?#B#]G7Q ? &HM+LG?P_! NB^6+;R&,"7ZW)D9P)Q,
M0V*^V?@W_P $QOB;\1?C+\0?VH?^"D_Q9\->/O&?Q ^%-Q\-%\.>!/#\VEZ!
MH/A>XD:6[M(!<337%Q+/(VYIY6# ?*!MQCFOA[^P+_P54\ _!;1/V'M%_P""
M@'@_3?A-X<@M=*TKXAZ-X-NX?B F@VQ40V"S?:38Q3B%%M_MHB+;!O\ *WT
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MMIC#;))YTS(J[I9+A<NJ1E'\\TW_ (*%?MD']A#P[\#+3XR1S?%OQ%^V!?\
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M(W9CADGCU6*.&WB 58[:WCB@0*-L8.2?H?\ :6_8A^-_[3_PU^%7Q.U?XO\
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M^/VE?@]9_"&YU6RNO&5A\)/!&IVVL>++>UN([A+.6>^O98[&*22*-Y#"KO\
M+M!"DT ?>8((R#12(B1H(XU"JHPJ@8 %+0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF!S7=4 %%?+/B/\ X+7?\$P?"WB?4/#&I_M4V4J:1J!L=6\0:=X;U6\T.QN
MVQHYM6M[5["(JW!WS@+@YQ@U[#\>/VM_V:?V8_@ZG[0'QV^-.A>'O!TY@%CK
MES=^9'?O.NZ&.U6(,]U)(N61(5=G ) (!- 'HM%>*?LK_P#!13]C/]M36]6\
M*?LX_&RWUG7-"@2XU?PYJ.D7NDZI;0,0JSM9:A!!<>26('FB,IE@-V2,]?\
M'S]I_P" '[+ND:)KGQ_^*FE^%[?Q)XBM-!T#^T)&,FHZC<N$AMH8T#/([$\X
M!"J"S$*"0 =Y1139YX;:%[FYF6..-2TDCL JJ!DDD] * '45PO[/7[3/P&_:
MO\#7'Q-_9S^)VF^+O#UKK5WI,FLZ0S-;M=VTGES(CLH$BJW1TRC#!5F!S7=4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;+]GS4_!WB?XIZUXN\3:AHWB?7&U.U74[MKF:&UCEL$B<QEMJ;W7(')%?>=
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S/QE^
M)EC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<__ ":/X]_[ +_^
MAK0!Z5X<UF+Q'X>L/$,$+1I?V45PD;G)0.@8 ^XS5VL+X7?\DS\._P#8"M/_
M $2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>3_ +2G[4'_  SS?:39
M?\(/_:_]J13/N_M/[/Y6PH,?ZI]V=WMTH ]8HKY9_P"'EO\ U17_ ,N/_P"Y
MJ/\ AY;_ -45_P#+C_\ N:@#ZFHKY9_X>6_]45_\N/\ ^YJ/^'EO_5%?_+C_
M /N:@#ZFHKY9_P"'EO\ U17_ ,N/_P"YJ/\ AY;_ -45_P#+C_\ N:@#ZFHK
MY9_X>6_]45_\N/\ ^YJ/^'EO_5%?_+C_ /N:@#ZFHKY9_P"'EO\ U17_ ,N/
M_P"YJ/\ AY;_ -45_P#+C_\ N:@#ZFHKX%_;6_X+4ZW^S)^S/XE^,GACX!V%
MUJ>GBUMM,&K^)7%E#<75U#:QSW)2!6\B-YEDDPRDHC ,I((^5_V)/^"@G_!4
M'P7^TU\4?$7C'QOX'^*WAN?XLV-KXR\.FPN=).GP2Z#I;F[T:=[JX2"&(.A-
MHZ.)2LL@=7F. #]HJ*_,/]I[]J/_ (*&^/?B7?\ CKX _MJZ=\*O!ZV47E^&
M+KX;:9K0M&CC_?3->7)1F#$%L%0%'';-8_\ P2P_X*:?MJ^+?!_BKXL?M1_$
MF+XH>%]=U..+X7W/_"-V?AV9M/@,B2Z@\=M$Y*7+D&)7.1%"C_\ +4JH!^JE
M%?G+_P %&?\ @ME\1?V9/V5]7^)7PH^#.DVNNRZE8:79:WXAU:2YT[13=7*0
M&_NHHXHVDBB#D[0ZY8KDXR#X?XH_X*;?MW_L?Z[\.OB5XQ_:]L?C+I?BWQEI
MFC:AX#U?PEH^GG58+V5(FGTB;38(YHVA5O. F:Y4HK;FZ&@#]BJ*^6?^'EO_
M %17_P N/_[FH_X>6_\ 5%?_ "X__N:@#ZFHKY9_X>6_]45_\N/_ .YJ/^'E
MO_5%?_+C_P#N:@#ZFHKY9_X>6_\ 5%?_ "X__N:C_AY;_P!45_\ +C_^YJ /
MJ:BOEG_AY;_U17_RX_\ [FH_X>6_]45_\N/_ .YJ /J:BOEG_AY;_P!45_\
M+C_^YJ/^'EO_ %17_P N/_[FH ^IJ*^6?^'EO_5%?_+C_P#N:NY_9\_;&_X7
MOX\?P3_PKK^RMFGR7/VK^U_/SM9!MV^2G7=USVZ4 >VT444 %%%% !1110 4
M444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\
MZ&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^.4?\*!^$G_0I_\ D_<?_'*[&B@#CO\ A0/PD_Z%/_R?N/\ XY1_PH'X2?\
M0I_^3]Q_\<KL:* .._X4#\)/^A3_ /)^X_\ CE=_^S=\+? G@WXAOJ_AO0OL
MUP=.EC,GVJ5_E+(2,,Q'851KK_@I_P CBW_7D_\ -: /6:*** "BBB@ HHHH
M **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V
M7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\W^//\ Q^:;_P!<I?YK7I%>;_'G_C\TW_KE
M+_-: //Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BO-_CS_Q^
M:;_URE_FM=A]B\;_ /0;LO\ P&/^-<'\8X=:ANK :Q>PS$QR>688]N.5SF@#
MBZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "NO^"G_(XM_P!>3_S6N0KIOA1%J<OBEETFYCBE^ROEI4W#&5XQ
M0![%16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%9=G:>+4ND>^U
M:U>(-^\1+<@D>QK4H **** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V 7_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O-_CS_ ,?FF_\ 7*7^:UZ17F_QY_X_--_ZY2_S
M6@#S^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KK_@I_R.+?]>3_ ,UKD*Z_X*?\CBW_ %Y/_-: /6:*** "
MBBB@ HHHH **** "BBB@ HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-
M'\>_]@%__0UH [KX7?\ ),_#O_8"M/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KS?X\_\ 'YIO_7*7^:UZ17F_QY_X
M_--_ZY2_S6@#S^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KK_@I_P CBW_7D_\ -:Y"NO\ @I_R.+?]>3_S
M6@#UFBBB@ HHHH **** "BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7K
MRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\
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M?XBTG3O$&L'3KO2CX@C=M-O)K+4;:^%G>",%C;7'V;R)-H)"2L=K ;2 <_\
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MGDT/Q/HM_P"8+?4+-;G,]N5DADAE@E9RCJ"KN&^7Z@H **** "BBB@ HHHH
M**** "BBB@ HHHH *\W^//\ Q^:;_P!<I?YK7I%>;_'G_C\TW_KE+_-: //Z
M*** "BBB@ HHHH **** "BBLGQIX\\%_#G28M>\>>*+'2+*?4;33X;K4+A8D
M>ZNITM[>$%NKR321QJO5F< <F@#6HHHH **** "BBB@ HHHH **** "BBB@
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M_P#[FH_X>6_]45_\N/\ ^YJ^6:* /J;_ (>6_P#5%?\ RX__ +FH_P"'EO\
MU17_ ,N/_P"YJ^6:* /J;_AY;_U17_RX_P#[FH_X>6_]45_\N/\ ^YJ^6:*
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M!E.0>A%>4_&?]M[]ES]GOQLGPY^+WQ4CTG6Y-.COUT\:5>7#?9Y'D1)"8(7
M!:*08)S\O3I0!]^?\/+?^J*_^7'_ /<U'_#RW_JBO_EQ_P#W-7Q!\#OVD?@O
M^TAI5]K?P7\9'6;73;A8+V7^S;FV\N1EW!<3QH6XYXS7<T ?4W_#RW_JBO\
MY<?_ -S4?\/+?^J*_P#EQ_\ W-7RS10!]3?\/+?^J*_^7'_]S4?\/+?^J*_^
M7'_]S5\LT4 ?4W_#RW_JBO\ Y<?_ -S4?\/+?^J*_P#EQ_\ W-7RS10!]3?\
M/+?^J*_^7'_]S4?\/+?^J*_^7'_]S5\LT4 ?4W_#RW_JBO\ Y<?_ -S5[O\
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M?\%/^1Q;_KR?^:UR%=-\*(M3E\4LNDW,<4OV5\M*FX8RO&* /8J*Q_L7C?\
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M0 4444 %%%% !1110 4444 %%%% !77_  4_Y'%O^O)_YK7(5U_P4_Y'%O\
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M@#CO^% _"3_H4_\ R?N/_CE'_"@?A)_T*?\ Y/W'_P <KL:* .._X4#\)/\
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M_P *!^$G_0I_^3]Q_P#'*[&B@#CO^% _"3_H4_\ R?N/_CE'_"@?A)_T*?\
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M0 4444 %%%% !1110 4444 %%%% !77_  4_Y'%O^O)_YK7(5U_P4_Y'%O\
MKR?^:T >LT444 %%%% !1110 4444 %%%% !1110 5Y1^W/_ ,FC^/?^P"__
M *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\ DF?AW_L!6G_HE*W:POA=_P D
MS\._]@*T_P#1*5NT %>">(_^1AO_ /K]E_\ 0S7O=>">(_\ D8;_ /Z_9?\
MT,T 4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O8OA#_P B+;?]=9?_ $,UX[7L7PA_Y$6V_P"NLO\ Z&:
M.FHHHH **** "O-_CS_Q^:;_ -<I?YK7I%>;_'G_ (_--_ZY2_S6@#S^BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KK_ (*?\CBW_7D_\UKD*Z_X*?\ (XM_UY/_ #6@#UFBBB@ HHHH ***
M* "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]
M@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ KP3Q'
M_P C#?\ _7[+_P"AFO>Z\$\1_P#(PW__ %^R_P#H9H I4444 %%%% !1110
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M^B4K=K"^%W_),_#O_8"M/_1*5NT %>">(_\ D8;_ /Z_9?\ T,U[W7@GB/\
MY&&__P"OV7_T,T 4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O8OA#_ ,B+;?\ 767_ -#->.U[%\(?^1%M
MO^NLO_H9H Z:BBB@ HHHH *\W^//_'YIO_7*7^:UZ17F_P >?^/S3?\ KE+_
M #6@#S^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KK_@I_R.+?\ 7D_\UKD*Z_X*?\CBW_7D_P#-: /6:***
M "BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_
M .31_'O_ & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE
M*W: "O!/$?\ R,-__P!?LO\ Z&:][KP3Q'_R,-__ -?LO_H9H I4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@ HHHH **** "NO^"G_ ".+?]>3_P UKD*Z_P""G_(XM_UY/_-: /6:***
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M_P"AF@#IJ*** "BBB@ KS?X\_P#'YIO_ %RE_FM>D5YO\>?^/S3?^N4O\UH
M\_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGB/_ )&&_P#^OV7_ -#- %*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^P%:?^B4K=H *\$\1_\ (PW_ /U^R_\ H9KWNO!/$?\ R,-__P!?LO\ Z&:
M*5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7L7PA_P"1%MO^NLO_ *&:\=KV+X0_\B+;?]=9?_0S0!TU%%%
M!1110 5YO\>?^/S3?^N4O\UKTBO-_CS_ ,?FF_\ 7*7^:T >?T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=
M?\%/^1Q;_KR?^:UR%=?\%/\ D<6_Z\G_ )K0!ZS1110 4444 %%%% !1110
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M5GW^K.1U<Q]G[3DY?=ORWYI*.]I;7OL88FM]7HN=KV.JHKXWHK\C_P"(Y?\
M4O\ _*O_ -R/,_MC^Y^/_ /LBBOC>BC_ (CE_P!2_P#\J_\ W(/[8_N?C_P#
M[(HKXWHH_P"(Y?\ 4O\ _*O_ -R#^V/[GX_\ ^R**^-Z*/\ B.7_ %+_ /RK
M_P#<@_MC^Y^/_ /LBBOC>BC_ (CE_P!2_P#\J_\ W(/[8_N?C_P#[(HKXWHH
M_P"(Y?\ 4O\ _*O_ -R#^V/[GX_\ ^R**^-Z*/\ B.7_ %+_ /RK_P#<@_MC
M^Y^/_ /LBBOC>BC_ (CE_P!2_P#\J_\ W(/[8_N?C_P#[(HKXWHH_P"(Y?\
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MK>:_G$U]+! J-<2A%0/(0,NVQ$7)R<*!T JS10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7L7PA_Y$6V_P"NLO\ Z&:\=KV+X0_\B+;?]=9?
M_0S0!TU%%% !1110 5\F_P#!2O\ Y#GA+_KTO/\ T**OK*ODW_@I7_R'/"7_
M %Z7G_H45?GGBI_R0^)]:?\ Z<B<.9?[G+Y?F?,-%%%?R,?,A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7NG_!/;
M_DO,W_8OW'_HR*O"Z]T_X)[?\EYF_P"Q?N/_ $9%7U? W_)7X'_KY$Z,)_O4
M/4^W****_M$^L"BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\
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M^>>*G_)#XGUI_P#IR)PYE_N<OE^9\PT445_(Q\R%%%% !1110 4444 %%%%
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M;_DO,W_8OW'_ *,BKZO@;_DK\#_U\B=&$_WJ'J?;E%%%?VB?6!1110 4444
M%%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_
M .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !7@GB/\
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MQ \*FW@U#3I-9AU/3XK*>9#B6VFB#V[.$8"5(PI .6K[LKYX_:X_X)V?"?\
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M+;?]=9?_ $,T =-1110 4444 %?)O_!2O_D.>$O^O2\_]"BKZRKY-_X*5_\
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MOA=_R3/P[_V K3_T2E;M !7@GB/_ )&&_P#^OV7_ -#->]UX)XC_ .1AO_\
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M_P I/SW_ %JR_P#EG]R_^2,VBM+[!:?\\O\ QXT?8+3_ )Y?^/&C_B6CCO\
MZ"<-_P"!U?\ Y2'^M67_ ,L_N7_R1FT5I?8+3_GE_P"/&C[!:?\ /+_QXT?\
M2T<=_P#03AO_  .K_P#*0_UJR_\ EG]R_P#DC-HK2^P6G_/+_P >-'V"T_YY
M?^/&C_B6CCO_ *"<-_X'5_\ E(?ZU9?_ "S^Y?\ R1FT5I?8+3_GE_X\:/L%
MI_SR_P#'C1_Q+1QW_P!!.&_\#J__ "D/]:LO_EG]R_\ DC-HK2^P6G_/+_QX
MT?8+3_GE_P"/&C_B6CCO_H)PW_@=7_Y2'^M67_RS^Y?_ "1FT5I?8+3_ )Y?
M^/&C[!:?\\O_ !XT?\2T<=_]!.&_\#J__*0_UJR_^6?W+_Y(S:*TOL%I_P \
MO_'C1]@M/^>7_CQH_P"):.._^@G#?^!U?_E(?ZU9?_+/[E_\D9M%:7V"T_YY
M?^/&C[!:?\\O_'C1_P 2T<=_]!.&_P# ZO\ \I#_ %JR_P#EG]R_^2,VBM+[
M!:?\\O\ QXT?8+3_ )Y?^/&C_B6CCO\ Z"<-_P"!U?\ Y2'^M67_ ,L_N7_R
M1FT5I?8+3_GE_P"/&C[!:?\ /+_QXT?\2T<=_P#03AO_  .K_P#*0_UJR_\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]B^$/\
MR(MM_P!=9?\ T,UX[7L7PA_Y$6V_ZZR_^AF@#IJ*** "BBB@ KY:_P""BW_(
M9\*_]>MW_P"A15]2U\M?\%%O^0SX5_Z];O\ ]"BKW>&_^1Q3_P"WO_26?+<9
M_P#).U?6/_I2/FRBBBOT\_$ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KVS]@G_DN$W_ & ;C_T9%7B=>V?L$_\
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M?L$_\EPF_P"P#<?^C(J\3KVS]@G_ )+A-_V ;C_T9%7FYS_R*ZW^%GM<.?\
M(]P_^)'V91117Y*?OP4444 %%%% !1110 5\#_\ !6'XJ?L'^ _C5X=TW]JO
M_@KE\7_V>]:F\+++I_A?X=^-WTNUU&U^TS 7DD:V-QOD+AX]VX?+$HQQD_?%
M>7?$[6?VQK3XF:K9?![P/X OO":?#.^N-$O?$.LW<%Y+XN$N+.TF6*-U33FC
MP9)E#2J?NHU 'Y9?\-&_\$;?^EFK]I__ ,.Y-_\ *>OT^_8(\0_"+Q5^R1X.
MU_X#_M'^)?BYX3N+>Z.C_$3QAJIOM2UA1>3J[33F&$R%) \(_=KA8E'.,GQ#
M_A/?^#@3_HV[]E#_ ,.AXA_^5=?3_P  [[X\:E\)-'O?VFO#OA;2?',D<O\
M;VG^"]2N+S3(6$SB,037$44K@Q",MN1<.6 R "0#L*\H_;G_ .31_'O_ & 7
M_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\
MDF?AW_L!6G_HE*W: "O!/$?_ ",-_P#]?LO_ *&:][KP3Q'_ ,C#?_\ 7[+_
M .AF@"E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5[%\(?\ D1;;_KK+_P"AFO':]B^$/_(BVW_767_T,T =
M-1110 4444 %?+7_  46_P"0SX5_Z];O_P!"BKZEKY:_X*+?\AGPK_UZW?\
MZ%%7N\-_\CBG_P!O?^DL^6XS_P"2=J^L?_2D?-E%%%?IY^(!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7MG[!/\
MR7";_L W'_HR*O$Z]L_8)_Y+A-_V ;C_ -&15YN<_P#(KK?X6>UPY_R/</\
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MO^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %>">(_\ D8;_ /Z_9?\
MT,U[W7@GB/\ Y&&__P"OV7_T,T 4J*** "BBB@ HHHH **** "BBB@ HHHH
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M/_D8;_\ Z_9?_0S7L?V+QO\ ]!NR_P# 8_XU^<GQ1$J_$SQ$L[AG&NW>]E&
M3YSY-?#<<<:?ZFX>C5]A[7VC:^+EM9)_RROOY''C,7]52?+>_F?5=%?&]%?G
M7_$<O^I?_P"5?_N1P_VQ_<_'_@'V117QO11_Q'+_ *E__E7_ .Y!_;']S\?^
M ?9%%?&]%'_$<O\ J7_^5?\ [D']L?W/Q_X!]D45\;T4?\1R_P"I?_Y5_P#N
M0?VQ_<_'_@'V117QO11_Q'+_ *E__E7_ .Y!_;']S\?^ ?9%%?&]%'_$<O\
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M1_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H
M*_,_XL?\E2\2_P#8P7G_ */>OTPK\S_BQ_R5+Q+_ -C!>?\ H]Z_#/&__<,'
M_BG^2/'S?X(?,Y^BBBOYV/#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "OO+]A?\ Y-OTC_K[N_\ T>]?!M?>7["_
M_)M^D?\ 7W=_^CWK]:\&?^2KJ?\ 7F7_ *5 ]+*O]Y?I_D>O4445_41]$%%%
M% !7RU_P46_Y#/A7_KUN_P#T**OJ6OEK_@HM_P AGPK_ ->MW_Z%%7N\-_\
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MQ[_V 7_]#6@#NOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@
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M@5)172J455=3JTE]U_\ -G'*O.5"-+[*;?S:2?\ Z2CYDNOAO_P5*MO"]_\
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MV.\J  Q,1)49VYQDXR?1=7U;3-!TJZUW6K^*UL[*W>>[NIW"I#$BEF=B>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1PJJH  '  JS148O,L?CTEB*CE:[U[O=ONW97;NWU82J3G\3"BBBN$@****
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M_8!N/_1D5>;G/_(KK?X6>UPY_P CW#_XD?9E%%%?DI^_!1110 4444 %%%%
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MO_7K=_\ H45?4M?+7_!1;_D,^%?^O6[_ /0HJ]WAO_D<4_\ M[_TEGRW&?\
MR3M7UC_Z4CYLHHHK]//Q **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *]L_8)_Y+A-_P!@&X_]&15XG7MG[!/_ "7"
M;_L W'_HR*O-SG_D5UO\+/:X<_Y'N'_Q(^S****_)3]^"BBB@ HHHH ****
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M1FT5I?8+3_GE_P"/&C[!:?\ /+_QXT?\2T<=_P#03AO_  .K_P#*0_UJR_\
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M@[_H*_\ )*G_ ,@'^IW$?_/C_P FA_\ )'E-%>K?\,Q_]3O_ .4W_P"V4?\
M#,?_ %.__E-_^V4?\1$X._Z"O_)*G_R ?ZG<1_\ /C_R:'_R1Y317JW_  S'
M_P!3O_Y3?_ME'_#,?_4[_P#E-_\ ME'_ !$3@[_H*_\ )*G_ ,@'^IW$?_/C
M_P FA_\ )'E-%>K?\,Q_]3O_ .4W_P"V4?\ #,?_ %.__E-_^V4?\1$X._Z"
MO_)*G_R ?ZG<1_\ /C_R:'_R1Y317JW_  S'_P!3O_Y3?_ME'_#,?_4[_P#E
M-_\ ME'_ !$3@[_H*_\ )*G_ ,@'^IW$?_/C_P FA_\ )'E-%>K?\,Q_]3O_
M .4W_P"V4?\ #,?_ %.__E-_^V4?\1$X._Z"O_)*G_R ?ZG<1_\ /C_R:'_R
M1Y317JW_  S'_P!3O_Y3?_ME'_#,?_4[_P#E-_\ ME'_ !$3@[_H*_\ )*G_
M ,@'^IW$?_/C_P FA_\ )'E-%>K?\,Q_]3O_ .4W_P"V4?\ #,?_ %.__E-_
M^V4?\1$X._Z"O_)*G_R ?ZG<1_\ /C_R:'_R1Y317JW_  S'_P!3O_Y3?_ME
M'_#,?_4[_P#E-_\ ME'_ !$3@[_H*_\ )*G_ ,@'^IW$?_/C_P FA_\ )'E-
M>V?L$_\ )<)O^P#<?^C(JR?^&8_^IW_\IO\ ]LKT[]DWX,_\(#\49-<_X23[
M7NTJ:+ROL?E]6C.<[SZ>E<V-XXX6S#"SPU#$<TYJR7)-7?JXI?>ST\EX7SW"
M9M1K5:-HQDFWS1>GRE<^E****^1/U\**** "BBB@ HHHH **** "BBB@ KRC
M]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#NOA=_P DS\._]@*T
M_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ K\Y?BE_R4WQ'_P!AZ\_]'/7Z-5^<
MOQ2_Y*;XC_[#UY_Z.>OL>#_X]7T7YL_.O$/_ ':AZR_)&#1117W9^6!1110
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MLQC!!&_9MR",\5M_!;X\_![]HGP</'WP4^(%AXATH7#6\MQ9.0T$RXW12QN
M\,@!!*.JL 0<8(H5:BZGLU)<W:^OW \-B(T55<'R/K9V^_8ZZBN5NOC?\)[+
MXOVGP"N/'5C_ ,)E?:1)JEOX>1RUQ]C1@K3, "$7) &XC=@XS@XZJJ4HRO9[
M&<H3A;F5KZKS7<**XCX:?M(? _XQ^.O%7PT^&/Q%LM9UOP1=1VWBFRLUD/\
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M1117YF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%'P3^#'Q*\;_ +6?B'4HK#4M=TFTC\1:]KE^H@T^QLXR%2)GP+>(YWNH.UG
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M0 5V'P1_Y'-O^O)_YK7'UV'P1_Y'-O\ KR?^:UZ63_\ (TH_XD!ZY1117ZL
M4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_
M ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M
M !7YR_%+_DIOB/\ [#UY_P"CGK]&J_.7XI?\E-\1_P#8>O/_ $<]?8\'_P >
MKZ+\V?G7B'_NU#UE^2,&BBBONS\L"BBB@ HHHH **** "BBB@ HHHH ****
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M:I+<)F&!"1EW<*-J5&C&LX5(:)W;N[*+M:UK:OI>]]%;<#V7]I;]N/7/A?\
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M"Q'[Y\\U\SQ9_P BR/\ B7Y,^VX!_P"1U+_ _P XGM-%8_V+QO\ ]!NR_P#
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M,5Z63_\ (TH_XD![)16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XU^K
M;%%9=G:>+4ND>^U:U>(-^\1+<@D>QK4H **** "BBB@ HHHH **** "O*/VY
M_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M
M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ K\Y?BE_R4WQ'_ -AZ\_\ 1SU^C5?G
M+\4O^2F^(_\ L/7G_HYZ^QX/_CU?1?FS\Z\0_P#=J'K+\D8-%%%?=GY8%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+'_D[!_\71_PI'XH?]"Q_P"3L'_Q='^LO#G_ $&4O_!D/\P_L7.?^@:I_P"
M2_R.4HKJ_P#A2/Q0_P"A8_\ )V#_ .+H_P"%(_%#_H6/_)V#_P"+H_UEX<_Z
M#*7_ (,A_F']BYS_ - U3_P"7^1RE%=7_P *1^*'_0L?^3L'_P 71_PI'XH?
M]"Q_Y.P?_%T?ZR\.?]!E+_P9#_,/[%SG_H&J?^ 2_P CE**ZO_A2/Q0_Z%C_
M ,G8/_BZ/^%(_%#_ *%C_P G8/\ XNC_ %EX<_Z#*7_@R'^8?V+G/_0-4_\
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M\8_'/]CRZK;W+V"_V9=7'FK&T8<Y@B?;@LO7&<\5]%5^6W_!Q/\ \CG\+/\
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M$/\ T6S_ ,MO4O\ Y&H_X>:?L0_]%L_\MO4O_D:OR7HH_P"( \'?\_\ $?\
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M6C_AYI^Q#_T6S_RV]2_^1J/^'FG[$/\ T6S_ ,MO4O\ Y&K\EZ*/^( \'?\
M/_$?^!4__E0?\1+SW_GW2^Z7_P F?K1_P\T_8A_Z+9_Y;>I?_(U'_#S3]B'_
M *+9_P"6WJ7_ ,C5^2]%'_$ >#O^?^(_\"I__*@_XB7GO_/NE]TO_DS]:/\
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MS/P7X6R++ZF88>M6<Z2<DI2@U==[4T[>C1ZF2\?9QF.:T<+5ITU&<DG92O\
M*\G^1^R]%%%?G1^NA1110 4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L
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M_P#_ $?:U\55]J_\$%O^3X+O_L1;_P#]'VM?.\6_\DUB_P# SW^%O^2BPO\
MC1^R]%%%?RZ?TJ%%%% !1110 4444 %%%% !1110 5Y1^W/_ ,FC^/?^P"__
M *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\ DF?AW_L!6G_HE*W:POA=_P D
MS\._]@*T_P#1*5NT %> >)/^1BO_ /K]E_\ 0S7O]> >)/\ D8K_ /Z_9?\
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MS@CY&!"_-T!KZLHJ5B*:H*GR;.^_73IVT ^"?VGOVO=>_:F_92\3?LW>+_\
M@EE\;-4^('B?PU<:4/">M?#HG1+/5I(3&L_]M.WV(01RL)%N4EWA4#!5;@=U
MIOB']KK]A#X#_ ?P[XM^!E_\8]&\,>"(=&^*.K>#K=]1\2:7J,=K#'%=VENS
M*U];%EECEV SD;' /S*?KRBJ>+AR*"@N6[=KOJK:=O+\;@?%%G<_%#]O;]OG
MX-_'GPW^SQXZ\ ?#_P""$6OWUYXA^)/AR31;_7K_ %&Q^PQV5I93XN%@1299
M)9$56*JH&0"?1?B,?$'_  4'^$?[0G['/C3X'>+/ -E':7GA?1O%?B.Q9;37
M3/#*L>HV7RCS88Y%C8X)SD#/-?25%3+%7:<8VY4N7RUO?SU; _/WP9^TM\:?
MAM^Q#9?L*WG_  34^*MU\2](\ +X*AT?3O"(D\)7\Z6GV-;O^V2PM$L9 !*W
MF,)%5F4H6&3]8_L2? G7OV8?V0?AK^SSXIU]-4U/P;X+T_2=1OH68QR3PP*C
M^66P?+# JF0#M"\#I7J-%*MB?:Q<5&UW=[O7Y]/ZN 4445R@%%%% !1110 4
M444 %>R_![_D0[7_ *ZR_P#H9KQJO9?@]_R(=K_UUE_]#-?2\*_\C*7^%_F@
M.GHHHK]# **** "ORV_X.)_^1S^%G_8+U;_T9:U^I-?EM_P<3_\ (Y_"S_L%
MZM_Z,M:^T\/O^2LH>D__ $B1\?QY_P DO7]8?^EQ/S<HHHK^D#^>PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[5
M_P"""W_)\%W_ -B+?_\ H^UKXJK[5_X(+?\ )\%W_P!B+?\ _H^UKYWBW_DF
ML7_@9[_"W_)187_&C]EZ***_ET_I4**** "BBB@ HHHH **** "BBB@ KRC]
MN?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V
MK3_T2E;M87PN_P"29^'?^P%:?^B4K=H *\ \2?\ (Q7_ /U^R_\ H9KW^O /
M$G_(Q7__ %^R_P#H9KY#B[^!2]7^0%*BBBOA@"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O9?@]_R(=K_P!=9?\
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M *MF_P#+S_\ N.C_ (?9_P#5LW_EY_\ W'1_Q!_Q%_Z ?_*M'_Y8'^O7"O\
MT$?^23_^1/O"BO@__A]G_P!6S?\ EY__ ''1_P /L_\ JV;_ ,O/_P"XZ/\
MB#_B+_T _P#E6C_\L#_7KA7_ *"/_))__(GWA17P?_P^S_ZMF_\ +S_^XZ/^
M'V?_ %;-_P"7G_\ <='_ !!_Q%_Z ?\ RK1_^6!_KUPK_P!!'_DD_P#Y$^\*
M*^#_ /A]G_U;-_Y>?_W'1_P^S_ZMF_\ +S_^XZ/^(/\ B+_T _\ E6C_ /+
M_P!>N%?^@C_R2?\ \B?>%%?!_P#P^S_ZMF_\O/\ ^XZ/^'V?_5LW_EY__<='
M_$'_ !%_Z ?_ "K1_P#E@?Z]<*_]!'_DD_\ Y$^\**^#_P#A]G_U;-_Y>?\
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4U7_ -+IJ_.?%#_DG8?]?(_^DS/T'PV_Y'\_^O<O_2HGU=1117X"?N84444
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M\*?]\Q7^&/YL_+?$_P#W3#?XI?DCA:***_:S\="BBB@ HHHH **** "BBB@
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M10 4444 %%%% !7VK_P06_Y/@N_^Q%O_ /T?:U\55]J_\$%O^3X+O_L1;_\
M]'VM?.\6_P#)-8O_  ,]_A;_ )*+"_XT?LO1117\NG]*A1110 4444 %%%%
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M,_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ K^<W]J'_DYCXB?]CUJ_\
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MM/#[_DK*'I/_ -(D?'\>?\DO7]8?^EQ/S<HHHK^D#^>PHHHH **** "BBB@
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MD?.E%%%?4'S84444 %%%% !1110 5]J_\$%O^3X+O_L1;_\ ]'VM?%5?:O\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %?M]_P13_Y1[>%/^PIJO\
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MS[W\[6OVO;2^]M+V,UC<6L/[#G?+M;RO>W>U];;7UW"BBBNLY0HHHH ****
M"BBB@ K[5_X(+?\ )\%W_P!B+?\ _H^UKXJK[5_X(+?\GP7?_8BW_P#Z/M:^
M=XM_Y)K%_P"!GO\ "W_)187_ !H_9>BBBOY=/Z5"BBB@ HHHH **** "BBB@
M HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\
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M_DF?AW_L!6G_ *)2MV@ K^<W]J'_ ).8^(G_ &/6K_\ I;+7]&5?SF_M0_\
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M"]6_]&6M?J37Y;?\'$__ ".?PL_[!>K?^C+6OM/#[_DK*'I/_P!(D?'\>?\
M)+U_6'_I<3\W****_I _GL**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *^U?\ @@M_R?!=_P#8BW__ */M:^*J^U?^
M""W_ "?!=_\ 8BW_ /Z/M:^=XM_Y)K%_X&>_PM_R46%_QH_9>BBBOY=/Z5"B
MBB@ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\
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MOZ0/Y["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OM7_@@M_R?!=_]B+?_P#H^UKXJK[5_P"""W_)\%W_ -B+?_\
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M+9:_6?"G_?,5_AC^;/RWQ/\ ]TPW^*7Y(X6BBBOVL_'0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]OO^"*?_*/;
MPI_V%-5_]+IJ_$&OV^_X(I_\H]O"G_84U7_TNFK\Y\4/^2=A_P!?(_\ I,S]
M!\-O^1_/_KW+_P!*B?5U%%%?@)^YA1110 5^6W_!Q/\ \CG\+/\ L%ZM_P"C
M+6OU)K\MO^#B?_D<_A9_V"]6_P#1EK7VGA]_R5E#TG_Z1(^/X\_Y)>OZP_\
M2XGYN4445_2!_/84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5]J_\$%O^3X+O_L1;_P#]'VM?%5?:O_!!;_D^"[_[
M$6__ /1]K7SO%O\ R36+_P #/?X6_P"2BPO^-'[+T445_+I_2H4444 %%%%
M!1110 4444 %%%% !7E'[<__ ":/X]_[ +_^AK7J]8GQ(^'WASXJ^!=3^'?B
MZ*5]-U:V,%XL$I1RA(/##H>* &_"[_DF?AW_ + 5I_Z)2MVO X_A;^WII$:Z
M3X9^/'@F#3;4"'3X)O#;N\<"_+&K-_$0H )[FG?\*^_X*'_]'!>!/_"7>@#W
MJOYS?VH?^3F/B)_V/6K_ /I;+7[<?\*^_P""A_\ T<%X$_\ "7>OG+Q1_P $
M5KSQIXFU'QCXED\"7.I:M?S7FH7.[6$\V>5R\C[4N@JY9B<  #/  K[?@GB7
M \-XBM/$QE)322Y4GLWO=H^,XRX=QO$-"C##2BG!MOF;6Z6UDS\FJ*_5?_AQ
MC8?\^W@3_O\ ZW_\ET?\.,;#_GV\"?\ ?_6__DNOT3_B*7#_ /SZJ_\ @,/_
M ),^!_XAIGO_ #\I??+_ .0/RHHK]5_^'&-A_P ^W@3_ +_ZW_\ )='_  XQ
ML/\ GV\"?]_];_\ DNC_ (BEP_\ \^JO_@,/_DP_XAIGO_/RE]\O_D#\J**_
M5?\ X<8V'_/MX$_[_P"M_P#R71_PXQL/^?;P)_W_ -;_ /DNC_B*7#__ #ZJ
M_P#@,/\ Y,/^(:9[_P _*7WR_P#D#\J**_5?_AQC8?\ /MX$_P"_^M__ "71
M_P .,;#_ )]O G_?_6__ )+H_P"(I</_ //JK_X##_Y,/^(:9[_S\I??+_Y
M_*BBOU7_ .'&-A_S[>!/^_\ K?\ \ET?\.,;#_GV\"?]_P#6_P#Y+H_XBEP_
M_P ^JO\ X##_ .3#_B&F>_\ /RE]\O\ Y _*BBOU7_X<8V'_ #[>!/\ O_K?
M_P ET?\ #C&P_P"?;P)_W_UO_P"2Z/\ B*7#_P#SZJ_^ P_^3#_B&F>_\_*7
MWR_^0/RHHK]5_P#AQC8?\^W@3_O_ *W_ /)=<3\!O^"2/A[XV^#;KQ9I>C>$
M+:.VUN\T]H[VYU<N6@D*%ALN@-IQQW]:/^(I</\ _/JK_P" P_\ DP_XAIGO
M_/RE]\O_ ) _-ZBOU7_X<8V'_/MX$_[_ .M__)='_#C&P_Y]O G_ '_UO_Y+
MH_XBEP__ ,^JO_@,/_DP_P"(:9[_ ,_*7WR_^0/RHHK]5_\ AQC8?\^W@3_O
M_K?_ ,ET?\.,;#_GV\"?]_\ 6_\ Y+H_XBEP_P#\^JO_ (##_P"3#_B&F>_\
M_*7WR_\ D#\J**_5?_AQC8?\^W@3_O\ ZW_\ET?\.,;#_GV\"?\ ?_6__DNC
M_B*7#_\ SZJ_^ P_^3#_ (AIGO\ S\I??+_Y _*BBOU7_P"'&-A_S[>!/^_^
MM_\ R71_PXQL/^?;P)_W_P!;_P#DNC_B*7#_ /SZJ_\ @,/_ ),/^(:9[_S\
MI??+_P"0/RHHK]5_^'&-A_S[>!/^_P#K?_R71_PXQL/^?;P)_P!_];_^2Z/^
M(I</_P#/JK_X##_Y,/\ B&F>_P#/RE]\O_D#\J**_5?_ (<8V'_/MX$_[_ZW
M_P#)='_#C&P_Y]O G_?_ %O_ .2Z/^(I</\ _/JK_P" P_\ DP_XAIGO_/RE
M]\O_ ) _*BOV^_X(I_\ */;PI_V%-5_]+IJ\8_X<8V'_ #[>!/\ O_K?_P E
MU[?\%/V3OVO_ -G;X>VGPJ^#GQ;\":/H%C++):V']B75QL:1S(YWSN[G+,3R
MQQGC KY+C+C7*N(<JCAL-":DIJ7O**5DI+I)ZZ]CZGA'@_,\@S.6)Q$X.+@X
M^ZY-W;B^L5IIW/J:BO!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\
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M^JO_ (##_P"3/RS_ (AIGO\ S\I??+_Y _*BBOU7_P"'&-A_S[>!/^_^M_\
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M?\.,;#_GV\"?]_\ 6_\ Y+H_XBEP_P#\^JO_ (##_P"3#_B&F>_\_*7WR_\
MD#\J**_5?_AQC8?\^W@3_O\ ZW_\EUQ.A_\ !)'P]K7QWUWX*1:-X06ZT71+
M74);E[G5_)=9F("J!=;MPQSDX]*/^(I</_\ /JK_ . P_P#DP_XAIGO_ #\I
M??+_ .0/S>HK]5_^'&-A_P ^W@3_ +_ZW_\ )='_  XQL/\ GV\"?]_];_\
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MP7XY^.>J:7#H_P /3J$=W+X5\-Z7;M!86T\L9*&ZE\R2:94)5691P=R+]D4
M?,7[8?\ P3\U3]N;]H?PFGQ_^(DU[\!/#GAJZDU/X4:;J-W9?\)'XB>=!#/J
M,D#K]ILH;<-LMRP'G'<P=?EKP/\ 9'^&/@;]D+_@M3X@_8\_89O=0LOA(OP,
M77_BA\/H=8N+S1O"?B%]02/3GMEF=_L-S<VWFLULA57B19-F I'7_P#!6O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 445\W>.O\ @H/_ ,(7XVUCP=_PJ/[3_9.JW%E]I_M_9YOE2LF_
M;Y!VYVYQDXSU- 'TC17RS_P\M_ZHK_Y<?_W-6KX%_P""@_\ PFGC;1_!W_"H
M_LW]K:K;V7VG^W]_E>;*J;]OD#=C=G&1G'44 ?2-%%% !1110 4444 %%%%
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MNIOV>_C]?>'/&?QTO$M7>TMM5\)M)+#:.5^2,7[+I2L#AI?(E/S;&( /'O\
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MZ#)XBUFT ^VV.CPI87*R^2S",W%P\$+R;E4D*7J/QU_P6&\$ZA^RQ\$_CO\
MLW?"6Y\6>(OV@?%<?ACP%X3\1:U'HL5EJJBX%W#J5VR3"W^S26D\3B-)7>1
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M1GB[2[J7Q1\+?[7_ .$0N8KUXXH/[2M5M;OS(P=LNZ) !N^Z>17?T4 %%%%
M!1110 4444 %%%% !7 ?M.?LT?"C]KSX-7_P&^-FEW5[X<U+4-.O;JWL[U[>
M1IK&^@OK<B1"" )[:(D=P"#P:[^B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KPCQ?_ ,C;JG_81G_]&-7N]>$>+_\ D;=4_P"P
MC/\ ^C&H SJT?"'_ "-NE_\ 81@_]&+6=6CX0_Y&W2_^PC!_Z,6@#W>BBB@
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M'*JQV7B3R-*@E,D\AVQ22,+F .Q&]YQ&#ND (!]P_"?_ (*>_L5?&;X#^/\
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M=)\0^,])O];U601Z?IOB&_TB*/27G=_D1G\N\BB9L;7?.1G( /HS]FO]O?\
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M?A5X?6PN5B-\]M'HVL1I+,D=P=TES#&C@"/>V#O^4 ^_**** "BBB@ HHHH
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MY9#*MGYX7S/($A+B+.P,2V,\US/Q<_9-_97_ &@/$.F>+OCS^S1\/_&VK:(
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M:.UN;I(V7SQ;H]ULB?,9:XWE2T:$>81>./$W[.'P?^//_!"WP3J\NF>)]?\
MC;:^%?@R8#AK3P7XR:;49IX?XF73[5-=#.HPC6\0XR,@'[ 45F>"?!OAKX<^
M#-(^'O@O28K#1]!TNWT[2;&$82VMH(UBBC7V5%4#V%:= !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7Q'\5_V0_VB/$OQ2\2^(]$
M^'OGV6H>(+RYM)O[6M%\R*2=V1L-*",J0<$ CO7VY17RW%/".6\78>G1QDYQ
M4&VN1Q3NU;6\9'-B<+3Q22DWIV/@/_ABC]IO_HF?_E9LO_CU=!\*/V0_VB/#
M7Q2\->(];^'OD66G^(+.YNYO[6M&\N*.=&=L+*2<*"< $GM7VY17Q^'\'.&,
M-B(5HUJUXM-7E"UT[_\ /LYHY7AXR33>GI_D%%%%?K)Z04444 >5_MC?LA?"
M_P#;@^#!^!7Q?U+6K31CX@TO6/.T&[CAN/M%A>17<(W21R+L,D2AAMR5) (/
M(9^V;^QS\*?VY?@J?@E\6K_6=.MX->T[6]&U[PU=QV^I:/J5C<I<6]W:RR1R
M+'(K(5R4;*2.,<YKU>B@#YV_:8_X)M?"[]HCXS:;^TGX:^,WQ)^%7Q)L-"_L
M2Y\=?"KQ!;V%YJNF;S(MG>QW-M<6US&LA9TWPED8_*PP *WA[_@E'^Q[I?[+
M?C#]D_Q/X<USQ3I'Q"U8ZQX\\3>*/$,USKVNZOOC=-3FOP5D6YC>&%HFCV+$
M8EV*HR#])44 ?*G@+_@DW\.]'^)7@[XD?&O]K'XY?&(?#W64UCP1H'Q4\:6U
MYIVDZG&C1PWWEVMG;M=7$2NXCEN7F9"Y8?,=U'Q0_P""2OPH\8?&'Q;\9OA!
M^TO\:?@[>?$*=;GX@Z1\)?&<&GZ?X@NP@C:\EAN+6?R+IHU57GM6@D;&XL6R
MU?5=% 'S+X[_ ."3/[*'B'X*?#'X+?#'_A)_AE_PIF^DO/A?XK^'FMBUUC09
MYD=+ITGN(YUG^TK+)YXN$E$Q=BX).:=\(/\ @EI\%OA3^TUX?_;)U7XN_$GQ
MI\3M$T/4](NO%WC7Q!;W4^K6=YY'[B=(K:**** P;H8K5((D:>=RCM*S'Z8H
MH \>_9[_ &'/@3^SK^RO=?L;Z'I][XA\#:@^N?VG8>*I8[E[V+5KRZN[R"4Q
MQQJT;-=S(%VC"8!).6/D_P &?^"-WP"^$?C/P-K.K_'GXP^.O#7PMU!+_P"%
MWPX\?>-([[0?"MU$C1VTUO$MM'-,]M&[) ;J:?R0?DP0"/KFB@#S/]G3]E+X
M;?LPZU\2==^'FHZO<3?%/XCWGC;Q&-5NHY%BU&YMK:WD2 )&FR$):1$*V]@2
MQ+'( /V/?V4OAM^Q)^SSH?[,_P (M1U>[\/^'[G4)[*?7;J.:Z9KR_N+Z7>\
M<<:D"6YD"X484*#D@D^F44 ?/'[0W_!.3X?_ !R_: M?VI_!?QW^)OPI^(*>
M&E\/:KXD^&&MV=NVLZ6DK316UY!?6EU!*(Y))&201K*N\@/@ #EO"W_!&W]D
M_P '?#OXY_#71O$?CI[3]H?PW:Z3\1[Z_P#$:7=[</%;W,$E^EQ/"[F[G^UR
MR2R2F12^W:B*-E?6%% 'CWQW_8E^$?[0_P"SYX;_ &:_'.JZ[!H'A;5] U'3
MI]-O(H[IY='N8+BU$CO$RLK/;H' 4%@6 *Y!''_'[_@F5\,?C1\>[O\ :;\"
M?'CXJ?"3QKK6B0:/XOUCX3^)K?3SXFLH"WV>.^CN+:X1WB#NL<\8CG16*B0
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M/GQ5^#_CK6-$@TCQ7KWPE\2VUB?$=G!N^SI?0W=K<PRO"'=8YU19D5MHDV@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$M+2'QII5[J=@;>6:!HWALY;JUN7@E\I?W1&^,@X( /UBHK\\_B]XU_X*"_
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M3?CGKUEXBUZ^\?:CJ\6H^&=42QAM98(1:VKC5;%#$7AB>2S90[+N&2U?<U%
M'XR?M<?LC?%3]C+]EKP%^QA\8_CSX*U+4/B[^VEJOB\>.OB(&7P?J=DT5SJ(
ML_%%N4B28W3KQ8HPBDN$BQ+M0BO4?@)\7O&_[!OQW^'/[+=S\+OV*]7\,?'+
MQB/#NK^'?V8=$N-%UN+S+2YE_M2YL&EN$N;&%(V261G4QK*I!P=M?ICX_P#A
MS\/?BOX5NO GQ2\":-XET.] %[HVOZ7%>6EP <@/#,K(^",\@URWP>_9)_93
M_9YU&XUCX ?LR?#WP-=W<9CNKKP?X+L=,DF0G)5VMHD+ GG![T ?'WP:_8B_
MX*W?LA? J?\ 84_93^.?P9_X5AITEW9?#_XE^+(M4?Q7X5TFXFDD6(V$<1L]
M0N+82E896N(4;8A>/ *U]W> _#VJ>$? ^C>%-<\77WB"]TS2K>TO->U18UN=
M2ECC5'N91$JQB21@78(JKEC@ 8%:M% 'YF>&=&_;87_@MG^UWXU_8OUOX?7-
M[I_@[X;6FN>$/B7/>VFG:FD^GZDT5RMY9132P36[0.%7R9$D2YD!V%48='=?
M\$>OCUK?[(GBOPGXR^+GA/5?C'\4OV@]"^*'Q(UZ.&YM='B:RU2RN/[-L5V2
M3>1#:V@BA,@W.[%G*!OE_0:UT/1;+5+K7++2+6&]OEC6]O(K=5EN!&"(P[@9
M<*&8#).,G'6K5 'S-_P4$_8P^+7Q\\:?"G]J']EKQQX?T'XO_!+7K^^\(/XP
MMYI-'U:QU"U^R:CIEY]GS+%'-$(R)HU=HVB4A#G(\9^)'P$_:@\$:E\4?^"J
MO[?&K:#+XF^'/P&U_1OAWX"^!5U>7"Z):O"UU>W\5[?0Q2SZC,88XT;R(XX4
MCZ2$EA]_T$!@589!Z@T ?AY^RCH'C[]BK]D'PM^VOX"\3?\ !-O6]2\-_#Z+
M49?&-[HEQ:>*M3<6GFS1SZU'<N9]2E):-Y/)5I)20R\X'Z%_L4?"WXC_ !:_
M:CN/^"INNZ1:^'M"^,W[//@RUM/!=[+*=5T>\C-U?317 :)4VJ+U$!#;BR-E
M$XKUZR_8$_83TSQH/B3IW[%7PEM_$0N1<#7X/AQI:7HF!+"3SQ!YF[))W9SD
MUZU0!\*?!G]BC_@H_P#LB^-?B]X&_9A\9?!BX\%_%CXJ:QXVA\?>+FU,^)/#
M\^J.KSH]A% UMJA@(Q TEU "%4."!MKG_@E_P2'^/'PH_9"_97_9LO\ XG>&
MM1OO@#^T?=^/=>U>>]N7_M72I+S7IT2,_9U+7A758-X94CW))A\;<_H710!\
M_:W^R7X]U/\ X*D^'?VY(=?TA?#&D? K5/!-QI;2R_;WOKG6+.^295\OR_)$
M=LZDEPVXKA2,D<)IO[!/[2_A[X@_M9?$#X8?M&6'@/6_CGXBT+5?A[XHT;3E
MU"YT)]/TFTLV%W;740B=9)+=U949B8925>-\%?KRB@#X#^(G["'_  4*_;2^
M+OP@\1?MK:9^SOX:L/A/\2-+\8MXO^%QU:]\0:O/I[F2*SB-];0C3K:9\><H
MFN"5 4'C)^_*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *X+6/C?_9.KW6E?\(QYGV:Y>+S/MN-VUB,XV<=*[VO
M!?&/_(W:K_V$I_\ T8U?.\18_%X"C"5"5FV[Z)]/-,#M/^%__P#4I?\ D_\
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MT#Q%X"^*DVNW&B:U<0336EIJ%O/IMH&67R'3SH'=$8 $'<* /L*BOB?XA?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-1T'3ET:]NYM1BM9K6"5(%MH9/,F\V]M42!<RRM*!&CX;&-\"O\ @I?^QO\
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M302^(+/2?AYIEM%J<D,ZW$+W"1P 3,DR)*I<$JZ*PP0#0!\V?LZ>"?"VI_\
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MAX4\/>%K2RTVZ69-DPDM88UB<.ORME3N'!R* /S*_:B^%^G>$/\ @VA^ /\
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M#TO7;_PO\)OB!_:FHZ1=)=VEG<W4.F-% TL99/.58ED>+.]4FA9@!*A/F/\
MP3Q_:8_85^!?_! N?X3?MJ3:;>W/A.W\0^&/C-\+)IXI/$&IZ_+JEVMQIXM&
MECEFO+J256B^92?-1@ZA2R_I'\.?V7?V9O@]#HMO\(_V=O OA:/PV+P>'8_#
MGA&RL1I8N_+%U]F$,2^1YWE1>9LQYGE)NSM&*^K?LD_LIZ]\8K?]HC7/V9?A
M[>_$"U=&M?'5WX+L9-8A9!M0I>M$9U*C@$/P.!0!\E7/B7P-\,O^"\W@;4O%
M%S!X1TC4OV)KS3]"@\17B6Q$L/B2RF:SW.Y5IHH<,RAF("ELD FO-M>\.?\
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20240930_g2.jpg
<TEXT>
begin 644 biib-20240930_g2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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MN:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/#>A?%;Q=\-_[1UWPUIMW>:*5T^XE%['%?WS);*8+MXU 6UF,D<C%2/U'HH
M^!?VO_\ @FY^VSIO['?PF_8%_P""9_Q?\)>$_AEX3T<:5\04\7:]J.GZQXBL
M8EB$=K'?:?;2O;QW!^T-<M$(I&WJL;(I<5WO[%OPC_X*6_L^2^$?@KKGP6_9
M5\'_  AT*-K:XTGX8:GKXO;6 1N5-O'<VJ1/(TI5G:1LMN=B68Y/U[10!\Q_
M!?4/VP?BU^U1^TY\-OBI\1;>W^%-BNCZ+\+-1\,6?V/4])N[C2C+J6+AHAYL
MT1N+61)09$1WV [HY$7S:Q^!W_!=?0OA&W[+ME^T;\"M5TU-.;1[7X[ZU;ZR
M?%8L2AC6\ETI8S:3:@J'/FF[$;R .R'YL_<M% 'QO>_\$Z_VA/V7O@S\%/!G
M_!-3]HF'09O@MX?FT67P5\0WN9?#?C>TG1?-DU%;0AX+L3!IX[F)&V-+(OEL
MC8&?H_[%G[=_[4O[6?PN_:._X*$^*OA3H6@?!;4[S6/!?@+X17.I7_\ :>L7
M%N;=;N^OM0@MV5(49BD,4(W,V7<@;:^V** /BFR_8Z_;[_8X^,?Q+\0?\$ZM
M=^$6L^ _BQXLN/%VI>#?BU>ZI8MX8\07*J+VYLIM/@G^TVUPZ+,UM((MDF[9
M( QKJ?@E^Q!^T/\ LD_L1>._ O[/OQC\/ZK\?O'VN:EXNU_XB>+-+>/2]0\4
MW\J--.]O$LC16J1HD$42AML<*=\U]6T4 ?+WQQ_9^_X*):]HGPF^-/P._:;\
M.:;\4_!'AP67C[P=KRWI\$>-IY[>%;MI8[?;-;/'<1M);7*QLR*Q1HV5B!Q.
MB?L6?MW?M1?M;_"_]I/_ (*$^*OA5H6@_!;4+W5O!7@'X1W&I7XU+5[FW-LM
MY?W^H06[!(8V8I#%" S-EW(&T_:]% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8?M*_ME_LV?L@6
MFD7W[17Q(_X1V+7I)H]);^Q[R[\]H0AD&+6&0K@2)][&<\9P:\G_ .'UG_!,
MK_HY;_RS=:_^0Z^:?^#E3_D5/A%_V$=:_P#1=G7Y05^V\'>&V1\0\/4<?B:E
M13GS747%+23BK7@WLNY^%\:>)V?<.<1ULOPU*DX0Y;.49M^]",G>TTMWVV/W
MU_X?6?\ !,K_ *.6_P#+-UK_ .0Z/^'UG_!,K_HY;_RS=:_^0Z_ JBOI_P#B
M#G#'_/ZM_P"!0_\ E9\K_P 1JXI_Y\T?_ 9__+#]]?\ A]9_P3*_Z.6_\LW6
MO_D.C_A]9_P3*_Z.6_\ +-UK_P"0Z_ JBC_B#G#'_/ZM_P"!0_\ E8?\1JXI
M_P"?-'_P&?\ \L/WU_X?6?\ !,K_ *.6_P#+-UK_ .0Z/^'UG_!,K_HY;_RS
M=:_^0Z_ JBC_ (@YPQ_S^K?^!0_^5A_Q&KBG_GS1_P# 9_\ RP_?7_A]9_P3
M*_Z.6_\ +-UK_P"0Z/\ A]9_P3*_Z.6_\LW6O_D.OP*HH_X@YPQ_S^K?^!0_
M^5A_Q&KBG_GS1_\  9__ "P_?7_A]9_P3*_Z.6_\LW6O_D.C_A]9_P $RO\
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M_P V%%%%>8>R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.G_A7Y'YAF7_ ",*O^)_F%%%%=1Q!1110 4444 %%%% !1110 4444 %%%%
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M *]+_P!+F?TUX*_\DU7_ .OS_P#2(!1117Y&?L04444 %%%% !1110 4444
M%%%% !1110 4444 ?CK_ ,%<O^3[?%?_ %XZ9_Z0PU\TU]+?\%<O^3[?%?\
MUXZ9_P"D,-?--??8'_<Z?^%?D?F&9?\ (PJ_XG^84445U'$%%%% !1110 44
M44 %%%% !1110 4444 ?H'_P09_Y&/XF?]>.E?\ H=U7Z.U^<7_!!G_D8_B9
M_P!>.E?^AW5?H[7Q6<?\C"?R_)'Z'D'_ "*X?/\ -A1117F'LA1110 4444
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M_0=1_P#!L/\ Y(/]4^*?^@"M_P""I_\ R)RM%=5_PIOQ?_T%O"O_ (76D_\
MR31_PIOQ?_T%O"O_ (76D_\ R31_K3PQ_P!!U'_P;#_Y(/\ 5/BG_H K?^"I
M_P#R)RM%=5_PIOQ?_P!!;PK_ .%UI/\ \DT?\*;\7_\ 06\*_P#A=:3_ /)-
M'^M/#'_0=1_\&P_^2#_5/BG_ * *W_@J?_R)RM%=5_PIOQ?_ -!;PK_X76D_
M_)-'_"F_%_\ T%O"O_A=:3_\DT?ZT\,?]!U'_P &P_\ D@_U3XI_Z *W_@J?
M_P B>V?\$>_^4D7PO_["-[_Z;KJOZ!J_G^_X)N1Z1\ _VVO ?Q=^+7CCPKI/
MAW1;VZDU+4/^$OT^?R5>RGC4^7#.[MEW4?*IZYZ9-?L+_P /2/\ @GS_ -'6
M>%?_  (D_P#B*_ /%?,,!F.?4:F$JQJ15))N,E)7YYNUTWKJM#^B/"++LPRW
MAZM3QE&5.3JMI3BXMKD@KV:3M=/7R/?**\#_ .'I'_!/G_HZSPK_ .!$G_Q%
M'_#TC_@GS_T=9X5_\")/_B*_+S]5/?**\#_X>D?\$^?^CK/"O_@1)_\ $4?\
M/2/^"?/_ $=9X5_\")/_ (B@#WRBO _^'I'_  3Y_P"CK/"O_@1)_P#$4?\
M#TC_ ()\_P#1UGA7_P ")/\ XB@#WRBO _\ AZ1_P3Y_Z.L\*_\ @1)_\11_
MP](_X)\_]'6>%?\ P(D_^(H ]\HKP/\ X>D?\$^?^CK/"O\ X$2?_$4?\/2/
M^"?/_1UGA7_P(D_^(H ]\HKP/_AZ1_P3Y_Z.L\*_^!$G_P 11_P](_X)\_\
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MV?C_ /GU+_P%_P"14HJW_95I_P!#EX5_\+'3O_C]']E6G_0Y>%?_  L=._\
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M^RK3_H<O"O\ X6.G?_'Z/KN#_P"?D?O7^8?V?C_^?4O_  %_Y'WQ_P $&?\
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M'?"O_A/6W_Q%=310!RW_  HSX)?]$=\*_P#A/6W_ ,11_P *,^"7_1'?"O\
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M-% '+?\ "C/@E_T1WPK_ .$];?\ Q%'_  HSX)?]$=\*_P#A/6W_ ,174T4
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MK_X3UM_\11_PHSX)?]$=\*_^$];?_$5U-% '+?\ "C/@E_T1WPK_ .$];?\
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MJ.H_8._;NTC]M31/&6B:Y\)=:^'GQ!^&?BEO#OQ'\ :]=0W,VD7WEK+&T5S
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M@^'=M;WOBKX?ZYJD%_')IUQGR-2L+Z#$=]:,04,BJC1N-CHI(SXI_P $F_\
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M" ?J!167X'\7Z3\0?!6C^/= $PL-;TNWU"R%Q'LD\F:-9$W+_"VUAD=C6I0
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M 6B?#K0)9Y+'0-(MM.LGNG#2M#!$L2%R  6VJ,D #/85KT44 %%%% !1110
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=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20240930_g3.jpg
<TEXT>
begin 644 biib-20240930_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHK%\>?$;P'\+]%A\1_$7Q=I^BV%QJEGIL%WJ5RL
M4<EY=W$=M;0!FX+RSRQQ(O5F=0.30!M4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]5N)_P#H!K?^"I__ "(?ZV<+?]!]'_P;#_Y(^IZ*^6/^'UG_  3*_P"CEO\
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MY^?^"/?_ "DB^%__ &$;W_TW75?T#5_-_C)_R4=#_KTO_2YG]->"O_)-5_\
MK\__ $B 4445^1G[$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YA?\ !RI_R*GP
MB_[".M?^B[.OR@K]7_\ @Y4_Y%3X1?\ 81UK_P!%V=?E!7]7>&/_ "16&]9_
M^G)'\B^*?_)<XKTI_P#IN 4445]\?GH4444 %%%% !1110 4444 %%%% !11
M10!]+?\ !'O_ )21?"__ +"-[_Z;KJOZ!J_GY_X(]_\ *2+X7_\ 81O?_3==
M5_0-7\W^,G_)1T/^O2_]+F?TUX*_\DU7_P"OS_\ 2(!1117Y&?L04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1161X
M^\?>#OA=X.U#X@_$'Q!;Z5HNE6YGU'4;HD1P1@@%F(!XR10!KT5X'_P](_X)
M\_\ 1UGA7_P(D_\ B*/^'I'_  3Y_P"CK/"O_@1)_P#$4 >^45X'_P /2/\
M@GS_ -'6>%?_  (D_P#B*/\ AZ1_P3Y_Z.L\*_\ @1)_\10![Y17@?\ P](_
MX)\_]'6>%?\ P(D_^(H_X>D?\$^?^CK/"O\ X$2?_$4 >^45X'_P](_X)\_]
M'6>%?_ B3_XBC_AZ1_P3Y_Z.L\*_^!$G_P 10!\??\'*G_(J?"+_ +".M?\
MHNSK\H*_1W_@O+^U9^SM^TEX<^&=I\"OBWI/B:32+W57U)-,D9C;K(EJ$+9
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MO_A/6W_Q%'_"C/@E_P!$=\*_^$];?_$5U-% '+?\*,^"7_1'?"O_ (3UM_\
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M5(8PQZG:@ R?6KM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M M$^'6@2SR6.@:1;:=9/=.&E:&")8D+D  MM49( &>PK7HHH **** "BBB@
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20240930_g4.jpg
<TEXT>
begin 644 biib-20240930_g4.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
M\ )8 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BN%_:>_:!\$?LH_L[>-OVE/B0
M[C1/ _AF\UG4(XC^\G2")G$*>LDC (H[LX%?*?[5'[4/[:?[,O[/'[)>J>,/
M&FGP>//BE^TEX,\,?%&*'1+<P16&KO=37FEP*R'8L $=ND_^N*P!V;>[$@'W
M-17SU\;?^"IG[$_P"^(WB+X+^-OB9JMYXW\+R6*:IX*\->"]6U;56^UVQNH6
M@M[2VD:Y00KODDBW)#N02LC.@;TW]G/]I+X)?M:_"+2_CM^SUX^MO$GA?5_,
M6TU&WADB99(Y&CEAEAF5)8)4=65XI%5U(((% '<45Y3^T?\ MN?LO_LD:WX>
M\-_M"?%%/#U_XKM=0G\-VC:3>73ZB+(0>?'%]GADS-FYMTCA_P!9,\JI$LCG
M;7F>D_\ !8[]@O7? NI>+]'\?>)[C4M(U]M%U'P%%\.-:/BJ"^6'SS&VB?9/
MMP7R?WIE\GR@O)<8( !]145\M?'3]NOX.?$[]@NR_:Y_9J_;3TOP5X7U;Q)H
M]I9?$67P+<:TL3RZM!926$NG%!-%-+*YM6\Q%:!I-[ !":NZ7^TE\6[K_@L9
MK?[(,VNP'P)9?LTZ9XPM],^PQ>8NK3>(+ZRDF\[;YA4P01KLSM!&<9)- 'TQ
M17Y]?LE_MU?&;XS?\$U/V7/VC_C5^UEIO@CQ7\2/C!I^C:YJ+?#T:BGBP2:O
MJ%LNA1Q6Z!-/>YC@C07N L)C+$_-7T;^TO\ \%)_V2?V4/B#;_"+XF^+]=U'
MQ?/I)U:7PIX(\%:IXAU&STT,5-]<P:;;SM;6^00))0H;:=N[!P >\45XO=_\
M%$/V+;/]F_PW^UY)\?\ 2)/AMXLU>QTO0O%MM#/-;2WEW="UABD"1E[<^>?+
MD,JH(65O-,>UL8?[/_\ P5(_8I_::^,,7P)^%?Q,U,^)+_39M2\.VVO^#M4T
MF'Q%918\VZTR>]MHHM0B7():!G^7YQE/FH ^A**^9/C)_P %??V$O@9\0?$?
MP[\8_$#Q)>R^"K@6_CS6?"WPZUO6=)\+R[ YCU"_L;26WM756!=7?=&#\X6M
M#]K/]K'4/@AH'PD_:M\#^-],U?X1:WXMTS2/'$]J(IK>32]<:*UTW6H+E<D+
M#>RV8.TF-X+R9B"R1D 'T71110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!\<_\ !?B*[;_@D_\ $R^B5FM=/U#PSJ&LJH/.FV_B/3)[W./X1;1S
M%O\ 9!KFO^"Y,B2VO['\L3AE;]NCX=E64Y!&^]YK[+^*_P +_!'QM^%_B/X-
M_$O1(]2\.^*]#NM(UW3Y3A;BTN8FAECR.1E'89'(ZBN%^ _[-1\,_L\?#_X-
M_M*'0?B/JWPXEM3HGB35M%CF=Y[!GBT_5-LRMY&H"W$;/+&01,TI0A6% 'SK
M^Q9X7\/S_P#!<#]MKQK/I$#ZK:^&_AE96U^T8,L-O+I-Y)+$K=0KO#$S#N8D
MS]T5H?\ !%P".V_:KM8U"Q0_MI>/1%&HP%!>S<X';+,Q^I-?7NC_  ^\!>'O
M%NL^/M \$:18Z[XB6V7Q!K5GIL45WJ8MT9+<7$RJ'F$2,RIO)V!B%P":/"/P
M_P# 7@#^T_\ A _!&D:)_;>KS:KK/]D:;%;?;[^;'G7<WEJ/-G?:NZ5LNVT9
M)Q0!\<?MVZ-I6L?\%E/V%#JNGPW'V1/B=<6PF0,(Y5T*S"N ?XADX/8\CFH_
MV=O#>@#_ (+[_M)>)QH]L-03X'^!8UO1"/,"2SZCY@W=<-]G@SZ^2G]T5]EZ
MQ\/O 7B'Q9HWCW7_  1I%]KOAT7(\/ZU>:;%+=Z8+A!'<"WF92\'FHJJ^PC>
MJ@-D"BP^'W@+2O&FH?$C2_!&D6WB+5[."TU77X--B2]O;>$N88I9POF2)&9'
M**Q(7>V ,F@#\;/B=%%:_P#!*O\ :LL+:-8X+?\ X*/7D<$*+A8T_P"$]T@[
M5 X R3P/6OM;0_\ E8G\3?\ 9E^B?^I9JE?4US^S]\!KWPWJG@V\^"7A&72-
M;\0'7=:TJ7PW:M;7^JF=+@W\\1CVRW)FC27SF!?>BMNR :UT^'_@./QY)\4X
M_!.D+XGFTA-*E\1KIL0OWL$E:9+0W&WS# LKO((RVT,[,!DDT ?C;\ ?^4+7
M_!.O_L\3PK_ZD6L5]0_L2?$[X:_L_P#_  52_;1\)?M+>/M$\,^,?$_B3P[X
MD\.7WB;4HK/^U_"B:0D%N]M),RB6&VE2XBDVDB-R=V":^VK']G[X#:9X1T'X
M?Z;\$O"-OH/A758M4\,:)!X;M4M-'OHY'DCNK6$1[+>97D=UDC"L&=B""2:H
M_&O]E?\ 9A_:4_L__AHO]G'P'X__ +(=GTK_ (37PA9:K]B9L;C%]JB?RR<#
M)7&<4 ?C=XI\+:!\4?\ @GI\6O&%AI$5Y\(OBK_P4DTO4?A[#)!_H>KZ'/KV
MFVUQ=6ZD8-I<7$=T5  4_.<?-S]\?\%&HX[/_@HM^PK=VL2QRQ_%3Q1!'(BX
M*QOX5OPZ ]E( R.AP*^M=<^$WPK\3^%M/\#>)?AIX?U'1-(N+6?2M'OM&@FM
M;*6V96MI(HG0I&T3*K1LH!0J"N,"K/B#X?\ @+Q9KVC>*?%7@C2-3U/PY=27
M/A[4=0TV*:?2YY(VB>6WD=2T#M&S(60@E6*DX)% 'Y=IHTW@3X@?'_XC?\$U
M_P#@KE\//!.FW/Q.U[5_BO\ !#]H'P5;/86GB-R!J,KSS26]_9V<YC# [)(F
M4EHV(K9_:V_:&U#]K;_@U_O?C=)\'+/P)JOCKP!H]MHG@_1[<P6UKJ$VLVMG
M8BSCQE(9)O)E@7DB.2/D_>/WK\4OV*_V-_CEXV@^)?QK_9+^&7C#Q':JBVWB
M#Q3X#T[4+V)5QM"SSPO(H&!C!XQ6/^TI^RO-^T?XW^%6GZWK=G:> ?A_XOC\
M5ZOX=BMSYFL:E8H/[)@)&$2V@G<W3+@EI+6V4#;OH ]CB$BQ*LSAG"C<P&,G
MN:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\*_\%&?^"MWCS]GOQ9J/P8_9!_9SU[XC
M>*_"'C?P9I7Q U4-96VCZ,=:U.SB@TLS75S"9+^YM[E1'Y:O'!]IBEF94#"O
MNJOR?_X*S_LTZ+XC\1>,OVH/V$_VV4T3Q-J?QY^&F@?%_P  FSM=8T:7Q+;:
MYH\&F7=S$=L]E<VZR6;R+%(!/' (V )9J /T#_9L_;(\!?M!_!_7/BQK_A#Q
M#\-Y/"&JWFF>.=!^(]I'I]QX?N[5%>?SI1(UO) (W61;F*5X71@0V0P7R_\
M9%_X*U_!']MO]L+QA^S%\"?".KWNA>%_!-MXBT[XCW*F'3_$<4M[):,UA&Z!
MI[99(I%6Z!V2-')L#*%D:#]AKX\?$3]M3PA\9_V1/V]_A9X&U/Q7\,/%@\(^
M/D\+PRW'AOQ/:7-C!>0RQPW6YTWPSA)K:0OM92"<-M7BOA'I>F:'_P '"7Q(
MT71=.@L[.S_9+\,06EI:PK'%!$FN7ZJB*H 50   !@  "@#[IKY7^-?[7?\
MP4H\!_%'7/"OPC_X)&WOCCPQI]V8])\7CXZ:!IBZG"%!\[[-<?O(1DD;7YXS
MWKZHKX\_X+1?%+QE9_ #P;^R%\+/$=UI/BC]H_XE:9\.;?5[!\7&EZ5=%Y=6
MO8_0QV$-P@8<JTR,.E &G^Q__P %1;;XZ_L6>-?VZ_VC_@>_P@\%>#;W5!]N
MNO%=OK4&J6&G@K/?VLUK&JS0F9)88C'O$QCS&6#H3PK_ /!6;]KCPWX!TO\
M:;^)W_!)CQSHGP5U26VE?Q+:^-K+4/$VG:;<NJPZA=>'H(C*D>)$=XHYY9HU
M))C^4BL7_@X%\#V/P2_X(>>+O WP8\ VR^%_!3>$8&\,6Q\N#^Q++6].#6V>
M=L0CC57/.(PY.1FLO]L_X(?MR_L@_LB^*_\ @HCHO_!3OQOK'Q)\ >'W\5:]
MX5U2#3QX"UB"!1+<:3;Z8MNLEO"\8:*"83M<;BK-(S-D 'O_ .U'_P %"/$_
MPQ^/.B_LB_LI_LU:A\8_BKJWAC_A)K[0H?$D&B:9H.B&8P1WE_J$Z2"'S90R
M111Q2R/Y;G:H +7_ -D']O/6OCS\6?%'[+G[0?[/6J?"+XO^$=(MM:O_  7J
M.N6^JVNI:/<2-%%J>G7]N%2[M_-1HG)2-XY,*R@FO&O'OP]_:^\)?M;:'_P5
M$_8M^$7A_P >+\4O@YI&D?$;X/>)?%J:)J<"PN]U9WUE>21/%NC^UR0RQ2JB
MG:I4[F^7S7X(+^UA\1?^#A7P]\3/VA-(\/\ A?6;7]E_5?[2^'WA;63J<7AS
M1I-:M5L8[R_\N);F]N+H74K*D:QI';QA"^UI& /TYKY'^/G_  5J\!_!W]O[
MX??L&>&/A+J7BFZ\5>(;70_%?B^TU-(+'POJ-W:3WEI9R*48W%P]M;23M&I7
MRHW@9C^^45Z'_P %)/VM_$?[$O['OBOX\^!/AGJOC#Q-:PQV7A;0-)T>YO3/
MJ-PWE0R31VR/(+:,GS92HSY<;!<NR@_E7\1?VI/V)_@3J_['/AS0?B1\0O$^
MOZ'^T-<^,OC#XTU?X'^++&[\0ZQ>:5>B]U!8[C2XY+EFFD1([>!9)(X(XU"[
M(L@ _<FBLWP9XNT/Q_X/TGQWX9DN'TW6]-@O]/>\L)K69H)HUDC+PSHDL+;6
M&8Y%5U.0R@@@:5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 RXF%O ]PR.PC0L5C7+' S@#N?:OR ^$'[7/_!4C]NS]I#X/_M1?
ML[?'_P"&.@1>./@]X]UWP9\);SP]>WFEPV^GZOHENNFZQ=1W\9?4)#*@:Y2)
M/LA65%CD$K$?KOKVHWFD:%>ZMI^BW&I7%K:230:=9M&LMTZJ66)#(RH&8@*"
MS*N2,D#)K\%?VBOB-_P1K^*W[9?AO]HKP;\4-=_9?\7WOPE\9ZA\1[?P;K%S
MX;\6:'XUBO=$%K97-A$1YUVY>_\ W21,MYL9\OL#* ?L#\=_VIOC=\%?@5X.
MUW3/V1O$7C#XI^-/LVGVGP]\+7T<UGINJR6QEF^VZFP6*UL(61U:[9>?D"QL
MSJE>>_\ !&O]I[]I7]JK]F[QGXO_ &L=<T.^\8>'/C1XI\,7+^&[#[/80Q:?
M>>0D4 (#M&I#!7DS(RX+DG-=G^Q)\??B!8?L&?!_X@?M_P#BO2/!_P 0]>\$
M6$OB>/Q)>0:9)+?&%6<O'(4$<[*5>2( ;'9EVKC ^>O^"#?QL^#*?!WXL>$W
M^+GA@:KJO[4_C^72],.OV_VB\CEU9S$\4>_=(KCE2H(8=,T ?>7CWQ+=>#/
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MPCLNO7FIQZLW]CV=WYZPI;&,8NH9 N#(_P!W&<\YP*_/C_A]9_P4U_Z.6_\
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M $<M_P"6;HO_ ,AT?\/K/^"FO_1RW_EFZ+_\AU\L44?ZK<,?] -'_P %0_\
MD0_ULXI_Z#ZW_@V?_P D?4__  ^L_P""FO\ T<M_Y9NB_P#R'1_P^L_X*:_]
M'+?^6;HO_P AU\L44?ZK<,?] -'_ ,%0_P#D0_ULXI_Z#ZW_ (-G_P#)'Z,?
M\$W/^"IG[=_Q\_;:\!_"+XM?'7^UO#NM7MU'J6G_ /",:7!YRI93R*/,AMD=
M<.BGY6'3'3(K]A*_GY_X(]_\I(OA?_V$;W_TW75?T#5^ >*^7X#+L^HT\)2C
M3BZ2;48J*OSS5[)+71:G]$>$68YAF7#U:IC*TJDE5:3G)R:7)!VNVW:[>GF%
M%%%?EY^JA1110 4444 %%%% !1110 4444 %%%% !1110!^.O_!7+_D^WQ7_
M ->.F?\ I##7S37TM_P5R_Y/M\5_]>.F?^D,-?--??8'_<Z?^%?D?F&9?\C"
MK_B?YA11174<04444 %%%% !1110 4444 %%%% !1110!^@?_!!G_D8_B9_U
MXZ5_Z'=5^CM?G%_P09_Y&/XF?]>.E?\ H=U7Z.U\5G'_ ",)_+\D?H>0?\BN
M'S_-A1117F'LA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?F%_P<J?\BI\(O^PCK7_HNSK\H*_5_P#X.5/^14^$7_81UK_T
M79U^4%?U=X8_\D5AO6?_ *<D?R+XI_\ )<XKTI_^FX!1117WQ^>A1110 444
M4 %%%% !1110 4444 %%%% 'TM_P1[_Y21?"_P#["-[_ .FZZK^@:OY^?^"/
M?_*2+X7_ /81O?\ TW75?T#5_-_C)_R4=#_KTO\ TN9_37@K_P DU7_Z_/\
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M ",)_+\D?H>0?\BN'S_-A1117F'LA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?F%_P<J?\BI\(O^PCK7_HNSK\H*_5_P#X
M.5/^14^$7_81UK_T79U^4%?U=X8_\D5AO6?_ *<D?R+XI_\ )<XKTI_^FX!1
M117WQ^>A1110 4444 %%%% !1110 4444 %%%% 'TM_P1[_Y21?"_P#["-[_
M .FZZK^@:OY^?^"/?_*2+X7_ /81O?\ TW75?T#5_-_C)_R4=#_KTO\ TN9_
M37@K_P DU7_Z_/\ ](@%%%%?D9^Q!1110 4444 %%%% !1110 4444 %%%%
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M"-[_ .FZZK^@:OY^?^"/?_*2+X7_ /81O?\ TW75?T#5_-_C)_R4=#_KTO\
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MCJ* -^BOEG_AT/\ LS?]#_\ %/\ \./>_P"-'_#H?]F;_H?_ (I_^''O?\:
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M_#CWO^- 'U-17RS_ ,.A_P!F;_H?_BG_ .''O?\ &C_AT/\ LS?]#_\ %/\
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M.A_V9O\ H?\ XI_^''O?\:/^'0_[,W_0_P#Q3_\ #CWO^-'^L/\ TZ_\F_X
M?ZJ_]/O_ "7_ .V/R%HK]>O^'0_[,W_0_P#Q3_\ #CWO^-'_  Z'_9F_Z'_X
MI_\ AQ[W_&C_ %A_Z=?^3?\  #_57_I]_P"2_P#VQ^0M%?KU_P .A_V9O^A_
M^*?_ (<>]_QH_P"'0_[,W_0__%/_ ,./>_XT?ZP_].O_ ";_ ( ?ZJ_]/O\
MR7_[8_(6BOUZ_P"'0_[,W_0__%/_ ,./>_XT?\.A_P!F;_H?_BG_ .''O?\
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MH?\ 9F_Z'_XI_P#AQ[W_ !H_X=#_ +,W_0__ !3_ /#CWO\ C0!]345\L_\
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M49+7./M,5MJ-O!+/#DC,L:L@W#)Y&0#WJBO#/VGO^"D_[$W['/BZR^'?Q_\
MCA#IOB34+$WMMX8T;0[_ %G5/LH;;]H:STV">>.'=D"5T"$@@'@X[C]G']IS
MX _M=?"^V^,_[-?Q5TGQAX9NIY($U/29B1%.F-\$J, \$JY&Z*15==PR!D4
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@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20240930_g5.jpg
<TEXT>
begin 644 biib-20240930_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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MN:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:[=+GT6 Q?U["QK<MKWTO?9V\@HHHKE.P**** "BBB@ HHHH **** "BBB@
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MN%N;FO:,7>_+'^;:W3<****^1/L0HHHH **** "BBB@ HHHH **** "BBB@
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MQ7I3_P#3< HHHK[X_/0HHHH **** "BBB@ HHHH **** "BBB@#Z6_X(]_\
M*2+X7_\ 81O?_3==5_0-7\_/_!'O_E)%\+_^PC>_^FZZK^@:OYO\9/\ DHZ'
M_7I?^ES/Z:\%?^2:K_\ 7Y_^D0"BBBOR,_8@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH _'7_@KE_P GV^*_^O'3/_2&&OFFOI;_ (*Y?\GV^*_^O'3/
M_2&&OFFOOL#_ +G3_P *_(_,,R_Y&%7_ !/\PHHHKJ.(**** "BBB@ HHHH
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M9/\ DHZ'_7I?^ES/Z:\%?^2:K_\ 7Y_^D0"BBBOR,_8@HHHH **** "BBB@
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M^+OP]U;X:^)KS4+>PUBU-O=3:5>M;7"*2#F.5/F0\=10!OT5\L_\.A_V9O\
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M;WM?8_ FBOWV_P"'0_[,W_0__%/_ ,./>_XT?\.A_P!F;_H?_BG_ .''O?\
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M=#_LS?\ 0_\ Q3_\./>_XT?\.A_V9O\ H?\ XI_^''O?\: /J:BOEG_AT/\
MLS?]#_\ %/\ \./>_P"-'_#H?]F;_H?_ (I_^''O?\: /J:BOEG_ (=#_LS?
M]#_\4_\ PX][_C1_PZ'_ &9O^A_^*?\ X<>]_P : /AO_@KE_P GV^*_^O'3
M/_2&&OFFOUZ_X=#_ +,W_0__ !3_ /#CWO\ C1_PZ'_9F_Z'_P"*?_AQ[W_&
MO?H9Y[&C&G[.]DEOV^1\OB>&_K&(G5]K;F;=N7O\S\A:*_7K_AT/^S-_T/\
M\4__  X][_C1_P .A_V9O^A_^*?_ (<>]_QK7_6'_IU_Y-_P#'_57_I]_P"2
M_P#VQ^0M%?KU_P .A_V9O^A_^*?_ (<>]_QH_P"'0_[,W_0__%/_ ,./>_XT
M?ZP_].O_ ";_ ( ?ZJ_]/O\ R7_[8_(6BOUZ_P"'0_[,W_0__%/_ ,./>_XT
M?\.A_P!F;_H?_BG_ .''O?\ &C_6'_IU_P"3?\ /]5?^GW_DO_VQ^0M%?KU_
MPZ'_ &9O^A_^*?\ X<>]_P :/^'0_P"S-_T/_P 4_P#PX][_ (T?ZP_].O\
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M^'T?PU\#:IK5Y8174MPLVOZM)>W!:0@D&63YB..!VH [2BBB@ HHHH ****
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MA^QA\*O"7CW6_"UY9^$/$T^C&%-,U"2(K#<%XE=T",0<JK$8X!H ^M?V3/\
MDU;X9_\ 9/M&_P#2&&O0*\C_ &(?V/?@]^P]^SUHOP/^#OPWT#PU%%;07/B*
M'PY;&.WOM6^RP0W%WR 6:0PK\Q )"C(%>N4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?G__ ,$P;&S^,7_!3_\
M;6_:3^(=HEYXK\.?$33?A_X;FNUWR:/H%E8)(L%OG_4QW$LC3N%P'<;CR*;K
M&DV'P6_X..M(L?AO:+9V7QM_9MOKGXCZ98_NX[N^TO456SU.4+C,PBD:V$G7
M:<=>:Z[X^_L=_MA?LZ?M2^/OV]O^";>N^"=1U#XC:!:#XI?"?XB)>166N7NG
M0-'::AI]U9J\EM>&']PT;1M%-D%BK88>1_\ !(GQ5\+OV^OBIXY_;@^+O[6?
MAWQ!\??&OPPM_#E]X"\ F;3KCX1>'_-+2:4J3EKE+T7K%YKB0 &:(>4NQ06
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1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20240930_g6.jpg
<TEXT>
begin 644 biib-20240930_g6.jpg
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M&R^_9Y_9^^ FJ_$CQ/H.G07WBU;36;;3K/18IP6@CEN+@[6GD4;UB R5^;(
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M5/#MA<ZEI(F&EZA<6B//9B50LOE2$;H]Z@!MI&X  YJ_2,RHI=V  &22> *
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MRQS7MK- \GG;<&3RW8,V<'G<:_PX_P""<LVJ?LG_ !+^#/[0GC"TO_%'Q?\
M$5[XB\5ZIH<#"UT[4IGCDA^RJ^&:.&2*-QNP6((. 1@ ]]^+/@3PIXF^"'B/
MX;:II=LNBWOA>[T^6T\L")+=K=H]H'0 +TQTP*\C_P""3OBK7O&/_!.[X6ZQ
MXDED>YCT*6S1I2<F&VNI[>'KV\J*/'MBN6UZR_X*=>//A//^S%KWPW\&:==W
M^F'1]6^,L/BXS126C)Y4MW%IODK,+IXB2%+A!(<Y X'2?M)1_%7]B_\ 8O\
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M]XI^-_CC6IM?U>[OG>#3&U&XDC0Q1[L,+>W@!$:M@L4YV[\#RW]G+X6?MX?
MC5-0^(_B']CSPQXT^(FO#_BH_B!X@^+R&\NAG(@A06&VTMEX"P1X4 +DMM!
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M%"J">_ '-6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,+P_\,_ 7A7Q
MIX@^(OA[PO:VFM^*FM6\1:E$I$E^;:+R8#(<\[(_E&.U;M%% !1110 4444
M%%%% !1110 4444 %%%% !4%[IFFZDT#ZCI\$YMIQ-;&:(.8I " ZY'RL 2,
MCGD^M3T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3KB0XCCU!0+@(3T5I$(50>6(P,T[_@KO;GQ/^SYX5^%&CMOU_P 7_%+0=/\
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M'O#FO1WDOAW7M*1[Q=*FGF9YC%!=-^Z*.SX@(18VXVKC%>&_!CX >!_V<_\
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M'S?+L565*E.\GY/UZH]PHHHKWST@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***AU'4M.TBQEU/5K^&UMH5W37%Q*$2-?5F8@ ?6@":BN7\/?&[X,>+
MM5&A>%/B[X7U.^+[19Z?K]M-+N]-B.3GD<8KJ* "BBB@ HHHH **** "BBB@
M HHHH *KW6E:7?7=M?WNFV\T]F[/9SRPJSP,RE69"1E25)4D8R"1WJQ10 44
M44 97BKP1X6\;KIR>*M)6\32M5AU*QCDD<(EU"28I"JD!RC'<H;(#*K ;E4C
M5HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ^&_^"S/^M^'/^[J_P#[95\/U]P?\%F?];\.?]W5_P#VRKX?K\$X
MU_Y*:O\ ]N_^D1/S?/\ _D;5/E_Z2@HHKZ%\%?L8Z);_  \\2ZA\7_BAH'A_
M7[;1+"^LM/N;J=WTA;BYA5)+T11L(_,20*$R67S%9@ #7A8/ 8G'2:I+9-MM
MI)63>[TN[.W^5SSJ&&JXEM06WR6U_P!#YZHKT.T_9O\ &</Q_P!*_9^\1WEK
M9WVJW]M#!J5LXN;>2&<!H[F-E(\R,H0PY!['!R!T=U\!OV6K.YDL[G]MRP62
M*0I(H\ :H<,#@\A<&KAEF,FFVE&S<7S2C#5;KWFMKZV*CA*\KW25G;5I:_-H
M\9HKNOA'\"]5^,7BS5-+T'Q)8V6B:';R7FL>)M4#16UI9HV!*PP6W-QMC'S$
MG'8D=7-^RWX)\8>&M7UC]G[X^V7C*_T&Q>^U/0YM!GTVZ:U3[\L E+"<+U(R
M&QVR0"J66XRO3YX1NM;:QN[;\J;O*W]U,4,)7J0YHKOU5W;>RO=_*YXU17??
M"WX<?!3Q=X>EU/XC_M&VOA&^2\:.+3)O"U[?&2(*I$OF0*5&6++MZC9GN*Z/
MXA_LV_"_PM\&)_C)X,_:-M?$-N-22PL;/_A%KNR:]GRID6-I\9"1DNS $#A2
M06%.&6XJI0=6/*TE=^_"]E_=YN;Y6N..%K3IN:M9*_Q1O;TO?\#QZBBO9D_9
M<\">#-%TNY_:!_:!LO!NJZS9)>66A0Z!<:C<06[C*/<^45$&X<[?F;!Z9R!C
MAL)7Q5_9I66[;44K[7<FEKTUU,Z5"I6OR].[27WNR/&:*[3XW_!#Q)\#?$MK
MH^L:G9:G8ZII\=_H>MZ7*7MM0M7SMD0D CH05/(/J"">+K.M1JX>JZ=16DMT
M34ISI3<)JS05]R?\$9O]5\1O][2/_;VOANON3_@C-_JOB-_O:1_[>U])P5_R
M4U#_ +>_](D>KD'_ "-J?S_])9]P4445^]GZ0%%%% !1110 4444 %%%% !1
M110 4444 %%%% !7SWXV_8M_9_UR0_$?]M+QY<>/;@7B"&7QIK'V31;&21PD
M<-M8(Z6R9+*@\P2RN< NQ-?0E?+O_!135O _@WXA?!7XG?'FR:;X7>'?&-[<
M>+));&2ZM;.]:PD33;FXB16)C2<L Q4A7=,]: ,[XU_!_P#X(W_#7Q9I_P &
M_C)\//A+X<UO5D0V=A_9\-C<A7;:CM+ %:$,1P[LN<'!X->S_ W]G2Y^ &KW
M.F^#_B[XEU'P=+:;;'PGXFO3J/\ 9<P==K6UY*3.L.S<IAD:09(*LF"&^+=+
M\0?!CQA^SO\ M-_MN?&'PS%>Z?\ %G7;O0?AL^J:2S76KVL%F;735M$=?,5I
M9@2N "##N.-@(^[OV>]%\6^&_@%X'\.^/BYUVP\'Z9;:T9&W-]K2UC6;)[G>
M&YH ["BBHKRUCOK5[29F"R+ABC8/X&@"6BL?_A!](_Y^;W_P+:C_ (0?2/\
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M )%\O\3_ "1L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5]Z?2&Q16/\
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MHV4KWM[T[--+FYG9Z7.R+YJ#YKJ')\-O=O;1WVUEK?>[L?+=%%%?&'@GN?\
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M +>_](D>QD'_ "-J?S_])9]P4445^]GZ0%%%% !1110 4444 %%%% !1110
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M#?\ PJM2_P#C5?1WAB7Q%-X;T^;Q?:VL&K/8Q-JD-C(SP1W!0>8L;-@L@?<
M3R1C-?"G_"(_L3?])S/BG_XD!IO_ ,8K[C\ QZ9#X%T6+1/%,^NV2Z3;"TUN
MZO%N)=0B$2[+AY5 $K2+ARX #%B1UH UJ*** "BBB@ HHHH **** "O#/^"D
MO_)F'C#_ 'M._P#3A;5[G7AG_!27_DS#QA_O:=_Z<+:O*SW_ )$F*_Z]S_\
M26<68_\ (OK?X9?DS\KJ***_G _+ HHHH **** "BBB@ HHHH **** "BBB@
M#W/_ ()M?\GG^#_]W4?_ $WW-?JC7Y7?\$VO^3S_  ?_ +NH_P#ION:_5&OV
M?P[_ .1)4_Z^/_TF!]YPO_R+Y?XG^2"BBBOO3Z0**** "BBB@ HHHH ****
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MBEHEM=ZG\O\ B)Q-G>7\8XK#X>KRPCR67+%[TX-ZN+>[/;/^&Q/^J=?^5?\
M^TT?\-B?]4Z_\J__ -IKQ.BOH?\ B7_PC_Z%O_E;$?\ RT^*_P!<N)/^?_\
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M: +EMIW_  0^N[=+F*3]F<*Z@J);K0D8#W5F!!]B*^I/":^%T\+:8G@@V/\
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MN)/^?_\ Y+#_ .1/;/\ AL3_ *IU_P"5?_[31_PV)_U3K_RK_P#VFO$Z*/\
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M1_PV)_U3K_RK_P#VFO$Z*/\ B7_PC_Z%O_E;$?\ RT/]<N)/^?\ _P"2P_\
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M+0%D)M]7\,:I#I.M0Q9SB>RN/W%PX!QO@E3=C/E+FO>J* /FU/VZ/CGK\O\
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M?_!RY_Q\_!?_ *Y^(?YZ;7Y:5_67AK_R1.$_[?\ _3DS^0?%#_DNL7_W#_\
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ML)_W$_\ 34S]2Z***_DX_KP**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OE7_@ME_P HSOB-_P!=-&_]/%E7
MU57RK_P6R_Y1G?$;_KIHW_IXLJ][A7_DI\#_ -?J7_I<3Y_BS_DEL?\ ]>:O
M_I$C\#:***_LX_B,**** "BBB@ HHHH **** "BBB@ HHHH ^JO^")W_ "DQ
M^''^YK/_ *9[VOWRK\#?^")W_*3'X<?[FL_^F>]K]\J_FOQB_P"2GI?]>8_^
MEU#^GO!;_DEJW_7Z7_I%,****_)S]>"BBB@ HHHH **** "BBB@ HHHH ***
M* /RN_X.7/\ CY^"_P#US\0_STVORTK]2_\ @Y<_X^?@O_US\0_STVORTK^L
MO#7_ )(G"?\ ;_\ Z<F?R#XH?\EUB_\ N'_Z:@%%%%?='P(4444 %%%% !11
M10 4444 %%%% !7ZH_\ !M'_ ,>_QH_W_#O\M3K\KJ_5'_@VC_X]_C1_O^'?
MY:G7PGB9_P D3BO^X?\ Z<@?H'A;_P EUA/^XG_IJ9^I=%%%?R<?UX%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9WB[Q=X;\!^&[SQ
MAXPU>*PTRPB\V\O)\[(DR!DXR>I% &C17DO_  W=^R'_ -%XT3_OJ3_XBC_A
MN[]D/_HO&B?]]2?_ !% 'K5%>2_\-W?LA_\ 1>-$_P"^I/\ XBC_ (;N_9#_
M .B\:)_WU)_\10!ZU17DO_#=W[(?_1>-$_[ZD_\ B*/^&[OV0_\ HO&B?]]2
M?_$4 >M5\J_\%LO^49WQ&_ZZ:-_Z>+*O4/\ AN[]D/\ Z+QHG_?4G_Q%?/\
M_P %1?V@/@E^T7^PUXU^#OP;^*6B:QXCU=]-.GZ=]N6W\WRM2M9I/WDY2-<1
MQNWS,,XP,D@5[7#=6E0XBP=6K)1C&K3;;=DDIIMMO1)+=GA\3T:N(X;QM*E%
MRE*E4225VVX-))+5MO9(_#VBO3/^&0/CS_T =$_\+32?_DJC_AD#X\_] '1/
M_"TTG_Y*K^M?]:>&/^@ZC_X-A_\ )'\??ZI\4_\ 0!6_\%3_ /D3S.BO3/\
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M_P"^I/\ XB@#UJBO)?\ AN[]D/\ Z+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_\
MB* /6J*\E_X;N_9#_P"B\:)_WU)_\11_PW=^R'_T7C1/^^I/_B* /6J*\E_X
M;N_9#_Z+QHG_ 'U)_P#$4?\ #=W[(?\ T7C1/^^I/_B* /6J*\E_X;N_9#_Z
M+QHG_?4G_P 11_PW=^R'_P!%XT3_ +ZD_P#B* /@C_@Y<_X^?@O_ -<_$/\
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M_P"2J/\ AD#X\_\ 0!T3_P +32?_ )*H_P!:>&/^@ZC_ .#8?_)!_JGQ3_T
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M$T\/_P#@F@_^(H_X5-\*_P#HFGA__P $T'_Q%=!10!S_ /PJ;X5_]$T\/_\
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MC@;EW>X5\C_L'+_:G[=7[5GB'7_FUJ/Q=HUD#+R\=A':2BW ST5E&??:.N*
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q_]KG]E1OVC=/\
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M*JCV  %3T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS>'?VU%\?_LK_M6_LYW'@?QUX?CM+SQ1X>M];?R]1@X-O=PWEHT;N@*("-Q
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MXGCY_P#\BFI\O_2D?#M%%%?@A^;GW%_P1E_YJ1_W!_\ V^K[BKX=_P"",O\
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MM?B+HG[0;?LV_ ']GS_A.]<T[P[%K7B6XN_%<6DVVF6\TC1PH'>*4S2N48[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20240930_g7.jpg
<TEXT>
begin 644 biib-20240930_g7.jpg
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M!'C?PA^V!XO_ ."<WAW1[D>#_P!H#QCIGC%;J#Y8['3@7EUZ/<.C2M9J@48
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M&8==IGC?P7\,?^"L'CN;XC^+M,T&/7/A%HSZ/+K%_';)>".\G201M(0&*MU
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MQ U^#2]$T6RDN]3U"Y)V00H,LQ !)/8  DD@ $D"OGM?^"H7@2VT"+XD:_\
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MYJE[\(?V?OBK\1/#FB7<EMJ7C'P5X52XTTR1G$H@>2:-[K80=QB1A@9!8$4
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M7@+XZS_M8>.?V%+G]JSQ]-X#TK0;#Q/;:[-K?F>)$6XW1'3EU%E+K 9%,F\
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M !1110 4444 %07NF:;J30/J.GP3FVG$UL9H@YBD (#KD?*P!(R.>3ZU/10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\
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MC?A_X[\+?%'P+H_Q(\$:HM[H^O:9!?Z9=JI'FP2H'1L'E3M89!Y!X/(H /\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6O._VJ_VF/%7[/LO@[0/A]\%KGQYX
MB\;:]+IFD:%:Z[!IS%H[66Y=S+<#RP D1X8K]>QQOAI^T)^V7XK\=Z;X>^('
M_!/C4/"NC75QLU#Q#-\3='O%L8\$[S# QDDY &%&>: /7?\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O#/\
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MT[_TX6U>5GO_ "),5_U[G_Z2SBS'_D7UO\,OR9^5U%%%?S@?E@4444 %%%%
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M]B\;_P#0;LO_  &/^- &Q7AG_!27_DS#QA_O:=_Z<+:O6_L7C?\ Z#=E_P"
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M_H-V7_@,?\:/L7C?_H-V7_@,?\: /C/_ (+,_P"M^'/^[J__ +95\/U]J?\
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MT 7J*** "BBB@ HHHH **** "O#/^"DO_)F'C#_>T[_TX6U>YUX9_P %)?\
MDS#QA_O:=_Z<+:O*SW_D28K_ *]S_P#26<68_P#(OK?X9?DS\KJ***_G _+
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M^,G_ $./_E/M_P#XW1_PT5\9/^AQ_P#*?;__ !NC_B5CQ!_Z"L+_ .!U?_E
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MHHH **** "BBB@ HHHH *\4_;-^"WQ]^+%EX2UO]FO7?!^B^*O"^NO?V>O\
MBF&Z=[-6A:)U@\@[6$B.T<B2JZ,C= RJR^UU4U[7]!\+:1/X@\3ZW::=86J;
M[F]O[E8885SC+.Y"J.>I- 'S:F@_\%B$0*WQ!_9Z8@8+-H>LY/OQ)BOH_P ,
M)XCC\-Z>GC&:SDU=;&(:K)IRLMNUSL'FF(/\P3?NVAN<8SS7'_\ #5G[+O\
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M?]3G_P MO_NX?\1'_P"H7_R?_P"T/MBBOB>BC_B4K_J<_P#EM_\ =P_XB/\
M]0O_ )/_ /:'VQ17Q/11_P 2E?\ 4Y_\MO\ [N'_ !$?_J%_\G_^T/MBBOB>
MBC_B4K_J<_\ EM_]W#_B(_\ U"_^3_\ VA]L45\3T4?\2E?]3G_RV_\ NX?\
M1'_ZA?\ R?\ ^T/U+_X)M?\ )Y_@_P#W=1_]-]S7ZHU^!O\ P1._Y28_#C_<
MUG_TSWM?OE7D8_P\_P"(:5EE?UGZQSKVG-R>SMS7CRVYY[<E[WZVMIK^V^&^
M=_V]D53$>SY+5'&U[[1@[WLNX4445Q'Z"%%%% !1110 4444 %%%% !1110
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MK\G/UX**** "BBB@ HHHH **** "BBB@ HHHH _*[_@Y<_X^?@O_ -<_$/\
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MB6UQ:>5IG@7PP&NULR75O.N;^55:>8 ;-L21Q %C\YP5],HH **** "BBB@
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M%+"XZ,KJ05(]0<UTX_+\;FD)4JW*E%TYP=F_?BW*7,KZQ=DE\+LWY,Y\OS'
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M#H#)(Q8CGUKIK+]J#]I?3;.'3M._:(\=6]O;Q+'!!!XMO42-%&%55$N
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MJ_\ !;+_ )1G?$;_ *Z:-_Z>+*O>X5_Y*? _]?J7_I<3Y_BS_DEL?_UYJ_\
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MPM_Y+K"?]Q/_ $U,_4NBBBOY./Z\"BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% 'U5_P1._Y28_#C_<UG_TSWM?OE7X&_\
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M_0=1_P#!L/\ Y(_C[_5/BG_H K?^"I__ ")YG17IG_#('QY_Z .B?^%II/\
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MPQ_T'4?_  ;#_P"2#_5/BG_H K?^"I__ ")YG17IG_#('QY_Z .B?^%II/\
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M('QY_P"@#HG_ (6FD_\ R57V?^M/#'_0=1_\&P_^2/B/]4^*?^@"M_X*G_\
M(GF=%>F?\,@?'G_H Z)_X6FD_P#R51_PR!\>?^@#HG_A::3_ /)5'^M/#'_0
M=1_\&P_^2#_5/BG_ * *W_@J?_R)YG17IG_#('QY_P"@#HG_ (6FD_\ R51_
MPR!\>?\ H Z)_P"%II/_ ,E4?ZT\,?\ 0=1_\&P_^2#_ %3XI_Z *W_@J?\
M\B>9T5Z9_P ,@?'G_H Z)_X6FD__ "51_P ,@?'G_H Z)_X6FD__ "51_K3P
MQ_T'4?\ P;#_ .2#_5/BG_H K?\ @J?_ ,B>9T5Z9_PR!\>?^@#HG_A::3_\
ME4?\,@?'G_H Z)_X6FD__)5'^M/#'_0=1_\ !L/_ )(/]4^*?^@"M_X*G_\
M(GF=%>F?\,@?'G_H Z)_X6FD_P#R51_PR!\>?^@#HG_A::3_ /)5'^M/#'_0
M=1_\&P_^2#_5/BG_ * *W_@J?_R)YG7ZH_\ !M'_ ,>_QH_W_#O\M3K\^O\
MAD#X\_\ 0!T3_P +32?_ )*K[]_X(=:UX<_8^A^)R?M&>+M$\.GQ"VC'1_\
MB=6UW]H\C[=YO_'J\FS;YT?WL9W<9P<?%>(>?Y%C>$,31P^*ISF^2T8SBV[5
M(-V2;;LE?T/N/#CA[/\  \98:OB<)5A!<]Y2ISBE>G-*[:25V[>I^J=%>2_\
M-W?LA_\ 1>-$_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\17\RG]2GK5%>2_\
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M:>'_ /P30?\ Q%'_  J;X5_]$T\/_P#@F@_^(KH** .?_P"%3?"O_HFGA_\
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M1_PJ;X5_]$T\/_\ @F@_^(KH** .?_X5-\*_^B:>'_\ P30?_$4?\*F^%?\
MT33P_P#^":#_ .(KH** .?\ ^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#
M_P#X)H/_ (BN@HH Y_\ X5-\*_\ HFGA_P#\$T'_ ,11_P *F^%?_1-/#_\
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MYX)FB\._$&^DTRS\:+? 06.J8)AM)HRF5\W@(^[D[L@!2:U/VB?VBK+X%?\
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M;K3_  7X7\#V5Q'INE"Y79<7+2W),L\TD9V'(50.@/&/HNBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /RQ_X.7?^:*_]S)_
M[BZ_+&OU._X.7?\ FBO_ ',G_N+K\L:_K'PS_P"2(PG_ '$_].S/Y"\4?^2Z
MQ?\ W#_]-0"OU._X-HO^:U?]RW_[E*_+&OU._P"#:+_FM7_<M_\ N4H\3/\
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M9\WN^SY;\T91WYW:U[[/:P5Q'[2/P)\*_M-? SQ+\"/&EQ-!IWB333;27-N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20240930_g8.jpg
<TEXT>
begin 644 biib-20240930_g8.jpg
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M-.T;Q1H_@V31+W5-,EMA=>5870E1?,4?/&SJKKU1CAL&O"/&_P"R=\6_B-\
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M%:^%;VS;QWXTLKO3=1%U=+Y+6]G9W1,C)Y1<O*P1<A0N[K7COPD^#G@[X,_
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MM)4&G78>UN"T$#1S*70@!7C<*Q##;BO4)?VK?C=\2_''B[1/V6?@%I'BG1O
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MZSLTB@"M]X>6H"X.3D8YS5G3]/L-)L8=+TJQAMK:WB6.WM[>()'$@& JJ.%
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M]%@1Q:6$42Z:RHJ*SR-AOWDLC,2>,:__  2"N?BS-^Q#X*A\=Z-X=M]#CT"
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MPGHK6KZ-X7TZT:QMFMK(VME'&;>$D$QIM V(2 2HP,@4 ?$WP!TS3]/_ ."
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/ ?C[]H#]HS6]-L?V,=6\)_&)O >A/8>)--GL[>UT#5AJ=_YVM"^AG#36S(
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MTMM/&LL,RAK$91XV5U8<,K C@U0_X?R?\$HO^CJO_+&UW_Y!I+*,U:NL//\
M\ E_D-Y_D,79XNE_X,C_ )GU[17R%_P_D_X)1?\ 1U7_ )8VN_\ R#1_P_D_
MX)1?]'5?^6-KO_R#3_L?-O\ H'G_ . 2_P A?ZPY!_T%TO\ P9#_ #/KVBOD
M+_A_)_P2B_Z.J_\ +&UW_P"0:/\ A_)_P2B_Z.J_\L;7?_D&C^Q\V_Z!Y_\
M@$O\@_UAR#_H+I?^#(?YGU[17R%_P_D_X)1?]'5?^6-KO_R#1_P_D_X)1?\
M1U7_ )8VN_\ R#1_8^;?] \__ )?Y!_K#D'_ $%TO_!D/\SZ]HKY"_X?R?\
M!*+_ *.J_P#+&UW_ .0:/^'\G_!*+_HZK_RQM=_^0:/['S;_ *!Y_P#@$O\
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M<EI,EAIRS:C?QW&GM*LSR07T"+\\YB;>X16B"!,?3O[2/Q:\0^!M(TKX>?#
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MNFHERMO'J5O:P7T\A7S-]PC23"+(5(Y8@1O#&N%_9L_9#_:>^)/_  3K\._
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M!>O_  XU_P 1:IJM_P#8=;N_".E?:+/1KNZEEN[BXN&!'DVB2RNHDQTV\<T
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M HKVS]C7]DVP_:*\66&K_$+QU:^&O!D?C+1] U"_D$C7-]>7\S+%96BQQO\
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M$RO^CEO_ "S=:_\ D.C_ (?6?\$RO^CEO_+-UK_Y#H_U6XG_ .@&M_X*G_\
M(A_K9PM_T'T?_!L/_DCZGHKY8_X?6?\ !,K_ *.6_P#+-UK_ .0Z]S^ G[0O
MP?\ VG?A[%\5?@=XO_MS0)KJ6VBO_P"S[BVS+&<.NRXC1Q@]]N#VS7)C,DSG
M+Z7M<5AJE.-[7E"45?M=I*YUX//<DS&M[+"8JG4E:]HSC)V[V3;L=I1117F'
MJA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU*4KRM=*5K05OLQL[;+5VC'6Y1117MG@A1110!^YO_!!3_E'MI?_ &-&J?\
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MHH Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !K8HH Q_L7C?_H-V7_@,?\
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MRCVTO_L:-4_]&K7V?7\<<8_\E5C?^OL_S9_:O!7_ "26!_Z]0_)&/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%%?-'TYC_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!^%7_!=F/4
M8O\ @H!J::I<1RR_\(QIF7B3:,>4<<5\<5]G_P#!>O\ Y2$ZI_V*^E_^BFKX
MPK^R.#O^25P7_7J'Y(_BKC7_ )*['?\ 7V?YA1117TA\P%%%% !1110 4444
M %%%% !1110 5^WG_!":V\32_P#!/_3'TO4[:*+_ (2?4\)+"6.?-&>:_$.O
MW-_X(*?\H]M+_P"QHU3_ -&K7Y=XN_\ )*Q_Z^Q_*1^K^#?_ "5LO^O4OSB?
M6_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q17\R']2F/]B\;_\ 0;LO
M_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&
M/^-;%% &/]B\;_\ 0;LO_ 8_XUH:;'J,5J$U2XCEEW'+Q)M&.W%6** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\,O^"]?_*0
MG5/^Q7TO_P!%-7[FU^&7_!>O_E(3JG_8KZ7_ .BFK]2\(O\ DJI?]>I?G$_*
M/&/_ ))&/_7V'Y2/C"BBBOZ:/Y:"BBKLGAOQ!#X<A\7RZ)=+I5Q>R6<&I- P
M@DN(T1Y(E?&"ZI+&Q7.0'4]Q2<HJUWN-1E*]EL4J***8@HHHH **** "BBB@
M HHHH _<W_@@I_RCVTO_ +&C5/\ T:M?9]?&'_!!3_E'MI?_ &-&J?\ HU:^
MSZ_CCC'_ )*K&_\ 7V?YL_M7@K_DDL#_ ->H?D@HHHKYH^G"BBB@ HHHH **
M** "BBB@ HHHH **** /PR_X+U_\I"=4_P"Q7TO_ -%-7QA7V?\ \%Z_^4A.
MJ?\ 8KZ7_P"BFKXPK^R.#O\ DE<%_P!>H?DC^*N-?^2NQW_7V?YA1117TA\P
M%%%% !1110 4444 %%%% !1110 5^YO_  04_P"4>VE_]C1JG_HU:_#*OW-_
MX(*?\H]M+_[&C5/_ $:M?EWB[_R2L?\ K['\I'ZOX-_\E;+_ *]2_.)]GT44
M5_,A_4H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+_KU#\D?Q5QK_P E=CO^OL_S"BBBOI#Y@**** "BBB@ HHHH **** "BBB@
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MK:%+^SML@S7#W%Q<$S*"4%L%R M?=M?,/Q6^*7C+X@?M$ZQIOP _8=\)^/\
M6_AK+;V5[X[\6ZU:Z>^GWLT"7(MK-VMIIFV1S1L[*R &3 SUH R/V5OA1X/_
M &8_VRY?V>_@[XKU6_TM_A(FJ>/K2\UZ>_2/7%O88H+MO.=_(GN(GNF9%V!E
MB1MH %?6M>(_LS']HMOB+XCUGXQ_LI>"? D>N0)=ZAKWAKQ0M]=:I>QB.*-9
MP((RP6$-ABQQM  ^8U[=0 4444 %%%% !1110 4444 %?AE_P7K_ .4A.J?]
MBOI?_HIJ_<VOPR_X+U_\I"=4_P"Q7TO_ -%-7ZEX1?\ )52_Z]2_.)^4>,?_
M "2,?^OL/RD?&%%%%?TT?RT%%%% !1110 4444 %%%% !1110 4444 ?N;_P
M04_Y1[:7_P!C1JG_ *-6OL^OC#_@@I_RCVTO_L:-4_\ 1JU]GU_''&/_ "56
M-_Z^S_-G]J\%?\DE@?\ KU#\D%%%%?-'TX4444 %%%% !1110 4444 %%%%
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MC,%@J&!I5Z563E._NR@HZ+1R34Y77->*T5[2VL<_17U3^PC^TI^U9J6O:?\
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M !1110 4444 %%%% !1110 4444 ?AE_P7K_ .4A.J?]BOI?_HIJ^,*^S_\
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MK7V?7QA_P04_Y1[:7_V-&J?^C5K[/K^..,?^2JQO_7V?YL_M7@K_ ))+ _\
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M>N_\*O\  W_0#_\ )F7_ .*H_P"%7^!O^@'_ .3,O_Q5'_$1<D_Y]U/NC_\
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M_P#DS+_\51_Q$7)/^?=3[H__ "8?\0\SK_GY3^^7_P @>145Z[_PJ_P-_P!
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MOQ1J/ASPRVHZ'X)L+UK>;7)A+&CJ&3]XRQQLTC1QXD?: I'-:'QO^&7A"W^
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M#7Z[_P!G:?\ \^,/_?H5^1G_  6,BBA_;5OTAC5%_P"$>T_A5P/]6:]G(O\
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MBB@ K]P/^"$7B+1--_X)^Z9:WVI112#Q/J9*,><>:*_#^OW)_P""#%G:3?\
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M_P"O4/R1_%7&O_)78[_K[/\ ,****^D/F HHHH **** "BBB@ HHHH ****
M"OW-_P"""G_*/;2_^QHU3_T:M?AE7[F_\$%/^4>VE_\ 8T:I_P"C5K\N\7?^
M25C_ -?8_E(_5_!O_DK9?]>I?G$^SZ***_F0_J4**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OR(_P""R/\
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M$3_H1_\ ES1./ZQ2[GC]%>P>1_M_I1Y'^W^E'USQ$_Z$?_ES1#ZQ2[GZ,?\
M!&__ ),GT_\ [&'4/_1@KZHKYT_X);+L_9-LAG_F-WO_ *&*^BZ\>M+%RJR>
M*I^SJ7]Z%U+E?5<RT=NZT9^J96U++:+7\J_(****S.\**** "BBB@ HHHH *
M*** "BBB@ HHHH _#+_@O7_RD)U3_L5]+_\ 135\85^C?_!9O]G1_B5^V[J'
MB@>+OL>_P[I\?D?V?YF-L9&<^8O\J^4O^&-I/^BA_P#E)_\ MU?TEPWX@\-9
M?D&%PU9UN>$(I\N%Q4E=+6THT7&2\XMI]&?R3Q;PQGF*XGQE:E2O&5233YH+
M2_9RN>(T5[=_PQM)_P!%#_\ *3_]NH_X8VD_Z*'_ .4G_P"W5[?_ !$WA/O7
M_P#"/&?_ "@^=_U0XA_Y\K_P.'_R1XC5K0M#UGQ/K=GX:\.:5<7^HZC=1VUA
M8VD)DEN)I&")&BKDLS,0 !R20*]D_P"&-I/^BA_^4G_[=7U!_P $V?@%X1^'
MWBZ%=.^(GAZR\<2^.= GT_5/$?A^.3S=(CG<WMC9M)YBV]U,Q@Q+\KE5*(06
M-88KQ/X<AAY2P\:TII:*6&Q4(_.4J*22W[]%J=V6\#YUC,;"E6AR1>[YH-_)
M<VK>R\S\]+BWGM+B2TNH6CEB<I)&ZX96!P01V(-,K[D_:F_95\8ZM\7O#VJ_
MM*:=I=K L[MJ&M^#-$M;6?Q+8?:BQ<S02M:M.D9,0E$6\?+YH<@5L_M=? [P
MQ\3OV6/@Y#X*TC2_!^EZ9K/BF.PTS3-.:7]P7TX)YLKR[YYOD)>5CEV8X"*%
M4<M+Q8X=J^R_=UK2OS-8?$M1LG\/[E.;;2LHKX6Y.RBSIJ< 9Q&.(:WII.,6
MXJ4KRBM?>M&RE=W;NU973N? 5%?2OP4_8$M/B)\8?"W@+5?B(XM-9\0V=G=F
M+3 K"*29%?:?-.#M)P<'FOL#7/AA\=M1^)>M_"WP5\??AXVB;;NRTG]G6_\
M"\CZ:+!4=8K1F39$;Y5"N6$RS^:#EU;*#7$^*7#U-_N(U963D^:AB862MLG0
M;;=]-%'3XKBP' .<XJFYUH\NJBK.$KM]_P!Y'1:;<TG?2+LS\JJ*]O?]C29'
M*/\ $ J0<%3I'0^G^NI/^&-I/^BA_P#E)_\ MU=G_$3>$^]?_P (\9_\H/*_
MU0XA_P"?/_D\/_DCQ&BO;O\ AC:3_HH?_E)_^W4?\,;2?]%#_P#*3_\ ;J/^
M(F\)]Z__ (1XS_Y0+_5#B'_GRO\ P.'_ ,D>(U^YO_!!3_E'MI?_ &-&J?\
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M_P"FR]%T6R)JUZM;XW?^M?F^KW84445L9!1110!^F?\ P2Y_Y-.LO^PW>_\
MH8KZ)KYV_P""7/\ R:=9?]AN]_\ 0Q7T37XAGG_(XK_XW^9^Q9/_ ,BJC_A7
MY!1117E'I!1110 4444 %%%% !1110 4444 %%%% 'YF_P#!4?\ Y.PO?^P)
M9?\ H!KYUKZ*_P""H_\ R=A>_P#8$LO_ $ U\ZU^X9'_ ,B>A_@7Y'X[G'_(
MUK?XG^84445ZAYH5ZC^S+\1/A1X2\8Z/9_%/PBS10>*;#4;/Q)8W(BN-/:*5
M21(&1A+;D89D 5AMRISQ7EU%8XBA#$473E=)]G9FM"M*A552-KKNKGI_Q/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5^9O_!4?_D["]_[ EE_Z :_3*OS-_P""H_\ R=A>_P#8$LO_ $ U]=P7_P C
MA_X'^:/E^+O^14O\2_)GSK1117ZL?F84444 %%%% !1110 4444 %%%% !11
M10!^F?\ P2Y_Y-.LO^PW>_\ H8KZ)KYV_P""7/\ R:=9?]AN]_\ 0Q7T37XA
MGG_(XK_XW^9^Q9/_ ,BJC_A7Y!1117E'I!1110 4444 %%%% !1110 4444
M%%%% 'YF_P#!4?\ Y.PO?^P)9?\ H!KYUKZ*_P""H_\ R=A>_P#8$LO_ $ U
M\ZU^X9'_ ,B>A_@7Y'X[G'_(UK?XG^84445ZAYH4444 %%%% !1110 4444
M%%%% !7Z9_\ !+G_ )-.LO\ L-WO_H8K\S*_3/\ X)<_\FG67_8;O?\ T,5\
MEQI_R)U_C7Y,^HX1_P"1J_\ "_S1]$T445^4'Z8%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YF_P#!4?\
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M_P!AN]_]#%?F97Z9_P#!+G_DTZR_[#=[_P"ABODN-/\ D3K_ !K\F?4<(_\
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MYQ_R-:W^)_F%%%%>H>:/-Q<&W%H9W,2N76+<=H8@ G'3) '/L*9110 4444
M%%%% !1110 4444 %?IG_P $N?\ DTZR_P"PW>_^ABOS,K],_P#@ES_R:=9?
M]AN]_P#0Q7R7&G_(G7^-?DSZCA'_ )&K_P +_-'T31117Y0?I@4444 %%%%
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MA\OI4ZBM)12?J>]45X+_ ,-<_'#_ *,9\=_^!,%'_#7/QP_Z,9\=_P#@3!7
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M_1)O'?\ X3,'_P ET?ZU9!_S^_\ )9__ "(?ZM9W_P ^O_)H_P"9XW7Z9_\
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M3_98O/!G@3QI965W9:I-?^!(+RUU6*=XW,L@B>&1+A&CXF#%BKLAX8U]#44
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MF1@N<=JU/"/@SP?\/]!@\*^ _">F:)I=L"+;3=(L([:WB!Z[8XP%7\!6E10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>!?\
M%%_C7\3?@1\$M+\7_"GQ-_96HW/BJ"SFN/L4,^Z%K:Y<IMF1U'S1H<@9XZ\F
MNG!X6ICL5"A3:3D[*^WZG/B\33P>&E6FFU%7TW/?:*_++_AX[^V;_P!%D_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDBVX\K8T2@;<?+E>A(KVST#U?Q_X^\'_  L\%:I\1OB!KT.EZ)HMD]WJ>H7
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MMUV:YTK_ ()C_%#X56UQ)+HG@#]I1O#?A4RN6VZ9!X@LGB0,>2%,KJ/0+@<
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M@#V?X@?$+P-\*?!U_P#$'XD^*['1-$TR'S;_ %/4K@10PKD 98]R2  .22
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M^:J#R^HINRMT5_PNOS/S4HKK/^'KO[??_1>O_+6TK_Y%H_X>N_M]_P#1>O\
MRUM*_P#D6ODO^(+XS_H,C_X _P#Y(_//98#_ )^2_P# %_\ )GW?_P $A/\
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MK7X]3TBZGN(8+V*-T5Y()Y()5PX!^66*1>G5>,C!K,^,WQZ^#_[/?AF+Q?\
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M?MB^'_VBO@GIWAS0-#F\&7WA[QQHEK:_93=H95N+.>&.&/RVD64,KLY4^60
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MV?O >I^$;G_A+[J;QOX1URSDM;W3-8E"F;S;=G98MX"L!&0AP> P8#M?B/\
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M0?&/X^^#/C1^UEKO@33]/^'4UU=^&?#'@%[RY%U?3P^2;BZN;N.)MJ(3MC1
M"QRS'&#ZI\+M*_:%L/B#XVO/B[XG\.WWAJZU*%O 5IH\$BW-G:A7\U;HLBAG
M),>"I8<'F@#NJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *^0_^"TG[4/QT_9,_9;T'XC?L_>./[ UF]\?VNFW
M-Y_9EK=[[5[&^E:/9<Q2(,O#&=P ;Y<9P2#]>5\"_P#!Q?\ \F2^%O\ LJEC
M_P"FW4Z^GX,P]#%<4X2E6@I0E-)II-/1[IZ,^5XWQ&(PG">+K4)N$XPNG%M-
M.ZV:U1\"?\/K/^"FO_1RW_EFZ+_\AT?\/K/^"FO_ $<M_P"6;HO_ ,AU\L45
M_5'^JW#'_0#1_P#!4/\ Y$_DS_6SBG_H/K?^#9__ "1^\'_!%S]J'XZ?M9_L
MMZ_\1OV@?'']OZS9>/[K3;:\_LRUM-EJEC8RK'LMHHT.'FD.X@M\V,X  ^O*
M^!?^#=#_ ),E\4_]E4OO_3;IE??5?ROQGAZ&%XIQ=*C!1A&=DDDDM%LEHC^M
M."<1B,7PIA*U>;G.4$VY-MMW>[>K,_Q9XM\+^ _#5]XR\:^(+/2M)TVV:XU#
M4M0N%BAMXE&6=W8@*!ZFO+?AK^W[^R)\6_&5CX \$?&."75=5R-'@U#2;RQ3
M4B!G%M)=0QQW)QR!$S9[4_\ ;M_9]\5?M._LSZW\*/ VJV%KK$MU97^FIJRL
MUE=36MU%<+;W 4$F*0Q[3P<9!P<8KP_XJ?M8O#H.E>#/^"E7[!^O^$O#T&N6
M,T7C/1M5CU71=.O8ID:WNVN;1DFLE\P+CJV&*'(9@?F#ZD]V^+G[<G[+'P*\
M=2?#/XJ?%>+2]=BLX[J73AI5Y<.L,F=CDPPNH!VGOVK8\%?M5?L\?$?X5ZS\
M:_ OQ7TO5/#/AVVN+C7M2M'9CIZ01F67SHMOF1LJ*6VE0Q'0'(KYOUOXZ67P
M5_X*B_$35I?AAXV\5)J/POT%$B\#^&9=4DA FN&WR+&?D4YX)ZFL;Q!X3^('
MB[PE^UG^U;J7PDUGP#X;\8?!ZYT[2M#\16J6VH:I-::7>>9J%Q;JQ\D_O!&@
M8[V4$D"@#ZG\6?M7_L\>!-*\%Z[XP^*-CIUG\0Y($\&W5S%*J:B9EC:/!V8C
M#++&<R;0-W..:Z?QY\2/!/PQTVSU?QWK\>G6VH:O::79RR1NPEN[F588(AL!
M(+R,J@G@9Y(%?%GC?X0>#/C[X(_8Y^#GQ!L3<:1X@^'FH6MT%P'C)\**4E0G
M[LB.%=6[,BGM2>,_B]XS\3_L_P#A_P" OQKOA)\1OA=\>/!>C>)YFR#JEO\
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M7OB/_9&ISV*7D5K_ &/>7&Z%G=%?=#"ZC+1N,9SQTY%?"&M_&7X16&K^'_\
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MWN3?QL)K%K6*-HHPXV&*4RY5P0RE3N /N&BBB@ HHHH **** "BBB@ HHHH
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MQ+\"_$SX?V'Q3\">)(-2\/ZI8B\L-3@#;)8""=P# ,.AR" 0001F@#R/P_\
MLK^.=)U3]G2]GUW267X/:!<6/B$))+F[DDT46 :WRGS+Y@W'?L.WMGBL3]LO
M]A36/V@?C-\.OCI\,O%-EHNL>&O$FF-XMBO&=8M:T>UOHKU8CL1LS12Q9CR
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MG[.'B;X%> H;/3%U+P1>Z#HL<NY;>T$EF]O"#M#$(N5Z G X!J;]G;X=:O\
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M_BQ_BE\6_C?XF\.2_$'X@^!9?"NDV>@^>=*T'3A%-Y<"RRH)IB\TQEDD*+R
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M=^R;\3-:T71=(NTN/$5MIE@-%N?-U"=5W327>]8M\HC9FA^4[N"!D^M^"/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20240930_g9.jpg
<TEXT>
begin 644 biib-20240930_g9.jpg
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MIKG@?68-"UW_ (2K;K;6[V\T46IM8F (EN6(<KY_FK'^\"MPM?4O[/$DDWP
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MA_90UKXYZC\3?#FJ^!I]=EN->L[4:IX;FBG2-!/-:11(\,P<A0Z!MR\' .X
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M ODIO:3<R>3GS1L)W?=&.?3]8T71O$.ES:'K^DVU]97,>RXL[R!98I5_NLC
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M:10!6^\/+4!<')R,<YJSI^GV&DV,.EZ58PVUM;Q+';V]O$$CB0# 55'"@#@
M<"@#S/\ :6_:)^%OP..A>'/C?HMY!X3\937.E:IXJG11I6E%HODCO9=P:%9]
MQ17QL!!W,O&?EU-'_9<^$W[7OPMM_P#@FQXGTJXUWQ)XA,'Q+T/P9KYU+39?
M#BQ.9KF\"R21V\D3^7Y3 HS%R/FX%?=]_86.J64NFZG917-O.A2:">,.DBGJ
MK*>"#Z&LWPG\/_ ?@*"6V\"^"=(T6.=@T\>DZ;%;+(1T+"-1D_6@#Y@_9/\
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MI^BP(XM+"*)=-945%9Y&PW[R61F)/&-?_@D%<_%F;]B'P5#X[T;P[;Z''H$
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M98]]L8 S[T :5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\%O%^@:EI?C/0]3DU/Q%X,GTBV\'V]C=1S2NDLR+')+Y4;P)';-(&$IY"\T
M>J>(O!W[9OQ6^(OB:?3/C+_PJSPSI%ZEIX2M]-\/Z=JMQK:B%'>^NFN!((XC
M([1K @BDQ$2S#(K8_8H^-_B[]H+]GZP\?^/+2P75X=4U'2[Z\TE6%GJ#V=Y-
M:F[MPQ)$<GE;P,G!)&2!FO"?VEOVM?%?Q&^*>K? %_ GQ7\+?#W37-OX@\4^
M%?A[J5Y?^)L\/;6,\$+):VI&0]R"97!Q&$&9*];\.?M(_"7X6_L_^'M3^$_P
M(\;KH=OJ-MH>F^$M/\&SVU_80E_+$[VLX1T@3&YI#G(.[G.: .4^-GQY\<7'
M[7%Y^SYJ_P"TA:?!O0;'PC:ZMHNKS:;8O<>)II))1<+%/J*26Z);B- T:H9#
MYA;(4<=Y^Q5\7?''Q?\ A_K]_P"+_$EKXDM-&\77>E^'?&UCIXM8?$UA''"R
MWJ(I\LCS))82\7[IS 63 .!XM\7M/^$VH?M1>,-?_;6^%6O^//"<UO9+\,'L
M_"UYKVD:9;FU5+N)K.TCE,%VUP'8S21DLAC"2+M*CM/V [2Y\!V7CFTM+77_
M  _\-[CQ%"_PO\,^,)9?M^G60M8Q< 1S,TMO;M<;S%#(0R*#E5W<@'TO16;_
M ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF/AC_ *#4'_?5'_"8^&/^
M@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@
MU!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :
M5%9O_"8^&/\ H-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )
MCX8_Z#4'_?5 &E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/
M^@U!_P!]4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4
M :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\ H-0?]]4?
M\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF
M/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U
M!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\
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M /GQA_[]"C^SM/\ ^?&'_OT*^2O^'[__  2E_P"CJ/\ RQ]=_P#D&C_A^_\
M\$I?^CJ/_+'UW_Y!KK_LC-O^@>?_ (!+_(\__6'(/^@NE_X,A_F?6(T/1%NV
MOUT>U$[1B-IA;KO* DA2<9P"2<>Y]:D_L[3_ /GQA_[]"ODK_A^__P $I?\
MHZC_ ,L?7?\ Y!H_X?O_ /!*7_HZC_RQ]=_^0:/[(S;_ *!Y_P#@$O\ (/\
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M *!Y_P#@$O\ (/\ 6'(/^@NE_P"#(?YGUK_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5\E?\ #]__ ()2_P#1U'_ECZ[_ /(-'_#]_P#X)2_]'4?^6/KO_P @T?V1
MFW_0//\ \ E_D'^L.0?]!=+_ ,&0_P SZU_L[3_^?&'_ +]"C^SM/_Y\8?\
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M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
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M_P"17_\ BJ/^$*\/?\^/_D5__BJ/J'$G_0NJ_P#@>'_^7A_:F"_F_!G[E_\
M!NU_RC6TC_L;=6_]&K7W/7Q3_P $!-/M=,_X)VZ7:6<>Q!XIU0@9)ZRKZU]K
M5^&YY&M#.*\:L'"2G*\79M.^S<6UIY-KS/ZQX4G&IPU@Y1V=./Y!1117E'T
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M1BN6I!N,ER5'9K=74&G\F?J=17Y8_P#$2[_U95_YD?\ ^]U'_$2[_P!65?\
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MLK&\>>&RU[3&N8_M%FD]NK,MPQ  CEVQ2*^TL#7KGBK]LSX?_"W]JSX->/\
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M;_P04_Y1[:7_ -C1JG_HU:^SZ^,/^""G_*/;2_\ L:-4_P#1JU]GU_''&/\
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M7X9?\%Z_^4A.J?\ 8KZ7_P"BFK]N_P#A,?#'_0:@_P"^J_#[_@N[?V>I?\%
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MLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZKYH^G-*BLW_A,?#'_0:@_P"^J/\
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M)&/_ %]A^4CXPHHHK^FC^6@HHHH **** "BBB@ HHHH **** "BBB@#]R?\
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M5_9'!W_)*X+_ *]0_)'\5<:_\E=CO^OL_P PHHHKZ0^8"BBB@ HHHH ****
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M4O"+_DJI?]>I?G$_*/&/_DD8_P#7V'Y2/C"BBBOZ:/Y:"BBB@ HHHH ****
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MHU3_ -&K7X95^YO_  04_P"4>VE_]C1JG_HU:_+O%W_DE8_]?8_E(_5_!O\
MY*V7_7J7YQ/L^BBBOYD/ZE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1\84445_31_+04444 %%%% !1110 4444 %%%% !1110!^YO_!!3_E'MI?\
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MPK:7,^H7B^?&56&.U99F(8*QV,#M5B>,U\7?\*]_X)V_](U_VDO_  CO%/\
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MU3\+K+XE:WXACTW4-(E3P6WB23P]8I9Q0C3YK=8I39DR))<(RK^\6?+$%1N
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MH_\ ZFC_ ,DO_LZ/]=>&?^?_ /Y+/_Y$/]3.)?\ GQ_Y-#_Y(X&BN^_X4?\
M]31_Y)?_ &='_"C_ /J:/_)+_P"SH_UUX9_Y_P#_ )+/_P"1#_4SB7_GQ_Y-
M#_Y(X&BN^_X4?_U-'_DE_P#9T?\ "C_^IH_\DO\ [.C_ %UX9_Y__P#DL_\
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MP4R,D+L0NYE&XC&6 [UUE !1110 4444 %%%% !1110 5^1'_!9'_D]C4/\
ML7M/_P#19K]=Z_(C_@LC_P GL:A_V+VG_P#HLU[.1?[Z_1_H?/\ $G_(N7^)
M?J?*U%%%?7GP84444 %%%% !1110 4444 %%%% !1110!^O'_!&__DR?3_\
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M'?\ 7V?YA1117TA\P%%%% !1110 4444 %%%% !1110 5^YO_!!3_E'MI?\
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M+J1K:]WW5JDOVB%)402PLQ)VJ3)&&4..K50T[]B#XI+\"?$/QO\ %ES;:/\
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MQE86VK:?&)AK]^2&"L<>8,<C-?3_ /9VG_\ /C#_ -^A7SW_ ,$MU"_LG60
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M ..4?\,V_!O_ *%'_P G[C_XY1_Q$F?_ $*,5]^$_P#FH7^HF:_\_:?WR_\
MD#Y9K]R?^"#%G:3?\$^-+>:UC=O^$HU/ED!/^M%?FY_PS;\&_P#H4?\ R?N/
M_CE?JW_P2.\):!X)_8XL-"\-6/V:U77K]Q%YKO\ ,9!DY<D_K7Q''_&$L]R)
M89X"O0]^+YJCH<NBEI^[KU)7=_Y;::M:7_1?##AC'91Q)*O6G!KV<E[KE?5Q
M[Q7;N?2O]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%345^+']!$/]G:?_SXP_\
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MUN%%%%,04444 %%%% !1110 5^F?_!+G_DTZR_[#=[_Z&*_,ROTS_P""7/\
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M\+O"'B32_@_<>)-7U;Q1I1TN:_\ $&GP6<5A9/(DDJK'%-*996\M5W$J%&<
MYHI86K&-&4H>_&,%LFE9Z^\U=-)WTMKMS#J8FG)U8QG[CE-[M/5::)V:;7GI
MORG:?L\>._C;XZO=#\.?#OQWX/\ !^A:9+;V=YH<FHV\']J8 ,LLMK(6FOGD
M!.1A@2=JA<8'D/QT30X_C-XI3PSX7N-$T\:]=?8])N[<PR6D?F-B-HS_ *L@
M?P_P].U=,-1_9-\2O9>(=:L_%_ANYAMH4U+0=!LH+JVN)44*SPW$]PLD._;N
M(=9-I8X+# J#Q_\ %3X<_&;XC>-OB;\1]%UBSN]7M2WABTT:6)XX+E52.(7+
M28+)L0;F4;BV3CFNK#P=+%RJ1IM)K72SO=;N_OO=WZ6\SEKS53"JG*:;OIK=
M6L_+W>BMU^1U/CKXA>,?V;O!G@'PE\(]8.CR:OX1M_$&O7UM$GFZC/=22%8Y
M20=\4<:(@C/RY+$@DYKFOVK/#FA:5X]TGQ9X<TFWT^W\7^$M-U]].M$VPVLU
MQ%^^2-?X4\U78#H V!@ "I(_B)\'_B5X(\.Z!\9Y_$6GZGX4LFT^SU/0+""Z
M%_8>8TD<$BRRQ>4\9=U5P6!5AE<KD\S\:?B:/BOXX;Q!9Z3_ &=IMI8V^G:)
MIOF[_LEE;Q+%#&6P-S;5RQ[LS'@<4\)0J0Q";C9KFYG_ #7>FO7NOY5IIL&)
MK0G0:4KI\O*NUEKIT[/N]==SDZ***]@\H*_3/_@ES_R:=9?]AN]_]#%?F97Z
M9_\ !+G_ )-.LO\ L-WO_H8KY+C3_D3K_&OR9]1PC_R-7_A?YH^B:***_*#]
M,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<_\ )IUE_P!AN]_]#%?1-?.W_!+G_DTZR_[#=[_Z&*^B:_$,\_Y'%?\ QO\
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M5/[4GPC^.'[2GQ8F^*'_  SUX[T7SK&&W^P_V1!<X\L$;M_VA.N>FWBO.O\
MAB7XX?\ 1)O'?_A,P?\ R77ZIE7$F2X;+:5*I5M*,4FN66]O)'YKF609OB,P
MJU*=.\7)M:QV^\\;HKV3_AB7XX?]$F\=_P#A,P?_ "71_P ,2_'#_HDWCO\
M\)F#_P"2Z[_]:L@_Y_?^2S_^1.+_ %:SO_GU_P"31_S/&Z*]D_X8E^.'_1)O
M'?\ X3,'_P ET?\ #$OQP_Z)-X[_ /"9@_\ DNC_ %JR#_G]_P"2S_\ D0_U
M:SO_ )]?^31_S/&Z*]D_X8E^.'_1)O'?_A,P?_)='_#$OQP_Z)-X[_\ "9@_
M^2Z/]:L@_P"?W_DL_P#Y$/\ 5K._^?7_ )-'_,\;HKV3_AB7XX?]$F\=_P#A
M,P?_ "71_P ,2_'#_HDWCO\ \)F#_P"2Z/\ 6K(/^?W_ )+/_P"1#_5K._\
MGU_Y-'_,\;HKV3_AB7XX?]$F\=_^$S!_\ET?\,2_'#_HDWCO_P )F#_Y+H_U
MJR#_ )_?^2S_ /D0_P!6L[_Y]?\ DT?\SQNBO9/^&)?CA_T2;QW_ .$S!_\
M)='_  Q+\</^B3>._P#PF8/_ )+H_P!:L@_Y_?\ DL__ )$/]6L[_P"?7_DT
M?\SQNOTS_P""7/\ R:=9?]AN]_\ 0Q7QA_PQ+\</^B3>._\ PF8/_DNOIG]E
MSQY\</V:_A/!\+_^&1/'>M>3>SW'V[RH+;/F-G;LWOT]=W-?.\3YYE>8Y:J6
M'J<TN9.UI+2S[I'O<.Y/F6 S!U*\+1Y6MT]=.S9]?T5X+_PUS\</^C&?'?\
MX$P4?\-<_'#_ *,9\=_^!,%?GQ]R>]45X+_PUS\</^C&?'?_ ($P4?\ #7/Q
MP_Z,9\=_^!,% 'O5%>"_\-<_'#_HQGQW_P"!,%'_  US\</^C&?'?_@3!0![
MU17@O_#7/QP_Z,9\=_\ @3!7J?PC\=^)/B+X/7Q)XJ^&VI^%+MKAXSI.K.K3
M!5QA\KQ@]OI0!T]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !6?XLT[7=7\+ZCI7ACQ"=)U*Y
ML98M/U1;9)C:3LA"2^6X*OM;#;6&#C!K0HH ^5OA1^W[JVA?LM^*];^/FCH_
MQ5^&NJ_\(UXD\+V"!9-8UEW\NP-L@'*7A:-D95V\R$#:E4_V@=)_X*!?"O\
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MAR>#]0NWL4ED\17T5M/-=R0R,"4@MWB2 .G^LD\_DA!GZ]K\]OCBW[2?PO\
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M9^'_  [97LGF7EIH6BP6D4[[=NYTB10QV\9(/'%9/A3]FC]G'P'XI/CGP/\
ML_\ @G1M;+,QUC2?"EG;W66^\?-CC#\YYYYKMJ* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHKP+_ (*+_&OXF_ CX):7XO\
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M_(HH_P"$\@_;M_9]\5?M._LSZW\*/ VJV%KK$MU97^FIJRLUE=36MU%<+;W
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M5F9B@!X7&?6O O[/_BSPO^V7X]_:-OM6TZ31_%?A72-+L;.)Y#<Q2VC3&1I
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M(/$%D\2!CR0IE=1Z!<#@"OM7]O7X6^"/BO\ LC^/=*\;6D.W3/#%[JNF:BP
MDTR]MH'FANHGZQNCH#D$9&0>": .X@^,OPSG^+D_P(3Q7"OBZ#15U=M$EAD2
M1[$R>6)T+*%D3?\ *=I.#P<59U#XG>!-+^(NG?"6\\0QCQ'JVFW&H6.DI&[R
M-:PLBR3-M4B- TB*&<J&8X7)R*^1_BU8?$SQ]^Q1\'_^"B7A2-3\3OAMX-L?
M$UZTK>6-:TR2RC?5+.0_W98M\J]2&&%P6S7J_P"PSX>USXAZ9JO[;/Q'L?*\
M0?%6&WNM$LI'#G1O#: MIUDI&0&9'-S*5P&DG.1\@H ]_HKD/BW\?O@G\!+&
MSU+XT_%/0_"]OJ,K16,VMZ@ENL[J 652Y&2 03]:Z/P[XAT/Q=X?L?%?AC5H
M+_3=3LXKO3KZUD#Q7$$B!XY$8<,K*P((Z@B@#*\!?%;X??$^YUZS\!^)8M1E
M\,:]-HNO)'$Z_9+^)4:2 [U&2!(ARN5^;K4OA?XD^"/&GB'7_"GAC7X[O4/"
M]_'9:_;)&X-G.\*3HC%@ 28Y$;*DCYO7BO _^"='_(U_M%?]G$ZW_P"DME6Q
M^R1_R<M^T?\ ]E%TW_TQ6% 'L_Q ^(7@;X4^#K_X@_$GQ78Z)HFF0^;?ZGJ5
MP(H85R ,L>Y)  '))  )(%>??"?]N?\ 95^-OC&#X??#SXL13:U=PM-I^FZE
MI5YITM]&HW,UN+N&+[0 OS'R]W )Z#-9O[>?P ^(/[0?P<TO3?A7/I3^(/"O
MC+3/$VEZ7KV[[!JTEE*7^QW& ?W;@GMC<JYP,L/)_%_[66DZIXK\&>%O^"B'
M[$'B3P#+:>+K.?POXP35(]3T:RU=6Q;R&^M'1H-S' 5E*D$AQM#$ 'V)1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %?*W_!7O\ Y-KT/_L>;;_TCO:^J:^9O^"JW[0?Q>_9M_9Z
MT;QS\%O%W]BZK=^,[>PN+K[!;W.^W:TNY&3;/&ZC+1(<@9^7&<$YY<=E<LZP
MD\#&7*ZBM>U[?(\_-5!Y?44W96Z*_P"%U^9^:E%=9_P]=_;[_P"B]?\ EK:5
M_P#(M'_#UW]OO_HO7_EK:5_\BU\E_P 07QG_ $&1_P# '_\ )'YY[+ ?\_)?
M^ +_ .3/N_\ X)"?\FUZY_V/-S_Z1V5?5-?,W_!*G]H/XO?M)?L]:SXY^-/B
M[^VM5M/&=Q86]U]@M[;9;K:6DBIM@C13AI7.2,_-C. ,?3-?6X+*Y9+A(8&4
MN9TU:]K7^1^B96H++Z:B[JW56_"[_,\[_:F_9VT#]J+X-W_PJUG7+G2+EKB"
M^T37;%0T^EZA;R"6WN4!(#%7497(W*6&1G(^3?VG_B=^T)=ZM8_L=?MU_&?X
M<?#[P5XFT+[5K'Q!T**\C?Q':Q3A)]-B-P%ALKF10K2#,@$<OR9R5'W-XL\6
M^%_ ?AJ^\9>-?$%GI6DZ;;-<:AJ6H7"Q0V\2C+.[L0% ]37DW@;]NG]C'XY>
M*[#X;^'?BE87VHZG)NT:TUG1+NTCU%U&0;62[@CCN&P<CRF8GM74=XEE^RAX
M:\2_M!R_%'QSX<\-:KX1TCP#8>'/ 'A^>S%RME&)7FNIGCFC*(S;;6-"I8[(
M3G&<'/'['TW@G]K-?CK\%K/PYH/AW6OA[=>'?%^@VUL;7SIUF\ZSNXHX8]C.
M"SQN6*D(1C<>*]9'Q6^'O_"UC\#AXDB_X2H>'AKO]C^4^_\ L_S_ +/Y^[;L
MQYHV8W;L]L<UF>(OVA?@[X5\7:SX#UCQF@U?P[X;;7]<L+6SGN'L=/&?WTGE
M(P4G:2J$[V )52.: /G7]F[X(?\ !3[]F;X'^'?@3X3G^ M_IWARS:WM;S4;
MW6O.E4R/)E]D*KG+D< =*] \8_![]L?P5\4[[XP_L\_$7PGJ \46%HOBOP/X
M\N;X:;;WL,0C-SIUQ"LDEN& PT1C*L1N.&/'LO@;XA^"?B5X&T[XF>!?$MKJ
M6@ZM8K>:?JD#_NI8&&0_."ON" 5(((!!%<S>_M3?L^:7\%8OVBM6^*>FV7@J
MX!-KK]Z7ABN/G9 (U=0\A9E;8%4EQRNX$&@#SWX-_LL?%+6?C9XE_:5_:WUK
MPOJ7B+7O!8\(6GASPE!/_9EAHQF:>6)I;@++<22R-EF*H  0!@@+S7@#]GO]
MOK]G'P(_[/W[/WQ'^'&J>#+)I8?"?B#QHE\-8T.S=B5@:&&-H;TPAB(V9XP0
MH##'RCUKX(_MB?LV_M%:Y=^%OA%\3H-0U:QMQ<7.D7FGW-C>" G'G+!=Q1R/
M'D@;U4KDCGD5U?@?XK?#[XD:IX@T7P1XEBO[KPMK#:5K\,<3J;.\5%<Q-N4!
MB%=3E<CGK0!\_?%/_@GYK"?L#K^R1\%/%EE-KB:O9:K<>(/%3R(FI7Z:C'?7
M-Q.85=P9'5\  X!5<X&:;\1/@%_P4!_:>\.R?!_]H'XE?#+PKX'U5E3Q2/AU
M;ZC-J>IVF07LUEN]J0)(!M9P&;!(P02I^D/&WC3PM\./!^J>/_&^M1:=H^BV
M$M[JE_/G9;P1(7=R "3A03@ D] ":J_#3XG> _C#X"TWXG_#3Q+!J^@ZO;F;
M3M2MU8),@8J2 P###*P((!!!&* ,;XM?"5/%G[.'B;X%> H;/3%U+P1>Z#HL
M<NY;>T$EF]O"#M#$(N5Z G X!J;]G;X=:O\ "#]G[P+\)?$%Y;7%_P"%_!VF
M:1?7%FS&&6:VM(H79"P5BA9"1D X(R!TKRZW_P""J/[ MU:)J,7[0]G]E<_+
M=OHNH+#UQDR-;A0,\9)P*].O?VB?@E8:MX.T>?XCZ<TGQ \S_A#)X&:6WU8I
M&)"(IT!B)*$%06!?/RY- ':45@^./B=X$^&\^BVOC7Q#'8S>(M:BTG1(#&[O
M>7D@8I$BHI)^5&8MC:JJ2Q !-<)\6?VYOV5O@CXQG^'WQ$^*\4&MVD"S7^F:
M;I-YJ,ME&PRK7 M(9?LX(((,FW@@]#F@#@+O]G?]L#X%_&?QQX\_9'\0_#K4
M?#WQ#UA=:UCP_P#$%KZW?3M3,212RV\UHDGF)($5F1U&"  1@D]E\"OV?OBK
M\'_A?XXU34O'FE:M\3_'>HWFMZEK2V3PZ;!J3VR06T,<9W.+6%885&[<[ ,3
MRV!Z;\/OB)X%^*_@^Q^('PU\66&N:)J47F6.IZ;<++#,N2#AAW!!!!Y!!! (
M(K9H \/\9? O]I;XE_ 7PE%KWQNLM!^+/A:_CU-=?T"&5M(O+I?,5K>>V/EF
M:UDB?:RD!E.&7D8/$_$G]G;]M[]J_2M,^%'[3VM?"W0O T>LV>H>(T\"RZC=
M7^KBUF6=+=?M<<:6L;2(I9@9&&  >N?J2>:*WA>XF?:D:EG;T &2:POA?\4/
M 7QH\!:;\3_AAXBBU;0=7B:73M1AC=%G0.R$@.JL/F5AR!TH Q&TK]H7_AHH
M:ROB?P[_ ,*P_P"$7\IM(\B3^U/[7\[/F[]FSR/*XQNSN[=Z[JL/X<_$GP1\
M6_",'CSX=:_'J>D74]Q#!>Q1NBO)!/)!*N' /RRQ2+TZKQD8-9GQF^/7P?\
MV>_#,7B_XR^/;+0K&XNEMK1KG<\MU.W2*&*,-),Y&3M16. 3B@#KZ*\[^"/[
M5_[/O[1=[?Z3\(?B-#J6H:6BR:CI%U8W%C?6Z-P)'MKJ..8(20-^S;D@9KT2
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R'_P %I/VH
M?CI^R9^RWH/Q&_9^\<?V!K-[X_M=-N;S^S+6[WVKV-]*T>RYBD09>&,[@ WR
MXS@D'Z\KX%_X.+_^3)?"W_95+'_TVZG7T_!F'H8KBG"4JT%*$II--)IZ/=/1
MGRO&^(Q&$X3Q=:A-PG&%TXMIIW6S6J/@3_A]9_P4U_Z.6_\ +-T7_P"0Z/\
MA]9_P4U_Z.6_\LW1?_D.OEBBOZH_U6X8_P"@&C_X*A_\B?R9_K9Q3_T'UO\
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MG?V9];^%'@;5;"UUB6ZLK_34U96:RNIK6ZBN%M[@*"3%(8]IX.,@X.,5X?\
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M-VE>#?CM^T%^V2;5-5T_X5?#73/#V@K#)^ZO)WA?59XPXZ;GN+%"PS@#_9%
M'UW17QI\3/%/[97[-G[-MA^VYXP_:1G\3W%A!I^J>-OAY+X=L8=)>PN)(EFM
MK)XXA<0R0K-E97E?>8_F7YL5T'CCQG^U'\:OVT_$_P"SA\*?CDW@[PA8^"-$
MUV;6K/1+2YO+8RR72-#;^=&?FG(C9GDWB-;8A5!D) !]&^$/B=X$\>ZYK_AO
MPCXACO;[PMJ8T_7[=(W4V=R8DE$;%E 8[)$;*Y'S=<T?$'XG^!/A7I]AJGC_
M ,11Z;;ZIK-KI-A)+&[":\N9!'!"-BG!=R "< =R*^0%^/>J_LS:)^UO\8O#
MNE07VK6'Q0L;;1;2Y)\J2]NK'3;6#?@@E!),K, 02JD9'6H_VPOA'^T5\-_"
M'PKU+XA_M/7_ ([M[WXU>$E\0V&KZ#96T=O<F_C836+6L4;11AQL,4IERK@A
ME*G< ?<-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\"_\
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M7P*\3_!WQM\5/$WB'5+"YA\=_$&37M+2R=RT%NUG;0!)=RJ ^Z%CA2PP1SU
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MNL2W5E?Z:FK*S65U-:W45PMO<!028I#'M/!QD'!QBO#_ (J?M8O#H.E>#/\
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MN0 2<*"< $GH 357X:?$[P'\8? 6F_$_X:>)8-7T'5[<S:=J5NK!)D#%20&
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M'DXR9&MPH&>Y.*]R\6_\BKJ?_8/F_P#0#7Y]_LD?MYV?[.W_  32\(_\)?\
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M:=<3Q1N@2YMY6BFCPZ@Y5U92>AQP2*WJ^:?^"4O]O?\ #,FJ_P#"4FV.I_\
M"S/$_P#:1LE80^?_ &I/YGEAB2$W9QDDXQFOI:@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K\Y_^#G+_DPOPC_V5ZP_]->JU^C%%=F7XOZAC88CEORN
M]KVO\]3S<XR_^U<LJX3FY>=6O:]OE=7^\_D3HK^NRBOMO]?/^H?_ ,G_ /M3
M\Q_XA1_U&?\ E/\ ^W/SG_X-C?\ DPOQ=_V5Z_\ _37I5?HQ117Q688OZ_C9
MXCEY>9WM>]OGH?IV3Y?_ &5EE+"<W-R*U[6O\KNWWG ?M)_!SQ)\;/APOAWP
M/\3M1\'^(--U2VU7P_KVGDLL%Y;ON19X0P6Y@;E7A;Y6!SU KQ3XL? ']O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670686160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,719,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675588288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 2,530.3<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
<td class="nump">$ 7,449.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">638.7<span></span>
</td>
<td class="nump">659.6<span></span>
</td>
<td class="nump">1,726.9<span></span>
</td>
<td class="nump">1,915.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">542.7<span></span>
</td>
<td class="nump">736.3<span></span>
</td>
<td class="nump">1,509.5<span></span>
</td>
<td class="nump">1,891.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">588.4<span></span>
</td>
<td class="nump">788.2<span></span>
</td>
<td class="nump">1,723.7<span></span>
</td>
<td class="nump">1,941.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">130.3<span></span>
</td>
<td class="nump">60.9<span></span>
</td>
<td class="nump">295.5<span></span>
</td>
<td class="nump">164.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">69.3<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
<td class="nump">197.3<span></span>
</td>
<td class="nump">164.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on sale of priority review voucher, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
<td class="nump">248.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expense</a></td>
<td class="nump">2,014.8<span></span>
</td>
<td class="nump">2,671.5<span></span>
</td>
<td class="nump">5,606.7<span></span>
</td>
<td class="nump">6,444.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax (benefit) expense</a></td>
<td class="nump">451.0<span></span>
</td>
<td class="num">(141.2)<span></span>
</td>
<td class="nump">1,614.5<span></span>
</td>
<td class="nump">1,005.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">62.5<span></span>
</td>
<td class="num">(72.9)<span></span>
</td>
<td class="nump">249.0<span></span>
</td>
<td class="nump">92.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">388.5<span></span>
</td>
<td class="num">(68.3)<span></span>
</td>
<td class="nump">1,365.5<span></span>
</td>
<td class="nump">912.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 388.5<span></span>
</td>
<td class="num">$ (68.1)<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
<td class="nump">$ 911.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings (loss) per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="nump">$ 9.38<span></span>
</td>
<td class="nump">$ 6.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings (loss) per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="nump">$ 9.35<span></span>
</td>
<td class="nump">$ 6.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings (loss) per share attributable to Biogen Inc.</a></td>
<td class="nump">145,700<span></span>
</td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">145,500<span></span>
</td>
<td class="nump">144,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings (loss) per share attributable to Biogen Inc.</a></td>
<td class="nump">146,100<span></span>
</td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
<td class="nump">145,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,769.4<span></span>
</td>
<td class="nump">$ 1,805.2<span></span>
</td>
<td class="nump">$ 5,380.9<span></span>
</td>
<td class="nump">$ 5,414.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">446.2<span></span>
</td>
<td class="nump">420.9<span></span>
</td>
<td class="nump">1,284.7<span></span>
</td>
<td class="nump">1,253.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 250.2<span></span>
</td>
<td class="nump">$ 304.2<span></span>
</td>
<td class="nump">$ 555.6<span></span>
</td>
<td class="nump">$ 781.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670461120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 388.5<span></span>
</td>
<td class="num">$ (68.1)<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
<td class="nump">$ 911.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(41.0)<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">41.0<span></span>
</td>
<td class="num">(30.5)<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="num">(11.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">388.8<span></span>
</td>
<td class="num">(54.6)<span></span>
</td>
<td class="nump">1,373.5<span></span>
</td>
<td class="nump">917.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">$ 388.8<span></span>
</td>
<td class="num">$ (54.8)<span></span>
</td>
<td class="nump">$ 1,373.5<span></span>
</td>
<td class="nump">$ 918.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670546128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,699.2<span></span>
</td>
<td class="nump">$ 1,049.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,469.2<span></span>
</td>
<td class="nump">2,527.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">674.0<span></span>
</td>
<td class="nump">1,182.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,830.5<span></span>
</td>
<td class="nump">6,859.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,210.9<span></span>
</td>
<td class="nump">3,309.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">380.4<span></span>
</td>
<td class="nump">420.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">9,805.5<span></span>
</td>
<td class="nump">8,363.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,485.8<span></span>
</td>
<td class="nump">6,219.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">968.7<span></span>
</td>
<td class="nump">928.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">631.4<span></span>
</td>
<td class="nump">745.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">28,313.2<span></span>
</td>
<td class="nump">26,844.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion notes payable and term loan</a></td>
<td class="nump">1,748.1<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">499.1<span></span>
</td>
<td class="nump">257.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">422.7<span></span>
</td>
<td class="nump">403.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expense and other</a></td>
<td class="nump">2,755.1<span></span>
</td>
<td class="nump">2,623.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,425.0<span></span>
</td>
<td class="nump">3,434.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable and term loan</a></td>
<td class="nump">4,545.8<span></span>
</td>
<td class="nump">6,788.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">882.4<span></span>
</td>
<td class="nump">641.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">357.0<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">744.1<span></span>
</td>
<td class="nump">781.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,954.3<span></span>
</td>
<td class="nump">12,045.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments, contingencies and guarantees</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Inc. shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">488.5<span></span>
</td>
<td class="nump">302.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(145.7)<span></span>
</td>
<td class="num">(153.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">18,993.1<span></span>
</td>
<td class="nump">17,627.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">16,358.9<span></span>
</td>
<td class="nump">14,799.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">28,313.2<span></span>
</td>
<td class="nump">26,844.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $2.0 and $2.4, respectively</a></td>
<td class="nump">1,536.2<span></span>
</td>
<td class="nump">1,664.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $2.0 and $2.4, respectively</a></td>
<td class="nump">$ 451.9<span></span>
</td>
<td class="nump">$ 435.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675180848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts Receivable, Allowance for Credit Loss, Current</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674849808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,365.5<span></span>
</td>
<td class="nump">$ 912.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">489.2<span></span>
</td>
<td class="nump">354.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">68.7<span></span>
</td>
<td class="nump">62.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationOfInventoryStepUp', window );">Amortization of acquired inventory step-up</a></td>
<td class="nump">185.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">216.1<span></span>
</td>
<td class="nump">209.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(99.7)<span></span>
</td>
<td class="num">(377.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">(Gain) loss on strategic investments</a></td>
<td class="nump">22.7<span></span>
</td>
<td class="nump">275.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of priority review voucher, net</a></td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">95.1<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of business acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(207.4)<span></span>
</td>
<td class="num">(34.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense and other current liabilities</a></td>
<td class="num">(84.2)<span></span>
</td>
<td class="nump">293.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">62.1<span></span>
</td>
<td class="num">(114.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(65.7)<span></span>
</td>
<td class="num">(71.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by (used in) operating activities</a></td>
<td class="nump">2,114.6<span></span>
</td>
<td class="nump">1,534.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(114.4)<span></span>
</td>
<td class="num">(211.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">7,380.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(5,140.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition, net of cash acquired</a></td>
<td class="nump">1,074.8<span></span>
</td>
<td class="nump">6,335.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity interest in Samsung Bioepis</a></td>
<td class="nump">406.8<span></span>
</td>
<td class="nump">788.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of priority review voucher</a></td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(179.1)<span></span>
</td>
<td class="num">(34.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">96.7<span></span>
</td>
<td class="nump">106.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(4.4)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow provided by (used in) investing activities</a></td>
<td class="num">(780.6)<span></span>
</td>
<td class="num">(3,448.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(34.8)<span></span>
</td>
<td class="num">(48.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings</a></td>
<td class="nump">650.0<span></span>
</td>
<td class="nump">159.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">997.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Net (distribution) contribution to noncontrolling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(6.6)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow provided by (used in) financing activities</a></td>
<td class="num">(691.4)<span></span>
</td>
<td class="nump">795.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">642.6<span></span>
</td>
<td class="num">(1,118.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="num">(12.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,049.9<span></span>
</td>
<td class="nump">3,419.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">1,699.2<span></span>
</td>
<td class="nump">2,287.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of business acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">127.6<span></span>
</td>
<td class="num">(76.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of business acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">$ (15.9)<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationOfInventoryStepUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Inventory Step-Up</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationOfInventoryStepUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501682022560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">167.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 13,388.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 73.3<span></span>
</td>
<td class="num">$ (164.9)<span></span>
</td>
<td class="nump">$ 16,466.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 13,397.9<span></span>
</td>
<td class="num">$ (9.5)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">912.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911.4<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(86.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">217.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">14,479.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">242.2<span></span>
</td>
<td class="num">(159.3)<span></span>
</td>
<td class="nump">17,377.9<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">14,483.8<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">168.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="nump">14,460.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
<td class="num">(172.8)<span></span>
</td>
<td class="nump">17,446.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">14,466.9<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="num">(68.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">64.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">14,479.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">242.2<span></span>
</td>
<td class="num">(159.3)<span></span>
</td>
<td class="nump">17,377.9<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 14,483.8<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">14,799.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">302.5<span></span>
</td>
<td class="num">(153.7)<span></span>
</td>
<td class="nump">17,627.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,365.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(66.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">224.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">16,358.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">488.5<span></span>
</td>
<td class="num">(145.7)<span></span>
</td>
<td class="nump">18,993.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2024</a></td>
<td class="nump">15,889.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">407.5<span></span>
</td>
<td class="num">(146.0)<span></span>
</td>
<td class="nump">18,604.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">388.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 16,358.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 488.5<span></span>
</td>
<td class="num">$ (145.7)<span></span>
</td>
<td class="nump">$ 18,993.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NoncontrollingInterestCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NoncontrollingInterestCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683682144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2024, we completed the acquisition of HI-Bio. As a result of this transaction we acquired HI-Bio's lead asset, felzartamab, an anti-CD38 antibody currently being evaluated for three leading indications, AMR, PMN and IgAN. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets, as well as TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2023 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on advancing our pipeline in neurology, specialized immunology and rare diseases.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. In November 2023 we terminated the Neurimmune Agreement, which resulted in the deconsolidation of our variable interest entity, Neurimmune. For additional information on the deconsolidation of Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2023 Form&#160;10-K.</span><span style="color:#3051f2;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024 the SEC issued a final rule under SEC Release No. 33-11275, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new rule will require large accelerated filers to disclose material climate-related risks that are reasonably likely to have a material impact on their business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and/or material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the new rules will require disclosure within the notes to the financial statements of the effects of severe weather events and other natural conditions and information on any climate-related targets or goals, subject to certain materiality thresholds. The final rule, if adopted, includes a phased-in compliance period which will begin phasing in with our annual report for the year ending December 31, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that this new rule will have on our company's disclosures.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023 the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. All disclosure requirements under this standard are also required for public entities with a single reportable segment. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. While this accounting standard will increase disclosures, we do not expect the adoption of this standard to have a material impact on our consolidated financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675184592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 2:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acquisitions</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Human Immunology Biosciences</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody, is currently being evaluated for three leading indications, Antibody-Mediated Rejection (AMR), Primary Membranous Nephropathy (PMN) and Immunoglobulin A Nephropathy (IgAN). Felzartamab has received Breakthrough Therapy Designation and ODD from the FDA for development in the treatment of PMN and AMR and has received ODD in the treatment of antibody-mediated rejection in kidney transplant recipients. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we paid shareholders of HI-Bio approximately $1.15&#160;billion at closing and may pay up to an additional </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$650.0&#160;million in potential future development and regulatory milestone payments.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $1.15&#160;billion paid includes approximately $74.5&#160;million related to HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, of which $56.4&#160;million was recognized as share-based compensation payments to settle non-vested equity awards attributable to the post-acquisition service period and therefore not reflected as a component of total purchase price paid. Of the total $56.4&#160;million, we recognized approximately $42.5&#160;million as a charge to research and development expense with the remaining $13.9&#160;million as a charge to selling, general and </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing we also paid an additional </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$43.7&#160;million related to working capital adjustments as of the transaction close date, which was included as a component of total purchase price paid.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded this acquisition through available cash on hand and accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the lead program felzartamab, the HI-Bio pipeline acquired includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial, and the potential for continued development in a range of complement-mediated diseases.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Consideration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of HI-Bio is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of July&#160;2, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to HI-Bio shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,622.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> Represents total consideration paid to shareholders of HI-Bio of $1.15&#160;billion, plus an additional $43.7&#160;million related to working capital adjustments as of the transaction close date, less $56.4&#160;million of cash paid for HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, which were recognized as compensation attributable to the post-acquisition service period and therefore not reflected as a component of total consideration. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Contingent Consideration:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We may make certain contingent payments to the former shareholders of HI-Bio upon the achievement of certain development and regulatory milestones. As of the acquisition date, the maximum aggregate amount payable for these potential milestones was $650.0&#160;million. The acquisition-date fair value of these milestones was approximately $485.1&#160;million and was estimated utilizing a probability-adjusted discounted cash flow calculation using an appropriate discount rate dependent on the nature and timing of the milestone payments, which ranged from </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.2% to 7.0%, and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">probabilities of technological and regulatory success ranging from 67.0% to near certain probability.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Of the total contingent consideration, approximately $279.3&#160;million related to milestones classified as short-term and reflected as a component of accrued expense and other with the remaining $205.8&#160;million reflected as a component of other long-term liabilities within our condensed consolidated balance sheets. The short-term liability relates to the fourth patient dosed in a phase 3 clinical trial of felzartamab in a first and s</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">econd indication, which would trigger milestone payments of $150.0&#160;million each.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent changes in the fair value of the contingent consideration obligation will be recognized as (gain) loss on fair value remeasurement of contingent consideration within our condensed consolidated statements of income. This fair value measurement was based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements. For additional information related to the fair value of this obligation, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Contractual Commitments: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired HI-Bio's pre-existing in-license commitments under third-party agreements, which include tiered royalties on potential future sales of felzartamab and izastobart/HIB210, ranging from high-single digit to mid-teen percentages, as well as potential future development, regulatory and commercial milestone payments related to felzartamab and izastobart/HIB210 of up to $130.0&#160;million, $230.0&#160;million and $640.0&#160;million, respectively. Because the achievement of these milestones was not considered probable as of the transaction close date, such contingencies have not been recorded in our financial statements.</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Preliminary Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation of the separately identifiable assets acquired and liabilities assumed as of July&#160;2, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July&#160;2, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (IgAN)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">920.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (AMR)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (PMN)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expense and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(304.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,622.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intang</span><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ible assets:</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets comprised of $1.6&#160;billion of IPR&amp;D related to HI-Bio's lead asset felzartamab. This includes $920.0&#160;million of IPR&amp;D related to felzartamab indication for IgAN, $450.0&#160;million of IPR&amp;D related to felzartamab indication for AMR and $265.0&#160;million of IPR&amp;D related to felzartamab indication for PMN. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing cash flow analyses and a discount rate of 14.5%. These fair value measurements were based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acq</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uired that could not be individually identified and separately recognized. We recognized goodwill of approximately $256.5&#160;million, which is not deductible for tax purposes. The goodwill recognized from our acquisition of HI-Bio is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-related expenses:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acquisition-related expense, primarily comprised</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of advisory and legal fees, and other transaction costs, totaled approximately $2.8&#160;million and were recorded within selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Assumptions in the Allocations of Purchase Price</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he results of operations of HI-Bio, along with the estimated fair values of the assets acquired and liabilities assumed in the HI-Bio acquisition, have been included in our condensed consolidated financial statements since the closing of the HI-Bio acquisition on July&#160;2, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management's analysis related to certain matters, such as finalizing our assessment of intangible assets, goodwill and income taxes, among other items. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. The final determination may result in asset and liability fair values that are different than the preliminary estimates. There were no purchase price allocation adjustments during the third quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the acquisition date, our results of operations include the results of operations of HI-Bio. HI-Bio operations had an immaterial impact on our results of operations for the three and nine months ended September 30, 2024. Due to the immateriality of HI-Bio's historic revenue and expenses, additional pro forma information combining the results of operations of Biogen and HI-Bio have not been included.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a  biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction we acquired SKYCLARYS (omaveloxolone), the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs. The acquisition of Reata is expected to complement our global portfolio of neuromuscular and rare disease therapies. The addition of SKYCLARYS is anticipated to provide potential operating synergies with SPINRAZA and QALSODY.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we paid Reata shareholders $172.50 in cash for each issued and outstanding Reata share, which totaled approximately $6.6&#160;billion. In addition, we agreed to pay approximately $983.9&#160;million in cash for Reata's outstanding equity awards, inclusive of employer taxes, of which approximately $590.5&#160;million was attributable to pre-acquisition services and is therefore reflected as a component of total purchase price paid. Of the $983.9&#160;million paid to Reata's equity award holders, we recognized approximately $393.4&#160;million as compensation attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded this acquisition through available cash, cash equivalents and marketable securities, supplemented by the issuance of a $1.0 billion term loan under our 2023 Term Loan. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Consideration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of Reata is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to Reata shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,602.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of Reata equity compensation pre-acquisition services and related taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents cash consideration transferred of $172.50 per outstanding Reata common stock based on 38.3&#160;million Reata shares outstanding at closing.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We finalized purchase accounting for this acquisition in the third quarter of 2024. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, and reflects measurement period adjustments made to the amounts initially recorded as of the acquisition date on September&#160;26, 2023. The measurement period adjustments summarized below resulted from updates to our valuation assumptions related to the estimated amounts and timing of future cash flows associated with certain intangible assets, updates of our assumptions related to the quantities, selling location and remaining manufacturing and selling costs of acquired inventory, and other assets and liabilities. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as adjusted)</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,259.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology for SKYCLARYS (U.S.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,200.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development (omaveloxolone)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,300.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payable to Blackstone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(300.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(909.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,724.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes measurement period adjustments recorded in the first quarter of 2024 that increased accrued expense and other by $4.9&#160;million, deferred tax liability by $4.1&#160;million and goodwill by $9.0&#160;million, as well as </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">measurement period adjustments recorded in the third quarter of 2024 that increased other current assets by $1.0&#160;million and accrued expense and other by $3.9&#160;million, and decreased deferred tax liability by $7.2&#160;million and goodwill by $4.3&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total inventory acquired was</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $1.3&#160;billion, which reflects a step-up in the fair value of finished goods and work-in-process inventory for SKYCLARYS. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold, which is expected to be sold over a period of approximately 4 years from the acquisition date. For the three and nine months ended September 30, 2024, amortization from the fair value step-up adjustment was approximately $50.9&#160;million and $185.1&#160;million, respectively. The three and nine months ended September 30, 2024, include approximately $2.5&#160;million and $48.5&#160;million, respectively, of inventory used for clinical purposes, which is reflected within research and development expense within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intang</span><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ible assets:</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets are comprised of $4.2&#160;billion related to SKYCLARYS commercialization rights in the U.S., $2.3&#160;billion of IPR&amp;D related to the omaveloxolone program outside the U.S., which had not yet received regulatory approval in the E.U. as of the acquisition date, $100.0&#160;million related to a rare pediatric disease priority voucher which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party and $40.0&#160;million related to other clinical programs. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing a discount rate of 14.3% and the estimated fair value of the priority review voucher was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our valuation of the SKYCLARYS commercialization rights reflects the assumption that, using an economic consumption model, the related $4.2&#160;billion intangible asset will be amortized over its expected economic life. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon SKYCLARYS </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receiving E.U. regulatory approval in February 2024, we began selling the product in certain countries in Europe, and began amortizing the $2.3&#160;billion I</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PR&amp;D asset related to the program outside the U.S. over its expected economic life using an economic consumption model. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $121.2&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. We recognized goodwill of approximately $469.2&#160;million, which is not deductible for tax purposes. The goodwill recognized from our acquisition of Reata is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-related expenses:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acquisition-related expense, primarily comprised of regulatory, advisory and legal fees, and other transaction costs, totaled approximately $26.3&#160;million and were recorded within selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675352720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Dispositions</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $2.3&#160;billion. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing, with approximately $1.3&#160;billion in cash to be deferred over two payments. The first deferred payment of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$812.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2023 and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the second deferred payment of $437.5&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2024, we recognized</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> a gain</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$7.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to reflect the change in fair value associated with the passage of time related to the second deferred payment </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">due to us, which was received in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2023, we recognized a gain of approximately $13.7&#160;million to reflect the change in fair value associated with changes in interest rates and the passage of time related to the first deferred payment due to us, which was received in April 2023. Additionally, for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three and nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2023, we recognized gains of approximately $7.1&#160;million and $16.9&#160;million, respectively, to reflect the changes in fair value associated with changes in interest rates and the passage of time related to the second deferred payment due to us, which was received in April 2024. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $103.0&#160;million upon the closing of the PRV purchase, of which approximately $14.4&#160;million was paid to Ionis. Our net portion of approximately $88.6&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675184592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring, Business Transformation and Other Cost Saving Initiatives</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Fit for Growth Restructuring Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately 1,000 employees and we expect to incur restructuring charges ranging from approximately $260.0&#160;million to $280.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Integration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimate we will incur total integration charges ranging from approximately $35.0&#160;million to $40.0&#160;million, related to severance and employment costs, which are expected to be paid by the end of 2024. These amounts were substantially incurred during 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We do not intend to occupy this building and are evaluating opportunities to sublease the property. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HI-Bio Integration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, following the close of our HI-Bio acquisition in July 2024, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we incurred approximately $1.5&#160;million of severance and employment costs, which are reflected in restructuring charges within our condensed consolidated statements of income for the three and nine months ended September 30, 2024.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restructuring Reserve</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to workforce reductions are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of January 1</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683603040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">507.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">527.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,159.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">956.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,805.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">611.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">739.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">768.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">677.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">571.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">616.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">604.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,299.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,631.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,648.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,814.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,678.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,493.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">453.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">455.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,331.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,975.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,380.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,414.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 25.9% and 14.8% of gross product revenue for the three months ended September 30, 2024, and 25.6% and 12.9% of gross product revenue for the nine months ended September 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 26.9% and 10.5% of gross product revenue for the three months ended September 30, 2023, and 27.1% and 9.1% of gross product revenue for the nine months ended September 30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">605.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,004.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,625.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(439.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,391.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,831.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(514.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(692.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">923.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">928.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Manufacturing, Royalty and Other Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized in the table below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">742.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers. During the first quarter of 2023 we began recognizing contract manufacturing revenue for LEQEMBI, upon accelerated approval of LEQEMBI in the U.S. Prior to accelerated approval, our share of contract manufacturing amounts related to LEQEMBI were recognized in research and development expense within our condensed consolidated statements of income.</span></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, </span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we are not the principal, as well as royalties we receive from net sales on products related to patents that we have out-licensed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675392512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,803.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,926.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,563.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,609.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,469.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,527.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,563.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,609.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term inventory is included in investments and other assets within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recorded approximately $1.3&#160;billion of acquired inventory, which includes measurement period adjustments, related to SKYCLARYS as a result of our acquisition of Reata in September 2023. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold, which is expected to be sold over a period of approximately 4 years from the acquisition date. For the three and nine months ended September 30, 2024, amortization from the fair value step-up adjustment was approximately $50.9&#160;million and $185.1&#160;million, respectively. The three and nine months ended September 30, 2024, include approximately $2.5&#160;million and $48.5&#160;million, respectively, of inventory used for clinical purposes, which is reflected within research and development expense within our condensed consolidated statements of income. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501668874512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired and in-licensed rights and patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-21 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,552.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,697.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,855.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,180.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,440.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,739.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13-31 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,548.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,445.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,548.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,429.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,101.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,142.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,958.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,728.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,869.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,859.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,682.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,682.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,340.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,340.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,948.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,142.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,805.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,232.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,869.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,363.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets, totaled </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$130.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$295.5 million, respectively, compared to $60.9 million and $164.0 million, respectivel</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, a</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mortization of acquired intangible assets, excluding impairment charges, totaled $110.1 million and $275.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$164.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, in the prior year comparative periods. The increases were primarily due to amortization for the Reata acquisition acquired intangible assets associated with SKYCLARYS. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets reflects impairment charges of $20.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, related to intangible assets associated with Samsung Bioepis commercializ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ation rights terminated during the third quarter of 2024. For the three and nine months ended September 30, 2023, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no impair</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ment charges.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our 2019 Development and Commercialization Agreement with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between 2 to 31 years, with a remaining weighted average useful life of 13 years for acquired and in-licensed rights and patents and 10 years for developed technology and other. In connection with our acquisition of Reata in September 2023 we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately $4.2&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset, with an estimated fair value of approximately $2.3&#160;billion, from IPR&amp;D to completed technology.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value associated with our IPR&amp;D assets as of December 31, 2023, related to the IPR&amp;D programs we acquired in connection with our acquisition of Reata in September 2023, with an estimated fair value of approximately $2.3&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset from IPR&amp;D to completed technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value associated with our IPR&amp;D assets as of September 30, 2024, primarily relates to the IPR&amp;D programs we acquired in connection with our acquisition of HI-Bio in July 2024, with an estimated fair value of approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.6&#160;billion.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease PRV that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $100.0&#160;million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisitions of Reata and HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">615.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,219.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from HI-Bio acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from Reata acquisition</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,485.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to Reata measurement period adjustments recognized during the nine months ended September 30, 2024.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisitions of Reata and HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675410944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,156.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,506.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value as of September 30, 2024 and December 31, 2023. In addition, there have been no changes to our valuation techniques as of September 30, 2024 and December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4% - 5.8%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rates were calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of our contingent consideration obligations, which ranged from 67.0% to near certain probability as of September 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 as of September 30, 2024 and December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligation, which was classified as a Level 3 measurement:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.176%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three and Nine Months Ended September 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration resulting from HI-Bio acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, approximately $287.1 million of the fair value of the total contingent consideration obligation was classified as short-term and reflected as a component of accrued expense and other within our condensed consolidated balance sheets with the remaining $221.8 million reflected as a component of other long-term liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the three and nine months ended September 30, 2024, the changes in the fair value of our contingent consideration obligations were primarily due to changes in interest rates used to revalue our contingent consideration liabilities, the passage of time and updates to the expected timing of achieving certain milestones which will trigger contingent consideration payments.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan 364-day tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,739.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,739.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan three-year tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,721.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,339.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,493.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,034.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">475.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,943.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,545.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,137.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,788.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,683.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,293.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,287.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,938.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we drew $1.0 billion from our 2023 Term Loan, comprised of a $500.0 million floating rate 364-day tranche and a $500.0 million floating rate three-year tranche. As of September 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The fair values of our Senior Notes as of September 30, 2024, compared to December 31, 2023, remained flat reflecting a mix of higher and lower U.S. treasury yields and credit spreads across the maturity spectrum. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675184592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our money market funds approximates fair value due to their short-term maturities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable equity securities, classified as available-for-sale:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(421.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">734.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(429.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">948.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(542.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(563.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.747%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,698.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,380.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of December 31, 2023, we have sold all of our marketable debt securities. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three and nine months ended September 30, 2023, primarily relate to sales of U.S. treasuries and corporate bonds.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, our strategic investment portfolio was comprised of investments totaling $353.3 million and $460.7 million, respectively, which are included in other current assets and investments and other assets within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio as of September 30, 2024, was primarily due to the decrease in the fair value of our investment in Sage common stock, partially offset by an increase in the fair value of our investment in Denali common stock. Additionally, we sold a portion of our Denali and Sangamo common stock during 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our strategic investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2023 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501676093424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of September 30, 2024 and December 31, 2023, had durations of 1 to 15 months and 1 to 12 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,569.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,686.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized losses of approximately $41.5&#160;million to be settled over the next 15 months, of which approximately $38.5&#160;million of these net unrealized losses are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2024 and December 31, 2023, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $1,339.6 million and $1,301.5 million as of September 30, 2024 and December 31, 2023, respectively. Net gains of $23.4 million and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net losses of $6.6 million related to these contracts were recorded as a component of other (income) expense, net for the three and nine months ended September 30, 2024, respectively, compared to net losses of $22.6 million and $28.0 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501676105904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,604.4 million and $2,402.5 million as of September 30, 2024 and December 31, 2023, respectively. For the three and nine months ended September 30, 2024, depreciation expense totaled $72.7 million and $213.9 million, respectively, compared to $64.1 million and $190.7 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we built a large-scale biologics manufacturing facility in Solothurn, Switzerland. This facility includes 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of December 31, 2023, we had approximately $728.8 million capitalized as construction in progress related to this facility. In the second quarter of 2021 a portion of this facility (the first manufacturing suite) received a GMP multi-product license from SWISSMEDIC and was placed into service. The second manufacturing suite, which was also licensed to operate by SWISSMEDIC, became operational in the first quarter of 2024, resulting in approximately $717.3&#160;million of fixed assets being placed into service. Solothurn has been approved for the manufacture of LEQEMBI.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675392512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6100 Legacy Drive Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $121.2&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675384480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text">Credit Agreement<div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $1.0 billion from the 2023 Term Loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of December 31, 2023, we repaid $350.0&#160;million of the 364--day tranche. The remaining $150.0&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the first quarter of 2024 we repaid $250.0&#160;million of the three-year tranche, with the remaining $250.0&#160;million portion of the three-year tranche being subsequently repaid in full during the second quarter of 2024. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675381776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and nine months ended September 30, 2024 and 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(172.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.372%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683769872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income (loss) per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675956736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we recognized Reata equity-based compensation expense, inclusive of employer taxes, of approximately $393.4&#160;million attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we recognized HI-Bio equity-based compensation expense, inclusive of employer taxes, of approximately $56.4&#160;million attributable to the post-acquisition service period, of which $42.5&#160;million was recognized as a charge to research and development expense with the remaining $13.9&#160;million as a charge to selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HI-Bio equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the Reata and HI-Bio equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to Reata and HI-Bio employees and required no future services to vest. For additional information on our acquisition of Reata and HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Omnibus Equity Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024 our shareholders approved the 2024 Omnibus Equity Plan for share-based awards to our prospective and current employees, non-employee directors, officers or consultants. Awards granted from the 2024 Omnibus Equity Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2024 Omnibus Equity Plan consist of 3.7 million shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) on the date that our shareholders approved the 2024 Omnibus Equity Plan, plus shares that were subject to awards under the 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) that remain unissued upon the cancellation, surrender, exchange, termination or forfeiture of such awards. The 2024 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a 1.5-to-1 ratio.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not made any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan since our shareholders approved the 2024 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan in the future, except that unused shares under the 2017 Omnibus Equity Plan have been carried over for use under the 2024 Omnibus Equity Plan. Awards outstanding under the 2017 Omnibus Equity Plan and the Directors Plan as of the date our shareholders approved the 2024 Omnibus Equity Plan will remain outstanding and subject to the terms and conditions of the 2017 Omnibus Equity Plan and the Directors Plan, as applicable, and the relevant award agreements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024 our shareholders approved the 2024 ESPP. The 2024 ESPP, which became effective on July 1, 2024, replaced the 2015 ESPP, which expired on June 30, 2024. The maximum number of shares of our common stock that may be purchased under the 2024 ESPP is 2.5 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675412256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings, including valuation allowances</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased inventory valuation step-up and intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, compared to the same periods in 2023, our effective tax rate includes a decrease in our valuation allowance related to changes in projected future foreign taxable income, partially offset by the impact of certain foreign uncertain tax positions.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for the three months ended September 30, 2023, reflects a tax benefit of $72.9&#160;million recognized as a result of a pretax loss from operations of $141.2&#160;million recorded during the third quarter of 2023, which was driven, in part, by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses. For all other periods presented, the effective tax rates reflect tax expense on pretax income from operations in the respective periods.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nine months ended September 30, 2023, was also impacted by the resolution of an uncertain tax matter related to tax credits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2019 or state, local or non-U.S. income tax examinations for years before 2013.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $55.0&#160;million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683679152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(252.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2024, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $53.3&#160;million, partially offset by a decrease in the fair value of Sage common stock of approximately $22.7&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $295.6&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage common stock of approximately $90.2&#160;million, partially offset by an increase in the fair value of Denali and Sangamo common stock of approximately $70.1&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $265.0&#160;million.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata related accrued expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,755.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div>Other long-term liabilities were $744.1 million and $781.1 million as of September 30, 2024 and December 31, 2023, respectively, and included accrued income taxes totaling $162.0 million and $403.2 million, respectively<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675364720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 19:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborative and Other Relationships</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">U.S.:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">Canada:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0&#160;million. There will be a 50.0% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUNSUMIO (mosunetuzumab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. Under our collaboration with Genentech, we were responsible for 30.0% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S. In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COLUMVI (glofitamab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 we entered into an agreement with Genentech related to the commercialization and sharing of economics for COLUMVI, a bispecific antibody for the treatment of B-cell non-Hodgkin's lymphoma, which was subsequently granted accelerated approval by the FDA in June 2023. Under the terms of this agreement, we will have no payment obligations. Genentech will have sole decision-making rights on the commercialization of COLUMVI within the U.S. and we will receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 Roche announced that COLUMVI, in combination with chemotherapy GemOx (glofitamab-gxbm), demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma</span><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Formulas</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN and LUNSUMIO Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a 30.0% share on the first $50.0&#160;million of combined co-promotion operating profits earned each calendar year. As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $150.0&#160;million.</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $350.0&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was 35.0%.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share on the first $50.0&#160;million of operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second GAZYVA Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the Second GAZYVA Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for GAZYVA was 35.0%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023 we accrued a $31.0&#160;million payable to Eisai related to the termination of an agreement whereby Eisai co-promoted or distributed our MS products in certain Asia-Pacific markets and settings. As of December 31, 2023, we paid approximately $16.0 million of the $31.0&#160;million payable. The remaining portion was subsequently paid in January 2024. This termination fee is included in selling, general and administrative expense in our condensed consolidated statements of income for the nine months ended September 30, 2023.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LEQEMBI (lecanemab) Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease (the LEQEMBI Collaboration).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We and Eisai co-promote LEQEMBI and share profits and losses equally. We currently manufacture LEQEMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 the FDA granted traditional approval of LEQEMBI. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Outside of the U.S., LEQEMBI is now approved in Japan (September 2023), China (January 2024), South Korea (May 2024), Hong Kong (July 2024), Israel (July 2024), United Arab Emirates (August 2024) and Great Britain (August 2024).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of LEQEMBI in the U.S., we began recognizing our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, within other revenue in our condensed consolidated statements of income, as we are not the principal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of LEQEMBI sales and marketing expense and development expense are recorded within selling, general and administrative expense and research and development expense, respectively, within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s discussed above were approximately $93.2&#160;million and $1.4&#160;million as of September 30, 2024 and December 31, 2023, respectively. Amounts payable to Eisai related to the agreements discussed above were approximately $146.2&#160;million and $118.4&#160;million as of September 30, 2024 and December 31, 2023, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the treatment of PPD and potential treatment of MDD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">epilepsy. In July 2024 we and Sage announced that the Phase 2 KINETIC 2 dose-range study of BIIB124 did not meet its endpoints. Based on these results, we discontinued our further development of BIIB124.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. ZURZUVAE for PPD became commercially available in the U.S. during the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024 we and Sage agreed to not pursue further development of zuranolone for the potential treatment of MDD. This decision was based on the significant new investment and time we expect would be needed to conduct the additional studies required to support approval of this indication.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. During the fourth quarter of 2023 we accrued a milestone payment due to Sage of $75.0&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S., which was recorded within intangible assets, net in our condensed consolidated balance sheets, and subsequently paid in January 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, we recognized net profit-sharing expense of approximately $9.0 million and $20.5 million, respectively, to reflect Sage's 50.0% share of net collaboration results in the U.S. for ZURZUVAE for PPD, compared to net loss reimbursement of approximately $5.9 million in both prior year comparative periods. These amounts are recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Sage collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Sage collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease (LRRK2 Collaboration) and also entered into a separate agreement to obtain an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its ATV-enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. In July 2024 we terminated our license with Denali for the ATV-enabled anti-amyloid beta program. This termination also results in the termination of the exclusive option agreement, as discussed above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LRRK2 Collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, we recorded approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">zero and $2.8 million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the prior year comparative periods.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024 we notified Samsung Bioepis of our decision to terminate our 2019 Development and Commercialization Agreement (the DCA Agreement) solely within the U.S. and Canada. As a result of this termination we recognized impairment charges of approximately $20.2 million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which were recorded within amortization and impairment of acquired intangible assets within our condensed consolidated statements of income for the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2024. Biogen will transfer commercialization rights for BYOOVIZ and OPUVIZ in the U.S. and Canada back to Samsung Bioepis over a period of up to 18 months. During this transition period, we will continue to commercialize BYOOVIZ. The termination does not impact the other markets in the DCA Agreement.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Samsung Bioepis up to approximately $165.0 million in additional development, regulatory and sales-based milestones associated with the remaining major markets covered by the agreement.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2024, we recognized net profit-sharing expense of approximately $60.3&#160;million and $176.8&#160;million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of approximately $56.4 million and $170.4 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024 we exercised our option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years. In connection with this exercise, we paid Samsung Bioepis an option exercise fee of $60.0 million in July 2024 which was recognized in intangible assets, net within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufa</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cturing, royalty and other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were approximately $20.9&#160;million and $9.9&#160;million as of September 30, 2024 and December 31, 2023, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were approximately $82.6&#160;million and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$73.7&#160;million as of September 30, 2024 and December 31, 2023, respectively.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span> to our consolidated financial statements included in our 2023 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675175712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2007 we consolidated the results of Neurimmune as we determined we were the primary beneficiary because we had the power through the collaboration to direct the activities that most significantly impacted the entity's economic performance and we were required to fund 100.0% of the research and development costs incurred in support of the collaboration. The collaboration and license agreement with Neurimmune was for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023 we notified Neurimmune of our decision to terminate the Neurimmune Agreement. Subsequent to the termination, we reconsidered our relationship with Neurimmune and determined that we were no longer the primary beneficiary of the variable interest entity. As a result, we recorded a net gain on the deconsolidation of Neurimmune of approximately $3.0&#160;million, which was recorded in other (income) expense, net within our consolidated statements of income for the year ended December 31, 2023, included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $23.6 million and $16.4 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683765408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims, investigations and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2023 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. If an estimate of the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation asserted against Biogen</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are defendants in three securities actions pending in the District Court, one filed by Nadia Shash and Amjad Khan in November 2020 and related to ADUHELM, one filed by the Oklahoma Firefighters Pension and Retirement System in February 2022 and related to ADUHELM and one filed by Thomas Allen Gray in June 2024 and related to statements about our compliance controls, 2023 earnings guidance and other matters. All allege violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation asserted against Reata</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in March 2024 the United States District Court for the Eastern District of Texas granted final approval of the previously disclosed settlement of litigation filed by putative stockholders of Reata (later acquired by Biogen) alleging violations of the federal securities laws by Reata, certain of its former officers and directors, and certain underwriters under 15 U.S.C. &#167;78j(b) and &#167;78t(a), 17 C.F.R. &#167;240.10b-5, and 15U.S.C. &#167;&#167;77k, 77l(a)(2) and 77o, and dismissed the action with prejudice.  </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Actions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and members of the Board of Directors are named as defendants in five derivative actions pending in the District Court, one filed by The Booth Family Trust in February 2022, one filed by Elaine Wang in July 2022, one filed by Jonathan Blaufarb (Blaufarb I) in July 2024, one filed by Lawrence Hollin in October 2024 and one filed by Jonathan Blaufarb (Blaufarb II) in October 2024. The Booth, Wang and Blaufarb II actions relate to ADUHELM and other matters, and the Blaufarb and Hollin actions relate to statements about our compliance controls, 2023 earnings guidance and other matters. The actions allege breach of fiduciary duty, waste of corporate assets and other common law claims, and violations of the Securities Exchange Act of 1934, 15 U.S.C. &#167;78a et seq. The actions seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#8217; fees and costs payable to the plaintiffs. The Booth and Wang actions are stayed.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Technical Boards of Appeal of the European Patent Office upheld the validity of Fresenius Kabi Deutschland GmbH's (Fresenius Kabi's) European Patent 3 145 488 (the EP '488 Patent), which expires in May 2035. In June 2022 Fresenius Kabi filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes the French counterpart of the EP &#8216;488 Patent. In March 2024 the D&#252;sseldorf Regional Court dismissed Fresenius Kabi's claim of infringement of the German counterpart of the EP '488 Patent and Fresenius Kabi has appealed to the Higher Regional Court of D&#252;sseldorf.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Former Convergence Shareholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, asserted claims of $200.0 million for alleged breaches of the contract pursuant to which we acquired Convergence. In June 2023 Shareholder Representative Services LLC and 24 former shareholders filed a suit against us in the High Court of Justice of England and Wales asserting one of the 2019 claims and seeking payment of $49.9&#160;million, interest and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the District Court dismissed the previously disclosed action filed against us by Humana in September 2020. Humana had alleged damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients and had alleged violations of the federal RICO Act and state laws. In December 2023 Humana appealed to the United States Court of Appeals for the First Circuit and the appeal is pending.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023 Genentech, Inc. filed suit against us in the U.S. District Court for the Northern District of California and claims that it is owed royalties of approximately $92.7&#160;million on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen, together with interest and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lender Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2024, BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP filed suit against us and Reata Pharmaceuticals, Inc. in the Supreme Court of the State of New York alleging breach of a loan agreement with Reata and seeking payment of approximately $23.2&#160;million, plus interest, costs and attorneys' fees.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Antitrust Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August and September 2024, four suits were filed against us in the U.S. District Court for the Northern District of Illinois, by Local No. 1 Health Fund; the Mayor and City Council of Baltimore; New York State Teamsters Council Health and Hospital Fund; and Teamsters Local 237 Welfare Fund and Teamsters Local 237 Retirees' Benefit Fund. Plaintiffs allege violations of federal antitrust laws including 15 U.S.C. &#167;&#167; 1, 2 and 13(c) and various state laws, based on contracts with pharmacy benefit managers related to TECFIDERA and VUMERITY. Plaintiffs seek declarations of the actions as class actions, monetary, declaratory and equitable relief, and attorneys' fees and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received subpoenas from the SEC seeking information relating to ADUHELM and its launch, and our equity plans. We have also received subpoenas from the DOJ and SEC seeking information relating to our business operations in several foreign countries. The Italian Competition Authority is investigating Biogen and other companies in relation to our biosimilar product BYOOVIZ.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TYSABRI Biosimilar Patent Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#167;262, seeking a declaratory judgment of patent infringement.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annulment Proceedings in the General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 Mylan Ireland filed an action in the General Court of the European Union (General Court) to annul the EMA's decision not to validate its applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. In October 2024 the General Court dismissed the action.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674772208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 388.5<span></span>
</td>
<td class="num">$ (68.1)<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
<td class="nump">$ 911.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683490032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674772208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Business Overview</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;2, 2024, we completed the acquisition of HI-Bio. As a result of this transaction we acquired HI-Bio's lead asset, felzartamab, an anti-CD38 antibody currently being evaluated for three leading indications, AMR, PMN and IgAN. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets, as well as TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2023 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on advancing our pipeline in neurology, specialized immunology and rare diseases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. In November 2023 we terminated the Neurimmune Agreement, which resulted in the deconsolidation of our variable interest entity, Neurimmune. For additional information on the deconsolidation of Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2023 Form&#160;10-K.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Climate-Related Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024 the SEC issued a final rule under SEC Release No. 33-11275, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new rule will require large accelerated filers to disclose material climate-related risks that are reasonably likely to have a material impact on their business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and/or material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the new rules will require disclosure within the notes to the financial statements of the effects of severe weather events and other natural conditions and information on any climate-related targets or goals, subject to certain materiality thresholds. The final rule, if adopted, includes a phased-in compliance period which will begin phasing in with our annual report for the year ending December 31, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that this new rule will have on our company's disclosures.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023 the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. All disclosure requirements under this standard are also required for public entities with a single reportable segment. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. While this accounting standard will increase disclosures, we do not expect the adoption of this standard to have a material impact on our consolidated financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683758368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of HI-Bio is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of July&#160;2, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to HI-Bio shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,622.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> Represents total consideration paid to shareholders of HI-Bio of $1.15&#160;billion, plus an additional $43.7&#160;million related to working capital adjustments as of the transaction close date, less $56.4&#160;million of cash paid for HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, which were recognized as compensation attributable to the post-acquisition service period and therefore not reflected as a component of total consideration. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of Reata is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to Reata shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,602.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of Reata equity compensation pre-acquisition services and related taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents cash consideration transferred of $172.50 per outstanding Reata common stock based on 38.3&#160;million Reata shares outstanding at closing.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.</span></div>September&#160;26, 2023. The measurement period adjustments summarized below resulted from updates to our valuation assumptions related to the estimated amounts and timing of future cash flows associated with certain intangible assets, updates of our assumptions related to the quantities, selling location and remaining manufacturing and selling costs of acquired inventory, and other assets and liabilities. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as adjusted)</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,259.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology for SKYCLARYS (U.S.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,200.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development (omaveloxolone)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,300.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payable to Blackstone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(300.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(909.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,724.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes measurement period adjustments recorded in the first quarter of 2024 that increased accrued expense and other by $4.9&#160;million, deferred tax liability by $4.1&#160;million and goodwill by $9.0&#160;million, as well as </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">measurement period adjustments recorded in the third quarter of 2024 that increased other current assets by $1.0&#160;million and accrued expense and other by $3.9&#160;million, and decreased deferred tax liability by $7.2&#160;million and goodwill by $4.3&#160;million.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation of the separately identifiable assets acquired and liabilities assumed as of July&#160;2, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July&#160;2, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (IgAN)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">920.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (AMR)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (PMN)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expense and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(304.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,622.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683738992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to workforce reductions are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of January 1</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670674176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">507.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">527.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,159.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">956.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,805.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">611.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">739.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">768.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">677.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">571.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">616.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">604.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,299.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,631.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,648.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,814.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,678.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,493.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">453.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">455.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,331.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,975.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,380.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,414.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">605.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,004.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,625.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(439.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,391.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,831.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(514.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(692.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">923.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">928.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized in the table below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">742.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501805269024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,803.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,926.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,563.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,609.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,469.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,527.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,563.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,609.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675362400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired and in-licensed rights and patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-21 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,552.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,697.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,855.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,180.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,440.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,739.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13-31 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,548.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,445.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,548.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,429.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,101.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,142.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,958.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,728.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,869.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,859.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,682.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,682.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,340.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,340.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,948.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,142.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,805.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,232.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,869.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,363.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">615.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,219.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from HI-Bio acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from Reata acquisition</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,485.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to Reata measurement period adjustments recognized during the nine months ended September 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674922656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,156.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,506.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4% - 5.8%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text">The following table provides a roll forward of the fair value of our contingent consideration obligation, which was classified as a Level 3 measurement:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.176%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three and Nine Months Ended September 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration resulting from HI-Bio acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan 364-day tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,739.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,739.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan three-year tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,721.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,339.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,493.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,034.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">475.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,943.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,545.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,137.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,788.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total notes payable and term loan</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,683.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,293.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,287.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,938.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we drew $1.0 billion from our 2023 Term Loan, comprised of a $500.0 million floating rate 364-day tranche and a $500.0 million floating rate three-year tranche. As of September 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683704592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable equity securities, classified as available-for-sale:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(421.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">734.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(429.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">948.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(542.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">979.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(563.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.747%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,698.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,380.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683749696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,569.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,686.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income (in millions):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock', window );">Derivative Instruments, Unrealized Gain (Loss)</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.8)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683729536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(172.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.372%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501676457104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675185824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we recognized Reata equity-based compensation expense, inclusive of employer taxes, of approximately $393.4&#160;million attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we recognized HI-Bio equity-based compensation expense, inclusive of employer taxes, of approximately $56.4&#160;million attributable to the post-acquisition service period, of which $42.5&#160;million was recognized as a charge to research and development expense with the remaining $13.9&#160;million as a charge to selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HI-Bio equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the Reata and HI-Bio equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to Reata and HI-Bio employees and required no future services to vest. For additional information on our acquisition of Reata and HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501805795056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings, including valuation allowances</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased inventory valuation step-up and intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501668888624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(252.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2024, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $53.3&#160;million, partially offset by a decrease in the fair value of Sage common stock of approximately $22.7&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $295.6&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage common stock of approximately $90.2&#160;million, partially offset by an increase in the fair value of Denali and Sangamo common stock of approximately $70.1&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $265.0&#160;million.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata related accrued expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,755.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501805213344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaTableTextBlock', window );">Co-promotion profit sharing formula</a></td>
<td class="text">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PretaxProfitSharingFormulaTableTextBlock', window );">Pretax profit sharing formula</a></td>
<td class="text">Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock', window );">Summary of activity related to the UCB collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock', window );">Summary of Activity Related to Denali Therapeutics Collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock', window );">Summary of Activity Related to Sage Therapeutics</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Sage collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Sage collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pretax Profit Sharing Formula [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Denali Therapeutics Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Sage Therapeutics</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to the UCB Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675179792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501666114576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75.0)<span></span>
</td>
<td class="num">$ (64.8)<span></span>
</td>
<td class="num">$ (224.0)<span></span>
</td>
<td class="num">$ (217.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,485.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,485.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,219.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588.4<span></span>
</td>
<td class="nump">788.2<span></span>
</td>
<td class="nump">1,723.7<span></span>
</td>
<td class="nump">1,941.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388.5<span></span>
</td>
<td class="num">(68.3)<span></span>
</td>
<td class="nump">1,365.5<span></span>
</td>
<td class="nump">912.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638.7<span></span>
</td>
<td class="nump">659.6<span></span>
</td>
<td class="nump">1,726.9<span></span>
</td>
<td class="nump">1,915.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member', window );">Felzartamab And Izastobart/HIB210 | Milestone Payment, Future Development | Human Immunology Biosciences Pre-Existing In License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member', window );">Felzartamab And Izastobart/HIB210 | Milestone Payment, Regulatory | Human Immunology Biosciences Pre-Existing In License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member', window );">Felzartamab And Izastobart/HIB210 | Milestone Payment, Commercial | Human Immunology Biosciences Pre-Existing In License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">640.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards', window );">Outstanding equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 983.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.8<span></span>
</td>
<td class="nump">217.1<span></span>
</td>
<td class="nump">124.5<span></span>
</td>
<td class="nump">276.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.3<span></span>
</td>
<td class="nump">234.9<span></span>
</td>
<td class="nump">150.9<span></span>
</td>
<td class="nump">333.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">1,137.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Range of outcomes, value, high</a></td>
<td class="nump">650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards', window );">Non-vested equity awards</a></td>
<td class="nump">74.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">56.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment', window );">Working capital adjustment</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">485.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">279.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of contingent consideration obligations</a></td>
<td class="nump">205.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">256.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_IntangibleAssetMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Measurement Input, Probability Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 1,150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Minimum | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Maximum | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Maximum | Phase 3 Clinical Trial, Felzartamab One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Maximum | Phase 3 Clinical Trial, Felzartamab Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">42.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Other clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,602.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 387.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 387.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices', window );">Equity compensation pre-acquisition services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod', window );">Inventory amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate', window );">Intangible assets discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseArea', window );">Operating lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Fair Value Adjustment to Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Clinical Inventory | Fair Value Adjustment to Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Secured Debt | The Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Acquisition cost expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Other clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Working Capital Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Indefinite Lived Intangible Assets Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Business, Gross, Non-Vested Equity Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Businesses, Gross, Outstanding Equity Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentFutureDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentFutureDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentCommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentCommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=biib_MeasurementInputProbabilityRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=biib_MeasurementInputProbabilityRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ClinicalInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ClinicalInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501672063536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Purchase Price Consideration (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75.0)<span></span>
</td>
<td class="num">$ (64.8)<span></span>
</td>
<td class="num">$ (224.0)<span></span>
</td>
<td class="num">$ (217.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 1,137.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent consideration</a></td>
<td class="nump">485.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">1,622.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment', window );">Working capital adjustment</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">56.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 1,150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,602.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,193.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 387.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 387.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired', window );">Number of common stock shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Number of Common Stock Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Working Capital Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501662644448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Preliminaty Purchase Price Allocation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 6,485.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,219.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">267.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">1,259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets(1)</a></td>
<td class="nump">54.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">121.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther', window );">Accrued expense and other(1)</a></td>
<td class="num">(110.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Debt payable</a></td>
<td class="num">(159.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Contingent payable to Blackstone</a></td>
<td class="num">(300.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(909.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(151.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">6,724.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">469.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total assets acquired and liabilities assumed</a></td>
<td class="nump">7,193.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther', window );">Adjustment, accrued expense and other</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability', window );">Deferred tax liability</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill', window );">Adjustment, goodwill</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">4,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Other clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(304.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total assets acquired and liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (IgAN)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (AMR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (PMN)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">$ 1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | In-process research and development | Felzartamab (IgAN)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | In-process research and development | Felzartamab (AMR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | In-process research and development | Felzartamab (PMN)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Other clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expense And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabIgANMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabIgANMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabAMRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabAMRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabPMNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabPMNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674917840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on sale of priority review voucher, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 88.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=biib_IonisPharmaceuticalsInc.Member', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">$ 103.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Equity Method Investment, Amount Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture', window );">Proceeds from divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 437.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=biib_IonisPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=biib_IonisPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501682093824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 76.0<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">62.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
<td class="nump">114.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">62.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">96.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges | Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674859824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Restructuring and Related Cost, Expected Cost Remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Restructuring and Related Cost, Expected Cost Remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction', window );">Expected operating expense reduction</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Expected number of positions eliminated | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">$ 37.7<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="nump">$ 62.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">62.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Activities, Expected Operating Expense Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674788144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 76.0<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501669069888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
<td class="nump">114.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Costs | 2023 and 2022 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">$ 45.5<span></span>
</td>
<td class="nump">$ 75.4<span></span>
</td>
<td class="nump">32.3<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">$ 35.9<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">58.7<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payment</a></td>
<td class="num">(4.7)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
<td class="num">(42.2)<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAdjustment', window );">Foreign currency and other adjustments</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending</a></td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 45.5<span></span>
</td>
<td class="nump">$ 59.3<span></span>
</td>
<td class="nump">$ 32.3<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 59.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023And2022CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023And2022CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501685873136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 2,530.3<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
<td class="nump">$ 7,449.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,769.4<span></span>
</td>
<td class="nump">1,805.2<span></span>
</td>
<td class="nump">5,380.9<span></span>
</td>
<td class="nump">5,414.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">813.0<span></span>
</td>
<td class="nump">790.9<span></span>
</td>
<td class="nump">2,405.8<span></span>
</td>
<td class="nump">2,293.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">956.4<span></span>
</td>
<td class="nump">1,014.3<span></span>
</td>
<td class="nump">2,975.1<span></span>
</td>
<td class="nump">3,121.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,053.9<span></span>
</td>
<td class="nump">1,159.0<span></span>
</td>
<td class="nump">3,279.6<span></span>
</td>
<td class="nump">3,493.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">546.0<span></span>
</td>
<td class="nump">631.8<span></span>
</td>
<td class="nump">1,631.6<span></span>
</td>
<td class="nump">1,814.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">507.9<span></span>
</td>
<td class="nump">527.2<span></span>
</td>
<td class="nump">1,648.0<span></span>
</td>
<td class="nump">1,678.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">390.9<span></span>
</td>
<td class="nump">405.0<span></span>
</td>
<td class="nump">1,190.7<span></span>
</td>
<td class="nump">1,188.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">175.0<span></span>
</td>
<td class="nump">206.9<span></span>
</td>
<td class="nump">512.9<span></span>
</td>
<td class="nump">571.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">198.1<span></span>
</td>
<td class="nump">677.8<span></span>
</td>
<td class="nump">616.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">232.8<span></span>
</td>
<td class="nump">239.5<span></span>
</td>
<td class="nump">739.3<span></span>
</td>
<td class="nump">768.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">40.1<span></span>
</td>
<td class="nump">58.1<span></span>
</td>
<td class="nump">127.9<span></span>
</td>
<td class="nump">199.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">192.7<span></span>
</td>
<td class="nump">181.4<span></span>
</td>
<td class="nump">611.4<span></span>
</td>
<td class="nump">568.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">158.1<span></span>
</td>
<td class="nump">165.5<span></span>
</td>
<td class="nump">451.4<span></span>
</td>
<td class="nump">419.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">134.9<span></span>
</td>
<td class="nump">148.8<span></span>
</td>
<td class="nump">385.0<span></span>
</td>
<td class="nump">372.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">66.4<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">237.5<span></span>
</td>
<td class="nump">277.7<span></span>
</td>
<td class="nump">732.0<span></span>
</td>
<td class="nump">825.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">143.5<span></span>
</td>
<td class="nump">180.1<span></span>
</td>
<td class="nump">428.7<span></span>
</td>
<td class="nump">492.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">94.0<span></span>
</td>
<td class="nump">97.6<span></span>
</td>
<td class="nump">303.3<span></span>
</td>
<td class="nump">333.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">176.2<span></span>
</td>
<td class="nump">212.2<span></span>
</td>
<td class="nump">537.5<span></span>
</td>
<td class="nump">604.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">115.6<span></span>
</td>
<td class="nump">148.7<span></span>
</td>
<td class="nump">344.0<span></span>
</td>
<td class="nump">397.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">60.6<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
<td class="nump">193.5<span></span>
</td>
<td class="nump">207.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">61.3<span></span>
</td>
<td class="nump">65.5<span></span>
</td>
<td class="nump">194.5<span></span>
</td>
<td class="nump">220.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">31.4<span></span>
</td>
<td class="nump">84.7<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">33.4<span></span>
</td>
<td class="nump">34.1<span></span>
</td>
<td class="nump">109.8<span></span>
</td>
<td class="nump">125.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">406.1<span></span>
</td>
<td class="nump">456.3<span></span>
</td>
<td class="nump">1,299.6<span></span>
</td>
<td class="nump">1,412.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">227.5<span></span>
</td>
<td class="nump">244.8<span></span>
</td>
<td class="nump">690.0<span></span>
</td>
<td class="nump">750.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">178.6<span></span>
</td>
<td class="nump">211.5<span></span>
</td>
<td class="nump">609.6<span></span>
</td>
<td class="nump">662.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">19.4<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
<td class="nump">67.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">19.4<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
<td class="nump">67.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember', window );">Rare Disease Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">494.8<span></span>
</td>
<td class="nump">449.9<span></span>
</td>
<td class="nump">1,452.8<span></span>
</td>
<td class="nump">1,331.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember', window );">Rare Disease Product Revenue | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">240.4<span></span>
</td>
<td class="nump">152.1<span></span>
</td>
<td class="nump">703.8<span></span>
</td>
<td class="nump">455.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember', window );">Rare Disease Product Revenue | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">254.4<span></span>
</td>
<td class="nump">297.8<span></span>
</td>
<td class="nump">749.0<span></span>
</td>
<td class="nump">875.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_QALSODYMember', window );">QALSODY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_QALSODYMember', window );">QALSODY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_QALSODYMember', window );">QALSODY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">381.4<span></span>
</td>
<td class="nump">448.2<span></span>
</td>
<td class="nump">1,151.8<span></span>
</td>
<td class="nump">1,328.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">153.1<span></span>
</td>
<td class="nump">150.5<span></span>
</td>
<td class="nump">458.9<span></span>
</td>
<td class="nump">453.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">228.3<span></span>
</td>
<td class="nump">297.7<span></span>
</td>
<td class="nump">692.9<span></span>
</td>
<td class="nump">875.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember', window );">Completed technology for SKYCLARYS (U.S.)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">102.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">280.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember', window );">Completed technology for SKYCLARYS (U.S.) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">81.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">230.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember', window );">Completed technology for SKYCLARYS (U.S.) | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">20.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">49.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">196.6<span></span>
</td>
<td class="nump">194.3<span></span>
</td>
<td class="nump">591.6<span></span>
</td>
<td class="nump">581.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">192.3<span></span>
</td>
<td class="nump">188.2<span></span>
</td>
<td class="nump">572.5<span></span>
</td>
<td class="nump">560.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">118.1<span></span>
</td>
<td class="nump">112.8<span></span>
</td>
<td class="nump">354.1<span></span>
</td>
<td class="nump">331.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">118.1<span></span>
</td>
<td class="nump">112.8<span></span>
</td>
<td class="nump">354.1<span></span>
</td>
<td class="nump">331.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">54.1<span></span>
</td>
<td class="nump">54.4<span></span>
</td>
<td class="nump">162.1<span></span>
</td>
<td class="nump">167.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">54.1<span></span>
</td>
<td class="nump">54.4<span></span>
</td>
<td class="nump">162.1<span></span>
</td>
<td class="nump">167.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">47.1<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">47.1<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember', window );">TOFIDENCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember', window );">TOFIDENCE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember', window );">TOFIDENCE | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OtherProductsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">56.9<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OtherProductsMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OtherProductsMember', window );">Other | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember', window );">ZURZUVAE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">49.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember', window );">ZURZUVAE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">49.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember', window );">ZURZUVAE | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_PLEGRIDYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_QALSODYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_QALSODYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BYOOVIZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TOFIDENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZURZUVAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670428128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,062.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,625.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(12.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,831.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(692.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,151.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">173.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">605.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(439.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(160.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">185.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">857.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,004.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(33.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,391.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(514.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">923.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">15.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">13.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(17.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 42.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column E<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column D<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column C<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column C<br> -Subparagraph (2)<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column B<br> -Publisher SEC<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501668870096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues- Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,151.0<span></span>
</td>
<td class="nump">$ 1,062.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">150.7<span></span>
</td>
<td class="nump">135.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,000.3<span></span>
</td>
<td class="nump">$ 926.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501684962768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 2,530.3<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
<td class="nump">$ 7,449.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">94.8<span></span>
</td>
<td class="nump">98.9<span></span>
</td>
<td class="nump">285.3<span></span>
</td>
<td class="nump">315.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">446.2<span></span>
</td>
<td class="nump">420.9<span></span>
</td>
<td class="nump">1,284.7<span></span>
</td>
<td class="nump">1,253.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember', window );">Royalty Attributed To OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 346.8<span></span>
</td>
<td class="nump">$ 319.1<span></span>
</td>
<td class="nump">$ 985.8<span></span>
</td>
<td class="nump">$ 928.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670680944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 2,530.3<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
<td class="nump">$ 7,449.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember', window );">Contract manufacturing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">221.9<span></span>
</td>
<td class="nump">252.9<span></span>
</td>
<td class="nump">474.1<span></span>
</td>
<td class="nump">742.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">28.3<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">81.5<span></span>
</td>
<td class="nump">38.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 250.2<span></span>
</td>
<td class="nump">$ 304.2<span></span>
</td>
<td class="nump">$ 555.6<span></span>
</td>
<td class="nump">$ 781.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670526080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 2,530.3<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
<td class="nump">$ 7,449.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">25.90%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
<td class="nump">27.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">14.80%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
<td class="nump">9.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 250.2<span></span>
</td>
<td class="nump">$ 304.2<span></span>
</td>
<td class="nump">$ 555.6<span></span>
</td>
<td class="nump">$ 781.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">LEQEMBI Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNonControlingInterestRecognized', window );">Share of non-controling interest recognized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNonControlingInterestRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Non-Controling Interest Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNonControlingInterestRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675120144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Components of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 368.9<span></span>
</td>
<td class="nump">$ 426.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">1,803.8<span></span>
</td>
<td class="nump">1,926.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">391.0<span></span>
</td>
<td class="nump">255.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InventoryNetCurrentAndNoncurrent', window );">Inventory</a></td>
<td class="nump">2,563.7<span></span>
</td>
<td class="nump">2,609.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">2,469.2<span></span>
</td>
<td class="nump">2,527.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">$ 94.5<span></span>
</td>
<td class="nump">$ 81.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Net Current and Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675708800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 388.5<span></span>
</td>
<td class="num">$ (68.3)<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
<td class="nump">$ 912.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">638.7<span></span>
</td>
<td class="nump">$ 659.6<span></span>
</td>
<td class="nump">1,726.9<span></span>
</td>
<td class="nump">$ 1,915.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">1,259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod', window );">Inventory amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Fair Value Adjustment to Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">50.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Fair Value Adjustment to Inventory | Clinical Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ClinicalInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ClinicalInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675821664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Summary of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 14,101.5<span></span>
</td>
<td class="nump">$ 11,728.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,142.9)<span></span>
</td>
<td class="num">(5,869.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">7,958.6<span></span>
</td>
<td class="nump">5,859.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Cost</a></td>
<td class="nump">15,948.4<span></span>
</td>
<td class="nump">14,232.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">6,142.9<span></span>
</td>
<td class="nump">5,869.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">9,805.5<span></span>
</td>
<td class="nump">8,363.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">1,682.9<span></span>
</td>
<td class="nump">2,340.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember', window );">Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">10,552.9<span></span>
</td>
<td class="nump">8,180.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,697.9)<span></span>
</td>
<td class="num">(2,440.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">7,855.0<span></span>
</td>
<td class="nump">5,739.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 2,697.9<span></span>
</td>
<td class="nump">2,440.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 3,548.6<span></span>
</td>
<td class="nump">3,548.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,445.0)<span></span>
</td>
<td class="num">(3,429.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">103.6<span></span>
</td>
<td class="nump">119.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 3,445.0<span></span>
</td>
<td class="nump">$ 3,429.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501676642784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 130,300,000<span></span>
</td>
<td class="nump">$ 60,900,000<span></span>
</td>
<td class="nump">$ 295,500,000<span></span>
</td>
<td class="nump">$ 164,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">20,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife', window );">Weighted-Average remaining useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife', window );">Weighted-Average remaining useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_CompletedTechnologyMember', window );">Completed Technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_CompletedTechnologyMember', window );">Completed Technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 110,100,000<span></span>
</td>
<td class="nump">$ 60,900,000<span></span>
</td>
<td class="nump">$ 275,300,000<span></span>
</td>
<td class="nump">$ 164,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">4,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_CompletedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_CompletedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675972784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2024 (remaining three months)</a></td>
<td class="nump">$ 125.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">510.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">550.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">585.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">615.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">$ 655.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501805592864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Changes in Goodwill (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 6,219,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">5,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">6,485,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill resulting from acquisition</a></td>
<td class="nump">256,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill resulting from acquisition</a></td>
<td class="nump">4,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">$ 469,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501664056688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">287.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 221.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 802.4<span></span>
</td>
<td class="nump">610.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">304.7<span></span>
</td>
<td class="nump">416.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,156.0<span></span>
</td>
<td class="nump">1,506.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative contracts</a></td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">287.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative contracts</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">221.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">542.9<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">542.9<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">304.7<span></span>
</td>
<td class="nump">416.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">304.7<span></span>
</td>
<td class="nump">416.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">802.4<span></span>
</td>
<td class="nump">610.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">851.3<span></span>
</td>
<td class="nump">660.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative contracts</a></td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative contracts</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">287.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">221.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">508.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 508.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Current, Fair Value Disclosure,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 30: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674255248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 02, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">287,100,000<span></span>
</td>
<td class="nump">287,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 221,800,000<span></span>
</td>
<td class="nump">$ 221,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Measurement Input, Probability Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=biib_MeasurementInputProbabilityRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=biib_MeasurementInputProbabilityRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670387264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details) - Fair Value, Inputs, Level 3 [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 508.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Minimum | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Maximum | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Weighted Average | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501682192608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Debt Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 5,683,500<span></span>
</td>
<td class="nump">$ 6,287,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion notes payable and term loan</a></td>
<td class="nump">1,748,100<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">6,293,900<span></span>
</td>
<td class="nump">6,938,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NotesPayableCurrentFairValueDisclosure', window );">Notes payable, current, fair value disclosure</a></td>
<td class="nump">1,739,900<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion notes payable and term loan</a></td>
<td class="nump">1,748,100<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,721,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NotesPayableCurrentFairValueDisclosure', window );">Notes payable, current, fair value disclosure</a></td>
<td class="nump">1,739,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion notes payable and term loan</a></td>
<td class="nump">1,748,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,746,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.25% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,279,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.25% Senior Notes due May 1, 2030 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,339,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">1,494,500<span></span>
</td>
<td class="nump">1,493,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,079,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">1,101,000<span></span>
</td>
<td class="nump">1,100,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">490,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">475,500<span></span>
</td>
<td class="nump">472,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,034,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">1,474,800<span></span>
</td>
<td class="nump">1,474,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TermLoan2023ThreeYearTrancheMember', window );">2023 Term Loan Three-Year Tranche | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NonCurrentPortionOfNotesPayableAndTermLoanMember', window );">Non-Current Portion Of Notes Payable And Term Loan | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">3,943,600<span></span>
</td>
<td class="nump">6,137,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">4,545,800<span></span>
</td>
<td class="nump">6,788,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility | Line of Credit | Reata Pharmaceuticals, Inc | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember', window );">Credit Facility Floating Rate 364-Day Tranche | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember', window );">The Credit Facility Floating Rate Three-Year Tranche | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NotesPayableCurrentFairValueDisclosure', window );">Notes payable, current, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion notes payable and term loan</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember', window );">The Credit Facility Floating Rate Three-Year Tranche | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NotesPayableCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Current, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NotesPayableCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TermLoan2023ThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TermLoan2023ThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NonCurrentPortionOfNotesPayableAndTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NonCurrentPortionOfNotesPayableAndTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501668928256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Business Combination, Contingent Consideration, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration resulting from HI-Bio acquisition</a></td>
<td class="nump">485.1<span></span>
</td>
<td class="nump">485.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">$ 508.9<span></span>
</td>
<td class="nump">$ 508.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501682198480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 802.4<span></span>
</td>
<td class="nump">$ 610.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 802.4<span></span>
</td>
<td class="nump">$ 610.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501673995824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">$ 734.3<span></span>
</td>
<td class="nump">$ 979.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(429.6)<span></span>
</td>
<td class="num">(563.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">304.7<span></span>
</td>
<td class="nump">416.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember', window );">Equity Securities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">58.3<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8.2)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">50.1<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Equity Securities, Non-Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">676.0<span></span>
</td>
<td class="nump">948.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(421.4)<span></span>
</td>
<td class="num">(542.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">$ 254.6<span></span>
</td>
<td class="nump">$ 406.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674142144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 5,698.6<span></span>
</td>
<td class="nump">$ 7,380.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="nump">$ 18.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501805788720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 353.3<span></span>
</td>
<td class="nump">$ 460.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670481568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedGainOnDerivatives', window );">Unrealized Gain on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedLossOnDerivatives', window );">Unrealized Loss on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43.0)<span></span>
</td>
<td class="num">(34.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized Gain (Loss) on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41.5)<span></span>
</td>
<td class="num">(34.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months', window );">Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</a></td>
<td class="nump">$ 41.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</a></td>
<td class="nump">38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</a></td>
<td class="nump">$ 23.4<span></span>
</td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="num">$ (6.6)<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 1,339.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,339.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,301.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">29.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,686.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,686.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign exchange contract | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">$ (2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,569.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,569.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">32.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 72.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain on Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Loss on Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501669623856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 2,604.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,604.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,402.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">72.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.1<span></span>
</td>
<td class="nump">213.9<span></span>
</td>
<td class="nump">$ 190.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 3,210.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,210.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,309.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 728.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property, Plant and Equipment, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 717.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674198096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details Textual) - Reata Pharmaceuticals, Inc<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseArea', window );">Operating lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">$ 151.8<span></span>
</td>
<td class="nump">$ 151.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">$ 121.2<span></span>
</td>
<td class="nump">$ 121.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501664873776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details) - Line of Credit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember', window );">Credit Facility Floating Rate 364-Day Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember', window );">The Credit Facility Floating Rate Three-Year Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember', window );">The Credit Facility Floating Rate Three-Year Tranche | Floating Rate 364-Day Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember', window );">The Credit Facility, Terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility | Secured Debt | Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember', window );">2023 Term Loan | Floating Rate 364-Day Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths', window );">Repayments of Short-Term Debt, Maturing in More than Three Months</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember', window );">2023 Term Loan | 2023 Term Loan Three-Year Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=biib_FloatingRate364DayTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=biib_FloatingRate364DayTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=biib_TermLoan2023ThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=biib_TermLoan2023ThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501684120448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Repurchases (Details) - 2020 Share Repurchase Program - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501665209376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">$ (146.0)<span></span>
</td>
<td class="num">$ (172.8)<span></span>
</td>
<td class="num">$ (153.7)<span></span>
</td>
<td class="num">$ (164.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(145.7)<span></span>
</td>
<td class="num">(159.3)<span></span>
</td>
<td class="num">(145.7)<span></span>
</td>
<td class="num">(159.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="num">(7.8)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(145.7)<span></span>
</td>
<td class="num">(159.3)<span></span>
</td>
<td class="num">(145.7)<span></span>
</td>
<td class="num">(159.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="num">(14.5)<span></span>
</td>
<td class="num">(25.0)<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(31.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(31.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="num">(49.1)<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(41.0)<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(31.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(31.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">29.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(17.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(153.1)<span></span>
</td>
<td class="num">(144.5)<span></span>
</td>
<td class="num">(126.1)<span></span>
</td>
<td class="num">(163.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(112.1)<span></span>
</td>
<td class="num">(175.0)<span></span>
</td>
<td class="num">(112.1)<span></span>
</td>
<td class="num">(175.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="nump">41.0<span></span>
</td>
<td class="num">(30.5)<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="num">(11.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">41.0<span></span>
</td>
<td class="num">(30.5)<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="num">(11.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (112.1)<span></span>
</td>
<td class="num">$ (175.0)<span></span>
</td>
<td class="num">$ (112.1)<span></span>
</td>
<td class="num">$ (175.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501686166288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">$ (14.8)<span></span>
</td>
<td class="num">$ (300.0)<span></span>
</td>
<td class="num">$ (193.7)<span></span>
</td>
<td class="num">$ (248.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">62.5<span></span>
</td>
<td class="num">(72.9)<span></span>
</td>
<td class="nump">249.0<span></span>
</td>
<td class="nump">92.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,465.8<span></span>
</td>
<td class="nump">2,530.3<span></span>
</td>
<td class="nump">7,221.2<span></span>
</td>
<td class="nump">7,449.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 388.5<span></span>
</td>
<td class="num">(68.1)<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
<td class="nump">911.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="num">$ (8.1)<span></span>
</td>
<td class="num">(12.6)<span></span>
</td>
<td class="num">$ (5.2)<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="num">$ (8.5)<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501686293024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 388.5<span></span>
</td>
<td class="num">$ (68.1)<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
<td class="nump">$ 911.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">145,700<span></span>
</td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">145,500<span></span>
</td>
<td class="nump">144,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">146,100<span></span>
</td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
<td class="nump">145,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670650096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75.0)<span></span>
</td>
<td class="num">$ (64.8)<span></span>
</td>
<td class="num">$ (224.0)<span></span>
</td>
<td class="num">$ (217.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.1<span></span>
</td>
<td class="nump">452.0<span></span>
</td>
<td class="nump">275.4<span></span>
</td>
<td class="nump">609.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.7<span></span>
</td>
<td class="nump">449.4<span></span>
</td>
<td class="nump">267.4<span></span>
</td>
<td class="nump">601.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.2)<span></span>
</td>
<td class="num">(98.5)<span></span>
</td>
<td class="num">(50.5)<span></span>
</td>
<td class="num">(126.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588.4<span></span>
</td>
<td class="nump">788.2<span></span>
</td>
<td class="nump">1,723.7<span></span>
</td>
<td class="nump">1,941.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">387.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">387.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 393.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, General and Administrative Expense</a></td>
<td class="nump">196.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="nump">$ 197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.8<span></span>
</td>
<td class="nump">217.1<span></span>
</td>
<td class="nump">124.5<span></span>
</td>
<td class="nump">276.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.3<span></span>
</td>
<td class="nump">234.9<span></span>
</td>
<td class="nump">150.9<span></span>
</td>
<td class="nump">333.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.5<span></span>
</td>
<td class="nump">$ 350.9<span></span>
</td>
<td class="nump">$ 216.9<span></span>
</td>
<td class="nump">$ 474.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501682111216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75.0)<span></span>
</td>
<td class="num">$ (64.8)<span></span>
</td>
<td class="num">$ (224.0)<span></span>
</td>
<td class="num">$ (217.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.1<span></span>
</td>
<td class="nump">452.0<span></span>
</td>
<td class="nump">275.4<span></span>
</td>
<td class="nump">609.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.7<span></span>
</td>
<td class="nump">449.4<span></span>
</td>
<td class="nump">267.4<span></span>
</td>
<td class="nump">601.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">387.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">387.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">174.7<span></span>
</td>
<td class="nump">175.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675339088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments - Narrative (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plans (in shares)</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_OmnibusEquityPlan2024Member', window );">Omnibus Equity Plan 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share based compensation arrangement, authorized (in shares)</a></td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RatioOfNumberOfSharesReservedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio Of Number Of Shares Reserved Under Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RatioOfNumberOfSharesReservedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_OmnibusEquityPlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_OmnibusEquityPlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501686163920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(11.90%)<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="num">(6.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">24.60%<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(7.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent', window );">GILTI</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="nump">14.80%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="num">(7.80%)<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">13.90%<span></span>
</td>
<td class="nump">51.60%<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501668902272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">$ (62.5)<span></span>
</td>
<td class="nump">$ 72.9<span></span>
</td>
<td class="num">$ (249.0)<span></span>
</td>
<td class="num">$ (92.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax (benefit) expense</a></td>
<td class="num">(451.0)<span></span>
</td>
<td class="nump">$ 141.2<span></span>
</td>
<td class="num">(1,614.5)<span></span>
</td>
<td class="num">$ (1,005.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501676340192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (11.6)<span></span>
</td>
<td class="num">$ (95.9)<span></span>
</td>
<td class="num">$ (49.1)<span></span>
</td>
<td class="num">$ (252.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">59.8<span></span>
</td>
<td class="nump">63.8<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">175.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">(Gains) losses on investments, net</a></td>
<td class="num">(39.1)<span></span>
</td>
<td class="nump">317.3<span></span>
</td>
<td class="nump">22.2<span></span>
</td>
<td class="nump">289.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (gains) losses, net</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
<td class="nump">248.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains) losses recognized on equity securities</a></td>
<td class="num">(39.1)<span></span>
</td>
<td class="nump">302.0<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="nump">273.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net (gains) losses realized on equity securities</a></td>
<td class="num">(10.9)<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="num">(28.2)<span></span>
</td>
<td class="nump">297.6<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
<td class="nump">268.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,151.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,062.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">288.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expense</a></td>
<td class="nump">280.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">178.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Reata related accrued expense</a></td>
<td class="nump">82.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">637.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expense and other</a></td>
<td class="nump">2,755.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,755.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,623.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="nump">53.3<span></span>
</td>
<td class="nump">$ 295.6<span></span>
</td>
<td class="nump">90.2<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,000.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 926.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674903776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28.2)<span></span>
</td>
<td class="nump">$ 297.6<span></span>
</td>
<td class="nump">$ 27.3<span></span>
</td>
<td class="nump">$ 268.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net gains (losses) realized during the period on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">744.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">744.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 781.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 6,602.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
<td class="nump">$ 295.6<span></span>
</td>
<td class="nump">90.2<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SangamoMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SangamoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SangamoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501874850832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - OCREVUS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage', window );">Royalty operating profit threshold for highest royalty rate percentage</a></td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Reductioninroyaltyrate', window );">Reduction in royalty rate</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PeriodOfCollaborationAgreement', window );">Collaboration agreement term</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MosunetuzumabMember', window );">Mosunetuzumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfFutureDevelopmentCosts', window );">Percentage of future development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future royalties percentage to be received on sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfFutureDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Future Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfFutureDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period Of Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty operating profit threshold for highest royalty rate percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MosunetuzumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MosunetuzumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501664998240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Profit Sharing (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of co promotion operating profits first fifty million</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">Until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour', window );">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment', window );">Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">Until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</a></td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</a></td>
<td class="nump">150.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SalesTriggerGrossSalesThreshold', window );">Sales trigger gross sales threshold</a></td>
<td class="nump">$ 350.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits first fifty million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SalesTriggerGrossSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales trigger gross sales threshold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SalesTriggerGrossSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales to be achieved in any twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674573008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Eisai (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsMadeToTerminationAgreement', window );">Payments Made To Termination Agreement</a></td>
<td class="nump">$ 16.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">LEQEMBI Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccruedPaymentToTerminationAgreement', window );">Payable Due To Termination Agreement</a></td>
<td class="nump">$ 31.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedPaymentToTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Payment To Termination Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedPaymentToTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsMadeToTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Made To Termination Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsMadeToTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670398544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details) - E2609 and BAN2401 - Eisai - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</a></td>
<td class="nump">$ 77.7<span></span>
</td>
<td class="nump">$ 88.5<span></span>
</td>
<td class="nump">$ 255.6<span></span>
</td>
<td class="nump">$ 282.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">38.8<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
<td class="nump">141.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">82.3<span></span>
</td>
<td class="nump">81.7<span></span>
</td>
<td class="nump">238.1<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 164.6<span></span>
</td>
<td class="nump">$ 163.4<span></span>
</td>
<td class="nump">$ 476.2<span></span>
</td>
<td class="nump">$ 191.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501668950112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">$ 68.7<span></span>
</td>
<td class="nump">$ 62.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccountsReceivableFromCollaborator', window );">Amounts receivable</a></td>
<td class="nump">93.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccountsPayableToCollaborator', window );">Amounts payable</a></td>
<td class="nump">$ 146.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccountsPayableToCollaborator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, To Collaborator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccountsPayableToCollaborator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccountsReceivableFromCollaborator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, From Collaborator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccountsReceivableFromCollaborator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501669163728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 588.4<span></span>
</td>
<td class="nump">$ 788.2<span></span>
</td>
<td class="nump">$ 1,723.7<span></span>
</td>
<td class="nump">$ 1,941.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">LEQEMBI Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNonControlingInterestRecognized', window );">Share of non-controling interest recognized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNonControlingInterestRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Non-Controling Interest Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNonControlingInterestRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501686012496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details) - Research and development - UCB Pharma S.A. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="nump">$ 13.6<span></span>
</td>
<td class="nump">$ 52.3<span></span>
</td>
<td class="nump">$ 46.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 26.1<span></span>
</td>
<td class="nump">$ 23.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501674559440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNetProfitFromSageTherapeuticsPercent', window );">Share of net profit from sage therapeutics, Percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">$ 69.3<span></span>
</td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="nump">$ 197.3<span></span>
</td>
<td class="nump">$ 164.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">8.4<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">36.0<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">79.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">28.4<span></span>
</td>
<td class="nump">54.0<span></span>
</td>
<td class="nump">82.9<span></span>
</td>
<td class="nump">152.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 14.2<span></span>
</td>
<td class="nump">$ 27.0<span></span>
</td>
<td class="nump">$ 41.5<span></span>
</td>
<td class="nump">$ 76.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNetProfitFromSageTherapeuticsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Net Profit From Sage Therapeutics, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNetProfitFromSageTherapeuticsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501683470144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details) - Research and development - Denali Therapeutics - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 14.9<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="nump">$ 44.5<span></span>
</td>
<td class="nump">$ 51.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 26.7<span></span>
</td>
<td class="nump">$ 30.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501673647024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Other Arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 542.7<span></span>
</td>
<td class="nump">$ 736.3<span></span>
</td>
<td class="nump">$ 1,509.5<span></span>
</td>
<td class="nump">$ 1,891.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 26.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 42.5<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670986944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Samsung Bioepis (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>product</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.3<span></span>
</td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="nump">$ 197.3<span></span>
</td>
<td class="nump">$ 164.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.3<span></span>
</td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="nump">$ 176.8<span></span>
</td>
<td class="nump">$ 170.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContingentCommercializedRightsNumberOfProducts', window );">Contingent Commercialized Rights, Number Of Products | product</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Expected profit share percentage</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborativeArrangementTermExtension', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborativeArrangementTermExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborativeArrangementTermExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContingentCommercializedRightsNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Commercialized Rights, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContingentCommercializedRightsNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501675713968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">$ 23.6<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Deconsolidation, gain (loss), amount</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45501670339680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.9<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=biib_GenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=biib_LenderDisputeMember', window );">Lender Dispute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="nump">$ 23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=biib_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=biib_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=biib_LenderDisputeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=biib_LenderDisputeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>126
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M5M1O#Y1L*=< ]?V.,7FZT#<X/^OV^%]02P,$%     @ YH->691J9D^#!
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ME AM .]7G*OGAAZ@OE":_@-02P,$%     @ YH->6?K=LB@1!P  5R   !@
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6R]FFUOVS80Q[\*X09%"R2R2.K)
M:6*@2;&MP-H%2;N]9B3:%BJ++D79R;??2;(MR:3H9#7V)I;LX^E/\G@_'I6K
MC9 _B@7G"CTML[RX'BV46EV.QT6\X$M6.&+%<_AE)N22*;B5\W&QDIPE=:-E
M-B:N&XR7+,U'TZOZNSLYO1*ERM*<WTE4E,LED\\W/!.;ZQ$>[;ZX3^<+57TQ
MGEZMV)P_</5]=2?A;KSWDJ1+GA>IR)'DL^O11WQYZ[E5@]KB[Y1OBLXUJKKR
M*,2/ZN9S<CUR*T4\X[&J7##X6/-;GF65)]#Q<^MTM']FU;![O?/^6]UYZ,PC
M*_BMR/Y)$[6X'D4CE/ 9*S-U+S9_\&V'_,I?++*B_HLV6UMWA.*R4&*Y;0P*
MEFG>?+*G[4!T&F!OH '9-B O;4"W#6C=T499W:U/3+'IE10;)"MK\%9=U&-3
MMX;>I'DUC0]*PJ\IM%/36Y$G,"D\07!5B"Q-F(*;&Y:Q/.;HH7)<H'??<U8F
M*?SR'EV@[P^?T+NS]^@,I3GZDF89S$=Q-58@IW(ZCK>/OFD>308>_<!7#J+N
M.2(N\0S-;^W-/_$8FN.Z.>TW'\,@[$>"[$>"U/[HT$B44O)<(584T.5+4W\:
M!Y[90;7@+HL5B_GU"%94P>6:CZ9OW^# _6#JW8F<]?I*]WVE-N_36U8L$,L3
M%%<7_&>9KED&G3?.8N,JJ%U566$]Q<%DXI"K\;K;'X.9ZTV<R=ZLI]3;*_6L
M2C_G:] EY+-)6=,T[#R2>(&NS&#FD]#QS,K\O3+?JNPOM> 2EF@W:DPB&R]^
MY^E!Z!THU&TPCHA97[#7%UCU?1.*92_0%VBC$T34=?P#B28S?^)0L\AP+S*T
MBKR3 "2IGL_1"A*.JF.R"L<5D$*=HYPKD^10TT()=CNAUD@VF%%WXH1FR=%>
M<F2?=Q#,5)K/4<:!'Y:1C?3G1ZYS./>1-O<><<T2)WN)DR.+1K%\GCYF.W6#
M(SG1)$XBU]<F?Z)IC&@P,/78;='C6F7^+D2R 7P8T>'J\>9%OA,=*#/9$=S-
M 7UQ'2YBJ[A/?,9AZ21(L:=F%(TRL3Z 0=0)L:U*@QF)G&! 9(LL;*5$G1T+
M5:V5HEXZHLY)PQ&Y==<;+8JUD-R:=><[]/P!L2USL!TZ34*RB*-ZGHXHIEH^
M-QD&D>=U@J,OL84-]EZT!\A2]IAFJ4JY>2. K=!Z[4[@5-[ZG6XYANT@VW5Z
M)62]L\Z%X@5:L6=6)Q (*\7E$F6"Y<:Q\+79P*$7.?APU@R0\P<2'6XAAX]0
MCCVU8HWR='!YL'O1U.EFQ!_<(^"6;]@.N(]Q+,IJ>=HDZJ#R"-&3B,',I4,$
MQBW/L!UH(%&6D.CXTZJJ!-I$8M2J0XV$OJ^/I\$N('0PY;5HPW:V];<UG85J
M5*N#R_?((=VP3D'J46]H9$D+.&('W-?7K22BL\SS/9UY!KL@C*(AYI&6>>05
MS-L-K7'G372@11'10&(P"SP\E*=)IU2S<^]/D<\OZK$4![NQ(P%!=+)1_W"A
M&8P\=R!3D19_Q(Z_IE[(]LJ/*=4A%P+B#M>9R2S"';.^VI:$Q%YW-<OLF$:]
MLL)XXG=7SE:EP9"X$-H#^96T\")'X"66R[39 9VC6.15*/ \!L'U>IN73$)=
MP0?T6WV;P8N,M?RO.^KWO^4?":P[EIM40'_1YSQV4+%@DB]$EG!9O'T3$1Q^
MJ(LI]6P^S;"2]=7'&2?RUA^'EK/D6"&YRUV%$O$/J">91&N6E1R=N8[K8@2)
MHADAXUB$VI)W#V/89M)7W:*7V-%;12_LN,R27?^(9AVQKIX?[$9]W2V$B1W"
M'Y,DK?:*D")6+$TNTAS%;)5"RC *U?GJ :X.,6PPHRYQ!NH.VE*8VBD,^YMR
M66;UN693(,5B"4&XJ ZCUQRE.=QS]"X31?'>> "F\_8"0_(ZY(;1SJ=#!PZT
MY3*U<_F>*P9?P1:-R1P2G/F83F<MCB83JH6$R3 ,2#BT-Z,MEJD=R]\D,+B4
MS[N 9@J&NC 6SE2O1"_() QUM<<-^VH[9Z OJ4>;!&F4J*,5!]2/M',FDZ$7
M0I$Q0#?:4IB^DL+[ [(!R8:C3F,);3*TE="T!3*U _FKR"5O%ML=DP,R_P,N
MA\ES*F_]#K<$IG8"O^"] 3TI:4_EK=_?EK3TA16MY#%/UU5I4Q\O(C%#+,O$
MIGYQ-!,2):)\5+,R0VS7!$S.B./640P7WCDX*5:\?I67F4-%+WHAI09Z0!OL
M@L ;S!(MHJD=T?='@]G:_M63>R)O_=ZV8*>37PYFZ];@U?T]D;?^RZ5V;^ =
MW1O\C\&\%=-]1^;Y6..)R8SZVINT<>>M;_7*_0N3\S0OH!">03O7"2$ORN8M
M=G.CQ*I^$?PHE!++^G+!&50+E0'\/A-"[6ZJ=\O[_R68_@M02P,$%     @
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MQ"6Z^%&RW3('F4LT1C\>/Z.+7R[1+R@OT;>\*" R\GI: S"E?IKM0=PU(/
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M=((/XFI+D8A.$G=<DQ9KXL7Z=;-E>:7BJ@I87M:L?,H7$%<F):^=-2JQ<.#
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M9A#]0 :2ZC.^5.?B-+Z/8_9]7EUJZ.@.@>UJ5UMS%KVU"C5]H#36:3PX-*:
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MHCX*'R_150;H_XH>= +MYZ@:\(W)#)RA(@T/\ ;GDYZZ7GA7S1<*04'Y>HQ
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MZ667$7B0+73PEHSHPVE;0_FGE*&DEMI!19-:+%MP2+ "2YLD-4BKA!ZZ4:A
M%Q],@?\*84J2"*U,"IO68.IM\3F$Q0;XK( .GPT^2O>$/V EZYM'!=T=7:!K
M=R3-F+_N&T-+V2ZX@E[;5>6S\_"K[E(WZT&C96")1!JRA:/GD'/$NTGA4>E-
MN3%N:<FMD/0K3+/Q[=DDPAT*!!3>V^?PK&V0?9-\M.3 KH(;'^/1]U',5FG
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M0J[7L )\;2,K4DN,M=9H0B?1;$ QIHU1=V#Z$'<+O*4E"%;LK-,%/&18'J#
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M(K1].3F&&BIWVW!/$VU26PAI8254C2"<,YD4G&#!WRQ8T2&U_Q!0:O<$HH(
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MKD6KO[7ZEFB78<%W='.M?=R"N]/N/\0LKLZWXO$/R#MAE]RW%"Y(=9 >/D_
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MXC+_DG\GGD91 UX0$5I$XWD#JT->(EP%[SKBR<.LH4*\3$ZAFOU$_,-(0(4
M]OY[]_;+NQ<A+@'(T*=]?GP]#'0$@7U(3&C]UJF,#Y#4V//1Q*/Q-( >B?5]
M]B_^OUAJXB$^?/^I,BZ@8O$_ES'MT17=OUS&U)<N)D+S)#I^LI"H"F"];$X?
M/#'1=.[#,J CS&Y 'VBJ+I!DD$N%0LIEH"1:DW.&K=M:B1,G2H#)D"UKJ?(3
MIT]LC66[?_*[E<<K[C29#R=8<]O/-6'&B@YYB"-H+Q-P3_&E1EFTV3*_8P/%
M9;S9*]R  _20?10/G/"0 O L0>BM K5YWB.5\8QM42 PU2?!<@V><QZR2H^:
M&DU4;0/Z=][ZSB!XO>.J#I2BJTH;5Y=A:TT@72\;.Y@1B SDX[:1GR.]O: L
M=]M9^GLBRR#TH(P.K]A/&I23#-'@G:1E0S+J/(ZC=CF1<^[)62L0&>5E!98O
M,TH @-UY]D30W[\_N99ZCY^O.O_4=M@ ]$&V;L8^HNMV!SSY&S%UQTU?[%VG
M'><BJ-<SJQ$K%:A5ED_L^ZCM9*CI$Q79U8&,PT?:!J\:%'6>!\F/DO"T"'@J
MGL#3Z!%,W(;#"_:V<8;T6"S9?/_VUA)T\ B+F>CO?Y]AZ4^=_.U.?A_&=_"^
M[U)SGD+J$.T/O,3,QM8:H#.?^H5]2ONQ[YKC@IA*,\?:^H:'$AQ/DBAYPX[C
M:31[0_-(H&^:+7YSM!'6G3S_K;8NI'4,L*,]P'.>_.C1.8W99 J3R0( V#HQ
MHSW$'#HZ)^#6*3F!S=FKG6C1]7@<Q6^>3TJ-2J=C-J&]19I@2['S9,&F"Q#Q
M+AW1'(ZD<;1XM2/'"3D +YYUHM]<Q'!AGS,]A3>'SO9&O1/< I/5GU/3_@9K
MR7"8V[WMCL*OP@GP3CR<HZ,2:]JP*+'"4"P[I@-FPMET>'"Z\N?!2^V<+OPM
M'> (0P+X?:4!C<T#&>C^07#Y!U!+ P04    " #F@UY9O"D+%%,,  "U)
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M?GB4]/RLMGFQ:NE^()HJ:U7A'A?PAM"T =]G"FZI7^B YA?#T_\ 4$L#!!0
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M"X4OQGCXH),F6K1-S@IDLS4_)K^E3H=?) :(L$]<[?.-%)E)5+K/*>!'?@S
MHG5+?1R;BJ&-^ @?B"F)G!U"(=_18]YS# ]KJ,&2=<J>^%6E[ H=1JBMFL.Q
MS8IS/R? MFXA_T.(TCM\)[B"VIH4I<2M:[NC)*A[L(.-#_'4B7I1Y69&IN"3
M=5Y4.+=R7L1M(K7]&QDW"CK0ZVT"8<OY&?/9%O/-"/-= LAU1'WWJ*5L#CT$
M))_9=W6V_]G*==\H9\N%;BFDQ%\\D($,KQ\ C;&PA6*>!9\;#$SS G)*JHF$
M0.?41#>+@FJ &(71"_CI*)R\P+^Q>"%^^5+411ZE!]J"D#)&A_O <M-M0IHQ
M!=]"4"1;DT/Y$'X$4H/>< ,@R==6C4"R%BCI<D!],9)++-.X\O%,PZJD 0P<
MY&2@;3!5Q\Z3JMA)9"A%LBA0=AZDU:;BC#';N _Y-UG&I 2/R,W@7WYL@**V
MIFH4<[TR.W[*Z8+7H0R=-3.##<_N:Y@.:L!ER1\27VW'%V'O!1V0*PDJRI92
MYQWVUP>S;5-46,W(W*C]N0/^Y-?K.$+B[881D(6A-9ZLS-M(^-I\WO'5ZRU9
M?^_X*NP#1>3UL)/F*[ZRQ0!-'N31H;^^.P,FI 3Q]PKFXU/)F NK? 7(Y"?5
MQ04ULG:U-U5%[4\[KMPHLG5C@8>,,_9G2:XOC,CQB+#Q2MJDR8O?Y**-L5?0
M;IS"'L@&%"MT2*/X;)-W+G?3"\Q$9]\OH0DVQ&\T4NK.-/=9[&W+:H"2OM!Y
M7H=Z :QADN<,#W;@8&VAKMVBR0C-V'6-%*#ECH+@'Y,M+E2>;)WO,UAG\S=K
MV-73O]C8NH[^N(#-?Q*I<3P/Z% E);>Z9@<Y1+\NQP>ZCDX!!Q'4<).I\&#)
M""@K6?.%,P?<^]2/76HK[W<O6BFY-WV&"O9XEUL:6Y[1"++.<O.ZMZO!?(:(
MJ74@X]A6U.I\H>;<>YEA'%R/0X\H8B;1Z\= _33I=SZ^?5ZG;U[(>T[]6*<1
M]A@C_M#4Y O/^';.>CX;@)JBCINRC9N<XB;S<:,.Q(UOM>+OXI2<CX$\ 28U
M;$XC@-)T:;>-L2^3C)#PAE7U6<<.ZFC&\US ]E1[R7-TYB6N"H_DZG*F#A5^
MNGF4*%V3MV WU!2]6*@C_#3I&)IO,=R[',UEY8,$X%I<;QJ7#FCR#=?^73=>
M9]P8;]PY1T]J53>[;W"CWNRN;8E#UPWV5QWO^RJWIB%).^3RC0#U)\W +=@,
M> ARGEW?#'K<5,E"5:6.J; LK,S D]DSNPLV-*%'KD1DOH-AN95.7,<_0U3I
M6;FEPOO&@9O6<:.,%K,DM&E+<][TE%9]B1IL.QP]\-^6\I<=TM65%/CU(&I^
MW@B6'>.Z87/[[KI66@%/P-N7?O\]N<1[(W,Q'$=GB>3!31Y#[.XP;W/5'_5X
MBNP_H[ W NZZ4[F&B:D%=&S+C0#]4>"1;S^X&$Y1LO 93?:,TG?8(VESIM>U
MJ4]KQ.TN.<^/__];9Z9Z2%I.;&=K0HN-P+L<C7I$S/__"D%WR8!#9'!60#1&
M"S$(!WM)?8#NV:KH#_K!$-)%^(RF$>\=7$S#(=\3,AB%@]YSV(EH:P];!_0U
M2Z]/*@IZDVEXP?<T4!^&_>/LC'C/,"(E!]%%A.-Q'TV9%MT/06._2&_5S%8T
M#/#<C/HBFO9@M.AB!*&BZ01\11?T#=(>DSWE <-@&@VASR@81>C/Q#CH#R\@
MT#BXF!!A/YD^1@$H*AA/AF#E%+L&T.S47TTN^)N&<3 =$J7G8?!;)4M)J#NQ
M:B5.2=>SNFBW \%M)PRX?%O-_1RJB3CUSM;4>O2CDA$DMZ*[\<DY[OB6QTY^
M#&0]9I!QD56%U)SPYU6:/F?"N"OEXS'1,(!2*6^J)*>.\5OGU/>/NTB%HMQD
M9@>TK&IY.Z[)T*+]?IG&]=94BV4]&88B-N,73OO&HH\T?B;L0#=6^X^F([<.
M.M01>L-+ZQ'+HZ0>U/"/Q$9KW51=,JN$I;\0T:5>4"7D"8^!0.*/\"Z$E1F>
MK\5:JS3Q Z 8Q^A2U#_N@==:X_P7,!DA 9[.$[)!]3IJW,X\<5?09YCX^XWT
M]OT$X[SS2YE,V07_'@B0GE"!_]%,N]K^Y.BU_Z7-YG7_>Z4/TJ+?<R)5<VQ%
MAAR=".M_ ^1O2E/P[VYFIBQ-QI=+B*TLO8#G<P/YZQLZH/TAUM5_ 5!+ P04
M    " #F@UY95=$X<: &   B$@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6R]6%M3VS@4_BN:E.G C'$2QX2$ C/0RRZSTY:!7AYV]D&QE5B#;+F2
M0LC^^OV.[#A.(8'V81\2ZW)T=,YWKO;I0IL[FPGAV$.N"GO6R9PK3[I=FV0B
MYS;4I2BP,]4FYPY3,^O:T@B>^D.YZD:]WK";<UETSD_]VK4Y/]5SIV0AK@VS
M\SSG9GDIE%Z<=?J=U<*-G&6.%KKGIR6?B5OAOI;7!K-NPR65N2BLU 4S8GK6
MN>B?7,9$[PF^2;&PK3$C329:W]'D*CWK]$@@H43BB /'XUZ\%4H1(XCQH^;9
M::ZD@^WQBOL'KSMTF7 KWFKU7:8N.^N,.BP54SY7[D8O_A2U/D?$+]'*^G^V
MJ&B/<&,RMT[G]6',<UE43_Y0X] Z,.IM.1#5!R(O=W61E_(==_S\U.@%,T0-
M;C3PJOK3$$X69)1;9[ K<<Z=?Y %+Q+)%;LJK#-SX.WL:=>!-1%TDYK-9<4F
MVL)FS#[JPF66O2]2D6Z>[T*D1JYH)==EM)/AK2A#-N@%+.I%\0Y^@T;/@><W
MV,+OJK@7UGGM O9.3!SC1<K>_YA+MV2W(ID;Z:2P[.^+"6" K_SS% C5'?'3
M=U#\G-B2)^*L@P"QPMR+SOGK5_UA[\T.#>)&@W@7]Y=;:C>;+YE@4ZT0C+*8
M,<<G2M01*?^%_GINV+2YB5LKG(5+N@Q.YU8@Z2E3PEKF,EZP<8^E?&G9U.@<
M*P(S)XBDG)LD0\ P621J#K? @"7<9AYZ/Q# _YXKTH0VZ?)$PX,*"VJ,K%:2
MV*6(/ 69("IYNCUA^U<%PD$I1+8]8!=>)OB,$_E$F,9QZHUW(JG7^WY]0-XJ
MEE#)W"'O3>=%:MD>&_6B,,9SV.^%Q^R+=D#@T2H43+@Q2T(/HL^]JB1X_I@E
M+TNC'R20 VA3+DU](L7/:0(+2S;3QATZ8?(6Q"'[3"P],V\B47FJ77OJ#!G7
MLGVE82- P(U DDRTJ8'6X&[8/K#7N3A@XJ$D5 -60+K=4%N'A_<N4JUB$+(G
M_,:N':="8(>X 4L4O$E.)6[@@.:>2T6DAR@LAQ8^<++=BC\9.P=@N#-E?Q@H
M7_]_('@_[@)LUR;$FQL#G6'HHU$XP./UJU'4C]Y@M#\*HP/:Z(7]9[@4NCA<
M<1H>#\->PV8_COIA?,"BHS@<ULZUT[Y[['@0_RQ)'(W#(<DRZ,7PQFWN_?\"
M-NA#HPTQH6J/I$3(#'\!L7%,T#>('<51V#]@<6\81B]#;'P\#L>;HAP-!\1D
MC\7]83ABUT8G0J1UNFJ)YFM"JQ"0OY<;Q*T$2 F,?-;#WY(I)28MB8@.E0 =
M @4-FB;ES5"%+FU6T>N#MXDE'Q]5J#U*=.A$?([]DADA-FKNX[@9--2?4 .>
M);Y^7EF$0# <C[RUCX/!J = ;S:5@N'QB]?+M88 ?\#Z(^Q\!ZX<_LB56OH\
M"2+*'CCA.+HTF-5*W[&YS.CY+%OG"E\T@L>E@R1L66%M@'!;A 1L(5C&[T&L
M%0!7JDGC6ZT9>CQYFGKIX(RRJ)IBDE57*;4M/AAZG0)6*D%UD)IF]DFC.D8!
MNUA36A;4Y0!$6Y+RNB:OTW/X".5I;7#GW8-@*<CT>65ZL<7T$-!(\CT8Q A%
MY1OB-/[]-;P-F8/P%D#4_H Z4VI#E!/("TG08F VDPEK=5J^B-EF1S8[#(<=
M7%SJ57-@6[N^%W@<WA E$<;!S=A$ L4D*[32LR6$R4M>^&RRR&22U;5P2IT_
M%*;NI:YXJ;0)H)H;?]^Z*_%&&0553OSF:_1'KZ^H.\;?,4] <;S ^P8][[$"
M=O#=4E(BJQJ$!6JT\!:C.##*=Q5M($B3WP2C,C^RZZZ<&6XONG3\B;C1SYMT
M 7U)#",))]]#K#5RE,=)S;W!T0 YH<YM_KJ]>$@]5KT44.HLA7]M4\NV;=NF
MJ_J<506I&U9BM@$CYA5AJZ/]E8:SZG]2D1A1=;0OP8%O@3;P"*UC;MT.;MQ
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M$"-1MN5+7+Y'L'N'WM #AJ,#B/%20^'D?!B?/V,]&,67NZM#$CU$LZP1[ P
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MGUB>L%Z6LJ/ZGDS+WK+&D]#!D K#AW="*2Y+J Y0=<6,>K!4?16+]U;L 6'
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M&^^JER;CN'1)>;":;CG)V<T-TY++VD"'&AX:IG$56<)UMU%QP-@.&.E/,#[
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M7U#PGF[Z#4O?'^A5\ SU:/;94N9&W,NB46T!TXLB7\G@K"=>IOOUG@DJ'6^
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M5BF7%28Y>1; [Z7#2.]NV,'N'P,7?P!02P,$%     @ YH->60$0!U#N!0
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M%)5X@?!I8^9D!HM;1H]K0D1"]8C01A&*-,B@6'FJ5]Z8EE5T@HX.1ZAM6IH
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MZO4LCG?Q*Q6T(4U&2N;R9ZJX8NF*[_O6#XI,%>0#F703@:(F EC?(C/\TGT
M2"LOS__G_.H$:7B@  .*L_#3BA'8ZR99-XYJ'JX%#@WA0B 89.O ]3*@:MJS
M5=0[9+@*N!*\-?,>!7_-E8\UD7!#J]@2]VB47;MRAF?6/KA+@._S.+PATZ5
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M'>SHO,7^D\4+?I$Q,N,L#OG/.8ZA$AJ [^E=GO8?VJ!XL_6;_P!02P,$%
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M/WM!<,F6*A,5N4CZ)@.:V9KLZ%,-/3DK7-18.!V/A^,?V>,F "0=4L0R.:W
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MOB,.#Q,(V.Y[H8>'IA-4=*EVCCE2%60@7J"/\,97\+5(=<4Y"L?2VW@8HB[
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M@CL%$L4M>34\B/6]D,L!;$E8@QXUX[TJ_<$ANN)D1@R;1CT[R!^8T<G_*9*
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MZ_"+P%X>K9&)9,7YO=G<K,>.9RX$%#)E&+#^[& *E!HB?8T_#:?32AK@\?K
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MK6]A% 8114@3%<03%9-P>)2S1K[WPW <3 ;L@UA:%.VS"V _1,#F@VY[:9?
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M%N]UW-S@15IJ$L#_*Z5LTZ$)VJOY_"]02P,$%     @ YH->63S7"SVR"@
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MY=U35),]3+(E%9$-H.&@-J!\>E1E4#B1>CSA>)+ZZJ1O4&Z52[!AV80&9$#
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M)P@%YM8Q,!J>\0J%<$0DX]>.,VBW=,##^9[]QN=.N2R9P2LE'GEARW'0#Z#
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M2LGD4A1&JH)I,3OO70:G[T?TOGWABQ1KT[EGI,E4J:\TN,[.>SX!$KE(2Y+
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MAA7VWZ"L >Z74IK-Q%[0=_3S?P!02P,$%     @ YH->68$+6^%3!0  %A
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M$SR)K_['Y0XZ](M8%B](NGKVOBK^05 2@S?H.:,7(C, ;TA 9) Q11+0/9=
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M<FMS:&5E=',O<VAE970T,RYX;6RE5=MNVS@0_96!BBQLH-7=;I*U#21M=S=
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MK,B5U,X"T/V([C=6M7XL;I2E(>N7-=UJJ)T!?:^4LON-"S#>DZMO4$L#!!0
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MS$3B#ES^>B$5_OM$?:+0%T_< ,G4Z<)B=-4^Z]%^Z?E96^&,3V"$ 02#\ /
MX%?VYXJ5+Y*H]->VFNV36NMUHG"&TD*FTZ4V#J8W_P9/CP!%"6PS5,"0];H/
M;#E;&]=+J=!S=XEFH "'VN*FJ?Q:WM.-BNNIN^G%)=\)UW.9&9:(&9:VFST<
M+75Q<5:\6)6[RZJILE:E;K@0/!::)N#_F5)V_4(*RMO+X3]02P,$%     @
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M;!?1^XA54/.MQ">]_P*'>KS 4DOKOVP?8F>3B)5;B[H[@$E!)U3X\Y?#.9P
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M;=<,M%WS,4M(BJZ3)$M9S%9/:!HQ$48T#6G;M#'5TD[M#DB8"PGS(&$^)"P
M@C7$8F_%8L./_#:D8B!A+B3,@X3YD+  "-90C+-5C*,=7OYDDL1(JJ%>D'(S
M]$#BK'6@=P[&-XPMIVLUA\&9-M^I"H"$>9 P'Q(6 ,$:"AAN%3#4*D#M:62D
M)GHUY8?U[4V;!$J24Y- ?SCHXCT%:/.=J@!(F <)\R%A 1"LH8#15@&CUQ10
MV]468\&2<MZZK9R.#B2 ;=/L[BV&9MJ,IVH $N9!PGQ(6  $:V@ &SOCP]"J
MX"OC]VH<0"'91/F<0!;_9D+FR_\V&52PQE!@=9T]%>A3GBH#4)H'2O-!:0$4
MK2F%F@>&WVP[6*'KPAC8!\.#O@$G"^.8G%Y5:U"K9>SM\XX"!5I0\Y6;NU=N
M_O V#_V'YIP^1"P3\1.ZH1O&9?O@K$]RZEH>E.:"TCQ0F@]*"Z!H32GMW#_\
M!O8?!O7_0&DN*,T#I?F@M "*UE3.S@7$>AOPA,T@/K3$,!X8^\,\J)\'2O-
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M8&UY(]FF.-=YQZ1D27&YID2M)_(*ZOLE8_+Y)D^P/=X\^1]02P,$%     @
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M" TMW"YS&.-$&@"\7PBA-QOCH/ECD/P!4$L#!!0    ( .:#7EE$.S0K404
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M?4T0_36F.K)X@)B@PX8<4)QMK\#- 5,#C,%O*,QP-9?*G,PB\"O9001N<TS
M.CQ2<Q!D,8G#(ELQ^ @ZJ.(,HB,$#WF2 )J7IQ!%X/T2DC!.\ =J_GF]!._?
M?0#O0)R!NSA):#MXIA#:J<(U95-WX*;J@'ZF P:XRS.RP\#-(AAQ]/ZP?CJ@
M5^A@-B.JOX[HC3X(7,.]# SU"NBJ;G+\N1V6_WS(!N7+8?E=B*A<.RMWQSMO
M<.2K\<[SY-YXYWER__^-?/#-?>\D@M%,+:/D&6.F5C5OBFGT.C'^_(7:@X#
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MS0E?LY/ZL*J^87@K3V-N,6.XE)<;!%-$A %_OL:8'6^$@_;(,/H#4$L#!!0
M   ( .:#7EG%*8&!B@0  #8:   9    >&PO=V]R:W-H965T<R]S:&5E=#8P
M+GAM;+69VX[;-A! ?X50@R(!$NONR]8V$%LJND VW:Z;]J'H RW1LAJ)=$G*
MSA;Y^)"2+%LJK7@!^L769>8,AT....3T0.AGMD6(@R]YAMG,V'*^NS--%FU1
M#MF [! 6;S:$YI"+6YJ8;$<1C$NE/#,=RQJ:.4RQ,9^6SQ[I?$H*GJ48/5+
MBCR']'F!,G*8&;9Q?/"4)ELN'YCSZ0XF:(7XI]TC%7=F0XG3'&&6$@PHVLR,
M]_9=:(^D0BGQ1XH.[.P:2%?6A'R6-_?QS+!DBU"&(BX14/SMT1)EF22)=OQ;
M0XW&IE0\OS[2?RZ=%\ZL(4-+DOV9QGP[,\8&B-$&%AE_(H=?4.V0+WD1R5CY
M"PZ5K&\9("H8)WFM+%J0I[CZAU_JCCA3<-T+"DZMX%RKX-8*[K4*7JW@7:O@
MUPJEZV;E>]EQ >1P/J7D *B4%C1Y4?9^J2WZ*\5RH*PX%6]3H<?G3VB/<($8
M> <^0DJA#!MX'2 .TXR] :] BL%#FF4BJ&QJ<F%1ZIE135]4=.<"W04/!/,M
M R&.4:S0#_KU)SWZIO"T<=<YNKMP>H$KM!L UWH+',OQP*=5 %Z_>@,.6Y(A
M!C-$%4U<7D]TKR,&VML8ZFQCJV/=9ARYI0GW@HD@93!)*$I@.?_)!M0C"_SU
M08B">XYR]K=J!%5<3\V5>?*.[6"$9H9(A S1/3+F/_Y@#ZV?5+'2"0MTPD)-
ML%9PO"8X7A]]_K'(UXC*H)QBSL#7_C&UJ)A^R93?F_W<F9K[\][^KD3P78FP
M3Z+EK-\XZ_<Z^TA)7$1<?,6JS*9RK2(,SXUZ0W\P[OBG$/-=:^!VG/R_V,AQ
M[$'74X68YTW.:"UWAXV[PUYWQ<3C-%T7G%#P*T8J;WL!+YUA.F&!3EBH"=:*
MPJB)PNA&Z6^D,S@Z88%.6*@)U@K.N G.N#\C(!HAS,6Z5P;FF!? AI)<+*7^
M$1,G/DTB9;ZH^+9W-G>M@>-/.OE"+3;LB 47:,-.OE"+C6QUOI@TG3&Y.E_\
M?B J;WL!+QV2.F&!3EBH"=:*@FV=UMW6C3)&#=84'ZVT0"LMU$5KA^BL-+)O
MG#=J YTY;'O=A<8%.<OO9(X+<DXGPX1J.6MR(7?8SJE+G-XN68IRC(KB7OB/
MBXVX*&B*D[> DF>8\6< <0P(WXK%9MU=RE[IM?'B :R3%FBEA;IH[6B=:C+[
M5D69K;4JTTH+M-)"7;1VB$Z5F=U?FEU3K=2(=AUB=>N+I4+,M;RN6* 0\WU_
MT%U]*,1&X_.BINWPJ3JS^\NS#^%OX</B'BQ)EL$UH>705'K=RWGQ$-1)"[32
M0EVT=D1.!:0]O%66T%I9:J4%6FFA+EH[1*?JTNZMC^:K+:3E(@03_"Z2WV B
M1!*08HZ$/9D^(I+@]#_E)NNBIMM.:SG@=_.'UNKQ*INA+IM5OYIG^^ YHDEY
M ,% 1 K,JZW,YFESR/&^W-KO/%_8=TM;\3R0AR+EOOL)7YVH/$":I)B!#&V$
M*6LP$G.:5H<4U0TGNW(7?DTX)WEYN44P1E0*B/<;0OCQ1AIHCHKFWP!02P,$
M%     @ YH->61-T7+G+ @  ) @  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C$N>&ULK99=3]LP%(;_BI6A"226[Z^R-A*T0G"!A*@8%],NW/2TM7#LS'9;
M^/>SDY*%UG1<[*:QX_.^?LZ)/SK<<O$L5P *O524R9&S4JJ^\#Q9KJ#"TN4U
M,#VRX*+"2G?%TI.U #QO1!7U0M]/O0H3YA3#YMV]*(9\K2AA<"^07%<5%J]7
M0/EVY 3.VXL'LEPI\\(KAC5>PA348WTO=,_K7.:D B8)9TC 8N1<!A?CW,0W
M 3\(;&6OC4PF,\Z?3>=V/G)\ P042F4<L'YL8 R4&B.-\7OGZ713&F&__>9^
MW>2N<YEA"6-.G\A<K49.[J Y+/":J@>^O8%=/HGQ*SF5S2_:MK&9[Z!R+16O
M=F)-4!'6/O'+K@X]01!_( AW@O"S@F@GB)I$6[(FK0E6N!@*OD7"1&LWTVAJ
MTZAU-H29KSA50H\2K5/%+=L 4UR\HF]HS*N:,]V5B"_0WY'3"2A,J#S3,8_3
M"3H].4,GB#!T1RC5WT(./:51C*%7[J:]:J<-/YAV"K6+(O\<A7X86^3CX_()
ME%H>-/+HO=S3!>BJ$'95"!N_Z)]5F!!94B[7 M#/RYE40J^S7[;\6L/8;FCV
MWH6L<0DC1V\N"6(#3O'U2Y#ZWVW9_B>S=[E'7>[1,??B 6_U@E(@"*;6+]G*
MTT9N#H5-$:6Y.QAZFWX*AU%QF/:BWK'%'5M\E.U)'P%FH=6"ER"M=*U!UILW
MR/W(S??P+&$#S9?;^9*.+SG*=TT8T7MOCI:<SZUXK3[I%V\0[+$E!VQADKBQ
M'2WMT-*C:-V2ME&EEAG3R,WVP"QAJ3]P SM9UI%EGR,[UP><$+IM0\P.YX[3
M@1ON(5K"DC#[J'AYAYA_%I%Q=H0R/UCU@]A-]A@/@_*@5^N6T.N=X>;^O,-B
M29A$%!9:YKN97B6BO9/:CN)U<ZS/N-*71--<Z6L<A G0XPO.U5O'W!3='X/B
M#U!+ P04    " #F@UY95=(+;WX$  !1'   &0   'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6S-F5UOVS84AO\*H15#"[36ER7;F6V@L20TP%($"=I=#+M@
M)-KF*I$N2<?)L!\_ZB.R9:FJG9R+W=@2Q?<YXGDEDB*G.RZ^R34A"CUF*9,S
M8ZW4YL(T9;PF&98#OB%,7UERD6&E3\7*E!M!<%*(LM1T+,LW,TR9,9\693=B
M/N5;E5)&;@22VRS#XNF2I'PW,VSCN>"6KM8J+S#GTPU>D3NBOFQNA#XS:TI"
M,\(DY0P)LIP9'^V+R/9R05'C*R4[>7",\J;<<_XM/[E*9H:5WQ%)2:QR!-9_
M#V1!TC0GZ?OX7D&-.F8N/#Q^ID=%XW5C[K$D"Y[^01.UGAEC R5DB;>INN6[
M3Z1J4'&#,4]E\8MV55W+0/%6*IY58GT'&67E/WZL$G$@T)QN@5,)G&/!\ <"
MMQ*XIT885H+AJ1&\2N"=*O K@5_DODQ6D>D *SR?"KY#(J^M:?E!85>AU@FF
M+'^R[I305ZG6J?D5>R!,<?&$/J#/6 B<&XW>!D1AFLIWNO3+78#>OGF'WB#*
MT#5-4_U R*FI=/ <8<95H,LRD/.#0"ZZYDRM)0I90I(.?="OG_3H3=WHNN7.
M<\LOG5[@'=D,D&N]1X[E##ON9W&ZW.UJSNNBAZ^+'IT@=_PN>2.7;OT4N07/
M_>E3].?O^A*Z4B23?W4])"5GV,W)N]$+N<$QF1FZGY1$/!!C_NLOMF_]UN40
M)"R A(60L @(UG!V6#L[[*///^O!C;*89Z3+S5+K%]I\#'N8N^/QP)N:#X<V
MM6M]\,<#MUDK:->R7=\[AH7M:A/;&?C-6E%OHUZ8,J].F=>;L@67"O$EDC@E
M\CTBCW&Z32A;(9QQH>@_N!Q268)HML%4Z'&ZJ(_C[ULJB"YF"K,5O4\)PE(2
MU=G;EO<P.LB#[XX'HZ/4>ZUL^=[D.%M!FV6/''\P.4I]&V9/;&]@'^6^-SLO
MS+U?Y][OS?TMT8,@NEEC/>F(R5;1&*?:@RL6=^6PEW5N9P0)"R!A(20L H(U
MW!W5[HZ AID1I+.0L  2%D+"(B!8P]EQ[>RX][VMG>TRLY1ZA_V.XQUU3HM>
M_KDFG1(QA(P8E;!)8_2SK#IB(ZF3.JF3TY+:''DV1%#>-0._[,6=^]9 P@)(
M6 @)B_HM&*(G@H7L>4-L:_^E9KUP;$/_HDA/)-!7G&X)^IC\K;\;BUF%XJCW
MS>J/>*[CH+0 E!:"TB(H6O-)./AFMX'&P0H$93 D+0"EA:"T"(K6--C9&^R\
MXJNK$A_.USWK>+:^Z ]QMEGMF/:X-?</08-&4+2F"_M%#;OWR_JU':ZNM-#(
M7/637AAT4024%H#20E!:!$5K/A[[E1%["-4+ RU'5 9#T@)06@A*BZ!H38/W
MZSCV_V$AQVXOJSBM);3^.SW;\W;(86O9+@2-&4'12B_-@QV/C(A5L3<E4<RW
M3)7+UG5IO?_UL=CU.2J_M"\6=D=Y8%^$Y>[6'E]NMEUCL:),HI0L=2AK,-(-
M$^7^57FB^*;8;[GG2O&L.%P3G!"15]#7EYRKYY,\0+V+./\/4$L#!!0    (
M .:#7EG[3IEE.@8  "$I   9    >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM
M;+6:46_;-A#'OPKA%4,"U+9$2K;4.0;29.T"M$/0K-M#L0=%IFVADNB2M)T,
M^_"C9%44+8J>4OHEL>R[O^Z.1^E'2K,]H5_9&F,.GK(T9U>#->>;-^,QB]<X
MB]B(;' N?ED2FD5<'-+5F&THCA:E4Y:.H>-,QEF4Y(/YK/SNGLYG9,O3),?W
M%+!MED7T^2U.R?YJX Z^?_$I6:UY\<5X/MM$*_R ^>?-/15'XUIED60X9PG)
M <7+J\&U^^;&\PJ'TN+/!.]9XS,H4GDDY&MQ<+>X&CA%1#C%,2\D(O%OAV]P
MFA9*(HYOE>B@/F?AV/S\7?U=F;Q(YC%B^(:D?R4+OKX:! .PP,MHF_)/9/\;
MKA+R"[V8I*S\"_:5K3, \99QDE7.(H(LR0__HZ>J$ T'U^MP@)4#_+\.J')
M9:*'R,JT;B,>S6>4[ $MK(5:\:&L3>DMLDGR8A@?.!6_)L*/S^]R'N6KY#'%
MX)HQS!F(\@5X3\ABGZ0I&(*'P_@"L@1MVXM;S*,D99?"\//#+;AX=0E>@20'
M'X6S&"4V&W,19'&J<5P%]/80$.P(Z %O1@ YKP%TH*=QOS&[W^)8N+NE.U+=
MQZ(T=7U@71]8ZJ$.O7=)GG \_"!Z;=$NP&OPNYAI7ZX?&:>B(?_6I7O0]_3Z
MQ2Q]PS91C*\&8AHR3'=X,/_Y)W?B_*)+WI*84@I4EP*9U$^6XCTE3#O@!]E)
M*5M<5G9SUW,==^3/QKMF<AH[=PJ#45#;*7%[==R>,>[K.-YFVS3B(NSKC%">
M_!,5EQ!=J >E:2.$X<3UX"@\"E5CYP>3L"M4OP[5-X8JNDD7E=\ZVS3T@]'D
M**B#F=\P\P,_U$<TJ2.:&/N_H^4O?GV*T^TBR5?UM>+RQ#R8V)P'EL24DDSK
MDDR-@W1#F':4IJU1<OW0"T;>T3!I[#R(8%?O!'58@;4V#UHA:+N\;69J\K .
M-'Q)DX>MDX6!X[<N$F&KR0,T0?J(7$?>!1UC3'?Y<$-)C!D#1<-$-%Z7-\(%
MW@G2V0ANT<9L5NW;U+;4U!HT2, ],=4%_ABO\>#+!^$#[CC.F':.5V>P50]+
M:FH]Y)W?-=Y-RWE>-D&N;]C*79G(DZ ]BRJ[9LM"Y#D=+2OOQJ[Y=GQ/$T(3
M_BP:=E?@\HYL!>-3;:1&I=[#8DE-S5O>S5WO[&UJ!(;>];"DIM9#(H-K9H:3
M;=K& M=QCGO4;*2&)MG!-=Z'YW_0:"%6G6)%6@;(BT.01QG6KPNL$H(M-35U
MR0CN].Q=:L20WO6PI*;60\*):Z:3DUT:M!IP<@Q.9ALU, DCKIE&KN-OVX2*
M 2J"2_)AFL0X9^*8%AL A\;="*C*N;YIC>J]!\F2FKK4E10$G7,O=JT"D2TU
MM1P2B* 1,%Z^X*UT%3)P?+^-!AK#P V<$=1W-6SL6IC9I<]B +8Y9@@GX;0=
MK<[0\YS1M"-<R3+0S#(=2X+*JSGAIX%_O"*HK)1ERA2%C96#&I4D#7B*-&RM
M?:%5X+"EII9% @<T T>OWO);>SKZUFIO<1@[2R((-"-(C\L[^!=\%#,^VV;:
M3*S2B2TUM2J23J"93LQ7MI-D JV2B2TUM1:23*"93'YE/,G*9DZ3)08720Z>
M<439I39SLQ8\N&JS-'J^-$N).= :YA3S('KJG =6@<>6FKJA+8$'_0CPG)P'
MR"KMV%)3:R%I!YEII]<\.*$%W>Z)8'9]:9J2C)"9C&X/.WHB38[C=4Y2LGHN
MNY_PCMT3LV#O43[+(YS&,QQT9L1'5C>3;*FIY9"(A\S/AE[^3,MK@0WRO?8S
M&=1^4G1DIT8N*0S9HS#4WMT9(L]K/7]K0Y@P@^'([0A64A@R4U@'WU=>ZCH)
MM6NH,7,[^1Y)"D*G]FAL\3VR"D2VU-2R2"!"]AXD55)AL[TUC16T)XNIKR35
M(#/5F"_F9J W2_<>LW. C"=!QCLKR'A60<:6FEH+"3*>19 YH>6B;I QN[XT
M30DRWH^ C!GBS=*]Q_L<2.-)I/%^!&E.][Y5GK&EIM:B\:J+F6?Z];Y9"QD@
MWNS:-\UQX_VUXN7!CQ%=)3D#*5X*>6<T%6!"#^_C'0XXV92OM#T2SDE6?ESC
M:(%I82!^7Q+"OQ\4;\G5;T7._P-02P,$%     @ YH->68$/=93X"   (6<
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MA!1-2=48E9IL)J!I0I,M)V8\Q4<:[<L4))L R2;3),O)L$=@X*./]FH* $X
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MGE"./I.T!'0#1)0<U"J0 KU#'PGG1$<1O<$@"4W%KTM7JB&UH9O4^*L*'[R
M#]$-R^5!H#C?PK;'?CULOQBP=Y6KC;_!D[]7P2#P'HH1"KVW*/"",?ITC]&;
MG_O\6MO!X&',[V4Z0E[P0TP\C,&0J-GX!A/V8SIBA<WB" TW?)&[D>@Z%Y*7
M>E6@O_Y0'="UA$S\W;<6*MJXGZ93WH4H2 (K1^4T ?P!G.B7G_RI]UM? &S"
ML$U8; G6"<FX"<EXB!Y="J%V#YH5ZKTU,4D.A.]!](6C(BT,26\8#Y&W=!_:
M&O^P!QZ<S;G"68)UA)LTPDT&A5NK/$+SO9&,J7UN"SJ[J:V*;5*Z-\U>$2OJ
MI"51,)_YGOY\(^;)/?'@3,\5=3(0PXY2TT:IZ:LH-?UN(D'@S_N4.KDG'ISI
MN4I9@G5$G36BS@9%_5!F)$?765;F+&7[1W1%F4@HY$G_NSM(.S>5VH1AF[#8
M$JP3DGD3DKG5W6UN,R0V8=@F++8$ZX1DT81D\2JI9Y!Z;FALPO#B^U0W6X0]
MJ2ZV-&Q'=]][+@.\5U%^&'NN]%9IN*9UQ/<F??M,;&O@KOJM(LS_W[L#^K==
MF:F$593R+;KE;$,V-*7R$=T1";VQ&1ST[-C8I&&KM-@6K1N^X#E\@=6=I,;9
M"HQ-&K9*BVW1NH%YKE_]P5HLPE0DK%01X2^](E9+5JLT7-/\L/W7?C2=?9NZ
MK):C;NLH*0-56>HS/(&,BM6I4G.W.2>\-*=C[G/WZI#Q1A6F-!<HA9TR]48S
M5:GPZMRNNI"L, =3&R8ERTSS $3M/+J#>KYC3#Y=Z &:T]/H/U!+ P04
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M9-G_E!,M<M=S3(4V'8P;+DS/B-)N,,]G0NC'B6UCZBXT_@502P,$%     @
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MRMA#.<'AM-K7=V'O.UH^KQ\)@XZ$OS02]_F1"-1(3&EHQ]*Q6Y8_#)AG]LH
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M,ZHYEY>RU)8.''WP)(HU.HGF''E731[\)[ 7!H2U 6$;^IX!S!@ 1%\4\.N
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M^'WZ_!>K'LB6O%4:Y<5?]%S9&B.T.N0\C2MG<0=QF)3_Z4LE1,L!6R<<2.5
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M*2[NYS<]IV@1R4@B"@@L/YY(0+*L0)+M^%J#]G8Q"\?][Z_H<=EYV9E'S$G
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M$%E]*6L5+;2*%EE%BVVAM?.@T?W(_&K6^A9+':^UK^0JJPJDOG!%OO(Z)]2
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M2RNPZD&*:?D)7ZN). #8[@< IP(X;8#W 6!8 8:G9G K@'MJ!J\">*=F\"N
M?RH@J !!(58YNX4T"RCA;,+9'O \6K'E%X6^!5HI@FENQ97DZENL<'+V66X1
M!W-&!2,X@1(E(,(4TAA# E92-2C?27"Q0!)B(L 7]"HS2"[!-?BZ6H"+3Y?@
M$\ 4/&!"E+7$Q)2J5SFW&5<]F)<]<#[HP1 \,"JW H0T04D'/NS'CWOPIIJ-
M>DJ<MRFY<WH)5V@W (Y_!1S+&7:-YP3XT"K@;@=\<3J\*WOX:]FC7\N^[(<O
M4*S@=A>\(<6P=N>PX',_X/M'U>*-JJ="5;V8;2C^3_E3%3!E6F6Z6-5>D5^
M-<0<O$"2(<#6 /W(L/P)!(HSCB5&7::\ZTV<OP!NQ [&:&JH"B\0?T'&[,\_
M;-_ZJ\L1)9E?D.7%_V5V[8P&SL1\.13^.,H9!P._&15V1 6#83,HZ@CR1^VH
MI:8Q-J1S:^G<$Z6[($P()"Z5AI 4"B9*%[HI5-PACEFAZ4FJ]>8\5[62+#A4
MS;8&XY9JQU'NP&UIUL'DM8.BXR#O2#%-XVLHYM6*>;V*E:\"PNCF6B*> H+A
M,R8?2M%+=JX4WM'<!*X[L%M2Z$P9GI0RTIERZ1T]M<'(/DC9D,VO9?-[9;N-
M8YZIATK50Y8B(.%KMUZ]+.?J59)Y!R.Q_7:YTYDP/"%AI#/ATC_2RK6&!R6]
MH550:Q7T:O6$U!H-/&ZA6D3'*),XAD1<@7L:=RG6RW6N8CK)%CK)0IUDD4ZR
MI2:RAE5&M55&O5;YPJ1:@4L.J8#EKJU8WW3Y9'1D5=^WG/:+;-Z;[UP'Z"0+
M=9)%.LF6FL@:#AC7#ACW.N">4:R*PPK2#4S9%5@@JM9/ -)$M6TZG=!+>&[%
MT$FVT$D6ZB2+=)(M-9$U_&);[WMYZW=ME_HSGVNMBJVQ%AZV%\.+*JJY8?*.
M-DP=9&.KO?F*JJAQ8\ODM9;?ND;9U._@+,;NU:]ZU#OGOQ=Y]OSK9%MH90NU
MLD5:V9:ZV)K^<-[]X?RVY[LW\]G^<HZ?7&<0M)]OG3G#CIR!-;#&AW_MFJ"S
M TM=;*4YS(,SW13Q37%<+T#,,BK+ [2ZM?Y)X+8X"&^US^V;A=W1'MHW47G@
M_TY?_O[P /DF-QE!:Y7*&@1JV\7+(_WR1K)=<:+\S*1D:7&Y13!!/ ]0WZ\9
MDV\W>8+ZAY79_U!+ P04    " #F@UY9L&*C10\$  #F%   &0   'AL+W=O
M<FMS:&5E=',O<VAE970Y,2YX;6S%6&%OHS@0_2LC;G7:E6X+)DG;]))(;;JG
MNP_15LUU[[,#DX 6;,XV27.Z'W\V4" 1]64CJGYI,'B>YSW&PZLG.RZ^RPA1
MP7.:,#EU(J6R&]>5080IE1<\0Z:?K+E(J=)#L7%E)I"&15":N+[G7;HIC9DS
MFQ3W'L1LPG.5Q P?!,@\3:G8WV'"=U.'."\W'N--I,P-=S;)Z :7J)ZR!Z%'
M;HT2QBDR&7,& M=3YY;<S,G8!!0SOL6XDZUK,%16G'\W@S_"J>.9C##!0!D(
MJG^V.,<D,4@ZC[\K4*=>TP2VKU_0?RO(:S(K*G'.D[_B4$53Y]J!$-<T3]0C
MW_V.%:&1P0MX(HN_L*OF>@X$N50\K8)U!FG,RE_Z7 G1"M XW0%^%>"?&C"H
M @8%T3*S@M8]570V$7P'PLS6:.:BT*:(UFQB9E[C4@G]--9Q:J;I)W3%!35J
M F4A?%41"GC$A!J=911G$C[#U_GCEV]/2_AXCXK&B?RD[STM[^'CAT_P 6(&
MBSA)S/R)JW1:!MP-JA3NRA3\5U(@L.!,11*^L!##COBY/7YLB7>U'+4F_HLF
M=[X5<$'%!0S(+^![Y*HK'WOX$C,=[IEP?VA)9U"_HD&!-WP%KY*^2UAKH.D
M-S*C 4X=O<4EBBTZLY]_(I?>KUVL>@([X#BL.0X+],%I92@$91O4W4+)HB89
M9Y^#UZ: TI>2%FVAL_R&?:K4$]B!2J-:I9&U$A[YGB9J#[J)&QG8!C+!U[%6
M(-*+13P)03=VB'3K0JE 5-/U7 0=$FBQ=&ONDJA<=URL:SK_=C;VO(F[;3.W
MYG8F\\N:^:6=.89YV?=UJVGSZB)30A&_Q<:[&!VQL:YW)INKFLV5E4VKVLV7
M;".P*F04:1<A.QHAL$<JNDI_;HT\D^5US?+ZE+X%_X+^X.K/*8,_Z3/<YBKB
M(E;[+J)6P!_=J3V!'7 ?U]S'[]?/QGVJU!/8@4K$:]R'=U)':[H3* XKU XQ
M0*U+EQVXJS"/-K@W.-KA]J7/I=8R5N3$\E_$+$[SSIUMQ_C1=]D7VB%COV'L
MOU_15VOWI51/:(=*-8Z.V"W=>65?8I+A0=F3P?&7S;[VN=P:)T>L%JA=]_3Y
MU;KOU9/UA7;(N'%E9/2.==^3[:J4>@L31QH71_['QIU5]YU^SOQK=5CV;^'H
M2&/IB-V%+;C,&:K\GSREJTX:/7FQBNU;.#O26#MR_8XEWZL-[ OM4*G&"!*K
M@YH]-*7.U[#.52X00MQBPK-"C8!+U2U#KSZO0CO:18UG*NFYK9.D%,6F.&"3
M.L><J?)0J;Y;'^+=%D=7;C.]/ %<4+&)F80$USK4N[C2K4>4AVKE0/&L.)=:
M<:5X6EQ&2$,49H)^ON9<O0S, O71YNP_4$L#!!0    ( .:#7EEK.?4[ZP,
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M90+]*A$: ,]WG*OSC9Z@[H 7?P%02P,$%     @ YH->6=/8QY<B P  HPL
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M;^^@U'-M^&).I?U%VS+6<U"\EHIG)5A7D!%6//%SZ<,>0//4 _P2X+\&!$<
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ML*%;;J[E[@,T_HPM7RJY=K]DU\@&'DFWVLBR :,%)1/U/[UOXK '0)YN0-@
MPL> T1. J %$IVH8-8#1J1K&#<"Y[M>^N\#%U-#%3,D=458:V>S"1=^A,5Y,
MV#I9&X5/&>+, @/,Z:U4U.:+4)&1?TP!BEP#IS:3NF"5)F_(NJXC(C?DPN:6
MF6^U#&3$2'(1WWQ(/JW('AU6P<L8#&5<OT*"FW5,7CY_19X3)LB*<6[)9[Y!
M'ZPE?MK8NZSM#9^P-R(K*4RA22(RR#KP\7'\VR-X'V/7!C!\". R/$JXAFI
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MEI>;/LH3R?)BD\(]DY)EQ>$6HP1SW4#=7S/ULE^=: 7UUIOEOU!+ P04
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M#QI' $5K"N30NK3Z>Y?W6:X,\JR7"D'0BG07$=#V)"C-!:5Y):V^1CAF>XF
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MX>+%+K+B1+(LW\2T9%*R)#_<$!P1K@>HSU>,R=<3[:#:R[?X%U!+ P04
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M,CX&D4=1D_UC$)D<@<C+5WMJ/D=D> PBNV]29%"?UUJ'PJTC86/UX.@]]'_
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M%1^GSWT_WHJ^UE7 =YH]73[;W[[_NORZ6-\P5Z;;^XSQZ2]02P,$%     @
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( .:#7EE?C+$D[P   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( .:#7EF97)PC$ 8  )PG   3
M      "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ YH->
M63DV/$[!!0  N1X  !@              ("!#@@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( .:#7EF:#4M5 @@  /<F   8
M      " @04.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" #F@UY9E&IF3X,$  !<$@  &               @($]%@  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ YH->6?K=LB@1!P  5R   !@
M             ("!]AH  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( .:#7ED)V( _K@(   4'   8              " @3TB  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #F@UY9F_"0)JX(   R
M*0  &               @($A)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ YH->6;REDI/B#0  %*8  !@              ("!!2X
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .:#7EDFI#LA
MD!   -(K   8              " @1T\  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " #F@UY9(UT]/@X7  ##3P  &
M@('C3   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ YH->
M67\OL=;B!   90T  !D              ("!)V0  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " #F@UY98+2I6"H(   L&   &0
M        @(% :0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( .:#7EF\*0L44PP  +4D   9              " @:%Q  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ YH->63HMZQG.!   0 L
M !D              ("!*WX  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " #F@UY9^\$?F& )   ]'   &0              @($P@P
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .:#7EEVIK\_
M<@P  )0E   9              " @<>,  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ YH->6571.'&@!@  (A(  !D
M ("!<)D  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #F
M@UY9.*03LL\(  "%&@  &0              @(%'H   >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .:#7EF3[#:Y=P0  '$*   9
M          " @4VI  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#
M%     @ YH->6?NKY)KE P  AP@  !D              ("!^ZT  'AL+W=O
M<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #F@UY9O0FZC8 #  !*
M"   &0              @($7L@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
M;%!+ 0(4 Q0    ( .:#7EE!:C4DZP4  !T3   9              " @<ZU
M  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ YH->69-[
M9I=W P  P@<  !D              ("!\+L  'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6Q02P$"% ,4    " #F@UY9=>2CT"@)  "D'0  &0
M    @(&>OP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M .:#7EG1I1:WU@8  "00   9              " @?W(  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ YH->60$0!U#N!0  P!   !D
M             ("!"M   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " #F@UY9K][LQX09  #E6@  &0              @($OU@  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .:#7ED.$$A;U@4
M +X/   9              " @>KO  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ YH->6?+R%R[J#P  ,2D  !D              ("!
M]_4  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #F@UY9
MR(! >YD"  #H!P  &0              @($8!@$ >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .:#7ED >H^K0P(  (H&   9
M      " @>@( 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ YH->63 MR1B8$   )BT  !D              ("!8@L! 'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #F@UY9MZA>)P<'   S$@
M&0              @($Q' $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( .:#7EG4+N\$SP0  *8/   9              " @6\C 0!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ YH->63S7"SVR
M"@  !2   !D              ("!=2@! 'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " #F@UY9E9;V6<X"   E!@  &0
M@(%>,P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .:#
M7EFY4]^F' 4  &@,   9              " @6,V 0!X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ YH->6:$\9"]J"   _!@  !D
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M=#0Q+GAM;%!+ 0(4 Q0    ( .:#7EDS,7%C]@4   H4   9
M  " @5%7 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
MYH->60V@/',] P  ,P<  !D              ("!?ET! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " #F@UY96,<&,K(%  "/$   &0
M            @('R8 $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( .:#7ED>H.1!HP4  ,D4   9              " @=MF 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ YH->67,"(YQ7 @
M3@4  !D              ("!M6P! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " #F@UY9B>R2.LL6  "/0@$ &0              @(%#
M;P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( .:#7EG]
MLQ/LW04  .HL   9              " @46& 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ YH->699GPF;P"P  X(0  !D
M     ("!68P! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .:#7EE$.S0K404  &$B   9              "
M@0NQ 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ YH->
M68[JLXF2%P  _28! !D              ("!D[8! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " #F@UY9B,6'E:,$  !H%@  &0
M        @(%<S@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( .:#7EE(U*9TBP(  %<'   9              " @3;3 0!X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ YH->677K'J)*!   !Q8
M !D              ("!^-4! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    " #F@UY90X+Q_L0#   ^%   &0              @(%YV@$
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( .:#7EG%*8&!
MB@0  #8:   9              " @73> 0!X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ YH->61-T7+G+ @  ) @  !D
M ("!->,! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " #F
M@UY95=(+;WX$  !1'   &0              @($WY@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( .:#7EG[3IEE.@8  "$I   9
M          " @>SJ 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#
M%     @ YH->68$/=93X"   (6<  !D              ("!7?$! 'AL+W=O
M<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #F@UY9@8AT?H "  "/
M!@  &0              @(&,^@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM
M;%!+ 0(4 Q0    ( .:#7EE8EHST/@,  /,*   9              " @4/]
M 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ YH->60G_
M(R0'"@  K68  !D              ("!N  " 'AL+W=O<FMS:&5E=',O<VAE
M970V-RYX;6Q02P$"% ,4    " #F@UY9#@5QZ<D#  !)%0  &0
M    @('V"@( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    (
M .:#7EEZSH6?\0(  )$*   9              " @?8. @!X;"]W;W)K<VAE
M971S+W-H965T-CDN>&UL4$L! A0#%     @ YH->6=,:7#T?"0  Z58  !D
M             ("!'A(" 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"
M% ,4    " #F@UY9P%AR8O4"  ! "   &0              @(%T&P( >&PO
M=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( .:#7EFQ*\5-D (
M #$(   9              " @: > @!X;"]W;W)K<VAE971S+W-H965T-S(N
M>&UL4$L! A0#%     @ YH->69LDS3JE P  W \  !D              ("!
M9R$" 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " #F@UY9
M6@V\HK$"   G!P  &0              @(%#)0( >&PO=V]R:W-H965T<R]S
M:&5E=#<T+GAM;%!+ 0(4 Q0    ( .:#7EF'$Z\<:P(  #L&   9
M      " @2LH @!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%
M  @ YH->68RJQB,8#   _XH  !D              ("!S2H" 'AL+W=O<FMS
M:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " #F@UY9Z)UOZ40%  "R*0
M&0              @($<-P( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+
M 0(4 Q0    ( .:#7EGVSPQ#NP(  &$(   9              " @9<\ @!X
M;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ YH->69H=1)=O
M!   %!P  !D              ("!B3\" 'AL+W=O<FMS:&5E=',O<VAE970W
M.2YX;6Q02P$"% ,4    " #F@UY9@^*155T"   _!@  &0
M@($O1 ( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( .:#
M7EE;\/<^PP<  # X   9              " @<-& @!X;"]W;W)K<VAE971S
M+W-H965T.#$N>&UL4$L! A0#%     @ YH->618)J<46!@  ?2@  !D
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M=#@V+GAM;%!+ 0(4 Q0    ( .:#7EEH2<1DWP,  %X/   9
M  " @2MJ @!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @
MYH->69!>H'4N P  6@H  !D              ("!06X" 'AL+W=O<FMS:&5E
M=',O<VAE970X."YX;6Q02P$"% ,4    " #F@UY99G4*T!,'   -+   &0
M            @(&F<0( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4
M Q0    ( .:#7EF%.Q:=GP0  &09   9              " @?!X @!X;"]W
M;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @ YH->6;!BHT4/!
MYA0  !D              ("!QGT" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX
M;6Q02P$"% ,4    " #F@UY9:SGU.^L#   E#0  &0              @($,
M@@( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( .:#7EGC
M*R:*;@(   P'   9              " @2Z& @!X;"]W;W)K<VAE971S+W-H
M965T.3,N>&UL4$L! A0#%     @ YH->6<4^O1/D P  #0\  !D
M     ("!TX@" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .:#7EGY0<VB&@,  '0)   9              "
M@=&< @!X;"]W;W)K<VAE971S+W-H965T.3DN>&UL4$L! A0#%     @ YH->
M689"-E,2 P  6 P  !H              ("!(J " 'AL+W=O<FMS:&5E=',O
M<VAE970Q,# N>&UL4$L! A0#%     @ YH->65X:62I[!0  UR<  !H
M         ("!;*," 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL4$L! A0#
M%     @ YH->62IW'&,7 P  F D  !H              ("!'ZD" 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @ YH->6<F)4J]@ P
M\!   !H              ("!;JP" 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N
M>&UL4$L! A0#%     @ YH->6<2VGEU4 P  #!8   T              ( !
M!K " 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #F@UY9EXJ[',     3 @
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8;6Q02P4&     &\ ;P"$'@  ?<$"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>794</ContextCount>
  <ElementCount>414</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>169</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Dispositions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Dispositions</Role>
      <ShortName>Dispositions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Acquisitions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Acquisitions - Purchase Price Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails</Role>
      <ShortName>Acquisitions - Purchase Price Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Acquisitions - Preliminaty Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails</Role>
      <ShortName>Acquisitions - Preliminaty Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Dispositions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DispositionsDetailsTextual</Role>
      <ShortName>Dispositions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Dispositions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Revenues - Revenues by product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails</Role>
      <ShortName>Revenues - Revenues by product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Revenues- Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Revenues - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues - Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Inventory - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails</Role>
      <ShortName>Inventory - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Fair Value Measurements - Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails</Role>
      <ShortName>Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Fair Value Measurements - Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesDetailsTextual</Role>
      <ShortName>Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Leases</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails</Role>
      <ShortName>Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails</Role>
      <ShortName>Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Share-based Payments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails</Role>
      <ShortName>Share-based Payments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Income Taxes - Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails</Role>
      <ShortName>Income Taxes - Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails</Role>
      <ShortName>Collaborative and Other Relationships - OCREVUS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails</Role>
      <ShortName>Collaborative and Other Relationships - Profit Sharing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Collaborative and Other Relationships - Eisai (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails</Role>
      <ShortName>Collaborative and Other Relationships - Eisai (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails</Role>
      <ShortName>Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails</Role>
      <ShortName>Collaborative and Other Relationships - Samsung Bioepis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="biib-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9954544 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="biib-20240930.htm">biib-20240930.htm</File>
    <File>biib-20240930.xsd</File>
    <File>biib-20240930_cal.xml</File>
    <File>biib-20240930_def.xml</File>
    <File>biib-20240930_lab.xml</File>
    <File>biib-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20240930_g1.jpg</File>
    <File>biib-20240930_g10.jpg</File>
    <File>biib-20240930_g11.jpg</File>
    <File>biib-20240930_g12.jpg</File>
    <File>biib-20240930_g2.jpg</File>
    <File>biib-20240930_g3.jpg</File>
    <File>biib-20240930_g4.jpg</File>
    <File>biib-20240930_g5.jpg</File>
    <File>biib-20240930_g6.jpg</File>
    <File>biib-20240930_g7.jpg</File>
    <File>biib-20240930_g8.jpg</File>
    <File>biib-20240930_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1624">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>133
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "biib-20240930.htm": {
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "biib-20240930.htm"
     ]
    },
    "schema": {
     "local": [
      "biib-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "biib-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 323,
   "keyCustom": 91,
   "axisStandard": 42,
   "axisCustom": 3,
   "memberStandard": 61,
   "memberCustom": 100,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 6
   },
   "contextCount": 794,
   "entityCount": 1,
   "segmentCount": 169,
   "elementCount": 886,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1624,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.biogenidec.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "longName": "9952151 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "longName": "9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "9952153 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952154 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "longName": "9952156 - Statement - Condensed Consolidated Statement of Equity Statement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "longName": "9952158 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.biogenidec.com/role/Dispositions",
     "longName": "9952159 - Disclosure - Dispositions",
     "shortName": "Dispositions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives",
     "longName": "9952160 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.biogenidec.com/role/Revenues",
     "longName": "9952161 - Disclosure - Revenues",
     "shortName": "Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.biogenidec.com/role/Inventory",
     "longName": "9952162 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "longName": "9952163 - Disclosure - Intangible Assets and Goodwill",
     "shortName": "Intangible Assets and Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "longName": "9952164 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "longName": "9952165 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "longName": "9952166 - Disclosure - Derivative Instruments",
     "shortName": "Derivative Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipment",
     "longName": "9952167 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.biogenidec.com/role/Leases",
     "longName": "9952168 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.biogenidec.com/role/Indebtedness",
     "longName": "9952169 - Disclosure - Indebtedness",
     "shortName": "Indebtedness",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.biogenidec.com/role/Equity",
     "longName": "9952170 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "longName": "9952171 - Disclosure - Earnings per Share",
     "shortName": "Earnings per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "longName": "9952172 - Disclosure - Share-based Payments",
     "shortName": "Share-based Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "longName": "9952173 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "longName": "9952174 - Disclosure - Other Consolidated Financial Statement Detail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "longName": "9952175 - Disclosure - Collaborative and Other Relationships",
     "shortName": "Collaborative and Other Relationships",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "longName": "9952176 - Disclosure - Investments in Variable Interest Entities",
     "shortName": "Investments in Variable Interest Entities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.biogenidec.com/role/Litigation",
     "longName": "9952177 - Disclosure - Litigation",
     "shortName": "Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.biogenidec.com/role/AcquisitionsTables",
     "longName": "9954472 - Disclosure - Acquisitions (Tables)",
     "shortName": "Acquisitions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables",
     "longName": "9954473 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "longName": "9954474 - Disclosure - Revenues (Tables)",
     "shortName": "Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "longName": "9954475 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "longName": "9954476 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "longName": "9954477 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "longName": "9954478 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "longName": "9954479 - Disclosure - Derivative Instruments (Tables)",
     "shortName": "Derivative Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "longName": "9954480 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "longName": "9954481 - Disclosure - Earnings per Share (Tables)",
     "shortName": "Earnings per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "longName": "9954482 - Disclosure - Share-Based Payments (Tables)",
     "shortName": "Share-Based Payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "longName": "9954483 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "longName": "9954484 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "longName": "9954485 - Disclosure - Collaborative and Other Relationships (Tables)",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
     "longName": "9954487 - Disclosure - Acquisitions - Narrative (Details)",
     "shortName": "Acquisitions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-104",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
     "longName": "9954488 - Disclosure - Acquisitions - Purchase Price Consideration (Details)",
     "shortName": "Acquisitions - Purchase Price Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
     "longName": "9954489 - Disclosure - Acquisitions - Preliminaty Purchase Price Allocation (Details)",
     "shortName": "Acquisitions - Preliminaty Purchase Price Allocation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-121",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.biogenidec.com/role/DispositionsDetailsTextual",
     "longName": "9954490 - Disclosure - Dispositions (Details Textual)",
     "shortName": "Dispositions (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-147",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
     "longName": "9954491 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:OtherRestructuringCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
     "longName": "9954492 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:BusinessCombinationIntegrationRelatedCosts",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:BusinessCombinationIntegrationRelatedCosts",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
     "longName": "9954493 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
     "longName": "9954494 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-196",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
     "longName": "9954495 - Disclosure - Revenues - Revenues by product (Details)",
     "shortName": "Revenues - Revenues by product (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-332",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
     "longName": "9954496 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)",
     "shortName": "Revenues Reserves for Discounts and Allowances (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2",
     "longName": "9954497 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)",
     "shortName": "Revenues- Reserves for Discounts and Allowances (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-489",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
     "longName": "9954498 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "shortName": "Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-497",
      "name": "biib:ShareOfCoPromotionProfits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
     "longName": "9954499 - Disclosure - Revenues - Other Revenues (Details)",
     "shortName": "Revenues - Other Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-501",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
     "longName": "9954500 - Disclosure - Revenues - Narrative (Details)",
     "shortName": "Revenues - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "biib:NumberOfWholesalers",
      "unitRef": "wholesaler",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "biib:NumberOfWholesalers",
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "biib:NumberOfWholesalers",
      "unitRef": "wholesaler",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "biib:NumberOfWholesalers",
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
     "longName": "9954501 - Disclosure - Inventory - Components of Inventory (Details)",
     "shortName": "Inventory - Components of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.biogenidec.com/role/InventoryNarrativeDetails",
     "longName": "9954502 - Disclosure - Inventory - Narrative (Details)",
     "shortName": "Inventory - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
     "longName": "9954503 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)",
     "shortName": "Intangible Assets and Goodwill - Summary of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "longName": "9954504 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails",
     "longName": "9954505 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)",
     "shortName": "Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
     "longName": "9954506 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)",
     "shortName": "Intangible Assets and Goodwill - Changes in Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
     "longName": "9954507 - Disclosure - Fair Value Measurements - Assets and Liabilities at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Assets and Liabilities at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9954508 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails",
     "longName": "9954509 - Disclosure - Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details)",
     "shortName": "Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-543",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-543",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
     "longName": "9954510 - Disclosure - Fair Value Measurements - Debt Instruments (Details)",
     "shortName": "Fair Value Measurements - Debt Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "longName": "9954511 - Disclosure - Fair Value Measurements (Details 2)",
     "shortName": "Fair Value Measurements (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "longName": "9954512 - Disclosure - Financial Instruments (Details)",
     "shortName": "Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "longName": "9954513 - Disclosure - Financial Instruments (Details 1)",
     "shortName": "Financial Instruments (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "longName": "9954514 - Disclosure - Financial Instruments (Details 3)",
     "shortName": "Financial Instruments (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "longName": "9954515 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-578",
      "name": "biib:StrategicInvestmentPortfolio",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-578",
      "name": "biib:StrategicInvestmentPortfolio",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "longName": "9954516 - Disclosure - Derivative Instruments (Details)",
     "shortName": "Derivative Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:UnrealizedGainOnDerivatives",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:UnrealizedGainOnDerivatives",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "longName": "9954517 - Disclosure - Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.biogenidec.com/role/LeasesDetailsTextual",
     "longName": "9954518 - Disclosure - Leases (Details Textual)",
     "shortName": "Leases (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-117",
      "name": "biib:OperatingLeaseArea",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R79": {
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "longName": "9954519 - Disclosure - Indebtedness (Details)",
     "shortName": "Indebtedness (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-570",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-633",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "longName": "9954520 - Disclosure - Share Repurchases (Details)",
     "shortName": "Share Repurchases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-635",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-635",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "longName": "9954521 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
     "longName": "9954522 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-680",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "longName": "9954523 - Disclosure - Earnings per Share (Details)",
     "shortName": "Earnings per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
     "longName": "9954524 - Disclosure - Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)",
     "shortName": "Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
     "longName": "9954525 - Disclosure - Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)",
     "shortName": "Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-724",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails",
     "longName": "9954526 - Disclosure - Share-based Payments - Narrative (Details)",
     "shortName": "Share-based Payments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-732",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-732",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails",
     "longName": "9954527 - Disclosure - Income Taxes - Tax Rate (Details)",
     "shortName": "Income Taxes - Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954528 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R89": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "longName": "9954529 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "longName": "9954530 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
     "longName": "9954531 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)",
     "shortName": "Collaborative and Other Relationships - OCREVUS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-741",
      "name": "biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-741",
      "name": "biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
     "longName": "9954532 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)",
     "shortName": "Collaborative and Other Relationships - Profit Sharing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-744",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-744",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
     "longName": "9954533 - Disclosure - Collaborative and Other Relationships - Eisai (Details)",
     "shortName": "Collaborative and Other Relationships - Eisai (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-748",
      "name": "biib:PaymentsMadeToTerminationAgreement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-748",
      "name": "biib:PaymentsMadeToTerminationAgreement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
     "longName": "9954534 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-749",
      "name": "biib:ExpenseIncurredByCollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-749",
      "name": "biib:ExpenseIncurredByCollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
     "longName": "9954535 - Disclosure - Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)",
     "shortName": "Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-757",
      "name": "biib:AccountsReceivableFromCollaborator",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
     "longName": "9954536 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R97": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
     "longName": "9954537 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-758",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-758",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
     "longName": "9954538 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "biib:ShareOfNetProfitFromSageTherapeuticsPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-763",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
     "longName": "9954539 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-775",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-775",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
     "longName": "9954541 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)",
     "shortName": "Collaborative and Other Relationships - Other Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-779",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
     "longName": "9954542 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)",
     "shortName": "Collaborative and Other Relationships - Samsung Bioepis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-785",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "longName": "9954543 - Disclosure - Investments in Variable Interest Entities (Details)",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "longName": "9954544 - Disclosure - Litigation (Details)",
     "shortName": "Litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.25% Senior Notes due May 1, 2030",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2020ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "A2020ShareRepurchaseProgramMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Share Repurchase Program",
        "label": "2020 Share Repurchase Program [Member]",
        "documentation": "2020 Share Repurchase Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2023And2022CostSavingInitiativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "A2023And2022CostSavingInitiativesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 and 2022 Cost Saving Initiatives",
        "label": "2023 and 2022 Cost Saving Initiatives [Member]",
        "documentation": "2023 and 2022 Cost Saving Initiatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2023CostSavingInitiativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "A2023CostSavingInitiativesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Cost Saving Initiatives",
        "label": "2023 Cost Saving Initiatives [Member]",
        "documentation": "2023 Cost Saving Initiatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2023TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "A2023TermLoanMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Term Loan",
        "label": "2023 Term Loan [Member]",
        "documentation": "2023 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.150% Senior Notes due May 1, 2050",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AVONEXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "AVONEXMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AVONEX",
        "label": "AVONEX [Member]",
        "documentation": "AVONEX"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r993"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r1312"
     ]
    },
    "biib_AccountsPayableToCollaborator": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "AccountsPayableToCollaborator",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts payable",
        "label": "Accounts Payable, To Collaborator",
        "documentation": "Accounts Payable, To Collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AccountsReceivableFromCollaborator": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "AccountsReceivableFromCollaborator",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts receivable",
        "label": "Accounts Receivable, From Collaborator",
        "documentation": "Accounts Receivable, From Collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of accounts receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r916",
      "r1014",
      "r1316",
      "r1317"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net of allowance for doubtful accounts of $2.0 and $2.4, respectively",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income taxes",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r164"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Expenses and Other",
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other",
        "label": "Accrued Liabilities [Member]",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "biib_AccruedPaymentToTerminationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "AccruedPaymentToTerminationAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable Due To Termination Agreement",
        "label": "Accrued Payment To Termination Agreement",
        "documentation": "Accrued Payment To Termination Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Royalties and licensing fees",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r935"
     ]
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfunded status of postretirement benefit plans",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r13",
      "r25",
      "r120",
      "r1134",
      "r1135",
      "r1136"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r235",
      "r771"
     ]
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on cash flow hedges",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r265",
      "r266",
      "r609",
      "r942",
      "r1134"
     ]
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on securities available for sale",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r257",
      "r265",
      "r266",
      "r1134"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive income (loss)",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r121",
      "r244",
      "r767",
      "r804",
      "r808"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r25",
      "r615",
      "r618",
      "r675",
      "r799",
      "r800",
      "r1134",
      "r1135",
      "r1136",
      "r1152",
      "r1153",
      "r1154",
      "r1157"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustments",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13",
      "r25",
      "r118",
      "r119",
      "r265",
      "r266",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r1134"
     ]
    },
    "biib_AcquiredAndInLicensedRightsAndPatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "AcquiredAndInLicensedRightsAndPatentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired and in-licensed rights and patents",
        "label": "Acquired And In Licensed Rights And Patents [Member]",
        "documentation": "Acquired And In Licensed Rights And Patents"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Consolidated Financial Statement Detail",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r993",
      "r1352"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r1152",
      "r1153",
      "r1154",
      "r1157",
      "r1274",
      "r1353"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Adjustments Relating To Prior Years",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net income to net cash flow from operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AdministrativeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "AdministrativeSpaceMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative Space",
        "label": "Administrative Space [Member]",
        "documentation": "Administrative Space"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1040",
      "r1050",
      "r1082"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1043",
      "r1053",
      "r1085"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1044",
      "r1054",
      "r1078",
      "r1086",
      "r1090",
      "r1098"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense",
        "terseLabel": "Share-based Payment Arrangement, Expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r562"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Current",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r346",
      "r387"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization and impairment of acquired intangible assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "documentation": "Amortization and Impairment of Acquired Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AmortizationOfInventoryStepUp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "AmortizationOfInventoryStepUp",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired inventory step-up",
        "label": "Amortization Of Inventory Step-Up",
        "documentation": "Amortization Of Inventory Step-Up"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analysis of change In reserves",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "documentation": "Analysis of amount of and change in product revenue reserves."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairment charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r36"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r174",
      "r239",
      "r283",
      "r327",
      "r330",
      "r339",
      "r340",
      "r382",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r605",
      "r610",
      "r650",
      "r761",
      "r856",
      "r948",
      "r949",
      "r993",
      "r1021",
      "r1228",
      "r1229",
      "r1303"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r248",
      "r283",
      "r382",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r605",
      "r610",
      "r650",
      "r993",
      "r1228",
      "r1229",
      "r1303"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r981"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "biib_BENEPALIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BENEPALIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BENEPALI",
        "label": "BENEPALI [Member]",
        "documentation": "BENEPALI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BYOOVIZMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BYOOVIZMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BYOOVIZ",
        "label": "BYOOVIZ [Member]",
        "documentation": "BYOOVIZ"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r1319",
      "r1320"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80",
      "r431",
      "r1319",
      "r1320"
     ]
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and diluted earnings per share",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "documentation": "Basic and diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "biib_BiologicsManufacturingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BiologicsManufacturingMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "documentation": "Biologics Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BiosimilarsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BiosimilarsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biosimilars",
        "label": "Biosimilars [Member]",
        "documentation": "Biosimilars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r595",
      "r972",
      "r973"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r595",
      "r972",
      "r973"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessAcquisitionNumberOfCommonStockSharesAcquired",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock shares acquired",
        "label": "Business Acquisition, Number of Common Stock Shares Acquired",
        "documentation": "Business Acquisition, Number of Common Stock Shares Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in dollars per share)",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition related costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r12"
     ]
    },
    "biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity compensation pre-acquisition services",
        "label": "Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services",
        "documentation": "Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r59",
      "r598"
     ]
    },
    "biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital adjustment",
        "label": "Business Combination, Consideration Transferred, Working Capital Adjustment",
        "documentation": "Business Combination, Consideration Transferred, Working Capital Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "verboseLabel": "Contingent consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r1143"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of outcomes, value, high",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration obligations",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r154",
      "r599",
      "r629",
      "r630",
      "r631"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current portion of contingent consideration obligations",
        "terseLabel": "Contingent consideration obligations",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r154"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r630",
      "r631"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Noncurrent portion of contingent consideration obligations",
        "terseLabel": "Contingent consideration obligations",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r154"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r596"
     ]
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Integration related costs",
        "label": "Business Combination, Integration Related Costs",
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs."
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment, accrued expense and other",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expense And Other",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Expense And Other"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred tax liability",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Adjustment, goodwill",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accrued liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets and liabilities, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Contingent payable to Blackstone",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets(1)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expense and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accrued expense and other(1)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred tax liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory amortization period",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total identifiable net assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "negatedTerseLabel": "Operating lease liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets acquired and liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition cost expensed",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed",
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]",
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "documentation": "Information by type of transaction recognized separately from acquisition of asset and assumption of liability in business combination."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Separately Recognized Transactions [Domain]",
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Abstract]",
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "BusinessOverviewPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business Overview",
        "label": "Business Overview [Policy Text Block]",
        "documentation": "Describes an overview of the company and its operations."
       }
      }
     },
     "auth_ref": []
    },
    "currency_CAD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "CAD",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Canadian dollar",
        "label": "Canada, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CHF": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "CHF",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swiss franc",
        "label": "Switzerland, Francs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1278"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Line Items]",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial Instruments",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r1167"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r132",
      "r279"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r132"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1315"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents",
        "label": "Cash Equivalents, at Carrying Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Hedging [Member]",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "biib_CashflowsoperatingexpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "CashflowsoperatingexpensesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows, operating expenses",
        "label": "Cash flows, operating expenses [Member]",
        "documentation": "Cash flows, operating expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CashflowsrevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "CashflowsrevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows, revenue",
        "label": "Cash flows, revenue [Member]",
        "documentation": "Cash flows, revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r329",
      "r492",
      "r493",
      "r494",
      "r496",
      "r499",
      "r504",
      "r506",
      "r812",
      "r813",
      "r814",
      "r815",
      "r961",
      "r1108",
      "r1145"
     ]
    },
    "biib_ClinicalInventoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ClinicalInventoryMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Inventory",
        "label": "Clinical Inventory [Member]",
        "documentation": "Clinical Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment",
        "label": "Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment",
        "documentation": "Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment."
       }
      }
     },
     "auth_ref": []
    },
    "biib_CoPromotionProfitSharingFormulaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "CoPromotionProfitSharingFormulaTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Co-promotion profit sharing formula",
        "label": "Co Promotion Profit Sharing Formula [Table Text Block]",
        "documentation": "Co-promotion profit sharing formula."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "biib_Collaborationexpensesaccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "Collaborationexpensesaccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration expense",
        "label": "Collaboration expenses accrual",
        "documentation": "Collaboration expenses accrual"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Collaborationprofitlosssharing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "Collaborationprofitlosssharing",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration profit sharing/(loss reimbursement)",
        "label": "Collaboration profit (loss) sharing",
        "documentation": "Collaboration profit (loss) sharing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaborative and Other Relationships",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r180",
      "r191"
     ]
    },
    "biib_CollaborativeArrangementTermExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "CollaborativeArrangementTermExtension",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement term",
        "label": "Collaborative Arrangement, Term Extension",
        "documentation": "Collaborative Arrangement, Term Extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangements and non-collaborative arrangement transactions",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments, contingencies and guarantees",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r167",
      "r764",
      "r842"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1012",
      "r1013",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1152",
      "r1153",
      "r1157",
      "r1274",
      "r1350",
      "r1353"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r108",
      "r843",
      "r862",
      "r1353",
      "r1354"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value $0.0005 per share",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r766",
      "r993"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "biib_CompletedTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "CompletedTechnologyMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Completed Technology",
        "label": "Completed Technology [Member]",
        "documentation": "Completed Technology"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss) attributable to Biogen Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r261",
      "r263",
      "r271",
      "r755",
      "r779",
      "r781"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r64",
      "r74",
      "r261",
      "r263",
      "r270",
      "r754",
      "r779",
      "r780"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r156",
      "r261",
      "r263",
      "r269",
      "r753",
      "r779"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r217",
      "r289",
      "r605",
      "r606",
      "r610",
      "r611",
      "r680",
      "r922",
      "r1128",
      "r1129",
      "r1130",
      "r1227",
      "r1230",
      "r1231"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r217",
      "r289",
      "r605",
      "r606",
      "r610",
      "r611",
      "r680",
      "r922",
      "r1128",
      "r1129",
      "r1130",
      "r1227",
      "r1230",
      "r1231"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r943"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "biib_ContingentCommercializedRightsNumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ContingentCommercializedRightsNumberOfProducts",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Commercialized Rights, Number Of Products",
        "label": "Contingent Commercialized Rights, Number Of Products",
        "documentation": "Contingent Commercialized Rights, Number Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type [Domain]",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ContractManufacturingAndOtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ContractManufacturingAndOtherRevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract manufacturing revenue",
        "label": "Contract manufacturing and other revenue [Member]",
        "documentation": "Other corporate revenues [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ContractOptionExerciseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ContractOptionExerciseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option exercise fee",
        "label": "Contract Option Exercise Fee",
        "documentation": "Contract Option Exercise Fee"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ContractualAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ContractualAdjustmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual adjustments",
        "label": "Contractual Adjustments [Member]",
        "documentation": "Contractual adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r717"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost and expense",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r287",
      "r288",
      "r466",
      "r494",
      "r679",
      "r700",
      "r759",
      "r939",
      "r941"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r1225"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r1225",
      "r1226"
     ]
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]",
        "documentation": "Information by currency."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Provisions Relating To Sales In Current Year",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "documentation": "Current provisions to product revenue reserves relating to sales in current year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Indebtedness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indebtedness",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r281",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r451",
      "r452",
      "r462",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r478",
      "r485",
      "r486",
      "r488",
      "r664"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r99",
      "r100",
      "r163",
      "r166",
      "r289",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r992",
      "r1146",
      "r1213",
      "r1214",
      "r1215",
      "r1296",
      "r1297"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, gross",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r166",
      "r489"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r487",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r992",
      "r1146",
      "r1296",
      "r1297"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r289",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r992",
      "r1146",
      "r1213",
      "r1214",
      "r1215",
      "r1296",
      "r1297"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r44",
      "r47",
      "r86",
      "r148",
      "r149",
      "r289",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r487",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r992",
      "r1146",
      "r1296",
      "r1297"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gains",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized losses",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt and equity securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable equity securities",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeconsolidationGainOrLossAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deconsolidation, gain (loss), amount",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r567"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r188",
      "r1148"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r567",
      "r762"
     ]
    },
    "biib_DenaliTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "DenaliTherapeuticsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denali Therapeutics",
        "label": "Denali Therapeutics Inc [Member]",
        "documentation": "Denali Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r37"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r327",
      "r335",
      "r340",
      "r948",
      "r949"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative contracts",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r627",
      "r628",
      "r640",
      "r649",
      "r822",
      "r823",
      "r824",
      "r826",
      "r827",
      "r829",
      "r830",
      "r831",
      "r833",
      "r834",
      "r849",
      "r850",
      "r898",
      "r900",
      "r902",
      "r903",
      "r904",
      "r905",
      "r941",
      "r981",
      "r985",
      "r1013",
      "r1279",
      "r1280",
      "r1281",
      "r1351"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r834",
      "r848",
      "r849",
      "r850",
      "r852",
      "r853",
      "r854",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860",
      "r870",
      "r871",
      "r872",
      "r873",
      "r876",
      "r877",
      "r878",
      "r879",
      "r898",
      "r899",
      "r902",
      "r904",
      "r1011",
      "r1013",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1289",
      "r1290"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset, fair value",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r117",
      "r159",
      "r160",
      "r249",
      "r941"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, fair value",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r117",
      "r159",
      "r160",
      "r249",
      "r941"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r81",
      "r83",
      "r161",
      "r831",
      "r834",
      "r848",
      "r849",
      "r850",
      "r852",
      "r853",
      "r854",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860",
      "r870",
      "r871",
      "r872",
      "r873",
      "r876",
      "r877",
      "r878",
      "r879",
      "r898",
      "r899",
      "r902",
      "r904",
      "r941",
      "r1011",
      "r1013",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1289",
      "r1290"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities:",
        "label": "Derivative Instruments and Hedges, Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Instruments",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r613",
      "r620"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r78",
      "r81"
     ]
    },
    "biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Unrealized Gain (Loss)",
        "label": "Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]",
        "documentation": "Derivative Instruments, Unrealized Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities:",
        "label": "Derivative Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative contracts",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative contracts",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, Notional Amount",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1272",
      "r1273"
     ]
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeRemainingMaturity1",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Range of durations of foreign currency forward contracts",
        "label": "Derivative, Remaining Maturity",
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives [Line Items]",
        "label": "Derivatives, Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Designated as hedging instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology and other",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1206",
      "r1207",
      "r1210",
      "r1211"
     ]
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of dilutive securities:",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Abstract]",
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues by product",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1234"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based Payments",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r530",
      "r559",
      "r560",
      "r561",
      "r975"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Dispositions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dispositions",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r137"
     ]
    },
    "biib_DistributorOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "DistributorOneMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor One",
        "label": "Distributor One [Member]",
        "documentation": "Distributor one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_DistributorTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "DistributorTwoMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor Two",
        "label": "Distributor Two [Member]",
        "documentation": "Distributor two."
       }
      }
     },
     "auth_ref": []
    },
    "biib_DivestituresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "DivestituresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]",
        "documentation": "Divestitures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "biib_E2609andBAN2401Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "E2609andBAN2401Member",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "E2609 and BAN2401",
        "label": "E2609 and BAN2401 [Member]",
        "documentation": "E2609 and BAN2401 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "EUR",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Euro",
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income per share:",
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings (loss) per share attributable to Biogen Inc.",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r307",
      "r313",
      "r315",
      "r320",
      "r321",
      "r322",
      "r326",
      "r593",
      "r602",
      "r624",
      "r625",
      "r756",
      "r782",
      "r944"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted earnings (loss) per share attributable to Biogen Inc.",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r307",
      "r315",
      "r320",
      "r321",
      "r322",
      "r326",
      "r593",
      "r602",
      "r624",
      "r625",
      "r756",
      "r782",
      "r944"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Earnings per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r323",
      "r324",
      "r325"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r977"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r569",
      "r583",
      "r977"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Taxes on foreign earnings",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r573",
      "r977",
      "r1149",
      "r1264"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GILTI",
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent",
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r1264",
      "r1266"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchased intangible assets",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization."
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1264",
      "r1266"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r1149",
      "r1264",
      "r1265"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r977",
      "r1149",
      "r1264"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Credits and net operating loss utilization",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r1149",
      "r1264"
     ]
    },
    "biib_EisaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "EisaiMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eisai",
        "label": "Eisai [Member]",
        "documentation": "Eisai [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Capitalized share-based compensation costs",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax effect",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Costs",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee stock purchase plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of revenues from major distributors",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "documentation": "Entity wide percentage of revenue from major distributors."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r230",
      "r264",
      "r265",
      "r266",
      "r295",
      "r296",
      "r297",
      "r299",
      "r305",
      "r308",
      "r310",
      "r328",
      "r383",
      "r386",
      "r424",
      "r507",
      "r581",
      "r582",
      "r590",
      "r591",
      "r592",
      "r594",
      "r601",
      "r602",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r623",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r666",
      "r669",
      "r675",
      "r777",
      "r799",
      "r800",
      "r801",
      "r820",
      "r883"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r589",
      "r1110",
      "r1111",
      "r1112",
      "r1268",
      "r1269",
      "r1270",
      "r1271"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, ownership interest",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Amount Sold",
        "label": "Equity Method Investment, Amount Sold",
        "documentation": "Amount of the entity's equity method investment which has been sold."
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquityMethodInvestmentsExpectedProfitShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "EquityMethodInvestmentsExpectedProfitShare",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected profit share percentage",
        "label": "Equity Method Investments, Expected Profit Share",
        "documentation": "Equity Method Investments, Expected Profit Share"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquitySecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "EquitySecuritiesCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, Current",
        "label": "Equity Securities, Current [Member]",
        "documentation": "Equity Securities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r648",
      "r934"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (gains) losses recognized on equity securities",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r1184"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less: Net (gains) losses realized on equity securities",
        "terseLabel": "Net gains (losses) realized during the period on equity securities",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r1184"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net unrealized (gains) losses recognized on equity securities",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r1184"
     ]
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "EquitySecuritiesNonCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "documentation": "Equity Securities, Non-Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1040",
      "r1050",
      "r1082"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1037",
      "r1047",
      "r1079"
     ]
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "biib_ExpenseIncurredByCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ExpenseIncurredByCollaboration",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total development expense incurred by the collaboration related to the advancement of LEQEMBI",
        "label": "Expense Incurred By Collaboration",
        "documentation": "Total expense incurred by collaboration."
       }
      }
     },
     "auth_ref": []
    },
    "biib_Expenseincurredbythecollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "Expenseincurredbythecollaboration",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "documentation": "Expense incurred by the collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "Expensereflectedwithinstatementsofincome",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "documentation": "Expense reflected within statements of income"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FAMPYRAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FAMPYRAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAMPYRA",
        "label": "FAMPYRA [Member]",
        "documentation": "FAMPYRA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FLIXABIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FLIXABIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FLIXABI",
        "label": "FLIXABI [Member]",
        "documentation": "FLIXABI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FUMADERMAndADUHELMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FUMADERMAndADUHELMMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FUMADERM And ADUHELM",
        "label": "FUMADERM And ADUHELM [Member]",
        "documentation": "FUMADERM And ADUHELM"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FacilityLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FacilityLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Location [Axis]",
        "label": "Facility Location [Axis]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FacilityLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FacilityLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Location [Domain]",
        "label": "Facility Location [Domain]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FacilityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FacilityTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Type [Axis]",
        "label": "Facility Type [Axis]",
        "documentation": "Facility Type"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FacilityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FacilityTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Type [Domain]",
        "label": "Facility Type [Domain]",
        "documentation": "Facility Type"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentToInventoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentToInventoryMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Adjustment to Inventory",
        "label": "Fair Value Adjustment to Inventory [Member]",
        "documentation": "Fair value adjustment to acquisition-date inventory allocated (included) to (in) reported pro forma earnings (supplemental pro forma information)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of assets and liabilities recorded at fair value",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r640",
      "r981"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r640",
      "r981"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r630",
      "r631",
      "r985"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r630",
      "r631",
      "r985"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r630",
      "r985"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r639",
      "r640",
      "r642",
      "r684",
      "r685",
      "r686",
      "r957",
      "r958",
      "r969",
      "r970",
      "r971",
      "r981",
      "r985"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r629",
      "r631",
      "r981",
      "r1280",
      "r1291"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r637",
      "r638",
      "r639",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r750",
      "r981",
      "r986"
     ]
    },
    "biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FairValueIndefiniteLivedIntangibleAssetsDiscountRate",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets discount rate",
        "label": "Fair Value Indefinite Lived Intangible Assets Discount Rate",
        "documentation": "Fair Value Indefinite Lived Intangible Assets Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r519",
      "r524",
      "r628",
      "r640",
      "r684",
      "r969",
      "r970",
      "r971",
      "r981"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r519",
      "r524",
      "r628",
      "r629",
      "r640",
      "r685",
      "r957",
      "r958",
      "r969",
      "r970",
      "r971",
      "r981"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Unobservable Inputs (Level 3)",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r628",
      "r629",
      "r630",
      "r631",
      "r640",
      "r686",
      "r957",
      "r958",
      "r969",
      "r970",
      "r971",
      "r981",
      "r985"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration, Liability [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r636",
      "r641"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r629",
      "r631",
      "r981",
      "r1280",
      "r1291"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r641"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration resulting from HI-Bio acquisition",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r641"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, beginning of period",
        "periodEndLabel": "Fair value, end of period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r641"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r639",
      "r640",
      "r642",
      "r684",
      "r685",
      "r686",
      "r957",
      "r958",
      "r969",
      "r970",
      "r971",
      "r981",
      "r985"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value, Measurements Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1291"
     ]
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r79",
      "r84"
     ]
    },
    "biib_FelzartamabAMRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FelzartamabAMRMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Felzartamab (AMR)",
        "label": "Felzartamab (AMR) [Member]",
        "documentation": "Felzartamab (AMR)"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FelzartamabAndIzastobartHIB210Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FelzartamabAndIzastobartHIB210Member",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Felzartamab And Izastobart/HIB210",
        "label": "Felzartamab And Izastobart/HIB210 [Member]",
        "documentation": "Felzartamab And Izastobart/HIB210"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FelzartamabIgANMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FelzartamabIgANMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Felzartamab (IgAN)",
        "label": "Felzartamab (IgAN) [Member]",
        "documentation": "Felzartamab (IgAN)"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FelzartamabPMNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FelzartamabPMNMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Felzartamab (PMN)",
        "label": "Felzartamab (PMN) [Member]",
        "documentation": "Felzartamab (PMN)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r487",
      "r504",
      "r620",
      "r647",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r698",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r778",
      "r952",
      "r981",
      "r983",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r994",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1276",
      "r1279",
      "r1280",
      "r1281",
      "r1288",
      "r1291"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average remaining useful life",
        "label": "Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life",
        "documentation": "Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "verboseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r398",
      "r418",
      "r954"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r930",
      "r954"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remaining three months)",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1359"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r930",
      "r954"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r930",
      "r954"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r930",
      "r954"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r930",
      "r954"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r421",
      "r422",
      "r718",
      "r719",
      "r930"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r418",
      "r719",
      "r954"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r418",
      "r421",
      "r422",
      "r423",
      "r718",
      "r930",
      "r954"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r421",
      "r422",
      "r930"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r1207"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FloatingRate364DayTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FloatingRate364DayTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floating Rate 364-Day Tranche",
        "label": "Floating Rate 364-Day Tranche [Member]",
        "documentation": "Floating Rate 364-Day Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570"
     ]
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months",
        "documentation": "Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative contracts",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628"
     ]
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative contracts",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange (gains) losses, net",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r651",
      "r652",
      "r653",
      "r654",
      "r880"
     ]
    },
    "us-gaap_ForeignExchangeContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignExchangeContractMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange contract",
        "label": "Foreign Exchange Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r941",
      "r969",
      "r980",
      "r981"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1044",
      "r1054",
      "r1086"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1044",
      "r1054",
      "r1086"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1044",
      "r1054",
      "r1086"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1044",
      "r1054",
      "r1086"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1044",
      "r1054",
      "r1086"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "biib_FumarateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FumarateMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fumarate",
        "label": "Fumarate [Member]",
        "documentation": "Fumarate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FutureContingentMilestoneTypesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "documentation": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FutureContingentMilestoneTypesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Contingent Milestone Types [Domain]",
        "label": "Future Contingent Milestone Types [Domain]",
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty percentage to be received",
        "label": "Future Royalties Percentage To Be Received On Sale Of Product",
        "documentation": "Future royalties percentage to be received on sale of product."
       }
      }
     },
     "auth_ref": []
    },
    "biib_GAZYVAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "GAZYVAMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GAZYVA",
        "label": "GAZYVA [Member]",
        "documentation": "GAZYVA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gain on interest rate swap",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on sale",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of priority review voucher, net",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on foreign currency derivative instruments not designated as hedging instruments",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82"
     ]
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on investments in equity securities",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of priority review voucher, net",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "biib_GenentechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "GenentechMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech",
        "label": "Genentech [Member]",
        "documentation": "Genentech"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, beginning of period",
        "periodEndLabel": "Goodwill, end of period",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r399",
      "r751",
      "r949",
      "r953",
      "r982",
      "r993",
      "r1190",
      "r1197"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill resulting from acquisition",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r953"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible Assets and Goodwill",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1200"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated impairment losses related to goodwill",
        "verboseLabel": "Accumulated impairment losses related to goodwill",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r408",
      "r953"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r953"
     ]
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillOtherIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Goodwill, Other Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of roll forward of the changes in goodwill",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r612"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "biib_HumanImmunologyBiosciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "HumanImmunologyBiosciencesMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Human Immunology Biosciences",
        "label": "Human Immunology Biosciences [Member]",
        "documentation": "Human Immunology Biosciences"
       }
      }
     },
     "auth_ref": []
    },
    "biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Human Immunology Biosciences Pre-Existing In License Commitments",
        "label": "Human Immunology Biosciences Pre-Existing In License Commitments [Member]",
        "documentation": "Human Immunology Biosciences Pre-Existing In License Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "biib_IMRALDIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "IMRALDIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMRALDI",
        "label": "IMRALDI [Member]",
        "documentation": "IMRALDI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r1144",
      "r1209",
      "r1212"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "verboseLabel": "In-process research and development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1209",
      "r1210",
      "r1211"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income tax (benefit) expense",
        "negatedTerseLabel": "Income (loss) before income tax (benefit) expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r169",
      "r173",
      "r757",
      "r773",
      "r946",
      "r948",
      "r1159",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r17",
      "r22",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r139"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r431",
      "r436",
      "r633",
      "r636",
      "r641",
      "r796",
      "r798",
      "r867",
      "r930",
      "r984",
      "r1321"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r436",
      "r633",
      "r636",
      "r641",
      "r796",
      "r798",
      "r867",
      "r930",
      "r984",
      "r1321"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r1267"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r565",
      "r569",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r584",
      "r586",
      "r587",
      "r588",
      "r817",
      "r977"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax (benefit) expense",
        "terseLabel": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income Tax Expense (Benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r189",
      "r309",
      "r310",
      "r327",
      "r336",
      "r340",
      "r568",
      "r569",
      "r585",
      "r787",
      "r977"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax assets and liabilities",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expense and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) loss on strategic investments",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r276"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in operating assets and liabilities, net of effects of business acquired:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other changes in operating assets and liabilities, net",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock units",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r322",
      "r529"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r416",
      "r420",
      "r954"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r420",
      "r423",
      "r954"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost and net",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r420",
      "r954"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r416",
      "r420",
      "r954"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1044",
      "r1054",
      "r1078",
      "r1086",
      "r1090",
      "r1098"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1102"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1102"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1102"
     ]
    },
    "biib_IntangibleAssetMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "IntangibleAssetMeasurementInput",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input",
        "label": "Intangible Asset, Measurement Input",
        "documentation": "Intangible Asset, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "documentation": "Intangible assets excluding goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "totalLabel": "Net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r1207",
      "r1209"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r330",
      "r334",
      "r337",
      "r340",
      "r663",
      "r948",
      "r949"
     ]
    },
    "biib_InterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "InterestInSubsidiary",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest in subsidiary (less than given percentage)",
        "label": "Interest In Subsidiary",
        "documentation": "Interest in subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNetAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Income (Expense), Net",
        "label": "Interest Income (Expense), Operating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_InterferonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "InterferonMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interferon",
        "label": "Interferon [Member]",
        "documentation": "Interferon"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r936"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Line Items]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "terseLabel": "Inventory, current",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r933",
      "r993"
     ]
    },
    "biib_InventoryNetCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "InventoryNetCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory",
        "label": "Inventory, Net Current and Noncurrent",
        "documentation": "Inventory, Net Current and Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, noncurrent",
        "label": "Inventory, Noncurrent",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r938"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Work in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r937"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess and obsolescence charges related to inventory",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r333",
      "r340",
      "r948",
      "r1137"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r825",
      "r826",
      "r829",
      "r832",
      "r889",
      "r891",
      "r893",
      "r896",
      "r897",
      "r906",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r1013"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type Categorization [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r825",
      "r826",
      "r829",
      "r832",
      "r889",
      "r891",
      "r893",
      "r896",
      "r897",
      "r906",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r1013"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, All Other Investments [Abstract]",
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable equity securities",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1278",
      "r1288"
     ]
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in Variable Interest Entities [Abstract]",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "documentation": "Investments In Variable Interest Entities."
       }
      }
     },
     "auth_ref": []
    },
    "biib_IonisPharmaceuticalsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "IonisPharmaceuticalsInc.Member",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ionis",
        "label": "Ionis Pharmaceuticals Inc. [Member]",
        "documentation": "Ionis Pharmaceuticals Inc."
       }
      }
     },
     "auth_ref": []
    },
    "biib_IonisSangamoDenaliAndSageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "IonisSangamoDenaliAndSageMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ionis, Sangamo, Denali and Sage",
        "label": "Ionis, Sangamo, Denali and Sage [Member]",
        "documentation": "Ionis, Sangamo, Denali and Sage"
       }
      }
     },
     "auth_ref": []
    },
    "currency_JPY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "JPY",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Japan, Yen",
        "label": "Japan, Yen"
       }
      }
     },
     "auth_ref": []
    },
    "biib_LEQEMBICollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "LEQEMBICollaborationMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEQEMBI Collaboration",
        "label": "LEQEMBI Collaboration [Member]",
        "documentation": "LEQEMBI Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Litigation",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "biib_LenderDisputeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "LenderDisputeMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Dispute",
        "label": "Lender Dispute [Member]",
        "documentation": "Lender Dispute"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r1298"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r283",
      "r382",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r606",
      "r610",
      "r611",
      "r650",
      "r841",
      "r945",
      "r1021",
      "r1228",
      "r1303",
      "r1304"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r168",
      "r769",
      "r993",
      "r1147",
      "r1185",
      "r1292"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r234",
      "r283",
      "r382",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r606",
      "r610",
      "r611",
      "r650",
      "r993",
      "r1228",
      "r1303",
      "r1304"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r1277"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r102"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes payable and term loan",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r166",
      "r475",
      "r490",
      "r957",
      "r958",
      "r992",
      "r1313"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r1213",
      "r1214",
      "r1215"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r41",
      "r1213",
      "r1214",
      "r1215"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r450",
      "r563",
      "r955",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r450",
      "r563",
      "r955",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Brazil tax assessment, including interest and penalties",
        "label": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Estimate of Possible Loss",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446",
      "r449",
      "r450",
      "r563",
      "r955"
     ]
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MSProductRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "MSProductRevenuesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MS Product Revenues",
        "label": "MS Product Revenues [Member]",
        "documentation": "MS Product Revenues [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r964",
      "r1004",
      "r1008",
      "r1234",
      "r1318",
      "r1322",
      "r1323",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349"
     ]
    },
    "biib_MarketStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "MarketStockUnitsMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Market stock units",
        "label": "Market Stock Units [Member]",
        "documentation": "Market stock units."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r200",
      "r202",
      "r203",
      "r205",
      "r228",
      "r229",
      "r445",
      "r446",
      "r447",
      "r448",
      "r526",
      "r563",
      "r631",
      "r716",
      "r795",
      "r797",
      "r809",
      "r833",
      "r834",
      "r890",
      "r892",
      "r894",
      "r895",
      "r907",
      "r928",
      "r929",
      "r951",
      "r961",
      "r974",
      "r985",
      "r986",
      "r990",
      "r991",
      "r1005",
      "r1232",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "biib_MeasurementInputProbabilityRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "MeasurementInputProbabilityRateMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Probability Rate",
        "label": "Measurement Input, Probability Rate [Member]",
        "documentation": "Measurement Input, Probability Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r630",
      "r631",
      "r985"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r630",
      "r631",
      "r985"
     ]
    },
    "biib_MilestonePaymentCommercialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "MilestonePaymentCommercialMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, Commercial",
        "label": "Milestone Payment, Commercial [Member]",
        "documentation": "Milestone Payment, Commercial"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MilestonePaymentFutureDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "MilestonePaymentFutureDevelopmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, Future Development",
        "label": "Milestone Payment, Future Development [Member]",
        "documentation": "Milestone Payment, Future Development"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MilestonePaymentRegulatoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "MilestonePaymentRegulatoryMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, Regulatory",
        "label": "Milestone Payment, Regulatory [Member]",
        "documentation": "Milestone Payment, Regulatory"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r200",
      "r202",
      "r203",
      "r205",
      "r228",
      "r229",
      "r445",
      "r446",
      "r447",
      "r448",
      "r526",
      "r563",
      "r631",
      "r716",
      "r795",
      "r797",
      "r809",
      "r833",
      "r834",
      "r890",
      "r892",
      "r894",
      "r895",
      "r907",
      "r928",
      "r929",
      "r951",
      "r961",
      "r974",
      "r985",
      "r986",
      "r990",
      "r1005",
      "r1232",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1236"
     ]
    },
    "biib_MosunetuzumabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "MosunetuzumabMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mosunetuzumab",
        "label": "Mosunetuzumab [Member]",
        "documentation": "Mosunetuzumab"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r964",
      "r1004",
      "r1008",
      "r1234",
      "r1318",
      "r1322",
      "r1323",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flow from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flow from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) attributable to Biogen Inc.",
        "terseLabel": "Net income (loss) attributable to Biogen Inc.",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r134",
      "r170",
      "r232",
      "r259",
      "r262",
      "r266",
      "r283",
      "r298",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r309",
      "r310",
      "r319",
      "r382",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r593",
      "r602",
      "r625",
      "r650",
      "r776",
      "r864",
      "r881",
      "r882",
      "r1019",
      "r1228"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r157",
      "r259",
      "r262",
      "r305",
      "r309",
      "r310",
      "r775",
      "r1136"
     ]
    },
    "biib_NeurimmuneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "NeurimmuneMember",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neurimmune",
        "label": "Neurimmune [Member]",
        "documentation": "Neurimmune."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "biib_NonCurrentPortionOfNotesPayableAndTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "NonCurrentPortionOfNotesPayableAndTermLoanMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Portion Of Notes Payable And Term Loan",
        "label": "Non-Current Portion Of Notes Payable And Term Loan [Member]",
        "documentation": "Non-Current Portion Of Notes Payable And Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1044",
      "r1054",
      "r1078",
      "r1086"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of World",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1355",
      "r1356",
      "r1357",
      "r1358"
     ]
    },
    "biib_NoncontrollingInterestCapitalContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "NoncontrollingInterestCapitalContribution",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital contribution from noncontrolling interest",
        "label": "Noncontrolling Interest, Capital Contribution",
        "documentation": "Noncontrolling Interest, Capital Contribution"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r507",
      "r1152",
      "r1153",
      "r1154",
      "r1157",
      "r1353"
     ]
    },
    "us-gaap_NondesignatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NondesignatedMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not designated as hedging instrument",
        "label": "Not Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_NonrecurringAdjustmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrecurringAdjustmentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrecurring Adjustment [Axis]",
        "label": "Nonrecurring Adjustment [Axis]",
        "documentation": "Information by nonrecurring adjustment directly attributable to business combination included in pro forma revenue and earnings."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_NonrecurringAdjustmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrecurringAdjustmentDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrecurring Adjustment [Domain]",
        "label": "Nonrecurring Adjustment [Domain]",
        "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r166",
      "r1313",
      "r1314"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion notes payable and term loan",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100"
     ]
    },
    "biib_NotesPayableCurrentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "NotesPayableCurrentFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable, current, fair value disclosure",
        "label": "Notes Payable, Current, Fair Value Disclosure",
        "documentation": "Notes Payable, Current, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes payable, fair value",
        "label": "Notes Payable, Fair Value Disclosure",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r99",
      "r100",
      "r1278",
      "r1288"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r950",
      "r1160"
     ]
    },
    "biib_NumberOfSquareFeet": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "NumberOfSquareFeet",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of square feet",
        "label": "Number of Square Feet",
        "documentation": "Number of Square Feet"
       }
      }
     },
     "auth_ref": []
    },
    "biib_NumberOfWholesalers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "NumberOfWholesalers",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of wholesalers",
        "label": "Number of Wholesalers",
        "documentation": "Number of Wholesalers"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OCREVUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "OCREVUSMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OCREVUS",
        "label": "OCREVUS [Member]",
        "documentation": "OCREVUS"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OmnibusEquityPlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "OmnibusEquityPlan2024Member",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omnibus Equity Plan 2024",
        "label": "Omnibus Equity Plan 2024 [Member]",
        "documentation": "Omnibus Equity Plan 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expense",
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "negatedTerseLabel": "Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "biib_OperatingLeaseArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "OperatingLeaseArea",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease area",
        "label": "Operating Lease Area",
        "documentation": "Operating Lease Area"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r993"
     ]
    },
    "biib_OtherAssetsCurrentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "OtherAssetsCurrentFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets, receivable",
        "label": "Other Assets, Current, Fair Value Disclosure,",
        "documentation": "Other Assets, Current, Fair Value Disclosure,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments and other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "biib_OtherClinicalProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "OtherClinicalProgramsMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other clinical programs",
        "label": "Other Clinical Programs [Member]",
        "documentation": "Other Clinical Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r256",
      "r777"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r25",
      "r265",
      "r656",
      "r659",
      "r662",
      "r777",
      "r1134"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r256",
      "r777"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r256",
      "r258"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r777"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r20",
      "r260",
      "r263",
      "r268",
      "r305",
      "r656",
      "r657",
      "r662",
      "r752",
      "r777",
      "r1134",
      "r1135"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss), net of tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r13",
      "r156",
      "r260",
      "r263",
      "r305"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r120",
      "r121",
      "r777"
     ]
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r84"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Component of accrued expenses and other",
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expense and other",
        "terseLabel": "Total accrued expense and other",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r993"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Noncurrent Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other (income) expense, net",
        "terseLabel": "Other (income) expense",
        "negatedTerseLabel": "Other (income) expense",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "biib_OtherProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "OtherProductsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Products [Member]",
        "documentation": "Other Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherRestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Depreciation and Other Costs",
        "label": "Other Restructuring Costs",
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "biib_OtherresearchanddiscoveryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "OtherresearchanddiscoveryMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and discovery",
        "label": "Other research and discovery [Member]",
        "documentation": "Other research and discovery [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherrevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "OtherrevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "documentation": "Other revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherrevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "OtherrevenuesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other revenues [Table Text Block]",
        "documentation": "Other revenues [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1032",
      "r1042",
      "r1052",
      "r1084"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1045",
      "r1055",
      "r1087"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1045",
      "r1055",
      "r1087"
     ]
    },
    "biib_PLEGRIDYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PLEGRIDYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PLEGRIDY",
        "label": "PLEGRIDY [Member]",
        "documentation": "PLEGRIDY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "biib_PayablesToDivestitureOfInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PayablesToDivestitureOfInterestInJointVenture",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables to divestiture of interest in joint venture",
        "label": "Payables To Divestiture Of Interest In Joint Venture",
        "documentation": "Payables To Divestiture Of Interest In Joint Venture"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentDueAtFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PaymentDueAtFirstAnniversaryMember",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Due At First Anniversary",
        "label": "Payment Due At First Anniversary [Member]",
        "documentation": "Payment Due At First Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentDueAtSecondAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PaymentDueAtSecondAnniversaryMember",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Due At Second Anniversary",
        "label": "Payment Due At Second Anniversary [Member]",
        "documentation": "Payment Due At Second Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1114",
      "r1140"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r1142"
     ]
    },
    "biib_PaymentsMadeToTerminationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PaymentsMadeToTerminationAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments Made To Termination Agreement",
        "label": "Payments Made To Termination Agreement",
        "documentation": "Payments Made To Termination Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r273",
      "r347"
     ]
    },
    "biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PaymentsToAcquireBusinessGrossNonVestedEquityAwards",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-vested equity awards",
        "label": "Payments To Acquire Business, Gross, Non-Vested Equity Awards",
        "documentation": "Payments To Acquire Business, Gross, Non-Vested Equity Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transaction value",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r597"
     ]
    },
    "biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PaymentsToAcquireBusinessesGrossOutstandingEquityAwards",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding equity awards",
        "label": "Payments to Acquire Businesses, Gross, Outstanding Equity Awards",
        "documentation": "Payments to Acquire Businesses, Gross, Outstanding Equity Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of co promotion operating profits first fifty million",
        "label": "Percentage Of Co Promotion Operating Profits First Fifty Million",
        "documentation": "Percentage of co promotion operating profits first fifty million."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four",
        "documentation": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After Second GAZYVA Threshold Date",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three",
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option three."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Until Second GAZYVA Threshold Date",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two",
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option two."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfFutureDevelopmentCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PercentageOfFutureDevelopmentCosts",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future development costs",
        "label": "Percentage Of Future Development Costs",
        "documentation": "Percentage Of Future Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance stock units settled in cash",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "documentation": "Performance Stock Units Settled in Cash [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance stock units settled in stock",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "documentation": "Performance Stock Units Settled in Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PeriodOfCollaborationAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PeriodOfCollaborationAgreement",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement term",
        "label": "Period Of Collaboration Agreement",
        "documentation": "Period Of Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Phase3ClinicalTrialFelzartamabOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "Phase3ClinicalTrialFelzartamabOneMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 3 Clinical Trial, Felzartamab One",
        "label": "Phase 3 Clinical Trial, Felzartamab One [Member]",
        "documentation": "Phase 3 Clinical Trial, Felzartamab One"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Phase3ClinicalTrialFelzartamabTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "Phase3ClinicalTrialFelzartamabTwoMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 3 Clinical Trial, Felzartamab Two",
        "label": "Phase 3 Clinical Trial, Felzartamab Two [Member]",
        "documentation": "Phase 3 Clinical Trial, Felzartamab Two"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Plan assets for deferred compensation",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential future milestone payments commitment to third party",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "documentation": "Potential future milestone payments commitment to third party approximately."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1012",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1350",
      "r1353"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r492"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value $0.001 per share",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r765",
      "r993"
     ]
    },
    "biib_PretaxProfitSharingFormulaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PretaxProfitSharingFormulaTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pretax profit sharing formula",
        "label": "Pretax Profit Sharing Formula [Table Text Block]",
        "documentation": "Pretax Profit Sharing Formula [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PriorityReviewVoucherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "PriorityReviewVoucherMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Priority review voucher",
        "label": "Priority Review Voucher [Member]",
        "documentation": "Priority Review Voucher"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDivestitureOfInterestInJointVenture",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from divestiture of interest in joint venture",
        "label": "Proceeds from Divestiture of Interest in Joint Venture",
        "documentation": "The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from borrowings",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r812"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1115",
      "r1141"
     ]
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (distribution) contribution to noncontrolling interest",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities and sales",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r1168"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sales and maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equity interest in Samsung Bioepis",
        "label": "Proceeds from Sale of Equity Method Investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of intangible assets",
        "label": "Proceeds from Sale of Intangible Assets",
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of strategic investments",
        "label": "Proceeds from Sale of Other Investments",
        "documentation": "Amount of cash inflow from the sale of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of priority review voucher",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract manufacturing, royalty and other revenue",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1235"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product, net",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r226",
      "r341",
      "r717",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r931",
      "r962",
      "r1003",
      "r1005",
      "r1006",
      "r1009",
      "r1010",
      "r1131",
      "r1223",
      "r1224",
      "r1234",
      "r1318",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r226",
      "r341",
      "r717",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r931",
      "r962",
      "r1003",
      "r1005",
      "r1006",
      "r1009",
      "r1010",
      "r1131",
      "r1223",
      "r1224",
      "r1234",
      "r1318",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r259",
      "r262",
      "r277",
      "r283",
      "r298",
      "r305",
      "r309",
      "r310",
      "r382",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r593",
      "r602",
      "r604",
      "r607",
      "r608",
      "r625",
      "r650",
      "r757",
      "r774",
      "r819",
      "r864",
      "r881",
      "r882",
      "r978",
      "r979",
      "r1020",
      "r1136",
      "r1228"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Additions",
        "label": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r182",
      "r186",
      "r187"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, plant and equipment, net",
        "terseLabel": "Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r672",
      "r758",
      "r772",
      "r993"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "biib_QALSODYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "QALSODYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "QALSODY",
        "label": "QALSODY [Member]",
        "documentation": "QALSODY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r200",
      "r202",
      "r203",
      "r205",
      "r228",
      "r229",
      "r445",
      "r446",
      "r447",
      "r448",
      "r518",
      "r526",
      "r553",
      "r554",
      "r555",
      "r563",
      "r631",
      "r687",
      "r699",
      "r716",
      "r795",
      "r797",
      "r809",
      "r833",
      "r834",
      "r890",
      "r892",
      "r894",
      "r895",
      "r907",
      "r928",
      "r929",
      "r951",
      "r961",
      "r974",
      "r985",
      "r986",
      "r990",
      "r991",
      "r1005",
      "r1013",
      "r1216",
      "r1232",
      "r1280",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r200",
      "r202",
      "r203",
      "r205",
      "r228",
      "r229",
      "r445",
      "r446",
      "r447",
      "r448",
      "r518",
      "r526",
      "r553",
      "r554",
      "r555",
      "r563",
      "r631",
      "r687",
      "r699",
      "r716",
      "r795",
      "r797",
      "r809",
      "r833",
      "r834",
      "r890",
      "r892",
      "r894",
      "r895",
      "r907",
      "r928",
      "r929",
      "r951",
      "r961",
      "r974",
      "r985",
      "r986",
      "r990",
      "r991",
      "r1005",
      "r1013",
      "r1216",
      "r1232",
      "r1280",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310"
     ]
    },
    "biib_RareDiseaseProductRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "RareDiseaseProductRevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rare Disease Product Revenue",
        "label": "Rare Disease Product Revenue [Member]",
        "documentation": "Rare Disease Product Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "biib_RatioOfNumberOfSharesReservedUnderPlan": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "RatioOfNumberOfSharesReservedUnderPlan",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ratio of total number of shares reserved under the plan",
        "label": "Ratio Of Number Of Shares Reserved Under Plan",
        "documentation": "Ratio Of Number Of Shares Reserved Under Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from marketable debt securities",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gains) losses on investments, net",
        "label": "Realized Investment Gains (Losses)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "biib_ReataIntegrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ReataIntegrationMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reata Integration",
        "label": "Reata Integration [Member]",
        "documentation": "Reata Integration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReataPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ReataPharmaceuticalsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reata Pharmaceuticals, Inc",
        "label": "Reata Pharmaceuticals, Inc [Member]",
        "documentation": "Reata Pharmaceuticals, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r25",
      "r265",
      "r656",
      "r661",
      "r662",
      "r777",
      "r1134"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1037",
      "r1047",
      "r1079"
     ]
    },
    "biib_Reductioninroyaltyrate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "Reductioninroyaltyrate",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in royalty rate",
        "label": "Reduction in royalty rate",
        "documentation": "Reduction in royalty rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r525",
      "r676",
      "r677",
      "r763",
      "r770",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r861",
      "r863",
      "r888"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r676",
      "r677",
      "r678",
      "r679",
      "r763",
      "r770",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r861",
      "r863",
      "r888"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r525",
      "r676",
      "r677",
      "r763",
      "r770",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r861",
      "r863",
      "r888",
      "r1302"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of borrowings",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r815"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of Short-Term Debt, Maturing in More than Three Months",
        "label": "Repayments of Short-Term Debt, Maturing in More than Three Months",
        "documentation": "The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year)."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r287",
      "r288",
      "r466",
      "r494",
      "r679",
      "r700",
      "r759",
      "r940",
      "r941"
     ]
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs, percentage",
        "label": "Research and Development Costs, Percentage",
        "documentation": "Research and Development Costs, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense asset acquired",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r930",
      "r948",
      "r1311"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1263"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReserveforCashDiscountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ReserveforCashDiscountsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounts",
        "label": "Reserve for Cash Discounts [Member]",
        "documentation": "Reserve for Cash Discounts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Axis]",
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r231",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r326",
      "r384",
      "r385",
      "r591",
      "r592",
      "r593",
      "r594",
      "r601",
      "r602",
      "r622",
      "r623",
      "r624",
      "r625",
      "r665",
      "r667",
      "r674",
      "r675",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r810",
      "r1165"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1038",
      "r1048",
      "r1080"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1039",
      "r1049",
      "r1081"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1046",
      "r1056",
      "r1088"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Domain]",
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r231",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r326",
      "r384",
      "r385",
      "r591",
      "r592",
      "r593",
      "r594",
      "r601",
      "r602",
      "r622",
      "r623",
      "r624",
      "r625",
      "r665",
      "r667",
      "r674",
      "r675",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r810",
      "r1165"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r435",
      "r438",
      "r443"
     ]
    },
    "biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected operating expense reduction",
        "label": "Restructuring And Related Activities, Expected Operating Expense Reduction",
        "documentation": "Restructuring And Related Activities, Expected Operating Expense Reduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected cost",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r437",
      "r440",
      "r442"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Cost, Expected Cost Remaining",
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected number of positions eliminated",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Expense",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r439",
      "r440",
      "r1217"
     ]
    },
    "us-gaap_RestructuringChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringChargesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r143"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r440",
      "r441"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r441",
      "r442"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restructuring reserve, beginning",
        "periodEndLabel": "Restructuring reserve, ending",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r441"
     ]
    },
    "us-gaap_RestructuringReserveTranslationAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveTranslationAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign currency and other adjustments",
        "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r150",
      "r768",
      "r803",
      "r808",
      "r816",
      "r844",
      "r993"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r295",
      "r296",
      "r297",
      "r299",
      "r305",
      "r308",
      "r310",
      "r383",
      "r386",
      "r424",
      "r581",
      "r582",
      "r590",
      "r591",
      "r592",
      "r594",
      "r601",
      "r602",
      "r614",
      "r616",
      "r617",
      "r619",
      "r623",
      "r666",
      "r669",
      "r799",
      "r801",
      "r820",
      "r1353"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenue",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r267",
      "r283",
      "r327",
      "r331",
      "r332",
      "r338",
      "r340",
      "r341",
      "r342",
      "r344",
      "r382",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r650",
      "r757",
      "r948",
      "r1228"
     ]
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "documentation": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "documentation": "Revenues from anti-cd20 therapeutic programs"
       }
      }
     },
     "auth_ref": []
    },
    "biib_RituxanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "RituxanMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RITUXAN",
        "label": "RITUXAN [Member]",
        "documentation": "RITUXAN."
       }
      }
     },
     "auth_ref": []
    },
    "biib_RocheGroupGenentechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "RocheGroupGenentechMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech",
        "label": "Roche Group Genentech Member",
        "documentation": "Roche group Genentech."
       }
      }
     },
     "auth_ref": []
    },
    "biib_RoyaltyAttributedToOCREVUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "RoyaltyAttributedToOCREVUSMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Attributed To OCREVUS",
        "label": "Royalty Attributed To OCREVUS [Member]",
        "documentation": "Royalty Attributed To OCREVUS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty and other revenue",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1235"
     ]
    },
    "biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty operating profit threshold for highest royalty rate percentage",
        "label": "Royalty operating profit threshold for highest royalty rate percentage",
        "documentation": "Royalty operating profit threshold for highest royalty rate percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "biib_SKYCLARYSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SKYCLARYSMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Completed technology for SKYCLARYS (U.S.)",
        "label": "SKYCLARYS [Member]",
        "documentation": "SKYCLARYS"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SPINRAZAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SPINRAZAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPINRAZA",
        "label": "SPINRAZA [Member]",
        "documentation": "SPINRAZA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SageTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SageTherapeuticsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sage Therapeutics",
        "label": "Sage Therapeutics Inc. [Member]",
        "documentation": "Sage Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Sales [Member]",
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesReturnsAndAllowancesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returns",
        "label": "Sales Returns and Allowances [Member]",
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SalesTriggerGrossSalesThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SalesTriggerGrossSalesThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales trigger gross sales threshold",
        "label": "Sales Trigger Gross Sales Threshold",
        "documentation": "Sales trigger gross sales threshold."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SamsungBiosimilarAgreementMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Samsung Bioepis",
        "label": "Samsung Biosimilar Agreement [Member]",
        "documentation": "Samsung bio-similar agreement."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SangamoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SangamoMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sangamo",
        "label": "Sangamo [Member]",
        "documentation": "Sangamo"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r1127",
      "r1156"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported",
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r310",
      "r326",
      "r591",
      "r593",
      "r594",
      "r601",
      "r602",
      "r622",
      "r623",
      "r624",
      "r665",
      "r667",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r810",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1155",
      "r1165",
      "r1186",
      "r1187",
      "r1275",
      "r1300",
      "r1301"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r311",
      "r527",
      "r1109",
      "r1156"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r1293",
      "r1294"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r595"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of fair and carrying value of debt instruments",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]",
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r81",
      "r612"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of fair value and presentation of derivatives",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and diluted earnings per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r977",
      "r1264"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r589",
      "r1110",
      "r1111",
      "r1112",
      "r1268",
      "r1269",
      "r1270",
      "r1271"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of assets and liabilities recorded at fair value",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1278"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r418",
      "r421",
      "r422",
      "r423",
      "r718",
      "r930",
      "r954"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r953"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of roll forward of the changes in goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r420",
      "r423",
      "r954"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Components of inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r114",
      "r115",
      "r116"
     ]
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Disclosure of information about long-lived, depreciable assets that are subject to operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense), net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r672"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r441",
      "r442"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r140",
      "r141"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r142"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r146",
      "r148",
      "r149",
      "r150",
      "r241",
      "r242",
      "r243",
      "r329",
      "r492",
      "r493",
      "r494",
      "r496",
      "r499",
      "r504",
      "r506",
      "r812",
      "r813",
      "r814",
      "r815",
      "r961",
      "r1108",
      "r1145"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Variable Interest Entities [Table]",
        "label": "Variable Interest Entity [Table]",
        "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r605",
      "r606",
      "r610",
      "r611",
      "r695",
      "r696",
      "r697"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated future amortization for acquired intangible assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1208"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r201",
      "r204",
      "r206",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r342",
      "r343",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r824",
      "r828",
      "r830",
      "r891",
      "r893",
      "r897",
      "r908",
      "r915",
      "r918",
      "r919",
      "r920",
      "r921",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r932",
      "r963",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1007",
      "r1013",
      "r1234",
      "r1318",
      "r1322",
      "r1323",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general and administrative",
        "terseLabel": "Selling, General and Administrative Expense",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SeniorNotes3.250DueFebruary152051Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SeniorNotes3.250DueFebruary152051Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.250% Senior Notes, Due February 15, 2051",
        "label": "Senior Notes 3.250%, Due February 15, 2051 [Member]",
        "documentation": "Senior Notes 3.250%, Due February 15, 2051"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.200% Senior Notes due 2045",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.050% Senior Notes due 2025",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SettlementLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reata related accrued expense",
        "label": "Settlement Liabilities, Current",
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income",
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation arrangement, authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556"
     ]
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense included in total costs and expenses",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "documentation": "Share based compensation expense included in costs and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ShareOfCoPromotionProfits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ShareOfCoPromotionProfits",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA",
        "label": "Share Of Co Promotion Profits",
        "documentation": "Share of co promotion profits."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ShareOfNetProfitFromSageTherapeuticsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ShareOfNetProfitFromSageTherapeuticsPercent",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of net profit from sage therapeutics, Percent",
        "label": "Share Of Net Profit From Sage Therapeutics, Percent",
        "documentation": "Share Of Net Profit From Sage Therapeutics, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ShareOfNonControlingInterestRecognized": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ShareOfNonControlingInterestRecognized",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of non-controling interest recognized",
        "label": "Share Of Non-Controling Interest Recognized",
        "documentation": "Share Of Non-Controling Interest Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant accounting policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r280"
     ]
    },
    "biib_SolothurnSwitzerlandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SolothurnSwitzerlandMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Solothurn, Switzerland",
        "label": "Solothurn, Switzerland [Member]",
        "documentation": "Solothurn, Switzerland [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r108",
      "r111",
      "r112",
      "r230",
      "r264",
      "r265",
      "r266",
      "r295",
      "r296",
      "r297",
      "r299",
      "r305",
      "r308",
      "r310",
      "r328",
      "r383",
      "r386",
      "r424",
      "r507",
      "r581",
      "r582",
      "r590",
      "r591",
      "r592",
      "r594",
      "r601",
      "r602",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r623",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r666",
      "r669",
      "r675",
      "r777",
      "r799",
      "r800",
      "r801",
      "r820",
      "r883"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r201",
      "r204",
      "r206",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r342",
      "r343",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r824",
      "r828",
      "r830",
      "r891",
      "r893",
      "r897",
      "r908",
      "r915",
      "r918",
      "r919",
      "r920",
      "r921",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r932",
      "r963",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1007",
      "r1013",
      "r1234",
      "r1318",
      "r1322",
      "r1323",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r328",
      "r669",
      "r717",
      "r811",
      "r821",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r843",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r852",
      "r853",
      "r854",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r863",
      "r865",
      "r866",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r883",
      "r1014"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r311",
      "r527",
      "r1109",
      "r1113",
      "r1156"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r328",
      "r345",
      "r669",
      "r717",
      "r811",
      "r821",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r843",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r852",
      "r853",
      "r854",
      "r855",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r863",
      "r865",
      "r866",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r883",
      "r1014"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1041",
      "r1051",
      "r1083"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plans (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r107",
      "r108",
      "r150"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock award plan, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r107",
      "r108",
      "r150",
      "r539"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r108",
      "r150"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock award plan",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r108",
      "r111",
      "r112",
      "r150"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r48",
      "r107",
      "r108",
      "r150"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Repurchase Program, Authorized Amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Biogen Inc. shareholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r72",
      "r230",
      "r231",
      "r265",
      "r295",
      "r296",
      "r297",
      "r299",
      "r305",
      "r308",
      "r383",
      "r386",
      "r424",
      "r507",
      "r581",
      "r582",
      "r590",
      "r591",
      "r592",
      "r594",
      "r601",
      "r602",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r623",
      "r656",
      "r658",
      "r662",
      "r667",
      "r675",
      "r800",
      "r801",
      "r818",
      "r845",
      "r862",
      "r884",
      "r885",
      "r913",
      "r1020",
      "r1147",
      "r1185",
      "r1292",
      "r1353"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r282",
      "r491",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r621",
      "r886",
      "r887",
      "r914"
     ]
    },
    "us-gaap_StockholdersEquityOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityOther",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Stockholders' Equity, Other",
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "biib_StrategicInvestmentPortfolio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "StrategicInvestmentPortfolio",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Strategic investment portfolio",
        "label": "Strategic Investment Portfolio",
        "documentation": "Strategic investment portfolio."
       }
      }
     },
     "auth_ref": []
    },
    "biib_StrategicInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "StrategicInvestmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic Investments",
        "label": "Strategic Investments [Member]",
        "documentation": "Strategic investments."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Denali Therapeutics Collaboration",
        "label": "Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]",
        "documentation": "Summary of Activity Related to Denali Therapeutics Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Sage Therapeutics",
        "label": "Summary of Activity Related to Sage Therapeutics [Table Text Block]",
        "documentation": "Summary of Activity Related to Sage Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of activity related to the UCB collaboration",
        "label": "Summary of Activity Related to the UCB Collaboration [Table Text Block]",
        "documentation": "Summary of Activity Related to the UCB Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total reserves included in consolidated balance sheets",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "documentation": "Summary of share-based compensation expense associated with different programs."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TECFIDERAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "TECFIDERAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TECFIDERA",
        "label": "TECFIDERA [Member]",
        "documentation": "TECFIDERA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TOFIDENCEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "TOFIDENCEMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TOFIDENCE",
        "label": "TOFIDENCE [Member]",
        "documentation": "TOFIDENCE"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100"
     ]
    },
    "biib_TermLoan2023ThreeYearTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "TermLoan2023ThreeYearTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Term Loan Three-Year Tranche",
        "label": "Term Loan 2023 Three-Year Tranche [Member]",
        "documentation": "Term Loan 2023 Three-Year Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityFloatingRate364DayTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "TheCreditFacilityFloatingRate364DayTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility Floating Rate 364-Day Tranche",
        "label": "The Credit Facility Floating Rate 364-Day Tranche [Member]",
        "documentation": "Credit Facility Floating Rate 364-Day Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityFloatingRateThreeYearTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "TheCreditFacilityFloatingRateThreeYearTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility Floating Rate Three-Year Tranche",
        "label": "The Credit Facility Floating Rate Three-Year Tranche [Member]",
        "documentation": "The Credit Facility Floating Rate Three-Year Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "TheCreditFacilityMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility",
        "label": "The Credit Facility [Member]",
        "documentation": "The Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityTerminatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "TheCreditFacilityTerminatedMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility, Terminated",
        "label": "The Credit Facility, Terminated [Member]",
        "documentation": "The Credit Facility, Terminated"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one",
        "label": "Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One",
        "documentation": "Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in any 12 months under option one",
        "label": "Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One",
        "documentation": "Threshold of gross sales to be achieved in any twelve consecutive months under option one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Time-vested restricted stock units",
        "label": "Time Vested Restricted Stock Units [Member]",
        "documentation": "Time vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trademarks and trade names",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1209",
      "r1210",
      "r1211"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r487",
      "r504",
      "r620",
      "r647",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r698",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r778",
      "r981",
      "r983",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r994",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1276",
      "r1279",
      "r1280",
      "r1281",
      "r1288",
      "r1291"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, treasury stock, shares",
        "periodEndLabel": "Ending balance, treasury stock, shares",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r108",
      "r111"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r440",
      "r441"
     ]
    },
    "biib_TysabriProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "TysabriProductMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TYSABRI",
        "label": "TYSABRI product [Member]",
        "documentation": "TYSABRI product [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_UCBPharmaS.A.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "UCBPharmaS.A.Member",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UCB Pharma S.A.",
        "label": "UCB Pharma S.A. [Member]",
        "documentation": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain (Loss) on Derivatives",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r876",
      "r877",
      "r878",
      "r879",
      "r901"
     ]
    },
    "biib_UnrealizedGainOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "UnrealizedGainOnDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain on Derivatives",
        "label": "Unrealized Gain on Derivatives",
        "documentation": "Unrealized Gain on Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_UnrealizedLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "UnrealizedLossOnDerivatives",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Loss on Derivatives",
        "label": "Unrealized Loss on Derivatives",
        "documentation": "Unrealized Loss on Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r179",
      "r181",
      "r183",
      "r184"
     ]
    },
    "biib_VUMERITYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "VUMERITYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VUMERITY",
        "label": "VUMERITY [Member]",
        "documentation": "VUMERITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r294"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of information about valuation allowance and qualifying account and reserve."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ]
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments in Variable Interest Entities",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity [Line Items]",
        "label": "Variable Interest Entity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606",
      "r610",
      "r611",
      "r695",
      "r696",
      "r697"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "documentation": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r699",
      "r928",
      "r929",
      "r985",
      "r1305",
      "r1307",
      "r1310"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dilutive potential common shares",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings (loss) per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r322"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares used in calculating:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings (loss) per share attributable to Biogen Inc.",
        "terseLabel": "Weighted average number of common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r322"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "biib_ZURZUVAEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20240930",
     "localname": "ZURZUVAEMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ZURZUVAE",
        "label": "ZURZUVAE [Member]",
        "documentation": "ZURZUVAE"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-9"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>134
<FILENAME>0000875045-24-000032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-24-000032-xbrl.zip
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MMV""G,YD$H26/">N9Q*\Q0X7^T&8#%I(DK H2ZN%7")"V6XH&(R D1=0?NK
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MXF>44@ZN$?V)_:S/1"@I)1BD;!-1OD4IG2#]?B+$JRBE"J3?3X3X$VDU@//
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MT[6P<=W?EA<JS_$7>KR=4?>O %P^IC9DG%.7^@?&$"",?/#'4$T(@:!"KCU
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M=#P>VGP\GF;676.RJ(6CS5.ADZP>/ACUDS5@KT+X=7*BX'+>G-+D&^'7NW'
MAIL !WJ2GR)\D P,=G.,]5"\*NMD316V>".HV@],^+*'1D6%V86*Q$]-/=R7
M:E0U(&1PNMSHT#4Z\R;O#A=I1MS>3=[<:SH#$_S?,7M,,Z9<\55RB*@5#LYJ
M>HVH,A2Q=SP4#\Y*C:H6JE1AB TQ58*(8%L4U2K'!1T^)36-RK;1(#H#@6UW
M,20^W_,<ZO/YD^UZGD$QF0P"ZF%FK%]TV/3^L&FEL<.V9BT<-?<:M)?!'^X^
MRU73GX0!TLZV9_O]%'9U?3H6DC 6VMGT57!RC;KN]ZKT^]?"GIV-7PLCG)0[
M?G8CG$]?$7%^,7@H X8<0M1I/" [P!#83##R HICL8B9%6K)/L&?'K'PFJ//
M-/?M.@!W'GCP?#;@/!D0A[=H:][2K>6&;E*HQXC;PVN-V9\=I\F/WND.-_SD
MBJ !L8D_*Z[I2W7('W?>8D;SJ&3Q4^HX6M;TA^0)6T=_8^JNP=?) 4#II%0L
M?=%AFAI4)0G"7B"IH9E*):9Z8_!0.J:J%P0QU1MQ97S$'90';P9>'N_*;D#>
MPYY/@VA_.L.$1&B$]6CLA]<=+-JT%3;I&A8H'IS5M)-1Q<F\O9Q@&YNS=0*U
MM =,=("ZMV4"V]B<;>M4T>LH5>GH;\_OW\;H;&Y^J:#"T*@"00H3#9E<R+:7
M8-+@E!*70LS-=K(C^-%X< -SC.G:$\0TI>T4N["FOG(]K^M<0 SL>H0]L3M\
M.1E@ZV2G^LYD1S.@I*%.\A"I:>5./(M\2C RVAHB+Z!0/S@[.5FS'<F+J2Z:
M)>2.DY)G"5'Z?D:#JBX_?N 3<4QW@G^)-Y?3,=1[8B@/Z@!_/>\#O(F[4RX5
M.Z,.;^EHK<H-7K.-0)U-PJ]H34@5"GP1*"6$@Q-^DD'JV:,.AY+2B9+" 3O%
MN*&7,2I#""]BHJ2 4&(:8NJKGK-]#(+Y;%]=?1["GC0EMK<)VW0N0OBN.TR?
M\',1"@D&1GI[<@FY<XM=33\"(GX^0JU>W'G]FJ18T4STONU1/X(AM@?-8:U0
M2RP@DQ5<N2:B+392_0B(:@=GM<-*I;+KKEWZO(0MC1V&TP9?+_F+,<!@'FR$
M,I?AHR?CTP [>$C\7W3@M^? +[0$4X$OJ3L)9U &T"91YN,ZWCFW3GC?'7K"
M7OO)IPC:E#B(SCH^GG@WKL/>2EV^!4P'WD_QNCTX3^H'9Y5J<5?11'.SZ"5!
M>Y'<TH4>VTEH[3Y"&X>M) 67IKG=H\J]0FVWV(+OVE\K[KQ@49-@A@)4>?#8
MX$<%% K5G0^6T['N3K%NXF%M'EA]J^ 5ND>4Z)V'S;L&Y6PB?TGOBY31&'(;
M!+!I_:4U4[PWA7]R!GEYZ/1)]7D^J;^16+*I.[T,,=,VAJ\<G#5*:9^7IA=N
MIK)P4_IP[P;[L9(9RIM:NMQ3]'?+-P=B2=0:#J@>G)5/3G22K9C#V$^4^"I2
MV&#/R9J]P[0NF 4.V9Y"=I--^/D%Y5IR>^W*"JNL,4R2(>FKO'("46AQYS!4
MRVK;QUEA0ZX$6P;R?4H&@8_8P06^:S@K(BD[U8"KI!Y?1!$^P!V&__KH2>MQ
M'XK(P"8+9;NY9(D[=QNQ^K6E18V&7J,JOM/M)SQ[!VR>PP.*=W!6V&%T5\Y8
M+0\<(HQ"BH6BYA#Q'))D )8(<[ C$N1>MJ%",&:\'H>=$W>$'0.L=9Q89K15
M%K)K>Z5"F/^]OS;(F+?8)>)<U[G+*>F Z2;J;R6+>^D9J3#)QIZ13@?(2A2]
MKBM4N-#Y<DK[SD*G&*QK]Z#=PT>2B1T5WF*AFIK$JYV'=A["TZ=U7:#&-.SB
MSB>Z[Q/G4>84ORMNFRK ^UWY='FG$;0RE-AR Y;4/*_0&T_?MA!IODO!"F<^
M<9YBRL\3Q*<;!R.VL&"R-DH)=GLN379WB#]''CP&(^I !;P72$I2C,E)0)VA
MF/D6TSY#P>O22NEY;-".T!3_G&-L'B,4%C$".S/JN*;>_D?;JNA2]OA-@%8L
MF'U5"=D(W-HSX&X01+9&\ D;.JR\1+#XL4/-QKEAXV3(N $)VW%9O=TI-1F+
MK\:[8%M/!+?% CMHIZS 40QJ) 07Q Y\;.F40#NA/:8$$<K6]><B3PIVG?NJ
M_9#V0RDG!:]@N*33 LW(HADY*4(N\\1 O0T0-"&+KT8*B<$KR&735HY+8E9S
MISG*J(=L/CID(ST?_)M_P-81@I*A$0YS,<\(/,C5X#U05#.P^8;S>O1/C_ZE
M/_J7Y[4J85_<=0)RW*6;88^^"28#3+M#[M2\;N![/G)8,ZTJ7XLI-D4VRZQ2
MU>>'R!C?;(#$&]O@?Q@2-0:)G8]2T"O:!$)BSXBHAR2A7OJ67Y)X8^KEAR%Q
M$I+$CGY##YFD,F2B&3*A."JRRHMNL:Y'\),9:SN?V:!)4K5(:@=0E HZEE*-
M*?:.B6)(%'IC4'6(XGW1U"Z@*+TKQ$XDGOK,0PKXUR(/9[_"?^*G+SW'Q&P'
M@\AB9[\.*/MQ5"3],_VS-3]+ME\7"V]U[!+KV'T,@;)INA,HP QZAN&X/O98
MN.R/L8>AHZ/ (BS0AAYNL7U\^5]\C1AB7P^)@QR3(!N*#U],H$;>\<:Z1^^N
ME,(D(S[$_I1B)J,_X"^/Q/+',>DL_3#L@J>%Q4_0  H!=+'Q)U*U\\EJDRS_
MEQ69L1JIXCHNU>L8#P>U2M5L#!JF63<;N%2QZHTA1O^W5#V(?S2F"TH;X:,!
MQ>CG$1I"+4^1_8AF'F.KI<:8$.?H6>,_;[>-K3,<OKMU3IXU3GU-XX3T"^["
M#<_2. 67C2F["\J%I"J/,:;,P?WC;5/5#\[N>.+I#@UV7@CK%K]^1F?K8+ [
M9HMF%=6M]V.VM$4S')R==[I?VS=&YZ9U;#1O+HS^_7F_<]%I]CKM_D?9+9T:
MM+HW%^V;?OO"@+_ZW:O.1?,./O3OX)_K]LU=W^A>PJ7KVU[[&]S7^=YFM>U>
MM]6HWJ<Y.Q^RX4AXC<W.HOGE1>FW)KX[,@'VO\&/1L^=(.>],2,OW;- ['E+
M3A = 2FQA:31,#WO+W.^Y\M,H:@VFGKX-/[C2[P=.7'X&_F/OD3/BIP$([=G
M$1PW6WAYP7O'A9#[(GTL>G-T^1@N?7[Y?;5\7*V?K+U4."ZN_7[3HQK')[7*
M3D_:_'WY9+<GI5&F:GG].W8O4[5>DK!,KZ,@8U,AUF=5\XHUMJE82)@"J_:"
M17G5+EW*@EWC#IP[-J[A_K%GM,'G6T8?3R&DA=S4*!<.MYCA\:H(D(4VNH$K
MVS91OGK JS-F^/]VVD_F8YA(6"=<CXE2H539ICFVJ?7VFT[LN>52Z4W0<N6/
MLHG&F\;;N_&6,6K6VYGN>>5&;O>K^^!VIB6]G6DV5H!D:4<Z,=N9EO1VIMH]
M9,T]['$[TY+>SE0[#_GJF.9VIB5YMS/-2N;4]<>8&FSXG^(Q=CSR@%<S*;VN
M38TEDDL#:]$CCMC]# 8"X77O4 P%_1M;Q@@1)YJDC2%!!^KPL!E0XA/L&>@!
M$9OGZN D#0]X@)_WQ@;/ET]Y"\?,]9SM]Z2JO*>WECOZTDD\<?-?NK0/C=^?
M6Z9I_1EX/IO4 V3='=ZAIQW.;RK5]?E-XBG^8]G>OD#T$BQ\@4S:\SGUQ._]
MI#XBV$:?.*D:V[R1'^R1;<ILG<G.J[@E31X4C/U,Y(V-H>T^&F-LC;"GP[V=
MA=D7\=X&8?:U7M0",UR"%;XQ(WP%*_&NQ681][!I(\\C0V@@5I:F8VWH2<6#
MLTIQS>*<C;JNIEOU@KLD@%(Z."LU=CU?70=XP@A&$GXI\_W$-+U(3R\?B.:2
MP$F%'0N\XV+R/0=T\5QU* _>#*$\WJ4CX3@2GK*^ /\.L(.'!&+@ 52)0UW'
MQ!^60-_ALFY#>P#/\+MN7<^GV">4KVP\#XUT:T.%MLLSJVQ3XK(6)%2=[2(,
M.#4&G.UGR^@X618A5#SGU!ET7D;,FG/4")O% X@?L"5F!^=\1(2M@%+LF#/#
MAR=[-@_W##2WC8[V]CS@?>E2>*T3F^&.62%\)<LO%S;9KKLT-BB@FG 5"?+>
MP;B)(JA2.#@K%]:,?>MH3S;2D81S*GQ/-,TYRG!.$E%>L@AB&Z@5UVRTN"_.
MR=C,V3O71[;AOC5_=JV(]XZ [F/3Y3- O!^(]N)><.M2WCV6UH;>N;<(.I._
MKH.4DY3N)%E\L0YRZ2)+O@3\ YK?.Y'%AJK*.Z_KD1=!FK02CQ;?B:SJP=E)
M8E&AQ(C+.V=]8*S]G<BJ'9Q5=]4$]4JL'23!S3'DODXRR#T]OQ%3KNE KR54
M]7"OAQVWKM?L*T7WVX^"N"."3H!C*VM(5O(M$C3G)!82O@J8W380J#3X!@+U
MW1,-S4@R,%*2\>!N/%0ML'7W]9WS"!WM[27: P,P:U/7MMD&_?^/O6]_3AQ)
M$OY7%.S>=ST1F &)IWN."-IVSW+7;7N->^9F?[D0HC#: 8G5PX_]Z[_,JA((
M(X$$ B2<L['=-.A1E>_,RH>)+>:8ZT77S-!9<<:6WJI_=+N"B[Y$18HJQ4:-
MJA1/SWY'M_:24=$ZM:C1J5QT+IPW 9,;^:*1?#F]?#F2[;:K5.&E,BD31,F
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M?>O=7MTH@[_=W#P69"N?%I*XK,!SX353H$VWK+!7@X%?-V<@$2:Z ^)\9OM
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MKJ3,]ZS1IM*)IB9<<CJ;.P>'9#]2P/*[6BW?T9GB"$#'-A@;N4*I8?V8",>
M_2&K(%$RSG3G3R8'0B[*(S^D1,QVP \'_5> /!81 =U_%U!_NQM_7T!\68^:
MHIJHV=BQFHC$9FX]B#WI)8$CT2QU6V6M74W;+XD$;$(+D^3H(>3H>VNB]ZR;
M4P3R5]M!1EERQ#4;IJG);+9(BN:!APYK?*8AEP1"M%WJ-LJU>C7?37(*(S\Y
MDEPSZ #^P'1/7U2W\6AZ4,[V(>6H%$\DC<Y%&@4-#IE[R[!3(5"X_&646A3A
M(6Y9TQHI6DZ0*$HLBO[6O_ABVB2+CA,MS) O6E4\,*FVTF3XD P]NMHB490F
M;,>+_7D#,YR?QQSFXJQ79:#/7-]Z4D!2L;E)OF;&,;N[L6@:]YUY$WO47W9N
MC!([M5*W7FU2,^JSC<BEH@:UU&VUVP68%55PH1C3"X\D8=:2,,TA7DN+:85'
MHO!<1.$&<D@<@&W5\]D4+_>]3'._P$(KFE @P*6!U4=Q_]^/)8X2%CB5L-6)
ML*C(J3^#P&@2"FCR&OY<URH41LA%90:!K*,Y!4<QIGF%SA8/$INL-FDTP1G;
MT$FH (M5J\V(Y@T41Z"^T3DPX;[:3IBP0R3]KNIEG;0[I2ZE?)^7.;<[-;3Q
MU"YBUFF.;+M:IQ#R+4D=:E1Y$]6A'J6)4TRE8$(NJ>&Q0C6+(2-4;5HH>9L!
M-:5+HVAC4]!RO=Y.TR:"2DYW+SD=FY9N&<<H.3U6O6GJ8E.*:Q\TY".--,5A
M4]T#2\"S%=-U?: Z)F(_MO$G2@G%Q1GU%T,<4@]06$ZI5_30U&7JXY.E'_4@
M</)H/^JOOYO>9&)/$3B8M([(^(*XN JA(DIB:SP^2EEOQ=3PAZ.+.CC:[4HU
MS[Y5883H YL+S/"9.[;CV"^PEX\9(L]2#B[@ZMZ-O]G6TR-S9J) 9YV>&]B]
MK)J"H$G0Y5?0I4%\$X=9=/+=Q;LPDFSU!/"#B[(#G?;UI7G]GK03ITBUJ48U
M%\QRJ(/ . )9)P2<MMAIY>P@D!SV0T?R/\&&/<<<^HCKGSBE!?]"_QW P+^R
MIU.,' 6U(23#LY/ARU2E[Z;%<\VYYX6.&'/2=&UI=TB6YX&M#B7+MQ'*&D%T
MJG@"GB^)7FB!2:D=F1Y51A'W5]OA4/X:G%9L/*_LU,!5S^*TDB1='B5=2F+
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M ]^OG2+"2'@E?B&XGC=<T\FAM7SKG>10G>10SO"ZENFY$UX;F+:9?.H]H?7
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M@?[ /!V^%!!GNF/!\N,[G9)\C01B</I&$G9O2-J>%*Y?3/N)64K?,BK\W_R
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M,)<!E>E %M@*#0A@A,6Y_!.',>^0-C8MW3),?0K+AR]X>[1*[-[EN^MJI=6
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M?P2^<<I>\35,=^&>%]N9CD =L8KR.U,F.CQ05X:.K8^4N>UX8T"#C<)FQD;
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M@NBE\KWS?-P@+V75TUJL4L84,<1D36PL77P"P<IF0.0B$86GPH16R0\9Q$D
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M'%NZ0K6&F%XO;?AWQ5B2#%(]JEY1;CB5+6*6)KH6SLST^&GMXA0P%A%.*,@
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MK_0Y'J3U%OU.4TLL%<2W%COG-\+V>A%O5@SQZG"OU5#U4+B[OB@#0!D0]%I
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M!-N&![6(P8.3E!IA'Z/8)"61U3/37\V9/U."=AN+21ZP6DZ,\A3.#:?C+%_
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M#"8Z5P*@=@?BA&S+<( LM>%2ND2JP7JIVU'C#\IRU@@A Q]T)=QZJ,C>GC(
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M@F./R;'[ H,LFS^SJK'A\$DX<F\7+$915HP6+TM%G*1J#OKDR"?Y]_5S*N@
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M6"6'ZJ.!ZJ,*GA$\<^D\DU6;U*FMD-,[7@J&$1ER%<Z0,^6#M2N#Q0TB "X
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M*U0=6:A?RYJ+2R^C5]@"/&: BOV0:F\+>V2_HDDML36C$+8]<B<AN9[]Y</
M"T%U>[_VQG3=]$L?DM]*+B.4O&M6'T56_/9"*#?D6# G*37)DY.W&_#63YNO
MPXUJ&5KJ6W)#R?FZ9NNYOK%M48K<,!R#MT4I#4TU>5L4ER?%Y:(X)9\I[UZ4
MF&5P0 _7V2R#)U#"Q# #,<R@5. 5PPQ$:_29T^7G7O!34[3Q%@,-N#E7,=!
M##00 PW*=*YBH($8:""Z2I\F \7*6VR3N=S>*+S9W*E3NC87,J3_2Y7)@K\$
M?S'P5XXD26S35UA7-L%+'"%*\%(AO)0U6](L,R.)WM@7VAO;.MKH*8.US:/
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M]DO+W0=4\)+@I4OAI:SJIUYK&D5/$!))@B))\,CH/WB< 9AO#':7 +@ .!<
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M)-@<8*5IM86L:$7):_C#F<9:;1T%=NA!9AL%]B7P<52,E'J@N0[NU@O=Y^>
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M%IQO!X>& [ASVPL<&+4I(+B ?BJJO+?6>#NM=:"U;O,Q@DJ0=$Y2A3WHH!M
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M(3P[#&_\UYXWIA[K1:>9-A8)>T,/$=6B9]WJ_S'U C( _KJ'E[V1AZ7\\!X
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M&JW6U$[JFIY_7W1%C$EKGMA^4'4@>=W0[899,D,[2_"[NJC*J6RSPZHP9=M
MH.EZFD>GC#[/"\#8J2!&-=,4Q- 0DU8ZP73H=9?56JN".6.=^KJS"KON^+'[
M+P!5.:\[=E@5=MW9]+I3T_H5EM&W= $8.Q7$MEUWV&A*J9RGA7L/2]S_NI^2
M:\V#=^4HW\^@LFY-'KT$97;?<(+"U1)-!M[7ZXJL%#;*(!L!2V \50Z)N729
M Z!8E"JC*;6F65?TM$R_W):[@"6OL#P1*EG"4)J*V4".49R3\M0PS(JV$X**
M.YUZWW"8XF]=#37NNJ7:#;N@@:8"/F>\*MGQ4]A5J6.\W#:=%$!MO2H%EJHD
MBICN-X/"QG!R9[L>#3N78OVWQU>3P.]C;_]M/9EY< .4ALO:XP$94NX !HL\
MZEAY)0'V0,[1($&D$!S@F=P[67%&H53YM=$*-;\TP[A=W;0K51EV 2C[K[_9
MJJ)^$"3BET0E$P16606!"(1E1]G>D:['1IF-6?R:+A]>*B;"K2=$&=MU(T@D
M!,$V0>#P)@@NQ8C^$GA^X$7O8$)_]\B;]-V?]OFM3N"3UQ;L(0SDXPHJ=<^(
MM/R":E,6Z1C0EPN01,*\$A:P(!'/G*Z4D].%9IL=1GL&4A8"([4@& D#2=BP
M@D0\<[K&%Z=?BI'Z%+@#\NH&OX?Q.6.4-\+7*(UY;?+*)U,)8_5D$FE/W[5"
M)))>:YIZZ338RS:$A*W*/8GX8W2CE(PN%-CL*-K3'ZH0%)G%H$B80<)2%23B
MF=$MKAB]T-9O#<LH@\U*:Y.]]6'N/-BJ17X_8[56,@Y> QH._"D>QXP*F<=^
M5;C[>(&'5"W5>G\>9$HQV>'I*+I=:RI&W='MAEYLU6(!)#Z3T2<873!ZM8OE
M=:?X8GG![X+?+X7?CWFQ=TAT^+5NR+6F4[=EH^A.+5QQ^2YFYHMG3V*';>59
M3EB3.__$_F3PH^C<AD+[**F:RMC103"A8$*NF;!L'3$,E;DCAN!%P8M<\^(Q
M+\1B=%4-AX-IIL;85^1,'$@=_3]%+CQP/F]B=23%QK^7AHHD)-+1OS_Q0P]W
M>QT0$&4@YSZ\>8/H94:_I6\E6Y477W%[L*MIM/TK2QOJ$Z!U<!0H*O(^+*JX
M,-5:&]"Q].=+L)!BS^2J%Q#W]RMW""N^=D=O[GN(A[ZTL5=O//MQTVK@.:X?
MP=:-#H>%\9R5LL\81(!X/Z#7T3584R3 3\&Z7*[6([T$R/E_\PQB$=6R"!GV
M3-WH.SVGW[?Z#E'U@>4,B?L?J]9\0JQ+_E"Z0:%!1\Z[S56"L@#/L"WV_6\
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MVZ(4NZ'IYLZ?VM,$FM^A1!O2,F[G Q9V8D>%&^UP,K:A86G2F'(^\=5QQH:
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M CKL(.71]&UD4]+\D\71&>%8=MHY#CH(&,HP9\!,MS>#@LZ'IL 7D_/ %[N
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M'"$I0;BR,4P"T&C!?()=C;.V;[CH_D5HVJO5M%GDIM=.P/4\R_/H-8;M5D?
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MA=Y,;:K]N-'F,.);;?FJO3EHHL/:#E2=__">VD(Z[I,@=J+S>7%5'3!/[@L
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MWBO\LK \A._RW #I!GDIX#1@>YV;M(RS[!4]2]S62ZDFJ<U6A@FNHJ_+V)3
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M;793;/.M^=SP8Q5+;8H^F&6_^0&,)8(CLET+2]-930(,KR%&L<&"9_"!@=#
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M./TIN2)B]3N-851;C.KB3KUO?9#@ON:A#T[%KQ/ZX&)<D="P+8L^4% ?5!^
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MS(2ZA)_MXJ"(OQ/-=6UCZO%-LVN13X;U0DTR-O56054T[R2+6+-L8):TA92
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M/CB)S\MEYU+6*T]V%OH\GL\OP>;@APAU+M1YF6RN7H;/):'.H]CY"G<8+&-
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M%+X[9[HC,,O30/<]CL"8[F;6-EYC]^S,/S<$*FQ-"XG5PV[FT]_,K"JI)"1
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M"XA$P1:PR-@ [=/0Y#)?<A&9-F3ZLJA]=ZVD=:/)>Z\QS963*@D;#_9M@L7
M-@*+P%_DC2#ZF0)#M">F:%[,B#$\CXI>O)4U[\P\F3@!\OU[$M9W\HX0B].R
MFX7OY97X/>H3[05CSS1,W371Q@;3V'6 %]@,3&#V'29@<T;Q" \X@8=W'[=
M#_P'QP6B0W8-HTW-T(CF[)B!F<UYJ_PE=J_F9^X).!G^D>QE31,BAB]-Z[]
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MO8V<%$E0VKM["Q>M'XZ,C'.K)^+(Q(1!X#E$:])"2DK*&'FD601$7T 52%-
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MR9G!PC# !4)%/0YD'?R(9$14"&PA6GC[;CXYH -*@C!1'4[B<^F!_^"XIK\
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M/ L5QOP)\Z[N=9O G.]MKLNBDI739]ZLQ/I$U>+5!CQA[<JQ4;"X#AK$ X(
M]N#W_+W,2/5^U[/;]83YB')A4H,42- E0IOE>KE'%@_IR3%]6B+7EF30B[>
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M,))B3IO-J0!M*4!;7F6/"M"6 K2E0--X%7HK0%L*,GL+,OOY0%N6C8X42Z6
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M-*A&8,:8KV$.-K.-.8IEKZR=Z>C!<:C'+'F"O,#R/2H#P')#N97D\9D&+LG
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M22=O,,?'JFTQW;)V'KA<(4!.BK,R.<@@_8(<BS1A&4%8UO/$)!%A) X@8CC
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M[7N2(URCL'@G&L;3#QP[=) 3>:A)"J 449Y2Y&#>23%#SJ/,62I7:V $?QW
M6"E*=0[5L@*;=!WC:5:*S(B]FD^1&5%D1NS%\G:2&;%%"L1;*95? LQ61#W;
M1-'8!8$ES)=#,VM#DZ6>XK%+^&Y3O>="$Q#*2:25C!>:V"68<52BBA&WLOP&
M83^DQB5-RD2[*%[RA7K(Y0B#Z&94#3?%..&,&6"%*]$?G906;(MK\EH44MW
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M=W:2JX02_C#H.I[??[D ?JL-<#U4J)-*X9OLR+O80^^I$33N,G_VLHN@M!*
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M&,'4D6=Q+J/I($C%5D=0BOB"X]YYK1(I#:681YTKY['6,BZY\)7F,DJZ,HA
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M8!\9<#QGP7!^5%#.F0A&%9Q99$"*7&227<I^1,F\)="NG(A/X07"#T7("I1
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M^[EXXL ^*)Y8+U?KR M/3H!U_;*U[E>O'&4Y*++LQX-@4[5.N=UI[(1-G;2
M39WL(YNRV'1I!T,F]3*$NPL>=LV[YDHEKJ1=]1,XQBN8UPN;)]F\L;%*781+
M^2/SQ@/3%^O-<CNN+Z9QR$(3VT(32] ]#RMOQ_4D8ZL@6PM?D7GAQ>/'R/2(
M$&@C381<\#\</RL^_VR*PX!L[>3C2E_6BT_C8VR'ZF62UI>C,"7(D)=8^T>U
MTBQ7Y0TIX17IP#%G7I%BZ[?9^ANE,[4"GQP>0J-1[L3.H%I9XE,'9]?F)96Q
M/OEV3SW!CL5Q3>G_/N[F\-KEY@;1G\VHZ%G.Z.6);$)'M%^W#]'=Q3CPI5JA
M(#"]"/(="^TPC&V(LK;8KP8HVJ;,=;"<<<:3>3GXN0H*Z$5IU%3-%N*8BGIV
MAE '^F2AI%Y3DD/L52*K5_8##_F/:\(?6 NDPB(H@*B!':%X(3:FS2S-6-CZ
MC/??C!<EQ5\ID0S--:TK-\I3J-)9O0W3^U$(5FU(YJJ,<"/2%104E>3(IYTI
M"J]:N1ZJ=X(N8#ENLA5>@Z<B\QX%SG3J,8)KB%,.H3/ \P2O&[6E7R9:WMG'
MX_UA,?<(>Q1B78I!. \RSYA7L*NU)-0C,:+L*+>?<OZ_4T8)3/ ?C6:YPGL]
MB[7Q?*9PLF&3/+4JGM9NSD13MG#Z6.,8+TA,GT(FPNT!7I3M]8.WNBC$S)(7
M F.(?][=_'GWM=NG,_]'K98@#*S#D!D\J82?<GJ;^H/J.?Q!]<(?M%?^H/UU
M6_.H76\XNB5TK/Y_KOM7HTU\U6_F[FD6[IY#<?><-$_*K9B_IU$^*1P^A</G
M9_0Z]!RNS_*:,L7G4ZLDW WU<JUP^>S8Y?,_^FS^\9SWU/#B+K<./!/;_]I)
MN5X<P&X/8/293J";?@*=*"S 3Z!9G,"N3Z [PP*3OZ,"'30V37<F&Z5)N WL
MGF3?FQQMT>,]L,*C.NF4&W'7:+7Q\_E&=VXH9^;K'I2/J=Y(\XI.8G(OU:L4
M.4#"9G7F=UZ!';&)$(PM#O.@MEC@[2Y-K,Y.=K]^0;?)JWO*#\^?DJ2)I#A.
M4$7HVDLXXJJ=5M+A@OU6@7'Y"P&V1'YKV^-<3@[OLHES;U,_8=X-H)ZL5KUA
MU%T">: GG-Y(M\?4UB.&.(8(_)8R5(/3N&T+9#)" 2*\)F"W4U"SG0A*2)25
M86MK*K'R0G"@3R9'+?S,&Y&+;FXQ: ;AZ/<D1$A:SV)JX( @&R&L,?D/#>F7
MXFGJJ;[7A,NS5F[N8J,;R8W^,C@^@RU1=OJ'N)D_,@-?4MU2>?ASKTOZ#> 1
MI207 !G^(EQ H4H<DIC"9N#?!7V^+GVJ42Q]:\4VE9#3%KW^H%YA-XY.8RN5
M)4U+HFO5BI-P=6$@K_2"=6D;+R\2=LH1"@6.(HRU2KD6^A.5R[O<WI3Z$'D:
M;P;%2\)?+C1S4H1FBM#,SD,S44UNV,BAI%T,_GTW@'_\0>&:7O=ZP*NN1L.[
MFYZ"./-F@9N]L:D/UECJZ1[O[SS!/U"O>033F3)_$$F,+2M$Y98V%DQ1S^P9
MI]:T+@U020QPSB;B]]72&MRQ(NU@9R?_NPI ESBC6KD:GA'U[O8Y?4RQLIQ<
M)0JZC]0--H&6*Q^X\RXN6POJVYKZ!K;V6V MN)7VQ"&'+$8:UK)M).QX)#1@
M'U7A+!A+S[!H%T*]%(CN0L371]VT>"(A4B\,]@"L+I4&"\2:$+'F9">(-8U:
M@5CS8R+6O"EVS$V_AVW'SOM?^Q?#Z\L=](EZ'>#&;@]4Z9'2&O!\\+4_NAW<
M;@K=^((]0C9;P9>[R^Z5-KB\O+L:7@P__Z&=#8:CWJ!_U7N%!3R?K0VYP.&B
MHR;UU'621[<LB?QF>E[ #.%$]SU?Y^!N! ?C15*JI.GHYGDD30JF8!FA\_S8
MPYZ!H%AA9Y$'&U9_OQ!8>PL0;I/ $^CJ!+S()R32ZU'TA3GYY$PA1&Y,XIT%
ML-09'+#$HD-7E5<6T_D508)U 4!8TJ;,^EMW?7VFCTL\?]DWCWOG]3;]-7:,
M10F1Z"*D.-XZ0S8Q,(2RAP U."Q/MC=@<:(=1U>,<GPI)W3#_A+>UW?=RYOW
M)>U:M *Z!,T03AFA%*_8'"0VK.]AH;V[OKQZ3[L\P*4YF 0>("5TXX\-[KM7
M[\O:IVA!! 2./8% .AO:&4H9J0C<TD8NP-) 6-'(>3<\/^?J+![PI_,N+4_!
M00_SRF$P7_KX8(+T8UB.:/VNO!9'3/N1W-[HI-QP8^#Y;Z9ALX7H'63IU&UZ
M8LYYQP9* $]7B;#/N.P.A:96<,]?B"$A<\XL"7L^#DS+D'!]^ M0>KE#DPB(
M2/$0T!OO*,^>=C?L!$)]S]5@&ESJN6X:_&HBO":AD(=[MF2/+BF4.F]+)AMJ
M()#_'/Y_,%_NY?X&#MP-M^H?)\U*,H")-3)13[(EV'\52A4;L<#/F.<[-N[G
M8A;K'O)F%*#M\9:#21U:('&B7&.2\,C3A(!?0R:;& 'K/B(05A ;8U-PLL"3
MOF;U>=%AC8(2-+"HC,)_N08A*J,@>?L#W4.,NNZHI]TZ<QB]76F6M#.YZ[UH
MU_<!LHY?5SQ.%D(,A_$8RE$Q.=XQ5>B!_C+#SWW1P0G4EKF B9UB;SV4\;PE
MH=!X5&HB(-D#$! *I+0,M)+^(T.\,05(R1&(I&44S\(&*-B1X6\=F. 8?O7/
M+X.S6K6B:$Y-_:8:RG9%;<)[IET_8-"PRG,FE'Y>L:Z0LKV'D=0[=,W%$BQ"
M W<D%G&:HO>)L,=#B91 ]@Z[6R5UAY(&8_*B9-B?/;R$5[!/&FCJW6CV^W#I
M!.8Y(F-CI)]RQ2@ I$L0>XYS3OC8,]&+B$C)X)HA(3UCPLY;]X;<S.X;=2_Z
MVO"3=GTS&-Y@+.BF_W70_UW[.KSK?>G?' 9/4""_ETP^S!64#>ZI2'5.=\R%
M=\MRU>N;KR7%6RXJ+F.:4S+6+6HP2[P&FP>!,1=J0;#W2#.F(5SHH0<=7H/3
M"XT)G2L)0OD29:_UI%(7S$63*JFS"O:-H\T#=X)<J$3%K>0G3:J_C61^"R4J
MH/X,,Q\XM@DL9BBP40DV7EC&\6':[?+)\C#Q+)A[+,B&;^2&BU2UA<!%UQZ=
M8/* [5GQ50(0?\554RX8#"9@6W,%(]:PSB1Q$!4< M.LE[1STY/^YX)IOKZ[
M3_5/:H,K[5_]/[3>\.*B>S:\Z=X.OO8UZN""WL O@^O#< !>]/_=OSP;:.\L
MAIW708-Z_^)G\1)7Y,XVD>A&2&K>)BM8BC-7V\E0'W[RPJM\VU#?1O-([%)M
M*=#7-SW=U$3[,C@#T4V#IQ8;F%H6>N,P4XPR3\YA(0$HU\Z<V<=@.C-+@YWG
MC4"1,PNR+"&@"3 5WY5]+<C004_E@NG< 21T;70Y2F*.G'243LH,93X,_V2R
MJ8TTG\,'8%$SIB,P^#2PM#%H!U.15LJ;S7:MOV%O9LS]U8MP+_)T82WH[KET
M!SI V.8%W;OZ9,+FTL,BM Z2\MBYD(FF.F<7W \L282T"#C/P5?J3PVDQ]M1
M<64K!'M7O;V9!" ;5FO7YW>?NJ+5+QG7&N;&XV"_Z7: _O%:D[249D$JKT J
ME_^?O6_O3AM)^OXJ?;+)^V3.P0H2B(LSFW.(33+L^I(%G-F9?_8(:$ ;(;&Z
MV/%\^K>J6P(!X@ZB!3W/LXX-NG1755=755?]RIC14&'51.@@N Y8M'C4$W1&
MIA?I'8,)2AACB,X.(IF!2[N!#[LDZAHC\!W3_B]K],6N>J'T!VJ/16EBI^+A
MH<L IHY#^(*]']NNT?T1MD7C!FKHA.";S>D$CF\>':DG!%LWOR/\CI3WX\O[
M(\@BND(3[<A/R%B_=WBUT_-(K3>"9<#W4R[Q->P[#QPU)F>AX%]V@,-3LSWL
M<<?.2]D:8MNHR=8,-G^&Y8)=3#V4\HD9J82K;M)_#:7!8,YCW$N.SGJB!TK%
MF(*@U((!<)W+2:3<& 15V*DZ4D/H8'0Q2,["G+]1P_*'719,B7I;-Z?G2K4!
M0YG"P>.N23Z[YJ0W=?0\+GNO+%[)GL:^_<8J,*-34P8%QZWYFFMT2'UD8H!&
M6E?I6O7,7/_M_EL4>*K?UR9-/;$AW8 ES($!#SR=1E;N:S-;YHP2\&"#A/5_
MA5WJHU.N\.'\1?Q1DL^I\CEQ_</[?W/ 6OFG$YZ6-SS7H)9D3:H.S@M/\^!+
M*.H&R:U7RX#?AS%/&5EV,X1E%67.#@UL&D;M!:7^</^M-KD:?YGX)IM:FI+#
M!_)+YO?$+V"C,9;?NL& M(P^]5^G_(MQN@7VV!!6)VRTLCWG8K)S6;9SOY"T
M91&/"1[;O]6;['#@@ G-Z9P&?*G?_5EKMFOWM<_9. )><'DQ<A+%6&)I(>LS
M1Q-#?E@>S%)",<"'/G#[JHOUQ9OF>VX5&3XY]Y]N,L+UZ:EOW$Z"X<>L)+YW
M/6-!_ICE ,V>1/ TG@+Y]MMC_>&/FQ;Y^A@=2?3ATK'I.I;Y5X"B,Z8#!S-]
MB W;L$6^=*_Z>  19ED7\W>DA]MU%W/',>B;8QF9%%Z+O<"?,>K'XL,CAT4]
M*!#Q*DST;MW5>2)P-!P^A!'ET99QF%5-[=[8,4&>9D]#)H<:YHB9"%&24?*+
M^""2[O&(TP%FL.2$$5K\/T"*/0S4].)O]Q3RV8BRV5D;<7Z&XN5"TO>BAJG,
MW>M$T2(V5B-\X-Q,0TB/;*R/"03W>YOE#KH>M?<]+3WABMEJI6@?"KB=/;;K
MTV4RI4+D=$Q+"GB:!3=@@>N3Y@(LQAX"$?4<)D,#$X1P]GDL#A0IXBO;P-%Y
MKZ,QF*4&!C--NV],BB9:][49R<1H(L[@A7)!1%6,,4H6Z??#4Z))V(J;U\9F
MONW);8O;1NOF\:'=>'BJWY)OS<>OS=H]+SUJM9]N&QFI.FK5OM;CF1./#[L-
M6XP$\7DS)-R.6E@69 Q@JV!)5Q@H'P>NAS#P@>LS^8^EFH'X_Q5@Y8R%F?F1
M,3+-*ITQ2^YO;W';B(7-6?BF$]/.!"T;$Q<=W((G\J;]3#U_4A#@PZ+#D?)"
M$_+B!!;&"^!2VHL046P&I,>2AJ?I5+CZ38;*%*;4LI4UQBR>R5J:1/6G940"
MU!BL3ZEEL"F=T'T)E0MP,1OY86HU!Q[39 +/7 H?F:0UF<L/IL/0',O,L5,H
MO/O6T\-7K*ZL?VNT0$^HU;AWR*%8'N_OZTV$:VG\R90BJ7UMUNOL^VQ8&?-J
M$'0>J"!,RS)&7@!6(-B'=&QZ4>[E1'OA@7N$L\2^X02:*V*Z6<!HJJ%Z9=^_
M1S5U>U.;?O0+(OA@&FN8=#K38NC&L(V>H<P8K,QOZU-W.184JN7/?SP^?F_\
MR1?7MR?\-?GA!'<GG-G"Y,$BQU-6(#,OY>$E:&HE3&U5R&T$-&7.]&KB=^0F
MADU493"/7T6C07+?(J(L2TIQ0'7C5A3VB<%Q.TQ%A%V4HLG,D'*3<H2M.1:J
MUQG:2$U[=IKV$#;:86KU'YNWM;.R.N,'-S/JML:* ==KV5E[A]>6=1G2I1$M
MTQRZ;F%!6?0^-<QA(S6/971@$&!B\L6T32X:2)@#PDH%POY?R_'V'/*E=O_M
MCR8X=8]1C8<:E?:'#^R;5ICOUP&ZNL'8!]<2;$\_#,;QZLO(P3694/MAB@':
MJQC# W<0Z_U#'%O$!# YO"'EHYBK[PBA!H@Z@<.ZI^Y?\10;;^:,S@ =Z[-3
MN)58!.%<H[(_CD<8#H*YX'S&"OD=;G61QR_8S^S')*JT. HGJE2?;!SPGG5D
MGPXEX^O\<Z/Q6<WK&5_:DR/"T)ED)3OS\C6-SJ@?-%*[:XW!(9N&9T)*L,)&
M[OV9@ZAG8JWUN,[)A.?E2,_L,7-A1*G/UL<&P< 7UA%P6@*)FF:)RQL.\1Q$
M3E//2N1F! T^&1JP 5"+@U*$27_T)ZH2C^\ESCC2KI,]!/<3M..2F*ZI3"XW
MD4-[0*T1$NS5[H%&3*%B^7!"4<R&XS:#VC8-7BU3-QKY9^.AWF[<P&\8Q+WB
M1<VSF@<>EH;V6'5X<+D9$)7#P+WI$N[M8O(FU,)R-:17RFMH<!@8N-;37;N%
M=>F/W^K<1<L&$%RS_KW^\%3/@++'@% ?W#[G)=[Z!C5NP(M@O&%T%,!B,"8K
M:_\O; /3F+BH<1DP=9M\0C+PDO)\0[HC=)D7C+ =PE_,CPUES;M>F$-&$.P+
M)25?V [!?OGG>N$P+3XK2JFJRS%=_)@*E</T5A!S3.5\8?MV#X5)NX<5'1LP
M'7N[?@U[Z=!Y(S"Y60,'6IEIO[!Z8I->NS.7;42 75I6')0$"W8P[U<11@+:
MK,+_GIV&D?HBT,MBCXHLBD$R#=Z#.QZB[8 W3']B;3N>_"'+P//R?ME70JK3
MAB@+H:<>^V]I)Y0#MT'1]++1[1R9GAC5V(!DZZ>\CICIT"P5&<1V'<>C66&5
M ';P_](2P'U;-FQ$S+?D9HCA,4G0 Q'T71)!U^P"2^>_A@1"6@K?PA:WH?=^
MO;?-L(?\'%4X17GXIF,XQ#P$><;Q%8XX ]C.@B3X;YF'M$77%,FH:-NIB76$
MCI,G3PZ@0P]L%B93YNT\-;::9GQZ+(%"N/E5U FDZ#XSC>1]XQEOOU!7+G1M
M\_N7RI^8#"J<AC^GF_"[_?3/P=5,*@IXF9HYG#9)91KE:EZIKI36XRB-#77#
MX55 *E0MJ$KA>$0]W;SV7.GI61H'=E>%LS12F9^F*:I(AH9X]D0Z;% JHI@3
MJ<SWW1Z' %ERX2(4S9<9%,T=(SWG:TY7]5+4\D ,-23]G3ECIW(2!76AIJ6:
MRZO%8UJ7%TK78GZ-L2-MF@-2^[U>5JH+!]Y"ZXOS8X%23IT#.UAS:C4#MES;
MP58$X]GC.]89*07#;N,CT P9%6JN7*KN:O=M<R8LNE%XCLPMJ[M:C"?@[*8,
M3)=/*=F:E;RN:*M9)3F29KA>7:<3Q67'?AE,6;*L"KI2V=JTVCB12[+M2&S3
ME+Q 7%MC*D?5,[9CT^5,EE=E[:K,)KTO"W+S\C&&>!("ZVIYK 68]"\*>WWO
MFL5T 1'68K&TS@J3(?"3>JN53)Z49M0(+FHR9^4(,ER*6H*+2-1SB[YJ^IHS
M'#$UQKFQH72J5-HCF7FKP%>.KD$0G<1%[-&180=]^(6!G>:(Z[P:5@@7SR%)
MW5DPAQ#"1-I]"THB+^T^D1FDKCLT%E.+9]1"*>2+:Y:#I.H.,JRMV0.EP7'0
M4_?B#E%&R8)#LD M[Q">EYD/JS(?Y@VZPY8'[''4<!XEBAL20'R#2<L52_K!
M#_^S9NVF>726DAV<W]61/A)3,UL-F:*N.VF=9!HJ+94):CF]D%\7S!/T;#_5
M(_PT?)GU>BA%=9/IDLQ4]9"(Q9KI**@T_)U24=$%2FR1Z4B;IB,)PS7!BD&C
M@417%AE$\@YRM0\05 &(V',"1#K>#\@M[ J2V@CDBT1ZT89QH;T&=@[(L0_8
MOUH"QTK@6 D<>PH9E,"Q$CA67()*X%@)'"N!8R5P[,$&<+ZH0Q(X5D XM[3.
M7O,[G[UF[(0UH^>HA<))LL(S>UAZ7D>BF3OXU*KKY%4F9.Z2YKI&2<N32@D>
M*_S!C:IJBBZ2K2&>29$*'XIK2B4E>FPV_3B)'KNAD5(MZV(5Z4BG9TY#J6(5
MN9VY=9E3-57DBI^,TA6D6&!,@G.S:MZK15T"R)Z8!T4)('OF +)9-2GT7*&R
M#B-&F,Q7"1V[#0!F<=>H@L#(F.=6AJ'GBFM[%(B:7WZ.H+&:4I:@L:);4X6"
M4A0EWU^R;6.VY9620%S+;.:S1 \](HJ[5BFNVP%D"/2D+"J+E9=SWJ$Z6!!Z
MX9AG[)=*UY+(1#VW\%MAYP"'9,-!N[.>*,OAS$R]W<%#I<$W'W[1]350SM+<
M.VT04RQK_+RMDG)E77Z!I.I.R+>K]SUI9!P4"T33=X@S21X<E >5$V0<G/=Y
M=RJPH7RN"T@<$E3T$.3)@+&5T[2=,PP/0:,,V-%'6REBBL3^<*7I"D1FZ_.$
MT< GK>L[O:)-Q]'*%8O5S;(^!-&GV^6$"* =4W+M-@11%4 )9KIP42#M*&+!
MHPAJ,QW?OJ*HN^:09$R3BF^ II3LE16."U7(^<$W8+Y1OSCX0<S>W]^8.BU3
MK5RFM-\I%?5NM5/M=LO=*M6*O7*U3XW_J,7*F_A=X6Q>S)X_O&;;'7MC_+NH
M+;-ILY%U+*?[8YY$0.N/_!G%DE*LJG./&!GNP+091TH,H'9'2M[3GAF,EM!2
MU=814V/X8,W'VZ>;-FG6O]<?GNISC??F"9,X^9'Q\XK/MJSDU?*[CR.8'/^@
MQ#]8)$\2U7>@K/;NS=*QQJA<6$[EO:P$-;\9C6>+-XCI$2\8P?C@&3UB>*3O
M6);SXEW/4G_57)B\SUE=,"?+&'OT.OKEXQQ%V4T?PV>%V@(KFN=IC J ?_UQ
M826$$<?9A:+ 5Q\2/@>COU1._"JOJ%M^KA>27[+LCF6#*BFE8D6.*9-CTA6U
M4CK0F J5XMG2Z=S'="C>B2A/NE(N;_ON%,:TADYGEG.4'.38UKW1RV< K]X>
MNO30^.K[P'EJZAZ8Y E>SP7 DL=GO9:FJ9$N%2G>%YU\+>FR_HS,*NX3=438
M'R9<T)7"X7]_[;@?/FT, 9R:N&:'C"'Z%J/C[QLB<$DR)F<!2=+MU/* R=ZF
M!+Q,&DEE)Y6=.&24RDXP9;=ASFX&^M^\9?39N*G0Y1%HEP9!T;&*[=AT.9'D
M5?*J\[Y*+A-YE;Q*+A-YE;Q*+A-YE;Q*+A-YE;Q*A*OD,I%7R:OD,I%7R:OD
M,I%7R:OD,I%7R:M$N&K-,MGUB%[(3/K[P/+-L45)JVM1U_',7?'8(^(<IZ?-
M60$W;4 #\0%F]&)I3RB>-+N6; 7 )$7YPD0Y7SYXRS$IRE*43S!Y-9?7"^<J
MS)/[Q6NAEPJPAE[=%1W\>)P5!69D>T,U5<V7BBV_!L;NV HNE3F6"NJZCCMB
M],238I9E,=.U\CKD62EF4LSV-]=4V-0WPFP\M: E&5]GV'*U5#S9NC];G,S4
MM)+ 8)C'5U=IH!^J>7UW_$,1-=@EN8_OJT+Q3A3/41Z*RJOD53)W0%XEKY++
M1%XEKY++1%XEKQ+A*KE,Y%7RJGV72=9R,IN&2\FMZ5'#D\W2EU))*^:5HDC=
MN&6S]#D&Z47)()$95*P6U^522 :=,E"M579-L3[IJ4I&CWY575/4E>265-U!
MAJOE-4I&4G4'U5VLKLGRE53=Q:04F:CGMKL5UU%;S-WMW-B@[MQ2?5\VR.B6
MO$I>)8/ \BIYE5PF\BIYE5PF\BIYE0A7R64BKY)7R64BKY)7R64BKY)7G7Z9
M9"V/Z[/I>"8\VW!W!=6;7';&22A*0:1#H REH*0#*%75)(/$9E!I5U2HBV=0
M.N>KZIJL(C&/N3.:PE&2*5R'E^!*90THBJ3J+HI[G>DCJ;I3-HO V8;GMK<)
M9AM>*!?4=9!5,H%+7B6O$C6L=?H!RJOD5:>_2BX3>96\2BX3>96\2MBSQ)[Y
M?+K@QJ,_I&[DY!U^$+JB;3",CV/',WW3 >^06H9O/M./B YZI2DXB7FZ&1[%
M!R!V[!1[E!%1'H4N1%,$"Z=DZ"0GG:,VB98@,GNTHE@';1GB3TIA2J&TVWF?
M@^1%KF3/*$W7'>1+FNYR@K2Z^%S2=)>U+["<GMNNIJT##1)I6]O".,'1E,-1
M98(1]FB;M@Y)Q"\IFIZ!M.*VXQL6&;M.+^CZQ*7/U YHCMC43[N-S\5WB,U:
M>]B*6CAXTVX1O"<IP9<BP56]M"NHJ)1@@?AXN1*LYLJEZEG*\#;6_CDV6(.?
M!]]=SZ;-VO;F:'H:+Q6S?>M^MEEK9ENNK@LZIJV]I'2=CW2IN;RZME94RI>4
MKYWEJY+7=^W]+/MPG\"6DHVX92/N2VW$7="5BD"]G(]V*'2.;N)[3<D+Q#M1
M',3PP"8:2'1E$>1FS[.N38_$IB0N !%[3M"QZ.SV+E^T[8O.<E+G]Z*+>M>&
M1\/[C$TO;Y)IWJ6V3UWAK- OCDO\(24/\ VYA\N''JG;/=HC+3KVZ:A#75+(
MYW8Y;M^'IIJZREY@_VT>']^/#0<^*"@G9Y;DM>(&_L#Z*:^EYA:VA5#BNY1N
MA>/1+:,/R"RT7C*/WS=L H^V3,?V<H3^[()B(F/JHD@: ^HMV-<'V5R.J5)2
M(=N3;?JT]VO'_?"IY1L^W027, 4IS0X!F]3SB=-G%/S=<:V>).!V!&3):Y)H
MVQ'M'9.W34EW@022>DWJ-:G7,D>TX^BU#?/M]Z7/00.DR?1YR^AS,S3L 94$
M2A(@DD"<-:[.3@M(R#/Y^\#RS;%%2:MK4=?QS%UAQL4Z/LQ8_NEACP]32D$M
M%=1=4:-/<(J83B:U%.:L"G.Q(E[>K11F*<S;3[Z0T\K5<]7,EY[X45J;'WVY
MV1^'2[ ]BN9+Q9[?.L?VL HNE3FJN8I:7*?@Q,A3DX*6;4$KE2N[UJ-(09."
MMKG)5JP6%#T+@G8AM0.EXLG8<4&E Q=?-Y"YH@%-+2C5PV6>9ZUD(*MNX_N2
MHHK"-5'<Q<RFLR5/KFFXE-R:'C6\O0_ZSA?@M9PO2 1>H1E4K.X:B)<,2N>L
MI*AK<@V)O,]I9;&6T(9LR*BK6-3U-;ZBI.H.,(-E72E+JAY<>1<*ZUH]2KKN
MU#=@]7F$F'YN1O<W5=LY\TCRX9! FJ>"K3XSU_VSZ7@F/-MP=\V^O 2_XV32
MEGFG(Q7^Z&5MW9&)9-!)&505;-?,$(/2,6M4Z;:G:+*OZR4EB;J#CBGE92SD
M\%2MK&L;**FZ"SRDR$0]M\VM*M:1P85R05T34\V:QRY;*<M6RD?;=05K-IHA
M=RD=_DAO5FCVE':M5+IX_J1D"@@53CUS7T.V4CZ"_I<T/7CVG<@N<49I*ELI
MI[BK%04[)5S)!ME*>=4:*&?@Y/Y4?93YQ!>@WF6'ST.01WS?2LL5\_JN =5#
MT.A$;IE<'7)U;+(ZJF5]5S- K@ZY.LYZ=>BY0F5?$*$LKHYMG)^CK10Q;?7]
MFTZG*Q"B5!#O"L]R>@V<BG.T!KGEA(HVG02SG%8M;-9M6!!]*B572BZ'(\(*
MFXU:YTK)%8MU%RZY>JZX:8=W@24WR505R")-)3=SP];=0AB>*1#DR-!<R61<
M2<DCZ4B!X;L.023Q79SWA8)2W!4KZ@ D$N<(5"2=FP;C\TKIL'P_=_^?'6I^
M\ V8;Y1&"S^B<8T,=V#:T>2Q 3E>.+=_P> M8^S1Z^B7CSW3&UO&Z[5IL]>S
MFSZ&SPK)K"]F]C+*\:\_OI@]?WA=K2I%57_W9G+L&KZ8?POF_;O9+8)_#HL_
MKY83O\HK:N+G2Q^E*FI>/\RC-$4O5U8^*KGU>V%%Y_=9T5TBGX=I+KUP6;+D
MG"B+7-LYBWQZR'\"NTC#!4D>')^,J&$#>?O!M 589DD:2\P_&4U980,Q[:X5
M]*A'OCS=UV[KS?L<J=T^_5:_NR>&W2-_/C7_?/I>J^?("[QU2#JT:XPH2/]H
M1-VN:5C6*S&>#=-B6@^&A^W GY260GJ!"]QB?_>=P/6'Y'^!X?KP2J=/L/.R
MLL#&N65=U)0R*L%%$H=ZA"GK^(WA*L]/;S$ZL-P#?_DM"ZW+CF+^J_F->*)7
MY\HU8C]QS&;O[V],G9:I5BY3VN^4BGJWVJEVN^5NE6K%7KG:I\9_5%U]$]TU
M=*?::4"O.BXU?EP9?9CGM6&]&*\>ZJGX=@;[SQSYYRFWE#[]_L%$=J&)&RXU
MQJH>[3JNP7@+=@IU^7KZU1!J/&3HTO[?W_QM/:_*;SZUV=*!17$#+P01]'[]
M8'Q*D@/V(UWS@GGHG//;V!=:5:E4BP<Q"DIEI9HO;6(4S&[+I4TL &9+'A1'
M9KUU>D][9C!:IB?4C0S4^Z>[=N/;79VT;N[JS<=6H[6%Q;K V=AW<W+3L9SN
MCP4I<<:A=!1+2K&JSCUB5LI4G=EFYFA /+<+S##-SA5H_V*^6LC_9U!2_CL>
MO"&&Y<<Y%LY5T_/CG[M(;2$/-S+)F-.?JV8Y,GY>\=O+S#C^B*HPE$'^P2(=
MWFSZ\-4DU)+V)!.TB>U?7U49 >/"MNBF]=E_'P_C(U4WT'UO/OV_OU4TK?3Q
M>%9,5=$WLK_XZKW"I7I=4$I(K:^6TS$LTOZC5?O<;$0)FP14M8NXR3WR5L\K
M&H$A6:"W<Z3O.B/RMJB7E$+T(9HR:*00WX%O\B5%G?NFF"..2Q#,XUV.C%T3
MQ!1F"%8/Q5O J@I?!9;2F/K,&,F1P.X;S[!=H KO#@W;IA;IO=I G*XW8SRA
MZ65,!HQ?P2NZ:$_!KUT0)L/$@< V;K.]!V8+ _A!?6^Y517S5 N1FELN9 >2
MI8V8**PT%>+25+_YT@ #N98D3R6E/"].6@'>F2A.&CBZE41Q@L]!FGHNV+@V
MZ;S.B4"/CIA<>/"Y2[W PD;<9!3U=IT.<$!MF'Z7 &N!0CX3K0<'3?#:"+\P
M<N2S:_QE6DS.(G&J*T\*B&L -YE4>#G*E%:*RU$#5VV?NL#Z!$$J)B@F,""G
MXC4G2>4%&0L54U'1-Q*E,>@/-#H)B@IWFO#10Y@+N&JTWP=QZ;ZB9G*-\0'E
MXMB;V/D(S/>G^WJST?XC25S*2G%>6M22OD3OJ'IER3;&A65A%]MTNX);P;/G
MP0"GW_>HSR3.GFR#,9$S4>P]IKE>'-?J3::GK'9]$X4L]7!KEORAM4'292Y2
M'D4V<I)*Y2IFJVX8V]PX0E%,,IU%\DS*,<^D*#V3S3P3J;OGC<;E+HBJ:DII
M07GGBO"QEJR^<UJU.KUE1H%7DMV0V4V?>18+(YI8"+OX+*C10U,!I(L9C_Q#
MV N<%\/N4B^'5L8+M2QNN"[Q:6;WA'"0HMN@Y^G+:!6E.B^7Y5)EB526P<V9
M]YJY3!:D,W/V^FVU,U,M++K%%4U?XLR4P2W.+XNR%*0S<Q8"L^#,3'>=MP5U
MZKA,@G)J=:J-9H-RNCIU?F;$I9SLS<SY(P,^H$AXX'_+][D$.=G4T"V_6>+1
M2-?E**Z+IK/L)-^GBR<\R<[+R4Y[[UOQ5<!/X3W#@I],]B=;8&ZR:G*D]OWQ
MH?[O'/EV5__:;-S")Y%!AQ+\I7;_[8]F;2.U5EJ^NZ4Q^09?L& 9$OIS3+L^
M+%%$68@1Y076-K#<]DV;KV!0^OB@>:,A7-5H2<8L5]('50!K&T,2Q E<?'((
MX<!L")"8X6S ?=8&C>+II ;"PV/LUBL8LZ0SZ>,0V21X4\2&%QS<&%[T3'L+
M(7W\@UDFH2)3R.^4=*AEPHSA2\,G_< /7!J*0>RQ(^,5+B1&#]:Y1S'IHM\'
MHL$[.FP_"X?290?)P"(O-DR9:+$@?:7\01(M2GF9:'&>B19)Z9V:##C*!(RP
M#6^M62>WC5:]UJH+EWH1.2TS9KA:F7=C\),5 =#*JM2,0E&7 ="(@C(W8Q,_
M$,.=2"YF#+6^-1Z:M3]K26Y@4EA4SR\]TRHL2\U0RDE>X-3)LZD?12!ST;$5
M!B4-EQU?K8U[)@4A=@LH),B1#!R@P##'KSECEB](3CP+H[IX'*I5EQZ>:Y4E
MD4LPS&?C36A@6X['+'(@#0A# *X*V! ]ED%-FH'GF4:8(LT=$V[]P\5Q.3)'
M8Z/+)L-<A)\@FSX:\V^+>E0(&8Y'(>WA=&[<J[ \)WS"U.SWP<0'OP>>Z W-
M\8A&\7?\+OG-X!8!Q6W2#5R7VMU7<+]0O =4RN[A93>,>K7^^<?-7:WY1\RW
M!8:^5?-:D@3R8 "R]2VVA)E< ,SCRG/^:5%R_@LZDP,#8[%=9V";?^$SUN;A
MYX@7=#SZOP#XB0L#?66C^[_ # .H<%F3&KZ18X+U5HNK8OANUFM>/K8$OYBY
MPOC0U54%\1F8+KQM=@)%A<C4@0S'W[;WN@LI)@\L-Y"KJS($I($L#>1C&<CZ
MXOEL$<S@^;.SZ)BDLG" $AG(A>T-Y"6';])V.*7=JU:TA(/6LKZ0+,)%HE35
MEH@$[.U5:?CN++SR&'A?BUBKY-=8Q%HA'SOV%<,D+L;/J(4TB;>QKDKRQ#HK
M%O,)3]":ADLQYX]IZ57'V-'&E2/_JMVU'O'(>H]2<@^6,:R.A?6*2V:RT.(+
MS.E@/A@-TX-</SH-3EK.^-(6'?MTU*'NFAIU<4[2I_KE@!1E!$U4GA&O.7,G
M[]ZJ]']3_:J0ADV^T(X+M[_R? &F)&^F>G-A!$R#XMD_LQ+ BO#1.,!'?JDQ
MRZ0'1DH8P>TY(*9=;CL,X&%JB;Q2P^7?.A8LTZV$E;UZK6K.@$@M)F> 6?,"
M?,1,W:2%SU)\9W(U+".P@6[) H+D9<3Z??J"T"Z8-W-YV@<W!L'TPU2^*TSU
MP$W0')BK"AXO-[M!/4QV0U5F-\CL!FGA75QVP^?&8ZMQWP"]G55<"36_*GNA
M6-FY?*LL@[,'",ZRUUV;/@RZF]V !I+O2V1H@JJFS*ZQ,4-U!(\:>@3C9+V8
M2U'(Y\*(!B:J@B'50_N&6>%H78YA6$[/FUK)^$T4^.5)J]/<TTG<A((]MA2
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M%#:TONG/ 1ZYSJMAP48?V9:./:W9>[P!XCZU^"$" UF>.3,QP(#@Q.9UZ#0
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M\%3OM;Q27?#)#F:."5+8O9^^%)1S!44['./VYMWI"/'N/,(IRW ]/&JXF+(
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ML3TV&0ZN>#,'87]F"QK\H!D[<';/+^@17OKLGJ\6(G-NB;>!EM%@X-(!/(B
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M(6-0F)4M]^23"]"1T@$E<[+DR$H7*2/.K$S87)FP63U$PB;H+YFP>=X)F^)
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M:8A"-C8\+^K4:HZB>O >>W)XM,TKP?$EX+WR@AI0 29]9CAMH=J<R*$799Z
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M*_;H*W:-0;'3Y$]L:BP$?,(5N19!;D=5=A@K/D\.04FMU.O2(U/R[3R=#D2
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M#BRG8UC$-OS G>04AO  CNTII,V25;N^XR)$@.&3$:L>!XZ9?>">[5NO"$$
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MP++FK1.9-VUX ^LLAL1BW<J8(HBUWISM (UM )_9P0);LC@JUKX4AO]CAAO
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M"A< Q]:>G1<:O+.&)^8=1ET)N4>!?<R7/29&BJ1G*?EHQO%!>TN'PV(%2U_
MK,]II*7G CELTGD-741LM8IQPSW7RWK96[U>U(VD[^:IV:P_M$FMU:JW-^IY
M6X#GSH"[J)4H@FRBS>=?7^$G1XF 3I7 TETDJ0WRFT__[V\532M]/.56@.V8
M9^F61RJ]90"Y$TF/B_A2_/F/DD_I\TG5RDIUPJ>X1C.Z7>Z6NJ P@4?@@^;
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MV'WXF9\__NGI9_UBW4,]?+;[_-FC^_A0EU]J8^DW!U4 ;L\Z+#5AV@RZM&Z
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M^/?0TD"(=KH26$A_VQ\:B4Q6:.RQ):%8A<M"Y*#DI_K,PBV69X9V;"R[N#:
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M?8?>.65>E>2#<@EB,V#P'CUX]"""EF*V!N9^X8UYPIKNZ>5-!&2>RX&5YDY
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M>-'X4E$>5>$1""V)JUMK-*/62D79=K1KR$9MC>#=&$&<3"78>U,U]T$7Y\,
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M>=Z:7L'QT&03""@BI#IN,8*,* G_6B0FQZA4_HZ9 .<#A\YNL*K6+<2NE[]
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M(W,\X'H)7.T?3!63^EQ8]%[?DDIT.!^>HD_QM!&9$5-]:S=8"%#,',?*DRH
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MM=JNA1M?"R9B:LZZEIB!.?E?5#,3DQ@T$",7I-0CVH]D+GJ+!>+XHKI0-X"
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M2.V5@_E,N;UE!\,T^ R61G6*\,91&9N59S_$'[, ZP06@A-.HSZ+OOY,AY[
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M,SVU%RI+I(U0N8!_EXF4*V]7)EB+Z,$\$^DXVR0N9$ZW8;VO=.@Q>F3W"#_
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M\SX LK9PU_=FVB[V4'%KN,QT_ERM@4@<V@-!\2(M6:2X%@X3[HP(<QB#7C?
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MUW^R_+9. G<!._W0_ME%)D+Z.WCX- @//Z->C>C2+=>M-OZR_Z^/[UEL+?#
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M,/S?1&0* _FFT%0Q46*3/PY;>":@B>"(%6*T@%K@=#*<NY1X1\,::R83MBH
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M;-!K]'^_7-]UAK^,JC7)%;.A[@,AC,DV#[L67VGDBO9>K4<EB0TZQ9?N?!*
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MJCI\?RI4"-TY7J ?_O+_4$L#!!0    ( .:#7ED32T; A2,  ')L 0 5
M8FEI8BTR,#(T,#DS,%]C86PN>&UL[7U9<QO)L>Z[?X7NG->;5NV+P_8)CC2:
MJXB9D4+2')\W1"U94I\! 9X&J,6__F8U08JK! +58$MVA*TAP28[EZ\JE\K*
M_.M_?CR>/WJ/_:I;+O[V _\S^^$1+M(R=XNW?_OA]S?/P/WPGW__TY_^^G\
M_OO'5[\\>KI,I\>X6#]ZTF-88W[TH5N_>[1^AX_^L>S_Z-Z'1R_G85V6_3'
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M'VX;NK8"XP.72;=/.376UXB^X%G)T.>"VF?O?^MF1@:71$[ $$T]F_40.;?
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MKT?'M<'I+,B0)5>.3+%VM2Z801"9 9?"8XD^YMRZ">A(K$QI%Q\1O3?2K1,
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M99-*YQT2/GLJ:4OKMOF\_A/#"O_^I_\/4$L#!!0    ( .:#7EDF1=^9:ND
M $F."@ 5    8FEI8BTR,#(T,#DS,%]D968N>&UL['U9=UO)D>9[_XJ:FM<)
M5^Z+3[OGJ%2+-:,JZ4BR/?V$DTNDA#8(J %0*OG73^0EP!4@+XB\( FI3]OF
M O%^&?'=S(C(6/[]?_]Q,OGN$\X7X]GT+]_S/['OO\-IFN7Q]/U?OO_;NU_
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M:#M516L(C%D@\\ASX8J1MK6Y>/GYQZ#K>\MS@%3<KJCERA)'(G%7,"(843,
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MUF,^F0MTRIH(!FO:28RIYJE)PHLA!I=2MJT[$?9#]N09,X "AFC>=3,.V/F
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M#T$/$%K8C"TRJXS1$&SBH.H S%!D F^CKMVZ(I;6#9D/I_P[ DP'T?T.\AU
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MMX::'&#DS.6]]VV8G+T/JWDXJX(_SK#(4"_VT=-VRQR'(#(9I2KY) 5FM&G
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M'LG$JSW4('!1P#.64]):1=LZ[-4#UC%1IK46!MAOKKH%'\+\_3F%A8M>6AV
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MD5^RG84\;2.AYMD=O_YR\O+G#[^<G.>3E[_^_><WOUR'6U-4GAQ'@QA ,2W
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M/&*G;NP;C)W>P'8Q[;H^[&KF$VUY):,&(<B?599'B(+1;NJ8\?2^1#K>1I3
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M4'<)E&PETM93'ZYJ>]Y.SY>).U/Z2Y]?GR]PAO/%!TS3S^>3?V$^91RSULA
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MQC<5&Z?5[)_>UCG3@ZSHY.MTMIC\:_EI[W$VF>935XJ/B6D(/!5Z+TV!&%
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MU!^J@]U5'6[Y_D^M/02'MC /B7QZ4#P22MJ;H/!8QP5B";FU;G1#]@/?GPQ
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M*,$.8-#=1OD8/"X#Q\(L.*9R;7-&\!SS@(11(_>\8W>Q'N_\!DC/6S6&D/L
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M&BC[3/5LROC]L:T-)#^ 8U3KTN<%9[5?_$><?9LD.E3?E<>.@NHGS!__H]4
MG0YK&>@^IN4Z]C3(O(6"3 ^,W8/76,>M-V0X&F02E,T*HJSS,9SR4M,?)M<Z
M^'GXFKII+/K!*VH/4EO7RU0G9?']YB"YROZYOE'1SF6M0>=Z0\]3@=H4#!C+
M'#FS19EN+9>>?,SX'N#^Z)L.(OO66;CWD=WT#UL-;M<,.0H-)O)2RXD8Q%(2
M6/19,2TL,W(KQ;C_I+]THP$# W5]OT%',LN7(WKNXW[U[>WDQ72^N+Y54<(Q
MF;4AB=1R)-+K>@''(96@DF>&H]6#>H3=L8ZO>_MR& ?B;X#;S77X3F4QWD4A
MP+OZ/L@Z;2GY  F3I+?#FNQ:SZ19AV4_*6##LSD=@(JA[9G[[]%)2A=?+\["
M O/?9M/Y_-?S&8:SR;_H6Q+T3UBF,W*>_SQ%26OWU@$/=>.6Z"%RQ@%S#EH:
M5HKMUFVV$: CUZF]<=>Z;?GV:WA#W]VL@3N7-/<2DD]8K;]<*[H4:-KK&7/2
M&-ZM4KT1H+_T;QCN!LBM?TQ IX+9@#$C2:&V\B?C$9Q1$:QS"I-.4:O6U;&/
MX3AR-6I&P=HD^Q&"?D^$U3[AGXN+<'9/>[>/!W9YU&"APM[K;!1%?*19QXU-
M'QA&9K0 8R393F99?UG;\2MA?(XH1!ZA[56S&.&-0_/(4^8_?;_UW67(0KEL
M&+UZY,G4AB*>)!$"G=TR"<FB<ES>G_?3,&C:#>-8T<-F>K(^#WL 4@XE<OA3
M.*.W&S]^05R\J7][U?M(I\2MTW0Z6U:]YDB+B49#\3+($*40OG4.W3HL^T_/
M'D(![O>+:D'$$&W$'L&U:J?0 =E0#>?6HMI3I[DF['50B1U$/ZYR).\,FE2@
M:$D(8_;@$<F@\YD,?XS)ZC'VCWUVE1M9)_I(? !=>+?X@K.WT_-T>?]^.:Y^
M%:316O% &R.2*0]*6@'1\ PF8N1"1"9T:[?J"3A[:#S7B+7I,"(?X )Z7319
MA<AKRR52]DS+10S@!6&SY"=*#"7$U-IP/[",I%&MBA8T#-"UHFGPL,M:_DI/
M6J.-311DR*R/;=@]]/2D'+CE1B'(@K0WYV0@B*A!&JX5!A3(6J?['KZF;IF>
M=#"*VH?4UN&\CXM9K?2:I)ORKY4=8)6+3-+!+URI^3&6T>E1F]?'P@0+:%/I
MEH*R_AG///FD%W'3]E)OG97T"*PZSK!,SR;34Z%B<$8*0&;JQ$)3(#@R/'-(
M+ 23N9)Z6W6X?LI!=';>[1*PK2374MPX3O$29Y-OY%U\PS;]7)[\O"81A^Z(
M&X45;AXXO^[@=Z,JRFHID5L(>=D,J" $E HL0\9D\:R(UK<63P+:V0U;?>+\
MUF,>\T9_^G[S%UY,SY>QO;IU_O3][Y@_T^[Z$N>3S^?AQBTAOS0SFVJ;;%73
M!Z("QVN%7DF,-K^@7&K=^F:XU8P5K&BG?0\\O<-@>M]QC?EL<<O#O@PP_X*+
M+]-\LX<__"EB'1FYM"==88I$G< 7B60-. :1)0LRQVBR4,'93I$U G)+I>F[
M&W7>%>.^;BX.1<6F>Z"ZH<5><:_#=662=D'6YTIC@S(^C6;<BXEQ69T.2LFX
M2A-M*98S UI[.CV2HW-$&@=):\,P9%%XIU9:!Z@L:^X&#E57^C#1_"H@?)U?
MG'_^:3(E$W]R%F8GGV>X/%NO7%-9C%(^%6!)D[N;1 1?NU+&I+,)B)A-M\'0
MFYXTGA?8FI+I4/)LZ.K7-5^6NJ3+218.C;<1->CH RB!",ZS!(+7/AS,!(+3
MX/6__<R_#)'=J6@874E7&$Y/SLZN\$QP=<O5!5,'DV).SOOGZ;=_7SWK4E56
MW]VHRE-8QC<HMF=G.I!H&V[[3V+#8*43W("1=0IJYAR\\@B):^ZDC_2#I]R9
MPZ7["9-@6+;[2'0(EG_^]<-I]EIJ08>,]HS.'#J P+/, "5+2G#T*CX51>_-
M*CUSO-.\G?3OT]E7= V/ZVL,+_[^BC 8YI7S@,YF4(6,$6=CI$5DKJ7"Z.-3
MZ3"]Z:-G'@-]?44WQ-OW_[W_[90+[@57&FS1OK8ELY<=SZR)WCJ7U=,]BWO3
M1\\\!OKZBFX(R^C%R4LZ$3QZ&1"8(SU2V7B(D4G@R5B3,L80GFH#V?_M.WEY
M#/3U%=T )5NOS]/T*WY<A,72 ;N35+F<P)%# +[<UX.LHY=4)*0IZI1L\,W#
M$4_ ^<LS&H2X\71J-0^X [C!6I$_ 6Q?7<@;T=A-/7;@8)!.Y$^!#"(;(4,]
MV+*J?48X..0)6*)WPR63M&C=6W@/"K*Q__@^]*./Z ?0BUKRO$K[2<AKWR':
M'ED4=#Y*"Y$+#T5H*61QP876?<=N/7X?W<:;$7._^&Y+J0Z0ROZ.SE]:UOGG
MG__\G5X$O$(5<HC>Z0 ^)S*F?,$:11#@0BZJ!)V,;CUL[W$DQT1[ UD/TL7I
MD22EVDQCV=!@93%]P+.E&.9?)K]?IJ:2L1P3[7&YS@!5KCBHK:P(NHV29",C
MMN_JNPW2OZS5L>E>V[A@>R5]!-8JA;X#L(&,V+6@]F/ CL'L=$A:!MC<U@/T
MGJ6LZ=RE39?.72T51)MKB-S1CSDF*5MWCQY97S;8LP>E+GW8:)U44.<TE+/I
M'_,9?L/SB]6QS(NUR<H,VI$YKQBG_=59!<;;HA(6EN[/&%V32O#XYX]OV#22
M_K2MZ%H7"%Q#FJZL+;RTMJZK%[P7F2<&NI8EJR0L! (%-@K/M"5!W(]/;.)U
MS9..B^$6XAQ@@Z_X7A&^JZ5?@?+,L9"L(RAHR:3V GQB GCQR6L?7&H^/?I1
M(,]=!=I)>8 ZV\<.L ^3^7]?WL@0$.]IC1GKC">N$)PPF=12>\%#1I=:]Q!Z
M"L]?3L@PU#U4*]U.K6[+8?42=< VD+?Q%*[#<3BV8W&M>C2B8-!KDT<PHA!&
MVF#J+1X9R<H)"(9[8":FR-#:V'QJY_CJL85_,;QV])'\ %KQ:CI#VB9__C-]
M"60JK0!>'9C1YR*3"R!R;4J;BP?':@EMD0PSF<@8<F.U>!+0/CIQMN+N?H58
M,\$/<,F^MEE2G7%MN,CD1S,&2E1S##,YTR:YG IFJ5HWPC^T/G0':J$TH>RA
M*ID!FY)U0?:C=ZSKQ5[W[F3;B'[DCG7<*"=10I#.$$P1("P=-F9](8<PT1G\
MS)5BVXYU ^E$'XD/U;'NQ2.]TZ*6+BC.P4I=3T#G(23#(,?(A7$I>=;ZXGL=
MEL/J5=>'K\=ZU>TJ[ $,CY.49A>8WTQ"G)PMNY!?X7+6:&,C*;G+=:9Y'=0A
M5880;%!!,XZFM8.R#LO1*$$388_<NS)BX5J4""75&E$N:.]SM8!$.!>B"T7F
MUIE=SZ9WY:[[00.1#W!K>@_:0VT5F9-+Y"5PX6N&"S/@:0N#9(4KR".WO+5/
ML@G3L>K%;L(?(%_XH2=U.24ST&'%,)+[) D5"P)<"37Z&[Q-4DD66S<.>AS)
M7TYJ:[H>*I%MKT2K08@=< V;JO, TW[<TQ:\;52%'80^7"+.0WQ>8C:AFL1$
M&JAH:QZD\@32!Y>+$"FWSB,<5QDVN*5CZD(?60\2,KD$A/ED?H7Q)C2P&FF*
M(B_]<.]=!&60OF)<0>"!F\"MYK;U%7D'6'N+X^_(X8/(25L"!O!8R3C*URA7
M>08JV)AC 1\YJR,%+'TE(F@IM==:U6A18YUX!,:1Z,"N F[<]NE#C=8L=SRK
M<_99>C A54/($PBK"033Q211K!*=KB0VM'BY?N!?MN2.)#S4!+>S)JR2RCK
M:-@B[M:CQV_?LJ7P[].W@^2&>*57F:"8O= 6H; ZP-ZGNK,8!PPQ**$P:]ZI
M<'G?!#[1D*4M?WT$UIBW7TA27R^^7@%!R3CS=*@(CW6.#T?P@CM ,DH#"=]8
MWX*Y.P\=MZG:UF*?MI!9XVYIOX0_;P-Q)3LZU4$(4D<E$IT!=01M+BI'IQF+
MH9-3M8F\VP]]AN1M+;,A9G#0WWM73F:SNK#K 1#)9NF,)>>/$1[%R22G)7'0
MR6ED!8UK/M'^42!_&4N-R7JH07[G8-\-G#HZ@@S]</.3Y5 )DDG-"5]5'G>
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M8+*Z"#)W%^NPJPQ>90>18]+<96-5[*3PAS__):FX@01;O].THY79_"Q,$_[
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MF2$FN#^ L1:9W$&9"M>.)UFK5_3EKNMTO3=@2GA>K!=AC-WF/K+79T$[:F>
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M%?NX3E@ZF7Q;?/KPY\=__?5EA[$PO9_1A(BQV\H:\3!N@7@WGX?I\<KB:@'
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MGW[6*S:0EEHX'.+MY]49^>4DS.G ')1^^^"31B+A/KW*0Z3BLEQ*DHF#TB:
M\HIV',\#)&FX$($'A6]4W%X93Q=XU-D6*#'2^^\-@BLA4>R:Z;^"TI36:8$W
M*FYO6QZ!BMO'$ Z6BBN3PV "!TV@R5\-$@(=<.!S-BS$E+QXH^*V-86GJ+A]
M5#(:&;,+J%=$Q>VEHTZLS&T$/)KV<W+.R553L%)[\UH&(>0"P@O!5-""F5=
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M\LI#3!8CXP5RX!3D,24@N,S!!.,9%SYHWJD6O:.J;S]]W!.^D5H>4/0.,AV
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MDH0\F1[_.ET2ZL7R3S+OX^GD?S ?">N5=-X"<X7V4V?R91(_BZ14JJ7K=ZE
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M/"<[$H[<EU1 6L<PD2.2<NOA2)O1['J,W?OD-8G<D9.&*D".Y%.I6J3B;0F
M6? L:Q,THX=>XZC9JT;ZOGM*-1#O(>2I?KQS'\+BLGBI!.64%A$R1U4K:R-$
M$26($%*@K<MQWZFG[Q-AZ?TG[RLWU4*5LV8B;9Q_N(VF5NY?!6P=,#5,06W"
M,7X":E?];%3UCL(=2_%:>(JBI""[1MKU/,]DUUQ",4Y$'3CFTHDP?U *?R3I
M-(:^^\BT=4SR"T[I$"#7=9T_R9DGG5R!P"JUC,4$(5$,[:2FP%EZ;ZSK%$7<
M^>!Q4TUM1#UK)*?6>:;?JB<[_VFR^':^O,Y[2<Z+DI+"%E=G7U"DX"(WD%2P
MEKF0+>O&/W_@PY^[[G:5UP"E2+>]AHLK-O&G\IE^,"$'HO["$:<()UGAR<6L
M[$ZI# 0E32T,USFP2)IKS7GI!&S\('X4/[R%&@9(*=X!^5,X"\>X^#([/SY9
M_BN<GN.1]]F3OQG QCI1*Q$V'XR"Z)"[XGU$;)U4?!+42[61'<7?>N[02F@+
M3/]V//O^[YCRO[_[.\SSJL?6]/3BZ?S,+4.X^3F7-E#;65^I_O8G]TK:]$'9
M*%.S*@!Z3R=(+;BH78TO9R#>(,R]O_CQ.^O:C16L:VSOIOGS:9C>Z"/2F*DS
M!,1='(NOY!+_JS:IR'_2G_-)+:?ZLIRE__J+U'O5E4M[ADY% 0Q]H=U0(#CO
M*\=8Q\""K_V?.WD:79XV_BXRI-W<\DJ:"[MUI<=GG)?9_"Q,$_[ ]067RU/,
MD^GJ6VN4* JJF#EP4]N ,]I>@PT2LDJ8Z8QT=%!V,HG.CWS!=C&,V%L7?WRD
MHV1V@9<0/Y_7008+K*N[BH^B3!PY VLDHR#9N#I.-)'.=2RN&*G*DS<%71[T
M@@VAI8@;EGAT,%(*W*[BY%*"8I8AE,!H _.&0F0A(V3/E%;*179W(-966\./
M)[Y@@QA$Z W+.58@?P_S_\+EO8/,*V\QZ0@A4OBDHK'@>:JS4XS30G'%=+?R
MY8<__P5KO8% ^Y96K+]=_XB$_O____X?4$L#!!0    ( .:#7EFD,L/2H[X
M *+T   4    8FEI8BTR,#(T,#DS,%]G,2YJ<&?LO >XXU:9/^P[?6YR2260
M ,DPJ41,9,F6+0]IJI9LR[:*+=O @KIE-5N6+<FTI2^!77KHL 06"+"PE"3
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MR<AMPV4LF,PKW78$61ZAB?J45CT%DF8-7O+"F5S&VFVOJO7XAMSTNW)_:W.
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M;4C*G-![5;26M.I%?U$%NVQI+*@^>O/BN#R+.%<9KZ,M';B],:-:RFK2[ZY
M7D&+L82V8Z,$<S#!:<2\-X(& @XO>Z-Y9/HC>L73,4ABPRP'*+I).3"6@Q4"
MN#B1JF[;KG?Z7+?$-+P5*K6FO$"B,1<S4S->PAVQG\/-KIBT5=Z>E]BRI=BX
MZ_%$%UIUU#*PMUR"Z[:'8!:BP$0W6,7XS!:@R!K" ":8DL\@&&?D:;Y@^V0B
M(03ET*,!L2(0B.IT&SVKWS$C(\N'U6YG:[,XP&:P,,@3;*078P@3?$R.YK%A
M35NR+^6L.$/@W!7&3M%26@LR*<UQ"*@5&I6J03V$0WX@=?KDM+_*UA'),DS-
M;D$EH03)#7CEE&V<:,YM;#K2L1XLE/(8\WTVT92V7LJ@U:C$4W);['<)9Q[;
M?'V9!%Q85!5V86:E-1K$Z_,,:X]7HT' 8\K*K<#=23[6!P*RJ(4STF+1R3#F
M:'E6'T_5H577.]V1*KK526U9"8'U*)F#])9S6,VW-O65C57Q)=0?,G9OJFIE
MGQ38*4448T?O1S+!UM#.<!$6Y_BTUFWD!C0=N]QL.-+!&3KBP$<P7RT7T<K8
M;0#<.V(%W;,P=88%>;41JAD]GB0J6W664JV.Q')- _B^UQ86[$)7E2I 6BS5
MF<VG49_'Z2#)AU.Q+;,L"C0",N!PT9CSI2:JS_N&2#69/EF9,.,>:VBJYROU
M$@&1I?IPH<@.GGBH,RC*.*AK.N%*AX)A5NQ!>$N#Z!R*> U8K^+#7IQ X QM
MJEMVDVG"LASC $G/Z(@,S#H/@BZ+RGU\!1.-S(84#K'AJ 1B3J2V.E&U R]X
MF -9'4&!%F!;AK@2Z=D>C9<2!D\@M67+^BQ?C*;1P!M-^:52#@-LV,,$NK1B
M$7N$SQ=B3M)>93#(LI21J9P: %M1MC9SB$<%-1CH.6%3<=#N-VHHW5:J\RQ#
MI>Y,+(4@"Q@#'UUH,3;!(6A47PQC":OZ*5^UBDYOP4=^HQP/TG6]T!+L=*65
MYT:[2\6H"2!&M]NIE*PJ[$\P7L^G46.\D&/-MX1&G/DERJ/<S*FE 02[2N @
MBRFNFI.*E)M5H--:N]QK=H4ENURY<$HW)A60&]IU&.ZUV "_0RJ5P9WYHX0'
M(V8"MV8KSW1F?"U="99#^$-O:S-LMU&OM>+*G5*UVZUZ-EN.,9"3.CZ&30%.
MP$9YNSL>3H<J++;J]#SC\%5-A0">* 5>$8#=.$;,UBP1C3G EA6SKD$*G+=@
MN>.EE7%L8@TM,:(&'\ML'YM-]-E@M%"Q.EP/T"'08:\\,@32[.A3$#>:(-FJ
M7A>;V/[( !;2YX=5"%G0EC;@X>F\VF0]UW!GXXK. %T,BB-/ZP[HIL;/%&E6
M8PQQ7B]/,4B"0PMS$,92=;2W!'-'21?DT_IRFL^H%=^$YXMF$$Y NJDJQ52P
M&4XP4'A>ZGF<T^5QOX3!%=A,9KX?]71?ESO,H)?3PRY?%6;X$H1SW095&XDJ
M+D>-:I9<FXV4C.*4P \QT?:QZ3)0Y0K"]9VB/Q[-YSUS'K-VS^,Q+LB+NAM-
MBYV:O4P !O;F?6D"<$BK'[4;7&/DYW1QL&(AQ?8@."4%?U)$5^S8GHVA6,D6
MM<ZPGIKJ$*1W"-)*-#KQ)BVDGE:Y%FI/?*[HNA"0&RA#V,022Z0K&U(G#NI]
M,>^P;3D&*,,*3*[9=L,P"B9ZI8V7K*'9P$-+5I<U=EYN->U>AYA'?.1-!LBH
MM];II.D0#8D<5,=ANV+3K;8_DQIQ4&/#/$O+L4NTL"X--SD_["T[=C"HS(I5
M8]KI9W;)\P?#1L\(VG8B9)I3V]K$2XMHE:7I8FEP\C:W3ES#K)6-SP1\8O=@
ML5SJQH9FJ[#:G?5QJ]U5@,>S*]G.ISZ(IX:=@[(S*;DP0(.@VI]K$ZR+9T&N
M#?T($FJ^U>A3>1]B,Q'I.[EG6M'*K-A=KDW! :=H$\H0*I!2(>'68*7"@9XG
MI*5X=0C@D$9210-DQ!#=%CP"7KY:A8GNX"U>[ R$#ERT[$P8-K#:8*7$ Y@;
M =P&![P/]M<(.T%FRUT#+WE0!-4JH/J(;$\?P"L>H:IX#HHPNZ?7R]YH.&@&
M4D#5';DA]SFR.\=G-9M!5@/,[-.*Q/!N7J6YZ;3B!,9$E$,\LT%>6"[@9E,L
M>?U5S2P"F*C4>G%J=>0QWW>HE.?)R$B*UJ*N:S,/T982QR[-<=O.Z\C,0O&B
MHJF#+J+!SFBI5$$&C&E<3N"4XT=]-)Z0&3[HL?.JD#-*V1I;\&BU6I9^KYR$
M1NM/5Y;P.N0 Q I"#L%2(+Z-$&Y4JF5<&;8&P:+8K58&*51N@ 0/-U 4SZ$!
MWQ[8?2X) DU2J#EOT,52$]9:,3+UZ[.JU&F.)OT$"JI=D&5DPC<;%<";GBPU
M7$F1+"T-@Q()F*6C"9RG-K9$$QCW)I!9FZQ6JQ$FXJDEF_TQ,\]Z<M_*$:HT
M\FA#ZV]M1I+DCS0W6HTT4("N,@CO+%85RZH/2FQE!2DES!W8 =74I9IJ(VTY
M86IJO5RIJPS3M 90;\J7J@Z4K7IF!'0J#.$^5Y&K^ASNAXW*R.YQP0"[>VYJ
M3^_ \4BH<;5:JVP;=0M2=5<&>)RJ+T?\2@+6*RV*<;7;S#F\#M2?63&WI,.R
M F)@9G5QPJ^LY!H"*RT@RH91,IA6J^S*H*2#N?8J\-.T474&O6&$]U* D?!Q
MS70 C$*)"MWI6,EP!8W\*6=:8DV;>)6&'O3T/M3D7<G.!D(LR7&;*RW:,5]R
M_6JX,C%U$21= ?5*39 7G+3DT56+\-0(\D9%U&J7,3IOK0*JK[BVT 6&G>%>
MR8K2S!JNPYN5C85^C8602G,^Z".<[:JZ7[5;(+]L;0YF$H.3%3S4:U-MF'/U
M3MAV.$RW@W8+$Q>ZV]%*;62:E#*AJ#'-2B<1.7F1H6V*KNK8O*U'<)V($+Y#
M1K7U)QA2VTU5PQK:JUHQ5Y1&9-+SV-?1/N4J)7XB#7.TQ).<UV+,13#L</-
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M-F]"Y3JS]GIK)/(2QS>]9*HI3*#6.V+@R_EX5JR8$AH[C,L$?!.8_)_P!P$
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MOM_KM8K#H;%%\"X!&4#+A=Z$M1>3;+^ZR/^\0GXJXQ8)4]T_P0"\?3O( )Q
MQFLHOAQM69T9Z!%-3C(*O:D=9K-8-*JS-8Y0SWD^9<C%V8 RCAH;/K3K4RE7
MO2NM1W3U[IBZ?60O]7SKWB37+$UJJCB*6!: R\]=(<^E5]K&+/I2-!M+QYM,
MBK:M%IO6.G\Y^ :IV*2K>%W>#ASZP<D.%B\I''&MP9^D#CZ)J,BJ#>44RA'S
M\:)+#XO@SR1ZN8H+/Z>6P[_/PA=<VSQOBXWLK=;]XY;!*K'T*X9\DQ*AR(SL
M&ME(6+7GSE$ F.A_6EM+705XB_J7"/VDIFO^1=[>H0:^1^G-?0/J[F#-+;-^
M"V+%#8QY[Y8-&5J0<]0C$&GQ.8@SK)2Z):AT$>[=JH5:(X.U3ULCU4<]J^$9
MS:?:P0S 5!U$^8[>?CTJEP'02B7UQ#Y1*C)R>NQ;4N,26)XOF]Y.S=AV#T]K
MBANKK1]TMIXZ>%A3.^CZ>PI\L*(O7*O"556S8:MTY<F8WQ4[*6_CRHTGBI+"
M\9(O,GSA!NMWISF>YXZZJ5P%ZWQQ=E<H*5F)#SQR$2X7$)\$519U1VO="!"D
M $U3>DM?O?HJU'+4*7017@QI@"V(%RMN'^%EVQ"70>T, .\&.4[]T_60)Q(,
M0%IE/2?HMMYWX51";6V[W73/7;<J/<E(*R$^X7O(J>^RJFG*+-LEC4/9R0=V
MP'6:[!BA>#YM("E& EEUETTB[^U_EZ%E3FO2\)A"PFL07/<9@!\C._11.=8P
MZ4C Q4V>>TQ9E7& /COM(64!O4N*(U4OH6)DV3T@.^=D?I&_Z/5!J+XL+J1[
MW_HAN</YVZ\_%BVW$$NUV&J=P#QJ<-1"C=[7 &5C[O#%!AG8@RL3V>I6XF$>
M:1<*ZYI,RL[M-!"0W$7*-9HV(4V1_P1T7VO<ZF^R'"X=H3KZ\-4&PF*<>EW(
M'&P:3^S76) Y-M]G[7ZX;(5HWS0$"Y4IZ2._=FR'T+S9B'L8A27D>=E8JDQH
M49VR"?]^+YWW:C&UE2KUI6G+PL3F,,4\_M/:W-#Z\>VYC87L_(]W>ODE^X**
MA73<G>M_]-Q%7:WQ).EI2;FPY;OYAWLDT\]H>5(#%%\ZFZ_Q+&SQJ[1$5G[)
M^Y(P:M@H?A7S;&'0B:)L$?V;OM.BQP#X, "1K+@*5OW, A_R?81?Z<7P@IA<
M#47? *.[F&2KE]Q-D#N:?=V8UV?JW-R.*V#84 : @([,/S^0UM/G6>0YTABJ
MU5, XW::]'U8#P2? @>]<1WW@2F^;#8I:I_Z<AEC9J?54\337/A;6.5KS:!&
MHP1[4@" LW9\O87_.4\A[?<6?!&$A2C:Y&X_RIOK#%+ZB.$XB1PC\&"<!9Y/
M2DP?R&^Z2$DYOCN9%VXS6I/PPZIBK=P8<>O-D!JYD>".OX<'=K _?N$^ZNSF
M+@B:Y;O% "1\!"TH[@^F/,'40WO5*L-LQZ790^HO2"\ +=R8=2"4GDJ@7HKQ
M49#H^3(:2\4LHBX5BC>:ZO!0G)_]ERN4__W!NAJ>\'6JL%1S-'0KVL:,JY0;
M5N[?<J5ALCYC?X]K9J'<7^!,;HWL(*1DL?A0;S4@<,LO:"B\+- 4J>A@A:GO
MA'I.?&\&V4PA@F)I_A)0%[R]\/Z/S6!/'^1BMF& A^M0DZ'_CXP&39CEC& &
M-N1>:*/B-M;Y\3Y>\;:WS>&QS).TTIOZJ_5'I5F[%0[FZ:*87X^B%R<2DP,F
M%:V*?KB/LP1=5,E9"Z./$TIR9$=>3A_HN_PT^0H6A:WK'53P&O!W^<W7K.9E
MP.'E[N!5):7/H&IY&7B_,]4U<<2],@97*3"1K(?4,S!8)21/-92+U'IG/%3I
M\B$_M)-R>=6=NPD\\3)0PYP@)IBQKR'YKO_.OCS) YE[5S;2^T*Y3S\;TZ]#
M!NFGCI#96JQVV>J++\/%B4B16#AA"$W+:&E&KB"%Y%#@(>?GUXMJ"I%;5\;I
M6[*)1UG*?&/YMSWBRHM>$<@VS_G&E/_N20/%VT7[6_@^/XWL\)ANU"J1-[QO
M7?=P(C7+UWA<RGA(;;/HTN,\6HKE!JHZ:Q6SZ!M#R%%U !';/%?SFG:[)0^Y
MWE6ZDU*_,  M\^13X.$7_@EJ<>D'>@>ZPWHC%J8Z4*K<_TFG_RW&*2;?=2H9
M85%7706"SY<[A&K^X.L>2;IS2)6"/!@CA*_6, "N#  GD 4Z0K\9Z?$;661+
M&M)B +)R?S, \XX]V"<>F<7/@C!;*5/E?_/P6B#FX/TNX@8UQ2WQR.][,K59
MXG.%LUL0\;F*YS*V[!.?O$M7@B;L.\Q-W'-='X_[GQI\$S1.WQEW-1T[R''-
M&O>LSMC+->@1<HGP*/=.<LU!I=^L\17,2GZ,>;.,*3<0SS33L9[/Z,0C8W>:
M+GXV"GWM7>,>(P=UAE3!#UH'U;OH\E6X\/1L7_&A#J*7['P*A6MKI$F]&RK:
MA)^K))0BT^[^C+@ ?0S^%90\0Z2^E><YYDE;S-<9G-WVKL<H"U^;N"U;D1G:
M-1:AI[4V^MN'S#8RZN:5(&EHI\!:X/K;N>D0*2GGWZC);YA[.]UYI,%(<KK
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M*J@6LR/O0+E!Y1BC^A8[^V<T%V;>O5!;7A-[%;[:5_F>W:O-#5$0$LS\(<X
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M=O,)4OM:,6:X+=%@<U?Z'&Q5A?0NJWP506M _:1]P<&IO'H+>M%"5OMK73G
M\W&9M&L_>;<(_NE%=:XS6CS0F?FS6DHFE[4$2-'8X*W&L#HI?8^N\K'(X6>9
M+R)Q-O2@=:0"#];/5I$2DQQ[K$BT!G4>?IL3>WD!UO+A18LSC>B* Q7V2>'T
M",Q]>I]*M:0E'PD^/BP/6GJ"VQ8]=U?&1O=[]:T9O>2&2[W7NO\:NL/W&@8!
M/8=-3[?!ZO;"1!M^O717[A0(DG+)$.OGJIE,[C[2%(W*.?5U]P1; '*0%/L>
M/VE&J")N, !W-NABHWA[?]#?/P,Z6#) CL W1?LM+7#D A7^)B]&:@E=QK;
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MX,T6O;4F_4@?+^BPNQ@L!TVE.SW*R!F>R$=8].6XGO<55AL5&PO8@FAO^VH
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MIXC"-ZQ;[-=6ZXQ#4:9VZ+?5R\AMT/XKV+Z>P%)<8F,PC)H&HT:3+75"!+%
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M<J1)+4:*L'V3,^)*1G[D^SCP_3*H0DRW5>>8KQ?WF^3-V?:8BP)@2TOI@=<
M?M&) <1YJHYPCJS@O8FTX81AU<H479/"G>_;,,GUU <]BR_E/Q3@\@5B)$I$
M#TTF]PA5I'"*#"G<E^LT*?/1"'B V\01-5#5N)$H?3[%[5W<TFNALQJ8S;WM
M4\PP#\'U[(#]G;"P*QVN6*"0T8?PTY$4$!CV@#_!C%F^-+*2 J:&WK N'DF;
MU7"7)5:+Y'*4%;$\6+^'3%_DO-2Z^@TZH5&K9N1YL-N$Z,W?N'-;HGLEV7[H
MR:\MWOK^Z@.(.F+4C@>G3.46H;-Y>N%7)X 14*T6[H#V[I,^V<8OCVN_/O*^
M^N'HNPX_VOHR-]11K.48N1:R=*O3\7OQ,R\IR^IUC&X3@GH>/5^5-1'A$)$@
MSGD8JE8T#@*10O_($^E#>!N39AD ZA=Q9NF%3C-+KRC/07/H1>;-09A2YP/5
MD"EUIF$TT?<M_LC-[4BZSC\P,I&+)@;L/YZGQKDR  DPLCD;+8VY<^RPWH_V
ML-_H0":/N&_A"U&.J(7W\_LO>!$$A3G8>F;0,819])>-& #/GB,M1 ?J6) !
MF*ZB<56TB(3H#&M=) F:X66C%:5"Q;6'L<J\_MY9TH:CFX^3+DN<KKX $'T'
MB4?A'G&1I)QB82[9N@<=],LYE'88UP_X]C J/;!4U@C#673=A+IO7L^Z.O/7
MC3TJSQ*=C45Y1Q5OX,E">DE#80&X\@Y= 5YUQ<S:8WN_GO,"5\M"=>\P )T
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MU,[/!@=^!'^&HN>K,'"4BRQW7?H"[/R\:U*GWI3X(Y':&M:F:OFSV;ASO3V
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M:+!T@/C_,D[ "[/MJ&3>Y71DH7M&OMVI.N6K_J5]GP-VOWVOA2>N_&FCX7H
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M=P6?'ZI@-AQA2SS2G.PE55\>%R3W!TJH;+";QC6?]\3>>A<.#+WDQ!0!M:K
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MU+.RDH^0S[XS'6,CR.I-H><  MVU%"MD(+HK&8*(RA$"5_KX(Z8:W0&*Q>_
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M0DEXNA1BB3%QW,.[^NR?L0MP:0]%$Y.[LY_W?[/F3?QY\IJZX4O5UGM=]9"
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M?%/Y&-.Q#Y+23)I'%;9M_+<*[1[;/]V -V?[&B_.%&W!/]-C8LH_>CWY4GU
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M(9!3#M1BCD#2[G$9V):,QX%[H]DP;+\G)/3CH]8,84<)4H'O5T-RQ-K.0:=
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M-# Y,S!?9S$P+FIP9^R[!U13W;LG''J7WIL"BDH3I F1@+PT$1!$JA 5D$Y
M6M"04*1W$%!\!1$0E!+I2DGHB$B3WDE0E":)0CB2D$R\<^_,G?_]YGXSLV;6
M^N9;=V<])^7L?=;S[/V4WV^?$]H<;0W$=]74PA3$P,@ NDU_@6@_0">,/&%W
MO4!>('ICH"V"C$&,#'_:GR/CG\;,].?(PLS,Q,S*PLKZ3\+&P4X7-E96=BYV
M#LX_C?Z)FXN3^\^7/Q?YST,969B86#C96-DX_Z<;K0O$S\[4Q7B/B4$.Q,C/
MP,3/0.L#R=)U9/DG]1A _]P8&)F865C9Z&IPT3LT\]'59V*B*\U"UYA^-II^
M'L3,SR)P2MV(5=#V#IM<B)!&;$XIN_R5^FYANPF"PL6[]^,X.$5$Q<0E3I]1
M/'ONO*:6MH[N)3WCOTQ,S<PMKMZPO^G@Z.3LXN'I=<_;Q]<O-"P\(A(>]2#^
M44)B4G)*:F[>X_R"PB=/BUZ6E5>\JJQZ_::AL:FYI?7=^[:>WK[^@<$/0Q\_
M3TY-S\S.S2_@\.M?OFY\^[ZY1?SY:_^ = C\/OIC%P.(B>%?VO^C7?QTNQC_
MK ';'[L8&"/_=.!G9CFESBI@9,MV)T103B.67>A*3FE]-X?\13N"\-W[$YPB
M"IJXT\0_IOV39?]CAL7]+UGV7PS[KW8M@+B9&.B+Q\0/@H".*2]3SX+^'6'"
MKP+G.@>[&<@WJ:-'D;OGWE2TQM8)]M- BW'X(SR[6\''3]V=+[R09^;392K'
MBV:!:"(;E>,U61-@ZR]IVMN9\)6I-DCQ8LU_>"+^#=3MEMMP%/CNRJCNCW(E
MC'.9(;L4BT(V0]TZ*9F@EJ&UM[A("B5B4G!6IGNFXZ>(R;-:EOXZ#Z/!8Z^Z
MLJ,^,[1 U*?>_) /8>:>J:0(B:Z-92$UD6,\_H3&:U;&?<7BQ#.%>"M1BX([
M$EL:<TOE W.-P17CNG;PY59=J1CND8ND9F!U3389PT<HV;U!!OMB>#]34*_K
M"G'+L"O$)-(;YZV@=,*<^^O6),]<YG!G.8U3=S)+M'1ZH"V.?310*K1),9G*
M3%$Y+B[X(<L,3(=AQ8!<&JCOKJ2_U>67K3FJ'E#%L%;>#6N6MB]G6Y<^\ZJ;
MA&"%.FS788N5 U N,!=.-@;"!SY7 3CB99[A:2 Q?Z0>H:_-/B+E3N=Z0])(
M]_LB"V?',/T<>Y$EHW7L<1:"'[_'07$"?E7#G_7,+D1CWA-OHC73TH9-,V"U
MV,::<4O^V^"^E;KV1%/[S($8/;5%_WZL")B7K K,TC5FW7]FF>$RV1OYTR(T
MM/9RVIQA2][%Y9Y-H817Z0F>-H4A5*T!_PW9-!I(!*,]3 ,Q[P/&Q(OKCDF(
MM'>(T#77=ZJ:EQ\$6O]R:5H.E+<YZW/W3LBYY2<-OST.%[5(BKLL:[O>>,4N
M&TD*A/#%[RBQ'<=C:?/6+/C-I)6_@@\'F.%]TAF,S;0W<;8?.S>[1@/U="JN
M0?MX(% "6SJ%B2VEZ1C6W5KP4MT7[!NJ:;W9@!>C)-XKT/CPYH.%9!73 EB1
M;(_P^(PT !S72G8Y"*R#/:^)C)^/H*Q;$F9IK*_^(F7__N7BKI;#EPA5#$W,
M*+]B7W5O8*L41KZ%B #*JH$RA^,G$._+%_O=A0C(^M *MZVCV73K9P;OHP(B
MEDPJ_VII5'IC<-U2:2"S*\90\@T-M"N[AA:#QY.ZCHO!CJ7PN]1?U\;#5_F'
M:K=$9C()<PIMRA-_3>J*I8,?R17(*QM*S8Y">) L"/WCI^M$QQZ;3%2]8A^O
MY-8XO,RNDU"2TG'JI3MTP7]&YV+3S+;"^ ?YIN<Z3Y:LZDW'NY](C;,M0ABI
M&H ^*0$P>8'P(7#G22OU:7.%!DI_>NB5T.!@[GG=_$1F73J#_'TI@4OH/,A:
M#;;!N\M-9RTI&>7S7+_[,!@^0'>_!85(ESZ#4UBW;>U2?]A)OA1*Q3*_4@^W
MMSQ;T5$2R8UP$:$+L.'0'%:$LJL$S0EGS5EW@0G8R'3+4\W/X,]_-63K//^I
M?E=WR94Y7? ;E'!CCQ$^BX?LI+P&''$TT*,#:?\;>7UM0O6;1V[/QBZ:R50'
M*J3S,RB<5U*_')?[X#K;$^0"%(1AHPZ@&O,+.@F6W6T%.3RS_3".I6V^^:W9
MV4DW!8G4[.3&D5-##L'"(>_>LH$=:^$>I#? X$O* T))-W:!BX1J(-3(\KW
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M=B;*!@\-Y19;OP@RW?((/WVZ5V/YYS]R!5Z9.7]P!J;$ L_^8:;H][&7-$H
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M;1?MMFTZL+NC3PM4F:Y5VE5G0NJO:GI2;*2W>4.@B@+[/$T; \FUI-\\S<8
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M07;^0>-7OR]STH&_%<OZ5=MRT<,C2 JID0[X!4+_]A.X_>_V_[O]_[KV;[N
M-JBN7XYJM!E,2!MQZ[D>CBLQM+X$&?EQ'A-9?-$$4Y)[4<)77>#"B<I(]A]X
MYS/G#]W=!V(S)LRM\6>=ODG@Z^W^O#!;S*&/1W+VX=)$CS\'H8@'%_&2[U<3
MVI3>-\JH8J]<]M*.R :KBC!I%;_UK)@.!.]N^5JF _OT%"/=7N4CKO1(I7WB
M1\@L#%R7GT^4-#//Q<UI6!2&O(:@+VS/3U'+ZGR0PQ^JA3)I/2.0((HN/G?.
MF5_H]N7^V>B+O**=)1%ZCG;'>8?[S#6O(KX<@V\_=)T9A'/3CEE29$M(5UWQ
M#O'?)'^><GY?<*ZT6S*4_8C7[.503<MG<2)Q\IV]Z2]>W[YA:%03-^XS^6.-
MZ]%3<=%IYBJ3LMK2Q;SA17+1=RCI5'QP]:4TOP%+D;YBE+#Q8IEB;]/@B&]>
M^I<G=LV.=YD*Y0I.7W!9ATB] R[4XPNPCX88&U=L&M!%4>\057K[/&]UK71+
M:[F9#5E55[_;*3C7RE-8%U#B)1Y2K8.'\2S=)J&:*ZD_LK/&CS@Y_Q3(3+;3
MW*-J\\3D$R"8_(P)SD9ZVY0L,Y!)% ^O5O7-6504T^VDI;NO=Y[I9U*\&-T9
M"+ D _M*'+1??. ]L=J.%>*9=64:"NF+U1)S\D#&CI9U#E/"!U4.D\)QZRE+
M6RH"_1N]N=?.4&">CFDAX^\?';K[:"].D2CM_1,382E(9*.&^[$T4P-\:H6L
MFAW/46/7GG7>5[T7)1LPV%.=*!T&Y[A;V>W\GA2>GT831-D$9^A:WMTQG;_H
M&+5<)_N50W!0PXULXM?/,U!H/.G70P>.G BR;==EJ96M?> FLE_S',[__-'>
M=Q+:^O8C%VFL?BF9MUX<.U^UF-=;B?PP_W/$KW.ME7$%@CN5_C@K6:YG^,WF
MWA^2B?BE$NI;+K/-, +3)P8H_\+E@$GJF=,#NW[XBRT=X%?)H@[_5T2?:[M[
MI_Y_6GNAT72 8)*GWG&;^NE8Q:<*$RNPB5?:/(Y-JUC_7'/T!2'@_K2@D[!'
MQK=X8QDIQS;%F<JA2^*8:(?5<W1@Z[1?"*5+G@Z\BH7OQE3=A3U_V:Z40VN,
M/S)"&X*R_G 2/<3O6=N6A+JL7&]I8(DA,Z=HD>]3Y#5NUI$:/A]15Z7B/A9
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MHAP>VH@_:%4P*F?_6JG$-Z3UKH@'P3=O%L.I9X*J=VH8-[5V*R0]H ,/F-7
M*K\[Q)RE X]S:7Q^UY<[L#/W-"@NE&ZJ5+<:%T49Z?E+4",12S"$;BL98Y<-
MBW?7OHTZ#5D?QG^K316H*8^]OL#7>,YF#MB9EE_ $LR<1QAI7/$K"8Q!=&"*
MG>R$$+!23-JD Q*K.H]E4%(U2G.UFKTP1[:,1<.=4!*<M75X7DLY/.GVTR<K
M1U=<9I]D\HJ4RQ,])_<CKG>Y]'XY:WS86QXN]V#%-K=Y>>5T*$8]!G:DJSSW
M6/V\P?>!/#MU7?D.<9NU2%2O'I0.-)C@]0)N3U 8>Y2YIJ49T6SV&(>IJDM*
MXZ:C.F2NLEB!R]<\]BYR5(Q/GS"/O=]L;-0EO(]$!Z:= 4\)/8)XO:.*!8=9
M>9]UC,'@TV4MGQR>TY_,LH=KSW\[(&P:+?0N9L&$WX;"Q;QI15!L&.?!&X'6
MV=^[&1,AJ>R0;:\@S.K,H?ZHF!PJN<+FQ.(_=''D!Z.ULL+W))/2Z?/(HBX*
MY\5-59(KH3N_6NL]1:W;[]A$VVD+4H!JMQQ558[\Y N79+)/.<NM<X[CIU#>
MT>TO(&]VWM"! XB;V8;R"[A9 <MS+DF*#D\HS E:)WIU+,U\T])M!LW"24]*
MCRN_^=Q</H[U;K-+,PLK0G;XY#D[ZCF01J>=62DRI,$I.L!%0M5YJ^?BEZ3W
M7T,8W"]HB?M$>AY],T:7_4.4E@CKOC;>/:9J1U^Z:C$VP: 4/>I;90=\UXB
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MP*6#GH[#] @U<1]<LRQ4&<YUNKD/VI-"$Q]G"UJ:<5HTKS54^"!'&_&,873
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MB@$Q_ID\3$#A.9&C4<F$D/QF\7A964U%3&??ZNOF8]%?I<5NMNS-E7M_,2<
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M1P<'W*FN'12E UK8<O[(V8IRS\9SJA7WKE][$<C+4/1@-.QW#&]+;Y0'5^0
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M0@C&:S1%<E@0H?X("?F?P4%/YVH'SPQ<NU;\3$+FOD70=(E@H'D!4].^ ,L
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MX9^DF>%#$2Q!7$I,[5FBJ8>@+]&V>](_SQ]DDQ%:.\AJ.H,Y^>=Q!!.ZX$<
MZ;O00"W[&]%XTULGXRY&]KH8PC>/4E=QCM-?::#^QQ4?6A>?K=! 6!:L#WE;
MF5??AZ7.'(YKZ$<GC\D59*MGZN*51[F;/U^;[U=88<**.=TVOJD<^7R3A9/:
M$Y>DG-==B.5"=NQ7XG9\IGS2[J.)7.!G0;G7$=I-//;:P6]:3]!9-C=CT%A<
M:C5@<7X VOX6H('RFF096 UVEP^UA@8ZV#C?[#DK[^';@,(!RCE]+9!U^JNA
M43F*Q =IZR?*^]XG<@4YNRT^L$S7]'JZ+ISPR;A\9.2(XMHDJ_;2B6>\[R/H
M!?O ?]"];!KH3]*))-EB_% ;"D#K:D ?POM#2B+F31>,,&1!0%8-LV7*'KOM
M$/)QR QRBV3G[NFJ>VN64X^)!OJVGV+ $R5$F$&+V5SLE^102T[.+MI:C!_;
MFETYV7\>,!=6?SMH%4VPD-CAH_*A!B7T?@M(U\2?_C(PW/<AICJ-.?&-N4:P
MAXM\'-^AKW1#  >"93E]L\9> ^9(B07K_B'##>,L'ZD_UE1RY.]PKY782%U=
M417%_7%"E:<TF8F^K7D@Z1EA$C7Z5&=X-^>>R5#.^YU&]^YV>P16T.<SF@7A
M0?3^9H*JHX&&M[=0OAD)C>7?!]3.VG%V&S&K<6\L"O.LMW.*YQH07 5RAVYH
MTW<FDM,)^EL/^U50N'FDF.?N# VD3N (;XYP-!S0]0[-N:W7/UQ+U]:=>+^L
MWF73G7O8LKR4Y.]-Z!C ,7?6*__7T1R2?SN: XF\=_2M_QS#0T5+6*70)&J8
M\1L/DQH'06199%*<#5HBYK@Q*F!>45P25,#Y,*_ILD$KZVUZP3=CI?.DX%KV
MY%Z74!@-I+8PY%Q2NKQSJJ_Q@4-O:*)I_EK%<^>B[H'V'?X4 @:/3"&:3A97
M$780'/+^$WW5S/;53"2;Y+$5F#\BP,'31/-@6ZR-\74(44OQ8"9'+;5-2:.
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MIAL>8OH?+_A_RPL&AHO^(NI["B&26FO220TMP#3O4NX#(QP#F;JS_[@'XC:
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M\@]_%_^MZ%?3WKYK/2</#.2+)K*#Q66\+.M7\4*G,T]T?E%P]'_(\0?0!HY
M/O_C&@)*S^)/3DW!?J3V7$ ,#71_$+)ATA^#8KQ'%=B$5%] '5,+ BB.W_ZN
MYX-K#M3C=X []W 0BN^F,X77$?Z>8Q>0&OUYU'<* 4W]M@M,D6),6PBUB#!)
MO5DI\A&[409NJA9&-;N$;092$UX LMB:K?7_+UG\97HUY40&HM<@<Z@M[F*
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M8:WIDH+ IX4UB-3\6Q"/DQ/1>WIEX*'9B=--3>:N1H[0QEA^;L*L_P:LCVR
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MEE\6L=6"P\5SL;#G_5YD1Q'3-_Y79V[3.4")\%\! _F0YRX=(MUH:D)0[JI
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ML6?4676?_-^$?:"#>G6XZ6-Z>H;/!:/)],N+>$G)#\:*RCFFCI2EOWGC?!!
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M(BSOBN.4,#M>O[VU8>8_D+C#S@UJ^3_1A[]5>(X#1BOEVC9UUP2"$]I_Y3O
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MZ2>I*/\%.79U_4G C_-7^&MQ>=Q)QK4,^RJ$D3U2/8.2=($')CYX[R(LRA$
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MV:,A"4SM9<:;7UN>;B#?O+PM_;V+G%LW)9JX/EPEO47Y451E.1FY-.+V<6[
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M_U8C="X#9B0^S*>-PCZ_A%O[7CK.D,64<1[@6NVAU"2LWB^*-(EJ*X0M6[8
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MES]T.\]52N0>HY+ ?LF+QYC3*6 TJ@-2TQUMN8<*VPE8=#6@'A^SL@VLK4E
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MA27NVAO5A@-S Y3S2UW1#_3#U T1EA<#?]WU*GRY\?C]UL%L9+O_L-(*CJM
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MVZJ>/M W&8)IK,K3G?[Y_R0)#"R8^ ]02P,$%     @ YH->686/]FOZ) $
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MXSA?!=)#2GQ.+.P5   4/W1A:62^V/_C2$%Y=-"-DJSUAB<#.EW?2(][^]T
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M4@AR?,'Z 2JT4W/_TW1/O#>X>@UQ=MDC@!;S]6!0SL3Q*8>:XC\D(]V?B]N
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MK)Z;=^T0KY%7;G21]]CR^/F%:H=[E) Q8\7G6SSCN>IF[$!>"RX<E1*'D!0
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M\C_MBKUQ&<N#]I<P0S"PLK4O =>$S>>H)&;, 0XP0%HSU+:)@AE22O8T@G4
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MD(,EE#D\4#H,/=A_\1T<H#IQ]5&G:4#@/-L/'*G%_:4H^SF-Q-KR'@GMR>,
M>Q#$8R"3'<KF)GP.B4B>$0,788$D+?R78LL\,; 6,@_G #4BX.HV=B?\>&()
M2=W+OJ%F1KH" T(J"J*F_:4@^%H+[LKIM\;L3=D<X&,H/086(<@7'."!RN+N
MEZ\8&TC,!0[0%(SX2]&?1@A9>)<#K+($F)O!I_PB&E]AM3F1R-;:_S_+30G
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M2%BMY<5RUY4QR\'YW#(B!]#(]EX_YFI3RP$*Y69@O;CA.+1[9'Z@@-+XE):
M%(NVK,7S%LT*Z=@!OBJ74OM:2Q]-ABWRX@H;Q&+[-GKO3Y,0ONZ3!]98,"^_
MA=I/0]<9FWR-+4KSJUC/*^ZE(OK<%#,.M8N%N%YU&71*N]J92MS-PRA1]+>T
MH7JP-]=0F\@EC2F'Z6'08UH:!=6 VPEANRBDVK+V!L3V.E\U[A3O"[=G9UUG
M9RFQ9[BL48H?+:._4LKGPPCYI+H\. (5^M2!1+ ^*>1MU6[(QB7G%#G9QN6W
MWLZ0-]P7;0L_7E><$=R[R;QOYS'^I$^^2<H5<@1%^T^?UDK[/2V+ENSLRD/]
MGSN*RP5[2JCP0B[G2MYU%P[HSWHR)/0#=='<SH)'._6V9#T'>  N% *LL>$
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MJ]/7H-71)IY%W9^DKB.WOSPQ2^;DV.&88]*:XOW''WV(+)JH0]\"'%@&J+V
MUB1<!F#]9TYE!A>?TW7G,1\F[&I=)O/F'LC'?.>:2[C?/I/*9*H9(4P4(,0Z
M,E-'U.O"1LIO833EW8NQ,$!(A?J,G$X6/-2]^],)BGGSE'OQC6#&][DSB&W]
M(X2F@0B)X5QC&ODA[($483T*SC(-+6-. B:@<V;7/L^BX.*,)49'%8VW[VV0
MFTXY+J6N;;\'_LD_U*0\9(.&89<EFUI"!T?V1/(XZ!DC;2Z@3("^X G51?$Q
M0*J7@8L+'JZ3/QC;X8V,<P-[=^:N2\?U35=)C]>M/YZ$:N1?\YSHY0<T*5TQ
MOH92]&^M,BY1A>=,J[K,^X( FF_%R&'2#EN5@DUI5R%S%XH7YPM9ZK,8<;O)
MF$*6;NBZR<[*=]6FDT)L.;>U@M=-.YSO-WYHJQQ+-66FW3"^E&YY?G8^;6AU
M]$;8K2^PJBR:J&8+^2,/PL1\@/MIWKGV%;/-,)!"4S"-)R$\G=[;G4\;W[_S
M6J1EMY\SY7E(9J].%F.$2IB793FB3!FF\W"6]9Q,5FQM"M^LKF.5=\Y(PD+C
M?F)- /'U;OSS%]6-,1:DL^>+DSII9;LI'R2.(8Z%$BBQ;8@[^LDI9< *Y4OL
M,V<@W-;YV)&&H>_W_2X-: Q&UDO2=J=O*N3??-_UUOM+;!?. Q[$DT 4'A[N
MFAQI3MD C(M(JGM $]B:WJ7J+XU.BMSYM.N0W($+J16F1-:)'+]%4Z3!C']F
M[BU&+WO;:7]AU '.$ZX^]RV\JBM1@>'0C! TS@BGT'STXF>TQ] TN<7O4X,*
M%V:WB^Q(7-)..WXU>>H!%J\*:\9 #?GHU:W,\8V ^X0OK"U'_?[N7K,/0:_+
M:1<%IF['*YU!--MWG%"I:K</M*@OJZHEYX[=!&E?S]_/N?_.1)&=9:-H*.9U
M+/)OJ0@B-(5!9?T60<'D\)?\.&F^_W=*\>L5N%G+7^(BS= 8!*"JV"(0F>)@
ML"[LDL7(<BPW2^Q; .C.9_A7Y_]T,-#/Y$7E9X6^.@Z2G32D%'=#.!O\IB0I
MQ?;B9/U(%1;$S?AWGF'_>ZF&P_R!WTP=>@6(-R&F?B13P6__\RG5LB96V'>N
M$_XC[#/ICV1TS07D3:GW""#?UA:T!IW,UXM_+:7^$YEO!./@4V[_E?B&!T'T
M^-..@:SY $.,VU4!=J:%!\Y!=4)S>2F@<!GK/E]+4#9:+/EV@A2&5>_88<&M
MZ"N!>] .DQ!2ZA5+GC0="0!N$@YG@+8M:_$@;^&<06 1B$<L"X$"$<XZMA(9
MSX:!DC$+LY;-@WR&<6=A#''"+-A!*AAF[.+Z'Y?#_OO5<.H^S* R]PP/0H..
M"ZO2T?%P*DBM9SUYD'L8UA-,^VE0<%JS2WD0(JQ1W&&"(XYI!R7:(.C3]_(@
M*S8\R)UB'L0&NVK'@]3 0_?B6M; \CA0$Y1BN;8\R,(C'F2K!?<1?*F$!_%"
MTVT14=_!XFV+/(@=G%W(@XP=X^[.XOR&^6S-_<"9*" (?BWD*I&YCS&KICQ(
M0RS;1'/M-EA5+.<1J\4$#>TS95L0.*? KDCA08*A_P>9KOH'C,/HG66!XUT
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MA7'V>'XUEL6\YF*6%Q!K9ZS+GA3$LP4X[_Z-*]*X0H*']4>0AXAK6UC#4$%
MV6/ P63$T @W#KAU2XDAR$G&/92IQJUMFVZI/\K<[73-/OUM4*+DSI$>'29N
MWH+A;],?5,$_L4+;Q3*J*RPZS]9A7"^90(A%%"!%OO=?'L!];HQ4EDZF[CMI
M]<39/*E(36B[!(6Q'G49IAG09F#D[^>"W%N_\,T[B(9NK*^K,RJ/2=Z&-S+=
M\JRF=K$[1+%IP=D722K1P17W\C5P4K@*XZ@0^G2S/Q^2"(WW:T0(Z!G+# <9
M'6G*&"NZ]28O0:5QG4[RL=UF\5\5KI1.Y$\>X]PQAJ(L1YYQ)=E\G.??L9+
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MJ!J9,P;= =Z-T 9[C\T$L-P9$#/$"8I7:VQ-T,-H_3^];O,+CH&XH_.KT@<
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M*M198UJKH!./00 @ZSS2!/:QB"@XYM.\?E&&7-OTSSP6"\1? $TU+L5,:(%
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M;D4WJT^\W)F/8GW*@8P1P4SDD_FY6]$M( NF6V$W(8T5TYMS4F*"QX3#220
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MO^])!>7W_@O*3./$;P4=>Q[NWNN1N?):=&..N9.0=KO&JG/O.RS]- Y0\GM
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MFSY*!1T#7!*'L>Z'A/]1Y&(Z7C?>>O#U)EXA1&G]UQ9X:AG7=]==S*11083
MI^(Y;C8YV&S"V8Q7S<>!$A/*-(KJQ?I"?5&-'33KZG:>)BU9&,!F;/RFX1#X
M<<RXZ%';1!LC+CTF4F7_KT'S1R;QG]QR--\@X%746.@4C4/-==V%AHAJ8:&U
M/#77+>!&"=T<Z)YSZB(_'TM4-#DUSFHI-6YO26<')6_5>&>+;4_<O85#65SH
M%)BB$2!"$">,$1%<S:(KM>2!F&ZQ;%.^!^\/]\WG'H%'*Z7HMT;YNN7]8[.$
MFXSD$L_$ F'KFB4-HJ33T:+'6(05:&+2.\/(=;4>)1\'$"]7($09QDO&!M2O
M$^^<ZV,/7XY?0YI FC^;U.6TWO\4N>6,T\S3:[_*1\%$00*XS,1RM_.0M$II
M$=4Y1> >B54FQR)9\!RQOF0$PL>-1HW)>?MD2>=<'I5%MK6-?JPY/H1T>BN=
M!*E?6UL_^H<*&GXI$J8(7"40$\RVRB\/R6!C=<7OD_!:8E44Z5"Z5PMKZ%.,
M?,+RB[Q3!4[/2F\:/:XMDRS^U%D7*Q:<Q@#-ZGIA^94;)ZC1^'SH.F=EYJ+\
MF:Z?I!JA;JR;^$?_K;]6:A?/##X-<K,5[!WYW'H\><S&@%!>%5>EM%UT$RV!
M?AD941,LEEKH&$(4G(9E4M31BJ*JQH1.14,/7MN]Y<IM)(TKJH7Z["O7M<R9
MOHA=EC]RRT772GREU1<9O-,C15 U['D"N&T%TH_%866<?43Y[!%Y<./R<9ZX
M@6]JB1FZK#-OM%3GGLO#9GZXO:RV.'69[P4L+O1)6 %.; XT4FO@^X P3NIB
MP6^MW^T1"&)SA<]SHG^C\ZMWYMW<<*.MB32K-T?W3DIF>Z%X&+-+TMUS\#QL
M\R)M..;(.)&JAW)<]!A;)-XU\O+85G*Q87NN7L]&P6D<$8*&"[PPDU02;&&?
MP!P5QI'K]Z'??/N#K<FUX2PJ1;IJ/:_HOCCR$&W0TI[U^?//&)1%]:\_45N(
M/4UW*]Y6FDX9/ AWQ+8PN#0./(O:-ME#30^1%Q&%R8*#*$WVY>\ZB'PC@$2S
M'2>0MS[IBY[4(/$^TJ-*C^ONF7,@H8PWAEKHFN'O0*NQL=0IISYJZPID@<5;
M[F$HN1I-@7YL9 ]4-9)B#B:R4^HU.IJR \<?6N<TALKH!WER;D;6'#L0NG?*
MV+Y4J,23$ZH?Z*?JD5T 73X9K..1NL6;>%V98X-,6,88(]J,73_]<&DB1M!U
ME*Y)2M\87K1N4],EA3>O.SWD:!07B=URT<>HH@<42Y04OT+RLR4:VTSHI6Y$
M[__0RKA.W>CLPUOTR>Y)ZMBL(C/^1Z%^YH>\[K$\[LXE+[V/;BZ?'IHJX&-%
M5!CS(56%+ ^D,'T6(J($AZ/@BHNN6U#KL9IH'Y#(Q&YP[>2GK%,QO:FGHKVE
M_4CP1_*U.).B?6JF6K)7U*>$0:(*++.AXTNV<ZP 1LVE(I %(1# CO^0#LUQ
MW>4/GXFF>]^?Z31NZ,LLN5=Z-8>DHE9(F]$\%?Q2I[=-TFD/8;SHKE!)X(CB
M\ W!2=:/D3QXRPHDK=%9.]&D-S_HSF^LSM>R_?8OB"]BX+M2K"Q1$S%7"KSF
MF8;F&>60#+ZVJ(UB)0&WULE>W+0N#0K]8U6HO[D)/"V18-DT;!YVDU!W6Q9?
ML^FCKN?O8-^4%%W_N+7D4I*"[3&CRE.WUFZN,IR7S%@J[R1ALT07M50^$)Q&
M:8H5C G",V %\V]LG/ D$[M>:)BUR.JO;_ML3![C(KFM%]^Y/8[P7]1?@;P)
MS0N2R<-U7EB!A#-F.ODE8!10T<,@F7"56/?7,]A86CY5%DQYR9!_4,DYS.OU
MV^2CUO& W)6G6S$S^>ME_ZO04SF6$Q;M:"D.5J@:)%Y/$KBMR@,)@4H/1U4,
M8"%"55:#6;?&5?7L'+1N8KU7/-NX25G!0^*@;+UWF$2&WKRLW(F@CU;MG4^3
M2Q;X"4^(NL0[)4WX-5"9>&H+E&M*541K/\&,7'&U >1R'_*&,T4_;P\UAM"/
M3'C%*P\/]^1[["LIUPKUK/%_4^N-$%I^H,9105-\'[;P)'JKJ,N.<3U$!33A
M_,!EZV_*W\O#%&-A.7:S]A.S1$4_7X>VI;_/B;TL#;K46JZ;T1=ID50-9A"J
M'(ME/KZ$^3A)Y^<Y.UDM #%,D[&'E6%7[;3^M!-E[TAI%<S\O22C2,4P,7OW
M$$P[1858YD-L,W4 EB_>(?EX%&J$)</(P-B!]X4!3Z)@ZL;ON3^=M[/W<-DD
M<E>KQK'#98#WIS[K]).R>E>RZ9Y;]"T$I^NX#$"!/RIY/?7KG$T[CT$;*70D
M9;H:!X"T@/%0W,FF46.=N#NDI+8;3=9O%E5L]FW.+#:JA.WT:&HF=6$&H"HK
MD"C\=2CO."%'HNY\X$74UJ-/@+ #S6!0-4IB5(PY8(\[%U4_-7 Y->G<Y7,7
M)S;M4^Q);NOQ9[SV/=9WE%40POLB5*WG.&2Y.HD'X2I_1NBRV,V$EU;K4=2C
MP$ N.2(U?EL+VVLV]/68<3O.8%^KMW1-S4V<I8W.DU0B(Y+:C,#9,L =/CFP
MN "B:"O9NEXH/^ZLC*Q]UBSJLFH@YL]\N5LVM"2\I??:=.M0G&*)E'0:4LS0
M=P'+> /\DX!/D:N:\*+$5WL?[7>Z#.M5RC4_6E850.R-B4\XJ7O^?JCEUMQ7
M[G>K?8U4E"14!LM\D$15HEZ@7G-5!NTDCL,8+ 9^]>#5A6$.6>2(&O0A\+A^
M18R"9]V9CS/1@2'5R&K_@VN'U]8'Y9HH;:ZYMH2$-V.9=2N0IJ0";)S/= ^-
M-4##:47^<\]%6W.Z5/O$^CZJ 8/QU=\=RB/H'XU+'Z@A4NA>Z022D5Y#UDSK
M7Z7>%<C4N'C]28&O$ ,J PQ^+H#KL5*8$FX&'R )0TR85#3]OHA2'3?AX+OL
M@$Q)1"ATC=W=ZF_1:]W_Q'@PN>9\P18Y$][J'4;I19@YK#XL"@F9PLP%XGM6
M('+H[2 #RY)\%QSETQUH-U%KK9-:,$H_8S=;7QT85*82AL0[!;\B[*KQJ*O@
M(81J(WR*Z.$*)!0V'?,R1!8H*F0A"Z&M,-P?ZKH85^>V=^Q*1?W)O2_>AWU(
MC(G9TZ)P9DCCGL[N&EGCF%O]F];_X_!U13<EKG\GN"SQA'GD6,(WS7=H?Y"5
MRO&6==D1$,"]\&A\P:+4#+?+5F%G2H#\NN"+0[]4;[@B>5BALH"?#J8(-J$U
M>3[7,.:H SX@BZ? ;J1RX-(_;M5^Z,_$=)0V/#GC73M;K'/TN0\"TW08>/3[
MIO,CINO9#=X(YC)7GN<E5D@2F*'<V<M<6#WZU+L*UF)O -FF 55_J*EM(C;"
MGGZV(YWMM>YL.EO?@KYMR?>0U8[.W?(X I59 R.^$V5@SV%SJ<3>0+7 VLET
MM(WQW-VZ,S;K&I'WQQ3\/^W8IWQW/L=^G=/EHIA>H;I &]N]#[.Z+WW 50TS
M*V%9>)RKIG^@T)4WF9NPCZD$"8[6M.?'?]\TL^-,7U)2K.JLMWDQJ5Q[BP<G
M'9)OJ*TETA1$85Z+Y40D; 1,'S.X E%&UK6.H1-9TZW3!.XQV[83]CJZMT_2
M;$\\NR3CK)*FKPC!K&Z@G((AX#,,%GQ!B<70$Z:*.O] <\9^0%71ZS"&H)<_
M+ZLDZM'4&5B.[;+;Z-SKN>U,_T;I>+47-YF>JDYZC6L:?_!S5WUH-%9#L@3P
M:M0("W?^' !["8<(=5K&+LQ3>'+7)(.,5_^1U$:]4%S.YARE9(V-3=AGP4P/
M-A_^^07S#C(AJL*>I8+FFMP,P1X0R8\$10">B<'7H1QZ0S:_GPGAO>EH+:NT
M2[4Y02Q+7/*YH'I44?K$V["TC\AV?_>[:OM^?8<KP\+P,PBF%;>:LTA?S7==
M9"MEZ=ROZ[> >4%5R%) R*]CSTFXD^,-P\2VNK#D<S(T0V>9L%*Y[(UA2I_7
M7JR"VGM*IK>;J)GL(MC,P(PY4%7B$E-M^*FBZE8NE(W+<T]3]<&QK6A#95F&
M3RV(?2]2O.[T?4*:3)-;_5INBP;HU+V8:2SOV I$#[U!5.V<0@!-@C2Q&V$(
MQO3X,8#16[CC]=S</L*/P(SFR,"P,\X7^,Q#82E[(N]>,KG>-L_N0K &%BH
M/!NZD,]AI.%)B_WUL!S'@3Y3(HKL8>MM'&O;M?&U6&E+5'GTSE]'-IEL-U\8
MMRF]Y+>CGH-]#A>JN/>M0#; SBKEPIJIW ^ @P\PF2^V^K84I;\'@&?/^51X
M97N01A.^/DCFN#%D[C\[$1?.3C9"5CCER TYP'DG"'2HI ?##\7T\B2AFKL$
M4)0IVXF4^PTH/#^%"-J>Y?7]N;=T<-+1_OZ.J- E>6:6IW02+MGJ#F_M]].O
MH(=196Q\%EE.8L4AH*Q_]EP<K.DW?$IGY$S'Z9Q<S+!2+E$WZ^_1G3-JO!3
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M7E2JW<Y7,_Q+#,0VE^"*D.F(%.2KX:?;J]XV7%=TL_(<G]QJS"0/+.0!XJV
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M=O?*?]GC_^_X?QH2F[/_!U!+ P04    " #F@UY9N,2%&CDU 0"QN@$ %0
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M;X'-Y^>'C1:$+8:WAL/; 0%)0:GM^RR$I,]<%MX1*+/_;LK3C6J6U1VR9X=
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M>-\YR)-U&'NIA5/ MF<DTZV[\;&UW[R/U#(:NS%;+,*#B^:C+;3)Y&Y_3$!
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MDU*$?U0CM?>]]>7S_I40;(E: GX\C0<8YDLX_5NW]E9J<9I@DX?883 9R?.
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M >S<7[O1"OSNCL567DKPLS()&#$4O;[WC)+[_9R+'[Q"0@P/\>_<::NV82V
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MC$T3=E_F,5VOM<?CC5^-F-IO7-B%Q D$:4I'\_.V=3^AB- ^,Q-A+@LB=H
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M<( -T?!LK9H\H5;3ZL[ &[$AT_)K\;-C6(;0_N%ZD&!O]08Y,IH;\?: O5N
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MX5R)6\ENF6:ZSYP\A?)>*N7).H_@ ^L=+?@CXC4=KWK95]-M 4UB:0,F6)/
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MV.:TATJ.ZL[R6D730V[/NUG[AAG\S BUN,A52='>8LR<<EB2B,JTF$Z.B5?
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MATVUMF^3O4IXL:U /KZA4;NUJJ9R@FRN?X$+EP)*,@^QANB&'A [R,W1GAI
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M?&,C5K[0J:3W!.-=X?@>]+:9B[<-;MU>_>%@F_9LLL3N1KN<#8/)ZN@=&."
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M6$.5%XF-&F\W[8 E+,7?_L,U!4L&ZL1AGY4;@O^^? K?([O3BB;\R\NC^MN
MM_M%%A>07"67;_H;@3<0,/<=O7C:+._9XUC."N[[WTKJ+PSZ7'O!DX<0$(-=
M>I11#-6%E$/QI802!ALR?B<'1TF'0A@@![S50/<@%\^;M2Z]4_]$9/3E'W[[
M]*>I&C#W5QAG-*@<,LI'@])3C'+.W7-H9A;+/G8;X4OGXNE_Z8PXY NX(Q=T
M<=%XU@'8(1=M=P#'SOQL=ZY+/7[^O17HL% \389U]GDGF98Z<EL2%G&@K?GP
M'T5Y1 R1$@M,XS""0)\EG  ZQO*8*W]Q<08OCAK)B.*&X: DS5FD,'$$0"W.
M:W"W*W=WP=AG.?;K;Q#W5Y;L2N.4\1#78V"5^(+6L 9>PT#DF$WO0% X#Z'H
M)++4K&Z]/@J'&DDE3(APU96_+NV![1"8Z?O#+^$-$!F', OZ0D2V* ;65GA!
MV)E?!?=,-2R!0H\&9\T\: L9JVF [6R-I2/KQKC;_Z5+3H NL52$\Z"YP8PM
M5PIP=Z00L[;_;'=L,=6,_565LXO3OX"!U?;]'H9I,FTH!$M(=QG^)43[N^FM
MG,PP0"T8ED>B)E5R867[=8/7?W%QH2T6.7V2!-7 Q<+H_J+(3?(T"L\-3862
MQ<;'X:!;AO+];6WEU]8<-_WE@@A=3Q_.T$513V!SQ""1S?AID]ZY*"A5;&9I
MD6F,;V'R#Z-R.AK<7,[!\Y.YT>6POO1[:K;_'-L+0S Y2?20@E:&<N!OBI)2
M'%=NZE*K93\H^5_Z MT#\D 4=-*!ILS%V1"AE!9T>_+/9K=FY'!G)* -T&5.
M.:RS^1,Z8/:"?"0L'ZN8^?$/I[;!*7 KGI,U6(]GB7<#LY7NG$._N#;:*+*@
M?!$F1S!D>_*>*T#"+"#;H-<P=S*.F?.'8^XJ_M5O->*7EIQ3(NX@4FC PB9(
M$NC3. M'4DHI*Q,)O+4^T@$L'L7AAML6%"<68;)O$K.PM'X[>XW#^L-[<7[F
M*Q*_".LIN!Z_U8:Q*-\!"/Z:&"<$:6%;8#3!J02,_VD3Z7]@B^0'#/T(3(MW
M,<6@Y@*8P9HX$;YY_&Z;Y"B.E;Z>0%=DKG:Y\D'/.P_CM&$%M^A\VG^3T.7^
MJ0G= T6)3QG:ELI",(K'TC)*S'D(M_'TI2V34+IZ,.%#F/G2X2_(N6G4XHFV
MCV%[X K-X2$F/A%GG^$O_-V^^TNI_W_LS/\+;'<"^[>;)SDP"[U^XV+/(R:N
MGIEO3]JUSSGORSV'0=R0K8OV?^MD[?],)^LG,@X_*]4%/$.S?^O1#QZ:6FK2
MC]LW&&_U"]3'_?O;YI9*R?_YC7,_(T*NM-5,.ANV[MOW84=A'#MA!;M$O\<<
M7A @[T)3<5_;6L)@R_B1@%ATXEX;.,U[H&3_\'([MP;&42HPM3I0#?^]: K?
MQ.0IH4'FU]?_KK=9G3*0 %>S[_W)"?[D!/^/. $AB^ADUA=%0HMKF9@AP_S
MO*>@E4&OW@'"$'BI14H,3;ZE_X$Z4BU*6G-MQZ.4K;;>9Y/>^<5+;N[]H,TB
M3)HP,>8=?@5\E'GZ%O:!LJPGUAQM9D .!2T6_MA#:+;#N9/PI3I"6?HV3<7X
MY#,[HUM/U%9OD* R^<.<D1H^I/T',%[V'MO*O\^X^=&QU>5E90?R;]Y>7W/
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MMZVVGN5FOJR<'"5S\958(9$1S6[#!G@X,EI3&;KLAEV(;S6,2DPQM:!4UDJ
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M;0NMP)9[7;_7ORN?^I&CJ=Z0>?[<\YNU;>9R]$TN#^+63W,9\2 X1\M(X@@
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M;D>2: PB4S;+=TZ&<A:0DV4,6&^^#X,8CPT'<ES9H9T\-_?A<OV5]0 G.YW
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M0&\&H.<(./1FC_1S5MN;QO59F=XH6/^?T_<_%^5(OJN43<GH]"-5(05\CY6
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M^_LO>]+U7[L7E,W^<>R7^ ^!PGY#S(+K\.=04*[5.G(!44U8O""@V>%]:D:
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M)/ZZU'1HI_)24Y!%0S(]* $E6E(U;+1 TOQT<>ZKDK/5MMLOGZN]8Z&N#I^
MQIDU+E:@V39\\5D&(HXB1Z(^1>WA[^=/KA&CZEOP<N ,/33>V#Y/T?BA"/]F
M@7?I@+JSG<R.B+3IKGNV"R(XY_YW:XWTP1CX0:YLJV#<$;BQ!SF+/+98M[)"
M)T+TMQFB^YH"F2_5,F;<)N^ [!P??_1^S7_;A'[UUQ.>3P[(IYNGC:U96D%P
MY[CG>,_YBEA#P4=BL>=YE0@_(J@]WY.>1) 4$'WA+O>]0%PCE2CZNSFN@F9Q
M:N*LFUN%GN,(4RF0F3MV(\.E4$\E,#'A^@RN0_ %9Z[N$%8:(/6TPX?P-[Q
M\0"&E$)_2#%X=P-R(:P^'WDN22-)@-..B;D]Q3.1&Y"?=)O#+T\,M!R %Q9&
MPC>OX+[#V)#5X #L(5:3S>*+#Y?BAA#;Y\<#-=@90'3_/3IL^[FJ*)^(&SZ!
MGDW/#8TR/G)&-88+1#2BGDHI"_[]/'</N"FO.0/L<D(MX2$? =IP4 3:\RL
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M?:W16[_4NX7O=]?->I+B,*&D:F-<OUD;B=<23)Q&\L6[:,29W0S5KV9:KXI
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MQ_R5.M"%KI(\2H<R$_09IS$5TUJCV%RE9W_W1=K5*?7-P@O8%/YV\KHL_[.
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MPFB.CTL[6]:>*;WO%5&L?7@C+:#U]4->P4DWX8\ZM\'H\Q2F:>)%]/!H\RV
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M6U [;[S7-_3#6=5:Q_F^4_(\GWA8;0<ZBT_% N^*X-P&)WPP'47C @LZM."
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M:I6+=;_1K1+R,L=E:GP\JD:-RMJO*A[UNU92MK7$,N%^M-+Q&)8L88Q<(;>
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MM2]]M.6&^_X*AE[,2VP[ZL'(I4';0[S.XP;7E7#R1X^5YL:;"X1S7J!I-EQ
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MPJEC%76+L?6HN8Q<.<;[O-/>[_I>ZC]M"1R(/W!H:X'AY=W[M%1_S?E\C[A
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M;QH/"7, DE4YTQJ(FY<A@=2U'$AKB*42E 12U9W8ZCE0K"U3Z@L[NZ&; $G
MA"1Q"($ NUZ5K^[$JL/QSV[B !5+BZN)!%N0U$YH"EI:9MAC+I)+:Y[C,V*=
MTJI&D-'N8S>.YOX^\S M5+SYT#?G>O8"_NU.]B/J -ONH1&\D*Q]ROF$EH:I
MYVE?K L'&#TOK%W1"3'7M"O2@3^33>\_3?7;%::4%,4]P5R,_;%<K',[\RC-
MK#GK3DC,9.2]T)A,J^.Z'A_4"U6E!O?DU.*G(_\ [/\V5A+^YC#B;'"]?VLD
MMVW\-TK[/YW]I[/_$&?7T== !;8L\PKU M8",IL+0XH'/SEESQVZ7_1HN+JR
M\:>$%SOBC6.U*^*%_TWP]Q>,3[?5#%:%Q89WS%<M-,=YWW.S^X2V<>.56 KM
MD^8:!+LS(4T.8!4# W/RAJW_=8?,V/ AY1:F]E B>LT6"_MX;;T%QF_[AQX?
MQW^J^Z>Z_X_4(;)05-=(L:_F\JQFIE,E)LRJ<?0AY<EHYN7"_8.B=H[Y&N3C
MP!Y[K>SJSFC\U\3TGU^#ROHS0Q@F4YJ$R-Q5J$QILU\]^FK=TY++\RL_4*6;
MNINJ%7 9X0$N3+(=.0 PP'+E #7$#;B^.P>:K+FO65@C%L58QAS@)8$DL/F
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M45POIG+@-$/FXK7.=;*J.C0UYB]H?T'V>\"B_B%D_P?8O^&B .L%^!#R!"0
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MR22&O?:J,56&!_0E/^8!V7O[VG27*CDRK;!U93.X/)8#_EBONV@5P1+A?B5
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M%ZZ\%K;R[OBO.C\1WL#_ %!+ P04    " #F@UY9G,M)TH$L  !J/0  %
M &)I:6(M,C R-# Y,S!?9S4N:G!G[7IY.%3_^_>Q[_M.C*Q%2(463)(M'XF*
M4":5;&E:"!E.4?:E%$IE"B6)2;;*,ME)$EDREEDDV3*3C,/,G'E.G]_V7,_W
M\_Q^?;_7<SW??[YOUSTSKIGS?M_W_;J7UWVNP_W,I0#2^^R=[ $>7A[@./('
M<+\#DC:GL"?\ 7\ 63S<4< 6X.7YM7Z]\OY:_'R_7@7X^?GX!04$!?\4(1%A
M1(0$!87%A$5$?RWDD[B8J/BO?WYM\F^7\@KP\0F("@D*B?[=B_L6D!$&Z+Q'
M^'BT %X9'CX9'FXK@$)T%/A3/1[@WQ</+Q^_@* 0HH88\H-J:41]/CY$:0%$
M8^3;&.1[@%]&0':]J8V@G)N?D-9Y^2U7;SX2UMY3T:3@WD?7V7KB0IR(J**2
MLHJJKI[^AHT&V\S,+;;OV&F[U\[>P=%IW\%#AST\CWAYGSSE?SH@,"CX8ECX
MI8C(J,OQUZXG)"8EIV3=NIV=DWOG;EY!8='C)\5/2YZ]K*RJKJE]]?I-<TMK
M6WM'9]>[_D\#@T/#GT=(5-KDEZFOT]]F9AD_EGXN,U>@U;5?=O$ ?#S_L?[2
M+AG$+MY?& C]LHN'-^+7#V3X!=:;"LK:N GYG9?3VG)56'[/S4<532+:6]WI
M"B<N](DJZFRCZC)^F?:G9;]G6-P_9-E_&O9?=I$ <3X>!#P^&0 -<-@%*1N
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M1IYZ/_*ZUI'*!;RVOBN1[9P.C<J_Q04$,CAQRV3>65^3/G8,+3K=V7%XU&X
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M['*Q*WM\\W&%V]?*,9^[Q[)#BTQ?3US!L5C'(CM@4638XN_CW"$0*0\Q"EP
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M25I];+]0JI0RU$AV@ =KZ&E245CLLXGNP+D:"LEG3$5%Q7NSY+1XRENV,^L
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MGO>\#LZ91WF:KDU73D^MQ.#-7I\H)%IBHS$GZ7HI'.;?Z@+^K7%(.-+,N,"
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MT:)Z5J,A)>T3.\(Y=RR%1.KW<FG0 &Y[5<">NRL&#AZ4C=-M$.S2".9(/>B
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MTB1>6*<X\PFGA_*4Z0_H/*$@NO'Q<+'&V2PIE#EX@G1%V+6=]\K*<=.DZNJ
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M8Q.#X;?_IF.,Y_L#_,03#UL<94GNX+N)"0K0;NQ]M"QH3'I_MLE;[G-UQ->
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MIGV@ B:CA7Z[SN(O@>1 _Q"&K.6VCCR$'^E";&S@,@/P$Q\_,&%NP.QA]8A
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MF;!M=_L5SC#XBI4-$[8$!Q.?_EH*JOWMQ>_65/UAKN:O@TA..0DT<X4Q867
MMCO;C##4A&:OY]!'S+:3_9S5$2-D<^/ZZ'_F/$ZS%CS94G9+R[O.;7LV#9@=
M:\'E_"8T^0U)0U:OP0;^:GW7&(H)XX$X<S3$H16 M5#XLR(C3< >7G?W3Z;?
MB_R;)Z%W0TW_*V>G]X_STE^OX>>_ VOEP6N; <05/5.H%(BM=TE"/8B,Q6#_
MN*8V[C<YB#GD;WR.84?"TE\I&]( )LS@&GB1<AER .0_W.$Z9%^X&>K!WX;L
M7CA5,1I4!^4!/(DXF=T_Z?6;\<-Q_?-4&H.EAKAU^@MFDPMB_M<8>K]V,2B#
ME?^I VJWS$!V.R9,X@<58@96\FX,-7.S7I,5+)VG%31Z1Q$$RQV(VSX%6+\7
MP$0F)'G[YY#;MPTQ8^U;8A Y6)_"@J]$R(H0>"R,4R/^9/+;N;_SHF]$Z@EO
M>GHCJ9&6V Z^77;>;,$G_OK=^)B4!(9O-)AP'4PA6X(Z3L3U;>2VYAFHF2L>
MZZ-_6HZT4@%RW(8,'!, U:N]#M&NCVW5_34)]C=G^U2I !4BOO<?OSXRVXQI
MTI  FKW"_^$)3I!IF0W#=_YV$?3?J1S]\]\&L,;G[2^<E08A&3/;!'_O8PE9
M>1\7. ;,9F.R/2&C%H?W_VE5RK^]N-^-+?/ZN'U#"U92@B,4?#[)M^ZI'&QM
M7BT0;>)7;I[3A#ET6D,M/#!,.\Z$=?IT(I:S$=0P!*D"?P^Q+2L@SE@79\(.
M71 NUO25I2MY+P0S89KC5Y@P7#H3-B;!A 4M,5XR83.5#IC-'@Q=$_:DEWL"
M3QXF%L 9O)%<X'8L$Q:2!@I6;%QFPE(IJ0#Q!D YLF/^-_9Q_6\O0_W*F>[2
M9+S7V(ON!+[T1Z(YZ(+4C%1G89%>HKXJ^MW&9.DJ*D^WSQ'AJW*U_U##XNJ9
M'V?.7>5>?#AL<5,YG,WTTVM;@:)!EP'1CTDN58?U'ON@#+4^BP11BK(U6VYD
M&(G&#;H>$(WI+=FX2E=/K9(#^5G&VQDP3T.ZC#P&U$W[RV?L/'(],P@QHQH-
M'H#Z012  SDH8R;L C>>?),)V^+Z/H.]!K7B G45NGD4\BUV?:CW8K)^?\_"
MQQ8,A/X=_0FL7 2S*88,& 0JU<:_,LQR__/:I#$<2=';')!!!=Z%@)=M.[,>
ML;8#,I5=ADS8*[4?86OMU'N<T="]3@2YJ O8DHK^Z^=_TQKX' ;B*1V[W.C<
M"/#*JJIT-X+T4D,-NL4&C7=-MPY4KYS?W>I+X6/"WL\AJ(IP^LO_?7M$W>]W
M$%+#A%'%^FN(W. /3*EL .XLZEY9ISS X<B>'7G9B E[GE(SWK+J.9AERQCB
MJHQ\*ZJY=7-<11GV:GOQ;UX#^E,LX<^^^X3%W1:[U1.6P>W3K(-,<>W7SYTK
M6D6DTD5:*5MN!WHSPM.DW+WN+2J75;@;FQ7J$&;G)]HM4BL3_NHF0*TWN@E8
MLY8WI,T9@B?PYQ WU)W"5I!4U^4!3C"\(90)\X>&H,[H;S6!K>=(-P-_<6+M
MO_LO2U\65NQO?@?_B_^^Y_QWU.[I_^JJC49353Q #30[%#(0!YDP=46\C/0Z
M%\@>GD,%-JHQI'#P1\JI3K4K:FJ)37V<&\/%F0/T5=M)H+'GU?+P1/.F1V3E
MN B"A0FK/8;RA2R4 ZK4BX]0@YI-&"JD#>#5G;++![0/A67N_>S78'(BL4JG
MV)/@K U<WK*O<Q5NIPS9AV&#:DR2X6(9 AXQCS-9%[H<!SY6_7LL$5OX;XU9
MN^Y_7[_X_QY2_"V@3O?3S[$U8K9A,QBJA2."'H=$0U_F*,9RH!L[Z :&!+EZ
M@GBP88BEEBJ";I#W&>R<\*]H@YB 6>Q]HBJB*F)I7%F9BCVX2@\7K.%+5$:9
MJ+2M6)Q-MGR<O7LAUF5 >AO^B-3(:4\5/E=K5D>2JF%/68E3J9?N3C1S$?T\
M7&78J_KOL7GIK==@QO\C'NZ-YP!/^G".M0?SUA,Y4/HNN8YY<G6E\>D+I_&^
MOK")>]=W+_YIP\7E+$<".L_N9%+.SUH/MW.+\2-CQV;&.[*;1.:-C2X(,6%T
M*;<7P)J^&@*20P[_(!/&*(BGISJ2?BV7NP@UQ^RB)LR#"2-GX[BA)LF3F3!P
M[_O_QB=>Z).Q8&@FU BR/AO4)*M=1W:T0Q;TD6K&A%WIAL@P]63@/S@%MU(-
M?OMD"AP:27DX7=,3XO-0B?N22$@&ER'$<D<3.<$3T=2;Q'U0PQ-](%+-V@%0
MN#O^JX[_5<?_JN-_U?$_7\<\%_CE3C7U>_*++-K%^:7[;UVT=\T_)IY->+^_
M-^<_?AA;&]YQF1#\#2CH#WA UQO+4S+J75=W-HZ^1L:_6#L/J$+1#A^[=''?
M/7_ST!W:V5*9+?;_.-O3C&J8Z[#YZTARKQRZ'+FD*DO3UG&,JH:T_T3X.:3[
M2(!X:E^>PR<?XFJ6..NZB.!&.'(1H$H'+]#2?<*GNA=0(F/GAP4D?;7P9\XU
M75#CN=4K. C;P$(<+R#),07>B[\C&\Z#$[M*&%8[ZB%_Z?K9C9!O,2SM@(IM
M(TZ"Q7LCAI%31'Q*P 9KP*GVI*6\<3<A:H-Y; UXL%,T2N4T#_<!^55#R4.#
M%YXE>$;.?U.V4>%D0P^.:'2B%7R\1^T7C6AR2)12C]K]E?I1AC6QKF_[1U+6
M;:V*Q(&/H2)GKID)FL3N]V'[H!Z]L.Y/D3-EA-+9\F9+ME&@?!+I\5N%+ IK
MC%B%DW[F%6V"L((C]_[,:2EVF,$.A55$O0MR(Z@3[PP\_[5C+B#,QZ^V).5@
M 4670.68)\5]+YSM] DC[;,L2=^\>_KLTQ'SR)V[^6TNR._8]/(U>XIWI+D)
M@7W"ZHSX-+)Z_2?<[LZUP2VOQHH#1T<K(E13&[\<D8Z1*YMVG+7.O26 J(6S
MS, /KN/#R@V>OYP?$2DH*.ISJXO0KU-,\7Y9H4.H0&VIP+A>)2_RP<@5^,'"
M,4P=DM<G4(OQ$KCG;SAF'4ER,;!2ND4Q:0QWD;>4Q-J,W3I%\/+PO$[/^':S
MB?93JK$3L,,3$JJ)Q;+/O63L+Y/![/?.UD=[)[I09B27QX>.+KWR%U;2/,8:
M=(/#I(<4_&%_*B=$'+@1]O"?QJ03MX=G337@72,K)ATH:5*;BF9#MK]\Y/'2
MPN(0%M&"JQ.D"["26UG-PB8TN9].Q )\C6$XO!2^Z,:*YN]!>7U"A!97[59A
MC4R[50^/L[,QW*D7DR[9H*065L8J )L'7(F#XS7(?/@+%P7)2G;?L>'[4_RR
M\$O=;CP\Q=WC]Z+T!M+M[@I=,K\;ZGYN68*]8WS8,VF]US/7Q<A&XK1+U_7G
MTZZ3;/QTY]7S&U&4TEJ\(.3VZAIGT1W(P^C3/EK+8]'U,@C#> 2'.36Q;VS\
M4I<(_MG"6LBKVR6V$46%=R\Z6E^JG=R-OP(>I,Y7PP^JL63."^^D1,7E$2Z[
M<%?V6VA]X/[^Z'O^<8>!-!L66(MNBI9V'LRSY]_Y8P7<$&P4<2Z^E:V5#5-$
M%/97&P8F9M;A0_K+O3=>XP2[BO<\R%L;/#JH63\Y-*#G=9^DQ9\4M7MR>(E[
M!;$@A"=@2LT6S<>. E-]:93'D??V5U8^/D30E?G6KFG'OTE0'7MZ'C)/9,GG
MW#%B1"Y-$>Q@PE@49(.$U2NZ,=<[UEK;;([J-EJ4&*X'=:T<S!4-V7$_(N>+
M44HC6QTP*-V ()<I1#]EP@KA"\M9*%T*YPO2"[JY)V%-0"LAO;(9)R$\9P><
M>WQ;*3[D)UML[:Y18/3CU0=H>?"[\/$.+849G,I/@J4\,*]1K;I8)5RQ3\IU
M _L>K5*Z>,"%Y"/.>%N$81V:;T>EKOE,K2RQ(PM"B&(679)'TSDG1P_R.J(]
M(IZZPPN5%OUX&PWYJ4FCQ&@<]US*3FK@Z&2 E7=->=Z0F:[+%'_8%&$*'C,F
MTO&%A?6I]HFJ>)P\(ZP8P>,(E!K6R9S?*.^*C&X8!FKZ2A_#!\0, F6#CR>T
M:G8//GK]2ND<I-M41([!!'"M[SDY&1B\J^%.^EU&O((AH;:!L#_E0(>G<Z2F
M@L3R9UR'3=0/+>V')D?R;=)9]^DH&\7>EL>0KR,)AQ$[,=':X-[YL66J:4#_
MXK2EAE2^P+?N_(I%8  )N+9CW)(JW-HV?;%>W0A[(. )LB8<^RR7/*Y?3HY;
M;^O93.1(XR2X3,6,S2Y-GBI8^F'_*AGP7!Q\FB9L2[,#NXU\E*XF;5A3.3]$
M'Z'?HMR/%4MY0?+;?Z3K?=Q^^^NXNRN#EEJ"WNT!$[N, LPOJ")"$27MU?@=
M=!;R\N*.-,6T,6=9 3U'E]%W(A>*5F6]*BK>7U/LU*IS00L^7E%\<,=WAR%;
M'GH$SPMR.&V+;2XZTHXZ:>P@I^!SJC]6C[7"^0?FSSINR@E=*<V_%-(AJ<9K
M?")PJ#\7;,'L>,"$W<<.-%83=_0;66E6RJ5KNSWR,697:+@6T_1^)<?.7HKS
MV)W'V!C -1<S>*#R:-H<IE0IL%((O=?16C0?1_E"U?'U\,HZHO=B1:-#-D9D
MXZYD1-,QXY-G R18EG.DCIZ_7M!;1%6P4IP4+_GZPJXT42[N%=_.3YP/+^[^
M^!_/TOQN]R:<\1FPTV*D>4+ZAYI;G:(<6X-6)Y_\[&7(2LV1-E(N>OOZU!?]
M0\?T6%NXK<[)%1L>XW9[#2JAKE Q%/NQ]?X%*%SODJ8RR/VD]H"U)'\ERZI2
M\H*W:>AX$WM%N&=Y5>PA3:$OV+<"!R;+;J!7P"!3LU Z^VBTH$RY3WLUP?2S
MC.BJC%9V9OW#XVB->ZM'%M4XM#-@OHA%%MIYE%T?^CC5;SQS 4]QZJ]%BY&7
M8D_&@$*4_5RW?0"S+X\Y)]I8#?)8<J7B$H]7[#L2 &ODS@%;F+!BS*(LA:UZ
MNWWQ[3AQASG5[!LH$HC\0DZHS=5K%/B8MAL57%Y6>2RD(U_#XJ3@(]8UD3FI
M_WYL:_L>=".2?&/Y /UA#]X!>]AG?M0L0LW*TT)&VI3R&/.IG?'""9@DU$A8
M*^?%LD[&78N,'UHLFYXAOK#>Q_A0^8BD[U&#*!6.)&?6*2I%P[YTHZ33K*K2
ML](KPM\4L[U4X<@_=^<.M^AJQ)/B(SM6@44OB%Q-4(]3<C<\*8A:SD#$+@TA
MJF4=H;A(,L-YEG3>V=:A]=&1"%33\55>B2B\[&9^1^+&\@L\.XJ-'%ASQN<R
M:3/ TVIWCTO,5/^E[A-%09:18=&25WLOVARZ:'/N4L3:Y[#_P'GZT_@(?$%"
M/4-ZXQEFHX#Q$@6\GT&?[EU[4]3.YR L4Y#H(E)WIK[N<-.=$[?L0R\8G5AJ
M>7IF]R(3=LGH GPOV#BBW@4XM1.<M:EXFA7J(3D=R55YW#O78>0@53)#JR_S
M0GE$2X*9R]&Z2(6>=M;SM<_RN=B685P_%9:?(DJT:Q!A: G*]$(FQ;N&4!(Z
MKGYM[@GFN88DH_Q646M7&%8LKK=0+MV5&WC88J1(>GB&K0*SDWJ,FNXS03VO
MJTIHL+6Z,TOQSSIN58$:KJ!$G4U)-LV#H9@P&@)LP?,4,6$$SAN,STR8$S+$
MXG3I>#B6X_2S-$?K(U_B#TA?[JXDJG2)R/'??S6Q%1$=<.[;_H-L'9 :%W);
M9$E%.5#$J]N\+S)24)89,QKG*DIN%>G;FS_+*"VR/>$;P[UOX"[OVU*I6G37
M17[NE>D%"DWRU_E6]R,Y-AJ_66 7UGUSG'E/3M>AI?H_H2YZY<R;L8G_*"^3
M"SP.D8.;M]_EG'->M)!@J<%)HMN)1=X-R"#A_12.3$K2-7)T?32;DUO6X!SZ
M2&FY_^XYTY%(-_7T%;=$MN<Y,6U5?/G& 3?)>&[$_>A!XD8Q^0-5G'8-I4NU
M);7O1-[^!HK!.3X5[_62L=B3;J[Q0YC\O$3['O_=JB#8A)UA[]IU5@'KMW=3
M'>,)BG$/OE@0+KP<O/1.)/*(5-8&;(?QO_BIP_^Z_M==Z%N_-BSC5S6!I7M,
MV) 5^E;_G#==J(()DS<#IPP9]?V3D< M*B1)1+7^D:(:P#192_S*!/^/=!@R
MFTAVX:7W86GQ3-BF)#)>8?O=KRP8T.;$A'UU8\+<7_\CX:4E^X^$UT^V%\05
MJ[N()7$P\>WV.VL[FBVZRQ11 %\@C2$((D;DY/()#6&>I+6LTW4'$!C? U_J
M7MPZO;^Z7&BQ$=7_L;\5(%M<-Z1SG1^S9B//,&';/OG8B?'MM6U#:\I.!S17
M%<68\):GW2!FH0:^*T +Z>IGS]?F 11&-U@B"?!1LQ=HI0&'PXZ/?-*TPT!U
M5<MGTI;!_#]O2P4U?M[E@+IP%]*B@.4#"A.VI[>YG5%1C.(?,Z=#/(5C@!&]
M!@^V5JHB3V7FT?7(GQ,3BV-)H^:+V)>X[I4FWN,U9Z1T3U]\S]D9-E$I-TX4
M<D;RT U'96Q)"DMO/\R4]+D[@*<2MY4"S7W39$X]JML]\UU_):9N(CELRV^L
M_QMV#[H>421>+2M,9^NO-+3W&C<,>42U;\B?2Y&JZA'I7UR2N0^H3KK:/;QO
M+L+Q^<-#G7$^%J :?:@35$ /0SP64[T<ZHZ<TQ!,JL4=^/&ZO+AN+WQ)_/4;
M O^A5+'.O1):"W<F'ET0WB2SC+<_PSLB@KZ@3*GNI6FZ7_$51>&T2T.:DC&$
M,3U?CHZV!NJ@T,H9GUFK##0*_6V;M[9]P /<6S6V/"A2C>.*HUMES&I(:B;Z
MFR[=NF_I?VF\*?*]XS5=I<L<TR8<EY)C8U-LJU.XR<1(A+TT,H306,-),#2A
M=N;Y^'HY:$C\G'T29=MK%]P6,KCEO1.>GUN0VB"RIY/C:?)3SJZY5;<PH,@D
MH98S&L,.LK:3S-U.4M]ZY-;N3D^XRU.[P ,XB;W,/N<&EZB^[36=@>H?)\)1
M=HR/"IB!V@T+ZG>O=K;F\79.Y#S XSFO(MJ-E=5_4<"$?7"]A-UO;& ^?#/P
M2];NMQ3.C0=D[04H=.SB9[S]!!Z9$RC&!!<+MO,<(B4-VXRM$%HFY>\/JW\M
M\_:IK+]SE.7!284[[^-%69;V;>&8L(TI:O8X$P;WP=3 "PP7XK)16MUTP4]Z
MZ<Z@6"7%Y6.XC=>>_&E+2_FYQ8?-R6=KLM3))M%=W!0Z'JK*8C]-BDJK'SG)
M"$%YC"(/4L_7IYS\2ME%?%KIQTINM?-[>+&,I_2,EZD=WV%N$]C^P^QGV$K
M-GBQ61#@,"R-+(RM42U]@3(9I5%LQ^%LSED!R[KO8I\(?9 ^=4-"1BCG<1EK
MA.?GX U_ZOQH-,%R=".<4DLJ'XGDLHXR/[4[S?5$T@,/'7;7"]_9V@1M4]YL
MFSU'"5#;2,1!(Q1 DP9[\87O&I_1O4C415DU(]*\OPN]2HOC0-604GRD8/G.
MD#U#%W9I3>]ZNOIKMD2V1C8(\6O.YBT/1D@>X-49]?>V)M__6#X=98]/&5-7
M55Y:"AB6J>QZ<[#AR!E";DSEM/@QN&<_+P4!V2#NL$]K-7H7Q6(D:5G8.3K#
M ; KY0CP>I%Q\M*M!U8YOOS3Q6@?.A(Y,'B5\:88",? 0$ZP8W/D5.?:R9XB
MMZC^0TX/Q89[=$5IJ *KX<\TWSUB^>P26N?-GEDGT*SH1Z@FE,:QTH5JBG9C
M"F^*O_&8<+$+/'3D@.L*=XI(NOR'0[9O3864*%K<T>X.+,M/I$ENA.7Z1/_2
M19-1V9^FB+WTRSBJ'0D?1"2_=$;S49^4>BN5EX<'VCF[>4CIBBOF;_F]V<*<
M+P\2'8W$#K@CN5#G&5\@)LN.VDWEI]C7(O^/8JXKJ,FNZSX*B(7RHH""0E "
MHB!10(H@41$148JB* A1Z2+-1I202)$>JH(:)0H(2@L@G9!015&,% E)A!2:
M+U(2@? @*5^X^>>?^:^^J__BW)TY<^;,WFNM?6;OM4E@SVY^P]'8VWWD'.=R
MP-\R.#%FDC8'S>B:TD*^DI(Y4#EFWBI+6W2;C$@4 VQ7<.]'])%<T69_;OV8
M@9<>ONMA''UOUP%5S_.>FMT.,)RQM\X3QH'.P/CA&U (.?L)Y('HR\.Y:(X3
M;;[](?FQR/@+3Z%M,<XA5.VGWM;IY+CBYWK C6.NI?$[E_5#5CX<TUCZ'U,E
M25TJ\T(,O)"@<WBZL(K04,IF@@94P0!F-14SBT75JTL0WA@A&EGKNT&NB %!
M\DT4>;$096FK[,9*F)SZB>">0JR\ARS+B@'&]&HR24-2Z1J)@=[3$E: BYAN
M/R^N,F4PGXUM1*.2,\;1F1F83T5KSJEG_'-%-$Q-5_H,9M4"&<N/'R1J&S8K
MQ Q%+S; I.7-\!'RE1U/KS48Q?^Z4Z^QX(7@A#(2^-6@[^L1Y )G[9O/K<L=
M$7^WP7WLRN B B)Y5W[=M-&?E  ?1:V+,FD;6Z6S9-8ZPH;%0(\)>H\8H'I"
MQ( C_UXG>@A22Y[]S4;$\TF;>,LSM6P(< 4I!MP2VL-!^GPWDUY'MZKOZ=LT
M$;_%]]KZN8[LRH.>K;&Q2WLKH]*Y4QS%.)(!<HL=^)QUP!.VZ!GIF+QZMME6
MNS?>5JXPMN?E+A5SK1B%C>4EH#$_OVZ0["OA$!$%PG64L.%-M"F1.U<E,PVV
MS[?696GX7ZP>F.V_$LQ2.H@<>N#KK?M1+O/]SL1OMP1F\?-LIUE++G^5;RO$
M61N#'NUT4H%A+D__).]4.D:8Q:^V2X2U-;YP4>;V*.=>#3G1NF0!K)8T8K"8
M[2@=[C;VJ19>=O>-7[]$&@/T!6?5@TFZARJ,J^R!O(<^;AUD2#EQ'YM,3^=H
MKCFX;@(A/(\NZQW-I&C23B2N'?N.DA_P]UJTS:GS'Y&]+=W/MA@;?:B23I53
MK><MM$,^3'T,!:&Y20)_EAC TBE=!RS;U>^_-7ML95=VT^R0U_"A>UUO^^.Q
M1<C,I^%AA4_IX3$UZY8ET/H%MBU U1HZ8),2=>*;_C/ITGC:'MFK:6%AME<)
M1L),T6:4*:C-=;#KMU8/N#/,F*Y3;<+^=2JY.J)FZ$77\=_ L=/;>''%]?$.
MEMR+!1BH9X>U"BH!J9);S!2S(3NFO33JP%+.RBS1OCR JKNEMG^&M8T2+%?P
M+"^XIYF:L6Y7C"T0==A+DI?\6C E'_T]>-54L$Z(A[,MJ2;S"EWER!S.?%=X
MH"G=E]AO$O8Z(OF"285+6JNR3-L(5?,X;VV"E,S*PZN)%%!GA+CY>^5[3_+J
M.W$0:9#2'J&IU4SZ,)BU E7RG&G,.9'=WJ<Z6JCZ3>%X, VR$>/-?!0H>>I3
M(+80EK!$T.X85>:*:M_"!+HO*G[->SUX]8HQZU%T[A.Y*:/FFH\,D'',^M_\
M1C&08BV=SDEHGU<2F&6[O/@:1-<8RH,%C_MDC10E99Q);=C?<_F@=L8Q L4I
M"5&SO9N9PJQ,:'>*1\@);")\>=HG/#V<>7<,YJ@ Z*@F7>50$^/.85U9,O>&
M68P[R_[KJ?)'$J"S:D$\/#^6N]Q%V#!RE<)&)$"D#%$1&/_ VVV&L-K+X?[!
M!W>I>@08/EMO;B25NC@!]X,,#W1@ZF1GZM^B^YF[T+N1%?,<3%I9T8\9P?5B
M9 G_!]'JCR4NH.Q:\L5D/;8S?O>%ACG*#D!J5L+M=$5^<C4H6RXXVA=JI6]8
MA,*,,9SD;* 1-V!55KP>SGT91ZY56?".;W-$MR[2?N$;D16Z#U%I-],WY@'7
M/%> 9"+ B6(PU)DG4]D:^/2>@_;]3PU7T!Q'9^SCCX>BDQ>=Z#;\NV#$JA&>
M-M:*5_ =VAN_S'_2OZ0A24*OH6)R,XD8N:_??CS+S]Q/2??B^J+CNX]+*"F(
MBD.9"O-G2'M$??BM8L#_'4K_0!E3GM4'Q;L&5?Z.$A8$&TRKF,9JMFD.9$7X
M6[G%!H@!Q45%1BG_!UB?C[I+_G%841:U#W>V#P5C[_3TF_PV.$*YY=](>NGQ
M"6O03#K]V?SB[$MUQ+ ^>PRU3]B""<0#79SR"Y=K!V:)JDWWAFH?4LU<&(<?
M,[JEOJX\.'FF_7"$P81+Q"$+J-2,^G_9M <WP+ FF"OYY&4CS)PAV2#H[\M\
M\A4V7AG^XV=6#F+)$>T8&DF_S7QQ/N=GVE!+/5R+D[X9,W257^>[1/&?M8AB
M^O>&7/YHN5 Z2J6%>J]X$P;G0=,449";\ MF]0EA<%J/$ZH,'S+(JI <YHA&
M1-+O>.2XY/Q,7JZM5]C.+1:Z4P(F$5?Y>13<"!]5/YE:0+:L)43E#6WFP ,A
MT=8JPB+2!F0NRPYKJ!OKR--]$5S86 ]\#M7R118Y(W6@)\,494,4W6=_$3ZG
M4RE9.UFR A7C3H@\@X_D^<\J<BL@<I1BC*\7<LKQ.XS1:7SYR9_A%4,.;:_/
M)T-%Z7%4Q[T(\@Z,-QP\C=9 *8$>7/R%FH$:?!Q&"04OEQX<H<T9F S[)7Y\
MJSSW/"[Y]K#T'#1Y;6+WDZ0^5Z3][F1J6%WAEG9J:@[-&'"XVSM3$$K3]@\1
M]SJ5;$S\S/GO5SYG*#5+ 0MV[6) LGU41EA!VH_^3D^KOV[Z?*P7=KQVH.P-
M;(I1F[JU>W?V_NUR/C+WLULMNAY.**];@+3":%)C;NWDS4@<WXU7OAQ3.Q^K
M/MXT'.,:V7!OL&Y0\XI\<U''.OJ ^8+4^E,;@=1+;G%BP$^BN/26._"/,T1?
MO62%KT6:A#@#@U-/\T'^O'V+&(C+=AHX,8.])'W]UD*WIA)TE'QWJ_&GOQ^3
M :Y$3%<M8XD7KG,IW1(D(NGA,!+%L<G!,)H =GY^H/E!^KO!]K";<G&G1Q^^
M\][SI_S5:W_M5U7"I_ @Q41RK5,'C)[-?P0^9;%$ZQM^>#MM L_O?.,?&GKO
M^H'&+ M_A-&#4;O4QG#UDA-OCD.SE^25@7\VMJG\Z4Z 2R"&X<9W)PT*]JVJ
M"<Z!4>^1&\3 A0;R@-5>GE$/"$_(>Z!N?[VVX8-.8=RGKVU0M9U5+R=PTP_U
MI-KAO@2:D^2^"F@H2.:G"_.M=P>.ZH))8Y&109:3WV?4&>?ZR[1VI'W[H9%2
M/37I?Z<QT<NX$=<KTA2U02 U9%ID)[S2+$T0SEHA[?A2<%,5O8-GFI/K[9GT
MMMG,=')2=OT&5[]K#*A,S+LQG=+??_6DQC&)S.JIV24>DW]GD.SGE,14EO#1
M0V,P<''Q!THG"!6R]$ [(;CZK*YS3EA-RLZS>[9^T/,Y]P9[3PRH8WS(R:,&
MH LWBJ0&$CKXI".@363QZ/"KFQ9,AT%-?>V@<*F::V<265D5RIDU*.)XU#9;
M ,7@6?*]A456OAR\#'I0M(67$$.TY.$ZW&V_99;1-X;,$8^6!U9_]5&]?6A3
M6+0C3:7UT^T.Z6MII:S<=@J=-,4AB@$U>" EA6Z]I]_#J4\@P])M.J<N_TUM
M;BHR1G.:-78SJ^1=8RMT/-)6$GM^."Y!M-F&6SAMO1D,Y.6RF5@KBZ.SG71K
M L](_N1O==3Y9O.82W4Z,-6C#->JU R !11\)WNGTTHH? =P72%*-;:SMXP2
M>+1WM."]\,FQW.UNVR3ZGG/^I$O\[9)'+_>GCH]3W_7]+P//_Z,UWQ'TCWR!
MUQGU/'-$>P4%!='[G8(JAGZ.=;.M6^*>*@1YT>FK)H)F2,)=MSD=%2Z")X^9
MUA<#4 E;47!BP%4,_+LL<I $%D1!#+2I828+,3\E"B^T=&Z_'J'E\VW*#*HZ
M;QL>E_.73B7BZ/,M]=;9Z^+^IFTUL2 $_0X*82S,(:D"95E^,,]M]LZJ+K*8
MC^9>:B[^]T5.$U]W=-D5-FXWCC@>QB#6^DW<N'90$>IFL^HFHM#WSMJO6B)+
M68Z-!F'82(> F8KQJRD.G7L<'H!3X\^U;\A"UUM2\UV\W@^C)G@V?#N0RK-C
M(]J9*N=X#F?Z128"_2W6SSDU=5E33J17K__Q[#IRT%[.3*\$$:+F=#:MB:Q
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MUDVZT_:QRV=-MN-;LO>KUO2AL..U5G#C@] QW35!OYYW2].$U4;HKRO+QUG
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MI7^9<W)J?;<^YJN19FVQ+2D9^<6U;:WH),>]NQ ;,)$<0X0.WFG/(U7V31Q
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MLUC5-X."LUO=(O;1*U<#U/HTG:-M/_TO9 ;6\+]/C2__7X[-OSP4-M2O=BS
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M4:%W"37QW;)(EQ:;L5WV0;M>O0DO5>6S>?)NWV0^>YJF)M]*>ZD/+=!&6&R
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M3'5TF8NC#[9M\&Z3Y8NDR@NQ@&]NL)?8%@EU_=.[;[L:_]]^_Q<$6]+X(UC
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M_%(/635\\(B5R"R N><]/!B9]\E/SK( Z#IQ+SR@>!\X;=GQ[9>"J$N'S%G
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MD.^:-9[<"5?.WF8M=8,L57;UM^>WKOF9[@V A$#V$5,QA<6%QU1Q4D%/Q93
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M.[D>M$7T@0UOKU2WVZ9)<[0I]#- M>%]V 0\B'[47*![[A?)_,)^!:8MI 2
MV?#Y,D '3Q3PC@6F*4<V7WMY/^S4J5LV+*,Z+)MB\50HS9<,[44?!(2WBP'I
M8KC#S$!NN@>AW;NG4"/ 3D)74/A2CK@[Z8;FT+),OAQ$4S(K2-9_FBZ/.$N.
M[T.QK4#XVR)*==?2*UQV];<30]4XKKX_A1=6Q1R^6\F'J"!CNK!L],.(FV1_
MA#(#%!T!-)F[JEZ1>M5 #$K V:]ER$6/*4BDUGXQB*S^,7*\>(A/PK6W@R\R
MT1A\ "ZPS;;_I $%J#BFTWG\(/Q!7N3^5/*.V>2]KVI W=4#TJ_+"KRRX,WS
MX6RVT;V\=]C#C/@HZ7V0>$A34S\Z%@U"BO41#6H(,([J HXFHJ1:_<B)\?F/
M),G2=QL_'K>*)]J+2I;T:-X0S&L'$WY$(7S=F0D[SBP>_IWNO)0S_"_),R;U
M-=.>=:&-[PI/K_%F*#X*\+89NAB3D9'73(9T&6F,88,$TNCZ4S0-5$")O[-&
MS.+8EB5)\D:[CSHF)S3IO%[S^9\2!\)RKF^)L,2@F-9%)V@&U*- \G8&!=6=
MN$DR[S+2A_+ )WH$*N*E(G].JI.4?=:$COX>$R+<LE.0'AC>^"&_A*%ZT=S)
MN8\V319ALYE6&E( M3>U#*%+%@+R]%K:&IT,=UJP3\SLWIM*>&=?O>BQ:_[!
M<B 580PH4\)M][.19P&W&4)8N][+:N2$?\6RV,&2H7$\\U+@6B[%K2C./3LR
M*U+5YA4L+4/VG\ N%$%8MC1D@#D"=*"+C+:AK*63?SM,+E(@CW3N6I.F8O=K
M+\R(_93E'3=1M(7D5$IV'0Y_P?^+@"&I+_[LT$R?W=G. 'Q+X5=ZP_/8<--1
MY3YN\@'FEZ8"W$.MLJ]Y11^4S]/0TGH_&%WU3A,T(^Q-#:'Y4\)[K*VVGP->
M5$V7%3RW3E>(H7/J:#)RM-JO);+U5!Y]NG=.Y]9)A8S,T\J6BO9L+.^XWP-@
M<AE!HQ>;-).+YV6 ;GZ-Z'(6Q<0&W9X;0.K4MDZ$"H;>Z[!RF9W]*JR@_.1Z
M6Z7@79$3:PV+V(-&_'"#A='.ST@0 LJ\DF$ O@\EM"E]O[[5OT##NC62LU>]
MN5?<W%8H.0+NRBUI.%*-/OG9H@^$C(*K]LO) ;$+).6!><%)L?6+,SJ?-3:'
M2]D.5BVE>J9VGM6J%%B$L='<*9"$#AY4%Q1A2[4[VAS6(4>>23 \1L!(X*3C
MJ(;.;C5E;1"_T(^@N!55[_??UM9AH8CCY-*F**0D@.IJ1$J\'5.8T/'W=R]>
M#JEOG%92L'%/_,P!_Q3]IO> ,2=K*6*_$CGB'-\_FHQJX'R("":T#EMS#M!E
MR:2T](JOU]Y&^WI,E%U14S-3/'G)PR.%Y"7Y0L"0Z>I'>+H;!=O3BHZBBTQ7
M5Q+)ZS$-8%EXM?\QG/XAE_1:7[(89TG3%<.G:VIS\^WISONO:%<6\E'QX#HF
MW&'B*,#  %V!?/5,32UV&MGE]<JWQE0D*"+\5)HCMU=HJJC"K;#WN\%9O]?C
MD%S(23D]YHZA-!\@BC),V*[2[X-(PV_)<N--DOK-VR+43WP-.&R?S#YL?;*U
M^12AXY/$'=,'08FTTQ3A[0?[Q70P<EJ! $EL@[YPI4G%=,FI3M T2LZNE19;
MRW:[=H5L7]A?K<GQ5;CS\$FGXCTVUMI/#%  Z6Y/%UI,W4B5!G;E',!RM6D:
MM5; W?C@UYW]&F].NR2<4 ^DE1X]AL@Y[ZP^IL];0KZCL-]!/_$9$._&UYLG
MH[R^C]-%X9D_+D5M#1HZ8=Y<4]K,,.'[=>T^2/I6SE76G2*[M%J)R8*8=(I^
M#SH)*S=*$J8RKU!W*44N-H"H$>WHQD<6C]M*U7TYU7 CI\FNO0<7HJCT(]LC
M24_. V1I_YZS?/\571)A0A&@":T; _Z$=5:_IL+#3>,(<1F<;-6C]%!I%_PR
MYLS3)X$<NFEF[NE/%(13I$ 5^GWK<^RHA;(F&-]MA'"Q-:$$"&'O7M:"K]UK
MDKH_[9E,=1FB'H$U/F$W3,N_*F!0>!+E#4U&U9ME412V'Y(QG=CHG/F3K6^!
MJ=?S;E^ ^#[E2_5)8G6U3E7J^,&G@P9/2PWN9/1SYP2WL<XC'-LIREUH0.5L
M_$"5"P&5W##*\PO%-1"794-.CZO6=:B?E)^2^J9&F5,UM!@;[GT4,/38HHH!
M^IS/;(CD\"3D:5<XIGMGS\\?)KVE;F*9N3=&%&],][KQVM#T(5[2\XZ$IU"E
M=M<+WA$HG5OP)0PY@N)'GD88 0$AK_WP(J& #I@/'F0W.3YX9+*@S-*CN?EX
M]ZG%"-_<N\7:CU]>65IL 30ICMM1,XB0<L1I8(<*,2$TD^I[.R9HEH21T(:S
M\KM6JSZ&LX>C+;SMSFW,<GD-<RR*_H[O@<05'B;C:<(QG6@^I!ZR/P^=7A]*
MT:M$>!$<&WVV4D_,;EGM'FEO:+A1:W48+]D;F'G_;HYU9][$?EJ'S"\CX?W7
MZNNH6W@.Q'4RMOL<P:6$8I9*N0 S\0ME541Y2B&DDJ5C[[!U>.R/O.#]EO(P
M DP3N;6R-+PM!-2$>]^A6(&CUO-.W[Q;639D&'V:HR-\OQ IS:RKP\ACOFZ"
M9-?8_NS7 -9^G&1G)4*1JU3*^_W>X;''1YZ"KD127^0Q:B3<L;?CU'XR4AEN
MTM7"OE3Q9L6(OST&.E%/#<N+>.:L)2HH(O0!:LSA_Q$I@?QJ!X<0RN(12A7(
M/G2]8,OXIJJ5599 ]_(SWHSNA#G+QYY>E_E56%]2'$E1E""[_2*:-U4#(;!?
M6+6U']'M<,;KU\I>4Y)13QE/1+GS^8F331F+=[IL%<X=R?IQTT/P>>T G9OE
MI0M]Y,%,/UJ,=G+R=IO5"W@'C!,/YQ_?-DA<H@A]46IQZCK%G5G1EO$V%\1V
M<PYY71H%HLD22=K;WP#*XE=8MW-J3@9FV4A 2J\XW)/2!_\T.W\P1U^!W\/;
M9D&X_BUG%3RLE7J&%C*%%*994""Q=%D_K5_SHOM5I4 L881C0SAP_G!=0^84
MA=7RX;#\_5:).Q^><NJPM%+P1!0)_)KV8+^0IDD97FA/CW7[3<S[ZCP/^/?%
M7ZG/YB@(DYM>J#^D$W+LWF%V^!?50SV!JI-*^Q5(?80592"Y'CKKO2"602R0
M[LSK;3%KK@*2^SDO2L65<<>]JZTQ;4!'F%VS+7TR($<K5SPP]0,O1E>DF>V7
M&9U"\$\AV*EZ")-QVFE"4.)!%-':I:]0%&V=.37?O2QX08N/)/3]4=;"!<DB
M>^\3862D!"!._KT=0EGOA7(B(O=3$1&+\5.TX/)?='X*-+I>=>0BG]D0I?>U
MOV;38_6&WLNN$A\$+7HX!A19YQN"YM9[SJ [1]D05H M>8\!@E$T>@.\ZF$\
M\!-+R^I'7<V.9@<NMCR)/V0>\,UZR4*T8Z'S2%0U-R0!)HTXQV0C\@"4 $N%
M\)+:-,MG >G>\:R70%0#G[9M*GV@@9A1%-OSTIPW74*UV>*60)^ $.(0$$]N
M[8(=8(!\,*ST#ZRFS4 (,?**+07:S0!Q?2TXO\0CZS#O<O];_"FJ]0>_L?=C
MK^Y^(%AY*$=84Z"]Z>G@IIT>:/(#6"=4\J<;]R?:$:*J8"50;)S7[=CRQ%E3
MZ-QA/)OG<;4 %1,%M3E'+LF'1IA_593]ZQ.868 E(?61N#U\*L(,$E!UA;!=
M1V" )/T>7,XBK_=(!3X=*>[SUS:5R1W[:J(X8WW8YL>3RQ;7[X(X9Z\Z/@$\
MB.O)=$[Z1R@3J;[.W)-5L/GD[!1:X&%^8GKF9YT$Z4>:*'MO5HSDAHAV4.2;
MTR -9FQP#!"AK!<KZTS3:B./)K<I8U8<M-Q^YL%2:9I&SXY6!,GQ8@(]I3U5
M)*W,,^1C,E]X/A2P+VI3Z$.3;34>&DE.A9)XK,9HWD2#=6Z_)@<WE08R)J9Z
M?<Y"C-1HN<;KWWCJKK2_<.[&E_(C$FF.VX5,Y(US0IR9Z!"&9RWDQC>@17X6
M&E$<<I2FZ]$\U_$NKKXA51^I$>'6V.7O1=>-S]UA];I["K07E[2!!]-G8+Q(
M&5\C\<@0$\J%O9V4 .38"[@RE/SEMW^(_(O[/#B5KUPI)^?'1>T-A0M5R P0
M*9'L" /LF7$QH]I/D-I8V3;@HV93]?>K&LX>[A-X/JQ;\7!7DS;D>'R!5GG_
MA8!=4=M)5-<%U*UWNOM&/2Z3#21ELZG%IS_IVE,T_9" (C\A4V%KQ9/S9QZ%
M<V4*IF=OGS3S>/A X!&,J;2[,2D0P74CP>4]:)(.6-!E&87+:7%,IFF&E Z7
M^U)[4?Y-UR8E%?C//[XS!#U^NI/S]1A,!CF$(MMA^<RI&C_==(#=^\2O$38-
M.0!\I@\'B;GU;F+31I?GT2,WJX!#:?)ON9S>'/,R,[^C'XV,!1JH-@AYX.Q+
M'ZG^N@K7E0F@T;A0<(RF>6,O=:WQTLWS 46/A.6YWH=E/;(_G",I"=H\KCJ"
ME$5.8;F1BCZ%RI,!XM?&=078YY[1[ FCAWZ.SZXXWT->N9A&/C6L4*2M\-+S
M]B&)Q\88LO(V%C"G6OP:]X5PD1KVS3[*"N%MLWHU7D#%GO(.BB3[G'!B\\^V
M?-QV.!-]\M3Q3M"#;-$?V/H3B=0+0)GI.$*=>A;HL2!_R-TKAPK"B^B?KW]9
M;CPB^:Q*_2NOW<</HBQ/2,:]I,!YC0 B.)4!JH.0TLES"]?1];?J*-HF0+S_
M&UD/<XIU0<;D/4CMW.YKE,STXYX$68K@-?% Z)"5',CH35&'&_E5#:5I>PHH
MIO!3N\'U8ECR[T[Z <IUNM@G(CF[(,MU!9?]YDAK:W/.VL&H6"^4NKSQRVA-
M9=U9>A]6FBY/,VFD8+KPJ3.-N87ZS#J*&PNM<NC_?$X.$TA1FPZG6Q#%<L39
M'R->9M0\- ;)?345)4*D$+I4!X0+,!=$GNAT.]T!A)(W>LZY?'7L/W.VO:"_
MM!)F6%G4CQ\5XKF:*F*Q4>_U]*W]XM&'9UN2=F,(&OWX)# +LUMAY9@L0];H
M^/!B 6</A&^1TO&,2!TYPZ7+HZJI\W;$Z_YVJ$7IX_NW+MPI[PMY_BU@ ( 1
M\'..VUD 7P#5R0=;OU9&@ H!F5T-:'8X]ZCEV]QSC;6(]M)2?#Y+(:$TV?U^
M;_G5H;!R;G909) I8K 8^0E5'T0*I>HCU"CHU>&R<X1$&DHG<1$J-L*K;T50
M(>78-SM5+07A+^X<:M,4<[!?6? 4O+SNS*0S"O1Q/"]2UA]??Q1#4>[&"C>H
M?CV^"*6XQN:M.+M.ZHW<:;IC[2_BY@DY,6-N=^C0N<$%UI4'JGU8?W2JG![Y
MBU10)S;JP9,["&-*0-MO9WP]CQ: NOB0-?S-L/2!LANJ(A=IEH8U:<;!5YCD
M ])Q%/BQJ+_J2Z82XWO;[S=81SA_BNTO*S<4[/7.^A#<>MOO31M+)\B&L\;V
M.J0?CQ,G#'2JJI^ 2EN7?UF1VEJN(]-C7OI>@?E)E:S$,CF7Z*V <AYM&?FT
M:W%F(4@^^B0#Q$_7!@:N @'>+X&LG@Z5L56/CC8R/GE3\AZUSEOAB=73GN]>
M"2W97U(^N\=$FQF?/9ZT.SU*YTZDJOLAQ>J ^&*P. QPOIJPTJ%>0P[XUG(K
MP?/P\?DOQP-BWPY=0]Z,FFS\VMTNO@@EF9![%A[MB654#E3\RIM)Q$$!<\1I
MPMGCUF8,D$V:KH#B6)^X18:%NL*A8H7GCU58QWPPSQD@+SPNW1[8I[H@KI*K
MGV'\E'N,9,GK\84]QE/U'EZA)7CK[:YPF;%!J0^9PB+W'15O',"J'H@$;Z.G
M(3ZR^H22!^&KHP2J%4;$;V_DU?.\4@8H9WI/M'X\(-\N4SE4.^&*HEFSTC-+
MNY>QH ?JHAO0OF6L+^1SUA6R1F\R%H>^#J26 .D##[SC#:&$=#%?,<'ZI3T3
MB7=O(YQNPCU3:[N%7*^%9&W,F!,%1&EN^Z]1?E!)VD$@E)+E2!:(Z9"\]MF4
MR.?8(S9=]=I?JN&;66BL4G.<9QS7S=E6OT!OA#?K0X&2GY@\(P%$^/X+A#01
MD@RI@Z0I@ ^UA9!W+L0[DTWW!H+<]9-NG[CY>&[@E+1\FL^/E![%)%$GT1O-
M'^^C$^78]M_1A>D?\P9(5XA!<V<HAKY,M.2WQJS,\[\CDQZ2/SNY:P^^JKRI
M87CGU1%(0=MS?:;<Q/A@!&8:!' NS!H*)<_U0C@-O7S)Z^<IL/B%:4/WBJH6
M5W\Q*]UZNSYO7Q&*SG&G]T._3RGI\;W.NA[?'21)NP484._T4%7\83);X,0.
MF2D$GU&K>G^[MY\NE&]$9%GJX%)]DB+\%O_Y>..YW)B'X:!(B*F(#<O_T#R@
MMU#R@FWQX64.?R)8%,:L%'64W^Y6 &J[@1P?BY2B71H+4FJB*,5AB;ICH17'
M"#=K/C1QD?-[513@WV&:%VO3_:C(MS0H>9B 35V_,=G&+#"3J37U./5J7>NC
MTO$)WA!5BQ*,(<48G+]7#M00US_[&U.J:R@:_6?B>[ L](E#?E*<:1KJIOUO
M$.*!(R)2Q6J44^^<;N5^X+#X+)(B%&7#O7-6:&(!U8O%P0B1V4VD[XNP9&=Z
M1OD7_Q;1G(1[TOEGS^@VWLN,6*Y4*_8YDJ&H"?K(4U<.*C3_W#W_Q67_L7&A
MPTBAPUA3H&;*O7X#!^_8-O8%&*LB!5#N>G YK0G:\?U>U1G58&W4_;8&Z73E
MK%_&8 7Z *1^8)5"AC&_.B12_(EZB027GQWZOUJR1JM=E<H[ZC=($SMJ -5$
M08$C55]K-W%@7=S(=2%2:X> 7=5D@M1B_W3Z"_@#,,YMIE>0S^:^X+*4[M1\
M44#)TT8QB?>%RH/=45H_)#$U= 'Z8 <?<(^N:Z0IY9TTTX<6VA(0Q[TJ>S&0
MJF55$H5X,C\>Z+D1LI3Z:(U:++.'K"GZ.7]D?.G3UOY1W-[0TME<L?#':C47
ML5\];Y@(W%1A)4+2]LKB9^C<QXH1[E,HOSDL"##I8X .QF41!, _'<]<;XD<
M^2;U*/.++RDD(BCX@/:!S)0 M2N!1#/<1Z;2(Z.= '&J/<(&"*8:PP>(UIMX
M7J]QPW/$=@>^4[[ZF5WN=RGFONJI;9I?++G?.YBQ1.\F:?F39CMD:&??D8O@
M0HN=>=H_@Q\JC*&M$G"'!P./J+Z]:[D\.541Q VXC?9@R0G.\,!N=>7W/I#:
MQ3K3IHVTNX5.TF'/GZ=XY(%V3;:+QG6:(5[KL_D66=#8*D?B:,_[G"_]>FQ?
MDIMD->LSTDV22$8G'F+)5S1B3KPX@!=H<Z@TMV/]?$A@T8T!"B7L<^SA<$,[
M%^KSI(\5YWP\%I"=<U"! 7+XR=5=RXR"A$+#F0"PQ;O)A>DUG59?#?5B.*EZ
MGEVK-SUUJ-KLJ@SOP_N=FR\$8K >6!QT.PAP98#8NB?;6"G:?7F7LRH_+SMO
MK+B)3I9:!&U!&J]_';[M'D7>40T6&6/SY*TJ>$$KDVG([8'*T+@IN:MC%;0(
M8*Z:=G+B,'!,.6ZF3V]L]O;85A$%NJWZ3(.T%(>/Q*[%B-HYS_G<YN#</+%(
M^/%00Y</XM!*UDM7GWX<I9/_3.=]GI62K-A1U:>=F]?MOX:<^T2S+K5F(HQ9
M_:1:M7A 7\%6R[!(\>D>A6@)[TD;S@$W[K$.(7C6 %H"J0A7WGY&R>VS#KH(
M0()?^AO)M\9;!8@J!)TAJEXM[,:)Y*UHR29(-RH"RJ=X2##RY1&PU2>LN\:C
M,&?3E#"*)9/R7GH')UYG59M>5L-L^<I^+OR>B'$<HQTC! GX>/1(<<;54V4U
M;3/N_3+020)5[<3GO#C!?]GL],BUB4TJW]%^68V+-7$XW+Q2VOS\_.&,WH<W
MCI<3C&5 IT18EE#U321A<M-"\*>VTQ2L:5M,-U(K[\?%*4/[,RKC]45CB(SY
MX7<ZJD;$). SE\$S^.CPZV+Z,/H@UA\?V\@ D:W3A9<=I=83#<_? ')? MJP
M,SGY&O%BRMK7Y]DS+4C?$FG88U%F-[\AOG!3.^C= U=K<ZTG5XN:FPJXK=DH
M\98B6PY7NC@_30<]HH,!@4X;JX %&-NRE%K(6]_%\7N?JW+.GQ$3+!_<^\3Y
M 5R+ZAV-!]=">J')^#KL %YV64ZH)9=H5$;$\[H!Z;9I'_'V8UM"66J/A[6/
M#XU9**49EQV_ZFF/G07WS4M/-&C@6.G<+,3AU_585J#I>M*.Y:1R[9/=O1/I
M9<DHDF+BU?=CPXV.QB)UQZ-9OFAO-B4A#BZDR_3P-:6V29?Z"\Y9+KD,O%D>
MNZX&W?\N= P7V6>^B.'  8N=9[ ]V^V9_7PNEH6=7YQ[8TGC3A\B,EROZ:N<
M9GE2;?Q>(0D$C8<=:CM"\>A\8,YT8@^['1>/\:7 ?!VQWID:1@=%M(P&15WO
M<IWR8@L7): ;!6@B IUX$(()8JQ='8KD-[0+4R0V"B1E"Z@? 5]H"F3_2NJM
M;(VW:Z0$YERZ(W)H:KU0@)P;CV EG-7NG#\T7E0S7A_!=;M^3L5,B$O>../%
M-O<+I.@5&.!.GNA[$#5%LR7_/C]9/<2N[[AW2=OBZCWI LL_%?<<R4;3VW]N
M&$'&$KU[L*S(:2,1H(!B0'2,PW"F(>Q? 6D?5U;<E5J=^QUX[H-7I^_<'\KH
M-[K*RV'I5T%5I<_!6(UXZ'TX<*R1+H"_3%Y/,9(  L$"\*PN_9V,@8K(VOXC
M@1DFMZ'/3C\W2Q5,T7KW^ 8Y>!,?;\1L7.30Q14C0;)<:NEU2\$TR\VO)R1D
MLPZ3U)(.2H(67QF7P0#6S@>81'6:UQNXLD7S% DDUE+5GR_\I9O3.C/["S;J
MA4 &G9\63&ZB"2ML@X"((OJG0UR&WD2S]N8)PV-*WQQ2=;>^?LD-8,NZ/"Q:
M>2?YZ?0UKQLUOR<?EP5MWZ"8=XZ":0'U (DRL-T)P!;!2;CLBF6Z"!D3V^;O
M%>Q%R/>]'V'%]>B55>(WUITFQ: [>N57)2 V\-Q..C>EJ+M#DXS,K>"YV?_%
M[P$B9->EIC5PRR DZGEHY^:;,[!N\*,]N9=BF"+$23*IX&OK6O3*S(7HTPI!
M]E[&YW9$6'Z;IG>MS^UTRADRXQWWJP?&N;5OTK<Q]'@E+SU%U\E[8M-)L*_T
MD>V)O*&DI%$%=^Q]M93>0DT,LS-&-P-U^JLF"^6(\&)X&-XDW?@AW&'18K(L
M;XVHH16D\W5 4>7Q6P.]A'GC<[<SHM#EKD(7--]'9<=).GD*+MOX.E_.?ND[
MYBMU]%F0M^\!4O3TN&C:J9DQ>V-0I KK#^@<>E$\J4V  B- >M0UB$:YY/5+
ME%!Z>5YN+PEJW5"P^2IZ5L[ (+R5@^M6\Y<A.6-X2BPO'*.[G[^5+@!#=5WA
MP\2B?-""M,MU#<"1<A<K8F2@R\$ ^GA+>XRE?X!Z:KW@D )O*07K;^%XY_B0
MT2A%/ ZA3R0=M^;I*P373*EY'1[V+L<I4HSXS6R[.#EQSU[!3;H?J#IWI!(B
MSXQ5!N3AWN-FS26;'CV^Y%O/EV#!5M[Y7H2%HM\IJPV=8( 6'NZEZ(4%]]<B
MY"AJXVS&^A;=6\_27RO^T*U80$G!0Q::2,GD5B*J/Q4Y84K&)Z%N5?#Q]'3(
M3Y\0XSFU91%HMQ+AD/W>XENF6&H_47\WPLSB0,= 3#==JN&30*QZFX&'7,X-
MG\OYLD4\(=+>=^_?",#=O:L9DV7[JY"/')]8?X2 $H)?L9[4Z>/F*(CTD'D+
MPMZ[?YN;,I>FPKH$F14F0J.,U%%=YXW.PO&$QF*QE\6C! QW3U EKCI@2RP!
MUOO;Y##1IZ?X@N+UUYHR0B!=$JI^AW2.G+MM"MA#^D93'DS@EG_=S<G1(Q_V
MQ51_O5;<E" D'L$6DG/\C>BS9\9'6P.T>PKEQF[I2QG%>/DJN RP6@;X9=0D
M&>X&?S?>=53VVY0\]<N: HXU5%_D$9TP="%40:XV6EYX'50^6_*SFH4E^MUA
M&4W)7]&1/JR+#- CL"B=$X$"NE[0/\$:H"0/<HD?SFMZ/1[,?2\HH25TJC'*
M$"O_Y?(O_;VP(I/;O,7#"9D*; 4]14#H(I03.8AM@O3A^6FW*6?3XS9124*^
MS/[FT%[UM;2A8/4Q+ME_#FIT_I"U=-&IE((^&3W5GQ%!T6B.RC6%UGK BO"T
M-+&G3^T!7TOMR=-LAYZQR6U5$%%<<&@_SGM;(X6F6>:W[=63;WUYR""AB3^U
MT=C,[ 'QH9$+ *$H=,H=VW]#/TF?KP-R>%!Q2&FR:WJ<#@,DNC&=AY[US%G9
M6Q*S0?PLRA@_]%/"@(/+1;0'1I_$LJ"""LX?,])!3J %:#SDP.FMHTWD$\6+
M(T9\WGTDZ3CSR=S1D8)7W]F<&: JQ*WSV.,S7S0(&'[+%PQ0MZIR_&J^U08;
M9/;5&!_V"<>!^_"Y)MF:I!X&*%:2;$5/6(]%D0N90$I481VAGT*.X^ODTD]$
MD6,6+SEDT"! (J$LRXI2.M6K2FCMV^4-,UM6Q*4J*H^8&7C<8_6H68 '=5D)
M/$3SHH+P7( T_>!7HHO5.K?_ [G7H93\B^3I6EQ.NF=--Z2N.B7_F\6)0L1
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M9U83^8!N2@+Z+'):;!(8!$Q^XO2K/^FB/;^8D!G>($?^<6*#,AF'F'H+\$*
M1MQE#$Z@M\7?03;FP<D_A]EUY]Z?5?"+&9=V[DW$'^<UJ&)AF*G49L1/*L20
MF81NRY;A-S81SP'%LA[YZ9>"Y8\^0%/ZQXBO2Y\.-ZT38?IGLXB_/3 )JAE\
M0$2,XE?"Z"L'Q^&&[+4BY!5;H(=@K"(EHH[L&ZC7AE2-NV&JV.^VMIQ*CZ_9
ML'2R0OUQGR#<32<#NXG[ESA+W# @R&W\00H39$/QD&],74F@V:"LYU8*QGMV
MV\9ZJ'NXY7LF]0AJR![?=Y5MXQ5;XK -02^,"7*&C"I AU<F5F(V;.CRC&.2
M19,+ACW!(>N)MC;?'!XO-<PB1$.BLN<R>&\Y10NZ@BR'*HF0\M/TG%&B8M0&
M,@[Q/OTQ[*!([6Z[>8&MB(9KU3CKO$6',[E6'QXK-=]FCY#SJ0!I.]J/_:)W
M_X  ])[_8K7Y?\LLL$S[LYV[P7D5F9^4NIRK#WCEAC_T3[SWG2L[DK^C,530
MWU+;2;;^6!<!<^02H1,&58A^4&?>MIAVS]UHSP'QFOBC4]%0/H4BN;N69W=]
MW>(VP%QM4F""6IK)U8N#?D6,KB9ARFVR(@$;V U-PS:?\XIW3;9RA0ZG05RB
M45:W&WDW.V#O]5GYN[F37B:UP3Q)R,T&RFM2)"$AB52P>:=OEH2)453-R,?1
M+'-2LV[@XL*/#?4)?EP[$7.*+TBZU6"51ZP2-F2332R74RDPC@MZ5C+PLM8"
M(SS9PX/RN%]?A<H;V8'U'F]Q"GS>@G*[?V9,_R*M=XPAG-<MOA*R)BN^@I9)
MC[T.18Q1?)L%.I:J"3WJK=E\I,J.=D'$8V63MZ[OK6TDD0'D@YZS(3==(G=_
M'[M[BC=QMUKMM3=>\C?KO,,Q'HA$3#FR;<%[M$!WZ$B@8XO2@CT+AER5(+>A
MX:G;'YCI6D+K[->M.J62]#'LM)BFD"SW9\.8$ZX&U_15]ZUHA6Z?*6#I7NDP
M'"?7#<K^N$NQ@-,<K]=*J:!8T?=EC(S60I*'OE>EYN7Z?Z6XQU!Y-Z7H91CW
MFD5OV@4B/N%<!9A=^RC%0G;,T*"JJNJ"GY"SAB?$0%\SYZ-+1DY458"<@\5^
M6:@\S)R21>R-PQ]3Q<0TG:M/"(5"OSHU8I+Y+KO-:+BX2Q-NL($T0"S!E*O.
M2DUJ>0(5Q%S6D+ZL-+0YSPLQEV[G#?^Z\=G$N.9;A;?<+/,LC,TP]=+2/RKN
M&QE;VN)B^NS[1SH@.J%FU .,?F2E<Q[ZYYV5#Q C^RU(>"QZWP]<)C[:OJ5]
M<-2D7S[,Q&=Z)2I%+JY%>@TY_CF#V*"W^9Q")_:.A$SZ-Y+1[:?UV(?*'K#Q
MW*-W&]ZY]O1#P1[_SD%+G^DHN2#).&UE?K/3V2(/B+G<<">U<?28T1D=R7[/
M$>,ANP$V75860_D(2>X[TU)>EGO38L?=#>Y[2O9;QC0U9IXQD,YIO-1UZ(]S
M:12G7\WG*Y #&/HW@9#PC6$*L21Y,PR&$;@BN(]V;TZ,[/931MY_NB-WFV/S
M:5_3*7@OLF)_5),FQ7&SEV)$ZL8R3B7T.7VA>>:5(]QL;4;U>$?X&ON]GX,L
M'YQ0YHNW/:US>V,:!B6BN>!=0 ]"/+VC=IB@)4*^*\G=>G1NA33:JJW:#Q\H
M4(L5CM.7J'R3+-:VMRA@,RT5;N&M:C.S[Z%6RJ8Q&>#SDQU9'2)GZ;D,7MIY
MTIM-3QZD#VGM2K)6]>TOT_G4&YT?)$EFH,<?[Y\.6TI=A2PFHF!L9-Q2$1$J
MPF@;X6X '\[ZX##0?BX[+*\R.[YP@;BJ5KG*Z2Y>WN&YB52ZTLR7=DI?=:/M
MOWLQ^)?D[=^?'%;FN#OJ#)5LI!18C[,:%LY0)19M"$B/?<.B4UZ7XHXF/34R
MSVF*?S.8L7:RICYW29$#/@(N T!S)0(N0BDF91'V->93<+J4Z!*/$<7'6:UE
M51EY4-N;-UNJ6<)KT@R/]\UHA#:O<19WFO%/(IQ,$O%ER&;P$U\[]P#D,15(
MK,"S<KV@26\."M08(V"4JRR=:*2,O^B9%]B)U\;*3*>I7>C:AL=L;V!O<E]\
M\&QV165TQK/B16;L3.-DD);PRM!L'Z*$LF7/;7MB.3]Y6E_RJUGR=.6;KZ9U
M[GCGCA([=TS9<BPYRVC0$T)P",0TX]3*.8Y6U;*4IK_M\#V>='ESAC7V25*N
MO%#NIUO"SW)!A^<7&IRH%VF<)(X6##=%><([IB&4B#\:N& 2J3^D:3,Y*NT)
MOMJ7^U)!H'U$NM3+L.*]#F^&V+G"FYMO86W%LYFR54'F N_#BLX:IHVHE2PN
M9^G+(SVD[N0]2.!SWBAL=W\F)N(QGU(W8XN2'!T+J(\?C<]R*:+X3@8\:5"E
M"@7F3D@B"]P/$DVX*&N&7]$K:7R,;LET%X\'/,>H6]M(UY>V"CTU>Y<_L_A"
MV=Y0^$6BB4GD"'P;1V'5H^,D*])<]:JEV7<UP=XS89LP%VU[Z)FV^RJ6!LVF
MCXLZ1WS3E=T60GG'7/-^^!H*6WAE91I=U"Q2S:L,"6C(VOBZ 0F#"#9(D+HW
M$91JTNJ"\5>3J(:0O#D@#"(\V)SYY&]C;(HK4C.PBL]%PW4'[TZ$58?96^EP
MYPFIRG#+&&OTK$',^3I68[;QM2_O&EFO%PVD?1V(6;__K'*M ?FQ^Q5 $&H_
M_XMFMWR1/)%M592@HL1'IH$^,*OI@DV-P$H%06..&2#@G[%).BEB3_.$A'@%
M]@1%MJ^P,<:R3Y+--]-)LR84P=")S56C\(+X]1Y3XH]WT9I8Z>B&7"I>V6O_
M=]EL7[OJI;.W)^1-)BRCY.!2-"WR_IAU_N-1[B)@$BKOTTXX<9N<>M.QTBDC
MZE:)_RD-\^A)57( 319/D?*FBT$WDP'7T6B#T%+/@VW@O2/0I?C<!64@ E6P
M(0Z)DM;/^=@IX0D;V:_9^KY[7]W'*W=-I_P303? <RES(WC;=U.0A%DL?TTS
M'%1H8F%T(7DT=Q55/5GP>TNA7ACR]'0)^QSUW-%C+EOYQ*WX\%U5N4(3 CL)
M?T1\FM(?((*:]:N%6E-2+,.@Z+=8 I$F)S+T^7X&&;BI]L_5S!U7AO6?!17(
M'T84((]\B+_%0DS"F0Z&08DW/10YT[MD?X@)2C;<\]MLZ7&@@IG$@C\M_P\H
M#3#'_[IY_?_^A:U=GV'6?7!Q2B1AO" 7=IQ<B8S4U-=T56ET9X*N\KX;>9=D
MR//D?;32HW1^/CD.=W+OB,CL9A2I.M'E:T7OZ"RA SMV:/-,0FH.!=V\N7HU
MRT'GV?8J7F<FXID&F_0(G^*9KAV!)GY*,0K>AF#'>"9&56$J35H6%*.M\5&.
M W[LHC=(-H'))APW\UY<B]?V\(LQ<[X:+=&BA%[A@96QZ$YP>-/3-,W(ZK;D
M1CHZ'N,%B81R+J4;.,?JD.#AGAX^=QEW'9<.]]E?-0 9W"KD3S(.;-X*WE[9
MU"4C%W6()B+S:HARJ<4ECK"-9_W\*Y4'&,<,"6NJZ"R^TT$K'D=29D]7I]?,
M>BW":L$7_]X] ^1>!JO)1"+K J9:,K?0O<XEZS1IYD4>;=9^KXO0OMU-:]B2
M2?9DEY6C=NHB^HK^/6,U6QYEVRO1&;I2YPAMD:_ZTRMBMTK38NQ2EN$!??:
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M7=2VW[;0:NO%&].\PC9-.WYSGI7:<11.QU<PP4&&6"!O"X0'Q@EN#;$LC_S
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MGT(%W5'_5K9QKK?L@9STP%&YJY(2*2?2!2.,;+^6J"0^@?# A6AVX&-^$*Y
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M@IOJ+22 MP4P)$P/^'*?#O?VA9U;?\\IPC],BLYXT[C!#..6+<:'-.C.+O2
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MO;CK$TV7(D_RG>1NX$'R:G,&NK2=MD[V=""+A'G#WJ5\+<S@4_ 9J=04FP#
M ?+E%@G]D":5[YII]TYTU*A?3JRJ.DJDWC&.!?K!(O4?WVCQ?]<3R$OC@DY"
M6_&/P'LK,+RTDV3U38M<7V*AW$P-E4MY.1Q5:IL_G/05UO>ZDW\2+5EW+]#Z
M^>(-:3.WLQJR2SLO* U&FB("YOE9URT'?/&NZ&Y%2N#*$D#L=%*8(/DE0(<D
M_?R5E03&,&;="K(Z/H#9%FDJH%_IP62#89AMSADF""=4OBVUI0=(7(B9*WHW
M0"0>P#PH663\1%H1D0F*&9=D#'[U;##7>J$.=HA@?X>J+'\R>D@4F:EW5DQS
M8\*R"=?M>*KRU)FB+X4#/O[^H^O:*0>C"^*PNA6<!@;SU'!N)+&7AP+] !=H
M(J?'PRZXY+F=\RRW=1=(>WVO[)+WL;CR^K)=YS=4IS'L"&_\,"<1'U<"VS61
M&'?/\.U\K8"F0$1*D$-FTIXS5<GS?).U9Z8.9)2/U":$?2M$2U)JJ??AW>#=
M#7Y26$@,DIO8O_&M9+(NW5C ?!I;HN3BF,*F\$JX ./^C62Y9$[5A.E1+$MH
M'B3%ME#%&Z3>2,]2!=4E@[[AA.RGND[IGV.],P1E3GKF73KZ12@&M"X@VZMI
M1;5D](KL[6_@+:5@B?$)+UW(AZ]P-E=;GC8H*LQ(4TO<[RS&]K[=5_*+NF^"
M1P%YMC5Q+^WTP-T-A/ ">6YH) +MEC?<+>[58E.?8<$G*KCK>$/<VX,3+LDL
M(*_K]H9DE\T? '/?'[CL'0'E@LOIY'M4;9;9]A:P2ZX&7'FS-Y>33:'FC!;5
M4I^DMYE($:1><:VV!M@W1W2P=Q1J4>H('I7UOMOC1!>KG#'/E:[F]FG^YO9[
MKGNJ<FJFZ:^TV3'M[?07Z1U#+NW=N4R0NWKD)B937CE1V7_LY5JU_Z)OG.]-
M"#_F+F:X>C.4?,/^(*61#*:*F66W*8I6,CH::L98-7*:?MSVXW?][GAVLD#T
MH99VS)KB8W"5XN(852\PY1HILAD1G>1AG98*-"P\<Z[ZFLJ1<D]+;=B5LU)[
MA(9FPJGG88)D]78[E\V0+PVA+KZ3$ XW\OC"N;WN##]4?=3'^F/U5T1=:_8F
MS2B<[P'YJ_PDD99:DR8Q>(XFX06X"&DVCF;(';X24VFRB.<8[>(L:ZA;'3$Y
M:5!TR%]6J&J_L#M4D ;T#C8L%QWO1UD\C"F]D#LG<L<+[];T_'3,T0HAGF_?
M7QP^*_I073JG(8!HN42EBL+$R/%;#V$^Y(0#E7;2CTILYD:,IG?FWL019PQO
MWC%T3+B2FB[\8\^WPA(FZ""ENH6A21I,CVO@)@IJV>A_10V%0DP'EGE<O41O
M/_TQ?^56:/'%?\U/VFZ[, [-,4&28SF(;V1/)NA-0.J&*@S0"RP/F* 4KS[(
M8F 5$]2O\7$S$,'0NP%I#3J[0HN1#0:__+GL- 2_"(]%-(LR05.CE1BJB )B
M/>%S4SXZ#3&1A%CU','3$WDA.WHN4#-+XHM+3)#86R:("+'O!/)?UZ-)/86/
M8<I78C!N^&&D#>7ZA*=%"^YFVOQ')LC(R,JJI#2_LBZ&X+F\^_%54[[-[,-*
MAP^?M@>3S3;+ A\(RS8C2:;H;Q H*3WR%4[..;8]6*U8I#AG#E=V-=[;'Z<6
MEV*E^)Q7V(;MVI3RGO7()2F2;RM24%M(,1+&0=:X3D)$J8R9CIJ3&(T%R=TL
MT_7+.ME'FKUN>9D3O%,?]5Z3;=.6@^VB8P ;]XY<I>VB;!.A3T;VAVT$G3#A
M6A!A/9?:GA?J(51T(N: 5^Y-5%P62,[>[M6+/?:G%X3:J\G]W1-H&C<O41*E
MB.40#"Q2!8?O'!*WWT_Z5/?FZ2-5K'>2(T3T!<G$[.;X<1*RE8,WT'"SG%[L
MI_@DL_<A3'V2(PQWSC_U-25F4+Z2W=3#2&'MTU<%^<'$9$2@V/F.$&GQ1]#+
M@7LV?<B\CYF@NU >QI>3A7/8\SA-]C<_@KV07,F"S^]4)%LX3)2.A=N=/Q$]
M,75H$>&:&!F,:5L!2%\']& #),C3&T%,W.\>K!/?-GDJXF2IIT0X_\>(6X]>
M<#XTWO5!2WK/%%B0=ISDTH'?"^^ [-<^_BTK7JP5S*'*:O.JAH-?F\LT^37$
M__*]4M1PDHF["3_-GHR,9H)<F" .&@L%!Q.GQ)/J)SL>KWMS?AK>?Z.:,5CM
M(7_]PE3>)Y"VB;9#YZDSW,L,,#V5YOMF'EF>M[BSG-Q-"CE?4T8^H"_1\SW9
M->>#:I/9#/24E\:F<&-YFP-\&/$NOXQZGN9,\2,/$-)C[E;8.6+MQ0<$V\KL
ME4NLAQ(]0KGG6_W%G%WS8D]/[:+B6!ZV@>Y9,D$"?M P*.D&1TQU)O0#1H@R
M@8=!2$1-D0,#2UXB VXU&GF\O*<>"IX1-+Q_V,<&469?70CO1U8&)#)!7NQB
MS4H4#:P\@4+[7[R]9U03T;O_.PK2(2*]2$!0D*I(44$"*DU$FA"*$!61)J "
M$B0F%.E-0.$G"$$1$6DB55KHH(CT+H0D6"B!1#0,I-UX[KIO[KIO_G>=<U[,
MFYFUINW]?)_/=\^S]X@Q$\N'!-;@+>G/%C[=BW@DKCG$71M\4+WNE#A :1ZI
M0DK1,%3?>$Z3X!188TWSC87',HDX@559S_07=DH?4SPL_C,XOC_F//9$4(]8
MUZ!$#[*"9@D2"'AQ5%C>,BPM3-C0 L01_N1_QCL4(?&65*[>H.#J*>_D&.OK
M1QSG-&^G6XR^;@!0554,']#\1@6(80G @ZA./9E$?[31B,G+-]H?@T-(E#O+
M?N5BIM!(#>Z#W^('% )/#CCLX,GGZ!>1@;3;("R*:NA:F^?8%NG]@;(4?SOT
M7N5::&'N]-V8[&%E4K'1U5/7X_6_@!,T(>8+8VOZN37HOGI\O()<O4<F?T>Z
M3Z5V?+!V\8V0[Y;W?CQ>_'%<@%Z7;8[\-R*2Q=$-(4P25)"EN(@L(Z@FO0;]
MEY/"A@UMJ4=I;X/RX+][G=::4X!;STN<G6\3#$\Z"V\?A-QF/F4)XEE?V8!0
MPU8JXO#?A:@:!;#1DLK;VXZ!M::8ISUK2-I.#71-?)HB<J*R1ZX6(<LP +&4
MH<X.$_ D/=22JM%30\Q,PAX*]T,?\9MN^=Z6=]?_X?J=]VXE<.W:^:/MN690
M#;'\O;@!G. _QXH[S('(NN6??>E.!,FL&\0@I; M,H3?*^ -4<VG.3ZX2ZSW
M:D*=H5JQ]T[:<Z7[@:^9G%QWG0W$X*5QOE@Q%"<FNMF  (AQFJQWB3L_K15V
M^D:47#.%-AZ95?8?"1^K(8F5:L)7/ZZ%3=6$:=Z6C\^\,_2TE&L[G;E4L'?@
M$I1,6AX3BS;Q7)I%28 #G.8??M.?C>A[%9#U3;_EHY);MUC]H==">[)X,,*?
M9 0!_![ 1+<T-XTO\&0%*7R\5]:J=VA)\](QY-"[VO.$I,]QL;H'[HSR?F$#
M38F,O)&Y"M9GCJA//!J^@\;#UCOX,7.=R"@V8-I2G4KK8;Y .=!-0:>>?&R/
MG?2\GX(NQ3"%W&9..&?CT.!/EEV3"#MQ[<B3?IE#%B[J$2)\7T]$"JLN(\CQ
MU!IB2%R;'=T#C",L%1+8P/Y ;\^),$CBF[V(R;]Z"58O<XF!O9E#&3KZWRQ2
M%@KD_K-\G>O7/#A"V( VX#<$'W'@C\\5_6D<=95BT$ Z9],KV:%&>?!Q?P A
MY*AN/=S%"=@YI?U@RZ)+H&04\OI./7;^('I,:KZCE!@B@NOAI32G#%AE\/.\
MS6]Z\?CS2)UOUG=^'B[?>UY&,SG(4 ('? 67Q2.* !!*VDKLT*-D+JAB>W:@
M8C5_3S<\TCYSR]]D6&5Z5:T]7?!@]7>H-/>R$/  ^KXI W.;#4!1D$=.M.N4
MX:68EWU$P3]3QJ?>FJE(G35X._X\N,HG9C&^E3<G(C=QR)[DQY5"N[2[3DC<
MP%&WEV$;ZZ0@&"&O%P]99%RC#B1OHFS*P53GB2*MX^$:SV]N.RC9;[Y7.;EQ
M+;:OPSMM.0H73Z0**<A,%%/#I]KV/KAVM[R8#KCH>(U;P5M1\6#ICNB3TWV
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MQAZR@2$/3KBNN._J@+'@R)Y0)HN#![O*VR,^T9Q<G,W)Q5*<VWR$9P/<C]E
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M31F;O0*5>VL1BT@/UR -1,+I0MM"XJN/R4UJ0N=;7E1;GO/C^KF5@J'8#=^
M70]G9IL((#]\#KJG'Z7E0NI54(\4U=?X,^G=\;'Y17?U\N :",COKW@A-($^
M@OHW(!_-FE@ZG,-)_&0NJ@8A+QX%>?>A+,6RI^*119"=4_V@SNT/BV2K0Z8&
M=='#L19\1^W&%0RH9?$=\DC852H;2/_[MIX,-7^?NW,5AS726DX6;'VR3U6
MOY.[*%K,&2V+ND*!]D/W^>/$6++(7&&$V13YR_R#TN#*0[>$KCZ1YI'VN6X&
MQ/+U =XH=_!2D2;SA;$M1:/3?FXUM1QY9,=LS#OO_L(\O^;2TL$'"4I2&J-B
M,9WZAAMDRCH<-*/#D%($G20=K6H=ALXR^9151W/=[1-#^@VO[5N5KE?:?SBD
MNZ]+AJLT,AS'D+"D'6BIM[70F5<8V:A&>S2-A1](K-:]%7BWV#<M)\:K,(I^
MD7'H_53;X9(1*O2*OXEB)):28,>EU[A7:]7[V/PLE^A1/G7!_;N[]_VXZE^]
M1]VC&G5BA7^.!:$"B=(;MZF2#9(YKTR](Z*&/G&))TN(Y_PN.7DGR-G1-9J_
M6HPX0AZF:Z!$J6EL ,*A?GB*</#X@7PV<'DBK&#8PD-MUL=]V?V"SEP7]\%;
M"UV\+X>!NU*8.APYAJ)#@F481]*5P43"= EA*^EA][K[0")+L>%OZ^K\\^0C
MN1Z158?L3JKP50ZNG3 %T@Y%Z<0@ZG;Z$''_RL[OO0OP,AYO"$EF&4V&Z+?;
MN'NH)MK&.4;=BIV7)AF]<.]^WUWRX.=UZ2(/K@DT%'61HM.'X9UEF(*!Q"'A
MT(N3K[8UP\\9$'P2?#[Q"AG%\BG^YE.,-I.H,U6 DG1B,/5-O;CHCD.I7N"B
M3S'#C=+ >)B_OL>MVY@5&=9QLZ&--C!TROV3&-E'4?>%[N\32&PRK*Z)W$Z'
MK[K[=F?.1[F#'B^1LN=NC]A399&2GA9K;  N6:>Y&HP+S-!K2']MKMDYV -P
MS< <[?1<*.V](PW*CE^7HH5R7!&"+#6D(,DRNAZ?S :$C,TEJXK7J'HM#_[+
M)/#>4N%UOK&M(6*Z:BJ=7LK1-\K8!3>$&!C!DDAD'&$Y^2M<Q,YCYUD/4(MT
M@T@%N/1BX6+K3+@K1@2M BH3\8^O4W_V5*'/V5FU%!&E=6ZFCWE9J6;SPT7V
M[?JDF*].(0>[*D?2\ H=$-8(6B:UCX/TJ"B?EZ[?/+4:2JYM1@:7!6==$+_Q
M^OG@I_F4 >"%/2_"/!+?!9W'T1XQ7VV%_,$^AHF^G&P0UI*TM;1JJ6VN[6BR
M6+:BS3@,G#AO)4<+^L2E_^OI__A70G@_AG(M<U</#\',7:SGY'#!/;INQ[_Y
M)BN83V_ *-;GHV6L)XB9!QXLIMWD=BAF5W+J#TS]UZL4>LFVTU\G%E\(!P4*
MB%"Z6AYFS^P&XO:_,U[ <,YXD W,76S]=TH!SBFE=-D NGP-G?>4#0PVYKU<
M@3:%;-")-?,1--]IECA2SOE]P_31E@^X"2<7ET"-\JK@5\T>4='%.>()Y\KB
MTN+BTN")C*O,2J_#O)<HO@SQ"AIDAG&4\$M_2.85M2C]W<"[7RWA&T[*'HL-
MPR4JTS8_#@RX](B?$>ID*M&M&?)4U?Z11$$"GHMQ91(%)0H;7FV<0L%J_%<^
M=$4&T[-\'Y_P^(_<,Z3']^NADP)4NU0H@.$\V'P!@8$#T";(/()!S#+3R\JI
M[^Q [-?2>^4(]P%UJYNQ<F^G-;R/=0I*Y?FI C/\OU[8D4]2AYQ!+0ZSV21L
M=Q:)Y?2BM:@Z&U21S.5T ?F-CDF?&9\PW6;B:>6,,\=RSYNZ$H-#4S9QRWF0
M.R@(E<L,S/'S(/[-S-11!''A$8K9'O3N+T&^YZ]B7C;4FNV/%G6^IK9F5^R.
M_K+7ET>>"J+;F=TK%=X_M+R'M/C:F6?X9%'[=3"J[W.0Z*[E[8C-KQ8GAU63
M,+X0J55H8W ZW9&A-JVW8&0+-\VY"!:\]OITY+#C$JSH\]KAI,_!2JB7.FF]
M#Q+$]VT?*Z>02%+=B'19/./0$*'.VI]")\:O@ZGG9XI;^%43VLXHMP:ZAUUX
M>_N)IOWRP0KDEROHK5(4@I*8&)X)'E?MQ,3 W?4.(F%=7ONG]/$0OT#HGL["
MR[E WD^C_U'>5S+RS3BC81VMSL2VN56S%A3$F*55X4%G](*X.EMRD\-]E#_1
MRE6;BXZ+CG+/VO,-JKP_HPQ,(3BQXTO%])%#NCC1AA8 QX=Z<*(="G@[6$*#
ML./4C]JV6.+)P\/I\THB-YZ=9PQM*\EXV0+A.%&<+Q9 709+EVO26EKQ;F!B
M9T23F-_.WIU/<C;BE'HG]Z^73F;S<!^*COMHQAV*56)&PU:J6>,PFD<U[D_"
M='V;#H67]@ILHM9UXR1Q@=A#2/416XIXG1?2MUL!R/V-U X_?M,/O1!Q;MQB
M8,CRB>6A-_ONV\A?WS:1! _0T2A1L(YJV,L&N$),(%Z_T";4MGF&!G&H_:KG
MPE;"Z<>W//K>WY,VEEPI\N.*8 F<(\'XA@AV^UDC)CI4KX+7KBAKZG!I=6OX
M.X1ET*%?TY;DF;GL\Q(1E2>[/JU\B_EZ-Q(''LM,;Y,K7F<#TCB?$!ZP[O)4
M/98;2?1TZHZ0M65$2)(LILQ:4Z27=)W;RM-^S1J?!)9G_)?Q<Q7$FEY\&@TC
M@[M3)4>@O=^SB\5:C.L=%N'?TKS14K3[H[F%/^J@^C"WP<FX3Y^'1D4+_.E'
M,KG0LQU0YJL._M4E^5&],VTRCPA;\GZYC3@?0S\?C]0SA QI1F.6CU#UUZN[
MMP"/4@!52Q=#+TEBZWP98JK=$V KS19\7N77HIWU($_A2..$)D]JZ(\UL7>;
M^3;MZY*[%^\,0SY'W#7]]!?'C>F",6Y4<7RG85C-W';?V:G</%*A]AZI=PF"
M&P^.Z"*TNR[91OH?;BMAN0W\2'J>IQSXJ4G9O\::^6]UGUT36597/F(CD%K]
M\\I4]*B^L,:UO$L1?L<R?D1^^\_\11=NE1[NMTH)EJ:!M<QLECSC*H<JC$%O
M@EV_W2'_^:]-A"'(!JG"/]MJ;''A?)]685NORZ'((R=(V.?6WT)-%63H?& >
MT9!<0;()69 C9<:3QF$$H8G7E(''#).C<*MP^W?Y7\NBK1Q_U\R5R'SND_NY
MM=)3ZH=O&-FX0 TDNN"60^:R=5)8@M2=]&IC^W $!(P5] RQC1SCFO\4<IH-
M6%M]OGE2[N[K%XP^^"SN9N8<O0];!^]:P"6B=:?JUQ=:,R77]M[9OC%.ET[9
M_&U-<O04WQ18-I3^>M?.?>4&>($>SI$5@X\WZ.>0],XE+4I&7<6U@(?HYU03
M-N"00K^0':%SM UNL&HXK]63>PON?$NXZ1Z7"E<(31+,HY]FV%#LDO_"YNB=
M#[&/@S$$G9:"?I;HC.9*0_N$?O+YYVT+#QZX-D57<M]2ZEH^<=T(D<0&.%ED
M8XN"Z3= 0-#'47Z4'S'5 ?:6^@DY[]9J>\[UWK<:4WYU<H@G+)SWHZ,17(>N
MPAIFG0 U8&DL%88'-0%;!:X3M=ORRY(WPSP,8[L7/B==.%#UX8RV=SJ/X<=O
M<Y]JO(L%6K88,3JP]6D[)O?,")9BQ;&GEK!N/)WK&F8UJ.^1]*\/QRWMG1/X
ME&,U5K;BL76)#'%!FA?E*K9N:X-,PL:?38S1K-[$$<2GC6^(O&KIR HR'M%Y
M2C5](U<B9K7@VA+<.<@E !CI@$=W&,]]$S$;-Z@ZK->RZ2[,.K00 SEEHLW0
M8[[%^>+X?BUI39O(%SK*,*2JU\X/ARQW))R>MXE*.*#8;*>3<".V,I(DS'G[
M)@P?4)0N[\\&]K$!'RC4GY_(5.#KPR:A;MP9#KIGG.?U:&-\0/:CDU+V V>
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MT*U&B%&I?'I,IWX\Y"B%G';69O::]:'AH%O47FVE;(D"#8W/]"\87<9L==R
MPBGF6Y8^>AZMRGQA(LZX'\*+/#_0)7NLU:#!]Y7[M24/F5LM%@GXKVF,B2RY
M4Y_:+!I[U>.4%+E^X?E05RBJF>'#F!ZT*%4HHFE)<K(?6[/P.OC-UY7>[*39
M#]$#MY+FKF465/N!<518)U;@#UW8:8!U)-.V:4J_P/-8M[7W S&O:X/*L:*U
M5P0_ F+11ED(19V!=CCM]A@L$)/F=7B\N&.JTD3-=<&O,4]EU]%KT76U\7U(
M%W=QML]M(-;9:G#=@37[3_S\:A)8!T%X.>H"LZR&$1$21:WHMB'*"2/,/C1F
M+*W@^[L#)1M2#%).D&ZD.&D[=PF57EF&-/O]=\/V,@(\C6-=SNO&TYPU,7\6
MRF?PSK^Q#$DN6@XX1==B#9^%]D)B3/18W5-;QJ%!9=\6.:+HX1G2&&4T)V-P
MS?)(6IO#BQCL/P#?^1ZY<CKP1%G^%?FUU!_?KPSO(CP>#7RE!DL6&290]=2M
M^W73"VR>5\%M^MG 0QC7KYIZ#($*I3C@]D[7,.K#,ED72UC0?S_0DF,#)2EL
M8,B2XPY7+C$%6<?@.FS@91@;H-SD[('\P/]5564#Q?-8\ B,T4:W_/] 9E09
M&^#&,%]SNLHDMN[*1RH7J2D=UA0>!9/_MDJ;P<Q-3[=J97_];&Z;2^TO@V@F
MJOC^Z+\+0%W@/S^^B10Y^D7]]I/$(Y6['SW:VVI\,,VL;(*QEK&4R(VW3CE/
MO>6.S6A$_6FKVJF+YEQ"!)E#\NV)IVS%L%0#3"!4GH)W'@$=T)GZWV[7VYH>
M#=9U2VM]$?[<IO7[_9FU \BROLQH6!,;(-M26(AH&-38AE)@2D'7J!PG%GIW
M^3HV3]94>3]3.6DF/!DH49MS_4#J4+U8=.#:.;CS^!\M79+']%^-*".-TPJ!
MK:WEN:>+D\UN<Y!>/9I?Y05PRLN(TZ1JB1L^5.7^7!. DCA@)//WL./*PJI6
M:-GB@ON:&%>F]M*:7[9@@FIT;:NDBO<9B<Y'HK!HF"]4%*E#ZZ.&D/?G9[S0
M$P[MG+^2^&:5:JWT,<'&^NAM;0'RK//D?NDB$=/J 5H2&%'!\&)B&>&4@IZ=
MW.D=EAKE0=EKUV]>I_ANYO\8=W5X\?8VGTS7:>YE>:[Q1A2&M,7+T*2XE%/E
MB#SM(GFO_!KM(LK7I("GL>(RMY7,5'_M4Z'L._:*HM.+V\^X#&)N4.TZBU3B
M'"FL\ILZFOJGN>[D[N?_Q@7TO!Q4/&C&?3O:.+.'X_)P&6&%3K2P=JSGN!L:
MXB<E::+$K_*Q-=M6W)6GZ3-JZ(?P +JGJ1%9:;>@0Q.?AOEQ4$^DXRQ*EVJ;
MFUJ)#.S-]T8V:O2'I[J/D4->M;MF]-X9%J^];1P->[C\7KKF >C][V.1#(KW
M#>,*Z$N4_ALD"'\\]&;M1/^ONN*;KZ/7*DU\E)^<A9^B-M%JF5B8;Y!%ST7P
M(U7VL)'C)-$_C'EDO)^XMT?4']35:JB\?\G^H 6S]3[?"$_T288@'0;6=;.!
M1D0FQF^!['$EQY**B ]+U^[_JOKD6Y]6R>5;_OM,7]K]QX#PK_:;T.9,5V;<
MI6REF)RUH4#[S_(4E* 0E#U;GY"W(\8A)6 ,T: )'E#;V_GZO>CQ.[FG+$K\
M'-W;L<LS YF/H?6J\?A^!$];E'>-/^5;0_O0?*Z;UANO6ENQ^&PI(*YVZ@K?
MZ:YJJ0$\Q7YK=H*0F1Z"AH(CI/2GLKEY=[7^>@>5>2YZ^(_G9&K_^,'G)?B
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MT0;(/-HS9M7?&L$UKR,S;9+&2OZ$$7XS&,TG(>VV__?DTF9!K=[LP;G;ZM&
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M8YNY3I/5#F5\/_DNMULR]3BGY^)\_L]@+?ZN?ZOB2W.I28N_$WZC:)S< 19
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MOY69>&G!KLYB].HA1J;;9\_<.#U]^. +RP -8#54)!\!:0 QUHCR$NU7B!G
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M:(7$-,%8J9+A<PTVB6@6O/[UE_-KTT*Z.5D&&UWJ9@H!O_"O>R*$>9^KZS@
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MD9W!_"JX"Z4L])&^'3;92HJUGIMC(_+5N+YA1D7#Y'BZ]E">,QO7JFZLF*F
M!.?4Y_)@DH\?C!-?,E8/B[]OEF+VZ"7I*I^_6!PU+^2QV?-+-G5&\LW289,G
MW_&H#^A'). O$[CW/H-88II&;2WH7TT^.7Y)]!8=(KGYU[4@F-SK]GEN%M=J
MGE[MSPR<82;RLE<=KUD$ N@-@G;IY$\$#YBS:CVA:5EX")W>H K:JV]H\PV=
M#@]GS>%+5U/7;'YR5<0R<][..KBQ(ZX:NEA'#C04R>%.*Q F(+*07".Y91A0
MT:&YM4'HE7#@RONFF(S?@>+GLMF%"\PEX_ZG[JX+@IXT@&F#!CQYN%ZXI[B&
M/#A9\5L+S8E>;$=N/WYQF=H7I4H#3#01I5AA<C:]C4)=(N,0=DL0<J8:_<4[
M<@G\.AW0=D;)]?]R2<=)*,$*,C/2"16 &T/Z8*+AC)>)=3X07OW3I85L:VE%
MBI&1L\_TYZSW+UX25<)MVW->4ZB[P-CR1F>%?Q'5I8J![J$( ]W<#\2\T(M+
M5>N_M:BJXPW-Q2VQIDXR&2L%4_97(J2%1ML*KF24F[JU?I- )2O]YN ,\.-+
M;I"-L+14UFEP7)EUQ<RI1L*^I1DE%S"G'5=WK%)Q,G-%1YBNS>;BQJ9;YJ?:
M.Z**.NK!;$+Q(KZLVRVH;WJ!8 -[1.4D1(S+()G@MI9#&Q7EJYTDF9:'CIR-
M11RQJ<-\?4V?*#-9 "17'_+ZA]A(<DB[=!]"6LPP-_1-UY'2BH:ZSTH!&!-G
M.;5^C@\U%@%O.23?2^2M=:Z$U$R475+SSXW<[L@E\66B0XERXQ[YD.S)3H<X
M'2O+?/M G]W&-F)RDW>@0V/DLPG'*1K TB9'XD6,(R5E*$^H$G"&"0U_#E 5
M2UCM8R&Z?6O);&BH'Y?=7:Y_Z/)4PKC%/%,>HWDW039B_W@!]ZDT]9+RECL/
MBXH5+TS7H[Q_-H<F.X3Y8:H2^Y=KN\92[2]I2LO)SVLW:41$Y+:+M L4_<RR
M/M!^8V<B^$/J]I_Z0\JG5SD!>DQ$^B+W-/P*#S3]-P_ 'BKK21H@OT<GP)L^
MD] =O^F977)P/W3;W@.YL4D#M)!^!$=RIA/D8)?[ Y. '4PCZLP_K7(P3NK\
M L%%%;S!C1':6(223WN396B UQ@^"-J Q*J1A+9T+&]M=PRHJ*6U-N\(XF@
MD6^+XNQ(O8FD_G:<N4:&XC9[V#BM(5S#;"6X_;6*LKJZ/.1]0T5QG!R+Y]>6
MIU=-%7-*Q%-R9<V\FAQM?<G/#EZ8()SHK8(E>M<3MI]! TAS9N3SK33 P9X&
M/(/0@/;)<1K ,Y)* W[PTP %>K!__PP#D_0Y:( 1<M^:SC>.(LKL8#G0O].$
M3D!XZ?W'9#9RQ8P&;(5"B)S@ C4&NEVJ2KT(Q<D35"E,]#9&%TV.^;^7/X'L
M/;V$/#A, SX^0>^?H@&/BCO1.\+T@UBG =LLZZ&"^Q[_(._?Z/)OM>^A'D\_
M1 .^P*B7*^B$"5(^X;B<_@\B_XT^QH;:-."E#;G<D@9D<?\_:CSL+K4+VK!*
MUJ+'TZX_<8DJN$66AOA.JE32@%IT0\=LTX=KK>0%!:55 RWBNO_0,*B=J"XA
M-Q4\H7,L!#7,4M&>77SBP#"A*BL8Q4ED5L;>%MQ?]5:\\UE7T6W>SO+M>J0!
M/0A/19G_.U3KGTY';"Y9&$6]Q/\6^1552O?I:]0W#%F=3F]VZ:=S+M2&)+B#
MI@A,'N0^A&W;6U+;+7\E[INE(+?-!Z@=/=L9Q#BZ['&S[2]_\FFGB<QO:4R0
M*B8N=(M5%0Y\( LO1:H^<E&KK6F+P-9.U_<WI^.%? U:ZI1[>( TMQIS5/T[
MS8T"!4J=(82L3*DPY JG 3CO7C=MG&IBFW#%A@/=\_K7B]>VCAMF1^;[*.59
M'$]%E30^L$Q0NA*[\JA'Z]MTMU"3HY:CVOS,5?W3Y["X'#F%P<[OIZ0?&ZUJ
M3-_+&&H5\M*1>9[IOZKV7,<8DEYPO&TVI6C)W\3Y@GKRU2FTXJ7 :;!RZV;F
MP2UA_AOJY Z1^P)C3VZ6#D=H?/,4E1M"N-_$9>,)<R[XICWM'F6Z8_;N@?E+
M*(ST$@QOLX@6!B.O$AJ;/8,#BL/'N$Q_#?"YNUAQM:EZB]<3Y//,7]^]G;'O
M[J ;K;A:I;C(>1_]D,R%\T%HAA\1A0>@+%]KY4;@9).6C&;4>U4:!#W[JEH#
MYV5D4I.LSZ ,BEH(^YZW].=,'.?AY9B3*D[E\A7WVJH77&4R'2R3^?-L>[LU
MYE3OZ ^[6W7XGFG6VZN_E6O9.)L]2\JB4TM@9^%!(?<N)!99&X1G)+C[-N"A
MFPA-,/<M_,;H4?3DRVN<.5K!4264^,&,^._#ALS;%:06,#!)\6*=:E5T"J7*
MQO>D7K/+< =^;J$TLS;)P4*9=?BNF,[#5YOEI#-]SF9Y1,M:!X?UV7MW O%-
M%?)%2;O<,G]NJE"&Z<'#COQH4(\FB6G:T-N)O:@_]Q+_ 6BI9Y8@^PHUZ-T]
M9#ZT(5R1:J'$3;F?\/U!DCPJS_#Y/[MI\Q?!28R+*OR'ZK[$3AU<W-J7O0W;
M78=D0I/>3U,O;-ZC1!6NT MXU+%?#":"^,(:U&;^=9))>&V/(QBW5 'C"E>'
MBOH<,+]"'LVH#D*IKG@F?1SUH&,-?$U@N+TS[53KTYW+0RG]MIW72]WKZCU^
M(2QD*X**=-\Y*9E>3TJ3>M!6NNJY,GM?IJ6N]P?J&A&VF?7&#7Z+,-UM$U/(
MN\,M02?\OF\:4 EE8S_=3[Y\;/VE_MZ["Q7*%<<N]3T+4S_TXQ-#_^=RTE&R
M.E$J#O<>Z4WO_AT6^N=E"*;/#$NK?;R[M[_V17@&GFUY/UXMYDARZ3VR+7G,
M*^7TVT:UJR-GAG!%WPK;4(2A\W/M>(/AP/8-OT*OT,I<M:Q,6_>-ICY)EZOS
M/SNH.0C\CG^+OE@2G,<F5-<%T[UM*1V7=F8BQTL. '0S(QWKR3<H"1U'X2R4
M%YL=6G!+(E-J#NHN;OG+EK[ T\Q?ELI>TQ>F;U4]DI47H#Q/7:\N;<QJ;/%?
MNOW>[UV9@^^%P%$W5VK+9OW/M(N&+,))I9=*Y;5%%#_L6$ZC/5NGK41Q(78F
MH1*O_OQ1#=:,)AC9[)LUTIM0#]-R&E#L@.:L^*W]#S5X>9Z.P!\4(0<DR$>S
M=2H7_86KZL&NZF>YF1T[$Z0Z9.+5?^:/<K!X&,$=O6]N31=]HX.N1%$>^JX_
M88C*,4T#3K)-0C<=Z3KL7'9<=^=%?K#_5XG+4G1.^$&:K@OW1[-^>C@AK2!#
M1O]$!,O/(#+/9:H=GHZN7T??(G],HNHVEKC!HV7DXEEZ]:DIOD(#1BM@WM/$
M 1'Z9>WIT8:J(\]0*KI@VQ;7D!L34!FZ"/CH#O:?2?A'#$]1I!,54!5&+I&C
M7[T&1I<S:@43<=PS8T%^4'Q EV!+SB#;]Z.W'3W0?TC-J:(DQ37NI^P'2U0V
M#V$\K^=2E)X]",.FBO<AN MQ9@D!Y !L_K!.T.IX9PLSU_5KC)^:>'X^41[C
MX4V#*,*DI[9Z5!/=U4'H$EX:Y]U#\;+D@IV?.-96\S[E>41&RWM.:"J;K:@-
MISHW<]NG)2;] >7RA 3E[_4KCK \WSU_;^^JROO/5'0+7)^-]X[DC=[?;H7V
M:4R'[/BMK_\VW"04/NS@(4M0ZJCL9-=)A!BZ^X7_@';!B?$&--NZ[D.\8);E
MX2E=1&5%R,6I41O-<9Y:ON+-Y<=X'90@);8# JXN>N/E<&A)N!,A=2^]%*Y%
M@#T:21F_U.@SIIUKW5P;/YK,*2K[OD#F_.>KV^H,FK_N);99H<*'8*U$L\1=
MWRW4UFO?P.IJ3Y6?O;^5+&C AJ/)D@V&?VFD-YUM)IP;)]R/$MQH.?'\RE=?
ML8%'@8$!51]33II_O_/V[.*UVV<D'--J.6_T?$Q^6XH_MKDR-VMW*?]J5>.L
M77[22I2TXL_"!I5C7?H7%16L#3\BQMCNE'Q?.KR?:2&S;&6Q75V;VF#E.;+(
M_0@C'+>3_NBW%,\D7B/JQD_S>N6 RA)S5;FXZ-#XJ]?GQ($XF5CW7_>P*'$8
MO1L[]0WF(U8Y78?XPJ4_'U!9I;AJLF(Z^&'(6RER.I8[$<WG:#Q*/H7F">UZ
M#=XG_MSA.N,W'B'FV?,N+&_>8/;ZG4ZUFT F@YSF+ WH"4',PG;""P6A!*P?
MC(QHEP@35^LE:3-QA\$QC?56VU4%C0LC-R.:$8K*/9$FVGK6$BWR[2Y71T*+
M(E5FZX;<I+3EU^V?+#XX9512KE)=C:HN:6]OSO1]_;AM_,+RLZ_/<V2V+?0S
M_73WLC?# Z>__,N=^;]  &PV8H5N&1-T60H#HZ2*E5%37<BM?0O[LG2R"//8
M-Z? NM#[BO0^S[UTOY=D2"\C*\8'3_ZC7P;\FR\&_@( ?@8@1)%=]^D\[YAN
M&27I $9-\J-8=JON*Y3^JT1R<3]T7^:/+M?WS<%NNOBUXGV??R;BOTZ9_"O4
M_-\(M07#;+C !Y CQKC]$,O2L6K5FW6QEWQ$C&1[?=)E+H!=H18>-YH'CY2]
M+UD6]&_O+S[I/G0C6\#NXO\5[_]KX?Q?_6+B'T,2]/RKDU8AWJ-:T)N<Z:_4
M_\;>>T UU:UKH_$#105$>E."TE1 1)K4J$@7$9 N1*43(:(T)22* M(%% 2$
M2%<ID=Z)=!$0Z4U*0N\))002DKO\SKGWW]]6]]AGWWW//>,?O\,U!NC*N^:<
MZWV?]WGF?.>,"<2" *?I#Z,&WR,]-;H XSLO:%F_M/[3]<%B_&2W_#"M'?5>
MA^LQ0V'TA;?,)?_V^I%?N8H''?2_*B)S"10:<S7*^3VJ_F*I:JY@4+P<+O(<
MDUWB>N0_F QR_\_)(,L>M&'TC;(XJV KJ0$<:]^]CT>Z5P4#X[Y-7=C&]&#"
ML82/"'>*@JT;0,-#D'P( _*]\?.#,Q\)UY(SK$7CK7E)CM'#>)BY)5QKKW!"
M*O9RR_UF!V<'3VC2KGBVO*U;EY6*=_YD2544O,BNN8Z?]-$]]JSV](5Z?G[&
MP6$AH;T2"  X01,L5'6B!4ZI@=7?D%@02>2T'"R![E<*M7>7TZ^K^%@8Y,',
M["D5?RFCPX?R=%;"XD6VW/HQXV?-%ODA[R_'O4F?<728\BG!UO+R9L<9C0WL
M#D.*<5>=.-ET.(W8S4PC7GJL]BVGUM0M9X@YYPELEY0EN,&?T(X1F3[)#.74
M@_G4]A&+&^D@YK,UJ#RW!*$3Y.@/UIV*:=/6WP/B!_4+#5S$*^K]/"1>MGS0
M<*EI9;A3A@ZFRN"Q'+1A%9GG&E(+D",UAGAW4YST'O"*,1SS96'RV.,PST:5
M(=N;F3@1?ZR"M6*4+EX<YM??%U=9PUL/%=0X1-4A[T]'=H%+FM?"-BL0Q_,F
M)LA*376<O?EK20<QB.RJXM0>UTF68%V3*S$.+'E?#W]4LR)B5U@I:GZ-+:G[
M"/O7&J,Y;R).$9A"5DO"!7W[IIY:5_@G.E<DFT@EAHKSRNV$'[!6+SS#(QQ?
M()!HIVBVI,0S)V&^;@QEJ [*\JM4O=]<WR8)U2W)I+R?K>##S8N)INW7[KZ/
M$I@Q4TYS/26YT6:H5;:2%^=I-YA-MB&5DRD49:I=V5Z5E_MMIF UD;.EDS9T
MD* +OLNTK,]=(C0[K*LC4A1FSZ!W[)T<AUQ]0^%- F0_"@8=>=!"4R<8 =%+
M$2#?EV%Q(5A9#1OA5&%^'OG>#V.XQB<6HXC[[L4J)8HD:G^^TQ#!^/WA&C_R
M&Y:1RD# -"-9R()X#-BOO,E.I1?7XQW-0R9]$=3IE7>9,P@N+ N33(Y=D8K1
MFM7]^H%'_0-:UFU%?BV:#B(8_:CE8RPCGR:L-:'YJ,?W<G-.4B_VRZ.97"UX
MZTZ@034FMAJ9$65N?@8.-TRW,\=;3R+?JWA)= 7-1LRLZ@S7Z?K'F"3GY(ZI
M2HJ/351E3D,'3YBRLSF'S;P\L=8^(N,*05X[9R9OH^#K$UNT_>:&$=M>(71R
M@]8WK@%_+&N3\Q2+DZ@2^&.8#GJW[IMZNU7(V+U9MJ6S E\7$[A!JB#P?H(^
M,T'5JU%5\_5PG; &'-7FO9_,99LV#$*/E!@T5I?9+EC6=PD4=;J0]U4P*+ )
MT9N#64:[?B#C6;7G\/NWHDERT2&\>LZ.<-D^#=O\=ZVSGW/9)CX'#5?Y#YH2
MJIO1A1L(E=Y-+-@O#I_SS/NY?2R8:Y1\5M5_%,*I.:MZ0B.@3[SG8L1)X;SN
M%T\: JV,<J,:_:\>/XR(3<IRV)F<S5I5>*B]4%8]/&*363LS[4A&.T=B3%//
MO;)SJI3X/+66X_*E4W30(+?5::)J"S*9A6:N42)TD9X7U1#ZXZ-=ZLX0[&(P
MBXIV0@XJ ;5[S16\=T9O2TZ7$+\LE*R,"H^NX^L""BBD!#*>#BH!-R=CA$;(
M'NJ<^H$MO0:$V:<L+5J]\NVZ'.,#WY49'EI.V78^J0P_QC)Y3V%YALOS J(@
M4DISN\\$639:,.JQ9\2IC ENFBU=Q U6GE:LE<$:0/VM'NWG,K8+G47_G /J
MNC#/Z:#)9W8 @D^0)58380'OM;B>-NTFGFI]\S"][LO?E)ACIJ( U(S-%028
MD?-.,<4B$#L=^PE('^^0NCWIQ:B_*4[_VT\!W.;W__N6]8RDTO\J78_^FV)W
MT'_GIZA7?L6RX@"6-88M[L-.OK5.Z8]L:.<GM+QFP%S=T:Y3Q"Q''0%&PV(_
M0!K3=D3(N9&HZ8)6U. P[<?Z0@_XW"]7+WXQ4TWX@KT'^>T;^'V2_O[[(?]!
ME_\=H_=A)G(O-0M455AA92_Z>*E7?I\"E_'%_7][<<=,U<*::$*$E%7,9-<!
M[',%RPSP[>Z>755C3Y%SUP6L-"R_.3]0Y LR+;7]F-.JP/:4#BK'-)V^EHN7
M&:%<(7!@Q[[5,$W:^,\$!0ALF(SW*E$,6#2[M4#^_=R35;X \X$#3?>HRL*T
M8%D0=A^O>93 CY+OJS,8.QY'=OFZ6'^O7"[Z]$$7]+E22KWW6F72ME'@^FR#
MC9YXD)V!U9>$H.>,&5Q2F5$AKB(B@3I !W2D4S([ZV"68[56^Q3$N/:Q_::P
MS=3XXM'?E:/]TY_B)KL#+C07=@HU^78W75,@'<B+,MGW<I_0W@VN!OQ[=4@;
MX,$L5B.&@(.1>\:!#F)QI_IV'!CIH'QN$OQO*S(%47\57Q0-;-2%5II^'OR'
M7.A:L3L,.+8!PY^.??)WM;-U+KOW_SM*<?^5CS 0&FG,75S7 95Y:>M*L,*/
MS2/0JS@+ACUC3$3NOY-I_Z-!)[O_ETAWVV]Z\R<3_W\W.F=T\6'<PRQNX?.Y
M3Z[]HAMD U+V7K::#F'):B_#"<*/R:OQ9[&&/JOC(O.H6UYI$5RRN9Q \AD^
M  NIJ*@0=V1\6\;\@J=N!?,:*8DP(28TL8U(6/8B0<C&.DXBK9PP8.,O.7&<
M7&Y=VCMA5)O$6,DSX#'0>W54)$G1Q_PBRVO^I8O\X*+RAF@F6@>J[":V>*)^
M@GNQ?->&*FIHVCJ0D+2YO2!44?ZQ>?_HPZ^T*]OLZKWGSWYJYU#\!L+DPYI0
M3O84K?(F*/L2!) *CC*,9 [U^XS5?0IKK'YI\()2@Z$F3^WB)XR.@0V"+)93
M+B!$2VW5S[W^A;*F)/]*9I@0PFGZ[_]\2Y!3Q&B:'M^/UX<TT?CA&KLN-.O?
M:2/( ]1D('H]VEV&UA)I2@=IYP>@H7S_A>@3!AXP&YWS6_L_+7LC;D.= :__
M*ZJ0&[!%%U1I>C=Y?\PW1.,+%( G5!__,XT'<9EU'6E[UXQGYO<*4%U)@#UD
M+RU99ZE#)+?T#2DCWK#6;H3M*JN*=R6&U<2JVUOL/<&ZY;--WH"4',D@A%M&
MZ\0^I%(T<]I)[3:ZN&!XN0'/]ZQBJ48.\*K<4:Y<)05",LF./$4LOUA#A#>N
M,5W>50CZ7%8UL!7@U'6U4._+ZM'PY.$[H5FC3V>"I0./*'.3RMZ.']HKI/+G
MD'-P$DT8/NH9<@9^(D)(+*E1O[_1B&M<&&W0.[!F%+7.$V6CRZ\OZJ0[5+ =
M^?@ZZT/?QFJ9Q_>0]:D<A.B5KMPE:Z&XA_A:'7,R%/(DL"O7B%GO>,';;?/U
M=T^7Q^^"1$K"%:<#/GQ6)H<=TWI=(T>*L1M,T6J^;-BL$9">16F_7VLO_3+9
M;@4];H'+*[R34!Q'NAFE?\W3..YF<EOKMN^<W?)4=9C1>!7A(-9A;>0035:3
M< 0>$NV.STTV]8;=]G\W:M.LCHUWX-3Q%,UE:/F<F9L79,-G8L3=C0"4;V
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M2KT*!N'I#:(;+.GBZ]%KB,X*\+V"AYT^$R4S(8]+(4_LA O):,)VDY#D-X?
M$^_\4 UE"7*+O.%S+6:WH_KCG4X$%@Y]6C&7B!ALGB!@4),IV,U(U @0M@?7
M *!?-P,%N%,@KJ@RQ>B\SAS:-UGJJ?#&;PO-7NVHD(%'S^1T/&O/\=TLO,33
M)1?$/U9>!NM?FND:@C?0045?0X@R-ZK(O!1QA"7A0/8(9_Y [M0*DU5I:2J;
MRLG;D9ALOXZ@0$6N R,1#Q[#%E7^SQ+@_\PE0"9E(DR+'(<'ASQ*C20\;1E
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MSW@X<W-9\@"2FJNF:Q^%:41M@"FF9)F-WZ3P?QD!)4)%UN_F9WP-\AAXEW9
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MUM='WG,_E&K);! 8#B$&)C4Y/L"+&OZ(ZI0X7Q_?Z7CY T^IZ,MA?4$!B(6
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MT^@<-F@_),C+;U!)$9BGGT%<FVP<DPXJO%H84\$)%8F$UUY\UYL?Y<T%V.8
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MQ ;=PS:F9D;7,D2!@C= QE)OA/#>7+MV<[W"P_I^HG_6<X4PI^<*@?N[_+'
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M(8C^R4TY];ONJ=_N.29HCB@%;^%4^Z -QCUT?'K;0%9;'GE8L2#UC]:)HNQ
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MJ22V!FYLV_"AL?E\TFQ4V,WV=,: V^[#M]:SU\7M]M4F(HV (5H0,Z=+G;6
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MTI5=@D1S 1&5EBL,Q4WG!@*GKZ%^,B1'$5FITN_URC:YX&)SQ;\#:DJA+[@
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MQZ.P-]Z%*"9EUSB76C3(.D19;OP>=E2'7^9*_"4IDEJ1\03G UH"I8T\S"Y
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MY! %W(?$5P$R@F-.&$&,:D7$7HP\LPGI:8&.F'X(>5_Z\R%D:YG,%%I3'*,
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M[A6N57K=XY/T_]MJ+=+M?\4++O+FG>1T_!N5@%?4?,5QXN,TBF$0,KF6)H&
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M5L#@34O[T"45=YWF.+LK[_"WO^?-PT.Y5N&$=V5UO ?JBB#,4T21ZBJ*H'1
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M5^Q.OGO]+:]7?I3A@/D4<I*F$#&Y.\DB+Y8N"O8"A@(:,Z-TL;W19W9-6EI
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M+$12W^TNB9VF.GM\0I%6A2J?.N*6-\8F8-/;6SB&PLR,;(E?@0&.GH'MH<7
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M+M*(8E&0,"&I3//<RIRP)SFQ_=#&-7E+OLL*O$"55D2+)V"R@QV"%B$)[[C
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M,G;?HVE[M$B3(."2X21C30R38I9D!4[3D+.4J%BDH)17.[(3&_%7VX6^WK.
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MZ=MA.($L=EL0;;3@!-  =6&+2LL"ZGA '1.0QC]G  71C1, YJ@A?0$'U)5
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M3 [B#YI/D/'FLZ4<I#PPK%S>]W:'X'JUEO=5EX_:N%M7VK^M[Z)<4FEJAHB
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MWS:_U63NPB)5G.<2)TK%QH'3JY!SCI,XT)9#SK1?E\,NU@X3M/I$S[E,V]X
M^ZE=HC]O^_Q>H)4$!FI&@"-)&O$T#S&GIH%&F J<9TSJ_W 9%TDHHQAD7'F
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MQC*5J6T=E&%*RQ)G7&A!:6(GB<+2@P>H31*C:UJRK_L!.N@AXR!BCN>,H7
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MSV]7S%*Y7*WL65C=UQW6>G]HC9%W7H8T:FFC/G% @=T0 ,/6*J3L,/-S3.S
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MJEJ\.1C93/4J^-M,8]D21RL&&G;B!:_#;FILT("V:FN$MOR@(]T0-AX0NID
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M>FZ+PY<';:U6=[V3==O&5E11E3)8J5[5\B2+(5;AC1%!L4@+P7)FU3[B.)G
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ML0F;'>%@41^Q_Q@/*Y!\;+A.1G2\2NQ&''Z+=)KT:^]_SH)R011&?*&1V78
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M_^5'C@K@:9'>'WO6Q?BH6(>+[O&'W+3I\WK#VQO\K%S.6[?TKC^5KO=!\K2
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M.9@UN9BW]7V]Q$W;?P<1(2E*&(:LDB8,,7G6P85@,$8ER[.,2!-GE*9U?/C
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M^%EG[XUJR'9%OE9M7U+Q+7ZH-UUNZ17H.H)>VB/(YX2:6;17GR8[*]C-T)N
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M_&Y]C^O5(BVC)$5Y GFI.G#1@D*,,%-7RU$E&"U%8E4QZ26)X%?'FB#0%*_
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MS,L@LMPO& L\O6,X/\R,>P9CF?9W#>:ON>T;MO4_?MO=QG]H^'\^\A5][AT
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M0E50_2+>_^=CO7G^C6^^KR7%)]YE+K<+1&)6H2R#44J4JRI-(28T@32NLKS
ML:B*V&9[9TPY\!9NX .H>00M[F(KN>9%*H\<43*B@JJ_X?OV4:K0FWK-'TQ]
M7?8XFQF=(.C9V9Q]X+[UP'5L@(X/,&+$G[VQEMV3N3&G.ZNUL8;CT-C8#^#@
M".^&_,;E$5;;K3Z#NW>29#3.8Y02>6(LY-DQ90FLY$X&EDE&.8OB1""C<GGG
M206V)OW7?T?\?/J_+58&KG%O"-A9A-/"NWC&IU&P<(Q[0\/-+^[PE;#SBQO)
M-^D6GQYA/J^XD21[3G&S-]SV1F\;SNK-!TR5K^U9-Y#)JH@5.*K455W<);=B
MD@D8\:B(&*.XBJG-)N@EB<#VJ2,(!HI6;74F<#';M%PFK9TMLA34>A-R6A9/
MNXTC!&;=5IP6\'#_,/&DG>(Q7B_>KS9RD*_\KE9^E=5&]>Y9)!D2!4LK&!.B
M>E@E&2PC7L(\HPFE/"N%637=4P1";PHT2;"CJ7L]F2G=24RF5<Z'I):+OYV0
MQ@IW3I*).$_Y:J=I\L-.P4X..(MZG1-G4*ZSSSF>]_LF ;?K:RJ7SH:_>6SK
M%6];WO[:K-MV$8DXSHB(881)!!%B)20D+2"JBE24(JKRS*IP]3F"@56O*S"V
M&14&?%*%."T/[^= ,SRS>X3"\J@^='/9K$%/&^R(7P%-WN,!W5!07^?R<^3F
M/8X;"O_B%&[ZGL/AN^_>MA:]W_"YKSZ]6;]/\JC"*_;F^K,\%,2['K52571"
MV2[RF5%!251*RR!0 E%25; DD>JC3:L\SBF-:&I\1O?!46#3,6IY-S"Y+<XN
M]:CG3U\OOE_R%>%4%_X >QQ;G'>]3)*!<V!NZ.U,U1G4-8L:\P'_/2[[K%9@
M$O(>2DW,'1-SSX2;_^(EI$"L&^!EHGPESOE$<M)3XH70? X5G[CL^5V\#FRW
MHG'*%M?L'[?KS^O5#5]_YFN5$/UAM5-!@T7H[""!%Y==36"E+)()>//^"_@L
M_Z_XX'*WJK7DPWJ]6:TWAOO5\\A,+P]>0;$S^Y9X>$YJ,A9\XK IQ^@WJY3M
M]JCG1Y[%&!@+."BY^0NN!8H>&DYK/:OR\Y+W\3;7]^MFT\?B+'B2)ZA($8PB
MQ.2.DS&(4\YAG"=9++*8R:VG72:3"5F;+[E38M.8";U"XA%UVZI%!C":G4Y]
M0V.G_V/J5V!+7\-S;0*/0T4C<WF]E3@R(#ESS2-S$%X60;)XU^70JMJY?1&?
M=5#>1DI5K^X^]O$87SE=WZWJ_^)L4521*%23=9$(:20(3B'.40II2:N2\;3B
MD3 _EAK1#'WP5$RH??5*+H-TR\<N&*79<F)SN#&#T^0 Z1TDRR.BQN>+T-N$
M'0M@X %\#8B/S?'..TYN!S@?>%D>QZPDGSYPF0TUXY'*2K;]0Y/=JZZ]*ND2
MMZUN9:^CEA\W7X1!"2E]CTM22BJ5X!5CQB%"20Q+K'K$Q0EFB$15@8Q\?#Z8
M"6QE#UD#Z\=-Y\PPJJ+F<G%^T=28[>+F MS.8H?%VJ'GY>4@>6M_>0$K,W?"
MO!RTETTQ/8SIX#WZ"S?L5W6C^DY2V7;G,_8;'7\]L+W:-78$N%7*HSD B@4+
M[] )R0W\0I<+;>D14@1'0H(= )X</M,2N;EZ3HPYGY-G6J@]]\Z91_WUG4V&
M*-^((<[EQH*5HE01!116B"%(\A)G(D,BH>3ROK/)3'UGO]5ROZ8LE_R"=HO7
M%]+RYDG?EG3\#+UG$P^]9Q.K?')/P-BI[.G>L\E,O6>3($GD4Y1>O?=L,ITZ
M;O**:_>T-?WG]_52OM%V8;AR<5X^,GFHN5$>H/5J7,Q(>Y)[9\;XW+/-0Y8G
M#\3+,I;P9P*B-$UAF28%I%7"$B0(%A&W,PY^&0QN3SH6+8M=>9X$,^/R>L#:
MV:..-V6+>NY S]Z+,EO['.X\(V$:PX5 SULK.:_,S=Q\+@2P+]O5!:%BWWKK
M&[]3OL!?^?JNP0_?53V@OM-4%24E+F@&&8D)1#S.(4%)*G\4+*H8CI P:G(W
M227P<6=,T*']UFEPIDV<-Y'M+)6=M%8MN,Y*<T$KKM-CS]:2ZZQXX]9<YQ]V
MO,VN6WQWU_"[OD[$5[G+6CWR@\@PC(G:UA2049Y!1%(!<5Z6,"L8+Y,$$2ZL
M>G0940WN1=4T6U5OX*%9LT=JF.AH!YW9OL0[('9*O$]>N6AZ!FRB$NWOL6V$
M]G61;41SWIML&QA>7&5;O>QPESW$<K]=WY-ZM:TT4S/>!\:I! 7!FX:S;D\Q
MCGJZ:;@."6]K]=,WWCS5E+>+J$@KSDD&\P*7JI]7 4N:4IAQ+G]1X8(SHWY>
MH1@,;'GZM%HZ#@][:#C$.TY V[-B<0T<8J:FK=>/@+^=H1N8!2-NNZI;6W[!
MB.&KH2C$7BC?S<%<??LQYLKB?O^5Y\PM&.!UYLXN?" @L).Q!B'HSA>8$!"U
MO2B&D'0</9%]4\0OXOW]PW+]S'D_L ZX>(-;SL8\7"_U]Z]?Z8>PBZ[_\=MU
MNVE'/3%BD:0DCB&+2*5JK1%8%D3^$[.T(#B+1(DLG9*A> U_WZ$8A$1QN+_J
M#@UZ:^T'T27'Y ,KIGZI'ATJZLD?VEVU1;D]KO5EKJ7#,]A<&_H^?X3YLUNN
MNXG3K($^RQ!<-U)+[_142!/?32#3T;9O\4.]P4O%YI4*O7U4U5L"GE^" ^K+
M,QJ,SWF=I*'A?N$O#4[0L;K+N-+GC?Q$GW>V((J*DI1Q"A%C$409534VLPP6
MN<AP7 A<T,K.[D^1"VZZ]XA;%GN9@LG,9/H2W<[J[5&] AU=\&?_WR"FS$10
M7]5AIDC-6R?&0.@7%6-,WKET+_B5JP;-=//8J(*9*]9G*'9&1#?WC7.$.9=:
MGE,F5;WB&20Q17*SQPN4EVF&B%5)2PO:@9TCXS;A>[SH)7Y(T]7LN#51MH'9
M=F/E%3P[H[&/E:+HOT^R@Z#>MS#G*;_2IL08DM/;#/,A["-'O_+M"48%S>G
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M)]U^YU;+=UULJ#SD;/A=33^NGGB[45\7U4]$K)?U>D%8G"!6%/*,DE40Y:6
MI$P*6%9IB?Z_YJZL.7(;2;_/K\#C3(0PRP,D@7V8"%G=;?>&NZ7HEG?#ZP<%
M3JF\I2H-R>JV_.L7X%&'Q&(!*)#R2]N22.;!RJS,1.:7 K,DI]@N"#I):_)
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M?'GPONC/<M?HKU">R2*14,:$:7LE$:0"*1A)DJ:%4!@G3O9J1W9B\QWO_+T
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ML=A3).:S6TMA#ZS7]I[@F?+EHR:S^+,YTNN&[@V(P>UWN?PF.]2/%&.285%
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M@:51CJ9XKL[M+'A&/7H<&HXMB K:Q1Y8'7/OB#K"S5]S2=2XZKRW1)UXK,^
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M*N@KQ+?QJ\_#9KCD.B1OCY^:T<](9C12.(4",V$6R*IV\[6VUU1&65YD2/F
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MEQQ\2 YDSLH%P6JF=7 ;>)>J<0O%1S=])RFI(XM'@=<N<SMLW4[T(Q<Z1\:
M14_L94>;BYQ<\.CH&TI;;YLW,GH:B>.6A(]D#8=07Q?YR,/E.<F*11UE@. $
MKR.': \&9&!2#DH8;1&;=Q8]F+J1J\.?&98#::W?F\/M2(7]C:!$L<%Q#SS7
M/8?*$:_>@7:1DT>LDI'/U%KP$2H[&4XQZ,UA*R5UE0+?-G3]N/B(7_]CNOY4
M9Z81BS61NO\1/0N&<4&<:E;=8U$XN%!GOY2<72T5(!=YH!/\J;1V>:O8#$4/
M'.6#*K2+,_U]_KSE]6WY93$_HR#J?)/GYT9+49 #3[9.4E4:?.$"7"K*\T1_
M%JV#ZX=HZ?+&<"CH-5%(#\',C@O\9K6ZJ*/7[G DE/79&0V%T6%"OD< 9UV$
MDJ4EWT-S+9O?LWR7JBXO_P:S<VV5U!GL;M)3OT[GBWKGOK':VTFF$X6"G)A<
M6VK4UNW(.03,$C07V0C#:X?0 >'W.'5=7O(]!PP;*JU3.)+WL,D)[)'FQ$OC
M:ML"0,M(BBIF<,()0A+#.G$W1M'<(7P:B5U>]STG,%NIKP-T'B[-20Y<9L81
MD-?Y)=$D^DHP$&BL*R:G8%I7EAU.79=7?D-A<B"E=9#/J6S5?^J5Y1><709@
M)+%II&AG4^@Q3[?_8N<GW^7EM-[ WW[?<=WOE;[8--YZ3Y'33Z7D.B"].*93
M;4GO?0*5;0:4!<$HXYW@'$UL'>$\+X?C^A"-\T@=@Z.#K7-)]=NRR\G;^4DR
MF_ALM&8L 5DC#<I9<K5*M"01B@DB4S:PU'A_#,#&N/Y*XTTPMIH[\%E.8U:C
MQ% G/SCRZT")R,%+K&<C)B&RM[%YD]GAT3N89].3"7^2ZH[&Z>?-04%\+]<=
MH%4YSG5$K'O1@.+!@Q<Z ^<J4\"+#'EK"SP\6@<K?NH*K4]1W8EH_6F^>Q7P
MS//5%]L"V.N_N,U4B]GJ]Y=XEKGJW^&L_4SU#^M%_.LVSW6Y]'6\6"PC4T=1
MHA**<*P< \Q) L903+21V^:S-P\BK/&4]:2"(.=: S>2>*40E38-\<J,#=Q$
MLOZR=>OL3J>L-\+"=\:M/T7>';A^U]1?2J1>O"[FU=IN!CP''WE.H0!7B2PN
MK0^A]GMED7/!1<C2MN[R\BA!G6#I"$T_!)J3Q=X!AN[PL)WBFS@=#,K7S%A@
MH+31->ZW@%[7%Y>A2-_Z)G(O(9U@YG1%WXU;3Y9Z!]!Y=[7NQCAO!S;7$;XE
M) W),ZSSGPL$YR1$)A(1$9AW[5]FW:=C7. T4.^]BY<39=T!7D@>YXOY+@-$
M+;KL'7#&;$VU: AUQIY-43+A*""1K8^H>T2,6TS3'BFG2;D#F+Q(:5K%C[-W
M.$UOYML65%MF.)=224<&-]3Q=$77]N J@[.>:UE*B:S]Q-A'"!JW/*8]?-I)
MOP<HQ7AQ?K$I6=Q<45=!+?,GBG&G7_)EYZHM8Y%^V83,0=!> 954;3)J:VV9
M-UF%Y)QHW4'I8.+&O;8: &*#:*4#N+W/:Y)-3C_A<CZ=GZVN["_S04B-H"-)
M2,5: RN3 R%CR0&3D:KUVX_]E(Q[]=,>2 WDW0%J/M:[UXLZO)".[,O3^\J_
M4SQ:2^3;.E=.>4R FGFP,B2T$;4RK=^S/4C,N!<O[;'31NH=P.?=1H!;V@UJ
M(64Q0"<S221(!TZ0Y^>*CR8R9I1IWX?M9OUQ[SL&B+J.E6T'N*C331;S-7TJ
M_<39FSE]<EY=\9)*P<U\YR)+!,4R JI:#8519Y>$$]BZU.<Q>L9]I]T>-\UD
MWP&.]MPB>H_2U[HY9 I!R9C!"R^!(@!OG=*A-&^4>Y^*3MJ)-DPG'R?@#B"R
MDW+8U*:OWEZL5VN<UU*R268Z<.M%#1F)%^$2^,P] =\5A>B54:T+91^CIY.,
M\I&Z?CC7<YK@NZD/N7_/1P'A95'BNSKRF]2T7B^GX6+3)O+C8K^EG10;;2!'
M#9++AD( 3?O1*0Y2VYRC](RG]G=?+2COQ*JU@><(RNP&R'OBB\LM.A')*%\;
M_P1G,B@CB1VM:F<^I;.*(K#F/OJ#Q'3WLOX4N+41>3<(>K=<E.FZ=M:?",]$
M5*I %BJ05,AY=#R2WQ@=3S)BUJ5U'<C-ZMU5S9^"D2.%VH&3]5"JM/*RZ?SY
M$;].DN6Q,%\K0<E JJ@2A:?DD:82M)."U]%%C8%R"%W=U9R? J'FBA@17+7T
M\(%H=7OQ\ZI^IQ[1M9N#*]RI)!"8KOW#?#" W&<($H4N+CNM[C1YNU_;^+0E
MNZOW/@8Y TJY \.T.6[K8_F<7E\LJV]W>1!NCMY;9_+[/-W\V,1$'Y/F= "+
M6 O6$Y)'5Y-JCIF@+.KH6Q>)/)W*[HJW3W;%AU-2OS#\=YQ=Y/T,)N>82EY#
MY+)>9N= K 8'W&$4Z)Q)HGUU[1.)'#<S^CP@;*2B?C%XN<LVWWS[N>IN]=/7
MO(S3%7$HZGA3A1Z<X"1/[31XDB]D+J+7W*546M_Q/9W*<=M6/J<I/%U)_<)P
ML\_V,QB$P6(I-DXNUL%H7H"K<R:#)U$Z7:SR@^3+GD+DR%TJG]$6GJZC#D#X
M8K;YF9SV=X;[Z6O],D^80W(E3 "3:W%B"+%644OB+V- %V.RK?M&'T;987#[
MH]P4#*"-?MJ3W\\S;V+TB2&A:*-YO94C[X&1 4>6/10K),H8O%"M;[D?(&7D
MZ9V#Y_6?+N^>T7/4+84C+I7=;)U:+X!90%#!@_"6)55<=**U(7O&*R?^1[D$
M&$&;39\K#W0+SUA0%+PG$(K768^< BEF%63!743E<N(#OK0X\A;^CW*IT$SR
MG2#IX8LT'4S(LI9%ND!>@9"L#F-$(+.O:'\(5IJ_*3WM[I+_46X5VLB\[\X)
M'R[.SW'Y;5$^3,_FTS*-=2)3C(N+^7ICGF?36)O7W>+EL(8)!WYRHSX)Q_#1
MJ#W"_65N>N@%@UEZ#SE9P@GG#$(,"$%KI147(9;6SPP>IN9DI^PQR7XD8;ZD
MG_[K1#LN>:!0Q5AR-I70-4<='0AGDX@BV9B;IW /HFS<,K-&*+GG6[572K-$
M17-CM9G@M=J\A3O*)-WZ_4:&YV&:&IF7JV&B= "%Z7Q#XPUT7$DNH)1 +DT
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MM)>TR<D)[N^\>GZHE_3^!48'P:EZ6S06XMA ^#G/_H;+-9YC(,F\^1NNUHM
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M,3]PJ/2 E\WC"#XQ;EHP>F97[64-W.85L?7LVY63D4JRD?B2ZJ *Y;" LT&
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MARH1BE B@9<U)R#4(1G)1X@<N7 F&.5:]^;HLCI4^N2TE*8>/XI\+>LA*"G
M2NZB$\J)T+IAWP]8'3H&38=4AXZ15@?&P@/'W"80CBP4K.5KV28#*F4/+F!-
MT27K)YH4G)NTN.\N2<^G8G04%(9'Z$;+I0.8?:3/W6+9-FH>R')"FP20RU9
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M]N'CDP<0-#)AR6H$X\C/59L>.M7MI?V3F.1*._E/T5ZR=CS@,4F0/-;XM3.
MS@9(*HALDZ:SZG_;2S9%TR$!A#'2ZNZ<OWMKJ4S0)? ,(FS2M42D$Z@:1Y*>
M)852>>(C_QD'$$9!860 88Q<.H#9_?>:SLAD4JI.7FV7)J0B2XD[\L:BU"P;
MXV7K[OO/-( P2N2# PAC^-\!D.Z[RO:>>4R)@>(L@$HE5>986E51SI@<BV\]
MHNB9!1!&"7I@ &$,USL SPVV7,T,C#I8J<DYB\H38QPY6:SFI6KFO$\B\#3I
M$??\AG,V.]CVDD&/0-KNL2B,PCKZ+Q?AJI%)C E,@0]HK6"!QVESGOKNI3Q*
MR -[*8_A^-SE!(^V_+6T&B:- <^X))V:&?AZW6-XY$E+YDC5#BHN>)Z]E$?)
M<E0OY3&,[0(EI';I+_'0FG+,%KEFD"0=ZBK0EG+,TFZRAIGHHG%Z6'/E@2_L
MJ"ZX&68:L[FWD^F^V^F$A5;M)!C,=4JR<X"\<,C<>I&<RA+5E,?4LX\63>39
M[R>AWE"W7<Q1D;0W%.U%4X?@JEKEY9U#VJDLV$S_)3-I,>:6CH[.NB;2?@A.
M^[!^;_A\R:O%,GTXP]79="%'&V-(.DK@SI&':9&<2^MRG>^>1.)D/\9I1P^/
M"#G.VQ2C&8CV8?W>(/J:5V'92 N]PV\UBV3]R_+FJ-*CS)+C-B&8;!AM!]+4
M9"1P<.1Q,.NY2*JUAW\?+<^@_<4A0&HB@O%@\A=@.LV?ZD']<=)S;1-F/;X0
M6?K/\_597? 1$SPDZ1TP[LE,M(68EGR J%'I@E[$YK6_@XE[!NTO6I^ APNI
M;Q >(>=U/E"":(P'972=+>\U:&-*C"+9J%KG.^]M7,W;U:*Y<36&]0<:5Z].
MT[3I.%_SZ7E-![GX.WS[LEK6-FT')=(\\LQF*3!C:&^4O/+S8HV?/JWJ#B>2
MJZ>X>?EEDH'0@4MA%=#11ECC40!*PIKE6F@OA#"LM6/]"$F'*I]['G_A!K.2
MHK'&0JAU34H*#AA5@I)Y]J%((9LW)'Z(GGD]O9;8N*V'FDEAYG[Y[RZVZ-O5
M!]*DBW@1U\Z(@B?2HJID^H.G  &M!\YE<;Y8R>R@J6"/M,W_WKN[1,P>4ETV
M9'$?$%G34;Y=P7I[U:MU2>1[UIEZHA[D2M)6*AZ8=<6SX&-6K!U.[A(PWXR-
MPV5Z%R ',KB#2\?M0K;W]*5@X88E6C]*XDG@X,FZ ^NC3UE7M[-U'M$- F9'
MQZ$"O>W)[\W=N0-HOWW8TKXS#7>1'!6E%3&#V_0=QBS!(?D%5FH;),-2PK"
MV3TOF/<P.4!>R\;,FQL OYR?X(I\\-UPFAAR0AM <B= )<OH3"T90K8B6)L-
M^F%RO_G<><3=3DC+-AR;6]@?7[W\Y?7/K]Z_V$V/D@F90G+'T1#RZR0AC,6
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M8\30@=9[K!%6()_&9K^Y2M9DE=0FT<@<")=C-#(5)EI?U/U03<KVP=P4LND
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M'9Q7=_-%-G7OFA<HF1%?% H(QB52O;&FT$6I;B<MSE1>\N1=BP\Q;P[C<T=
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MTM2:X%H74^IL.%8[BF96F'79BM*Z+& [1>.^[@P+LX:Z&#M@7Q7'K*7UAHZ
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MA1R[P\*[\UFHCWLU\4D:]3;\O&L_C:U)QEZ =BOF7(;("H62JJ3$6=9*I\-
M\LS*.Z''OV#TM)1\U[!ZXF3600?#C8(262;^) =G.,E4)5-<3J+<G\M\"+*.
M<(0X^T70U4 !'3QZ/#JQQ##/Z+CUX$2HG2TU@Y"\!<L\F=]LDFG>O_'@Z3\G
MG;1PS /9T9+N$"V;#8:>,V1% Z:\FJ 5:PL LBH4"HC Z!_-NX6]F.D_>VEX
MM^D_^XB[ ]#<NG;8V$@R@U(;IH#GZ$#5$>).U2(&VD;**R-T:/W\_H"(OJ!R
MB&9G+<7< 4[^>#B\2$<NHK,<I*A%=:)FKM 1"C)[J4MFDF'KQO</J1CW&!H
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M7,/%F=%*)YT2F&R)_:@S^0L:@45;;#"2F;*M9?UQYVH3%D9^?3C%^7MZ57>
M]!LNK^7ZH=Q\<U6==":,=LPP#SZY^D 3(CAO!.U>7U3]C\>=QH@==& _3==N
MF'S1;Q"-E-(_T*Y*EGZ>,1=T*MP 0Y%J]4"I30@C""V,RY878ONT8+NF;3?
MO: 7C4&5TP'HUC7?LPM:_QM.%RM;7AL'5X/_:.Q_$_=O'K.QT*GPA<(O88S0
MUC%(V<O*N09OH@(18KW(0AE8ZPX/[:C?#;@OZ+5E9 4W@W;SX>(?Y[6IXO+G
MQ_- GS?-U47_7CV3(P:,/_N9C8:,[T=[HT'C=Q9]=6O1Z_'+2@3O) $CE^Q
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M$3)F[J25QM\O#&OP-G^S_K@1^\  .UC08_M<[R^K=_"A?/ZO2Y+C.\3EF:3
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MN3VAQ-EOT\66S;5.DE$D)84M&PN"#,U/RB463BGJN2A=3F?;F.J& 18F4U$
MV@VMN1=Y_2/:25@HXD6\?BY^]WUT.3M^__7C7W]^VZ-XUN ^"@76[#>WIN)J
M'#-22X.1])0CGBM/&\\X2LH;X6,*W)0V9MN(J[G+.OP S*/IU$[.EUU-PJ(
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M^!E/Z:B,4@>P.USVDME(84_ N528P-$09]3CK72-YW)#)R\K:'40LMT!Q-R
MOBKJZO76))D,0XDIC[@# \%$#J:M@05K$J?.EMY6WU(U'6@WKD:,VCIT^^U]
M!'N7*Z\0V,(<<8QCOMLP"'-#G>?)!1]Z:=)?*573( H,BZ88@D<C[-I^7R]#
M\!QSBHS&.=T0-T@[[9#2.,#2-33A0378?J543?MRK2PZK_'R,2<BFIS;BZ[Z
M[>/&D52_?NPOIZ;N'R50.X"IBJ+'&'%C++(J)41]%-HQ)9THG2CXM=X_>A83
MXY$@Z6D.?Q )#AD*5!-)&@L>J>&ELW^_W3_NR^GGR-DT@!<-G!,WW6CX0 TS
M+" -YV8$0_=@B6F+I!;$!Q$=P[T>.K[=/^[/E 'WCT-@:Y>!MY4HG,946PQF
MF)%P!C 1Z< E4L0*)6*,3X*/?]7[QT&P#RL),P"#!@C5Y[;+A>"4Q!1AFAW-
M,3!DD^:(\1"=,=IS4UJUO?#[QT$DV.'^<0@B#9"LZ+E64*RPQ08Q2K*C@RFD
MI0T(#IQ.*9.2*'Y9].S^U9=TV[G/SER-&(UXP#;X\\ 25YYH@PP1%,3*'+)"
M8I2X5 23%-GC\FYO_M5A%!CF7QV"1R/LVN[!\]PGJQ1%Q'K81R0'>7GM4=#"
M6A\T2VZ0$_]7\J_NR[6RZ+QD_^KBD_MP'-2'NK:W9_.3]IMO4[[0&*17#'@N
M4[[0QQ@C"_0$@Q.#W2F84NZM/'8_>RDE[XS  8F40U^5R\DNF4?<$T95")07
M+P7PY@O=E]//X L=PHL&SG2K8]*LX51[PU%2W,&6A1URD6,4.<?:1\95*ET8
M>_>8TI?D_QS$CEXQI4.@:H!O0^/:*$C+6L80T4$CKCE'EOB J ]"8:(P#Z6O
MG%Y!3.D@4NP94SH$H=HGJH7)-EUZYL"H"Z.9[W[$Z?5=GLZDL;$Y^-;#7&SP
MR-A<HQF.B%@ZHZ+J%U>ZI:.7%5LZ".'N0.)N0'<5/7=:G81*)B"?#$6<YB>D
M)&E$C2+42AE$\;OT-__G@7;F:L1H8%%LO.?X^(\?7X71Y/S(__MJ!(/[/#F9
M=C[.9N^[V?Q,&&L)XP'427Y&K3QH E IH&)T),EZ*MVSOHC;/-Q7Y& =Q+$A
M%UL% =^9V[#!N*ZV,^R;O9A=3<[?C;IX.3IP-.'*KIXO7'#[3)OR@6DEC&)@
M;UAF2<ZP$Y#3.")O7?(B)W;@;SZP?GMFQ-Y9!GLFM9@AGBQ')FB)HM!8<NJ9
M+/Y&YLT'MB^GG\$'-H07#9@PJ\_0B:;@@J=(P*Z$\CMTI)6V2 1%A%:$Q5 Z
MV<ZOX0,;Q(Y>/K A4#7 MZ'G;\ZQ(DHX%+#+M;2-1L9(#]/C.1EVC$:X-Q_8
M7J38TP<V!*':/K"?]AH8H*.QG1Z=3^-B8LO)*$Y 4%J@I$/*+RTYTO"_+#A*
MI':)B'X)EK?U]+*\8(,P[@XE\.JE.6ZW@X]POIM??XGS[QT<\G[$V2()^=-/
M8_S#7L2;;$$R8>;@P"D)\8A; J=.!::*5X(:QX@FKD@1H3W&^.K<6KMLML\*
M=&5"KYO';8F50+ A*2)K+6PBW$IDI2((^XBQ,U%SUBL4?PME-X^B9NV9YV)!
M=Q!(FM]K73 2:Z)1RMXX;F@N$<<3HL0+DXPVF+L7O->6AG/0MCI$M@V<"I:O
M;!?U.^[K\7?7]W]R4^.26R:<I<@H27/A)XZLPQ)YP61^"<.C+WT@Z#^Z5Y=Y
M9)_SZH% ;8RNRZ5L0+,S4.Y(,+%XSI*S0;J(& 4;61,20O&"M4]'4?=0<2B\
M-]!J!^$W1I^EOB942NNM1L'ZG.U16J0EL0ASJ86A&N/BE;>?CJ(=^NR"ZP::
M["#D!FA2]M932*.(3HB0B!%W'.9NE5GD/9$I,NUYZ:C&MR)_!]I8JQ&C]I'B
M?3>9CV VDWDN_1:G^49H]-\Q?!V=?Y_/_KC*J_PXG4R[<.7GLS/EM5+&"80C
MR95%"('U;C BP5L>K0A.\%X'C&']OJ98B2'DZ)X'J=HD7.T-F.4@D/P4ZJ:*
MTJ*JTEGTU"B< B+1PK04H\@%QI#&EB3-%.QO/=^F]>[S%;U.VYE\!T*H.O%F
M\T55RW 4PBC+RHYO*V'^>0GX C;QQT*>Q^E>=!*(_N<:O*NA.3MC1L*N$PS,
M%83*A<\)QA-%U(%UI(64U/0L\U=T7*^H&.#N!*Z'=&V2KP/@-$XO/N90JEE^
MR9Q@1^#*,\1<< BFYI!3"HX(2D1EM8$I]=W9>W3WBLH$[K&AE\:E/M,FBP"B
MX\LLHX__Y&4SBY]B/),D,2N30E(FES<%F 7A$60&YTV0GXVLO]VXLHM75!9P
M+Q-Q?_G79]'&XH84NRAQPDB9? ^4I,J^?HXH"V!P,"VILD,5U:YE)N5KYU,Q
M)!IP_AQYWUV!"+]&'T<_LLO@CS@_HUQ9D(!'@DC8R:G ^9S$D7.:,>MPD+2T
M%V?E0'KQ3;U:OI4#J2&F@8699_ ^9X]9V))9E#??G.%HHM0Q(AJR!>GS=6(N
M>RZE2M1ZDQ(I'H6W?5B]6*A_&1:6 K#=/"SW#O.CR5^@U_-\/T^@7_CXXV0.
M9Z6XSWN30>T7>F2R^YSV?%FRV#3O]?YY;>]WH?;&PPX:O4,^YOL8*0*RH.P0
M4]8+GR2%';:7-3.HVW*//];U=)L%C@J>G$-)IYQMWG&DHS:(:$J(43R7F3G8
MBXZ-0ZOC43XP0=:_Q2@'4^4 NY^/6F*XD]4B=ZM4$4>P#DC2$4P$+I!5TB//
M4DYMS9SO][YB2VC=NOY;>591$.BNL-0;9,[R4CQIE:?O4<)69!\+K#$M*'+P
M T\\')UUKX?#.W"G=DAF&62W4&4',==V0OP1KZ:CBXNKR6UR71L<E5IJ9*G6
MB!,+AUTO&0I>>>J4P>)QD-R:C?IQRVUAOPM472FY-7!T6ZD_KW^>*@AF#M-L
M]3-A\U-W@8SG!BGA1-#,&>Q*OU'=,J16WAB4WWD.@4EMO;(ZW4'.9C [B5.?
MH3N/9]E]YG2BB(0(,W+PE8MPRJ1)$^$-&'U*]5(VO;JK:[L41;<[J*@;T$\?
MHK__K/LW4-;'T]^[V>SH(GLLSBS6S@JB$ T8IJ-A)M9(@9@G)CB5C#6E@V:W
M#*FN?CH$NPZ!16V]]/-0^GGR;M3-H_\^Z<;=^?7[[N+23K(>_V[G1]/X(4*/
M%R"_<-J]BW]._#TC8MT6<(:Q-S'G:#$L&<2-(DB3(%!(,G 7',:/G>Q;O1P'
M&&;=.(F#Z<%VH&TY!\_O,)WS13M[>#N?-E+(I;EE=(4RXF3==1=FZ*\_3U(W
MO;A9 *Z[FO\<Q!<[SWKGSDF%$X^8BX12X %Q"TS0E$>D>%)6*6X=+QUKO^M8
M]]V '_9[9]^"+:M\Y!8%!X<;GM\I&I4LBH&2P'**3"D.*H&ZCLUG9=#C?;@
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MB"F-HR=6^5 Z#^7ZT=3U^12T(0H+OCD*7=^^BSA.)_"#$<@I_\(9@=.G5]3
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MET;<_WOBO$%^A]?HRQ_D?YR=Q?_U/_X_4$L#!!0    ( .:#7ED/&&$Q^ <
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M6Y;(KBR>96=XB]"%&:AA<<PP9C1"9(4H2[,;"N,<^.Y*X/]< OM[';>72H;
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M     &)I:6(M,C R-# Y,S N:'1M4$L! A0#%     @ YH->6?A]1K[;'P
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M,#(T,#DS,%]G,2YJ<&=02P$"% ,4    " #F@UY9G;3X4 SN  #?,@$ %0
M            @ 'O P4 8FEI8BTR,#(T,#DS,%]G,3 N:G!G4$L! A0#%
M  @ YH->686/]FOZ) $ 1)4! !4              ( !+O(% &)I:6(M,C R
M-# Y,S!?9S$Q+FIP9U!+ 0(4 Q0    ( .:#7EFXQ(4:.34! +&Z 0 5
M          "  5L7!P!B:6EB+3(P,C0P.3,P7V<Q,BYJ<&=02P$"% ,4
M" #F@UY9'F:TUE4N  #L/P  %               @ ''3 @ 8FEI8BTR,#(T
M,#DS,%]G,BYJ<&=02P$"% ,4    " #F@UY9>D/^P3\>  #$+   %
M        @ %.>P@ 8FEI8BTR,#(T,#DS,%]G,RYJ<&=02P$"% ,4    " #F
M@UY9%L(">[HK  "'/@  %               @ &_F0@ 8FEI8BTR,#(T,#DS
M,%]G-"YJ<&=02P$"% ,4    " #F@UY9G,M)TH$L  !J/0  %
M    @ &KQ0@ 8FEI8BTR,#(T,#DS,%]G-2YJ<&=02P$"% ,4    " #F@UY9
MP3?\0O&2   ]LP  %               @ %>\@@ 8FEI8BTR,#(T,#DS,%]G
M-BYJ<&=02P$"% ,4    " #F@UY9>UXXE*B<  !PO   %
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M &)I:6(M,C R-# Y,S!?<')E+GAM;%!+ 0(4 Q0    ( .:#7ED/&&$Q^ <
M . I   6              "  ?J'#@!B:6EB+3(P,C0Y,S!X97@S,3$N:'1M
M4$L! A0#%     @ YH->68_:<['M!P  4"@  !8              ( !)I .
M &)I:6(M,C R-#DS,'AE>#,Q,BYH=&U02P$"% ,4    " #F@UY9-4.D(&,%
M  #5(   %@              @ %'F X 8FEI8BTR,#(T.3,P>&5X,S(Q+FAT
7;5!+!08     %0 5 '$%  #>G0X    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>biib-20240930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20240930"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20240930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2024-10-29</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">biib:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentFutureDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentCommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabIgANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAMRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabPMNMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabIgANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAMRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabPMNMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ClinicalInventoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ClinicalInventoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:CompletedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:CompletedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityTerminatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:OmnibusEquityPlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:OmnibusEquityPlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MosunetuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:LenderDisputeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="employee">
        <measure>biib:Employee</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-30" unitRef="shares">145719340</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">145719340</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues contextRef="c-3" decimals="-5" id="f-31" unitRef="usd">1769400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-5" id="f-32" unitRef="usd">1805200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-5" id="f-33" unitRef="usd">5380900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-5" id="f-34" unitRef="usd">5414300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-5" id="f-35" unitRef="usd">446200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-5" id="f-36" unitRef="usd">420900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-5" id="f-37" unitRef="usd">1284700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-5" id="f-38" unitRef="usd">1253800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-5" id="f-39" unitRef="usd">250200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-5" id="f-40" unitRef="usd">304200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-5" id="f-41" unitRef="usd">555600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-5" id="f-42" unitRef="usd">781200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-5" id="f-43" unitRef="usd">2465800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-5" id="f-44" unitRef="usd">2530300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-5" id="f-45" unitRef="usd">7221200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-5" id="f-46" unitRef="usd">7449300000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-15" decimals="-5" id="f-47" unitRef="usd">638700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-16" decimals="-5" id="f-48" unitRef="usd">659600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-5" id="f-49" unitRef="usd">1726900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-17" decimals="-5" id="f-50" unitRef="usd">1915100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-15" decimals="-5" id="f-51" unitRef="usd">542700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-16" decimals="-5" id="f-52" unitRef="usd">736300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-5" id="f-53" unitRef="usd">1509500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-17" decimals="-5" id="f-54" unitRef="usd">1891100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-15" decimals="-5" id="f-55" unitRef="usd">588400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-16" decimals="-5" id="f-56" unitRef="usd">788200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-57" unitRef="usd">1723700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-17" decimals="-5" id="f-58" unitRef="usd">1941200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-15" decimals="-5" id="f-59" unitRef="usd">130300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-16" decimals="-5" id="f-60" unitRef="usd">60900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-1" decimals="-5" id="f-61" unitRef="usd">295500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-17" decimals="-5" id="f-62" unitRef="usd">164000000.0</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing contextRef="c-15" decimals="-5" id="f-63" unitRef="usd">69300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-16" decimals="-5" id="f-64" unitRef="usd">50500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-1" decimals="-5" id="f-65" unitRef="usd">197300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-17" decimals="-5" id="f-66" unitRef="usd">164500000</biib:Collaborationprofitlosssharing>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-5" id="f-67" unitRef="usd">23800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-16" decimals="-5" id="f-68" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-5" id="f-69" unitRef="usd">23800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-17" decimals="-5" id="f-70" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges contextRef="c-15" decimals="-5" id="f-71" unitRef="usd">6800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-16" decimals="-5" id="f-72" unitRef="usd">76000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-5" id="f-73" unitRef="usd">24900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-17" decimals="-5" id="f-74" unitRef="usd">120000000.0</us-gaap:RestructuringCharges>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-75" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-16" decimals="-5" id="f-76" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-77" unitRef="usd">88600000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-17" decimals="-5" id="f-78" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-15" decimals="-5" id="f-79" unitRef="usd">-14800000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-16" decimals="-5" id="f-80" unitRef="usd">-300000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-5" id="f-81" unitRef="usd">-193700000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-17" decimals="-5" id="f-82" unitRef="usd">-248200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses contextRef="c-15" decimals="-5" id="f-83" unitRef="usd">2014800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-16" decimals="-5" id="f-84" unitRef="usd">2671500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-5" id="f-85" unitRef="usd">5606700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-17" decimals="-5" id="f-86" unitRef="usd">6444100000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-87" unitRef="usd">451000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-88" unitRef="usd">-141200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-89" unitRef="usd">1614500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-90" unitRef="usd">1005200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-5" id="f-91" unitRef="usd">62500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-5" id="f-92" unitRef="usd">-72900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-93" unitRef="usd">249000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-5" id="f-94" unitRef="usd">92600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-5" id="f-95" unitRef="usd">388500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-5" id="f-96" unitRef="usd">-68300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-97" unitRef="usd">1365500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-5" id="f-98" unitRef="usd">912600000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-99" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-100" unitRef="usd">-200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-101" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-102" unitRef="usd">1200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-103" unitRef="usd">388500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-5" id="f-104" unitRef="usd">-68100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-105" unitRef="usd">1365500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-5" id="f-106" unitRef="usd">911400000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-107"
      unitRef="usdPerShare">2.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-109"
      unitRef="usdPerShare">9.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-110"
      unitRef="usdPerShare">6.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">2.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">9.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-114"
      unitRef="usdPerShare">6.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-5" id="f-115" unitRef="shares">145700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="-5" id="f-116" unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-117" unitRef="shares">145500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="-5" id="f-118" unitRef="shares">144700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-5" id="f-119" unitRef="shares">146100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="-5" id="f-120" unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-121" unitRef="shares">146000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="-5" id="f-122" unitRef="shares">145500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-123" unitRef="usd">388500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-5" id="f-124" unitRef="usd">-68100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-125" unitRef="usd">1365500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-5" id="f-126" unitRef="usd">911400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-15" decimals="-5" id="f-127" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-16" decimals="-5" id="f-128" unitRef="usd">14500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-129" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-17" decimals="-5" id="f-130" unitRef="usd">15700000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-15" decimals="-5" id="f-131" unitRef="usd">-41000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-16" decimals="-5" id="f-132" unitRef="usd">29600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-5" id="f-133" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-17" decimals="-5" id="f-134" unitRef="usd">1100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-15" decimals="-5" id="f-135" unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-16" decimals="-5" id="f-136" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-137" unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-17" decimals="-5" id="f-138" unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-5" id="f-139" unitRef="usd">41000000.0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-16" decimals="-5" id="f-140" unitRef="usd">-30500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-141" unitRef="usd">14000000.0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-17" decimals="-5" id="f-142" unitRef="usd">-11800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-5" id="f-143" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-16" decimals="-5" id="f-144" unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-145" unitRef="usd">8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-5" id="f-146" unitRef="usd">5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-5" id="f-147" unitRef="usd">388800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-16" decimals="-5" id="f-148" unitRef="usd">-54600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-149" unitRef="usd">1373500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-17" decimals="-5" id="f-150" unitRef="usd">917000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-151" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-152" unitRef="usd">-200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-153" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-154" unitRef="usd">1200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-155" unitRef="usd">388800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-156" unitRef="usd">-54800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-157" unitRef="usd">1373500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-158" unitRef="usd">918200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-5" id="f-159" unitRef="usd">1699200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-5" id="f-160" unitRef="usd">1049900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-19" decimals="-5" id="f-161" unitRef="usd">2000000.0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-18" decimals="-5" id="f-162" unitRef="usd">2400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-20" decimals="-5" id="f-163" unitRef="usd">1536200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-21" decimals="-5" id="f-164" unitRef="usd">1664100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-22" decimals="-5" id="f-165" unitRef="usd">451900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-23" decimals="-5" id="f-166" unitRef="usd">435900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-18" decimals="-5" id="f-167" unitRef="usd">2469200000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-19" decimals="-5" id="f-168" unitRef="usd">2527400000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-18" decimals="-5" id="f-169" unitRef="usd">674000000.0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-19" decimals="-5" id="f-170" unitRef="usd">1182000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-18" decimals="-5" id="f-171" unitRef="usd">6830500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-19" decimals="-5" id="f-172" unitRef="usd">6859300000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-18" decimals="-5" id="f-173" unitRef="usd">3210900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-19" decimals="-5" id="f-174" unitRef="usd">3309700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-18" decimals="-5" id="f-175" unitRef="usd">380400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-19" decimals="-5" id="f-176" unitRef="usd">420000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-18" decimals="-5" id="f-177" unitRef="usd">9805500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-19" decimals="-5" id="f-178" unitRef="usd">8363000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-18" decimals="-5" id="f-179" unitRef="usd">6485800000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-19" decimals="-5" id="f-180" unitRef="usd">6219200000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-18" decimals="-5" id="f-181" unitRef="usd">968700000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-19" decimals="-5" id="f-182" unitRef="usd">928600000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-18" decimals="-5" id="f-183" unitRef="usd">631400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-19" decimals="-5" id="f-184" unitRef="usd">745000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-18" decimals="-5" id="f-185" unitRef="usd">28313200000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-19" decimals="-5" id="f-186" unitRef="usd">26844800000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent contextRef="c-18" decimals="-5" id="f-187" unitRef="usd">1748100000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-19" decimals="-5" id="f-188" unitRef="usd">150000000.0</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-18" decimals="-5" id="f-189" unitRef="usd">499100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-19" decimals="-5" id="f-190" unitRef="usd">257400000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-18" decimals="-5" id="f-191" unitRef="usd">422700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-19" decimals="-5" id="f-192" unitRef="usd">403300000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-193" unitRef="usd">2755100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-194" unitRef="usd">2623600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-195" unitRef="usd">5425000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-196" unitRef="usd">3434300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt contextRef="c-18" decimals="-5" id="f-197" unitRef="usd">4545800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-19" decimals="-5" id="f-198" unitRef="usd">6788200000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-18" decimals="-5" id="f-199" unitRef="usd">882400000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-19" decimals="-5" id="f-200" unitRef="usd">641800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-18" decimals="-5" id="f-201" unitRef="usd">357000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-19" decimals="-5" id="f-202" unitRef="usd">400000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-18" decimals="-5" id="f-203" unitRef="usd">744100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-19" decimals="-5" id="f-204" unitRef="usd">781100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-18" decimals="-5" id="f-205" unitRef="usd">11954300000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-19" decimals="-5" id="f-206" unitRef="usd">12045400000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-18" id="f-207" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-19" id="f-208" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-18"
      decimals="3"
      id="f-209"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c-18" decimals="-5" id="f-210" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-19" decimals="-5" id="f-211" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-18"
      decimals="4"
      id="f-212"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockValue contextRef="c-18" decimals="-5" id="f-213" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-19" decimals="-5" id="f-214" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-18" decimals="-5" id="f-215" unitRef="usd">488500000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-19" decimals="-5" id="f-216" unitRef="usd">302500000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="-5" id="f-217" unitRef="usd">-145700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-5" id="f-218" unitRef="usd">-153700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-18" decimals="-5" id="f-219" unitRef="usd">18993100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-19" decimals="-5" id="f-220" unitRef="usd">17627600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue contextRef="c-18" decimals="-5" id="f-221" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-19" decimals="-5" id="f-222" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-5" id="f-223" unitRef="usd">16358900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-5" id="f-224" unitRef="usd">14799400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-18" decimals="-5" id="f-225" unitRef="usd">28313200000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-19" decimals="-5" id="f-226" unitRef="usd">26844800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-227" unitRef="usd">1365500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-5" id="f-228" unitRef="usd">912600000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-229" unitRef="usd">489200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-17" decimals="-5" id="f-230" unitRef="usd">354700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-1" decimals="-5" id="f-231" unitRef="usd">20200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-17" decimals="-5" id="f-232" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-5" id="f-233" unitRef="usd">68700000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-17" decimals="-5" id="f-234" unitRef="usd">62100000</us-gaap:InventoryWriteDown>
    <biib:AmortizationOfInventoryStepUp contextRef="c-1" decimals="-5" id="f-235" unitRef="usd">185100000</biib:AmortizationOfInventoryStepUp>
    <biib:AmortizationOfInventoryStepUp contextRef="c-17" decimals="-5" id="f-236" unitRef="usd">0</biib:AmortizationOfInventoryStepUp>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-237" unitRef="usd">216100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-17" decimals="-5" id="f-238" unitRef="usd">209300000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-5" id="f-239" unitRef="usd">23800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-17" decimals="-5" id="f-240" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-241" unitRef="usd">-99700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-17" decimals="-5" id="f-242" unitRef="usd">-377700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-1" decimals="-5" id="f-243" unitRef="usd">-22700000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-17" decimals="-5" id="f-244" unitRef="usd">-275700000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-5" id="f-245" unitRef="usd">88600000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-17" decimals="-5" id="f-246" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-5" id="f-247" unitRef="usd">-95100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-17" decimals="-5" id="f-248" unitRef="usd">-98600000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-24" decimals="-5" id="f-249" unitRef="usd">-127600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-25" decimals="-5" id="f-250" unitRef="usd">76500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-26" decimals="-5" id="f-251" unitRef="usd">15900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-27" decimals="-5" id="f-252" unitRef="usd">-3100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-5" id="f-253" unitRef="usd">207400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-17" decimals="-5" id="f-254" unitRef="usd">34900000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-5" id="f-255" unitRef="usd">-84200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-17" decimals="-5" id="f-256" unitRef="usd">293900000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-1" decimals="-5" id="f-257" unitRef="usd">62100000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-17" decimals="-5" id="f-258" unitRef="usd">-114800000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-5" id="f-259" unitRef="usd">65700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-17" decimals="-5" id="f-260" unitRef="usd">71400000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-261" unitRef="usd">2114600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="-5" id="f-262" unitRef="usd">1534700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-263" unitRef="usd">114400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-17" decimals="-5" id="f-264" unitRef="usd">211800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-5" id="f-265" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-17" decimals="-5" id="f-266" unitRef="usd">7380800000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-5" id="f-267" unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-17" decimals="-5" id="f-268" unitRef="usd">5140700000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-17" decimals="-5" id="f-269" unitRef="usd">6335600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-5" id="f-270" unitRef="usd">1074800000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-1" decimals="-5" id="f-271" unitRef="usd">406800000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-17" decimals="-5" id="f-272" unitRef="usd">788100000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-273" unitRef="usd">88600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-17" decimals="-5" id="f-274" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-5" id="f-275" unitRef="usd">179100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-17" decimals="-5" id="f-276" unitRef="usd">34400000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c-1" decimals="-5" id="f-277" unitRef="usd">96700000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c-17" decimals="-5" id="f-278" unitRef="usd">106200000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-5" id="f-279" unitRef="usd">4400000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-17" decimals="-5" id="f-280" unitRef="usd">1300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-281" unitRef="usd">-780600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="-5" id="f-282" unitRef="usd">-3448700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-5" id="f-283" unitRef="usd">34800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-17" decimals="-5" id="f-284" unitRef="usd">48000000.0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-5" id="f-285" unitRef="usd">650000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-17" decimals="-5" id="f-286" unitRef="usd">159900000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-5" id="f-287" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-17" decimals="-5" id="f-288" unitRef="usd">997200000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c-1" decimals="-5" id="f-289" unitRef="usd">0</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c-17" decimals="-5" id="f-290" unitRef="usd">4200000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-5" id="f-291" unitRef="usd">-6600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-17" decimals="-5" id="f-292" unitRef="usd">1900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-293" unitRef="usd">-691400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="-5" id="f-294" unitRef="usd">795400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-295" unitRef="usd">642600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-17" decimals="-5" id="f-296" unitRef="usd">-1118600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-5" id="f-297" unitRef="usd">6700000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="-5" id="f-298" unitRef="usd">-12800000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-5" id="f-299" unitRef="usd">1049900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-5" id="f-300" unitRef="usd">3419300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-5" id="f-301" unitRef="usd">1699200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-5" id="f-302" unitRef="usd">2287900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="-5" id="f-303" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-5" id="f-304" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-5" id="f-305" unitRef="shares">169500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-5" id="f-306" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-5" id="f-307" unitRef="usd">407500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-5" id="f-308" unitRef="usd">-146000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-5" id="f-309" unitRef="usd">18604600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-35" decimals="-5" id="f-310" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-5" id="f-311" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-5" id="f-312" unitRef="usd">15889100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-37" decimals="-5" id="f-313" unitRef="usd">388500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-5" id="f-314" unitRef="usd">388500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-5" id="f-315" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-5" id="f-316" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-39" decimals="-5" id="f-317" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-40" decimals="-5" id="f-318" unitRef="usd">7600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-15" decimals="-5" id="f-319" unitRef="usd">7600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-39" decimals="-5" id="f-320" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-40" decimals="-5" id="f-321" unitRef="usd">-1600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-5" id="f-322" unitRef="usd">-1600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-40" decimals="-5" id="f-323" unitRef="usd">-75000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-5" id="f-324" unitRef="usd">-75000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-40" decimals="-5" id="f-325" unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-15" decimals="-5" id="f-326" unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-41" decimals="-5" id="f-327" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-5" id="f-328" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-5" id="f-329" unitRef="shares">169500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-5" id="f-330" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-5" id="f-331" unitRef="usd">488500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-5" id="f-332" unitRef="usd">-145700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-5" id="f-333" unitRef="usd">18993100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-46" decimals="-5" id="f-334" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-5" id="f-335" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-5" id="f-336" unitRef="usd">16358900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-47" decimals="-5" id="f-337" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-5" id="f-338" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-48" decimals="-5" id="f-339" unitRef="shares">168700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-5" id="f-340" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-5" id="f-341" unitRef="usd">302500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-5" id="f-342" unitRef="usd">-153700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-5" id="f-343" unitRef="usd">17627600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-52" decimals="-5" id="f-344" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-5" id="f-345" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-5" id="f-346" unitRef="usd">14799400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-53" decimals="-5" id="f-347" unitRef="usd">1365500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-348" unitRef="usd">1365500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-54" decimals="-5" id="f-349" unitRef="usd">8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-5" id="f-350" unitRef="usd">8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-55" decimals="-5" id="f-351" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-56" decimals="-5" id="f-352" unitRef="usd">31200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-1" decimals="-5" id="f-353" unitRef="usd">31200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-55" decimals="-5" id="f-354" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-56" decimals="-5" id="f-355" unitRef="usd">-66000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-5" id="f-356" unitRef="usd">-66000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-56" decimals="-5" id="f-357" unitRef="usd">-224000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-358" unitRef="usd">-224000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-56" decimals="-5" id="f-359" unitRef="usd">3200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-1" decimals="-5" id="f-360" unitRef="usd">3200000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-41" decimals="-5" id="f-361" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-5" id="f-362" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-5" id="f-363" unitRef="shares">169500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-5" id="f-364" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-5" id="f-365" unitRef="usd">488500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-5" id="f-366" unitRef="usd">-145700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-5" id="f-367" unitRef="usd">18993100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-46" decimals="-5" id="f-368" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-5" id="f-369" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-5" id="f-370" unitRef="usd">16358900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-57" decimals="-5" id="f-371" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-5" id="f-372" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-58" decimals="-5" id="f-373" unitRef="shares">168600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-5" id="f-374" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-5" id="f-375" unitRef="usd">170700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-5" id="f-376" unitRef="usd">-172800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-5" id="f-377" unitRef="usd">17446000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-62" decimals="-5" id="f-378" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-5" id="f-379" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-5" id="f-380" unitRef="usd">14466900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-5" id="f-381" unitRef="usd">-6400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="-5" id="f-382" unitRef="usd">14460500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-66" decimals="-5" id="f-383" unitRef="usd">-68100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-67" decimals="-5" id="f-384" unitRef="usd">-68100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-68" decimals="-5" id="f-385" unitRef="usd">-200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-5" id="f-386" unitRef="usd">-68300000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-69" decimals="-5" id="f-387" unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-67" decimals="-5" id="f-388" unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-16" decimals="-5" id="f-389" unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-68" decimals="-5" id="f-390" unitRef="usd">2500000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-16" decimals="-5" id="f-391" unitRef="usd">2500000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-70" decimals="-5" id="f-392" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-71" decimals="-5" id="f-393" unitRef="usd">9300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-67" decimals="-5" id="f-394" unitRef="usd">9300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-16" decimals="-5" id="f-395" unitRef="usd">9300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-70" decimals="-5" id="f-396" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-71" decimals="-5" id="f-397" unitRef="usd">-2700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-67" decimals="-5" id="f-398" unitRef="usd">-2700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-5" id="f-399" unitRef="usd">-2700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-71" decimals="-5" id="f-400" unitRef="usd">-64800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-67" decimals="-5" id="f-401" unitRef="usd">-64800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-16" decimals="-5" id="f-402" unitRef="usd">-64800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-71" decimals="-5" id="f-403" unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-67" decimals="-5" id="f-404" unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-16" decimals="-5" id="f-405" unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-72" decimals="-5" id="f-406" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-5" id="f-407" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-73" decimals="-5" id="f-408" unitRef="shares">168700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-5" id="f-409" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-5" id="f-410" unitRef="usd">242200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-5" id="f-411" unitRef="usd">-159300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-5" id="f-412" unitRef="usd">17377900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-77" decimals="-5" id="f-413" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-77" decimals="-5" id="f-414" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-78" decimals="-5" id="f-415" unitRef="usd">14483800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-79" decimals="-5" id="f-416" unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-5" id="f-417" unitRef="usd">14479700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-80" decimals="-5" id="f-418" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-80" decimals="-5" id="f-419" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-81" decimals="-5" id="f-420" unitRef="shares">167900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-81" decimals="-5" id="f-421" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-82" decimals="-5" id="f-422" unitRef="usd">73300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-83" decimals="-5" id="f-423" unitRef="usd">-164900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-84" decimals="-5" id="f-424" unitRef="usd">16466500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-85" decimals="-5" id="f-425" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-85" decimals="-5" id="f-426" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-86" decimals="-5" id="f-427" unitRef="usd">13397900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-87" decimals="-5" id="f-428" unitRef="usd">-9500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-5" id="f-429" unitRef="usd">13388400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-88" decimals="-5" id="f-430" unitRef="usd">911400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-89" decimals="-5" id="f-431" unitRef="usd">911400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-90" decimals="-5" id="f-432" unitRef="usd">1200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-5" id="f-433" unitRef="usd">912600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-91" decimals="-5" id="f-434" unitRef="usd">5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-89" decimals="-5" id="f-435" unitRef="usd">5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-17" decimals="-5" id="f-436" unitRef="usd">5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-90" decimals="-5" id="f-437" unitRef="usd">4200000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-17" decimals="-5" id="f-438" unitRef="usd">4200000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-92" decimals="-5" id="f-439" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-93" decimals="-5" id="f-440" unitRef="usd">38700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-89" decimals="-5" id="f-441" unitRef="usd">38700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-17" decimals="-5" id="f-442" unitRef="usd">38700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-92" decimals="-5" id="f-443" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-93" decimals="-5" id="f-444" unitRef="usd">-86700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-89" decimals="-5" id="f-445" unitRef="usd">-86700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-17" decimals="-5" id="f-446" unitRef="usd">-86700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-93" decimals="-5" id="f-447" unitRef="usd">-217800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-89" decimals="-5" id="f-448" unitRef="usd">-217800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-17" decimals="-5" id="f-449" unitRef="usd">-217800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-93" decimals="-5" id="f-450" unitRef="usd">900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-89" decimals="-5" id="f-451" unitRef="usd">900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-17" decimals="-5" id="f-452" unitRef="usd">900000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-72" decimals="-5" id="f-453" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-5" id="f-454" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-73" decimals="-5" id="f-455" unitRef="shares">168700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-5" id="f-456" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-5" id="f-457" unitRef="usd">242200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-5" id="f-458" unitRef="usd">-159300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-5" id="f-459" unitRef="usd">17377900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-77" decimals="-5" id="f-460" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-77" decimals="-5" id="f-461" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-78" decimals="-5" id="f-462" unitRef="usd">14483800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-79" decimals="-5" id="f-463" unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-5" id="f-464" unitRef="usd">14479700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-465">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#x2019;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;2, 2024, we completed the acquisition of HI-Bio. As a result of this transaction we acquired HI-Bio's lead asset, felzartamab, an anti-CD38 antibody currently being evaluated for three leading indications, AMR, PMN and IgAN. For additional information on our acquisition of HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets, as well as TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2023 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on advancing our pipeline in neurology, specialized immunology and rare diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. In November 2023 we terminated the Neurimmune Agreement, which resulted in the deconsolidation of our variable interest entity, Neurimmune. For additional information on the deconsolidation of Neurimmune, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our audited consolidated financial statements included in our 2023 Form&#160;10-K.&lt;/span&gt;&lt;span style="color:#3051f2;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Climate-Related Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024 the SEC issued a final rule under SEC Release No. 33-11275, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Enhancement and Standardization of Climate-Related Disclosures for Investors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new rule will require large accelerated filers to disclose material climate-related risks that are reasonably likely to have a material impact on their business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and/or material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the new rules will require disclosure within the notes to the financial statements of the effects of severe weather events and other natural conditions and information on any climate-related targets or goals, subject to certain materiality thresholds. The final rule, if adopted, includes a phased-in compliance period which will begin phasing in with our annual report for the year ending December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that this new rule will have on our company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023 the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. All disclosure requirements under this standard are also required for public entities with a single reportable segment. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. While this accounting standard will increase disclosures, we do not expect the adoption of this standard to have a material impact on our consolidated financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock contextRef="c-1" id="f-466">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#x2019;s disease and launched the first approved treatment to target a genetic cause of ALS. Through our 2023 acquisition of Reata we market the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;2, 2024, we completed the acquisition of HI-Bio. As a result of this transaction we acquired HI-Bio's lead asset, felzartamab, an anti-CD38 antibody currently being evaluated for three leading indications, AMR, PMN and IgAN. For additional information on our acquisition of HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We commercialize a portfolio of biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets, as well as TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, in the U.S. and certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).&lt;/span&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-467">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2023 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2023 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on advancing our pipeline in neurology, specialized immunology and rare diseases.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-468"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-469">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. In November 2023 we terminated the Neurimmune Agreement, which resulted in the deconsolidation of our variable interest entity, Neurimmune. For additional information on the deconsolidation of Neurimmune, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary contextRef="c-1" decimals="INF" id="f-470" unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-471">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our audited consolidated financial statements included in our 2023 Form&#160;10-K.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-472">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Climate-Related Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024 the SEC issued a final rule under SEC Release No. 33-11275, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Enhancement and Standardization of Climate-Related Disclosures for Investors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new rule will require large accelerated filers to disclose material climate-related risks that are reasonably likely to have a material impact on their business, results of operations or financial condition. The required information about climate-related risks will also include disclosure of material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and/or material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2). Additionally, the new rules will require disclosure within the notes to the financial statements of the effects of severe weather events and other natural conditions and information on any climate-related targets or goals, subject to certain materiality thresholds. The final rule, if adopted, includes a phased-in compliance period which will begin phasing in with our annual report for the year ending December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024 the SEC voluntarily stayed implementation of the new climate-related disclosure requirements pending judicial review. Once the litigation is resolved, and if the rule remains in effect, the SEC will announce a new effective date. We are currently evaluating the potential impact that this new rule will have on our company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023 the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard requires disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. All disclosure requirements under this standard are also required for public entities with a single reportable segment. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. While this accounting standard will increase disclosures, we do not expect the adoption of this standard to have a material impact on our consolidated financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-473">&lt;div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Human Immunology Biosciences&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody, is currently being evaluated for three leading indications, Antibody-Mediated Rejection (AMR), Primary Membranous Nephropathy (PMN) and Immunoglobulin A Nephropathy (IgAN). Felzartamab has received Breakthrough Therapy Designation and ODD from the FDA for development in the treatment of PMN and AMR and has received ODD in the treatment of antibody-mediated rejection in kidney transplant recipients. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of this acquisition, we paid shareholders of HI-Bio approximately $1.15&#160;billion at closing and may pay up to an additional &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$650.0&#160;million in potential future development and regulatory milestone payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The $1.15&#160;billion paid includes approximately $74.5&#160;million related to HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, of which $56.4&#160;million was recognized as share-based compensation payments to settle non-vested equity awards attributable to the post-acquisition service period and therefore not reflected as a component of total purchase price paid. Of the total $56.4&#160;million, we recognized approximately $42.5&#160;million as a charge to research and development expense with the remaining $13.9&#160;million as a charge to selling, general and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon closing we also paid an additional &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$43.7&#160;million related to working capital adjustments as of the transaction close date, which was included as a component of total purchase price paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We funded this acquisition through available cash on hand and accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC Topic 805, Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the lead program felzartamab, the HI-Bio pipeline acquired includes izastobart/HIB210, an anti-C5aR1 antibody currently in a Phase 1 trial, and the potential for continued development in a range of complement-mediated diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Price Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration transferred for the acquisition of HI-Bio is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of July&#160;2, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to HI-Bio shareholders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,622.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; Represents total consideration paid to shareholders of HI-Bio of $1.15&#160;billion, plus an additional $43.7&#160;million related to working capital adjustments as of the transaction close date, less $56.4&#160;million of cash paid for HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, which were recognized as compensation attributable to the post-acquisition service period and therefore not reflected as a component of total consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Contingent Consideration:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; We may make certain contingent payments to the former shareholders of HI-Bio upon the achievement of certain development and regulatory milestones. As of the acquisition date, the maximum aggregate amount payable for these potential milestones was $650.0&#160;million. The acquisition-date fair value of these milestones was approximately $485.1&#160;million and was estimated utilizing a probability-adjusted discounted cash flow calculation using an appropriate discount rate dependent on the nature and timing of the milestone payments, which ranged from &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;6.2% to 7.0%, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;probabilities of technological and regulatory success ranging from 67.0% to near certain probability.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; Of the total contingent consideration, approximately $279.3&#160;million related to milestones classified as short-term and reflected as a component of accrued expense and other with the remaining $205.8&#160;million reflected as a component of other long-term liabilities within our condensed consolidated balance sheets. The short-term liability relates to the fourth patient dosed in a phase 3 clinical trial of felzartamab in a first and s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;econd indication, which would trigger milestone payments of $150.0&#160;million each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent changes in the fair value of the contingent consideration obligation will be recognized as (gain) loss on fair value remeasurement of contingent consideration within our condensed consolidated statements of income. This fair value measurement was based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements. For additional information related to the fair value of this obligation, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8, Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Contractual Commitments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We acquired HI-Bio's pre-existing in-license commitments under third-party agreements, which include tiered royalties on potential future sales of felzartamab and izastobart/HIB210, ranging from high-single digit to mid-teen percentages, as well as potential future development, regulatory and commercial milestone payments related to felzartamab and izastobart/HIB210 of up to $130.0&#160;million, $230.0&#160;million and $640.0&#160;million, respectively. Because the achievement of these milestones was not considered probable as of the transaction close date, such contingencies have not been recorded in our financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preliminary Purchase Price Allocation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary purchase price allocation of the separately identifiable assets acquired and liabilities assumed as of July&#160;2, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;July&#160;2, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (IgAN)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;920.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (AMR)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (PMN)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other clinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expense and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(304.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,622.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intang&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ible assets:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Intangible assets comprised of $1.6&#160;billion of IPR&amp;amp;D related to HI-Bio's lead asset felzartamab. This includes $920.0&#160;million of IPR&amp;amp;D related to felzartamab indication for IgAN, $450.0&#160;million of IPR&amp;amp;D related to felzartamab indication for AMR and $265.0&#160;million of IPR&amp;amp;D related to felzartamab indication for PMN. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing cash flow analyses and a discount rate of 14.5%. These fair value measurements were based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acq&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uired that could not be individually identified and separately recognized. We recognized goodwill of approximately $256.5&#160;million, which is not deductible for tax purposes. The goodwill recognized from our acquisition of HI-Bio is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-related expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acquisition-related expense, primarily comprised&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of advisory and legal fees, and other transaction costs, totaled approximately $2.8&#160;million and were recorded within selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assumptions in the Allocations of Purchase Price&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he results of operations of HI-Bio, along with the estimated fair values of the assets acquired and liabilities assumed in the HI-Bio acquisition, have been included in our condensed consolidated financial statements since the closing of the HI-Bio acquisition on July&#160;2, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management's analysis related to certain matters, such as finalizing our assessment of intangible assets, goodwill and income taxes, among other items. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. The final determination may result in asset and liability fair values that are different than the preliminary estimates. There were no purchase price allocation adjustments during the third quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the acquisition date, our results of operations include the results of operations of HI-Bio. HI-Bio operations had an immaterial impact on our results of operations for the three and nine months ended September 30, 2024. Due to the immateriality of HI-Bio's historic revenue and expenses, additional pro forma information combining the results of operations of Biogen and HI-Bio have not been included.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Reata Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a  biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction we acquired SKYCLARYS (omaveloxolone), the first and only drug approved in the U.S. and the E.U. for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs. The acquisition of Reata is expected to complement our global portfolio of neuromuscular and rare disease therapies. The addition of SKYCLARYS is anticipated to provide potential operating synergies with SPINRAZA and QALSODY.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of this acquisition, we paid Reata shareholders $172.50 in cash for each issued and outstanding Reata share, which totaled approximately $6.6&#160;billion. In addition, we agreed to pay approximately $983.9&#160;million in cash for Reata's outstanding equity awards, inclusive of employer taxes, of which approximately $590.5&#160;million was attributable to pre-acquisition services and is therefore reflected as a component of total purchase price paid. Of the $983.9&#160;million paid to Reata's equity award holders, we recognized approximately $393.4&#160;million as compensation attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We funded this acquisition through available cash, cash equivalents and marketable securities, supplemented by the issuance of a $1.0 billion term loan under our 2023 Term Loan. For additional information on our 2023 Term Loan, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC Topic 805, Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Price Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration transferred for the acquisition of Reata is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;26, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to Reata shareholders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,602.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of Reata equity compensation pre-acquisition services and related taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents cash consideration transferred of $172.50 per outstanding Reata common stock based on 38.3&#160;million Reata shares outstanding at closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Price Allocation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We finalized purchase accounting for this acquisition in the third quarter of 2024. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, and reflects measurement period adjustments made to the amounts initially recorded as of the acquisition date on September&#160;26, 2023. The measurement period adjustments summarized below resulted from updates to our valuation assumptions related to the estimated amounts and timing of future cash flows associated with certain intangible assets, updates of our assumptions related to the quantities, selling location and remaining manufacturing and selling costs of acquired inventory, and other assets and liabilities. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Recognized as of Acquisition Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as adjusted)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,259.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology for SKYCLARYS (U.S.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development (omaveloxolone)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other clinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent payable to Blackstone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(300.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(909.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,724.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;469.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes measurement period adjustments recorded in the first quarter of 2024 that increased accrued expense and other by $4.9&#160;million, deferred tax liability by $4.1&#160;million and goodwill by $9.0&#160;million, as well as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;measurement period adjustments recorded in the third quarter of 2024 that increased other current assets by $1.0&#160;million and accrued expense and other by $3.9&#160;million, and decreased deferred tax liability by $7.2&#160;million and goodwill by $4.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Total inventory acquired was&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately $1.3&#160;billion, which reflects a step-up in the fair value of finished goods and work-in-process inventory for SKYCLARYS. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold, which is expected to be sold over a period of approximately 4 years from the acquisition date. For the three and nine months ended September 30, 2024, amortization from the fair value step-up adjustment was approximately $50.9&#160;million and $185.1&#160;million, respectively. The three and nine months ended September 30, 2024, include approximately $2.5&#160;million and $48.5&#160;million, respectively, of inventory used for clinical purposes, which is reflected within research and development expense within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intang&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ible assets:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Intangible assets are comprised of $4.2&#160;billion related to SKYCLARYS commercialization rights in the U.S., $2.3&#160;billion of IPR&amp;amp;D related to the omaveloxolone program outside the U.S., which had not yet received regulatory approval in the E.U. as of the acquisition date, $100.0&#160;million related to a rare pediatric disease priority voucher which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party and $40.0&#160;million related to other clinical programs. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing a discount rate of 14.3% and the estimated fair value of the priority review voucher was based on recent external purchase and sale transactions of similar vouchers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our valuation of the SKYCLARYS commercialization rights reflects the assumption that, using an economic consumption model, the related $4.2&#160;billion intangible asset will be amortized over its expected economic life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon SKYCLARYS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;receiving E.U. regulatory approval in February 2024, we began selling the product in certain countries in Europe, and began amortizing the $2.3&#160;billion I&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PR&amp;amp;D asset related to the program outside the U.S. over its expected economic life using an economic consumption model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $121.2&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. We recognized goodwill of approximately $469.2&#160;million, which is not deductible for tax purposes. The goodwill recognized from our acquisition of Reata is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-related expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acquisition-related expense, primarily comprised of regulatory, advisory and legal fees, and other transaction costs, totaled approximately $26.3&#160;million and were recorded within selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-94" decimals="-5" id="f-474" unitRef="usd">1150000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-95" decimals="-5" id="f-475" unitRef="usd">650000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-94" decimals="-5" id="f-476" unitRef="usd">1150000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:PaymentsToAcquireBusinessGrossNonVestedEquityAwards contextRef="c-96" decimals="-5" id="f-477" unitRef="usd">74500000</biib:PaymentsToAcquireBusinessGrossNonVestedEquityAwards>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-96" decimals="-5" id="f-478" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-96" decimals="-5" id="f-479" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-97" decimals="-5" id="f-480" unitRef="usd">42500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-98" decimals="-5" id="f-481" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment contextRef="c-96" decimals="-5" id="f-482" unitRef="usd">43700000</biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-483">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration transferred for the acquisition of HI-Bio is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of July&#160;2, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to HI-Bio shareholders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,622.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; Represents total consideration paid to shareholders of HI-Bio of $1.15&#160;billion, plus an additional $43.7&#160;million related to working capital adjustments as of the transaction close date, less $56.4&#160;million of cash paid for HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, which were recognized as compensation attributable to the post-acquisition service period and therefore not reflected as a component of total consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration transferred for the acquisition of Reata is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;26, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to Reata shareholders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,602.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of Reata equity compensation pre-acquisition services and related taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents cash consideration transferred of $172.50 per outstanding Reata common stock based on 38.3&#160;million Reata shares outstanding at closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.&lt;/span&gt;&lt;/div&gt;September&#160;26, 2023. The measurement period adjustments summarized below resulted from updates to our valuation assumptions related to the estimated amounts and timing of future cash flows associated with certain intangible assets, updates of our assumptions related to the quantities, selling location and remaining manufacturing and selling costs of acquired inventory, and other assets and liabilities. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Recognized as of Acquisition Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as adjusted)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,259.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology for SKYCLARYS (U.S.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development (omaveloxolone)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other clinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent payable to Blackstone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(300.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(909.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,724.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;469.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes measurement period adjustments recorded in the first quarter of 2024 that increased accrued expense and other by $4.9&#160;million, deferred tax liability by $4.1&#160;million and goodwill by $9.0&#160;million, as well as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;measurement period adjustments recorded in the third quarter of 2024 that increased other current assets by $1.0&#160;million and accrued expense and other by $3.9&#160;million, and decreased deferred tax liability by $7.2&#160;million and goodwill by $4.3&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-96" decimals="-5" id="f-484" unitRef="usd">1137300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-96" decimals="-5" id="f-485" unitRef="usd">485100000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-96" decimals="-5" id="f-486" unitRef="usd">1622400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-94" decimals="-5" id="f-487" unitRef="usd">1150000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment contextRef="c-96" decimals="-5" id="f-488" unitRef="usd">43700000</biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-96" decimals="-5" id="f-489" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-95" decimals="-5" id="f-490" unitRef="usd">650000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-95" decimals="-5" id="f-491" unitRef="usd">485100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-99" decimals="3" id="f-492" unitRef="number">0.062</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-100" decimals="3" id="f-493" unitRef="number">0.070</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-101" decimals="3" id="f-494" unitRef="number">0.670</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-95" decimals="-5" id="f-495" unitRef="usd">279300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-95" decimals="-5" id="f-496" unitRef="usd">205800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-102" decimals="-5" id="f-497" unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-103" decimals="-5" id="f-498" unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-104" decimals="-5" id="f-499" unitRef="usd">130000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-105" decimals="-5" id="f-500" unitRef="usd">230000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-106" decimals="-5" id="f-501" unitRef="usd">640000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-502">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary purchase price allocation of the separately identifiable assets acquired and liabilities assumed as of July&#160;2, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;July&#160;2, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (IgAN)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;920.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (AMR)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (PMN)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other clinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expense and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(304.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,622.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-95" decimals="-5" id="f-503" unitRef="usd">62500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-107" decimals="-5" id="f-504" unitRef="usd">920000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-108" decimals="-5" id="f-505" unitRef="usd">450000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-109" decimals="-5" id="f-506" unitRef="usd">265000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-110" decimals="-5" id="f-507" unitRef="usd">7900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-95" decimals="-5" id="f-508" unitRef="usd">1000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-95" decimals="-5" id="f-509" unitRef="usd">1200000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c-95" decimals="-5" id="f-510" unitRef="usd">1100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities contextRef="c-95" decimals="-5" id="f-511" unitRef="usd">35000000.0</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-95" decimals="-5" id="f-512" unitRef="usd">304400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-95" decimals="-5" id="f-513" unitRef="usd">1200000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-95" decimals="-5" id="f-514" unitRef="usd">1365900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill contextRef="c-95" decimals="-5" id="f-515" unitRef="usd">256500000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-95" decimals="-5" id="f-516" unitRef="usd">1622400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-95" decimals="-8" id="f-517" unitRef="usd">1600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-111" decimals="-5" id="f-518" unitRef="usd">920000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-112" decimals="-5" id="f-519" unitRef="usd">450000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-113" decimals="-5" id="f-520" unitRef="usd">265000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:IntangibleAssetMeasurementInput contextRef="c-114" decimals="3" id="f-521" unitRef="number">0.145</biib:IntangibleAssetMeasurementInput>
    <us-gaap:Goodwill contextRef="c-95" decimals="-5" id="f-522" unitRef="usd">256500000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-115" decimals="-5" id="f-523" unitRef="usd">2800000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-116" decimals="-5" id="f-524" unitRef="usd">2800000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-117"
      decimals="1"
      id="f-525"
      unitRef="usdPerShare">172.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-118" decimals="-8" id="f-526" unitRef="usd">6600000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-119" decimals="-5" id="f-527" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices contextRef="c-118" decimals="-5" id="f-528" unitRef="usd">590500000</biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-119" decimals="-5" id="f-529" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <us-gaap:OperatingExpenses contextRef="c-118" decimals="-5" id="f-530" unitRef="usd">393400000</us-gaap:OperatingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-118" decimals="-5" id="f-531" unitRef="usd">196400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-118" decimals="-5" id="f-532" unitRef="usd">197000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-120" decimals="-8" id="f-533" unitRef="usd">1000000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-118" decimals="-5" id="f-534" unitRef="usd">6602900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices contextRef="c-118" decimals="-5" id="f-535" unitRef="usd">590500000</biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-118" decimals="-5" id="f-536" unitRef="usd">7193400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-117"
      decimals="1"
      id="f-537"
      unitRef="usdPerShare">172.50</us-gaap:BusinessAcquisitionSharePrice>
    <biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired
      contextRef="c-117"
      decimals="-5"
      id="f-538"
      unitRef="shares">38300000</biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-121" decimals="-5" id="f-539" unitRef="usd">267300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-121" decimals="-5" id="f-540" unitRef="usd">15900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-121" decimals="-5" id="f-541" unitRef="usd">1259000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c-121" decimals="-5" id="f-542" unitRef="usd">54600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-122" decimals="-5" id="f-543" unitRef="usd">4200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-123" decimals="-5" id="f-544" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-124" decimals="-5" id="f-545" unitRef="usd">100000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-125" decimals="-5" id="f-546" unitRef="usd">40000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-121" decimals="-5" id="f-547" unitRef="usd">121200000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther contextRef="c-121" decimals="-5" id="f-548" unitRef="usd">110300000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt contextRef="c-121" decimals="-5" id="f-549" unitRef="usd">159900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability contextRef="c-121" decimals="-5" id="f-550" unitRef="usd">300000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-121" decimals="-5" id="f-551" unitRef="usd">909300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-121" decimals="-5" id="f-552" unitRef="usd">151800000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet contextRef="c-121" decimals="-5" id="f-553" unitRef="usd">-2500000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-121" decimals="-5" id="f-554" unitRef="usd">6724200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill contextRef="c-121" decimals="-5" id="f-555" unitRef="usd">469200000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-121" decimals="-5" id="f-556" unitRef="usd">7193400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther contextRef="c-126" decimals="-5" id="f-557" unitRef="usd">4900000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability contextRef="c-126" decimals="-5" id="f-558" unitRef="usd">-4100000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill contextRef="c-126" decimals="-5" id="f-559" unitRef="usd">-9000000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets contextRef="c-127" decimals="-5" id="f-560" unitRef="usd">1000000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther contextRef="c-127" decimals="-5" id="f-561" unitRef="usd">3900000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpenseAndOther>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability contextRef="c-127" decimals="-5" id="f-562" unitRef="usd">-7200000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill contextRef="c-127" decimals="-5" id="f-563" unitRef="usd">-4300000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-117" decimals="-8" id="f-564" unitRef="usd">1300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod contextRef="c-117" id="f-565">P4Y</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod>
    <us-gaap:ProfitLoss contextRef="c-128" decimals="-5" id="f-566" unitRef="usd">50900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-129" decimals="-5" id="f-567" unitRef="usd">185100000</us-gaap:ProfitLoss>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-130" decimals="-5" id="f-568" unitRef="usd">2500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-131" decimals="-5" id="f-569" unitRef="usd">48500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-132" decimals="-8" id="f-570" unitRef="usd">4200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-133" decimals="-8" id="f-571" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-134" decimals="-5" id="f-572" unitRef="usd">100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-135" decimals="-5" id="f-573" unitRef="usd">40000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate contextRef="c-117" decimals="3" id="f-574" unitRef="number">0.143</biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-132" decimals="-8" id="f-575" unitRef="usd">4200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-133" decimals="-8" id="f-576" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:OperatingLeaseArea contextRef="c-117" decimals="0" id="f-577" unitRef="sqft">327400</biib:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-117" id="f-578">P16Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-117" decimals="-5" id="f-579" unitRef="usd">151800000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-117" id="f-580">P15Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-117" decimals="-5" id="f-581" unitRef="usd">121200000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <us-gaap:Goodwill contextRef="c-117" decimals="-5" id="f-582" unitRef="usd">469200000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="c-136" decimals="-5" id="f-583" unitRef="usd">26300000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-584">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Sale of Joint Venture Equity Interest in Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $2.3&#160;billion. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing, with approximately $1.3&#160;billion in cash to be deferred over two payments. The first deferred payment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$812.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was received in April 2023 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the second deferred payment of $437.5&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was received in April 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended September 30, 2024, we recognized&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; a gain&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$7.5&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;to reflect the change in fair value associated with the passage of time related to the second deferred payment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;due to us, which was received in April 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended September 30, 2023, we recognized a gain of approximately $13.7&#160;million to reflect the change in fair value associated with changes in interest rates and the passage of time related to the first deferred payment due to us, which was received in April 2023. Additionally, for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;three and nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended September 30, 2023, we recognized gains of approximately $7.1&#160;million and $16.9&#160;million, respectively, to reflect the changes in fair value associated with changes in interest rates and the passage of time related to the second deferred payment due to us, which was received in April 2024. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Sale of Priority Review Voucher&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $103.0&#160;million upon the closing of the PRV purchase, of which approximately $14.4&#160;million was paid to Ionis. Our net portion of approximately $88.6&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the nine months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-137" decimals="3" id="f-585" unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-138" decimals="-5" id="f-586" unitRef="usd">2300000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:ProceedsFromDivestitureOfInterestInJointVenture contextRef="c-139" decimals="-8" id="f-587" unitRef="usd">1000000000</us-gaap:ProceedsFromDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-140" decimals="-8" id="f-588" unitRef="usd">1300000000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-141" decimals="-5" id="f-589" unitRef="usd">812500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-142" decimals="-5" id="f-590" unitRef="usd">437500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-143" decimals="-5" id="f-591" unitRef="usd">7500000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-144" decimals="-5" id="f-592" unitRef="usd">13700000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-145" decimals="-5" id="f-593" unitRef="usd">7100000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-146" decimals="-5" id="f-594" unitRef="usd">16900000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="c-147" decimals="-5" id="f-595" unitRef="usd">103000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:AccountsPayableCurrent contextRef="c-148" decimals="-5" id="f-596" unitRef="usd">14400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-597" unitRef="usd">88600000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-598">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2023 Fit for Growth Restructuring Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately 1,000 employees and we expect to incur restructuring charges ranging from approximately $260.0&#160;million to $280.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our 2023 cost saving initiatives are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Costs:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Reata Integration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimate we will incur total integration charges ranging from approximately $35.0&#160;million to $40.0&#160;million, related to severance and employment costs, which are expected to be paid by the end of 2024. These amounts were substantially incurred during 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our Reata integration are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We do not intend to occupy this building and are evaluating opportunities to sublease the property. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;HI-Bio Integration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, following the close of our HI-Bio acquisition in July 2024, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we incurred approximately $1.5&#160;million of severance and employment costs, which are reflected in restructuring charges within our condensed consolidated statements of income for the three and nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Restructuring Reserve&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and spending related to workforce reductions are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Workforce Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction contextRef="c-149" decimals="-8" id="f-599" unitRef="usd">1000000000</biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="c-150"
      decimals="INF"
      id="f-600"
      unitRef="employee">1000</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-151" decimals="-5" id="f-601" unitRef="usd">260000000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-152" decimals="-5" id="f-602" unitRef="usd">280000000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-603">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our 2023 cost saving initiatives are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our Reata integration are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1 contextRef="c-153" decimals="-5" id="f-604" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-153" decimals="-5" id="f-605" unitRef="usd">9100000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-153" decimals="-5" id="f-606" unitRef="usd">9100000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-154" decimals="-5" id="f-607" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-154" decimals="-5" id="f-608" unitRef="usd">5900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-154" decimals="-5" id="f-609" unitRef="usd">5900000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-155" decimals="-5" id="f-610" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-155" decimals="-5" id="f-611" unitRef="usd">3500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-155" decimals="-5" id="f-612" unitRef="usd">3500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-156" decimals="-5" id="f-613" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-156" decimals="-5" id="f-614" unitRef="usd">200000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-156" decimals="-5" id="f-615" unitRef="usd">200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-157" decimals="-5" id="f-616" unitRef="usd">4600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-157" decimals="-5" id="f-617" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-157" decimals="-5" id="f-618" unitRef="usd">4600000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-158" decimals="-5" id="f-619" unitRef="usd">37700000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-158" decimals="-5" id="f-620" unitRef="usd">17300000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-158" decimals="-5" id="f-621" unitRef="usd">55000000.0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-159" decimals="-5" id="f-622" unitRef="usd">4600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-159" decimals="-5" id="f-623" unitRef="usd">12600000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-159" decimals="-5" id="f-624" unitRef="usd">17200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-160" decimals="-5" id="f-625" unitRef="usd">37700000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-160" decimals="-5" id="f-626" unitRef="usd">23400000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-160" decimals="-5" id="f-627" unitRef="usd">61100000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-161" decimals="-5" id="f-628" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-161" decimals="-5" id="f-629" unitRef="usd">12500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-161" decimals="-5" id="f-630" unitRef="usd">12500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-162" decimals="-5" id="f-631" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-162" decimals="-5" id="f-632" unitRef="usd">17400000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-162" decimals="-5" id="f-633" unitRef="usd">17400000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-163" decimals="-5" id="f-634" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-163" decimals="-5" id="f-635" unitRef="usd">10600000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-163" decimals="-5" id="f-636" unitRef="usd">10600000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-164" decimals="-5" id="f-637" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-164" decimals="-5" id="f-638" unitRef="usd">700000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-164" decimals="-5" id="f-639" unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-165" decimals="-5" id="f-640" unitRef="usd">20200000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-165" decimals="-5" id="f-641" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-165" decimals="-5" id="f-642" unitRef="usd">20200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-166" decimals="-5" id="f-643" unitRef="usd">62600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-166" decimals="-5" id="f-644" unitRef="usd">33800000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-166" decimals="-5" id="f-645" unitRef="usd">96400000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-150" decimals="-5" id="f-646" unitRef="usd">20200000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-150" decimals="-5" id="f-647" unitRef="usd">23100000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-150" decimals="-5" id="f-648" unitRef="usd">43300000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-167" decimals="-5" id="f-649" unitRef="usd">62600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-167" decimals="-5" id="f-650" unitRef="usd">51900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-167" decimals="-5" id="f-651" unitRef="usd">114500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-168" decimals="-5" id="f-652" unitRef="usd">35000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-169" decimals="-5" id="f-653" unitRef="usd">40000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:SeveranceCosts1 contextRef="c-170" decimals="-5" id="f-654" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-170" decimals="-5" id="f-655" unitRef="usd">1600000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-170" decimals="-5" id="f-656" unitRef="usd">1600000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-171" decimals="-5" id="f-657" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-171" decimals="-5" id="f-658" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-171" decimals="-5" id="f-659" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-172" decimals="-5" id="f-660" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-172" decimals="-5" id="f-661" unitRef="usd">2900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-172" decimals="-5" id="f-662" unitRef="usd">2900000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-173" decimals="-5" id="f-663" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-173" decimals="-5" id="f-664" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-173" decimals="-5" id="f-665" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-174" decimals="-5" id="f-666" unitRef="usd">700000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-174" decimals="-5" id="f-667" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-174" decimals="-5" id="f-668" unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-175" decimals="-5" id="f-669" unitRef="usd">21000000.0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-175" decimals="-5" id="f-670" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-175" decimals="-5" id="f-671" unitRef="usd">21000000.0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-176" decimals="-5" id="f-672" unitRef="usd">700000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-176" decimals="-5" id="f-673" unitRef="usd">4500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-176" decimals="-5" id="f-674" unitRef="usd">5200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-177" decimals="-5" id="f-675" unitRef="usd">21000000.0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-177" decimals="-5" id="f-676" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-177" decimals="-5" id="f-677" unitRef="usd">21000000.0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-178" decimals="-5" id="f-678" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-178" decimals="-5" id="f-679" unitRef="usd">4900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-178" decimals="-5" id="f-680" unitRef="usd">4900000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-179" decimals="-5" id="f-681" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-179" decimals="-5" id="f-682" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-179" decimals="-5" id="f-683" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-180" decimals="-5" id="f-684" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-180" decimals="-5" id="f-685" unitRef="usd">8900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-180" decimals="-5" id="f-686" unitRef="usd">8900000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-181" decimals="-5" id="f-687" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-181" decimals="-5" id="f-688" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-181" decimals="-5" id="f-689" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-182" decimals="-5" id="f-690" unitRef="usd">3200000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-182" decimals="-5" id="f-691" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-182" decimals="-5" id="f-692" unitRef="usd">3200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-183" decimals="-5" id="f-693" unitRef="usd">21000000.0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-183" decimals="-5" id="f-694" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-183" decimals="-5" id="f-695" unitRef="usd">21000000.0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-184" decimals="-5" id="f-696" unitRef="usd">3200000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-184" decimals="-5" id="f-697" unitRef="usd">13800000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-184" decimals="-5" id="f-698" unitRef="usd">17000000.0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-185" decimals="-5" id="f-699" unitRef="usd">21000000.0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-185" decimals="-5" id="f-700" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-185" decimals="-5" id="f-701" unitRef="usd">21000000.0</us-gaap:RestructuringCharges>
    <biib:OperatingLeaseArea contextRef="c-117" decimals="0" id="f-702" unitRef="sqft">327400</biib:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-117" id="f-703">P16Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts contextRef="c-115" decimals="-5" id="f-704" unitRef="usd">1500000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts contextRef="c-116" decimals="-5" id="f-705" unitRef="usd">1500000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-706">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and spending related to workforce reductions are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Workforce Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-186" decimals="-5" id="f-707" unitRef="usd">75400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-187" decimals="-5" id="f-708" unitRef="usd">35900000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-188" decimals="-5" id="f-709" unitRef="usd">11500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-189" decimals="-5" id="f-710" unitRef="usd">7100000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-188" decimals="-5" id="f-711" unitRef="usd">42200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-189" decimals="-5" id="f-712" unitRef="usd">15600000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-188" decimals="-5" id="f-713" unitRef="usd">-800000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-189" decimals="-5" id="f-714" unitRef="usd">-600000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-190" decimals="-5" id="f-715" unitRef="usd">45500000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-191" decimals="-5" id="f-716" unitRef="usd">28000000.0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-192" decimals="-5" id="f-717" unitRef="usd">6600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-193" decimals="-5" id="f-718" unitRef="usd">17800000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-192" decimals="-5" id="f-719" unitRef="usd">11900000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-193" decimals="-5" id="f-720" unitRef="usd">13400000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-192" decimals="-5" id="f-721" unitRef="usd">0</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-193" decimals="-5" id="f-722" unitRef="usd">100000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-194" decimals="-5" id="f-723" unitRef="usd">40200000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-195" decimals="-5" id="f-724" unitRef="usd">32300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-196" decimals="-5" id="f-725" unitRef="usd">6800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-197" decimals="-5" id="f-726" unitRef="usd">58700000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-196" decimals="-5" id="f-727" unitRef="usd">4700000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-197" decimals="-5" id="f-728" unitRef="usd">31800000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-196" decimals="-5" id="f-729" unitRef="usd">2100000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-197" decimals="-5" id="f-730" unitRef="usd">-100000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-198" decimals="-5" id="f-731" unitRef="usd">40200000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-199" decimals="-5" id="f-732" unitRef="usd">59300000</us-gaap:RestructuringReserve>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-733">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;546.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;507.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;527.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,159.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;381.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;956.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,769.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;790.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,014.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,805.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in certain international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;611.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;739.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;568.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;768.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;451.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;419.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;677.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,190.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;571.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;616.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,188.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;604.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;492.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;825.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;690.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,299.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;750.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;662.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,631.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,648.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,814.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,678.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,493.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;458.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;453.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,328.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;703.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;749.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,452.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;455.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,331.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;572.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;591.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;581.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,405.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,975.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,380.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,293.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,414.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in certain international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 25.9% and 14.8% of gross product revenue for the three months ended September 30, 2024, and 25.6% and 12.9% of gross product revenue for the nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 26.9% and 10.5% of gross product revenue for the three months ended September 30, 2023, and 27.1% and 9.1% of gross product revenue for the nine months ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;857.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;605.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,625.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(439.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,391.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,831.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(514.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(692.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;923.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;926.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Revenue from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty revenue on sales of OCREVUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;985.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;928.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;315.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;446.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,253.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Contract Manufacturing, Royalty and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing, royalty and other revenue is summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;742.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract manufacturing, royalty and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;555.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;781.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Manufacturing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers. During the first quarter of 2023 we began recognizing contract manufacturing revenue for LEQEMBI, upon accelerated approval of LEQEMBI in the U.S. Prior to accelerated approval, our share of contract manufacturing amounts related to LEQEMBI were recognized in research and development expense within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as we are not the principal, as well as royalties we receive from net sales on products related to patents that we have out-licensed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-734">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;546.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;507.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;527.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,159.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;381.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;956.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,769.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;790.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,014.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,805.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in certain international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;611.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;739.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;568.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;768.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;451.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;419.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;677.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,190.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;571.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;616.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,188.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;604.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;492.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;825.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;690.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,299.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;750.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;662.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,631.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,648.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,814.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,678.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,493.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;458.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;453.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,328.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;703.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;749.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,452.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;455.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,331.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;572.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;591.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;581.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,405.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,975.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,380.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,293.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,414.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in certain international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues contextRef="c-200" decimals="-5" id="f-735" unitRef="usd">40100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-201" decimals="-5" id="f-736" unitRef="usd">192700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-202" decimals="-5" id="f-737" unitRef="usd">232800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-203" decimals="-5" id="f-738" unitRef="usd">58100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-204" decimals="-5" id="f-739" unitRef="usd">181400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-205" decimals="-5" id="f-740" unitRef="usd">239500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-206" decimals="-5" id="f-741" unitRef="usd">134900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-207" decimals="-5" id="f-742" unitRef="usd">23200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-208" decimals="-5" id="f-743" unitRef="usd">158100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-209" decimals="-5" id="f-744" unitRef="usd">148800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-210" decimals="-5" id="f-745" unitRef="usd">16700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-211" decimals="-5" id="f-746" unitRef="usd">165500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-212" decimals="-5" id="f-747" unitRef="usd">175000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-213" decimals="-5" id="f-748" unitRef="usd">215900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-214" decimals="-5" id="f-749" unitRef="usd">390900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-215" decimals="-5" id="f-750" unitRef="usd">206900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-216" decimals="-5" id="f-751" unitRef="usd">198100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-217" decimals="-5" id="f-752" unitRef="usd">405000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-218" decimals="-5" id="f-753" unitRef="usd">115600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-219" decimals="-5" id="f-754" unitRef="usd">60600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-220" decimals="-5" id="f-755" unitRef="usd">176200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-221" decimals="-5" id="f-756" unitRef="usd">148700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-222" decimals="-5" id="f-757" unitRef="usd">63500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-223" decimals="-5" id="f-758" unitRef="usd">212200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-224" decimals="-5" id="f-759" unitRef="usd">27900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-225" decimals="-5" id="f-760" unitRef="usd">33400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-226" decimals="-5" id="f-761" unitRef="usd">61300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-227" decimals="-5" id="f-762" unitRef="usd">31400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-228" decimals="-5" id="f-763" unitRef="usd">34100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-229" decimals="-5" id="f-764" unitRef="usd">65500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-230" decimals="-5" id="f-765" unitRef="usd">143500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-231" decimals="-5" id="f-766" unitRef="usd">94000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-232" decimals="-5" id="f-767" unitRef="usd">237500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-233" decimals="-5" id="f-768" unitRef="usd">180100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-234" decimals="-5" id="f-769" unitRef="usd">97600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-235" decimals="-5" id="f-770" unitRef="usd">277700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-236" decimals="-5" id="f-771" unitRef="usd">227500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-237" decimals="-5" id="f-772" unitRef="usd">178600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-238" decimals="-5" id="f-773" unitRef="usd">406100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-239" decimals="-5" id="f-774" unitRef="usd">244800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-240" decimals="-5" id="f-775" unitRef="usd">211500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-241" decimals="-5" id="f-776" unitRef="usd">456300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-242" decimals="-5" id="f-777" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-243" decimals="-5" id="f-778" unitRef="usd">19400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-244" decimals="-5" id="f-779" unitRef="usd">19400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-245" decimals="-5" id="f-780" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-246" decimals="-5" id="f-781" unitRef="usd">20000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-247" decimals="-5" id="f-782" unitRef="usd">20000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-248" decimals="-5" id="f-783" unitRef="usd">546000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-249" decimals="-5" id="f-784" unitRef="usd">507900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-250" decimals="-5" id="f-785" unitRef="usd">1053900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-251" decimals="-5" id="f-786" unitRef="usd">631800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-252" decimals="-5" id="f-787" unitRef="usd">527200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-253" decimals="-5" id="f-788" unitRef="usd">1159000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-254" decimals="-5" id="f-789" unitRef="usd">153100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-255" decimals="-5" id="f-790" unitRef="usd">228300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-256" decimals="-5" id="f-791" unitRef="usd">381400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-257" decimals="-5" id="f-792" unitRef="usd">150500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-258" decimals="-5" id="f-793" unitRef="usd">297700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-259" decimals="-5" id="f-794" unitRef="usd">448200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-260" decimals="-5" id="f-795" unitRef="usd">81800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-261" decimals="-5" id="f-796" unitRef="usd">20500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-262" decimals="-5" id="f-797" unitRef="usd">102300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-263" decimals="-5" id="f-798" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-264" decimals="-5" id="f-799" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-265" decimals="-5" id="f-800" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-266" decimals="-5" id="f-801" unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-267" decimals="-5" id="f-802" unitRef="usd">5600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-268" decimals="-5" id="f-803" unitRef="usd">11100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-269" decimals="-5" id="f-804" unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-270" decimals="-5" id="f-805" unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-271" decimals="-5" id="f-806" unitRef="usd">1700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-272" decimals="-5" id="f-807" unitRef="usd">240400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-273" decimals="-5" id="f-808" unitRef="usd">254400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-274" decimals="-5" id="f-809" unitRef="usd">494800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-275" decimals="-5" id="f-810" unitRef="usd">152100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-276" decimals="-5" id="f-811" unitRef="usd">297800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-277" decimals="-5" id="f-812" unitRef="usd">449900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-278" decimals="-5" id="f-813" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-279" decimals="-5" id="f-814" unitRef="usd">118100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-280" decimals="-5" id="f-815" unitRef="usd">118100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-281" decimals="-5" id="f-816" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-282" decimals="-5" id="f-817" unitRef="usd">112800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-283" decimals="-5" id="f-818" unitRef="usd">112800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-284" decimals="-5" id="f-819" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-285" decimals="-5" id="f-820" unitRef="usd">54100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-286" decimals="-5" id="f-821" unitRef="usd">54100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-287" decimals="-5" id="f-822" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-288" decimals="-5" id="f-823" unitRef="usd">54400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-289" decimals="-5" id="f-824" unitRef="usd">54400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-290" decimals="-5" id="f-825" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-291" decimals="-5" id="f-826" unitRef="usd">16200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-292" decimals="-5" id="f-827" unitRef="usd">16200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-293" decimals="-5" id="f-828" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-294" decimals="-5" id="f-829" unitRef="usd">20200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-295" decimals="-5" id="f-830" unitRef="usd">20200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-296" decimals="-5" id="f-831" unitRef="usd">4100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-297" decimals="-5" id="f-832" unitRef="usd">3900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-298" decimals="-5" id="f-833" unitRef="usd">8000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-299" decimals="-5" id="f-834" unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-300" decimals="-5" id="f-835" unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-301" decimals="-5" id="f-836" unitRef="usd">6900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-302" decimals="-5" id="f-837" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-303" decimals="-5" id="f-838" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-304" decimals="-5" id="f-839" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-305" decimals="-5" id="f-840" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-306" decimals="-5" id="f-841" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-307" decimals="-5" id="f-842" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-308" decimals="-5" id="f-843" unitRef="usd">4300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-309" decimals="-5" id="f-844" unitRef="usd">192300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-310" decimals="-5" id="f-845" unitRef="usd">196600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-311" decimals="-5" id="f-846" unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-312" decimals="-5" id="f-847" unitRef="usd">188200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-313" decimals="-5" id="f-848" unitRef="usd">194300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-314" decimals="-5" id="f-849" unitRef="usd">22000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-315" decimals="-5" id="f-850" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-316" decimals="-5" id="f-851" unitRef="usd">22000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-317" decimals="-5" id="f-852" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-318" decimals="-5" id="f-853" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-319" decimals="-5" id="f-854" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-320" decimals="-5" id="f-855" unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-321" decimals="-5" id="f-856" unitRef="usd">1800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-322" decimals="-5" id="f-857" unitRef="usd">2100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-323" decimals="-5" id="f-858" unitRef="usd">900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-324" decimals="-5" id="f-859" unitRef="usd">1100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-325" decimals="-5" id="f-860" unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-326" decimals="-5" id="f-861" unitRef="usd">22300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-327" decimals="-5" id="f-862" unitRef="usd">1800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-328" decimals="-5" id="f-863" unitRef="usd">24100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-329" decimals="-5" id="f-864" unitRef="usd">900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-330" decimals="-5" id="f-865" unitRef="usd">1100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-331" decimals="-5" id="f-866" unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-332" decimals="-5" id="f-867" unitRef="usd">813000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-333" decimals="-5" id="f-868" unitRef="usd">956400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-3" decimals="-5" id="f-869" unitRef="usd">1769400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-334" decimals="-5" id="f-870" unitRef="usd">790900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-335" decimals="-5" id="f-871" unitRef="usd">1014300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-5" id="f-872" unitRef="usd">1805200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-336" decimals="-5" id="f-873" unitRef="usd">127900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-337" decimals="-5" id="f-874" unitRef="usd">611400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-338" decimals="-5" id="f-875" unitRef="usd">739300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-339" decimals="-5" id="f-876" unitRef="usd">199300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-340" decimals="-5" id="f-877" unitRef="usd">568900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-341" decimals="-5" id="f-878" unitRef="usd">768200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-342" decimals="-5" id="f-879" unitRef="usd">385000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-343" decimals="-5" id="f-880" unitRef="usd">66400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-344" decimals="-5" id="f-881" unitRef="usd">451400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-345" decimals="-5" id="f-882" unitRef="usd">372600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-346" decimals="-5" id="f-883" unitRef="usd">47300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-347" decimals="-5" id="f-884" unitRef="usd">419900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-348" decimals="-5" id="f-885" unitRef="usd">512900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-349" decimals="-5" id="f-886" unitRef="usd">677800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-350" decimals="-5" id="f-887" unitRef="usd">1190700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-351" decimals="-5" id="f-888" unitRef="usd">571900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-352" decimals="-5" id="f-889" unitRef="usd">616200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-353" decimals="-5" id="f-890" unitRef="usd">1188100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-354" decimals="-5" id="f-891" unitRef="usd">344000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-355" decimals="-5" id="f-892" unitRef="usd">193500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-356" decimals="-5" id="f-893" unitRef="usd">537500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-357" decimals="-5" id="f-894" unitRef="usd">397200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-358" decimals="-5" id="f-895" unitRef="usd">207700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-359" decimals="-5" id="f-896" unitRef="usd">604900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-360" decimals="-5" id="f-897" unitRef="usd">84700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-361" decimals="-5" id="f-898" unitRef="usd">109800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-362" decimals="-5" id="f-899" unitRef="usd">194500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-363" decimals="-5" id="f-900" unitRef="usd">95400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-364" decimals="-5" id="f-901" unitRef="usd">125400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-365" decimals="-5" id="f-902" unitRef="usd">220800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-366" decimals="-5" id="f-903" unitRef="usd">428700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-367" decimals="-5" id="f-904" unitRef="usd">303300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-368" decimals="-5" id="f-905" unitRef="usd">732000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-369" decimals="-5" id="f-906" unitRef="usd">492600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-370" decimals="-5" id="f-907" unitRef="usd">333100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-371" decimals="-5" id="f-908" unitRef="usd">825700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-372" decimals="-5" id="f-909" unitRef="usd">690000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-373" decimals="-5" id="f-910" unitRef="usd">609600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-374" decimals="-5" id="f-911" unitRef="usd">1299600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-375" decimals="-5" id="f-912" unitRef="usd">750100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-376" decimals="-5" id="f-913" unitRef="usd">662100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-377" decimals="-5" id="f-914" unitRef="usd">1412200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-378" decimals="-5" id="f-915" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-379" decimals="-5" id="f-916" unitRef="usd">57300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-380" decimals="-5" id="f-917" unitRef="usd">57300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-381" decimals="-5" id="f-918" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-382" decimals="-5" id="f-919" unitRef="usd">67500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-383" decimals="-5" id="f-920" unitRef="usd">67500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-384" decimals="-5" id="f-921" unitRef="usd">1631600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-385" decimals="-5" id="f-922" unitRef="usd">1648000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-386" decimals="-5" id="f-923" unitRef="usd">3279600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-387" decimals="-5" id="f-924" unitRef="usd">1814600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-388" decimals="-5" id="f-925" unitRef="usd">1678900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-389" decimals="-5" id="f-926" unitRef="usd">3493500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-390" decimals="-5" id="f-927" unitRef="usd">458900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-391" decimals="-5" id="f-928" unitRef="usd">692900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-392" decimals="-5" id="f-929" unitRef="usd">1151800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-393" decimals="-5" id="f-930" unitRef="usd">453000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-394" decimals="-5" id="f-931" unitRef="usd">875600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-395" decimals="-5" id="f-932" unitRef="usd">1328600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-396" decimals="-5" id="f-933" unitRef="usd">230400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-397" decimals="-5" id="f-934" unitRef="usd">49900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-398" decimals="-5" id="f-935" unitRef="usd">280300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-399" decimals="-5" id="f-936" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-400" decimals="-5" id="f-937" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-401" decimals="-5" id="f-938" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-402" decimals="-5" id="f-939" unitRef="usd">14500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-403" decimals="-5" id="f-940" unitRef="usd">6200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-404" decimals="-5" id="f-941" unitRef="usd">20700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-405" decimals="-5" id="f-942" unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-406" decimals="-5" id="f-943" unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-407" decimals="-5" id="f-944" unitRef="usd">2600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-408" decimals="-5" id="f-945" unitRef="usd">703800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-409" decimals="-5" id="f-946" unitRef="usd">749000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-410" decimals="-5" id="f-947" unitRef="usd">1452800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-411" decimals="-5" id="f-948" unitRef="usd">455500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-412" decimals="-5" id="f-949" unitRef="usd">875700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-413" decimals="-5" id="f-950" unitRef="usd">1331200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-414" decimals="-5" id="f-951" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-415" decimals="-5" id="f-952" unitRef="usd">354100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-416" decimals="-5" id="f-953" unitRef="usd">354100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-417" decimals="-5" id="f-954" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-418" decimals="-5" id="f-955" unitRef="usd">331000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-419" decimals="-5" id="f-956" unitRef="usd">331000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-420" decimals="-5" id="f-957" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-421" decimals="-5" id="f-958" unitRef="usd">162100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-422" decimals="-5" id="f-959" unitRef="usd">162100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-423" decimals="-5" id="f-960" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-424" decimals="-5" id="f-961" unitRef="usd">167600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-425" decimals="-5" id="f-962" unitRef="usd">167600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-426" decimals="-5" id="f-963" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-427" decimals="-5" id="f-964" unitRef="usd">47100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-428" decimals="-5" id="f-965" unitRef="usd">47100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-429" decimals="-5" id="f-966" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-430" decimals="-5" id="f-967" unitRef="usd">60700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-431" decimals="-5" id="f-968" unitRef="usd">60700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-432" decimals="-5" id="f-969" unitRef="usd">18100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-433" decimals="-5" id="f-970" unitRef="usd">9200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-434" decimals="-5" id="f-971" unitRef="usd">27300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-435" decimals="-5" id="f-972" unitRef="usd">21300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-436" decimals="-5" id="f-973" unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-437" decimals="-5" id="f-974" unitRef="usd">22500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-438" decimals="-5" id="f-975" unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-439" decimals="-5" id="f-976" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-440" decimals="-5" id="f-977" unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-441" decimals="-5" id="f-978" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-442" decimals="-5" id="f-979" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-443" decimals="-5" id="f-980" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-444" decimals="-5" id="f-981" unitRef="usd">19100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-445" decimals="-5" id="f-982" unitRef="usd">572500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-446" decimals="-5" id="f-983" unitRef="usd">591600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-447" decimals="-5" id="f-984" unitRef="usd">21300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-448" decimals="-5" id="f-985" unitRef="usd">560500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-449" decimals="-5" id="f-986" unitRef="usd">581800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-450" decimals="-5" id="f-987" unitRef="usd">49300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-451" decimals="-5" id="f-988" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-452" decimals="-5" id="f-989" unitRef="usd">49300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-453" decimals="-5" id="f-990" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-454" decimals="-5" id="f-991" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-455" decimals="-5" id="f-992" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-456" decimals="-5" id="f-993" unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-457" decimals="-5" id="f-994" unitRef="usd">5600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-458" decimals="-5" id="f-995" unitRef="usd">7600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-459" decimals="-5" id="f-996" unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-460" decimals="-5" id="f-997" unitRef="usd">5900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-461" decimals="-5" id="f-998" unitRef="usd">7800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-462" decimals="-5" id="f-999" unitRef="usd">51300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-463" decimals="-5" id="f-1000" unitRef="usd">5600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-464" decimals="-5" id="f-1001" unitRef="usd">56900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-465" decimals="-5" id="f-1002" unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-466" decimals="-5" id="f-1003" unitRef="usd">5900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-467" decimals="-5" id="f-1004" unitRef="usd">7800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-468" decimals="-5" id="f-1005" unitRef="usd">2405800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-469" decimals="-5" id="f-1006" unitRef="usd">2975100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-5" id="f-1007" unitRef="usd">5380900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-470" decimals="-5" id="f-1008" unitRef="usd">2293300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-471" decimals="-5" id="f-1009" unitRef="usd">3121000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-5" id="f-1010" unitRef="usd">5414300000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="c-17"
      decimals="INF"
      id="f-1011"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-1"
      decimals="INF"
      id="f-1012"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-15"
      decimals="INF"
      id="f-1013"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-16"
      decimals="INF"
      id="f-1014"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-472"
      decimals="INF"
      id="f-1015"
      unitRef="number">0.259</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-473"
      decimals="INF"
      id="f-1016"
      unitRef="number">0.148</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-474"
      decimals="INF"
      id="f-1017"
      unitRef="number">0.256</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-475"
      decimals="INF"
      id="f-1018"
      unitRef="number">0.129</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:NumberOfWholesalers
      contextRef="c-17"
      decimals="INF"
      id="f-1019"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-1"
      decimals="INF"
      id="f-1020"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-15"
      decimals="INF"
      id="f-1021"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-16"
      decimals="INF"
      id="f-1022"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-476"
      decimals="3"
      id="f-1023"
      unitRef="number">0.269</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-477"
      decimals="3"
      id="f-1024"
      unitRef="number">0.105</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-478"
      decimals="INF"
      id="f-1025"
      unitRef="number">0.271</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-479"
      decimals="INF"
      id="f-1026"
      unitRef="number">0.091</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="c-1" id="f-1027">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;857.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;605.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,625.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(439.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,391.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,831.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(514.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(692.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;923.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-480" decimals="-5" id="f-1028" unitRef="usd">173300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-481" decimals="-5" id="f-1029" unitRef="usd">857100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-482" decimals="-5" id="f-1030" unitRef="usd">31600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-19" decimals="-5" id="f-1031" unitRef="usd">1062000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-483" decimals="-5" id="f-1032" unitRef="usd">605100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-484" decimals="-5" id="f-1033" unitRef="usd">2004700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-485" decimals="-5" id="f-1034" unitRef="usd">15600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-1" decimals="-5" id="f-1035" unitRef="usd">2625400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-483" decimals="-5" id="f-1036" unitRef="usd">-7600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-484" decimals="-5" id="f-1037" unitRef="usd">33600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-485" decimals="-5" id="f-1038" unitRef="usd">-13100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-1" decimals="-5" id="f-1039" unitRef="usd">12900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-483" decimals="-5" id="f-1040" unitRef="usd">439700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-484" decimals="-5" id="f-1041" unitRef="usd">1391100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-485" decimals="-5" id="f-1042" unitRef="usd">400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-1" decimals="-5" id="f-1043" unitRef="usd">1831200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-483" decimals="-5" id="f-1044" unitRef="usd">160800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-484" decimals="-5" id="f-1045" unitRef="usd">514100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-485" decimals="-5" id="f-1046" unitRef="usd">17400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-1" decimals="-5" id="f-1047" unitRef="usd">692300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-486" decimals="-5" id="f-1048" unitRef="usd">185500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-487" decimals="-5" id="f-1049" unitRef="usd">923000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-488" decimals="-5" id="f-1050" unitRef="usd">42500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-18" decimals="-5" id="f-1051" unitRef="usd">1151000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="c-1" id="f-1052">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;926.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-489" decimals="-5" id="f-1053" unitRef="usd">150700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-490" decimals="-5" id="f-1054" unitRef="usd">135500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-491" decimals="-5" id="f-1055" unitRef="usd">1000300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-492" decimals="-5" id="f-1056" unitRef="usd">926500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-18" decimals="-5" id="f-1057" unitRef="usd">1151000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-19" decimals="-5" id="f-1058" unitRef="usd">1062000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock contextRef="c-1" id="f-1059">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty revenue on sales of OCREVUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;985.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;928.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;315.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;446.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,253.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <us-gaap:Revenues contextRef="c-493" decimals="-5" id="f-1060" unitRef="usd">346800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-494" decimals="-5" id="f-1061" unitRef="usd">319100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-495" decimals="-5" id="f-1062" unitRef="usd">985800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-496" decimals="-5" id="f-1063" unitRef="usd">928200000</us-gaap:Revenues>
    <biib:ShareOfCoPromotionProfits contextRef="c-497" decimals="-5" id="f-1064" unitRef="usd">94800000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-498" decimals="-5" id="f-1065" unitRef="usd">98900000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-499" decimals="-5" id="f-1066" unitRef="usd">285300000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-500" decimals="-5" id="f-1067" unitRef="usd">315000000.0</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-497" decimals="-5" id="f-1068" unitRef="usd">4600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-498" decimals="-5" id="f-1069" unitRef="usd">2900000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-499" decimals="-5" id="f-1070" unitRef="usd">13600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-500" decimals="-5" id="f-1071" unitRef="usd">10600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues contextRef="c-7" decimals="-5" id="f-1072" unitRef="usd">446200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-5" id="f-1073" unitRef="usd">420900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-5" id="f-1074" unitRef="usd">1284700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-5" id="f-1075" unitRef="usd">1253800000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock contextRef="c-1" id="f-1076">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing, royalty and other revenue is summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;742.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract manufacturing, royalty and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;555.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;781.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues contextRef="c-501" decimals="-5" id="f-1077" unitRef="usd">221900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-502" decimals="-5" id="f-1078" unitRef="usd">252900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-503" decimals="-5" id="f-1079" unitRef="usd">474100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-504" decimals="-5" id="f-1080" unitRef="usd">742900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-505" decimals="-5" id="f-1081" unitRef="usd">28300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-506" decimals="-5" id="f-1082" unitRef="usd">51300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-507" decimals="-5" id="f-1083" unitRef="usd">81500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-508" decimals="-5" id="f-1084" unitRef="usd">38300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-5" id="f-1085" unitRef="usd">250200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-5" id="f-1086" unitRef="usd">304200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-5" id="f-1087" unitRef="usd">555600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-5" id="f-1088" unitRef="usd">781200000</us-gaap:Revenues>
    <biib:ShareOfNonControlingInterestRecognized
      contextRef="c-509"
      decimals="2"
      id="f-1089"
      unitRef="number">0.500</biib:ShareOfNonControlingInterestRecognized>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-1091">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;368.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,803.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,926.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,563.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,469.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,527.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,563.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Long-term inventory is included in investments and other assets within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recorded approximately $1.3&#160;billion of acquired inventory, which includes measurement period adjustments, related to SKYCLARYS as a result of our acquisition of Reata in September 2023. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold, which is expected to be sold over a period of approximately 4 years from the acquisition date. For the three and nine months ended September 30, 2024, amortization from the fair value step-up adjustment was approximately $50.9&#160;million and $185.1&#160;million, respectively. The three and nine months ended September 30, 2024, include approximately $2.5&#160;million and $48.5&#160;million, respectively, of inventory used for clinical purposes, which is reflected within research and development expense within our condensed consolidated statements of income. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-1090">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;368.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,803.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,926.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,563.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,469.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,527.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,563.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,609.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-18" decimals="-5" id="f-1092" unitRef="usd">368900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-19" decimals="-5" id="f-1093" unitRef="usd">426900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-18" decimals="-5" id="f-1094" unitRef="usd">1803800000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-19" decimals="-5" id="f-1095" unitRef="usd">1926800000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-18" decimals="-5" id="f-1096" unitRef="usd">391000000.0</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-19" decimals="-5" id="f-1097" unitRef="usd">255400000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-18" decimals="-5" id="f-1098" unitRef="usd">2563700000</biib:InventoryNetCurrentAndNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-19" decimals="-5" id="f-1099" unitRef="usd">2609100000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:InventoryNet contextRef="c-18" decimals="-5" id="f-1100" unitRef="usd">2469200000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-19" decimals="-5" id="f-1101" unitRef="usd">2527400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent contextRef="c-18" decimals="-5" id="f-1102" unitRef="usd">94500000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-19" decimals="-5" id="f-1103" unitRef="usd">81700000</us-gaap:InventoryNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-18" decimals="-5" id="f-1104" unitRef="usd">2563700000</biib:InventoryNetCurrentAndNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-19" decimals="-5" id="f-1105" unitRef="usd">2609100000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-117" decimals="-8" id="f-1106" unitRef="usd">1300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod contextRef="c-117" id="f-1107">P4Y</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod>
    <us-gaap:ProfitLoss contextRef="c-128" decimals="-5" id="f-1108" unitRef="usd">50900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-129" decimals="-5" id="f-1109" unitRef="usd">185100000</us-gaap:ProfitLoss>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-130" decimals="-5" id="f-1110" unitRef="usd">2500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-131" decimals="-5" id="f-1111" unitRef="usd">48500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-1112">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquired and in-licensed rights and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-21 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,552.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,697.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,855.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,180.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,440.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,739.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13-31 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,548.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,445.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,548.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,429.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,101.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,142.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,958.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,869.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,859.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,682.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,682.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,340.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,340.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,948.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,142.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,805.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,232.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,869.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,363.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization and Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets, totaled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$130.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$295.5 million, respectively, compared to $60.9 million and $164.0 million, respectivel&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;y, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2024, a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mortization of acquired intangible assets, excluding impairment charges, totaled $110.1 million and $275.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, compared to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.9 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$164.0 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, in the prior year comparative periods. The increases were primarily due to amortization for the Reata acquisition acquired intangible assets associated with SKYCLARYS. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets reflects impairment charges of $20.2 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, related to intangible assets associated with Samsung Bioepis commercializ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ation rights terminated during the third quarter of 2024. For the three and nine months ended September 30, 2023, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; no impair&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our 2019 Development and Commercialization Agreement with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between 2 to 31 years, with a remaining weighted average useful life of 13 years for acquired and in-licensed rights and patents and 10 years for developed technology and other. In connection with our acquisition of Reata in September 2023 we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately $4.2&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset, with an estimated fair value of approximately $2.3&#160;billion, from IPR&amp;amp;D to completed technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value associated with our IPR&amp;amp;D assets as of December 31, 2023, related to the IPR&amp;amp;D programs we acquired in connection with our acquisition of Reata in September 2023, with an estimated fair value of approximately $2.3&#160;billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset from IPR&amp;amp;D to completed technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value associated with our IPR&amp;amp;D assets as of September 30, 2024, primarily relates to the IPR&amp;amp;D programs we acquired in connection with our acquisition of HI-Bio in July 2024, with an estimated fair value of approximately&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.6&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease PRV that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $100.0&#160;million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisitions of Reata and HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;510.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;550.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;615.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;655.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,219.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from HI-Bio acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from Reata acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,485.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Relates to Reata measurement period adjustments recognized during the nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisitions of Reata and HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2024, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ac&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="c-1" id="f-1113">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquired and in-licensed rights and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-21 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,552.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,697.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,855.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,180.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,440.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,739.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13-31 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,548.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,445.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,548.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,429.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,101.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,142.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,958.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,869.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,859.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,682.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,682.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,340.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,340.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,948.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,142.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,805.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,232.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,869.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,363.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-510" id="f-1114">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-511" id="f-1115">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-512" decimals="-5" id="f-1116" unitRef="usd">10552900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-512" decimals="-5" id="f-1117" unitRef="usd">2697900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-512" decimals="-5" id="f-1118" unitRef="usd">7855000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-513" decimals="-5" id="f-1119" unitRef="usd">8180200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-513" decimals="-5" id="f-1120" unitRef="usd">2440700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-513" decimals="-5" id="f-1121" unitRef="usd">5739500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-514" id="f-1122">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-515" id="f-1123">P31Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-516" decimals="-5" id="f-1124" unitRef="usd">3548600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-516" decimals="-5" id="f-1125" unitRef="usd">3445000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-516" decimals="-5" id="f-1126" unitRef="usd">103600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-517" decimals="-5" id="f-1127" unitRef="usd">3548600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-517" decimals="-5" id="f-1128" unitRef="usd">3429100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-517" decimals="-5" id="f-1129" unitRef="usd">119500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-18" decimals="-5" id="f-1130" unitRef="usd">14101500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-18" decimals="-5" id="f-1131" unitRef="usd">6142900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-18" decimals="-5" id="f-1132" unitRef="usd">7958600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-19" decimals="-5" id="f-1133" unitRef="usd">11728800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-19" decimals="-5" id="f-1134" unitRef="usd">5869800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-19" decimals="-5" id="f-1135" unitRef="usd">5859000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-518" decimals="-5" id="f-1136" unitRef="usd">1682900000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-518" decimals="-5" id="f-1137" unitRef="usd">1682900000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-519" decimals="-5" id="f-1138" unitRef="usd">2340000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-519" decimals="-5" id="f-1139" unitRef="usd">2340000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-520" decimals="-5" id="f-1140" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-520" decimals="-5" id="f-1141" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-521" decimals="-5" id="f-1142" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-521" decimals="-5" id="f-1143" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-522" decimals="-5" id="f-1144" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-522" decimals="-5" id="f-1145" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-523" decimals="-5" id="f-1146" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-523" decimals="-5" id="f-1147" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-18" decimals="-5" id="f-1148" unitRef="usd">15948400000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-18" decimals="-5" id="f-1149" unitRef="usd">6142900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-18" decimals="-5" id="f-1150" unitRef="usd">9805500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-19" decimals="-5" id="f-1151" unitRef="usd">14232800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-19" decimals="-5" id="f-1152" unitRef="usd">5869800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-19" decimals="-5" id="f-1153" unitRef="usd">8363000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-15" decimals="-5" id="f-1154" unitRef="usd">130300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-1" decimals="-5" id="f-1155" unitRef="usd">295500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-16" decimals="-5" id="f-1156" unitRef="usd">60900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-17" decimals="-5" id="f-1157" unitRef="usd">164000000.0</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-127" decimals="-5" id="f-1158" unitRef="usd">110100000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-524" decimals="-5" id="f-1159" unitRef="usd">275300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-525" decimals="-5" id="f-1160" unitRef="usd">60900000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-526" decimals="-5" id="f-1161" unitRef="usd">164000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-1" decimals="-5" id="f-1162" unitRef="usd">20200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-15" decimals="-5" id="f-1163" unitRef="usd">20200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-17" decimals="-5" id="f-1164" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-16" decimals="-5" id="f-1165" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-527" id="f-1166">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-528" id="f-1167">P31Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife contextRef="c-512" id="f-1168">P13Y</biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife>
    <biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife contextRef="c-516" id="f-1169">P10Y</biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-132" decimals="-8" id="f-1170" unitRef="usd">4200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-133" decimals="-8" id="f-1171" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-133" decimals="-8" id="f-1172" unitRef="usd">2300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-529" decimals="-8" id="f-1173" unitRef="usd">1600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-134" decimals="-5" id="f-1174" unitRef="usd">100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-1175">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;510.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;550.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;615.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;655.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-18" decimals="-5" id="f-1176" unitRef="usd">125000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-18" decimals="-5" id="f-1177" unitRef="usd">510000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-18" decimals="-5" id="f-1178" unitRef="usd">550000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-18" decimals="-5" id="f-1179" unitRef="usd">585000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-18" decimals="-5" id="f-1180" unitRef="usd">615000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-18" decimals="-5" id="f-1181" unitRef="usd">655000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-1182">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,219.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from HI-Bio acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from Reata acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,485.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Relates to Reata measurement period adjustments recognized during the nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-19" decimals="-5" id="f-1183" unitRef="usd">6219200000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-115" decimals="-5" id="f-1184" unitRef="usd">256500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-524" decimals="-5" id="f-1185" unitRef="usd">4700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-1" decimals="-5" id="f-1186" unitRef="usd">5400000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill contextRef="c-18" decimals="-5" id="f-1187" unitRef="usd">6485800000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-18" decimals="INF" id="f-1188" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-1190">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;542.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,506.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;660.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-1189">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;542.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,506.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;660.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Denali, Sangamo and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value as of September 30, 2024 and December 31, 2023. In addition, there have been no changes to our valuation techniques as of September 30, 2024 and December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2023 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Level 3 Assets and Liabilities Held at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4% - 5.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 - 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rates were calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of our contingent consideration obligations, which ranged from 67.0% to near certain probability as of September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers of assets or liabilities into or out of Level 3 as of September 30, 2024 and December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of HI-Bio in July 2024 we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligation, which was classified as a Level 3 measurement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.176%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Three and Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration resulting from HI-Bio acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2024, approximately $287.1 million of the fair value of the total contingent consideration obligation was classified as short-term and reflected as a component of accrued expense and other within our condensed consolidated balance sheets with the remaining $221.8 million reflected as a component of other long-term liabilities in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;F&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or the three and nine months ended September 30, 2024, the changes in the fair value of our contingent consideration obligations were primarily due to changes in interest rates used to revalue our contingent consideration liabilities, the passage of time and updates to the expected timing of achieving certain milestones which will trigger contingent consideration payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial Instruments Not Carried at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 Term Loan 364-day tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,739.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,739.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 Term Loan three-year tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,721.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,746.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,339.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,493.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,079.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,034.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,474.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,474.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;475.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;472.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current portion of notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,943.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,545.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,788.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,683.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,293.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,287.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,938.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata we drew $1.0 billion from our 2023 Term Loan, comprised of a $500.0 million floating rate 364-day tranche and a $500.0 million floating rate three-year tranche. As of September 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The fair values of our Senior Notes as of September 30, 2024, compared to December 31, 2023, remained flat reflecting a mix of higher and lower U.S. treasury yields and credit spreads across the maturity spectrum. For additional information related to our Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-530" decimals="-5" id="f-1191" unitRef="usd">802400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-531" decimals="-5" id="f-1192" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-532" decimals="-5" id="f-1193" unitRef="usd">802400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-533" decimals="-5" id="f-1194" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-530" decimals="-5" id="f-1195" unitRef="usd">304700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-531" decimals="-5" id="f-1196" unitRef="usd">304700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-532" decimals="-5" id="f-1197" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-533" decimals="-5" id="f-1198" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-530" decimals="-5" id="f-1199" unitRef="usd">6000000.0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-531" decimals="-5" id="f-1200" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-532" decimals="-5" id="f-1201" unitRef="usd">6000000.0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-533" decimals="-5" id="f-1202" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-530" decimals="-5" id="f-1203" unitRef="usd">42800000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-531" decimals="-5" id="f-1204" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-532" decimals="-5" id="f-1205" unitRef="usd">42800000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-533" decimals="-5" id="f-1206" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:DerivativeAssets contextRef="c-18" decimals="-5" id="f-1207" unitRef="usd">100000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-531" decimals="-5" id="f-1208" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-532" decimals="-5" id="f-1209" unitRef="usd">100000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-533" decimals="-5" id="f-1210" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-530" decimals="-5" id="f-1211" unitRef="usd">1156000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-531" decimals="-5" id="f-1212" unitRef="usd">304700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-532" decimals="-5" id="f-1213" unitRef="usd">851300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-533" decimals="-5" id="f-1214" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-530" decimals="-5" id="f-1215" unitRef="usd">31600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-531" decimals="-5" id="f-1216" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-532" decimals="-5" id="f-1217" unitRef="usd">31600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-533" decimals="-5" id="f-1218" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-530" decimals="-5" id="f-1219" unitRef="usd">287100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-531" decimals="-5" id="f-1220" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-532" decimals="-5" id="f-1221" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-533" decimals="-5" id="f-1222" unitRef="usd">287100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-530" decimals="-5" id="f-1223" unitRef="usd">2400000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-531" decimals="-5" id="f-1224" unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-532" decimals="-5" id="f-1225" unitRef="usd">2400000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-533" decimals="-5" id="f-1226" unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-530" decimals="-5" id="f-1227" unitRef="usd">221800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-531" decimals="-5" id="f-1228" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-532" decimals="-5" id="f-1229" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-533" decimals="-5" id="f-1230" unitRef="usd">221800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-530" decimals="-5" id="f-1231" unitRef="usd">542900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-531" decimals="-5" id="f-1232" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-532" decimals="-5" id="f-1233" unitRef="usd">34000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-533" decimals="-5" id="f-1234" unitRef="usd">508900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-534" decimals="-5" id="f-1235" unitRef="usd">610700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-535" decimals="-5" id="f-1236" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-536" decimals="-5" id="f-1237" unitRef="usd">610700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-537" decimals="-5" id="f-1238" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-534" decimals="-5" id="f-1239" unitRef="usd">416800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-535" decimals="-5" id="f-1240" unitRef="usd">416800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-536" decimals="-5" id="f-1241" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-537" decimals="-5" id="f-1242" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-538" decimals="-5" id="f-1243" unitRef="usd">430000000.0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-539" decimals="-5" id="f-1244" unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-540" decimals="-5" id="f-1245" unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-541" decimals="-5" id="f-1246" unitRef="usd">430000000.0</biib:OtherAssetsCurrentFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-534" decimals="-5" id="f-1247" unitRef="usd">11900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-535" decimals="-5" id="f-1248" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-536" decimals="-5" id="f-1249" unitRef="usd">11900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-537" decimals="-5" id="f-1250" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-534" decimals="-5" id="f-1251" unitRef="usd">37500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-535" decimals="-5" id="f-1252" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-536" decimals="-5" id="f-1253" unitRef="usd">37500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-537" decimals="-5" id="f-1254" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-534" decimals="-5" id="f-1255" unitRef="usd">1506900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-535" decimals="-5" id="f-1256" unitRef="usd">416800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-536" decimals="-5" id="f-1257" unitRef="usd">660100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-537" decimals="-5" id="f-1258" unitRef="usd">430000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-534" decimals="-5" id="f-1259" unitRef="usd">31600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-535" decimals="-5" id="f-1260" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-536" decimals="-5" id="f-1261" unitRef="usd">31600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-537" decimals="-5" id="f-1262" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-534" decimals="-5" id="f-1263" unitRef="usd">31600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-535" decimals="-5" id="f-1264" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-536" decimals="-5" id="f-1265" unitRef="usd">31600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-537" decimals="-5" id="f-1266" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-542"
      decimals="3"
      id="f-1267"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-1268" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-15" decimals="INF" id="f-1269" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-1270">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4% - 5.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 - 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-543" decimals="-5" id="f-1271" unitRef="usd">508900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-544"
      decimals="3"
      id="f-1272"
      unitRef="number">0.054</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-545"
      decimals="3"
      id="f-1273"
      unitRef="number">0.058</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-546"
      decimals="3"
      id="f-1274"
      unitRef="number">0.056</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-101"
      decimals="3"
      id="f-1275"
      unitRef="number">0.670</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-1276">The following table provides a roll forward of the fair value of our contingent consideration obligation, which was classified as a Level 3 measurement:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.176%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Three and Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration resulting from HI-Bio acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-36" decimals="-5" id="f-1277" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-19" decimals="-5" id="f-1278" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-1" decimals="-5" id="f-1279" unitRef="usd">485100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-15" decimals="-5" id="f-1280" unitRef="usd">485100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-5" id="f-1281" unitRef="usd">23800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-15" decimals="-5" id="f-1282" unitRef="usd">23800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-18" decimals="-5" id="f-1283" unitRef="usd">508900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-18" decimals="-5" id="f-1284" unitRef="usd">287100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-18" decimals="-5" id="f-1285" unitRef="usd">221800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="c-1" id="f-1286">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 Term Loan 364-day tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,739.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,739.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 Term Loan three-year tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,721.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,746.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,339.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,493.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,079.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,034.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,474.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,474.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;475.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;472.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current portion of notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,943.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,545.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,788.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total notes payable and term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,683.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,293.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,287.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,938.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata we drew $1.0 billion from our 2023 Term Loan, comprised of a $500.0 million floating rate 364-day tranche and a $500.0 million floating rate three-year tranche. As of September 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <biib:NotesPayableCurrentFairValueDisclosure contextRef="c-547" decimals="-5" id="f-1287" unitRef="usd">0</biib:NotesPayableCurrentFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-547" decimals="-5" id="f-1288" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <biib:NotesPayableCurrentFairValueDisclosure contextRef="c-548" decimals="-5" id="f-1289" unitRef="usd">150000000.0</biib:NotesPayableCurrentFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-548" decimals="-5" id="f-1290" unitRef="usd">150000000.0</us-gaap:NotesPayableCurrent>
    <biib:NotesPayableCurrentFairValueDisclosure contextRef="c-549" decimals="-5" id="f-1291" unitRef="usd">1739900000</biib:NotesPayableCurrentFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-549" decimals="-5" id="f-1292" unitRef="usd">1748100000</us-gaap:NotesPayableCurrent>
    <biib:NotesPayableCurrentFairValueDisclosure contextRef="c-550" decimals="-5" id="f-1293" unitRef="usd">0</biib:NotesPayableCurrentFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-550" decimals="-5" id="f-1294" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <biib:NotesPayableCurrentFairValueDisclosure contextRef="c-551" decimals="-5" id="f-1295" unitRef="usd">1739900000</biib:NotesPayableCurrentFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-551" decimals="-5" id="f-1296" unitRef="usd">1748100000</us-gaap:NotesPayableCurrent>
    <biib:NotesPayableCurrentFairValueDisclosure contextRef="c-552" decimals="-5" id="f-1297" unitRef="usd">150000000.0</biib:NotesPayableCurrentFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-552" decimals="-5" id="f-1298" unitRef="usd">150000000.0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-553" decimals="-5" id="f-1299" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-553" decimals="-5" id="f-1300" unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-554" decimals="-5" id="f-1301" unitRef="usd">500000000.0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-554" decimals="-5" id="f-1302" unitRef="usd">500000000.0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-549" decimals="-5" id="f-1303" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-549" decimals="-5" id="f-1304" unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-555" decimals="-5" id="f-1305" unitRef="usd">1721500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-550" decimals="-5" id="f-1306" unitRef="usd">1746600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-556" decimals="-5" id="f-1307" unitRef="usd">1339400000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-556" decimals="-5" id="f-1308" unitRef="usd">1494500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-557" decimals="-5" id="f-1309" unitRef="usd">1279300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-558" decimals="-5" id="f-1310" unitRef="usd">1493800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-559" decimals="-5" id="f-1311" unitRef="usd">1079200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-559" decimals="-5" id="f-1312" unitRef="usd">1101000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-560" decimals="-5" id="f-1313" unitRef="usd">1089700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-561" decimals="-5" id="f-1314" unitRef="usd">1100700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-562" decimals="-5" id="f-1315" unitRef="usd">1034100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-562" decimals="-5" id="f-1316" unitRef="usd">1474800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-563" decimals="-5" id="f-1317" unitRef="usd">1049000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-564" decimals="-5" id="f-1318" unitRef="usd">1474300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-565" decimals="-5" id="f-1319" unitRef="usd">490900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-565" decimals="-5" id="f-1320" unitRef="usd">475500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-566" decimals="-5" id="f-1321" unitRef="usd">498200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-567" decimals="-5" id="f-1322" unitRef="usd">472800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-568" decimals="-5" id="f-1323" unitRef="usd">3943600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-568" decimals="-5" id="f-1324" unitRef="usd">4545800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-569" decimals="-5" id="f-1325" unitRef="usd">6137700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-569" decimals="-5" id="f-1326" unitRef="usd">6788200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-18" decimals="-5" id="f-1327" unitRef="usd">5683500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-18" decimals="-5" id="f-1328" unitRef="usd">6293900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-19" decimals="-5" id="f-1329" unitRef="usd">6287700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-19" decimals="-5" id="f-1330" unitRef="usd">6938200000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-120" decimals="-8" id="f-1331" unitRef="usd">1000000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-570" decimals="-3" id="f-1332" unitRef="usd">500000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-571" decimals="-3" id="f-1333" unitRef="usd">500000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-1334">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of our money market funds approximates fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable equity securities, classified as available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;676.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(421.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;734.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(429.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;948.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(542.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(563.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.747%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,698.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,380.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of December 31, 2023, we have sold all of our marketable debt securities. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized losses for the three and nine months ended September 30, 2023, primarily relate to sales of U.S. treasuries and corporate bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2024 and December 31, 2023, our strategic investment portfolio was comprised of investments totaling $353.3 million and $460.7 million, respectively, which are included in other current assets and investments and other assets within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in our strategic investment portfolio as of September 30, 2024, was primarily due to the decrease in the fair value of our investment in Sage common stock, partially offset by an increase in the fair value of our investment in Denali common stock. Additionally, we sold a portion of our Denali and Sangamo common stock during 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our strategic investments in Denali, Sangamo and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-1335">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-572" decimals="-5" id="f-1336" unitRef="usd">802400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-573" decimals="-5" id="f-1337" unitRef="usd">610700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-18" decimals="-5" id="f-1338" unitRef="usd">802400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-19" decimals="-5" id="f-1339" unitRef="usd">610700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-1340">The following tables summarize our marketable equity securities, classified as available-for-sale:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;676.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(421.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;734.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(429.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;948.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(542.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;979.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(563.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-574" decimals="-5" id="f-1341" unitRef="usd">58300000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-574" decimals="-5" id="f-1342" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-574" decimals="-5" id="f-1343" unitRef="usd">8200000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-574" decimals="-5" id="f-1344" unitRef="usd">50100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-575" decimals="-5" id="f-1345" unitRef="usd">676000000.0</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-575" decimals="-5" id="f-1346" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-575" decimals="-5" id="f-1347" unitRef="usd">421400000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-575" decimals="-5" id="f-1348" unitRef="usd">254600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-18" decimals="-5" id="f-1349" unitRef="usd">734300000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-18" decimals="-5" id="f-1350" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-18" decimals="-5" id="f-1351" unitRef="usd">429600000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-18" decimals="-5" id="f-1352" unitRef="usd">304700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-576" decimals="-5" id="f-1353" unitRef="usd">31600000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-576" decimals="-5" id="f-1354" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-576" decimals="-5" id="f-1355" unitRef="usd">21000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-576" decimals="-5" id="f-1356" unitRef="usd">10600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-577" decimals="-5" id="f-1357" unitRef="usd">948300000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-577" decimals="-5" id="f-1358" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-577" decimals="-5" id="f-1359" unitRef="usd">542100000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-577" decimals="-5" id="f-1360" unitRef="usd">406200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-19" decimals="-5" id="f-1361" unitRef="usd">979900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-19" decimals="-5" id="f-1362" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-19" decimals="-5" id="f-1363" unitRef="usd">563100000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-19" decimals="-5" id="f-1364" unitRef="usd">416800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="c-1" id="f-1365">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.747%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,698.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,380.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-16" decimals="-5" id="f-1366" unitRef="usd">5698600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-17" decimals="-5" id="f-1367" unitRef="usd">7380800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-16" decimals="-5" id="f-1368" unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-17" decimals="-5" id="f-1369" unitRef="usd">1400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-16" decimals="-5" id="f-1370" unitRef="usd">-16300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-17" decimals="-5" id="f-1371" unitRef="usd">-18400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio contextRef="c-578" decimals="-5" id="f-1372" unitRef="usd">353300000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio contextRef="c-579" decimals="-5" id="f-1373" unitRef="usd">460700000</biib:StrategicInvestmentPortfolio>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-1374">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts and foreign currency options in effect as of September 30, 2024 and December 31, 2023, had durations of 1 to 15 months and 1 to 12 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,569.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,686.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the net unrealized losses of approximately $41.5&#160;million to be settled over the next 15 months, of which approximately $38.5&#160;million of these net unrealized losses are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2024 and December 31, 2023, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $1,339.6 million and $1,301.5 million as of September 30, 2024 and December 31, 2023, respectively. Net gains of $23.4 million and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net losses of $6.6 million related to these contracts were recorded as a component of other (income) expense, net for the three and nine months ended September 30, 2024, respectively, compared to net losses of $22.6 million and $28.0 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-580" id="f-1375">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-581" id="f-1376">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-582" id="f-1377">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-583" id="f-1378">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="c-1" id="f-1379">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,569.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,686.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-584" decimals="-5" id="f-1380" unitRef="usd">1569200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-585" decimals="-5" id="f-1381" unitRef="usd">1169000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-586" decimals="-5" id="f-1382" unitRef="usd">32900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-587" decimals="-5" id="f-1383" unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-588" decimals="-5" id="f-1384" unitRef="usd">72100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-589" decimals="-5" id="f-1385" unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-590" decimals="-5" id="f-1386" unitRef="usd">12700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-591" decimals="-5" id="f-1387" unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-592" decimals="-5" id="f-1388" unitRef="usd">1686900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-593" decimals="-5" id="f-1389" unitRef="usd">1169000000</us-gaap:DerivativeNotionalAmount>
    <biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock contextRef="c-1" id="f-1390">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock>
    <biib:UnrealizedGainOnDerivatives contextRef="c-1" decimals="-5" id="f-1391" unitRef="usd">1500000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedGainOnDerivatives contextRef="c-17" decimals="-5" id="f-1392" unitRef="usd">0</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedLossOnDerivatives contextRef="c-1" decimals="-5" id="f-1393" unitRef="usd">43000000.0</biib:UnrealizedLossOnDerivatives>
    <biib:UnrealizedLossOnDerivatives contextRef="c-17" decimals="-5" id="f-1394" unitRef="usd">34800000</biib:UnrealizedLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-1" decimals="-5" id="f-1395" unitRef="usd">-41500000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-17" decimals="-5" id="f-1396" unitRef="usd">-34800000</us-gaap:UnrealizedGainLossOnDerivatives>
    <biib:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months contextRef="c-18" decimals="-5" id="f-1397" unitRef="usd">41500000</biib:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months contextRef="c-18" decimals="-5" id="f-1398" unitRef="usd">38500000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-1399">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-594" decimals="-5" id="f-1400" unitRef="usd">-7600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-595" decimals="-5" id="f-1401" unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-596" decimals="-5" id="f-1402" unitRef="usd">2900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-597" decimals="-5" id="f-1403" unitRef="usd">-2100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-598" decimals="-5" id="f-1404" unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-599" decimals="-5" id="f-1405" unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-600" decimals="-5" id="f-1406" unitRef="usd">300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-601" decimals="-5" id="f-1407" unitRef="usd">900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-602" decimals="-5" id="f-1408" unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-603" decimals="-5" id="f-1409" unitRef="usd">18300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-604" decimals="-5" id="f-1410" unitRef="usd">4000000.0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-605" decimals="-5" id="f-1411" unitRef="usd">-1500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-606" decimals="-5" id="f-1412" unitRef="usd">-8500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-607" decimals="-5" id="f-1413" unitRef="usd">2100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-608" decimals="-5" id="f-1414" unitRef="usd">-1600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-609" decimals="-5" id="f-1415" unitRef="usd">-2000000.0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeNotionalAmount contextRef="c-610" decimals="-5" id="f-1416" unitRef="usd">1339600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-611" decimals="-5" id="f-1417" unitRef="usd">1301500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-15" decimals="-5" id="f-1418" unitRef="usd">23400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-1" decimals="-5" id="f-1419" unitRef="usd">-6600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-16" decimals="-5" id="f-1420" unitRef="usd">22600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-17" decimals="-5" id="f-1421" unitRef="usd">28000000.0</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-1422">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-612" decimals="-5" id="f-1423" unitRef="usd">900000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-613" decimals="-5" id="f-1424" unitRef="usd">300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-614" decimals="-5" id="f-1425" unitRef="usd">100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-615" decimals="-5" id="f-1426" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-616" decimals="-5" id="f-1427" unitRef="usd">29200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-617" decimals="-5" id="f-1428" unitRef="usd">26500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-618" decimals="-5" id="f-1429" unitRef="usd">2400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-619" decimals="-5" id="f-1430" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-620" decimals="-5" id="f-1431" unitRef="usd">5100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-621" decimals="-5" id="f-1432" unitRef="usd">11600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-622" decimals="-5" id="f-1433" unitRef="usd">2400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-623" decimals="-5" id="f-1434" unitRef="usd">5100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-1435">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,604.4 million and $2,402.5 million as of September 30, 2024 and December 31, 2023, respectively. For the three and nine months ended September 30, 2024, depreciation expense totaled $72.7 million and $213.9 million, respectively, compared to $64.1 million and $190.7 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we built a large-scale biologics manufacturing facility in Solothurn, Switzerland. This facility includes 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of December 31, 2023, we had approximately $728.8 million capitalized as construction in progress related to this facility. In the second quarter of 2021 a portion of this facility (the first manufacturing suite) received a GMP multi-product license from SWISSMEDIC and was placed into service. The second manufacturing suite, which was also licensed to operate by SWISSMEDIC, became operational in the first quarter of 2024, resulting in approximately $717.3&#160;million of fixed assets being placed into service. Solothurn has been approved for the manufacture of LEQEMBI.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-18" decimals="-5" id="f-1436" unitRef="usd">2604400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-19" decimals="-5" id="f-1437" unitRef="usd">2402500000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-1438" unitRef="usd">72700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-1439" unitRef="usd">213900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-16" decimals="-5" id="f-1440" unitRef="usd">64100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-17" decimals="-5" id="f-1441" unitRef="usd">190700000</us-gaap:Depreciation>
    <biib:NumberOfSquareFeet
      contextRef="c-624"
      decimals="INF"
      id="f-1442"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="c-625"
      decimals="INF"
      id="f-1443"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="c-626"
      decimals="INF"
      id="f-1444"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross contextRef="c-627" decimals="-5" id="f-1445" unitRef="usd">728800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-628" decimals="-5" id="f-1446" unitRef="usd">717300000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1447">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;6100 Legacy Drive Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $121.2&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <biib:OperatingLeaseArea contextRef="c-117" decimals="0" id="f-1448" unitRef="sqft">327400</biib:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-117" id="f-1449">P16Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-117" decimals="-5" id="f-1450" unitRef="usd">151800000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-117" id="f-1451">P15Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-117" decimals="-5" id="f-1452" unitRef="usd">121200000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1453">Credit Agreement&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $1.0 billion from the 2023 Term Loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of December 31, 2023, we repaid $350.0&#160;million of the 364--day tranche. The remaining $150.0&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, during the first quarter of 2024 we repaid $250.0&#160;million of the three-year tranche, with the remaining $250.0&#160;million portion of the three-year tranche being subsequently repaid in full during the second quarter of 2024. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-629" decimals="-3" id="f-1454" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-120" decimals="-8" id="f-1455" unitRef="usd">1000000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-570" decimals="-3" id="f-1456" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-571" decimals="-3" id="f-1457" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-630" decimals="-3" id="f-1458" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths contextRef="c-631" decimals="-5" id="f-1459" unitRef="usd">350000000</us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-632" decimals="-5" id="f-1460" unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-633" decimals="-5" id="f-1461" unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-634" decimals="-5" id="f-1462" unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1463">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and nine months ended September 30, 2024 and 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in AOCI, net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.626%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(144.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(172.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from AOCI:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-635" decimals="INF" id="f-1464" unitRef="usd">5000000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-636" decimals="-8" id="f-1465" unitRef="usd">2100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1466">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in AOCI, net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.626%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(144.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(172.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-637" decimals="-5" id="f-1467" unitRef="usd">9800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-638" decimals="-5" id="f-1468" unitRef="usd">-2700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-639" decimals="-5" id="f-1469" unitRef="usd">-153100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-36" decimals="-5" id="f-1470" unitRef="usd">-146000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-640" decimals="-5" id="f-1471" unitRef="usd">-49100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-641" decimals="-5" id="f-1472" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-642" decimals="-5" id="f-1473" unitRef="usd">41000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-15" decimals="-5" id="f-1474" unitRef="usd">-7800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-640" decimals="-5" id="f-1475" unitRef="usd">8100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-641" decimals="-5" id="f-1476" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-642" decimals="-5" id="f-1477" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-15" decimals="-5" id="f-1478" unitRef="usd">8100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-640" decimals="-5" id="f-1479" unitRef="usd">-41000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-641" decimals="-5" id="f-1480" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-642" decimals="-5" id="f-1481" unitRef="usd">41000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-5" id="f-1482" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-643" decimals="-5" id="f-1483" unitRef="usd">-31200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-644" decimals="-5" id="f-1484" unitRef="usd">-2400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-645" decimals="-5" id="f-1485" unitRef="usd">-112100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="-5" id="f-1486" unitRef="usd">-145700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-646" decimals="-5" id="f-1487" unitRef="usd">-25000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-647" decimals="-5" id="f-1488" unitRef="usd">-2600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-648" decimals="-5" id="f-1489" unitRef="usd">-126100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-5" id="f-1490" unitRef="usd">-153700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-649" decimals="-5" id="f-1491" unitRef="usd">-11400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-650" decimals="-5" id="f-1492" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-651" decimals="-5" id="f-1493" unitRef="usd">14000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-1" decimals="-5" id="f-1494" unitRef="usd">2800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-649" decimals="-5" id="f-1495" unitRef="usd">5200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-650" decimals="-5" id="f-1496" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-651" decimals="-5" id="f-1497" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-1" decimals="-5" id="f-1498" unitRef="usd">5200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-649" decimals="-5" id="f-1499" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-650" decimals="-5" id="f-1500" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-651" decimals="-5" id="f-1501" unitRef="usd">14000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-5" id="f-1502" unitRef="usd">8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-643" decimals="-5" id="f-1503" unitRef="usd">-31200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-644" decimals="-5" id="f-1504" unitRef="usd">-2400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-645" decimals="-5" id="f-1505" unitRef="usd">-112100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="-5" id="f-1506" unitRef="usd">-145700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-652" decimals="-5" id="f-1507" unitRef="usd">-14500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-653" decimals="-5" id="f-1508" unitRef="usd">-13400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-654" decimals="-5" id="f-1509" unitRef="usd">-400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-655" decimals="-5" id="f-1510" unitRef="usd">-144500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-65" decimals="-5" id="f-1511" unitRef="usd">-172800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-656" decimals="-5" id="f-1512" unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-657" decimals="-5" id="f-1513" unitRef="usd">29000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-658" decimals="-5" id="f-1514" unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-659" decimals="-5" id="f-1515" unitRef="usd">-30500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-16" decimals="-5" id="f-1516" unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-656" decimals="-5" id="f-1517" unitRef="usd">12000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-657" decimals="-5" id="f-1518" unitRef="usd">600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-658" decimals="-5" id="f-1519" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-659" decimals="-5" id="f-1520" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-16" decimals="-5" id="f-1521" unitRef="usd">12600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-656" decimals="-5" id="f-1522" unitRef="usd">14500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-657" decimals="-5" id="f-1523" unitRef="usd">29600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-658" decimals="-5" id="f-1524" unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-659" decimals="-5" id="f-1525" unitRef="usd">-30500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-16" decimals="-5" id="f-1526" unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-660" decimals="-5" id="f-1527" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-661" decimals="-5" id="f-1528" unitRef="usd">16200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-662" decimals="-5" id="f-1529" unitRef="usd">-500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-663" decimals="-5" id="f-1530" unitRef="usd">-175000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-29" decimals="-5" id="f-1531" unitRef="usd">-159300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-664" decimals="-5" id="f-1532" unitRef="usd">-15700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-665" decimals="-5" id="f-1533" unitRef="usd">15100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-666" decimals="-5" id="f-1534" unitRef="usd">-1100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-667" decimals="-5" id="f-1535" unitRef="usd">-163200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-28" decimals="-5" id="f-1536" unitRef="usd">-164900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-668" decimals="-5" id="f-1537" unitRef="usd">2300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-669" decimals="-5" id="f-1538" unitRef="usd">18900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-670" decimals="-5" id="f-1539" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-671" decimals="-5" id="f-1540" unitRef="usd">-11800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-17" decimals="-5" id="f-1541" unitRef="usd">10000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-668" decimals="-5" id="f-1542" unitRef="usd">13400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-669" decimals="-5" id="f-1543" unitRef="usd">-17800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-670" decimals="-5" id="f-1544" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-671" decimals="-5" id="f-1545" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-17" decimals="-5" id="f-1546" unitRef="usd">-4400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-668" decimals="-5" id="f-1547" unitRef="usd">15700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-669" decimals="-5" id="f-1548" unitRef="usd">1100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-670" decimals="-5" id="f-1549" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-671" decimals="-5" id="f-1550" unitRef="usd">-11800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-17" decimals="-5" id="f-1551" unitRef="usd">5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-660" decimals="-5" id="f-1552" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-661" decimals="-5" id="f-1553" unitRef="usd">16200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-662" decimals="-5" id="f-1554" unitRef="usd">-500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-663" decimals="-5" id="f-1555" unitRef="usd">-175000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-29" decimals="-5" id="f-1556" unitRef="usd">-159300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="c-1" id="f-1557">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from AOCI:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-672" decimals="-5" id="f-1558" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-673" decimals="-5" id="f-1559" unitRef="usd">-15200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-674" decimals="-5" id="f-1560" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-675" decimals="-5" id="f-1561" unitRef="usd">-17000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-672" decimals="-5" id="f-1562" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-673" decimals="-5" id="f-1563" unitRef="usd">3200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-674" decimals="-5" id="f-1564" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-675" decimals="-5" id="f-1565" unitRef="usd">3600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues contextRef="c-676" decimals="-5" id="f-1566" unitRef="usd">-7600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-677" decimals="-5" id="f-1567" unitRef="usd">-1700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-678" decimals="-5" id="f-1568" unitRef="usd">2900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-679" decimals="-5" id="f-1569" unitRef="usd">18300000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c-676" decimals="-5" id="f-1570" unitRef="usd">1500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-677" decimals="-5" id="f-1571" unitRef="usd">-1200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-678" decimals="-5" id="f-1572" unitRef="usd">8500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-679" decimals="-5" id="f-1573" unitRef="usd">-2100000</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-676" decimals="-5" id="f-1574" unitRef="usd">-100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-677" decimals="-5" id="f-1575" unitRef="usd">-100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-678" decimals="-5" id="f-1576" unitRef="usd">-200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-679" decimals="-5" id="f-1577" unitRef="usd">-300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-676" decimals="-5" id="f-1578" unitRef="usd">1100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-677" decimals="-5" id="f-1579" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-678" decimals="-5" id="f-1580" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-679" decimals="-5" id="f-1581" unitRef="usd">-2300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-680" decimals="-5" id="f-1582" unitRef="usd">-8100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-681" decimals="-5" id="f-1583" unitRef="usd">-12600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-682" decimals="-5" id="f-1584" unitRef="usd">-5200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-683" decimals="-5" id="f-1585" unitRef="usd">4400000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1586">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income (loss) per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1587">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-1588" unitRef="usd">388500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-5" id="f-1589" unitRef="usd">-68100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-1590" unitRef="usd">1365500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-5" id="f-1591" unitRef="usd">911400000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-15"
      decimals="-5"
      id="f-1592"
      unitRef="shares">145700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-16"
      decimals="-5"
      id="f-1593"
      unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1594" unitRef="shares">145500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-17"
      decimals="-3"
      id="f-1595"
      unitRef="shares">144700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-684"
      decimals="-5"
      id="f-1596"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-685"
      decimals="-5"
      id="f-1597"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-686"
      decimals="-5"
      id="f-1598"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-687"
      decimals="-5"
      id="f-1599"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-688"
      decimals="-5"
      id="f-1600"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-689"
      decimals="-5"
      id="f-1601"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-690"
      decimals="-5"
      id="f-1602"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-691"
      decimals="-5"
      id="f-1603"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-15"
      decimals="-5"
      id="f-1604"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-16"
      decimals="-5"
      id="f-1605"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-5" id="f-1606" unitRef="shares">500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-17"
      decimals="-5"
      id="f-1607"
      unitRef="shares">800000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-15"
      decimals="-5"
      id="f-1608"
      unitRef="shares">146100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-16"
      decimals="-5"
      id="f-1609"
      unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1610" unitRef="shares">146000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-17"
      decimals="-3"
      id="f-1611"
      unitRef="shares">145500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1612">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(98.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income (loss) attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we recognized Reata equity-based compensation expense, inclusive of employer taxes, of approximately $393.4&#160;million attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of HI-Bio in July 2024 we recognized HI-Bio equity-based compensation expense, inclusive of employer taxes, of approximately $56.4&#160;million attributable to the post-acquisition service period, of which $42.5&#160;million was recognized as a charge to research and development expense with the remaining $13.9&#160;million as a charge to selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reata equity awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;HI-Bio equity awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Relates to the Reata and HI-Bio equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to Reata and HI-Bio employees and required no future services to vest. For additional information on our acquisition of Reata and HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2024 Omnibus Equity Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024 our shareholders approved the 2024 Omnibus Equity Plan for share-based awards to our prospective and current employees, non-employee directors, officers or consultants. Awards granted from the 2024 Omnibus Equity Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2024 Omnibus Equity Plan consist of 3.7 million shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) on the date that our shareholders approved the 2024 Omnibus Equity Plan, plus shares that were subject to awards under the 2017 Omnibus Equity Plan (including shares available by reason of a predecessor plan) that remain unissued upon the cancellation, surrender, exchange, termination or forfeiture of such awards. The 2024 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a 1.5-to-1 ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not made any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan since our shareholders approved the 2024 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2017 Omnibus Equity Plan or the Directors Plan in the future, except that unused shares under the 2017 Omnibus Equity Plan have been carried over for use under the 2024 Omnibus Equity Plan. Awards outstanding under the 2017 Omnibus Equity Plan and the Directors Plan as of the date our shareholders approved the 2024 Omnibus Equity Plan will remain outstanding and subject to the terms and conditions of the 2017 Omnibus Equity Plan and the Directors Plan, as applicable, and the relevant award agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2024 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024 our shareholders approved the 2024 ESPP. The 2024 ESPP, which became effective on July 1, 2024, replaced the 2015 ESPP, which expired on June 30, 2024. The maximum number of shares of our common stock that may be purchased under the 2024 ESPP is 2.5 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1613">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(98.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income (loss) attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we recognized Reata equity-based compensation expense, inclusive of employer taxes, of approximately $393.4&#160;million attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of HI-Bio in July 2024 we recognized HI-Bio equity-based compensation expense, inclusive of employer taxes, of approximately $56.4&#160;million attributable to the post-acquisition service period, of which $42.5&#160;million was recognized as a charge to research and development expense with the remaining $13.9&#160;million as a charge to selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-692" decimals="-5" id="f-1614" unitRef="usd">69800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-693" decimals="-5" id="f-1615" unitRef="usd">217100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-694" decimals="-5" id="f-1616" unitRef="usd">124500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-695" decimals="-5" id="f-1617" unitRef="usd">276300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-696" decimals="-5" id="f-1618" unitRef="usd">61300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-697" decimals="-5" id="f-1619" unitRef="usd">234900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-698" decimals="-5" id="f-1620" unitRef="usd">150900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-699" decimals="-5" id="f-1621" unitRef="usd">333400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-15" decimals="-5" id="f-1622" unitRef="usd">131100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-16" decimals="-5" id="f-1623" unitRef="usd">452000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-5" id="f-1624" unitRef="usd">275400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-17" decimals="-5" id="f-1625" unitRef="usd">609700000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-15" decimals="-5" id="f-1626" unitRef="usd">2400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-16" decimals="-5" id="f-1627" unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-1628" unitRef="usd">8000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-17" decimals="-5" id="f-1629" unitRef="usd">8500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-15" decimals="-5" id="f-1630" unitRef="usd">128700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-16" decimals="-5" id="f-1631" unitRef="usd">449400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-1" decimals="-5" id="f-1632" unitRef="usd">267400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-17" decimals="-5" id="f-1633" unitRef="usd">601200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-15" decimals="-5" id="f-1634" unitRef="usd">24200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-16" decimals="-5" id="f-1635" unitRef="usd">98500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-5" id="f-1636" unitRef="usd">50500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-17" decimals="-5" id="f-1637" unitRef="usd">126500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-700" decimals="-5" id="f-1638" unitRef="usd">104500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-701" decimals="-5" id="f-1639" unitRef="usd">350900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-702" decimals="-5" id="f-1640" unitRef="usd">216900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-703" decimals="-5" id="f-1641" unitRef="usd">474700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OperatingExpenses contextRef="c-118" decimals="-5" id="f-1642" unitRef="usd">393400000</us-gaap:OperatingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-118" decimals="-5" id="f-1643" unitRef="usd">196400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-118" decimals="-5" id="f-1644" unitRef="usd">197000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-96" decimals="-5" id="f-1645" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-97" decimals="-5" id="f-1646" unitRef="usd">42500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-98" decimals="-5" id="f-1647" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-1648">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reata equity awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;HI-Bio equity awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Relates to the Reata and HI-Bio equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to Reata and HI-Bio employees and required no future services to vest. For additional information on our acquisition of Reata and HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-704" decimals="-5" id="f-1649" unitRef="usd">59100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-705" decimals="-5" id="f-1650" unitRef="usd">53400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-706" decimals="-5" id="f-1651" unitRef="usd">174700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-707" decimals="-5" id="f-1652" unitRef="usd">175000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-708" decimals="-5" id="f-1653" unitRef="usd">13000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-709" decimals="-5" id="f-1654" unitRef="usd">7800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-710" decimals="-5" id="f-1655" unitRef="usd">35200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-711" decimals="-5" id="f-1656" unitRef="usd">27100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-712" decimals="-5" id="f-1657" unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-713" decimals="-5" id="f-1658" unitRef="usd">2000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-714" decimals="-5" id="f-1659" unitRef="usd">8200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-715" decimals="-5" id="f-1660" unitRef="usd">8800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-716" decimals="-5" id="f-1661" unitRef="usd">-500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-717" decimals="-5" id="f-1662" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-718" decimals="-5" id="f-1663" unitRef="usd">-2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-719" decimals="-5" id="f-1664" unitRef="usd">4800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-720" decimals="-5" id="f-1665" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-721" decimals="-5" id="f-1666" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-722" decimals="-5" id="f-1667" unitRef="usd">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-723" decimals="-5" id="f-1668" unitRef="usd">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-724" decimals="-5" id="f-1669" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-725" decimals="-5" id="f-1670" unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-726" decimals="-5" id="f-1671" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-727" decimals="-5" id="f-1672" unitRef="usd">4200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-127" decimals="-5" id="f-1673" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-525" decimals="-5" id="f-1674" unitRef="usd">387000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-524" decimals="-5" id="f-1675" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-526" decimals="-5" id="f-1676" unitRef="usd">387000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-116" decimals="-5" id="f-1677" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-728" decimals="-5" id="f-1678" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-115" decimals="-5" id="f-1679" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-729" decimals="-5" id="f-1680" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-15" decimals="-5" id="f-1681" unitRef="usd">131100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-16" decimals="-5" id="f-1682" unitRef="usd">452000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-5" id="f-1683" unitRef="usd">275400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-17" decimals="-5" id="f-1684" unitRef="usd">609700000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-15" decimals="-5" id="f-1685" unitRef="usd">2400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-16" decimals="-5" id="f-1686" unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-1687" unitRef="usd">8000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-17" decimals="-5" id="f-1688" unitRef="usd">8500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-15" decimals="-5" id="f-1689" unitRef="usd">128700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-16" decimals="-5" id="f-1690" unitRef="usd">449400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-1" decimals="-5" id="f-1691" unitRef="usd">267400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-17" decimals="-5" id="f-1692" unitRef="usd">601200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-730"
      decimals="-5"
      id="f-1693"
      unitRef="shares">3700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <biib:RatioOfNumberOfSharesReservedUnderPlan
      contextRef="c-731"
      decimals="1"
      id="f-1694"
      unitRef="number">1.5</biib:RatioOfNumberOfSharesReservedUnderPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-732"
      decimals="-5"
      id="f-1695"
      unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1696">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings, including valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased inventory valuation step-up and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2024, compared to the same periods in 2023, our effective tax rate includes a decrease in our valuation allowance related to changes in projected future foreign taxable income, partially offset by the impact of certain foreign uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate for the three months ended September 30, 2023, reflects a tax benefit of $72.9&#160;million recognized as a result of a pretax loss from operations of $141.2&#160;million recorded during the third quarter of 2023, which was driven, in part, by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses. For all other periods presented, the effective tax rates reflect tax expense on pretax income from operations in the respective periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The nine months ended September 30, 2023, was also impacted by the resolution of an uncertain tax matter related to tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2019 or state, local or non-U.S. income tax examinations for years before 2013.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;decrease by up to approximately $55.0&#160;million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1697">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings, including valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased inventory valuation step-up and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-15" decimals="3" id="f-1698" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-16" decimals="3" id="f-1699" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1700" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-17" decimals="3" id="f-1701" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-15" decimals="3" id="f-1702" unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-16" decimals="3" id="f-1703" unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1704" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-17" decimals="3" id="f-1705" unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-15" decimals="3" id="f-1706" unitRef="number">-0.119</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-16" decimals="3" id="f-1707" unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-1708" unitRef="number">-0.070</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-17" decimals="3" id="f-1709" unitRef="number">-0.061</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-15" decimals="3" id="f-1710" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-16" decimals="3" id="f-1711" unitRef="number">-0.246</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-1712" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-17" decimals="3" id="f-1713" unitRef="number">0.077</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-15" decimals="3" id="f-1714" unitRef="number">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-16" decimals="3" id="f-1715" unitRef="number">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-1" decimals="3" id="f-1716" unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-17" decimals="3" id="f-1717" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-15" decimals="3" id="f-1718" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-16" decimals="3" id="f-1719" unitRef="number">0.148</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-1" decimals="3" id="f-1720" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-17" decimals="3" id="f-1721" unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-15" decimals="3" id="f-1722" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-16" decimals="3" id="f-1723" unitRef="number">-0.078</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1724" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-17" decimals="3" id="f-1725" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-15" decimals="3" id="f-1726" unitRef="number">0.139</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-16" decimals="3" id="f-1727" unitRef="number">0.516</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1728" unitRef="number">0.154</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-17" decimals="3" id="f-1729" unitRef="number">0.092</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-5" id="f-1730" unitRef="usd">-72900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-1731" unitRef="usd">-141200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-18" decimals="-5" id="f-1732" unitRef="usd">55000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="c-1" id="f-1733">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other (Income) Expense, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(252.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains) losses on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;289.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains) losses realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the three months ended September 30, 2024, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $53.3&#160;million, partially offset by a decrease in the fair value of Sage common stock of approximately $22.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $295.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage common stock of approximately $90.2&#160;million, partially offset by an increase in the fair value of Denali and Sangamo common stock of approximately $70.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $265.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accrued Expense and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;926.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reata related accrued expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;637.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,755.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,623.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;Other long-term liabilities were $744.1 million and $781.1 million as of September 30, 2024 and December 31, 2023, respectively, and included accrued income taxes totaling $162.0 million and $403.2 million, respectively</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c-1" id="f-1734">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(252.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains) losses on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;289.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest contextRef="c-15" decimals="-5" id="f-1735" unitRef="usd">11600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-16" decimals="-5" id="f-1736" unitRef="usd">95900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-5" id="f-1737" unitRef="usd">49100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-17" decimals="-5" id="f-1738" unitRef="usd">252700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="c-15" decimals="-5" id="f-1739" unitRef="usd">59800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-16" decimals="-5" id="f-1740" unitRef="usd">63800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-5" id="f-1741" unitRef="usd">190300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-17" decimals="-5" id="f-1742" unitRef="usd">175400000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-15" decimals="-5" id="f-1743" unitRef="usd">39100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-16" decimals="-5" id="f-1744" unitRef="usd">-317300000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-1" decimals="-5" id="f-1745" unitRef="usd">-22200000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-17" decimals="-5" id="f-1746" unitRef="usd">-289600000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-15" decimals="-5" id="f-1747" unitRef="usd">-4900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-16" decimals="-5" id="f-1748" unitRef="usd">-11400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-5" id="f-1749" unitRef="usd">-25600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-17" decimals="-5" id="f-1750" unitRef="usd">-30800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-5" id="f-1751" unitRef="usd">-800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-16" decimals="-5" id="f-1752" unitRef="usd">-3400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-1753" unitRef="usd">-4700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-5" id="f-1754" unitRef="usd">-5100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-15" decimals="-5" id="f-1755" unitRef="usd">-14800000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-16" decimals="-5" id="f-1756" unitRef="usd">-300000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-5" id="f-1757" unitRef="usd">-193700000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-17" decimals="-5" id="f-1758" unitRef="usd">-248200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="c-1" id="f-1759">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains) losses realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the three months ended September 30, 2024, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $53.3&#160;million, partially offset by a decrease in the fair value of Sage common stock of approximately $22.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $295.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage common stock of approximately $90.2&#160;million, partially offset by an increase in the fair value of Denali and Sangamo common stock of approximately $70.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $265.0&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-15" decimals="-5" id="f-1760" unitRef="usd">-39100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-16" decimals="-5" id="f-1761" unitRef="usd">302000000.0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-5" id="f-1762" unitRef="usd">21900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-17" decimals="-5" id="f-1763" unitRef="usd">273600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-15" decimals="-5" id="f-1764" unitRef="usd">-10900000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-16" decimals="-5" id="f-1765" unitRef="usd">4400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-1" decimals="-5" id="f-1766" unitRef="usd">-5400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-17" decimals="-5" id="f-1767" unitRef="usd">5300000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-15" decimals="-5" id="f-1768" unitRef="usd">-28200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-16" decimals="-5" id="f-1769" unitRef="usd">297600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-1770" unitRef="usd">27300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-17" decimals="-5" id="f-1771" unitRef="usd">268300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-733" decimals="-5" id="f-1772" unitRef="usd">53300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-734" decimals="-5" id="f-1773" unitRef="usd">22700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-735" decimals="-5" id="f-1774" unitRef="usd">295600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-736" decimals="-5" id="f-1775" unitRef="usd">90200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-737" decimals="-5" id="f-1776" unitRef="usd">70100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-738" decimals="-5" id="f-1777" unitRef="usd">265000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-1778">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;926.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reata related accrued expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;637.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,755.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,623.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-491" decimals="-5" id="f-1779" unitRef="usd">1000300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-492" decimals="-5" id="f-1780" unitRef="usd">926500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1781" unitRef="usd">288700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1782" unitRef="usd">335100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <biib:Collaborationexpensesaccrual contextRef="c-18" decimals="-5" id="f-1783" unitRef="usd">280600000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual contextRef="c-19" decimals="-5" id="f-1784" unitRef="usd">214600000</biib:Collaborationexpensesaccrual>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-18" decimals="-5" id="f-1785" unitRef="usd">178700000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-19" decimals="-5" id="f-1786" unitRef="usd">191500000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-18" decimals="-5" id="f-1787" unitRef="usd">287100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-19" decimals="-5" id="f-1788" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1789" unitRef="usd">82300000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1790" unitRef="usd">117500000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1791" unitRef="usd">637400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1792" unitRef="usd">838400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1793" unitRef="usd">2755100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1794" unitRef="usd">2623600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-18" decimals="-5" id="f-1795" unitRef="usd">744100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-19" decimals="-5" id="f-1796" unitRef="usd">781100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-18" decimals="-5" id="f-1797" unitRef="usd">162000000.0</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-19" decimals="-5" id="f-1798" unitRef="usd">403200000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-1799">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 19:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Genentech, Inc. (Roche Group)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RITUXAN&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt"&gt;U.S.:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt"&gt;Canada:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCREVUS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0&#160;million. There will be a 50.0% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LUNSUMIO (mosunetuzumab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. Under our collaboration with Genentech, we were responsible for 30.0% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S. In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;COLUMVI (glofitamab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022 we entered into an agreement with Genentech related to the commercialization and sharing of economics for COLUMVI, a bispecific antibody for the treatment of B-cell non-Hodgkin's lymphoma, which was subsequently granted accelerated approval by the FDA in June 2023. Under the terms of this agreement, we will have no payment obligations. Genentech will have sole decision-making rights on the commercialization of COLUMVI within the U.S. and we will receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024 Roche announced that COLUMVI, in combination with chemotherapy GemOx (glofitamab-gxbm), demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Formulas&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RITUXAN and LUNSUMIO Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a 30.0% share on the first $50.0&#160;million of combined co-promotion operating profits earned each calendar year. As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After LUNSUMIO Approval until the First Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First Threshold Date until the Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;First Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $150.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Second Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $350.0&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was 35.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GAZYVA Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share on the first $50.0&#160;million of operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Second GAZYVA Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023 the Second GAZYVA Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for GAZYVA was 35.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our audited consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2023 we accrued a $31.0&#160;million payable to Eisai related to the termination of an agreement whereby Eisai co-promoted or distributed our MS products in certain Asia-Pacific markets and settings. As of December 31, 2023, we paid approximately $16.0 million of the $31.0&#160;million payable. The remaining portion was subsequently paid in January 2024. This termination fee is included in selling, general and administrative expense in our condensed consolidated statements of income for the nine months ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LEQEMBI (lecanemab) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease (the LEQEMBI Collaboration).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We and Eisai co-promote LEQEMBI and share profits and losses equally. We currently manufacture LEQEMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023 the FDA granted traditional approval of LEQEMBI. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Outside of the U.S., LEQEMBI is now approved in Japan (September 2023), China (January 2024), South Korea (May 2024), Hong Kong (July 2024), Israel (July 2024), United Arab Emirates (August 2024) and Great Britain (August 2024).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon commercialization of LEQEMBI in the U.S., we began recognizing our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, within other revenue in our condensed consolidated statements of income, as we are not the principal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share of LEQEMBI sales and marketing expense and development expense are recorded within selling, general and administrative expense and research and development expense, respectively, within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of LEQEMBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;282.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the LEQEMBI Collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Eisai related to the agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s discussed above were approximately $93.2&#160;million and $1.4&#160;million as of September 30, 2024 and December 31, 2023, respectively. Amounts payable to Eisai related to the agreements discussed above were approximately $146.2&#160;million and $118.4&#160;million as of September 30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;UCB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the treatment of PPD and potential treatment of MDD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;epilepsy. In July 2024 we and Sage announced that the Phase 2 KINETIC 2 dose-range study of BIIB124 did not meet its endpoints. Based on these results, we discontinued our further development of BIIB124.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. ZURZUVAE for PPD became commercially available in the U.S. during the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2024 we and Sage agreed to not pursue further development of zuranolone for the potential treatment of MDD. This decision was based on the significant new investment and time we expect would be needed to conduct the additional studies required to support approval of this indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. During the fourth quarter of 2023 we accrued a milestone payment due to Sage of $75.0&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S., which was recorded within intangible assets, net in our condensed consolidated balance sheets, and subsequently paid in January 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2024, we recognized net profit-sharing expense of approximately $9.0 million and $20.5 million, respectively, to reflect Sage's 50.0% share of net collaboration results in the U.S. for ZURZUVAE for PPD, compared to net loss reimbursement of approximately $5.9 million in both prior year comparative periods. These amounts are recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to the Sage collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Sage collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease (LRRK2 Collaboration) and also entered into a separate agreement to obtain an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its ATV-enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. In July 2024 we terminated our license with Denali for the ATV-enabled anti-amyloid beta program. This termination also results in the termination of the exclusive option agreement, as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the LRRK2 Collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to the Denali collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2024, we recorded approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$26.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$42.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;zero and $2.8 million, respectively, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Development and Commercialization Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2024 we notified Samsung Bioepis of our decision to terminate our 2019 Development and Commercialization Agreement (the DCA Agreement) solely within the U.S. and Canada. As a result of this termination we recognized impairment charges of approximately $20.2 million, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which were recorded within amortization and impairment of acquired intangible assets within our condensed consolidated statements of income for the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended September 30, 2024. Biogen will transfer commercialization rights for BYOOVIZ and OPUVIZ in the U.S. and Canada back to Samsung Bioepis over a period of up to 18 months. During this transition period, we will continue to commercialize BYOOVIZ. The termination does not impact the other markets in the DCA Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also pay Samsung Bioepis up to approximately $165.0 million in additional development, regulatory and sales-based milestones associated with the remaining major markets covered by the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended September 30, 2024, we recognized net profit-sharing expense of approximately $60.3&#160;million and $176.8&#160;million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of approximately $56.4 million and $170.4 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2024 we exercised our option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years. In connection with this exercise, we paid Samsung Bioepis an option exercise fee of $60.0 million in July 2024 which was recognized in intangible assets, net within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufa&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cturing, royalty and other revenue in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Samsung Bioepis related to the agreements discussed above were approximately $20.9&#160;million and $9.9&#160;million as of September 30, 2024 and December 31, 2023, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were approximately $82.6&#160;million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$73.7&#160;million as of September 30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt; to our consolidated financial statements included in our 2023 Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-739"
      decimals="INF"
      id="f-1800"
      unitRef="number">0.135</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-740"
      decimals="INF"
      id="f-1801"
      unitRef="number">0.240</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage contextRef="c-741" decimals="-5" id="f-1802" unitRef="usd">900000000</biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage>
    <biib:Reductioninroyaltyrate
      contextRef="c-741"
      decimals="INF"
      id="f-1803"
      unitRef="number">0.500</biib:Reductioninroyaltyrate>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-742"
      decimals="INF"
      id="f-1804"
      unitRef="number">0.030</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:PeriodOfCollaborationAgreement contextRef="c-741" id="f-1805">P11Y</biib:PeriodOfCollaborationAgreement>
    <biib:PercentageOfFutureDevelopmentCosts
      contextRef="c-743"
      decimals="INF"
      id="f-1806"
      unitRef="number">0.300</biib:PercentageOfFutureDevelopmentCosts>
    <biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
      contextRef="c-744"
      decimals="INF"
      id="f-1807"
      unitRef="number">0.300</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-745" decimals="-5" id="f-1808" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-745" decimals="-5" id="f-1809" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionProfitSharingFormulaTableTextBlock contextRef="c-1" id="f-1810">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After LUNSUMIO Approval until the First Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First Threshold Date until the Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:CoPromotionProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-745" decimals="-5" id="f-1811" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-745" decimals="-5" id="f-1812" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="c-744"
      decimals="INF"
      id="f-1813"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-744"
      decimals="INF"
      id="f-1814"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour
      contextRef="c-744"
      decimals="INF"
      id="f-1815"
      unitRef="number">0.300</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour>
    <biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="c-746" decimals="-5" id="f-1816" unitRef="usd">500000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
    <biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne contextRef="c-746" decimals="-5" id="f-1817" unitRef="usd">150000000</biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne>
    <biib:SalesTriggerGrossSalesThreshold contextRef="c-746" decimals="-5" id="f-1818" unitRef="usd">350000000</biib:SalesTriggerGrossSalesThreshold>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-745"
      decimals="INF"
      id="f-1819"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-745"
      decimals="INF"
      id="f-1820"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-745" decimals="-5" id="f-1821" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-745" decimals="-5" id="f-1822" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PretaxProfitSharingFormulaTableTextBlock contextRef="c-1" id="f-1823">Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:PretaxProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-745" decimals="-5" id="f-1824" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-745" decimals="-5" id="f-1825" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="c-745"
      decimals="INF"
      id="f-1826"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-745"
      decimals="INF"
      id="f-1827"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="c-746" decimals="-5" id="f-1828" unitRef="usd">500000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-745"
      decimals="INF"
      id="f-1829"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:AccruedPaymentToTerminationAgreement contextRef="c-747" decimals="-5" id="f-1830" unitRef="usd">31000000</biib:AccruedPaymentToTerminationAgreement>
    <biib:PaymentsMadeToTerminationAgreement contextRef="c-748" decimals="-5" id="f-1831" unitRef="usd">16000000</biib:PaymentsMadeToTerminationAgreement>
    <biib:AccruedPaymentToTerminationAgreement contextRef="c-747" decimals="-5" id="f-1832" unitRef="usd">31000000</biib:AccruedPaymentToTerminationAgreement>
    <biib:ShareOfNonControlingInterestRecognized
      contextRef="c-509"
      decimals="2"
      id="f-1833"
      unitRef="number">0.500</biib:ShareOfNonControlingInterestRecognized>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock contextRef="c-1" id="f-1834">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of LEQEMBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;282.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the LEQEMBI Collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration contextRef="c-749" decimals="-5" id="f-1835" unitRef="usd">77700000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-750" decimals="-5" id="f-1836" unitRef="usd">88500000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-751" decimals="-5" id="f-1837" unitRef="usd">255600000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-752" decimals="-5" id="f-1838" unitRef="usd">282600000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-749" decimals="-5" id="f-1839" unitRef="usd">38800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-750" decimals="-5" id="f-1840" unitRef="usd">44300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-751" decimals="-5" id="f-1841" unitRef="usd">127800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-752" decimals="-5" id="f-1842" unitRef="usd">141300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration contextRef="c-753" decimals="-5" id="f-1843" unitRef="usd">164600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-754" decimals="-5" id="f-1844" unitRef="usd">163400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-755" decimals="-5" id="f-1845" unitRef="usd">476200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-756" decimals="-5" id="f-1846" unitRef="usd">191000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-753" decimals="-5" id="f-1847" unitRef="usd">82300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-754" decimals="-5" id="f-1848" unitRef="usd">81700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-755" decimals="-5" id="f-1849" unitRef="usd">238100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-756" decimals="-5" id="f-1850" unitRef="usd">95500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AccountsReceivableFromCollaborator contextRef="c-757" decimals="-5" id="f-1851" unitRef="usd">93200000</biib:AccountsReceivableFromCollaborator>
    <biib:AccountsReceivableFromCollaborator contextRef="c-748" decimals="-5" id="f-1852" unitRef="usd">1400000</biib:AccountsReceivableFromCollaborator>
    <biib:AccountsPayableToCollaborator contextRef="c-757" decimals="-5" id="f-1853" unitRef="usd">146200000</biib:AccountsPayableToCollaborator>
    <biib:AccountsPayableToCollaborator contextRef="c-748" decimals="-5" id="f-1854" unitRef="usd">118400000</biib:AccountsPayableToCollaborator>
    <biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock contextRef="c-1" id="f-1855">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-758" decimals="-5" id="f-1856" unitRef="usd">19200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-759" decimals="-5" id="f-1857" unitRef="usd">13600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-760" decimals="-5" id="f-1858" unitRef="usd">52300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-761" decimals="-5" id="f-1859" unitRef="usd">46200000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-758" decimals="-5" id="f-1860" unitRef="usd">9500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-759" decimals="-5" id="f-1861" unitRef="usd">6800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-760" decimals="-5" id="f-1862" unitRef="usd">26100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-761" decimals="-5" id="f-1863" unitRef="usd">23100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="c-762" decimals="-5" id="f-1864" unitRef="usd">75000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:Collaborationprofitlosssharing contextRef="c-763" decimals="-5" id="f-1865" unitRef="usd">9000000.0</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-764" decimals="-5" id="f-1866" unitRef="usd">20500000</biib:Collaborationprofitlosssharing>
    <biib:ShareOfNetProfitFromSageTherapeuticsPercent contextRef="c-18" decimals="2" id="f-1867" unitRef="number">0.500</biib:ShareOfNetProfitFromSageTherapeuticsPercent>
    <biib:Collaborationprofitlosssharing contextRef="c-765" decimals="-5" id="f-1868" unitRef="usd">5900000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-766" decimals="-5" id="f-1869" unitRef="usd">5900000</biib:Collaborationprofitlosssharing>
    <biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock contextRef="c-1" id="f-1870">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to the Sage collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Sage collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-767" decimals="-5" id="f-1871" unitRef="usd">8400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-768" decimals="-5" id="f-1872" unitRef="usd">72000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-769" decimals="-5" id="f-1873" unitRef="usd">29600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-770" decimals="-5" id="f-1874" unitRef="usd">158900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-767" decimals="-5" id="f-1875" unitRef="usd">4200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-768" decimals="-5" id="f-1876" unitRef="usd">36000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-769" decimals="-5" id="f-1877" unitRef="usd">14800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-770" decimals="-5" id="f-1878" unitRef="usd">79500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration contextRef="c-771" decimals="-5" id="f-1879" unitRef="usd">28400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-772" decimals="-5" id="f-1880" unitRef="usd">54000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-773" decimals="-5" id="f-1881" unitRef="usd">82900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-774" decimals="-5" id="f-1882" unitRef="usd">152300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-771" decimals="-5" id="f-1883" unitRef="usd">14200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-772" decimals="-5" id="f-1884" unitRef="usd">27000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-773" decimals="-5" id="f-1885" unitRef="usd">41500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-774" decimals="-5" id="f-1886" unitRef="usd">76100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock contextRef="c-1" id="f-1887">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to the Denali collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-775" decimals="-5" id="f-1888" unitRef="usd">14900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-776" decimals="-5" id="f-1889" unitRef="usd">12600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-777" decimals="-5" id="f-1890" unitRef="usd">44500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-778" decimals="-5" id="f-1891" unitRef="usd">51300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-775" decimals="-5" id="f-1892" unitRef="usd">8900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-776" decimals="-5" id="f-1893" unitRef="usd">7600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-777" decimals="-5" id="f-1894" unitRef="usd">26700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-778" decimals="-5" id="f-1895" unitRef="usd">30800000</biib:Expensereflectedwithinstatementsofincome>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-779" decimals="-5" id="f-1896" unitRef="usd">26500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-780" decimals="-5" id="f-1897" unitRef="usd">42500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-781" decimals="-5" id="f-1898" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-782" decimals="-5" id="f-1899" unitRef="usd">2800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:ContingentCommercializedRightsNumberOfProducts
      contextRef="c-783"
      decimals="INF"
      id="f-1900"
      unitRef="product">2</biib:ContingentCommercializedRightsNumberOfProducts>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-783"
      decimals="INF"
      id="f-1901"
      unitRef="number">0.450</biib:EquityMethodInvestmentsExpectedProfitShare>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-1" decimals="-5" id="f-1902" unitRef="usd">20200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-15" decimals="-5" id="f-1903" unitRef="usd">20200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-784" decimals="-5" id="f-1904" unitRef="usd">165000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-784"
      decimals="INF"
      id="f-1905"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing contextRef="c-785" decimals="-5" id="f-1906" unitRef="usd">60300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-786" decimals="-5" id="f-1907" unitRef="usd">176800000</biib:Collaborationprofitlosssharing>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-784"
      decimals="INF"
      id="f-1908"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing contextRef="c-787" decimals="-5" id="f-1909" unitRef="usd">56400000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-788" decimals="-5" id="f-1910" unitRef="usd">170400000</biib:Collaborationprofitlosssharing>
    <biib:CollaborativeArrangementTermExtension contextRef="c-784" id="f-1911">P5Y</biib:CollaborativeArrangementTermExtension>
    <biib:ContractOptionExerciseFee contextRef="c-784" decimals="-5" id="f-1912" unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <us-gaap:AccountsReceivableNet contextRef="c-789" decimals="-5" id="f-1913" unitRef="usd">20900000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-790" decimals="-5" id="f-1914" unitRef="usd">9900000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-789" decimals="-5" id="f-1915" unitRef="usd">82600000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-790" decimals="-5" id="f-1916" unitRef="usd">73700000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c-1" id="f-1917">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2007 we consolidated the results of Neurimmune as we determined we were the primary beneficiary because we had the power through the collaboration to direct the activities that most significantly impacted the entity's economic performance and we were required to fund 100.0% of the research and development costs incurred in support of the collaboration. The collaboration and license agreement with Neurimmune was for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2023 we notified Neurimmune of our decision to terminate the Neurimmune Agreement. Subsequent to the termination, we reconsidered our relationship with Neurimmune and determined that we were no longer the primary beneficiary of the variable interest entity. As a result, we recorded a net gain on the deconsolidation of Neurimmune of approximately $3.0&#160;million, which was recorded in other (income) expense, net within our consolidated statements of income for the year ended December 31, 2023, included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2024 and December 31, 2023, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $23.6 million and $16.4 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="c-791"
      decimals="INF"
      id="f-1918"
      unitRef="number">1.000</biib:ResearchAndDevelopmentCostsPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount contextRef="c-791" decimals="-5" id="f-1919" unitRef="usd">3000000</us-gaap:DeconsolidationGainOrLossAmount>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="c-18" decimals="-5" id="f-1920" unitRef="usd">23600000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="c-19" decimals="-5" id="f-1921" unitRef="usd">16400000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c-1" id="f-1922">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims, investigations and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2023 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. If an estimate of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Loss Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Litigation asserted against Biogen&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are defendants in three securities actions pending in the District Court, one filed by Nadia Shash and Amjad Khan in November 2020 and related to ADUHELM, one filed by the Oklahoma Firefighters Pension and Retirement System in February 2022 and related to ADUHELM and one filed by Thomas Allen Gray in June 2024 and related to statements about our compliance controls, 2023 earnings guidance and other matters. All allege violations of federal securities laws under 15 U.S.C. &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seek declarations of the actions as class actions and monetary relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Litigation asserted against Reata&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in March 2024 the United States District Court for the Eastern District of Texas granted final approval of the previously disclosed settlement of litigation filed by putative stockholders of Reata (later acquired by Biogen) alleging violations of the federal securities laws by Reata, certain of its former officers and directors, and certain underwriters under 15 U.S.C. &#xa7;78j(b) and &#xa7;78t(a), 17 C.F.R. &#xa7;240.10b-5, and 15U.S.C. &#xa7;&#xa7;77k, 77l(a)(2) and 77o, and dismissed the action with prejudice.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and members of the Board of Directors are named as defendants in five derivative actions pending in the District Court, one filed by The Booth Family Trust in February 2022, one filed by Elaine Wang in July 2022, one filed by Jonathan Blaufarb (Blaufarb I) in July 2024, one filed by Lawrence Hollin in October 2024 and one filed by Jonathan Blaufarb (Blaufarb II) in October 2024. The Booth, Wang and Blaufarb II actions relate to ADUHELM and other matters, and the Blaufarb and Hollin actions relate to statements about our compliance controls, 2023 earnings guidance and other matters. The actions allege breach of fiduciary duty, waste of corporate assets and other common law claims, and violations of the Securities Exchange Act of 1934, 15 U.S.C. &#xa7;78a et seq. The actions seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#x2019; fees and costs payable to the plaintiffs. The Booth and Wang actions are stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024, the Technical Boards of Appeal of the European Patent Office upheld the validity of Fresenius Kabi Deutschland GmbH's (Fresenius Kabi's) European Patent 3 145 488 (the EP '488 Patent), which expires in May 2035. In June 2022 Fresenius Kabi filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes the French counterpart of the EP &#x2018;488 Patent. In March 2024 the D&#xfc;sseldorf Regional Court dismissed Fresenius Kabi's claim of infringement of the German counterpart of the EP '488 Patent and Fresenius Kabi has appealed to the Higher Regional Court of D&#xfc;sseldorf.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, asserted claims of $200.0 million for alleged breaches of the contract pursuant to which we acquired Convergence. In June 2023 Shareholder Representative Services LLC and 24 former shareholders filed a suit against us in the High Court of Justice of England and Wales asserting one of the 2019 claims and seeking payment of $49.9&#160;million, interest and costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Humana Patient Assistance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023 the District Court dismissed the previously disclosed action filed against us by Humana in September 2020. Humana had alleged damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients and had alleged violations of the federal RICO Act and state laws. In December 2023 Humana appealed to the United States Court of Appeals for the First Circuit and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023 Genentech, Inc. filed suit against us in the U.S. District Court for the Northern District of California and claims that it is owed royalties of approximately $92.7&#160;million on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen, together with interest and costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lender Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2024, BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP filed suit against us and Reata Pharmaceuticals, Inc. in the Supreme Court of the State of New York alleging breach of a loan agreement with Reata and seeking payment of approximately $23.2&#160;million, plus interest, costs and attorneys' fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August and September 2024, four suits were filed against us in the U.S. District Court for the Northern District of Illinois, by Local No. 1 Health Fund; the Mayor and City Council of Baltimore; New York State Teamsters Council Health and Hospital Fund; and Teamsters Local 237 Welfare Fund and Teamsters Local 237 Retirees' Benefit Fund. Plaintiffs allege violations of federal antitrust laws including 15 U.S.C. &#xa7;&#xa7; 1, 2 and 13(c) and various state laws, based on contracts with pharmacy benefit managers related to TECFIDERA and VUMERITY. Plaintiffs seek declarations of the actions as class actions, monetary, declaratory and equitable relief, and attorneys' fees and costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received subpoenas from the SEC seeking information relating to ADUHELM and its launch, and our equity plans. We have also received subpoenas from the DOJ and SEC seeking information relating to our business operations in several foreign countries. The Italian Competition Authority is investigating Biogen and other companies in relation to our biosimilar product BYOOVIZ.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TYSABRI Biosimilar Patent Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#xa7;262, seeking a declaratory judgment of patent infringement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Annulment Proceedings in the General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 Mylan Ireland filed an action in the General Court of the European Union (General Court) to annul the EMA's decision not to validate its applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. In October 2024 the General Court dismissed the action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-792" decimals="-5" id="f-1923" unitRef="usd">200000000.0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-19" decimals="-5" id="f-1924" unitRef="usd">49900000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-793" decimals="-5" id="f-1925" unitRef="usd">92700000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-794" decimals="-5" id="f-1926" unitRef="usd">23200000</us-gaap:LossContingencyDamagesSoughtValue>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-15" id="f-1927">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-15" id="f-1928">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-15" id="f-1929">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-15" id="f-1930">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
